PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Castelli, M; Camps, M; Gillieron, C; Leroy, D; Arkinstall, S; Rommel, C; Nichols, A				Castelli, M; Camps, M; Gillieron, C; Leroy, D; Arkinstall, S; Rommel, C; Nichols, A			MAP kinase phosphatase 3 (MKP3) interacts with and is phosphorylated by protein kinase CK2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASES; RAT-BRAIN DEVELOPMENT; CASEIN KINASE-2; CATALYTIC ACTIVATION; TYROSINE-PHOSPHATASE; GROWTH-FACTOR; SUBSTRATE; PATHWAY; ERK2; DIFFERENTIATION	Mitogen-activated protein (MAP) kinases play a central role in controlling a wide range of cellular functions following their activation by a variety of extracellular stimuli. MAP kinase phosphatases (MKPs) represent a subfamily of dual specificity phosphatases, which negatively regulate MAP kinases. Although ERK2 activity is regulated by its phosphorylation state, MKP3 is regulated by physical interaction with ERK2, independent of its enzymatic activity (Camps, M., Nichols, A., Gillieron, C., Antonsson, B., Muda, M., Chabert, C., Boschert, U., and Arkinstall, S., (1998) Science 280, 1262-1265; Farooq, A., Chaturvedi, G., Mujtaba, S., Plotnikova, O., Zeng, L., Dhalluin, C., Ashton, R., and Zhou, M. M. (2001), Mol. Cell 7, 387-399; Zhou, B., and Zhang, Z. Y. (1999) J. Biol. Chem. 274, 35526-35534). The interaction of ERK2 and MKP3 allows the reciprocal cross-regulation of their catalytic activity. Indeed, MKP3 acts as a negative regulator on ERK2-MAP kinase signal transduction activity, representing thus a negative feedback for this MAPK pathway. To identify novel proteins able to complex MKP3, we used the yeast two-hybrid system. Here we report that MKP3 and protein kinase CK2 form a protein complex, which can include ERK2. The phosphatase activity of MKP3 is then slightly increased in vitro, whereas in transfected cells, ERK2 dephosphorylation is reduced. In addition, we demonstrated that CK2 selectively phosphorylates MKP3, suggesting cross-regulation between CK2alpha and MKP3, as well as a modulation of ERK2-MAPK signaling by CK2alpha via MKP3.	Serono Int SA, Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Serono Reprod Biol Inst Inc, Randolph, MA 02368 USA	Merck & Company; Serono International S.A.	Nichols, A (corresponding author), Serono Int SA, Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland.	anthony.nichols@serono.com		Camps, Montserrat/0000-0002-9849-8657				Aitken A, 1999, MOL BIOTECHNOL, V12, P241, DOI 10.1385/MB:12:3:241; Blanquet PR, 2000, PROG NEUROBIOL, V60, P211, DOI 10.1016/S0301-0082(99)00026-X; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Camps M, 1998, FEBS LETT, V425, P271, DOI 10.1016/S0014-5793(98)00250-6; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; DIAZNIDO J, 1992, J NEUROCHEM, V58, P1820, DOI 10.1111/j.1471-4159.1992.tb10058.x; DIAZNIDO J, 1994, CELL MOL BIOL RES, V40, P581; Farooq A, 2001, MOL CELL, V7, P387, DOI 10.1016/S1097-2765(01)00186-1; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Halfar K, 2001, DEVELOPMENT, V128, P1687; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Hu XT, 2000, CELL GROWTH DIFFER, V11, P191; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Lebrin F, 1999, MOL CELL BIOCHEM, V191, P207, DOI 10.1023/A:1006888228156; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN ME, 1990, INT J DEV NEUROSCI, V8, P47; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; SERRANO L, 1989, EXP CELL RES, V181, P263, DOI 10.1016/0014-4827(89)90200-0; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526	36	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44731	44739		10.1074/jbc.M407669200	http://dx.doi.org/10.1074/jbc.M407669200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15284227	hybrid			2022-12-27	WOS:000224505600061
J	Marsee, DK; Venkateswaran, A; Tao, HY; Vadysirisack, D; Zhang, ZX; Vandre, DD; Jhiang, SM				Marsee, DK; Venkateswaran, A; Tao, HY; Vadysirisack, D; Zhang, ZX; Vandre, DD; Jhiang, SM			Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM/IODIDE SYMPORTER; TRANSFORMING ACTIVITY; RET PROTOONCOGENE; CRYSTAL-STRUCTURE; ANTITUMOR AGENT; HSP90 CHAPERONE; CANCER; COMPLEX; KINASE; EXPRESSION	RET/PTC1 is a rearranged form of the RET tyrosine kinase commonly seen in papillary thyroid carcinomas. It has been shown that RET/PTC1 decreases expression of the sodium/iodide symporter (NIS), the molecule that mediates radioiodide therapy for thyroid cancer. Using proteomic analysis, we identify hsp90 and its co-chaperone p50(cdc37) as novel proteins associated with RET/PTC1. Inhibition of hsp90 function with 17-allylamino-17-demothoxygeldanamycin (17-AAG) reduces RET/PTC1 protein levels. Furthermore, 17-AAG increases radioiodide accumulation in thyroid cells, mediated in part through a protein kinase A-independent mechanism. We show that 17-AAG does not increase the total amount of NIS protein or cell surface NIS localization. Instead, 17-AAG increases radioiodide accumulation by decreasing iodide efflux. Finally, the ability of 17-AAG to increase radioiodide accumulation is not restricted to thyroid cells expressing RET/PTC1. These findings suggest that 17-AAG may be useful as a chemotherapeutic agent, not only to inhibit proliferation but also to increase the efficacy of radioiodide therapy in patients with thyroid cancer.	Ohio State Univ, Coll Med, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Med Sci Program, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Integrated Biomed Sci Grad Program, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Biochem Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Jhiang, SM (corresponding author), Ohio State Univ, Coll Med, Dept Physiol & Cell Biol, 304 Hamilton Hall, Columbus, OH 43210 USA.	jhiang.1@osu.edu			NATIONAL CANCER INSTITUTE [R01CA060074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [T32DE014320] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA60074] Funding Source: Medline; NIDCR NIH HHS [T32DE14320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMBESIIMPIOMBAT.FS, 1982, COLD SPRING HARBOR C, V9, P483; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Braga-Basaria M, 2004, J CLIN ENDOCR METAB, V89, P2982, DOI 10.1210/jc.2003-031767; Buzzoni R, 2003, TUMORI, V89, P544, DOI 10.1177/030089160308900518; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Cho JY, 1999, ONCOGENE, V18, P3659, DOI 10.1038/sj.onc.1202709; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Furuya F, 2004, ENDOCRINOLOGY, V145, P2865, DOI 10.1210/en.2003-1258; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GERARD C, 1994, MOL CELL ENDOCRINOL, V106, P195, DOI 10.1016/0303-7207(94)90203-8; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Gruning T, 2003, EUR J ENDOCRINOL, V148, P395, DOI 10.1530/eje.0.1480395; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; Iwashita T, 1996, ONCOGENE, V12, P481; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Knauf JA, 2003, ONCOGENE, V22, P6830, DOI 10.1038/sj.onc.1206829; Knauf JA, 2003, ONCOGENE, V22, P4406, DOI 10.1038/sj.onc.1206602; Lin XQ, 2004, J CLIN ENDOCR METAB, V89, P2344, DOI 10.1210/jc.2003-031963; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Nikiforov YE, 1997, CANCER RES, V57, P1690; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Park JW, 2003, J CLIN ENDOCR METAB, V88, P3346, DOI 10.1210/jc.2002-020340; PICKER E, 2003, CIRC RES, V92, pE87; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Riedel C, 2001, J BIOL CHEM, V276, P21458, DOI 10.1074/jbc.M100561200; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Segev DL, 2003, SURG ONCOL, V12, P69, DOI 10.1016/S0960-7404(03)00037-9; SMALLRIDGE RC, 1994, AM J PHYSIOL, V267, pE323, DOI 10.1152/ajpendo.1994.267.2.E323; Smida J, 1999, INT J CANCER, V80, P32, DOI 10.1002/(SICI)1097-0215(19990105)80:1<32::AID-IJC7>3.3.CO;2-C; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/BF00689048; Trapasso F, 1999, EUR J ENDOCRINOL, V140, P447, DOI 10.1530/eje.0.1400447; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xing S, 1998, J BIOL CHEM, V273, P4909, DOI 10.1074/jbc.273.9.4909; Xu WP, 2002, CELL STRESS CHAPERON, V7, P91, DOI 10.1379/1466-1268(2002)007<0091:HNGRTI>2.0.CO;2; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009	46	52	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43990	43997		10.1074/jbc.M407503200	http://dx.doi.org/10.1074/jbc.M407503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15302866	hybrid			2022-12-27	WOS:000224383100077
J	Mills, JA; Motichka, K; Jucker, M; Wu, HP; Uhlik, BC; Stern, RJ; Scherman, MS; Vissa, VD; Pan, F; Kundu, M; Ma, YF; McNeil, M				Mills, JA; Motichka, K; Jucker, M; Wu, HP; Uhlik, BC; Stern, RJ; Scherman, MS; Vissa, VD; Pan, F; Kundu, M; Ma, YF; McNeil, M			Inactivation of the mycobacterial rhamnosyltransferase, which is needed for the formation of the arabinogalactan-peptidoglycan linker, leads to irreversible loss of viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; MASS-SPECTROMETRY; ESCHERICHIA-COLI; CELL-WALLS; O-ANTIGEN; TUBERCULOSIS; BIOSYNTHESIS; POLYSACCHARIDE; TRANSFORMATION; EXPRESSION	Temperature-sensitive mutant 2-20/32 of Mycobacterium smegmatis mc(2)155 was isolated and genetically complemented with a Mycobacterium tuberculosis H37Rv DNA fragment that contained a single open reading frame. This open reading frame is designated Rv3265c in the M. tuberculosis H37Rv genome. Rv3265c shows homology to the Escherichia coli gene wbbL, which encodes a dTDP-Rha:alpha-D-GlcNAc-pyrophosphate polyprenol, alpha-3-L-rhamnosyltransferase. In E. coli this enzyme is involved in O-antigen synthesis, but in mycobacteria it is required for the rhamnosyl-containing linker unit responsible for the attachment of the cell wall polymer mycolyl-arabinogalactan to the peptidoglycan. The M. tuberculosis wbbL homologue, encoded by Rv3265c, was shown to be capable of restoring an E. coli K12 strain containing an insertionally inactivated wbbL to O-antigen positive. Likewise, the E. coli wbbL gene allowed 2-20/32 to grow at higher non-permissive temperatures. The rhamnosyltransferase activity of M. tuberculosis WbbL was demonstrated in 2-20/32 as was the loss of this transferase activity in 2-20/32 at elevated temperatures. The wbbL of the temperature-sensitive mutant contained a single-base change that converted what was a proline in m(c)2155 to a serine residue. Exposure of 2-20/32 to higher non-permissive temperatures resulted in bacteria that could not be recovered at the lower permissive temperatures.	Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA; Chugai Biopharmaceut Inc, San Diego, CA 92121 USA; Bose Inst, Dept Chem, Kolkata 700009, W Bengal, India; Dalian Med Univ, Dept Mol Biol & Biochem, Dalian 116027, Peoples R China	Colorado State University; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Department of Science & Technology (India); Bose Institute; Dalian Medical University	McNeil, M (corresponding author), Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.	mmcneil@colostate.edu	McNeil, Michael/G-3325-2019; Stern, Robert/N-8344-2019	Stern, Robert/0000-0002-8083-4632	NIAID NIH HHS [AI-33706] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033706] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; Eckstein TM, 1998, J BACTERIOL, V180, P5567, DOI 10.1128/JB.180.21.5567-5573.1998; GARBE TR, 1994, MICROBIOL-SGM, V140, P133, DOI 10.1099/13500872-140-1-133; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; HOOKE AM, 1994, METHOD ENZYMOL, V235, P448; Jackson M, 1999, MOL MICROBIOL, V31, P1573, DOI 10.1046/j.1365-2958.1999.01310.x; JANN B, 1994, CARBOHYD RES, V264, P305, DOI 10.1016/S0008-6215(05)80014-X; Khoo KH, 1996, BIOCHEMISTRY-US, V35, P11812, DOI 10.1021/bi961055+; LIU D, 1994, MICROBIOL-UK, V140, P49, DOI 10.1099/13500872-140-1-49; Ma YF, 2002, J BACTERIOL, V184, P3392, DOI 10.1128/JB.184.12.3392-3395.2002; Ma YF, 1997, MICROBIOL-SGM, V143, P937, DOI 10.1099/00221287-143-3-937; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; McNeil M., 1996, MYCOBACTERIUM AVIUM, P263; McNeil M., 1996, TUBERCULOSIS, P171; Mikusova K, 1996, J BIOL CHEM, V271, P7820, DOI 10.1074/jbc.271.13.7820; PASCOPELLA L, 1994, INFECT IMMUN, V62, P1313, DOI 10.1128/IAI.62.4.1313-1319.1994; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Stern RJ, 1999, MICROBIOL-UK, V145, P663, DOI 10.1099/13500872-145-3-663; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X	28	68	75	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43540	43546		10.1074/jbc.M407782200	http://dx.doi.org/10.1074/jbc.M407782200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15294902	hybrid			2022-12-27	WOS:000224383100024
J	Panorchan, P; Schafer, BW; Wirtz, D; Tseng, Y				Panorchan, P; Schafer, BW; Wirtz, D; Tseng, Y			Nuclear envelope breakdown requires overcoming the mechanical integrity of the nuclear lamina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-FILAMENT NETWORKS; INTERMEDIATE-FILAMENTS; IN-VITRO; ALPHA-ACTININ; TAIL DOMAIN; PHOSPHORYLATION SITES; ASSEMBLY PROPERTIES; CDC2 KINASE; ORGANIZATION; HEAD	In prophase cells, lamin B1 is the major component of the nuclear lamina, a filamentous network underlying the nucleoplasmic side of the nuclear membrane, whereas lamin A/C is dissociated from the scaffold. In vivo fluorescence microscopy studies have shown that, during the G(2)/M transition, the first gap in the nuclear envelope ( NE) appears before lamin B1 disassembly and is caused by early spindle microtubules impinging on the NE. This result suggests that the mechanical tearing of the NE by microtubules plays a central role to the progression of mitosis. To investigate whether this microtubule-induced NE deformation is sufficient for NE breakdown, we assess the mechanical resilience of a reconstituted lamin B1 network. Quantitative rheological methods demonstrate that human lamin B1 filaments form stiff networks that can resist much greater deformations than those caused by microtubules impinging on the NE. Moreover, lamin B1 networks possess an elastic stiffness, which increases under tension, and an exceptional resilience against shear deformations. These results demonstrate that both mechanical tearing of the lamina and biochemical modification of lamin B1 filaments are required for NE breakdown.	Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Civil Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Tseng, Y (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	yiider@jhu.edu	Schafer, Benjamin/C-9104-2009; Wirtz, Denis/A-3257-2010					AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; [Anonymous], 1980, VISCOELASTIC PROPERT; Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; Bousquet O, 2001, J CELL BIOL, V155, P747, DOI 10.1083/jcb.200104063; Buendia B, 1997, EXP CELL RES, V230, P133, DOI 10.1006/excr.1996.3395; Coulombe PA, 2000, TRENDS CELL BIOL, V10, P420, DOI 10.1016/S0962-8924(00)01828-6; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; Fudge DS, 2003, BIOPHYS J, V85, P2015, DOI 10.1016/S0006-3495(03)74629-3; Furukawa K, 1998, J BIOL CHEM, V273, P4213, DOI 10.1074/jbc.273.7.4213; Georgatos SD, 1997, J CELL SCI, V110, P2129; GIEFFERS C, 1991, EUR J CELL BIOL, V55, P191; Gruenbaum Y, 2000, J STRUCT BIOL, V129, P313, DOI 10.1006/jsbi.2000.4216; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; Heidemann SR, 2004, TRENDS CELL BIOL, V14, P160, DOI 10.1016/j.tcb.2004.02.003; HEITLINGER E, 1992, J STRUCT BIOL, V108, P74, DOI 10.1016/1047-8477(92)90009-Y; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; HOGER TH, 1990, CHROMOSOMA, V100, P67; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Karabinos A, 2003, J MOL BIOL, V325, P241, DOI 10.1016/S0022-2836(02)01240-8; Krauss SW, 2003, P NATL ACAD SCI USA, V100, P10752, DOI 10.1073/pnas.1934680100; Ma LL, 2001, NAT CELL BIOL, V3, P503, DOI 10.1038/35074576; Ma LL, 1999, J BIOL CHEM, V274, P19145, DOI 10.1074/jbc.274.27.19145; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; Moir RD, 2000, J CELL BIOL, V149, P1179, DOI 10.1083/jcb.149.6.1179; MOIR RD, 1991, J CELL SCI, V99, P363; Morse DC, 1998, MACROMOLECULES, V31, P7044, DOI 10.1021/ma980304u; Mucke N, 2004, J MOL BIOL, V335, P1241, DOI 10.1016/j.jmb.2003.11.038; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; Palmer A, 1999, BIOPHYS J, V76, P1063, DOI 10.1016/S0006-3495(99)77271-1; PANORCHAN P, 2004, IN PRESS PHYS REV E; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; ROGERS KR, 1995, EUR J CELL BIOL, V66, P136; SATO M, 1988, J CELL BIOL, V106, P1205, DOI 10.1083/jcb.106.4.1205; Schirmer EC, 2001, J CELL BIOL, V153, P479, DOI 10.1083/jcb.153.3.479; Tseng Y, 2004, J CELL SCI, V117, P2159, DOI 10.1242/jcs.01073; Tseng Y, 2001, BIOPHYS J, V81, P1643, DOI 10.1016/S0006-3495(01)75818-3; Tseng Y, 2001, J MOL BIOL, V310, P351, DOI 10.1006/jmbi.2001.4716; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; Xu JY, 2000, J BIOL CHEM, V275, P35886, DOI 10.1074/jbc.M002377200; Yamada S, 2003, J STRUCT BIOL, V143, P45, DOI 10.1016/S1047-8477(03)00101-1; ZEWE M, 1991, EUR J CELL BIOL, V56, P342	42	58	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43462	43467		10.1074/jbc.M402474200	http://dx.doi.org/10.1074/jbc.M402474200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292200	hybrid			2022-12-27	WOS:000224383100015
J	Bederman, IR; Kasumov, T; Reszko, AE; David, F; Brunengraber, H; Kelleher, JK				Bederman, IR; Kasumov, T; Reszko, AE; David, F; Brunengraber, H; Kelleher, JK			In vitro modeling of fatty acid synthesis under conditions simulating the zonation of lipogenic [C-13]acetyl-CoA enrichment in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY-MASS-SPECTROMETRY; ISOTOPOMER DISTRIBUTION ANALYSIS; RAT-LIVER; STABLE ISOTOPES; ZONAL DISTRIBUTION; FASTED STATE; METABOLISM; ASSAY; GLUCOKINASE; CHOLESTEROL	In the companion report (Bederman, I. R., Reszko, A. E., Kasumov, T., David, F., Wasserman, D. H., Kelleher, J. K., and Brunengraber, H. (2004) J. Biol. Chem. 279, 43207-43216), we demonstrated that, when the hepatic pool of lipogenic acetyl-CoA is labeled from [C-13]acetate, the enrichment of this pool decreases across the liver lobule. In addition, estimates of fractional synthesis calculated by isotopomer spectral analysis (ISA), a nonlinear regression method, did not agree with a simpler algebraic two-isotopomer method. To evaluate differences between these methods, we simulated in vitro the synthesis of fatty acids under known gradients of precursor enrichment, and known values of fractional synthesis. First, we synthesized pentadecanoate from [U-C-13(3)]propionyl-CoA and four gradients of [U-C-13(3)]malonyl-CoA enrichment. Second, we pooled the fractions of each gradient. Third, we diluted each pool with pentadecanoate prepared from unlabeled malonyl-CoA to simulate the dilution of the newly synthesized compound by pre-existing fatty acids. This yielded a series of samples of pentadecanoate with known values of (i) lower and upper limits for the precursor enrichment, (ii) the shape of the gradient, and (iii) the fractional synthesis. At each step, the mass isotopomer distributions of the samples were analyzed by ISA and the two-isotopomer method to determine whether each method could correctly (i) detect gradients of precursor enrichment, (ii) estimate the gradient limits, and (iii) estimate the fractional synthesis. The two-isotopomer method did not identify gradients of precursor enrichment and underestimated fractional synthesis by up to 2-fold in the presence of gradients. ISA uses all mass isotopomers, correctly identified imposed gradients of precursor enrichment, and estimated the expected values of fractional synthesis within the constraints of the data.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Case Western Reserve University; Case Western Reserve University; Massachusetts Institute of Technology (MIT)	Brunengraber, H (corresponding author), Case Western Reserve Univ, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.	hxb8@cwru.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058533, R01DK035543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM066309] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07319, DK35543, DK58533] Funding Source: Medline; NIGMS NIH HHS [P50-GM66309] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarsland A, 1998, J LIPID RES, V39, P1280; Aarsland A, 1996, J CLIN INVEST, V98, P2008, DOI 10.1172/JCI119005; Aarsland A, 1997, AM J CLIN NUTR, V65, P1774, DOI 10.1093/ajcn/65.6.1774; Bandsma RHJ, 1998, BIOCHEM J, V329, P699, DOI 10.1042/bj3290699; Bederman IR, 2004, J BIOL CHEM, V279, P43207, DOI 10.1074/jbc.M403838200; Brunengraber DZ, 2002, ANAL BIOCHEM, V306, P278, DOI 10.1006/abio.2002.5720; Brunengraber H, 1997, ANNU REV NUTR, V17, P559, DOI 10.1146/annurev.nutr.17.1.559; Chinkes DL, 1996, AM J PHYSIOL-ENDOC M, V271, pE373, DOI 10.1152/ajpendo.1996.271.2.E373; FISCHER W, 1982, H-S Z PHYSIOL CHEM, V363, P375, DOI 10.1515/bchm2.1982.363.1.375; Hellerstein MK, 1999, AM J PHYSIOL-ENDOC M, V276, pE1146, DOI 10.1152/ajpendo.1999.276.6.E1146; HELLERSTEIN MK, 1993, AM J PHYSIOL, V265, pE814, DOI 10.1152/ajpendo.1993.265.5.E814; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; HELLERSTEIN MK, 1991, J CLIN INVEST, V87, P1841, DOI 10.1172/JCI115206; Hudgins LC, 1996, J CLIN INVEST, V97, P2081, DOI 10.1172/JCI118645; Jungermann K, 1996, ANNU REV NUTR, V16, P179, DOI 10.1146/annurev.nu.16.070196.001143; Kasumov T, 2002, ANAL BIOCHEM, V305, P90, DOI 10.1006/abio.2002.5639; KATZ N, 1989, EUR J BIOCHEM, V180, P185, DOI 10.1111/j.1432-1033.1989.tb14631.x; KATZ N, 1977, FEBS LETT, V83, P272, DOI 10.1016/0014-5793(77)81021-1; KATZ NR, 1983, EUR J BIOCHEM, V130, P297, DOI 10.1111/j.1432-1033.1983.tb07151.x; KATZ NR, 1983, EUR J BIOCHEM, V135, P103, DOI 10.1111/j.1432-1033.1983.tb07623.x; KELLEHER JK, 1992, AM J PHYSIOL, V262, pE118, DOI 10.1152/ajpendo.1992.262.1.E118; KELLEHER JK, 1995, ANN BIOMED ENG, V23, pS72; KNUDSEN CT, 1992, EUR J BIOCHEM, V204, P359, DOI 10.1111/j.1432-1033.1992.tb16644.x; Landau BR, 1996, J CLIN INVEST, V98, P378, DOI 10.1172/JCI118803; Landau BR, 1996, AM J PHYSIOL-ENDOC M, V271, pE1110, DOI 10.1152/ajpendo.1996.271.6.E1110; LANDAU BR, 1995, J CLIN INVEST, V95, P172, DOI 10.1172/JCI117635; LEE WNP, 1992, BIOL MASS SPECTROM, V21, P114, DOI 10.1002/bms.1200210210; Lee WNP, 1996, ADV EXP MED BIOL, V399, P95; LINN TC, 1981, ARCH BIOCHEM BIOPHYS, V209, P613, DOI 10.1016/0003-9861(81)90320-9; MIETHKE H, 1985, BIOL CHEM H-S, V366, P493, DOI 10.1515/bchm3.1985.366.1.493; Ostlund RE, 1996, J MASS SPECTROM, V31, P1291, DOI 10.1002/(SICI)1096-9888(199611)31:11<1291::AID-JMS424>3.0.CO;2-5; PREVIS SF, 1996, AM J PHYSL, V271; PUCH, 1999, AM J PHYSL, V277, pE1022; Reszko AE, 2001, ANAL BIOCHEM, V298, P69, DOI 10.1006/abio.2001.5349; ROSENBLATT J, 1992, AM J PHYSIOL, V263, pE584, DOI 10.1152/ajpendo.1992.263.3.E584; TISSEYRE B, 1995, BIOPROCESS ENG, V13, P113; TRUS M, 1980, J HISTOCHEM CYTOCHEM, V28, P579, DOI 10.1177/28.6.7391551; WEEKS G, 1969, J BACTERIOL, V97, P827, DOI 10.1128/JB.97.2.827-836.1969; Yang DW, 2000, AM J PHYSIOL-ENDOC M, V278, pE469, DOI 10.1152/ajpendo.2000.278.3.E469; Yang DW, 1998, ANAL BIOCHEM, V258, P315, DOI 10.1006/abio.1998.2632; Yang DW, 1999, J MASS SPECTROM, V34, P1130	41	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43217	43226		10.1074/jbc.M403837200	http://dx.doi.org/10.1074/jbc.M403837200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15284243	hybrid			2022-12-27	WOS:000224226400106
J	Ichimiya, T; Manya, H; Ohmae, Y; Yoshida, H; Takahashi, K; Ueda, R; Endo, T; Nishihara, S				Ichimiya, T; Manya, H; Ohmae, Y; Yoshida, H; Takahashi, K; Ueda, R; Endo, T; Nishihara, S			The twisted abdomen phenotype of Drosophila POMT1 and POMT2 mutants coincides with their heterophilic protein O-mannosyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; MANNOSYL-TRANSFERASE; GENE POMT1; GLYCOSYLATION; DYSTROGLYCAN; MELANOGASTER; MUTATIONS; FAMILY; OLIGOSACCHARIDES	Walker-Warburg syndrome, caused by mutations in protein O-mannosyltransferase-1 (POMT1), is an autosomal recessive disorder characterized by severe brain malformation, muscular dystrophy, and structural eye abnormalities. As humans have a second POMT, POMT2, we cloned each Drosophila ortholog of the human POMT genes and carried out RNA interference (RNAi) knockdown to investigate the function of these proteins in vivo. Drosophila POMT2 (dPOMT2) RNAi mutant flies showed a "twisted abdomen phenotype," in which the abdomen is twisted 30 - 60degrees, similar to the dPOMT1 mutant. Moreover, dPOMT2 interacted genetically with dPOMT1, suggesting that the dPOMTs function in collaboration with each other in vivo. We expressed dPOMTs in Sf21 cells and measured POMT activity. dPOMT2 transferred a mannose to the dystroglycan protein only when it was coexpressed with dPOMT1. Likewise, dPOMT1 showed POMT activity only when coexpressed with dPOMT2, and neither dPOMT showed any activity by itself. Each dPOMT RNAi fly totally reduced POMT activity, despite the specific reduction in the level of each dPOMT mRNA. The expression pattern of dPOMT2 mRNA was found to be similar to that of dPOMT1 mRNA using whole mount in situ hybridization. These results demonstrate that the two dPOMTs function as a protein O-mannosyltransferase in association with each other, in vitro and in vivo, to generate and maintain normal muscle development.	Soka Univ, Cell Biol Lab, Dept Bioinformat, Fac Engn, Tokyo 1928577, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Tokyo Metropolitan Inst Gerontol, Glycobiol Res Grp, Fdn Res Aging & Promot Human Welf, Itabashi Ku, Tokyo 1730015, Japan; Natl Inst Genet, Invertebrate Genet Lab, Shizuoka 4418540, Japan	Soka University; Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute of Gerontology; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Nishihara, S (corresponding author), Soka Univ, Cell Biol Lab, Dept Bioinformat, Fac Engn, 1-236 Tangi Cho, Tokyo 1928577, Japan.	shoko@t.soka.ac.jp		Nishihara, Shoko/0000-0002-1668-2603; Manya, Hiroshi/0000-0003-1573-9177				Beltran-Valero de Bernabe D, 2002, AM J HUM GENET, V71, P1033, DOI 10.1086/342975; Bourdineaud JP, 1998, MOL MICROBIOL, V27, P85, DOI 10.1046/j.1365-2958.1998.00660.x; BRIDGES CB, 1923, 3 CHROMOSOME GROUP M, P1; Chiba A, 1997, J BIOL CHEM, V272, P2156; DEMEREC M, 1942, GENE, V41, P190; Deng WM, 2003, DEVELOPMENT, V130, P173, DOI 10.1242/dev.00199; Ecker M, 2003, EMBO REP, V4, P628, DOI 10.1038/sj.embor.embor864; Endo T, 2003, BIOL PHARM BULL, V26, P1641, DOI 10.1248/bpb.26.1641; Endo T, 1999, BBA-GEN SUBJECTS, V1473, P237, DOI 10.1016/S0304-4165(99)00182-8; FINNE J, 1979, J BIOL CHEM, V254, P295; Girrbach V, 2003, J BIOL CHEM, V278, P12554, DOI 10.1074/jbc.M212582200; Girrbach V, 2000, J BIOL CHEM, V275, P19288, DOI 10.1074/jbc.M001771200; Harty C, 2001, MOL BIOL CELL, V12, P1093, DOI 10.1091/mbc.12.4.1093; Jurado LAP, 1999, GENOMICS, V58, P171, DOI 10.1006/geno.1999.5819; Kamiyama S, 2003, J BIOL CHEM, V278, P25958, DOI 10.1074/jbc.M302439200; Lommel M, 2004, MOL CELL BIOL, V24, P46, DOI 10.1128/MCB.24.1.46-57.2004; LUSSIER M, 1995, J BIOL CHEM, V270, P2770, DOI 10.1074/jbc.270.6.2770; Manya H, 2004, P NATL ACAD SCI USA, V101, P500, DOI 10.1073/pnas.0307228101; Manya H, 2003, BIOCHEM BIOPH RES CO, V306, P93, DOI 10.1016/S0006-291X(03)00924-0; MartinBlanco E, 1996, P NATL ACAD SCI USA, V93, P6048, DOI 10.1073/pnas.93.12.6048; Sanders SL, 1999, J CELL BIOL, V145, P1177, DOI 10.1083/jcb.145.6.1177; Sarkar M, 2001, BIOL CHEM, V382, P209, DOI 10.1515/BC.2001.028; Takahashi S, 2001, GLYCOBIOLOGY, V11, P37, DOI 10.1093/glycob/11.1.37; Takemae H, 2003, J BIOL CHEM, V278, P15571, DOI 10.1074/jbc.M301123200; Tsitilou SG, 2003, BIOCHEM BIOPH RES CO, V312, P1372, DOI 10.1016/j.bbrc.2003.11.059; Willer T, 2002, GLYCOBIOLOGY, V12, P771, DOI 10.1093/glycob/cwf086; Winder SJ, 2001, TRENDS BIOCHEM SCI, V26, P118, DOI 10.1016/S0968-0004(00)01731-X; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Zakrzewska A, 2003, CURR GENET, V43, P11, DOI 10.1007/s00294-003-0368-5	29	73	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42638	42647		10.1074/jbc.M404900200	http://dx.doi.org/10.1074/jbc.M404900200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15271988	hybrid			2022-12-27	WOS:000224226400037
J	Tosha, T; Yoshioka, S; Ishimori, K; Morishima, I				Tosha, T; Yoshioka, S; Ishimori, K; Morishima, I			L358P mutation on cytochrome P450cam simulates structural changes upon putidaredoxin binding - The structural changes trigger electron transfer to oxy-P450cam from electron donors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HEME PROXIMAL SITE; REDUCED PUTIDAREDOXIN; COMPLEX-FORMATION; CRYSTAL-STRUCTURE; SINGLE TURNOVER; P450(CAM); ROLES; HYDROXYLATION; P-450CAM	To investigate the functional and structural characterization of a crucial cytochrome P450cam ( P450cam)putidaredoxin (Pdx) complex, we utilized a mutant whose spectroscopic property corresponds to the properties of the wild type P450cam in the presence of Pdx. The H-1 NMR spectrum of the carbonmonoxy adduct of the mutant, the Leu- 358 --> Pro mutant (L358P), in the absence of Pdx showed that the ring current-shifted signals arising from D-camphor were upfield-shifted and observed as resolved signals, which are typical for the wild type enzyme in the presence of Pdx. Signals from the beta-proton of the axial cysteine and the gamma-methyl group of Thr-252 were also shifted upfield and downfield, respectively, in the L358P mutant as observed for Pdx-bound wild type P450cam. The close similarity in the NMR spectra suggests that the heme environment of the L358P mutant mimics that of the Pdx-bound enzyme. The functional analysis of the L358P mutant has revealed that the oxygen adduct of the L358P mutant can promote the oxygenation reaction for D-camphor with nonphysiological electron donors such as dithionite and ascorbic acid, showing that oxygenated L358P is "activated" to receive electron from the donor. Based on the structural and functional characterization of the L358P mutant, we conclude that the Pdx-induced structural changes in P450cam would facilitate the electron transfer from the electron donor, and the Pdx binding to P450cam would be a trigger for the electron transfer to oxygenated P450cam.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan	Kyoto University	Ishimori, K (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan.	koichiro@scl.kyoto-u.ac.jp; morisima@mds.moleng.kyoto-u.ac.jp	Ishimori, Koichiro/S-1247-2016; Ishimori, Koichiro/AAQ-4434-2021; Tosha, Takehiko/AAR-2404-2020	Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462; Tosha, Takehiko/0000-0002-8971-0759				Aoki M, 1998, INORG CHIM ACTA, V272, P80, DOI 10.1016/S0020-1693(97)05946-X; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BREWER CB, 1988, J BIOL CHEM, V263, P791; BREWER CB, 1986, ARCH BIOCHEM BIOPHYS, V249, P515, DOI 10.1016/0003-9861(86)90029-9; Case DA, 1995, J BIOMOL NMR, V6, P341; Davidson VL, 2002, BIOCHEMISTRY-US, V41, P14633, DOI 10.1021/bi026812k; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; Gunsalus I C, 1978, Methods Enzymol, V52, P166; Hishiki T, 2000, J BIOCHEM, V128, P965, DOI 10.1093/oxfordjournals.jbchem.a022848; JOHNSON CE, 1958, J CHEM PHYS, V29, P1012, DOI 10.1063/1.1744645; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Lian L. Y., 1993, NMR MACROMOLECULES P, P153; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; Makino R., 1984, Proceedings of the IXth International Conference on Raman Spectroscopy (papers in summary form only received), P492; Makino R., 1982, OXYGENASES OXYGEN ME, P467; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; Mouro C, 1999, FEBS LETT, V455, P302, DOI 10.1016/S0014-5793(99)00898-4; Mueller Ernest J., 1995, P83; Nagano S, 2003, BIOCHEMISTRY-US, V42, P14507, DOI 10.1021/bi035410p; Nagano S, 2004, J BIOL CHEM, V279, P42844, DOI 10.1074/jbc.M404217200; OGG RJ, 1994, J MAGN RESON SER B, V104, P1, DOI 10.1006/jmrb.1994.1048; Pochapsky SS, 2003, BIOCHEMISTRY-US, V42, P5649, DOI 10.1021/bi034263s; Poulos TL, 1996, J BIOL INORG CHEM, V1, P356, DOI 10.1007/s007750050064; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Shimada H, 1999, J BIOL CHEM, V274, P9363, DOI 10.1074/jbc.274.14.9363; SHIRO Y, 1989, J AM CHEM SOC, V111, P7707, DOI 10.1021/ja00202a007; Sjodin T, 2001, BIOCHEMISTRY-US, V40, P6852, DOI 10.1021/bi002510b; SLIGAR SG, 1974, BIOCHEM BIOPH RES CO, V61, P290, DOI 10.1016/0006-291X(74)90565-8; Sun DP, 2002, BIOCHEMISTRY-US, V41, P13926, DOI 10.1021/bi026654x; Tosha T, 2002, BIOCHEMISTRY-US, V41, P13883, DOI 10.1021/bi0261037; Tosha T, 2003, J BIOL CHEM, V278, P39809, DOI 10.1074/jbc.M304265200; Unno M, 1997, J AM CHEM SOC, V119, P6614, DOI 10.1021/ja963785a; Unno M, 2002, J BIOL CHEM, V277, P2547, DOI 10.1074/jbc.M108917200; Unno M, 1996, J BIOL CHEM, V271, P17869, DOI 10.1074/jbc.271.30.17869; Yoshioka S, 2002, J AM CHEM SOC, V124, P14571, DOI 10.1021/ja0265409; Yoshioka S, 2001, EUR J BIOCHEM, V268, P252, DOI 10.1046/j.1432-1033.2001.01872.x; Yoshioka S, 2000, J INORG BIOCHEM, V81, P141, DOI 10.1016/S0162-0134(00)00097-0; Yoshizawa K, 2001, J AM CHEM SOC, V123, P9806, DOI 10.1021/ja010593t	41	48	49	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42836	42843		10.1074/jbc.M404216200	http://dx.doi.org/10.1074/jbc.M404216200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15269211	hybrid			2022-12-27	WOS:000224226400060
J	Zhang, Z; Palzkill, T				Zhang, Z; Palzkill, T			Dissecting the protein-protein interface between beta-lactamase inhibitory protein and class A beta-lactamases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOT-SPOTS; BINDING-ENERGY; SWISS-MODEL; RESIDUES; POTENT; SITE; IDENTIFICATION; DISPLAY; SURFACE; DESIGN	beta-Lactamase inhibitory protein ( BLIP) binds and inhibits a diverse collection of class A beta-lactamases at a wide range of affinities. Alanine-scanning mutagenesis was previously performed to identify the amino acid sequence requirements of BLIP for inhibiting TEM-1 beta-lactamase and SME-1 beta-lactamase. Two hotspots of binding energy, one from each domain of BLIP, were identified (Zhang, Z., and Palzkill, T. ( 2003) J. Biol. Chem. 278, 45706 - 45712). This study has been extended to examine the amino acid sequence requirements of BLIP for binding to the SHV-1 beta-lactamase, which is a poor binding substrate (K-i = 1.1 muM), and the Bacillus anthracis Bla1 enzyme (K-i = 2.5 nM). The two hotspots previously identified as important for binding TEM-1 and SME-1 beta-lactamase were also found to be important for binding Bla1. The hotspot from the second domain of BLIP, however, does not make substantial contributions to SHV-1 binding. This may explain why BLIP binds to SHV-1 beta-lactamase with much weaker affinity than to the other three enzymes. Three regions, including two loops that insert into the active pocket of TEM-1 beta-lactamase and the Glu-73 - Lys-74 buried charge motif, exhibit strikingly different effects on the binding affinity of BLIP toward the various enzymes when mutated and, therefore, act as specificity determinants. Analysis of double mutants of BLIP that combine specificity-determining residues suggests that these residues contribute to the poor affinity between the second domain of BLIP and SHV-1 beta-lactamase.	Baylor Coll Med, Dept Mol Virol & Microbiol, Struct & Computat Biol & Mol Biophys Program, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Palzkill, T (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Struct & Computat Biol & Mol Biophys Program, 1 Baylor Plaza, Houston, TX 77030 USA.	timothyp@bcm.tmc.edu			NIAID NIH HHS [AI32956] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032956, R37AI032956] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; Albeck S, 1999, BIOCHEMISTRY-US, V38, P11, DOI 10.1021/bi981772z; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Chakrabarti P, 2002, PROTEINS, V47, P334, DOI 10.1002/prot.10085; Chen YH, 2003, J BACTERIOL, V185, P823, DOI 10.1128/JB.185.3.823-830.2003; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; DENNIS MS, 1994, J BIOL CHEM, V269, P22137; DORAN JL, 1990, J BACTERIOL, V172, P4909, DOI 10.1128/jb.172.9.4909-4918.1990; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu ZJ, 2000, PROTEINS, V39, P331, DOI 10.1002/(SICI)1097-0134(20000601)39:4<331::AID-PROT60>3.0.CO;2-A; Huang WZ, 1998, ANTIMICROB AGENTS CH, V42, P2893, DOI 10.1128/AAC.42.11.2893; Huang WZ, 2000, J BIOL CHEM, V275, P14964, DOI 10.1074/jbc.M001285200; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; Jones S, 1997, J MOL BIOL, V272, P121, DOI 10.1006/jmbi.1997.1234; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kortemme T, 2002, P NATL ACAD SCI USA, V99, P14116, DOI 10.1073/pnas.202485799; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuzin AP, 1999, BIOCHEMISTRY-US, V38, P5720, DOI 10.1021/bi990136d; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Ma BY, 2003, P NATL ACAD SCI USA, V100, P5772, DOI 10.1073/pnas.1030237100; Materon IC, 2003, ANTIMICROB AGENTS CH, V47, P2040, DOI 10.1128/AAC.47.6.2040-2042.2003; NUSS JM, 1993, PROTEINS, V15, P121, DOI 10.1002/prot.340150204; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Petrosino J, 1999, J BIOL CHEM, V274, P2394, DOI 10.1074/jbc.274.4.2394; Queenan AM, 2000, ANTIMICROB AGENTS CH, V44, P3035, DOI 10.1128/AAC.44.11.3035-3039.2000; Rudgers GW, 1999, J BIOL CHEM, V274, P6963, DOI 10.1074/jbc.274.11.6963; Rudgers GW, 2001, PROTEIN ENG, V14, P487, DOI 10.1093/protein/14.7.487; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; Sougakoff W, 2002, ACTA CRYSTALLOGR D, V58, P267, DOI 10.1107/S0907444901019606; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P290, DOI 10.1038/nsb0396-290; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Teufel DP, 2003, BIOCHEMISTRY-US, V42, P1451, DOI 10.1021/bi026852o; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsai CJ, 1997, PROTEIN SCI, V6, P53; Tzouvelekis LS, 1999, CURR PHARM DESIGN, V5, P847; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; Zhang Z, 2003, J BIOL CHEM, V278, P45706, DOI 10.1074/jbc.M308572200	44	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42860	42866		10.1074/jbc.M406157200	http://dx.doi.org/10.1074/jbc.M406157200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15284234	hybrid			2022-12-27	WOS:000224226400063
J	Cho, KA; Ryu, SJ; Oh, YS; Park, JH; Lee, JW; Kim, HP; Kim, KT; Jang, IS; Park, SC				Cho, KA; Ryu, SJ; Oh, YS; Park, JH; Lee, JW; Kim, HP; Kim, KT; Jang, IS; Park, SC			Morphological adjustment of senescent cells by modulating caveolin-1 status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; RHO-FAMILY GTPASES; ACTIN CYTOSKELETON; TYROSINE PHOSPHORYLATION; REPLICATIVE SENESCENCE; REGULATES TYROSINE; UROKINASE RECEPTOR; PROTEIN; EXPRESSION; ACTIVATION	Morphological change is one of the cardinal features of the senescent phenotype; for example, senescent human diploid cells have a flat large shape. However, the mechanisms underlying such senescence-related morphological alterations have not been well studied. To investigate this situation, we characterized the senescence-dependent changes of cellular structural determinants in terms of their levels and activities. These determinants included integrins, focal adhesion complexes, and small Rho GTPases, and special emphasis was placed on their relationships with caveolin-1 status. We observed that the expression integrin beta(1) and focal adhesion kinase (FAK) were increased and that the phosphorylations of FAK and paxillin, hallmarks of focal adhesion formation, were also increased in senescent human diploid fibroblast cells. Moreover, the Rho GTPases Rac1 and Cdc42 were found to be highly activated in senescent cells. In addition, focal adhesion complexes and Rho GTPases were up-regulated in the caveolin-rich membrane domain in the senescent cells. Activated Rac1 and Cdc42 directly interacted with caveolin-1 in senescent cells. Interestingly, caveolin-1 knock-out senescent cells, achieved by using small interfering RNA and antisense oligonucleotide, showed disrupted focal adhesion formation and actin stress fibers via the inactivation of FAK, which resulted in morphological adjustment to the young cell-like small spindle shape. Based on the results obtained, we propose that caveolin-1 plays an important role in senescence-associated morphological changes by regulating focal adhesion kinase activity and actin stress fiber formation in the senescent cells.	Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Aging & Apoptosis Res Ctr, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Park, SC (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Aging & Apoptosis Res Ctr, 28 Yungon Dong, Seoul 110799, South Korea.	scpark@snu.ac.kr	Lee, Jung Weon/F-9149-2012; Lee, Jung Weon/AAC-1146-2020	Lee, Jung Weon/0000-0003-2722-8200				BARRY ST, 1994, J CELL SCI, V107, P2033; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; Chen QM, 2000, J CELL SCI, V113, P4087; Cho KA, 2003, J BIOL CHEM, V278, P27789, DOI 10.1074/jbc.M208105200; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hayflick L, 1985, Clin Geriatr Med, V1, P15; Kolyada AY, 2003, AM J PHYSIOL-CELL PH, V285, pC1116, DOI 10.1152/ajpcell.00177.2003; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LINSKENS MHK, 1995, SCIENCE, V267, P17, DOI 10.1126/science.7848496; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Panetti TS, 2002, FRONT BIOSCI-LANDMRK, V7, pD143, DOI 10.2741/panetti; Park SC, 2002, ANN NY ACAD SCI, V959, P45, DOI 10.1111/j.1749-6632.2002.tb02081.x; Park WY, 2000, J BIOL CHEM, V275, P20847, DOI 10.1074/jbc.M908162199; Park WY, 2001, ANN NY ACAD SCI, V928, P79; Razani B, 2000, BIOCHEMISTRY-US, V39, P13916, DOI 10.1021/bi001489b; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; Sieg DJ, 1999, J CELL SCI, V112, P2677; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Teixeira A, 1999, J NEUROCHEM, V72, P120, DOI 10.1046/j.1471-4159.1999.0720120.x; Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285	34	140	145	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42270	42278		10.1074/jbc.M402352200	http://dx.doi.org/10.1074/jbc.M402352200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15263006	hybrid			2022-12-27	WOS:000224075500119
J	Crowder, RJ; Enomoto, H; Yang, M; Johnson, EM; Milbrandt, J				Crowder, RJ; Enomoto, H; Yang, M; Johnson, EM; Milbrandt, J			Dok-6, a novel p62 Dok family member, promotes Ret-mediated neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; ENTERIC NERVOUS-SYSTEM; MICE LACKING GDNF; NEUROTROPHIC FACTOR; CELL-LINE; PHOSPHATIDYLINOSITOL 3-KINASE; DOCKING SITE; AUTOPHOSPHORYLATION SITES; NEURONAL DIFFERENTIATION; MEMBRANE RECRUITMENT	Activation of Ret, the receptor-tyrosine kinase for the glial cell line-derived neurotrophic factor ( GDNF) family ligands (GFLs), results in the recruitment and assembly of adaptor protein complexes that function to transduce signals downstream of the receptor. Here we identify Dok-6, a novel member of the Dok-4/5 subclass of the p62 Dok family of intracellular adaptor molecules, and characterize its interaction with Ret. Expression analysis reveals that Dok-6 is highly expressed in the developing central nervous system and is co-expressed with Ret in several locations, including sympathetic, sensory, and parasympathetic ganglia, as well as in the ureteric buds of the developing kidneys. Pull-down assays using the Dok-6 phosphotyrosine binding (PTB) domain and GDNF-activated Ret indicate that Dok-6 binds to the phosphorylated Ret Tyr(1062) residue. Moreover, ligand activation of Ret resulted in phosphorylation of tyrosine residue(s) located within the unique C terminus of Dok-6 predominantly through a Src-dependent mechanism, indicating that Dok-6 is a substrate of the Ret-Src signaling pathway. Interestingly, expression of Dok-6 potentiated GDNF-induced neurite outgrowth in GDNF family receptor alpha1 (GFRalpha1)-expressing Neuro2A cells that was dependent upon the C-terminal residues of Dok-6. Taken together, these data identify Dok-6 as a novel Dok-4/5-related adaptor molecule that may function in vivo to transduce signals that regulate Ret-mediated processes such as axonal projection.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol & Mol Biol & Pharmacol, St Louis, MO 63110 USA; RIKEN Ctr Dev Biol, Lab Neuronal Differentiat & Regenerat, Chuo Ku, Kobe, Hyogo 6500047, Japan	Washington University (WUSTL); Washington University (WUSTL); RIKEN	Milbrandt, J (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	jeff@pathbox.wustl.edu		Milbrandt, Jeffrey/0000-0002-5477-7689	NIA NIH HHS [AG13730] Funding Source: Medline; NIDDK NIH HHS [T32-DK07296] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013730] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Baloh RH, 2000, J BIOL CHEM, V275, P3412, DOI 10.1074/jbc.275.5.3412; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Cai DS, 2003, J BIOL CHEM, V278, P25323, DOI 10.1074/jbc.M212430200; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Cong F, 1999, MOL CELL BIOL, V19, P8314; Coulpier M, 2002, J BIOL CHEM, V277, P1991, DOI 10.1074/jbc.M107992200; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; ENCINAS M, 2004, J BIOL CHEM; Enomoto H, 2000, DEVELOPMENT, V127, P4877; Enomoto H, 2001, DEVELOPMENT, V128, P3963; Enomoto H, 1998, NEURON, V21, P317, DOI 10.1016/S0896-6273(00)80541-3; Favre C, 2003, GENES IMMUN, V4, P40, DOI 10.1038/sj.gene.6363891; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Gugasyan R, 2002, J CELL BIOL, V158, P115, DOI 10.1083/jcb.200112066; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Honma Y, 2002, NEURON, V35, P267, DOI 10.1016/S0896-6273(02)00774-2; Hosooka T, 2001, MOL CELL BIOL, V21, P5437, DOI 10.1128/MCB.21.16.5437-5446.2001; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lee SL, 1996, MOL CELL BIOL, V16, P4566; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Liang XQ, 2002, J BIOL CHEM, V277, P13732, DOI 10.1074/jbc.M200277200; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Master Z, 2001, EMBO J, V20, P5919, DOI 10.1093/emboj/20.21.5919; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Murakami H, 2002, J BIOL CHEM, V277, P32781, DOI 10.1074/jbc.M202336200; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Rice DS, 1998, DEVELOPMENT, V125, P3719; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schlessinger Joseph, 2003, Sci STKE, V2003, pRE12, DOI 10.1126/stke.2003.191.re12; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; Suzu S, 2000, EMBO J, V19, P5114, DOI 10.1093/emboj/19.19.5114; TAHIRA T, 1990, ONCOGENE, V5, P97; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; Wick MJ, 2001, J BIOL CHEM, V276, P42843, DOI 10.1074/jbc.M102116200; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8; Zhao MM, 2001, J EXP MED, V194, P265, DOI 10.1084/jem.194.3.265; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	75	80	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42072	42081		10.1074/jbc.M403726200	http://dx.doi.org/10.1074/jbc.M403726200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15286081	hybrid			2022-12-27	WOS:000224075500100
J	Huang, CL; Cheng, JC; Liao, CH; Stern, A; Hsieh, JT; Wang, CH; Hsu, HL; Tseng, CP				Huang, CL; Cheng, JC; Liao, CH; Stern, A; Hsieh, JT; Wang, CH; Hsu, HL; Tseng, CP			Disabled-2 is a negative regulator of integrin alpha(IIb)beta(3)-mediated fibrinogen adhesion and cell signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSIDE-OUT; LINKED KINASE; OUTSIDE-IN; PLATELET; PHOSPHORYLATION; BINDING; DOMAIN; PROTEIN; MECHANISM; ALPHA-IIB-BETA-3	(D) under bar is (ab) under bar led-(2) under bar ( DAB2) is an adapter protein that is up-regulated during megakaryocytic differentiation of hematopoietic cells and is abundantly expressed in platelets. In this study, the role of DAB2 in integrin alpha(IIb)beta(3)-mediated matrix protein fibrinogen adhesion and cell signaling was investigated. In K562 cells differentiating to the megakaryocytic lineage, down-regulation of DAB2 by DAB2 small interfering RNA augmented integrin alpha(IIb)beta(3) activation and resulted in an increase in cell adhesion to fibrinogen. Ectopic expression of DAB2 reversed the DAB2 small interfering RNA effect or, by itself, decreased fibrinogen adhesion of K562 cells. Mutational analysis revealed that a DAB2 Ser(24) phosphorylation mutant (S24A) abrogated the inhibitory function of DAB2. The spatial and temporal association/interaction of DAB2 and platelet integrin alpha(IIb)beta(3) (CD61) in both megakaryocytic cells and platelets led us to examine the effect of Ser(24) phosphorylation on the interaction between DAB2 and integrin beta(3). Through cellular localization and co-immunoprecipitation analysis, we demonstrate for the first time that Ser(24) phosphorylation promotes membrane translocation of DAB2 and its subsequent interaction with integrin beta(3), thereby defining a mechanism for DAB2 in regulating integrin alpha(IIb)beta(3) activation and inside-out signaling. Consistent with the effect on fibrinogen adhesion, Ser(24) phosphorylation of DAB2 was also involved in the negative regulation of alpha(IIb)beta(3)-induced T cell factor transcriptional activity. In contrast, the S24A mutant acted like wild-type DAB2 and inhibited both beta-catenin- and plakoglobin-mediated T cell factor transactivation. Hence, DAB2 elicits distinct regulatory mechanisms in alpha(IIb)beta(3) and beta-catenin/plakoglobin signaling in a Ser(24) phosphorylation-dependent and -independent manner, respectively. These findings indicate Ser(24) phosphorylation as a molecular basis for DAB2 acting as a negative regulator in alpha(IIb)beta(3) inside-out signaling and contribute to our understanding of DAB2 in megakaryocytic differentiation and platelet function.	Chang Gung Univ, Grad Inst Med Biotechnol, Tao Yuan 333, Taiwan; Chang Gung Univ, Grad Inst Nat Prod, Tao Yuan 333, Taiwan; China Med Univ, Dept Med Technol, Taichung 404, Taiwan; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75390 USA; Kaohsiung Med Univ, Fac Biotechnol, Kaohsiung 807, Taiwan	Chang Gung University; Chang Gung University; China Medical University Taiwan; New York University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Kaohsiung Medical University	Tseng, CP (corresponding author), Chang Gung Univ, Grad Inst Med Biotechnol, 259 Wen Hwai 1st Rd, Tao Yuan 333, Taiwan.	ctseng@mail.cgu.edu.tw	Wang, Chi-Huei/C-9655-2009	TSENG, CHING-PING/0000-0002-2587-210X; HUANG, Chien-Ling/0000-0002-6396-5649; Liao, Hsiang-Ruei/0000-0003-0843-4375				Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Calvete JJ, 1999, P SOC EXP BIOL MED, V222, P29, DOI 10.1111/j.1525-1373.1999.09993.x; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; Geum D, 2002, J BIOL CHEM, V277, P19913, DOI 10.1074/jbc.M104396200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; He JQ, 2003, ONCOGENE, V22, P4524, DOI 10.1038/sj.onc.1206767; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Huang Y, 2001, LAB INVEST, V81, P863, DOI 10.1038/labinvest.3780295; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kalinichenko VV, 2002, J BIOL CHEM, V277, P12369, DOI 10.1074/jbc.M112162200; Kleeff J, 2002, DIS COLON RECTUM, V45, P1242, DOI 10.1007/s10350-004-6399-2; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2002, EMBO J, V21, P1555, DOI 10.1093/emboj/21.7.1555; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Motegi S, 2003, EMBO J, V22, P2634, DOI 10.1093/emboj/cdg278; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Pasquet JM, 2002, THROMB HAEMOSTASIS, V88, P115; Phillips DR, 2001, THROMB HAEMOSTASIS, V86, P246; Racke FK, 2001, J BIOL CHEM, V276, P522, DOI 10.1074/jbc.M005236200; Rosenbauer F, 2002, EMBO J, V21, P211, DOI 10.1093/emboj/21.3.211; SCHLAEPFER DD, 1994, NATURE, V372, P786; Shattil SJ, 1999, THROMB HAEMOSTASIS, V82, P318; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Shikata Y, 2003, FASEB J, V17, P2240, DOI 10.1096/fj.03-0198com; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447; TAUB R, 1989, J BIOL CHEM, V264, P259; Tseng CC, 2000, FEBS LETT, V475, P232, DOI 10.1016/S0014-5793(00)01700-2; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; Tseng CP, 2003, FEBS LETT, V541, P21, DOI 10.1016/S0014-5793(03)00281-3; Tseng CP, 2001, BIOCHEM BIOPH RES CO, V285, P129, DOI 10.1006/bbrc.2001.5133; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Wohn KD, 1999, BRIT J HAEMATOL, V104, P901, DOI 10.1046/j.1365-2141.1999.01242.x; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Yang DH, 2002, DEV BIOL, V251, P27, DOI 10.1006/dbio.2002.0810; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200	46	43	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42279	42289		10.1074/jbc.M402540200	http://dx.doi.org/10.1074/jbc.M402540200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280374	hybrid			2022-12-27	WOS:000224075500120
J	Sobczak, K; Krzyzosiak, WJ				Sobczak, K; Krzyzosiak, WJ			Imperfect CAG repeats form diverse structures in SCA1 transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYGLUTAMINE-INDUCED DISEASE; DEPENDENT PROTEIN-KINASE; FRAGILE-X PREMUTATION; RNA DOUBLE HELIX; TRINUCLEOTIDE REPEATS; TRIPLET REPEATS; BASE-PAIRS; ATAXIN-1; INTERRUPTIONS; NEURODEGENERATION	The expanded CAG repeat in the coding sequence of the spinocerebellar ataxia type 1 (SCA1) gene is responsible for SCA1, one of the hereditary human neurodegenerative diseases. In the normal SCA1 alleles usually 1 - 3 CAT triplets break the continuity of the CAG repeat tracts. Here we show what is the structural role of the CAU interruptions in the SCA1 transcripts. Depending on their number and localization within the repeat tract the interruptions either enlarge the terminal loop of the hairpin formed by the repeats, nucleate the internal loops in its stem structure, or force the repeats to fold into two smaller hairpins. Thus, the interruptions destabilize the CAG repeat hairpin, which is likely to decrease its ability to participate in the putative RNA pathogenesis mechanism driven by the long CAG repeat hairpins.	Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, PL-61704 Poznan, Poland	Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Krzyzosiak, WJ (corresponding author), Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, Noskowskiego 12-14, PL-61704 Poznan, Poland.	wlodkrzy@ibch.poznan.pl		Sobczak, Krzysztof/0000-0001-8352-9812				Antal M, 2002, NUCLEIC ACIDS RES, V30, P912, DOI 10.1093/nar/30.4.912; BAEYENS KJ, 1995, NAT STRUCT BIOL, V2, P56, DOI 10.1038/nsb0195-56; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; Bowater RP, 2001, PROG NUCLEIC ACID RE, V66, P159; Broude NE, 2003, EXPERT REV MOL DIAGN, V3, P269, DOI 10.1586/14737159.3.3.269; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; Ciesiolka J, 1998, J MOL BIOL, V275, P211, DOI 10.1006/jmbi.1997.1462; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Doktycz MJ, 1998, P NATL ACAD SCI USA, V95, P14614, DOI 10.1073/pnas.95.25.14614; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; GACY AM, 1995, CELL, V81, P533; GIEGE R, 2001, RNA, P71; GORNICKI P, 1989, J BIOMOL STRUCT DYN, V6, P971, DOI 10.1080/07391102.1989.10506525; Hagerman PJ, 2004, AM J HUM GENET, V74, P805, DOI 10.1086/386296; Jasinska A, 2003, NUCLEIC ACIDS RES, V31, P5463, DOI 10.1093/nar/gkg767; Jin P, 2003, NEURON, V39, P739, DOI 10.1016/S0896-6273(03)00533-6; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KRZYZOSIAK WJ, 1988, BIOCHEMISTRY-US, V27, P5771, DOI 10.1021/bi00415a056; Lima WF, 1997, J BIOL CHEM, V272, P18191, DOI 10.1074/jbc.272.29.18191; Lima WF, 1997, J BIOL CHEM, V272, P27513, DOI 10.1074/jbc.272.44.27513; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Matsuyama Z, 1999, J MED GENET, V36, P546; McLaughlin BA, 1996, AM J HUM GENET, V59, P561; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; Napierala M, 1997, J BIOL CHEM, V272, P31079, DOI 10.1074/jbc.272.49.31079; Okazawa H, 2002, NEURON, V34, P701, DOI 10.1016/S0896-6273(02)00697-9; Orr HT, 2004, TRENDS NEUROSCI, V27, P233, DOI 10.1016/j.tins.2004.03.003; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Orr HT, 2001, GENE DEV, V15, P925, DOI 10.1101/gad.888401; Orr HT, 2000, NEUROBIOL DIS, V7, P129, DOI 10.1006/nbdi.2000.0305; Pearson CE, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P585; Pearson CE, 1998, BIOCHEMISTRY-US, V37, P2701, DOI 10.1021/bi972546c; Peel AL, 2001, HUM MOL GENET, V10, P1531, DOI 10.1093/hmg/10.15.1531; Richards RI, 1997, TRENDS BIOCHEM SCI, V22, P432, DOI 10.1016/S0968-0004(97)01108-0; Rolfsmeier ML, 2000, MOL CELL BIOL, V20, P173, DOI 10.1128/MCB.20.1.173-180.2000; Sambrook J., 2001, MOL CLONING; Schneider C, 2001, J MOL BIOL, V305, P659, DOI 10.1006/jmbi.2000.4338; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Sobczak K, 2004, HUM MUTAT, V24, P236, DOI 10.1002/humu.20075; Sobczak K, 2003, NUCLEIC ACIDS RES, V31, P5469, DOI 10.1093/nar/gkg766; Tanaka Y, 1999, NUCLEIC ACIDS RES, V27, P949, DOI 10.1093/nar/27.4.949; Tapscott SJ, 2001, SCIENCE, V293, P816, DOI 10.1126/science.1063517; Tian B, 2000, RNA, V6, P79, DOI 10.1017/S1355838200991544; Waldsich C, 2002, EMBO J, V21, P5281, DOI 10.1093/emboj/cdf504; Waldsich C, 2002, GENE DEV, V16, P2300, DOI 10.1101/gad.231302; Wrzesinski J, 2000, NUCLEIC ACIDS RES, V28, P1785, DOI 10.1093/nar/28.8.1785	49	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41563	41572		10.1074/jbc.M405130200	http://dx.doi.org/10.1074/jbc.M405130200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292212	hybrid			2022-12-27	WOS:000224075500040
J	Lallemand-Breitenbach, V; Quesnoit, M; Braun, V; El Marjou, A; Pous, C; Goud, B; Perez, F				Lallemand-Breitenbach, V; Quesnoit, M; Braun, V; El Marjou, A; Pous, C; Goud, B; Perez, F			CLIPR-59 is a lipid raft-associated protein containing a cytoskeleton-associated protein glycine-rich domain (CAP-Gly) that perturbs microtubule dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC LINKER PROTEIN; TRANS-GOLGI NETWORK; PLASMA-MEMBRANE; DROSOPHILA-MELANOGASTER; ENDOPLASMIC-RETICULUM; CYSTEINE RESIDUES; BINDING PROTEIN; CELL-MEMBRANES; PLUS ENDS; IN-VIVO	We recently have identified a new cytoplasmic linker protein (CLIP), CLIPR-59, which is involved in the regulation of early endosome/trans-Golgi network dynamics. In contrast with CLIP-170, CLIPR-59 is not localized to microtubules at steady state but is associated with the trans-Golgi network and the plasma membrane. Here we show that the last 30 amino acids (C30) are sufficient for membrane targeting and that two cysteines in the C30 domain are palmitoylated. We demonstrate that CLIPR-59 is associated with lipid rafts via its C-terminal palmitoylated domain. In vitro experiments suggest that CLIPR-59 and its microtubule-binding domain alone have a better affinity for unpolymerized tubulin or small oligomers than for microtubules. In contrast with the CLIP-170 microtubule-binding domain, the CLIPR-59 microtubule-binding domain diminishes microtubule regrowth after nocodazole washout in vivo, showing that this domain can prevent microtubule polymerization. In contrast with the role of linker between membranes and microtubules that was proposed for CLIP function, CLIPR-59 thus may have an "anti-CLIP" function by preventing microtubule-raft interactions.	Inst Curie, Sect Rech, CNRS, Unite Mixte Rech 144, F-75248 Paris 05, France; Univ Paris Sud, Fac Pharm, Equipe Accueil Doctorale 1595, F-92296 Chatenay Malabry, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Sorbonne Universite; UDICE-French Research Universities; Universite Paris Saclay	Perez, F (corresponding author), Inst Curie, Sect Rech, CNRS, Unite Mixte Rech 144, F-75248 Paris 05, France.	franck.perez@curie.fr	POÜS, Christian/R-5089-2018; Goud, Bruno/GWC-4807-2022; Perez, Franck/A-1558-2014	POUS, Christian/0000-0002-2502-7854; Lallemand, Valerie/0000-0001-9852-204X; Perez, Franck/0000-0002-9129-9401				Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Choi JH, 2002, EMBO REP, V3, P988, DOI 10.1093/embo-reports/kvf197; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; De Zeeuw CI, 1997, NEURON, V19, P1187, DOI 10.1016/S0896-6273(00)80411-0; Diamantopoulos GS, 1999, J CELL BIOL, V144, P99, DOI 10.1083/jcb.144.1.99; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Falguieres T, 2001, MOL BIOL CELL, V12, P2453, DOI 10.1091/mbc.12.8.2453; Feierbach B, 1999, J CELL BIOL, V144, P113, DOI 10.1083/jcb.144.1.113; Fivaz M, 2002, EMBO J, V21, P3989, DOI 10.1093/emboj/cdf398; Gavet O, 1998, J CELL SCI, V111, P3333; Gonzalo S, 1999, J BIOL CHEM, V274, P21313, DOI 10.1074/jbc.274.30.21313; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; Holmfeldt P, 2003, MOL BIOL CELL, V14, P3716, DOI 10.1091/mbc.E03-03-0126; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; Hoogenraad CC, 2000, J CELL SCI, V113, P2285; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; Infante C, 1999, J CELL BIOL, V145, P83, DOI 10.1083/jcb.145.1.83; Klopfenstein DR, 2001, J CELL BIOL, V153, P1287, DOI 10.1083/jcb.153.6.1287; Komarova YA, 2002, J CELL BIOL, V159, P589, DOI 10.1083/jcb.200208058; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lutjens R, 2000, EUR J NEUROSCI, V12, P2224, DOI 10.1046/j.1460-9568.2000.00112.x; Maekawa S, 2001, J BIOCHEM-TOKYO, V129, P691, DOI 10.1093/oxfordjournals.jbchem.a002908; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; Noda Y, 2001, J CELL BIOL, V155, P77, DOI 10.1083/jcb.200108042; Perez F, 2002, J CELL BIOL, V156, P631, DOI 10.1083/jcb.200111003; PIERRE P, 1994, J CELL SCI, V107, P1909; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; Rickard JE, 1996, TRENDS CELL BIOL, V6, P178, DOI 10.1016/0962-8924(96)10017-9; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Scheel J, 1999, J BIOL CHEM, V274, P25883, DOI 10.1074/jbc.274.36.25883; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sisson JC, 2000, J CELL BIOL, V151, P905, DOI 10.1083/jcb.151.4.905; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SWAROOP A, 1987, P NATL ACAD SCI USA, V84, P6501, DOI 10.1073/pnas.84.18.6501; Thiemann M, 2000, EUR J BIOCHEM, V267, P6264, DOI 10.1046/j.1432-1327.2000.01713.x; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; Vaughan PS, 2002, J CELL BIOL, V158, P305, DOI 10.1083/jcb.200201029; Washbourne P, 2001, BIOCHEM J, V357, P625, DOI 10.1042/0264-6021:3570625; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261	51	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41168	41178		10.1074/jbc.M406482200	http://dx.doi.org/10.1074/jbc.M406482200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262990	hybrid			2022-12-27	WOS:000223916800116
J	Lye, E; Mirtsos, C; Suzuki, N; Suzuki, S; Yeh, WC				Lye, E; Mirtsos, C; Suzuki, N; Suzuki, S; Yeh, WC			The role of interleukin 1 receptor-associated kinase-4 (IRAK-4) kinase activity in IRAK-4-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; BACTERIAL-INFECTIONS; MICE LACKING; KAPPA-B; FAMILY; ACTIVATION; PATHWAY; ADAPTER; INNATE; MEMBER	Interleukin 1 receptor (IL-1R)-associated kinase-4 (IRAK-4) is required for various responses induced by IL-1R and Toll-like receptor signals. However, the molecular mechanism of IRAK-4 signaling and the role of its kinase activity have remained elusive. In this report, we demonstrate that IRAK-4 is recruited to the IL-1R complex upon IL-1 stimulation and is required for the recruitment of IRAK-1 and its subsequent activation/degradation. By reconstituting IRAK-4-deficient cells with wild type or kinase-inactive IRAK-4, we show that the kinase activity of IRAK-4 is required for the optimal transduction of IL-1-induced signals, including the activation of IRAK-1, NF-kappaB, and JNK, and the maximal induction of inflammatory cytokines. Interestingly, we also discover that the IRAK-4 kinase-inactive mutant is still capable of mediating some signals. These results suggest that IRAK-4 is an integral part of the IL-1R signaling cascade and is capable of transmitting signals both dependent on and independent of its kinase activity.	Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Adv Med Discovery Inst, Univ Hlth Network, Toronto, ON M5G 2C1, Canada; RIKEN, Res Ctr Allergy & Immunol, Tsurumi Ku, Kanagawa 2300045, Japan	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; RIKEN	Yeh, WC (corresponding author), Univ Toronto, Dept Med Biophys, 620 Univ Ave 706, Toronto, ON M5G 2C1, Canada.	wyeh@uhnres.utoronto.ca						Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Akira S, 2000, J ENDOTOXIN RES, V6, P383, DOI 10.1177/09680519000060050901; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Burns K, 2003, J EXP MED, V197, P263, DOI 10.1084/jem.20021790; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kollewe C, 2004, J BIOL CHEM, V279, P5227, DOI 10.1074/jbc.M309251200; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; Medvedev AE, 2003, J EXP MED, V198, P521, DOI 10.1084/jem.20030701; Morse D, 2003, J BIOL CHEM, V278, P36993, DOI 10.1074/jbc.M302942200; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Qin JZ, 2004, J BIOL CHEM, V279, P26748, DOI 10.1074/jbc.M400785200; Suzuki N, 2003, J IMMUNOL, V171, P6065, DOI 10.4049/jimmunol.171.11.6065; Suzuki N, 2003, J IMMUNOL, V170, P4031, DOI 10.4049/jimmunol.170.8.4031; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Thomas JA, 1999, J IMMUNOL, V163, P978; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986	37	103	125	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40653	40658		10.1074/jbc.M402666200	http://dx.doi.org/10.1074/jbc.M402666200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15292196	hybrid			2022-12-27	WOS:000223916800055
J	Makhov, AM; Subramanian, D; Holley-Guthrie, E; Kenney, SC; Griffith, JD				Makhov, AM; Subramanian, D; Holley-Guthrie, E; Kenney, SC; Griffith, JD			The Epstein-Barr virus polymerase accessory factor BMRF1 adopts a ring-shaped structure as visualized by electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; PROCESSIVITY FACTOR; LYTIC ORIGIN; IN-VITRO; DOWNSTREAM COMPONENT; CATALYTIC SUBUNIT; PROTEIN-KINASE; EA-D; REPLICATION; ORILYT	Epstein-Barr virus (EBV) encodes a set of core replication factors used during lytic infection in human cells that parallels the factors used in many other systems. These include a DNA polymerase and its accessory factor, a helicase/primase, and a single strand binding protein. The EBV polymerase accessory factor has been identified as the product of the BMRF1 gene and has been shown by functional assays to increase the activity and processivity of the polymerase. Unlike other members of this class of factors, BMRF1 is also a transcription factor regulating certain EBV genes. Although several polymerase accessory factors, including eukaryotic proliferating cell nuclear antigen, Escherichia coli beta protein, and T4 gene 45 protein have been shown to form oligomeric rings termed sliding clamps, nothing is known about the oligomeric state of BMRF1 or whether it forms a ring. In this work, BMRF1 was purified directly from human cells infected with an adenovirus vector expressing the BMRF1 gene product. The protein was purified to near homogeneity, and examination by negative staining electron microscopy revealed large, flat, ring-shaped molecules with a diameter of 15.5 +/- 0.8 nm and a distinct 5.3-nm diameter hole in the center. The size of these rings is consistent with an oligomer of 6 monomers, nearly twice as large as the trimeric proliferating cell nuclear antigen ring. Unlike the herpes simplex virus UL42 homologue, BMRF1 was found to self-associate in solution. These findings extend the theme of polymerase accessory factors adopting ring-shaped structures and provide an example in which the ring is significantly larger than any previously described sliding clamp.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Griffith, JD (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.	jdg@med.unc.edu			NCI NIH HHS [CA19014] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA019014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen MR, 2000, J VIROL, V74, P3093, DOI 10.1128/JVI.74.7.3093-3104.2000; Chen XL, 2004, J BIOL CHEM, V279, P28375, DOI 10.1074/jbc.M400032200; FIXMAN ED, 1995, J VIROL, V69, P2998, DOI 10.1128/JVI.69.5.2998-3006.1995; FIXMAN ED, 1992, J VIROL, V66, P5030, DOI 10.1128/JVI.66.8.5030-5039.1992; Gershburg E, 2002, J VIROL, V76, P998, DOI 10.1128/JVI.76.3.998-1003.2002; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; GRUFFAT H, 1995, J VIROL, V69, P1878, DOI 10.1128/JVI.69.3.1878-1886.1995; HAMMERSCHMIDT W, 1988, CELL, V55, P427, DOI 10.1016/0092-8674(88)90028-1; Jeruzalmi D, 2002, CURR OPIN STRUC BIOL, V12, P217, DOI 10.1016/S0959-440X(02)00313-5; KALLIN B, 1985, J VIROL, V54, P561, DOI 10.1128/JVI.54.2.561-568.1985; KIEFF E, 1990, P1889; KIEHL A, 1995, J VIROL, V69, P1669, DOI 10.1128/JVI.69.3.1669-1677.1995; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, J MOL BIOL, V241, P265, DOI 10.1006/jmbi.1994.1495; LI JS, 1987, J VIROL, V61, P2947, DOI 10.1128/JVI.61.9.2947-2949.1987; MILLER G, 1990, P1921; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; Randell JCW, 2004, J MOL BIOL, V335, P409, DOI 10.1016/j.jmb.2003.10.064; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; SCHEPERS A, 1993, J VIROL, V67, P4237, DOI 10.1128/JVI.67.7.4237-4245.1993; TSURUMI T, 1993, J VIROL, V67, P1681, DOI 10.1128/JVI.67.3.1681-1687.1993; TSURUMI T, 1994, J VIROL, V68, P3354, DOI 10.1128/JVI.68.5.3354-3363.1994; TSURUMI T, 1993, J VIROL, V67, P7648, DOI 10.1128/JVI.67.12.7648-7653.1993; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; Westphal EM, 1999, CANCER RES, V59, P1485; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; Zhang Q, 1997, VIROLOGY, V230, P22, DOI 10.1006/viro.1997.8470; Zhang Q, 1996, J VIROL, V70, P5131, DOI 10.1128/JVI.70.8.5131-5142.1996	28	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40358	40361		10.1074/jbc.M408733200	http://dx.doi.org/10.1074/jbc.M408733200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15286084	hybrid, Green Published			2022-12-27	WOS:000223916800018
J	Xu, NJ; Yu, YX; Zhu, JM; Liu, H; Shen, L; Zeng, R; Zhang, X; Pei, G				Xu, NJ; Yu, YX; Zhu, JM; Liu, H; Shen, L; Zeng, R; Zhang, X; Pei, G			Inhibition of SNAP-25 phosphorylation at Ser(187) is involved in chronic morphine-induced down-regulation of SNARE complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SYNAPTOSOME-ASSOCIATED PROTEIN; RAT PHEOCHROMOCYTOMA CELLS; SYNAPTIC VESICLE DOCKING; MEMBRANE-FUSION COMPLEX; LONG-TERM POTENTIATION; NEUROTRANSMITTER RELEASE; OPIOID RECEPTOR; PC12 CELLS; DEPENDENT PHOSPHORYLATION	Opiate abuse has been shown to cause adaptive changes in presynaptic release and protein phosphorylation-mediated synaptic plasticity, but the underlying mechanisms remain unclear. Neuronal SNARE proteins serve as important regulatory molecules underlying neural plasticity in view of their major role in the process of neurotransmitter release. In the present study, the expression of SNAP-25, a t-SNARE protein essential for vesicle release, was found to be dramatically regulated in hippocampus after chronic morphine treatment, which was visualized with two-dimensional gel electrophoresis. The spots of SNAP-25 in the gel were shifted along the dimension of isoelectric point, indicating a likely change of the post-transcriptional modification. Immunoblotting analysis with specific antibody to Ser(187), a protein kinase C (PKC) phosphorylation site of SNAP-25, revealed that the specific phosphorylation was correspondingly decreased, which was correlated with morphine-induced inhibition of PKC activity. Moreover, the level of ternary complex of SNARE proteins in either synaptosomes or PC12 cells was significantly reduced after chronic morphine treatment. This suggests a causal relationship between the inhibition of PKC-dependent SNAP-25 phosphorylation and the down-regulation of SNARE complex formation after chronic morphine treatment. Further analysis of SNARE complex formed by transfection of the wild-type or Ser(187) mutants of SNAP-25 showed that only wild-type-formed complex was inhibited by morphine treatment. Thus, these results indicate that chronic morphine treatment inhibits phosphorylation of SNAP-25 at Ser(187) and leads to a down-regulation of SNARE complex formation, which presents a potential molecular mechanism for the alteration of exocytotic process and neural plasticity during opiate abuse.	Chinese Acad Sci, Grad Sch, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol,Lab Mol Cell Biol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai Inst Biol Sci, Inst Neurosci,Lab Sensory Syst, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Pei, G (corresponding author), Chinese Acad Sci, Grad Sch, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol,Lab Mol Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	gpei@sibs.ac.cn	Xu, Nan-Jie/N-3391-2016; XU, Nan-Jie/AAJ-4363-2020	Xu, Nan-Jie/0000-0003-2147-3352; XU, Nan-Jie/0000-0003-2147-3352				ABOOD ME, 1995, J PHARMACOL EXP THER, V274, P1566; Araki N, 2000, ELECTROPHORESIS, V21, P1880, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1880::AID-ELPS1880>3.3.CO;2-0; Bao L, 2003, NEURON, V37, P121, DOI 10.1016/S0896-6273(02)01103-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cerezo M, 2002, EUR J PHARMACOL, V452, P57, DOI 10.1016/S0014-2999(02)02245-8; Duman JG, 2003, AM J PHYSIOL-CELL PH, V285, pC237, DOI 10.1152/ajpcell.00091.2003; Escriba PV, 1999, BRIT J PHARMACOL, V127, P343, DOI 10.1038/sj.bjp.0702555; Finley MFA, 2003, NEUROPHARMACOLOGY, V45, P857, DOI 10.1016/S0028-3908(03)00283-1; Finley MFA, 2002, J NEUROSCI, V22, P1266, DOI 10.1523/JNEUROSCI.22-04-01266.2002; Fundytus ME, 1996, EUR J PHARMACOL, V300, P173, DOI 10.1016/0014-2999(95)00871-3; Genoud S, 1999, J NEUROCHEM, V72, P1699, DOI 10.1046/j.1471-4159.1999.721699.x; HAAS HL, 1980, J PHYSIOL-LONDON, V308, P315, DOI 10.1113/jphysiol.1980.sp013473; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Itakura M, 1999, BIOCHEM BIOPH RES CO, V265, P691, DOI 10.1006/bbrc.1999.1756; Iwasaki S, 2000, J BIOCHEM-TOKYO, V128, P407, DOI 10.1093/oxfordjournals.jbchem.a022768; Kataoka M, 2000, J NEUROCHEM, V74, P2058, DOI 10.1046/j.1471-4159.2000.0742058.x; Koticha DK, 2002, J CELL SCI, V115, P3341; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Lonart G, 2000, J BIOL CHEM, V275, P27703; Lou LG, 1997, BIOCHEM BIOPH RES CO, V236, P626, DOI 10.1006/bbrc.1997.7027; Lu WY, 2001, NEURON, V29, P243, DOI 10.1016/S0896-6273(01)00194-5; Mansouri FA, 1999, BRAIN RES, V815, P419, DOI 10.1016/S0006-8993(98)01148-2; Mansouri FA, 1997, BRAIN RES, V769, P119, DOI 10.1016/S0006-8993(97)00608-2; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Nagy G, 2002, J NEUROSCI, V22, P9278; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nestler EJ, 2001, SCIENCE, V292, P2266, DOI 10.1126/science.1063024; Niu SY, 2000, JPN J PHARMACOL, V84, P412, DOI 10.1254/jjp.84.412; ORTIZ J, 1995, J NEUROSCI, V15, P1285; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Pozzo-Miller LD, 1999, J NEUROSCI, V19, P4972; Pu L, 2002, J NEUROSCI, V22, P1914, DOI 10.1523/JNEUROSCI.22-05-01914.2002; Renger JJ, 2001, NEURON, V29, P469, DOI 10.1016/S0896-6273(01)00219-7; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; Shoji-Kasai Y, 2002, EUR J NEUROSCI, V15, P1390, DOI 10.1046/j.1460-9568.2002.01972.x; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sorensen JB, 2003, CELL, V114, P75, DOI 10.1016/S0092-8674(03)00477-X; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tian JH, 2003, J BIOL CHEM, V278, P26265, DOI 10.1074/jbc.M300492200; Tsuboi T, 2001, BIOCHEM BIOPH RES CO, V282, P621, DOI 10.1006/bbrc.2001.4603; Ventayol P, 1997, N-S ARCH PHARMACOL, V355, P491, DOI 10.1007/PL00004974; Williams JT, 2001, PHYSIOL REV, V81, P299, DOI 10.1152/physrev.2001.81.1.299; Xu NJ, 2003, J NEUROSCI, V23, P4775; Yoshikawa M, 2000, BRAIN RES, V859, P217, DOI 10.1016/S0006-8993(00)01961-2	52	35	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40601	40608		10.1074/jbc.M406896200	http://dx.doi.org/10.1074/jbc.M406896200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15277518	hybrid			2022-12-27	WOS:000223916800048
J	Chen, K; Holschneider, DP; Wu, WH; Rebrin, I; Shih, JC				Chen, K; Holschneider, DP; Wu, WH; Rebrin, I; Shih, JC			A spontaneous point mutation produces monoamine oxidase A/B knock-out mice with greatly elevated monoamines and anxiety-like behavior	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGGRESSIVE-BEHAVIOR; PLUS-MAZE; B GENES; MOLECULAR-BASIS; A-DEFICIENT; SEROTONIN; PHENYLETHYLAMINE; LOCALIZATION; EXPRESSION; PATIENT	A spontaneous monoamine oxidase A (MAO A) mutation (A863T) in exon 8 introduced a premature stop codon, which produced MAO A/B double knock-out ( KO) mice in a MAO B KO mouse colony. This mutation caused a nonsense-mediated mRNA decay and resulted in the absence of MAO A transcript, protein, and catalytic activity and abrogates a DraI restriction site. The MAO A/B KO mice showed reduced body weight compared with wild type mice. Brain levels of serotonin, norepinephrine, dopamine, and phenylethylamine increased, and serotonin metabolite 5-hydroxyindoleacetic acid levels decreased, to a much greater degree than in either MAO A or B single KO mice. Observed chase/ escape and anxiety-like behavior in the MAO A/B KO mice, different from MAO A or B single KO mice, suggest that varying monoamine levels result in both a unique biochemical and behavioral phenotype. These mice will be useful models for studying the molecular basis of disorders associated with abnormal monoamine neurotransmitters.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90089 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Shih, JC (corresponding author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, 1985 Zonal Ave,Rm 528, Los Angeles, CA 90089 USA.	jcshih@usc.edu		Holschneider, Daniel/0000-0002-4297-8280	NIMH NIH HHS [R37 MH039085, R37 MH039085-23, R37 MH38635, R01 MH NS62148] Funding Source: Medline; NINDS NIH HHS [K23 NS062148] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039085, R01MH062148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS062148] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; Binda C, 2003, P NATL ACAD SCI USA, V100, P9750, DOI 10.1073/pnas.1633804100; BLANCHARD RJ, 1977, BEHAV BIOL, V21, P197, DOI 10.1016/S0091-6773(77)90308-X; BRAIN PF, 1970, COMMUN BEHAV BIOL, V5, P7; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; BRUNNER HG, 1993, AM J HUM GENET, V52, P1032; Cao BJ, 1998, PSYCHOPHARMACOLOGY, V139, P185, DOI 10.1007/s002130050703; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Chen K, 1996, J NEUROCHEM, V66, P797; Clement Y, 1998, NEUROSCI BIOBEHAV R, V22, P623, DOI 10.1016/S0149-7634(97)00058-4; COLE BJ, 1987, BEHAV NEUROSCI, V101, P476, DOI 10.1037/0735-7044.101.4.476; COLLINS FA, 1992, AM J MED GENET, V42, P127, DOI 10.1002/ajmg.1320420126; DERRY JMJ, 1989, NUCLEIC ACIDS RES, V17, P8403, DOI 10.1093/nar/17.20.8403; FIALA ES, 1981, CARCINOGENESIS, V2, P165, DOI 10.1093/carcin/2.3.165; File SE, 2003, EUR J PHARMACOL, V463, P35, DOI 10.1016/S0014-2999(03)01273-1; Frazer A, 1994, BASIC NEUROCHEMISTRY, P304; Gargiulo PA, 1996, NEUROPSYCHOBIOLOGY, V33, P189, DOI 10.1159/000119276; Garpenstrand H, 2002, EUR NEUROPSYCHOPHARM, V12, P135, DOI 10.1016/S0924-977X(01)00148-1; Geha RM, 2002, J BIOL CHEM, V277, P17209, DOI 10.1074/jbc.M110920200; Geha RM, 2001, J BIOL CHEM, V276, P9877, DOI 10.1074/jbc.M006972200; Gingrich JA, 2003, CNS SPECTRUMS, V8, P572, DOI 10.1017/S1092852900018848; Griebel G, 1997, NEUROPHARMACOLOGY, V36, P793, DOI 10.1016/S0028-3908(97)00034-8; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; Grimsby J, 1997, NAT GENET, V17, P206, DOI 10.1038/ng1097-206; Gross C, 2002, NATURE, V416, P396, DOI 10.1038/416396a; Hendricks TJ, 2003, NEURON, V37, P233, DOI 10.1016/S0896-6273(02)01167-4; Holmes A, 2003, GENES BRAIN BEHAV, V2, P365, DOI 10.1046/j.1601-1848.2003.00050.x; Holschneider DP, 2002, AM J PHYSIOL-HEART C, V282, pH1751, DOI 10.1152/ajpheart.00600.2001; Insel TR, 1998, BIOL PSYCHIAT, V44, P207, DOI 10.1016/S0006-3223(98)00094-8; Inui A, 2000, PHARMACOL REV, V52, P35; Kim JJ, 1997, P NATL ACAD SCI USA, V94, P5929, DOI 10.1073/pnas.94.11.5929; KNOLL J, 1993, INHIBITORS MONOAMINE; KRUESI MJP, 1990, ARCH GEN PSYCHIAT, V47, P419; LAIRES A, 1993, FOOD CHEM TOXICOL, V31, P989, DOI 10.1016/0278-6915(93)90008-M; LAN NC, 1989, GENOMICS, V4, P552, DOI 10.1016/0888-7543(89)90279-6; LAPIN IP, 1993, PHARMACOL BIOCHEM BE, V44, P241, DOI 10.1016/0091-3057(93)90305-D; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lykke-Andersen J, 2001, CURR BIOL, V11, pR88, DOI 10.1016/S0960-9822(01)00036-7; Mar A, 2000, PSYCHOPHARMACOLOGY, V150, P52, DOI 10.1007/s002130000400; MOSNAIM AD, 1989, GEN PHARMACOL, V20, P463, DOI 10.1016/0306-3623(89)90196-1; Ou XM, 2004, J BIOL CHEM, V279, P21021, DOI 10.1074/jbc.M312638200; Popova N K, 2001, Neurosci Behav Physiol, V31, P597, DOI 10.1023/A:1012364910091; Ramboz S, 1998, P NATL ACAD SCI USA, V95, P14476, DOI 10.1073/pnas.95.24.14476; Rebrin I, 2001, J BIOL CHEM, V276, P29499, DOI 10.1074/jbc.M100431200; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; Shih JC, 1999, BRAIN RES, V835, P104, DOI 10.1016/S0006-8993(99)01478-X; SHIH JC, 1991, NEUROPSYCHOPHARMACOL, V4, P1; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; SIMON P, 1993, PHARMACOL BIOCHEM BE, V45, P685, DOI 10.1016/0091-3057(93)90525-X; van Praag HM, 1998, ACTA PSYCHIAT SCAND, V98, P81; Voikar V, 2001, PHYSIOL BEHAV, V72, P271, DOI 10.1016/S0031-9384(00)00405-4; Wong WK, 2003, J BIOL CHEM, V278, P36227, DOI 10.1074/jbc.M305549200; Wong WK, 2002, J BIOL CHEM, V277, P22222, DOI 10.1074/jbc.M202844200; WU HF, 1993, MOL PHARMACOL, V43, P888; Yudofsky SC, 1997, J NEUROPSYCH CLIN N, V9, P541	58	106	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39645	39652		10.1074/jbc.M405550200	http://dx.doi.org/10.1074/jbc.M405550200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15272015	Green Accepted, hybrid			2022-12-27	WOS:000223791500055
J	Naegele, S; Morley, SJ				Naegele, S; Morley, SJ			Molecular cross-talk between MEK1/2 and mTOR signaling during recovery of 293 cells from hypertonic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; ACTIVATED PROTEIN-KINASE; CAP-DEPENDENT TRANSLATION; GENE-PRODUCTS; FACTOR 4G; PHOSPHORYLATION; BINDING; TUBERIN; MNK1; TSC2	To investigate the role for initiation factor phosphorylation in de novo translation, we have studied the recovery of human kidney cells from hypertonic stress. Previously, we have demonstrated that hypertonic shock causes a rapid inhibition of protein synthesis, the disaggregation of polysomes, the dephosphorylation of eukaryotic translation initiation factor (eIF)4E, 4E-BP1, and ribosomal protein S6, and increased association of 4E-BP1 with eIF4E. The return of cells to isotonic medium promotes a transient activation of Erk1/2 and the phosphorylation of initiation factors, promoting an increase in protein synthesis that is independent of a requirement for eIF4E phosphorylation. As de novo translation is associated with the phosphorylation of 4E-BP1, we have investigated the role of the signaling pathways required for this event by the use of cell-permeable inhibitors. Surprisingly, although rapamycin, RAD001, wortmannin, and LY294002 inhibited the phosphorylation of 4E-BP1 and its release from eIF4E, they did not prevent the recovery of translation rates. These data suggest that only a small proportion of the available eIF4F complex is required for maximal translation rates under these conditions. Similarly, prevention of Erk1/2 activity alone with low concentrations of PD184352 did not impinge upon de novo translation until later times of recovery from salt shock. However, U0126, which prevented the phosphorylation of Erk1/2, ribosomal protein S6, TSC2, and 4E-BP1, attenuated de novo protein synthesis in recovering cells. These results indicate that the phosphorylation of 4E-BP1 is mediated by both phosphatidylinositol 3-kinase-dependent rapamycin-sensitive and Erk1/2-dependent signaling pathways and that activation of either pathway in isolation is sufficient to promote de novo translation.	Univ Sussex, Sch Life Sci, Biochem Lab, Brighton BN1 9QG, E Sussex, England	University of Sussex	Morley, SJ (corresponding author), Univ Sussex, Sch Life Sci, Biochem Lab, Brighton BN1 9QG, E Sussex, England.	s.j.morley@sussex.ac.uk						Allen LF, 2003, SEMIN ONCOL, V30, P105, DOI 10.1053/j.seminoncol.2003.08.012; Blenis J, 2003, FASEB J, V17, pA149; Brown VI, 2003, PEDIATR RES, V53, p287A; Bushell M, 2000, EUR J BIOCHEM, V267, P1083, DOI 10.1046/j.1432-1327.2000.01101.x; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Fraser CS, 1999, BIOCHEM J, V342, P519, DOI 10.1042/0264-6021:3420519; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 2001, PROG MOLEC, V27, P143; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Iijima Y, 2002, J BIOL CHEM, V277, P23065, DOI 10.1074/jbc.M200328200; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Krymskaya VP, 2003, CELL SIGNAL, V15, P729, DOI 10.1016/S0898-6568(03)00040-8; Kwiatkowski DJ, 2003, CANCER BIOL THER, V2, P471, DOI 10.4161/cbt.2.5.446; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; Lehman JA, 2002, BIOCHEM BIOPH RES CO, V293, P463, DOI 10.1016/S0006-291X(02)00238-3; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; MADER S, 1995, MOL CELL BIOL, V15, P4990; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; MORLEY SJ, 1995, J CELL SCI, V108, P1751; Morley SJ, 2003, CELL SIGNAL, V15, P741, DOI 10.1016/S0898-6568(03)00008-1; Morley SJ, 2001, PROG MOLEC, V27, P1; Morley SJ, 2002, J BIOL CHEM, V277, P32855, DOI 10.1074/jbc.C200376200; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; Novoa I, 1999, MOL CELL BIOL, V19, P2445; Parra-Palau JL, 2003, J BIOL CHEM, V278, P44197, DOI 10.1074/jbc.M302398200; Preiss T, 2003, BIOESSAYS, V25, P1201, DOI 10.1002/bies.10362; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Proud CG, 2002, EUR J BIOCHEM, V269, P5337, DOI 10.1046/j.1432-1033.2002.03289.x; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Pyronnet S, 2000, BIOCHEM PHARMACOL, V60, P1237, DOI 10.1016/S0006-2952(00)00429-9; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Shi YY, 2002, J BIOL CHEM, V277, P15712, DOI 10.1074/jbc.M200043200; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Wang LJ, 2002, FEBS LETT, V531, P285, DOI 10.1016/S0014-5793(02)03536-6; Wang LJ, 2001, J BIOL CHEM, V276, P32670, DOI 10.1074/jbc.M102776200; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909	54	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46023	46034		10.1074/jbc.M404945200	http://dx.doi.org/10.1074/jbc.M404945200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15292274	hybrid			2022-12-27	WOS:000224694900088
J	Cao, Y; Knochel, S; Donow, C; Miethe, J; Kaufmann, E; Knochel, W				Cao, Y; Knochel, S; Donow, C; Miethe, J; Kaufmann, E; Knochel, W			The POU factor Oct-25 regulates the Xvent-2B gene and counteracts terminal differentiation in Xenopus embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-4; HOMEOBOX GENE; TRANSCRIPTION FACTOR; STEM-CELLS; MAMMALIAN EMBRYO; DOMAIN PROTEIN; NEURAL FATE; EXPRESSION; BMP-4; PROMOTER	The Xvent-2B promoter is regulated by a BMP-2/4-induced transcription complex comprising Smad signal transducers and specific transcription factors. Using a yeast one-hybrid screen we have found that Oct-25, a Xenopus POU domain protein related to mammalian Oct-3/4, binds as an additional factor to the Xvent-2B promoter. This interaction was further confirmed by both in vitro and in vivo analyses. The Oct-25 gene is mainly transcribed during blastula and gastrula stages in the newly forming ectodermal and mesodermal germ layers. Luciferase reporter gene assay demonstrated that Oct-25 stimulates transcription of the Xvent-2B gene. This stimulation depends on the Oct-25 binding site and the bone morphogenetic protein-responsive element. Furthermore, Oct-25 interacts in vitro with components of the Xvent-2B transcription complex, like Smad1/4 and Xvent-2. Overexpression of Oct-25 results in anterior/posterior truncations and lack of differentiation for neuroectoderm- and mesoderm-derived tissues including blood cells. This effect is consistent with an evolutionarily conserved role of class V POU factors in the maintenance of an undifferentiated cell state. In Xenopus, the molecular mechanism underlying this process might be coupled to the expression of Xvent proteins.	Univ Ulm, Biochem Abt, D-89081 Ulm, Germany	Ulm University	Knochel, W (corresponding author), Univ Ulm, Biochem Abt, Albert Einstein Allee 11, D-89081 Ulm, Germany.	walter.knoechel@medizin.uni-ulm.de		Cao, Ying/0000-0001-8286-9591				Ault KT, 1997, DEV BIOL, V192, P162, DOI 10.1006/dbio.1997.8737; Burgess S, 2002, DEVELOPMENT, V129, P905; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; CLEMENT JH, 1995, MECH DEVELOP, V52, P357, DOI 10.1016/0925-4773(95)00413-U; DALE L, 1992, DEVELOPMENT, V115, P573; FRANK D, 1992, DEVELOPMENT, V115, P439; Friedle H, 2002, J BIOL CHEM, V277, P23872, DOI 10.1074/jbc.M201831200; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Henig C, 1998, MECH DEVELOP, V71, P131, DOI 10.1016/S0925-4773(98)00006-9; Henningfeld KA, 2000, J BIOL CHEM, V275, P21827, DOI 10.1074/jbc.M000978200; Henningfeld KA, 2002, J BIOL CHEM, V277, P2097, DOI 10.1074/jbc.M108524200; HINKLEY CS, 1992, MOL CELL BIOL, V12, P638, DOI 10.1128/MCB.12.2.638; Karaulanov E, 2004, EMBO J, V23, P844, DOI 10.1038/sj.emboj.7600101; Klemm JD, 1996, GENE DEV, V10, P27, DOI 10.1101/gad.10.1.27; Ku MC, 2003, BIOCHEM BIOPH RES CO, V311, P702, DOI 10.1016/j.bbrc.2003.10.053; Ladher R, 1996, DEVELOPMENT, V122, P2385; Lee HS, 2002, BIOCHEM BIOPH RES CO, V298, P815, DOI 10.1016/S0006-291X(02)02570-6; Metz A, 1998, MECH DEVELOP, V74, P29, DOI 10.1016/S0925-4773(98)00059-8; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Onichtchouk D, 1998, DEVELOPMENT, V125, P1447; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Rastegar S, 1999, MECH DEVELOP, V81, P139, DOI 10.1016/S0925-4773(98)00239-1; Reim G, 2002, DEVELOPMENT, V129, P917; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Schmidt JE, 1996, DEVELOPMENT, V122, P1711; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; Schuler-Metz A, 2000, J BIOL CHEM, V275, P34365, DOI 10.1074/jbc.M003915200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shim S, 2002, NUCLEIC ACIDS RES, V30, P3107, DOI 10.1093/nar/gkf437; Soodeen-Karamath S, 2001, MOL REPROD DEV, V58, P137, DOI 10.1002/1098-2795(200102)58:2&lt;137::AID-MRD2&gt;3.0.CO;2-6; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Wei Z, 1999, MOL CELL BIOL, V19, P1271; WHITFIELD T, 1993, DEV BIOL, V155, P361, DOI 10.1006/dbio.1993.1035; WHITFIELD TT, 1995, DEV BIOL, V169, P759, DOI 10.1006/dbio.1995.1185; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; Xu RH, 1999, DEV BIOL, V208, P352, DOI 10.1006/dbio.1999.9205; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Zhu ZL, 2002, DEV CELL, V3, P557, DOI 10.1016/S1534-5807(02)00270-8	45	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43735	43743		10.1074/jbc.M407544200	http://dx.doi.org/10.1074/jbc.M407544200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292233	hybrid			2022-12-27	WOS:000224383100048
J	Neeley, WL; Delaney, JC; Henderson, PT; Essigmann, JM				Neeley, WL; Delaney, JC; Henderson, PT; Essigmann, JM			In vivo bypass efficiencies and mutational signatures of the guanine oxidation products 2-aminoimidazolone and 5-guanidino-4-nitroimidazole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXYNITRITE-INDUCED REACTIONS; REPAIR DNA-POLYMERASES; SIMIAN KIDNEY-CELLS; ESCHERICHIA-COLI; NITRIC-OXIDE; POL-IV; CARBON-DIOXIDE; ONE-ELECTRON; ERROR-PRONE; INDUCED MUTAGENESIS	The in vivo mutagenic properties of 2-aminoimidazolone and 5-guanidino-4-nitroimidazole, two products of peroxynitrite oxidation of guanine, are reported. Two oligodeoxynucleotides of identical sequence, but containing either 2-aminoimidazolone or 5-guanidino-4-nitroimidazole at a specific site, were ligated into single-stranded M13mp7L2 bacteriophage genomes. Wild-type AB1157 Escherichia coli cells were transformed with the site-specific 2-aminoimidazolone- and 5-guanidino-4-nitroimidazole-containing genomes, and analysis of the resulting progeny phage allowed determination of the in vivo bypass efficiencies and mutational signatures of the DNA lesions. 2-Aminoimidazolone was efficiently bypassed and 91% mutagenic, producing almost exclusively G to C transversion mutations. In contrast, 5-guanidino-4-nitroimidazole was a strong block to replication and 50% mutagenic, generating G to A, G to T, and to a lesser extent, G to C mutations. The G to A mutation elicited by 5-guanidino-4-nitroimidazole implicates this lesion as a novel source of peroxynitrite-induced transition mutations in vivo. For comparison, the error-prone bypass DNA polymerases were overexpressed in the cells by irradiation with UV light ( SOS induction) prior to transformation. SOS induction caused little change in the efficiency of DNA polymerase bypass of 2-aminoimidazolone; however, bypass of 5-guanidino-4-nitroimidazole increased nearly 10-fold. Importantly, the mutation frequencies of both lesions decreased during replication in SOS-induced cells. These data suggest that 2-aminoimidazolone and 5-guanidino-4- nitroimidazole in DNA are substrates for one or more of the SOS-induced Y-family DNA polymerases and demonstrate that 2-aminoimidazolone and 5-guanidino-4- nitroimidazole are potent sources of mutations in vivo.	MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Essigmann, JM (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	jessig@mit.edu						Bjelland S, 2003, MUTAT RES-FUND MOL M, V531, P37, DOI 10.1016/j.mrfmmm.2003.07.002; Burney S, 1999, CHEM RES TOXICOL, V12, P513, DOI 10.1021/tx980254m; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; CADET J, 1994, J AM CHEM SOC, V116, P7403, DOI 10.1021/ja00095a052; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; De Bont R, 2004, MUTAGENESIS, V19, P169, DOI 10.1093/mutage/geh025; Dedon PC, 2004, ARCH BIOCHEM BIOPHYS, V423, P12, DOI 10.1016/j.abb.2003.12.017; Delaney JC, 1999, CHEM BIOL, V6, P743, DOI 10.1016/S1074-5521(00)80021-6; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fuchs RPP, 2001, BIOCHEM SOC T, V29, P191, DOI 10.1042/0300-5127:0290191; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Gu F, 2002, BIOCHEMISTRY-US, V41, P7508, DOI 10.1021/bi020148q; Henderson PT, 2003, BIOCHEMISTRY-US, V42, P9257, DOI 10.1021/bi0347252; Henderson PT, 2002, BIOCHEMISTRY-US, V41, P914, DOI 10.1021/bi0156355; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Ikeda H, 1999, J AM CHEM SOC, V121, P10836, DOI 10.1021/ja992020a; Jaruga P, 2002, FREE RADICAL BIO MED, V32, P414, DOI 10.1016/S0891-5849(01)00821-8; Joffe A, 2003, CHEM RES TOXICOL, V16, P966, DOI 10.1021/tx025578w; Juedes MJ, 1996, MUTAT RES-FUND MOL M, V349, P51, DOI 10.1016/0027-5107(95)00152-2; Kim SR, 2001, MOL GENET GENOMICS, V266, P207; Kino K, 2001, CHEM BIOL, V8, P369, DOI 10.1016/S1074-5521(01)00019-9; Kino K, 1998, J AM CHEM SOC, V120, P7373, DOI 10.1021/ja980763a; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; Kroeger KM, 2004, BIOCHEMISTRY-US, V43, P6723, DOI 10.1021/bi049813g; Lee JA, 2002, CHEM RES TOXICOL, V15, P7, DOI 10.1021/tx010093d; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Luo WC, 2001, ORG LETT, V3, P2801, DOI 10.1021/ol0161763; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1998, CHEM RES TOXICOL, V11, P714, DOI 10.1021/tx980076x; Lymar SV, 1996, CHEM RES TOXICOL, V9, P845, DOI 10.1021/tx960046z; Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8; Maor-Shoshani A, 2003, P NATL ACAD SCI USA, V100, P14760, DOI 10.1073/pnas.2433503100; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Neeley WL, 2004, ORG LETT, V6, P245, DOI 10.1021/ol036188j; Niles JC, 2001, J AM CHEM SOC, V123, P12147, DOI 10.1021/ja004296k; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Ohshima H, 2003, ARCH BIOCHEM BIOPHYS, V417, P3, DOI 10.1016/S0003-9861(03)00283-2; Olinski R, 2002, FREE RADICAL BIO MED, V33, P192, DOI 10.1016/S0891-5849(02)00878-X; Pamir B, 2003, CHEM RES TOXICOL, V16, P487, DOI 10.1021/tx020093t; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; Qiu ZH, 1997, J BIOL CHEM, V272, P8611, DOI 10.1074/jbc.272.13.8611; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9; Shafirovich V, 2001, J BIOL CHEM, V276, P24621, DOI 10.1074/jbc.M101131200; Shen X, 2002, J BIOL CHEM, V277, P5265, DOI 10.1074/jbc.M109575200; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Torun L, 2003, PHOTOCHEM PHOTOBIOL, V77, P370, DOI 10.1562/0031-8655(2003)077<0370:PODMIA>2.0.CO;2; Tretyakova NY, 1999, CHEM RES TOXICOL, V12, P459, DOI 10.1021/tx980235c; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Vialas C, 1999, NUCLEOS NUCLEOT, V18, P1061, DOI 10.1080/15257779908041645; Vialas C, 2000, J AM CHEM SOC, V122, P2157, DOI 10.1021/ja992860p; Vialas C, 1998, J AM CHEM SOC, V120, P11548, DOI 10.1021/ja981597+; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wagner J, 2002, DNA REPAIR, V1, P159, DOI 10.1016/S1568-7864(01)00012-X; WOODGATE R, 1991, MOL GEN GENET, V229, P10, DOI 10.1007/BF00264207; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; Yang W, 2003, CURR OPIN STRUC BIOL, V13, P23, DOI 10.1016/S0959-440X(02)00003-9	64	55	56	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43568	43573		10.1074/jbc.M407117200	http://dx.doi.org/10.1074/jbc.M407117200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15299010	hybrid			2022-12-27	WOS:000224383100028
J	Sadir, R; Imberty, A; Baleux, F; Lortat-Jacob, H				Sadir, R; Imberty, A; Baleux, F; Lortat-Jacob, H			Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CXCR4; SULFATE PROTEOGLYCANS; FACTOR 1-ALPHA; CATHEPSIN-G; SDF-1; EXPRESSION; BINDING; INHIBITION; LIGAND; FACTOR-1-ALPHA	Stromal cell-derived factor-1 (SDF-1) is a CXC chemokine that is constitutively expressed in most tissues and displayed on the cell surface in association with heparan sulfate (HS). Its numerous biological effects are mediated by a specific G protein-coupled receptor, CXCR4. A number of cells inactivate SDF-1 by specific processing of the N-terminal domain of the chemokine. In particular, CD26/dipeptidyl peptidase IV (DPP IV), a serine protease that co-distributes with CXCR4 at the cell surface, mediates the selective removal of the N-terminal dipeptide of SDF-1. We report here that heparin and HS specifically prevent the processing of SDF-1 by DPP IV expressed by Caco-2 cells. The level of processing increases with the level of differentiation of these cells, which correlates with an increase of DPP IV activity. A mutant SDF-1 that does not interact with HS is readily cleaved by DPP IV, a process that is not inhibited by HS, demonstrating that a productive interaction between HS and SDF-1 is required for the protection to take place. Moreover, we found that protection depends on the degree of polymerization of the HS sulfated S-domains. Finally a structural model of SDF-1, in complex with HS oligosaccharides of defined length, rationalizes the experimental data. The mechanisms by which HS regulates SDF-1 may thus include, in addition to its ability to locally concentrate the chemokine at the cell surface, a control of selective protease cleavage events that directly affect the chemokine activity.	Univ Grenoble 1, CNRS,Unite Mixte Rech 5075, CEA, Inst Biol Struct, F-38027 Grenoble 01, France; Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble 09, France; Inst Pasteur, Unite Chim Organ, F-75724 Paris, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Lortat-Jacob, H (corresponding author), Univ Grenoble 1, CNRS,Unite Mixte Rech 5075, CEA, Inst Biol Struct, 41 Rue Horowitz, F-38027 Grenoble 01, France.	Hugues.Lortat-Jacob@ibs.fr	Imberty, Anne/P-6451-2018	Imberty, Anne/0000-0001-6825-9527				Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BERTHOD H, 1965, J CHIM PHYS, V62, P942, DOI 10.1051/jcp/1965620942; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Coulomb-L'Hermine A, 1999, P NATL ACAD SCI USA, V96, P8585, DOI 10.1073/pnas.96.15.8585; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; David NB, 2002, P NATL ACAD SCI USA, V99, P16297, DOI 10.1073/pnas.252339399; Delgado MB, 2001, EUR J IMMUNOL, V31, P699, DOI 10.1002/1521-4141(200103)31:3<699::AID-IMMU699>3.0.CO;2-6; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; Durinx C, 2000, EUR J BIOCHEM, V267, P5608, DOI 10.1046/j.1432-1327.2000.01634.x; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Herrera C, 2001, J BIOL CHEM, V276, P19532, DOI 10.1074/jbc.M004586200; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; IMBERTY A, 1999, PERSPECTIVES STRUCTU, P392; Kerneis S, 1997, SCIENCE, V277, P949, DOI 10.1126/science.277.5328.949; Lambeir AM, 2001, J BIOL CHEM, V276, P29839, DOI 10.1074/jbc.M103106200; Lazarini F, 2003, GLIA, V42, P139, DOI 10.1002/glia.10139; Ledoux D, 2003, FEBS LETT, V537, P23, DOI 10.1016/S0014-5793(03)00064-4; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Netelenbos T, 2002, J LEUKOCYTE BIOL, V72, P353; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Ohnishi Y, 2000, J INTERF CYTOK RES, V20, P691, DOI 10.1089/10799900050116390; Ohtsuki T, 1998, FEBS LETT, V431, P236, DOI 10.1016/S0014-5793(98)00763-7; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; Pablos JL, 2003, J IMMUNOL, V170, P2147, DOI 10.4049/jimmunol.170.4.2147; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; Proost P, 1998, FEBS LETT, V432, P73, DOI 10.1016/S0014-5793(98)00830-8; Reiss K, 2002, NEUROSCIENCE, V115, P295, DOI 10.1016/S0306-4522(02)00307-X; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; Salmivirta M, 1998, GLYCOBIOLOGY, V8, P1029, DOI 10.1093/glycob/8.10.1029; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; Sierra MD, 2004, BLOOD, V103, P2452; Sweeney EA, 2002, BLOOD, V99, P44, DOI 10.1182/blood.V99.1.44; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Valenzuela-Fernandez A, 2002, J BIOL CHEM, V277, P15677, DOI 10.1074/jbc.M111388200; Valenzuela-Fernandez A, 2001, J BIOL CHEM, V276, P26550, DOI 10.1074/jbc.M100411200; Van Damme J, 1999, Chem Immunol, V72, P42, DOI 10.1159/000058725; van der Voort R, 2000, J EXP MED, V192, P1115, DOI 10.1084/jem.192.8.1115; Volpi N, 1996, BBA-GEN SUBJECTS, V1290, P299, DOI 10.1016/0304-4165(96)00033-5; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; Yao L, 2003, BLOOD, V102, P3900, DOI 10.1182/blood-2003-02-0641; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183	56	167	168	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43854	43860		10.1074/jbc.M405392200	http://dx.doi.org/10.1074/jbc.M405392200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292258	hybrid			2022-12-27	WOS:000224383100062
J	Wu, XY; Zagranichnaya, TK; Gurda, GT; Eves, EM; Villereal, ML				Wu, XY; Zagranichnaya, TK; Gurda, GT; Eves, EM; Villereal, ML			A TRPC1/TRPC3-mediated increase in store-operated calcium entry is required for differentiation of H19-7 hippocampal neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION CHANNELS; CA2+ ENTRY; HEK-293 CELLS; INFLUX; PROTEIN; TRPC4; BRAIN; MICE	Store-operated calcium entry (SOCE) and TRPC protein expression were investigated in the rat-derived hippocampal H19-7 cell line. Thapsigargin-stimulated Ba2+ entry and the expression of TRPC1, TRPC3, TRPC4, TRPC5, TRPC6, and TRPC7 mRNA and protein were observed in proliferating H19-7 cells. When cells were placed under differentiating conditions, a change in TRPC homolog expression profile occurred. The expression of TRPC1 and TRPC3 mRNA and protein dramatically increased, while the expression of TRPC4 and TRPC7 mRNA and protein dramatically decreased; in parallel a 3.4-fold increase in the level of thapsigargin-stimulated Ba2+ entry was observed and found to be inhibited by 2-aminoethoxydiphenylborane. The selective suppression of TRPC protein levels by small interfering RNA ( siRNA) approaches indicated that TRPC1 and TRPC3 are involved in mediating SOCE in proliferating H19-7 cells. Although TRPC4 and TRPC7 are expressed at much higher levels than TRPC1 and TRPC3 in proliferating cells, they do not appear to mediate SOCE. The co-expression of siRNA specific for TRPC1 and TRPC3 in proliferating cells inhibited approximately the same amount of SOCE as observed with expression of either siRNA alone, suggesting that TRPC1 and TRPC3 work in tandem to mediate SOCE. Under differentiating conditions, co-expression of siRNA for TRPC1 and TRPC3 blocked the normal 3.4-fold increase in SOCE and in turn blocked the differentiation of H19-7 cells. This study suggests that placing H19-7 cells under differentiating conditions significantly alters TRPC gene expression and increases the level of SOCE and that this increase in SOCE is necessary for cell differentiation.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Chicago, Ben May Inst, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Villereal, ML (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Abbott 532,947 E 58th St, Chicago, IL 60637 USA.	mitch@bsd.uchicago.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baba A, 2003, J NEUROSCI, V23, P7737; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BYRON KL, 1995, J PHYSIOL-LONDON, V485, P455, DOI 10.1113/jphysiol.1995.sp020742; EVES EM, 1994, BRAIN RES, V656, P396, DOI 10.1016/0006-8993(94)91484-2; Eves EM, 1996, J NEUROCHEM, V67, P1908; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Herms J, 2003, J BIOL CHEM, V278, P2484, DOI 10.1074/jbc.M206769200; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Jackson M B, 1999, Adv Neurol, V79, P511; KWAN CY, 1990, J BIOL CHEM, V265, P678; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Nilius B, 2003, CELL CALCIUM, V33, P293, DOI 10.1016/S0143-4160(03)00042-3; Obukhov AG, 2002, J BIOL CHEM, V277, P16172, DOI 10.1074/jbc.M111664200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Pizzo P, 2001, J NEUROCHEM, V79, P98, DOI 10.1046/j.1471-4159.2001.00539.x; Plant TD, 2003, CELL CALCIUM, V33, P441, DOI 10.1016/S0143-4160(03)00055-1; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; Tozzi A, 2003, EUR J NEUROSCI, V18, P2133, DOI 10.1046/j.1460-9568.2003.02936.x; Trebak M, 2003, CELL CALCIUM, V33, P451, DOI 10.1016/S0143-4160(03)00056-3; TSIEN RW, 1995, TRENDS NEUROSCI, V18, P52; VILLEREAL ML, 1992, REV PHYSIOL BIOCH P, V119, P67; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Wu XY, 2002, J BIOL CHEM, V277, P13597, DOI 10.1074/jbc.M110881200; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0	35	209	221	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43392	43402		10.1074/jbc.M408959200	http://dx.doi.org/10.1074/jbc.M408959200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15297455	hybrid			2022-12-27	WOS:000224383100008
J	Chiara, F; Goumans, MJ; Forsberg, H; Ahgren, A; Rasola, A; Aspenstrom, P; Wernstedt, C; Hellberg, C; Heldin, CH; Heuchel, R				Chiara, F; Goumans, MJ; Forsberg, H; Ahgren, A; Rasola, A; Aspenstrom, P; Wernstedt, C; Hellberg, C; Heldin, CH; Heuchel, R			A gain of function mutation in the activation loop of platelet-derived growth factor beta-receptor deregulates its kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; TYROSINE KINASE; PHOSPHATIDYLINOSITOL-3 KINASE; SIGNAL TRANSDUCERS; MET PROTOONCOGENE; CELLS; PHOSPHORYLATION; TRANSFORMATION; DOMAIN; MASTOCYTOSIS	The platelet-derived growth factor receptors (PDGFRs) are receptor tyrosine kinases implicated in multiple aspects of cell growth, differentiation, and survival. Recently, a gain of function mutation in the activation loop of the human PDGFRalpha has been found in patients with gastrointestinal stromal tumors. Here we show that a mutation in the corresponding codon in the activation loop of the murine PDGFRbeta, namely an exchange of asparagine for aspartic acid at amino acid position 849 (D849N), confers transforming characteristics to embryonic fibroblasts from mutant mice, generated by a knock-in strategy. By comparing the enzymatic properties of the wild-type versus the mutant receptor protein, we demonstrate that the D849N mutation lowers the threshold for kinase activation, causes a dramatic alteration in the pattern of tyrosine phosphorylation kinetics following ligand stimulation, and induces a ligand-independent phosphorylation of several tyrosine residues. These changes result in deregulated recruitment of specific signal transducers. The GTPase-activating protein for Ras (RasGAP), a negative regulator of the Ras mitogenic pathway, displayed a delayed binding to the mutant receptor. Moreover, we have observed enhanced ligand-independent ERK1/2 activation and an increased proliferation of mutant cells. The p85 regulatory subunit of the phosphatidylinositol 3'-kinase was constitutively associated with the mutant receptor, and this ligand-independent activation of the phosphatidylinositol 3'-kinase pathway may explain the observed strong protection against apoptosis and increased motility in cellular wounding assays. Our findings support a model whereby an activating point mutation results in a deregulated PDGFRbeta with oncogenic predisposition.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; AZU, Lab Expt Cardiol, Hart Long Cent Utrecht Cardiol, NL-3584 CX Utrecht, Netherlands; Univ Turin, Sch Med, Div Mol Oncol, Inst Canc Res & Treatment, I-10060 Turin, Italy	Ludwig Institute for Cancer Research; University of Turin	Heuchel, R (corresponding author), Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.	Rainer.Heuchel@licr.uu.se	Goumans, Marie-José/AAG-4994-2021; Goumans, Marie Jose/U-1455-2019; Heuchel, Rainer/P-7875-2019	Goumans, Marie Jose/0000-0001-9344-6746; Heuchel, Rainer/0000-0002-2782-585X; chiara, federica/0000-0003-2396-3080; Rasola, Andrea/0000-0003-4522-3008				Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; Chiara F, 2004, J BIOL CHEM, V279, P19732, DOI 10.1074/jbc.M314070200; Chiara F, 2003, J BIOL CHEM, V278, P29352, DOI 10.1074/jbc.M302404200; De Vita G, 2000, CANCER RES, V60, P3727; DeMali KA, 1997, J BIOL CHEM, V272, P9011; Ekman S, 2002, ONCOGENE, V21, P1870, DOI 10.1038/sj.onc.1205210; Ekman S, 1999, ONCOGENE, V18, P2481, DOI 10.1038/sj.onc.1202606; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Heuchel R, 1999, P NATL ACAD SCI USA, V96, P11410, DOI 10.1073/pnas.96.20.11410; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Irusta PM, 2002, J BIOL CHEM, V277, P38627, DOI 10.1074/jbc.M204890200; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Nagata H, 1997, INT ARCH ALLERGY IMM, V113, P184, DOI 10.1159/000237541; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Persson C, 2004, MOL CELL BIOL, V24, P2190, DOI 10.1128/MCB.24.5.2190-2201.2004; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; Rasola A, 2001, CYTOMETRY, V45, P151, DOI 10.1002/1097-0320(20011001)45:2<151::AID-CYTO1157>3.0.CO;2-I; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; Tallquist MD, 2000, GENE DEV, V14, P3179, DOI 10.1101/gad.844700; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434	36	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42516	42527		10.1074/jbc.M406051200	http://dx.doi.org/10.1074/jbc.M406051200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15284236	hybrid, Green Published			2022-12-27	WOS:000224226400023
J	Han, ZY; Harty, RN				Han, ZY; Harty, RN			The NS3 protein of bluetongue virus exhibits viroporin-like properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-A VIRUS; MEMBRANE PERMEABILIZATION; INFECTED-CELLS; ESCHERICHIA-COLI; LIPID-BILAYERS; INSECT CELLS; 2B PROTEIN; RELEASE; ROTAVIRUS; SEQUENCE	Viroporins compose a group of small hydrophobic transmembrane proteins that can form hydrophilic pores through lipid bilayers. Viroporins have been implicated in promoting virus release from infected cells and in affecting cellular functions including protein trafficking and membrane permeability. Nonstructural protein 3 (NS3) of bluetongue virus has been shown previously to be important for efficient release of newly made virions from infected cells. In this report, we demonstrate that NS3 possesses properties commonly associated with viroporins. Our findings indicate that: (i) NS3 localizes to the Golgi apparatus and plasma membrane in transfected cells, (ii) NS3 can homo-oligomerize in transfected cells, (iii) targeting of NS3 to the Golgi apparatus and plasma membrane correlates with the enhanced permeability of cells to the translation inhibitor hygromycin B (hyg-B), (iv) amino acids 118-148 comprising transmembrane region 1 (TM1) of NS3 are critical for Golgi targeting and hyg-B permeability, and (v) deletion of amino acids 156-181 comprising transmembrane region 2 (TM2) of NS3 has little to no affect on Golgi targeting and hyg-B permeability. These viroporin-like properties may contribute to the role of NS3 in virus release and may have important implications for pathogenicity of bluetongue virus infections.	Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Harty, RN (corresponding author), Univ Penn, Sch Vet Med, Dept Pathobiol, 3800 Spruce St, Philadelphia, PA 19104 USA.	rharty@vet.upenn.edu						Agirre A, 2002, J BIOL CHEM, V277, P40434, DOI 10.1074/jbc.M205393200; Aldabe R, 1996, J BIOL CHEM, V271, P23134, DOI 10.1074/jbc.271.38.23134; ALONSO MA, 1982, EUR J BIOCHEM, V127, P567; ARROYO J, 1995, J VIROL, V69, P4095, DOI 10.1128/JVI.69.7.4095-4102.1995; Bansal OB, 1998, J VIROL, V72, P3362, DOI 10.1128/JVI.72.4.3362-3369.1998; Beaton AR, 2002, P NATL ACAD SCI USA, V99, P13154, DOI 10.1073/pnas.192432299; BENEDUCE F, 1995, VIRUS RES, V36, P299, DOI 10.1016/0168-1702(95)00009-F; Bodelon G, 2002, J BIOL CHEM, V277, P17789, DOI 10.1074/jbc.M202018200; Browne EP, 2000, J GEN VIROL, V81, P1955, DOI 10.1099/0022-1317-81-8-1955; Chang YS, 1999, J VIROL, V73, P6257, DOI 10.1128/JVI.73.8.6257-6264.1999; Chavez A, 1998, ANALYST, V123, P2251, DOI 10.1039/a804562c; de Jong AS, 2003, J BIOL CHEM, V278, P1012, DOI 10.1074/jbc.M207745200; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; Freed EO, 2002, J VIROL, V76, P4679, DOI 10.1128/JVI.76.10.4679-4687.2002; Gonzalez ME, 2003, FEBS LETT, V552, P28, DOI 10.1016/S0014-5793(03)00780-4; Han ZY, 2003, J VIROL, V77, P1793, DOI 10.1128/JVI.77.3.1793-1800.2003; HYATT AD, 1989, VIROLOGY, V173, P21, DOI 10.1016/0042-6822(89)90218-3; HYATT AD, 1993, VIROLOGY, V193, P592, DOI 10.1006/viro.1993.1167; HYATT AD, 1991, J GEN VIROL, V72, P2263, DOI 10.1099/0022-1317-72-9-2263; LAMA J, 1995, FEBS LETT, V367, P5, DOI 10.1016/0014-5793(95)00523-C; Lama J, 1996, J GEN VIROL, V77, P2109, DOI 10.1099/0022-1317-77-9-2109; LAMA J, 1992, BIOCHEM BIOPH RES CO, V188, P972, DOI 10.1016/0006-291X(92)91327-M; Licata JM, 2003, J VIROL, V77, P1812, DOI 10.1128/JVI.77.3.1812-1819.2003; MUSTER T, 1994, J VIROL, V68, P4031, DOI 10.1128/JVI.68.6.4031-4034.1994; Perez M, 1997, VIROLOGY, V235, P342, DOI 10.1006/viro.1997.8696; Probst C, 1998, J VIROL, V72, P8013, DOI 10.1128/JVI.72.10.8013-8020.1998; Ruiz MC, 1997, J GEN VIROL, V78, P2883, DOI 10.1099/0022-1317-78-11-2883; SANZ MA, 1994, LEUKEMIA, V8, P1599; Spada E, 1998, RES VIROLOGY, V149, P209, DOI 10.1016/S0923-2516(98)80002-2; Tian P, 1996, J VIROL, V70, P6973, DOI 10.1128/JVI.70.10.6973-6981.1996; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; TOSTESON MT, 1993, P NATL ACAD SCI USA, V90, P10549, DOI 10.1073/pnas.90.22.10549; van Niekerk M, 2001, VIROLOGY, V279, P499, DOI 10.1006/viro.2000.0709; van Staden V, 1998, ARCH VIROL, P251; VanKuppeveld FJM, 1997, VIROLOGY, V227, P111, DOI 10.1006/viro.1996.8320; VANSTADEN V, 1995, ARCH VIROL, V140, P289, DOI 10.1007/BF01309863; WADEEVANS AM, 1990, NUCLEIC ACIDS RES, V18, P4920, DOI 10.1093/nar/18.16.4920; WU XY, 1992, J VIROL, V66, P7104, DOI 10.1128/JVI.66.12.7104-7112.1992	38	75	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43092	43097		10.1074/jbc.M403663200	http://dx.doi.org/10.1074/jbc.M403663200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292261	hybrid			2022-12-27	WOS:000224226400093
J	Moran, AE; Hunt, DH; Javid, SH; Redston, M; Carothers, AM; Bertagnolli, MM				Moran, AE; Hunt, DH; Javid, SH; Redston, M; Carothers, AM; Bertagnolli, MM			Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							EPIDERMAL-GROWTH-FACTOR; CYCLOOXYGENASE-2 INHIBITOR CELECOXIB; FOCAL ADHESION KINASE; FACTOR RECEPTOR; BETA-CATENIN; TYROSINE KINASES; TUMOR-FORMATION; PROTEIN-KINASE; E-CADHERIN; C-CBL	Overexpression of the epidermal growth factor receptor ( EGFR) and its increased tyrosine kinase activity are implicated in colorectal cancer (CRC) development and malignant progression. The C57BL/6J-Min/+ (Min/+) mouse is a model for CRC and develops numerous intestinal adenomas. We analyzed the normal mucosa of Min/+ and Apc(+/+) (WT) littermate mice together with Apc-null adenomas to gain insight into the roles of Egfr in these intestinal tissues. Protein analyses showed that Egfr activity was highest in the tumors, and also up-regulated in Min/+ relative to WT enterocytes. Expression of ubiquitylated Egfr (Egfr-Ub) was increased in Min/+ enterocytes and tumors. Tumors exhibited increased association of Egfr with clathrin heavy chain (CHC), Gab1, and p85alpha, the regulatory subunit of phosphoinositide 3-kinase (PI3K), and tumors also overexpressed c-Src, PDK1, and Akt. Immunohistochemistry for Akt-p-Ser473 revealed a low level of this active kinase in Min/+ and WT enterocytes and its strong presence in tumors. Prostaglandin E-2 (PGE(2)) is a product of cyclooxygenase-2 (Cox-2) activity that is up-regulated in Min/+ tumors and transactivates Egfr. PGE(2) expression was significantly higher in untreated Min/+ tumors and reduced by treatment with the Cox-2 inhibitor, celecoxib. Dietary administration of this NSAID also inhibited Egfr activity in tumors. Increased activation of the EGFR-PI3K-Akt signaling pathway in tumors relative to Apc(+/+) and Apc(Min/+) enterocytes provides potential opportunities for therapeutic interventions to differentially suppress tumor formation, promotion, progression, and/or recurrence.	Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Cornell Univ, Weill Coll Med, Dept Surg, New York, NY 10021 USA; Strang Canc Prevent Ctr, New York, NY 10021 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Cornell University; Harvard University; Brigham & Women's Hospital	Bertagnolli, MM (corresponding author), Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.	mbertagnolli@partners.org						Aggarwal BB, 2003, ANTICANCER RES, V23, P363; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; Boolbol SK, 1996, CANCER RES, V56, P2556; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Calvert PM, 2002, ANN INTERN MED, V137, P603, DOI 10.7326/0003-4819-137-7-200210010-00012; Carothers AM, 2001, J BIOL CHEM, V276, P39094, DOI 10.1074/jbc.M103450200; CARPENTIER JL, 1986, EXP CELL RES, V166, P312, DOI 10.1016/0014-4827(86)90479-9; CHAKRABORTI S, 1989, AM J PHYSIOL, V257, pL430, DOI 10.1152/ajplung.1989.257.6.L430; Chan PC, 2003, J BIOL CHEM, V278, P44075, DOI 10.1074/jbc.M305745200; Chiu CH, 1997, CANCER RES, V57, P4267; COUET J, 1997, J BIOL CHEM, V43, P30636; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; FRAHADI A, 2003, J GASTROEN HEPATOL, V18, P479; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; GROSS KH, 2000, J CLIN ONCOL, V18, P1967; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Haigis KM, 2002, P NATL ACAD SCI USA, V99, P8927, DOI 10.1073/pnas.132275099; HAIGLER HT, 1979, J CELL BIOL, V83, P82, DOI 10.1083/jcb.83.1.82; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Hansen-Petrik MB, 2002, CANCER RES, V62, P403; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Huls G, 2003, LANCET, V362, P230, DOI 10.1016/S0140-6736(03)13915-3; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Jacoby RF, 2000, CANCER RES, V60, P5040; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Khaleghpour K, 2004, CARCINOGENESIS, V25, P241, DOI 10.1093/carcin/bgg195; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; LUONGO C, 1994, CANCER RES, V54, P5947; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mahmoud NN, 1999, CANCER RES, V59, P353; Mahmoud NN, 1997, CANCER RES, V57, P5045; Mahmoud NN, 1998, CARCINOGENESIS, V19, P87, DOI 10.1093/carcin/19.1.87; Mahmoud NN, 2000, CARCINOGENESIS, V21, P921, DOI 10.1093/carcin/21.5.921; Mariner DJ, 2004, J CELL SCI, V117, P1339, DOI 10.1242/jcs.01001; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; MUAKAMI M, 2004, J BIOL CHEM, V43, P3; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Rahme E, 2003, GASTROENTEROLOGY, V125, P404, DOI 10.1016/S0016-5085(03)00880-1; Ravid T, 2002, J BIOL CHEM, V277, P31214, DOI 10.1074/jbc.M204677200; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ritland SR, 2000, CANCER RES, V60, P4678; Roberts RB, 2002, P NATL ACAD SCI USA, V99, P1521, DOI 10.1073/pnas.032678499; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; SANO H, 1995, CANCER RES, V55, P3785; SAPPENBECK TS, 2000, DEVELOPMENT, V127, P2629; SCHALKWIJK CG, 1995, EUR J BIOCHEM, V231, P593, DOI 10.1111/j.1432-1033.1995.tb20737.x; SCHEVING LA, 1989, J BIOL CHEM, V264, P1735; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Scita G, 2001, J CELL BIOL, V154, P1031, DOI 10.1083/jcb.200103146; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sonoshita M, 2002, CANCER RES, V62, P6846; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Sorkina T, 2002, J BIOL CHEM, V277, P27433, DOI 10.1074/jbc.M201595200; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Takeda H, 2003, CANCER RES, V63, P4872; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; van Rossum GSAT, 2004, BBA-MOL CELL BIOL L, V1636, P183, DOI 10.1016/j.bbalip.2003.12.008; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; Weyant MJ, 2000, CLIN CANCER RES, V6, P949; Weyant MJ, 2001, CANCER RES, V61, P2547; Weyant MJ, 2001, CANCER RES, V61, P118; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Xie H, 1998, J CELL SCI, V111, P615; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zhao S, 2002, EXP CELL RES, V279, P354, DOI 10.1006/excr.2002.5622	105	80	84	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43261	43272		10.1074/jbc.M404276200	http://dx.doi.org/10.1074/jbc.M404276200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15294912	hybrid			2022-12-27	WOS:000224226400111
J	DeHaven, W; Cuevas, J				DeHaven, W; Cuevas, J			VPAC receptor modulation of neuroexcitability in intracardiac neurons - Dependence on intracellular calcium mobilization and synergistic enhancement by PAC1 receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; PARASYMPATHETIC CARDIAC GANGLIA; PHOSPHOLIPASE-C ACTIVATION; BINDING-SITES; CYCLIC-AMP; CA2+ RELEASE; EVOKED CURRENTS; PEPTIDE PACAP; RAT-BRAIN; CELLS	Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) have been found within mammalian intracardiac ganglia, but the cellular effects of these neuropeptides remain poorly understood. Fluorometric calcium imaging and whole cell patch clamp recordings were used to examine the effects of PACAP and VIP on [Ca2+](i) and neuroexcitability, respectively, in intracardiac neurons of neonatal rats. PACAP and VIP evoked rapid increases in [Ca2+](i) that exhibited both transient and sustained components. Pharmacological experiments using PAC(1) and VPAC receptor-selective antagonists demonstrated that the elevations in [Ca2+](i) result from the activation of VPAC receptors. The transient increases in [Ca2+](i) were shown to be the product of Ca2+ mobilization from caffeine/ryanodine-sensitive intracellular stores and were not due to inositol 1,4,5-trisphosphate-mediated calcium release. In contrast, the sustained [Ca2+](i) elevations were dependent on extracellular Ca2+ and were blocked by the transient receptor channel antagonist, 2-aminoethoxydiphenyl borate, which suggests that they are due to Ca2+ entry via store-operated channels. In addition to elevating [Ca2+](i), both PACAP and VIP depolarized intracardiac neurons, and PACAP was further shown to augment action potential firing in these cells. Depolarization of intracardiac neurons by the neuropeptides was dependent on activation of VPAC receptors and the concomitant increases in [Ca2+](i). Although activation of PAC1 receptors alone had no direct effects on neuroexcitability, PAC(1) receptor stimulation potentiated the VPAC receptor-induced depolarizations. Furthermore, enhanced action potential firing was only observed upon concurrent stimulation of PAC(1) and VPAC receptors, which indicates that these receptors act synergistically to enhance neuroexcitability in intracardiac neurons.	Univ S Florida, Coll Med, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Cuevas, J (corresponding author), Univ S Florida, Coll Med, Dept Pharmacol & Therapeut, 12901 Bruce B Downs Blvd,MDC 9, Tampa, FL 33612 USA.	jcuevas@hsc.usf.edu	Cuevas, Javier/I-4941-2012		NHLBI NIH HHS [R01 HL63247] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063247] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTON PA, 1993, IMMUNOPHARM IMMUNOT, V15, P429, DOI 10.3109/08923979309035238; ARMOUR JA, 1993, PEPTIDES, V14, P191, DOI 10.1016/0196-9781(93)90029-G; Basler I, 1995, EUR J PHARM-MOLEC PH, V291, P335, DOI 10.1016/0922-4106(95)90074-8; Beker F, 2003, J NEUROPHYSIOL, V90, P1956, DOI 10.1152/jn.01079.2002; Braas KM, 1998, J NEUROSCI, V18, P9766; Calupca MA, 2000, J COMP NEUROL, V423, P26; Cardell LO, 1997, BRIT J PHARMACOL, V120, P1096, DOI 10.1038/sj.bjp.0700992; CAUVIN A, 1991, REGUL PEPTIDES, V35, P161, DOI 10.1016/0167-0115(91)90478-Y; CAUVIN A, 1990, PEPTIDES, V11, P773, DOI 10.1016/0196-9781(90)90194-A; Champion HC, 1996, ANN NY ACAD SCI, V805, P429; Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226; CHRISTOPHE J, 1993, BIOCHIM BIOPHYS ACTA, V1154, P183, DOI 10.1016/0304-4157(93)90011-C; CHU A, 1990, MOL PHARMACOL, V37, P735; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Cuevas J, 1996, J PHYSIOL-LONDON, V493, P503, DOI 10.1113/jphysiol.1996.sp021399; Cuevas J, 1997, J NEUROPHYSIOL, V78, P1890, DOI 10.1152/jn.1997.78.4.1890; Cuevas J, 1998, J NEUROSCI, V18, P10335; DeHaven WI, 2002, NEUROSCI LETT, V328, P45, DOI 10.1016/S0304-3940(02)00445-7; DELLA NG, 1983, NEUROSCIENCE, V9, P605, DOI 10.1016/0306-4522(83)90177-X; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P215, DOI 10.1113/jphysiol.1991.sp018466; GOTTSCHALL PE, 1990, ENDOCRINOLOGY, V127, P272, DOI 10.1210/endo-127-1-272; GOTTSCHALL PE, 1991, FASEB J, V5, P194, DOI 10.1096/fasebj.5.2.1848519; GOURLET P, 1995, EUR J PHARMACOL, V287, P7, DOI 10.1016/0014-2999(95)00467-5; Grimaldi M, 2000, ANN NY ACAD SCI, V921, P312; GULBENKIAN S, 1993, CIRC RES, V73, P579, DOI 10.1161/01.RES.73.3.579; Hashimoto H, 2002, BIOCHEM BIOPH RES CO, V297, P427, DOI 10.1016/S0006-291X(02)02144-7; Hirose M, 1997, EUR J PHARMACOL, V338, P35, DOI 10.1016/S0014-2999(97)01312-5; Horackova M, 2000, TISSUE CELL, V32, P377, DOI 10.1054/tice.2000.0126; HUANG M, 1993, PEPTIDES, V14, P755, DOI 10.1016/0196-9781(93)90109-T; ISHIZUKA Y, 1992, REGUL PEPTIDES, V40, P29, DOI 10.1016/0167-0115(92)90081-5; KARASAWA Y, 1990, EUR J PHARMACOL, V187, P9; KASE H, 1991, PFLUG ARCH EUR J PHY, V419, P668, DOI 10.1007/BF00370314; Kawasaki J, 1997, BRIT J PHARMACOL, V121, P977, DOI 10.1038/sj.bjp.0701206; Kohlmeier KA, 1999, J NEUROSCI, V19, P4073; LAM HC, 1990, EUR J BIOCHEM, V193, P725, DOI 10.1111/j.1432-1033.1990.tb19392.x; Langer I, 2001, CELL CALCIUM, V30, P229, DOI 10.1054/ceca.2001.0230; Lee SH, 2003, J NEUROPHYSIOL, V90, P1224, DOI 10.1152/jn.00280.2003; LEECH CA, 1995, ENDOCRINOLOGY, V136, P1530, DOI 10.1210/en.136.4.1530; Liu DM, 2000, EUR J NEUROSCI, V12, P2243, DOI 10.1046/j.1460-9568.2000.00116.x; Luo X, 1999, J BIOL CHEM, V274, P17684, DOI 10.1074/jbc.274.25.17684; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MacKenzie CJ, 2001, ENDOCRINOLOGY, V142, P1209, DOI 10.1210/en.142.3.1209; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Moro O, 1997, J BIOL CHEM, V272, P966, DOI 10.1074/jbc.272.2.966; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; Payet MD, 2003, J BIOL CHEM, V278, P1663, DOI 10.1074/jbc.M206470200; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; RAWLINGS SR, 1995, ENDOCRINOLOGY, V136, P2088, DOI 10.1210/en.136.5.2088; RIGEL DF, 1989, AM J PHYSIOL, V257, pH1082, DOI 10.1152/ajpheart.1989.257.4.H1082; ROBBERECHT P, 1992, EUR J BIOCHEM, V207, P239, DOI 10.1111/j.1432-1033.1992.tb17043.x; SEABROOK GR, 1990, AM J PHYSIOL, V259, pH997, DOI 10.1152/ajpheart.1990.259.4.H997; Seebeck J, 1996, N-S ARCH PHARMACOL, V354, P424, DOI 10.1007/BF00168432; SHIVERS BD, 1991, ENDOCRINOLOGY, V128, P3055, DOI 10.1210/endo-128-6-3055; Smith AB, 1999, NEUROSCI LETT, V264, P105, DOI 10.1016/S0304-3940(99)00180-9; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SUDA K, 1992, NEUROSCI LETT, V137, P19, DOI 10.1016/0304-3940(92)90288-I; Tanaka K, 1998, J NEUROCHEM, V70, P1652; WARREN JB, 1991, EUR J PHARMACOL, V197, P131, DOI 10.1016/0014-2999(91)90511-N; Weigl L, 2003, N-S ARCH PHARMACOL, V367, P353, DOI 10.1007/s00210-003-0705-8; WEIHE E, 1984, CELL TISSUE RES, V236, P527; Xia MH, 1996, J CLIN IMMUNOL, V16, P21, DOI 10.1007/BF01540969; XU ZJ, 1992, J PHYSIOL-LONDON, V456, P425, DOI 10.1113/jphysiol.1992.sp019344; Xue HH, 2000, J BIOCHEM, V128, P329, DOI 10.1093/oxfordjournals.jbchem.a022757; Yonezawa T, 1996, EUR J PHARMACOL, V315, P289, DOI 10.1016/S0014-2999(96)00609-7; Zhou CJ, 2001, PEPTIDES, V22, P1111, DOI 10.1016/S0196-9781(01)00437-5	65	35	35	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40609	40621		10.1074/jbc.M404743200	http://dx.doi.org/10.1074/jbc.M404743200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15280371	hybrid			2022-12-27	WOS:000223916800049
J	Muller, EA; Danner, DJ				Muller, EA; Danner, DJ			Tissue-specific translation of murine branched-chain alpha-ketoacid dehydrogenase kinase mRNA is dependent upon an upstream open reading frame in the 5 '-untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-OXO ACID DEHYDROGENASE; SECONDARY STRUCTURE; GENE-EXPRESSION; ACTIVITY STATE; COMPLEX; PROMOTER; TRANSCRIPTION; IDENTIFICATION; METABOLISM; CLONING	The committed step in the pathway for leucine, isoleucine, and valine catabolism is catalyzed by branched-chain alpha-ketoacid dehydrogenase (BCKD). This multienzyme complex is itself regulated through reversible subunit phosphorylation by a specific kinase (BCKD-kinase). Although BCKD is present in the mitochondria of all mammalian cells, BCKD-kinase has a tissue-specific pattern of expression. Various experimental, nutritional, and hormonal conditions have been used to alter the expression of BCKD-kinase, yet little is known regarding the regulation of basal BCKD-kinase expression under normal conditions including the mechanism of its tissue specificity in any organism. Here we use tissue-derived cultured cells to explore the mechanisms used to control BCKD-kinase expression. Whereas the amount of BCKD-kinase protein is significantly higher in mitochondria from C2C12 myotubes than in BNL Cl. 2 liver cells, gene transcription and stability of BCKD-kinase mRNA share similar properties in these two cell types. Our results show that the amount of protein synthesized is regulated at the level of translation of BCKD-kinase mRNA and that an upstream open reading frame in the 5'- untranslated region of this transcript controls its translation. The location and putative 19-residue peptide are conserved in the mouse, rat, chimpanzee, and human genes. Likewise, gene structure of mouse, chimpanzee, and human BCKD-kinase is conserved, whereas the rat gene has lost intron 9.	Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Danner, DJ (corresponding author), Emory Univ, Sch Med, Dept Human Genet, 615 Michael St,Rm 305C, Atlanta, GA 30322 USA.	ddanner@genetics.emory.edu			NIGMS NIH HHS [T32 GM008169, 5T32GM-08490, 5T32GM-08169, T32 GM008490] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008490, T32GM008169] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Borchert A, 2003, J BIOL CHEM, V278, P2571, DOI 10.1074/jbc.M209064200; CHUANG DT, 1981, BIOCHEM J, V200, P59, DOI 10.1042/bj2000059; CHUANG DT, 1995, METABOLIC MOL BASES, P1239; DANCIS J, 1960, BIOCHIM BIOPHYS ACTA, V43, P342, DOI 10.1016/0006-3002(60)90448-0; Danner DJ, 2000, METHOD ENZYMOL, V324, P336; DANNER DJ, 1988, METHOD ENZYMOL, V166, P108; Denson LA, 2001, J CLIN INVEST, V107, P1451, DOI 10.1172/JCI10994; Ding Y, 2003, NUCLEIC ACIDS RES, V31, P7280, DOI 10.1093/nar/gkg938; Ding Y, 2001, NUCLEIC ACIDS RES, V29, P1034, DOI 10.1093/nar/29.5.1034; Doering CB, 1998, GENE, V212, P213, DOI 10.1016/S0378-1119(98)00182-6; Doering CB, 2000, METAB ENG, V2, P349, DOI 10.1006/mben.2000.0164; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; GIBSON R, 1993, ARCH BIOCHEM BIOPHYS, V306, P22, DOI 10.1006/abbi.1993.1475; GILLIM SE, 1983, BIOCHEM BIOPH RES CO, V111, P74, DOI 10.1016/S0006-291X(83)80119-3; HARRIS RA, 1988, METHOD ENZYMOL, V166, P114; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Huang YS, 2000, METHOD ENZYMOL, V324, P498; Huang YS, 1998, BIOCHEM J, V334, P713, DOI 10.1042/bj3340713; Huang YS, 1996, BIOCHEM J, V313, P603, DOI 10.1042/bj3130603; Kasinski A, 2004, MOL BRAIN RES, V122, P180, DOI 10.1016/j.molbrainres.2003.08.023; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; Kobayashi R, 2000, ARCH BIOCHEM BIOPHYS, V375, P55, DOI 10.1006/abbi.1999.1635; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Laviano A, 1996, NUTRITION, V12, P358, DOI 10.1016/S0899-9007(96)80061-X; Lee J, 2002, NUCLEIC ACIDS RES, V30, P5110, DOI 10.1093/nar/gkf664; Martin KM, 2000, BIOCHEM J, V345, P529, DOI 10.1042/0264-6021:3450529; McConnell BB, 1996, J CELL BIOCHEM, V61, P118, DOI 10.1002/(SICI)1097-4644(19960401)61:1<118::AID-JCB13>3.0.CO;2-K; Meijer HA, 2003, NUCLEIC ACIDS RES, V31, P3174, DOI 10.1093/nar/gkg429; MENKES JH, 1959, PEDIATRICS, V23, P348; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Nellis MM, 2002, AM J PHYSIOL-ENDOC M, V283, pE853, DOI 10.1152/ajpendo.00133.2002; ODESSEY R, 1982, BIOCHEM J, V204, P353, DOI 10.1042/bj2040353; PAXTON R, 1984, ARCH BIOCHEM BIOPHYS, V231, P48, DOI 10.1016/0003-9861(84)90361-8; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; POPOV KM, 1995, ARCH BIOCHEM BIOPHYS, V316, P148, DOI 10.1006/abbi.1995.1022; Raney A, 2000, J BIOL CHEM, V275, P24444, DOI 10.1074/jbc.M003364200; Sitler TL, 1998, BBA-MOL CELL RES, V1404, P385, DOI 10.1016/S0167-4889(98)00086-X; Tarumi T, 2002, J BIOL CHEM, V277, P18510, DOI 10.1074/jbc.M201886200; Vilela C, 2003, MOL MICROBIOL, V49, P859, DOI 10.1046/j.1365-2958.2003.03622.x; WAGENMAKERS AJM, 1984, BIOCHEM J, V220, P273, DOI 10.1042/bj2200273; Wang Z, 1997, MOL CELL BIOL, V17, P4904, DOI 10.1128/MCB.17.9.4904; Wu Z, 2003, ENDOCRINOLOGY, V144, P3251, DOI 10.1210/en.2003-0015	45	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44645	44655		10.1074/jbc.M406550200	http://dx.doi.org/10.1074/jbc.M406550200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302860	hybrid			2022-12-27	WOS:000224505600051
J	Dufour, G; Demers, MJ; Gagne, D; Dydensborg, AB; Teller, IC; Bouchard, V; Degongre, I; Beaulieu, JF; Cheng, JQ; Fujita, N; Tsuruo, T; Vallee, K; Vachon, PH				Dufour, G; Demers, MJ; Gagne, D; Dydensborg, AB; Teller, IC; Bouchard, V; Degongre, I; Beaulieu, JF; Cheng, JQ; Fujita, N; Tsuruo, T; Vallee, K; Vachon, PH			Human intestinal epithelial cell survival and anoikis - Differentiation state-distinct regulation and roles of protein kinase B/Akt isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TRANSIENT MOSAIC PATTERNS; INDUCED APOPTOSIS-ANOIKIS; CRYPT-VILLUS AXIS; PHOSPHATIDYLINOSITOL 3-KINASE; BCL-2 HOMOLOGS; MICE LACKING; ENTEROCYTIC DIFFERENTIATION; COMPLEX MODULATIONS; SIGNAL-TRANSDUCTION	We have shown previously that human intestinal epithelial cell survival and anoikis are distinctively regulated according to the state of differentiation. Here we analyzed the roles of protein kinase B/Akt isoforms in such differentiation state distinctions. Anoikis was induced in undifferentiated and differentiated enterocytes by inhibition of focal adhesion kinase (Fak; pharmacologic inhibition or overexpression of dominant-negative mutants) or beta(1) integrins (antibody blocking) or by maintaining cells in suspension. Expression/ activation parameters of Akt isoforms (Akt-1, Akt-2, and Akt-3) and Fak were analyzed. Activity of Akt isoforms was also blocked by inhibition of phosphatidylinositol 3-kinase or by overexpression of dominant-negative mutants. Here we report the following. 1) The expression/activation levels of Akt-1 increase overall during enterocytic differentiation, and those of Akt-2 decrease, whereas Akt-3 is not expressed. 2) Akt-1 activation is dependent on beta(1) integrins/Fak signaling, regardless of the differentiation state. 3) Akt-2 activation is dependent on beta(1) integrins/Fak signaling in undifferentiated cells only. 4) Activation of Akt-1 is phosphatidylinositol 3-kinase-dependent, whereas that of Akt-2 is not. 5) Akt-2 does not promote survival or apoptosis/anoikis. 6) Akt-1 is essential for survival. 7) Akt-2 cannot substitute for Akt-1 in the suppression of anoikis. Hence, the expression and regulation of Akt isoforms show differentiation state-specific distinctions that ultimately reflect upon their selective implication in the mediation of human intestinal epithelial cell survival. These data provide new insights into the synchronized regulation of cell survival/death that is required in the dynamic renewal process of tissues such as the intestinal epithelium.	Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Canadian Inst Hlth Res Grp Funct Dev & Physiopath, Sherbrooke, PQ J1H 5N4, Canada; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr, Dept Pathol, Tampa, FL 33612 USA; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; CHU Sherbrooke, Ctr Rech Clin, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Tokyo; University of Sherbrooke	Vachon, PH (corresponding author), Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Canadian Inst Hlth Res Grp Funct Dev & Physiopath, Sherbrooke, PQ J1H 5N4, Canada.	Pierre.H.Vachon@USherbrooke.ca	Teller, Inga/AAW-1093-2020; Beaulieu, Jean-Francois/D-2054-2010	Teller, Inga/0000-0002-1708-8702; Fujita, Naoya/0000-0002-9631-9264				Aliaga JC, 1999, AM J PHYSIOL-GASTR L, V277, pG631, DOI 10.1152/ajpgi.1999.277.3.G631; Altomare DA, 1998, ONCOGENE, V16, P2407, DOI 10.1038/sj.onc.1201750; Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Basora N, 1999, J BIOL CHEM, V274, P29819, DOI 10.1074/jbc.274.42.29819; Basora N, 1997, GASTROENTEROLOGY, V113, P1510, DOI 10.1053/gast.1997.v113.pm9352853; BEAULIEU JF, 1991, BIOCHEM J, V280, P599, DOI 10.1042/bj2800599; BEAULIEU JF, 1992, J CELL SCI, V102, P427; BEAULIEU JF, 1999, FRONT BIOSCI, V4, P310; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Frisch SM, 1999, METH MOL B, V129, P251; Fujio Y, 2001, CELL DEATH DIFFER, V8, P1207, DOI 10.1038/sj.cdd.4400919; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Gauthier R, 2001, AM J PHYSIOL-CELL PH, V280, pC1540, DOI 10.1152/ajpcell.2001.280.6.C1540; Gauthier R, 2001, J CELL BIOCHEM, V82, P339, DOI 10.1002/jcb.1172; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grossmann J, 2002, AM J GASTROENTEROL, V97, P1421, DOI 10.1016/S0002-9270(02)04143-6; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147; Grossmann J, 2001, GASTROENTEROLOGY, V120, P79, DOI 10.1053/gast.2001.20879; Grossmann J, 1998, AM J PHYSIOL-GASTR L, V274, pG1117, DOI 10.1152/ajpgi.1998.274.6.G1117; Harnois C, 2004, J CELL PHYSIOL, V198, P209, DOI 10.1002/jcp.10399; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Laprise P, 2003, J CELL BIOCHEM, V89, P1115, DOI 10.1002/jcb.10581; Laprise P, 2002, J CELL PHYSIOL, V191, P69, DOI 10.1002/jcp.10075; Laprise P, 2002, J BIOL CHEM, V277, P8226, DOI 10.1074/jbc.M110235200; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Levy P, 2003, J CELL PHYSIOL, V197, P336, DOI 10.1002/jcp.10345; Levy P, 1998, J CELL PHYSIOL, V177, P618, DOI 10.1002/(SICI)1097-4652(199812)177:4<618::AID-JCP12>3.0.CO;2-R; Liu AX, 1998, CANCER RES, V58, P2973; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nolan K, 1999, MOL CELL BIOL, V19, P6120; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Pageot LP, 2000, MICROSC RES TECHNIQ, V49, P394; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Potten CS, 1997, AM J PHYSIOL-GASTR L, V273, pG253, DOI 10.1152/ajpgi.1997.273.2.G253; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Ringel MD, 2001, CANCER RES, V61, P6105; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sumitani S, 2002, ENDOCRINOLOGY, V143, P820, DOI 10.1210/en.143.3.820; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thomson ABR, 2003, DIGEST DIS SCI, V48, P1546, DOI 10.1023/A:1024719925058; Thomson ABR, 2003, DIGEST DIS SCI, V48, P1565, DOI 10.1023/A:1024724109128; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; Vachon PH, 1997, J CLIN INVEST, V100, P1870, DOI 10.1172/JCI119716; Vachon PH, 1996, J CELL PHYSIOL, V166, P198, DOI 10.1002/(SICI)1097-4652(199601)166:1<198::AID-JCP21>3.0.CO;2-A; Vachon PH, 1996, J CELL BIOL, V134, P1483, DOI 10.1083/jcb.134.6.1483; Vachon PH, 2001, HISTOL HISTOPATHOL, V16, P497, DOI 10.14670/HH-16.497; Vachon PH, 2000, INT J DEV BIOL, V44, P891; Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072; Vandromme M, 2001, J BIOL CHEM, V276, P8173, DOI 10.1074/jbc.M005587200; Wary KK, 1999, METH MOL B, V129, P35; Yu CF, 2000, AM J PHYSIOL-GASTR L, V278, pG952, DOI 10.1152/ajpgi.2000.278.6.G952; Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zinda MJ, 2001, CLIN CANCER RES, V7, P2475	74	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44113	44122		10.1074/jbc.M405323200	http://dx.doi.org/10.1074/jbc.M405323200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15299029	hybrid			2022-12-27	WOS:000224383100091
J	Gutierrez, S; Liu, JL; Javed, A; Montecino, M; Stein, GS; Lian, JB; Stein, JL				Gutierrez, S; Liu, JL; Javed, A; Montecino, M; Stein, GS; Lian, JB; Stein, JL			The vitamin D response element in the distal osteocalcin promoter contributes to chromatin organization of the proximal regulatory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DNA INTERACTIONS; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; OSTEOBLAST DIFFERENTIATION; MEDIATED TRANSACTIVATION; DEPENDENT TRANSCRIPTION; MOLECULAR-MECHANISMS; ORDERED RECRUITMENT; GENE-TRANSCRIPTION; RECEPTOR	Vitamin D receptor (VDR) and Runx2 are key regulators of tissue-specific gene transcription. Using the bone-related osteocalcin (OC) gene, we have previously shown that Runx2 is required for the extensive chromatin remodeling that accompanies gene activation. Here, we have addressed the direct contribution of the VDR to chromatin remodeling events necessary for regulation of OC transcription using mutational analysis. Our studies demonstrate that both the distal and proximal DNase I-hypersensitive sites characteristic of the transcriptionally active OC promoter are not enhanced in the absence of a functional vitamin D response element ( VDRE). Furthermore, restriction enzyme accessibility studies reveal that nucleosomal reorganization of the proximal promoter occurs in response to vitamin D and this reorganization is abrogated by mutation of the VDRE. These findings indicate that binding of liganded VDR in the distal promoter directly impacts the chromatin structure of the proximal promoter. We find that, in the absence of functional Runx sites, the VDR cannot be recruited to the OC promoter and, therefore, the VDRE is not competent to mediate vitamin D responsiveness. On the other hand, chromatin immunoprecipitation assays show that Runx2 association with the OC promoter is not significantly impaired when the VDRE is mutated. Chromatin immunoprecipitation assays also demonstrate that basal levels of histone acetylation occur in the absence of Runx2 binding but that the VDRE and vitamin D are required for enhanced acetylation of histones H3 and H4 downstream of the VDRE. Together our results support a stepwise model for chromatin remodeling of the OC promoter and show that binding of the liganded VDR . retinoid X receptor directly impacts both the distal and proximal regulatory domains.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA; Univ Concepcion, Dept Bioquim & Biol Mol, Concepcion 4079100, Chile	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Universidad de Concepcion	Stein, JL (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	janet.stein@umassmed.edu		Javed, Amjad/0000-0002-0847-8266	FOGARTY INTERNATIONAL CENTER [R03TW000990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR048818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE012528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; FIC NIH HHS [R03TW00990] Funding Source: Medline; NIAMS NIH HHS [P01AR48818] Funding Source: Medline; NIDCR NIH HHS [DE12528] Funding Source: Medline; NIDDK NIH HHS [P30DK32520] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Aslam F, 1999, ENDOCRINOLOGY, V140, P63, DOI 10.1210/en.140.1.63; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; BREEN EC, 1994, P NATL ACAD SCI USA, V91, P12902, DOI 10.1073/pnas.91.26.12902; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DEMAY MB, 1989, J BIOL CHEM, V264, P2279; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Frenkel B, 1996, ENDOCRINOLOGY, V137, P1080, DOI 10.1210/en.137.3.1080; FRENKEL B, 1993, BIOCHEMISTRY-US, V32, P13636, DOI 10.1021/bi00212a031; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; Javed A, 1999, MOL CELL BIOL, V19, P7491; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; LIAN J, 1989, P NATL ACAD SCI USA, V86, P1143, DOI 10.1073/pnas.86.4.1143; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; Montecino M, 1996, J CELL BIOCHEM, V63, P221, DOI 10.1002/(SICI)1097-4644(19961101)63:2<221::AID-JCB9>3.0.CO;2-#; Montecino M, 1996, BIOCHEMISTRY-US, V35, P5093, DOI 10.1021/bi952489s; MONTECINO M, 1994, BIOCHEMISTRY-US, V33, P348, DOI 10.1021/bi00167a045; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Mymryk JS, 1997, METHODS, V12, P105, DOI 10.1006/meth.1997.0452; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P5129, DOI 10.1073/pnas.87.13.5129; PAREDES R, 2004, IN PRESS MOL CELL BI; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Shen JL, 2002, J BIOL CHEM, V277, P20284, DOI 10.1074/jbc.M112440200; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Stein G., 1995, ENDOCR REV, V4, P290; TERPENING CM, 1991, MOL ENDOCRINOL, V5, P373, DOI 10.1210/mend-5-3-373; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; YOON K, 1988, BIOCHEMISTRY-US, V27, P8521, DOI 10.1021/bi00423a003	43	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43581	43588		10.1074/jbc.M408335200	http://dx.doi.org/10.1074/jbc.M408335200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15299011	hybrid			2022-12-27	WOS:000224383100030
J	Kruman, II; Schwartz, E; Kruman, Y; Cutler, RG; Zhu, XX; Greig, NH; Mattson, MP				Kruman, II; Schwartz, E; Kruman, Y; Cutler, RG; Zhu, XX; Greig, NH; Mattson, MP			Suppression of uracil-DNA glycosylase induces neuronal apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; CELL-CYCLE REGULATION; DAMAGE; P53; HOMOCYSTEINE; INHIBITOR; ENZYME; FOLATE; MISINCORPORATION; TRANSCRIPTION	A chronic imbalance in DNA precursors, caused by one-carbon metabolism impairment, can result in a deficiency of DNA repair and increased DNA damage. Although indirect evidence suggests that DNA damage plays a role in neuronal apoptosis and in the pathogenesis of neurodegenerative disorders, the underlying mechanisms are poorly understood. In particular, very little is known about the role of base excision repair of misincorporated uracil in neuronal survival. To test the hypothesis that repair of DNA damage associated with uracil misincorporation is critical for neuronal survival, we employed an antisense (AS) oligonucleotide directed against uracil-DNA glycosylase encoded by the UNG gene to deplete UNG in cultured rat hippocampal neurons. AS, but not a scrambled control oligonucleotide, induced apoptosis, which was associated with DNA damage analyzed by comet assay and up-regulation of p53. UNG mRNA and protein levels were decreased within 30 min and were undetectable within 6-9 h of exposure to the UNG AS oligonucleotide. Whereas UNG expression is significantly higher in proliferating as compared with nonproliferating cells, such as neurons, the levels of UNG mRNA were increased in brains of cystathionine beta-synthase knockout mice, a model for hyperhomocysteinemia, suggesting that one-carbon metabolism impairment and uracil misincorporation can induce the up-regulation of UNG expression.	Sun Hlth Res Inst, Sun City, AZ 85351 USA; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; NIA, Neurosci Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Banner Research; Banner Health; Banner Sun Health Research Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University	Kruman, II (corresponding author), Sun Hlth Res Inst, 10515 Santa Fe Dr, Sun City, AZ 85351 USA.	inna.kruman@sunhealth.org	Cutler, Roy G./L-5572-2013; Mattson, Mark P/F-6038-2012		NATIONAL INSTITUTE ON AGING [Z01AG000313, ZIAAG000311, Z01AG000312, ZIAAG000313, ZIAAG000312, Z01AG000311] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adimoolam S, 2003, DNA REPAIR, V2, P947, DOI 10.1016/S1568-7864(03)00087-9; APRELIKOVA ON, 1982, FEBS LETT, V137, P193, DOI 10.1016/0014-5793(82)80347-5; Ballestar E, 2002, CARCINOGENESIS, V23, P1103, DOI 10.1093/carcin/23.7.1103; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Brooks PJ, 2000, NEUROCHEM INT, V37, P403, DOI 10.1016/S0197-0186(00)00051-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; De Marco P, 2000, AM J MED GENET, V95, P216, DOI 10.1002/1096-8628(20001127)95:3<216::AID-AJMG6>3.0.CO;2-F; Dietrich P, 2003, MOL CELL NEUROSCI, V24, P430, DOI 10.1016/S1044-7431(03)00201-X; Duthie GG, 1999, P NUTR SOC, V58, P1015, DOI 10.1017/S0029665199001330; Fenech M, 2001, MUTAT RES-FUND MOL M, V480, P51, DOI 10.1016/S0027-5107(01)00168-3; FRIEDBERG E, 1995, REPAIR MUTAGENESIS; Gobbel GT, 1998, J NEUROSCI, V18, P147; GOULIAN M, 1980, P NATL ACAD SCI-BIOL, V77, P1956, DOI 10.1073/pnas.77.4.1956; HANAWALT PC, 1992, ANN NY ACAD SCI, V663, P17, DOI 10.1111/j.1749-6632.1992.tb38644.x; Haug T, 1998, NUCLEIC ACIDS RES, V26, P1449, DOI 10.1093/nar/26.6.1449; HO L, 1991, MUTAT RES, V255, P123, DOI 10.1016/0921-8777(91)90047-S; HUSCHTSCHA LI, 1994, EXP CELL RES, V212, P161, DOI 10.1006/excr.1994.1131; IMPELLIZZERI KJ, 1991, J BACTERIOL, V173, P6807, DOI 10.1128/jb.173.21.6807-6810.1991; James SJ, 1997, CARCINOGENESIS, V18, P287, DOI 10.1093/carcin/18.2.287; KANDEL ER, 1989, PRINCIPLES NEURAL SC, P19; Karahalil B, 2002, FASEB J, V16, P1895, DOI 10.1096/fj.02-0463com; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Krokan HE, 1997, BIOCHEM J, V325, P1; Kruman II, 2004, NEURON, V41, P549, DOI 10.1016/S0896-6273(04)00017-0; Kruman II, 2002, J NEUROSCI, V22, P1752, DOI 10.1523/JNEUROSCI.22-05-01752.2002; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Le Page F, 2000, CANCER RES, V60, P5548; Lin LH, 2000, J NEUROCHEM, V74, P1098; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lindahl T, 2000, COLD SPRING HARB SYM, V65, P127, DOI 10.1101/sqb.2000.65.127; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; MATTSON MP, 1989, J NEUROSCI, V9, P3728; MCCOMBE P, 1976, INT J RADIAT BIOL, V29, P523, DOI 10.1080/09553007614550621; Morris EJ, 1996, J CELL BIOL, V134, P757, DOI 10.1083/jcb.134.3.757; Morris EJ, 1999, BIOTECHNIQUES, V26, P282, DOI 10.2144/99262st02; NAGELHUS TA, 1995, EXP CELL RES, V220, P292, DOI 10.1006/excr.1995.1318; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; Nouspikel T, 2002, DNA REPAIR, V1, P59, DOI 10.1016/S1568-7864(01)00005-2; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Park DS, 1998, J NEUROSCI, V18, P830; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Quinn CT, 1997, J CLIN ONCOL, V15, P2800, DOI 10.1200/JCO.1997.15.8.2800; Rolig RL, 2000, TRENDS NEUROSCI, V23, P417, DOI 10.1016/S0166-2236(00)01625-8; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Scott JM, 1999, P NUTR SOC, V58, P441, DOI 10.1017/S0029665199000580; SKOVBY F, 1989, HAEMOSTASIS, V19, P4; SLUPPHAUG G, 1991, NUCLEIC ACIDS RES, V19, P5131, DOI 10.1093/nar/19.19.5131; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; Storb U, 2002, CURR BIOL, V12, pR725, DOI 10.1016/S0960-9822(02)01247-2; Tu GC, 1998, J BIOL CHEM, V273, P25125, DOI 10.1074/jbc.273.39.25125; Van Triest B, 2000, ANN ONCOL, V11, P385, DOI 10.1023/A:1008351221345; Wagner C, 1995, FOLATE HLTH DIS, P23; WALSH MJ, 1995, J BIOL CHEM, V270, P5289, DOI 10.1074/jbc.270.10.5289; WARNER M, 1985, MOL CELL BIOL, V12, P3560; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; Zhu XX, 2002, J MED CHEM, V45, P5090, DOI 10.1021/jm020044d	58	48	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43952	43960		10.1074/jbc.M408025200	http://dx.doi.org/10.1074/jbc.M408025200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15297456	hybrid			2022-12-27	WOS:000224383100073
J	Zhang, Z; Lapolla, SM; Annis, MG; Truscott, M; Roberts, GJ; Miao, YW; Shao, YL; Tan, CB; Peng, J; Johnson, AE; Zhang, XJC; Andrews, DW; Lin, JL				Zhang, Z; Lapolla, SM; Annis, MG; Truscott, M; Roberts, GJ; Miao, YW; Shao, YL; Tan, CB; Peng, J; Johnson, AE; Zhang, XJC; Andrews, DW; Lin, JL			Bcl-2 homodimerization involves two distinct binding surfaces, a topographic arrangement that provides an effective mechanism for Bcl-2 to capture activated Bax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PHOTO-CROSS-LINKING; FAMILY-MEMBERS; SIGNAL SEQUENCE; BH4 DOMAIN; BIOPHYSICAL CHARACTERIZATION; INDEPENDENT MECHANISMS; ENDOPLASMIC-RETICULUM; APOPTOTIC ACTIVITY; PROTEIN BCL-2	The homo- and heterodimerization of Bcl-2 family proteins is important for transduction and integration of apoptotic signals and control of the permeability of mitochondria and endoplasmic reticulum membranes. Here we mapped the interface of the Bcl-2 homodimer in a cell-free system using site-specific photocross-linking. Bcl-2 homodimer-specific photoadducts were detected from 11 of 17 sites studied. When modeled into the structure of Bcl-2 core, the interface is composed of two distinct surfaces: an acceptor surface that includes the hydrophobic groove made by helices 2 and 8 and the loop connecting helices 4 and 5 and a donor surface that is made by helices 1-4 and the loop connecting helices 2 and 3. The two binding surfaces are on separate faces of the three-dimensional structure, explaining the formation of Bcl-2 homodimers, homo- oligomers, and Bcl-2/Bax hetero-oligomers. We show that in vitro the Bcl-2 dimer can still interact with activated Bax as a larger oligomer. However, formation of a Bax/Bcl-2 heterodimer is favored, since this interaction inhibits Bcl-2 homodimerization. Our data support a simple model mechanism by which Bcl-2 interacts with activated Bax during apoptosis in an effective manner to neutralize the proapoptotic activity of Bax.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Oklahoma Med Res Fdn, Crystallog Res Program, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; McMaster University; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Oklahoma Medical Research Foundation	Lin, JL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 940 Stanton L Young Blvd,BMSB 935,POB 26901, Oklahoma City, OK 73190 USA.	jialing-lin@ouhsc.edu	Johnson, Arthur E/G-3457-2012	Andrews, David/0000-0002-9266-7157; Truscott, Mary/0000-0002-2324-6383; Annis, Matthew/0000-0002-8776-004X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062964] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM062964, R01 GM062964] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Annis MG, 2004, BBA-MOL CELL RES, V1644, P115, DOI 10.1016/j.bbamcr.2003.07.001; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; Denis GV, 2003, J BIOL CHEM, V278, P5775, DOI 10.1074/jbc.M210202200; Denisov AY, 2003, J BIOL CHEM, V278, P21124, DOI 10.1074/jbc.M301798200; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; HACKER G, 1995, CURR BIOL, V5, P622, DOI 10.1016/S0960-9822(95)00126-6; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hinds MG, 2003, EMBO J, V22, P1497, DOI 10.1093/emboj/cdg144; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Kim KM, 2001, BIOCHEMISTRY-US, V40, P4911, DOI 10.1021/bi002368e; Kim PK, 2004, MOL CELL, V14, P523, DOI 10.1016/S1097-2765(04)00263-1; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; Li LY, 2001, J BIOL CHEM, V276, P27354, DOI 10.1074/jbc.M103821200; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Lin JL, 2001, J BIOL CHEM, V276, P41733, DOI 10.1074/jbc.M103475200; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Mathura VS, 2003, J MOL MODEL, V9, P298, DOI 10.1007/s00894-003-0152-y; McCallum CD, 2000, J CELL BIOL, V149, P591, DOI 10.1083/jcb.149.3.591; McCormick PJ, 2003, MOL CELL, V12, P329, DOI 10.1016/S1097-2765(03)00304-6; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; StClair EG, 1997, J BIOL CHEM, V272, P29347; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wei MC, 2000, GENE DEV, V14, P2060; Woo JS, 2003, CELL DEATH DIFFER, V10, P1310, DOI 10.1038/sj.cdd.4401303; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	60	61	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43920	43928		10.1074/jbc.M406412200	http://dx.doi.org/10.1074/jbc.M406412200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15302859	hybrid, Green Accepted			2022-12-27	WOS:000224383100070
J	Barr, RK; Hopkins, RM; Watt, PM; Bogoyevitch, MA				Barr, RK; Hopkins, RM; Watt, PM; Bogoyevitch, MA			Reverse two-hybrid screening identifies residues of JNK required for interaction with the kinase interaction motif of JNK-interacting protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; PEPTIDE INHIBITOR; CELL-DEATH; DOCKING INTERACTIONS; MAP KINASES; IN-VITRO; ACTIVATION; PATHWAY; SPECIFICITY; NEURONS	The development of specific inhibitors for the c-Jun N-terminal kinase (JNK) family of mitogen-activated protein kinases (MAPKs) has been a recent research focus because of the association of JNK with cell death in conditions such as stroke and neurodegeneration. We have demonstrated previously the presence of critical inhibitory residues within an 11-mer peptide (TI-JIP) based on the sequence of JNK-interacting protein-1 (JIP-1). However, the corresponding region of JNK bound by this JIP-1-based peptide was unknown. To identify this region, we used a novel reverse two-hybrid approach with TI-JIP as bait. We screened a library of JNK1 mutants that had been generated by random PCR mutagenesis and found three mutants of JNK1 that failed to interact with TI-JIP. The mutations in JNK1 were L131R, R309W, and Y320H. Of these mutated residues, Leu-131 and Tyr-320 were located on a common face of the JNK protein close to other residues implicated previously in the interactions of MAPKs with substrates, phosphatases, and scaffolds. To test whether these JNK1 mutants were thus affected in their regulation, we evaluated their activation in mammalian cells in response to hyperosmolarity or cotransfection with a constitutively active upstream kinase or their direct phosphorylation by either MAPK kinase (MKK)4 or MKK7. In each situation, all three JNK mutants were not activated or phosphorylated to the same level as wildtype JNK. Therefore, the results of our unbiased reverse two-hybrid screening approach have identified residues of JNK responsible for binding JIP-1-based peptides as well as MKK4 or MKK7.	Univ Western Australia, Sch Biomed & Chem Sci, Cell Signalling Lab, Perth, WA 6009, Australia; Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6009, Australia; Phylogica Ltd, Subiaco, WA 6008, Australia; Western Australian Inst Med Res, Perth, WA 6000, Australia	University of Western Australia; University of Western Australia; University of Western Australia	Bogoyevitch, MA (corresponding author), Univ Western Australia, Sch Biomed & Chem Sci, Cell Signalling Lab, 35 Stirling Highway, Perth, WA 6009, Australia.	marieb@cyllene.uwa.edu.au		Bogoyevitch, Marie/0000-0001-9745-3716; Barr, Renae/0000-0003-1601-7299				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Barr RK, 2004, J BIOL CHEM, V279, P36327, DOI 10.1074/jbc.M402181200; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bogoyevitch MA, 2004, BBA-PROTEINS PROTEOM, V1697, P89, DOI 10.1016/j.bbapap.2003.11.016; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Borasio GD, 1998, NEUROREPORT, V9, P1435, DOI 10.1097/00001756-199805110-00034; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chang TS, 2003, J BIOL CHEM, V278, P48092, DOI 10.1074/jbc.M309421200; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Duttweiler HM, 1996, TRENDS GENET, V12, P340, DOI 10.1016/S0168-9525(96)80008-4; Heo JS, 2004, EMBO J, V23, P2185, DOI 10.1038/sj.emboj.7600212; JIANG R, 1999, PROTEIN PHOSPHORYLAT, P315; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Maroney AC, 1998, J NEUROSCI, V18, P104; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Mooney LM, 2004, J BIOL CHEM, V279, P11843, DOI 10.1074/jbc.M311841200; Moore DD, 1995, GLOB MOB SURV; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Pirvola U, 2000, J NEUROSCI, V20, P43, DOI 10.1523/JNEUROSCI.20-01-00043.2000; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Saporito MS, 2002, PROGR MED CHEM, V40, P23, DOI 10.1016/S0079-6468(08)70081-X; Serebriiskii I, 1999, J BIOL CHEM, V274, P17080, DOI 10.1074/jbc.274.24.17080; Shim J, 2000, J BIOL CHEM, V275, P14107, DOI 10.1074/jbc.275.19.14107; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Wang J, 2003, J NEUROSCI, V23, P8596; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhang JL, 2003, J BIOL CHEM, V278, P29901, DOI 10.1074/jbc.M303909200; [No title captured]	45	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43178	43189		10.1074/jbc.M405900200	http://dx.doi.org/10.1074/jbc.M405900200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15271995	hybrid			2022-12-27	WOS:000224226400102
J	Fortenberry, YM; Whinna, HC; Gentry, HR; Myles, T; Leung, LLK; Church, FC				Fortenberry, YM; Whinna, HC; Gentry, HR; Myles, T; Leung, LLK; Church, FC			Molecular mapping of the thrombin-heparin cofactor II complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING EXOSITE-I; PROTEIN-C INHIBITOR; DERMATAN SULFATE; ANTITHROMBIN-III; GLYCOSAMINOGLYCAN-BINDING; CRYSTAL-STRUCTURE; ALPHA-THROMBIN; FACTOR-VIII; ACTIVATION; SITE	We used 55 Ala-scanned recombinant thrombin molecules to define residues important for inhibition by the serine protease inhibitor (serpin) heparin cofactor II (HCII) in the absence and presence of glycosaminoglycans. We verified the importance of numerous basic residues in anion-binding exosite-1 (exosite-1) and found 4 additional residues, Gln(24), Lys(65), His(66), and Tyr(71) (using the thrombin numbering system), that were resistant to HCII inhibition with and without glycosaminoglycans. Inhibition rate constants for these exosite-1 (Q24A, K65A, H66A, Y71A) thrombin mutants (0.02-0.38 x 10(8) M-1 min(-1) for HCII-heparin when compared with 2.36 x 10(8) M-1 min(-1) with wild-type thrombin and 0.03-0.53 x 10(8) M-1 min(-1) for HCII-dermatan sulfate when compared with 5.23 x 10(8) M-1 min(-1) with wild- type thrombin) confirmed that the structural integrity of thrombin exosite-1 is critical for optimal HCII-thrombin interactions in the presence of glycosaminoglycans. However, our results are also consistent for HCII-glycosaminoglycan-thrombin ternary complex formation. Ten residues surrounding the active site of thrombin were implicated in HCII interactions. Four mutants (Asp(51), Lys(52), Lys(145)/Thr(147)/Trp(148), Asp(234)) showed normal increased rates of inhibition by HCII-glycosaminoglycans, whereas four mutants (Trp(50), Glu(202), Glu(229), Arg(233)) remained resistant to inhibition by HCII with glycosaminoglycans. Using 11 exosite-2 thrombin mutants with 20 different mutated residues, we saw no major perturbations of HCII-glycosaminoglycan inhibition reactions. Collectively, our results support a "double bridge" mechanism for HCII inhibition of thrombin in the presence of glycosaminoglycans, which relies in part on ternary complex formation but is primarily dominated by an allosteric process involving contact of the "hirudin-like" domain of HCII with thrombin exosite-1.	Univ N Carolina, Sch Med, Carolina Cardiovasc Biol Ctr, Dept Pathol & Lab Med,Div Hematol Oncol Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Carolina Cardiovasc Biol Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Carolina Cardiovasc Biol Ctr, Dept Med, Chapel Hill, NC 27599 USA; Stanford Univ, Sch Med, Dept Med, Div Hematol, Stanford, CA 94305 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Stanford University	Church, FC (corresponding author), Univ N Carolina, Sch Med, Carolina Cardiovasc Biol Ctr, Dept Pathol & Lab Med,Div Hematol Oncol Med, Campus Box 7035,932 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	fchurch@email.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057530, R01HL032656, F32HL076108] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32-HL-076108, HL-04063, HL-06350, HL-32656, HL-57530] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arocas V, 2000, BIOCHEMISTRY-US, V39, P8512, DOI 10.1021/bi9928243; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Bauman SJ, 1999, J BIOL CHEM, V274, P34556, DOI 10.1074/jbc.274.49.34556; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BLINDER MA, 1989, J BIOL CHEM, V264, P5128; BLINDER MA, 1990, J BIOL CHEM, V265, P286; BODE W, 1992, PROTEIN SCI, V1, P426; Carter WJ, 2004, J BIOL CHEM, V279, P26387, DOI 10.1074/jbc.M402364200; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; COLEMAN RW, 2001, HEMOSTASIS THROMBOSI; Cooper ST, 2002, THROMB RES, V107, P67, DOI 10.1016/S0049-3848(02)00180-9; De Cristofaro R, 2003, BIOCHEM J, V373, P593, DOI 10.1042/BJ20030167; Desai U, 2000, J BIOL CHEM, V275, P18976, DOI 10.1074/jbc.M001340200; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; Hall SW, 2001, THROMB HAEMOSTASIS, V86, P1466, DOI 10.1055/s-0037-1616750; Han JH, 1997, J BIOL CHEM, V272, P28660, DOI 10.1074/jbc.272.45.28660; He L, 2002, J CLIN INVEST, V109, P213, DOI 10.1172/JCI200213432; He XH, 1997, BIOCHEMISTRY-US, V36, P8969, DOI 10.1021/bi9704717; Hoffman M, 2003, EXP MOL PATHOL, V75, P109, DOI 10.1016/S0014-4800(03)00073-X; Holland CA, 2000, FEBS LETT, V484, P87, DOI 10.1016/S0014-5793(00)02131-1; Huntington JA, 2003, STRUCTURE, V11, P469, DOI 10.1016/S0969-2126(03)00049-2; Liaw PCY, 1999, J BIOL CHEM, V274, P27597, DOI 10.1074/jbc.274.39.27597; Mitchell JW, 2002, J BIOL CHEM, V277, P19823, DOI 10.1074/jbc.M200630200; Myles T, 2002, BLOOD, V100, P2820, DOI 10.1182/blood-2002-03-0843; Myles T, 2001, BIOCHEMISTRY-US, V40, P4972, DOI 10.1021/bi0023549; Myles T, 1998, J BIOL CHEM, V273, P31203, DOI 10.1074/jbc.273.47.31203; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; PHILLIPS JE, 1993, J BIOL CHEM, V268, P3321; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; PRATT CW, 1992, J BIOL CHEM, V267, P8795; RAGG H, 1990, J BIOL CHEM, V265, P5211; RAGG H, 1990, J BIOL CHEM, V265, P22386; Rezaie AR, 1997, BIOCHEMISTRY-US, V36, P1026, DOI 10.1021/bi9620823; Rezaie AR, 1996, BIOCHEMISTRY-US, V35, P1918, DOI 10.1021/bi952065y; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; Schedin-Weiss S, 2002, BIOCHEMISTRY-US, V41, P12369, DOI 10.1021/bi020406j; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; Shirk RA, 2000, J BIOL CHEM, V275, P18085, DOI 10.1074/jbc.M001659200; Shirk RA, 1996, ARTERIOSCL THROM VAS, V16, P1138, DOI 10.1161/01.ATV.16.9.1138; STONE SR, 1987, BIOCHEMISTRY, V26; SUZUKI K, 1983, J BIOL CHEM, V258, P163; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; Tollefsen DM, 1997, ADV EXP MED BIOL, V425, P35; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; Tsiang M, 1997, J BIOL CHEM, V272, P12024, DOI 10.1074/jbc.272.18.12024; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; Verhamme IM, 2004, J BIOL CHEM, V279, P9785, DOI 10.1074/jbc.M313962200; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; WHINNA HC, 1991, J BIOL CHEM, V266, P8129; YE J, 1994, J BIOL CHEM, V269, P17965; Yun TH, 2003, J BIOL CHEM, V278, P48112, DOI 10.1074/jbc.M306925200	63	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43237	43244		10.1074/jbc.M406716200	http://dx.doi.org/10.1074/jbc.M406716200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292227	Green Published, hybrid			2022-12-27	WOS:000224226400108
J	Jez, JM; Cahoon, RE				Jez, JM; Cahoon, RE			Kinetic mechanism of glutathione synthetase from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-B; INITIAL VELOCITY; FLEXIBLE LOOP; SUBSTRATE; LIGASE; IDENTIFICATION; BIOSYNTHESIS; MUTATIONS; PHOSPHATE; BINDING	Glutathione synthetase (GS) catalyzes the ATP-dependent formation of the ubiquitous peptide glutathione from gamma-glutamylcysteine and glycine. The bacterial and eukaryotic GS form two distinct families lacking amino acid sequence homology. Moreover, the detailed kinetic mechanism of the bacterial and the eukaryotic GS remains unclear. Here we have overexpressed Arabidopsis thaliana GS (AtGS) in an Escherichia coli expression system and purified the recombinant enzyme for biochemical characterization. AtGS is functional as a homodimeric protein with steady-state kinetic properties similar to those of other eukaryotic GS. The kinetic mechanism of AtGS was investigated using initial velocity methods and product inhibition studies. The best fit of the observed data was to the equation for a random Ter-reactant mechanism in which dependencies between the binding of some substrate pairs were preferred. The binding of either ATP or gamma-glutamylcysteine increased the binding affinity of AtGS for the other substrate by 10-fold. Likewise, the binding of ATP or glycine increased binding affinity for the other ligand by 3.5-fold. In contrast, binding of either glycine or gamma-glutamylcysteine causes a 6.7-fold decrease in binding affinity for the second molecule. Product inhibition studies suggest that ADP is the last product released from the enzyme. Overall, these observations are consistent with a random Ter-reactant mechanism for the eukaryotic GS in which the binding order of certain substrates is kinetically preferred for catalysis.	Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA	Donald Danforth Plant Science Center	Jez, JM (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	jjez@danforthcenter.org						AINSLIE GR, 1972, J BIOL CHEM, V247, P946; Anderson MS, 1996, BIOCHEMISTRY-US, V35, P16264, DOI 10.1021/bi961872+; Brekken DL, 1998, J BIOL CHEM, V273, P26317, DOI 10.1074/jbc.273.41.26317; COOPER BF, 1995, METHOD ENZYMOL, V249, P188; Copley SD, 2002, GENOME BIOL, V3; DANENBERG KD, 1975, BIOCHEMISTRY-US, V14, P28, DOI 10.1021/bi00672a006; Dinescu A, 2004, J BIOL CHEM, V279, P22412, DOI 10.1074/jbc.M401334200; DODDMOOZ E, 1967, BIOCHEMISTRY-US, V6, P1722; Emanuele JJ, 1997, BIOCHEMISTRY-US, V36, P7264, DOI 10.1021/bi970266r; Gali RR, 1997, BIOCHEM J, V321, P207, DOI 10.1042/bj3210207; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Gogos A, 2002, STRUCTURE, V10, P1669, DOI 10.1016/S0969-2126(02)00906-1; Hara T, 1996, BIOCHEMISTRY-US, V35, P11967, DOI 10.1021/bi9605245; HELL R, 1988, PHYSIOL PLANTARUM, V72, P70, DOI 10.1111/j.1399-3054.1988.tb06624.x; Jez JM, 2004, J BIOL CHEM, V279, P33463, DOI 10.1074/jbc.M405127200; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; JOYCE BK, 1966, J BIOL CHEM, V241, P5725; KATO H, 1987, J BIOCHEM, V101, P207, DOI 10.1093/oxfordjournals.jbchem.a121893; May MJ, 1998, J EXP BOT, V49, P649, DOI 10.1093/jexbot/49.321.649; MEEK TD, 1980, BIOCHEMISTRY-US, V19, P5513, DOI 10.1021/bi00565a008; Meierjohann S, 2002, BIOCHEM J, V363, P833, DOI 10.1042/0264-6021:3630833; MEISTER A, 1976, ANNU REV BIOCHEM, V45, P559, DOI 10.1146/annurev.bi.45.070176.003015; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MULLINS LS, 1990, J BIOL CHEM, V265, P8993; NISHIMURA JS, 1964, J BIOL CHEM, V239, P2553; Njalsson R, 2000, BIOCHEM J, V349, P275, DOI 10.1042/0264-6021:3490275; Njalsson R, 2001, BIOCHEM BIOPH RES CO, V289, P80, DOI 10.1006/bbrc.2001.5961; Noctor G, 1998, J EXP BOT, V49, P623, DOI 10.1093/jexbot/49.321.623; Polekhina G, 1999, EMBO J, V18, P3204, DOI 10.1093/emboj/18.12.3204; Segel IH, 1975, ENZYME KINETICS BEHA; TANAKA T, 1992, BIOCHEMISTRY-US, V31, P2259, DOI 10.1021/bi00123a007; TANAKA T, 1993, BIOCHEMISTRY-US, V32, P12398, DOI 10.1021/bi00097a018; Vatamaniuk OK, 1999, P NATL ACAD SCI USA, V96, P7110, DOI 10.1073/pnas.96.12.7110; VIOLA RE, 1982, METHOD ENZYMOL, V87, P353; Wang CL, 1997, BIOCHEM J, V322, P241, DOI 10.1042/bj3220241; Wang CL, 1997, BIOCHEM J, V326, P563, DOI 10.1042/bj3260563; Wang CL, 1996, PLANT MOL BIOL, V31, P1093, DOI 10.1007/BF00040827; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106; Zenk MH, 1996, GENE, V179, P21, DOI 10.1016/S0378-1119(96)00422-2	39	51	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42726	42731		10.1074/jbc.M407961200	http://dx.doi.org/10.1074/jbc.M407961200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15302873	hybrid			2022-12-27	WOS:000224226400047
J	Nagano, S; Tosha, T; Ishimori, K; Morishima, I; Poulos, TL				Nagano, S; Tosha, T; Ishimori, K; Morishima, I; Poulos, TL			Crystal structure of the cytochrome P450cam mutant that exhibits the same spectral perturbations induced by putidaredoxin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; MYCOBACTERIUM-TUBERCULOSIS; COMPLEX-FORMATION; RESONANCE RAMAN; COMPOUND-I; HYDROXYLATION; P450(CAM); MECHANISM; MUTATION; MODELS	The cytochrome P450cam active site is known to be perturbed by binding to its redox partner, putidaredoxin (Pdx). Pdx binding also enhances the camphor monooxygenation reaction (Nagano, S., Shimada, H., Tarumi, A., Hishiki, T., Kimata- Ariga, Y., Egawa, T., Suematsu, M., Park, S.- Y., Adachi, S., Shiro, Y., and Ishimura, Y. ( 2003) Biochemistry 42, 14507 - 14514). These effects are unique to Pdx because nonphysiological electron donors are unable to support camphor monooxygenation. The accompanying H-1 NMR paper ( Tosha, T., Yoshioka, S., Ishimori, K., and Morishima, I. ( 2004) J. Biol. Chem. 279, 42836 - 42843) shows that the conformation of active site residues, Thr-252 and Cys-357, and the substrate in the ferrous ( Fe(II)) CO complex of the L358P mutant mimics that of the wild-type enzyme complexed to Pdx. To explore how these changes are transmitted from the Pdx-binding site to the active site, we have solved the crystal structures of the ferrous and ferrous-CO complex of wild-type and the L358P mutant. Comparison of these structures shows that the L358P mutation results in the movement of Arg-112, a residue known to be important for putidaredoxin binding, toward the heme. This change could optimize the Pdx-binding site leading to a higher affinity for Pdx. The mutation also pushes the heme toward the substrate and ligand binding pocket, which relocates the substrate to a position favorable for regio-selective hydroxylation. The camphor is held more firmly in place as indicated by a lower average temperature factor. Residues involved in the catalytically important proton shuttle system in the I helix are also altered by the mutation. Such conformational alterations and the enhanced reactivity of the mutant oxy complex with nonphysiological electron donors suggest that Pdx binding optimizes the distal pocket for monooxygenation of camphor.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA; Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; Kyoto University	Poulos, TL (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	poulos@uci.edu	Ishimori, Koichiro/S-1247-2016; Tosha, Takehiko/AAR-2404-2020; Ishimori, Koichiro/AAQ-4434-2021	Ishimori, Koichiro/0000-0002-5868-0462; Tosha, Takehiko/0000-0002-8971-0759; Ishimori, Koichiro/0000-0002-5868-0462	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033688] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33688] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Case DA, 1995, J BIOMOL NMR, V6, P341; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Fedorov R, 2003, ARCH BIOCHEM BIOPHYS, V409, P25, DOI 10.1016/S0003-9861(02)00555-6; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GERBER NC, 1992, J AM CHEM SOC, V114, P8742, DOI 10.1021/ja00048a081; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; ISHIMURA Y, 1987, CYTOCHROME P450 NEW, V17, P151; JOHNSON CE, 1958, J CHEM PHYS, V29, P1012, DOI 10.1063/1.1744645; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamachi T, 2003, J AM CHEM SOC, V125, P4652, DOI 10.1021/ja0208862; KANEMOTO RH, 1989, J BACTERIOL, V171, P2506, DOI 10.1128/jb.171.5.2506-2512.1989; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; La Mar G.N., 2000, PORPHYRIN HDB, V5, P185; Leys D, 2003, J BIOL CHEM, V278, P5141, DOI 10.1074/jbc.M209928200; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; Nagano S, 2003, BIOCHEMISTRY-US, V42, P14507, DOI 10.1021/bi035410p; Nickerson D, 1998, ACTA CRYSTALLOGR D, V54, P470, DOI 10.1107/S0907444997012195; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pochapsky SS, 2003, BIOCHEMISTRY-US, V42, P5649, DOI 10.1021/bi034263s; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; SHARROCK M, 1976, BIOCHIM BIOPHYS ACTA, V420, P8, DOI 10.1016/0005-2795(76)90340-8; Shimada H, 1999, J BIOL CHEM, V274, P9363, DOI 10.1074/jbc.274.14.9363; Sjodin T, 2001, BIOCHEMISTRY-US, V40, P6852, DOI 10.1021/bi002510b; Sun HR, 2003, INORG CHEM, V42, P6032, DOI 10.1021/ic034705o; Tosha T, 2003, J BIOL CHEM, V278, P39809, DOI 10.1074/jbc.M304265200; Tosha T, 2004, J BIOL CHEM, V279, P42836, DOI 10.1074/jbc.M404216200; TWISK J, 1995, J CLIN INVEST, V95, P1235, DOI 10.1172/JCI117773; Unno M, 1997, J AM CHEM SOC, V119, P6614, DOI 10.1021/ja963785a; Unno M, 2002, J BIOL CHEM, V277, P2547, DOI 10.1074/jbc.M108917200; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Yoshioka S, 2002, J AM CHEM SOC, V124, P14571, DOI 10.1021/ja0265409; Yoshioka S, 2000, J INORG BIOCHEM, V81, P141, DOI 10.1016/S0162-0134(00)00097-0; Yoshizawa K, 2001, J AM CHEM SOC, V123, P9806, DOI 10.1021/ja010593t	41	54	54	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42844	42849		10.1074/jbc.M404217200	http://dx.doi.org/10.1074/jbc.M404217200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15269210	hybrid			2022-12-27	WOS:000224226400061
J	Endo, A; Surks, HK; Mochizuki, S; Mochizuki, N; Mendelsohn, ME				Endo, A; Surks, HK; Mochizuki, S; Mochizuki, N; Mendelsohn, ME			Identification and characterization of zipper-interacting protein kinase as the unique vascular smooth muscle myosin phosphatase-associated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; RHO-KINASE; PHOSPHORYLATION; SUBUNIT; INHIBITION; ALPHA; SENSITIZATION; RELAXATION; ACTIVATION; ISOFORMS	Excitation-contraction coupling in smooth muscle involves activation of myosin light chain (MLC) phosphorylation, which increases activity of the myosin actin-activated ATPase, resulting in contraction. Phosphorylation of MLC phosphatase (SMPP-1M) by Rho-associated kinase or endogenous SMPP-1M-associated kinase inhibits SMPP-1M, enhancing MLC phosphorylation and contraction. However, the precise identity of SMPP-1M-associated kinase remains unclear. Biochemical evidence strongly supports the idea that SMPP-1M-associated kinase is related to the human serine/ threonine leucine zipper-interacting protein kinase (hZIPK), which is important in cell apoptosis, and the SMPP-1M-associated kinase has therefore been called ZIP-like kinase (MacDonald, J. A., Borman, M. A., Murani, A., Somlyo, A. V., Hartshorne, D. J., and Haystead, T. A. J. ( 2001) Proc. Natl. Acad. Sci. U. S. A. 98, 2419 - 2424). Whether the vascular smooth muscle SMPP-1M-associated kinase is a truncated version of hZIPK, native hZIPK, or a unique homologue of hZIPK is unclear. Here we show that only native hZIPK mRNA and protein are detectable in human vascular smooth muscle cells (VSMCs). High stringency screening of a human aortic cDNA library for the SMPP-1M-associated kinase identified 18 positive clones, all of which proved to be clones of hZIPK. PCR-based studies of VSMC RNA revealed native hZIPK transcripts but no evidence for splice variants of hZIPK or a ZIP-like kinase. Northern blotting studies of multiple vascular and non-vascular tissue RNAs, including human bladder RNA, showed only 2.3 kb of mRNA predicted for full-length hZIPK. Immunoblotting showed native full-length 52-kDa hZIPK expression in VSMCs. Full-length and N-terminal hZIPK bound the C-terminal domain ( amino acids 681 847) of the myosin binding subunit (MBS) of SMPP-1M. hZIPK immunoprecipitated with the MBS of SMPP-1M and dominant negative RhoA inhibited the hZIPK-MBS interaction. These data identify hZIPK as the unique SMPP-1-associated kinase expressed in human vesicular smooth muscle and support a role for Rho in promoting the hZIPK-MBS interaction.	Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Jikei Univ, Sch Med, Dept Internal Med, Div Cardiol,Minato Ku, Tokyo 1058461, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Struct Anal, Osaka 5658565, Japan	Tufts Medical Center; Tufts University; Tufts University; Jikei University; National Cerebral & Cardiovascular Center - Japan	Mendelsohn, ME (corresponding author), Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA.	mmendelsohn@tufts-nemc.org			PHS HHS [ML55309] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Borman MA, 2002, J BIOL CHEM, V277, P23441, DOI 10.1074/jbc.M201597200; Broustas CG, 2002, J BIOL CHEM, V277, P3053, DOI 10.1074/jbc.M106343200; Eto M, 2001, J BIOL CHEM, V276, P29072, DOI 10.1074/jbc.M103206200; Etter EF, 2001, J BIOL CHEM, V276, P34681, DOI 10.1074/jbc.M104737200; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kandabashi T, 2002, ARTERIOSCL THROM VAS, V22, P243, DOI 10.1161/hq0202.104274; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Khatri JJ, 2001, J BIOL CHEM, V276, P37250, DOI 10.1074/jbc.M105275200; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Muranyi A, 2001, FEBS LETT, V493, P80, DOI 10.1016/S0014-5793(01)02283-9; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Niiro N, 2001, J BIOL CHEM, V276, P29567, DOI 10.1074/jbc.M102753200; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Surks HK, 2003, J BIOL CHEM, V278, P51484, DOI 10.1074/jbc.M305622200; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; TRINKLEMULCAHY L, 1995, J BIOL CHEM, V270, P18191, DOI 10.1074/jbc.270.31.18191; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460	26	37	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42055	42061		10.1074/jbc.M403676200	http://dx.doi.org/10.1074/jbc.M403676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292222	hybrid			2022-12-27	WOS:000224075500098
J	Zhang, YJ; Chen, K; Tu, YZ; Wu, CY				Zhang, YJ; Chen, K; Tu, YZ; Wu, CY			Distinct roles of two structurally closely related focal adhesion proteins, alpha-parvins and beta-parvins, in regulation of cell morphology and survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-LINKED KINASE; ACTIN CYTOSKELETON; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; SHAPE MODULATION; LD4 MOTIF; ILK; MIGRATION; PINCH; RAC	Proteins at cell-extracellular matrix adhesions (e.g. focal adhesions) are crucially involved in regulation of cell morphology and survival. We show here that CH-ILKBP/actopaxin/alpha-parvin and affixin/beta-parvin (abbreviated as alpha- and beta-parvin, respectively), two structurally closely related integrin-linked kinase (ILK)-binding focal adhesion proteins, are co-expressed in human cells. Depletion of alpha-parvin dramatically increased the level of beta-parvin, suggesting that beta-parvin is negatively regulated by alpha-parvin in human cells. Loss of PINCH-1 or ILK, to which alpha- and beta-parvin bind, significantly reduced the activation of Rac, a key signaling event that controls lamellipodium formation and cell spreading. We were surprised to find that loss of alpha-parvin, but not that of beta-parvin, markedly stimulated Rac activation and enhanced lamellipodium formation. Overexpression of beta-parvin, however, was insufficient for stimulation of Rac activation or lamellipodium formation, although it was sufficient for promotion of apoptosis, another important cellular process that is regulated by PINCH-1, ILK, and alpha-parvin. In addition, we show that the interactions of ILK with alpha- and beta-parvin are mutually exclusive. Overexpression of beta-parvin or its CH2 fragment, but not a CH2 deletion mutant, inhibited the ILK-alpha-parvin complex formation. Finally, we provide evidence suggesting that inhibition of the ILK-alpha-parvin complex is sufficient, although not necessary, for promotion of apoptosis. These results identify Rac as a downstream target of PINCH-1, ILK, and parvin. Furthermore, they demonstrate that alpha- and beta-parvins play distinct roles in mammalian cells and suggest that the formation of the ILK-alpha-parvin complex is crucial for protection of cells from apoptosis.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wu, CY (corresponding author), Univ Pittsburgh, Dept Pathol, 707B Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	carywu@pitt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065188] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65188] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Brown E, 1996, IMMUNOL LETT, V54, P189, DOI 10.1016/S0165-2478(96)02671-5; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fox JEB, 1999, THROMB HAEMOSTASIS, V82, P385; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Fukuda T, 2003, J CELL BIOL, V160, P1001, DOI 10.1083/jcb.200212113; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Olski TM, 2001, J CELL SCI, V114, P525; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Terpstra L, 2003, J CELL BIOL, V162, P139, DOI 10.1083/jcb.200302066; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; Tu YZ, 2001, FEBS LETT, V491, P193, DOI 10.1016/S0014-5793(01)02195-0; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Velyvis A, 2003, NAT STRUCT BIOL, V10, P558, DOI 10.1038/nsb938; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Zamir E, 2001, J CELL SCI, V114, P3583; Zhang YJ, 2002, J BIOL CHEM, V277, P38328, DOI 10.1074/jbc.M205576200; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	40	80	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41695	41705		10.1074/jbc.M401563200	http://dx.doi.org/10.1074/jbc.M401563200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15284246	hybrid			2022-12-27	WOS:000224075500057
J	Reyes-Grajeda, JP; Moreno, A; Romero, A				Reyes-Grajeda, JP; Moreno, A; Romero, A			Crystal structure of ovocleidin-17, a major protein of the calcified Gallus gallus eggshell - Implications in the calcite mineral growth pattern	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; LOCALIZATION; PURIFICATION; COMPONENT; PERLUCIN; PROGRAM; DOMAIN; SYSTEM	Ovocleidin-17 (OC17) from Gallus gallus is one of the best candidates to control and regulate the deposition of calcium carbonate in the calcified eggshell layer. Here, the crystal structure of monomeric OC17, determined at a resolution of 1.5 Angstrom, was refined to a crystallographic R-factor of 20.1%. This is the first protein directly involved in a non-pathological biomineralization process resolved by x-ray diffraction to date. The protein has a mixed alpha/beta structure containing a single C-type lectin-like domain. However, although OC17 shares the conserved scaffold of the C-type lectins, it does not bind carbohydrates. Nevertheless, in vitro OC17 modifies the crystalline habit of calcium carbonate (CaCO3) and the pattern of crystal growth at intervals of 5-200 mug/ml. Determining the three-dimensional structure of OC17 contributes to a better understanding of the biological behavior of structurally related biomolecules and of the mechanisms involved in eggshell and other mineralization processes.	CSIC, Dept Estructura & Func Prot, Ctr Invest Biol, Madrid 28040, Spain; Univ Nacl Autonoma Mexico, Inst Quim, Mexico City 04510, DF, Mexico	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Universidad Nacional Autonoma de Mexico	Romero, A (corresponding author), CSIC, Dept Estructura & Func Prot, Ctr Invest Biol, Ramiro Maeztu 9, Madrid 28040, Spain.	romero@cib.csic.es	Romero, Antonio/K-5754-2014; Moreno, Abel/K-6801-2019	Romero, Antonio/0000-0002-6990-6973; Reyes, Juan Pablo/0000-0001-6498-3286				Alexandrov NN, 1996, PROTEINS, V25, P354, DOI 10.1002/(SICI)1097-0134(199607)25:3<354::AID-PROT7>3.3.CO;2-W; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bertrand JA, 1996, EMBO J, V15, P2678, DOI 10.1002/j.1460-2075.1996.tb00628.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano W.L, PYMOL MOL GRAPHICS S; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Fincham AG, 1999, J STRUCT BIOL, V126, P270, DOI 10.1006/jsbi.1999.4130; GARCIAARCHILLA B, 1994, IMA J NUMER ANAL, V14, P1; Gerbaud V, 2000, J BIOL CHEM, V275, P1057, DOI 10.1074/jbc.275.2.1057; HINCKE MT, 1995, CALCIFIED TISSUE INT, V56, P578, DOI 10.1007/BF00298593; Hincke MT, 1999, J BIOL CHEM, V274, P32915, DOI 10.1074/jbc.274.46.32915; Hincke MT, 1995, CONNECT TISSUE RES, V31, P227, DOI 10.3109/03008209509010814; Hincke MT, 2000, MATRIX BIOL, V19, P443, DOI 10.1016/S0945-053X(00)00095-0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lakshminarayanan R, 2002, P NATL ACAD SCI USA, V99, P5155, DOI 10.1073/pnas.072658899; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Mann K, 2000, EUR J BIOCHEM, V267, P5257, DOI 10.1046/j.1432-1327.2000.01602.x; Mann K, 1999, BIOCHEM MOL BIOL INT, V47, P997; Mann K, 1999, FEBS LETT, V463, P12, DOI 10.1016/S0014-5793(99)01586-0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moradian-Oldak J, 1998, BIOPOLYMERS, V46, P225, DOI 10.1002/(SICI)1097-0282(19981005)46:4<225::AID-BIP4>3.0.CO;2-R; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ng KKS, 2002, J BIOL CHEM, V277, P16088, DOI 10.1074/jbc.M200493200; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Nys Y, 1999, POULT AVIAN BIOL REV, V10, P143; Panheleux M, 1999, BRIT POULTRY SCI, V40, P240, DOI 10.1080/00071669987665; Reyes-Grajeda JP, 2002, PROTEIN PEPTIDE LETT, V9, P253, DOI 10.2174/0929866023408805; Roberts J. R., 1994, Poultry Science Reviews, V5, P245; SILYNROBERTS H, 1986, PROC R SOC SER B-BIO, V227, P303, DOI 10.1098/rspb.1986.0025; Solomon SE, 1999, BRIT POULTRY SCI, V40, P5, DOI 10.1080/00071669987764; Weiss IM, 2000, BIOCHEM BIOPH RES CO, V267, P17, DOI 10.1006/bbrc.1999.1907; Zelensky AN, 2003, PROTEINS, V52, P466, DOI 10.1002/prot.10626	34	66	70	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40876	40881		10.1074/jbc.M406033200	http://dx.doi.org/10.1074/jbc.M406033200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15263013	hybrid			2022-12-27	WOS:000223916800083
J	Sakai, T; Liu, L; Teng, XC; Mukai-Sakai, R; Shimada, H; Kaji, R; Mitani, T; Matsumoto, M; Toida, K; Ishimura, K; Shishido, Y; Mak, TW; Fukui, K				Sakai, T; Liu, L; Teng, XC; Mukai-Sakai, R; Shimada, H; Kaji, R; Mitani, T; Matsumoto, M; Toida, K; Ishimura, K; Shishido, Y; Mak, TW; Fukui, K			Nucling recruits Apaf-1/pro-caspase-9 complex for the induction of stress-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CASPASE ACTIVATION; CYTOCHROME-C; CELL-DEATH; CONFERS RESISTANCE; KAPPA-B; PROTEIN; APAF-1; MITOCHONDRIA; RELEASE; IDENTIFICATION	Nucling is a novel protein isolated from murine embryonal carcinoma cells with an up-regulated expression during cardiac muscle differentiation. We show here that Nucling was up-regulated by proapoptotic stimuli and important for the induction of apoptosis after cytotoxic stress. We further demonstrated that overexpressed Nucling was able to induce apoptosis. In Nucling-deficient cells, the expression levels of Apaf-1 and cytochrome c, which are the major components of an apoptosis-promoting complex named apoptosome, were both down-regulated under cellular stress. A deficiency of Nucling also conferred resistance to apoptotic stress on the cell. After UV irradiation, Nucling was shown to reside in an Apaf-1/pro-caspase-9 complex, suggesting that Nucling might be a key molecule for the formation and maintenance of this complex. Nucling induced translocation of Apaf-1 to the nucleus, thereby distributing the Nucling/Apaf-1/pro-caspase-9 complex to the nuclear fraction. These findings suggest that Nucling recruits and transports the apoptosome complex during stress-induced apoptosis.	Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan; Univ Tokushima, Sch Med, Tokushima 7708503, Japan; Univ Toronto, Adv Med Discovery Inst, Toronto, ON M5G 2C1, Canada	Tokushima University; Tokushima University; University of Toronto	Fukui, K (corresponding author), Univ Tokushima, Inst Enzyme Res, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	kiyo@ier.tokushima-u.ac.jp		Fukui, Kiyoshi/0000-0002-7438-4938				Belmokhtar CA, 2003, J BIOL CHEM, V278, P29571, DOI 10.1074/jbc.M302924200; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Honarpour N, 2001, P NATL ACAD SCI USA, V98, P9683, DOI 10.1073/pnas.171283198; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Kimura H, 1999, J BIOCHEM-TOKYO, V126, P340, DOI 10.1093/oxfordjournals.jbchem.a022455; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu L, 2004, BIOCHEM J, V380, P31, DOI 10.1042/BJ20031300; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; McDonnell MA, 2003, CELL DEATH DIFFER, V10, P1005, DOI 10.1038/sj.cdd.4401271; Porter AG, 1999, TRENDS CELL BIOL, V9, P394, DOI 10.1016/S0962-8924(99)01624-4; Ritter PM, 2000, EUR J CELL BIOL, V79, P358, DOI 10.1078/S0171-9335(04)70040-0; Ruiz-Vela A, 2002, FEBS LETT, V517, P133, DOI 10.1016/S0014-5793(02)02607-8; Sakai T, 2003, J BIOCHEM, V133, P429, DOI 10.1093/jb/mvg056; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Sanchis D, 2003, CELL DEATH DIFFER, V10, P977, DOI 10.1038/sj.cdd.4401267; Shuster CB, 1996, CELL MOTIL CYTOSKEL, V35, P175; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XD, 2001, GENE DEV, V15, P2922; Welch AY, 2002, INT J BIOCHEM CELL B, V34, P864, DOI 10.1016/S1357-2725(01)00159-5; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wolf BB, 2001, J BIOL CHEM, V276, P34244, DOI 10.1074/jbc.M011778200; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu F, 2002, J BIOL CHEM, V277, P15819, DOI 10.1074/jbc.M200154200; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	35	47	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41131	41140		10.1074/jbc.M402902200	http://dx.doi.org/10.1074/jbc.M402902200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15271982	hybrid			2022-12-27	WOS:000223916800112
J	Visch, HJ; Rutter, GA; Koopman, WJH; Koenderink, JB; Verkaart, S; de Groot, T; Varadi, A; Mitchell, KJ; van den Heuvel, LP; Smeitink, JAM; Willems, PHGM				Visch, HJ; Rutter, GA; Koopman, WJH; Koenderink, JB; Verkaart, S; de Groot, T; Varadi, A; Mitchell, KJ; van den Heuvel, LP; Smeitink, JAM; Willems, PHGM			Inhibition of mitochondrial Na+-Ca2+ exchange restores agonist-induced ATP production and Ca2+ handling in human complex I deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; LEIGH-SYNDROME; INOSITOL 1,4,5-TRISPHOSPHATE; OXIDATIVE-PHOSPHORYLATION; UBIQUINONE OXIDOREDUCTASE; YARROWIA-LIPOLYTICA; INSULIN-SECRETION; INTACT-CELLS; CALCIUM; APOPTOSIS	Human mitochondrial complex I ( NADH: ubiquinone oxidoreductase) of the oxidative phosphorylation system is a multiprotein assembly comprising both nuclear and mitochondrially encoded subunits. Deficiency of this complex is associated with numerous clinical syndromes ranging from highly progressive, often early lethal encephalopathies, of which Leigh disease is the most frequent, to neurodegenerative disorders in adult life, including Leber's hereditary optic neuropathy and Parkinson disease. We show here that the cytosolic Ca2+ signal in response to hormonal stimulation with bradykinin was impaired in skin fibroblasts from children between the ages of 0 and 5 years with an isolated complex I deficiency caused by mutations in nuclear encoded structural subunits of the complex. Inhibition of mitochondrial Na+-Ca2+ exchange by the benzothiazepine CGP37157 completely restored the aberrant cytosolic Ca2+ signal. This effect of the inhibitor was paralleled by complete restoration of the bradykinin-induced increases in mitochondrial Ca2+ concentration and ensuing ATP production. Thus, impaired mitochondrial Ca2+ accumulation during agonist stimulation is a major consequence of human complex I deficiency, a finding that may provide the basis for the development of new therapeutic approaches to this disorder.	Univ Med Ctr Nijmegen, Nijmegen Ctr Mitochondrial Disorders, Dept Pediat, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Microscop Imaging Ctr, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Univ Bristol, Henry Wellcome Signalling Labs, Bristol BS8 1TD, Avon, England; Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; University of Bristol; University of Bristol	Smeitink, JAM (corresponding author), Univ Med Ctr Nijmegen, Nijmegen Ctr Mitochondrial Disorders, Dept Pediat, POB 9101, NL-6500 HB Nijmegen, Netherlands.	j.smeitink@cukz.umcn.nl	Koenderink, Jan/N-3578-2014; Smeitink, Jan A.M./D-6064-2011; van den Heuvel, Lambertus/AAM-1772-2021; van den Heuvel, L.P.W.J./H-8044-2014; Willems, P.H.G.M./L-4759-2015; Koopman, Werner J.H./AAC-9668-2020; Smeitink, Jan/C-1351-2013; Koopman, Werner J.H./D-3592-2009; Groot, Theun/A-2596-2015	van den Heuvel, Lambertus/0000-0003-3917-6727; van den Heuvel, L.P.W.J./0000-0003-3917-6727; Willems, P.H.G.M./0000-0002-0915-1599; Koopman, Werner J.H./0000-0002-5340-6747; Koopman, Werner J.H./0000-0002-5340-6747; Rutter, Guy/0000-0001-6360-0343				Ahlers PM, 2000, J BIOL CHEM, V275, P23577, DOI 10.1074/jbc.M002074200; Ahlers PM, 2000, BBA-BIOENERGETICS, V1459, P258, DOI 10.1016/S0005-2728(00)00160-2; Ainscow EK, 2002, DIABETES, V51, pS162, DOI 10.2337/diabetes.51.2007.S162; Ainscow EK, 2001, BIOCHEM J, V353, P175, DOI 10.1042/0264-6021:3530175; Alvarez J, 2002, CELL CALCIUM, V32, P251, DOI 10.1016/S0143416002001860; ASSIMACOPOULOSJEANNET F, 1986, J BIOL CHEM, V261, P8799; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Budde SMS, 2000, BIOCHEM BIOPH RES CO, V275, P63, DOI 10.1006/bbrc.2000.3257; Carrozzo R, 2001, NEUROLOGY, V56, P687, DOI 10.1212/WNL.56.5.687; COX DA, 1993, J BIOL CHEM, V268, P938; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; GUNTER KK, 1994, J BIOENERG BIOMEMBR, V26, P471, DOI 10.1007/BF00762732; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Koopman WJH, 2003, AM J PHYSIOL-CELL PH, V285, pC1263, DOI 10.1152/ajpcell.00097.2003; Koopman WJH, 2003, J BIOL CHEM, V278, P13672, DOI 10.1074/jbc.M211256200; Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M; Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; MOUDY AM, 1995, P NATL ACAD SCI USA, V92, P729, DOI 10.1073/pnas.92.3.729; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; ROBINSON BH, 1990, PEDIATR RES, V28, P549, DOI 10.1203/00006450-199011000-00027; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; RUTTER GA, 1990, INT J BIOCHEM, V22, P1081, DOI 10.1016/0020-711X(90)90105-C; Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Szabadkai G, 2003, J BIOL CHEM, V278, P15153, DOI 10.1074/jbc.M300180200; Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6; van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716; van der Westhuizen FH, 2003, NEUROPEDIATRICS, V34, P14, DOI 10.1055/s-2003-38618; VANDEPUT FHMM, 1994, J BIOL CHEM, V269, P12438; VazquezMemije ME, 1996, J INHERIT METAB DIS, V19, P43, DOI 10.1007/BF01799347; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488	51	88	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40328	40336		10.1074/jbc.M408068200	http://dx.doi.org/10.1074/jbc.M408068200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15269216	hybrid			2022-12-27	WOS:000223916800014
J	Chung, TL; Hsiao, HH; Yeh, YY; Shia, HL; Chen, YL; Liang, PH; Wang, AHJ; Khoo, KH; Li, SSL				Chung, TL; Hsiao, HH; Yeh, YY; Shia, HL; Chen, YL; Liang, PH; Wang, AHJ; Khoo, KH; Li, SSL			In vitro modification of human centromere protein CENP-C fragments by small ubiquitin-like modifier (SUMO) protein - Definitive identification of the modification sites by tandem mass spectrometry analysis of the isopeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; KINETOCHORE; YEAST; NUCLEAR; DOMAINS; MIF2; CONJUGATION; ASSOCIATION; METHIONINE; EXPRESSION	Protein sumoylation by small ubiquitin-like modifier (SUMO) proteins is an important post-translational regulatory modification. A role in the control of chromosome dynamics was first suggested when SUMO was identified as high-copy suppressor of the centromere protein CENP-C mutants. CENP-C itself contains a consensus sumoylation sequence motif that partially overlaps with its DNA binding and centromere localization domain. To ascertain whether CENP-C can be sumoylated, tandem mass spectrometry (MS) based strategy was developed for high sensitivity identification and sequencing of sumoylated isopeptides present among in-gel-digested tryptic peptides of SDS-PAGE fractionated target proteins. Without a predisposition to searching for the expected isopeptides based on calculated molecular mass and relying instead on the characteristic MS/MS fragmentation pattern to identify sumolylation, we demonstrate that several other lysine residues located not within the perfect consensus sumoylation motif psiKXE/D, where psi represents a large hydrophobic amino acid, and X represnts any amino acid, can be sumolylated with a reconstituted in vitro system containing only the SUMO proteins, E1-activating enzyme and E2-conjugating enzyme (Ubc9). In all cases, target sites that can be sumoylated by SUMO-2 were shown to be equally susceptible to SUMO-1 attachments which include specific sites on SUMO-2 itself, Ubc9, and the recombinant CENP-C fragments. Two non-consensus sites on one of the CENP-C fragments were found to be sumoylated in addition to the predicted site on the other fragment. The developed methodologies should facilitate future studies in delineating the dynamics and substrate specificities of SUMO-1/2/3 modifications and the respective roles of E3 ligases in the process.	Kaohsiung Med Univ, Coll Life Sci, Dept Biotechnol, Kaohsiung 807, Taiwan; Acad Sinica, Core Facil Proteom Res, Taipei 11529, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan; Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 804, Taiwan	Kaohsiung Medical University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Sun Yat Sen University	Khoo, KH (corresponding author), Kaohsiung Med Univ, Coll Life Sci, Dept Biotechnol, Kaohsiung 807, Taiwan.	kkhoo@gate.sinica.edu.tw; lissl@kmu.edu.tw	Liang, Po-Huang/H-6610-2015; Khoo, Kay-Hooi/E-1989-2019	Liang, Po-Huang/0000-0003-1207-5256; Khoo, Kay-Hooi/0000-0003-2906-406X; Chen, Yi-Ling/0000-0002-9789-2441				Bencsath KP, 2002, J BIOL CHEM, V277, P47938, DOI 10.1074/jbc.M207442200; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; BROWN MT, 1995, GENE, V160, P111, DOI 10.1016/0378-1119(95)00163-Z; Everett RD, 1999, J CELL SCI, V112, P3443; Fukagawa T, 2001, NUCLEIC ACIDS RES, V29, P3796, DOI 10.1093/nar/29.18.3796; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jiang XY, 1996, J MASS SPECTROM, V31, P1309, DOI 10.1002/(SICI)1096-9888(199611)31:11<1309::AID-JMS423>3.0.CO;2-R; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Lagerwerf FM, 1996, RAPID COMMUN MASS SP, V10, P1905, DOI 10.1002/(SICI)1097-0231(199612)10:15<1905::AID-RCM755>3.0.CO;2-9; LANINI L, 1995, MOL BIOL CELL, V6, P1049, DOI 10.1091/mbc.6.8.1049; Lee CL, 2003, PROTEOMICS, V3, P2472, DOI 10.1002/pmic.200300586; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mannen H, 1996, BIOCHEM BIOPH RES CO, V222, P178, DOI 10.1006/bbrc.1996.0717; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Obuse C, 2004, GENES CELLS, V9, P105, DOI 10.1111/j.1365-2443.2004.00705.x; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; Pluta AF, 1998, J CELL SCI, V111, P2029; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Song K, 2002, EXP CELL RES, V275, P81, DOI 10.1006/excr.2002.5495; Su HL, 2002, GENE, V296, P65, DOI 10.1016/S0378-1119(02)00843-0; Sugimoto K, 1997, CHROMOSOME RES, V5, P132, DOI 10.1023/A:1018422325569; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Trazzi S, 2002, J STRUCT BIOL, V140, P39, DOI 10.1016/S1047-8477(02)00506-3; Wattenberg A, 2002, J AM SOC MASS SPECTR, V13, P772, DOI 10.1016/S1044-0305(02)00414-2; Westermann S, 2003, J CELL BIOL, V163, P215, DOI 10.1083/jcb.200305100; Yang CH, 1996, MOL CELL BIOL, V16, P3576	32	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39653	39662		10.1074/jbc.M405637200	http://dx.doi.org/10.1074/jbc.M405637200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15272016	hybrid			2022-12-27	WOS:000223791500056
J	Yi, L; Celebi, N; Chen, MY; Dalbey, RE				Yi, L; Celebi, N; Chen, MY; Dalbey, RE			Sec/SRP requirements and energetics of membrane insertion of subunits a, b, and c of the Escherichia coli F1F0 ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; M13 PROCOAT PROTEIN; PF3 COAT PROTEIN; INNER MEMBRANE; CHARGED RESIDUES; SEC TRANSLOCASE; YIDC; EXPORT; BIOGENESIS; OXA1	Previously, the role of YidC in the membrane protein biogenesis of the F-0 sector of the Escherichia coli F1F0 ATP synthase was investigated. Whereas subunits a and c of the F1F0 ATP synthase were strictly dependent on YidC for membrane insertion, subunit b required YidC for efficient insertion (Yi, L., Jiang, F., Chen, M., Cain, B., Bolhuis, A., and Dalbey, R. E. ( 2003) Biochemistry 42, 10537 - 10544). In this paper, we investigated other protein components and energetics that are required in the membrane protein assembly of the F-0 sector subunits. We show here that the Sec translocase and the signal recognition particle (SRP) pathway are required for membrane insertion of subunits a and b. In contrast, subunit c required neither the Sec machinery nor the SRP pathway for insertion. While the proton motive force was not required for insertion of subunits b and c, it was required for translocation of the negatively charged periplasmic NH2-terminal tail of subunit a, whereas periplasmic loop 2 of subunit a could insert in a proton motive force-independent manner. Taken together, the in vivo data suggest that subunits a and b are inserted by the Sec/SRP pathway with the help of YidC, and subunit c is integrated into the membrane by the novel YidC pathway.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Dalbey, RE (corresponding author), Ohio State Univ, Dept Chem, Columbus, OH 43210 USA.	dalbey@chemistry.ohio-state.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063862] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63862] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; Chen MY, 2002, BIOL CHEM, V383, P1565, DOI 10.1515/BC.2002.176; Chen MY, 2002, J BIOL CHEM, V277, P7670, DOI 10.1074/jbc.M110644200; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; DALBEY RE, 2004, IN PRESS BIOCH BIOPH; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Facey SJ, 2003, EUR J BIOCHEM, V270, P1724, DOI 10.1046/j.1432-1033.2003.03531.x; Fillingame RH, 2000, J EXP BIOL, V203, P9; GELLER BL, 1985, J BIOL CHEM, V260, P3281; Kiefer D, 1999, EMBO J, V18, P6299, DOI 10.1093/emboj/18.22.6299; KUHN A, 1988, EUR J BIOCHEM, V177, P267, DOI 10.1111/j.1432-1033.1988.tb14372.x; Luirink J, 2001, FEBS LETT, V501, P1, DOI 10.1016/S0014-5793(01)02616-3; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; Ridder ANJA, 2000, BIOCHEMISTRY-US, V39, P6521, DOI 10.1021/bi000073v; ROHRER J, 1990, SCIENCE, V250, P1418, DOI 10.1126/science.2124001; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Samuelson JC, 2001, J BIOL CHEM, V276, P34847, DOI 10.1074/jbc.M105793200; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Stuart RA, 2002, BBA-MOL CELL RES, V1592, P79, DOI 10.1016/S0167-4889(02)00266-5; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Laan M, 2004, J CELL BIOL, V165, P213, DOI 10.1083/jcb.200402100; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; Woolhead CA, 2001, J BIOL CHEM, V276, P40841, DOI 10.1074/jbc.M106523200; Yi L, 2003, BIOCHEMISTRY-US, V42, P10537, DOI 10.1021/bi034309h; ZIMMERMANN R, 1982, J BIOL CHEM, V257, P6529	38	90	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39260	39267		10.1074/jbc.M405490200	http://dx.doi.org/10.1074/jbc.M405490200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15263011	hybrid			2022-12-27	WOS:000223791500010
J	Xue, M; Vines, CM; Buranda, T; Cimino, DF; Bennett, TA; Prossnitz, ER				Xue, M; Vines, CM; Buranda, T; Cimino, DF; Bennett, TA; Prossnitz, ER			N-formyl peptide receptors cluster in an active raft-associated state prior to phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LIPID RAFTS; BETA-ARRESTINS; SIGNAL-TRANSDUCTION; CAVEOLAE; ACTIVATION; INTERNALIZATION; DESENSITIZATION; CHEMOTAXIS; BINDING	In response to ligand binding, G protein-coupled receptors undergo phosphorylation and activate cellular internalization machinery. An important component of this process is the concentration of receptors into clusters on the plasma membrane. Aside from organizing the receptor in anticipation of internalization, little is known of the function of ligand-mediated G protein-coupled receptor clustering, which has traditionally been thought of as being a phosphorylation-dependent event prior to receptor internalization. We now report that following receptor activation, the N-formyl peptide receptor (FPR) forms distinct membrane clusters prior to its association with arrestin. To determine whether this clustering is dependent upon receptor phosphorylation, we used a mutant form of the FPR, DeltaST-FPR, which lacks all phosphorylation sites in the carboxyl-terminal domain. We found that activation of the signaling-competent DeltaST-FPR resulted in rapid receptor clustering on the plasma membrane independent of G(i) protein activation. This clustering required receptor activation since the D71A mutant receptor, which binds ligand but is incapable of transitioning to an active state, failed to induce receptor clustering. Furthermore we demonstrated that FPR-mediated clustering and signaling were cholesterol-dependent processes, suggesting that translocation of the active receptor to lipid rafts may be required for maximal signaling activity. Finally we showed that FPR stimulation in the absence of receptor phosphorylation resulted in translocation of FPR to GM1-rich clusters. Our results demonstrate for the first time that formation of a clustered activated receptor state precedes receptor phosphorylation, arrestin binding, and internalization.	Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Univ New Mexico Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center	Prossnitz, ER (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA.	eprossnitz@salud.umn.edu	Prossnitz, Eric/I-4599-2019; Prossnitz, Eric R./B-4543-2008	Prossnitz, Eric/0000-0001-9190-8302; 	NATIONAL CANCER INSTITUTE [R24CA088339] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014668, P20RR011830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K25AI060036, R29AI036357, T32AI007538, R01AI036357] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA88339] Funding Source: Medline; NCRR NIH HHS [P20 RR11830, 1 S10 RR14668] Funding Source: Medline; NIAID NIH HHS [AI36357, K25AI60036, K25 AI060036, T32 AI007538] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; Bickel PE, 2002, AM J PHYSIOL-ENDOC M, V282, pE1, DOI 10.1152/ajpendo.2002.282.1.E1; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Fraile-Ramos A, 2003, TRAFFIC, V4, P243, DOI 10.1034/j.1600-0854.2003.00079.x; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; Gomez-Mouton C, 2004, J CELL BIOL, V164, P759, DOI 10.1083/jcb.200309101; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Haasemann M, 1998, J CELL SCI, V111, P917; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Key TA, 2001, J BIOL CHEM, V276, P49204, DOI 10.1074/jbc.M109475200; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lasley RD, 2000, J BIOL CHEM, V275, P4417, DOI 10.1074/jbc.275.6.4417; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li N, 2003, PROTEOMICS, V3, P536, DOI 10.1002/pmic.200390067; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Pierini LM, 2001, P NATL ACAD SCI USA, V98, P9471, DOI 10.1073/pnas.181353098; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P10686, DOI 10.1074/jbc.270.18.10686; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; Prossnitz ER, 1999, BIOCHEMISTRY-US, V38, P2240, DOI 10.1021/bi982274t; Revankar CM, 2004, J BIOL CHEM, V279, P24578, DOI 10.1074/jbc.M402121200; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sabourin T, 2002, MOL PHARMACOL, V61, P546, DOI 10.1124/mol.61.3.546; Sadir R, 2001, CYTOKINE, V14, P19, DOI 10.1006/cyto.2000.0854; Samsonov AV, 2001, BIOPHYS J, V81, P1486, DOI 10.1016/S0006-3495(01)75803-1; Santini F, 2002, J CELL BIOL, V156, P665, DOI 10.1083/jcb.200110132; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; Slaughter N, 2003, CLIN IMMUNOL, V108, P138, DOI 10.1016/S1521-6616(03)00097-4; SPIEGEL S, 1982, BIOCHIM BIOPHYS ACTA, V687, P27, DOI 10.1016/0005-2736(82)90166-3; VanCompernolle SE, 2003, J IMMUNOL, V171, P2050, DOI 10.4049/jimmunol.171.4.2050; Vilven JC, 1998, J RECEPT SIGNAL TR R, V18, P187, DOI 10.3109/10799899809047744; Vines CM, 2003, J BIOL CHEM, V278, P41581, DOI 10.1074/jbc.C300291200; Vines CM, 2002, J IMMUNOL, V169, P6760, DOI 10.4049/jimmunol.169.12.6760	44	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45175	45184		10.1074/jbc.M407053200	http://dx.doi.org/10.1074/jbc.M407053200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302864	hybrid			2022-12-27	WOS:000224505600111
J	Eisen-Vandervelde, AL; Waggoner, SN; Yao, ZQ; Cale, EM; Hahn, CS; Hahn, YS				Eisen-Vandervelde, AL; Waggoner, SN; Yao, ZQ; Cale, EM; Hahn, CS; Hahn, YS			Hepatitis C virus core selectively suppresses interleukin-12 synthesis in human macrophages by interfering with AP-1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-12 P40 PROMOTER; CELL-DIFFERENTIATION; TYROSINE-PHOSPHATASE; INFECTED PATIENTS; IMMUNE-RESPONSES; DENDRITIC CELLS; MEASLES-VIRUS; NITRIC-OXIDE; T-CELLS; PROTEIN	Hepatitis C virus (HCV) is remarkably efficient at establishing persistent infection, suggesting that it has evolved one or more strategies aimed at evading the host immune response. T cell responses, including interferon-gamma production, are severely suppressed in chronic HCV patients. The HCV core protein has been previously shown to circulate in the bloodstream of HCV-infected patients and inhibit host immunity through an interaction with gC1qR. To determine the role of the HCV core-gC1qR interaction in modulation of inflammatory cytokine production, we examined interleukin (IL)-12 production, which is critical for the induction of interferon-gamma synthesis, in lipopolysaccharide-stimulated human monocyte/macrophages. We found that core protein binds the gC1qR displayed on the cell surface of monocyte/macrophages and inhibits the production of IL-12p70 upon lipopolysaccharide stimulation. This inhibition was found to be selective in that HCV core failed to affect the production of IL-6, IL-8, IL-1beta, and tumor necrosis factor alpha. In addition, suppression of IL-12 production by core protein occurred at the transcriptional level by inhibition of IL-12p40 mRNA synthesis. Importantly, core-induced inhibition of IL-12p40 mRNA synthesis resulted from impaired activation of AP-1 rather than enhanced IL-10 production. These results suggest that the HCV core-gC1qR interaction may play a pivotal role in establishing persistent infection by dampening TH1 responses.	Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; Aventis Pharmaceut, Bridgewater, NJ 08807 USA	University of Virginia; University of Virginia; University of Virginia; Sanofi-Aventis	Hahn, YS (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Box 801386, Charlottesville, VA 22903 USA.	ysh5e@virginia.edu		Waggoner, Stephen/0000-0001-9658-2874	NIDDK NIH HHS [DK66754] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066754] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accapezzato D, 2004, EUR J IMMUNOL, V34, P438, DOI 10.1002/eji.200324540; ALTER MJ, 1997, HEPATOLOGY S1, V26, P62; Amaraa R, 2002, IMMUNOL LETT, V83, P209, DOI 10.1016/S0165-2478(02)00102-5; Becker C, 2001, J IMMUNOL, V167, P2608, DOI 10.4049/jimmunol.167.5.2608; Braun L, 2000, EMBO J, V19, P1458, DOI 10.1093/emboj/19.7.1458; Cerny A, 1999, HEPATOLOGY, V30, P595, DOI 10.1002/hep.510300312; CHEHIMI J, 1994, J EXP MED, V179, P1361, DOI 10.1084/jem.179.4.1361; CHEN A, 1994, J IMMUNOL, V153, P1430; Dolganiuc A, 2003, J IMMUNOL, V170, P5615, DOI 10.4049/jimmunol.170.11.5615; Duenas-Carrera S, 2001, BIOTECHNOL APPL BIOC, V33, P47, DOI 10.1042/BA20000076; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P621; Gerotto M, 1999, J VIROL, V73, P7241, DOI 10.1128/JVI.73.9.7241-7247.1999; GHEBREHIWET B, 1990, CLIN IMMUNOL IMMUNOP, V54, P148, DOI 10.1016/0090-1229(90)90014-H; GUNJI T, 1994, ARCH VIROL, V134, P293, DOI 10.1007/BF01310568; Ha SJ, 2004, J IMMUNOL, V172, P525, DOI 10.4049/jimmunol.172.1.525; Hino K, 2000, J VIRAL HEPATITIS, V7, P36; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; Kanto T, 1999, J IMMUNOL, V162, P5584; KANTO T, 1995, J HEPATOL, V22, P440, DOI 10.1016/0168-8278(95)80107-3; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; Knutson KL, 1998, J BIOL CHEM, V273, P645, DOI 10.1074/jbc.273.1.645; Kurita-Taniguchi M, 2000, J IMMUNOL, V165, P5143, DOI 10.4049/jimmunol.165.9.5143; Large MK, 1999, J IMMUNOL, V162, P931; Lee CH, 2001, VIROLOGY, V279, P271, DOI 10.1006/viro.2000.0694; Lerat H, 1996, J CLIN INVEST, V97, P845, DOI 10.1172/JCI118485; Liu ZX, 2002, J VIROL, V76, P990, DOI 10.1128/JVI.76.3.990-997.2002; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; Magor BG, 2001, DEV COMP IMMUNOL, V25, P651, DOI 10.1016/S0145-305X(01)00029-5; Matsunaga K, 2001, INFECT IMMUN, V69, P1929, DOI 10.1128/IAI.69.3.1929-1933.2001; Matthews DA, 1998, J GEN VIROL, V79, P1677, DOI 10.1099/0022-1317-79-7-1677; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; Nelson DR, 1997, J IMMUNOL, V158, P1473; Piazzolla G, 2000, J CLIN IMMUNOL, V20, P54, DOI 10.1023/A:1006694627907; Polakos NK, 2001, J IMMUNOL, V166, P3589, DOI 10.4049/jimmunol.166.5.3589; Rehermann B, 1996, J VIROL, V70, P7092, DOI 10.1128/JVI.70.10.7092-7102.1996; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; Sarih M, 2000, IMMUNOL LETT, V74, P117, DOI 10.1016/S0165-2478(00)00210-8; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 2000, INT IMMUNOL, V12, P113, DOI 10.1093/intimm/12.1.113; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Trinchieri G, 1998, ADV IMMUNOL, V70, P83, DOI 10.1016/S0065-2776(08)60387-9; Trinchieri G, 2003, IMMUNITY, V19, P641, DOI 10.1016/S1074-7613(03)00296-6; Tsai SL, 1997, HEPATOLOGY, V25, P449; Ulsenheimer A, 2003, HEPATOLOGY, V37, P1189, DOI 10.1053/jhep.2003.50194; Weinmann AS, 2001, NAT IMMUNOL, V2, P51, DOI 10.1038/83168; Yamada M, 2004, EUR J IMMUNOL, V34, P221, DOI 10.1002/eji.200324026; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yao ZQ, 2003, VIROLOGY, V314, P271, DOI 10.1016/S0042-6822(03)00419-7; Yao ZQ, 2001, J IMMUNOL, V167, P5264, DOI 10.4049/jimmunol.167.9.5264; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223; Zhu C, 2001, J BIOL CHEM, V276, P18519, DOI 10.1074/jbc.M100440200	58	82	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43479	43486		10.1074/jbc.M407640200	http://dx.doi.org/10.1074/jbc.M407640200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292184	hybrid			2022-12-27	WOS:000224383100017
J	Ridgway, P; Brown, KD; Rangasamy, D; Svensson, U; Tremethick, DJ				Ridgway, P; Brown, KD; Rangasamy, D; Svensson, U; Tremethick, DJ			Unique residues on the H2A.Z containing nucleosome surface are important for Xenopus laevis development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE VARIANT H2A.Z; EARLY MAMMALIAN DEVELOPMENT; INACTIVE X-CHROMOSOME; RNA INTERFERENCE; GENE-EXPRESSION; CELL-MIGRATION; EMBRYOS; PROTEIN; CHROMATIN; TRANSCRIPTION	Critical to vertebrate development is a complex program of events that establishes specialized tissues and organs from a single fertilized cell. Transitions in chromatin architecture, through alterations in its composition and modification markings, characterize early development. A variant of the H2A core histone, H2A.Z, is essential for development of both Drosophila and mice. We recently showed that H2A.Z is required for proper chromosome segregation. Whether H2A.Z has additional specific functions during early development remains unknown. Here we demonstrate that depletion of H2A.Z by RNA interference perturbs Xenopus laevis development at gastrulation leading to embryos with malformed, shortened trunks. Consistent with this result, whole embryo in situ hybridization indicates that endogenous expression of H2A.Z is highly enriched in the notochord. H2A.Z modifies the surface of a canonical nucleosome by creating an extended acidic patch and a metal ion-binding site stabilized by two histidine residues. To examine the significance of these specific surface regions in vivo, we investigated the consequences of overexpressing H2A.Z and mutant proteins during X. laevis development. Overexpression of H2A.Z slowed development following gastrulation. Altering the extended acidic patch of H2A.Z reversed this effect. Remarkably, modification of a single stabilizing histidine residue located on the exposed surface of an H2A.Z containing nucleosome was sufficient to disrupt normal trunk formation mimicking the effect observed by RNA interference. Taken together, these results argue that key determinants located on the surface of an H2A.Z nucleosome play an important specific role during embryonic patterning and provide a link between a chromatin structural modification and normal vertebrate development.	Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 0200, Australia	Australian National University; John Curtin School of Medical Research	Ridgway, P (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 0200, Australia.	Pat.Ridgway@anu.edu.au; David.Tremethick@anu.edu.au	Brown, Karl/M-7303-2019	Tremethick, David/0000-0001-5274-8078; Brown, Karl/0000-0003-1847-2789				ALLIS CD, 1982, CELL, V31, P131, DOI 10.1016/0092-8674(82)90412-3; ALLIS CD, 1980, CELL, V20, P609, DOI 10.1016/0092-8674(80)90307-4; ALMOUZNI G, 1995, EMBO J, V14, P1752, DOI 10.1002/j.1460-2075.1995.tb07164.x; CARR AM, 1994, MOL GEN GENET, V245, P628, DOI 10.1007/BF00282226; Chadwick BP, 2001, J CELL BIOL, V152, P375, DOI 10.1083/jcb.152.2.375; Clarkson MJ, 1999, NATURE, V399, P694, DOI 10.1038/21436; Costanzi C, 2000, DEVELOPMENT, V127, P2283; Dhillon N, 2000, MOL CELL, V6, P769, DOI 10.1016/S1097-2765(00)00076-9; ERNST SG, 1987, NUCLEIC ACIDS RES, V15, P4629, DOI 10.1093/nar/15.11.4629; Faast R, 2001, CURR BIOL, V11, P1183, DOI 10.1016/S0960-9822(01)00329-3; Faber J., 1994, NORMAL TABLE XENOPUS, P2; Fan JY, 2002, NAT STRUCT BIOL, V9, P172, DOI 10.1038/nsb767; GERHART J, 1986, ANNU REV CELL BIOL, V2, P201, DOI 10.1146/annurev.cb.02.110186.001221; Glavic A, 2004, DEV BIOL, V272, P89, DOI 10.1016/j.ydbio.2004.04.020; Hatch CL, 1996, BBA-GENE STRUCT EXPR, V1305, P59, DOI 10.1016/0167-4781(95)00223-5; Hayward DC, 2001, DEV GENES EVOL, V211, P10; Iouzalen N, 1996, NUCLEIC ACIDS RES, V24, P3947, DOI 10.1093/nar/24.20.3947; Jackson JD, 1996, TRENDS BIOCHEM SCI, V21, P466, DOI 10.1016/S0968-0004(96)20028-3; KELLER R, 1992, CURR TOP DEV BIOL, V27, P39, DOI 10.1016/S0070-2153(08)60532-3; Kwan KM, 2003, DEVELOPMENT, V130, P1961, DOI 10.1242/dev.00412; Lemaitre JM, 1998, J CELL BIOL, V142, P1159, DOI 10.1083/jcb.142.5.1159; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Nakano H, 2000, BIOCHEM BIOPH RES CO, V274, P434, DOI 10.1006/bbrc.2000.3178; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pauls S, 2001, DEV GENES EVOL, V211, P603, DOI 10.1007/s00427-001-0196-x; PRIOLEAU MN, 1994, CELL, V77, P439, DOI 10.1016/0092-8674(94)90158-9; Rangasamy D, 2004, NAT STRUCT MOL BIOL, V11, P650, DOI 10.1038/nsmb786; Rangasamy D, 2003, EMBO J, V22, P1599, DOI 10.1093/emboj/cdg160; Ridgway P, 2004, METHOD ENZYMOL, V375, P239; Saka Y, 2001, DEV BIOL, V229, P307, DOI 10.1006/dbio.2000.0101; Santisteban MS, 2000, CELL, V103, P411, DOI 10.1016/S0092-8674(00)00133-1; SIVE HL, 2000, EARLY DEV XENOPUS LA, P39; Steinbach OC, 1997, NATURE, V389, P395, DOI 10.1038/38755; Sullivan KF, 2001, CURR OPIN GENET DEV, V11, P182, DOI 10.1016/S0959-437X(00)00177-5; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; VANDAAL A, 1992, MOL BIOL CELL, V3, P593, DOI 10.1091/mbc.3.6.593; Vermaak D, 1998, CURR BIOL, V8, P533, DOI 10.1016/S0960-9822(98)70206-4; WHITE EM, 1988, NUCLEIC ACIDS RES, V16, P179, DOI 10.1093/nar/16.1.179; WINKLBAUER R, 1990, DEV BIOL, V142, P155, DOI 10.1016/0012-1606(90)90159-G; WUNSCH AM, 1991, MECH AGEING DEV, V59, P299, DOI 10.1016/0047-6374(91)90140-U; ZernickaGoetz M, 1996, DEVELOPMENT, V122, P3719; Zhou Y, 2002, NUCLEIC ACIDS RES, V30, P1664, DOI 10.1093/nar/30.7.1664	44	67	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43815	43820		10.1074/jbc.M408409200	http://dx.doi.org/10.1074/jbc.M408409200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15299007	hybrid			2022-12-27	WOS:000224383100057
J	Yang, TB; Chaudhuri, S; Yang, LH; Chen, YP; Poovaiah, BW				Yang, TB; Chaudhuri, S; Yang, LH; Chen, YP; Poovaiah, BW			Calcium/calmodulin up-regulates a cytoplasmic receptor-like kinase in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; SIGNALING PATHWAYS; GLUTAMATE-DECARBOXYLASE; ARABIDOPSIS-THALIANA; DISEASE RESISTANCE; GENE ENCODES; CALCIUM; DOMAIN; FAMILY; TOBACCO	Calcium/calmodulin-dependent kinases play an important role in protein phosphorylation in eukaryotes. However, not much is known about calcium/calmodulin-dependent protein phosphorylation and its role in signal transduction in plants. By using a protein-protein interaction-based approach, we have isolated a novel plant-specific calmodulin-binding receptor-like cytoplasmic kinase (CRCK1) from Arabidopsis thaliana, as well as its ortholog from Medicago sativa ( alfalfa). CRCK1 does not show high homology to calcium/calmodulin-dependent protein kinases in animals. In contrast, it shows high homology in the kinase domain to serine/threonine receptor-like kinases in plants. However, it contains neither a transmembrane domain nor an extracellular domain. Calmodulin binds to CRCK1 in a calcium-dependent manner with an affinity of similar to20.5 nM. The calmodulin-binding site in CRCK1 is located in amino acids 160-183, which overlap subdomain II of the kinase domain. CRCK1 undergoes autophosphorylation in the presence of Mg2+ at the threonine residue(s). The K-m and V-max values of CRCK1 for ATP are 1 muM and 33.6 pmol/mg/min, respectively. Calcium/calmodulin stimulates the kinase activity of CRCK1, which increases the V-max of CRCK1 similar to9-fold. The expression of CRCK1 is increased in response to stresses such as cold and salt and stress molecules such as abscisic acid and hydrogen peroxide. These results indicate the presence of a calcium/calmodulin-regulated receptor-like cytoplasmic kinase in plants. Furthermore, these results also suggest that calcium/calmodulin-regulated protein phosphorylation involving CRCK1 plays a role in stress signal transduction in plants.	Washington State Univ, Ctr Integrated Biotechnol, Pullman, WA 99164 USA; Washington State Univ, Dept Hort, Pullman, WA 99164 USA	Washington State University; Washington State University	Poovaiah, BW (corresponding author), Washington State Univ, Ctr Integrated Biotechnol, Pullman, WA 99164 USA.	poovaiah@wsu.edu						Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; ARAZI T, 1995, PLANT PHYSIOL, V108, P551, DOI 10.1104/pp.108.2.551; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BAUM G, 1993, J BIOL CHEM, V268, P19610; Becraft PW, 2002, ANNU REV CELL DEV BI, V18, P163, DOI 10.1146/annurev.cellbio.18.012502.083431; Charpenteau M, 2004, BIOCHEM J, V379, P841, DOI 10.1042/BJ20031045; Cheng SH, 2002, PLANT PHYSIOL, V129, P469, DOI 10.1104/pp.005645; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Choi JY, 2002, J BIOL CHEM, V277, P21630, DOI 10.1074/jbc.M110803200; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Hardie DG, 1999, ANNU REV PLANT PHYS, V50, P97, DOI 10.1146/annurev.arplant.50.1.97; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Hua W, 2003, BIOCHEM J, V376, P291, DOI 10.1042/BJ20030736; Kachroo A, 2002, PLANT CELL, V14, pS227, DOI 10.1105/tpc.010440; Knight H, 2000, INT REV CYTOL, V195, P269; LANCIOTTI RA, 1994, BIOCHEM J, V299, P183, DOI 10.1042/bj2990183; Lechner E, 2002, J BIOL CHEM, V277, P50069, DOI 10.1074/jbc.M204254200; Lee SH, 2000, BIOCHEM J, V350, P299, DOI 10.1042/0264-6021:3500299; Levy J, 2004, SCIENCE, V303, P1361, DOI 10.1126/science.1093038; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PATIL S, 1995, P NATL ACAD SCI USA, V92, P4897, DOI 10.1073/pnas.92.11.4897; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; POOVAIAH BW, 1987, CRC CR REV PLANT SCI, V6, P47, DOI 10.1080/07352688709382247; PRICE AH, 1994, PLANT CELL, V6, P1301, DOI 10.1105/tpc.6.9.1301; Reddy ASN, 1996, J BIOL CHEM, V271, P7052, DOI 10.1074/jbc.271.12.7052; Reddy ASN, 2001, PLANT SCI, V160, P381, DOI 10.1016/S0168-9452(00)00386-1; Sathyanarayanan PV, 2001, J BIOL CHEM, V276, P32940, DOI 10.1074/jbc.M009648200; Scheer JM, 2002, P NATL ACAD SCI USA, V99, P9585, DOI 10.1073/pnas.132266499; SchulzeMuth P, 1996, J BIOL CHEM, V271, P26684, DOI 10.1074/jbc.271.43.26684; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Shiu S.H., 2001, SCI STKE, pre22; Shiu SH, 2003, PLANT PHYSIOL, V132, P530, DOI 10.1104/pp.103.021964; SMITH JA, 1988, PLANTA, V174, P462, DOI 10.1007/BF00634474; Snedden WA, 2001, NEW PHYTOL, V151, P35, DOI 10.1046/j.1469-8137.2001.00154.x; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; Swiderski MR, 2001, PLANT J, V26, P101, DOI 10.1046/j.1365-313x.2001.01014.x; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; Tichtinsky G, 2003, TRENDS PLANT SCI, V8, P231, DOI 10.1016/S1360-1385(03)00062-1; Trewavas AJ, 1998, CURR OPIN PLANT BIOL, V1, P428, DOI 10.1016/S1369-5266(98)80268-9; van der Luit AH, 1999, PLANT PHYSIOL, V121, P705, DOI 10.1104/pp.121.3.705; Vanoosthuyse V, 2003, PLANT PHYSIOL, V133, P919, DOI 10.1104/pp.103.023846; VELUTHAMBI K, 1984, SCIENCE, V223, P167, DOI 10.1126/science.223.4632.167; Wang W, 1996, PLANT MOL BIOL, V31, P87, DOI 10.1007/BF00020609; Xiong LM, 2002, PLANT CELL, V14, pS165, DOI 10.1105/tpc.000596; Yang TB, 2000, J BIOL CHEM, V275, P3137, DOI 10.1074/jbc.275.5.3137; Yang TB, 2003, TRENDS PLANT SCI, V8, P505, DOI 10.1016/j.tplants.2003.09.004; Yang TB, 2002, J BIOL CHEM, V277, P45049, DOI 10.1074/jbc.M207941200; Yang TB, 2000, J BIOL CHEM, V275, P38467, DOI 10.1074/jbc.M003566200; Zhang L, 2003, TRENDS PLANT SCI, V8, P123, DOI 10.1016/S1360-1385(03)00013-X; Zheng HY, 2002, PLANT PHYSIOL, V129, P530, DOI 10.1104/pp.003970; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	58	60	73	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42552	42559		10.1074/jbc.M402830200	http://dx.doi.org/10.1074/jbc.M402830200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292241	hybrid			2022-12-27	WOS:000224226400027
J	Boudsocq, M; Barbier-Brygoo, H; Lauriere, C				Boudsocq, M; Barbier-Brygoo, H; Lauriere, C			Identification of nine sucrose nonfermenting 1-related protein kinases 2 activated by hyperosmotic and saline stresses in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PROTEIN-KINASE; ABSCISIC-ACID; SALT TOLERANCE; MAP KINASES; OSMOTIC STRESSES; CELL-SUSPENSIONS; OVER-EXPRESSION; CALCIUM; COLD; GENE	Several calcium-independent protein kinases were activated by hyperosmotic and saline stresses in Arabidopsis cell suspension. Similar activation profiles were also observed in seedlings exposed to hyperosmotic stress. One of them was identified to AtMPK6 (Droillard, M.J., Boudsocq, M., Barbier-Brygoo, H., and Lauriere, C. (2002) FEBS Lett. 527, 43-50) but the others remained to be identified. They were assumed to belong to the SNF1 (sucrose nonfermenting 1)-related protein kinase 2 (SnRK2) family, which constitutes a plant-specific kinase group. The 10 Arabidopsis SnRK2 were expressed both in cells and seedlings, making the whole SnRK2 family a suitable candidate. Using a family-specific antibody raised against the 10 SnRK2, we demonstrated that these non-MAPK protein kinases activated by hyperosmolarity in cell suspension were SnRK2 proteins. Then, the molecular identification of the involved SnRK2 was investigated by transient expression assays. Nine of the 10 SnRK2 were activated by hyperosmolarity induced by mannitol, as well as NaCl, indicating an important role of the SnRK2 family in osmotic signaling. In contrast, none of the SnRK2 were activated by cold treatment, whereas abscisic acid only activated five of the nine SnRK2. The probable involvement of the different Arabidopsis SnRK2 in several abiotic transduction pathways is discussed.	CNRS, UPR 2355, Inst Sci Vegetal, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lauriere, C (corresponding author), CNRS, UPR 2355, Inst Sci Vegetal, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	christiane.lauriere@isv.cnrs-gif.fr	Boudsocq, Marie/J-6074-2019; BARBIER-BRYGOO, HELENE/A-8435-2013	Boudsocq, Marie/0000-0001-8945-6773; 				An YQ, 1996, PLANT J, V10, P107, DOI 10.1046/j.1365-313X.1996.10010107.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Charrier B, 2002, PLANT PHYSIOL, V130, P577, DOI 10.1104/pp.009175; Covic L, 1999, BBA-MOL CELL RES, V1451, P242, DOI 10.1016/S0167-4889(99)00096-8; Droillard MJ, 2000, FEBS LETT, V474, P217, DOI 10.1016/S0014-5793(00)01611-2; Droillard MJ, 2002, FEBS LETT, V527, P43, DOI 10.1016/S0014-5793(02)03162-9; Ferrando A, 2000, PLANT J, V22, P553, DOI 10.1046/j.1365-313x.2000.00763.x; Gomez-Cadenas A, 1999, P NATL ACAD SCI USA, V96, P1767, DOI 10.1073/pnas.96.4.1767; Guo Y, 2001, PLANT CELL, V13, P1383, DOI 10.1105/tpc.13.6.1383; Halfter U, 2000, P NATL ACAD SCI USA, V97, P3735, DOI 10.1073/pnas.040577697; Hoyos ME, 2000, PLANT PHYSIOL, V122, P1355, DOI 10.1104/pp.122.4.1355; Hrabak EM, 2003, PLANT PHYSIOL, V132, P666, DOI 10.1104/pp.102.011999; Huang YF, 2000, PLANT PHYSIOL, V122, P1301, DOI 10.1104/pp.122.4.1301; Ichimura K, 2000, PLANT J, V24, P655, DOI 10.1046/j.1365-313x.2000.00913.x; Ishitani M, 2000, PLANT CELL, V12, P1667, DOI 10.1105/tpc.12.9.1667; Jonak C, 1996, P NATL ACAD SCI USA, V93, P11274, DOI 10.1073/pnas.93.20.11274; Kiegerl S, 2000, PLANT CELL, V12, P2247, DOI 10.1105/tpc.12.11.2247; Kobayashi Y, 2004, PLANT CELL, V16, P1163, DOI 10.1105/tpc.019943; Kreps JA, 2002, PLANT PHYSIOL, V130, P2129, DOI 10.1104/pp.008532; Li JX, 1996, PLANT CELL, V8, P2359, DOI 10.1105/tpc.8.12.2359; Liu JP, 2000, P NATL ACAD SCI USA, V97, P3730, DOI 10.1073/pnas.060034197; Liu YH, 2000, MOL PLANT MICROBE IN, V13, P118, DOI 10.1094/MPMI.2000.13.1.118; Martin ML, 2001, PLANT PHYSIOL, V125, P1442, DOI 10.1104/pp.125.3.1442; Mikolajczyk M, 2000, PLANT CELL, V12, P165, DOI 10.1105/tpc.12.1.165; Mizoguchi T, 1998, FEBS LETT, V437, P56, DOI 10.1016/S0014-5793(98)01197-1; Monks DE, 2001, PLANT CELL, V13, P1205, DOI 10.1105/tpc.13.5.1205; Mori IC, 1997, PLANT PHYSIOL, V113, P833, DOI 10.1104/pp.113.3.833; Munnik T, 1999, PLANT J, V20, P381, DOI 10.1046/j.1365-313x.1999.00610.x; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Mustilli AC, 2002, PLANT CELL, V14, P3089, DOI 10.1105/tpc.007906; Piao HL, 1999, PLANT PHYSIOL, V119, P1527, DOI 10.1104/pp.119.4.1527; Piao HL, 2001, PLANT J, V27, P305, DOI 10.1046/j.1365-313x.2001.01099.x; Qiu QS, 2002, P NATL ACAD SCI USA, V99, P8436, DOI 10.1073/pnas.122224699; Quintero FJ, 2002, P NATL ACAD SCI USA, V99, P9061, DOI 10.1073/pnas.132092099; Saijo Y, 2000, PLANT J, V23, P319, DOI 10.1046/j.1365-313x.2000.00787.x; Sanders D, 2002, PLANT CELL, V14, pS401, DOI 10.1105/tpc.002899; Sangwan V, 2002, PLANT J, V31, P629, DOI 10.1046/j.1365-313X.2002.01384.x; Seki M, 2001, PLANT CELL, V13, P61, DOI 10.1105/tpc.13.1.61; Shi HZ, 2000, P NATL ACAD SCI USA, V97, P6896, DOI 10.1073/pnas.120170197; URAO T, 1994, MOL GEN GENET, V244, P331, DOI 10.1007/BF00286684; Xiong LM, 2002, PLANT CELL, V14, pS165, DOI 10.1105/tpc.000596; Yoon GM, 1999, PLANT MOL BIOL, V39, P991, DOI 10.1023/A:1006170512542; Yoon HW, 1997, MOL GEN GENET, V255, P359, DOI 10.1007/s004380050507; Yoshida R, 2002, PLANT CELL PHYSIOL, V43, P1473, DOI 10.1093/pcp/pcf188; Zhang SQ, 1998, PLANT CELL, V10, P435, DOI 10.1105/tpc.10.3.435; Zhu JK, 1998, PLANT CELL, V10, P1181, DOI 10.1105/tpc.10.7.1181	46	326	397	7	77	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41758	41766		10.1074/jbc.M405259200	http://dx.doi.org/10.1074/jbc.M405259200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292193	hybrid			2022-12-27	WOS:000224075500064
J	Schroeder, TM; Kahler, RA; Li, XD; Westendorf, JJ				Schroeder, TM; Kahler, RA; Li, XD; Westendorf, JJ			Histone deacetylase 3 interacts with Runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CBFA1; LEUKEMIA-VIRUS ENHANCERS; IN-VIVO; CHROMATIN-STRUCTURE; RUNX2/CBFA1 GENE; HOMOLOGY-DOMAIN; NUCLEAR-MATRIX; FUSION PROTEIN; DNA-BINDING; C-JUN	The Runt domain transcription factor Runx2 (AML-3, and Cbfa1) is essential for osteoblast development, differentiation, and bone formation. Runx2 positively or negatively regulates osteoblast gene expression by interacting with a variety of transcription cofactor complexes. In this study, we identified a trichostatin A-sensitive autonomous repression domain in the amino terminus of Runx2. Using a candidate approach, we found that histone deacetylase ( HDAC) 3 interacts with the amino terminus of Runx2. In transient transfection assays, HDAC3 repressed Runx2-mediated activation of the osteocalcin promoter. HDAC inhibitors and HDAC3-specific short hairpin RNAs reversed this repression. In vivo, Runx2 and HDAC3 associated with the osteocalcin promoter. These data indicate that HDAC3 regulates Runx2-mediated transcription of osteoblast genes. Suppression of HDAC3 in MC3T3 preosteoblasts by RNA interference accelerated the expression of Runx2 target genes, osteocalcin, osteopontin, and bone sialoprotein but did not significantly alter Runx2 levels. Matrix mineralization also occurred earlier in HDAC3-suppressed cells, but alkaline phosphatase expression was not affected. Thus, HDAC3 regulates osteoblast differentiation and bone formation. Although HDAC3 is likely to affect the activity of multiple proteins in osteoblasts, our data show that it actively regulates the transcriptional activity of the osteoblast master protein, Runx2.	Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Univ Minnesota, Grad Program Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Minnesota, Grad Program Microbiol Immunol & Canc Biol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Orthopaed Surg, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Westendorf, JJ (corresponding author), Univ Minnesota, Ctr Canc, MMC 806,420 Delaware St SE, Minneapolis, MN 55455 USA.	weste047@umn.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048147, T32AR050938] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR050938, AR48147, T32 AR050938] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Gutierrez J, 2000, BIOCHEMISTRY-US, V39, P13565, DOI 10.1021/bi0013896; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; HONG L, 1993, J BIOL CHEM, V268, P305; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Javed A, 2000, J CELL SCI, V113, P2221; Kao HY, 2000, GENE DEV, V14, P55; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Koka S, 2003, J CELL SCI, V116, P1745, DOI 10.1242/jcs.00386; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kouraklis G., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P477, DOI 10.2174/1568011023353921; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; LENNY N, 1995, ONCOGENE, V11, P1761; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; MANOUKIAN AS, 1993, DEVELOPMENT, V118, P785; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Montecino M, 1996, BIOCHEMISTRY-US, V35, P5093, DOI 10.1021/bi952489s; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043; Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Shen JL, 2002, J BIOL CHEM, V277, P20284, DOI 10.1074/jbc.M112440200; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Sudhakar S, 2001, BIOCHEM BIOPH RES CO, V289, P616, DOI 10.1006/bbrc.2001.6033; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875; Tou LQ, 2003, MOL CELL ENDOCRINOL, V205, P121, DOI 10.1016/S0303-7207(03)00151-5; Vaillant F, 2002, J IMMUNOL, V169, P2866, DOI 10.4049/jimmunol.169.6.2866; Vaughan T, 2002, J BONE MINER RES, V17, P1527, DOI 10.1359/jbmr.2002.17.8.1527; Verdel A, 2000, CURR BIOL, V10, P747, DOI 10.1016/S0960-9822(00)00542-X; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo-reports/kvf193; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Wen YD, 2003, J BIOL CHEM, V278, P1841, DOI 10.1074/jbc.M206528200; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Xiao ZS, 2003, J CELL BIOCHEM, V88, P493, DOI 10.1002/jcb.10375; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001	82	188	199	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41998	42007		10.1074/jbc.M403702200	http://dx.doi.org/10.1074/jbc.M403702200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292260	hybrid			2022-12-27	WOS:000224075500093
J	Yang, SA; Carpenter, CL; Abrams, CS				Yang, SA; Carpenter, CL; Abrams, CS			Rho and Rho-kinase mediate thrombin-induced phosphatidylinositol 4-phosphate 5-kinase trafficking in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFICILE TOXIN-B; 4-PHOSPHATE 5-KINASE; PHOSPHATE KINASE; PLASMA-MEMBRANE; DOWNSTREAM EFFECTOR; RESTING PLATELETS; IN-VIVO; RAC; PROTEIN; 4,5-BISPHOSPHATE	Phosphatidylinositol 4-phosphate 5-kinase (PIP5K) catalyzes the rate-limiting step in the production of phosphatidylinositol 4,5-bisphosphate (PIP2), a signaling phospholipid that contributes to actin dynamics. We have shown in transfected tissue culture cells that PIP5K translocates from the cytosol to the plasma membrane following agonist-induced stimulation of Rho family GTPases. Nonetheless, it is unclear whether Rho GTPases induce PIP5K relocalization in platelets. We used PIP5K isoform-specific immunoblotting and lipid kinase assays to examine the intracellular localization of PIP5K in resting and activated platelets. Using differential centrifugation to separate the membrane skeleton, actin filaments and associated proteins, and cytoplasmic fractions, we found that PIP5K isoforms were translocated from cytosol to actin-rich fractions following stimulation of the thrombin receptor. PIP5K translocation was detectable within 30 s of stimulation and was complete by 2-5 min. This agonist-induced relocalization and activation of PIP5K was inhibited by 8-(4-parachlorophenylthio)cAMP, a cAMP analogue that inhibits Rho and Rac. In contrast, 8-(4-parachlorophenylthio)-cGMP, a cGMP analogue that inhibits Rac but not Rho, did not affect PIP5K translocation and activation. This suggests that Rho GTPase may be an essential regulator of PIP5K in platelets. Consistent with this hypothesis, we found that C3 exotoxin (a Rho-specific inhibitor) and HA1077 (an inhibitor of the Rho effector, Rho-kinase) also eliminated PIP5K activation and trafficking into the membrane cytoskeleton. Thus, these data indicate that Rho GTPase and its effector Rho-kinase have an intimate relationship with the trafficking and activation of platelet PIP5K. Moreover, these data suggest that relocalization of platelet PIP5K following agonist stimulation may play an important role in regulating the assembly of the platelet cytoskeleton.	Univ Penn, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	University of Pennsylvania; Harvard University; Harvard Medical School	Abrams, CS (corresponding author), Univ Penn, Div Hematol Oncol, Dept Med, 421 Curie Blvd,Rm 912,Biomed Res Bldg 2-3, Philadelphia, PA 19104 USA.	abrams@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [P01CA093615] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054500] Funding Source: NIH RePORTER; NCI NIH HHS [CA-93615] Funding Source: Medline; NHLBI NIH HHS [HL-54500] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; Azim AC, 2000, BLOOD, V95, P959, DOI 10.1182/blood.V95.3.959.003k22_959_964; Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362; Bodin S, 2001, BIOCHEMISTRY-US, V40, P15290, DOI 10.1021/bi0109313; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Chang JD, 2004, J BIOL CHEM, V279, P11672, DOI 10.1074/jbc.M309721200; Chatah NEH, 2001, J BIOL CHEM, V276, P34059, DOI 10.1074/jbc.M104917200; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; Dorahy DJ, 1998, BIOCHEM J, V333, P373, DOI 10.1042/bj3330373; Doughman RL, 2003, J BIOL CHEM, V278, P23036, DOI 10.1074/jbc.M211397200; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1993, J BIOL CHEM, V268, P25973; Gambaryan S, 2004, BLOOD, V103, P2593, DOI 10.1182/blood-2003-09-3349; Gratacap MP, 2001, J BIOL CHEM, V276, P47906, DOI 10.1074/jbc.M104442200; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; Hinchliffe KA, 1998, BIOCHEM J, V329, P115; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Leng LJ, 1998, BLOOD, V91, P4206, DOI 10.1182/blood.V91.11.4206.411k30_4206_4215; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Marshall SJ, 2004, BLOOD, V103, P2601, DOI 10.1182/blood-2003-09-3319; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; NEMOTO Y, 1992, J BIOL CHEM, V267, P20916; Padron D, 2003, J CELL BIOL, V162, P693, DOI 10.1083/jcb.200302051; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Saito K, 2003, IMMUNITY, V19, P669, DOI 10.1016/S1074-7613(03)00297-8; Schmidt M, 1996, N-S ARCH PHARMACOL, V354, P87, DOI 10.1007/BF00178707; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; van Horck FPG, 2002, CURR BIOL, V12, P241, DOI 10.1016/S0960-9822(01)00660-1; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; Weernink PAO, 2004, J BIOL CHEM, V279, P7840, DOI 10.1074/jbc.M312737200; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; WILSON DB, 1985, J BIOL CHEM, V260, P1046; Wonerow P, 2002, BIOCHEM J, V364, P755, DOI 10.1042/BJ20020128; Wong KW, 2003, J EXP MED, V198, P603, DOI 10.1084/jem.20021363; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	52	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42331	42336		10.1074/jbc.M404335200	http://dx.doi.org/10.1074/jbc.M404335200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15277528	hybrid			2022-12-27	WOS:000224075500125
J	Delumeau, O; Dutta, S; Brigulla, M; Kuhnke, G; Hardwick, SW; Volker, U; Yudkin, MD; Lewis, RJ				Delumeau, O; Dutta, S; Brigulla, M; Kuhnke, G; Hardwick, SW; Volker, U; Yudkin, MD; Lewis, RJ			Functional and structural characterization of RsbU, a stress signaling protein phosphatase 2C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGMA(B) TRANSCRIPTION FACTOR; BACILLUS-SUBTILIS; ENVIRONMENTAL-STRESS; ENERGY STRESS; SIGB OPERON; ACTIVATION; KINASE; PHOSPHORYLATION; EXPRESSION; REGULATORS	RsbU is a positive regulator of the activity of sigma(B), the general stress-response sigma factor of Gram(+) microorganisms. The N-terminal domain of this protein has no significant sequence homology with proteins of known function, whereas the C-terminal domain is similar to the catalytic domains of PP2C-type phosphatases. The phosphatase activity of RsbU is stimulated greatly during the response to stress by associating with a kinase, RsbT. This association leads to the induction of sigma(B) activity. Here we present data on the activation process and demonstrate in vivo that truncations in the N-terminal region of RsbU are deleterious for the activation of RsbU. This conclusion is supported by comparisons of the phosphatase activities of full-length and a truncated form of RsbU in vitro. Our determination of the crystal structure of the N-terminal domain of RsbU from Bacillus subtilis reveals structural similarities to the regulatory domains from ubiquitous protein phosphatases and a conserved domain of sigma-factors, illuminating the activation processes of phosphatases and the evolution of "partner switching." Finally, the molecular basis of kinase recruitment by the RsbU phosphatase is discussed by comparing RsbU sequences from bacteria that either possess or lack RsbT.	Univ Newcastle, Inst Cell & Mol Biosci, Fac Med Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Oxford, Dept Biochem, Microbiol Unit, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Max Planck Inst Terr Microbiol, Dept Biochem, D-35032 Marburg, Germany; Ernst Moritz Arndt Univ Greifswald, Lab Funct Genom, Sch Med, D-17487 Greifswald, Germany	Newcastle University - UK; University of Oxford; University of Oxford; Max Planck Society; Ernst Moritz Arndt Universitat Greifswald	Lewis, RJ (corresponding author), Univ Newcastle, Inst Cell & Mol Biosci, Fac Med Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	R.Lewis@ncl.ac.uk	; Lewis, Richard J./E-8674-2013	lewis, richard/0000-0003-2641-8643; Hardwick, Steven/0000-0001-9246-1864; Volker, Uwe/0000-0002-5689-3448; Lewis, Richard J./0000-0003-3470-923X				Akbar S, 2001, J BACTERIOL, V183, P1329, DOI 10.1128/JB.183.4.1329-1338.2001; ALPER S, 1994, CELL, V77, P195, DOI 10.1016/0092-8674(94)90312-3; Alper S, 1996, J MOL BIOL, V260, P165, DOI 10.1006/jmbi.1996.0390; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENSON AK, 1992, J BACTERIOL, V174, P749, DOI 10.1128/jb.174.3.749-757.1992; BOYLAN SA, 1993, J BACTERIOL, V175, P7931, DOI 10.1128/JB.175.24.7931-7937.1993; Brody MS, 2001, J BACTERIOL, V183, P6422, DOI 10.1128/JB.183.21.6422-6428.2001; Campbell EA, 2002, CELL, V108, P795, DOI 10.1016/S0092-8674(02)00662-1; Chen CC, 2003, MOL MICROBIOL, V49, P1657, DOI 10.1046/j.1365-2958.2003.03663.x; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Delumeau O, 2002, J BACTERIOL, V184, P5583, DOI 10.1128/JB.184.20.5583-5589.2002; Dufour A, 1996, J BACTERIOL, V178, P3701, DOI 10.1128/jb.178.13.3701-9sigma.1996; DUNCAN L, 1995, SCIENCE, V270, P641, DOI 10.1126/science.270.5236.641; Dutta S, 2003, ACTA CRYSTALLOGR D, V59, P191, DOI 10.1107/SO907444902020723; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gaidenko TA, 2002, J BACTERIOL, V184, P6109, DOI 10.1128/JB.184.22.6109-6114.2002; Gaits F, 1997, J BIOL CHEM, V272, P17873, DOI 10.1074/jbc.272.28.17873; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Hecker M, 2001, ADV MICROB PHYSIOL, V44, P35, DOI 10.1016/S0065-2911(01)44011-2; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IGO MM, 1986, J MOL BIOL, V191, P615, DOI 10.1016/0022-2836(86)90449-3; Jiang LH, 2001, FEBS LETT, V509, P142, DOI 10.1016/S0014-5793(01)03125-8; Johnson LN, 2001, CHEM REV, V101, P2209, DOI 10.1021/cr000225s; Kang CM, 1996, J BACTERIOL, V178, P3846, DOI 10.1128/jb.178.13.3846-3853.1996; Kang CM, 1998, MOL MICROBIOL, V30, P189, DOI 10.1046/j.1365-2958.1998.01052.x; KAROW ML, 1995, GENE, V163, P69, DOI 10.1016/0378-1119(95)00402-R; Kennelly PJ, 2001, CHEM REV, V101, P2291, DOI 10.1021/cr0002543; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lucet I, 2000, EMBO J, V19, P1467, DOI 10.1093/emboj/19.7.1467; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mukhopadhyay S, 1999, J BACTERIOL, V181, P6615, DOI 10.1128/JB.181.21.6615-6622.1999; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Obuchowski M, 2000, J BACTERIOL, V182, P5634, DOI 10.1128/JB.182.19.5634-5638.2000; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Scott JM, 2000, J BACTERIOL, V182, P1452, DOI 10.1128/JB.182.5.1452-1456.2000; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; Smirnova N, 1998, J BACTERIOL, V180, P3671, DOI 10.1128/JB.180.14.3671-3680.1998; Sonenshein AL., 2002, BACILLUS SUBTILIS IT, P369; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STULKE J, 1993, J GEN MICROBIOL, V139, P2041, DOI 10.1099/00221287-139-9-2041; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Vijay K, 2000, MOL MICROBIOL, V35, P180, DOI 10.1046/j.1365-2958.2000.01697.x; VOELKER U, 1995, J BACTERIOL, V177, P114, DOI 10.1128/jb.177.1.114-122.1995; VOELKER U, 1995, J BACTERIOL, V177, P3771, DOI 10.1128/jb.177.13.3771-3780.1995; Voelker U, 1997, J BACTERIOL, V179, P1980, DOI 10.1128/jb.179.6.1980-1984.1997; Volker U, 1999, J BACTERIOL, V181, P3942; WISE AA, 1995, J BACTERIOL, V177, P123, DOI 10.1128/jb.177.1.123-133.1995; Woodbury RL, 2004, J BACTERIOL, V186, P2789, DOI 10.1128/JB.186.9.2789-2797.2004; Yan JG, 1996, P NATL ACAD SCI USA, V93, P4953, DOI 10.1073/pnas.93.10.4953; Yang XF, 1996, GENE DEV, V10, P2265, DOI 10.1101/gad.10.18.2265; Zhu Y, 2000, P NATL ACAD SCI USA, V97, P7808, DOI 10.1073/pnas.97.14.7808	58	63	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40927	40937		10.1074/jbc.M405464200	http://dx.doi.org/10.1074/jbc.M405464200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15263010	hybrid			2022-12-27	WOS:000223916800089
J	Schaeffer, PJ; Wende, AR; Magee, CJ; Neilson, JR; Leone, TC; Chen, F; Kelly, DP				Schaeffer, PJ; Wende, AR; Magee, CJ; Neilson, JR; Leone, TC; Chen, F; Kelly, DP			Calcineurin and calcium/calmodulin-dependent protein kinase activate distinct metabolic gene regulatory programs in cardiac muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLING MITOCHONDRIAL BIOGENESIS; ACID OXIDATION ENZYME; SKELETAL-MUSCLE; RECEPTOR-ALPHA; IN-VIVO; TRANSCRIPTIONAL PATHWAY; COACTIVATOR PGC-1; TRANSGENIC MICE; CYCLOSPORINE-A; FIBER-TYPE	To learn more about the targets of Cn (Cn) and calcium/calmodulin-dependent protein kinase in cardiac muscle, we investigated their actions in cultured cardiac myocytes and the hearts of mice in vivo. Adenoviral-mediated expression of constitutively active forms of either pathway induced expression of peroxisome proliferator-activated receptor gamma coactivator 1alpha, a transcriptional coactivator involved in the control of multiple cellular energy metabolic pathways in cardiac myocytes. Transcriptional profiling studies demonstrated that Cn and calcium/calmodulin-dependent protein kinase activate distinct but overlapping metabolic gene regulatory programs. Expression of the nuclear receptor, peroxisome proliferator-activated receptor alpha, was markedly increased by Cn, but not calcium/calmodulin-dependent protein kinase, providing one mechanism whereby cellular fatty acid utilization genes are selectively activated by Cn. Transfection experiments demonstrated that Cn directly activates the mouse peroxisome proliferator-activated receptor alpha gene promoter. Co-transfection "add-back" experiments demonstrated that the transcription factors, myocyte enhancer factors 2C or 2D, were sufficient to confer Cn-mediated activation of the peroxisome proliferator-activated receptor alpha gene. Cn was also shown to directly activate a known peroxisome proliferator-activated receptor alpha target, muscle-type carnitine palmitoyltransferase I, providing a second mechanism by which Cn activates genes of cellular fatty acid utilization. Lastly, the gene expression of peroxisome proliferator-activated receptor gamma coactivator 1alpha and peroxisome proliferator-activated receptor alpha was reduced in the hearts of mice with cardiac-specific ablation of the Cn regulatory subunit. These data support a role for calcium-triggered signaling pathways in the regulation of cardiac energetics and identify pathway-specific control of metabolic targets.	Washington Univ, Sch Med, Cardiovasc Res Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Stanford University	Kelly, DP (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, St Louis, MO 63110 USA.	dkelly@im.wustl.edu	Kelly, Daniel/ABG-2056-2021; Wende, Adam/AFG-8878-2022	Wende, Adam/0000-0002-5536-4675; Neilson, Joel R./0000-0002-3408-608X	NHLBI NIH HHS [R01-HL58493] Funding Source: Medline; NIAMS NIH HHS [F32-AR48758] Funding Source: Medline; NIDDK NIH HHS [R01-DK45416] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR048758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045416] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Cresci S, 1996, AM J PHYSIOL-CELL PH, V270, pC1413, DOI 10.1152/ajpcell.1996.270.5.C1413; Disch DL, 1996, MOL CELL BIOL, V16, P4043; Eto Y, 2000, CIRCULATION, V101, P2134, DOI 10.1161/01.CIR.101.18.2134; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOKANSON JF, 1995, AM J RESP CRIT CARE, V151, P1848, DOI 10.1164/ajrccm.151.6.7767529; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Lehman JJ, 2002, CLIN EXP PHARMACOL P, V29, P339, DOI 10.1046/j.1440-1681.2002.03655.x; LEONE TC, 1995, J BIOL CHEM, V270, P16308, DOI 10.1074/jbc.270.27.16308; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Moore ML, 2001, J BIOL CHEM, V276, P1026, DOI 10.1074/jbc.M009352200; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Neilson JR, 2004, IMMUNITY, V20, P255, DOI 10.1016/S1074-7613(04)00052-4; Parsons SA, 2003, MOL CELL BIOL, V23, P4331, DOI 10.1128/MCB.23.12.4331-4343.2003; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Ryder JW, 2003, J BIOL CHEM, V278, P44298, DOI 10.1074/jbc.M304510200; Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837; Sayen MR, 2003, AM J PHYSIOL-CELL PH, V284, pC562, DOI 10.1152/ajpcell.00336.2002; Schiaffino S, 2002, TRENDS PHARMACOL SCI, V23, P569, DOI 10.1016/S0165-6147(02)02111-9; Stuewe SR, 2000, J MOL CELL CARDIOL, V32, P903, DOI 10.1006/jmcc.2000.1131; Torra IP, 2002, MOL ENDOCRINOL, V16, P1013; Turpeinen AK, 1996, MED SCI SPORT EXER, V28, P33, DOI 10.1097/00005768-199601000-00011; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; WHITE FC, 1987, J APPL PHYSIOL, V62, P1097, DOI 10.1152/jappl.1987.62.3.1097; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X	34	70	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39593	39603		10.1074/jbc.M403649200	http://dx.doi.org/10.1074/jbc.M403649200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262994	hybrid			2022-12-27	WOS:000223791500049
J	Noda, M; Kawahara, Y; Ichikawa, A; Matoba, Y; Matsuo, H; Lee, DG; Kumagai, T; Sugiyama, M				Noda, M; Kawahara, Y; Ichikawa, A; Matoba, Y; Matsuo, H; Lee, DG; Kumagai, T; Sugiyama, M			Self-protection mechanism in D-cycloserine-producing Streptomyces lavendulae - Gene cloning, characterization, and kinetics of its alanine racemase and D-alanyl-D-alanine ligase, which are target enzymes of D-cycloserine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROCOCCUS-FAECALIS V583; COMPLETE GENOME SEQUENCE; CELL-WALL BIOSYNTHESIS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; VANCOMYCIN RESISTANCE; BACILLUS-STEAROTHERMOPHILUS; MYCOBACTERIUM-SMEGMATIS; SUBSTRATE-SPECIFICITY; DDLA GENE	An antibiotic, D-cycloserine (DCS), inhibits the catalytic activities of alanine racemase (ALR) and D-alanyl-D-alanine ligase (DDL), which are necessary for the biosynthesis of the bacterial cell wall. In this study, we cloned both genes encoding ALR and DDL, designated alrS and ddlS, respectively, from DCS-producing Streptomyces lavendulae ATCC25233. Each gene product was purified to homogeneity and characterized. Escherichia coli, transformed with a pET vector carrying alrS or ddlS, displays higher resistance to DCS than the same host carrying the E. coli ALR- or DDL-encoded gene inserted into the pET vector. Although the S. lavendulae DDL was competitively inhibited by DCS, the K-i value (920 muM) was obviously higher (40similar to100-fold) than those for E. coli DdlA (9 muM) or DdlB (27 muM). The high K-i value of the S. lavendulae DDL suggests that the enzyme may be a self-resistance determinant in the DCS-producing microorganism. Kinetic studies for the S. lavendulae ALR suggest that the time-dependent inactivation rate of the enzyme by DCS is absolutely slower than that of the E. coli ALR. We conclude that ALR from DCS-producing S. lavendulae is also one of the self-resistance determinants.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Biotechnol, Minami Ku, Hiroshima 7348551, Japan	Hiroshima University	Sugiyama, M (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Biotechnol, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.	sugi@hiroshima-u.ac.jp	Matsuo, Hiroaki/B-4290-2008	Matsuo, Hiroaki/0000-0002-8730-5389				Andersen JM, 2002, BEHAV BRAIN RES, V129, P211, DOI 10.1016/S0166-4328(01)00318-7; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briggs GE, 1925, BIOCHEM J, V19, P338, DOI 10.1042/bj0190338; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P2017, DOI 10.1021/bi00222a002; Caceres NE, 1997, J BACTERIOL, V179, P5046, DOI 10.1128/jb.179.16.5046-5055.1997; DAUB E, 1988, BIOCHEMISTRY-US, V27, P3701, DOI 10.1021/bi00410a027; DUTKAMALEN S, 1990, MOL GEN GENET, V224, P364, DOI 10.1007/BF00262430; DUTKAMALEN S, 1992, GENE, V112, P53, DOI 10.1016/0378-1119(92)90302-6; ESAKI N, 1986, BIOCHEMISTRY-US, V25, P3261, DOI 10.1021/bi00359a027; EVERS S, 1994, GENE, V140, P97, DOI 10.1016/0378-1119(94)90737-4; Evers S, 1996, J MOL EVOL, V42, P706, DOI 10.1007/BF02338803; FAN C, 1994, SCIENCE, V266, P439, DOI 10.1126/science.7939684; Feng ZY, 2003, ANTIMICROB AGENTS CH, V47, P283, DOI 10.1128/AAC.47.1.283-291.2003; Fenn TD, 2003, BIOCHEMISTRY-US, V42, P5775, DOI 10.1021/bi027022d; GALAKATOS NG, 1986, BIOCHEMISTRY-US, V25, P3255, DOI 10.1021/bi00359a026; HEIFETS LB, 1991, AM REV RESPIR DIS, V144, P1; Hopwood D.A., 1985, GENETIC MANIPULATION; Ikeda K, 1996, J BIOCHEM-TOKYO, V120, P1141; Johannesen TS, 2002, EUR J PHARMACOL, V437, P73, DOI 10.1016/S0014-2999(02)01282-7; LAMBERT MP, 1972, J BACTERIOL, V110, P978, DOI 10.1128/JB.110.3.978-987.1972; LILLEY PE, 1993, GENE, V129, P9; Matsuo H, 2003, J ANTIBIOT, V56, P762, DOI 10.7164/antibiotics.56.762; MEZIANECHERIF D, 1994, FEBS LETT, V354, P140, DOI 10.1016/0014-5793(94)01096-X; NEUHAUS FC, 1962, J BIOL CHEM, V237, P778; NEUHAUS FC, 1981, PHARMACOL THERAPEUT, V14, P265, DOI 10.1016/0163-7258(81)90030-9; NEUHAUS FC, 1969, BIOCHEMISTRY-US, V8, P5119, DOI 10.1021/bi00840a066; Noda M, 2004, J BIOL CHEM, V279, P46153, DOI 10.1074/jbc.M404605200; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; Park IS, 1997, P NATL ACAD SCI USA, V94, P10040, DOI 10.1073/pnas.94.19.10040; Park IS, 1996, BIOCHEMISTRY-US, V35, P10464, DOI 10.1021/bi9603128; Peisach D, 1998, J AM CHEM SOC, V120, P2268, DOI 10.1021/ja973353f; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sammon AM, 1999, POSTGRAD MED J, V75, P129, DOI 10.1136/pgmj.75.881.129; Schneider JS, 2000, BRAIN RES, V860, P190, DOI 10.1016/S0006-8993(00)02036-9; Shaw JP, 1997, BIOCHEMISTRY-US, V36, P1329, DOI 10.1021/bi961856c; Strych U, 2001, FEMS MICROBIOL LETT, V196, P93, DOI 10.1016/S0378-1097(01)00045-3; WALSH CT, 1989, J BIOL CHEM, V264, P2393; WANG E, 1978, BIOCHEMISTRY-US, V17, P1313, DOI 10.1021/bi00600a028; WASSERMAN SA, 1984, BIOCHEMISTRY-US, V23, P5182, DOI 10.1021/bi00317a015; Watababe A, 1999, J BIOL CHEM, V274, P4189, DOI 10.1074/jbc.274.7.4189; Watanabe A, 1999, J BIOCHEM-TOKYO, V125, P987, DOI 10.1093/oxfordjournals.jbchem.a022406; Yokoigawa K, 2003, FEMS MICROBIOL LETT, V221, P263, DOI 10.1016/S0378-1097(03)00216-7; ZAWADZKE LE, 1991, BIOCHEMISTRY-US, V30, P1673, DOI 10.1021/bi00220a033	47	43	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46143	46152		10.1074/jbc.M404603200	http://dx.doi.org/10.1074/jbc.M404603200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15302885	hybrid			2022-12-27	WOS:000224694900101
J	Enserink, JM; Price, LS; Methi, T; Mahic, M; Sonnenberg, A; Bos, JL; Tasken, K				Enserink, JM; Price, LS; Methi, T; Mahic, M; Sonnenberg, A; Bos, JL; Tasken, K			The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the alpha(3)beta(1) integrin but not the alpha(6 beta 4) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE RAP1; ALPHA-6-BETA-4 INTEGRIN; PROTEIN-KINASE; CYCLIC-AMP; ACTIVATION; EPAC; MIGRATION; HEMIDESMOSOMES; FAMILY; RAC	Laminin-5 is an important constituent of the basal lamina. The receptors for laminin-5, the integrins alpha(3)beta(1) and alpha(6)beta(4), have been associated with epithelial wound migration and carcinoma invasion. The signal transduction mechanisms that regulate these integrins are not well understood. We report here that the small GTPase Rap1 regulates the adhesion of a number of cell lines to various extracellular matrix proteins including laminin-5. cAMP also mediates cell adhesion and spreading on laminin-5, a process that is independent of protein kinase A but rather dependent on Epac1, a cAMP-dependent exchange factor for Rap. Interestingly, although both alpha(3)beta(1) and alpha(6)beta(4) mediate adhesion to laminin-5, only alpha(3)beta(1)-dependent adhesion is dependent on Rap1. These results provide evidence for a function of the cAMP-Epac-Rap1 pathway in cell adhesion and spreading on different extracellular matrix proteins. They also define different roles for the laminin-binding integrins in regulated cell adhesion and subsequent cell spreading.	Univ Oslo, Ctr Biotechnol, N-0317 Oslo, Norway; Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	University of Oslo; Utrecht University; Utrecht University; Netherlands Cancer Institute	Tasken, K (corresponding author), Univ Oslo, Ctr Biotechnol, POB 1125, N-0317 Oslo, Norway.	kjetil.tasken@biotek.uio.no	Enserink, Jorrit/E-5383-2010	Enserink, Jorrit/0000-0002-2394-5387; Tasken, Kjetil/0000-0003-2841-4697				Baker SE, 1996, J CELL SCI, V109, P2509; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BOTTINI C, 1993, INT J CANCER, V54, P261, DOI 10.1002/ijc.2910540217; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Jones JCR, 1998, BIOESSAYS, V20, P488, DOI 10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO;2-I; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; Koster J, 2003, J CELL SCI, V116, P387, DOI 10.1242/jcs.00241; Kreidberg JA, 2000, CURR OPIN CELL BIOL, V12, P548, DOI 10.1016/S0955-0674(00)00130-7; Kuiperij HB, 2003, BBA-MOL CELL RES, V1593, P141, DOI 10.1016/S0167-4889(02)00365-8; LANGHOFER M, 1993, J CELL SCI, V105, P753; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Lohi J, 2001, INT J CANCER, V94, P763, DOI 10.1002/ijc.1539; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; McLeod SJ, 2004, J BIOL CHEM, V279, P12009, DOI 10.1074/jbc.M313098200; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Ruegg C, 2004, BBA-REV CANCER, V1654, P51, DOI 10.1016/j.bbcan.2003.09.003; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Su L, 2003, J BIOL CHEM, V278, P15232, DOI 10.1074/jbc.M211888200; Tiwari S, 2004, BLOOD, V103, P2661, DOI 10.1182/blood-2003-06-2154; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Tsygankova OM, 2004, J BIOL CHEM, V279, P5501, DOI 10.1074/jbc.M305824200; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Van Triest M, 2001, METHOD ENZYMOL, V333, P343	55	105	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44889	44896		10.1074/jbc.M404599200	http://dx.doi.org/10.1074/jbc.M404599200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302884	hybrid			2022-12-27	WOS:000224505600079
J	Roy, A; Levine, TP				Roy, A; Levine, TP			Multiple pools of phosphatidylinositol 4-phosphate detected using the pleckstrin homology domain of Osh2p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYSTEROL-BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; PHOSPHOINOSITIDE-BINDING; PH DOMAIN; 4-KINASE ISOFORMS; GOLGI-APPARATUS; LIPID KINASE; YEAST; SECRETION	Phosphatidylinositol (PtdIns) phosphate (PtdInsP) lipids are used as intracellular signposts for the recruitment and activation of peripheral membrane proteins. Whereas the distribution of most PtdInsPs is restricted to a single organelle, PtdIns(4)P is unique in that it exists in several discrete pools, and so proteins that bind PtdIns(4) P must use extra receptors to achieve a restricted localization. Here we compare the two highly related pleckstrin homology (PH) domains from Osh1p and Osh2p, yeast homologues of oxysterol-binding protein (OSBP), that target membranes using PtdIns(4) P, and in vitro bind both PtdIns(4) P and PtdIns(4,5) P(2). We show that Golgi targeting is specified by an additional site on PH(Osh1), which lies on a face of the domain not previously known to interact with receptors. In contrast, PH(Osh2) does not have a demonstrable second site, and targets multiple pools of PtdInsPs, each dependent on a different PtdIns 4-kinase. This lack of a second site in PH(Osh2) allows it to be used as an unbiased reporter for altered distribution of 4-phosphorylated PtdIns. For example, in cells with excess PtdIns(4) P caused by inactivation of the phosphatase Sac1p, PH(Osh2) indicates that PtdIns(4) P accumulates on the plasma membrane, whereas other Golgi-targeted PH domains fail to detect this change.	UCL, Inst Ophthalmol, Div Cell Biol, London EC1V 9EL, England	University of London; University College London	Levine, TP (corresponding author), UCL, Inst Ophthalmol, Div Cell Biol, Bath St, London EC1V 9EL, England.	tim.levine@ucl.ac.uk		Levine, Timothy/0000-0002-7231-0775				Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Audhya A, 2002, DEV CELL, V2, P593, DOI 10.1016/S1534-5807(02)00168-5; Balla A, 2002, J BIOL CHEM, V277, P20041, DOI 10.1074/jbc.M111807200; Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; Collins TJ, 2003, J EXP BIOL, V206, P1993, DOI 10.1242/jeb.00244; De Matteis MA, 2004, NAT CELL BIOL, V6, P487, DOI 10.1038/ncb0604-487; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Foti M, 2001, MOL BIOL CELL, V12, P2396, DOI 10.1091/mbc.12.8.2396; Funato K, 2001, J CELL BIOL, V155, P949, DOI 10.1083/jcb.200105033; Fushman D, 1998, J BIOL CHEM, V273, P2835, DOI 10.1074/jbc.273.5.2835; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Godi A, 2004, NAT CELL BIOL, V6, P393, DOI 10.1038/ncb1119; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Han GS, 2002, J BIOL CHEM, V277, P47709, DOI 10.1074/jbc.M207996200; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Insall RH, 2001, DEV CELL, V1, P743, DOI 10.1016/S1534-5807(01)00086-7; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Levine TP, 2001, MOL BIOL CELL, V12, P1633, DOI 10.1091/mbc.12.6.1633; Levine TP, 1998, CURR BIOL, V8, P729, DOI 10.1016/S0960-9822(98)70296-9; Li XM, 2002, J CELL BIOL, V157, P63, DOI 10.1083/jcb.200201037; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Nagel WG, 1998, MOL BIOL CELL, V9, P1981, DOI 10.1091/mbc.9.8.1981; Perera NM, 2004, J BIOL CHEM, V279, P5216, DOI 10.1074/jbc.M305068200; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Saxena A, 2002, J BIOL CHEM, V277, P49935, DOI 10.1074/jbc.M206497200; Schneiter R, 1999, J CELL BIOL, V146, P741, DOI 10.1083/jcb.146.4.741; SIKORSKI RS, 1989, GENETICS, V122, P19; Staehelin LA, 1997, PLANT J, V11, P1151, DOI 10.1046/j.1365-313X.1997.11061151.x; Stefan CJ, 2002, MOL BIOL CELL, V13, P542, DOI 10.1091/mbc.01-10-0476; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; Waugh MG, 2003, BIOCHEM J, V373, P57, DOI 10.1042/BJ20030089; Wei YJ, 2002, J BIOL CHEM, V277, P46586, DOI 10.1074/jbc.M206860200; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Wiederkehr A, 2000, J CELL BIOL, V149, P397, DOI 10.1083/jcb.149.2.397; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8	48	170	174	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44683	44689		10.1074/jbc.M401583200	http://dx.doi.org/10.1074/jbc.M401583200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15271978	hybrid			2022-12-27	WOS:000224505600055
J	Belanger, KD; Simmons, LA; Roth, JK; VanderPloeg, KA; Lichten, LB; Fahrenkrog, B				Belanger, KD; Simmons, LA; Roth, JK; VanderPloeg, KA; Lichten, LB; Fahrenkrog, B			The karyopherin Msn5/Kap142 requires Nup82 for nuclear export and performs a function distinct from translocation in RPA protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PHO4; PORE COMPLEX; YEAST NUCLEOPORIN; SACCHAROMYCES-CEREVISIAE; TRANSPORT KINETICS; PROTEOMIC ANALYSIS; LOCALIZATION; RECEPTOR; SUBSTRATE; NUP116P	Protein transport between the nucleus and cytoplasm requires interactions between nuclear pore complex proteins (nucleoporins) and soluble nuclear transport factors (karyopherins, importins, and exportins). Exactly how these interactions contribute to the nucleocytoplasmic transport of substrates remains unclear. Using a synthetic lethal screen with the nucleoporin NUP1, we have identified a conditional allele of NUP82, encoding an essential nuclear pore complex protein in Saccharomyces cerevisiae. This nup82-3 allele also exhibits synthetic genetic interactions with mutants of the karyopherin MSN5. nup82-3 mutants accumulate the Msn5 export substrate Pho4 within the nucleus at nonpermissive temperatures. The nuclear import of the RPA complex subunit Rfa2 is impaired in nup82-3 and in mutants of the karyopherin KAP95, but is not affected by the loss of MSN5. Interestingly, deletion of MSN5 results in retention of Rfa2-GFP within the nucleus under conditions in which it normally diffuses out. These data provide evidence that Nup82 is important for Msn5-mediated nuclear protein export and Kap95-mediated protein import. In addition, Msn5 may play a role independent of import in the localization of Rfa2.	Colgate Univ, Dept Biol, Hamilton, NY 13346 USA; Univ Basel, Maurice E Muller Inst Struct Biol, Biozentrum, CH-4056 Basel, Switzerland	Colgate University; University of Basel	Belanger, KD (corresponding author), Colgate Univ, Dept Biol, 13 Oak Dr, Hamilton, NY 13346 USA.	kbelanger@mail.colgate.edu	Fahrenkrog, Birthe/D-5840-2011	Fahrenkrog, Birthe/0000-0003-4080-9413; Belanger, Kenneth/0000-0002-7181-0188	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM065107] Funding Source: NIH RePORTER; NIGMS NIH HHS [R15 GM065107, R15 GM065107-01, GM-65107] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alepuz PM, 1999, GENETICS, V153, P1219; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Bailer SM, 2000, J BIOL CHEM, V275, P23540, DOI 10.1074/jbc.M001963200; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; Belgareh N, 1998, MOL BIOL CELL, V9, P3475, DOI 10.1091/mbc.9.12.3475; Blondel M, 1999, GENE DEV, V13, P2284, DOI 10.1101/gad.13.17.2284; Booth JW, 1999, J BIOL CHEM, V274, P32360, DOI 10.1074/jbc.274.45.32360; Boustany LM, 2002, GENE DEV, V16, P608, DOI 10.1101/gad.967602; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; Damelin M, 2000, MOL CELL, V5, P133, DOI 10.1016/S1097-2765(00)80409-8; DeVit MJ, 1999, CURR BIOL, V9, P1231, DOI 10.1016/S0960-9822(99)80503-X; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Fahrenkrog B, 2003, NAT REV MOL CELL BIO, V4, P757, DOI 10.1038/nrm1230; Fahrenkrog B, 1998, J CELL BIOL, V143, P577, DOI 10.1083/jcb.143.3.577; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gleizes PE, 2001, J CELL BIOL, V155, P923, DOI 10.1083/jcb.200108142; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Gorner W, 2002, EMBO J, V21, P135, DOI 10.1093/emboj/21.1.135; GRANDI P, 1995, J CELL BIOL, V130, P1263, DOI 10.1083/jcb.130.6.1263; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; Guthrie C, 1991, GUIDE YEAST GENETICS; Ho AK, 2000, MOL CELL BIOL, V20, P5736, DOI 10.1128/MCB.20.15.5736-5748.2000; Hurwitz ME, 1998, P NATL ACAD SCI USA, V95, P11241, DOI 10.1073/pnas.95.19.11241; HURWITZ ME, 1995, J CELL BIOL, V130, P1275, DOI 10.1083/jcb.130.6.1275; Jullien D, 1999, EMBO J, V18, P4348, DOI 10.1093/emboj/18.15.4348; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; Maniar HS, 1997, GENETICS, V145, P891; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Moy TI, 1999, GENE DEV, V13, P2118, DOI 10.1101/gad.13.16.2118; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pyhtila B, 2003, J BIOL CHEM, V278, P42699, DOI 10.1074/jbc.M307135200; Queralt E, 2003, MOL CELL BIOL, V23, P3126, DOI 10.1128/MCB.23.9.3126-3140.2003; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Roberts PM, 1998, METHOD CELL BIOL, V53, P545; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Solsbacher J, 2000, MOL CELL BIOL, V20, P8468, DOI 10.1128/MCB.20.22.8468-8479.2000; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stage-Zimmermann T, 2000, MOL BIOL CELL, V11, P3777, DOI 10.1091/mbc.11.11.3777; Strawn LA, 2004, NAT CELL BIOL, V6, P197, DOI 10.1038/ncb1097; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Strom AC, 2001, GENOME BIOL, V2; Vainberg IE, 2000, MOL CELL BIOL, V20, P3996, DOI 10.1128/MCB.20.11.3996-4005.2000; Woods R. A., 2001, METH MOL B, V177, P85; Yoshida K, 2001, J CELL BIOL, V152, P729, DOI 10.1083/jcb.152.4.729	53	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43530	43539		10.1074/jbc.M407641200	http://dx.doi.org/10.1074/jbc.M407641200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15294903	hybrid			2022-12-27	WOS:000224383100023
J	Lamers, MH; Gerogijevic, D; Lebbink, JH; Winterwerp, HHK; Agianian, B; de Wind, N; Sixma, TK				Lamers, MH; Gerogijevic, D; Lebbink, JH; Winterwerp, HHK; Agianian, B; de Wind, N; Sixma, TK			ATP increases the affinity between MutS ATPase domains - Implications for atp hydrolysis and conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; ESCHERICHIA-COLI MUTS; HMUTS-ALPHA; ABC-ATPASE; TRANSLOCATION MECHANISM; CRYSTAL-STRUCTURE; HETERODUPLEX DNA; SLIDING CLAMP; PROTEIN MUTS; BINDING	MutS is the key protein of the Escherichia coli DNA mismatch repair system. It recognizes mispaired and unpaired bases and has intrinsic ATPase activity. ATP binding after mismatch recognition by MutS serves as a switch that enables MutL binding and the subsequent initiation of mismatch repair. However, the mechanism of this switch is poorly understood. We have investigated the effects of ATP binding on the MutS structure. Crystallographic studies of ATP-soaked crystals of MutS show a trapped intermediate, with ATP in the nucleotide-binding site. Local rearrangements of several residues around the nucleotide-binding site suggest a movement of the two ATPase domains of the MutS dimer toward each other. Analytical ultracentrifugation experiments confirm such a rearrangement, showing increased affinity between the ATPase domains upon ATP binding and decreased affinity in the presence of ADP. Mutations of specific residues in the nucleotide-binding domain reduce the dimer affinity of the ATPase domains. In addition, ATP-induced release of DNA is strongly reduced in these mutants, suggesting that the two activities are coupled. Hence, it seems plausible that modulation of the affinity between ATPase domains is the driving force for conformational changes in the MutS dimer. These changes are driven by distinct amino acids in the nucleotide-binding site and form the basis for long-range interactions between the ATPase domains and DNA-binding domains and subsequent binding of MutL and initiation of mismatch repair.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Toxicogenet, NL-2333 AL Leiden, Netherlands; Univ Utrecht, Bijvoet Ctr, NL-3508 TB Utrecht, Netherlands	Netherlands Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University	Sixma, TK (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	t.sixma@nki.nl	Lamers, Meindert/AGG-8911-2022; Agianian, Bogos/O-8019-2016	Lamers, Meindert/0000-0002-4205-1338; Sixma, Titia K/0000-0001-6180-0632; Agianian, Bogos/0000-0003-1295-6846				Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Alani E, 2003, J BIOL CHEM, V278, P16088, DOI 10.1074/jbc.M213193200; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Antony E, 2003, BIOCHEMISTRY-US, V42, P7682, DOI 10.1021/bi034602h; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; Berends MJW, 2002, AM J HUM GENET, V70, P26, DOI 10.1086/337944; Biswas I, 1999, J BIOL CHEM, V274, P23673, DOI 10.1074/jbc.274.33.23673; Biswas I, 2000, BIOCHEM J, V347, P881, DOI 10.1042/0264-6021:3470881; Biswas I, 2001, J MOL BIOL, V305, P805, DOI 10.1006/jmbi.2000.4367; Bjornson KP, 2003, J BIOL CHEM, V278, P34667, DOI 10.1074/jbc.M305513200; Bjornson KP, 2003, J BIOL CHEM, V278, P18557, DOI 10.1074/jbc.M301101200; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; BLACKWELL LJ, 2001, J BIOL CHEM, V13, P13; Bowers J, 2000, J MOL BIOL, V302, P327, DOI 10.1006/jmbi.2000.4081; Das Gupta R, 2000, NAT GENET, V24, P53, DOI 10.1038/71684; Geourjon C, 2001, TRENDS BIOCHEM SCI, V26, P539, DOI 10.1016/S0968-0004(01)01907-7; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GROSSMAN L, 1988, FASEB J, V2, P2696, DOI 10.1096/fasebj.2.11.3294078; Hess MT, 2002, J BIOL CHEM, V277, P25545, DOI 10.1074/jbc.M202282200; Hirano M, 2002, EMBO J, V21, P5733, DOI 10.1093/emboj/cdf575; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Iaccarino I, 2000, J BIOL CHEM, V275, P2080, DOI 10.1074/jbc.275.3.2080; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joshi A, 2000, NUCLEIC ACIDS RES, V28, P853, DOI 10.1093/nar/28.4.853; Joshi A, 2002, BIOCHEMISTRY-US, V41, P3654, DOI 10.1021/bi015743r; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kato R, 2001, J MOL BIOL, V309, P227, DOI 10.1006/jmbi.2001.4752; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lamers MH, 2003, EMBO J, V22, P746, DOI 10.1093/emboj/cdg064; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Marti TM, 2002, J CELL PHYSIOL, V191, P28, DOI 10.1002/jcp.10077; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Natrajan G, 2003, NUCLEIC ACIDS RES, V31, P4814, DOI 10.1093/nar/gkg677; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PANUSKA JR, 1980, J BIOL CHEM, V255, P5208; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Sprang SR, 1997, CURR OPIN STRUC BIOL, V7, P849, DOI 10.1016/S0959-440X(97)80157-1; Stanislawska-Sachadyn A, 2003, PROTEIN EXPRES PURIF, V28, P69, DOI 10.1016/S1046-5928(02)00649-6; Studamire B, 1998, MOL CELL BIOL, V18, P7590, DOI 10.1128/MCB.18.12.7590; Tachiki H, 2000, J BIOL CHEM, V275, P40703, DOI 10.1074/jbc.M007124200; Verdon G, 2003, J MOL BIOL, V334, P255, DOI 10.1016/j.jmb.2003.08.065; Vergani P, 2003, J GEN PHYSIOL, V121, P17, DOI 10.1085/jgp.20028673; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659	50	59	65	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43879	43885		10.1074/jbc.M406380200	http://dx.doi.org/10.1074/jbc.M406380200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15297450	hybrid			2022-12-27	WOS:000224383100065
J	Maemoto, A; Qu, XQ; Rosengren, KJ; Tanabe, H; Henschen-Edman, A; Craik, DJ; Ouellette, AJ				Maemoto, A; Qu, XQ; Rosengren, KJ; Tanabe, H; Henschen-Edman, A; Craik, DJ; Ouellette, AJ			Functional analysis of the alpha-defensin disulfide array in mouse cryptdin-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBACTERIAL ACTIVITIES; ANTIMICROBIAL PEPTIDES; NEUTROPHIL DEFENSINS; BETA-DEFENSINS; DETERMINANTS; ACTIVATION; RESISTANCE; MUTATIONS; BNBD-12; NP-2	The alpha-defensin antimicrobial peptide family is defined by a unique tridisulfide array. To test whether this invariant structural feature determines alpha-defensin bactericidal activity, mouse cryptdin-4 (Crp4) tertiary structure was disrupted by pairs of site-directed Ala for Cys substitutions. In a series of Crp4 disulfide variants whose cysteine connectivities were confirmed using NMR spectroscopy and mass spectrometry, mutagenesis did not induce loss of function. To the contrary, the in vitro bactericidal activities of several Crp4 disulfide variants were equivalent to or greater than those of native Crp4. Mouse Paneth cell alpha-defensins require the proteolytic activation of precursors by matrix metalloproteinase-7 (MMP-7), prompting an analysis of the relative sensitivities of native and mutant Crp4 and proCrp4 molecules to degradation by MMP-7. Although native Crp4 and the alpha-defensin moiety of proCrp4 resisted proteolysis completely, all disulfide variants were degraded extensively by MMP-7. Crp4 bactericidal activity was eliminated by MMP-7 cleavage. Thus, rather than determining alpha-defensin bactericidal activity, the Crp4 disulfide arrangement confers essential protection from degradation by this critical activating proteinase.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Biol Sci, Irvine, CA 92697 USA; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Queensland	Ouellette, AJ (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA.	aouellet@uci.edu	Rosengren, K. Johan/P-4450-2016; Craik, David/B-1695-2010	Rosengren, K. Johan/0000-0002-5007-8434; Craik, David/0000-0003-0007-6796	NIDDK NIH HHS [DK44632] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044632, R55DK044632] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayabe T, 2002, J BIOL CHEM, V277, P5219, DOI 10.1074/jbc.M109410200; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Cummings JE, 2003, AUST J CHEM, V56, P1031, DOI 10.1071/CH03110; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; Gunn JS, 2000, INFECT IMMUN, V68, P3758, DOI 10.1128/IAI.68.6.3758-3762.2000; Hoover DM, 2000, J BIOL CHEM, V275, P32911, DOI 10.1074/jbc.M006098200; Hoover DM, 2001, J BIOL CHEM, V276, P39021, DOI 10.1074/jbc.M103830200; Hoover DM, 2003, ANTIMICROB AGENTS CH, V47, P2804, DOI 10.1128/AAC.47.9.2804-2809.2003; Hristova K, 1996, BIOCHEMISTRY-US, V35, P11888, DOI 10.1021/bi961100d; LEHRER RI, 1988, J IMMUNOL METHODS, V108, P153, DOI 10.1016/0022-1759(88)90414-0; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; Mandal M, 2002, PEPTIDES, V23, P413, DOI 10.1016/S0196-9781(01)00628-3; McManus AM, 2000, BIOCHEMISTRY-US, V39, P15757, DOI 10.1021/bi000457l; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; PARDI A, 1992, BIOCHEMISTRY-US, V31, P11357, DOI 10.1021/bi00161a013; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; Satchell DP, 2003, PEPTIDES, V24, P1795, DOI 10.1016/j.peptides.2003.08.020; Satchell DP, 2003, J BIOL CHEM, V278, P13838, DOI 10.1074/jbc.M212115200; Schibli DJ, 2002, J BIOL CHEM, V277, P8279, DOI 10.1074/jbc.M108830200; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; Shirafuji Y, 2003, J BIOL CHEM, V278, P7910, DOI 10.1074/jbc.M210600200; SKALICKY JJ, 1994, PROTEINS, V20, P52, DOI 10.1002/prot.340200107; Tanabe H, 2004, J BIOL CHEM, V279, P11976, DOI 10.1074/jbc.M310251200; Tanabe H, 2004, INFECT IMMUN, V72, P1470, DOI 10.1128/IAI.72.3.1470-1478.2004; TANG YQ, 1993, J BIOL CHEM, V268, P6649; Tang YQ, 1999, INFECT IMMUN, V67, P6139, DOI 10.1128/IAI.67.11.6139-6144.1999; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Wu ZB, 2003, P NATL ACAD SCI USA, V100, P8880, DOI 10.1073/pnas.1533186100; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130	36	116	120	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44188	44196		10.1074/jbc.M406154200	http://dx.doi.org/10.1074/jbc.M406154200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15297466	hybrid			2022-12-27	WOS:000224383100098
J	Kumar, P; Miller, AI; Polverini, PJ				Kumar, P; Miller, AI; Polverini, PJ			p38 MAPK mediates gamma-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION PATHWAYS; C-JUN; PHOSPHATIDYLINOSITOL 3-KINASE; IONIZING-RADIATION; DEATH PATHWAY; TUMOR-GROWTH; ANGIOGENESIS; KINASE; RADIOTHERAPY	Therapeutic radiation is widely used in cancer treatments. The success of radiation therapy depends not only on the radiosensitivity of tumor cells but also on the radiosensitivity of endothelial cells lining the tumor vasculature. Vascular endothelial growth factor ( VEGF) plays a critical role in protecting endothelial cells against a number of antitumor agents including ionizing radiation. Strategies designed to overcome the survival advantage afforded to endothelial cells by VEGF might aid in enhancing the efficacy of radiation therapy. In this report we examined the signaling cascade(s) involved in VEGF-mediated protection of endothelial cells against gamma-irradiation. gamma-Irradiation-induced apoptosis of human dermal microvascular endothelial cells (HDMECs) was predominantly mediated through the p38 MAPK pathway as an inhibitor of p38 MAPK (PD169316), and dominant negative mutants of p38 MAPK could significantly enhance HDMEC survival against gamma-irradiation. Inhibition of the PI3K and MAPK pathways markedly up-regulated gamma-irradiation-mediated p38 MAPK activation resulting in enhanced HDMEC apoptosis. In contrast, VEGF-treated HDMECs were protected from gamma-irradiation-induced apoptosis predominantly through the PI3K/Akt pathway. Bcl-2 expression was markedly elevated in VEGF-treated HDMECs, and it was significantly inhibited by the PI3K inhibitor LY294002. HDMECs exposed to irradiation showed a significant decrease in Bcl-2 expression. In contrast, VEGF-stimulated HDMECs, when irradiated, maintained higher levels of Bcl-2 expression. Taken together our results suggest that gamma-irradiation induces endothelial cell apoptosis predominantly via the activation of p38 MAPK, and VEGF protects endothelial cells against gamma-irradiation predominantly via the PI3K-Akt-Bcl-2 signaling pathway.	Univ Michigan, Sch Dent, Dept Oral Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Dept Oncol, Ann Arbor, MI 48109 USA; Univ Minnesota, Sch Dent, Dept Oral Sci, Minneapolis, MN 55455 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities	Polverini, PJ (corresponding author), Univ Michigan, Sch Dent, Dept Oral Med, 1011 N Univ Ave,Rm 1234, Ann Arbor, MI 48109 USA.	neovas@umich.edu	Kumar, Pawan/H-7777-2013; Polverini, Peter/AAJ-8392-2020		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013161] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 13161] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BREM H, 1993, J PEDIATR SURG, V28, P1253, DOI 10.1016/S0022-3468(05)80308-2; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chauhan D, 1999, CANCER RES, V59, P1192; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Choi JA, 2004, ONCOGENE, V23, P9, DOI 10.1038/sj.onc.1206982; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrer I, 1996, EUR J NEUROSCI, V8, P1286, DOI 10.1111/j.1460-9568.1996.tb01297.x; Fidler IJ, 2001, JNCI-J NATL CANCER I, V93, P1040, DOI 10.1093/jnci/93.14.1040; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; Geng L, 2001, CANCER RES, V61, P2413; Gorski DH, 1999, CANCER RES, V59, P3374; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Gridley DS, 1998, CANCER DETECT PREV, V22, P20, DOI 10.1046/j.1525-1500.1998.00010.x; Klement G, 2002, CLIN CANCER RES, V8, P221; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kumar P, 2003, BLOOD, V101, P3960, DOI 10.1182/blood-2002-04-1237; Lingen MW, 1998, CANCER RES, V58, P5551; Liu ZY, 1997, BLOOD, V90, P2253, DOI 10.1182/blood.V90.6.2253.2253_2253_2259; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; Mauceri HJ, 1998, NATURE, V394, P287, DOI 10.1038/28412; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Nor JE, 2001, CANCER RES, V61, P2183; Nor JE, 2000, J VASC RES, V37, P209, DOI 10.1159/000025733; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Shiah SG, 1999, CANCER RES, V59, P391; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Verheij M, 1998, RADIOTHER ONCOL, V47, P225, DOI 10.1016/S0167-8140(98)00007-3; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; WEICHSELBAUM RR, 1986, P NATL ACAD SCI USA, V83, P2684, DOI 10.1073/pnas.83.8.2684; WEICHSELBAUM RR, 1988, INT J RADIAT ONCOL, V15, P575, DOI 10.1016/0360-3016(88)90297-0; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	42	123	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43352	43360		10.1074/jbc.M405777200	http://dx.doi.org/10.1074/jbc.M405777200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292252	hybrid			2022-12-27	WOS:000224226400120
J	Ott, TR; Pahuja, A; Nickolls, SA; Alleva, DG; Struthers, RS				Ott, TR; Pahuja, A; Nickolls, SA; Alleva, DG; Struthers, RS			Identification of CC chemokine receptor 7 residues important for receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; PROTEIN-COUPLED RECEPTORS; HIGH ENDOTHELIAL VENULES; LYMPHOID-TISSUE CHEMOKINE; SITE-DIRECTED MUTAGENESIS; BETA-ADRENERGIC-RECEPTOR; HIGH-AFFINITY BINDING; LIGAND-BINDING; EXTRACELLULAR DOMAINS; TRANSMEMBRANE HELIX	The binding pocket of family A GPCRs that bind small biogenic amines is well characterized. In this study we identify residues on CC chemokine receptor 7 (CCR-7) that are involved in agonist-mediated receptor activation but not in high affinity ligand binding. The mutations also affect the ability of the ligands to induce chemotaxis. Two of the residues, Lys(3.33(137)) and Gln(5.42( 227)), are consistent with the binding pocket described for biogenic amines, while Lys(3.26(130)) and Asn(7.32(305)), are found at, or close to, the cell surface. Our observations are in agreement with findings from other peptide and chemokine receptors, which indicate that receptors that bind larger ligands contain contact sites closer to the cell surface in addition to the conventional transmembrane binding pocket. These findings also support the theory that chemokine receptors require different sets of interactions for high affinity ligand binding and receptor activation.	Neurocrine Biosci, Dept Exploratory Discovery, San Diego, CA 92130 USA; Neurocrine Biosci, Dept Mol Med, San Diego, CA 92130 USA; Neurocrine Biosci, Dept Mol Biol, San Diego, CA 92130 USA	Neurocrine Biosciences; Neurocrine Biosciences; Neurocrine Biosciences	Struthers, RS (corresponding author), Neurocrine Biosci, Dept Exploratory Discovery, San Diego, CA 92130 USA.	sstruthers@neurocrine.com						Baekkevold ES, 2001, J EXP MED, V193, P1105, DOI 10.1084/jem.193.9.1105; Baggiolini M, 2001, J INTERN MED, V250, P91, DOI 10.1046/j.1365-2796.2001.00867.x; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Blanpain C, 2003, J BIOL CHEM, V278, P5179, DOI 10.1074/jbc.M205684200; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; FRASER CM, 1989, MOL PHARMACOL, V36, P840; Frow EK, 2004, MED RES REV, V24, P267, DOI 10.1002/med.10062; GANTZ I, 1992, J BIOL CHEM, V267, P20840; Govaerts C, 2001, J BIOL CHEM, V276, P13217, DOI 10.1074/jbc.M011670200; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; HAN BM, 1995, BIOCHEMISTRY-US, V34, P13412, DOI 10.1021/bi00041a019; HAN BM, 1995, MOL ENDOCRINOL, V9, P1708, DOI 10.1210/me.9.12.1708; Han KH, 1999, J BIOL CHEM, V274, P32055, DOI 10.1074/jbc.274.45.32055; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; Howard OMZ, 1999, J BIOL CHEM, V274, P16228, DOI 10.1074/jbc.274.23.16228; Iwasaki A, 2000, J EXP MED, V191, P1381, DOI 10.1084/jem.191.8.1381; Katancik JA, 1997, BIOCHEM BIOPH RES CO, V232, P663, DOI 10.1006/bbrc.1997.6352; Katancik JA, 2000, CYTOKINE, V12, P1480, DOI 10.1006/cyto.2000.0742; LEONG SR, 1994, J BIOL CHEM, V269, P19343; Mayer MR, 2001, J BIOL CHEM, V276, P13911, DOI 10.1074/jbc.M011202200; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Mirzadegan T, 2000, J BIOL CHEM, V275, P25562, DOI 10.1074/jbc.M000692200; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Nagira M, 1997, J BIOL CHEM, V272, P19518, DOI 10.1074/jbc.272.31.19518; Neptune ER, 1999, J BIOL CHEM, V274, P2824, DOI 10.1074/jbc.274.5.2824; Ngo VN, 1998, J EXP MED, V188, P181, DOI 10.1084/jem.188.1.181; Nickolls SA, 2003, BIOCHEM PHARMACOL, V65, P1139, DOI 10.1016/S0006-2952(03)00040-6; Noda K, 1996, BIOCHEMISTRY-US, V35, P16435, DOI 10.1021/bi961593m; Ott TR, 2004, BIOCHEMISTRY-US, V43, P3670, DOI 10.1021/bi035895h; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perlman JH, 1997, BIOCHEMISTRY-US, V36, P15670, DOI 10.1021/bi9713310; PERLMAN JH, 1994, J BIOL CHEM, V269, P1610; PERLMAN JH, 1994, J BIOL CHEM, V269, P23383; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; STRADER CD, 1988, J BIOL CHEM, V263, P10267; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; Warnock RA, 2000, J EXP MED, V191, P77, DOI 10.1084/jem.191.1.77; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; Yoshida R, 1998, J BIOL CHEM, V273, P7118, DOI 10.1074/jbc.273.12.7118; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; Zhou NM, 2000, EUR J IMMUNOL, V30, P164, DOI 10.1002/1521-4141(200001)30:1<164::AID-IMMU164>3.0.CO;2-X; ZHOU W, 1995, J BIOL CHEM, V270, P18853, DOI 10.1074/jbc.270.32.18853; ZHU GC, 1992, J CELL BIOCHEM, V50, P159	54	21	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42383	42392		10.1074/jbc.M401097200	http://dx.doi.org/10.1074/jbc.M401097200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15284247	hybrid			2022-12-27	WOS:000224226400008
J	Zhang, X; Vincent, AS; Halliwell, B; Wong, KP				Zhang, X; Vincent, AS; Halliwell, B; Wong, KP			A mechanism of sulfite neurotoxicity - Direct inhibition of glutamate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-KETOGLUTARATE DEHYDROGENASE; MOLYBDENUM COFACTOR DEFICIENCY; OXIDASE DEFICIENCY; OXIDATIVE STRESS; MAMMALIAN-TISSUES; HYDROGEN-PEROXIDE; MOLECULAR-BASIS; HUMAN-BRAIN; MITOCHONDRIA; LIVER	Exposure of Neuro-2a and PC12 cells to micromolar concentrations of sulfite caused an increase in reactive oxygen species and a decrease in ATP. Likewise, the biosynthesis of ATP in intact rat brain mitochondria from the oxidation of glutamate was inhibited by micromolar sulfite. Glutamate-driven respiration increased the mitochondrial membrane potential (MMP), and this was abolished by sulfite but the MMP generated by oxidation of malate and succinate was not affected. The increased rate of production of NADH from exogenous NAD(+) and glutamate added to rat brain mitochondrial extracts was inhibited by sulfite, and mitochondria pre-incubated with sulfite failed to reduce NAD(+). Glutamate dehydrogenase (GDH) in rat brain mitochondrial extract was inhibited dose-dependently by sulfite as was the activity of a purified enzyme. An increase in the K-m ( glutamate) and a decrease in V-max resulting in an attenuation in V-max/K-m ( glutamate) at 100 muM sulfite suggest a mixed type of inhibition. However, uncompetitive inhibition was noted with decreases in both K-m (NAD(+)) and V-max, whereas V-max/K-m (NAD(+)) remained relatively constant. We propose that GDH is one target of action of sulfite, leading to a decrease in alpha-ketoglutarate and a diminished flux through the tricarboxylic acid cycle accompanied by a decrease in NADH through the mitochondrial electron transport chain, a decreased MMP, and a decrease in ATP synthesis. Because glutamate is a major metabolite in the brain, inhibition of GDH by sulfite could contribute to the severe phenotype of sulfite oxidase deficiency in human infants.	Natl Univ Singapore, Fac Med, Dept Biochem, Singapore 117597, Singapore	National University of Singapore	Wong, KP (corresponding author), Natl Univ Singapore, Fac Med, Dept Biochem, 8 Med Dr, Singapore 117597, Singapore.	bchsitkp@nus.edu.sg	Halliwell, Barry/C-8318-2009	Halliwell, Barry/0000-0002-3560-7123				Altland K, 1999, NEUROGENETICS, V2, P183, DOI 10.1007/s100480050081; Astashkin AV, 2002, J AM CHEM SOC, V124, P6109, DOI 10.1021/ja0115417; Baud O, 2001, PEDIATR RES, V50, P706, DOI 10.1203/00006450-200112000-00013; BECKSPEIER I, 1985, BIOCHIM BIOPHYS ACTA, V841, P81, DOI 10.1016/0304-4165(85)90276-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSH RK, 1986, AM J MED, V81, P816, DOI 10.1016/0002-9343(86)90351-7; CABRE F, 1990, BIOCHEM MED METAB B, V43, P159, DOI 10.1016/0885-4505(90)90021-R; Casella IG, 2002, ANALYST, V127, P647, DOI 10.1039/b111080m; Chinopoulos C, 1999, J NEUROCHEM, V73, P220, DOI 10.1046/j.1471-4159.1999.0730220.x; COHEN HJ, 1971, J BIOL CHEM, V246, P374; Cormier A, 2003, NEUROPHARMACOLOGY, V44, P642, DOI 10.1016/S0028-3908(03)00041-8; Dublin AB, 2002, AM J NEURORADIOL, V23, P484; Feng CJ, 2003, BIOCHEMISTRY-US, V42, P12235, DOI 10.1021/bi0350194; FILLA A, 1986, J NEUROCHEM, V46, P422, DOI 10.1111/j.1471-4159.1986.tb12985.x; Garrett RM, 1998, P NATL ACAD SCI USA, V95, P6394, DOI 10.1073/pnas.95.11.6394; Gibson GE, 2000, NEUROCHEM INT, V36, P97, DOI 10.1016/S0197-0186(99)00114-X; Halliwell B, 2003, FEBS LETT, V540, P3, DOI 10.1016/S0014-5793(03)00235-7; Irreverre F, 1967, BIOCHEM MED, V1, P187; JOHNSON JL, 1974, J BIOL CHEM, V249, P859; JOHNSON JL, 1976, J CLIN INVEST, V58, P551, DOI 10.1172/JCI108500; JOHNSON JL, 1976, J CLIN INVEST, V58, P543, DOI 10.1172/JCI108499; Kelly A, 2001, MENT RETARD DEV D R, V7, P287, DOI 10.1002/mrdd.1040; KESSLER DL, 1972, J BIOL CHEM, V247, P6566; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; KUREBAYASHI N, 1980, J BIOCHEM-TOKYO, V88, P871, DOI 10.1093/oxfordjournals.jbchem.a133041; LESTER MR, 1995, J AM COLL NUTR, V14, P229; Liu KJ, 1999, FREE RADICAL BIO MED, V26, P714, DOI 10.1016/S0891-5849(98)00251-2; Marshall KA, 1999, FREE RADICAL BIO MED, V27, P515, DOI 10.1016/S0891-5849(99)00094-5; Millard J, 2003, J CLIN PATHOL-MOL PA, V56, P270, DOI 10.1136/mp.56.5.270; Mitsuhashi H, 1998, J LEUKOCYTE BIOL, V64, P595, DOI 10.1002/jlb.64.5.595; MUDD SH, 1967, SCIENCE, V156, P1599, DOI 10.1126/science.156.3782.1599; NISHADI R, 2001, BRAIN RES PROTOC, V8, P176; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Reist M, 1998, J NEUROCHEM, V71, P2431; Reus K E, 2000, Ned Tijdschr Geneeskd, V144, P1836; Rieger D, 1997, ANAL BIOCHEM, V246, P67, DOI 10.1006/abio.1996.9978; Rothman DL, 2003, ANNU REV PHYSIOL, V65, P401, DOI 10.1146/annurev.physiol.65.092101.142131; Rupar CA, 1996, NEUROPEDIATRICS, V27, P299, DOI 10.1055/s-2007-973798; Salman MS, 2002, CAN J NEUROL SCI, V29, P91, DOI 10.1017/S0317167100001803; Schindelin H, 2001, ADV PROTEIN CHEM, V58, P47; SHI XL, 1994, J INORG BIOCHEM, V56, P155, DOI 10.1016/0162-0134(94)85002-X; SHI XL, 1994, BIOCHEM BIOPH RES CO, V205, P141, DOI 10.1006/bbrc.1994.2641; Siesjo B.K., 1978, BRAIN ENERGY METABOL; Simon N, 1997, LIFE SCI, V61, P659, DOI 10.1016/S0024-3205(97)00442-6; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; SORBI S, 1989, ACTA NEUROL SCAND, V80, P103, DOI 10.1111/j.1600-0404.1989.tb03849.x; TEJNOROVA I, 1978, TOXICOL APPL PHARM, V44, P251, DOI 10.1016/0041-008X(78)90186-2; Topcu M, 2001, J CHILD NEUROL, V16, P264, DOI 10.1177/088307380101600406; Tretter L, 2000, J NEUROSCI, V20, P8972; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; WILLIAMSON DH, 1975, METHOD ENZYMAT AN, V4, P2266; Wilson HL, 2004, J BIOL CHEM, V279, P15105, DOI 10.1074/jbc.M314288200; Woo WH, 2003, BIOCHEM BIOPH RES CO, V305, P619, DOI 10.1016/S0006-291X(03)00833-7	53	101	106	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43035	43045		10.1074/jbc.M402759200	http://dx.doi.org/10.1074/jbc.M402759200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15273247	hybrid			2022-12-27	WOS:000224226400086
J	Agboh, KC; Webb, TE; Evans, RJ; Ennion, SJ				Agboh, KC; Webb, TE; Evans, RJ; Ennion, SJ			Functional characterization of a P2X receptor from Schistosoma mansoni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; P-2X RECEPTOR; AMINO-ACIDS; ATP-BINDING; CHANNELS; AGONISTS; IDENTIFICATION; PERMEABILITY; PRAZIQUANTEL; IVERMECTIN	The cloning and characterization of a P2X receptor (schP2X) from the parasitic blood fluke Schistosoma mansoni provides the first example of a non-vertebrate ATP-gated ion channel. A number of functionally important amino acid residues conserved throughout vertebrate P2X receptors, including 10 extracellular cysteines, aromatic and positively charged residues involved in ATP recognition, and a consensus protein kinase C site in the amino-terminal tail, are also present in schP2X. Overall, the amino acid sequence identity of schP2X with human P2X(1-7) receptors ranges from 25.8 to 36.6%. ATP evoked concentration-dependent currents at schP2X channels expressed in Xenopus oocytes with an EC50 of 22.1 muM. 2', 3'-O-(4-Benzoylbenzoyl) adenosine 5'-triphosphate (Bz-ATP) was a partial agonist ( maximum response 75.4 +/- 4.4% that of ATP) with a higher potency (EC50 of 3.6 muM) than ATP. Suramin and pyridoxal-phosphate-6- azophenyl- 2', 4'-disulfonic acid blocked schP2X responses to 100 muM ATP with IC50 values of 9.6 and 0.5 muM, respectively. Ivermectin ( 10 muM) potentiated currents to both ATP and Bz-ATP by similar to 60% with a minimal effect on potency (EC50 of 18.2 and 1.6 muM, respectively). The relative permeability of schP2X expressed in HEK293 cells to various cations was determined under bi-ionic conditions. schP2X has a relatively high calcium permeability (P-Ca/P-Na = 3.80 +/- 0.29) and an estimated minimum pore diameter similar to that of vertebrate P2X receptors. SchP2X provides a useful comparative model for the better understanding of human P2X receptor function and may also provide an alternative drug target for treatment of schistosomiasis.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; De Montfort Univ, Leicester Sch Pharm, Cell Signalling Lab, Leicester LE1 9BH, Leics, England	University of Leicester; De Montfort University	Ennion, SJ (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, POB 138, Leicester LE1 9HN, Leics, England.	se15@le.ac.uk	Webb, Tania/AAT-9554-2020		Biotechnology and Biological Sciences Research Council [C17893] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Awasthi S, 2003, BMJ-BRIT MED J, V327, P431, DOI 10.1136/bmj.327.7412.431; BACKUS KH, 1994, J NEUROBIOL, V25, P1283, DOI 10.1002/neu.480251009; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; Bentley GN, 2003, GENE, V314, P103, DOI 10.1016/S0378-1119(03)00709-1; Bo XN, 2003, MOL PHARMACOL, V63, P1407, DOI 10.1124/mol.63.6.1407; Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Burnstock G, 2004, CURR OPIN PHARMACOL, V4, P47, DOI 10.1016/j.coph.2003.08.001; Burnstock G, 2001, DRUG DEVELOP RES, V53, P53, DOI 10.1002/ddr.1170; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Engels D, 2002, ACTA TROP, V82, P139, DOI 10.1016/S0001-706X(02)00045-1; Ennion S, 2000, J BIOL CHEM, V275, P29361, DOI 10.1074/jbc.M003637200; Ennion SJ, 2002, MOL PHARMACOL, V61, P303, DOI 10.1124/mol.61.2.303; Ennion SJ, 2002, BIOCHEM BIOPH RES CO, V291, P611, DOI 10.1006/bbrc.2002.6488; Evans RJ, 1996, J PHYSIOL-LONDON, V497, P413, DOI 10.1113/jphysiol.1996.sp021777; Fenwick A, 2003, TRENDS PARASITOL, V19, P509, DOI 10.1016/j.pt.2003.09.005; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; GarciaGuzman M, 1997, MOL PHARMACOL, V51, P109, DOI 10.1124/mol.51.1.109; Ismail M, 1999, AM J TROP MED HYG, V60, P932, DOI 10.4269/ajtmh.1999.60.932; Jensik PJ, 2001, AM J PHYSIOL-CELL PH, V281, pC954, DOI 10.1152/ajpcell.2001.281.3.C954; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Jones CA, 2000, BRIT J PHARMACOL, V129, P388, DOI 10.1038/sj.bjp.0703059; Jones CA, 2004, MOL PHARMACOL, V65, P979, DOI 10.1124/mol.65.4.979; Khakh BS, 1999, J NEUROSCI, V19, P7289, DOI 10.1523/JNEUROSCI.19-17-07289.1999; Kim MY, 1999, J EXP BIOL, V202, P407; Kohn AB, 2001, J BIOL CHEM, V276, P36873, DOI 10.1074/jbc.C100273200; Kucenas S, 2003, NEUROSCIENCE, V121, P935, DOI 10.1016/S0306-4522(03)00566-9; Lambrecht G, 2000, N-S ARCH PHARMACOL, V362, P340, DOI 10.1007/s002100000312; Lewis CJ, 2001, DRUG DEVELOP RES, V52, P164, DOI 10.1002/ddr.1111; MCLAREN DJ, 1977, NATURE, V269, P147, DOI 10.1038/269147a0; Noel F, 2001, MEM I OSWALDO CRUZ, V96, P85, DOI 10.1590/S0074-02762001000900012; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Paukert M, 2002, FEBS LETT, V513, P253, DOI 10.1016/S0014-5793(02)02324-4; POTHIER F, 1984, J EXP ZOOL, V230, P211, DOI 10.1002/jez.1402300206; Priel A, 2004, J GEN PHYSIOL, V123, P281, DOI 10.1085/jgp.200308986; Rettinger J, 2000, J BIOL CHEM, V275, P33542, DOI 10.1074/jbc.M002918200; Roberts JA, 2004, J BIOL CHEM, V279, P9043, DOI 10.1074/jbc.M308964200; Ruppelt A, 2001, J NEUROCHEM, V77, P1256, DOI 10.1046/j.1471-4159.2001.00348.x; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Verjovski-Almeida S, 2003, NAT GENET, V35, P148, DOI 10.1038/ng1237; WHITWORTH JAG, 1991, T ROY SOC TROP MED H, V85, P232, DOI 10.1016/0035-9203(91)90037-Y	41	78	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41650	41657		10.1074/jbc.M408203200	http://dx.doi.org/10.1074/jbc.M408203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292267	hybrid			2022-12-27	WOS:000224075500051
J	Jenkins, RH; Thomas, GJ; Williams, JD; Steadman, R				Jenkins, RH; Thomas, GJ; Williams, JD; Steadman, R			Myofibroblastic differentiation leads to hyaluronan accumulation through reduced hyaluronan turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKIN FIBROBLASTS; TRANSFORMING GROWTH-FACTOR-BETA-1; ARTICULAR CHONDROCYTES; DENDRITIC CELLS; ED-A; EXPRESSION; CD44; 4-METHYLUMBELLIFERONE; GENE; OLIGOSACCHARIDES	During the initiation and progression of fibrosis there is extensive differentiation of cells to a myofibroblastic phenotype. Because the synthesis of hyaluronan (HA) was recently linked to oncogenic epithelial-mesenchymal transformation, the present study investigated whether increased HA synthesis was also associated with myofibroblastic differentiation. HA synthesis and size were measured by incorporation of [H-3] glucosamine, ion exchange, and size exclusion chromatography. Hyaluronan synthase (HAS) or hyaluronidase (HYAL) mRNA levels were assessed by reverse transcription-PCR. HYAL was detected by immunoblotting and the degradation of [H-3] HA. Between 2- and 3-fold more HA appeared in the conditioned medium and became associated with the cells upon myofibroblastic differentiation. Inhibition of HAS and examination of HAS mRNA expression demonstrated that this was not the result of increased synthesis of HA or the induction of HAS 2. After differentiation, however, myofibroblasts metabolized exogenously supplied [H-3] HA at a slower rate than fibroblasts and expressed lower levels of both HYAL 1 and HYAL 2 mRNA. Immunoblotting revealed more HYAL 1 and 2 in the myofibroblast conditioned medium. After acidification, however, there was no difference in HA degradation. This suggests that much of the released HYAL is inactive and that the observed differences in HA degradation are caused by cell-associated rather than secreted activity. This was confirmed by immunohistochemical staining for HYAL 1 and HYAL 2. This finding indicates the potential importance of the HYAL enzymes in controlling fibrotic progression and contrasts HA synthesis as a mediator of oncogenic transformation with that of HA degradation controlling fibrogenic differentiation.	Univ Wales Coll Med, Inst Nephrol, Cardiff CF14 4XN, S Glam, Wales; Cardiff Inst Tissue Engn & Repair, Cardiff CF14 4XN, S Glam, Wales	Cardiff University; Cardiff University	Steadman, R (corresponding author), Univ Wales Coll Med, Inst Nephrol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	steadmanr@cf.ac.uk	Steadman, Robert/O-1614-2016	Steadman, Robert/0000-0002-1303-2496; Jenkins, Robert/0000-0001-8500-9044				Bochaton-Piallat ML, 2000, INVEST OPHTH VIS SCI, V41, P2336; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; CHOW G, 1995, J BIOL CHEM, V270, P27734, DOI 10.1074/jbc.270.46.27734; Croce MA, 2001, TISSUE CELL, V33, P326, DOI 10.1054/tice.2001.0180; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; Csoka TB, 1997, INVAS METAST, V17, P297; D'Souza AL, 2000, ARCH BIOCHEM BIOPHYS, V374, P59, DOI 10.1006/abbi.1999.1626; Desmouliere A, 2003, LAB INVEST, V83, P1689, DOI 10.1097/01.LAB.0000101911.53973.90; Evans RA, 2003, EXP CELL RES, V282, P90, DOI 10.1016/S0014-4827(02)00015-0; Flannery CR, 1998, BIOCHEM BIOPH RES CO, V251, P824, DOI 10.1006/bbrc.1998.9561; Frost GI, 1997, BIOCHEM BIOPH RES CO, V236, P10, DOI 10.1006/bbrc.1997.6773; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Goransson V, 2001, MATRIX BIOL, V20, P129, DOI 10.1016/S0945-053X(01)00129-9; GRESSNER AM, 1991, EUR J CLIN CHEM CLIN, V29, P293; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; Jones S, 2001, KIDNEY INT, V59, P1739, DOI 10.1046/j.1523-1755.2001.0590051739.x; Kakizaki I, 2002, EUR J BIOCHEM, V269, P5066, DOI 10.1046/j.1432-1033.2002.03217.x; Knudson Cheryl B., 2003, Birth Defects Research, V69, P174, DOI 10.1002/bdrc.10013; Knudson W, 2002, MATRIX BIOL, V21, P15, DOI 10.1016/S0945-053X(01)00186-X; KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902; Lepperdinger G, 2001, MATRIX BIOL, V20, P509, DOI 10.1016/S0945-053X(01)00170-6; Li YJ, 2000, AM J RESP CELL MOL, V23, P411, DOI 10.1165/ajrcmb.23.3.4102; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; Mullegger J, 2002, MECH DEVELOP, V111, P25, DOI 10.1016/S0925-4773(01)00593-7; Nakamura T, 1997, BIOCHEM MOL BIOL INT, V43, P263; NAKAMURA T, 1995, BIOCHEM BIOPH RES CO, V208, P470, DOI 10.1006/bbrc.1995.1362; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Ohno S, 2002, J PERIODONTOL, V73, P1331, DOI 10.1902/jop.2002.73.11.1331; Rai SK, 2001, P NATL ACAD SCI USA, V98, P4443, DOI 10.1073/pnas.071572898; Reitinger S, 2001, FEBS LETT, V505, P213, DOI 10.1016/S0014-5793(01)02813-7; SAPPINO AP, 1990, LAB INVEST, V63, P144; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Stair-Nawy S, 1999, BIOCHEM BIOPH RES CO, V266, P268, DOI 10.1006/bbrc.1999.1802; Stern R, 2003, GLYCOBIOLOGY, V13, p105R, DOI 10.1093/glycob/cwg112; Stern R, 2001, EXP CELL RES, V266, P167, DOI 10.1006/excr.2001.5206; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Tammi R, 2001, J BIOL CHEM, V276, P35111, DOI 10.1074/jbc.M103481200; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; THOMAS GJ, 1995, KIDNEY INT, V48, P1278, DOI 10.1038/ki.1995.412; Tian YC, 2003, AM J PHYSIOL-RENAL, V285, pF130, DOI 10.1152/ajprenal.00408.2002; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Xu XM, 2003, CANCER RES, V63, P5685; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	46	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41453	41460		10.1074/jbc.M401678200	http://dx.doi.org/10.1074/jbc.M401678200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15271981	hybrid			2022-12-27	WOS:000224075500027
J	Iwatsubo, K; Minamisawa, S; Tsunematsu, T; Nakagome, M; Toya, Y; Tomlinson, JE; Umemura, S; Scarborough, RM; Levy, DE; Ishikawa, Y				Iwatsubo, K; Minamisawa, S; Tsunematsu, T; Nakagome, M; Toya, Y; Tomlinson, JE; Umemura, S; Scarborough, RM; Levy, DE; Ishikawa, Y			Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; SITE-MEDIATED INHIBITION; CONGESTIVE-HEART-FAILURE; MOUSE CARDIAC MYOCYTES; TRANSGENIC MICE; ACTIVATION; NOREPINEPHRINE; PROTEINS; CARDIOMYOCYTES; STIMULATION	Adenylyl cyclase, a major target enzyme of beta-adrenergic receptor signals, is potently and directly inhibited by P-site inhibitors, classic inhibitors of this enzyme, when the enzyme catalytic activity is high. Unlike beta-adrenergic receptor antagonists, this is a non- or uncompetitive inhibition with respect to ATP. We have examined whether we can utilize this enzymatic property to regulate the effects of beta-adrenergic receptor stimulation differentially. After screening multiple new and classic compounds, we found that some compounds, including 1R, 4R-3-(6-aminopurin-9-yl)-cyclopentanecarboxylic acid hydroxyamide, potently inhibited type 5 adenylyl cyclase, the major cardiac isoform, but not other isoforms. In normal mouse cardiac myocytes, contraction induced by low beta-adrenergic receptor stimulation was poorly inhibited with this compound, but the induction of cardiac myocyte apoptosis by high beta-adrenergic receptor stimulation was effectively prevented by type 5 adenylyl cyclase inhibitors. In contrast, when cardiac myocytes from type 5 adenylyl cyclase knock-out mice were examined, beta-adrenergic stimulation poorly induced apoptosis. Our data suggest that the inhibition of beta-adrenergic signaling at the level of the type 5 adenylyl cyclase isoform by P-site inhibitors may serve as an effective method to prevent cardiac myocyte apoptosis induced by excessive beta-adrenergic stimulation without deleterious effect on cardiac myocyte contraction.	Univ Med & Dent New Jersey, New Jersey Med Sch, Cardiovasc Res Inst, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Cardiovasc Res Inst, Dept Med Cardiol, Newark, NJ 07103 USA; Yokohama City Univ, Sch Med, Dept Physiol, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Med, Yokohama, Kanagawa 2360004, Japan; Portola Pharmaceut Inc, San Francisco, CA 94080 USA; Scios Inc, Fremont, CA 94555 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Yokohama City University; Yokohama City University; Scios	Ishikawa, Y (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Cardiovasc Res Inst, Dept Cell Biol & Mol Med, 185 S Orange Ave, Newark, NJ 07103 USA.	ishikayo@umdnj.edu		Minamisawa, Susumu/0000-0003-4728-2116				BABICH M, 1985, J MOL CELL CARDIOL, V17, P565, DOI 10.1016/S0022-2828(85)80025-0; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; Boolell M, 1996, Int J Impot Res, V8, P47; BUCKNER CK, 1978, EUR J PHARMACOL, V47, P259, DOI 10.1016/0014-2999(78)90233-9; Calaghan S, 1998, BIOCHEM BIOPH RES CO, V248, P701, DOI 10.1006/bbrc.1998.9036; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Cohn JN, 2000, J AM COLL CARDIOL, V35, P569, DOI 10.1016/S0735-1097(99)00630-0; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; Gao MH, 1999, CIRCULATION, V99, P1618, DOI 10.1161/01.CIR.99.12.1618; Geng YJ, 1999, CIRC RES, V84, P34; GUPTA RC, 1993, CIRC RES, V72, P65, DOI 10.1161/01.RES.72.1.65; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; HOSONO M, 1992, J CARDIOVASC PHARM, V19, P625, DOI 10.1097/00005344-199204000-00021; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; Ishikawa Y, 1997, CIRC RES, V80, P297, DOI 10.1161/01.RES.80.3.297; Iwai-Kanai E, 1999, CIRCULATION, V100, P305, DOI 10.1161/01.CIR.100.3.305; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; Iwatsubo K, 2003, EXPERT OPIN THER TAR, V7, P441, DOI 10.1517/eott.7.3.441.22433; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; Johnson RA, 1997, J BIOL CHEM, V272, P8962; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KUZNETSOV V, 1995, CIRC RES, V76, P40, DOI 10.1161/01.RES.76.1.40; Levy DE, 2003, J MED CHEM, V46, P2177, DOI 10.1021/jm0205604; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; Long XL, 1998, J CLIN INVEST, V101, P1453, DOI 10.1172/JCI345; Minamisawa S, 1999, J BIOL CHEM, V274, P10066, DOI 10.1074/jbc.274.15.10066; Nyui N, 1997, BIOCHEM BIOPH RES CO, V235, P36, DOI 10.1006/bbrc.1997.6706; Okumura S, 2003, P NATL ACAD SCI USA, V100, P9986, DOI 10.1073/pnas.1733772100; Okumura S, 2003, CIRC RES, V93, P364, DOI 10.1161/01.RES.0000086986.35568.63; Onda T, 2001, J BIOL CHEM, V276, P47785, DOI 10.1074/jbc.M107233200; OPIE LH, 2001, HEART DIS TXB CARDIO, P443; POLSON JB, 1977, J PHARMACOL EXP THER, V200, P630; Prichard BNC, 2001, BLOOD PRESSURE, V10, P366, DOI 10.1080/080370501753400665; Rybin VO, 2003, MOL PHARMACOL, V63, P1338, DOI 10.1124/mol.63.6.1338; Sabbah HN, 2000, J AM COLL CARDIOL, V36, P1698, DOI 10.1016/S0735-1097(00)00913-X; Sambrano GR, 2002, NATURE, V420, P712, DOI 10.1038/nature01306; SHAFIQ J, 1992, CIRC RES, V71, P70, DOI 10.1161/01.RES.71.1.70; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 2000, BIOCHEMISTRY-US, V39, P14464, DOI 10.1021/bi0015562; Toya Y, 1998, J MOL CELL CARDIOL, V30, P97, DOI 10.1006/jmcc.1997.0575; Vantrimpont P, 1998, EUR HEART J, V19, P1552, DOI 10.1053/euhj.1998.1093; Yamamoto S, 2001, J MOL CELL CARDIOL, V33, P1829, DOI 10.1006/jmcc.2001.1446; Zaugg M, 2000, CIRCULATION, V102, P344; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607	48	85	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40938	40945		10.1074/jbc.M314238200	http://dx.doi.org/10.1074/jbc.M314238200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262973	hybrid			2022-12-27	WOS:000223916800090
J	Palamakumbura, AH; Jeay, S; Guo, Y; Pischon, N; Sommer, P; Sonenshein, GE; Trackman, PC				Palamakumbura, AH; Jeay, S; Guo, Y; Pischon, N; Sommer, P; Sonenshein, GE; Trackman, PC			The propeptide domain of lysyl oxidase induces phenotypic reversion of Ras-transformed cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL PROPEPTIDE; OSTEOBLASTIC MC3T3-E1 CELLS; REFRACTORY PROSTATE-CANCER; PROCOLLAGEN C-PROTEINASE; AMINO-ACID-SEQUENCE; GROWTH-FACTOR; MESSENGER-RNA; I COLLAGEN; TUMORIGENIC TRANSFORMATION; AUTOCRINE GROWTH	Lysyl oxidase is an extracellular enzyme critical for the normal biosynthesis of collagens and elastin. In addition, lysyl oxidase reverts ras-mediated transformation, and lysyl oxidase expression is down-regulated in human cancers. Since suramin inhibits growth factor signaling pathways and induces lysyl oxidase in ras-transformed NIH3T3 cells (RS485 cells), we sought to investigate the effects of suramin on the phenotype of transformed cells and the role of lysyl oxidase in mediating these effects. Suramin treatment resulted in a more normal phenotype as judged by growth rate, cell cycle parameters, and morphology. beta-aminopropionitrile, the selective inhibitor of lysyl oxidase enzyme activity, was remarkably unable to block suramin-induced reversion. By contrast, ectopic antisense lysyl oxidase demonstrated that lysyl oxidase gene expression mediated phenotypic reversion. Since lysyl oxidase is synthesized as a 50 kDa precursor and processed to a 30 kDa active enzyme and 18 kDa propeptide, the effects of these two products on the transformed phenotype of RS485 cells were then directly assessed in the absence of suramin. Here we report, for the first time, that the lysyl oxidase propeptide, and not the lysyl oxidase enzyme, inhibits ras-dependent transformation as determined by effects on cell proliferation assays, growth in soft agar, and Akt-dependent induction of NF-kappaB activity. Thus, the lysyl oxidase propeptide, which is released during extracellular proteolytic processing of pro-lysyl oxidase, functions to inhibit ras-dependent cell transformation.	Boston Univ, Goldman Sch Dent Med, Div Oral Biol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon 07, France	Boston University; Boston University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Trackman, PC (corresponding author), Boston Univ, Goldman Sch Dent Med, Div Oral Biol, 700 Albany St,Room W-210, Boston, MA 02118 USA.	trackman@bu.edu	Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X; JEAY, SEBASTIEN/0000-0001-7476-3340	NCI NIH HHS [CA82742] Funding Source: Medline; NIDCR NIH HHS [DE12425, DE12209] Funding Source: Medline; NIEHS NIH HHS [ES11624] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE012425, R01DE012209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011624] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AYCOCK RS, 1986, J BIOL CHEM, V261, P14355; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; Davies D, 1997, EUR J BIOCHEM, V246, P274, DOI 10.1111/j.1432-1033.1997.t01-1-00274.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; Fukumoto M, 2000, ANTICANCER RES, V20, P4059; Garcia-Schurmann JM, 1999, UROLOGY, V53, P535, DOI 10.1016/S0090-4295(98)00544-5; Giampuzzi M, 2001, J BIOL CHEM, V276, P29226, DOI 10.1074/jbc.M101695200; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAJNAL A, 1993, CANCER RES, V53, P4670; HAMALAINEN ER, 1995, J BIOL CHEM, V270, P21590, DOI 10.1074/jbc.270.37.21590; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; Hong HH, 2004, J CELL PHYSIOL, V200, P53, DOI 10.1002/jcp.10476; Hong HH, 1999, LAB INVEST, V79, P1655; Jeay S, 2003, MOL CELL BIOL, V23, P2251, DOI 10.1128/MCB.23.7.2251-2263.2003; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KAGAN HM, 1982, METHOD ENZYMOL, V82, P637; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; KUIVANIEMI H, 1986, FEBS LETT, V195, P261, DOI 10.1016/0014-5793(86)80172-7; LAROCCA RV, 1990, J CLIN ENDOCR METAB, V71, P497; LAROCCA RV, 1990, J STEROID BIOCHEM, V37, P893, DOI 10.1016/0960-0760(90)90439-R; MARIANI TJ, 1992, MATRIX, V12, P242, DOI 10.1016/S0934-8832(11)80067-3; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; McKnight S, 2003, CELL, V114, P150, DOI 10.1016/S0092-8674(03)00563-4; Mietz H, 1998, BRIT J OPHTHALMOL, V82, P816, DOI 10.1136/bjo.82.7.816; Mizuno M, 1996, BBA-MOL CELL RES, V1310, P97, DOI 10.1016/0167-4889(95)00151-4; Mizuno M, 2000, CALCIFIED TISSUE INT, V67, P391, DOI 10.1007/s002230001150; Nellaiappan K, 2000, J CELL BIOCHEM, V79, P576, DOI 10.1002/1097-4644(20001215)79:4<576::AID-JCB60>3.0.CO;2-A; Palamakumbura AH, 2003, J BIOL CHEM, V278, P30781, DOI 10.1074/jbc.M305238200; Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464; Palmieri D, 2000, J BIOL CHEM, V275, P32658, DOI 10.1074/jbc.M002698200; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Ren CZ, 1998, CANCER RES, V58, P1285; SAMID D, 1987, MOL CELL BIOL, V7, P2196, DOI 10.1128/MCB.7.6.2196; Seve S, 2002, CONNECT TISSUE RES, V43, P613, DOI 10.1080/03008200290001348; Small EJ, 2000, J CLIN ONCOL, V18, P1440, DOI 10.1200/JCO.2000.18.7.1440; Song SH, 2001, CANCER RES, V61, P6145; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Sullivan KA, 1997, BRAIN RES, V744, P199, DOI 10.1016/S0006-8993(96)01078-5; TANG SS, 1983, J BIOL CHEM, V258, P4331; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WU CH, 1986, J BIOL CHEM, V261, P482; Zanghi JA, 2000, BIOTECHNOL PROGR, V16, P319, DOI 10.1021/bp0000353; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	59	105	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40593	40600		10.1074/jbc.M406639200	http://dx.doi.org/10.1074/jbc.M406639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15277520	hybrid			2022-12-27	WOS:000223916800047
J	Shaw, WJ; Campbell, AA; Paine, ML; Snead, ML				Shaw, WJ; Campbell, AA; Paine, ML; Snead, ML			The COOH terminus of the amelogenin, LRAP, is oriented next to the hydroxyapatite surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-STATE NMR; DYNAMIC LIGHT-SCATTERING; DOUBLE-RESONANCE NMR; ENAMEL-MATRIX; RECOMBINANT AMELOGENIN; ROTATIONAL-ECHO; PEPTIDE; PROTEINS; BIOMINERALIZATION; CONFORMATION	The organic matrix in forming enamel consists largely of the amelogenin protein self-assembled into nanospheres that are necessary to guide the formation of the unusually long and highly ordered hydroxyapatite (HAP) crystallites that constitute enamel. Despite its ability to direct crystal growth, the interaction of the amelogenin protein with HAP is unknown. However, the demonstration of growth restricted to the c-axis suggests a specific protein-crystal interaction, and the charged COOH terminus is often implicated in this function. To elucidate whether the COOH terminus is important in the binding and orientation of amelogenin onto HAP, we have used solid state NMR to determine the orientation of the COOH terminus of an amelogenin splice variant, LRAP (leucine-rich amelogenin protein), which contains the charged COOH terminus of the full protein, on the HAP surface. These experiments demonstrate that the methyl (13)C-labeled side chain of Ala(46) is 8.0 Angstrom from the HAP surface under hydrated conditions, for the protein with and without phosphorylation. The experimental results provide direct evidence orienting the charged COOH-terminal region of the amelogenin protein on the HAP surface, optimized to exert control on developing enamel crystals.	Pacific NW Natl Lab, Richland, WA 99352 USA; Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA	United States Department of Energy (DOE); Pacific Northwest National Laboratory; University of Southern California	Shaw, WJ (corresponding author), Pacific NW Natl Lab, MS K2-57,POB 999, Richland, WA 99352 USA.	wendy.shaw@pnl.gov		Shaw, Wendy/0000-0002-4696-7415	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013045, R01DE015347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE013045, R01DE013404] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE015347, DE13404, R01 DE015347-01A2, DE13045] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AOBA T, 1987, CALCIFIED TISSUE INT, V41, P281, DOI 10.1007/BF02555230; Bak M, 2000, J MAGN RESON, V147, P296, DOI 10.1006/jmre.2000.2179; BENNETT AE, 1995, J CHEM PHYS, V103, P6951, DOI 10.1063/1.470372; Burkett SL, 2001, LANGMUIR, V17, P5059, DOI 10.1021/la010156s; FINCHAM AG, 1995, J STRUCT BIOL, V115, P50, DOI 10.1006/jsbi.1995.1029; FINCHAM AG, 1994, J STRUCT BIOL, V112, P103, DOI 10.1006/jsbi.1994.1011; Fincham AG, 1999, J STRUCT BIOL, V126, P270, DOI 10.1006/jsbi.1999.4130; FINCHAM AG, 1992, INT CONGR SER, V1002, P187; FINCHAM AG, 1983, BIOCHEM J, V211, P149, DOI 10.1042/bj2110149; GIBSON CW, 1991, BIOCHEM BIOPH RES CO, V174, P1306, DOI 10.1016/0006-291X(91)91564-S; Gibson CW, 2001, J BIOL CHEM, V276, P31871, DOI 10.1074/jbc.M104624200; Gougeon RD, 2002, LANGMUIR, V18, P3396, DOI 10.1021/la0115381; GULLION T, 1989, J MAGN RESON, V81, P196, DOI 10.1016/0022-2364(89)90280-1; GULLION T, 1991, J MAGN RESON, V92, P439, DOI 10.1016/0022-2364(91)90286-3; Hunter GK, 1996, CURR OPIN SOLID ST M, V1, P430, DOI 10.1016/S1359-0286(96)80036-2; Hunter GK, 1999, CALCIFIED TISSUE INT, V65, P226, DOI 10.1007/s002239900688; Long JR, 2001, BIOCHEMISTRY-US, V40, P15451, DOI 10.1021/bi010864c; Long JR, 1998, P NATL ACAD SCI USA, V95, P12083, DOI 10.1073/pnas.95.21.12083; Moradian-Oldak J, 1998, J STRUCT BIOL, V122, P320, DOI 10.1006/jsbi.1998.4008; Moradian-Oldak J, 2000, J STRUCT BIOL, V131, P27, DOI 10.1006/jsbi.2000.4237; Moradian-Oldak J, 1998, BIOPOLYMERS, V46, P225, DOI 10.1002/(SICI)1097-0282(19981005)46:4<225::AID-BIP4>3.0.CO;2-R; Moradian-Oldak J, 2002, MATRIX BIOL, V21, P197, DOI 10.1016/S0945-053X(01)00190-1; Moradian-Oldak J, 2001, MATRIX BIOL, V20, P293, DOI 10.1016/S0945-053X(01)00154-8; Paine ML, 2001, MATRIX BIOL, V20, P273, DOI 10.1016/S0945-053X(01)00153-6; Paine ML, 1997, J BONE MINER RES, V12, P221, DOI 10.1359/jbmr.1997.12.2.221; Paine ML, 2000, J STRUCT BIOL, V132, P191, DOI 10.1006/jsbi.2000.4324; Shaw WJ, 2000, J AM CHEM SOC, V122, P1709, DOI 10.1021/ja9842823; Shaw WJ, 2000, J AM CHEM SOC, V122, P7118, DOI 10.1021/ja000878q; SIMMER JP, 1994, CALCIFIED TISSUE INT, V54, P312, DOI 10.1007/BF00295956; SIMMER JP, 1995, CRIT REV ORAL BIOL M, V6, P84, DOI 10.1177/10454411950060020701; Viswanathan HL, 2003, J PERIODONTOL, V74, P1423, DOI 10.1902/jop.2003.74.10.1423	31	121	126	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40263	40266		10.1074/jbc.C400322200	http://dx.doi.org/10.1074/jbc.C400322200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15299015	hybrid			2022-12-27	WOS:000223916800005
J	Yu, BM; Paroutis, P; Davidson, AR; Howell, PL				Yu, BM; Paroutis, P; Davidson, AR; Howell, PL			Disruption of a salt bridge dramatically accelerates subunit exchange in duck delta 2 crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININOSUCCINATE LYASE ACTIVITY; DELTA-1 CRYSTALLIN GENE; ACTIVE-SITE; INTRAGENIC COMPLEMENTATION; BIOCHEMICAL-CHARACTERIZATION; ADENYLOSUCCINATE LYASE; MUTATIONAL ANALYSIS; OLIGOMERIC ENZYMES; II CRYSTALLIN; LENS	Intragenic complementation is a unique property of oligomeric enzymes with which to study subunit-subunit interactions. Complementation occurs when different subunits, each possessing distinct mutations that render the individual homomutant proteins inactive, interact to form a heteromutant protein with partial recovery of activity. In this paper, complementation events between human argininosuccinate lyase (ASL) and its homolog, duck delta2 crystallin, were characterized. Different active site mutants in delta2 crystallin complement by the regeneration of native-like active sites as reported previously for ASL. The complementarity of the ASL and delta2 crystallin subunit interfaces was illustrated by the in vivo formation of active hybrid tetramers from inactive ASL and inactive delta2 crystallin mutants. Subunits of both ASL and delta2 crystallin do not dissociate and reassociate in vitro at room temperature, even after 6 days of incubation, indicating that the multimerization interface is very strong. However, disruption of a salt bridge network in the tetrameric interface of delta2 crystallin caused a drastic acceleration of subunit dissociation. Double mutants combining these interface mutants with active site mutants of delta2 crystallin were able to dissociate and reassociate to form active tetramers in vitro within hours. These results suggest that exchange of subunits may occur without unfolding of the monomer. Intragenic complementation in these interface mutants occurs by reintroducing the native salt bridge interaction upon hetero-oligomerization. Our studies demonstrate the value of intragenic complementation as a tool for investigating subunit-subunit interactions in oligomeric proteins.	Hosp Sick Children, Res Inst, Dept Biol Struct & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Fac Med, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Davidson, AR (corresponding author), Univ Toronto, Dept Biochem, Fac Med, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	alan.davidson@utoronto.ca; howell@sickkids.on.ca						AbuAbed M, 1997, BIOCHEMISTRY-US, V36, P14012, DOI 10.1021/bi971407s; BARBOSA P, 1991, J BIOL CHEM, V266, P22319; Brosius JL, 2002, BIOCHEMISTRY-US, V41, P2217, DOI 10.1021/bi011998t; Chakraborty AR, 1999, BIOCHEMISTRY-US, V38, P2435, DOI 10.1021/bi982150g; CHIOU SH, 1992, BIOCHIM BIOPHYS ACTA, V1160, P317, DOI 10.1016/0167-4838(92)90094-T; CHIOU SH, 1991, BIOCHEM J, V273, P295, DOI 10.1042/bj2730295; Daggett V, 2003, NAT REV MOL CELL BIO, V4, P497, DOI 10.1038/nrm1126; DISTEFANO MD, 1990, BIOCHEMISTRY-US, V29, P2703, DOI 10.1021/bi00463a013; Elcock AH, 2001, P NATL ACAD SCI USA, V98, P2990, DOI 10.1073/pnas.061411798; Goodsell DS, 2000, ANNU REV BIOPH BIOM, V29, P105, DOI 10.1146/annurev.biophys.29.1.105; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LEE HJ, 1992, BIOCHEM J, V283, P597, DOI 10.1042/bj2830597; Lee TT, 1999, BIOCHEMISTRY-US, V38, P22, DOI 10.1021/bi982299s; MCINNES RR, 1984, P NATL ACAD SCI-BIOL, V81, P4480, DOI 10.1073/pnas.81.14.4480; NICKERSON JM, 1985, J BIOL CHEM, V260, P9100; NICKERSON JM, 1986, J BIOL CHEM, V261, P552; Piatigorsky J, 1996, BBA-PROTEIN STRUCT M, V1295, P158, DOI 10.1016/0167-4838(96)00030-1; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; POOKANJANATAVIP M, 1992, BIOCHEMISTRY-US, V31, P10303, DOI 10.1021/bi00157a018; Radford SE, 2000, TRENDS BIOCHEM SCI, V25, P611, DOI 10.1016/S0968-0004(00)01707-2; Sampaleanu LM, 2002, J BIOL CHEM, V277, P4166, DOI 10.1074/jbc.M107465200; Sampaleanu LM, 2001, BIOCHEMISTRY-US, V40, P2732, DOI 10.1021/bi002272k; SCRUTTON NS, 1990, P ROY SOC B-BIOL SCI, V242, P217, DOI 10.1098/rspb.1990.0127; SIMPSON A, 1994, NAT STRUCT BIOL, V1, P724, DOI 10.1038/nsb1094-724; Turner MA, 1997, P NATL ACAD SCI USA, V94, P9063, DOI 10.1073/pnas.94.17.9063; Valdar WSJ, 2001, PROTEINS, V42, P108; Vallee F, 1999, BIOCHEMISTRY-US, V38, P2425, DOI 10.1021/bi982149h; Vendruscolo M, 2003, CURR OPIN STRUC BIOL, V13, P82, DOI 10.1016/S0959-440X(03)00007-1; VOORTER CEM, 1993, EXP EYE RES, V56, P733, DOI 10.1006/exer.1993.1091; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31; WILLIAMS LA, 1979, BIOCHEMISTRY-US, V18, P1438, DOI 10.1021/bi00575a008; WISTOW GJ, 1990, GENE, V96, P263, DOI 10.1016/0378-1119(90)90262-P; Yu B, 2000, CELL MOL LIFE SCI, V57, P1637, DOI 10.1007/PL00000646; Yu B, 2001, BIOCHEMISTRY-US, V40, P15581, DOI 10.1021/bi011526e	34	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40972	40979		10.1074/jbc.M405300200	http://dx.doi.org/10.1074/jbc.M405300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15273245	hybrid			2022-12-27	WOS:000223916800094
J	Brown, DA; Bruce, JIE; Straub, SV; Yule, DI				Brown, DA; Bruce, JIE; Straub, SV; Yule, DI			CAMP potentiates ATP-evoked calcium signaling in human parotid acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; GLAND NUCLEOTIDE RECEPTORS; EXTRACELLULAR ATP; RYANODINE RECEPTOR; DUCT CELLS; PURINERGIC RECEPTORS; CONFOCAL MICROSCOPY; SALIVARY SECRETION; CYTOSOLIC CALCIUM; PHOSPHOLIPASE-C	In salivary acinar cells, intracellular calcium ([Ca2+](i)) signaling plays an important role in eliciting fluid secretion through the activation of Ca2+-activated ionic conductances. Ca2+ and cAMP have synergistic effects on fluid secretion such that peak secretion is elicited following activation of both parasympathetic and sympathetic pathways. We have recently demonstrated that cAMP exerts effects on Ca2+ release, through protein kinase A (PKA)-mediated phosphorylation of inositol 1,4,5-trisphosphate receptors (InsP(3)R) in mouse parotid acinar cells. To extend these findings, in the present study cross-talk between Ca2+ signaling and cAMP pathways in human parotid acinar cells was investigated. In human parotid acinar cells, carbachol stimulation evoked increases in the [Ca2+](i) and the initial peak amplitude was enhanced following PKA activation, consistent with reports from mouse parotid. Stimulation with ATP also evoked an increase in [Ca2+](i). The ATP-evoked Ca2+ elevation was largely dependent on extracellular Ca2+, suggesting the involvement of the P2X family of purinergic receptors. Pharmacological elevation of cAMP resulted in a similar to5-fold increase in the peak [Ca2+](i) change evoked by ATP stimulation. This enhanced [Ca2+](i) increase was not dependent on intracellular release from InsP(3)R or ryanodine receptors, suggesting a direct effect on P2XR. Reverse transcription-polymerase chain reaction and Western blot analysis confirmed the presence of P2X(4)R and P2X(7)R mRNA and protein in human parotid acinar cells. ATP-activated cation currents were studied using whole cell patch clamp techniques in HEK-293 cells, a null background for P2XR. Raising cAMP resulted in a similar to4.5-fold enhancement of ATP-activated current in HEK-293 cells transfected with P2X(4)R DNA but had no effects on currents in cells expressing P2X(7)R. These data indicate that in human parotid acinar cells, in addition to modulation of Ca2+ release, Ca2+ influx through P2X(4)R may constitute a further locus for the synergistic effects of Ca2+ and PKA activation.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester	Yule, DI (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Physiol & Pharmacol, 601 Elmwood Ave, Rochester, NY 14642 USA.	David_Yule@urmc.rochester.edu			NIDCR NIH HHS [R01-DE14756, P01-DE13539, T32-DE-07202] Funding Source: Medline; NIDDK NIH HHS [R01-DK-54568] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013539, T32DE007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054568] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ambudkar IS, 2000, CRIT REV ORAL BIOL M, V11, P4, DOI 10.1177/10454411000110010301; Amstrup J, 2003, BIOCHEM J, V374, P51, DOI 10.1042/BJ20030585; Arcuino G, 2002, P NATL ACAD SCI USA, V99, P9840, DOI 10.1073/pnas.152588599; BALDYSWALIGORSKA A, 1987, BIOCHIM BIOPHYS ACTA, V929, P190, DOI 10.1016/0167-4889(87)90175-3; BAUM BJ, 1993, ANN NY ACAD SCI, V694, P17; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BOBYOCK E, 1989, J DENT RES, V68, P1489, DOI 10.1177/00220345890680110401; Bowler JW, 2003, BRIT J PHARMACOL, V140, P567, DOI 10.1038/sj.bjp.0705459; Brown DA, 2003, AM J PHYSIOL-GASTR L, V285, pG804, DOI 10.1152/ajpgi.00150.2003; Bruce JIE, 2003, CELL CALCIUM, V34, P431, DOI 10.1016/S0143-4160(03)00150-7; Bruce JIE, 2002, J BIOL CHEM, V277, P1340, DOI 10.1074/jbc.M106609200; DiJulio DH, 1997, J BIOL CHEM, V272, P15687, DOI 10.1074/jbc.272.25.15687; DOBROSIELSKIVER.K, 1993, BIOL SALIVARY GLANDS, P153; Evans RL, 1999, J BIOL CHEM, V274, P29025, DOI 10.1074/jbc.274.41.29025; GALLACHER DV, 1982, NATURE, V296, P83, DOI 10.1038/296083a0; GarciaGuzman M, 1997, MOL PHARMACOL, V51, P109, DOI 10.1124/mol.51.1.109; Giovannucci DR, 2002, J PHYSIOL-LONDON, V540, P469, DOI 10.1113/jphysiol.2001.013453; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; He ML, 2003, AM J PHYSIOL-CELL PH, V285, pC467, DOI 10.1152/ajpcell.00042.2003; Jiang LH, 2000, MOL PHARMACOL, V58, P82, DOI 10.1124/mol.58.1.82; Jiang LH, 2003, J NEUROSCI, V23, P8903; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Kopperud R, 2003, FEBS LETT, V546, P121, DOI 10.1016/S0014-5793(03)00563-5; LARSSON O, 1989, ACTA PHYSIOL SCAND, V137, P231, DOI 10.1111/j.1748-1716.1989.tb08743.x; Lee MG, 1997, J BIOL CHEM, V272, P32951, DOI 10.1074/jbc.272.52.32951; Li Q, 2003, J BIOL CHEM, V278, P47554, DOI 10.1074/jbc.M308306200; Luo X, 1999, AM J PHYSIOL-CELL PH, V277, pC205, DOI 10.1152/ajpcell.1999.277.2.C205; Marks AR, 2002, CIRCULATION, V105, P272, DOI 10.1161/circ.105.3.272; MCMILLIAN MK, 1988, BIOCHEM J, V255, P291; Melvin JE, 1999, CRIT REV ORAL BIOL M, V10, P199, DOI 10.1177/10454411990100020601; Muller CE, 2002, CURR PHARM DESIGN, V8, P2353, DOI 10.2174/1381612023392937; Nehrke K, 2003, AM J PHYSIOL-CELL PH, V284, pC535, DOI 10.1152/ajpcell.00044.2002; NGUYEN HV, 2003, AM J PHYSIOL, V286, pG312; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Novak I, 2002, CELL PHYSIOL BIOCHEM, V12, P83, DOI 10.1159/000063784; Park K, 2001, ARCH ORAL BIOL, V46, P801, DOI 10.1016/S0003-9969(01)00047-4; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Priel A, 2004, J GEN PHYSIOL, V123, P281, DOI 10.1085/jgp.200308986; PUTNEY JW, 1986, ANNU REV PHYSIOL, V48, P75, DOI 10.1146/annurev.ph.48.030186.000451; PUTNEY JW, 1976, J PHARMACOL EXP THER, V198, P375; SAWAKI K, 1993, ARCH BIOCHEM BIOPHYS, V305, P546, DOI 10.1006/abbi.1993.1459; Schwiebert EM, 2003, BBA-BIOMEMBRANES, V1615, P7, DOI 10.1016/S0005-2736(03)00210-4; SOLTOFF SP, 1990, J GEN PHYSIOL, V95, P319, DOI 10.1085/jgp.95.2.319; SOLTOFF SP, 1990, ANN NY ACAD SCI, V603, P76; Sorensen CE, 2001, J BIOL CHEM, V276, P32925, DOI 10.1074/jbc.M103313200; Straub SV, 2002, J BIOL CHEM, V277, P31949, DOI 10.1074/jbc.M204318200; Tanimura A, 1999, AM J PHYSIOL-CELL PH, V276, pC1282, DOI 10.1152/ajpcell.1999.276.6.C1282; Tenneti L, 1998, J BIOL CHEM, V273, P26799, DOI 10.1074/jbc.273.41.26799; TENNETI L, 1993, BIOCHEM J, V295, P255, DOI 10.1042/bj2950255; Turner JT, 1999, CRIT REV ORAL BIOL M, V10, P210, DOI 10.1177/10454411990100020701; Turner JT, 1998, ANN NY ACAD SCI, V842, P70, DOI 10.1111/j.1749-6632.1998.tb09633.x; Turner JT, 1998, EUR J MORPHOL, V36, P170; TURNER RJ, 1993, ANN NY ACAD SCI, V694, P24, DOI 10.1111/j.1749-6632.1993.tb18339.x; VOLKNANDT W, 1986, J NEUROCHEM, V47, P1449, DOI 10.1111/j.1471-4159.1986.tb00778.x; Worthington RA, 2002, FEBS LETT, V512, P43, DOI 10.1016/S0014-5793(01)03311-7; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246; Yoshimura K, 1998, BBA-MOL CELL RES, V1402, P171, DOI 10.1016/S0167-4889(98)00007-X; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7; Zhang XJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1306, DOI 10.1152/ajpcell.1997.273.4.C1306	59	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39485	39494		10.1074/jbc.M406201200	http://dx.doi.org/10.1074/jbc.M406201200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262999	hybrid			2022-12-27	WOS:000223791500038
J	Wong, CK; Luo, W; Deng, Y; Zou, HY; Ye, ZY; Lin, SC				Wong, CK; Luo, W; Deng, Y; Zou, HY; Ye, ZY; Lin, SC			The DIX domain protein coiled-coil-DIX1 inhibits c-Jun N-terminal kinase activation by axin and dishevelled through distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT-SIGNALING PATHWAY; BETA-CATENIN; NEGATIVE REGULATOR; JNK ACTIVATION; COMPLEX; POLARITY; DVL; GSK3-BETA; ABILITY; ENCODES	Axin, Ccd1 (coiled-coil-DIX1), and dishevelled (Dvl or Dsh) are three known DIX domain proteins that play important roles in Wnt signaling. In addition, Dvl and Axin can activate the mitogen-activated protein kinase JNK via distinct mechanisms, through interaction with MEKK1/4 and Rac GTPase, respectively. Axin utilizes two distinct domains for interaction with MEKK1 and MEKK4. JNK activation by Axin is regulated by several factors in the Wnt pathway, whereas little is known about cross-regulation of Dvl-mediated JNK activation. In the present study, we have investigated whether Ccd1 could play a regulatory role in Axin- and Dvl-mediated JNK activation. Here we show that Ccd1 drastically inhibited JNK activation both by Axin and by Dvl. Although DIX domains are sufficient for dimer formation between Dvl and Ccd1, Ccd1 also required its coiled-coil domain for inhibition of JNK activation by Dvl. Interestingly, Rac remained associated with Dvl heterodimerized with Ccd1. How Ccd1 blocks Rac/Dvl signaling to JNK is unclear. In contrast, Axin, when complexed with Ccd1, did not bind to MEKK1. Furthermore, Ccd1 physically interacted with MEKK4 in their physiological concentrations and prevented MEKK4 from binding to Axin. Reduction of Ccd1 protein by small interfering RNA could elevate JNK signaling as assayed with an AP1-dependent transcriptional reporter. We have therefore demonstrated that Ccd1 inhibits Axin- mediated JNK activation by simultaneously adopting two distinct mechanisms, one through conformational changes that disallow MEKK1 binding and the other via direct sequestration of MEKK4.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Xiamen Univ, Sch Life Sci, State Key Lab Cell Biol & Tumor Cell Engn, Xiamen 361005, Fujian, Peoples R China	Hong Kong University of Science & Technology; Xiamen University	Lin, SC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.	linsc@ust.hk	Lin, SC/G-4666-2010					Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Capelluto DGS, 2002, NATURE, V419, P726, DOI 10.1038/nature01056; Ciani L, 2004, J CELL BIOL, V164, P243, DOI 10.1083/jcb.200309096; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; LIN SC, 1991, J BIOL CHEM, V266, P23347; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Luo W, 2003, J BIOL CHEM, V278, P37451, DOI 10.1074/jbc.M305277200; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; Polakis P, 2000, GENE DEV, V14, P1837; Rui HL, 2002, J BIOL CHEM, V277, P42981, DOI 10.1074/jbc.M208099200; Shiomi K, 2003, CURR BIOL, V13, P73, DOI 10.1016/S0960-9822(02)01398-2; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2002, J BIOL CHEM, V277, P17706, DOI 10.1074/jbc.M111982200; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	30	35	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39366	39373		10.1074/jbc.M404598200	http://dx.doi.org/10.1074/jbc.M404598200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262978	Green Published, hybrid			2022-12-27	WOS:000223791500022
J	Santos-Rosa, H; Bannister, AJ; Dehe, PM; Geli, V; Kouzarides, T				Santos-Rosa, H; Bannister, AJ; Dehe, PM; Geli, V; Kouzarides, T			Methylation of H3 lysine 4 at euchromatin promotes Sir3p association with heterochromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HISTONE H3; TELOMERIC HETEROCHROMATIN; MOLECULAR-MODEL; GENE-EXPRESSION; YEAST; SET1; ACETYLATION; ACETYLTRANSFERASE; CHROMATIN	Set1p methylates lysine 4 of histone H3 and can activate transcription by recruiting the chromatin-remodeling factor Isw1p. In addition, Lys-4-methylated H3 is required for maintenance of silencing at the telomeres, rDNA, and HML locus in Saccharomyces cerevisiae. The molecular mechanism underlying the role of Set1p in silencing is not known. Here we report that euchromatic methylation of H3 Lys-4 is necessary to maintain silencing at specific heterochromatic sites. Inactivation of Set1p catalytic activity or mutation of H3 Lys-4 leads to decreased binding of the silent information regulator Sir3p at heterochromatic sites. Concomitantly, there is an increase in the amount of Sir3p bound to genes located in subtelomeric regions. Consistent with this result is the finding that in vitro, Sir3p preferentially binds histone H3 tails when methylation is absent at H3 Lys-4, a situation found in heterochromatin. The inability of Sir3p to bind methylated H3 Lys-4 tails suggests a model whereby H3 Lys-4 methylation prevents Sir3p association at euchromatic sites and therefore concentrates Sir3p at unmodified, heterochromatic regions of the genome.	Wellcome Trust Canc Res United Kingdom Gurdon Ins, Cambridge CB2 1QR, England; Dept Pathol, Cambridge CB2 1QR, England; CNRS, Lab Ingn Syst Macromol, F-13402 Marseille 20, France; CNRS, Inst Biol Struct & Microbiol, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS)	Santos-Rosa, H (corresponding author), Wellcome Trust Canc Res United Kingdom Gurdon Ins, Tennis Court Rd, Cambridge CB2 1QR, England.	H.Santos-Rosa@gurdon.cam.ac.uk; T.Kouzarides@gurdon.cam.ac.uk	Dehe, Pierre-Marie/D-4135-2017	Dehe, Pierre-Marie/0000-0003-1558-6983; Kouzarides, Tony/0000-0002-8918-4162; Bannister, Andrew/0000-0002-6312-4436				Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Jackson DA, 2003, CHROMOSOME RES, V11, P387, DOI 10.1023/A:1024954123092; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Kristjuhan A, 2003, P NATL ACAD SCI USA, V100, P7551, DOI 10.1073/pnas.1332299100; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Labrador M, 2002, CELL, V111, P151, DOI 10.1016/S0092-8674(02)01004-8; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Morillon A, 2003, SCIENCE, V300, P492, DOI 10.1126/science.1081379; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ng HH, 2003, J BIOL CHEM, V278, P33625, DOI 10.1074/jbc.C300270200; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Rusche LN, 2003, ANNU REV BIOCHEM, V72, P481, DOI 10.1146/annurev.biochem.72.121801.161547; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Xu EY, 1999, GENETICS, V153, P25; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	29	96	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47506	47512		10.1074/jbc.M407949200	http://dx.doi.org/10.1074/jbc.M407949200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15280381	hybrid			2022-12-27	WOS:000224957000013
J	Cava, F; Zafra, O; Magalon, A; Blasco, F; Berenguer, J				Cava, F; Zafra, O; Magalon, A; Blasco, F; Berenguer, J			A new type of NADH dehydrogenase specific for nitrate respiration in the extreme thermophile Thermus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-LAYER GENE; ESCHERICHIA-COLI; ANAEROBIC GROWTH; REDUCTASE; SEQUENCE; BACTERIA; HB8; EXPRESSION; OXIDOREDUCTASES; TRANSFORMATION	A four-gene operon (nrcDEFN) was identified within a conjugative element that allows Thermus thermophilus to use nitrate as an electron acceptor. Three of them encode homologues to components of bacterial respiratory chains: NrcD to ferredoxins; NrcF to iron-sulfur-containing subunits of succinate-quinone oxidoreductase (SQR); and NrcN to type-II NADH dehydrogenases (NDHs). The fourth gene, nrcE, encodes a membrane protein with no homologues in the protein data bank. Nitrate reduction with NADH was catalyzed by membrane fractions of the wild type strain, but was severely impaired in nrc::kat insertion mutants. A fusion to a thermophilic reporter gene was used for the first time in Thermus spp. to show that expression of nrc required the presence of nitrate and anoxic conditions. Therefore, a role for the nrc products as a new type of membrane NDH specific for nitrate respiration was deduced. Consistent with this, nrc:: kat mutants grew more slowly than the wild type strain under anaerobic conditions, but not in the presence of oxygen. The oligomeric structure of this Nrc-NDH was deduced from the analysis of insertion mutants and a two-hybrid bacterial system. Attachment to the membrane of NrcD, NrcF, and NrcN was dependent on NrcE, whose cytoplasmic C terminus interacts with the three proteins. Interactions were also detected between NrcN and NrcF. Inactivation of nrcF produced solubilization of NrcN, but not of NrcD. These data lead us to conclude that the Nrc proteins form a distinct third type of bacterial respiratory NDH.	Univ Autonoma Madrid, Consejo Super Invest Cient, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, F-13402 Marseille 09, France	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Centre National de la Recherche Scientifique (CNRS)	Berenguer, J (corresponding author), Univ Autonoma Madrid, Consejo Super Invest Cient, Ctr Biol Mol Severo Ochoa, Campus Cantoblanco, E-28049 Madrid, Spain.	jberenguer@cbm.uam.es	Berenguer, Jose/R-2507-2019; Zafra, Olga/K-8110-2014; Cava, Felipe/L-2082-2017	Berenguer, Jose/0000-0002-9689-6272; Zafra, Olga/0000-0002-2379-3184; Cava, Felipe/0000-0001-5995-718X; Magalon, Axel/0000-0002-3375-738X				ARAI H, 1995, FEBS LETT, V360, P151; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; Brock T.D., 1978, THERMOPHILIC MICROOR, P72; Cava F, 2004, MOL MICROBIOL, V52, P677, DOI 10.1111/j.1365-2958.2004.04011.x; Cecchini G, 2003, FEBS LETT, V545, P31, DOI 10.1016/S0014-5793(03)00390-9; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; de Grado M, 1999, PLASMID, V42, P241, DOI 10.1006/plas.1999.1427; FARALDO MM, 1992, J BACTERIOL, V174, P7458, DOI 10.1128/jb.174.22.7458-7462.1992; FEE JA, 1986, BIOCHIM BIOPHYS ACTA, V853, P153, DOI 10.1016/0304-4173(86)90009-1; FERNANDEZHERRERO LA, 1995, MOL MICROBIOL, V17, P1, DOI 10.1111/j.1365-2958.1995.mmi_17010001.x; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; GENNIS RB, 1996, ESCHERICHIA COLI SAL, V1, P217; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Henne A, 2004, NAT BIOTECHNOL, V22, P547, DOI 10.1038/nbt956; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; Kerscher SJ, 2000, BBA-BIOENERGETICS, V1459, P274, DOI 10.1016/S0005-2728(00)00162-6; Korner H, 2003, FEMS MICROBIOL REV, V27, P559, DOI 10.1016/S0168-6445(03)00066-4; KOYAMA Y, 1990, APPL ENVIRON MICROB, V56, P2251, DOI 10.1128/AEM.56.7.2251-2254.1990; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LASA I, 1992, MOL MICROBIOL, V11, P1555; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; Macedo-Ribeiro S, 2001, J BIOL INORG CHEM, V6, P663, DOI 10.1007/s007750100243; Moreno R, 2003, PLASMID, V49, P2, DOI 10.1016/S0147-619X(02)00146-4; Perales C, 2003, NUCLEIC ACIDS RES, V31, P6473, DOI 10.1093/nar/gkg865; Poole RK, 2000, ADV MICROB PHYSIOL, V43, P165, DOI 10.1016/S0065-2911(00)43005-5; Ramirez S, 2000, J BACTERIOL, V182, P2179, DOI 10.1128/JB.182.8.2179-2183.2000; Ramirez-Arcos S, 1998, BBA-GENE STRUCT EXPR, V1396, P215, DOI 10.1016/S0167-4781(97)00183-8; Ramirez-Arcos S, 1998, J BACTERIOL, V180, P3137; Richardson DJ, 2000, MICROBIOL-SGM, V146, P551, DOI 10.1099/00221287-146-3-551; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Snell FD, 1949, COLORIMETRIC METHODS; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Unden G, 1997, BBA-BIOENERGETICS, V1320, P217, DOI 10.1016/S0005-2728(97)00034-0; VIERA J, 1987, METHOD ENZYMOL, V153, P3; Yano T, 1997, J BIOL CHEM, V272, P4201, DOI 10.1074/jbc.272.7.4201; Zafra O, 2002, FEBS LETT, V523, P99, DOI 10.1016/S0014-5793(02)02953-8	37	28	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45369	45378		10.1074/jbc.M404785200	http://dx.doi.org/10.1074/jbc.M404785200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15292214	hybrid			2022-12-27	WOS:000224694900012
J	Corton, JC; Apte, U; Anderson, SP; Limaye, P; Yoon, L; Latendresse, J; Dunn, C; Everitt, JI; Voss, KA; Swanson, C; Kimbrough, C; Wong, JS; Gill, SS; Chandraratna, RAS; Kwak, MK; Kensler, TW; Stulnig, TM; Steffensen, KR; Gustafsson, JA; Mehendale, HM				Corton, JC; Apte, U; Anderson, SP; Limaye, P; Yoon, L; Latendresse, J; Dunn, C; Everitt, JI; Voss, KA; Swanson, C; Kimbrough, C; Wong, JS; Gill, SS; Chandraratna, RAS; Kwak, MK; Kensler, TW; Stulnig, TM; Steffensen, KR; Gustafsson, JA; Mehendale, HM			Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-NULL MICE; PEROXISOME-PROLIFERATOR; GENE-EXPRESSION; ACETAMINOPHEN HEPATOTOXICITY; TISSUE-REPAIR; DIABETIC MICE; MOUSE-LIVER; PPAR-ALPHA; FATTY-ACID; DISEASE	The obesity epidemic in industrialized countries is associated with increases in cardiovascular disease (CVD) and certain types of cancer. In animal models, caloric restriction (CR) suppresses these diseases as well as chemical-induced tissue damage. These beneficial effects of CR overlap with those altered by agonists of nuclear receptors (NR) under control of the fasting-responsive transcriptional co-activator, peroxisome proliferator-activated co-activator 1alpha (PGC-1alpha). In a screen for compounds that mimic CR effects in the liver, we found statistically significant overlaps between the CR transcript profile in wild-type mice and the profiles altered by agonists of lipid-activated NR, including peroxisome proliferator-activated receptor alpha (PPARalpha), liver X receptor, and their obligate heterodimer partner, retinoid X receptor. The overlapping genes included those involved in CVD (lipid metabolism and inflammation) and cancer (cell fate). Based on this overlap, we hypothesized that some effects of CR are mediated by PPARalpha. As determined by transcript profiling, 19% of all gene expression changes in wild-type mice were dependent on PPARalpha, including Cyp4a10 and Cyp4a14, involved in fatty acid omega-oxidation, acute phase response genes, and epidermal growth factor receptor but not increases in PGC-1alpha. CR protected the livers of wild-type mice from damage induced by thioacetamide, a liver toxicant and hepatocarcinogen. CR protection was lost in PPARalpha-null mice due to inadequate tissue repair. These results demonstrate that PPARalpha mediates some of the effects of CR and indicate that a pharmacological approach to mimicking many of the beneficial effects of CR may be possible.	ToxicoGenomics, Chapel Hill, NC 27514 USA; NE Louisiana Univ, Coll Pharm, Dept Toxicol, Monroe, LA 71209 USA; GlaxoSmithKline, Res & Dev, Dept Safety Assessment, Res Triangle Pk, NC 27709 USA; Natl Ctr Toxicol Res, Pathol Associates Int, Jefferson, AR 72079 USA; CIIT Ctr Hlth Res, Res Triangle Pk, NC 27709 USA; ARS, Toxicol & Mycotoxin Res Unit, USDA, Athens, GA 30604 USA; Univ Calif Riverside, Dept Cell Biol & Neurosci, Environm Toxicol Grad Program, Riverside, CA 92521 USA; Allergan Pharmaceut Inc, Dept Biol & Chem, Irvine, CA 92612 USA; Allergan Pharmaceut Inc, Dept Reginoid Res, Irvine, CA 92612 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Karolinska Inst, Novum, Dept Biosci, S-14186 Huddinge, Sweden; Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden	University of Louisiana System; University of Louisiana Monroe; GlaxoSmithKline; US Food & Drug Administration (FDA); United States Department of Agriculture (USDA); University of California System; University of California Riverside; AbbVie; Allergan; AbbVie; Allergan; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Karolinska Institutet; Karolinska Institutet	Corton, JC (corresponding author), ToxicoGenomics, 209 Silver Creek Tr, Chapel Hill, NC 27514 USA.	ccorton@msn.com; mehendale@ulm.edu	Kensler, Thomas W/D-8686-2014	Kensler, Thomas W/0000-0002-6676-261X; Steffensen, Knut/0000-0001-6093-2801; Everitt, Jeffrey/0000-0003-0273-6284; Stulnig, Thomas/0000-0003-3300-6161	NIEHS NIH HHS [ES-09870] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009870] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967; Aghi M, 1999, J NATL CANCER I, V91, P1233, DOI 10.1093/jnci/91.14.1233; Anderson SP, 2002, HEPATOLOGY, V36, P544, DOI 10.1053/jhep.2002.35276; Apte UM, 2003, TOXICOL SCI, V72, P272, DOI 10.1093/toxsci/kfg021; Baldi A, 2003, EXP DERMATOL, V12, P213, DOI 10.1034/j.1600-0625.2003.00026.x; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; BARTLES JR, 1990, CANCER RES, V50, P669; Bauer M, 2004, PHYSIOL GENOMICS, V17, P230, DOI 10.1152/physiolgenomics.00203.2003; Bernard DJ, 2001, RECENT PROG HORM RES, V56, P417, DOI 10.1210/rp.56.1.417; Bugni JM, 2001, CARCINOGENESIS, V22, P1853, DOI 10.1093/carcin/22.11.1853; Chen C, 2000, TOXICOL SCI, V57, P338, DOI 10.1093/toxsci/57.2.338; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; Dhahbi JM, 2004, P NATL ACAD SCI USA, V101, P5524, DOI 10.1073/pnas.0305300101; Dhawan P, 2002, J LEUKOCYTE BIOL, V72, P9; Edwards PA, 2002, VASC PHARMACOL, V38, P249, DOI 10.1016/S1537-1891(02)00175-1; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El-Rifai W, 2002, CANCER RES, V62, P6823; FAN LQ, 1908, BIOCHEM PHARMACOL, V65, P949; Forster MJ, 2003, FASEB J, V17, P690, DOI 10.1096/fj.02-0533fje; Frame LT, 1998, ENVIRON HEALTH PERSP, V106, P313; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREENWELL A, 1991, CANCER LETT, V59, P251, DOI 10.1016/0304-3835(91)90149-C; Guan JZ, 2003, TOHOKU J EXP MED, V201, P251, DOI 10.1620/tjem.201.251; Hart RW, 1997, ENVIRON HEALTH PERSP, V105, P989, DOI 10.2307/3433316; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Higashitsuji H, 2002, CANCER CELL, V2, P335, DOI 10.1016/S1535-6108(02)00152-6; James WPT, 1998, EXP CLIN ENDOCR DIAB, V106, P1; Kari C, 2003, CANCER RES, V63, P1; Keenan KP, 1998, J TOXICOL ENV HEAL B, V1, P135, DOI 10.1080/10937409809524548; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kirkland JL, 2002, CLIN GERIATR MED, V18, P383, DOI 10.1016/S0749-0690(02)00023-X; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Maglich JM, 2004, J BIOL CHEM, V279, P19832, DOI 10.1074/jbc.M313601200; McCarroll SA, 2004, NAT GENET, V36, P197, DOI 10.1038/ng1291; Mehendale HM, 2000, TOXICOL SCI, V57, P187, DOI 10.1093/toxsci/57.2.187; Miller RA, 2002, MOL ENDOCRINOL, V16, P2657, DOI 10.1210/me.2002-0142; Miller RT, 2001, TOXICOL PATHOL, V29, P149, DOI 10.1080/019262301301418964; Murakami S, 2003, FASEB J, V17, P1565, DOI 10.1096/fj.02-1092fje; Nakamura Y, 2000, LEUKEMIA LYMPHOMA, V38, P505, DOI 10.3109/10428190009059269; Oberkofler H, 2003, BIOCHEM J, V371, P89, DOI 10.1042/BJ20021665; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Ramaiah SK, 1998, TOXICOL SCI, V45, P233, DOI 10.1006/toxs.1998.2511; Shankar K, 2003, FASEB J, V17, P1748, DOI 10.1096/fj.02-1186fje; Shankar K, 2003, TOXICOL SCI, V73, P220, DOI 10.1093/toxsci/kfg059; Shankar K, 2003, TOXICOL APPL PHARM, V188, P122, DOI 10.1016/S0041-008X(02)00037-6; Shin DJ, 2003, J BIOL CHEM, V278, P50047, DOI 10.1074/jbc.M309736200; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Standeven AM, 1997, BIOCHEM PHARMACOL, V54, P517, DOI 10.1016/S0006-2952(97)00209-8; Stulnig TM, 2002, MOL PHARMACOL, V62, P1299, DOI 10.1124/mol.62.6.1299; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Tobin KAR, 2000, MOL ENDOCRINOL, V14, P741, DOI 10.1210/me.14.5.741; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Torra IP, 2001, CURR OPIN LIPIDOL, V12, P245, DOI 10.1097/00041433-200106000-00002; Tsuchiya T, 2004, PHYSIOL GENOMICS, V17, P307, DOI 10.1152/physiolgenomics.00039.2004; Weindruch R, 2001, J GERONTOL A-BIOL, V56, P20, DOI 10.1093/gerona/56.suppl_1.20; Weindruch R, 2002, MECH AGEING DEV, V123, P177, DOI 10.1016/S0047-6374(01)00344-X; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; WEINDRUCH R, 1988, RETARDATION AGING DI, P73; Wong JS, 2002, TOXICOL APPL PHARM, V185, P180, DOI 10.1006/taap.2002.9540; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3; Zhang LB, 2004, J BIOL CHEM, V279, P2053, DOI 10.1074/jbc.M310357200	65	91	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46204	46212		10.1074/jbc.M406739200	http://dx.doi.org/10.1074/jbc.M406739200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15302862	hybrid			2022-12-27	WOS:000224694900107
J	Mishra, SK; Hawryluk, MJ; Brett, TJ; Keyel, PA; Dupin, AL; Jha, A; Heuser, JE; Fremont, DH; Traub, LM				Mishra, SK; Hawryluk, MJ; Brett, TJ; Keyel, PA; Dupin, AL; Jha, A; Heuser, JE; Fremont, DH; Traub, LM			Dual engagement regulation of protein interactions with the AP-2 adaptor alpha appendage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; GAMMA-ADAPTIN; COATED VESICLES; STRUCTURAL BASIS; NERVE-TERMINALS; AP2 COMPLEX; EAR DOMAIN; BINDING; PHOSPHORYLATION; RECRUITMENT	Clathrin-mediated endocytosis depends upon the coordinated assembly of a large number of discrete clathrin coat components to couple cargo selection with rapid internalization from the cell surface. Accordingly, the heterotetrameric AP-2 adaptor complex binds not only to clathrin and select cargo molecules, but also to an extensive family of endocytic accessory factors and alternate sorting adaptors. Physical associations between accessory proteins and AP-2 occur primarily through DP(F/W) or FXDXF motifs, which engage an interaction surface positioned on the C-terminal platform subdomain of the independently folded alpha subunit appendage. Here, we find that the WXX(F/W)X(D/E) interaction motif found in several endocytic proteins, including synaptojanin 1, stonin 2, AAK1, GAK, and NECAP1, binds a second interaction site on the bilobal alpha appendage, located on the N-terminal beta sandwich subdomain. Both alpha appendage binding sites can be engaged synchronously, and our data reveal that varied assemblies of interaction motifs with different affinities for two sites upon the alpha appendage can provide a mechanism for temporal ordering of endocytic accessory proteins during clathrin-mediated endocytosis.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Traub, LM (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, 3500 Terrace St,S325BST, Pittsburgh, PA 15261 USA.	traub@pitt.edu	Brett, Thomas/AAC-9147-2019; Mishra, Santosh/S-7516-2017; Heuser, John/H-5940-2012	Brett, Thomas/0000-0002-6871-6676; Mishra, Santosh/0000-0001-8616-2606; Fremont, Daved/0000-0002-8544-2689; Traub, Linton/0000-0002-1303-0298	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK061296, R01DK053249] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK53249, 5T32 DK061296-02] Funding Source: Medline; NIGMS NIH HHS [GM62414] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai HD, 2004, J BIOL CHEM, V279, P17411, DOI 10.1074/jbc.M401158200; Blondeau F, 2004, P NATL ACAD SCI USA, V101, P3833, DOI 10.1073/pnas.0308186101; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Chen H, 1999, J BIOL CHEM, V274, P3257, DOI 10.1074/jbc.274.6.3257; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; Collins BM, 2003, NAT STRUCT BIOL, V10, P607, DOI 10.1038/nsb955; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Conner SD, 2003, J CELL BIOL, V162, P773, DOI 10.1083/jcb.200304069; Conner SD, 2003, TRAFFIC, V4, P885, DOI 10.1046/j.1398-9219.2003.0142.x; Conner SD, 2002, J CELL BIOL, V156, P921, DOI 10.1083/jcb.200108123; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cousin MA, 2001, TRENDS NEUROSCI, V24, P659, DOI 10.1016/S0166-2236(00)01930-5; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; Haffner C, 2000, CURR BIOL, V10, P471, DOI 10.1016/S0960-9822(00)00446-2; Heuser J, 2000, TRAFFIC, V1, P545, DOI 10.1034/j.1600-0854.2000.010704.x; Jackson AP, 2003, J CELL BIOL, V163, P231, DOI 10.1083/jcb.200304079; Jha A, 2004, J BIOL CHEM, V279, P2281, DOI 10.1074/jbc.M305644200; Kent HM, 2002, STRUCTURE, V10, P1139, DOI 10.1016/S0969-2126(02)00801-8; Korolchuk VI, 2002, TRAFFIC, V3, P428, DOI 10.1034/j.1600-0854.2002.30606.x; Lafer EM, 2002, TRAFFIC, V3, P513, DOI 10.1034/j.1600-0854.2002.30801.x; Lee SY, 2004, P NATL ACAD SCI USA, V101, P546, DOI 10.1073/pnas.0307813100; Lui WWY, 2003, MOL BIOL CELL, V14, P2385, DOI 10.1091/mbc.e02-11-0735; Martina JA, 2001, J CELL BIOL, V153, P1111, DOI 10.1083/jcb.153.5.1111; Mattera R, 2004, J BIOL CHEM, V279, P8018, DOI 10.1074/jbc.M311873200; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Miller GJ, 2003, NAT STRUCT BIOL, V10, P599, DOI 10.1038/nsb953; Mills IG, 2003, J CELL BIOL, V160, P213, DOI 10.1083/jcb.200208023; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Nogi T, 2002, NAT STRUCT BIOL, V9, P527, DOI 10.1038/nsb808; Olusanya O, 2001, CURR BIOL, V11, P896, DOI 10.1016/S0960-9822(01)00240-8; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Ricotta D, 2002, J CELL BIOL, V156, P791, DOI 10.1083/jcb.200111068; Ritter B, 2003, EMBO REP, V4, P1089, DOI 10.1038/sj.embor.7400004; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Smythe E, 2003, EMBO REP, V4, P246, DOI 10.1038/sj.embor.embor776; Stang E, 2004, MOL BIOL CELL, V15, P3591, DOI 10.1091/mbc.E04-01-0041; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Traub LM, 2003, J CELL BIOL, V163, P203, DOI 10.1083/jcb.200309175; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Umeda A, 2000, EUR J CELL BIOL, V79, P336, DOI 10.1078/S0171-9335(04)70037-0; Walther K, 2004, P NATL ACAD SCI USA, V101, P964, DOI 10.1073/pnas.0307862100; Walther K, 2001, EMBO REP, V2, P634, DOI 10.1093/embo-reports/kve134; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; Wendland B, 2002, NAT REV MOL CELL BIO, V3, P971, DOI 10.1038/nrm970; Wenk MR, 2004, P NATL ACAD SCI USA, V101, P8262, DOI 10.1073/pnas.0401874101	54	62	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46191	46203		10.1074/jbc.M408095200	http://dx.doi.org/10.1074/jbc.M408095200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15292237	hybrid			2022-12-27	WOS:000224694900106
J	Rohde, CM; Schrum, J; Lee, AWM				Rohde, CM; Schrum, J; Lee, AWM			A juxtamembrane tyrosine in the colony stimulating factor-1 receptor regulates ligand-induced Src association, receptor kinase function, and down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; SIGNAL-TRANSDUCTION PATHWAYS; FACTOR-BETA-RECEPTOR; WW-LIKE DOMAIN; M-CSF RECEPTOR; C-CBL; STRUCTURAL BASIS; FAMILY KINASES; BINDING-SITE; V-FMS	Recent literature implicates a regulatory function of the juxtamembrane domain (JMD) in receptor tyrosine kinases. Mutations in the JMD of c-Kit and Flt3 are associated with gastrointestinal stromal tumors and acute myeloid leukemias, respectively. Additionally, autophosphorylated Tyr(559) in the JMD of the colony stimulating factor-1 (CSF-1) receptor (CSF-1R) binds to Src family kinases (SFKs). To investigate SFK function in CSF-1 signaling we established stable 32D myeloid cell lines expressing CSF-1Rs with mutated SFK binding sites (Tyr(559)-TFI). Whereas binding to I562S was not significantly perturbed, Y559F and Y559D exhibited markedly decreased CSF-1-dependent SFK association. All JMD mutants retained intrinsic kinase activity, but Y559F, and less so Y559D, showed dramatically reduced CSF-1-induced autophosphorylation. CSF-1-mediated wild-type (WT)-CSF-1R phosphorylation was not markedly affected by SFK inhibition, indicating that lack of SFK binding is not responsible for diminished Y559F phosphorylation. Unexpectedly, cells expressing Y559F were hyperproliferative in response to CSF-1. Hyperproliferation correlated with prolonged activation of Akt, ERK, and Stat5 in the Y559F mutant. Consistent with a defect in receptor negative regulation, c-Cbl tyrosine phosphorylation and CSF-1R/c-Cbl co-association were almost undetectable in the Y559F mutant. Furthermore, Y559F underwent reduced multiubiquitination and delayed receptor internalization and degradation. In conclusion, we propose that Tyr559 is a switch residue that functions in kinase regulation, signal transduction and, indirectly, receptor down-regulation. These findings may have implications for the oncogenic conversion of c-Kit and Flt3 with JMD mutations.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Lee, AWM (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA.	awmlee@umich.edu			NCI NIH HHS [R01-CA85368] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085368] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Baran CP, 2003, J BIOL CHEM, V278, P38628, DOI 10.1074/jbc.M305021200; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Binns KL, 2000, MOL CELL BIOL, V20, P4791, DOI 10.1128/MCB.20.13.4791-4805.2000; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bondzi C, 2000, CELL GROWTH DIFFER, V11, P305; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Chang PM, 2003, MOL CELL BIOL, V23, P3067, DOI 10.1128/MCB.23.9.3067-3078.2003; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Courtneidge SA, 2002, BIOCHEM SOC T, V30, P11, DOI 10.1042/bst0300011; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Davis JN, 1997, MOL CELL BIOL, V17, P7398, DOI 10.1128/MCB.17.12.7398; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; DeMali KA, 1999, EXP CELL RES, V253, P271, DOI 10.1006/excr.1999.4669; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Duffaud F, 2003, ONCOLOGY-BASEL, V65, P187, DOI 10.1159/000074470; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; Herbst R, 2000, EMBO J, V19, P67, DOI 10.1038/sj.emboj.7592228b; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; Irusta PM, 2002, J BIOL CHEM, V277, P38627, DOI 10.1074/jbc.M204890200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Joos H, 1996, J BIOL CHEM, V271, P24476, DOI 10.1074/jbc.271.40.24476; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lee AW, 1999, BLOOD, V93, P537, DOI 10.1182/blood.V93.2.537.402k30_537_553; LEE AW, 1992, J BIOL CHEM, V267, P16472; Lee AWM, 2000, MOL CELL BIOL, V20, P6779, DOI 10.1128/MCB.20.18.6779-6798.2000; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Marks D C, 1999, Mol Cell Biol Res Commun, V1, P144, DOI 10.1006/mcbr.1999.0123; Mol CD, 2003, J BIOL CHEM, V278, P31461, DOI 10.1074/jbc.C300186200; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; Novak U, 1996, ONCOGENE, V13, P2607; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Ota J, 2000, FEBS LETT, V466, P96, DOI 10.1016/S0014-5793(99)01767-6; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; Rohrschneider LR, 1997, MOL REPROD DEV, V46, P96; Rosenkranz S, 2000, J BIOL CHEM, V275, P9620, DOI 10.1074/jbc.275.13.9620; Scheijen B, 2002, ONCOGENE, V21, P3314, DOI 10.1038/sj.onc.1205317; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Till JH, 2002, STRUCTURE, V10, P1187, DOI 10.1016/S0969-2126(02)00814-6; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	79	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43448	43461		10.1074/jbc.M314170200	http://dx.doi.org/10.1074/jbc.M314170200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15297464	hybrid			2022-12-27	WOS:000224383100014
J	Chen, S; Unterbrink, A; Kadapakkam, S; Dong, JA; Gu, TT; Dickson, J; Chuang, HH; MacDougall, M				Chen, S; Unterbrink, A; Kadapakkam, S; Dong, JA; Gu, TT; Dickson, J; Chuang, HH; MacDougall, M			Regulation of the cell type-specific dentin sialophosphoprotein gene expression in mouse odontoblasts by a novel transcription repressor and an activator CCAAT-binding factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; RNA POLYMERASE-II; NUCLEAR FACTOR Y; DNA-BINDING; NF-Y; SEQUENCE DETERMINATION; COOPERATIVE BINDING; SIALOPROTEIN GENE; C-MYC/MAX; CBF/NF-Y	Dentin sialophosphoprotein (DSPP) is an extracellular matrix protein that is cleaved into dentin sialoprotein (DSP) and dentin phosphoprotein (DPP) with a highly restricted expression pattern in tooth and bone. Mutations of the DSPP gene are associated with dentin genetic diseases. Regulation of tissue-specific DSPP expression has not been described. To define the molecular basis of this cell-specific expression, we characterized the promoter responsible for the cell-specific expression of the DSPP gene in odontoblasts. Within this region, DNase I footprinting and electrophoretic mobility shift assays delineated one element that contains an inverted CCAAT-binding factor site and a protein-DNA binding site using nuclear extracts from odontoblasts. A series of competitive electrophoretic mobility shift assay analyses showed that the protein-DNA binding core sequence, ACCCCCA, is a novel site sufficient for protein binding. These two protein-DNA binding sequences are conserved at the same proximal position in the mouse, rat, and human DSPP gene promoters and are ubiquitously present in the promoters of other tooth/bone genes. Mutations of the CCAAT-binding factor binding site resulted in a 5-fold decrease in promoter activity, whereas abolishment of the novel protein-DNA binding site increased promoter activity by about 4.6-fold. In contrast to DSPP, expression levels of the novel protein were significantly reduced during odontoblastic differentiation and dentin mineralization. The novel protein was shown to have a molecular mass of 72 kDa. This study shows that expression of the cell type-specific DSPP gene is mediated by the combination of inhibitory and activating mechanisms.	Univ Texas, Hlth Sci Ctr, Dept Pediat Dent, Sch Dent, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	MacDougall, M (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat Dent, Sch Dent, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	MacDougall@uthscsa.edu	MacDougall, Mary/ABG-8212-2021		NIDCR NIH HHS [P01 DE113221, R03 DE014484] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE014484] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bleicher F, 1999, MATRIX BIOL, V18, P133, DOI 10.1016/S0945-053X(99)00007-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Butler WT, 1998, EUR J ORAL SCI, V106, P204, DOI 10.1111/j.1600-0722.1998.tb02177.x; Chen S, 1997, MOL ENDOCRINOL, V11, P3, DOI 10.1210/me.11.1.3; D'Souza RN, 1999, DEVELOPMENT, V126, P2911; DENT CL, 1991, MOL CELL BIOL, V11, P3925, DOI 10.1128/MCB.11.8.3925; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong J, 2002, J DENT RES, V81, pA475; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457; FENG JQ, 1998, AM ACAD ORTHOP SURG, P155; George A, 1996, J BIOL CHEM, V271, P32869, DOI 10.1074/jbc.271.51.32869; Gu K, 2000, EUR J ORAL SCI, V108, P35, DOI 10.1034/j.1600-0722.2000.00765.x; Hut QH, 2002, J BIOL CHEM, V277, P37191, DOI 10.1074/jbc.M205985200; Imbriano C, 2001, J BIOL CHEM, V276, P26332, DOI 10.1074/jbc.M101553200; Jackson SM, 1998, J LIPID RES, V39, P767; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Kim RH, 1999, CANCER RES, V59, P565; Li X, 2002, SCIENCE, V297, P1180; Liang SG, 1998, J BIOL CHEM, V273, P31590, DOI 10.1074/jbc.273.47.31590; Linde Anders, 1993, Critical Reviews in Oral Biology and Medicine, V4, P679; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MacDougall M, 1995, Connect Tissue Res, V33, P97, DOI 10.3109/03008209509016988; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Maxam A M, 1980, Methods Enzymol, V65, P499; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Qin CL, 2003, CONNECT TISSUE RES, V44, P179, DOI 10.1080/03008200390152296; Qin CL, 2001, J BIOL CHEM, V276, P904, DOI 10.1074/jbc.M006271200; Radomska HS, 1999, BLOOD, V94, P3772, DOI 10.1182/blood.V94.11.3772.423k19_3772_3780; Rajpar MH, 2002, HUM MOL GENET, V11, P2559, DOI 10.1093/hmg/11.21.2559; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; RIDALL AL, 1995, ANN NY ACAD SCI, V760, P59, DOI 10.1111/j.1749-6632.1995.tb44620.x; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; Ritchie HH, 2002, CONNECT TISSUE RES, V43, P331, DOI 10.1080/03008200290001041; Ritchie HH, 1997, EUR J ORAL SCI, V105, P405, DOI 10.1111/j.1600-0722.1997.tb02137.x; Sambrok J.A. D.W.R., 2001, MOL CLONING LAB MANU, V3rd; Snead ML, 1998, CONNECT TISSUE RES, V38, P279, DOI 10.3109/03008209809017048; Snyder SR, 2001, J BIOL CHEM, V276, P5323, DOI 10.1074/jbc.M009454200; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; STETLERSTEVENSON WG, 1986, CALCIFIED TISSUE INT, V38, P135, DOI 10.1007/BF02556873; Swanson HI, 1999, NUCLEIC ACIDS RES, V27, P3205, DOI 10.1093/nar/27.15.3205; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Thotakura SR, 2000, J BIOL CHEM, V275, P10272, DOI 10.1074/jbc.275.14.10272; Tournier B, 2003, FEBS LETT, V550, P149, DOI 10.1016/S0014-5793(03)00757-9; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; TRAUB W, 1992, MATRIX, V12, P251, DOI 10.1016/S0934-8832(11)80076-4; TRONCHE F, 1991, J MOL BIOL, V222, P31, DOI 10.1016/0022-2836(91)90735-O; Unterbrink A, 2002, CONNECT TISSUE RES, V43, P354, DOI 10.1080/03008200290000565; Walhout AJM, 1998, BBA-GENE STRUCT EXPR, V1397, P189, DOI 10.1016/S0167-4781(97)00227-3; Willy PJ, 2000, SCIENCE, V290, P982, DOI 10.1126/science.290.5493.982; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Xiao S, 2001, NAT GENET, V27, P345; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411; Yamakoshi Y, 2003, EUR J ORAL SCI, V111, P60, DOI 10.1034/j.1600-0722.2003.00009.x; Yamazaki H, 1999, BIOCHEM BIOPH RES CO, V260, P433, DOI 10.1006/bbrc.1999.0875; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	64	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42182	42191		10.1074/jbc.M402476200	http://dx.doi.org/10.1074/jbc.M402476200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292199	hybrid			2022-12-27	WOS:000224075500110
J	Lio, YC; Schild, D; Brenneman, MA; Redpath, JL; Chen, DJ				Lio, YC; Schild, D; Brenneman, MA; Redpath, JL; Chen, DJ			Human Rad51C deficiency destabilizes XRCC3, impairs recombination, and radiosensitizes S/G(2)-phase cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; POTENTIALLY LETHAL DAMAGE; CULTURED-MAMMALIAN-CELLS; SMALL INTERFERING RNAS; DNA-REPAIR GENE; HOMOLOGOUS RECOMBINATION; HELA-CELLS; CAENORHABDITIS-ELEGANS; CHROMOSOME STABILITY; MOUSE GENES	The highly conserved Rad51 protein plays an essential role in repairing DNA damage through homologous recombination. In vertebrates, five Rad51 paralogs (Rad51B, Rad51C, Rad51D, XRCC2, and XRCC3) are expressed in mitotically growing cells and are thought to play mediating roles in homologous recombination, although their precise functions remain unclear. Among the five paralogs, Rad51C was found to be a central component present in two complexes, Rad51C-XRCC3 and Rad51B-Rad51C-Rad51D-XRCC2. We have shown previously that the human Rad51C protein exhibits three biochemical activities, including DNA binding, ATPase, and DNA duplex separation. Here we report the use of RNA interference to deplete expression of Rad51C protein in human HT1080 and HeLa cells. In HT1080 cells, depletion of Rad51C by small interfering RNA caused a significant reduction of frequency in homologous recombination. The level of XRCC3 protein was also sharply reduced in Rad51C-depleted HeLa cells, suggesting that XRCC3 is dependent for its stability upon heterodimerization with Rad51C. In addition, Rad51C-depleted HeLa cells showed hypersensitivity to the DNA-cross-linking agent mitomycin C and moderately increased sensitivity to ionizing radiation. Importantly, the radiosensitivity of Rad51C-deficient HeLa cells was evident in S and G(2)/M phases of the cell cycle but not in G(1) phase. Together, these results provide direct cellular evidence for the function of human Rad51C in homologous recombinational repair.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif Irvine, Dept Radiat Oncol, Irvine, CA 92697 USA; Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Irvine; Rutgers State University New Brunswick	Lio, YC (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, MS74-157,1 Cyclotron Rd, Berkeley, CA 94720 USA.	YLio@lbl.gov	Classen, Scott/AAY-8176-2020		NCI NIH HHS [CA092584] Funding Source: Medline; NIGMS NIH HHS [GM030990] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062; Barendsen GW, 2001, INT J ONCOL, V19, P247; Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BELLI JA, 1969, SCIENCE, V165, P490, DOI 10.1126/science.165.3892.490; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Brenneman MA, 2000, MUTAT RES-DNA REPAIR, V459, P89, DOI 10.1016/S0921-8777(00)00002-1; Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P1653, DOI 10.1093/nar/26.7.1653; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; CHEONG N, 1994, MUTAT RES, V314, P77, DOI 10.1016/0921-8777(94)90063-9; CHOULIKA A, 1995, MOL CELL BIOL, V15, P1968; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Flygare J, 1996, BBA-MOL CELL RES, V1312, P231, DOI 10.1016/0167-4889(96)00040-7; French CA, 2003, J BIOL CHEM, V278, P45445, DOI 10.1074/jbc.M308621200; French CA, 2002, J BIOL CHEM, V277, P19322, DOI 10.1074/jbc.M201402200; GIACCIA A, 1985, SOMAT CELL MOLEC GEN, V11, P485, DOI 10.1007/BF01534842; Godthelp BC, 2002, NUCLEIC ACIDS RES, V30, P2172, DOI 10.1093/nar/30.10.2172; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Harborth J, 2001, J CELL SCI, V114, P4557; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Kawabata M, 1999, BIOCHEM BIOPH RES CO, V257, P156, DOI 10.1006/bbrc.1999.0413; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kurumizaka H, 2002, J BIOL CHEM, V277, P14315, DOI 10.1074/jbc.M105719200; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Lio YC, 2003, J BIOL CHEM, V278, P2469, DOI 10.1074/jbc.M211038200; Liu N, 2002, NUCLEIC ACIDS RES, V30, P1009, DOI 10.1093/nar/30.4.1009; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Liu YL, 2004, SCIENCE, V303, P243, DOI 10.1126/science.1093037; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Miller KA, 2002, J BIOL CHEM, V277, P8406, DOI 10.1074/jbc.M108306200; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; PHILLIPS RA, 1966, RADIAT RES, V29, P413, DOI 10.2307/3572022; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Pittman DL, 1998, GENOMICS, V49, P103, DOI 10.1006/geno.1998.5226; Rice MC, 1997, P NATL ACAD SCI USA, V94, P7417, DOI 10.1073/pnas.94.14.7417; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; Schild D, 2000, J BIOL CHEM, V275, P16443, DOI 10.1074/jbc.M001473200; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Sigurdsson S, 2001, GENE DEV, V15, P3308, DOI 10.1101/gad.935501; STAMATO TD, 1983, SOMAT CELL GENET, V9, P165, DOI 10.1007/BF01543175; Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Talwar N, 1997, RADIAT RES, V148, P48, DOI 10.2307/3579538; Tashiro S, 1996, ONCOGENE, V12, P2165; TAYLOR IW, 1980, J HISTOCHEM CYTOCHEM, V28, P1021, DOI 10.1177/28.9.6157714; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; TERASIMA T, 1963, SCIENCE, V140, P490, DOI 10.1126/science.140.3566.490; TERASIMA T, 1963, BIOPHYS J, V3, P11, DOI 10.1016/S0006-3495(63)86801-0; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; WATSON PA, 1991, CYTOMETRY, V12, P242, DOI 10.1002/cyto.990120306; WHITMORE GF, 1989, INT J RADIAT BIOL, V56, P657, DOI 10.1080/09553008914551881; Wiese C, 2002, NUCLEIC ACIDS RES, V30, P1001, DOI 10.1093/nar/30.4.1001; Yoshihara T, 2004, EMBO J, V23, P670, DOI 10.1038/sj.emboj.7600087; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746	69	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42313	42320		10.1074/jbc.M405212200	http://dx.doi.org/10.1074/jbc.M405212200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292210	Green Submitted, hybrid			2022-12-27	WOS:000224075500123
J	Chen, LS; Sheppard, TL				Chen, LS; Sheppard, TL			Chain termination and inhibition of Saccharomyces cerevisiae poly(A) polymerase by C-8-modified ATP analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-MYELOMA CELLS; MESSENGER-RNA; PURINE NUCLEOSIDES; CELLULAR PHARMACOLOGY; SELECTIVE-INHIBITION; NUCLEOTIDE ANALOGS; DNA-SYNTHESIS; POLYADENYLATION; 3'-END; MECHANISM	The nucleotide substrate specificity of yeast poly( A) polymerase (yPAP) toward various C-2- and C-8-modified ATP analogs was examined. P-32-Radiolabeled RNA oligonucleotide primers were incubated with yPAP in the absence of ATP to assay polyadenylation using unnatural ATP substrates. The C-2- modified ATP analogs 2-amino-ATP and 2-chloro (Cl)-ATP were excellent substrates for yPAP. 8-Amino-ATP, 8-azido-ATP, and 8-aza-ATP all produced chain termination of polyadenylation, and no primer extension was observed with the C-8-halogenated derivatives 8-Br-ATP and 8-Cl-ATP. The effects of modified ATP analogs on ATP-dependent poly( A) tail synthesis by yPAP were also examined. Whereas C-2 substitution (2-amino-ATP and 2-Cl-ATP) had little effect on poly( A) tail length, C-8 substitution produced moderate (8-amino-ATP, 8-azido-ATP, and 8-aza-ATP) to substantial (8-Br-ATP and 8-Cl-ATP) reduction in poly( A) tail length. To model the biochemical consequences of 8-Cl-Ado incorporation into RNA primers, a synthetic RNA primer containing a 3'-terminal 8-Cl-AMP residue was prepared. Polyadenylation of this modified RNA primer by yPAP in the presence of ATP was blocked completely. To probe potential mechanisms of inhibition, two-dimensional NMR spectroscopy experiments were used to examine the conformation of two C-8-modified AMP nucleotides, 8-Cl-AMP and 8-amino-AMP. C-8 substitution in adenosine analogs shifted the ribose sugar pucker equilibrium to favor the DNA-like C-2'-endo form over the C-3'-endo (RNA-like) conformation, which suggests a potential mechanism for polyadenylation inhibition and chain termination. Base-modified ATP analogs may exert their biological effects through polyadenylation inhibition and thus may provide useful tools for investigating polyadenylation biochemistry within cells.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA	Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Sheppard, TL (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	t-sheppard@northwestern.edu		Sheppard, Terry/0000-0001-8667-3633	NCI NIH HHS [R01 CA85915-02] Funding Source: Medline; NCRR NIH HHS [1-S10-RR13810] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085915] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013810] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTONA C, 1973, J AM CHEM SOC, V95, P2333, DOI 10.1021/ja00788a038; Birse CE, 1998, SCIENCE, V280, P298, DOI 10.1126/science.280.5361.298; CHEN F, 1995, NUCLEIC ACIDS RES, V23, P2614, DOI 10.1093/nar/23.14.2614; Chen LS, 2003, BIOORG MED CHEM LETT, V13, P1509, DOI 10.1016/S0960-894X(03)00204-X; Chen LS, 2002, NUCLEOS NUCLEOT NUCL, V21, P599, DOI 10.1081/NCN-120015071; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; DARNELL JE, 1971, SCIENCE, V174, P507, DOI 10.1126/science.174.4008.507; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; EVANS FE, 1976, J BIOL CHEM, V251, P6791; Gandhi V, 2002, CANCER CHEMOTH PHARM, V50, P85, DOI 10.1007/S00280-002-0456-0; GANDHI V, 1993, LEUKEMIA LYMPHOMA, V10, P49, DOI 10.3109/10428199309147356; Gandhi V, 2001, CANCER RES, V61, P5474; GHOSHAL K, 1991, NUCLEIC ACIDS RES, V19, P5871, DOI 10.1093/nar/19.21.5871; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HAFF LA, 1975, J BIOL CHEM, V250, P1838; Halgren RG, 1998, BLOOD, V92, P2893, DOI 10.1182/blood.V92.8.2893.420k01_2893_2898; HENTOSH P, 1991, BIOCHEMISTRY-US, V30, P547, DOI 10.1021/bi00216a032; Hirose Y, 2000, GENE DEV, V14, P1415; HOLMES RE, 1965, J AM CHEM SOC, V87, P1772, DOI 10.1021/ja01086a028; Hooker L, 2001, NUCLEIC ACIDS RES, V29, P2691, DOI 10.1093/nar/29.13.2691; IKEHARA M, 1972, BIOCHEMISTRY-US, V11, P830, DOI 10.1021/bi00755a023; LINGNER J, 1991, J BIOL CHEM, V266, P8741; LINGNER J, 1993, NUCLEIC ACIDS RES, V21, P2917, DOI 10.1093/nar/21.12.2917; LUDWIG J, 1981, ACTA BIOCHIM BIOPHYS, V16, P131; Martin G, 1998, RNA, V4, P226; Meksuriyen D, 1998, J BIOL CHEM, V273, P30939, DOI 10.1074/jbc.273.47.30939; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; Noronha A, 1998, NUCLEIC ACIDS RES, V26, P2665, DOI 10.1093/nar/26.11.2665; Plunkett W, 1996, HEMATOL CELL THER, V38, pS67; ROSE KM, 1978, BIOCHEM BIOPH RES CO, V81, P1418, DOI 10.1016/0006-291X(78)91294-9; ROSE KM, 1977, BIOCHIM BIOPHYS ACTA, V475, P548, DOI 10.1016/0005-2787(77)90069-7; ROSE KM, 1982, MOL PHARMACOL, V22, P517; Saenger W., 1984, PRINCIPLES NUCL ACID; Sawai H, 2003, J MED CHEM, V46, P4926, DOI 10.1021/jm030035k; SHUMAN S, 1988, J BIOL CHEM, V263, P8405; Stellrecht CM, 2003, CANCER RES, V63, P7968; TAVALE SS, 1970, J MOL BIOL, V48, P109, DOI 10.1016/0022-2836(70)90222-6; WAHLE E, 1995, J BIOL CHEM, V270, P2800, DOI 10.1074/jbc.270.6.2800; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Zaug AJ, 1996, NUCLEIC ACIDS RES, V24, P532, DOI 10.1093/nar/24.3.532; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zhelkovsky A, 1998, MOL CELL BIOL, V18, P5942, DOI 10.1128/MCB.18.10.5942; ZHELKOVSKY AM, 1995, J BIOL CHEM, V270, P26715, DOI 10.1074/jbc.270.44.26715	44	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40405	40411		10.1074/jbc.M401752200	http://dx.doi.org/10.1074/jbc.M401752200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15265873	hybrid			2022-12-27	WOS:000223916800025
J	Koivisto, P; Robins, P; Lindahl, T; Sedgwick, B				Koivisto, P; Robins, P; Lindahl, T; Sedgwick, B			Demethylation of 3-methylthymine in DNA by bacterial and human DNA dioxygenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ALKYLATION DAMAGE; OXIDATIVE DEMETHYLATION; REPAIR; ALKB; POLYMERASES; METHYLATION; GENOME; CELLS; MUTAGENESIS	Rare DNA lesions that are chemically stable and refractory to repair may add disproportionately to the accumulation of mutations in long lived cells. 3-Methylthymine is a minor lesion that is induced by DNA-methylating agents and for which no repair process has been described previously. Here we demonstrate that this lesion can be directly demethylated in vitro by bacterial and human DNA dioxygenases. The Escherichia coli AlkB and human ABH3 proteins repaired 3-methylthymine in both single-stranded and double-stranded polydeoxynucleotides, whereas the human ABH2 protein preferred a duplex substrate. Thus, the known substrates of these enzymes now include 3-methylthymine in DNA, as well as 1-methyladenine and 3-methylcytosine, which all have structurally similar sites of alkylation. Repair of 3-methylthymine by AlkB and ABH3 was optimal at pH 6, but inefficient. At physiological pH, 3-methylthymine, which is a minor methylated lesion, was more slowly repaired than the major lesion generated in single-stranded DNA, 3-methylcytosine. Our data suggest that 3-methylthymine residues in DNA will be repaired inefficiently in vivo and therefore may occur at a low steady-state level, but the residues should not gradually accumulate to high levels in long lived cells.	Canc Res UK London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Lindahl, T (corresponding author), Canc Res UK London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	Tomas.Lindahl@cancer.org.uk		Koivisto, Pertti/0000-0002-0416-0357				Aas PA, 2003, NATURE, V421, P859, DOI 10.1038/nature01363; ARAVIND L, 2001, GENOME BIOL, V2, DOI DOI 10.1186/gb-2001-2-3-research0007; BHANOT OS, 1990, BIOCHEMISTRY-US, V29, P10357, DOI 10.1021/bi00497a010; BODELL WJ, 1979, BIOCHEMISTRY-US, V18, P2860, DOI 10.1021/bi00580a029; BOITEUX S, 1982, BIOCHIMIE, V64, P637, DOI 10.1016/S0300-9084(82)80103-X; Daniels DS, 2000, MUTAT RES-DNA REPAIR, V460, P151, DOI 10.1016/S0921-8777(00)00024-0; DEMPLE B, 1985, P NATL ACAD SCI USA, V82, P2688, DOI 10.1073/pnas.82.9.2688; Dinglay S, 2000, GENE DEV, V14, P2097; Duncan T, 2002, P NATL ACAD SCI USA, V99, P16660, DOI 10.1073/pnas.262589799; Falnes PO, 2002, NATURE, V419, P178, DOI 10.1038/nature01048; Fang JL, 1997, CARCINOGENESIS, V18, P627, DOI 10.1093/carcin/18.4.627; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Goodman MF, 2000, CURR OPIN GENET DEV, V10, P162, DOI 10.1016/S0959-437X(00)00057-5; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Hausinger RP, 2004, CRIT REV BIOCHEM MOL, V39, P21, DOI 10.1080/10409230490440541; HUFF AC, 1987, J BIOL CHEM, V262, P12843; KATAOKA H, 1983, J BACTERIOL, V153, P1301, DOI 10.1128/JB.153.3.1301-1307.1983; Koivisto P, 2003, J BIOL CHEM, V278, P44348, DOI 10.1074/jbc.M307361200; Krokan HE, 2004, J MOL MED, V82, P280, DOI 10.1007/s00109-004-0528-1; Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597; KUSMIEREK JT, 1976, NUCLEIC ACIDS RES, V3, P989, DOI 10.1093/nar/3.4.989; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOVELESS A, 1969, MUTAT RES, V7, P1, DOI 10.1016/0027-5107(69)90043-8; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; Messerschmidt A, 1998, P NATL ACAD SCI USA, V95, P3443, DOI 10.1073/pnas.95.7.3443; O'Brien PJ, 2004, J BIOL CHEM, V279, P9750, DOI 10.1074/jbc.M312232200; SAFFHILL R, 1985, CHEM-BIOL INTERACT, V53, P121, DOI 10.1016/S0009-2797(85)80090-9; SASSANFAR M, 1991, J BIOL CHEM, V266, P2767; Sedgwick B, 2004, NAT REV MOL CELL BIO, V5, P148, DOI 10.1038/nrm1312; Sedgwick B, 2002, ONCOGENE, V21, P8886, DOI 10.1038/sj.onc.1205998; SINGER B, 1975, BIOCHEMISTRY-US, V14, P4353, DOI 10.1021/bi00691a001; Singer B, 1975, Prog Nucleic Acid Res Mol Biol, V15, P219, DOI 10.1016/S0079-6603(08)60121-X; Singer B., 1983, MOL BIOL MUTAGENS CA, P45; Trewick SC, 2002, NATURE, V419, P174, DOI 10.1038/nature00908; TREWICK SC, 2003, THESIS U COLL LONDON; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Viswanathan A, 1999, SCIENCE, V284, P159, DOI 10.1126/science.284.5411.159	38	83	85	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40470	40474		10.1074/jbc.M407960200	http://dx.doi.org/10.1074/jbc.M407960200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15269201	hybrid			2022-12-27	WOS:000223916800033
J	Malhotra, JD; Thyagarajan, V; Chen, CL; Isom, LL				Malhotra, JD; Thyagarajan, V; Chen, CL; Isom, LL			Tyrosine-phosphorylated and nonphosphorylated sodium channel beta 1 subunits are differentially localized in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; STRUCTURAL REQUIREMENTS; INTERCALATED DISKS; AUXILIARY SUBUNIT; SINOATRIAL NODE; ANKYRIN-BINDING; FIGQY TYROSINE; ALPHA-SUBUNITS; GAP-JUNCTIONS; TENASCIN-R	Voltage-gated sodium channel alpha and beta subunits expressed in mammalian heart are differentially localized to t-tubules and intercalated disks. Sodium channel beta subunits are multifunctional molecules that participate in channel modulation and cell adhesion. Reversible, receptor-mediated changes in beta1 tyrosine phosphorylation modulate its ability to recruit and associate with ankyrin. The purpose of the present study was to test our hypothesis that tyrosine-phosphorylated beta1 (pYbeta1) and nonphosphorylated beta1 subunits may be differentially localized in heart and thus interact with different cytoskeletal and signaling proteins. We developed an antibody that specifically recognizes pYbeta1 and investigated the differential subcellular localization of beta1 and pYbeta1 in mouse ventricular myocytes. We found that pYbeta1 colocalized with connexin-43, N-cadherin, and Na(v)1.5 at intercalated disks but was not detected at the t-tubules. Anti-pYbeta1 immunoprecipitates N-cadherin from heart membranes and from cells transfected with beta1 and N-cadherin in the absence of other sodium channel subunits. pYbeta1 does not associate with ankyrin(B) in heart membranes. N-cadherin and connexin-43 associate with Na(v)1.5 in heart membranes as assessed by co-immunoprecipitation assays. We propose that sodium channel complexes at intercalated disks of ventricular myocytes are composed of Na(v)1.5 and pYbeta1 and that these complexes are in close association with both N-cadherin and connexin-43. beta1 phosphorylation appears to regulate its localization to differential subcellular domains.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Isom, LL (corresponding author), Univ Michigan, Dept Pharmacol, 1301 MSRB 3,1150 W Med Ctr dr, Ann Arbor, MI 48109 USA.	lisom@umich.edu		Isom, Lori/0000-0002-9479-6729; Hoffman, Veena/0000-0003-4932-0892	NIMH NIH HHS [R01MH59980] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059980] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Balser JR, 1999, CARDIOVASC RES, V42, P327, DOI 10.1016/S0008-6363(99)00031-0; Barker RJ, 2001, CELL COMMUN ADHES, V8, P205, DOI 10.3109/15419060109080724; Barker RJ, 2002, CIRC RES, V90, P317, DOI 10.1161/hh0302.104471; Baruscotti M, 1997, J PHYSIOL-LONDON, V498, P641, DOI 10.1113/jphysiol.1997.sp021889; Beltran PJ, 2003, FRONT BIOSCI, V8, pD87, DOI 10.2741/941; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chen CL, 2004, J NEUROSCI, V24, P4030, DOI 10.1523/JNEUROSCI.4139-03.2004; Chen LS, 2001, J CELL BIOL, V154, P841, DOI 10.1083/jcb.200009004; Cohen SA, 1996, CIRCULATION, V94, P3083, DOI 10.1161/01.CIR.94.12.3083; Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346; Fransen E, 1997, HUM MOL GENET, V6, P1625, DOI 10.1093/hmg/6.10.1625; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; Gu SM, 1996, J MED GENET, V33, P103, DOI 10.1136/jmg.33.2.103; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Isom LL, 2002, FRONT BIOSCI, V7, P12; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; Isom LL, 2001, NEUROSCIENTIST, V7, P42, DOI 10.1177/107385840100700108; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; Jenkins SM, 2001, J CELL SCI, V114, P3823; Kamiguchi H, 1998, J NEUROSCI, V18, P5311, DOI 10.1523/JNEUROSCI.18-14-05311.1998; Kamiguchi H, 1998, J NEUROSCI, V18, P3749, DOI 10.1523/jneurosci.18-10-03749.1998; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Kazen-Gillespie KA, 2000, J BIOL CHEM, V275, P1079, DOI 10.1074/jbc.275.2.1079; Kizhatil K, 2002, J NEUROSCI, V22, P7948; Kostin S, 1999, CIRC RES, V85, P154, DOI 10.1161/01.RES.85.2.154; Kucera JP, 2002, CIRC RES, V91, P1176, DOI 10.1161/01.RES.0000046237.54156.0A; Lilien J, 2002, DEV DYNAM, V224, P18, DOI 10.1002/dvdy.10087; Lopatin AN, 2000, J MOL CELL CARDIOL, V32, P2007, DOI 10.1006/jmcc.2000.1232; Maier SKG, 2003, P NATL ACAD SCI USA, V100, P3507, DOI 10.1073/pnas.2627986100; Maier SKG, 2002, P NATL ACAD SCI USA, V99, P4073, DOI 10.1073/pnas.261705699; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Malhotra JD, 2002, J BIOL CHEM, V277, P26681, DOI 10.1074/jbc.M202354200; Malhotra JD, 2001, CIRCULATION, V103, P1303; Maltsev VA, 1997, AM J PHYSIOL-HEART C, V273, pH1832, DOI 10.1152/ajpheart.1997.273.4.H1832; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; McEwen DP, 2004, J BIOL CHEM, V279, P16044, DOI 10.1074/jbc.M400856200; Mohler PJ, 2004, P NATL ACAD SCI USA, V101, P9137, DOI 10.1073/pnas.0402546101; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; Ou YJ, 2003, J BIOL CHEM, V278, P1915, DOI 10.1074/jbc.M209938200; Papadatos GA, 2002, P NATL ACAD SCI USA, V99, P6210, DOI 10.1073/pnas.082121299; PETERS NS, 1994, CIRCULATION, V90, P713, DOI 10.1161/01.CIR.90.2.713; Ratcliffe CF, 2001, J CELL BIOL, V154, P427, DOI 10.1083/jcb.200102086; Ratcliffe CF, 2000, NAT NEUROSCI, V3, P437, DOI 10.1038/74805; Sinn HW, 2002, DEV DYNAM, V225, P1, DOI 10.1002/dvdy.10131; Srinivasan J, 1998, P NATL ACAD SCI USA, V95, P15753, DOI 10.1073/pnas.95.26.15753; Tuvia S, 1997, P NATL ACAD SCI USA, V94, P12957, DOI 10.1073/pnas.94.24.12957; UNDROVINAS AI, 1995, AM J PHYSIOL-HEART C, V269, pH203, DOI 10.1152/ajpheart.1995.269.1.H203; WONG EV, 1995, TRENDS NEUROSCI, V18, P168, DOI 10.1016/0166-2236(95)93896-6; Xiao ZC, 1999, J BIOL CHEM, V274, P26511, DOI 10.1074/jbc.274.37.26511; Yamasaki M, 1997, NEUROPEDIATRICS, V28, P175, DOI 10.1055/s-2007-973696; Yu FH, 2003, J NEUROSCI, V23, P7577; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785	53	90	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40748	40754		10.1074/jbc.M407243200	http://dx.doi.org/10.1074/jbc.M407243200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15272007	hybrid			2022-12-27	WOS:000223916800067
J	Nishina, K; Jenks, S; Supattapone, S				Nishina, K; Jenks, S; Supattapone, S			Ionic strength and transition metals control PrPSc protease resistance and conversion-inducing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR PRION PROTEIN; ALZHEIMER A-BETA; SCRAPIE PRION; NUCLEOCAPSID PROTEIN; COPPER-BINDING; ENCEPHALOPATHY AGENT; AGGREGATION; DISEASE; IDENTIFICATION; SITES	The essential component of infectious prions is a misfolded protein termed PrPSc, which is produced by conformational change of a normal host protein, PrPC. It is currently unknown whether PrPSc molecules exist in a unique conformation or whether they are able to undergo additional conformational changes. Under commonly used experimental conditions, PrPSc molecules are characteristically protease-resistant and capable of inducing the conversion of PrPC molecules into new PrPSc molecules. We describe the effects of ionic strength, copper, and zinc on the conformation-dependent protease resistance and conversion-inducing activity of PrPSc molecules in scrapie-infected hamster brains. In the absence of divalent cations, PrPSc molecules were >20-fold more sensitive to proteinase K digestion in low ionic strength buffers than in high ionic strength buffers. Addition of micromolar concentrations of copper or zinc ions restored the protease resistance of PrPSc molecules under conditions of low ionic strength. These transition metals also controlled the conformation of purified truncated PrP-(27-30) molecules at low ionic strength, confirming that the N-terminal octapeptide repeat region of PrPSc is not required for binding to copper or zinc ions. The protease-sensitive and protease-resistant conformations of PrPSc were reversibly interchangeable, and only the protease-resistant conformation of PrPSc induced by high ionic strength was able to induce the formation of new protease-resistant PrP (PrPres) molecules in vitro. These findings show that PrPSc molecules are structurally interconvertible and that only a subset of PrPSc conformations are able to induce the conversion of other PrP molecules.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Dartmouth Coll, Sch Med, Dept Med, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College	Supattapone, S (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	supattapone@dartmouth.edu			NIAID NIH HHS [T32AI007519] Funding Source: Medline; NINDS NIH HHS [NS046478] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046478] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adler V, 2003, J MOL BIOL, V332, P47, DOI 10.1016/S0022-2836(03)00919-7; Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Ben-Zaken O, 2003, J BIOL CHEM, V278, P40041, DOI 10.1074/jbc.M301152200; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BIETH J, 1974, BIOCHEM MED METAB B, V11, P350, DOI 10.1016/0006-2944(74)90134-3; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BOLTON DC, 1984, BIOCHEMISTRY-US, V23, P5898, DOI 10.1021/bi00320a002; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Callahan NA, 2001, J BIOL CHEM, V276, P28022, DOI 10.1074/jbc.M103629200; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; Cereghetti GM, 2001, BIOPHYS J, V81, P516, DOI 10.1016/S0006-3495(01)75718-9; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Derrington E, 2002, CR BIOL, V325, P17, DOI 10.1016/S1631-0691(02)01388-4; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; Gabus C, 2001, J BIOL CHEM, V276, P19301, DOI 10.1074/jbc.M009754200; Gabus C, 2001, J MOL BIOL, V307, P1011, DOI 10.1006/jmbi.2001.4544; GIBBS CJ, 1985, NEW ENGL J MED, V313, P734, DOI 10.1056/NEJM198509193131207; Hasnain SS, 2001, J MOL BIOL, V311, P467, DOI 10.1006/jmbi.2001.4795; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Jobling MF, 2001, BIOCHEMISTRY-US, V40, P8073, DOI 10.1021/bi0029088; Kramer ML, 2001, J BIOL CHEM, V276, P16711, DOI 10.1074/jbc.M006554200; LANSBURY PT, 1995, CHEM BIOL, V2, P1, DOI 10.1016/1074-5521(95)90074-8; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Maiti NR, 2001, J BIOL CHEM, V276, P2427, DOI 10.1074/jbc.M007862200; McKenzie D, 1998, J BIOL CHEM, V273, P25545, DOI 10.1074/jbc.273.40.25545; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; McLeod AH, 2004, BIOCHEM BIOPH RES CO, V317, P1165, DOI 10.1016/j.bbrc.2004.03.168; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; Moscardini M, 2002, J MOL BIOL, V318, P149, DOI 10.1016/S0022-2836(02)00092-X; Nandi PK, 2002, J MOL BIOL, V322, P153, DOI 10.1016/S0022-2836(02)00750-7; Nishina K, 2004, BIOCHEMISTRY-US, V43, P2613, DOI 10.1021/bi035889l; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Peretz D, 2001, PROTEIN SCI, V10, P854, DOI 10.1110/ps.39201; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Proske D, 2002, CHEMBIOCHEM, V3, P717, DOI 10.1002/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1981, P NATL ACAD SCI-BIOL, V78, P6675, DOI 10.1073/pnas.78.11.6675; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; PRUSINER SB, 1999, PRION BIOL DIS; Purdey M, 2000, MED HYPOTHESES, V54, P278, DOI 10.1054/mehy.1999.0836; Qin KF, 2002, J BIOL CHEM, V277, P1981, DOI 10.1074/jbc.M108744200; Quaglio E, 2001, J BIOL CHEM, V276, P11432, DOI 10.1074/jbc.M009666200; ROBERTS GW, 1986, NEW ENGL J MED, V315, P1231; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; Shaked GM, 2001, J BIOL CHEM, V276, P14324, DOI 10.1074/jbc.M007815200; Shaked Y, 2001, J VIROL, V75, P7872, DOI 10.1128/JVI.75.17.7872-7874.2001; Sigurdsson EM, 2003, J BIOL CHEM, V278, P46199, DOI 10.1074/jbc.C300303200; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; Supattapone S, 2001, J VIROL, V75, P3453, DOI 10.1128/JVI.75.7.3453-3461.2001; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997; Whittal RM, 2000, PROTEIN SCI, V9, P332; Wille H, 1996, J MOL BIOL, V259, P608, DOI 10.1006/jmbi.1996.0343; Wong BS, 2000, BIOCHEM BIOPH RES CO, V276, P1217, DOI 10.1006/bbrc.2000.3604; Wong BS, 2001, J NEUROCHEM, V78, P1400, DOI 10.1046/j.1471-4159.2001.00522.x; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Zeiler B, 2003, BIOTECHNOL APPL BIOC, V37, P173, DOI 10.1042/BA20020087	77	33	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40788	40794		10.1074/jbc.M406548200	http://dx.doi.org/10.1074/jbc.M406548200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262998	hybrid			2022-12-27	WOS:000223916800072
J	Ranganathan, S; Liu, CX; Migliorini, MM; von Arnim, CAF; Peltan, ID; Mikhailenko, I; Hyman, BT; Strickland, DK				Ranganathan, S; Liu, CX; Migliorini, MM; von Arnim, CAF; Peltan, ID; Mikhailenko, I; Hyman, BT; Strickland, DK			Serine and threonine phosphorylation of the low density lipoprotein receptor-related protein by protein kinase C alpha regulates endocytosis and association with adaptor molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GROWTH-FACTOR RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; CELLULAR INTERNALIZATION; DEPENDENT REGULATION; CYTOSOLIC ADAPTER; APOPTOTIC CELLS; LRP	The low density lipoprotein receptor-related protein (LRP) is a large receptor that participates in endocytosis, signaling pathways, and phagocytosis of necrotic cells. Mechanisms that direct LRP to function in these distinct pathways likely involve its association with distinct cytoplasmic adaptor proteins. We tested the hypothesis that the association of various adaptor proteins with the LRP cytoplasmic domain is modulated by its phosphorylation state. Phosphoamino acid analysis of metabolically labeled LRP revealed that this receptor is phosphorylated at serine, threonine, and tyrosine residues within its cytoplasmic domain, whereas inhibitor studies identified protein kinase Calpha(PKCalpha) as a kinase capable of phosphorylating LRP. Mutational analysis identified critical threonine and serine residues within the LRP cytoplasmic domain that are necessary for phosphorylation mediated by PKCalpha. Mutating these threonine and serine residues to alanines generated a receptor that was not phosphorylated and that was internalized more rapidly than wildtype LRP, revealing that phosphorylation reduces the association of LRP with adaptor molecules of the endocytic machinery. In contrast, serine and threonine phosphorylation was necessary for the interaction of LRP with Shc, an adaptor protein that participates in signaling events. Furthermore, serine and threonine phosphorylation increased the interaction of LRP with other adaptor proteins such as Dab-1 and CED-6/GULP. These results indicate that phosphorylation of LRP by PKCalpha modulates the endocytic and signaling function of LRP by modifying its association with adaptor proteins.	Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Alzheimers Dis Res Lab, Charlestown, MA 02129 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Harvard University; Massachusetts General Hospital	Strickland, DK (corresponding author), Univ Maryland, Sch Med, Dept Surg, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	strickla@usa.redcross.org	Peltan, Ithan/J-1853-2019	Peltan, Ithan/0000-0003-1730-234X	NHLBI NIH HHS [HL54710, HL50784] Funding Source: Medline; NIA NIH HHS [AG12406] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050784, P01HL054710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012406, R01AG012406] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Bioukar EB, 1999, J BIOL CHEM, V274, P21457, DOI 10.1074/jbc.274.30.21457; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; Conner SD, 2003, J CELL BIOL, V162, P773, DOI 10.1083/jcb.200304069; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; Gallagher E, 1998, J COMP NEUROL, V402, P238; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Horvitz HR, 1999, CANCER RES, V59, p1701S; KISHIMOTO A, 1987, J BIOL CHEM, V262, P9367; KISHIMOTO A, 1987, J BIOL CHEM, V262, P1344; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; Li YH, 2001, MOL CELL BIOL, V21, P1185, DOI 10.1128/MCB.21.4.1185-1195.2001; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; Muramatsu H, 2000, BIOCHEM BIOPH RES CO, V270, P936, DOI 10.1006/bbrc.2000.2549; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Su HP, 2002, J BIOL CHEM, V277, P11772, DOI 10.1074/jbc.M109336200; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; THEROUX SJ, 1992, J BIOL CHEM, V267, P16620; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; WILEY HS, 1982, J BIOL CHEM, V257, P4222; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	55	50	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40536	40544		10.1074/jbc.M407592200	http://dx.doi.org/10.1074/jbc.M407592200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15272003	hybrid			2022-12-27	WOS:000223916800041
J	Cho, DH; Hong, YM; Lee, HJ; Woo, HN; Pyo, JO; Mak, TW; Jung, YK				Cho, DH; Hong, YM; Lee, HJ; Woo, HN; Pyo, JO; Mak, TW; Jung, YK			Induced inhibition of ischemic/hypoxic injury by APIP, a novel apaf-1-interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CELL-DEATH; CASPASE ACTIVATION; MOLECULAR CHARACTERIZATION; APOPTOSIS; HYPOXIA; APAF-1; BCL-2; CED-4; MITOCHONDRIA	We describe the isolation and characterization of a new apaf-1-interacting protein (APIP) as a negative regulator of ischemic injury. APIP is highly expressed in skeletal muscle and heart and binds to the CARD of Apaf-1 in competition with caspase-9. Exogenous APIP inhibits cytochrome c-induced activation of caspase-3 and caspase-9, and suppresses cell death triggered by mitochondrial apoptotic stimuli through inhibiting the downstream activity of cytochrome c released from mitochondria. Conversely, reduction of APIP expression potentiates mitochondrial apoptosis. APIP expression is highly induced in mouse muscle affected by ischemia produced by interruption of the artery in the hindlimb and in C2C12 myotubes created by hypoxia in vitro, and the blockade of APIP up-regulation results in TUNEL-positive ischemic damage. Furthermore, forced expression of APIP suppresses ischemia/hypoxia-induced death of skeletal muscle cells. Taken together, these results suggest that APIP functions to inhibit muscle ischemic damage by binding to Apaf-1 in the Apaf-1/ caspase-9 apoptosis pathway.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Ontario Canc Inst, Dept Cellular & Mol Biol, Toronto, ON M5G 2C1, Canada	Gwangju Institute of Science & Technology (GIST); University of Toronto; University Toronto Affiliates; University Health Network Toronto	Jung, YK (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju 500712, South Korea.	ykjung@kjist.ac.kr	Lee, Ho-June/D-8855-2014	Lee, Ho-June/0000-0002-7019-2533; Jung, Yong-Keun/0000-0002-9686-3120; Woo, Ha-Na/0000-0002-6771-8151				Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chatterjee S, 2002, CIRCULATION, V106, pI212, DOI 10.1161/01.cir.0000032907.33237.55; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Kang PM, 2000, CIRC RES, V87, P118, DOI 10.1161/01.RES.87.2.118; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; MCARDLE A, 1997, INTRACELLULAR MECHAN, P90; McClintock DS, 2002, MOL CELL BIOL, V22, P94, DOI 10.1128/MCB.22.1.94-104.2002; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Santore MT, 2002, AM J PHYSIOL-LUNG C, V282, pL727, DOI 10.1152/ajplung.00281.2001; Semenza GL, 2000, ADV EXP MED BIOL, V475, P123; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	41	58	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39942	39950		10.1074/jbc.M405747200	http://dx.doi.org/10.1074/jbc.M405747200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262985	hybrid			2022-12-27	WOS:000223791500091
J	Sakaue, H; Ogawa, W; Nakamura, T; Mori, T; Nakamura, K; Kasuga, M				Sakaue, H; Ogawa, W; Nakamura, T; Mori, T; Nakamura, K; Kasuga, M			Role of MAPK phosphatase-1 (MKP-1) in adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MITOTIC CLONAL EXPANSION; PPAR-GAMMA; C/EBP-ALPHA; PHOSPHOINOSITIDE 3-KINASE; 3T3-L1 PREADIPOCYTES; INSULIN SENSITIVITY; GLUCOSE-UPTAKE; ADIPOGENESIS; EXPRESSION	Both time-dependent modulation of intracellular signaling molecules and sequential induction of transcriptional regulators are essential for the differentiation of preadipocytes into adipocytes. We have now shown that the activity, but not the abundance, of p42/p44 mitogen-activated protein kinase (MAPK) is down-regulated during adipocyte differentiation. This decrease in p42/p44 MAPK activity does not appear to be a direct effect of hormonal inducers of differentiation but rather represents a characteristic event of adipocyte differentiation that is achieved through a persistent change in intracellular signaling. Although the phosphorylation or abundance of MEK, an upstream kinase for p42/p44 MAPK, was not altered during differentiation, the abundance of MAPK phosphatase-1 (MKP-1), a negative regulator of p42/p44 MAPK, was increased with a time course similar to that of the down-regulation of p42/p44 MAPK activity. Ectopic expression of MKP-1 in preadipocytes reduced and depletion of endogenous MKP-1 in mature adipocytes increased the activity of p42/p44 MAPK. Prevention of the up-regulation of MKP-1 abundance in preadipocytes by expression of Mkp-1 antisense RNA resulted in persistence of p42/p44 MAPK activation and blocked differentiation, effects that were reversed by the MEK inhibitor PD98059. These results suggest that MKP-1 plays an essential role in adipocyte differentiation through down-regulation of p42/p44 MAPK activity.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis,Chuo Ku, Kobe, Hyogo 650017, Japan	Kobe University	Ogawa, W (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 650017, Japan.	ogawa@med.kobe-u.ac.jp	OGAWA, Wataru/AAQ-9586-2020; Sakaue, Hiroshi/ABE-2337-2021	Sakaue, Hiroshi/0000-0002-2468-2363				ALESSI DR, 1993, ONCOGENE, V8, P2015; BERNLOHR DA, 1985, BIOCHEM BIOPH RES CO, V132, P850, DOI 10.1016/0006-291X(85)91209-4; Camp HS, 1997, J BIOL CHEM, V272, P10811; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Engelman JA, 1999, J BIOL CHEM, V274, P35630, DOI 10.1074/jbc.274.50.35630; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; HAYASHI I, 1981, P NATL ACAD SCI-BIOL, V78, P3969, DOI 10.1073/pnas.78.6.3969; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kusari AB, 1997, MOL ENDOCRINOL, V11, P1532, DOI 10.1210/me.11.10.1532; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; NAVRE M, 1988, J CELL BIOL, V107, P279, DOI 10.1083/jcb.107.1.279; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Qiu ZL, 2001, J BIOL CHEM, V276, P11988, DOI 10.1074/jbc.M011729200; Rangwala SM, 2003, DEV CELL, V5, P657, DOI 10.1016/S1534-5807(03)00274-0; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Sakaue H, 1998, J BIOL CHEM, V273, P28945, DOI 10.1074/jbc.273.44.28945; Sakaue H, 2002, GENE DEV, V16, P908, DOI 10.1101/gad.983202; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Schliess F, 2000, GASTROENTEROLOGY, V118, P929, DOI 10.1016/S0016-5085(00)70179-X; Smas CM, 1997, MOL CELL BIOL, V17, P977, DOI 10.1128/MCB.17.2.977; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Zhang JW, 2004, P NATL ACAD SCI USA, V101, P43, DOI 10.1073/pnas.0307229101	35	63	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39951	39957		10.1074/jbc.M407353200	http://dx.doi.org/10.1074/jbc.M407353200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15269202	hybrid			2022-12-27	WOS:000223791500126
J	Prins, C; Cresawn, SG; Condit, RC				Prins, C; Cresawn, SG; Condit, RC			An isatin-beta-thiosemicarbazone-resistant vaccinia virus containing a mutation in the second largest subunit of the viral RNA polymerase is defective in transcription elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATE MESSENGER-RNAS; A18R DNA HELICASE; NASCENT RNA; TERNARY COMPLEXES; STAGE GENES; H4 SUBUNIT; TERMINATION; PROMOTER; SEQUENCE; PROTEIN	The vaccinia virus RNA polymerase is a multi-subunit enzyme that contains eight subunits in the postreplicative form. A prior study of a virus called IBTr90, which contains a mutation in the A24 gene encoding the RPO132 subunit of the RNA polymerase, demonstrated that the mutation results in resistance to the anti-poxvirus drug isatin-beta-thiosemicarbazone (IBT). In this study, we utilized an in vitro transcription elongation assay to determine the effect of this mutation on transcription elongation. Both wild type and IBTr90 polymerase complexes were studied with regard to their ability to pause during elongation, their stability in a paused state, their ability to release transcripts, and their elongation rate. We have determined that the IBTr90 complex is specifically defective in elongation compared with the WT complex, pausing longer and more frequently than the WT complex. We have built a homology model of the RPO132 subunit with the yeast pol II rpb2 subunit to propose a structural mechanism for this elongation defect.	Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Condit, RC (corresponding author), Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA.	condit@mgm.ufl.edu						AHN BY, 1989, J VIROL, V63, P226, DOI 10.1128/JVI.63.1.226-232.1989; AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; AHN BY, 1994, J BIOL CHEM, V269, P7552; BALDICK CJ, 1993, J VIROL, V67, P3515, DOI 10.1128/JVI.67.6.3515-3527.1993; BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BERTHOLET C, 1987, CELL, V50, P153, DOI 10.1016/0092-8674(87)90211-X; Black EP, 1996, J VIROL, V70, P47, DOI 10.1128/JVI.70.1.47-54.1996; BROYLES SS, 1990, J VIROL, V64, P5376, DOI 10.1128/JVI.64.11.5376-5382.1990; BROYLES SS, 1987, J VIROL, V61, P1738, DOI 10.1128/JVI.61.5.1738-1742.1987; Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0; COHRS RJ, 1989, J VIROL, V63, P948, DOI 10.1128/JVI.63.2.948-951.1989; CONDIT RC, 1981, VIROLOGY, V113, P224, DOI 10.1016/0042-6822(81)90150-1; CONDIT RC, 1991, VIROLOGY, V185, P857, DOI 10.1016/0042-6822(91)90559-T; COOPER JA, 1981, J VIROL, V39, P733, DOI 10.1128/JVI.39.3.733-745.1981; DENG L, 1994, J BIOL CHEM, V269, P14323; Deng L, 1998, GENE DEV, V12, P538, DOI 10.1101/gad.12.4.538; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; JIN DJ, 1991, J BIOL CHEM, V266, P14478; KANE EM, 1993, J VIROL, V67, P2689, DOI 10.1128/JVI.67.5.2689-2698.1993; KATES J, 1970, J MOL BIOL, V50, P1, DOI 10.1016/0022-2836(70)90100-2; KATZ E, 1973, J GEN VIROL, V21, P469, DOI 10.1099/0022-1317-21-3-469; Lackner CA, 2000, J BIOL CHEM, V275, P1485, DOI 10.1074/jbc.275.2.1485; Latner DR, 2000, VIROLOGY, V269, P345, DOI 10.1006/viro.2000.0243; Latner DR, 2002, VIROLOGY, V301, P64, DOI 10.1006/viro.2002.1538; LUO Y, 1991, J BIOL CHEM, V266, P13303; LUO Y, 1995, J VIROL, V69, P3852, DOI 10.1128/JVI.69.6.3852-3856.1995; MAHR A, 1984, J VIROL, V49, P510, DOI 10.1128/JVI.49.2.510-520.1984; Moss B, 2001, FIELDS VIROLOGY, P2849; PATEL DD, 1987, EMBO J, V6, P3787, DOI 10.1002/j.1460-2075.1987.tb02714.x; RODRIGUEZ JF, 1986, P NATL ACAD SCI USA, V83, P9566, DOI 10.1073/pnas.83.24.9566; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHWER B, 1987, CELL, V50, P163, DOI 10.1016/0092-8674(87)90212-1; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; SPENCER E, 1980, J BIOL CHEM, V255, P5388; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WRIGHT CF, 1995, J VIROL, V69, P2602, DOI 10.1128/JVI.69.4.2602-2604.1995; Xiang Y, 1998, J VIROL, V72, P7012, DOI 10.1128/JVI.72.9.7012-7023.1998; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417	45	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44858	44871		10.1074/jbc.M408167200	http://dx.doi.org/10.1074/jbc.M408167200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15294890	hybrid			2022-12-27	WOS:000224505600076
J	Gravante, B; Barbuti, A; Milanesi, R; Zappi, I; Viscomi, C; DiFrancesco, D				Gravante, B; Barbuti, A; Milanesi, R; Zappi, I; Viscomi, C; DiFrancesco, D			Interaction of the pacemaker channel HCN1 with filamin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN FILAMIN; RAT HIPPOCAMPAL-NEURONS; RABBIT SINOATRIAL NODE; ACTIN CYTOSKELETON; POTASSIUM CHANNELS; RECEPTOR CHANNELS; MOLECULAR-BASIS; ORGANIZATION; VOLTAGE; DOMAIN	Pacemaker channels are encoded by the HCN gene family and are responsible for a variety of cellular functions including control of spontaneous activity in cardiac myocytes and control of excitability in different types of neurons. Some of these functions require specific membrane localization. Although several voltage-gated channels are known to interact with intracellular proteins exerting auxiliary functions, no cytoplasmic proteins have been found so far to modulate HCN channels. Through the use of a yeast two-hybrid technique, here we showed that filamin A interacts with HCN1, an HCN isoform widely expressed in the brain, but not with HCN2 or HCN4. Filamin A is a cytoplasmic scaffold protein with actin-binding domains whose main function is to link transmembrane proteins to the actin cytoskeleton. Using several HCN1 C-terminal constructs, we identified a filamin A-interacting region of 22 amino acids located downstream from the cyclic nucleotide-binding domain; this region is not conserved in HCN2, HCN3, or HCN4. We also verified by immunoprecipitation from bovine brain that the filamin A-HCN1 interaction is functional in vivo. In filamin A-expressing cells (filamin(+)), HCN1 (but not HCN4) channels were expressed in hot spots, whereas they were evenly distributed on the membrane of cells lacking filamin A (filamin(-)) indicating that interaction with filamin A affects membrane localization. Also, in filamin(-) cells the gating kinetics of HCN1 were strongly accelerated relative to filamin(+) cells. The interaction with filamin A may contribute to localizing HCN1 channels to specific neuronal areas and to modulating channel activity.	Univ Milan, Dept Biomol Sci & Biotechnol, Lab Mol Physiol & Neurobiol, I-20133 Milan, Italy; Inst Nazl Fis Mat, Milano U Unit, I-20133 Milan, Italy	University of Milan	DiFrancesco, D (corresponding author), Univ Milan, Dept Biomol Sci & Biotechnol, Lab Mol Physiol & Neurobiol, Via Celoria 26, I-20133 Milan, Italy.	dario.difrancesco@unimi.it	Barbuti, Andrea/N-9805-2013; DiFrancesco, Dario/G-8408-2017; viscomi, Carlo/R-1940-2016	Barbuti, Andrea/0000-0002-4521-4913; DiFrancesco, Dario/0000-0002-7322-1790; Viscomi, Carlo/0000-0001-6050-0566				Accili EA, 1997, J PHYSIOL-LONDON, V500, P643, DOI 10.1113/jphysiol.1997.sp022049; Altomare C, 2003, J PHYSIOL-LONDON, V549, P347, DOI 10.1113/jphysiol.2002.027698; Altomare C, 2001, J GEN PHYSIOL, V117, P519, DOI 10.1085/jgp.117.6.519; CHANG F, 1991, J PHYSIOL-LONDON, V440, P367, DOI 10.1113/jphysiol.1991.sp018713; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Decher N, 2003, PFLUG ARCH EUR J PHY, V446, P633, DOI 10.1007/s00424-003-1127-7; Demontis GC, 2002, J PHYSIOL-LONDON, V542, P89, DOI 10.1113/jphysiol.2002.017640; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; Dyson JM, 2001, J CELL BIOL, V155, P1065, DOI 10.1083/jcb.200104005; Eldstrom J, 2002, FEBS LETT, V531, P529, DOI 10.1016/S0014-5793(02)03572-X; Hanlon MR, 2002, BIOCHEMISTRY-US, V41, P2886, DOI 10.1021/bi0119565; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; Lorincz A, 2002, NAT NEUROSCI, V5, P1185, DOI 10.1038/nn962; Magee JC, 1998, J NEUROSCI, V18, P7613; Meyer DK, 2000, J NEUROSCI, V20, P6743, DOI 10.1523/JNEUROSCI.20-18-06743.2000; Mitcheson JS, 1999, CELL PHYSIOL BIOCHEM, V9, P201, DOI 10.1159/000016317; Moosmang S, 1999, BIOL CHEM, V380, P975, DOI 10.1515/BC.1999.121; Moroni A, 2001, J BIOL CHEM, V276, P29233, DOI 10.1074/jbc.M100830200; Norenberg W, 1999, BRIT J PHARMACOL, V127, P1060, DOI 10.1038/sj.bjp.0702643; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Pedrazzini E, 1996, P NATL ACAD SCI USA, V93, P4207, DOI 10.1073/pnas.93.9.4207; Petrecca K, 2000, J NEUROSCI, V20, P8736; Prat AG, 1999, AM J PHYSIOL-CELL PH, V277, pC1160, DOI 10.1152/ajpcell.1999.277.6.C1160; Qu JH, 2002, PFLUG ARCH EUR J PHY, V444, P597, DOI 10.1007/s00424-002-0860-7; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sampson LJ, 2003, J BIOL CHEM, V278, P41988, DOI 10.1074/jbc.M307479200; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Viscomi C, 2001, J BIOL CHEM, V276, P29930, DOI 10.1074/jbc.M103971200; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; Wang J, 2002, NEURON, V36, P451, DOI 10.1016/S0896-6273(02)00968-6; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511	44	88	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43847	43853		10.1074/jbc.M401598200	http://dx.doi.org/10.1074/jbc.M401598200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292205	hybrid			2022-12-27	WOS:000224383100061
J	Tsang, SY; Lesso, H; Li, RA				Tsang, SY; Lesso, H; Li, RA			Dissecting the structural and functional roles of the S3-S4 linker of pacemaker (hyperpolarization-activated cyclic nucleotide-modulated) channels by systematic length alterations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATING KINETICS; HCN CHANNEL; IDENTIFICATION; POTASSIUM; PERTURBATIONS; DETERMINANT; MOVEMENT; INSIGHTS	I-f or I-h, a key player in neuronal and cardiac pacing, is encoded by the hyperpolarization-activated cyclic nucleotide-modulated (HCN) channel gene family. We have recently reported that the S3-S4 linker (i.e. residues (229)EKGMDSEVY(237) of HCN1) prominently influences the activation phenotypes of HCN channels and that part of the linker may conform a secondary helical structure. Here we further dissected the structural and functional roles of this linker by systematic alterations of its length. In contrast to voltage-gated K+ channels, complete deletion of the S3-S4 linker (Delta229-237) did not produce functional channels. Similarly, the deletions Delta229 - 234, Delta232 - 234, and Delta232 - 237 also abolished normal current activity. Interestingly, Delta229 - 231, Delta233 - 237, Delta234 - 237, Delta235 - 237, Delta229 - 231/ Delta233 - 237, Delta229 - 231/Delta234 237, and Delta229 - 231/Delta235 - 237 all yielded robust hyperpolarization-activated inward currents, indicating that loss-of-function caused by deletion could be rescued by keeping the single functionally important residue Met(232) alone. Whereas shortening the linker by deletion generally shifted steady-state activation in the depolarizing direction (e.g. DeltaV(1/2) of Delta229 - 231, Delta233 - 237, Delta235 - 237 >+10 mV relative to wild type), linker prolongation by duplicating the entire linker (Dup229 - 237) or by glutamine insertion (InsQ233Q, InsQQ233QQ and InsQQQ233QQQ, or Ins237QQQ) produced length-dependent progressive hyperpolarizing activation shifts ( - 35 mV < Delta V-1/2 < -4 mV). Based on these results, we conclude that only Met(232) is prerequisite for channels to function, but the length and other constituents of the S3-S4 linker shape the ultimate activation phenotype. Our results also highlight several evolutionary similarities and differences between HCN and voltage-gated K+ channels. Manipulations of the S3-S4 linker length may provide a flexible approach to customize HCN gating for engineering electrically active cells ( such as stem cell-derived neuronal and cardiac pacemakers) for gene- and cell-based therapies.	Johns Hopkins Univ, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University	Li, RA (corresponding author), Johns Hopkins Univ, Dept Med, 720 Rutland Ave,Ross 871, Baltimore, MD 21205 USA.	ronaldli@jhmi.edu	TSANG, Suk/Q-6402-2018	TSANG, Suk/0000-0002-9992-5454	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072857] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL072857-01A2] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azene EM, 2003, J PHYSIOL-LONDON, V547, P349, DOI 10.1113/jphysiol.2003.039768; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DURELL SR, 1992, BIOPHYS J, V1, P1; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Gonzalez C, 2000, J GEN PHYSIOL, V115, P193, DOI 10.1085/jgp.115.2.193; Gonzalez C, 2001, P NATL ACAD SCI USA, V98, P9617, DOI 10.1073/pnas.171306298; Henrikson CA, 2003, J BIOL CHEM, V278, P13647, DOI 10.1074/jbc.M211025200; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Lesso H, 2003, J BIOL CHEM, V278, P22290, DOI 10.1074/jbc.M302466200; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Mannikko R, 2002, NATURE, V419, P837, DOI 10.1038/nature01038; Mathur R, 1997, J GEN PHYSIOL, V109, P191, DOI 10.1085/jgp.109.2.191; NAKAI J, 1994, P NATL ACAD SCI USA, V91, P1014, DOI 10.1073/pnas.91.3.1014; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Sorensen JB, 2000, J GEN PHYSIOL, V115, P209, DOI 10.1085/jgp.115.2.209; Tsang SY, 2004, BIOPHYS J, V86, p293A; Vemana S, 2004, J GEN PHYSIOL, V123, P21, DOI 10.1085/jgp.200308916; Xue T, 2003, CIRCULATION, V108; Xue T, 2002, CIRC RES, V90, P1267, DOI 10.1161/01.RES.0000024390.97889.C6; Xue T, 2002, J BIOL CHEM, V277, P46233, DOI 10.1074/jbc.M204915200	22	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43752	43759		10.1074/jbc.M408747200	http://dx.doi.org/10.1074/jbc.M408747200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15299004	hybrid			2022-12-27	WOS:000224383100050
J	Liao, YJ; Shikapwashya, ON; Shteyer, E; Dieckgraefe, BK; Hruz, PW; Rudnick, DA				Liao, YJ; Shikapwashya, ON; Shteyer, E; Dieckgraefe, BK; Hruz, PW; Rudnick, DA			Delayed hepatocellular mitotic progression and impaired liver regeneration in early growth response-1-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SPINDLE ASSEMBLY CHECKPOINT; HEPATOCYTE PROLIFERATION; CELLULAR PROLIFERATION; PARTIAL-HEPATECTOMY; SIGNALING PATHWAY; RAPID ACTIVATION; PRIMARY RESPONSE; KAPPA-B; NGFI-A	The early growth response-1 transcription factor (Egr-1) is induced as part of the immediate-early gene expression response during early liver regeneration. In the studies reported here the functional significance of EGR-1 expression during liver regeneration was examined by characterizing the hepatic regenerative response to partial hepatectomy in Egr-1 null mice. The results of these studies showed that liver regeneration in Egr-1 null mice is impaired. Although activation of interleukin-6-STAT3 signaling, regulation of expression of hepatic C/ebpalpha, C/ebpbeta, cyclin D, and cyclin E and progression through the first wave of hepatocellular DNA synthesis occurred appropriately following partial hepatectomy in Egr-1 null mice, subsequent signaling events and cell cycle progression after the first round of DNA synthesis were deranged. This derangement was characterized by increased activation of the p38 mitogen-activated protein kinase and inhibition of hepatocellular metaphase-to-anaphase mitotic progression. Together these observations suggest that EGR-1 is an important regulator of hepatocellular mitotic progression. In support of this, microarray-based gene expression analysis showed that induction of expression of the cell division cycle 20 gene (Cdc20), a key regulator of the mitotic anaphase-promoting complex, is significantly reduced in Egr-1 null mice. Taken together these data define a novel functional role for EGR-1 in regulating hepatocellular mitotic progression through the spindle assembly checkpoint during liver regeneration.	Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cellular Biol & Physiol, St Louis, MO 63110 USA	St. Louis Children's Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)	Rudnick, DA (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,Box 8208, St Louis, MO 63110 USA.	rudnick_d@kids.wustl.edu		Hruz, Paul/0000-0002-1478-3355	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD033688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK064653, P30DK052574, K08DK002900] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33688] Funding Source: Medline; NIDDK NIH HHS [DK64653, DK02900, P30 DK52574] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERMAN P, 1992, AM J PHYSIOL, V263, P579; Ambrosino C, 2001, BIOL CELL, V93, P47, DOI 10.1016/S0248-4900(01)01124-8; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Diamond RH, 1996, AM J PHYSIOL-GASTR L, V271, pG121, DOI 10.1152/ajpgi.1996.271.1.G121; DIEHL AM, 1999, SCHIFFS DIS LIVER, P39; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Higgins GM, 1931, ARCH PATHOL, V12, P186; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Lee FYJ, 1999, HEPATOLOGY, V29, P677, DOI 10.1002/hep.510290320; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; Li W, 2002, J BIOL CHEM, V277, P28411, DOI 10.1074/jbc.M202807200; Li W, 2001, HEPATOLOGY, V33, P1377, DOI 10.1053/jhep.2001.24431; LIM RW, 1987, ONCOGENE, V1, P263; Luo XL, 2000, NAT STRUCT BIOL, V7, P224; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Peng Y, 1999, J BIOL CHEM, V274, P4513, DOI 10.1074/jbc.274.8.4513; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Rudnick DA, 2001, P NATL ACAD SCI USA, V98, P8885, DOI 10.1073/pnas.151217998; Servillo G, 1997, ONCOGENE, V14, P1601, DOI 10.1038/sj.onc.1200996; Servillo G, 2002, EXP CELL RES, V275, P143, DOI 10.1006/excr.2002.5491; Servillo G, 1998, GENE DEV, V12, P3639, DOI 10.1101/gad.12.23.3639; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	40	79	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43107	43116		10.1074/jbc.M407969200	http://dx.doi.org/10.1074/jbc.M407969200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15265859	hybrid			2022-12-27	WOS:000224226400095
J	Uzcategui, NL; Szallies, A; Pavlovic-Djuranovic, S; Palmada, M; Figarella, K; Boehmer, C; Lang, F; Beitz, E; Duszenko, M				Uzcategui, NL; Szallies, A; Pavlovic-Djuranovic, S; Palmada, M; Figarella, K; Boehmer, C; Lang, F; Beitz, E; Duszenko, M			Cloning, heterologous expression, and characterization of three aquaglyceroporins from Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORM; SACCHAROMYCES-CEREVISIAE; GLYCOLYTIC-ENZYMES; GLYCEROL UPTAKE; OSMOTIC-STRESS; CHANNEL; PROTEINS; DIHYDROXYACETONE; FACILITATOR; SELECTIVITY	Trypanosoma brucei, causative for African sleeping sickness, relies exclusively on glycolysis for ATP production. Under anaerobic conditions, glucose is converted to equimolar amounts of glycerol and pyruvate, which are both secreted from the parasite. As we have shown previously, glycerol transport in T. brucei occurs via specific membrane proteins (Wille, U., Schade, B., and Duszenko, M. ( 1998) Eur. J. Biochem. 256, 245 - 250). Here, we describe cloning and biochemical characterization of the three trypanosomal aquaglyceroporins (AQP; TbAQP1 - 3), which show a 40 - 45% identity to mammalian AQP3 and - 9. AQPs belong to the major intrinsic protein family and represent channels for small non-ionic molecules. Both TbAQP1 and TbAQP3 contain two highly conserved NPA motifs within the pore-forming region, whereas TbAQP2 contains NSA and NPS motifs instead, which are only occasionally found in AQPs. For functional characterization, all three proteins were heterologously expressed in yeast and Xenopus oocytes. In the yeast fps1Delta mutant, TbAQPs suppressed hypoosmosensitivity and rendered cells to a hyper-osmosensitive phenotype, as expected for unregulated glycerol channels. Under iso- and hyperosmotic conditions, these cells constitutively released glycerol, consistent with a glycerol efflux function of TbAQP proteins. TbAQP expression in Xenopus oocytes increased permeability for water, glycerol and, interestingly, dihydroxyacetone. Except for urea, TbAQPs were virtually impermeable for other polyols; only TbAQP3 transported erythritol and ribitol. Thus, TbAQPs represent mainly water/glycerol/ dihydroxyacetone channels involved in osmoregulation and glycerol metabolism in T. brucei. This function and especially the so far not investigated transport of dihydroxyacetone may be pivotal for the survival of the parasite survival under non-aerobic or osmotic stress conditions.	Univ Tubingen, Inst Biochem, D-72076 Tubingen, Germany; Univ Tubingen, Dept Pharmaceut Biochem, D-72076 Tubingen, Germany; Univ Tubingen, Inst Physiol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Duszenko, M (corresponding author), Univ Tubingen, Inst Physiol Chem, Hoppe Seyler Str 4, D-72076 Tubingen, Germany.	michael.duszenko@uni-tuebingen.de	Figarella, Katherine/S-6872-2019	Uzcategui, Nestor/0000-0002-3550-3308; Figarella, Katherine/0000-0003-3305-9167				Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; ALBERTYN J, 1994, CURR GENET, V25, P12, DOI 10.1007/BF00712960; BAKKER B, 1998, THESIS U AMSTERDAM A; Bakker BM, 2000, MOL BIOCHEM PARASIT, V106, P1, DOI 10.1016/S0166-6851(99)00197-8; Bakker BM, 1997, J BIOL CHEM, V272, P3207, DOI 10.1074/jbc.272.6.3207; BERMEYER HU, 1984, METHODS ENZYMATIC 1, V6, P504; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROHN FH, 1978, ACTA TROP, V35, P23; Clayton CE, 1996, PARASITOL TODAY, V12, P465, DOI 10.1016/S0169-4758(96)10073-9; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; Eisenthal R, 1998, J BIOL CHEM, V273, P5500, DOI 10.1074/jbc.273.10.5500; HAMM B, 1990, MOL BIOCHEM PARASIT, V40, P13, DOI 10.1016/0166-6851(90)90075-W; Hansen M, 2002, J BIOL CHEM, V277, P4874, DOI 10.1074/jbc.M110683200; Hedfalk K, 2004, J BIOL CHEM, V279, P14954, DOI 10.1074/jbc.M313126200; HESSE F, 1995, MOL BIOCHEM PARASIT, V70, P157, DOI 10.1016/0166-6851(95)00027-X; Jungwirth H, 2001, J BIOL CHEM, V276, P36419, DOI 10.1074/jbc.M104487200; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; MA TH, 1994, J BIOL CHEM, V269, P21845; Michels PAM, 2000, PARASITOL TODAY, V16, P482, DOI 10.1016/S0169-4758(00)01810-X; Molin M, 2003, J BIOL CHEM, V278, P1415, DOI 10.1074/jbc.M203030200; NELSON D, 2000, LEHNINGER PRINCIPLES, P410; Norbeck J, 1997, J BIOL CHEM, V272, P5544, DOI 10.1074/jbc.272.9.5544; OPPERDOES FR, 1977, FEBS LETT, V80, P360, DOI 10.1016/0014-5793(77)80476-6; OVERATH P, 1986, EUR J BIOCHEM, V160, P175, DOI 10.1111/j.1432-1033.1986.tb09955.x; Pavlovic-Djuranovic S, 2003, FEBS LETT, V555, P500, DOI 10.1016/S0014-5793(03)01313-9; SIKOSKI RS, 1989, GENETICS, V102, P19; Smith J.A., 2000, CURRENT PROTOCOLS MO; Steinborn K, 2000, BIOL CHEM, V381, P1071, DOI 10.1515/BC.2000.132; Sun JB, 2003, BIOTECHNOL PROGR, V19, P263, DOI 10.1021/bp025739m; Tamas MJ, 1999, MOL MICROBIOL, V31, P1087, DOI 10.1046/j.1365-2958.1999.01248.x; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; Wagner CA, 2000, CELL PHYSIOL BIOCHEM, V10, P1, DOI 10.1159/000016341; WALSH MC, 1994, J BACTERIOL, V176, P953, DOI 10.1128/JB.176.4.953-958.1994; WIEMER EAC, 1995, BIOCHEM J, V312, P479, DOI 10.1042/bj3120479; Wille U, 1998, EUR J BIOCHEM, V256, P245, DOI 10.1046/j.1432-1327.1998.2560245.x	35	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42669	42676		10.1074/jbc.M404518200	http://dx.doi.org/10.1074/jbc.M404518200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15294911	hybrid			2022-12-27	WOS:000224226400040
J	Chang, TS; Cho, CS; Park, S; Yu, SQ; Kang, SW; Rhee, SG				Chang, TS; Cho, CS; Park, S; Yu, SQ; Kang, SW; Rhee, SG			Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROGRAMMED CELL-DEATH; MANGANESE SUPEROXIDE-DISMUTASE; PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; GLUTATHIONE-PEROXIDASE; OXIDATIVE STRESS; MAMMALIAN PEROXIREDOXIN	Various proapoptotic stimuli increase the production of superoxide and H2O2 by mitochondria. Whereas superoxide impairs mitochondrial function and is removed by Mn2+-dependent superoxide dismutase, the role and metabolism of mitochondrial H2O2 during apoptosis have remained unclear. The effects on apoptotic signaling of depletion of peroxiredoxin (Prx) III, a mitochondrion-specific H2O2-scavenging enzyme, have now been investigated by RNA interference in HeLa cells. Depletion of Prx III resulted in increased intracellular levels of H2O2 and sensitized cells to induction of apoptosis by staurosporine or TNF-alpha. The rates of mitochondrial membrane potential collapse, cytochrome c release, and caspase activation were increased in Prx III-depleted cells, and these effects were reversed by ectopic expression of Prx III or mitochondrion-targeted catalase. Depletion of Prx III also exacerbated damage to mitochondrial macromolecules induced by the proapoptotic stimuli. Our results suggest that Prx III is a critical regulator of the abundance of mitochondrial H2O2, which itself promotes apoptosis in cooperation with other mediators of apoptotic signaling.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Ewha Womans Univ, Ctr Cell Signaling Res, Div Mol Life Sci, Seoul 120750, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Ewha Womans University	Rhee, SG (corresponding author), Bldg 50,Room 3523,S Dr,MSC 8015, Bethesda, MD 20892 USA.	sgrhee@nih.gov		CHO, CHUN-SEOK/0000-0002-9589-5745				Aoki K, 1999, MOL MED, V5, P224, DOI 10.1007/BF03402119; Araki M, 1999, J BIOL CHEM, V274, P2271, DOI 10.1074/jbc.274.4.2271; Bai JX, 2001, J BIOL CHEM, V276, P4315, DOI 10.1074/jbc.M008895200; Bajt ML, 2002, ANTIOXID REDOX SIGN, V4, P733, DOI 10.1089/152308602760598873; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Boveris A, 2000, IUBMB LIFE, V50, P245, DOI 10.1080/15216540051080912; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chang TS, 2002, J BIOL CHEM, V277, P25370, DOI 10.1074/jbc.M110432200; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Choi JH, 2002, ANTICANCER RES, V22, P3331; Crack PJ, 2001, J NEUROCHEM, V78, P1389, DOI 10.1046/j.1471-4159.2001.00535.x; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fujimura M, 1999, J NEUROSCI, V19, P3414; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JONES DP, 1981, ARCH BIOCHEM BIOPHYS, V210, P505, DOI 10.1016/0003-9861(81)90215-0; Kim SH, 2001, J NEURAL TRANSM-SUPP, P223; Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Lam EWN, 1997, CANCER RES, V57, P5550; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Legault J, 2000, BIOCHEM BIOPH RES CO, V272, P416, DOI 10.1006/bbrc.2000.2800; Levine RL, 2000, METH MOL B, V99, P15; Li JJ, 1997, CANCER RES, V57, P1991; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Luetjens CM, 2000, J NEUROSCI, V20, P5715; MAKINO N, 1994, J BIOL CHEM, V269, P1020; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Noh DY, 2001, ANTICANCER RES, V21, P2085; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Nonn L, 2003, MOL CANCER RES, V1, P682; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; PANFILI E, 1991, FEBS LETT, V290, P35, DOI 10.1016/0014-5793(91)81219-X; Pedrajas JR, 2000, J BIOL CHEM, V275, P16296, DOI 10.1074/jbc.275.21.16296; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Petrosillo G, 2001, FEBS LETT, V509, P435, DOI 10.1016/S0014-5793(01)03206-9; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RADI R, 1991, J BIOL CHEM, V266, P22028; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Rhee S G, 2000, Sci STKE, V2000, ppe1; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; ROTHE G, 1991, J IMMUNOL METHODS, V138, P133, DOI 10.1016/0022-1759(91)90074-P; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Van Remmen H, 2001, AM J PHYSIOL-HEART C, V281, pH1422, DOI 10.1152/ajpheart.2001.281.3.H1422; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang XD, 2001, GENE DEV, V15, P2922; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	86	310	321	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41975	41984		10.1074/jbc.M407707200	http://dx.doi.org/10.1074/jbc.M407707200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280382	hybrid			2022-12-27	WOS:000224075500090
J	Choi, JY; Martin, WE; Murphy, RC; Voelker, DR				Choi, JY; Martin, WE; Murphy, RC; Voelker, DR			Phosphatidylcholine and N-methylated phospholipids are nonessential in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID POLYMORPHISM; MASS-SPECTROMETRY; FUNCTIONAL ROLES; YEAST; PHOSPHATIDYLETHANOLAMINE; MEMBRANE; CLONING; MUTANTS; GENE; PHOSPHATIDYLSERINE	Phosphatidylcholine (PtdCho) is the most abundant phospholipid in numerous eukaryotes and is generally thought to be essential for membrane structure and cellular function. We designed a specific test of this idea by using genetic and biochemical manipulation of yeast. Yeast mutants (pem1 pem2Delta) lacking the phosphatidylethanolamine (PtdEtn) methyltransferase enzymes require choline for growth and cannot make N-methylated phospholipids. When these strains are grown on a glucose carbon source supplemented with 20 mM propanolamine (Prn), the PtdCho level declines precipitously to the limits of detection (<0.6%), and the hexagonal phase-forming, primary amine-containing lipids, PtdEtn and PtdPrn, constitute similar to 60% of the total phospholipid content of the cell. When the lipids were analyzed by mass spectrometry, there was no compensatory shift in unsaturation of the PtdEtn and PtdPrn toward more bilayer-forming species. Thus the majority of the cellular amino phospholipids remained hexagonal phase-forming. The pem1 pem2 Delta cells will also grow without choline, in the presence of Prn, on nonfermentable carbon sources (requiring functional mitochondria) and accumulate nearly 70% of their phospholipid as hexagonal phase-forming types. These data provide compelling evidence that the functions of PtdCho and N-methylated lipids in membranes are nonessential in Saccharomyces cerevisiae.	Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	National Jewish Health; National Jewish Health	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	voelkerd@njc.org			NIGMS NIH HHS [R24 GM067877, 2R37 GM32453] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453, R24GM067877] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bogdanov M, 1998, EMBO J, V17, P5255, DOI 10.1093/emboj/17.18.5255; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; Cullis P.R., 1996, NEW COMPREHENSIVE BI, V31, P1; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GRUNER SM, 1985, ANNU REV BIOPHYS BIO, V14, P211, DOI 10.1146/annurev.biophys.14.1.211; Henneberry AL, 2002, MOL BIOL CELL, V13, P3148, DOI 10.1091/mbc.01-11-0540; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; Howe AG, 2001, BBA-MOL CELL BIOL L, V1534, P65, DOI 10.1016/S1388-1981(01)00181-0; KAYGANICH KA, 1992, ANAL CHEM, V64, P2965, DOI 10.1021/ac00047a015; KODAKI T, 1987, J BIOL CHEM, V262, P15428; Pulfer M, 2003, MASS SPECTROM REV, V22, P332, DOI 10.1002/mas.10061; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Schneiter R, 1999, J CELL BIOL, V146, P741, DOI 10.1083/jcb.146.4.741; SMITH JD, 1988, BIOCHEM J, V254, P301, DOI 10.1042/bj2540301; Storey MK, 2001, J BIOL CHEM, V276, P48539, DOI 10.1074/jbc.M109043200; SUMMERS EF, 1988, GENETICS, V120, P909; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; Uhlson C, 2002, CHEM RES TOXICOL, V15, P896, DOI 10.1021/tx010183i; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073; Wu WI, 2000, J BIOL CHEM, V275, P14446, DOI 10.1074/jbc.275.19.14446; YEAGLE PL, 1989, FASEB J, V3, P1833, DOI 10.1096/fasebj.3.7.2469614	27	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42321	42330		10.1074/jbc.M405074200	http://dx.doi.org/10.1074/jbc.M405074200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15269223	hybrid			2022-12-27	WOS:000224075500124
J	Huber, SM; Duranton, C; Henke, G; van de Sand, C; Heussler, V; Shumilina, E; Sandu, CD; Tanneur, V; Brand, V; Kasinathan, RS; Lang, KS; Kremsner, PG; Hubner, CA; Rust, MB; Dedek, K; Jentsch, TJ; Lang, F				Huber, SM; Duranton, C; Henke, G; van de Sand, C; Heussler, V; Shumilina, E; Sandu, CD; Tanneur, V; Brand, V; Kasinathan, RS; Lang, KS; Kremsner, PG; Hubner, CA; Rust, MB; Dedek, K; Jentsch, TJ; Lang, F			Plasmodium induces swelling-activated ClC-2 anion channels in the host erythrocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; MALARIA-INFECTED ERYTHROCYTES; CHLORIDE CHANNELS; CATION-TRANSPORT; FALCIPARUM; PARASITE; MEMBRANE; VOLUME; K+; POTASSIUM	Intraerythrocytic growth of the human malaria parasite Plasmodium falciparum depends on delivery of nutrients. Moreover, infection challenges cell volume constancy of the host erythrocyte requiring enhanced activity of cell volume regulatory mechanisms. Patch clamp recording demonstrated inwardly and outwardly rectifying anion channels in infected but not in control erythrocytes. The molecular identity of those channels remained elusive. We show here for one channel type that voltage dependence, cell volume sensitivity, and activation by oxidation are identical to ClC-2. Moreover, Western blots and FACS analysis showed protein and functional ClC-2 expression in human erythrocytes and erythrocytes from wild type (Clcn2(+/+)) but not from Clcn2(-/-) mice. Finally, patch clamp recording revealed activation of volume-sensitive inwardly rectifying channels in Plasmodium berghei-infected Clcn2(+/+) but not Clcn2(-/-) erythrocytes. Erythrocytes from infected mice of both genotypes differed in cell volume and inhibition of ClC-2 by ZnCl2 (1 mM) induced an increase of cell volume only in parasitized Clcn2(+/+) erythrocytes. Lack of ClC-2 did not inhibit P. berghei development in vivo nor substantially affect the mortality of infected mice. In conclusion, activation of host ClC-2 channels participates in the altered permeability of Plasmodium-infected erythrocytes but is not required for intraerythrocytic parasite survival.	Univ Tubingen, Dept Physiol, Inst Trop Med, D-72076 Tubingen, Germany; Univ Tubingen, Dept Parasitol, Inst Trop Med, D-72076 Tubingen, Germany; Univ Hamburg, Bernhard Nocht Inst, D-20359 Hamburg, Germany; Univ Hamburg, Ctr Mol Neurobiol, D-20359 Hamburg, Germany; Univ Oldenburg, Dept Neurobiol, D-26111 Oldenburg, Germany; Univ Hamburg, Bernhard Nocht Inst, D-20251 Hamburg, Germany; Univ Hamburg, Ctr Mol Neurobiol, D-20251 Hamburg, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Bernhard Nocht Institut fur Tropenmedizin; University of Hamburg; University of Hamburg; Carl von Ossietzky Universitat Oldenburg; Bernhard Nocht Institut fur Tropenmedizin; University of Hamburg; University of Hamburg	Huber, SM (corresponding author), Univ Tubingen, Dept Physiol 1, Gmelinstr 5, D-72076 Tubingen, Germany.	stephan.huber@uni-tuebingen.de	Dedek, Karin/R-6948-2018; Kasinathan, Ravi/B-7657-2013; DURANTON, CHRISTOPHE/E-9582-2019; Heussler, Volker/H-9322-2019; Hübner, Christian/A-2950-2017; Lang, Karl S/R-2505-2016	Dedek, Karin/0000-0003-1490-0141; DURANTON, CHRISTOPHE/0000-0003-1127-2346; Heussler, Volker/0000-0001-8028-9825; Hübner, Christian/0000-0002-1030-4943; Huber, Stephan/0000-0002-9430-8334; Lang, Karl/0000-0001-9783-7605; Jentsch, Thomas/0000-0002-3509-2553				ATAMNA H, 1994, MOL BIOCHEM PARASIT, V67, P79, DOI 10.1016/0166-6851(94)90098-1; ATAMNA H, 1993, MOL BIOCHEM PARASIT, V61, P231, DOI 10.1016/0166-6851(93)90069-A; Atamna H, 1997, EUR J BIOCHEM, V250, P670, DOI 10.1111/j.1432-1033.1997.00670.x; Baumeister S, 2003, MOL BIOCHEM PARASIT, V132, P35, DOI 10.1016/j.molbiopara.2003.08.003; BECKER K, 1994, HISTOCHEMISTRY, V102, P389, DOI 10.1007/BF00268910; Biarnais T, 2002, PARASITE, V9, P51, DOI 10.1051/parasite/200209151; Binh VQ, 1997, AM J TROP MED HYG, V57, P594, DOI 10.4269/ajtmh.1997.57.594; Bosl MR, 2001, EMBO J, V20, P1289, DOI 10.1093/emboj/20.6.1289; Brand VB, 2003, CELL PHYSIOL BIOCHEM, V13, P347, DOI 10.1159/000075122; Clark S, 1998, J PHYSIOL-LONDON, V506, P665, DOI 10.1111/j.1469-7793.1998.665bv.x; Cossins AR, 1997, J EXP BIOL, V200, P343; DANON D, 1964, J LAB CLIN MED, V64, P668; Desai SA, 2000, NATURE, V406, P1001, DOI 10.1038/35023000; DUNN MJ, 1969, J CLIN INVEST, V48, P674, DOI 10.1172/JCI106025; Duranton C, 2004, J GEN PHYSIOL, V123, P417, DOI 10.1085/jgp.200308919; Duranton C, 2003, CELL PHYSIOL BIOCHEM, V13, P189, DOI 10.1159/000072421; Egee S, 2002, J PHYSIOL-LONDON, V542, P795, DOI 10.1113/jphysiol.2002.022970; Egee S, 1997, J PHYSIOL-LONDON, V504, P57, DOI 10.1111/j.1469-7793.1997.057bf.x; GINSBURG H, 1986, Z PARASITENKD, V72, P185, DOI 10.1007/BF00931146; Ginsburg H, 2004, J MEMBRANE BIOL, V197, P113, DOI 10.1007/s00232-003-0646-7; Ginsburg H, 2002, TRENDS PARASITOL, V18, P346, DOI 10.1016/S1471-4922(02)02322-X; GINSBURG H, 1994, PARASITE, V1, P5, DOI 10.1051/parasite/1994011005; GINSBURG H, 1998, MALARIA PARASITE BIO, P219; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Huber SM, 2002, TRENDS PARASITOL, V18, P346, DOI 10.1016/S1471-4922(02)02323-1; Huber SM, 2002, EMBO J, V21, P22, DOI 10.1093/emboj/21.1.22; JENSEN JB, 1978, AM J TROP MED HYG, V27, P743, DOI 10.4269/ajtmh.1978.27.743; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kirk K, 2001, PHYSIOL REV, V81, P495, DOI 10.1152/physrev.2001.81.2.495; KIRK K, 1992, BIOCHIM BIOPHYS ACTA, V1135, P8, DOI 10.1016/0167-4889(92)90159-9; Kirk K, 1998, ANNU REV PHYSIOL, V60, P719, DOI 10.1146/annurev.physiol.60.1.719; KIRK K, 1995, J BIOL CHEM, V270, P24270, DOI 10.1074/jbc.270.41.24270; KOMWATANA P, 1994, PFLUG ARCH EUR J PHY, V428, P641, DOI 10.1007/BF00374588; Lang PA, 2003, AM J PHYSIOL-CELL PH, V285, pC1553, DOI 10.1152/ajpcell.00186.2003; LEE P, 1988, AM J TROP MED HYG, V39, P157, DOI 10.4269/ajtmh.1988.39.157; LEIDA MN, 1981, BIOCHEM BIOPH RES CO, V103, P402, DOI 10.1016/0006-291X(81)90466-6; Lew VL, 2003, BLOOD, V101, P4189, DOI 10.1182/blood-2002-08-2654; Nehrke K, 2002, J BIOL CHEM, V277, P23604, DOI 10.1074/jbc.M202900200; OVERMAN RR, 1951, PHYSIOL REV, V31, P285, DOI 10.1152/physrev.1951.31.3.285; Staines HM, 1999, J MEMBRANE BIOL, V172, P13, DOI 10.1007/s002329900579; Staines HM, 2003, J PHYSIOL-LONDON, V552, P177, DOI 10.1113/jphysiol.2003.051169; Staines HM, 1998, BIOCHEM J, V334, P525, DOI 10.1042/bj3340525; Staines HM, 2001, AM J PHYSIOL-CELL PH, V280, pC1576, DOI 10.1152/ajpcell.2001.280.6.C1576; STRANGE K, 1996, AM J PHYSIOL, V270, P711; TANABE K, 1982, J CELL BIOL, V93, P680, DOI 10.1083/jcb.93.3.680; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Tiffert T, 2000, J PHYSIOL-LONDON, V525, P125, DOI 10.1111/j.1469-7793.2000.00125.x; TOSTESON DC, 1960, J GEN PHYSIOL, V44, P169, DOI 10.1085/jgp.44.1.169; Verloo P, 2004, J BIOL CHEM, V279, P10316, DOI 10.1074/jbc.M311540200; Wagner CA, 2000, CELL PHYSIOL BIOCHEM, V10, P1, DOI 10.1159/000016341	50	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41444	41452		10.1074/jbc.M407618200	http://dx.doi.org/10.1074/jbc.M407618200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15272009	hybrid, Green Published			2022-12-27	WOS:000224075500026
J	Planque, N; Raposo, G; Leconte, L; Anezo, O; Martin, P; Saule, S				Planque, N; Raposo, G; Leconte, L; Anezo, O; Martin, P; Saule, S			Microphthalmia transcription factor induces both retinal pigmented epithelium and neural crest melanocytes from neuroretina cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; ENDOTHELIN-B RECEPTOR; ZIPPER TRANSCRIPTION; COAT COLOR; IN-VITRO; MITF; PRECURSORS; DIFFERENTIATION; EXPRESSION; MOUSE	Mitf encodes a basic helix-loop-helix transcription factor that plays an essential role in the differentiation of the retinal pigmented epithelium (RPE) and neural crest-derived melanocytes. As cells containing melanogenic enzymes (TRP2) are found in Mitf mouse mutants, it is not clear whether Mitf is a downstream factor or a master regulator of melanocyte differentiation. To further study the role of Mitf in committing cells to the melanocyte lineage, we express Mitf in the cultured quail neuroretina cells. This leads to the induction of two types of pigmented cells: neural crest-derived melanocytes, according to their dendritic morphology, physiology, and gene expression pattern are observed together with pigmented epithelial RPE-like cells. The expression of Mitf is lower in pigmented epithelial RPE-like cells than in neural crest-derived melanocytes. Accordingly, overexpression of Mitf in cultured quail RPE causes cells to develop into neural crest-like pigmented cells. Thus, Mitf is sufficient for the proper differentiation of crest-like pigmented cells from retinal cells and its expression level may determine the type of pigment cell induced.	Ctr Univ Orsay, Inst Curie, Sect Rech, UMR 146, F-91405 Orsay, France; Inst Curie, Sect Rech, UMR 144, F-75231 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Saule, S (corresponding author), Ctr Univ Orsay, Inst Curie, Sect Rech, UMR 146, Batiment 110, F-91405 Orsay, France.	Simon.Saule@curie.u-psud.fr		Raposo, graca/0000-0001-9590-1298				Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; Amae S, 1998, BIOCHEM BIOPH RES CO, V247, P710, DOI 10.1006/bbrc.1998.8838; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Bejar J, 2003, DEVELOPMENT, V130, P6545, DOI 10.1242/dev.00872; Bumsted KM, 2000, INVEST OPHTH VIS SCI, V41, P903; Dupin E, 2000, P NATL ACAD SCI USA, V97, P7882, DOI 10.1073/pnas.97.14.7882; Dupin E, 2003, ONCOGENE, V22, P3016, DOI 10.1038/sj.onc.1206460; Dupin E, 2003, P NATL ACAD SCI USA, V100, P5229, DOI 10.1073/pnas.0831229100; Fischer AJ, 2000, DEV BIOL, V220, P197, DOI 10.1006/dbio.2000.9640; Fischer AJ, 2003, GLIA, V43, P70, DOI 10.1002/glia.10218; Goding CR, 2000, GENE DEV, V14, P1712; Guo CS, 1997, DEV BIOL, V184, P61, DOI 10.1006/dbio.1997.8520; Henion PD, 1997, DEVELOPMENT, V124, P4351; Hornyak TJ, 2001, MECH DEVELOP, V101, P47, DOI 10.1016/S0925-4773(00)00569-4; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; JACKSON IJ, 1994, ANNU REV GENET, V28, P189, DOI 10.1146/annurev.ge.28.120194.001201; Jin EJ, 2001, DEV BIOL, V233, P22, DOI 10.1006/dbio.2001.0222; King R., 1995, METABOLIC MOL BASES, P4353; Le Douarin NM, 1999, NEURAL CREST, V2; Lecoin L, 1998, P NATL ACAD SCI USA, V95, P3024, DOI 10.1073/pnas.95.6.3024; Liu XR, 1998, NAT GENET, V19, P117, DOI 10.1038/470; Luo R, 2003, DEVELOPMENT, V130, P321, DOI 10.1242/dev.00213; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Martinez-Morales JR, 2003, J BIOL CHEM, V278, P21721, DOI 10.1074/jbc.M301708200; Martinez-Morales JR, 2001, DEVELOPMENT, V128, P2019; Mouriaux F, 2003, EXP EYE RES, V76, P653, DOI 10.1016/S0014-4835(03)00082-4; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; NATAF V, 1995, EXP CELL RES, V218, P394, DOI 10.1006/excr.1995.1171; Nguyen MTT, 2000, DEVELOPMENT, V127, P3581; Niwa T, 2002, MECH DEVELOP, V118, P139, DOI 10.1016/S0925-4773(02)00256-3; Opdecamp K, 1997, DEVELOPMENT, V124, P2377; Pittack C, 1997, DEVELOPMENT, V124, P805; Planque N, 1999, CELL GROWTH DIFFER, V10, P525; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Raposo G, 2002, TRAFFIC, V3, P237, DOI 10.1034/j.1600-0854.2002.030401.x; SHERMAN L, 1993, DEVELOPMENT, V118, P1313; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; Turque N, 1996, EMBO J, V15, P3338, DOI 10.1002/j.1460-2075.1996.tb00699.x; Udono T, 2000, BBA-GENE STRUCT EXPR, V1491, P205, DOI 10.1016/S0167-4781(00)00051-8; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Wehrle-Haller B, 1999, DEV BIOL, V210, P71, DOI 10.1006/dbio.1999.9260; Wehrle-Haller B, 2001, DEV BIOL, V232, P471, DOI 10.1006/dbio.2001.0167; WESTON JA, 1991, CURR TOP DEV BIOL, V25, P133; Widlund HR, 2003, ONCOGENE, V22, P3035, DOI 10.1038/sj.onc.1206443; Yoshida H, 1996, DEVELOPMENT, V122, P1207	46	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41911	41917		10.1074/jbc.M404964200	http://dx.doi.org/10.1074/jbc.M404964200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15277526	hybrid			2022-12-27	WOS:000224075500082
J	Sinha, SK; Chaudhary, PM				Sinha, SK; Chaudhary, PM			Induction of apoptosis by X-linked ectodermal dysplasia receptor via a caspase 8-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DOMAIN-CONTAINING PROTEIN; NF-KAPPA-B; CELL-DEATH; ECTODYSPLASIN-A; TNF SUPERFAMILY; ACTIVATION; DROSOPHILA; EIGER; JNK	X-linked ectodermal dysplasia receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplasin-A2 (EDAA2). In this report, we demonstrate that although XEDAR lacks a death domain, it nevertheless induces apoptosis in an EDA-A2-dependent fashion. The apoptosis-inducing ability of XEDAR is dependent on the activation of caspase 8 and can be blocked by its genetic and pharmacological inhibitors. Although XEDAR-induced apoptosis can be blocked by dominant-negative Fas-associated death domain (FADD) protein and FADD small interfering RNA, XEDAR does not directly bind to FADD, tumor necrosis factor receptor-associated death domain (TRADD) protein, or RIP1. Instead, XEDAR signaling leads to the formation of a secondary complex containing FADD, caspase 8, and caspase 10, which results in caspase activation. Thus, XEDAR belongs to a novel class of death receptors that lack a discernible death domain but are capable of activating apoptosis in a caspase 8- and FADD-dependent fashion. XEDAR may represent an early stage in the evolution of death receptors prior to the emergence of the death domain and may play a role in the induction of apoptosis during embryonic development and adult life.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Hematol Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Hillman Canc Ctr, 5117 Ctr Ave,Suite 1-19A, Pittsburgh, PA 15213 USA.	chaudharypm@upmc.edu	Chaudhary, Preet/E-1970-2018		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015189] Funding Source: NIH RePORTER; NIDCR NIH HHS [1R01 DE 15189-01] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barnhart BC, 2003, CELL, V114, P148, DOI 10.1016/S0092-8674(03)00561-0; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bayes M, 1998, HUM MOL GENET, V7, P1661, DOI 10.1093/hmg/7.11.1661; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Eby MT, 2000, J BIOL CHEM, V275, P15336, DOI 10.1074/jbc.275.20.15336; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kanda H, 2002, J BIOL CHEM, V277, P28372, DOI 10.1074/jbc.C200324200; Kauppila S, 2003, ONCOGENE, V22, P4860, DOI 10.1038/sj.onc.1206715; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; Kumar A, 2001, J BIOL CHEM, V276, P2668, DOI 10.1074/jbc.M008356200; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mikkola ML, 1999, MECH DEVELOP, V88, P133, DOI 10.1016/S0925-4773(99)00180-X; Mikkola ML, 2003, CYTOKINE GROWTH F R, V14, P211, DOI 10.1016/S1359-6101(03)00020-0; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Newton K, 2004, MOL CELL BIOL, V24, P1608, DOI 10.1128/MCB.24.4.1608-1613.2004; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Peter ME, 2000, CELL DEATH DIFFER, V7, P759, DOI 10.1038/sj.cdd.4400735; PINHEIRO M, 1994, AM J MED GENET, V53, P153, DOI 10.1002/ajmg.1320530207; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; Srivastava AK, 1997, P NATL ACAD SCI USA, V94, P13069, DOI 10.1073/pnas.94.24.13069; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Wang Y, 2004, J CELL SCI, V117, P1525, DOI 10.1242/jcs.00994; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523	35	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41873	41881		10.1074/jbc.M407363200	http://dx.doi.org/10.1074/jbc.M407363200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280356	hybrid			2022-12-27	WOS:000224075500078
J	Takei, K; Yamaya, T; Sakakibara, H				Takei, K; Yamaya, T; Sakakibara, H			Arabidopsis CYP735A1 and CYP735A2 encode cytokinin hydroxylases that catalyze the biosynthesis of trans-Zeatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRASSINOSTEROID BIOSYNTHESIS; CYTOCHROME-P450 GENES; RESPONSE REGULATOR; ABSCISIC-ACID; CIS-ZEATIN; EXPRESSION; THALIANA; MAIZE; ENZYME; IDENTIFICATION	Cytokinins (CKs), a group of phytohormones, are adenine derivatives that carry either an isoprene-derived or an aromatic side chain at the N-6 terminus. trans-Zeatin (tZ), an isoprenoid CK, is assumed to play a central physiological role because of its general occurrence and high activity in bioassays. Although hydroxylation of isopentenyladenine-type CKs is a key step of tZ biosynthesis, the catalyzing enzyme has not been characterized yet. Here we demonstrate that CYP735A1 and CYP735A2 are cytochrome P450 monooxygenases (P450s) that catalyze the biosynthesis of tZ. We identified the genes from Arabidopsis using an adenosine phosphate-isopentenyltransferase (AtIPT4)/P450 co-expression system in yeast. Co-expression of AtIPT4 and CYP735A enabled yeast to excrete tZ and the nucleosides to the culture medium. In vitro, both CYP735As preferentially utilized isopentenyladenine nucleotides rather than the nucleoside and free base forms and produced tZ nucleotides but not the cis-isomer. The expression of CYP735A1 and CYP735A2 was differentially regulated in terms of organ specificity and response to CK. Root-specific induction of CYP735A2 expression by CK suggests that the trans-hydroxylation is involved in the regulation of CK metabolism and signaling in roots.	RIKEN, Inst Phys & Chem Res, Plant Sci Ctr, Yokohama, Kanagawa 2300045, Japan	RIKEN	Sakakibara, H (corresponding author), RIKEN, Inst Phys & Chem Res, Plant Sci Ctr, Suehiro 1-7-22, Yokohama, Kanagawa 2300045, Japan.	sakaki@postman.riken.go.jp	Ding, Cheng-Qiang/B-6287-2011; Sakakibara, Hitoshi/A-6040-2010	Sakakibara, Hitoshi/0000-0001-5449-6492				Astot C, 2000, P NATL ACAD SCI USA, V97, P14778, DOI 10.1073/pnas.260504097; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Beveridge CA, 1997, PLANT J, V11, P339, DOI 10.1046/j.1365-313X.1997.11020339.x; Bilyeu KD, 2001, PLANT PHYSIOL, V125, P378, DOI 10.1104/pp.125.1.378; Bishop GJ, 1999, P NATL ACAD SCI USA, V96, P1761, DOI 10.1073/pnas.96.4.1761; Brugiere N, 2003, PLANT PHYSIOL, V132, P1228, DOI 10.1104/pp.102.017707; BRZOBOHATY B, 1993, SCIENCE, V262, P1051, DOI 10.1126/science.8235622; CALLIS J, 1995, GENETICS, V139, P921; CHEN CM, 1984, PLANT PHYSIOL, V75, P442, DOI 10.1104/pp.75.2.442; Choe SW, 1998, PLANT CELL, V10, P231, DOI 10.1105/tpc.10.2.231; Collu G, 2001, FEBS LETT, V508, P215, DOI 10.1016/S0014-5793(01)03045-9; Corbesier L, 2003, J EXP BOT, V54, P2511, DOI 10.1093/jxb/erg276; de Vetten N, 1999, P NATL ACAD SCI USA, V96, P778, DOI 10.1073/pnas.96.2.778; FUJIWARA T, 1992, PLANT PHYSIOL, V99, P263, DOI 10.1104/pp.99.1.263; Hecht S, 2001, P NATL ACAD SCI USA, V98, P14837, DOI 10.1073/pnas.201399298; Helliwell CA, 1998, P NATL ACAD SCI USA, V95, P9019, DOI 10.1073/pnas.95.15.9019; Helliwell CA, 2001, PLANT CELL, V13, P2115, DOI 10.1105/tpc.13.9.2115; Inoue T, 2001, NATURE, V409, P1060, DOI 10.1038/35059117; Kakimoto T, 2001, PLANT CELL PHYSIOL, V42, P677, DOI 10.1093/pcp/pce112; Kasahara H, 2004, J BIOL CHEM, V279, P14049, DOI 10.1074/jbc.M314195200; Krall L, 2002, FEBS LETT, V527, P315, DOI 10.1016/S0014-5793(02)03258-1; Kuroha T, 2002, J EXP BOT, V53, P2193, DOI 10.1093/jxb/erf077; Kushiro T, 2004, EMBO J, V23, P1647, DOI 10.1038/sj.emboj.7600121; Martin RC, 1999, P NATL ACAD SCI USA, V96, P284, DOI 10.1073/pnas.96.1.284; Miyawaki K, 2004, PLANT J, V37, P128, DOI 10.1046/j.1365-313X.2003.01945.x; Mok DWS, 2001, ANNU REV PLANT PHYS, V52, P89, DOI 10.1146/annurev.arplant.52.1.89; Mok MC., 1994, CYTOKININS CHEM ACTI, P155, DOI DOI 10.1201/9781351071284; Morris SE, 2001, PLANT PHYSIOL, V126, P1205, DOI 10.1104/pp.126.3.1205; Murai N, 1994, CYTOKININS CHEM ACTI, P87; Nelson DR, 2004, PLANT PHYSIOL, V135, P756, DOI 10.1104/pp.104.039826; Nordstrom A, 2004, P NATL ACAD SCI USA, V101, P8039, DOI 10.1073/pnas.0402504101; OMURA T, 1964, J BIOL CHEM, V239, P2370; Paquette SM, 2000, DNA CELL BIOL, V19, P307, DOI 10.1089/10445490050021221; PERSSON BC, 1993, J BACTERIOL, V175, P7776, DOI 10.1128/JB.175.24.7776-7785.1993; Rashotte AM, 2003, PLANT PHYSIOL, V132, P1998, DOI 10.1104/pp.103.021436; Rohmer M, 1999, NAT PROD REP, V16, P565, DOI 10.1039/a709175c; Saito S, 2004, PLANT PHYSIOL, V134, P1439, DOI 10.1104/pp.103.037614; SCHMITZ RY, 1972, PLANT PHYSIOL, V50, P702, DOI 10.1104/pp.50.6.702; SPIESS LD, 1975, PLANT PHYSIOL, V55, P583, DOI 10.1104/pp.55.3.583; Strnad M, 1997, PHYSIOL PLANTARUM, V101, P674, DOI 10.1111/j.1399-3054.1997.tb01052.x; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; Takei K, 2001, PLANT CELL PHYSIOL, V42, P85, DOI 10.1093/pcp/pce009; Takei K, 2003, J PLANT RES, V116, P259, DOI 10.1007/s10265-003-0098-2; Takei K, 2003, J PLANT RES, V116, P265, DOI 10.1007/s10265-003-0099-1; Takei K, 2001, J BIOL CHEM, V276, P26405, DOI 10.1074/jbc.M102130200; TAKEI K, 2004, IN PRESS PLANT CELL, V45; Taniguchi M, 1998, FEBS LETT, V429, P259, DOI 10.1016/S0014-5793(98)00611-5; Turk EM, 2003, PLANT PHYSIOL, V133, P1643, DOI 10.1104/pp.103.030882; Urban P, 1997, J BIOL CHEM, V272, P19176, DOI 10.1074/jbc.272.31.19176; Venkateswarlu K, 1998, J BIOL CHEM, V273, P4492, DOI 10.1074/jbc.273.8.4492; Werck-Reichhart D., 2002, ARABIDOPSIS BOOK; Yamada H, 2001, PLANT CELL PHYSIOL, V42, P1017, DOI 10.1093/pcp/pce127; Yonekura-Sakakibara K, 2004, PLANT PHYSIOL, V134, P1654, DOI 10.1104/pp.103.037176	53	270	289	4	69	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41866	41872		10.1074/jbc.M406337200	http://dx.doi.org/10.1074/jbc.M406337200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280363	hybrid			2022-12-27	WOS:000224075500077
J	Wetzel, RK; Pascoa, JL; Arystarkhova, E				Wetzel, RK; Pascoa, JL; Arystarkhova, E			Stress-induced expression of the gamma subunit (FXYD2) modulates Na, K-ATPase activity and cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; PROTEIN-KINASE-C; GENE-EXPRESSION; IMMUNOCYTOCHEMICAL LOCALIZATION; HYPERTONIC STRESS; RENAL NA,K-ATPASE; FUNCTIONAL-ROLE; MESSENGER-RNAS; SODIUM-PUMP; APOPTOSIS	In kidney, the Na,K-ATPase is associated with a single span protein, the gamma subunit (FXYD2). Two splice variants are differentially expressed along the nephron and have a differential influence on Na,K-ATPase when stably expressed in mammalian cells in culture. Here we used a combination of gene induction and gene silencing techniques to test the functional impact of gamma by means other than transfection. NRK-52E cells (of proximal tubule origin) do not express gamma as a protein under regular tissue culture conditions. However, when they were exposed to hyperosmotic medium, induction of only the gammaa splice variant was observed, which was accompanied by a reduction in the rate of cell division. Kinetic analysis of stable enzyme properties from control (alpha1beta1) and hypertonicity-treated cultures (alpha1beta1gammaa) revealed a significant reduction (up to 60%) of Na,K-ATPase activity measured under V-max conditions with little or no change in the amounts of alpha1beta1. This effect as well as the reduction in cell growth rate was practically abolished when gamma expression was knocked down using specific small interfering RNA duplexes. Surprisingly, a similar induction of endogenous gammaa because of hypertonicity was seen in rat cell lines of other than renal origin: C6 (glioma), PC12 (pheochromocytoma), and L6 (myoblasts). Furthermore, exposure of NRK-52E cells to other stress inducers such as heat shock, exogenous oxidation, and chemical stress also resulted in a selective induction of gammaa. Taken together, the data imply that induction of gammaa may have adaptive value by being a part of a general cellular response to genotoxic stress.	Massachusetts Gen Hosp, Lab Membrane Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Arystarkhova, E (corresponding author), Massachusetts Gen Hosp, Lab Membrane Biol, Wellman 415,55 Fruit St, Boston, MA 02114 USA.	aristarkhova@helix.mgh.harvard.edu			NHLBI NIH HHS [HL-36271] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036271] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Arystarkhova E, 2003, ANN NY ACAD SCI, V986, P416, DOI 10.1111/j.1749-6632.2003.tb07223.x; Arystarkhova E, 2002, J BIOL CHEM, V277, P10162, DOI 10.1074/jbc.M111552200; Arystarkhova E, 2002, AM J PHYSIOL-RENAL, V282, pF393, DOI 10.1152/ajprenal.00146.2001; AUSTRUY E, 1993, CANCER RES, V53, P2888; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; BHUTADA A, 1990, AM J PHYSIOL, V258, pC1044, DOI 10.1152/ajpcell.1990.258.6.C1044; BOWEN JW, 1992, AM J PHYSIOL, V262, pC845, DOI 10.1152/ajpcell.1992.262.4.C845; BOWEN JW, 1987, AM J PHYSIOL, V252, pC179, DOI 10.1152/ajpcell.1987.252.2.C179; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Capasso JM, 2001, P NATL ACAD SCI USA, V98, P13414, DOI 10.1073/pnas.231309198; CAYANIS E, 1992, J MEMBRANE BIOL, V125, P163; Cornelius F, 2003, NEWS PHYSIOL SCI, V18, P119, DOI 10.1152/nips.01434.2003; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; CRAMBERT G, 2003, SCI STKE; Dmitrieva N, 2000, J BIOL CHEM, V275, P18243, DOI 10.1074/jbc.M000522200; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; Ferrandi M, 2004, J BIOL CHEM, V279, P33306, DOI 10.1074/jbc.M402187200; FerrerMartinez A, 1996, BIOCHEM J, V319, P337, DOI 10.1042/bj3190337; Feschenko MS, 2003, J NEUROSCI, V23, P2161; Feschenko MS, 1997, J BIOL CHEM, V272, P17726, DOI 10.1074/jbc.272.28.17726; FESCHENKO MS, 1995, J BIOL CHEM, V270, P14072, DOI 10.1074/jbc.270.23.14072; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; Horio M, 2001, NEPHROL DIAL TRANSPL, V16, P483, DOI 10.1093/ndt/16.3.483; Isaev NK, 2000, NEUROSCI LETT, V283, P41, DOI 10.1016/S0304-3940(00)00903-4; Jones DH, 2001, PHYSIOL GENOMICS, V6, P129, DOI 10.1152/physiolgenomics.2001.6.3.129; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; KAMITANI T, 1992, CIRC RES, V71, P1457, DOI 10.1161/01.RES.71.6.1457; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Kassed CA, 2004, FASEB J, V18, P723, DOI 10.1096/fj.03-0773fje; Kultz D, 2001, P NATL ACAD SCI USA, V98, P1999, DOI 10.1073/pnas.98.4.1999; Kultz D, 1998, J EXP BIOL, V201, P3015; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; Lash LH, 2002, BIOCHEM PHARMACOL, V64, P1533, DOI 10.1016/S0006-2952(02)01360-6; LESCALEMATYS L, 1990, J BIOL CHEM, V265, P17935; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; Michea L, 2000, AM J PHYSIOL-RENAL, V278, pF209, DOI 10.1152/ajprenal.2000.278.2.F209; Michea L, 2002, AM J PHYSIOL-RENAL, V282, pF981, DOI 10.1152/ajprenal.00301.2001; Muto S, 1998, J MEMBRANE BIOL, V162, P233, DOI 10.1007/s002329900361; Ohtaka A, 1996, AM J PHYSIOL-RENAL, V270, pF728, DOI 10.1152/ajprenal.1996.270.5.F728; Orlov SN, 1996, BIOCHEM BIOPH RES CO, V221, P708, DOI 10.1006/bbrc.1996.0661; Orlov SN, 2001, J HYPERTENS, V19, P1559, DOI 10.1097/00004872-200109000-00007; ORLOV SN, 2001, J BIOL CHEM, V276, P16545; Pihakaski-Maunsbach K, 2003, ANN NY ACAD SCI, V986, P401, DOI 10.1111/j.1749-6632.2003.tb07221.x; PRESSLEY TA, 1988, AM J PHYSIOL, V255, pC252, DOI 10.1152/ajpcell.1988.255.2.C252; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Wang XQ, 2003, J CELL SCI, V116, P2099, DOI 10.1242/jcs.00420; Wetzel Randall K., 2001, Journal of the American Society of Nephrology, V12, p43A; Wetzel RK, 2003, AM J PHYSIOL-RENAL, V285, pF121, DOI 10.1152/ajprenal.00241.2002; Wetzel RK, 2001, AM J PHYSIOL-RENAL, V281, pF531, DOI 10.1152/ajprenal.2001.281.3.F531; Xie ZJ, 2001, CELL MOL BIOL, V47, P383; Yin W, 2003, J MEMBRANE BIOL, V193, P177, DOI 10.1007/s00232-003-2016-x; YORDY MR, 1993, KIDNEY INT, V43, P940, DOI 10.1038/ki.1993.132	62	40	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41750	41757		10.1074/jbc.M405622200	http://dx.doi.org/10.1074/jbc.M405622200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280368	hybrid			2022-12-27	WOS:000224075500063
J	Guillet, V; Roblin, P; Werner, S; Coraiola, M; Menestrina, G; Monteil, H; Prevost, G; Mourey, L				Guillet, V; Roblin, P; Werner, S; Coraiola, M; Menestrina, G; Monteil, H; Prevost, G; Mourey, L			Crystal structure of leucotoxin S component - New insight into the staphylococcal beta-barrel pore-forming toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HEMOLYSIN; GAMMA-HEMOLYSIN; SECONDARY STRUCTURE; KEY RESIDUES; AUREUS; LEUKOCIDIN; MEMBRANE; PROGRAM; OLIGOMERIZATION; MUTAGENESIS	Staphylococcal leucocidins and gamma-hemolysins (leucotoxins) are bi-component toxins that form lytic transmembrane pores. Their cytotoxic activities require the synergistic association of a class S component and a class F component, produced as water-soluble monomers that form hetero-oligomeric membrane-associated complexes. Strains that produce the Panton-Valentine leucocidin are clinically associated with cutaneous lesions and community-acquired pneumonia. In a previous study, we determined the crystal structure of the F monomer from the Panton-Valentine leucocidin. To derive information on the second component of the leucotoxins, the x-ray structure of the S protein from the Panton-Valentine leucocidin was solved to 2.0 Angstrom resolution using a tetragonal crystal form that contains eight molecules in the asymmetric unit. The structure demonstrates the different conformation of the domain involved in membrane contacts and illustrates sequence and tertiary structure variabilities of the pore-forming leucotoxins. Mutagenesis studies at a key surface residue (Thr-28) further support the important role played by these microheterogeneities for the assembly of the bipartite leucotoxins.	CNRS IPBS, Grp Biophys Struct, Dept Mecanismes Mol Infect Mycobacteriennes, F-31077 Toulouse, France; Hosp Univ Strasbourg, Lab Physiopathol & Antibiol Infect Bacteriennes E, EA 3432, Inst Bacteriol,Fac Med, F-67000 Strasbourg, France; Ist Biofis, CNR ITC, Ist Biofis, Sez Trento, I-38050 Trento, Italy	Centre National de la Recherche Scientifique (CNRS); CHU Strasbourg; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); Istituto per le Tecnologie della Costruzione (ITC-CNR)	Prevost, G (corresponding author), CNRS IPBS, Grp Biophys Struct, Dept Mecanismes Mol Infect Mycobacteriennes, 205 Route Narbonne, F-31077 Toulouse, France.	gilles.prevost@medecine.u-strasbg.fr; lionel.mourey@ipbs.fr	Guillet, Valérie/C-6058-2011; Mourey, Lionel/B-5662-2009	Mourey, Lionel/0000-0002-8259-1259				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barth A, 1996, J BIOL CHEM, V271, P30637, DOI 10.1074/jbc.271.48.30637; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Colin DA, 2003, INFECT IMMUN, V71, P3724, DOI 10.1128/IAI.71.7.3724-3729.2003; COLIN DA, 1994, INFECT IMMUN, V62, P3184, DOI 10.1128/IAI.62.8.3184-3188.1994; Comai M, 2002, MOL MICROBIOL, V44, P1251, DOI 10.1046/j.1365-2958.2002.02943.x; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Ferreras M, 1998, BBA-BIOMEMBRANES, V1414, P108, DOI 10.1016/S0005-2736(98)00160-6; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; Gauduchon V, 2001, INFECT IMMUN, V69, P2390, DOI 10.1128/IAI.69.4.2390-2395.2001; Gouaux E, 1997, PROTEIN SCI, V6, P2631; Gouaux E, 1998, J STRUCT BIOL, V121, P110, DOI 10.1006/jsbi.1998.3959; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Gravet A, 1998, FEBS LETT, V436, P202, DOI 10.1016/S0014-5793(98)01130-2; Guillet V, 2004, ACTA CRYSTALLOGR D, V60, P310, DOI 10.1107/S090744490302910X; HENSLER T, 1994, INFECT IMMUN, V62, P2529, DOI 10.1128/IAI.62.6.2529-2535.1994; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JURSCH R, 1994, INFECT IMMUN, V62, P2249, DOI 10.1128/IAI.62.6.2249-2256.1994; KONIG B, 1995, J INFECT DIS, V171, P607, DOI 10.1093/infdis/171.3.607; KONIG B, 1994, INFECT IMMUN, V62, P4831; KRISHNASASTRY M, 1994, FEBS LETT, V356, P66, DOI 10.1016/0014-5793(94)01240-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Menestrina G, 2001, TOXICON, V39, P1661, DOI 10.1016/S0041-0101(01)00153-2; Menestrina G, 1999, BIOCHEM BIOPH RES CO, V254, P174, DOI 10.1006/bbrc.1998.9898; MENZIES BE, 1994, INFECT IMMUN, V62, P1843, DOI 10.1128/IAI.62.5.1843-1847.1994; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Meunier O, 1997, BBA-BIOMEMBRANES, V1326, P275, DOI 10.1016/S0005-2736(97)00031-X; Miles G, 2002, PROTEIN SCI, V11, P894, DOI 10.1110/ps.4360102; Montoya M, 2003, BBA-BIOMEMBRANES, V1609, P19, DOI 10.1016/S0005-2736(02)00663-6; Moussa LB, 1999, FEBS LETT, V461, P280, DOI 10.1016/S0014-5793(99)01453-2; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nguyen VT, 2003, EMBO J, V22, P4968, DOI 10.1093/emboj/cdg498; Olson R, 1999, NAT STRUCT BIOL, V6, P134; Pedelacq JD, 1999, STRUCTURE, V7, P277, DOI 10.1016/S0969-2126(99)80038-0; Pedelacq JD, 2000, INT J MED MICROBIOL, V290, P395; Prevost G, 2003, CEL MOL MEC TOX ACT, V5, P3; PREVOST G, 1995, FEBS LETT, V376, P135, DOI 10.1016/0014-5793(95)01260-9; Prevost G, 2001, CURR TOP MICROBIOL, V257, P53; ROUSSEL A, 1989, SILICON GRAPHIC GEOM, P71; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Staali L, 1998, J MEMBRANE BIOL, V162, P209, DOI 10.1007/s002329900358; Sugawara N, 1997, FEBS LETT, V410, P333, DOI 10.1016/S0014-5793(97)00618-2; Sugawara-Tomita N, 2002, J BACTERIOL, V184, P4747, DOI 10.1128/JB.184.17.4747-4756.2002; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; WALKER B, 1995, PROTEIN ENG, V8, P491, DOI 10.1093/protein/8.5.491; Werner S, 2002, INFECT IMMUN, V70, P1310, DOI 10.1128/IAI.70.3.1310-1318.2002	51	87	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41028	41037		10.1074/jbc.M406904200	http://dx.doi.org/10.1074/jbc.M406904200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262988	Green Published, hybrid			2022-12-27	WOS:000223916800101
J	Garrity, JD; Pauff, JM; Crowder, MW				Garrity, JD; Pauff, JM; Crowder, MW			Probing the dynamics of a mobile loop above the active site of L1, a metallo-beta-lactamase from Stenotrophomonas maltophilia, via site-directed mutagenesis and stopped-flow fluorescence spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; BACTEROIDES-FRAGILIS; PSEUDOMONAS-MALTOPHILIA; SEQUENCE-ANALYSIS; CRYSTAL-STRUCTURE; INHIBITORS; SERINE; CLASSIFICATION; PURIFICATION; DERIVATIVES	A structural feature shared by the metallo-beta-lactamases is a flexible loop of amino acids that extends over their active sites and that has been proposed to move during the catalytic cycle of the enzymes, clamping down on substrate. To probe the movement of this loop ( residues 152 - 164), a site-directed mutant of metallo-beta-lactamase L1 was engineered that contained a Trp residue on the loop to serve as a fluorescent probe. It was necessary first, however, to evaluate the contribution of each native Trp residue to the fluorescence changes observed during the catalytic cycle of wild-type L1. Five site-directed mutants of L1 (W39F, W53F, W204F, W206F, and W269F) were prepared and characterized using metal analyses, CD spectroscopy, steady-state kinetics, stopped-flow fluorescence, and fluorescence titrations. All mutants retained the wild-type tertiary structure and bound Zn(II) at levels comparable with wild type and exhibited only slight (<10-fold) decreases in k(cat) values as compared with wild-type L1 for all substrates tested. Fluorescence studies revealed a single mutant, W39F, to be void of the fluorescence changes observed with wild-type L1 during substrate binding and catalysis. Using W39F as a template, a Trp residue was added to the flexile loop over the active site of L1, to generate the double mutant, W39F/D160W. This double mutant retained all the structural and kinetic characteristics of wild-type L1. Stopped-flow fluorescence and rapid-scanning UV-visible studies revealed the motion of the loop (k(obs) = 27 +/- 2 s(-1)) to be similar to the formation rate of a reaction intermediate (k(obs) = 25 +/- 2 s(-1)).	Miami Univ, Dept Chem & Biochem, Oxford, OH 45056 USA	University System of Ohio; Miami University	Crowder, MW (corresponding author), Miami Univ, Dept Chem & Biochem, 112 Hughes Hall, Oxford, OH 45056 USA.	crowdemw@muohio.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM040052] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40052] Funding Source: Medline; NIGMS NIH HHS [GM40052] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arakawa Y, 2000, J CLIN MICROBIOL, V38, P40; Aung HP, 2000, BBA-PROTEIN STRUCT M, V1481, P349, DOI 10.1016/S0167-4838(00)00179-5; Bernstein NJ, 1999, BIOCHEMISTRY-US, V38, P10499, DOI 10.1021/bi990428e; Bounaga S, 2001, BIOORGAN MED CHEM, V9, P503, DOI 10.1016/S0968-0896(00)00257-1; BUSH K, 1989, ANTIMICROB AGENTS CH, V33, P264, DOI 10.1128/AAC.33.3.264; Bush K, 1998, ADV EXP MED BIOL, V456, P71; BUSH K, 1989, ANTIMICROB AGENTS CH, V33, P271, DOI 10.1128/AAC.33.3.271; Bush K, 1998, CLIN INFECT DIS, V27, pS48, DOI 10.1086/514922; Bush K, 2001, CLIN INFECT DIS, V32, P1085, DOI 10.1086/319610; Carenbauer AL, 2002, BMC BIOCHEM, V3; Carfi A, 1997, ACTA CRYSTALLOGR D, V53, P485, DOI 10.1107/S0907444997000966; Caselli E, 2000, CHEM BIOL, V49, P1; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Crowder MW, 1998, ANTIMICROB AGENTS CH, V42, P921, DOI 10.1128/AAC.42.4.921; Crowder MW, 1999, RRD ANTIMICROB AG  1, V3, P105; Diaz N, 2000, J AM CHEM SOC, V122, P4197, DOI 10.1021/ja994462s; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FELICI A, 1995, ANTIMICROB AGENTS CH, V39, P1300, DOI 10.1128/AAC.39.6.1300; FERSHT A, 1985, ENZYME STRUCTURE MEC, P420; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Garrity JD, 2004, J BIOL CHEM, V279, P920, DOI 10.1074/jbc.M309852200; Hammond GG, 1999, FEMS MICROBIOL LETT, V179, P289, DOI 10.1111/j.1574-6968.1999.tb08740.x; KHARDORI N, 1990, REV INFECT DIS, V12, P997; Kotra Lakshmi P., 1999, Archivum Immunologiae et Therapiae Experimentalis, V47, P211; Lee NLS, 2001, JAMA-J AM MED ASSOC, V285, P386, DOI 10.1001/jama.285.4.386; Levy SB, 1998, SCI AM, V278, P46, DOI 10.1038/scientificamerican0398-46; Lobley A, 2001, BIOPHYS J, V80, p373A; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; METT H, 1988, REV INFECT DIS, V10, P765; MUDER RR, 1987, ARCH INTERN MED, V147, P1672, DOI 10.1001/archinte.147.9.1672; Nagano R, 1999, ANTIMICROB AGENTS CH, V43, P2497, DOI 10.1128/AAC.43.10.2497; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Orellano EG, 1998, BIOCHEMISTRY-US, V37, P10173, DOI 10.1021/bi980309j; PAYNE DJ, 1993, J MED MICROBIOL, V39, P93, DOI 10.1099/00222615-39-2-93; Payne DJ, 1997, FEMS MICROBIOL LETT, V157, P171, DOI 10.1016/S0378-1097(97)00472-2; Payne DJ, 1997, ANTIMICROB AGENTS CH, V41, P135, DOI 10.1128/AAC.41.1.135; Prosperi-Meys C, 1999, FEBS LETT, V443, P109, DOI 10.1016/S0014-5793(98)01689-5; Rice LB, 2000, DRUG RESIST UPDATE, V3, P178, DOI 10.1054/drup.2000.0144; Salsbury FR, 2001, PROTEINS, V44, P448, DOI 10.1002/prot.1110; SAMBROOK J, 1989, MOL CLONING LAB MANU, pE39; SEGEL IH, 1993, ENZYME KINETICS BEHA, P44; Siemann S, 2002, ANTIMICROB AGENTS CH, V46, P2450, DOI 10.1128/AAC.46.8.2450-2457.2002; Spencer J, 2001, J BIOL CHEM, V276, P33638, DOI 10.1074/jbc.M105550200; STEWART JD, 1994, BIOCHEMISTRY-US, V33, P1994, DOI 10.1021/bi00174a004; Suarez D, 2001, J AM CHEM SOC, V123, P3759, DOI 10.1021/ja003796a; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Toney JH, 1999, BIOORG MED CHEM LETT, V9, P2741, DOI 10.1016/S0960-894X(99)00458-8; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; VILLARINO ME, 1992, INFECT CONT HOSP EP, V13, P201, DOI 10.1086/646510; WALSH TR, 1994, BBA-GENE STRUCT EXPR, V1218, P199, DOI 10.1016/0167-4781(94)90011-6; Walsh TR, 1997, ANTIMICROB AGENTS CH, V41, P1460, DOI 10.1128/AAC.41.7.1460; Walter MW, 1999, BIOORG CHEM, V27, P35, DOI 10.1006/bioo.1998.1111; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Williamson B, 1999, J DIGIT IMAGING, V12, P1, DOI 10.1007/BF03168740; Yang KW, 1999, ARCH BIOCHEM BIOPHYS, V368, P1, DOI 10.1006/abbi.1999.1293	55	29	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39663	39670		10.1074/jbc.M406826200	http://dx.doi.org/10.1074/jbc.M406826200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15271998	hybrid			2022-12-27	WOS:000223791500057
J	Howe, CJ; LaHair, MM; McCubrey, JA; Franklin, RA				Howe, CJ; LaHair, MM; McCubrey, JA; Franklin, RA			Redox regulation of the calcium/calmodulin-dependent protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; HYDROGEN-PEROXIDE; PHOSPHATASE 2A; T-LYMPHOCYTES; SERINE/THREONINE PHOSPHATASES; TYROSINE PHOSPHORYLATION; OXIDATIVE STRESS; CALMODULIN; CALCIUM; DOMAIN	Reactive oxygen intermediates (ROI) have been viewed traditionally as damaging to the cell. However, a predominance of evidence has shown that ROI can also function as important activators of key cellular processes, and ROI have been shown to play a vital role in cell signaling networks. The calcium/calmodulin-dependent protein kinases (CaM kinases) are a family of related kinases that are activated in response to increased intracellular calcium concentrations. In this report we demonstrate that hydrogen peroxide treatment results in the activation of both CaM kinase II and IV in Jurkat T lymphocytes. Surprisingly, this activation occurs in the absence of any detectable calcium flux, suggesting a novel means for the activation of these kinases. Treatment of Jurkat cells with phorbol 12-myristate 13-acetate (PMA), which does not cause a calcium flux, also activated the CaM kinases. The addition of catalase to the cultures inhibited PMA-induced activation of the CaM kinases, suggesting that similar to hydrogen peroxide, PMA also activates the CaM kinases via the production of ROI. One mechanism by which this likely occurs is through oxidation and consequential inactivation of cellular phosphatases. In support of this concept, okadaic acid and microcystin-LR,which are inhibitors of protein phosphatase 2A ( PP2A), induced CaM kinase II and IV activity in these cells. Overall, these results demonstrate a novel mechanism by which ROI can induce CaM kinase activation in T lymphocytes.	E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27834 USA; E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27834 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	Franklin, RA (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Brody Bldg, Greenville, NC 27834 USA.	franklinr@mail.ecu.edu		Franklin, Richard A./0000-0003-0299-9578; McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [R01 CA51025, R01 CA98195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051025, R01CA098195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Anderson KA, 2002, MOL CELL BIOL, V22, P23, DOI 10.1128/MCB.22.1.23-29.2002; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BAYER EA, 1985, ANAL BIOCHEM, V149, P529, DOI 10.1016/0003-2697(85)90609-8; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; Corti C, 1999, EUR J BIOCHEM, V262, P790, DOI 10.1046/j.1432-1327.1999.00441.x; Devadas S, 2002, J EXP MED, V195, P59, DOI 10.1084/jem.20010659; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; EKMAN P, 1993, ANAL BIOCHEM, V214, P138, DOI 10.1006/abio.1993.1468; FONG YL, 1989, J BIOL CHEM, V264, P16759; FONG YL, 1990, J BIOL CHEM, V265, P11091; FREEMAN ML, 1989, RADIAT RES, V117, P326, DOI 10.2307/3577333; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GEISER JR, 1993, MOL CELL BIOL, V13, P7913, DOI 10.1128/MCB.13.12.7913; GREENLEE DV, 1982, BIOCHEMISTRY-US, V21, P2759, DOI 10.1021/bi00540a028; HAIECH J, 1991, J BIOL CHEM, V266, P3427; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Howe CJ, 2002, J BIOL CHEM, V277, P30469, DOI 10.1074/jbc.M205036200; Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200; Hughes K, 1998, FEBS LETT, V441, P132, DOI 10.1016/S0014-5793(98)01537-3; Israel N, 1997, CELL MOL LIFE SCI, V53, P864, DOI 10.1007/s000180050106; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kitani T, 1997, J BIOCHEM-TOKYO, V121, P804; Kwon J, 2003, FREE RADICAL BIO MED, V35, P406, DOI 10.1016/S0891-5849(03)00318-6; Lechward K, 2001, ACTA BIOCHIM POL, V48, P921; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; O'Loghlen A, 2003, ARCH BIOCHEM BIOPHYS, V417, P194, DOI 10.1016/S0003-9861(03)00368-0; OLWIN BB, 1984, J BIOL CHEM, V259, P949; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; Quadroni M, 1998, BIOCHEMISTRY-US, V37, P6523, DOI 10.1021/bi972930+; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; SODERLING TR, 1991, PROG BRAIN RES, V89, P169; Sommer D, 2002, ARCH BIOCHEM BIOPHYS, V404, P271, DOI 10.1016/S0003-9861(02)00242-4; van Reyk DM, 2001, FREE RADICAL BIO MED, V30, P82, DOI 10.1016/S0891-5849(00)00449-4; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; Ye JP, 2000, ANN CLIN LAB SCI, V30, P65; Yoshimura Y, 1997, J BIOL CHEM, V272, P26354, DOI 10.1074/jbc.272.42.26354	53	112	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44573	44581		10.1074/jbc.M404175200	http://dx.doi.org/10.1074/jbc.M404175200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15294913	hybrid			2022-12-27	WOS:000224505600042
J	Inoue, Y; Inoue, J; Lambert, G; Yim, SH; Gonzalez, FJ				Inoue, Y; Inoue, J; Lambert, G; Yim, SH; Gonzalez, FJ			Disruption of hepatic C/EBP alpha results in impaired glucose tolerance and age-dependent hepatosteatosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; TRIGLYCERIDE TRANSFER PROTEIN; LIPOPROTEIN-LIPASE; KNOCKOUT MICE; CHOLESTERYL ESTERS; DIABETES-MELLITUS; SELECTIVE UPTAKE; IN-VIVO; LIVER; GENE	C/EBPalpha is highly expressed in liver and regulates many genes that are preferentially expressed in liver. Because C/EBPalpha-null mice die soon after birth, it is impossible to analyze the function of C/EBPalpha in the adult with this model. To address the function of C/EBPalpha in adult hepatocytes, liver-specific C/EBPalpha-null mice were produced using a floxed C/EBPalpha allele and the albumin-Cre transgene. Unlike whole body C/EBPalpha-null mice, mice lacking hepatic C/EBPalpha expression did not exhibit hypoglycemia, nor did they show reduced hepatic glycogen in adult. Expression of liver glycogen synthase, phosphoenolpyruvate carboxykinase, and glucose-6-phosphatase remained at normal levels. However, these mice exhibited impaired glucose tolerance due in part to reduced expression of hepatic glucokinase, and hyperammonemia from reduced expression of hepatic carbamoyl phosphate synthase-I. These mice also had reduced serum cholesterol and steatotic livers that was exacerbated with aging. This phenotype could be explained by increased expression of hepatic lipoprotein lipase and reduced expression of microsomal triglyceride transfer protein, apolipoproteins B100, and A-IV. These data demonstrate that hepatic C/EBPalpha is critical for ammonia detoxification and glucose and lipid homeostasis in adult mice.	NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; INSERM, U539, F-44035 Nantes, France	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Institut National de la Sante et de la Recherche Medicale (Inserm)	Gonzalez, FJ (corresponding author), NIH, Bldg 37,Rm 3106, Bethesda, MD 20892 USA.	fjgonz@helix.nih.gov	Inoue, Yusuke/O-6207-2018	Inoue, Yusuke/0000-0002-9710-7482; Lambert, Gilles/0000-0001-5632-0685	NATIONAL CANCER INSTITUTE [ZIABC005561, Z01BC005561] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Boelsterli UA, 2002, BIOCHEM PHARMACOL, V63, P1, DOI 10.1016/S0006-2952(01)00817-6; Burgess-Beusse BL, 1998, MOL CELL BIOL, V18, P7269, DOI 10.1128/MCB.18.12.7269; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; Davies N, 1997, BRIT J HAEMATOL, V99, P578, DOI 10.1046/j.1365-2141.1997.4603263.x; FOLCH J, 1957, J BIOL CHEM, V226, P497; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GIDHJAIN M, 1993, P NATL ACAD SCI USA, V90, P1932, DOI 10.1073/pnas.90.5.1932; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; HOWELL BW, 1989, MOL CELL BIOL, V9, P2928, DOI 10.1128/MCB.9.7.2928; Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0; Inoue Y, 2002, J BIOL CHEM, V277, P25257, DOI 10.1074/jbc.M203126200; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kim JW, 1998, BIOCHEM J, V336, P83, DOI 10.1042/bj3360083; Kimura T, 1998, J BIOL CHEM, V273, P27505, DOI 10.1074/jbc.273.42.27505; Lambert G, 2000, J LIPID RES, V41, P667; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Letteron P, 2003, HEPATOLOGY, V38, P133, DOI 10.1053/jhep.2003.50309; Leung GK, 2000, J BIOL CHEM, V275, P7515, DOI 10.1074/jbc.275.11.7515; Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898; Mead JR, 2002, J MOL MED, V80, P753, DOI 10.1007/s00109-002-0384-9; Merkel M, 1998, J CLIN INVEST, V102, P893, DOI 10.1172/JCI2912; MOORMAN AFM, 1991, FEBS LETT, V288, P133, DOI 10.1016/0014-5793(91)81019-5; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Rinninger F, 1998, J LIPID RES, V39, P1335; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Shen W, 2001, J BIOL CHEM, V276, P42812, DOI 10.1074/jbc.M106344200; TAKIGUCHI M, 1991, J BIOL CHEM, V266, P9186; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Weinstock PH, 1997, J LIPID RES, V38, P1782; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Williams LJS, 2000, J BIOL CHEM, V275, P30232, DOI 10.1074/jbc.M001286200; WU AL, 1979, J BIOL CHEM, V254, P7316; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200	48	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44740	44748		10.1074/jbc.M405177200	http://dx.doi.org/10.1074/jbc.M405177200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15292250	hybrid			2022-12-27	WOS:000224505600062
J	Giovedi, S; Vaccaro, P; Valtorta, F; Darchen, F; Greengard, P; Cesareni, G; Benfenati, F				Giovedi, S; Vaccaro, P; Valtorta, F; Darchen, F; Greengard, P; Cesareni, G; Benfenati, F			Synapsin is a novel Rab3 effector protein on small synaptic vesicles - I. Identification and characterization of the synapsin I-Rab3 interactions in vitro and in intact nerve terminals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPING NEUROMUSCULAR SYNAPSES; NEUROTRANSMITTER RELEASE; F-ACTIN; BINDING-PROTEIN; MEMBRANE-FUSION; PHOSPHORYLATION; RABPHILIN-3A; POOLS; MICE; PHOSPHOPROTEIN	Synapsins, a family of neuron-specific phosphoproteins, have been demonstrated to regulate the availability of synaptic vesicles for exocytosis by binding to both synaptic vesicles and the actin cytoskeleton in a phosphorylation-dependent manner. Although the above-mentioned observations strongly support a pre-docking role of the synapsins in the assembly and maintenance of a reserve pool of synaptic vesicles, recent results suggest that the synapsins may also be involved in some later step of exocytosis. In order to investigate additional interactions of the synapsins with nerve terminal proteins, we have employed phage display library technology to select peptide sequences binding with high affinity to synapsin I. Antibodies raised against the peptide YQYIETSMQ (syn21) specifically recognized Rab3A, a synaptic vesicle-specific small G protein implicated in multiple steps of exocytosis. The interaction between synapsin I and Rab3A was confirmed by photoaffinity labeling experiments on purified synaptic vesicles and by the formation of a chemically cross-linked complex between synapsin I and Rab3A in intact nerve terminals. Synapsin I could be effectively co-precipitated from synaptosomal extracts by immobilized recombinant Rab3A in a GTP-dependent fashion. In vitro binding assays using purified proteins confirmed the binding preference of synapsin I for Rab3A-GTP and revealed that the COOH-terminal regions of synapsin I and the Rab3A effector domain are required for the interaction with Rab3A to occur. The data indicate that synapsin I is a novel Rab3 interactor on synaptic vesicles and suggest that the synapsin-Rab3 interaction may participate in the regulation of synaptic vesicle trafficking within the nerve terminals.	Univ Genoa, Dept Expt Med, Sect Human Physiol, I-16132 Genoa, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; S Raffaele Vita Salute Univ, Dept Neurosci, I-20132 Milan, Italy; Inst Biol Physicochim, CNRS, UPR 1929, F-75005 Paris, France; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	University of Genoa; University of Rome Tor Vergata; Vita-Salute San Raffaele University; Centre National de la Recherche Scientifique (CNRS); Rockefeller University	Benfenati, F (corresponding author), Univ Genoa, Dept Expt Med, Sect Human Physiol, Via Benedetto XV 3, I-16132 Genoa, Italy.	benfenat@unige.it	Giovedì, Silvia/AAB-7614-2019; Flavia, Valtorta/F-3450-2012	Flavia, Valtorta/0000-0001-9556-4746; GIOVEDI', SILVIA/0000-0001-7949-4274	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039327, R01MH039327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015072] Funding Source: NIH RePORTER; NIA NIH HHS [AG15072] Funding Source: Medline; NIMH NIH HHS [MH39327] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BENFENATI F, 1993, J CELL BIOL, V123, P1845, DOI 10.1083/jcb.123.6.1845; BENFENATI F, 1992, NEURON, V8, P377, DOI 10.1016/0896-6273(92)90303-U; Benfenati F, 1999, PHILOS T R SOC B, V354, P243, DOI 10.1098/rstb.1999.0376; Bloom O, 2003, J CELL BIOL, V161, P737, DOI 10.1083/jcb.200212140; Brodin L, 1997, EUR J NEUROSCI, V9, P2503, DOI 10.1111/j.1460-9568.1997.tb01679.x; CECCALDI PE, 1995, J CELL BIOL, V128, P905, DOI 10.1083/jcb.128.5.905; CESARENI G, 1995, IMMUNOLOGICAL RECOGN, P43; Chi P, 2003, NEURON, V38, P69, DOI 10.1016/S0896-6273(03)00151-X; Chi P, 2001, NAT NEUROSCI, V4, P1187, DOI 10.1038/nn756; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; Diaz E, 1997, J CELL BIOL, V138, P283, DOI 10.1083/jcb.138.2.283; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FISCHER V, 1991, NATURE, V349, P79; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; Ghirardi M, 2001, J NEUROSCI RES, V65, P111, DOI 10.1002/jnr.1134.abs; Giovedi S, 2004, J BIOL CHEM, V279, P43769, DOI 10.1074/jbc.M404168200; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; Hilfiker S, 1998, NAT NEUROSCI, V1, P29, DOI 10.1038/229; Hosaka M, 1999, J BIOL CHEM, V274, P16747, DOI 10.1074/jbc.274.24.16747; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; Humeau Y, 2001, J NEUROSCI, V21, P4195, DOI 10.1523/JNEUROSCI.21-12-04195.2001; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LI L, 1995, P NATL ACAD SCI USA, V92, P9235, DOI 10.1073/pnas.92.20.9235; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Nielander HB, 1997, EUR J NEUROSCI, V9, P2712, DOI 10.1111/j.1460-9568.1997.tb01700.x; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Onofri F, 2000, J BIOL CHEM, V275, P29857, DOI 10.1074/jbc.M006018200; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Ryan TA, 1996, J CELL BIOL, V134, P1219, DOI 10.1083/jcb.134.5.1219; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; Schluter OM, 2002, J BIOL CHEM, V277, P40919, DOI 10.1074/jbc.M203704200; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; Stefani G, 1997, J PHYSIOL-LONDON, V504, P501, DOI 10.1111/j.1469-7793.1997.501bd.x; Takei Y, 1995, J CELL BIOL, V131, P1789, DOI 10.1083/jcb.131.6.1789; TARELLI FT, 1992, NEURON, V9, P1143, DOI 10.1016/0896-6273(92)90072-L; Terada S, 1999, J CELL BIOL, V145, P1039, DOI 10.1083/jcb.145.5.1039; TORRITARELLI F, 1990, J CELL BIOL, V110, P449, DOI 10.1083/jcb.110.2.449; Vaccaro P, 1997, MOL BRAIN RES, V52, P1, DOI 10.1016/S0169-328X(97)00219-2; VALTORTA F, 1992, J BIOL CHEM, V267, P11281; VALTORTA F, 1995, EUR J NEUROSCI, V7, P261, DOI 10.1111/j.1460-9568.1995.tb01062.x; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580	60	44	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43760	43768		10.1074/jbc.M403293200	http://dx.doi.org/10.1074/jbc.M403293200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15265865	hybrid			2022-12-27	WOS:000224383100051
J	Kim, S; Beausejour, C; Davalos, AR; Kaminker, P; Heo, SJ; Campisi, J				Kim, S; Beausejour, C; Davalos, AR; Kaminker, P; Heo, SJ; Campisi, J			TIN2 mediates functions of TRF2 at human telomeres	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; POLY(ADP-RIBOSE) POLYMERASE; LENGTH; POT1; END; LOCALIZATION; ASSOCIATION; ELONGATION; SENESCENCE; REGULATOR	Telomeres are protective structures at chromosome ends and are crucial for genomic stability. Mammalian TRF1 and TRF2 bind the double-stranded telomeric repeat sequence and in turn are bound by TIN2, TANK1, TANK2, and hRAP1. TRF1 is a negative regulator of telomere length in telomerase-positive cells, whereas TRF2 is important for telomere capping. TIN2 was identified as a TRF1-interacting protein that mediates TRF1 function. We show here that TIN2 also interacts with TRF2 in vitro and in yeast and mammalian cells. TIN2 mutants defective in binding of TRF1 or TRF2 induce a DNA damage response and destabilize TRF1 and TRF2 at telomeres in human cells. Our findings suggest that the functions of TRF1 and TRF2 are linked by TIN2.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Buck Inst Age Res, Novato, CA 94945 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Buck Institute for Research on Aging	Campisi, J (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd,Mailstop 84-171, Berkeley, CA 94720 USA.	JCAMPISI@LBL.GOV						Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Chang W, 2003, GENE DEV, V17, P1328, DOI 10.1101/gad.1077103; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Davalos AR, 2003, J CELL BIOL, V162, P1197, DOI 10.1083/jcb.200304016; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grossi S, 2001, MOL CELL BIOL, V21, P8117, DOI 10.1128/MCB.21.23.8117-8128.2001; Hultdin M, 1998, NUCLEIC ACIDS RES, V26, P3651, DOI 10.1093/nar/26.16.3651; Iwano T, 2004, J BIOL CHEM, V279, P1442, DOI 10.1074/jbc.M309138200; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Kim SH, 2003, EMBO REP, V4, P685, DOI 10.1038/sj.embor.embor872; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Liu D, 2004, NAT CELL BIOL, V6, P673, DOI 10.1038/ncb1142; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Rubio MA, 2002, J BIOL CHEM, V277, P28609, DOI 10.1074/jbc.M203747200; Shore D, 1997, TRENDS BIOCHEM SCI, V22, P233, DOI 10.1016/S0968-0004(97)01082-7; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; Stansel RM, 2001, EMBO J, V20, P5532; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	39	149	157	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43799	43804		10.1074/jbc.M408650200	http://dx.doi.org/10.1074/jbc.M408650200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292264	hybrid			2022-12-27	WOS:000224383100055
J	Lawhorn, BG; Gerdes, SY; Begley, TP				Lawhorn, BG; Gerdes, SY; Begley, TP			A genetic screen for the identification of thiamin metabolic genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; BACIMETHRIN; EXPRESSION; PYRIMIDINE; PYROPHOSPHATE; PURIFICATION; DERIVATIVES; RESISTANCE; MECHANISM; SYNTHASE	A genetic screen was developed for the identification of genes related to thiamin biosynthesis and degradation. Genes conferring resistance to bacimethrin or 4-amino-2-trifluoromethyl-5-hydroxymethylpyrimidine were selected from Escherichia coli and Bacillus subtilis genomic libraries. Hits from the selection included the known thiamin biosynthetic genes thiC, thiE, and dxs as well as five genes of previously unknown function ( E. coli yjjX, yajO, ymfB, and cof and B. subtilis yveN). The gene products YmfB and Cof catalyze the hydrolysis of 4-amino-2-methyl-5-hydroxymethylpyrimidine pyrophosphate to 4-amino-2-methyl-5-hydroxymethylpyrimidine phosphate. YmfB also converts thiamin pyrophosphate into thiamin phosphate.	Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA; Integrated Genom Inc, Chicago, IL 60612 USA	Cornell University	Begley, TP (corresponding author), Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA.	tpb2@cornell.edu	Begley, Tadhg/B-5801-2015					Baker LJ, 2001, STRUCTURE, V9, P539, DOI 10.1016/S0969-2126(01)00615-3; BARONE JA, 1959, J ORG CHEM, V24, P198, DOI 10.1021/jo01084a012; Begley TP, 1999, ARCH MICROBIOL, V171, P293, DOI 10.1007/s002030050713; Begley TP, 1996, NAT PROD REP, V13, P177, DOI 10.1039/np9961300177; DRAUTZ H, 1987, J ANTIBIOT, V40, P1431, DOI 10.7164/antibiotics.40.1431; Estramareix B, 1996, NEW J CHEM, V20, P607; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Lawhorn BG, 2004, ORG BIOMOL CHEM, V2, P2538, DOI 10.1039/b405429f; LOMOVSKAYA O, 1992, P NATL ACAD SCI USA, V89, P8938, DOI 10.1073/pnas.89.19.8938; MARQUARDT JL, 1992, J BACTERIOL, V174, P5748, DOI 10.1128/JB.174.17.5748-5752.1992; Miranda-Rios J, 2001, P NATL ACAD SCI USA, V98, P9736, DOI 10.1073/pnas.161168098; Mironov AS, 2002, CELL, V111, P747, DOI 10.1016/S0092-8674(02)01134-0; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; NEWELL PC, 1968, BIOCHEM J, V106, P279, DOI 10.1042/bj1060279; Park JH, 2003, BIOCHEMISTRY-US, V42, P12430, DOI 10.1021/bi034902z; Perandones F, 1998, J HETEROCYCLIC CHEM, V35, P413, DOI 10.1002/jhet.5570350226; POPJAK G, 1962, J BIOL CHEM, V237, P56; Reddick JJ, 1998, TETRAHEDRON, V54, P15983, DOI 10.1016/S0040-4020(98)01006-0; Reddick JJ, 2001, BIOORG MED CHEM LETT, V11, P2245, DOI 10.1016/S0960-894X(01)00373-0; Reddick JJ, 2001, BIOCHEMISTRY-US, V40, P10095, DOI 10.1021/bi010267q; REDDICK JJ, 2001, THESIS CORNELL U ITH; Settembre E, 2003, CURR OPIN STRUC BIOL, V13, P739, DOI 10.1016/j.sbi.2003.10.006; TOKUNAGA M, 1983, J BIOL CHEM, V258, P2102; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; VOSKOBOEV A I, 1976, Biokhimiya, V41, P1784; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; Zhang Y, 1997, J BACTERIOL, V179, P3030, DOI 10.1128/jb.179.9.3030-3035.1997; Zilles JL, 2000, J BACTERIOL, V182, P5606, DOI 10.1128/JB.182.19.5606-5610.2000; [No title captured]	29	43	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43555	43559		10.1074/jbc.M404284200	http://dx.doi.org/10.1074/jbc.M404284200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292217	hybrid			2022-12-27	WOS:000224383100026
J	Zhao, L; Hart, S; Cheng, JG; Melenhorst, JJ; Bierie, B; Ernst, M; Stewart, C; Schaper, F; Heinrich, PC; Ullrich, A; Robinson, GW; Hennighausen, L				Zhao, L; Hart, S; Cheng, JG; Melenhorst, JJ; Bierie, B; Ernst, M; Stewart, C; Schaper, F; Heinrich, PC; Ullrich, A; Robinson, GW; Hennighausen, L			Mammary gland remodeling depends on gp130 signaling through Stat3 and MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; EGF RECEPTOR; SECRETORY EPITHELIUM; INTERLEUKIN-6 FAMILY; TRANSGENIC MICE; CANCER-CELLS; NECK-CANCER; TRANSDUCER	The interleukin-6(IL6) family of cytokines signals through the common receptor subunit gp130, and subsequently activates Stat3, MAPK, and PI3K. Stat3 controls cell death and tissue remodeling in the mouse mammary gland during involution, which is partially induced by IL6 and LIF. However, it is not clear whether Stat3 activation is mediated solely through the gp130 pathway or also through other receptors. This question was explored in mice carrying two distinct mutations in the gp130 gene; one that resulted in the complete ablation of gp130 and one that led to the loss of Stat3 binding sites (gp130Delta/Delta). Deletion of gp130 specifically from mammary epithelium resulted in a complete loss of Stat3 activity and resistance to tissue remodeling comparable to that seen in the absence of Stat3. A less profound delay of mammary tissue remodeling was observed in gp130Delta/Delta mice. Stat3 tyrosine and serine phosphorylation was still detected in these mice suggesting that Stat3 activation could be the result of gp130 interfacing with other receptors. Experiments in primary mammary epithelial cells and transfected COS-7 cells revealed a p44/42 MAPK and EGFR-dependent Stat3 activation. Moreover, the gp130-dependent EGFR activation was independent of EGF ligands, suggesting a cytoplasmic interaction and cross-talk between these two receptors. These experiments establish that two distinct Stat3 signaling pathways emanating from gp130 are utilized in mammary tissue.	NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; Max Planck Inst Biochem, D-81399 Martinsried, Germany; NCI, Lab Canc & Dev Biol, NIH, Frederick, MD 21702 USA; NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA; Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Rhein Westfal TH Aachen, Dept Biochem, D-52074 Aachen, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Max Planck Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Ludwig Institute for Cancer Research; RWTH Aachen University	Hennighausen, L (corresponding author), NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA.	hennighausen@nih.gov	Schaper, Fred/F-1403-2013; Robinson, Gertraud/I-2136-2012; Ernst, Matthias/D-5111-2012	Schaper, Fred/0000-0002-8899-5414; Ernst, Matthias/0000-0002-6399-1177; Hennighausen, Lothar/0000-0001-8319-9841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK061000, Z01DK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albanell J, 2001, SEMIN ONCOL, V28, P56, DOI 10.1016/S0093-7754(01)90283-0; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Cunnick JM, 2002, J BIOL CHEM, V277, P9498, DOI 10.1074/jbc.M110547200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Derouet D, 2004, P NATL ACAD SCI USA, V101, P4827, DOI 10.1073/pnas.0306178101; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Ernst M, 2004, TRENDS GENET, V20, P23, DOI 10.1016/j.tig.2003.11.003; Ernst M, 2001, J EXP MED, V194, P189, DOI 10.1084/jem.194.2.189; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Grandis JR, 2000, LARYNGOSCOPE, V110, P868, DOI 10.1097/00005537-200005000-00016; Grant SL, 2002, ONCOGENE, V21, P460, DOI 10.1038/sj.onc.1205100; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hilfiker H, 1998, P NATL ACAD SCI USA, V95, P14564, DOI 10.1073/pnas.95.24.14564; Humphreys RC, 2002, ENDOCRINOLOGY, V143, P3641, DOI 10.1210/en.2002-220224; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Ishihara K, 2002, BBA-MOL CELL RES, V1592, P281, DOI 10.1016/S0167-4889(02)00321-X; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kritikou EA, 2003, DEVELOPMENT, V130, P3459, DOI 10.1242/dev.00578; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schere-Levy C, 2003, EXP CELL RES, V282, P35, DOI 10.1006/excr.2002.5666; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; Schmitz J, 2000, J IMMUNOL, V164, P848, DOI 10.4049/jimmunol.164.2.848; SHAMAY A, 1991, J ANIM SCI, V69, P4552, DOI 10.2527/1991.69114552x; Shillingford JM, 2003, J HISTOCHEM CYTOCHEM, V51, P555, DOI 10.1177/002215540305100501; Shillingford JM, 2002, MOL ENDOCRINOL, V16, P563, DOI 10.1210/me.16.3.563; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Viti J, 2003, J NEUROSCI, V23, P3385; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Wang YD, 2002, ONCOGENE, V21, P2584, DOI 10.1038/sj.onc.1205355; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Zang HS, 2001, EMBO J, V20, P3156, DOI 10.1093/emboj/20.12.3156; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhao L, 2002, MOL ENDOCRINOL, V16, P2902, DOI 10.1210/me.2001-0330	48	41	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44093	44100		10.1074/jbc.M313131200	http://dx.doi.org/10.1074/jbc.M313131200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292206	hybrid			2022-12-27	WOS:000224383100089
J	Abe, A; Hiraoka, M; Wild, S; Wilcoxen, SE; Paine, R; Shayman, JA				Abe, A; Hiraoka, M; Wild, S; Wilcoxen, SE; Paine, R; Shayman, JA			Lysosomal phospholipase A2 is selectively expressed in alveolar macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; RAT LUNG; 1-O-ACYLCERAMIDE SYNTHASE; PULMONARY SURFACTANT; 1-CYS PEROXIREDOXIN; MESSENGER-RNA; A(2); MICE; METABOLISM; ENZYME	Lung surfactant is the surface-active agent comprised of phospholipids and proteins that lines pulmonary alveoli. Surfactant stabilizes the alveolar volume by reducing surface tension. Previously, we identified a lysosomal phospholipase A2, termed LPLA2, with specificity toward phosphatidylcholine and phosphatidylethanolamine. The phospholipase is localized to lysosomes, is calcium-independent, has an acidic pH optimum, and transacylates ceramide. Here, we demonstrate that LPLA2 is selectively expressed in alveolar macrophages but not in peritoneal macrophages, peripheral blood monocytes, or other tissues. Other macrophage-associated phospholipase A2s do not show a comparable distribution. LPLA2 is of high specific activity and recognizes disaturated phosphatidylcholine as a substrate. The lysosomal phospholipase A2 activity is six times lower in alveolar macrophages from mice with a targeted deletion of the granulocyte macrophage colony-stimulating factor (GM-CSF), a model of impaired surfactant catabolism, compared with those from wild-type mice. However, LPLA2 activity and protein levels are measured in GM-CSF null mice in which GM-CSF is expressed as a transgene under the control of the surfactant protein C promoter. Thus LPLA2 may be a major enzyme of pulmonary surfactant phospholipid degradation by alveolar macrophages and may be deficient in disorders of surfactant metabolism.	Univ Michigan, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Shayman, JA (corresponding author), Univ Michigan, Dept Internal Med, Div Nephrol, Box 0676,Rm 1560,MSRBII,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	jshayman@umich.edu			NHLBI NIH HHS [HL64558] Funding Source: Medline; NIDDK NIH HHS [R01 DK55823] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055823] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe A, 2004, J LIPID RES, V45, P667, DOI 10.1194/jlr.M300342-JLR200; Abe A, 1996, J BIOL CHEM, V271, P14383, DOI 10.1074/jbc.271.24.14383; Abe A, 1998, J BIOL CHEM, V273, P8467, DOI 10.1074/jbc.273.14.8467; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; COFFEY M, 1992, J BIOL CHEM, V267, P570; Coffey MJ, 2000, J IMMUNOL, V165, P3592, DOI 10.4049/jimmunol.165.7.3592; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; FISHER AB, 1992, BIOCHEM J, V288, P407, DOI 10.1042/bj2880407; Fisher AB, 2001, AM J PHYSIOL-LUNG C, V280, pL748, DOI 10.1152/ajplung.2001.280.4.L748; HEATH M F, 1980, Pediatric Research, V14, P846; HEATH MF, 1980, PEDIATR RES, V14, P254, DOI 10.1203/00006450-198003000-00016; Hiraoka M, 2002, J BIOL CHEM, V277, P10090, DOI 10.1074/jbc.M111977200; Huffman JA, 1996, J CLIN INVEST, V97, P649, DOI 10.1172/JCI118461; Ikegami M, 1996, AM J PHYSIOL-LUNG C, V270, pL650, DOI 10.1152/ajplung.1996.270.4.L650; ISHIBASHI T, 1995, ANN NY ACAD SCI, V748, P630; Kim TS, 1998, AM J PHYSIOL-LUNG C, V274, pL750, DOI 10.1152/ajplung.1998.274.5.L750; Mo YQ, 2003, FEBS LETT, V555, P192, DOI 10.1016/S0014-5793(03)01199-2; Paine R, 2000, J IMMUNOL, V164, P2602, DOI 10.4049/jimmunol.164.5.2602; PETERSGOLDEN M, 1987, AM REV RESPIR DIS, V135, P1020; POST M, 1988, BIOCHIM BIOPHYS ACTA, V947, P249, DOI 10.1016/0304-4157(88)90011-1; Quintero OA, 2000, AM J PHYSIOL-LUNG C, V279, pL399, DOI 10.1152/ajplung.2000.279.2.L399; RAO RH, 1981, EXP LUNG RES, V2, P9, DOI 10.3109/01902148109052298; WANG R, 1994, BIOCHEM J, V304, P131, DOI 10.1042/bj3040131; Wang XS, 2003, J BIOL CHEM, V278, P25179, DOI 10.1074/jbc.M302706200; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4	26	63	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42605	42611		10.1074/jbc.M407834200	http://dx.doi.org/10.1074/jbc.M407834200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15294901	hybrid			2022-12-27	WOS:000224226400033
J	Rattner, A; Chen, JC; Nathans, J				Rattner, A; Chen, JC; Nathans, J			Proteolytic shedding of the extracellular domain of photoreceptor cadherin - Implications for outer segment assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISK MEMBRANE MORPHOGENESIS; CGMP-GATED CHANNEL; RDS MUTANT MICE; RETINAL DEGENERATION; ROD PHOTORECEPTORS; TRANSCRIPTION FACTOR; CYTOCHALASIN-D; LOCALIZATION; PROTEIN; MOUSE	Photoreceptor cadherin (prCAD) is a distinctive cadherin family member that is concentrated at the base of rod and cone outer segments and is required for their structural integrity. During retinal development, prCAD localizes to the site of the future outer segment before rhodopsin or other phototransduction proteins. In vivo, prCAD undergoes a single proteolytic cleavage that releases the ectodomain as a soluble fragment. The C-terminal fragment containing the transmembrane and cytosolic domains remains associated with the outer segment. In rds(-/-) retinas, in which outer segment assembly is severely disrupted because of the absence of retinal degeneration slow (RDS)/peripherin, an essential outer segment structural protein, the level of prCAD is increased, whereas the levels of other outer segment proteins are decreased relative to wild type retinas. Additionally, the ratio of intact: cleaved prCAD polypeptides is increased in rds(-/-) retinas. These data imply that prCAD ectodomain cleavage is an integral part of the outer segment assembly process, and they further suggest that outer segment assembly might be driven, at least in part, by the near irreversibility of proteolysis.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Rattner, A (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 805 PCTB,725 N Wolfe St, Baltimore, MD 21205 USA.	arattner@jhmi.edu		Nathans, Jeremy/0000-0001-8106-5460; Rattner, Amir/0000-0001-9542-6212				Angst BD, 2001, J CELL SCI, V114, P629; ARIKAWA K, 1992, J CELL BIOL, V116, P659, DOI 10.1083/jcb.116.3.659; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; Baumann G, 2002, J ENDOCRINOL, V174, P361, DOI 10.1677/joe.0.1740361; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; COOK NJ, 1989, J BIOL CHEM, V264, P6996; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Goldberg AFX, 1996, BIOCHEMISTRY-US, V35, P6144, DOI 10.1021/bi960259n; Hale IL, 1996, J COMP NEUROL, V376, P128, DOI 10.1002/(SICI)1096-9861(19961202)376:1<128::AID-CNE8>3.0.CO;2-5; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; JANSEN HG, 1984, J COMP NEUROL, V224, P71, DOI 10.1002/cne.902240107; JANSEN HG, 1990, CURR EYE RES, V9, P903, DOI 10.3109/02713689008999562; Kedzierski W, 1999, J BIOL CHEM, V274, P29181, DOI 10.1074/jbc.274.41.29181; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Liu Q, 2002, INVEST OPHTH VIS SCI, V43, P22; Mishra-Gorur K, 2002, J CELL BIOL, V159, P313, DOI 10.1083/jcb.200203117; MURESAN V, 1993, J CELL SCI, V104, P1229; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; OBATA S, 1992, CELL TISSUE RES, V269, P39, DOI 10.1007/BF00384724; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Pan Q, 2001, MOL CELL, V8, P873, DOI 10.1016/S1097-2765(01)00362-8; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Poetsch A, 2001, J BIOL CHEM, V276, P48009, DOI 10.1074/jbc.M108941200; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Rattner A, 2001, NEURON, V32, P775, DOI 10.1016/S0896-6273(01)00531-1; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schlondorff J, 1999, J CELL SCI, V112, P3603; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Siemens J, 2004, NATURE, V428, P950, DOI 10.1038/nature02483; STEINBERG RH, 1980, J COMP NEUROL, V190, P501, DOI 10.1002/cne.901900307; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; USUKURA J, 1987, EXP EYE RES, V45, P501, DOI 10.1016/S0014-4835(87)80061-1; VAUGHAN DK, 1989, INVEST OPHTH VIS SCI, V30, P339; WILLIAMS DS, 1988, J COMP NEUROL, V272, P161, DOI 10.1002/cne.902720202; YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61	41	36	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42202	42210		10.1074/jbc.M407928200	http://dx.doi.org/10.1074/jbc.M407928200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15284225	hybrid			2022-12-27	WOS:000224075500112
J	Wang, PB; Gilmore, AP; Streuli, CH				Wang, PB; Gilmore, AP; Streuli, CH			Bim is an apoptosis sensor that responds to loss of survival signals delivered by epidermal growth factor but not those provided by Integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY-MEMBER BIM; FOCAL ADHESION KINASE; PROTEIN BIM; BH3-ONLY PROTEIN; PROAPOPTOTIC ACTIVITY; PHOSPHORYLATION; EXPRESSION; BAX; ACTIVATION; PATHWAY	Anoikis is a rapid apoptosis response that is initiated within a few minutes after inhibition of integrin signaling. In mammary epithelia, anoikis is mediated by subcellular translocation of Bax from the cytosol to mitochondria where it activates the intrinsic apoptosis pathway. The Bcl-2 homology 3 domain-only protein, Bim, has been proposed to have a key role in the apoptosis response of an epithelial cell line with reduced sensitivity to loss of integrin signaling, which undergoes apoptosis over a period of several days in suspension culture. Here we tested the involvement of Bim in the rapid anoikis response of mouse mammary epithelial cells and discovered that Bim does not have a role in detecting integrin-mediated signals. Instead Bim senses the loss of survival cues mediated by epidermal growth factor. Cell lines selected over many passages in culture have lost much of their sensitivity to anoikis signals arising from an altered cellular microenvironment and may undergo apoptosis through acquired mechanisms.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Streuli, CH (corresponding author), Univ Manchester, Sch Biol Sci, Oxfrod Rd, Manchester M13 9PT, Lancs, England.	cstreuli@man.ac.uk						Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Baselga J, 2000, DRUGS, V60, P33, DOI 10.2165/00003495-200060001-00004; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Enders A, 2003, J EXP MED, V198, P1119, DOI 10.1084/jem.20030411; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Ilic D, 1998, J CELL BIOL, V143, P547; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Pullan S, 1996, J CELL SCI, V109, P631; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Schinzel A, 2004, J CELL BIOL, V164, P1021, DOI 10.1083/jcb.200309013; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Seward RJ, 2003, MOL IMMUNOL, V39, P983, DOI 10.1016/S0161-5890(03)00047-6; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Valentijn AJ, 2004, J BIOL CHEM, V279, P32848, DOI 10.1074/jbc.M313375200; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200; Wang ZQ, 2003, J BIOL CHEM, V278, P23861, DOI 10.1074/jbc.M301843200; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261	36	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41280	41285		10.1074/jbc.C400248200	http://dx.doi.org/10.1074/jbc.C400248200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292207	hybrid			2022-12-27	WOS:000224075500006
J	Wong, DA; Bassilian, S; Lim, S; Lee, WNP				Wong, DA; Bassilian, S; Lim, S; Lee, WNP			Coordination of peroxisomal beta-oxidation and fatty acid elongation in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS ISOTOPOMER; GLUTAMINE; ESTERS; COA	A major product of mitochondrial and peroxisomal beta-oxidation is acetyl-CoA, which is essential for multiple cellular processes. The relative role of peroxisomal beta-oxidation of long chain fatty acids and the fate of its oxidation products are poorly understood and are the subjects of our research. In this report we describe a study of beta-oxidation of palmitate and stearate using HepG2 cells cultured in the presence of multiple concentrations of [U-C-13(18)] stearate or [U-C-13(16)] palmitate. Using mass isotopomer analysis we determined the enrichments of acetyl-CoA used in de novo lipogenesis (cytosolic pool), in the tricarboxylic acid cycle (glutamate pool), and in chain elongation of stearate (peroxisomal pool). Cells treated with 0.1 mM [U-C-13(18)] stearate had markedly disparate acetyl-CoA enrichments (1.1% cytosolic, 1.1% glutamate, 10.7% peroxisomal) with increased absolute levels of C20:0, C22:0, and C24:0. However, cells treated with 0.1 mM [U-C-13(16)] palmitate had a lower peroxisomal enrichment (1.8% cytosolic, 1.6% glutamate, and 1.1% peroxisomal). At higher fatty acid concentrations, acetyl-CoA enrichments in these compartments were proportionally increased. Chain shortening and elongation was determined using spectral analysis. Chain shortening of stearate in peroxisomes generates acetylCoA, which is subsequently used in the chain elongation of a second stearate molecule to form very long chain fatty acids. Chain elongation of palmitate to stearate appeared to occur in a different compartment. Our results suggest that 1) chain elongation activity is a useful and novel probe for peroxisomal beta-oxidation and 2) chain shortening contributes a substantial fraction of the acetyl-CoA used for fatty acid elongation in HepG2 cells.	Harbor UCLA Res & Educ Inst, Dept Pediat, Sch Med, Torrance, CA 90502 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Lee, WNP (corresponding author), Harbor UCLA Med Ctr, 1124 W Carson St, Torrance, CA 90502 USA.	lee@gcrc.rei.edu		Wong, Derek/0000-0002-7762-2276	NCI NIH HHS [R01 CA42710] Funding Source: Medline; NCRR NIH HHS [M01-RR00425] Funding Source: Medline; NIDDK NIH HHS [DK56090-04] Funding Source: Medline; NIGMS NIH HHS [GM08243] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJIE HO, 1995, AM J PHYSIOL-ENDOC M, V269, pE247, DOI 10.1152/ajpendo.1995.269.2.E247; DARMAUN D, 1988, J CELL PHYSIOL, V134, P143, DOI 10.1002/jcp.1041340118; Haber S, 2001, BRAIN RES, V896, P102, DOI 10.1016/S0006-8993(01)02065-0; HELLERSTEIN MK, 1991, J BIOL CHEM, V266, P10920; KATZ J, 1993, J BIOL CHEM, V268, P25509; LEE WNP, 1992, BIOL MASS SPECTROM, V21, P114, DOI 10.1002/bms.1200210210; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; Lee WNP, 1998, J BIOL CHEM, V273, P20929, DOI 10.1074/jbc.273.33.20929; Lee WNP, 1996, DEV NEUROSCI-BASEL, V18, P469, DOI 10.1159/000111442; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; LONGMUIR KJ, 1988, BIOCHIM BIOPHYS ACTA, V961, P144, DOI 10.1016/0005-2760(88)90140-3; Lowenstein J M, 1975, Methods Enzymol, V35, P279, DOI 10.1016/0076-6879(75)35165-3; Moon YA, 2001, J BIOL CHEM, V276, P45358, DOI 10.1074/jbc.M108413200; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; Reszko AE, 2004, J BIOL CHEM, V279, P19574, DOI 10.1074/jbc.M400162200; VANCE DE, 2002, BIOCH LIPIDS LIPOPRO, P183; VANHOVE GF, 1993, J BIOL CHEM, V268, P10335; VEERKAMP JH, 1986, BIOCHEM MED METAB B, V35, P248, DOI 10.1016/0885-4505(86)90080-0; Yang DW, 2000, J NUTR, V130, p991S, DOI 10.1093/jn/130.4.991S; Yu XX, 1997, BIOL NEONATE, V72, P284, DOI 10.1159/000244495	20	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41302	41309		10.1074/jbc.M406766200	http://dx.doi.org/10.1074/jbc.M406766200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15277519	hybrid			2022-12-27	WOS:000224075500009
J	Grinninger, C; Wang, WG; Oskoui, KB; Voice, JK; Goetzl, EJ				Grinninger, C; Wang, WG; Oskoui, KB; Voice, JK; Goetzl, EJ			A natural variant type II G protein-coupled receptor for vasoactive intestinal peptide with altered function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; MODEL BASEMENT-MEMBRANE; T-CELL MIGRATION; EXPRESSION; SELECTIVITY; MICE; VIP1; GENE; PCR	The vasoactive intestinal peptide (VIP) and its G protein-coupled receptors VPAC(1) and VPAC(2) prominently mediate diverse physiological functions in the neural, endocrine, and immune systems. A deletion variant of mouse VPAC(2) has been identified in immune cells that lacks amino acids 367 - 380 at the carboxyl-terminal end of the seventh transmembrane domain. When expressed at equivalent levels in a human Jurkat T cell line, which has very low endogenous expression of human VPAC(1) and VPAC(2), wild-type and deletion-variant VPAC(2) bound the same amount of I-125-VIP with similar affinity. Unlike wild-type VPAC(2), however, deletion-variant VPAC(2) did not transduce VIP-elicited increases in intracellular concentration of cyclic AMP, chemotaxis, or suppression of generation of interleukin-2. Natural deletion of part of the last transmembrane domain of VPAC(2) thus abrogates signaling functions without apparent alterations of expression or ligand binding.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med, Rm UB8B,UC Box 0711,533 Parnassus & 4th Ave, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu			NIAID NIH HHS [AI29912] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029912, R01AI029912] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ajpru S, 2002, MOL BRAIN RES, V105, P29, DOI 10.1016/S0169-328X(02)00387-X; Goetzl EJ, 2001, P NATL ACAD SCI USA, V98, P13854, DOI 10.1073/pnas.241503798; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Juarranz MG, 1999, MOL PHARMACOL, V56, P1280, DOI 10.1124/mol.56.6.1280; Kaltreider HB, 1997, AM J RESP CELL MOL, V16, P133, DOI 10.1165/ajrcmb.16.2.9032120; Lutz EM, 1999, FEBS LETT, V458, P197, DOI 10.1016/S0014-5793(99)01135-7; Nicole P, 1998, J PHARMACOL EXP THER, V284, P744; Park CG, 2000, J PHARMACOL EXP THER, V295, P682; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; SREEDHARAN SP, 1994, BIOCHEM BIOPH RES CO, V203, P141, DOI 10.1006/bbrc.1994.2160; SREEDHARAN SP, 1995, P NATL ACAD SCI USA, V92, P2939, DOI 10.1073/pnas.92.7.2939; Voice JK, 2001, FASEB J, V15, P2489, DOI 10.1096/fj.01-0671com; Wang WG, 2004, FASEB J, V18, P1043, DOI 10.1096/fj.04-1555fje; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629; Xia MH, 1996, J CLIN IMMUNOL, V16, P21, DOI 10.1007/BF01540969; Xia MH, 1996, J IMMUNOL, V156, P160; Zheng YH, 2001, J IMMUNOL, V166, P2317, DOI 10.4049/jimmunol.166.4.2317; Zhou CJ, 2000, ANN NY ACAD SCI, V921, P373	20	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40259	40262		10.1074/jbc.C400332200	http://dx.doi.org/10.1074/jbc.C400332200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15302876	hybrid			2022-12-27	WOS:000223916800004
J	Kuwajima, T; Taniura, H; Nishimura, I; Yoshikawa, K				Kuwajima, T; Taniura, H; Nishimura, I; Yoshikawa, K			Necdin interacts with the Msx2 homeodomain protein via MAGE-D1 to promote myogenic differentiation of C2C12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P75 NEUROTROPHIN RECEPTOR; GROWTH SUPPRESSOR NECDIN; PRADER-WILLI-SYNDROME; NUCLEAR-PROTEIN; TERMINAL DIFFERENTIATION; TRANSCRIPTION FACTOR; POSTMITOTIC NEURONS; ECTOPIC EXPRESSION; CYCLE PROGRESSION; FAMILY PROTEIN	Necdin is a potent growth suppressor that is expressed predominantly in postmitotic cells such as neurons and skeletal muscle cells. Necdin shows a significant homology to MAGE (melanoma antigen) family proteins, all of which contain a large homology domain. MAGE-D1 (NRAGE, Dlxin-1) interacts with the Dlx/Msx family homeodomain proteins via an interspersed hexapeptide repeat domain distinct from the homology domain. Here we report that necdin associates with the Msx homeodomain proteins via MAGE-D1 to modulate their function. In vitro binding and co-immunoprecipitation analyses revealed that MAGE-D1 directly interacted with necdin via the homology domain and Msx1 (or Msx2) via the repeat domain. A ternary complex of necdin, MAGE-D1, and Msx2 was formed in vitro, and an endogenous complex containing these three proteins was detected in differentiating embryonal carcinoma cells. Co-expression of necdin and MAGE-D1 released Msx-dependent transcriptional repression. C2C12 myoblast cells that were stably transfected with Msx2 cDNA showed a marked reduction in myogenic differentiation, and co-expression of necdin and MAGE-D1 canceled the Msx2-dependent repression. These results suggest that necdin and MAGE-D1 cooperate to modulate the function of Dlx/Msx homeodomain proteins in cellular differentiation.	Osaka Univ, Inst Prot Res, Div Regulat Macromol Funct, Suita, Osaka 5650871, Japan	Osaka University	Yoshikawa, K (corresponding author), Osaka Univ, Inst Prot Res, Div Regulat Macromol Funct, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.	yoshikaw@protein.osaka-u.ac.jp		Kuwajima, Takaaki/0000-0002-8398-3131				AIZAWA T, 1992, DEV BRAIN RES, V68, P265, DOI 10.1016/0165-3806(92)90069-9; Albrecht DE, 2004, J BIOL CHEM, V279, P7014, DOI 10.1074/jbc.M312205200; Barker PA, 2002, J NEUROSCI RES, V67, P705, DOI 10.1002/jnr.10160; Bischof JM, 2003, DEV DYNAM, V228, P475, DOI 10.1002/dvdy.10398; Brunelli S, 2004, CIRC RES, V94, P1571, DOI 10.1161/01.RES.0000132747.12860.10; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; Dodig M, 1999, DEV BIOL, V209, P298, DOI 10.1006/dbio.1999.9258; Gerard M, 1999, NAT GENET, V23, P199, DOI 10.1038/13828; HAYASHI Y, 1995, BIOCHEM BIOPH RES CO, V213, P317, DOI 10.1006/bbrc.1995.2132; Hu B, 2003, P NATL ACAD SCI USA, V100, P10008, DOI 10.1073/pnas.1737765100; Hu GZ, 2001, DEVELOPMENT, V128, P2373; ILER N, 1995, MECH DEVELOP, V53, P87, DOI 10.1016/0925-4773(95)00427-0; Israsena N, 2002, J NEUROSCI RES, V69, P803, DOI 10.1002/jnr.10362; Jordan BWM, 2001, J BIOL CHEM, V276, P39985, DOI 10.1074/jbc.C100171200; Kendall SE, 2002, MECH DEVELOP, V117, P187, DOI 10.1016/S0925-4773(02)00204-6; Kobayashi M, 2002, J BIOL CHEM, V277, P42128, DOI 10.1074/jbc.M205024200; Kuwako K, 2004, J BIOL CHEM, V279, P1703, DOI 10.1074/jbc.M308454200; Marazzi G, 1997, DEV BIOL, V186, P127, DOI 10.1006/dbio.1997.8576; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; Masuda Y, 2001, J BIOL CHEM, V276, P5331, DOI 10.1074/jbc.M008590200; Matsuda T, 2003, J BIOL CHEM, V278, P29057, DOI 10.1074/jbc.M302199200; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muscatelli F, 2000, HUM MOL GENET, V9, P3101, DOI 10.1093/hmg/9.20.3101; Niinobe M, 2000, DEV NEUROSCI-BASEL, V22, P310, DOI 10.1159/000017455; Pold M, 2000, DEV COMP IMMUNOL, V24, P719, DOI 10.1016/S0145-305X(00)00027-6; Ren J, 2003, J NEUROSCI, V23, P1569; Saburi S, 2001, J BIOL CHEM, V276, P49378, DOI 10.1074/jbc.M108584200; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Salehi AH, 2002, J BIOL CHEM, V277, P48043, DOI 10.1074/jbc.M205324200; Sasaki A, 2002, J BIOL CHEM, V277, P22541, DOI 10.1074/jbc.M109728200; SONG KN, 1992, NATURE, V360, P477, DOI 10.1038/360477a0; Stuhmer T, 2002, DEVELOPMENT, V129, P245; Takahashi K, 2001, DEV DYNAM, V222, P252, DOI 10.1002/dvdy.1185; Takazaki R, 2002, EXP CELL RES, V277, P220, DOI 10.1006/excr.2002.5558; Taniguchi N, 2000, J BIOL CHEM, V275, P31674, DOI 10.1074/jbc.M005103200; Taniura H, 1999, J BIOL CHEM, V274, P16242, DOI 10.1074/jbc.274.23.16242; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; Taniura H, 2002, J CELL BIOCHEM, V84, P545, DOI 10.1002/jcb.10047.abs; Tcherpakov M, 2002, J BIOL CHEM, V277, P49101, DOI 10.1074/jbc.C200533200; Uetsuki T, 1996, J BIOL CHEM, V271, P918, DOI 10.1074/jbc.271.2.918; Williams ME, 2003, J BIOL CHEM, V278, P17483, DOI 10.1074/jbc.M300415200; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0; Yoshikawa K, 2000, NEUROSCI RES, V37, P1, DOI 10.1016/S0168-0102(00)00101-2	44	63	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40484	40493		10.1074/jbc.M404143200	http://dx.doi.org/10.1074/jbc.M404143200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15272023	hybrid			2022-12-27	WOS:000223916800035
J	Simard, CF; Brunet, GM; Daigle, ND; Motminy, V; Caron, L; Isenring, P				Simard, CF; Brunet, GM; Daigle, ND; Motminy, V; Caron, L; Isenring, P			Self-interacting domains in the C terminus of a cation-Cl- cotransporter described for the first time	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-2CL(-) COTRANSPORTER; FUNCTIONAL EXPRESSION; CHLORIDE COTRANSPORTER; MOLECULAR-CLONING; ION-TRANSPORT; BUMETANIDE BINDING; EPITHELIAL-CELLS; IN-VITRO; PROTEIN; NKCC1	The first isoform of the Na+-K+-Cl- cotransporter (NKCC1), a widely distributed member of the cation-Cl- cotransporter superfamily, plays key roles in many physiological processes by regulating the ion and water content of animal cells and by sustaining electrolyte secretion across various epithelia. Indirect studies have led to the prediction that NKCC1 operates as a dimer assembled through binding domains that are distal to the amino portion of the carrier. In this study, evidence is presented that NKCC1 possesses self-interacting properties that result in the formation of a large complex between the proximal and the distal segment of the cytosolic C terminus. Elaborate mapping studies of these segments showed that the contact sites are dispersed along the entire C terminus, and they also led to the identification of a critical interacting residue that belongs to a putative forkhead-associated binding domain. In conjunction with previous findings, our results indicate that the uncovered interacting domains are probably a major determinant of the NKCC1 conformational landscape and assembly into a high order structure. A model is proposed in which the carrier could alternate between monomeric and homo-oligomeric units via chemical-or ligand-dependent changes in conformational dynamics.	Univ Laval, Fac Med, Nephrol Res Grp, Dept Med, Quebec City, PQ G1R 2J6, Canada	Laval University	Isenring, P (corresponding author), Hotel Dieu Quebec Res Ctr, 10 Rue McMahon, Room 3852, Quebec City, PQ G1R 2J6, Canada.	paul.isenring@crhdq.ulaval.ca						BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bergeron MJ, 2003, AM J PHYSIOL-RENAL, V285, pF68, DOI 10.1152/ajprenal.00032.2003; Boettger T, 2002, NATURE, V416, P874, DOI 10.1038/416874a; CHENG S, 1999, J AM SOC NEPHROL, V10, pA34; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; DAndrea L, 1996, J BIOL CHEM, V271, P28969, DOI 10.1074/jbc.271.46.28969; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; Dowd BFX, 2003, J BIOL CHEM, V278, P27347, DOI 10.1074/jbc.M301899200; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Engelman DM, 2003, FEBS LETT, V555, P122, DOI 10.1016/S0014-5793(03)01106-2; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Flemmer AW, 2002, J BIOL CHEM, V277, P37551, DOI 10.1074/jbc.M206294200; Gagnon E, 2003, AM J PHYSIOL-CELL PH, V284, pC365, DOI 10.1152/ajpcell.00262.2002; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; Garon L, 2000, J BIOL CHEM, V275, P32027, DOI 10.1074/jbc.M000108200; Gerelsaikhan T, 2000, J BIOL CHEM, V275, P40471, DOI 10.1074/jbc.M007751200; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Hebert SC, 2004, PFLUG ARCH EUR J PHY, V447, P580, DOI 10.1007/s00424-003-1066-3; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Isenring P, 2001, COMP BIOCHEM PHYS A, V130, P487, DOI 10.1016/S1095-6433(01)00420-2; ISENRING P, 1997, INT SOC NEPHR; Jacoby SC, 1999, AM J PHYSIOL-CELL PH, V277, pC684, DOI 10.1152/ajpcell.1999.277.4.C684; Kim GH, 2000, AM J PHYSIOL-RENAL, V279, pF459, DOI 10.1152/ajprenal.2000.279.3.F459; Klein JD, 1999, AM J PHYSIOL-CELL PH, V277, pC425, DOI 10.1152/ajpcell.1999.277.3.C425; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Kurihara K, 1999, AM J PHYSIOL-CELL PH, V277, pC1184, DOI 10.1152/ajpcell.1999.277.6.C1184; Lauf PK, 2001, COMP BIOCHEM PHYS A, V130, P499, DOI 10.1016/S1095-6433(01)00421-4; Liedtke CM, 2003, AM J PHYSIOL-CELL PH, V284, pC487, DOI 10.1152/ajpcell.00357.2002; LYTLE C, 1992, J BIOL CHEM, V267, P25438; Moore-Hoon ML, 2000, BIOCHEMISTRY-US, V39, P3718, DOI 10.1021/bi992301v; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Piechotta K, 2003, J BIOL CHEM, V278, P52848, DOI 10.1074/jbc.M309436200; Piechotta K, 2002, J BIOL CHEM, V277, P50812, DOI 10.1074/jbc.M208108200; Race JE, 1999, AM J PHYSIOL-CELL PH, V277, pC1210, DOI 10.1152/ajpcell.1999.277.6.C1210; Rees DC, 2000, J BIOL CHEM, V275, P713, DOI 10.1074/jbc.275.2.713; Riechmann JL, 1999, MOL CELL BIOL, V19, P8505; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201; Zhang DC, 2000, BLOOD, V96, P2925	50	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40769	40777		10.1074/jbc.M406458200	http://dx.doi.org/10.1074/jbc.M406458200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15280386	hybrid			2022-12-27	WOS:000223916800070
J	Vazquez, G; Wedel, BJ; Kawasaki, BT; Bird, GS; Putney, JW				Vazquez, G; Wedel, BJ; Kawasaki, BT; Bird, GS; Putney, JW			Obligatory role of Src kinase in the signaling mechanism for TRPC3 cation channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; GROWTH-FACTOR RECEPTOR; PANCREATIC ACINAR-CELLS; SMOOTH-MUSCLE-CELLS; TRANSIENT RECEPTOR; PROTEIN-KINASE; CALCIUM-ENTRY; TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE; HUMAN PLATELETS	Members of the canonical transient receptor potential (TRPC) subfamily of cation channels are candidates for capacitative and non-capacitative Ca2+ entry channels. When ectopically expressed in cell lines, TRPC3 can be activated by phospholipase C-mediated generation of diacylglycerol or by addition of synthetic diacylglycerols, independently of Ca2+ store depletion. Apart from this mode of regulation, little is known about other receptor-dependent signaling events that modulate TRPC3 activity. In the present study the role of tyrosine kinases in receptor- and diacylglycerol-dependent activation of TRPC3 was investigated. In HEK293 cells stably expressing TRPC3, pharmacological inhibition of tyrosine kinases, and specifically of Src kinases, abolished activation of TRPC3 by muscarinic receptor stimulation and by diacylglycerol. Channel regulation was lost following expression of a dominant-negative mutant of Src, or when TRPC3 was expressed in an Src-deficient cell line. In both instances, wild-type Src restored TRPC3 regulation. We conclude that Src plays an obligatory role in the mechanism for receptor and diacylglycerol activation of TRPC3.	NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Vazquez, G (corresponding author), NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.	vazquez@niehs.nih.gov	Putney, James W/F-7247-2019; Bird, Gary/AAI-8186-2021	Putney, James W/0000-0002-3379-4789; Bird, Gary/0000-0003-1389-8748	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, Z01ES090087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Babnigg G, 1997, J BIOL CHEM, V272, P29434, DOI 10.1074/jbc.272.47.29434; Babnigg G, 2003, J BIOL CHEM, V278, P14872, DOI 10.1074/jbc.M210418200; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; BEVAN AP, 1995, AM J PHYSIOL-ENDOC M, V268, pE60, DOI 10.1152/ajpendo.1995.268.1.E60; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; Byron KL, 2002, J BIOL CHEM, V277, P7298, DOI 10.1074/jbc.M104726200; Cai WH, 2004, J BIOL CHEM, V279, P23691, DOI 10.1074/jbc.M313296200; Camello C, 1999, J PHYSIOL-LONDON, V516, P399, DOI 10.1111/j.1469-7793.1999.0399v.x; Chen NY, 2001, J BIOL CHEM, V276, P46722, DOI 10.1074/jbc.M107156200; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; Hassock SR, 2002, BLOOD, V100, P2801, DOI 10.1182/blood-2002-03-0723; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Igishi T, 1998, BIOCHEM BIOPH RES CO, V244, P5, DOI 10.1006/bbrc.1998.8208; Jiang XP, 2003, J BIOL CHEM, V278, P42867, DOI 10.1074/jbc.M304487200; Kanno H, 2003, AM J PHYSIOL-CELL PH, V284, pC988, DOI 10.1152/ajpcell.00582.2001; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Kwan HY, 2004, P NATL ACAD SCI USA, V101, P2625, DOI 10.1073/pnas.0304471101; Lawrence DS, 1998, PHARMACOL THERAPEUT, V77, P81, DOI 10.1016/S0163-7258(97)00052-1; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Redondo PC, 2003, BIOCHEM J, V370, P255, DOI 10.1042/BJ20021505; Rosado JA, 2004, J BIOL CHEM, V279, P1665, DOI 10.1074/jbc.M307963200; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Seow CJ, 2002, EUR J PHARMACOL, V443, P189, DOI 10.1016/S0014-2999(02)01534-0; Shuttleworth TJ, 1996, BIOCHEM J, V316, P819, DOI 10.1042/bj3160819; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; Vazquez G, 2003, J BIOL CHEM, V278, P21649, DOI 10.1074/jbc.M302162200; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Wedel BJ, 2003, J BIOL CHEM, V278, P25758, DOI 10.1074/jbc.M303890200; Wrenn RW, 2001, BIOCHEM BIOPH RES CO, V282, P882, DOI 10.1006/bbrc.2001.4657; Xu HS, 2003, J BIOL CHEM, V278, P11520, DOI 10.1074/jbc.M211061200; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	51	122	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40521	40528		10.1074/jbc.M405280200	http://dx.doi.org/10.1074/jbc.M405280200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15271991	hybrid			2022-12-27	WOS:000223916800039
J	Chen, EY; Bartlett, MC; Loo, TW; Clarke, DM				Chen, EY; Bartlett, MC; Loo, TW; Clarke, DM			The Delta F508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; DISEASE-ASSOCIATED MUTATIONS; CHANNEL-LINING RESIDUES; CHLORIDE CHANNEL; CROSS-LINKING; DRUG-BINDING; SELECTIVITY FILTER; CYTOPLASMIC LOOP; CFTR; NUCLEOTIDE	The most common mutation in cystic fibrosis (deletion of Phe-508 in the first nucleotide binding domain (DeltaF508)) in the cystic fibrosis transmembrane conductance regulator (CFTR) causes retention of the mutant protein in the endoplasmic reticulum. We previously showed that the DeltaF508 mutation causes the CFTR protein to be retained in the endoplasmic reticulum in an inactive and structurally altered state. Proper packing of the transmembrane (TM) segments is critical for function because the TM segments form the chloride channel. Here we tested whether the DeltaF508 mutation altered packing of the TM segments by disulfide cross-linking analysis between TM6 and TM12 in wild-type and DeltaF508 CFTRs. These TM segments were selected because TM6 appears to line the chloride channel, and cross-linking between these TM segments has been observed in the CFTR sister protein, the multidrug resistance P-glycoprotein. We first mapped potential contact points in wild-type CFTR by cysteine mutagenesis and thiol cross-linking analysis. Disulfide cross-linking was detected in CFTR mutants M348C(TM6)/T1142C(TM12), T351C(TM6)/T1142C(TM12), and W356C(TM6)/W1145C(TM12) in a wild-type background. The disulfide cross-linking occurs intramolecularly and was reducible by dithiothreitol. Introduction of the DeltaF508 mutation into these cysteine mutants, however, abolished cross-linking. The results suggest that the DeltaF508 mutation alters interactions between the TM domains. Therefore, a potential target to correct folding defects in the DeltaF508 mutant of CFTR is to identify compounds that promote correct folding of the TM domains.	Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	david.clarke@utoronto.ca	Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				Akabas MH, 1998, BIOCHEMISTRY-US, V37, P12233, DOI 10.1021/bi980969o; Akabas MH, 2000, J BIOL CHEM, V275, P3729, DOI 10.1074/jbc.275.6.3729; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BOAT TF, 1989, ACTA PAEDIATR SCAND, P25; Bruice T.W., 1982, J PROTEIN CHEM, V1, P47, DOI DOI 10.1007/BF01025550; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen EY, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-29; Chen EYJ, 2000, BIOCHEMISTRY-US, V39, P3797, DOI 10.1021/bi992620m; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Clarke LL, 2004, AM J PHYSIOL-CELL PH, V287, pC192, DOI 10.1152/ajpcell.00337.2003; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; ESTELLE CB, 2004, P NATL ACAD SCI USA, V101, P8221; Guinamard R, 1999, BIOCHEMISTRY-US, V38, P5528, DOI 10.1021/bi990155n; Gupta J, 2003, MOL MEMBR BIOL, V20, P45, DOI 10.1080/0968031000045824; Gupta J, 2001, BIOCHEMISTRY-US, V40, P6620, DOI 10.1021/bi002819v; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hille B, 1984, IONIC CHANNELS EXCIT; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kenyon G L, 1977, Methods Enzymol, V47, P407; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; Linsdell P, 1997, J GEN PHYSIOL, V110, P355, DOI 10.1085/jgp.110.4.355; Linsdell P, 2001, J PHYSIOL-LONDON, V531, P51, DOI 10.1111/j.1469-7793.2001.0051j.x; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2003, J BIOL CHEM, V278, P13603, DOI 10.1074/jbc.C300073200; Loo TW, 2004, J BIOL CHEM, V279, P38395, DOI 10.1074/jbc.M405623200; Loo TW, 2004, J BIOL CHEM, V279, P18232, DOI 10.1074/jbc.M400229200; Loo TW, 2004, J BIOL CHEM, V279, P7692, DOI 10.1074/jbc.M311825200; Loo TW, 2003, J BIOL CHEM, V278, P50136, DOI 10.1074/jbc.M310448200; Loo TW, 2003, J BIOL CHEM, V278, P20449, DOI 10.1074/jbc.C300154200; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; Loo TW, 2002, J BIOL CHEM, V277, P27585, DOI 10.1074/jbc.C200330200; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Ostedgaard LS, 1997, BIOCHEMISTRY-US, V36, P1287, DOI 10.1021/bi962174s; Powell K, 2002, ADV DRUG DELIVER REV, V54, P1395, DOI 10.1016/S0169-409X(02)00148-5; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rosenberg MF, 2004, J BIOL CHEM, V279, P39051, DOI 10.1074/jbc.M407434200; Rowntree RK, 2003, ANN HUM GENET, V67, P471, DOI 10.1046/j.1469-1809.2003.00028.x; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Sauna ZE, 2004, MOL PHARMACOL, V65, P675, DOI 10.1124/mol.65.3.675; Seibert FS, 1996, J BIOL CHEM, V271, P27493, DOI 10.1074/jbc.271.44.27493; Seibert FS, 1997, BIOCHEMISTRY-US, V36, P11966, DOI 10.1021/bi9712652; Seibert FS, 1996, J BIOL CHEM, V271, P15139, DOI 10.1074/jbc.271.25.15139; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180	57	80	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39620	39627		10.1074/jbc.M407887200	http://dx.doi.org/10.1074/jbc.M407887200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15272010	hybrid			2022-12-27	WOS:000223791500052
J	Diskin, R; Askari, N; Capone, R; Engelberg, D; Livnah, O				Diskin, R; Askari, N; Capone, R; Engelberg, D; Livnah, O			Active mutants of the human p38 alpha mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OF-FUNCTION MUTATION; MAP-KINASE; SIGNAL-TRANSDUCTION; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; PC12 CELLS; P38; PHOSPHORYLATION; DIFFERENTIATION	Mitogen-activated protein ( MAP) kinases compose a family of serine/threonine kinases that function in many signal transduction pathways and affect various cellular phenotypes. Despite the abundance of available data, the exact role of each MAP kinase is not completely defined, in part because of the inability to activate MAP kinase molecules individually and specifically. Based on activating mutations found in the yeast MAP kinase p38/Hog1 (Bell, M., Capone, R., Pashtan, I., Levitzki, A., and Engelberg, D. (2001) J. Biol. Chem. 276, 25351-25358), we designed and constructed single and multiple mutants of human MAP kinase p38alpha. Single (p38(D176A), p38(F327L), and p38(F327S)) and subsequent double (p38(D176A/F327L) and p38(D176A/F327S)) mutants acquired high intrinsic activity independent of any upstream regulation and reached levels of 10 and 25%, respectively, in reference to the dually phosphorylated wild type p38alpha. The active p38 mutants have retained high specificity toward p38 substrates and were inhibited by the specific p38 inhibitors SB-203580 and PD-169316. We also show that similar mutations can render p38gamma active as well. Based on the available structures of p38 and ERK2, we have analyzed the p38 mutants and identified a hydrophobic core stabilized by three aromatic residues, Tyr-69, Phe-327, and Trp-337, in the vicinity of the L16 loop region. Upon activation, a segment of the L16 loop, including Phe-327, becomes disordered. Structural analysis suggests that the active p38 mutants emulate the conformational changes imposed naturally by dual phosphorylation, namely, destabilization of the hydrophobic core. Essentially, the hydrophobic core is an inherent stabilizer that maintains low basal activity level in unphosphorylated p38.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, Wolfson Ctr Appl Struct Biol, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Livnah, O (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, Wolfson Ctr Appl Struct Biol, Safra Campus, IL-91904 Jerusalem, Israel.	oded.livnah@huji.ac.il	Capone, Ricardo F/D-1943-2010	Capone, Ricardo F/0000-0002-7327-9837				Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Bell M, 2003, J BIOL CHEM, V278, P14603, DOI 10.1074/jbc.C300006200; Bell M, 2001, J BIOL CHEM, V276, P25351, DOI 10.1074/jbc.M101818200; Bellon S, 1999, STRUCTURE, V7, P1057, DOI 10.1016/S0969-2126(99)80173-7; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Clerk A, 1998, BIOCHEM J, V333, P581, DOI 10.1042/bj3330581; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DeLano WL, 2002, PYMOL USERS MANUAL; Emrick MA, 2001, J BIOL CHEM, V276, P46469, DOI 10.1074/jbc.M107708200; FERRIN TE, 1991, J MOL GRAPHICS, V9, P27, DOI 10.1016/0263-7855(91)80030-4; Hall JP, 1996, MOL CELL BIOL, V16, P6715; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Puri PL, 2000, GENE DEV, V14, P574; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yaakov G, 2003, MOL CELL BIOL, V23, P4826, DOI 10.1128/MCB.23.14.4826-4840.2003; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	50	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47040	47049		10.1074/jbc.M404595200	http://dx.doi.org/10.1074/jbc.M404595200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15284239	hybrid			2022-12-27	WOS:000224832400089
J	Mithieux, G; Rajas, F; Gautier-Stein, A				Mithieux, G; Rajas, F; Gautier-Stein, A			A novel role for glucose 6-phosphatase in the small intestine in the control of glucose homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RAT SMALL-INTESTINE; GENE-EXPRESSION; KETONE-BODIES; IN-VIVO; GLUTAMINE; DISEASE; LIVER; METABOLISM; KIDNEY; ADAPTATIONS		Univ Lyon 1, Fac Med Laennec, INRA 1235, INSERM,U449, F-69372 Lyon 08, France	INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Mithieux, G (corresponding author), Univ Lyon 1, Fac Med Laennec, INRA 1235, INSERM,U449, Rue Guillaume Paradin, F-69372 Lyon 08, France.	mithieux@laennec.univ-lyon1.fr	RAJAS, Fabienne/P-4091-2016	RAJAS, Fabienne/0000-0002-9233-7633; Gilles, Mithieux/0000-0003-3579-8529; Gautier-Stein, Amandine/0000-0002-6003-1891				ADROGUE HJ, 1992, KIDNEY INT, V42, P1266, DOI 10.1038/ki.1992.414; ASHMORE J, 1959, VITAM HORM, V17, P91, DOI 10.1016/S0083-6729(08)60269-1; CERSOSIMO E, 1986, AM J PHYSIOL, V250, pE622, DOI 10.1152/ajpendo.1986.250.6.E622; Chatelain F, 1998, DIABETES, V47, P882, DOI 10.2337/diabetes.47.6.882; Croset M, 2001, DIABETES, V50, P740, DOI 10.2337/diabetes.50.4.740; Ekberg K, 1999, DIABETES, V48, P292, DOI 10.2337/diabetes.48.2.292; FIELD JB, 1965, J CLIN INVEST, V44, P1240, DOI 10.1172/JCI105230; FONDY TP, 1965, ANN NY ACAD SCI, V119, P888, DOI 10.1111/j.1749-6632.1965.tb47450.x; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Gautier-Stein A, 2003, NUCLEIC ACIDS RES, V31, P5238, DOI 10.1093/nar/gkg747; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; GINSBURG V, 1960, BIOCHIM BIOPHYS ACTA, V38, P427, DOI 10.1016/0006-3002(60)91278-6; GIRARD J, 1992, PHYSIOL REV, V72, P507, DOI 10.1152/physrev.1992.72.2.507; HANSON PJ, 1978, J PHYSIOL-LONDON, V278, P55, DOI 10.1113/jphysiol.1978.sp012292; HARTMANN F, 1989, METABOLISM, V38, P18, DOI 10.1016/0026-0495(89)90134-0; HERS H. G., 1964, ADVAN METAB DISORDERS, V1, P1; Laser B, 1996, J BIOL CHEM, V271, P28984, DOI 10.1074/jbc.271.46.28984; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; LYGRE DG, 1968, BIOCHEMISTRY-US, V7, P3219, DOI 10.1021/bi00849a026; Magnuson MA, 2003, J BIOL CHEM, V278, P32485, DOI 10.1074/jbc.R300020200; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; Mithieux G, 2004, AM J PHYSIOL-ENDOC M, V286, pE370, DOI 10.1152/ajpendo.00299.2003; Mithieux G, 1997, DIABETES, V46, P297; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; Nordlie RC, 1999, ANNU REV NUTR, V19, P379, DOI 10.1146/annurev.nutr.19.1.379; NORDLIE RC, 1976, GLUCONEOGENESIS ITS, P93; Portha B, 2001, DIABETES, V50, pS89, DOI 10.2337/diabetes.50.2007.S89; Rajas F, 1999, GASTROENTEROLOGY, V117, P132, DOI 10.1016/S0016-5085(99)70559-7; Rajas F, 2000, DIABETES, V49, P1165, DOI 10.2337/diabetes.49.7.1165; Santer R, 2003, GASTROENTEROLOGY, V124, P34, DOI 10.1053/gast.2003.50009; She PX, 2003, DIABETES, V52, P1649, DOI 10.2337/diabetes.52.7.1649; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; Stumpel F, 2001, P NATL ACAD SCI USA, V98, P11330, DOI 10.1073/pnas.211357698; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; Van Schaftingen E, 2002, BIOCHEM J, V362, P513, DOI 10.1042/0264-6021:3620513; WATFORD M, 1994, BBA-GEN SUBJECTS, V1200, P73, DOI 10.1016/0304-4165(94)90029-9; WINDMUELLER HG, 1978, J BIOL CHEM, V253, P69; WINDMUELLER HG, 1984, GLUTAMINE METABOLISM, P61	38	91	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44231	44234		10.1074/jbc.R400011200	http://dx.doi.org/10.1074/jbc.R400011200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302872	hybrid			2022-12-27	WOS:000224505600001
J	Toh, WH; Siddique, MM; Boominathan, L; Lin, KW; Sabapathy, K				Toh, WH; Siddique, MM; Boominathan, L; Lin, KW; Sabapathy, K			c-Jun regulates the stability and activity of the p53 homologue, p73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; PHYSICAL INTERACTION; P53-RELATED PROTEIN; MODULATION; INDUCTION; APOPTOSIS; PHOSPHORYLATION; MDM2; AP-1; ABL	Chemotherapeutic drugs and stress signals activate p73, the structural and functional homologue of p53, both by transcriptional activation and post-translational modifications. However, cisplatin, a DNA damage-inducing chemotherapeutic agent, is thought to regulate p73 only by affecting its stability through mechanisms involving the MLH-1/c-Abl signaling cascade. Here we show that c-Jun, a component of the AP-1 family of transcription factors, contributes to p73 induction by cisplatin. c-jun(-/-) cells are defective in p73 induction, and ectopic c-Jun expression augments p73 levels. c-Jun-mediated accumulation of p73 requires the transactivation activity of c-Jun and occurs in a c-Abl- and Mdm2-independent manner. c-Jun expression increases p73 half-life by preventing it from proteasome-mediated degradation, resulting in the potentiation of p73-mediated transcriptional activity. Moreover, mouse fibroblasts lacking c-Jun are resistant to cisplatin-induced apoptosis, and reintroduction of c-Jun restores p73 activation and sensitivity to cisplatin. Furthermore, p73-mediated apoptosis is abrogated in c-jun(-/-) cells. Together, these findings demonstrate a possible role for c-Jun in regulating p73 function and highlight the importance of the cooperativity between transcription factors in potentiating apoptosis.	Natl Canc Ctr, Div Cellular & Mol Res, Mol Carcinogenesis Lab, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 119260, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore	Sabapathy, K (corresponding author), Natl Canc Ctr, Div Cellular & Mol Res, Mol Carcinogenesis Lab, 11 Hosp Dr, Singapore 169610, Singapore.	cmrksb@nccs.com.sg	Lakshamanane, Boominathan/AAW-5331-2020					Agami R, 1999, NATURE, V399, P809; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Fuchs SY, 1996, ONCOGENE, V13, P1531; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gong JG, 1999, NATURE, V399, P806; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; LIN KW, 2004, IN PRESS NEOPLASIA, V6; Manson MM, 2000, BIOCHEM SOC T, V28, P7, DOI 10.1042/bst0280007; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Ohtsuka T, 2003, ONCOGENE, V22, P1678, DOI 10.1038/sj.onc.1206306; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shimodaira H, 2003, P NATL ACAD SCI USA, V100, P2420, DOI 10.1073/pnas.0438031100; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Tsai KKC, 2003, CANCER RES, V63, P3418; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	39	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44713	44722		10.1074/jbc.M407672200	http://dx.doi.org/10.1074/jbc.M407672200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302867	hybrid			2022-12-27	WOS:000224505600059
J	Conde, R; Cueva, R; Pablo, G; Polaina, J; Larriba, G				Conde, R; Cueva, R; Pablo, G; Polaina, J; Larriba, G			A search for hyperglycosylation signals in yeast glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE-GLYCOSYLATION EFFICIENCY; SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; N-GLYCOSYLATION; EXTERNAL INVERTASE; AMINO-ACID; MANNOSYLTRANSFERASE COMPLEX; STRUCTURAL REQUIREMENTS; MAJOR EXOGLUCANASE; PICHIA-ANOMALA	N-oligosaccharides of Saccharomyces cerevisiae glycoproteins are classified as core and mannan types. The former contain 13-14 mannoses whereas mannan-type structures consist of an inner core extended with an outer chain of up to 200-300 mannoses, a process known as hyperglycosylation. The selection of substrates for hyperglycosylation poses a theoretical and practical question. To identify hyperglycosylation determinants, we have analyzed the influence of the second amino acid (Xaa) of the sequon in this process using the major exoglucanase as a model. Our results indicate that negatively charged amino acids inhibit hyperglycosylation, whereas positively charged counterparts promote it. On the basis of the tridimensional structure of Exg1, we propose that Xaa influences the orientation of the inner core making it accessible to mannan polymerase I in the appropriate position for the addition of alpha-1,6-mannoses. The presence of Glu in the Xaa of the second sequon of the native exoglucanase suggests that negative selection may drive evolution of these sites. However, a comparison of invertases secreted by S. cerevisiae and Pichia anomala suggests that hyperglycosylation signals are also subjected to positive selection.	Univ Extremadura, Fac Ciencias, Dept Microbiol, E-06071 Badajoz, Spain; CSIC, Inst Agroquim & Tecnol Alimentos, Valencia 46980, Spain	Universidad de Extremadura; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA)	Larriba, G (corresponding author), Univ Extremadura, Fac Ciencias, Dept Microbiol, E-06071 Badajoz, Spain.	glarriba@unex.es	Larriba, Germán/E-3563-2013; Polaina, Julio/H-4498-2012	Cueva, Rosario/0000-0002-9445-0947; Polaina, Julio/0000-0001-9912-0640				BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BASCO RD, 1994, BIOCHEM J, V304, P917, DOI 10.1042/bj3040917; BASCO RD, 1993, YEAST, V9, P221, DOI 10.1002/yea.320090303; BASCO RD, 1990, FEBS LETT, V268, P99, DOI 10.1016/0014-5793(90)80982-O; Basco RD, 1996, BBA-MOL CELL RES, V1310, P110, DOI 10.1016/0167-4889(95)00156-5; BAUSE E, 1979, EUR J BIOCHEM, V101, P531, DOI 10.1111/j.1432-1033.1979.tb19748.x; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Cueva R, 1996, BBA-GEN SUBJECTS, V1289, P336, DOI 10.1016/0304-4165(95)00171-9; Cutfield SM, 1999, J MOL BIOL, V294, P771, DOI 10.1006/jmbi.1999.3287; DEALDANA CRV, 1991, GENE, V97, P173, DOI 10.1016/0378-1119(91)90049-H; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; HERNANDEZ LM, 1986, ARCH MICROBIOL, V146, P221, DOI 10.1007/BF00403220; HERNANDEZ LM, 1992, BIOCHEMISTRY-US, V31, P9823, DOI 10.1021/bi00155a039; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Jungmann J, 1999, J BIOL CHEM, V274, P6579, DOI 10.1074/jbc.274.10.6579; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; Kasturi L, 1997, BIOCHEM J, V323, P415, DOI 10.1042/bj3230415; KASTURI L, 1995, J BIOL CHEM, V270, P14756, DOI 10.1074/jbc.270.24.14756; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; Marshall R D, 1974, Biochem Soc Symp, P17; Orlean P., 1997, MOL CELLULAR BIOL YE, V21, P229; Perez JA, 2001, ARCH MICROBIOL, V175, P189, DOI 10.1007/s002030100253; Perez JA, 1996, CURR GENET, V29, P234, DOI 10.1007/s002940050041; Petrescu AJ, 2004, GLYCOBIOLOGY, V14, P103, DOI 10.1093/glycob/cwh008; RAMIREZ M, 1989, ARCH MICROBIOL, V151, P391, DOI 10.1007/BF00416596; Rayner JC, 1998, J BIOL CHEM, V273, P26836, DOI 10.1074/jbc.273.41.26836; Reddy A, 1999, GLYCOBIOLOGY, V9, P547, DOI 10.1093/glycob/9.6.547; REDDY VA, 1988, J BIOL CHEM, V263, P6978; ROITSCH T, 1989, EUR J BIOCHEM, V181, P525, DOI 10.1111/j.1432-1033.1989.tb14755.x; Sakon J, 1996, BIOCHEMISTRY-US, V35, P10648, DOI 10.1021/bi9604439; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; SIKORSKI RS, 1989, GENETICS, V122, P19; Stolz J, 2002, J BIOL CHEM, V277, P44801, DOI 10.1074/jbc.M208023200; Taylor SC, 2004, NAT STRUCT MOL BIOL, V11, P128, DOI 10.1038/nsmb715; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986	40	34	35	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43789	43798		10.1074/jbc.M406678200	http://dx.doi.org/10.1074/jbc.M406678200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15280361	hybrid			2022-12-27	WOS:000224383100054
J	Quelo, I; Gauthier, C; Hannigan, GE; Dedhar, S; St-Arnaud, R				Quelo, I; Gauthier, C; Hannigan, GE; Dedhar, S; St-Arnaud, R			Integrin-linked kinase regulates the nuclear entry of the c-Jun coactivator alpha-NAC and its coactivation potency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-ASSOCIATED COMPLEX; GLYCOGEN-SYNTHASE KINASE; AP-1 TRANSCRIPTION FACTORS; BETA-CATENIN; PROTEIN-KINASE; CELL-ADHESION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; BONE-FORMATION; IN-VITRO	Overexpression of the integrin-linked kinase (ILK) was shown to increase c-Jun-dependent transcription. We now show that this effect of ILK involves the c-Jun transcriptional coactivator, (n) under bar ascent polypeptide-associated complex (a) under bar nd (c) under bar oactivator alpha (alpha-NAC). ILK phosphorylated alpha-NAC on residue Ser-43 upon adhesion of cells to fibronectin. Co-expression of constitutively active ILK with alpha-NAC led to the nuclear accumulation of the coactivator. Conversely, alpha-NAC remained in the cytoplasm of cells transfected with a dominant-negative ILK mutant, and a mutated alpha-NAC at phosphoacceptor position Ser-43 (S43A) also localized outside of the nucleus. The S43A alpha-NAC mutant could not potentiate the effect of ILK on c-Jun-dependent transcription. We conclude that ILK-dependent phosphorylation of alpha-NAC induced the nuclear accumulation of the coactivator and that phosphorylation of alpha-NAC by ILK is required for the potentiation of c-Jun-mediated responses by the kinase. The results represent one of the rare examples of a transcriptional coactivator shuttling between the cytosol and the nucleus.	Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; British Columbia Canc Agcy, Vancouver, BC V6H 3Z6, Canada; Vancouver Hosp, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Surg, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 2T5, Canada	McGill University; University of Toronto; British Columbia Cancer Agency; University of British Columbia; University of British Columbia; McGill University; McGill University; McGill University	St-Arnaud, R (corresponding author), Shriners Hosp Children, Genet Unit, 1529 Cedar Ave, Montreal, PQ H3G 1A6, Canada.	rst-arnaud@shriners.mcgill.ca	Hannigan, Greg/A-5092-2009	Dedhar, Shoukat/0000-0003-4355-1657				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; Bannister AJ, 1995, ONCOGENE, V11, P2509; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; CARTER NA, 1997, CURRENT PROTOCOLS MO, V4; Cheng SL, 2001, J BONE MINER RES, V16, P277, DOI 10.1359/jbmr.2001.16.2.277; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cowles EA, 2000, J BIOMED MATER RES, V52, P725, DOI 10.1002/1097-4636(20001215)52:4<725::AID-JBM18>3.3.CO;2-F; Cressman DE, 1999, IMMUNITY, V10, P163, DOI 10.1016/S1074-7613(00)80017-5; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Danen EHJ, 2003, J PATHOL, V200, P471, DOI 10.1002/path.1416; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Franke J, 2001, J CELL SCI, V114, P2641; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hartl M, 2003, CURR CANCER DRUG TAR, V3, P41, DOI 10.2174/1568009033333781; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HURTUBISE M, 2003, THESIS MCGILL U MONT; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Lee SK, 2000, MOL ENDOCRINOL, V14, P915, DOI 10.1210/me.14.6.915; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; LIAN JB, 1991, J CELL BIOCHEM, V45, P9, DOI 10.1002/jcb.240450106; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; MONDAL K, 1995, BIOCHEM SOC T, V23, P460, DOI 10.1042/bst0230460; Moreau A, 1998, MOL CELL BIOL, V18, P1312, DOI 10.1128/MCB.18.3.1312; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Papachristou DJ, 2003, BONE, V32, P364, DOI 10.1016/S8756-3282(03)00026-7; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Quelo I, 2004, BIOCHEMISTRY-US, V43, P2906, DOI 10.1021/bi036256+; Quelo I, 2002, GENE EXPRESSION, V10, P255, DOI 10.3727/000000002783992433; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; Terpstra L, 2003, J CELL BIOL, V162, P139, DOI 10.1083/jcb.200302066; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yotov WV, 1998, MOL CELL BIOL, V18, P1303, DOI 10.1128/MCB.18.3.1303; Yotov WV, 1996, GENE DEV, V10, P1763, DOI 10.1101/gad.10.14.1763	56	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43893	43899		10.1074/jbc.M406310200	http://dx.doi.org/10.1074/jbc.M406310200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15299025	hybrid			2022-12-27	WOS:000224383100067
J	Ciccotosto, GD; Tew, D; Curtain, CC; Smith, D; Carrington, D; Masters, CL; Bush, AI; Cherny, RA; Cappai, R; Barnham, KJ				Ciccotosto, GD; Tew, D; Curtain, CC; Smith, D; Carrington, D; Masters, CL; Bush, AI; Cherny, RA; Cappai, R; Barnham, KJ			Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADICAL OXIDATIVE STRESS; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; A-BETA; HYDROGEN-PEROXIDE; LIPID-PEROXIDATION; SOLUBLE OLIGOMERS; NERVOUS-SYSTEM; PROTEIN-KINASE; MEMBRANE	The amyloid beta peptide (Abeta) is toxic to neuronal cells, and it is probable that this toxicity is responsible for the progressive cognitive decline associated with Alzheimer's disease. However, the nature of the toxic Abeta species and its precise mechanism of action remain to be determined. It has been reported that the methionine residue at position 35 has a pivotal role to play in the toxicity of Abeta. We examined the effect of mutating the methionine to valine in Abeta42 (AbetaM35V). The neurotoxic activity of AbetaM35V on primary mouse neuronal cortical cells was enhanced, and this diminished cell viability occurred at an accelerated rate compared with Abeta42. AbetaM35V binds Cu2+ and produces similar amounts of H2O2 as Abeta42 in vitro, and the neurotoxic activity was attenuated by the H2O2 scavenger catalase. The increased toxicity of AbetaM35V was associated with increased binding of this mutated peptide to cortical cells. The M35V mutation altered the interaction between Abeta and copper in a lipid environment as shown by EPR analysis, which indicated that the valine substitution made the peptide less rigid in the bilayer region with a resulting higher affinity for the bilayer. Circular dichroism spectroscopy showed that both Abeta42 and AbetaM35V displayed a mixture of alpha-helical and beta-sheet conformations. These findings provide further evidence that the toxicity of Abeta is regulated by binding to neuronal cells.	Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; Univ Melbourne, Ctr Neurosci, Melbourne, Vic 3010, Australia; Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Dept Psychiat,Lab Oxidat Biol,Genet & Aging Unit, Charlestown, MA 02129 USA; Monash Univ, Sch Phys & Mat Engn, Clayton, Vic 3168, Australia	University of Melbourne; University of Melbourne; Harvard University; Monash University	Barnham, KJ (corresponding author), Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.	kbarnham@unimelb.edu.au	Cappai, Roberto/B-3347-2010; Bush, Ashley I/A-1186-2007; Bush, Ashley/Y-2457-2019	Cappai, Roberto/0000-0002-9505-8496; Bush, Ashley I/0000-0001-8259-9069; Bush, Ashley/0000-0001-8259-9069; Curtain, Cyril/0000-0001-6955-320X				Aloia R.C., 1988, ADV MEMBRANE FLUIDIT, V1; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Barnham KJ, 2003, J BIOL CHEM, V278, P17401, DOI 10.1074/jbc.M300629200; Barnham KJ, 2004, FASEB J, V18, P1427, DOI 10.1096/fj.04-1890fje; Barnham KJ, 2003, J BIOL CHEM, V278, P42959, DOI 10.1074/jbc.M305494200; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bitan G, 2003, J AM CHEM SOC, V125, P15359, DOI 10.1021/ja0349296; Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Cuajungco MP, 2000, J BIOL CHEM, V275, P19439, DOI 10.1074/jbc.C000165200; Cuajungco MP, 2003, BRAIN RES REV, V41, P44, DOI 10.1016/S0165-0173(02)00219-9; Curtain C, 1999, EUR BIOPHYS J BIOPHY, V28, P427, DOI 10.1007/s002490050225; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Curtain CC, 2003, J BIOL CHEM, V278, P2977, DOI 10.1074/jbc.M205455200; DAVOUST J, 1982, J MAGN RESON, V48, P475, DOI 10.1016/0022-2364(82)90079-8; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; DURELL SR, 1994, BIOPHYS J, V67, P2137, DOI 10.1016/S0006-3495(94)80717-9; GORDON LM, 1985, J MEMBRANE BIOL, V84, P81, DOI 10.1007/BF01871650; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Harkany T, 1999, PROG NEURO-PSYCHOPH, V23, P963, DOI 10.1016/S0278-5846(99)00058-5; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; HARTMANN H, 1993, BIOCHEM BIOPH RES CO, V194, P1216, DOI 10.1006/bbrc.1993.1952; HARTMANN H, 1994, LIFE SCI, V55, P2011, DOI 10.1016/0024-3205(94)00381-5; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HORVATH LI, 1988, BIOCHEMISTRY-US, V27, P5296, DOI 10.1021/bi00414a052; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Hou LM, 2002, J BIOL CHEM, V277, P40173, DOI 10.1074/jbc.C200338200; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; HUBBELL WL, 1971, J AM CHEM SOC, V93, P314; Jung B, 2003, NEUROREPORT, V14, P2349, DOI 10.1097/00001756-200312190-00012; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Kim HJ, 2002, FASEB J, V16, P118, DOI 10.1096/fj.01-0987fje; Kourie JI, 2001, CELL MOL NEUROBIOL, V21, P173, DOI 10.1023/A:1010932603406; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MARSH D, 1989, BIOL MAGN RESON, V8, P255; MCINTYRE JO, 1982, BIOPHYS J, V37, P53, DOI 10.1016/S0006-3495(82)84595-5; Muller WE, 2001, BIOCHEM SOC T, V29, P617, DOI 10.1042/BST0290617; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Nishino S, 2001, INORG CHEM COMMUN, V4, P86, DOI 10.1016/S1387-7003(00)00213-6; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; Sponne I, 2004, FASEB J, V18, P836, DOI 10.1096/fj.03-0372fje; Varadarajan S, 1999, BRAIN RES BULL, V50, P133, DOI 10.1016/S0361-9230(99)00093-3; Varadarajan S, 2001, J AM CHEM SOC, V123, P5625, DOI 10.1021/ja010452r; Varadarajan S, 2000, J STRUCT BIOL, V130, P184, DOI 10.1006/jsbi.2000.4274; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang QW, 2004, J NEUROSCI, V24, P3370, DOI 10.1523/JNEUROSCI.1633-03.2004; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; [No title captured]	59	98	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42528	42534		10.1074/jbc.M406465200	http://dx.doi.org/10.1074/jbc.M406465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292164	hybrid			2022-12-27	WOS:000224226400024
J	Culetto, E; Baylis, HA; Richmond, JE; Jones, AK; Fleming, JT; Squire, MD; Lewis, JA; Sattelle, DB				Culetto, E; Baylis, HA; Richmond, JE; Jones, AK; Fleming, JT; Squire, MD; Lewis, JA; Sattelle, DB			The Caenorhabditis elegans unc-63 gene encodes a Levamisole-sensitive nicotinic acetylcholine receptor alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; MOLECULAR-CLONING; SEQUENCE; NEMATODE; HOMOLOG; FAMILY; MUTANTS; PROTEIN; GABA; RNA	The anthelmintic drug levamisole causes hypercontraction of body wall muscles and lethality in nematode worms. In the nematode Caenorhabditis elegans, a genetic screen for levamisole resistance has identified 12 genes, three of which (unc-38, unc-29, and lev-1) encode nicotinic acetylcholine receptor (nAChR) subunits. Here we describe the molecular and functional characterization of another levamisole-resistant gene, unc-63, encoding a nAChR alpha subunit with a predicted amino acid sequence most similar to that of UNC-38. Like UNC-38 and UNC-29, UNC-63 is expressed in body wall muscles. In addition, UNC-63 is expressed in vulval muscles and neurons. We also show that LEV-1 is expressed in body wall muscle, thus overlapping the cellular localization of UNC-63, UNC-38, and UNC-29 and suggesting possible association in vivo. This is supported by electrophysiological studies on body wall muscle, which demonstrate that a levamisole-sensitive nAChR present at the C. elegans neuromuscular junction requires both UNC-63 and LEV-1 subunits. Thus, at least four subunits, two alpha types (UNC-38 and UNC-63) and two non-alpha types (UNC-29 and LEV-1), can contribute to levamisole-sensitive muscle nAChRs in nematodes.	Univ Oxford, Dept Human Anat & Genet, Funct Genet Unit, MRC, Oxford OX1 3QX, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Cambridge, Babraham Inst, Mol Signalling Lab, Cambridge CB2 3EJ, England; Univ Illinois, Dept Biol, Chicago, IL 60607 USA	University of Oxford; University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Sattelle, DB (corresponding author), Univ Oxford, Dept Human Anat & Genet, Funct Genet Unit, MRC, S Parks Rd, Oxford OX1 3QX, England.	david.sattelle@anat.ox.ac.uk	Culetto, Emmanuel/AFQ-8565-2022	Jones, Andrew/0000-0002-7835-0890; Baylis, Howard/0000-0002-5959-3256; Culetto, Emmanuel/0000-0003-4725-2654	MRC [MC_U137761447] Funding Source: UKRI; Medical Research Council [MC_U137761447] Funding Source: Medline; NINDS NIH HHS [R01 NS041477-03, R01 NS041477-02, R01 NS041477, R01 NS041477-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041477] Funding Source: NIH RePORTER	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bamber BA, 1999, J NEUROSCI, V19, P5348; Baylis HA, 1997, RECEPTOR CHANNEL, V5, P149; BENIAN GM, 1993, GENETICS, V134, P1097; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; COULSON AR, 1995, CAENORHABDITIS ELEGA; Esmaeili B, 2002, DEVELOPMENT, V129, P853; Fitzgerald J, 2000, BRAIN RES, V877, P110, DOI 10.1016/S0006-8993(00)02692-5; Fleming JT, 1997, J NEUROSCI, V17, P5843; Hallam S, 2000, DEVELOPMENT, V127, P4239; Jones AK, 2004, BIOESSAYS, V26, P39, DOI 10.1002/bies.10377; Jones AK, 2003, GENOMICS, V82, P441, DOI 10.1016/S0888-7543(03)00153-8; Kagawa H, 1997, CELL STRUCT FUNCT, V22, P213, DOI 10.1247/csf.22.213; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEWIS JA, 1980, NEUROSCIENCE, V5, P967, DOI 10.1016/0306-4522(80)90180-3; LEWIS JA, 1987, J NEUROSCI, V7, P3059; Lindstrom JM, 2003, ANN NY ACAD SCI, V998, P41, DOI 10.1196/annals.1254.007; Martin RJ, 1997, VET J, V154, P11, DOI 10.1016/S1090-0233(05)80005-X; Maryon EB, 1996, J CELL BIOL, V134, P885, DOI 10.1083/jcb.134.4.885; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Millar NS, 2003, BIOCHEM SOC T, V31, P869, DOI 10.1042/BST0310869; Mongan NP, 1998, RECEPTOR CHANNEL, V6, P213; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PLASTERK RH, 1995, CAENORHABDITIS ELEGA; Richmond JE, 1999, NAT NEUROSCI, V2, P791, DOI 10.1038/12160; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SQUIRE MD, 1995, RECEPTOR CHANNEL, V3, P107; Sulston JHJ, 1988, NEMATODE CAENORHABDI; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876	34	111	146	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42476	42483		10.1074/jbc.M404370200	http://dx.doi.org/10.1074/jbc.M404370200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15280391	hybrid			2022-12-27	WOS:000224226400019
J	Hood, JL; Brooks, WH; Thomas, LR				Hood, JL; Brooks, WH; Thomas, LR			Differential compartmentalization of the calpain/calpastatin network with the endoplasmic reticulum and Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-CALPAIN; SIGNAL SEQUENCE; CRYSTAL-STRUCTURE; PROTEASE CALPAIN; CA2+ SENSITIVITY; T-CELLS; CALCIUM; SYSTEM; DOMAIN; LOCALIZATION	Calpain, a calcium-activated cysteine protease, is involved in modulating a variety of cell activities such as shape change, mobility, and apoptosis. The two ubiquitous isoforms of this protease, calpain I and II, are considered to be cytosolic proteins that can translocate to various sites in the cell. The activity of calpain is modulated by two regulatory proteins, calpastatin, the specific endogenous inhibitor of calpain, and the 28-kDa regulatory subunit. Using velocity gradient centrifugation, the results of this study confirm and greatly expand upon our previous finding that the calpain/calpastatin network is associated with the endoplasmic reticulum and Golgi apparatus in cells. Moreover, confocal microscopy demonstrates that calpain II colocalizes with specific proteins found in these organelles. Additional experiments reveal that hydrophobic rather than electrostatic interactions are responsible for the association of the calpain/calpastatin network with these organelles. Treatment of the organelles with Na2CO3 or deoxycholate reveal that calpain I, 78-kDa calpain II, and the regulatory subunit are "embedded" within the organelle membranes similar to integral membrane proteins. Proteinase K treatment of the organelles shows that calpain I and II, calpastatin, and the regulatory subunit localize to the cytosolic surface of the organelle membranes, and a subset of calpain II and the regulatory subunit are also found within the lumen of these organelles. These results provide a new and novel explanation for how the calpain/calpastatin network is organized in the cell.	Univ Kentucky, Med Ctr, Dept Microbiol Mol Genet & Immunol, Lexington, KY 40536 USA	University of Kentucky	Thomas, LR (corresponding author), Chandler Med Ctr MN 415, Dept Microbiol Mol Genet & Immunol, Lexington, KY 40536 USA.	tlrosz00@uky.edu	Hood, Joshua L./I-9797-2019	Hood, Joshua L./0000-0003-3998-4118				Beaudoin F, 2002, PLANTA, V215, P293, DOI 10.1007/s00425-002-0737-1; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Blaustein MR, 2001, TRENDS NEUROSCI, V24, P602, DOI 10.1016/S0166-2236(00)01891-9; Chakrabarti AK, 1996, J NEUROSCI RES, V44, P374; COTNER T, 1995, J BIOL CHEM, V270, P2379, DOI 10.1074/jbc.270.5.2379; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Dourdin N, 1997, EXP CELL RES, V235, P385, DOI 10.1006/excr.1997.3684; Evans JH, 2004, MOL BIOL CELL, V15, P371, DOI 10.1091/mbc.e03-05-0338; FOX JEB, 1993, J CELL BIOL, V120, P1051; Fu J, 2000, EUR J CELL BIOL, V79, P219, DOI 10.1078/S0171-9335(04)70025-4; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; GOLL D E, 1986, Ciencia Biologica Molecular and Cellular Biology, V11, P75; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hood JL, 2003, BIOCHEM BIOPH RES CO, V310, P1200, DOI 10.1016/j.bbrc.2003.09.142; Hosfield CM, 2001, J BIOL CHEM, V276, P7404, DOI 10.1074/jbc.M007352200; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Inomata M, 1996, ARCH BIOCHEM BIOPHYS, V328, P129, DOI 10.1006/abbi.1996.0152; Johnson GVW, 1997, BIOESSAYS, V19, P1011, DOI 10.1002/bies.950191111; Joliot A, 1998, CURR BIOL, V8, P856, DOI 10.1016/S0960-9822(07)00346-6; Kawasaki H, 1996, MOL MEMBR BIOL, V13, P217, DOI 10.3109/09687689609160599; Kjer-Nielsen L, 1999, J CELL SCI, V112, P1645; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; Melloni E, 2000, BIOCHEM BIOPH RES CO, V272, P472, DOI 10.1006/bbrc.2000.2796; Melloni E, 1998, BIOCHEM BIOPH RES CO, V249, P583, DOI 10.1006/bbrc.1998.9200; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Moremen KW, 2002, BBA-GEN SUBJECTS, V1573, P225, DOI 10.1016/S0304-4165(02)00388-4; Morford LA, 2002, BIOCHEM BIOPH RES CO, V295, P540, DOI 10.1016/S0006-291X(02)00676-9; Murachi T. M., 1983, CALCIUM CELL FUNCTIO, V4, P377; Nishihara H, 2001, BIOCHEM BIOPH RES CO, V285, P845, DOI 10.1006/bbrc.2001.5242; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Rock MT, 2000, EXP CELL RES, V261, P260, DOI 10.1006/excr.2000.5048; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; Sato K, 2001, BIOL CHEM, V382, P743, DOI 10.1515/BC.2001.090; SIMON J, 1996, BIOCHIM BIOPHYS ACTA, V1293, P201; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; TAM LY, 1994, J BIOL CHEM, V269, P32542; Tekirian TL, 2001, MOL BRAIN RES, V96, P14, DOI 10.1016/S0169-328X(01)00250-9; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279; Xie XL, 2001, PROTEIN SCI, V10, P2419, DOI 10.1110/ps.ps.36701	49	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43126	43135		10.1074/jbc.M408100200	http://dx.doi.org/10.1074/jbc.M408100200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15302874	hybrid			2022-12-27	WOS:000224226400097
J	Nakar, D; Handelsman, T; Shoham, Y; Fierobe, HP; Belaich, JP; Morag, E; Lamed, R; Bayer, EA				Nakar, D; Handelsman, T; Shoham, Y; Fierobe, HP; Belaich, JP; Morag, E; Lamed, R; Bayer, EA			Pinpoint mapping of recognition residues on the cohesin surface by progressive homologue swapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOCELLUM ENDOGLUCANASE CELD; CLOSTRIDIUM-THERMOCELLUM; DOCKERIN DOMAIN; CRYSTAL-STRUCTURE; SCAFFOLDING PROTEIN; CELLULOSOME SYSTEM; BINDING; CIPA; CELLULOLYTICUM; DEGRADATION	The high affinity cohesin-dockerin interaction dictates the suprastructural assembly of the multienzyme cellulosome complex. The connection between affinity and species specificity was studied by exploring the recognition properties of two structurally related cohesin species of divergent specificity. The cohesins were examined by progressive rounds of swapping, in which corresponding homologous stretches were interchanged. The specificity of binding of the resultant chimeric cohesins was determined by enzyme-linked affinity assay and complementary protein microarray. In succeeding rounds, swapped segments were systematically contracted, according to the binding behavior of previously generated chimeras. In the fourth and final round we discerned three residues, reputedly involved in interspecies binding specificity. By replacing only these three residues, we were able to convert the specificity of the resultant mutated cohesin, which bound preferentially to the rival dockerin with similar to 20% capacity of the wild-type interaction. These residues represent but 3 of the 16 contact residues that participate in the cohesin-dockerin interaction. This approach allowed us to differentiate, in a structure-independent fashion, between residues critical for interspecies recognition and binding residues per se.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Technion Israel Inst Technol, Dept Biotechnol & Food Engn, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Catalysis Sci & Technol, IL-32000 Haifa, Israel; CNRS, IBSM, F-13402 Marseille, France; Univ Aix Marseille 1, F-13331 Marseille, France; Zephyr ProteomiX, IL-11013 Kiryat Shemona, Israel; Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Tel Aviv University	Bayer, EA (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	ed.bayer@weizmann.ac.il	FIEROBE, Henri-Pierre/P-4372-2019; Shoham, Yuval/M-4409-2013					Bayer EA, 2004, ANNU REV MICROBIOL, V58, P521, DOI 10.1146/annurev.micro.57.030502.091022; BAYER EA, 1994, TRENDS BIOTECHNOL, V12, P379, DOI 10.1016/0167-7799(94)90039-6; Bayer EA, 1998, CURR OPIN STRUC BIOL, V8, P548, DOI 10.1016/S0959-440X(98)80143-7; BAYER EA, 1998, CARBOHYDRASES TRICHO, P39; Boraston AB, 1999, ROY SOC CH, P202; Carvalho AL, 2003, P NATL ACAD SCI USA, V100, P13809, DOI 10.1073/pnas.1936124100; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Fierobe HP, 1999, BIOCHEMISTRY-US, V38, P12822, DOI 10.1021/bi9911740; Fierobe HP, 2001, J BIOL CHEM, V276, P21257, DOI 10.1074/jbc.M102082200; HANDELSMAN T, LIGNOCELLULOSE BIODE, P194; Jindou S, 2004, J BIOL CHEM, V279, P9867, DOI 10.1074/jbc.M308673200; Lytle B, 1996, J BACTERIOL, V178, P1200, DOI 10.1128/jb.178.4.1200-1203.1996; Lytle BL, 2001, J MOL BIOL, V307, P745, DOI 10.1006/jmbi.2001.4522; Lytle BL, 2000, ARCH BIOCHEM BIOPHYS, V379, P237, DOI 10.1006/abbi.2000.1882; Mechaly A, 2000, PROTEINS, V39, P170, DOI 10.1002/(SICI)1097-0134(20000501)39:2<170::AID-PROT7>3.0.CO;2-H; Mechaly A, 2001, J BIOL CHEM, V276, P19678; Mechaly A, 2001, J BIOL CHEM, V276, P9883, DOI 10.1074/jbc.M009237200; Miras I, 2002, BIOCHEMISTRY-US, V41, P2115, DOI 10.1021/bi011854e; Pages S, 1997, PROTEINS, V29, P517, DOI 10.1002/(SICI)1097-0134(199712)29:4<517::AID-PROT11>3.3.CO;2-I; Rincon MT, 2003, J BACTERIOL, V185, P703, DOI 10.1128/JB.185.3.703-713.2003; SALAMITOU S, 1994, J BACTERIOL, V176, P2822, DOI 10.1128/JB.176.10.2822-2827.1994; SALAMITOU S, 1992, FEBS LETT, V304, P89, DOI 10.1016/0014-5793(92)80595-8; Sambrook J., 2001, MOL CLONING LAB MANU, V3rd ed.; Schaeffer F, 2002, BIOCHEMISTRY-US, V41, P2106, DOI 10.1021/bi011853m; Schwarz WH, 2001, APPL MICROBIOL BIOT, V56, P634, DOI 10.1007/s002530100710; Shimon LJW, 1997, STRUCTURE, V5, P381, DOI 10.1016/S0969-2126(97)00195-0; Spinelli S, 2000, J MOL BIOL, V304, P189, DOI 10.1006/jmbi.2000.4191; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Tavares GA, 1997, J MOL BIOL, V273, P701, DOI 10.1006/jmbi.1997.1326; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; Xu Q, 2004, J BACTERIOL, V186, P968, DOI 10.1128/JB.186.4.968-977.2004; Xu Q, 2003, J BACTERIOL, V185, P4548, DOI 10.1128/JB.185.15.4548-4557.2003; YARON S, 1995, FEBS LETT, V360, P121, DOI 10.1016/0014-5793(95)00074-J	33	15	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42881	42888		10.1074/jbc.M407350200	http://dx.doi.org/10.1074/jbc.M407350200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292269	hybrid			2022-12-27	WOS:000224226400066
J	Pennathur, S; Bergt, C; Shao, BH; Byun, J; Kassim, SY; Singh, P; Green, PS; McDonald, TO; Brunzell, J; Chait, A; Oram, JF; O'Brien, K; Geary, RL; Heinecke, JW				Pennathur, S; Bergt, C; Shao, BH; Byun, J; Kassim, SY; Singh, P; Green, PS; McDonald, TO; Brunzell, J; Chait, A; Oram, JF; O'Brien, K; Geary, RL; Heinecke, JW			Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE CHOLESTEROL TRANSPORT; PROTEIN-TYROSINE NITRATION; NITRIC-OXIDE; HYDROGEN-PEROXIDE; IN-VIVO; LIPID HYDROPEROXIDES; CATALYZED OXIDATION; SCAVENGER RECEPTOR; HYPOCHLOROUS ACID; MYELOPEROXIDASE	High density lipoprotein (HDL) is the major carrier of lipid hydroperoxides in plasma, but it is not yet established whether HDL proteins are damaged by reactive nitrogen species in the circulation or artery wall. One pathway that generates such species involves myeloperoxidase (MPO), a major constituent of artery wall macrophages. Another pathway involves peroxynitrite, a potent oxidant generated in the reaction of nitric oxide with superoxide. Both MPO and peroxynitrite produce 3-nitrotyrosine in vitro. To investigate the involvement of reactive nitrogen species in atherogenesis, we quantified 3-nitrotyrosine levels in HDL in vivo. The mean level of 3- nitrotyrosine in HDL isolated from human aortic atherosclerotic intima was 6-fold higher (619 +/- 178 mumol/mol Tyr) than that in circulating HDL (104 +/- 11 mumol/mol Tyr; p < 0.01). Immunohistochemical studies demonstrated striking colocalization of MPO with epitopes reactive with an antibody to 3- nitrotyrosine. However, there was no significant correlation between the levels of 3- chlorotyrosine, a specific product of MPO, and those of 3- nitrotyrosine in lesion HDL. We also detected 3- nitrotyrosine in circulating HDL, and linear regression analysis demonstrated a strong correlation between the levels of 3- chlorotyrosine and levels of 3- nitrotyrosine. These observations suggest that MPO promotes the formation of 3- chlorotyrosine and 3- nitrotyrosine in circulating HDL but that other pathways also produce 3- nitrotyrosine in atherosclerotic tissue. Levels of HDL isolated from plasma of patients with established coronary artery disease contained twice as much 3- nitrotyrosine as HDL from plasma of healthy subjects, suggesting that nitrated HDL might be a marker for clinically significant vascular disease. The detection of 3- nitrotyrosine in HDL raises the possibility that reactive nitrogen species derived from nitric oxide might promote atherogenesis. Thus, nitrated HDL might represent a previously unsuspected link between nitrosative stress, atherosclerosis, and inflammation.	Univ Washington, Div Metab Endocrinol & Nutr, Sch Med, Dept Med, Seattle, WA 98195 USA; Wake Forest Univ, Bowman Gray Sch Med, Div Surg Sci, Winston Salem, NC 27157 USA	University of Washington; University of Washington Seattle; Wake Forest University; Wake Forest Baptist Medical Center	Heinecke, JW (corresponding author), Univ Washington, Div Metab Endocrinol & Nutr, Sch Med, Dept Med, Box 356426, Seattle, WA 98195 USA.	heinecke@u.washington.edu	O'Brien, Kevin/CAH-4638-2022; O'Brien, Kevin Douglas/HDO-1461-2022	O'Brien, Kevin/0000-0002-2293-9196; O'Brien, Kevin Douglas/0000-0002-2293-9196; Shao, Baohai/0000-0001-8832-2845	NHLBI NIH HHS [HL55362, HL18645, P01 HL030086, HL64344] Funding Source: Medline; NIA NIH HHS [AG021191] Funding Source: Medline; NIDDK NIH HHS [DK02456] Funding Source: Medline; NIEHS NIH HHS [P30 ES07033] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645, R01HL055362, P01HL030086, R01HL064344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021191] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Baldus S, 2001, J CLIN INVEST, V108, P1759; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Bergt C, 2003, ARTERIOSCL THROM VAS, V23, P1488, DOI 10.1161/01.ATV.0000090570.99836.9C; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; BROWN MS, 1992, CELL, V71, P187, DOI 10.1016/0092-8674(92)90346-E; Byun J, 1999, FEBS LETT, V455, P243, DOI 10.1016/S0014-5793(99)00893-5; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P425, DOI 10.1016/0003-9861(52)90471-2; Chen K, 2003, FREE RADICAL BIO MED, V35, P117, DOI 10.1016/S0891-5849(03)00239-9; Christison J, 1996, BIOCHEM J, V314, P739, DOI 10.1042/bj3140739; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; Francis GA, 2000, BBA-MOL CELL BIOL L, V1483, P217, DOI 10.1016/S1388-1981(99)00181-X; Garner B, 1998, J BIOL CHEM, V273, P6088, DOI 10.1074/jbc.273.11.6088; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Gaut JP, 2002, ANAL BIOCHEM, V300, P252, DOI 10.1006/abio.2001.5469; Gaut JP, 2001, P NATL ACAD SCI USA, V98, P11961, DOI 10.1073/pnas.211190298; Getz GS, 2004, CURR OPIN LIPIDOL, V15, P261, DOI 10.1097/00041433-200406000-00005; GRAHAM A, 1993, FEBS LETT, V330, P181, DOI 10.1016/0014-5793(93)80269-Z; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Heinecke JW, 2002, FREE RADICAL BIO MED, V32, P1090, DOI 10.1016/S0891-5849(02)00792-X; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Heinecke JW, 1998, ATHEROSCLEROSIS, V141, P1, DOI 10.1016/S0021-9150(98)00173-7; Heller JI, 2000, J BIOL CHEM, V275, P9957, DOI 10.1074/jbc.275.14.9957; Hope HR, 2000, PROTEIN EXPRES PURIF, V18, P269, DOI 10.1006/prep.1999.1197; Ischiropoulos H, 2003, BIOCHEM BIOPH RES CO, V305, P776, DOI 10.1016/S0006-291X(03)00814-3; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; Marsche G, 2002, J BIOL CHEM, V277, P32172, DOI 10.1074/jbc.M200503200; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; Navab M, 2004, J LIPID RES, V45, P993, DOI 10.1194/jlr.R400001-JLR200; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; Oram JF, 1996, J LIPID RES, V37, P2473; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; Pennathur S, 2001, J CLIN INVEST, V107, P853, DOI 10.1172/JCI11194; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pfeiffer S, 2001, J BIOL CHEM, V276, P34051, DOI 10.1074/jbc.M100585200; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Rothblat GH, 1999, J LIPID RES, V40, P781; Shishehbor MH, 2003, JAMA-J AM MED ASSOC, V289, P1675, DOI 10.1001/jama.289.13.1675; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Tall AR, 2000, J CLIN INVEST, V106, P1205, DOI 10.1172/JCI11538; TAUROG A, 1991, ARCH BIOCHEM BIOPHYS, V287, P288, DOI 10.1016/0003-9861(91)90481-W; Vadseth C, 2004, J BIOL CHEM, V279, P8820, DOI 10.1074/jbc.M306101200; van Dalen CJ, 2000, J BIOL CHEM, V275, P11638, DOI 10.1074/jbc.275.16.11638; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617	59	222	239	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42977	42983		10.1074/jbc.M406762200	http://dx.doi.org/10.1074/jbc.M406762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292228	hybrid			2022-12-27	WOS:000224226400078
J	Schirmer, EC; Gerace, L				Schirmer, EC; Gerace, L			The stability of the nuclear lamina polymer changes with the composition of lamin subtypes according to their individual binding strengths	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-TYPE; PHOSPHORYLATION SITES; MUSCULAR-DYSTROPHY; ESCHERICHIA-COLI; EXPRESSION; ENVELOPE; CELLS; TAIL; DISEASE; DOMAIN	The nuclear lamina, which provides a structural scaffolding for the nuclear envelope, consists largely of a polymer of the intermediate filament lamin proteins. Although different cell types contain distinctive relative amounts of the major lamin subtypes ( A, C, B1, and B2), the functions of this variation are not understood. We have investigated the possibility that subtype variation affects lamina stability. We find that homotypic and heterotypic binding interactions of lamin B2 are substantially less resistant to chemical dissociation in vitro than those between the other lamin subtypes, whereas lamin A interactions are the most stable. Surprisingly, removal of the central four-fifths of the rod domain did not substantially weaken the interactions of lamins A and B2, suggesting that other regions also strongly contribute to their binding interactions. In contrast, this rod deletion strongly destabilizes the binding interactions of lamins B1 and C. Consistent with the binding studies, lamins are more readily solubilized by chemical extraction from cells enriched for lamin B2 than from cells enriched for lamin A. This suggests that the distinctive ensemble of heterotypic lamin interactions in a particular cell type affects the stability of the lamin polymer, and, correspondingly, could be relevant to tissue-specific properties of the lamina including its involvement in disease.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Gerace, L (corresponding author), 10550 N Torrey Pines Rd,IMM10,R209, La Jolla, CA 92037 USA.	lgerace@scripps.edu		Schirmer, Eric/0000-0003-2635-1338	NIGMS NIH HHS [GM28521, F32 GM19085] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019085, R01GM028521] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Broers JLV, 1997, HISTOCHEM CELL BIOL, V107, P505, DOI 10.1007/s004180050138; COLLINS SJ, 1987, BLOOD, V70, P1233; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P17381, DOI 10.1074/jbc.C200038200; GEORGATOS SD, 1988, P NATL ACAD SCI USA, V85, P4325, DOI 10.1073/pnas.85.12.4325; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Harborth J, 2001, J CELL SCI, V114, P4557; HASS R, 1992, EUR J CELL BIOL, V58, P1; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEITLINGER E, 1991, J CELL BIOL, V113, P485, DOI 10.1083/jcb.113.3.485; HEITLINGER E, 1992, J STRUCT BIOL, V108, P74, DOI 10.1016/1047-8477(92)90009-Y; Hoffmann K, 2002, NAT GENET, V31, P410, DOI 10.1038/ng925; HOULISTON E, 1988, DEVELOPMENT, V102, P271; Jansen MPHM, 1997, HISTOPATHOLOGY, V31, P304, DOI 10.1046/j.1365-2559.1997.2820881.x; Kammerer RA, 1998, J BIOL CHEM, V273, P10602, DOI 10.1074/jbc.273.17.10602; Kill IR, 1995, FEBS LETT, V377, P26, DOI 10.1016/0014-5793(95)01302-4; Konety BR, 1999, J CELL BIOCHEM, P183; Krimm I, 2002, STRUCTURE, V10, P811, DOI 10.1016/S0969-2126(02)00777-3; KROHNE G, 1987, EMBO J, V6, P3801, DOI 10.1002/j.1460-2075.1987.tb02716.x; Lammerding J, 2004, J CLIN INVEST, V113, P370, DOI 10.1172/JCI200419670; LEHNER CF, 1987, J CELL BIOL, V105, P577, DOI 10.1083/jcb.105.1.577; Liu J, 2000, MOL BIOL CELL, V11, P3937, DOI 10.1091/mbc.11.11.3937; Markiewicz E, 2002, J STRUCT BIOL, V140, P241, DOI 10.1016/S1047-8477(02)00573-7; Mattout-Drubezki A, 2003, CELL MOL LIFE SCI, V60, P2053, DOI 10.1007/s00018-003-3038-3; MOIR RD, 1991, J CELL SCI, V99, P363; Moir RD, 2000, J CELL BIOL, V151, P1155, DOI 10.1083/jcb.151.6.1155; Mounkes L, 2003, CURR OPIN GENET DEV, V13, P223, DOI 10.1016/S0959-437X(03)00058-3; Olins AL, 2001, EXP CELL RES, V268, P115, DOI 10.1006/excr.2001.5269; Omary M B, 1998, Subcell Biochem, V31, P105; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; Owens DW, 2003, BIOESSAYS, V25, P748, DOI 10.1002/bies.10316; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PRATHER RS, 1989, BIOL REPROD, V41, P123, DOI 10.1095/biolreprod41.1.123; ROBER RA, 1989, DEVELOPMENT, V105, P365; Sakaki M, 2001, J BIOCHEM-TOKYO, V129, P321, DOI 10.1093/oxfordjournals.jbchem.a002860; Schirmer EC, 2001, J CELL BIOL, V153, P479, DOI 10.1083/jcb.153.3.479; Stuurman N, 1996, J STRUCT BIOL, V117, P1, DOI 10.1006/jsbi.1996.0064; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Vaughan OA, 2001, J CELL SCI, V114, P2577; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; Worman HJ, 2002, TRENDS CELL BIOL, V12, P591, DOI 10.1016/S0962-8924(02)02401-7; Xu ZS, 1996, J CELL BIOL, V133, P1061, DOI 10.1083/jcb.133.5.1061; YE QA, 1995, EXP CELL RES, V219, P292, DOI 10.1006/excr.1995.1230	44	63	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42811	42817		10.1074/jbc.M407705200	http://dx.doi.org/10.1074/jbc.M407705200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15284226	hybrid			2022-12-27	WOS:000224226400057
J	Barclay, JW; Aldea, M; Craig, TJ; Morgan, A; Burgoyne, RD				Barclay, JW; Aldea, M; Craig, TJ; Morgan, A; Burgoyne, RD			Regulation of the fusion pore conductance during exocytosis by cyclin-dependent kinase 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; SYNAPTIC VESICLE ENDOCYTOSIS; MEMBRANE-FUSION; QUANTAL SIZE; PC12 CELLS; 3-DIMENSIONAL STRUCTURE; GRANULE EXOCYTOSIS; NEURONAL MIGRATION; VESICULAR VOLUME; RUN MECHANISM	Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine kinase involved in synaptogenesis and brain development, and its enzymatic activity is essential for slow forms of synaptic vesicle endocytosis. Recent work also has implicated Cdk5 in exocytosis and synaptic plasticity. Pharmacological inhibition of Cdk5 modifies secretion in neuroendocrine cells, synaptosomes, and brain slices; however, the specific mechanisms involved remain unclear. Here we demonstrate that dominant-negative inhibition of Cdk5 increases quantal size and broadens the kinetics of individual exocytotic events measured by amperometry in adrenal chromaffin cells. Conversely, Cdk5 overexpression narrows the kinetics of fusion, consistent with an increase in the extent of kiss-and-run exocytosis. Cdk5 inhibition also increases the total charge and current of catecholamine released during the amperometric foot, representing a modification of the conductance of the initial fusion pore connecting the granule and plasma membrane. We suggest that these effects are not attributable to an alteration in catecholamine content of secretory granules and therefore represent an effect on the fusion mechanism itself. Finally, mutational silencing of the Cdk5 phosphorylation site in Munc18, an essential protein of the late stages of vesicle fusion, has identical effects on amperometric spikes as dominant-negative Cdk5 but does not affect the amperometric feet. Cells expressing Munc18 T574A have increased quantal size and broader kinetics of fusion. These results suggest that Cdk5 could, in part, control the kinetics of exocytosis through phosphorylation of Munc18, but Cdk5 also must have Munc18-independent effects that modify fusion pore conductance, which may underlie a role of Cdk5 in synaptic plasticity.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liverpool.ac.uk	Aldea, Marcos/H-8154-2015; Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008; Morgan, Alan/AAI-8875-2020	Aldea, Marcos/0000-0003-2146-2733; Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387; Barclay, Jeff W/0000-0003-4320-2094; Morgan, Alan/0000-0002-0346-1289				Ahlijanian MK, 2000, P NATL ACAD SCI USA, V97, P2910, DOI 10.1073/pnas.040577797; Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; ALVAREZ DT, 1993, NATURE, V363, P554, DOI DOI 10.1038/363554A0; Aravanis AM, 2003, NATURE, V423, P643, DOI 10.1038/nature01686; Barclay JW, 2003, J NEUROBIOL, V56, P360, DOI 10.1002/neu.10247; Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200; Beffert U, 2004, J NEUROSCI, V24, P1897, DOI 10.1523/JNEUROSCI.4084-03.2004; Burgoyne RD, 2002, TRENDS NEUROSCI, V25, P176, DOI 10.1016/S0166-2236(00)02126-3; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Chen G, 2004, P NATL ACAD SCI USA, V101, P1063, DOI 10.1073/pnas.0307149101; Chergui K, 2004, P NATL ACAD SCI USA, V101, P2191, DOI 10.1073/pnas.0308652100; Choi S, 2003, PHILOS T ROY SOC B, V358, P695, DOI 10.1098/rstb.2002.1249; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Colliver TL, 2000, J NEUROSCI, V20, P5276, DOI 10.1523/JNEUROSCI.20-14-05276.2000; Connell-Crowley L, 2000, CURR BIOL, V10, P599, DOI 10.1016/S0960-9822(00)00487-5; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; Cousin MA, 2001, TRENDS NEUROSCI, V24, P659, DOI 10.1016/S0166-2236(00)01930-5; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Gandhi SP, 2003, NATURE, V423, P607, DOI 10.1038/nature01677; Graham ME, 2000, J NEUROSCI, V20, P1281; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; Graham ME, 2001, J CELL SCI, V114, P4397; Graham ME, 2002, P NATL ACAD SCI USA, V99, P7124, DOI 10.1073/pnas.102645099; Graham ME, 1997, J NEUROCHEM, V69, P2369; Gundelfinger ED, 2003, NAT REV MOL CELL BIO, V4, P127, DOI 10.1038/nrm1016; Han X, 2004, SCIENCE, V304, P289, DOI 10.1126/science.1095801; Henkel AW, 2001, J CELL SCI, V114, P4613; Holroyd P, 2002, P NATL ACAD SCI USA, V99, P16806, DOI 10.1073/pnas.222677399; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JANKOWSKI JA, 1992, J BIOL CHEM, V267, P18329; Kjaerulff O, 2002, NAT CELL BIOL, V4, pE245, DOI 10.1038/ncb1102-e245; Krupa B, 2004, TRENDS NEUROSCI, V27, P62, DOI 10.1016/j.tins.2003.11.006; Kwon YT, 1999, J COMP NEUROL, V415, P218, DOI 10.1002/(SICI)1096-9861(19991213)415:2<218::AID-CNE6>3.0.CO;2-F; Lee HY, 2004, J BIOL CHEM, V279, P16339, DOI 10.1074/jbc.M310976200; Lee SY, 2004, P NATL ACAD SCI USA, V101, P546, DOI 10.1073/pnas.0307813100; Lilja L, 2004, J BIOL CHEM, V279, P29534, DOI 10.1074/jbc.M312711200; Lilja L, 2001, J BIOL CHEM, V276, P34199, DOI 10.1074/jbc.M103776200; Lindau M, 2003, BBA-MOL CELL RES, V1641, P167, DOI 10.1016/S0167-4889(03)00085-5; Ma L, 2004, P NATL ACAD SCI USA, V101, P9266, DOI 10.1073/pnas.0403201101; Misura KMS, 2002, P NATL ACAD SCI USA, V99, P9184, DOI 10.1073/pnas.132274599; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nguyen C, 2003, J CELL BIOL, V163, P697, DOI 10.1083/jcb.200310038; Nguyen MD, 2001, NEURON, V30, P135, DOI 10.1016/S0896-6273(01)00268-9; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Pothos EN, 2002, J PHYSIOL-LONDON, V542, P453, DOI 10.1113/jphysiol.2002.018630; Richmond JE, 2002, CURR OPIN NEUROBIOL, V12, P499, DOI 10.1016/S0959-4388(02)00360-4; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; Smith DS, 2002, TRENDS CELL BIOL, V12, P28, DOI 10.1016/S0962-8924(01)02181-X; Sombers LA, 2004, J NEUROSCI, V24, P303, DOI 10.1523/JNEUROSCI.1119-03.2004; Staal RGW, 2004, NAT NEUROSCI, V7, P341, DOI 10.1038/nn1205; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Tomizawa K, 2002, J NEUROSCI, V22, P2590, DOI 10.1523/JNEUROSCI.22-07-02590.2002; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Turner KM, 1999, TRENDS NEUROSCI, V22, P459, DOI 10.1016/S0166-2236(99)01436-8; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Wang CT, 2001, SCIENCE, V294, P1111, DOI 10.1126/science.1064002; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Zheng M, 1998, J NEUROBIOL, V35, P141, DOI 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4	69	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41495	41503		10.1074/jbc.M406670200	http://dx.doi.org/10.1074/jbc.M406670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15273248	hybrid			2022-12-27	WOS:000224075500032
J	Conti, MA; Even-Ram, S; Liu, CY; Yamada, KM; Adelstein, RS				Conti, MA; Even-Ram, S; Liu, CY; Yamada, KM; Adelstein, RS			Defects in cell adhesion and the visceral endoderm following ablation of nonmuscle myosin heavy chain II-A in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRULATION; MIGRATION; MUTATION; DOMAIN	Previous work has shown that ablation or mutation of nonmuscle myosin heavy chain II-B (NMHC II-B) in mice results in defects in the heart and brain with death occurring between embryonic day 14.5 (E14.5) and birth (Tullio, A.N., Accili, D., Ferrans, V.J., Yu, Z.X., Takeda, K., Grinberg, A., Westphal, H., Preston, Y.A., and Adelstein, R. S. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 12407-12412). Here we show that mice ablated for NMHC II-A fail to develop a normal patterned embryo with a polarized visceral endoderm by E6.5 and die by E7.5. Moreover, A(-)/A(-) embryoid bodies grown in suspension culture constantly shed cells. These defects in cell adhesion and tissue organization are explained by loss of E-cadherin and beta-catenin localization to cell adhesion sites in both cell culture and in the intact embryos. The defects can be reproduced by introducing siRNA directed against NMHC II-A into wild-type embryonic stem cells. Our results suggest an essential role for a single, specific nonmuscle myosin isoform in maintaining cell-cell adhesions in the early mammalian embryo.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Transgen Core Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Conti, MA (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202,10 Ctr Dr,MSC 1762, Bethesda, MD 20892 USA.	contim@nhlbi.nih.gov	Pillay, Nischalan/F-9536-2012	Even-Ram, Sharona/0000-0002-5540-3822; Yamada, Kenneth/0000-0003-1512-6805; Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004218, Z01HL004218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000525] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Avizienyte E, 2004, MOL BIOL CELL, V15, P2794, DOI 10.1091/mbc.E03-12-0879; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; CALOGERO A, 1991, DEV BIOL, V146, P499, DOI 10.1016/0012-1606(91)90251-W; Chantler P D, 2003, IEE Proc Nanobiotechnol, V150, P111, DOI 10.1049/ip-nbt:20031076; Duncan SA, 1997, DEVELOPMENT, V124, P279; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Kolega J, 2003, MOL BIOL CELL, V14, P4745, DOI 10.1091/mbc.E03-04-0205; Krendel MF, 1999, CELL MOTIL CYTOSKEL, V43, P296, DOI 10.1002/(SICI)1097-0169(1999)43:4<296::AID-CM3>3.0.CO;2-U; Lo CM, 2004, MOL BIOL CELL, V15, P982, DOI 10.1091/mbc.E03-06-0359; Ma XF, 2004, MOL BIOL CELL, V15, P2568, DOI 10.1091/mbc.E03-11-0836; Martignetti J, 2002, HAEMATOLOGICA, V87, P897; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Takeda K, 2003, CIRC RES, V93, P330, DOI 10.1161/01.RES.0000089256.00309.CB; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407	16	266	279	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41263	41266		10.1074/jbc.C400352200	http://dx.doi.org/10.1074/jbc.C400352200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292239	hybrid			2022-12-27	WOS:000224075500002
J	Jinnin, M; Ihn, H; Yamane, K; Tamaki, K				Jinnin, M; Ihn, H; Yamane, K; Tamaki, K			Interleukin-13 stimulates the transcription of the human alpha 2(I) collagen gene in human dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-DEPENDENT PATHWAY; HUMAN SKIN FIBROBLASTS; HUMAN B-CELLS; I COLLAGEN; SCLERODERMA FIBROBLASTS; INCREASED EXPRESSION; SIGNAL-TRANSDUCTION; GROWTH; CYTOKINE; FIBROSIS	Interleukin (IL)-13 is a novel lymphokine produced by activated Type 2 helper cells. In this study, we examined the target genes of IL-13 by the cDNA microarray analysis in human dermal fibroblasts. We focused on the human alpha2(I) collagen gene, which was one of the IL-13-induced genes by the microarray analysis. IL-13 induced type I collagen protein as well as mRNA in a dose-dependent manner. Actinomycin D, an RNA synthesis inhibitor, significantly blocked the IL-13-mediated up-regulation of alpha2(I) collagen mRNA expression, whereas cycloheximide, a protein synthesis inhibitor, did not block this up-regulation. In addition, IL-13 treatment induced the promoter activity of alpha2(I) collagen by nuclear run-on transcription assay and chloramphenicol acetyltransferase assay. IL-13-mediated transcriptional activation of alpha2(I) collagen gene or type I collagen protein up-regulation was inhibited by the treatment of fibroblasts with a selective phosphoinositide 3-kinase (PI3K) inhibitor, LY294002, or STAT6 antisense oligonucleotide, but not by PD98059, a specific inhibitor of MEK/ERK, or SB202190 or SB203580, specific inhibitors of p38 MAPK; IL-13 induced the phosphorylation of PI3K p85 regulatory subunit and STAT6. These results suggest that IL-13 may play a role in the regulation of extracellular matrix and indicate the possible therapeutic value of the blockade of IL-13 signaling pathways via PI3K and STAT6 in fibrosis.	Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Ihn, H (corresponding author), Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	IN-DER@h.u-tokyo.ac.jp						BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CELANO P, 1989, BIOTECHNIQUES, V7, P942; Ceponis PJM, 2000, J BIOL CHEM, V275, P29132, DOI 10.1074/jbc.M003516200; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; Hill S, 1999, AM J RESP CELL MOL, V21, P728, DOI 10.1165/ajrcmb.21.6.3709; Hishikawa K, 2001, J BIOL CHEM, V276, P16797, DOI 10.1074/jbc.M010722200; Ichiki Y, 1997, J RHEUMATOL, V24, P90; Ihn H, 2000, ARTHRITIS RHEUM, V43, P2240, DOI 10.1002/1529-0131(200010)43:10<2240::AID-ANR11>3.0.CO;2-2; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Ihn H, 2002, J IMMUNOL, V168, P1895, DOI 10.4049/jimmunol.168.4.1895; Ihn H, 2001, ARTHRITIS RHEUM, V44, P474, DOI 10.1002/1529-0131(200102)44:2<474::AID-ANR67>3.3.CO;2-R; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; Ihn H, 2002, J INVEST DERMATOL, V119, P954, DOI 10.1046/j.1523-1747.2002.00383.x; Ihn H, 2001, J INVEST DERMATOL, V117, P301, DOI 10.1046/j.0022-202x.2001.01371.x; Ihn H, 2000, J INVEST DERMATOL, V114, P1011, DOI 10.1046/j.1523-1747.2000.00956.x; Ihn H, 2000, J IMMUNOL, V165, P2149, DOI 10.4049/jimmunol.165.4.2149; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; Kawakami T, 1998, J INVEST DERMATOL, V110, P47, DOI 10.1046/j.1523-1747.1998.00073.x; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; Kolodsick JE, 2004, J IMMUNOL, V172, P4068, DOI 10.4049/jimmunol.172.7.4068; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lee JH, 2001, AM J RESP CELL MOL, V25, P474, DOI 10.1165/ajrcmb.25.4.4522; MALEFYT RD, 1993, J IMMUNOL, V150, pA180; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MERSCHER S, 1994, BIOTECHNIQUES, V16, P1024; Minty A, 1997, EUR CYTOKINE NETW, V8, P203; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; Murata T, 1998, INT IMMUNOL, V10, P1103, DOI 10.1093/intimm/10.8.1103; Oriente A, 2000, J PHARMACOL EXP THER, V292, P988; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Reif S, 2003, J BIOL CHEM, V278, P8083, DOI 10.1074/jbc.M212927200; REITAMO S, 1994, J CLIN INVEST, V94, P2489, DOI 10.1172/JCI117618; Ricupero DA, 2001, AM J PHYSIOL-CELL PH, V281, pC99, DOI 10.1152/ajpcell.2001.281.1.C99; Wei LH, 2000, AM J PHYSIOL-CELL PH, V279, pC248, DOI 10.1152/ajpcell.2000.279.1.C248; Wright K, 1999, J BIOL CHEM, V274, P17193, DOI 10.1074/jbc.274.24.17193; Wright K, 1997, J BIOL CHEM, V272, P12626, DOI 10.1074/jbc.272.19.12626; Yuyama N, 2002, CYTOKINE, V19, P287, DOI 10.1006/cyto.2002.1972; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	44	63	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41783	41791		10.1074/jbc.M406951200	http://dx.doi.org/10.1074/jbc.M406951200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15271999	hybrid			2022-12-27	WOS:000224075500067
J	Luo, M; Jones, SM; Phare, SM; Coffey, MJ; Peters-Golden, M; Brock, TG				Luo, M; Jones, SM; Phare, SM; Coffey, MJ; Peters-Golden, M; Brock, TG			Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on Serine 523	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; ACTIVATING-FACTOR BIOSYNTHESIS; PHOSPHOLIPASE A(2); CYCLIC-AMP; NUCLEAR-LOCALIZATION; PULMONARY-FIBROSIS; B-4 BIOSYNTHESIS; DEFICIENT; ADENOSINE; SEQUENCE	Leukotrienes (LTs) are lipid messengers generated by leukocytes that drive inflammation and modulate neighboring cell function. The synthesis of LTs from arachidonic acid is initiated by the enzyme 5-lipoxygenase (5-LO). We report for the first time that LT synthesis is inhibited by the direct action of protein kinase A (PKA) on 5-LO. The catalytic subunit of PKA directly phosphorylated 5-LO in vivo and in vitro and inhibited activity in intact cells and in vitro. Mutation of Ser-523 on human 5-LO prevented phosphorylation by PKA and restored LT synthesis. Treatment with PKA activators inhibited LTB4 synthesis in 3T3 cells expressing wild type 5-LO but not in cells expressing the S523A mutant of 5-LO. The mechanism of inhibition of LTB4 synthesis did not involve either reduced membrane association of activated 5-LO or redistribution of 5-LO from the nucleus to the cytoplasm. Instead, PKA phosphorylation of recombinant 5-LO inhibited in vitro activity, as did co-transfection of cells with 5-LO plus the catalytic subunit of PKA. Also, substitution of Ser-523 with glutamic acid, mimicking phosphorylation, resulted in the total loss of 5-LO activity. These results indicate that PKA phosphorylates 5-LO on Ser-523, which inhibits the catalytic activity of 5-LO and reduces cellular LT generation. Thus, PKA activation, as can occur in response to adenosine, prostaglandin E2, beta-adrenergic agonists, and other mediators, is a means of directly reducing 5-LO activity and LT synthesis that may be important in limiting inflammation and maintaining homeostasis.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Brock, TG (corresponding author), Univ Michigan, Dept Internal Med, 6301 MSRB 2, Ann Arbor, MI 48109 USA.	brocko@umich.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050496] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL50496] Funding Source: Medline; NIAID NIH HHS [R01 AI43955] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bailie MB, 1996, J IMMUNOL, V157, P5221; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Borngraber S, 1999, J BIOL CHEM, V274, P37345, DOI 10.1074/jbc.274.52.37345; Brock TG, 1996, J IMMUNOL, V156, P2522; Coffey MJ, 1996, J IMMUNOL, V157, P393; Drazen J M, 1994, Adv Prostaglandin Thromboxane Leukot Res, V22, P251; Dwyer JH, 2004, NEW ENGL J MED, V350, P29, DOI 10.1056/NEJMoa025079; Evans GJO, 2001, J BIOL CHEM, V276, P47877, DOI 10.1074/jbc.M108186200; Flamand N, 2002, MOL PHARMACOL, V62, P250, DOI 10.1124/mol.62.2.250; Flamand N, 2000, AM J RESP CRIT CARE, V161, pS88, DOI 10.1164/ajrccm.161.supplement_1.ltta-18; FONTEH AN, 1993, J IMMUNOL, V151, P339; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gan QF, 1996, J BIOL CHEM, V271, P25412, DOI 10.1074/jbc.271.41.25412; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; HACKSHAW KV, 1992, J RHEUMATOL, V19, P252; HAM EA, 1983, P NATL ACAD SCI-BIOL, V80, P4349, DOI 10.1073/pnas.80.14.4349; Healy AM, 1999, J BIOL CHEM, V274, P29812, DOI 10.1074/jbc.274.42.29812; Hemak J, 2002, J MOL MODEL, V8, P102, DOI 10.1007/s00894-002-0076-y; Jones SM, 2002, J BIOL CHEM, V277, P38550, DOI 10.1074/jbc.M206070200; Kammer GM, 2002, ANN NY ACAD SCI, V968, P96, DOI 10.1111/j.1749-6632.2002.tb04329.x; Kooman W J, 1970, J Immunol, V105, P1096; Krump E, 1997, J EXP MED, V186, P1401, DOI 10.1084/jem.186.8.1401; Luo M, 2003, P NATL ACAD SCI USA, V100, P12165, DOI 10.1073/pnas.2133253100; MARONE G, 1987, BIOCHEM PHARMACOL, V36, P13, DOI 10.1016/0006-2952(87)90377-7; Meliton AY, 2003, J ALLERGY CLIN IMMUN, V112, P404, DOI 10.1067/mai.2003.1637; Munoz NM, 2003, J BIOL CHEM, V278, P38813, DOI 10.1074/jbc.M302476200; Murthy KS, 1998, J BIOL CHEM, V273, P34519, DOI 10.1074/jbc.273.51.34519; Orlic T, 2002, AM J PHYSIOL-CELL PH, V282, pC1261, DOI 10.1152/ajpcell.00479.2001; OZAKI T, 1990, AM REV RESPIR DIS, V141, P965, DOI 10.1164/ajrccm/141.4_Pt_1.965; Peters-Golden M, 2002, AM J RESP CRIT CARE, V165, P229, DOI 10.1164/ajrccm.165.2.2104050; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; Sheu JN, 1997, KIDNEY INT, V52, P71, DOI 10.1038/ki.1997.305; Shichijo M, 1999, J ALLERGY CLIN IMMUN, V103, pS421, DOI 10.1016/S0091-6749(99)70157-0; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; Strokin M, 2003, BRIT J PHARMACOL, V139, P1014, DOI 10.1038/sj.bjp.0705326; Surette ME, 1999, MOL PHARMACOL, V56, P1055, DOI 10.1124/mol.56.5.1055; TAKENAWA T, 1986, J BIOL CHEM, V261, P1092; Tenor H, 1996, BRIT J PHARMACOL, V118, P1727, DOI 10.1111/j.1476-5381.1996.tb15598.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UNDEM BJ, 1990, J BIOL CHEM, V265, P6750; WARDLAW AJ, 1989, J ALLERGY CLIN IMMUN, V84, P19, DOI 10.1016/0091-6749(89)90173-5; Werz O, 2002, J BIOL CHEM, V277, P14793, DOI 10.1074/jbc.M111945200; Werz O, 2001, BLOOD, V97, P2487, DOI 10.1182/blood.V97.8.2487; WIGHTMAN PD, 1990, J BIOL CHEM, V265, P9176; Wilborn J, 1996, J CLIN INVEST, V97, P1827, DOI 10.1172/JCI118612; WILBORN J, 1995, J CLIN INVEST, V95, P1861, DOI 10.1172/JCI117866; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	49	95	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41512	41520		10.1074/jbc.M312568200	http://dx.doi.org/10.1074/jbc.M312568200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280375	hybrid			2022-12-27	WOS:000224075500034
J	Williams, SA; Chen, LF; Kwon, H; Fenard, D; Bisgrove, D; Verdin, E; Greene, WC				Williams, SA; Chen, LF; Kwon, H; Fenard, D; Bisgrove, D; Verdin, E; Greene, WC			Prostratin antagonizes HIV latency by activating NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATION; NONPROMOTING PHORBOL; COMBINATION THERAPY; GENE-EXPRESSION; NUCLEAR FACTOR; PKC-THETA	A subset of quiescent memory CD4 T cells harboring integrated but transcriptionally silent proviruses poses a currently insurmountable barrier to the eradication of the human immunodeficiency virus (HIV) in infected patients. Induction of HIV gene expression in these latently infected cells by immune activating agents has been proposed as one approach to confer sensitivity to antiretroviral therapy. Interest has recently focused on the non-tumor-promoting phorbol ester, prostratin, as a potential agent to activate latent HIV proviruses. Using multiple Jurkat T cell lines containing integrated but transcriptionally latent HIV proviruses (J-Lat cells), we now demonstrate that prostratin effectively activates HIV gene expression in these latently infected cells. We further show that prostratin acts by stimulating IKK-dependent phosphorylation and degradation of IkappaBalpha, leading to the rapid nuclear translocation of NF-kappaB and activation of the HIV-1 long terminal repeat in a kappaB enhancer-dependent manner. In contrast, NFAT and AP-1 are not induced by prostratin. Using chromatin immunoprecipitation assays to identify host transcription factors recruited to the latent HIV-1 promoter in living cells, we find that prostratin induces RelA binding. Analysis of potential upstream signal transducers demonstrates that prostratin stimulates membrane translocation of classical, novel, and atypical protein kinase C (PKC) isoforms. Studies with isoform-specific PKC inhibitors suggest that the novel PKCs play a particularly prominent role in the prostratin response. These findings provide new insights into the molecular pathway through which prostratin antagonizes HIV latency highlighting a central role for the action of NF-kappaB.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Greene, WC (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, POB 419100, San Francisco, CA 94141 USA.	wgreene@gladstone.ucsf.edu	Fenard, David/D-9533-2011; Verdin, Eric/AAB-7999-2019	Fenard, David/0000-0003-0242-386X; Verdin, Eric/0000-0003-3703-3183; Williams, Samuel/0000-0003-2642-3039				Ainbinder E, 2002, MOL CELL BIOL, V22, P6354, DOI 10.1128/MCB.22.18.6354-6362.2002; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DEMARCHI F, 1992, J VIROL, V66, P2514, DOI 10.1128/JVI.66.4.2514-2518.1992; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; El Kharroubi A, 1998, MOL CELL BIOL, V18, P2535, DOI 10.1128/MCB.18.5.2535; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Foehr ED, 2000, J BIOL CHEM, V275, P34021, DOI 10.1074/jbc.C000507200; FORSDYKE DR, 1991, MED HYPOTHESES, V34, P24, DOI 10.1016/0306-9877(91)90060-C; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Gulakowski RJ, 1997, ANTIVIR RES, V33, P87, DOI 10.1016/S0166-3542(96)01004-2; GUSTAFSON KR, 1992, J MED CHEM, V35, P1978, DOI 10.1021/jm00089a006; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; Korin YD, 2002, J VIROL, V76, P8118, DOI 10.1128/JVI.76.16.8118-8123.2002; Kulkosky J, 2004, AIDS RES HUM RETROV, V20, P497, DOI 10.1089/088922204323087741; Kulkosky J, 2001, BLOOD, V98, P3006, DOI 10.1182/blood.V98.10.3006; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Pomerantz Roger J, 2002, Curr Opin Investig Drugs, V3, P1133; Robichaud GA, 2002, J BIOL CHEM, V277, P23733, DOI 10.1074/jbc.M201563200; Ron D, 1999, J BIOL CHEM, V274, P19003, DOI 10.1074/jbc.274.27.19003; Rothwarf D.M., 1999, SCI STKE, V1999, pRE1; SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037-4041.1990; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; SZALLASI Z, 1991, CANCER RES, V51, P5355; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Van Praag RME, 2001, J CLIN IMMUNOL, V21, P218, DOI 10.1023/A:1011091300321; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Zhang LQ, 2000, J CLIN INVEST, V106, P839, DOI 10.1172/JCI10565	44	245	274	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42008	42017		10.1074/jbc.M402124200	http://dx.doi.org/10.1074/jbc.M402124200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15284245	hybrid			2022-12-27	WOS:000224075500094
J	Akazawa, H; Komazaki, S; Shimomura, H; Terasaki, F; Zou, YZ; Takano, H; Nagai, T; Komuro, I				Akazawa, H; Komazaki, S; Shimomura, H; Terasaki, F; Zou, YZ; Takano, H; Nagai, T; Komuro, I			Diphtheria toxin-induced autophagic cardiomyocyte death plays a pathogenic role in mouse model of heart failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; CARDIAC MYOCYTES; DILATED CARDIOMYOPATHY; MECHANICAL-STRESS; GENE-EXPRESSION; APOPTOSIS; RECEPTOR; MICE; PATHWAY; DISEASE	It is still not clear whether loss of cardiomyocytes through programmed cell death causes heart failure. To clarify the role of cell death in heart failure, we generated transgenic mice (TG) that express human diphtheria toxin receptor in the hearts. A mosaic expression pattern of the transgene was observed, and the transgene-expressing cardiomyocytes (17.3% of the total cardiomyocytes) were diffusely scattered throughout the ventricles. Intramuscular injection of diphtheria toxin induced complete elimination of the transgene-expressing cardiomyocytes within 7 days, and similar to80% of TG showed pathophysiological features characteristic of heart failure and were dead within 14 days. Degenerated cardiomyocytes of the TG heart showed characteristic features indicative of autophagic cell death such as up-regulated lysosomal markers and abundant autophagosomes containing cytosolic organelles like cardiomyocytes of human dilated cardiomyopathy. The heart failure-inducible TG are a useful model for dilated cardiomyopathy, and provided evidence indicating that myocardial cell loss through autophagic cell death plays a causal role in the pathogenesis of heart failure.	Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, Chiba 2608670, Japan; Saitama Med Sch, Dept Anat, Moroyama, Iruma 3500495, Japan; Osaka Med Coll, Dept Internal Med, Div 3, Takatsuki, Osaka 5698686, Japan; Fdn Biomed Res & Innovat, Chuo Ku, Kobe, Hyogo 6508543, Japan	Chiba University; Saitama Medical University; Osaka Medical College; Institute for Biomedical Research & Innovation (IBRI)	Komuro, I (corresponding author), Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	komuro-tky@umin.ac.jp		Akazawa, Hiroshi/0000-0002-3574-9607				Akazawa H, 2000, GENES CELLS, V5, P499, DOI 10.1046/j.1365-2443.2000.00339.x; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; ANVERSA P, 1992, J CLIN INVEST, V89, P618, DOI 10.1172/JCI115628; Anversa P, 2000, CIRC RES, V86, P121, DOI 10.1161/01.RES.86.2.121; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Asakawa M, 2002, CIRCULATION, V105, P1240, DOI 10.1161/hc1002.105225; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; BURCH GE, 1968, AM J CARDIOL, V21, P261, DOI 10.1016/0002-9149(68)90328-7; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Cataldo AM, 1996, J NEUROSCI, V16, P186; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; de Lemos JA, 2003, LANCET, V362, P316, DOI 10.1016/S0140-6736(03)13976-1; ELSNER D, 1995, CURR OPIN CARDIOL, V10, P253; Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5; Hadfield TL, 2000, J INFECT DIS, V181, pS116, DOI 10.1086/315551; Hein S, 2003, CIRCULATION, V107, P984, DOI 10.1161/01.CIR.0000051865.66123.B7; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Kang PM, 2000, CIRC RES, V86, P1107; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Knaapen MWM, 2001, CARDIOVASC RES, V51, P304, DOI 10.1016/S0008-6363(01)00290-5; Komazaki S, 2002, FEBS LETT, V524, P225, DOI 10.1016/S0014-5793(02)03042-9; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; Kostin S, 2003, CIRC RES, V92, P715, DOI 10.1161/01.RES.0000067471.95890.5C; Lee P, 1998, P NATL ACAD SCI USA, V95, P11371, DOI 10.1073/pnas.95.19.11371; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lockshin RA, 2000, CELL DEATH DIFFER, V7, P2, DOI 10.1038/sj.cdd.4400649; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Mann DL, 1999, CIRCULATION, V100, P999, DOI 10.1161/01.CIR.100.9.999; MERCADIER JJ, 1990, J CLIN INVEST, V85, P305, DOI 10.1172/JCI114429; Mitamura T, 1997, J BIOL CHEM, V272, P27084, DOI 10.1074/jbc.272.43.27084; NADAL GB, 2003, CIRC RES, V92, P139; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Roberg K, 1998, AM J PATHOL, V152, P1151; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Saito M, 2001, NAT BIOTECHNOL, V19, P746, DOI 10.1038/90795; Saito S, 2000, J BIOL CHEM, V275, P34528, DOI 10.1074/jbc.M002844200; Schaper J, 1999, CIRC RES, V85, P867, DOI 10.1161/01.RES.85.9.867; Semenov DE, 2001, B EXP BIOL MED+, V131, P505, DOI 10.1023/A:1017956922385; Shimomura H, 2001, JPN CIRC J, V65, P965, DOI 10.1253/jcj.65.965; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; Takano H, 2000, CIRC RES, V87, P596, DOI 10.1161/01.RES.87.7.596; Toko H, 2002, J BIOL CHEM, V277, P24735, DOI 10.1074/jbc.M107669200; Uchiyama Y, 2001, ARCH HISTOL CYTOL, V64, P233, DOI 10.1679/aohc.64.233; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VANNESS BG, 1980, J BIOL CHEM, V255, P710; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664; Yamamoto S, 2000, J MOL CELL CARDIOL, V32, P161, DOI 10.1006/jmcc.1999.1064	52	71	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41095	41103		10.1074/jbc.M313084200	http://dx.doi.org/10.1074/jbc.M313084200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15272002	hybrid			2022-12-27	WOS:000223916800108
J	Boulatnikov, I; De Lisle, RC				Boulatnikov, I; De Lisle, RC			Binding of the golgi sorting receptor muclin to pancreatic zymogens through sulfated O-linked oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED SECRETORY PROTEINS; ACINAR-CELLS; ACIDIC PH; CARBOXYPEPTIDASE-E; GRANULE MEMBRANES; CRYSTAL-STRUCTURE; IN-VITRO; AMYLASE; GLYCOPROTEINS; CONDENSATION	Sorting and packaging of regulated secretory proteins involves protein aggregation in the trans-Golgi network and secretory granules. In this work, we characterized the pH-dependent interactions of pancreatic acinar cell-regulated secretory proteins (zymogens) with Muclin, a putative Golgi cargo receptor. In solution, purified Muclin co-aggregated with isolated zymogens at mildly acidic pH. In an overlay assay, [S-35] sulfate biosynthetically labeled Muclin bound directly at mildly acidic pH to the zymogen granule content proteins amylase, pro-lipase, pro-carboxypeptidase A1, pro-elastase II, chymotrypsinogen B, and Reg1. Denaturation of Muclin with reducing agents to break the numerous intrachain disulfide bonds in Muclin's scavenger receptor cysteine-rich and CUB domains did not interfere with binding. Non-sulfated [S-35]Met/Cys-labeled Muclin showed decreased binding in the overlay assay. Extensive Pronase E digestion of unlabeled Muclin was used to produce glycopeptides, which competed for binding of [S-35]sulfate-labeled Muclin to zymogens. The results demonstrate that the sulfated, O-glycosylated groups are responsible for the pH-dependent interactions of Muclin with the zymogens. The behavior of Muclin fulfils the requirement of a Golgi cargo receptor to bind to regulated secretory proteins under the mildly acidic pH conditions that exist in the trans-Golgi network.	Univ Kansas, Sch Med, Dept Anat, Kansas City, KS 66160 USA; Univ Kansas, Sch Med, Dept Cell Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	De Lisle, RC (corresponding author), Univ Kansas, Sch Med, Dept Anat, Kansas City, KS 66160 USA.	rdelisle@kumc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055998] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK055998-05, R01 DK055998-01A1, R01 DK055998-02, R01 DK055998-03, R01 DK055998-04, R01 DK055998, DK55998] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; Arvan P, 2002, CURR OPIN CELL BIOL, V14, P448, DOI 10.1016/S0955-0674(02)00344-7; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; Biederbick A, 2003, EUR J CELL BIOL, V82, P19, DOI 10.1078/0171-9335-00287; Bimmler D, 2004, J SURG RES, V118, P122, DOI 10.1016/S0022-4804(03)00342-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cawley NX, 2003, ENDOCRINOLOGY, V144, P292, DOI 10.1210/en.2002-220588; Cheng H, 1996, ANAT REC, V244, P327; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; CUMMINGS RD, 1993, GLYCOBIOLOGY PRACTIC; Dartsch H, 1998, EUR J CELL BIOL, V75, P211, DOI 10.1016/S0171-9335(98)80115-5; De Lisle RC, 2002, J CELL SCI, V115, P2941; De Lisle RC, 2000, EUR J CELL BIOL, V79, P892, DOI 10.1078/0171-9335-00121; DELISLE RC, 1991, ANAL BIOCHEM, V192, P1, DOI 10.1016/0003-2697(91)90173-Q; DELISLE RC, 1994, J CELL BIOCHEM, V56, P385, DOI 10.1002/jcb.240560315; DELISLE RC, 1984, AM J PHYSIOL, V246, pG411, DOI 10.1152/ajpgi.1984.246.4.G411; DeLisle RC, 1997, GASTROENTEROLOGY, V113, P521, DOI 10.1053/gast.1997.v113.pm9247472; Feinberg H, 2003, EMBO J, V22, P2348, DOI 10.1093/emboj/cdg236; FREEDMAN SD, 1993, BIOCHEM BIOPH RES CO, V197, P992, DOI 10.1006/bbrc.1993.2577; GASSER KW, 1988, AM J PHYSIOL, V255, pC705, DOI 10.1152/ajpcell.1988.255.6.C705; GORR SU, 1995, BIOCHEM BIOPH RES CO, V215, P82, DOI 10.1006/bbrc.1995.2436; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669; JACOB M, 1992, BIOCHEM CELL BIOL, V70, P1105, DOI 10.1139/o92-156; Kalus I, 2002, BIOCHEM J, V362, P433, DOI 10.1042/0264-6021:3620433; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; Kleene R, 2000, BIOCHEMISTRY-US, V39, P9893, DOI 10.1021/bi000876i; Kleene R, 1999, DIGESTION, V60, P305, DOI 10.1159/000007676; Laine J, 1999, BIOCHEM J, V338, P289, DOI 10.1042/0264-6021:3380289; Loh YP, 2004, J MOL NEUROSCI, V22, P63, DOI 10.1385/JMN:22:1-2:63; Loh YP, 2002, ANN NY ACAD SCI, V971, P416, DOI 10.1111/j.1749-6632.2002.tb04504.x; Matsushita H, 2002, J BIOL CHEM, V277, P4680, DOI 10.1074/jbc.M105877200; Oprins A, 2001, TRAFFIC, V2, P831, DOI 10.1034/j.1600-0854.2001.21112.x; ORCI L, 1987, NATURE, V326, P77, DOI 10.1038/326077a0; REGGIO HA, 1978, J CELL BIOL, V77, P288, DOI 10.1083/jcb.77.2.288; SCHEELE GA, 1975, J BIOL CHEM, V250, P5375; Schmidt K, 2000, J CELL SCI, V113, P2233; Tandon C, 2004, EUR J CELL BIOL, V83, P79, DOI 10.1078/0171-9335-00361	40	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40918	40926		10.1074/jbc.M406213200	http://dx.doi.org/10.1074/jbc.M406213200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15292166	hybrid			2022-12-27	WOS:000223916800088
J	Muntener, K; Zwicky, R; Csucs, G; Rohrer, J; Baici, A				Muntener, K; Zwicky, R; Csucs, G; Rohrer, J; Baici, A			Exon skipping of cathepsin B - Mitochondrial targeting of a lysosomal peptidase provokes cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED HEPATOCYTE APOPTOSIS; FEMORAL-HEAD CARTILAGE; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA; GOLGI-APPARATUS; QUALITY-CONTROL; ENZYME FORMS; PROTEASE; GENE; OSTEOARTHRITIS	The alternatively spliced messenger RNA of the human cysteine peptidase cathepsin B missing exons 2 and 3 encodes a truncated form of the enzyme lacking the signal peptide and part of the inhibitory propeptide. This deletion results in a new N-terminal leader sequence characteristic of proteins predestined for transport into mitochondria. We determined enzyme targeting to intracellular organelles by transfecting HeLa cells with constructs containing segments of variable length of the N terminus of truncated cathepsin B fused to green fluorescent protein. Co-localization of the constructs with mitochondria and the endoplasmic reticulum was probed with specific markers. None of the chimeric products were found in the endoplasmic reticulum, showing that truncated cathepsin B is misrouted from its regular biosynthetic pathway and forced to enter the mitochondria instead of lysosomes as its final destination. The first 20 amino acids of the new N terminus were necessary and sufficient for mitochondrial targeting, but only cells expressing the complete truncated cathepsin B sequence died by nuclear fragmentation. This new and unexpected behavior draws attention to an additional extralysosomal role for a cysteine peptidase with several recognized important pathophysiological functions. Mitochondrial targeting of cathepsin B may have significant consequences on cell life in pathological or physiological situations characterized by excessive transcription of the cathepsin B message lacking exons 2 and 3, as observed for instance in osteoarthritic cartilage.	Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, Light Microscopy Ctr, Inst Biochem, CH-8093 Zurich, Switzerland; Univ Zurich, Dept Physiol, CH-8057 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Baici, A (corresponding author), Univ Zurich, Dept Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	abaici@bioc.unizh.ch		Baici, Antonio/0000-0002-2980-0541; Rohrer, Jack/0000-0002-2058-490X				BAICI A, 1995, ANN RHEUM DIS, V54, P289, DOI 10.1136/ard.54.4.289; BAICI A, 1995, ANN RHEUM DIS, V54, P281, DOI 10.1136/ard.54.4.281; Berardi S, 2001, ARTHRITIS RHEUM, V44, P1819, DOI 10.1002/1529-0131(200108)44:8<1819::AID-ART319>3.0.CO;2-4; BERQUIN IM, 1995, GENE, V159, P143, DOI 10.1016/0378-1119(95)00072-E; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chacinska A, 2002, TRENDS CELL BIOL, V12, P299, DOI 10.1016/S0962-8924(02)02310-3; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; GONG QM, 1993, DNA CELL BIOL, V12, P299, DOI 10.1089/dna.1993.12.299; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Houseweart MK, 2003, CELL DEATH DIFFER, V10, P1329, DOI 10.1038/sj.cdd.4401309; Keppler D, 1996, ENZYME PROTEIN, V49, P94, DOI 10.1159/000468619; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mehtani S, 1998, J BIOL CHEM, V273, P13236, DOI 10.1074/jbc.273.21.13236; Mezzacasa A, 2002, TRAFFIC, V3, P833, DOI 10.1034/j.1600-0854.2002.31108.x; Muntener K, 2003, HISTOCHEM CELL BIOL, V119, P93, DOI 10.1007/s00418-002-0487-y; Roberts Lewis R., 1999, Cell Biochemistry and Biophysics, V30, P71, DOI 10.1007/BF02737885; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Turk D, 1996, FEBS LETT, V384, P211, DOI 10.1016/0014-5793(96)00309-2; Yan SQ, 1998, BIOL CHEM, V379, P113; Zwicky R, 2003, BIOL CHEM, V384, P1007, DOI 10.1515/BC.2003.113	25	47	49	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41012	41017		10.1074/jbc.M405333200	http://dx.doi.org/10.1074/jbc.M405333200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262981	hybrid			2022-12-27	WOS:000223916800099
J	Shang, WH; Adachi, Y; Nakamura, A; Copeland, T; Kim, SR; Kamata, T				Shang, WH; Adachi, Y; Nakamura, A; Copeland, T; Kim, SR; Kamata, T			Regulation of amphiphysin1 by mitogen-activated protein kinase - Its significance in nerve growth factor receptor-mediated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; CDK5; PHOSPHORYLATION; DOMAIN	Amphiphysin1, which can simultaneously bind to dynamin1 and the clathrin adaptor AP-2, is essential for dynamin1 recruitment during receptor-mediated endocytosis, but little is known about its regulatory mechanism. Here, we purified a 120-kDa mitogen-activated protein kinase ( MAPK) substrate protein from porcine brains and identified the protein as amphiphysin1. Serine phosphorylation of amphiphysin1 was rapidly induced by nerve growth factor (NGF) in PC12 cells, and the induction was blocked by a MAPK inhibitor. Furthermore, when phosphorylated by MAPK in vitro or by NGF treatment in vivo, amphiphysin1 failed to bind to AP-2, but its association with dynamin1 was unaffected. Consistent with this, mutation of consensus MAPK phosphorylation sites increased amphiphysin1 binding to AP-2 and their intracellular colocalization. Thus, we propose that MAPK phosphorylation of amphiphysin1 controls NGF receptor/TrkA-mediated endocytosis by terminating the amphiphysin1-AP-2 interaction. This perhaps helps to regulate the availability of amphiphysin1-dynamin1 complexes for binding to the endocytic vesicle.	Shinshu Univ, Dept Mol Biol & Biochem, Sch Med, Nagano 3908621, Japan; Shinshu Univ, Inst Aging & Adaptat, Sch Med, Grad Sch, Nagano 3908621, Japan; NCI, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA; Chungbuk Natl Univ, Dept Biochem, Coll Med, Cheongju, South Korea	Shinshu University; Shinshu University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Chungbuk National University	Kamata, T (corresponding author), Shinshu Univ, Dept Mol Biol & Biochem, Sch Med, Asahi 3-1-1, Nagano 3908621, Japan.	kamatat@sch.md.shinshu-u.ac.jp						ADACHI Y, 1992, J BIOL CHEM, V267, P21977; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Floyd SR, 2001, J BIOL CHEM, V276, P8104, DOI 10.1074/jbc.M008932200; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Jin YL, 2001, EXP MOL MED, V33, P69, DOI 10.1038/emm.2001.13; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miura K, 2001, J BIOL CHEM, V276, P46276, DOI 10.1074/jbc.M102387200; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Otsuka A, 2003, BIOCHEM BIOPH RES CO, V301, P769, DOI 10.1016/S0006-291X(03)00040-8; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5	18	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40890	40896		10.1074/jbc.M404527200	http://dx.doi.org/10.1074/jbc.M404527200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262992	hybrid			2022-12-27	WOS:000223916800085
J	Gupta, R; Srivastava, OP				Gupta, R; Srivastava, OP			Deamidation affects structural and functional properties of human alpha A-crystallin and its oligomerization with alpha B-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; HEAT-SHOCK PROTEINS; C-TERMINAL EXTENSION; HUMAN LENS; SUBUNIT EXCHANGE; MOLECULAR CHAPERONE; R116C MUTANT; MUTATION; CATARACTOGENESIS; PHOTOOXIDATION	To determine the effects of deamidation on structural and functional properties of alphaA-crystallin, three mutants (N101D, N123D, and N101D/N123D) were generated. Deamidated alphaB-crystallin mutants (N78D, N146D, and N78D/N146D), characterized in a previous study (Gupta, R., and Srivastava, O. P. (2004) Invest. Ophthalmol. Vis. Sci. 45, 206-214) were also used. The biophysical and chaperone properties were determined in (a) homoaggregates of alphaA mutants (N101D, N123D, and N101D/N123D) and (b) reconstituted heteroaggregates of alpha-crystallin containing (i) wild type alphaA (WT-alphaA): WT-alphaB crystallins, (ii) individual alphaA-deamidated mutants: WT-alphaB crystallins, and (iii) WT-alphaA: individual alphaB-deamidated mutant crystallins. Compared with the WT-alphaA, the three alphaA-deamidated mutants showed reduced levels of chaperone activity, alterations in secondary and tertiary structures, and larger aggregates. These altered properties were relatively more pronounced in the mutant N101D compared with the mutant N123D. Further, compared with heteroaggregates of WT-alphaA and WT-alphaB, the heteroaggregates containing deamidated subunits of either alphaA- or alphaB-crystallins and their counterpart WT proteins showed higher molecular mass, altered tertiary structures, lower exposed hydrophobic surfaces, and reduced chaperone activity. However, the heteroaggregate containing WT-alphaA and deamidated alphaB subunit showed lower chaperone activity, smaller oligomers, and 3-fold lower subunit exchange rate than heteroaggregate containing deamidated alphaA- and WT-alphaB subunits. Together, the results suggested that (a) both Asn residues (Asn-101 and Asn-123) are required for the structural integrity and chaperone function of alphaA-crystallin and (b) the presence of WT-alphaB in the alpha-crystallin heteroaggregate leads to packing-induced structural changes which influences the oligomerization and modulate chaperone activity.	Univ Alabama Birmingham, Dept Physiol Opt, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Srivastava, OP (corresponding author), Univ Alabama Birmingham, Dept Physiol Opt, Worrell Bldg,924 S 18th St, Birmingham, AL 35294 USA.	srivasta@uab.edu			NEI NIH HHS [EY-06400] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; ANDLEY UP, 1989, INVEST OPHTH VIS SCI, V30, P706; Bera S, 2002, BIOCHEMISTRY-US, V41, P12421, DOI 10.1021/bi0204140; Bera S, 2002, BIOCHEMISTRY-US, V41, P297, DOI 10.1021/bi011010v; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; Bhattacharyya J, 2001, J PEPT RES, V57, P428, DOI 10.1034/j.1399-3011.2001.00871.x; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Cobb BA, 2000, BIOCHEMISTRY-US, V39, P15791, DOI 10.1021/bi001453j; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Datta SA, 2000, J BIOL CHEM, V275, P41004, DOI 10.1074/jbc.M007686200; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; DEJONG WW, 1984, EUR J BIOCHEM, V141, P131; Fernando P, 2000, CELL STRESS CHAPERON, V5, P148, DOI 10.1379/1466-1268(2000)005<0148:FCOXSH>2.0.CO;2; GROENEN PJTA, 1993, FEBS LETT, V322, P69, DOI 10.1016/0014-5793(93)81113-E; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Gupta R, 2004, INVEST OPHTH VIS SCI, V45, P206, DOI 10.1167/iovs.03-0720; Hanson SRA, 2000, EXP EYE RES, V71, P195, DOI 10.1006/exer.2000.0868; Hejtmancik JF, 1997, PROTEIN ENG, V10, P1347, DOI 10.1093/protein/10.11.1347; Herbert B, 1999, ELECTROPHORESIS, V20, P660, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<660::AID-ELPS660>3.0.CO;2-Q; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; KANTOROW M, 1995, J BIOL CHEM, V270, P17215, DOI 10.1074/jbc.270.29.17215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORAND L, 1988, ADV POSTTRANSLATIONA, P79; Lund AL, 1996, EXP EYE RES, V63, P661, DOI 10.1006/exer.1996.0160; MCDERMOTT M, 1991, BIOCHEMISTRY-US, V30, P8653, DOI 10.1021/bi00099a023; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; Pasta SY, 2002, J BIOL CHEM, V277, P45821, DOI 10.1074/jbc.M206499200; PERUTZ MF, 1978, SCIENCE, V201, P1187, DOI 10.1126/science.694508; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; Putilina T, 2003, J BIOL CHEM, V278, P13747, DOI 10.1074/jbc.M208157200; Runkle S, 2002, MOL VIS, V8, P45; Santhoshkumar P, 2001, J BIOL CHEM, V276, P47094, DOI 10.1074/jbc.M107737200; Schroff NP, 2001, MOL CELL BIOCHEM, V220, P127, DOI 10.1023/A:1010834107809; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; Shroff NP, 2000, BIOCHEMISTRY-US, V39, P1420, DOI 10.1021/bi991656b; SIVAKUMAR LV, 1999, J BIOL CHEM, V274, P24137; Smith JB, 1996, EXP EYE RES, V63, P125, DOI 10.1006/exer.1996.0100; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130; Srivastava OP, 2003, MOL VIS, V9, P110; Studer S, 2002, EUR J BIOCHEM, V269, P3578, DOI 10.1046/j.1432-1033.2002.03049.x; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; Takemoto L, 2000, MOL VIS, V6, P164; Takemoto L, 1999, EXP EYE RES, V68, P641, DOI 10.1006/exer.1999.0668; Thampi P, 2003, BIOCHEMISTRY-US, V42, P11857, DOI 10.1021/bi030129w; THOMSON JA, 1989, BIOCHIM BIOPHYS ACTA, V994, P246, DOI 10.1016/0167-4838(89)90300-2; VANDENOETELAAR PJ, 1999, BIOCHEMISTRY-US, V29, P3488; VANKLEEF FSM, 1976, EUR J BIOCHEM, V66, P477	56	81	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44258	44269		10.1074/jbc.M405648200	http://dx.doi.org/10.1074/jbc.M405648200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15284238	hybrid			2022-12-27	WOS:000224505600006
J	Jiang, PH; Ji, QZ; Liu, Z; Snyder, LA; Benard, LMJ; Margolskee, RF; Max, M				Jiang, PH; Ji, QZ; Liu, Z; Snyder, LA; Benard, LMJ; Margolskee, RF; Max, M			The cysteine-rich region of T1R3 determines responses to intensely sweet proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE TASTE RECEPTOR; UMAMI TASTE; MAMMALIAN SWEET; CHORDA TYMPANI; GENE; IDENTIFICATION; MONELLIN; BRAZZEIN; FAMILY; LOCUS	A wide variety of chemically diverse compounds taste sweet, including natural sugars such as glucose, fructose, sucrose, and sugar alcohols, small molecule artificial sweeteners such as saccharin and acesulfame K, and proteins such as monellin and thaumatin. Brazzein, like monellin and thaumatin, is a naturally occurring plant protein that humans, apes, and Old World monkeys perceive as tasting sweet but that is not perceived as sweet by other species including New World monkeys, mouse, and rat. It has been shown that heterologous expression of T1R2 plus T1R3 together yields a receptor responsive to many of the above-mentioned sweet tasting ligands. We have determined that the molecular basis for species-specific sensitivity to brazzein sweetness depends on a site within the cysteine-rich region of human T1R3. Other mutations in this region of T1R3 affected receptor activity toward monellin, and in some cases, overall efficacy to multiple sweet compounds, implicating this region as a previously unrecognized important determinant of sweet receptor function.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Howard Hughes Med Inst, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Howard Hughes Medical Institute; Icahn School of Medicine at Mount Sinai	Max, M (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Box 1677,1425 Madison Ave, New York, NY 10029 USA.	max@inka.mssm.edu		Margolskee, Robert/0000-0002-9572-2887	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003155, R01DC003055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007135] Funding Source: NIH RePORTER; NIDA NIH HHS [T32DA007135-22] Funding Source: Medline; NIDCD NIH HHS [DC003155, DC003055] Funding Source: Medline; NIMH NIH HHS [MH58811] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Caldwell JE, 1998, NAT STRUCT BIOL, V5, P427, DOI 10.1038/nsb0698-427; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Damak S, 2003, SCIENCE, V301, P850, DOI 10.1126/science.1087155; Danilova V, 2002, J NEUROPHYSIOL, V88, P579, DOI 10.1152/jn.2002.88.2.579; Danilova V, 1998, J NEUROPHYSIOL, V80, P2102, DOI 10.1152/jn.1998.80.4.2102; Faus I, 2000, APPL MICROBIOL BIOT, V53, P145, DOI 10.1007/s002530050001; Hellekant G, 1997, PHYSIOL BEHAV, V61, P829, DOI 10.1016/S0031-9384(96)00562-8; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kitagawa M, 2001, BIOCHEM BIOPH RES CO, V283, P236, DOI 10.1006/bbrc.2001.4760; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Max M, 2001, NAT GENET, V28, P58, DOI 10.1038/88270; Montmayeur JP, 2001, NAT NEUROSCI, V4, P492, DOI 10.1038/87440; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Sainz E, 2001, J NEUROCHEM, V77, P896, DOI 10.1046/j.1471-4159.2001.00292.x; SOMOZA JR, 1993, J MOL BIOL, V234, P390, DOI 10.1006/jmbi.1993.1594; Temussi PA, 2002, FEBS LETT, V526, P1, DOI 10.1016/S0014-5793(02)03155-1; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4	21	222	232	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45068	45075		10.1074/jbc.M406779200	http://dx.doi.org/10.1074/jbc.M406779200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15299024	hybrid			2022-12-27	WOS:000224505600099
J	Koropatkin, NM; Holden, HM				Koropatkin, NM; Holden, HM			Molecular structure of alpha-D-glucose-1-phosphate cytidylyltransferase from Salmonella typhi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI GLUCOSE-1-PHOSPHATE THYMIDYLYLTRANSFERASE; CYTIDINE DIPHOSPHATE 3,6-DIDEOXYHEXOSES; ESCHERICHIA-COLI; GLUCOSE PYROPHOSPHORYLASE; CATALYTIC MECHANISM; ENZYMATIC SYNTHESIS; PURIFICATION; GENE	Dideoxysugars, which display biological activities ranging from mediating cell-cell interactions to serving as components in some antibiotics, are synthesized in various organisms via complex biochemical pathways that begin with the attachment of alpha-D-glucose 1-phosphate to either CTP or dTTP. Here we describe the three-dimensional structure of the alpha-D-glucose-1-phosphate cytidylyltransferase from Salmonella typhi, which catalyzes the first step in the production of CDP-tyvelose. For this investigation, the enzyme was crystallized in the presence of its product, CDP-glucose. In contrast to previous reports, the enzyme exists as a fully integrated hexamer with 32-point group symmetry. Each subunit displays a "bird-like" appearance with the "body" composed predominantly of a seven-stranded mixed beta-sheet and the two "wings" formed by beta-hairpin motifs. These two wings mediate subunit-subunit interactions along the 3-fold and 2-fold rotational axes, respectively. The six active sites of the hexamer are situated between the subunits related by the 2-fold rotational axes. CDP-glucose is anchored to the protein primarily by hydrogen bonds with backbone carbonyl oxygens and peptidic NH groups. The side chains of Arg(111) and Asn(188) from one subunit and Glu(178) and Lys(179) from the second subunit are also involved in hydrogen bonding with the ligand. The topology of the main core domain bears striking similarity to that observed for glucose-1-phosphate thymidylyltransferase and 4-diphosphocytidyl-2-C-methylerythritol synthetase.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	Hazel_Holden@biochem.wisc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK047814, R01DK047814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWELL G, 1971, MICROBIAL TOXINS, V4, P235; Barton WA, 2001, NAT STRUCT BIOL, V8, P545, DOI 10.1038/88618; BISHOP CT, 1982, POLYSACCHARIDES, V1, P291; Blankenfeldt W, 2000, EMBO J, V19, P6652, DOI 10.1093/emboj/19.24.6652; Hanessian S, 1966, Adv Carbohydr Chem Biochem, V21, P143; He XMM, 2002, ANNU REV BIOCHEM, V71, P701, DOI 10.1146/annurev.biochem.71.110601.135339; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KIMATA K, 1966, J BIOL CHEM, V241, P1099; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LINDBERG B, 1990, ADV CARBOHYD CHEM BI, V48, P279, DOI 10.1016/S0065-2318(08)60033-5; LINDQVIST L, 1994, J BIOL CHEM, V269, P122; LIU HW, 1994, ANNU REV MICROBIOL, V48, P223, DOI 10.1146/annurev.micro.48.1.223; LUDERITZ O, 1966, BACTERIOL REV, V30, P192; MATSUHASHI S, 1966, J BIOL CHEM, V241, P4267; MAYER RM, 1965, J BIOL CHEM, V240, P1900; NIKAIDO H, 1966, J BIOL CHEM, V241, P1376; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkhill J, 2001, NATURE, V413, P848, DOI 10.1038/35101607; Richard SB, 2001, NAT STRUCT BIOL, V8, P641, DOI 10.1038/89691; ROUSSEL A, 1998, SILICON GRAPHICS GEO, P77; RUBENSTE.PA, 1974, J BIOL CHEM, V249, P3789; Sivaraman J, 2002, J BIOL CHEM, V277, P44214, DOI 10.1074/jbc.M206932200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THORSON JS, 1994, J BACTERIOL, V176, P1840, DOI 10.1128/jb.176.7.1840-1849.1994; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WILLIAMS NR, 1980, CARBOHYDRATES CHEM B, V1; Zuccotti S, 2001, J MOL BIOL, V313, P831, DOI 10.1006/jmbi.2001.5073	30	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44023	44029		10.1074/jbc.M407755200	http://dx.doi.org/10.1074/jbc.M407755200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292268	hybrid			2022-12-27	WOS:000224383100081
J	Ryoo, K; Huh, SH; Lee, YH; Yoon, KW; Cho, SG; Choi, EJ				Ryoo, K; Huh, SH; Lee, YH; Yoon, KW; Cho, SG; Choi, EJ			Negative regulation of MEKK1-induced signaling by glutathione S-transferase Mu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEK KINASE 1; ACTIVATED PROTEIN-KINASE; INDUCED APOPTOSIS; ESCHERICHIA-COLI; JNK; CELLS; DOMAIN; TRANSDUCTION; INTERACT; RECEPTOR	Mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1) is an important component in the stress-activated protein kinase pathway. Glutathione S-transferase Mu 1-1 (GST M1-1) has now been shown to inhibit the stimulation of MEKK1 activity induced by cellular stresses such as UV and hydrogen peroxide. GST M1-1 inhibited MEKK1 activation in a manner independent of its glutathione-conjugating catalytic activity. In vitro binding and kinase assays revealed that GST M1-1 directly bound MEKK1 and inhibited its kinase activity. Co-immunoprecipitation analysis showed a physical association between endogenous GST M1-1 and endogenous MEKK1 in L929 cells. Overexpressed GST M1-1 interfered with the binding of MEKK1 to SEK1 in transfected HEK293 cells. Furthermore, GST M1-1 suppressed MEKK1-mediated apoptosis. Taken together, our results suggest that GST M1-1 functions as a negative regulator of MEKK1.	Konkuk Univ, Dept Anim Biotechnol, Seoul 143702, South Korea; Korea Univ, Natl Creat Res Iniat Ctr Cell Death, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Chungbuk Natl Univ, Dept Biochem, Sch Med, Cheongju 361763, South Korea; Chungbuk Natl Univ, Int Tumor Res, Cheongju 361763, South Korea	Konkuk University; Korea University; Chungbuk National University; Chungbuk National University	Cho, SG (corresponding author), Konkuk Univ, Dept Anim Biotechnol, Seoul 143701, South Korea.	ssangoo@konkuk.ac.kr; ejchoi@korea.ac.kr		Cho, Ssang-Goo/0000-0002-0968-7932				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng JZ, 1999, ARCH BIOCHEM BIOPHYS, V372, P29, DOI 10.1006/abbi.1999.1479; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kaga S, 1998, J IMMUNOL, V160, P4182; Kim JW, 2001, J BIOL CHEM, V276, P27064, DOI 10.1074/jbc.M009364200; Kwan R, 2001, MOL CELL BIOL, V21, P7183, DOI 10.1128/MCB.21.21.7183-7190.2001; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE HC, 1995, J BIOL CHEM, V270, P99, DOI 10.1074/jbc.270.1.99; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Saltzman A, 1998, FEBS LETT, V425, P431, DOI 10.1016/S0014-5793(98)00287-7; Sanghera JS, 1996, J IMMUNOL, V156, P4457; Schlesinger Thomas K., 1998, Frontiers in Bioscience, V3, pD1181; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; TOWNSEND AJ, 1989, J BIOL CHEM, V264, P21582; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAN MH, 1994, NATURE, V372, P798; Yang Y, 2001, J BIOL CHEM, V276, P19220, DOI 10.1074/jbc.M100551200; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	37	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43589	43594		10.1074/jbc.M404359200	http://dx.doi.org/10.1074/jbc.M404359200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15299005	hybrid			2022-12-27	WOS:000224383100031
J	Assefa, Z; Bultynck, G; Szlufcik, K; Kasri, NN; Vermassen, E; Goris, J; Missiaen, L; Callewaert, G; Parys, JB; De Smedt, H				Assefa, Z; Bultynck, G; Szlufcik, K; Kasri, NN; Vermassen, E; Goris, J; Missiaen, L; Callewaert, G; Parys, JB; De Smedt, H			Caspase-3-induced truncation of type 1 inositol trisphosphate receptor accelerates apoptotic cell death and induces inositol trisphosphate-independent calcium release during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITE; 1,4,5-TRISPHOSPHATE RECEPTOR; NEURODEGENERATIVE DISORDERS; NEURONAL DEATH; MITOCHONDRIAL; CASPASES; EXPRESSION; ACTIVATION; NECROSIS; CLEAVAGE	Inositol 1,4,5-trisphosphate receptor-deficient (IP3R-KO) B-lymphocytes were used to investigate the functional relevance of type 1 inositol 1,4,5-trisphosphate receptor (IP(3)R1) and its cleavage by caspase-3 in apoptosis. We showed that inositol 1,4,5-trisphosphate receptor-deficient cells were largely resistant to apoptosis induced by both staurosporine (STS) and B-cell receptor (BCR) stimulation. Expression of either the wild-type IP(3)R1 or an N-terminal deletion mutant (Delta1-225) that lacks inositol 1,4,5-trisphosphate- induced Ca2+ release activity restored sensitivity to apoptosis and the consequent rise in free cytosolic Ca2+ concentration ([Ca2+](i)). Expression of caspase-3-non-cleavable mutant receptor, however, dramatically slowed down the rate of apoptosis and prevented both Ca2+ overload and secondary necrosis. Conversely, expression of the "channel-only" domain of IP(3)R1, a fragment of the receptor generated by caspase-3 cleavage, strongly increased the propensity of the cells to undergo apoptosis. In agreement with these observations, caspase inhibitors impeded apoptosis and the associated rise in [Ca2+](i). Both the staurosporine- and B-cell receptor-induced apoptosis and increase in [Ca2+](i) could be induced in nominally Ca2+-free and serum-free culture media, suggesting that the apoptosis-related rise in [Ca2+](i) was primarily because of the release from internal stores rather than of influx through the plasma membrane. Altogether, our results suggest that IP(3)R1 plays a pivotal role in apoptosis and that the increase in [Ca2+](i) during apoptosis is mainly the consequence of IP(3)R1 cleavage by caspase-3. These observations also indicate that expression of a functional IP(3)R1 per se is not enough to generate the significant levels of cytosolic Ca2+ needed for the rapid execution of apoptosis, but a prior activation of caspase-3 and the resulting truncation of the IP(3)R1 are required.	Katholieke Univ Leuven, Afdeling Fysiol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Afdeling Biochem, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	De Smedt, H (corresponding author), Katholieke Univ Leuven, Afdeling Fysiol, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Humbert.DeSmedt@med.kuleuven.ac.be	Assefa, Zerihun/V-5641-2017; Nadif Kasri, Nael/E-2270-2012	Assefa, Zerihun/0000-0001-7803-5228; Nadif Kasri, Nael/0000-0002-7448-9289; Bultynck, Geert/0000-0002-5968-4828; Parys, Jan/0000-0002-3591-4967				ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Annunziato L, 2003, TOXICOL LETT, V139, P125, DOI 10.1016/S0378-4274(02)00427-7; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Bultynck G, 2004, BIOCHEM J, V381, P87, DOI 10.1042/BJ20040072; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Dussmann H, 2003, J CELL SCI, V116, P525, DOI 10.1242/jcs.00236; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; FURUICHI T, 1993, RECEPTOR CHANNEL, V1, P11; Hang LS, 2000, J NEUROCHEM, V75, P1852; Hirota J, 1999, J BIOL CHEM, V274, P34433, DOI 10.1074/jbc.274.48.34433; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; KAISER N, 1977, P NATL ACAD SCI USA, V74, P638, DOI 10.1073/pnas.74.2.638; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Mattson MP, 2001, APOPTOSIS, V6, P69, DOI 10.1023/A:1009676112184; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Nicotera P, 1998, TOXICOL LETT, V103, P139; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; PARYS JB, 1995, CELL CALCIUM, V17, P239, DOI 10.1016/0143-4160(95)90070-5; Paszty K, 2002, J BIOL CHEM, V277, P6822, DOI 10.1074/jbc.M109548200; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; Schulz JB, 1998, CELL DEATH DIFFER, V5, P847, DOI 10.1038/sj.cdd.4400420; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Scoltock AB, 2000, J BIOL CHEM, V275, P30586, DOI 10.1074/jbc.M004058200; SHARP AH, 1993, J NEUROSCI, V13, P3051; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Tombal B, 2002, CELL DEATH DIFFER, V9, P561, DOI 10.1038/sj.cdd.4400999; Uchida K, 2003, J BIOL CHEM, V278, P16551, DOI 10.1074/jbc.M300646200; Vermes I, 2000, J IMMUNOL METHODS, V243, P167, DOI 10.1016/S0022-1759(00)00233-7; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277; Yoshikawa F, 1999, BIOCHEM BIOPH RES CO, V257, P792, DOI 10.1006/bbrc.1999.0498	43	112	115	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43227	43236		10.1074/jbc.M403872200	http://dx.doi.org/10.1074/jbc.M403872200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15284241	hybrid, Green Published			2022-12-27	WOS:000224226400107
J	Biswas, A; Das, KP				Biswas, A; Das, KP			Role of ATP on the interaction of alpha-crystallin with its substrates and its implications for the molecular chaperone function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; B-CRYSTALLIN; A-CRYSTALLIN; NONOCULAR TISSUES; DENATURED PROTEIN; 2-MODE BINDING; LENS; MECHANISM; STATE; INTERMEDIATE	ATP plays a significant role in the function of molecular chaperones of the large heat shock protein families. However, its role in the functions of chaperones of the small heat shock protein families is not understood very well. We report here a study on the role of ATP on the structure and function of the major eye lens chaperone alpha-crystallin. Our in vitro study shows that at physiological temperature, ATP induces the association of alpha-crystallin with substrate proteins. The association process is reversible and low affinity in nature with unit binding stoichiometry. 4,4'-Dianilino-1,1'-binaphthyl-5,5-disulfonic acid, dipotassium salt, binding studies show that ATP induces the exposure of additional hydrophobic sites on alpha-crystallin, but no appreciable enhancement of the same was observed for the substrate protein gamma-crystallin or carbonic anhydrase. An equilibrium unfolding study reveals that ATP at 3 mM concentration stabilizes the alpha-crystallin structure by 4.5 kJ/mol. The compactness induced by ATP makes it more resistant to tryptic cleavage. ATP-induced association of chaperone alpha-crystallin with substrate enhanced its aggregation prevention ability and also enhanced the refolding yield of lactate dehydrogenase from the unfolded state. Our results suggest that the binding of ATP to alpha-crystallin and not its hydrolysis is required for all these effects, as replacement of ATP by its nonhydrolyzable analogue adenosine-5'-O-(3-thiotriphosphate), tetralithium salt, reproduced all the results faithfully. The implication of the ATP-induced reversible protein-protein association at physiological temperatures on the functional role of alpha-crystallin in vivo is discussed.	Bose Inst, Dept Chem, Prot Chem Lab, Kolkata 700009, W Bengal, India	Department of Science & Technology (India); Bose Institute	Das, KP (corresponding author), Bose Inst, Dept Chem, Prot Chem Lab, 93-1 APC Rd, Kolkata 700009, W Bengal, India.	kalipada@bosemain.boseinst.ac.in		Das, Kali/0000-0001-7686-9077				Bai YW, 1996, PROTEINS, V24, P145, DOI 10.1002/(SICI)1097-0134(199602)24:2<145::AID-PROT1>3.0.CO;2-I; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bhattacharyya J, 1998, BIOCHEM MOL BIOL INT, V46, P249; BOYLE D, 1994, EXP EYE RES, V58, P9, DOI 10.1006/exer.1994.1190; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; Cobb BA, 2002, BIOCHEMISTRY-US, V41, P483, DOI 10.1021/bi0112457; DAS BK, 1995, BIOCHEMISTRY-US, V34, P5242, DOI 10.1021/bi00015a038; Das KP, 1999, J BIOL CHEM, V274, P33209, DOI 10.1074/jbc.274.47.33209; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; Derham BK, 2001, EUR J BIOCHEM, V268, P713, DOI 10.1046/j.1432-1327.2001.01929.x; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; Ganea E, 2000, BIOCHEM J, V345, P467, DOI 10.1042/0264-6021:3450467; Goenka S, 2001, BIOCHEM J, V359, P547, DOI 10.1042/0264-6021:3590547; GREINER JV, 1985, INVEST OPHTH VIS SCI, V26, P537; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; HOWITZ J, 2003, EXP EYE RES, V76, P145; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KANTOROW M, 1995, J BIOL CHEM, V270, P17215, DOI 10.1074/jbc.270.29.17215; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; Koteiche HA, 2003, J BIOL CHEM, V278, P10361, DOI 10.1074/jbc.M211851200; Lee JS, 1998, BIOCHEM BIOPH RES CO, V244, P379, DOI 10.1006/bbrc.1998.8272; Manna T, 2001, J BIOL CHEM, V276, P39742, DOI 10.1074/jbc.M104061200; Mchaourab HS, 2002, J BIOL CHEM, V277, P40557, DOI 10.1074/jbc.M206250200; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Muchowski PJ, 1999, J BIOL CHEM, V274, P30190, DOI 10.1074/jbc.274.42.30190; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; PALMISANO DV, 1995, BBA-PROTEIN STRUCT M, V1246, P91, DOI 10.1016/0167-4838(94)00176-H; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAMAN B, 1995, J BIOL CHEM, V270, P19888, DOI 10.1074/jbc.270.34.19888; Rawat U, 1998, J BIOL CHEM, V273, P9415, DOI 10.1074/jbc.273.16.9415; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; REDDY MC, 1992, BIOCHEM BIOPH RES CO, V189, P1578, DOI 10.1016/0006-291X(92)90256-K; SAHA S, 2004, IN PRESS PROTEINS; Sathish HA, 2004, J BIOL CHEM, V279, P16425, DOI 10.1074/jbc.M313402200; Sathish HA, 2003, J BIOL CHEM, V278, P44214, DOI 10.1074/jbc.M307578200; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; Sun TX, 1999, J BIOL CHEM, V274, P34067, DOI 10.1074/jbc.274.48.34067; Szebeni A, 1999, PROTEIN SCI, V8, P905; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; WANG KY, 1994, J BIOL CHEM, V269, P13601; Wang KY, 2001, EUR J BIOCHEM, V268, P6335, DOI 10.1046/j.0014-2956.2001.02580.x; Wang KY, 2000, EUR J BIOCHEM, V267, P4705, DOI 10.1046/j.1432-1327.2000.01521.x; YOSHIDA M, 1993, PHILOS T ROY SOC B, V339, P305, DOI 10.1098/rstb.1993.0029	53	100	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42648	42657		10.1074/jbc.M404444200	http://dx.doi.org/10.1074/jbc.M404444200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292216	hybrid			2022-12-27	WOS:000224226400038
J	Constantinescu, A; Wu, M; Asher, O; Diamond, I				Constantinescu, A; Wu, M; Asher, O; Diamond, I			cAMP-dependent protein kinase type I regulates ethanol-induced cAMP response element-mediated gene expression via activation of CREB-binding protein and inhibition of MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; CYCLIC-AMP; B-RAF; TRANSCRIPTIONAL REGULATION; NUCLEAR TRANSLOCATION; SYNAPTIC PLASTICITY; SIGNALING PATHWAY; NG108-15 CELLS; CROSS-TALK; PC12 CELLS	We have shown that the two types of cAMP-dependent protein kinase (PKA) in NG108-15 cells differentially mediate forskolin-nand ethanol-induced cAMP response element (CRE)-binding protein (CREB) phosphorylation and CRE-mediated gene transcription. Activated type II PKA is translocated into the nucleus where it phosphorylates CREB. By contrast, activated type I PKA does not translocate to the nucleus but is required for CRE-mediated gene transcription by inducing the activation of other transcription cofactors such as CREB-binding protein (CBP). We show here that CBP is required for forskolin- and ethanol-induced CRE-mediated gene expression. Forskolin- and ethanol-induced CBP phosphorylation, demonstrable at 10 min, persists up to 24 h. CBP phosphorylation requires type I PKA but not type II PKA. In NG108-15 cells, ethanol and forskolin activation of type I PKA also inhibits several components of the MAPK pathway including B-Raf kinase, ERK1/2, and p90RSK phosphorylation. As a result, unphosphorylated p90RSK no longer binds to nor inhibits CBP. Moreover, MEK inhibition by PD98059 induces a significant increase of CRE-mediated gene activation. Taken together, our findings suggest that inhibition of the MAPK pathway enhances cAMP-dependent gene activation during exposure of NG108-15 cells to ethanol. This mechanism appears to involve type I PKA-dependent phosphorylation of CBP and inhibition of MEK-dependent phosphorylation of p90RSK. Under these conditions p90RSK is no longer bound to CBP, thereby promoting CBP-dependent CREB-mediated gene expression.	Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, Emeryville, CA 94608 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, Emeryville, CA 94608 USA; Univ Calif San Francisco, Grad Program Neurosci, Emeryville, CA 94608 USA; Univ Calif San Francisco, Ctr Neurobiol Addict, Emeryville, CA 94608 USA; Magen David Adom Natl Blood Serv Ctr, IL-52621 Ramat Gan, Israel	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Constantinescu, A (corresponding author), Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.	anconst@itsa.ucsf.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA010030] Funding Source: NIH RePORTER; NIAAA NIH HHS [R37 AA10030] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Adams JP, 2000, ACTA NEUROBIOL EXP, V60, P377; Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Akileswaran L, 2001, J BIOL CHEM, V276, P17448, DOI 10.1074/jbc.M101171200; Asher O, 2002, J PHARMACOL EXP THER, V301, P66, DOI 10.1124/jpet.301.1.66; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Brockmann D, 2003, CURR TOP MICROBIOL, V272, P97; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Constantinescu A, 2002, J BIOL CHEM, V277, P18810, DOI 10.1074/jbc.M112107200; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Curtis J, 1999, J NEUROSCI RES, V58, P88, DOI 10.1002/(SICI)1097-4547(19991001)58:1<88::AID-JNR9>3.3.CO;2-I; Davis MI, 1999, NEUROSCI LETT, V272, P95, DOI 10.1016/S0304-3940(99)00572-8; Deisseroth K, 2002, NEURON, V34, P179, DOI 10.1016/S0896-6273(02)00664-5; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DIAMOND I, 1987, P NATL ACAD SCI USA, V84, P1413, DOI 10.1073/pnas.84.5.1413; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gendron L, 2003, J BIOL CHEM, V278, P3606, DOI 10.1074/jbc.M202446200; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hendrickson RJ, 1998, EUR J PHARMACOL, V362, P251, DOI 10.1016/S0014-2999(98)00771-7; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; Hu BR, 1999, NEUROSCIENCE, V89, P437, DOI 10.1016/S0306-4522(98)00352-2; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Kalluri HSG, 2002, EUR J PHARMACOL, V439, P53, DOI 10.1016/S0014-2999(01)01599-0; Kapoor GS, 2003, J LIPID RES, V44, P584, DOI 10.1194/jlr.M200302-JLR200; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Licata SC, 2003, J NEUROCHEM, V85, P14, DOI 10.1046/j.1471-4159.2003.01662.x; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Medina DL, 2000, J BIOL CHEM, V275, P15549, DOI 10.1074/jbc.275.20.15549; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; Rimondini R, 2002, FASEB J, V16, P27, DOI 10.1096/fj.01-0593com; Roberto M, 2003, EUR J NEUROSCI, V17, P1646, DOI 10.1046/j.1460-9568.2003.02614.x; Roberto M, 2002, J NEUROPHYSIOL, V87, P2385, DOI 10.1152/jn.2002.87.5.2385; Sang NL, 2002, FRONT BIOSCI, V7, pD407, DOI 10.2741/sang; Sanna PP, 2002, BRAIN RES, V948, P186, DOI 10.1016/S0006-8993(02)03191-8; SAPRU MK, 1994, J PHARMACOL EXP THER, V271, P542; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; Seiler AEM, 2001, J NEUROCHEM, V76, P573, DOI 10.1046/j.1471-4159.2001.00025.x; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Waltereit R, 2003, MOL NEUROBIOL, V27, P99, DOI 10.1385/MN:27:1:99; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; WEISS F, 1992, ANN NY ACAD SCI, V654, P220, DOI 10.1111/j.1749-6632.1992.tb25970.x; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang XJ, 1996, J PHARMACOL EXP THER, V278, P338; Yao LN, 2002, CELL, V109, P733, DOI 10.1016/S0092-8674(02)00763-8; Zanassi P, 2001, J BIOL CHEM, V276, P11487, DOI 10.1074/jbc.M007631200	69	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43321	43329		10.1074/jbc.M406994200	http://dx.doi.org/10.1074/jbc.M406994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15299023	hybrid			2022-12-27	WOS:000224226400116
J	Kiss-Toth, E; Bagstaff, SM; Sung, HY; Jozsa, V; Dempsey, C; Caunt, JC; Oxley, KM; Wyllie, DH; Polgar, T; Harte, M; O'Neill, LAJ; Qwarnstrom, EE; Dower, SK				Kiss-Toth, E; Bagstaff, SM; Sung, HY; Jozsa, V; Dempsey, C; Caunt, JC; Oxley, KM; Wyllie, DH; Polgar, T; Harte, M; O'Neill, LAJ; Qwarnstrom, EE; Dower, SK			Human tribbles, a protein family controlling mitogen-activated protein kinase cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; SCAFFOLD PROTEINS; P38 KINASE; KAPPA-B; DROSOPHILA; IDENTIFICATION; MORPHOGENESIS; PATHWAYS; CHECKPOINT; EXPRESSION	Control of mitogen-activated protein kinase ( MAPK) cascades is central to regulation of many cellular responses. We describe here human tribbles homologues (Htrbs) that control MAPK activity. MAPK kinases interact with Trbs and regulate their steady state levels. Further, Trbs selectively regulate the activation of extracellular signal-regulated kinases, c-Jun NH2-terminal kinases, and p38 MAPK with different relative levels of activity for the three classes of MAPK observed depending on the level of Trb expression. These results suggest that Trbs control both the extent and the specificity of MAPK kinase activation of MAPK.	Univ Sheffield, No Gen Hosp, Div Clin Sci N, Cardiovasc Res Unit, Sheffield S5 7AU, S Yorkshire, England; Univ Sheffield, Royal Hallamshire Hosp, Cell Biol & Funct Genom Grp, Div Genom Med, Sheffield S10 2JF, S Yorkshire, England; Inst Biochem, H-6726 Szeged, Hungary; Trinity Coll Dublin, Dept Biochem, Dublin 2, Ireland	Northern General Hospital; University of Sheffield; University of Sheffield; Trinity College Dublin	Kiss-Toth, E (corresponding author), Univ Sheffield, No Gen Hosp, Div Clin Sci N, Cardiovasc Res Unit, Herries Rd, Sheffield S5 7AU, S Yorkshire, England.	E.Kiss-Toth@sheffield.ac.uk	Kiss-Toth, Endre/A-8596-2014; Polgár, Tímea/A-2089-2013; Kiss-Toth, Endre/AAC-4252-2020	Kiss-Toth, Endre/0000-0003-4406-4017; Polgár, Tímea/0000-0002-1367-6128; Kiss-Toth, Endre/0000-0003-4406-4017; dower, steve/0000-0002-4675-4225; Qwarnstrom, Eva/0000-0003-4417-8663; O'Neill, Luke/0000-0002-4333-2748				Bowers AJ, 2003, ONCOGENE, V22, P2823, DOI 10.1038/sj.onc.1206367; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Carlotti F, 1999, J BIOL CHEM, V274, P37941, DOI 10.1074/jbc.274.53.37941; Chau ASS, 1999, J BIOL CHEM, V274, P32085, DOI 10.1074/jbc.274.45.32085; DOWER SK, 2002, CURR GENOMICS, V3, P131; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gavin AC, 1999, MOL BIOL CELL, V10, P2971, DOI 10.1091/mbc.10.9.2971; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kiss-Toth E, 2000, J IMMUNOL METHODS, V239, P125, DOI 10.1016/S0022-1759(00)00151-4; Kiss-Toth E, 2001, ANAL BIOCHEM, V288, P230, DOI 10.1006/abio.2000.4858; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Maamra M, 1999, J BIOL CHEM, V274, P14791, DOI 10.1074/jbc.274.21.14791; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Mayumi-Matsuda K, 1999, BIOCHEM BIOPH RES CO, V258, P260, DOI 10.1006/bbrc.1999.0576; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Ord D, 2003, EXP CELL RES, V286, P308, DOI 10.1016/S0014-4827(03)00070-3; PERRELL JE, 2000, SCIENCE; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rorth P, 2000, MOL CELL, V6, P23; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; Sveiczer A, 2000, P NATL ACAD SCI USA, V97, P7865, DOI 10.1073/pnas.97.14.7865; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wilkin F, 1997, EUR J BIOCHEM, V248, P660, DOI 10.1111/j.1432-1033.1997.t01-1-00660.x; Wilkin F, 1996, J BIOL CHEM, V271, P28451, DOI 10.1074/jbc.271.45.28451; Wyllie DH, 2000, J IMMUNOL, V165, P7125, DOI 10.4049/jimmunol.165.12.7125; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zou XH, 2001, MOL CELL BIOL, V21, P4818, DOI 10.1128/MCB.21.14.4818-4828.2001	35	245	258	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42703	42708		10.1074/jbc.M407732200	http://dx.doi.org/10.1074/jbc.M407732200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15299019	hybrid			2022-12-27	WOS:000224226400044
J	Neiers, F; Kriznik, A; Boschi-Muller, S; Branlant, G				Neiers, F; Kriznik, A; Boschi-Muller, S; Branlant, G			Evidence for a new sub-class of methionine sulfoxide reductases B with an alternative thioredoxin recognition signature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-BOUND METHIONINE; ESCHERICHIA-COLI; NEISSERIA-MENINGITIDIS; CATALYTIC MECHANISM; KINETIC CHARACTERIZATION; EXPRESSION; REDUCTION; ENZYME; GENE; PILB	Methionine sulfoxide reductases catalyze the reduction of protein-bound methionine sulfoxide back to methionine via a thioredoxin-recycling process. Two classes of methionine sulfoxide reductases, called MsrA and MsrB, exist that display opposite stereoselectivities toward the sulfoxide function. Although they are structurally unrelated, they share a similar chemical mechanism that includes three steps with 1) formation of a sulfenic acid intermediate with a concomitant release of 1 mol of methionine per mole of enzyme; 2) formation of an intradisulfide Msr bond; and 3) reduction of the oxidized Msr by thioredoxin. In the MsrBs that have been biochemically, enzymatically, and structurally characterized so far, the cysteine involved in the regeneration of the catalytic Cys-117 is Cys-63. Cys-117 is located on a beta strand, whereas the recycling Cys-63 is on a loop near Cys-117. The distance between the two cysteines is compatible with formation of the Cys-117/Cys-63 intradisulfide bond. Analyses of MsrB sequences show that at least 37% of the MsrBs do not possess the recycling Cys-63. In the present study, it is shown that Cys-31 in the Xanthomonas campestris MsrB, which is located on another loop, can efficiently substitute for Cys-63. Such a result implies flexibility of the MsrB structures, at least of the loops on which Cys-31 or Cys-63 are located. The fact that about 25% of the putative MsrBs have no recycling cysteine supports other recycling processes in which thioredoxin is not operative.	Fac Sci, UMR CNRS UHP 7567, F-54506 Vandoeuvre Les Nancy, France	Universite de Lorraine	Branlant, G (corresponding author), Fac Sci, UMR CNRS UHP 7567, Bld Aiguillettes,BP 239, F-54506 Vandoeuvre Les Nancy, France.	guy.branlant@maem.uhp-nancy.fr	Neiers, Fabrice/AAM-1637-2021; Kriznik, Alexandre/S-1523-2019	Neiers, Fabrice/0000-0002-8965-4929; Kriznik, Alexandre/0000-0003-2627-8273; Boschi, Sandrine/0000-0001-8962-4749				Antoine M, 2003, J BIOL CHEM, V278, P45352, DOI 10.1074/jbc.M307471200; Boschi-Muller S, 2000, J BIOL CHEM, V275, P35908, DOI 10.1074/jbc.M006137200; Grimaud R, 2001, J BIOL CHEM, V276, P48915, DOI 10.1074/jbc.M105509200; Kryukov GV, 2002, P NATL ACAD SCI USA, V99, P4245, DOI 10.1073/pnas.072603099; Lowther WT, 2000, BIOCHEMISTRY-US, V39, P13307, DOI 10.1021/bi0020269; Lowther WT, 2002, NAT STRUCT BIOL, V9, P348, DOI 10.1038/nsb783; Moskovitz J, 1997, P NATL ACAD SCI USA, V94, P9585, DOI 10.1073/pnas.94.18.9585; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P2095, DOI 10.1073/pnas.93.5.2095; Moskovitz J, 2000, J BIOL CHEM, V275, P14167, DOI 10.1074/jbc.275.19.14167; MOSKOVITZ J, 1995, J BACTERIOL, V177, P502, DOI 10.1128/jb.177.3.502-507.1995; Mossner E, 1998, PROTEIN SCI, V7, P1233; Mulrooney SB, 1997, PROTEIN EXPRES PURIF, V9, P372, DOI 10.1006/prep.1996.0698; Olry A, 2004, BIOCHEMISTRY-US, V43, P11616, DOI 10.1021/bi049306z; Olry A, 2002, J BIOL CHEM, V277, P12016, DOI 10.1074/jbc.M112350200; Schoneich C, 1999, EXP GERONTOL, V34, P19, DOI 10.1016/S0531-5565(98)00066-7; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; Sharov VS, 1999, FEBS LETT, V455, P247, DOI 10.1016/S0014-5793(99)00888-1; Silver M, 1979, Methods Enzymol, V62, P135, DOI 10.1016/0076-6879(79)62208-5; Sun HY, 1999, BIOCHEMISTRY-US, V38, P105, DOI 10.1021/bi981295k; Taylor AB, 2003, J BACTERIOL, V185, P4119, DOI 10.1128/JB.185.14.4119-4126.2003; Tete-Favier F, 2000, STRUCTURE, V8, P1167, DOI 10.1016/S0969-2126(00)00526-8	22	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42462	42468		10.1074/jbc.M407464200	http://dx.doi.org/10.1074/jbc.M407464200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15280355	hybrid			2022-12-27	WOS:000224226400017
J	Shen, JS; Prywes, R				Shen, JS; Prywes, R			Dependence of site-2 protease cleavage of ATF6 on prior site-1 protease digestion is determined by the size of the luminal domain of ATF6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; TRANSCRIPTION FACTOR ATF6; ER STRESS; INTRAMEMBRANE PROTEOLYSIS; PROTEINS; GOLGI; SREBP; REQUIREMENTS; TRANSPORT; RELEASE	ATF6 is an endoplasmic reticulum (ER) membrane-anchored transcription factor activated by regulated intramembrane proteolysis in the ER stress response. The release of the cytosolic transcription factor domain of ATF6 requires the sequential processing by the Golgi site-1 and site-2 proteases (S1P and S2P). It has been unclear why S2P proteolysis relies on previous site-1 cleavage. One possibility is that S2P localizes to a different cellular compartment than S1P; however, here we show that S2P localizes to the same compartment as S1P, the cis/medial-Golgi. In addition, we have re-localized S1P and S2P to the ER with brefeldin A and find that the sequential cleavage of ATF6 is reconstituted in the ER. The mapping of the region of ATF6 required for sequential S1P and S2P cleavage showed that short luminal domains resulted in S1P-independent S2P cleavage. The addition of artificial domains onto these short ATF6 luminal domains restored the S1P dependence of S2P cleavage, suggesting that it is the size rather than specific sequences in the luminal domain that determines the S1P dependence of S2P cleavage. These results suggest that the bulky ATF6 luminal domain blocks S2P cleavage and that the role of S1P is to reduce the size of the luminal domain to prepare ATF6 to be an optimal S2P substrate.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prywes, R (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild 813B,MC 2420,1212 Amsterdam Ave, New York, NY 10027 USA.	mrp6@columbia.edu		SHEN, JINGSHI/0000-0001-9595-1148	NCI NIH HHS [CA50329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; GOLDE TE, 2003, SCI STKE; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Kanehara K, 2003, EMBO J, V22, P6389, DOI 10.1093/emboj/cdg602; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Okada T, 2003, J BIOL CHEM, V278, P31024, DOI 10.1074/jbc.M300923200; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Urban S, 2003, MOL CELL, V11, P1425, DOI 10.1016/S1097-2765(03)00181-3; Vanhove M, 2001, IMMUNITY, V15, P105, DOI 10.1016/S1074-7613(01)00163-7; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Ye J, 2000, P NATL ACAD SCI USA, V97, P5123, DOI 10.1073/pnas.97.10.5123; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Zelenski NG, 1999, J BIOL CHEM, V274, P21973, DOI 10.1074/jbc.274.31.21973	26	91	97	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43046	43051		10.1074/jbc.M408466200	http://dx.doi.org/10.1074/jbc.M408466200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15299016	hybrid			2022-12-27	WOS:000224226400087
J	Spatuzza, C; Renna, M; Faraonio, R; Cardinali, G; Martire, G; Bonatti, S; Remondelli, P				Spatuzza, C; Renna, M; Faraonio, R; Cardinali, G; Martire, G; Bonatti, S; Remondelli, P			Heat shock induces preferential translation of ERGIC-53 and affects its recycling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI INTERMEDIATE COMPARTMENT; UNFOLDED PROTEIN RESPONSE; HUMAN CD8 GLYCOPROTEIN; COAGULATION-FACTORS V; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; STRESS-RESPONSE; SECRETORY PATHWAY; LECTIN ERGIC-53; PLASMA-MEMBRANE	ERGIC-53 is a lectin-like transport receptor protein, which recirculates between the ER and the Golgi complex and is required for the intracellular transport of a restricted number of glycoproteins. We show in this article that ERGIC-53 accumulates during the heat shock response. However, at variance with the unfolded protein response, which results in enhanced transcription of ERGIC-53 mRNA, heat shock leads only to enhanced translation of ERGIC-53 mRNA. In addition, the half-life of the protein does not change during heat shock. Therefore, distinct signal pathways of the cell stress response modulate the ERGIC-53 protein level. Heat shock also affects the recycling pathway of ERGIC-53. The protein rapidly redistributes in a more peripheral area of the cell, in a vesicular compartment that has a lighter sedimentation density on sucrose gradient in comparison to the compartment that contains the majority of ERGIC-53 at 37 C. This effect is specific, as no apparent reorganization of the endoplasmic reticulum, intermediate compartment and Golgi complex is morphologically detectable in the cells exposed to heat shock. Moreover, the anterograde transport of two unrelated reporter proteins is not affected. Interestingly, MCFD2, which interacts with ERGIC-53 to form a complex required for the ER-to-Golgi transport of specific proteins, is regulated similarly to ERGIC-53 in response to cell stress. These results support the view that ERGIC-53 alone, or in association with MCFD2, plays important functions during cellular response to stress conditions.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Ist Dermatol S Maria & S Gallicano, I-00144 Rome, Italy; Univ Molise, Dipartimento Sci & Tecnol Ambiente & Terr, I-86170 Isernia, Italy; Univ Salerno, Dipartimento Sci Farmaceut, I-84034 Fisciano Salerno, Italy	University of Naples Federico II; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); University of Molise; University of Salerno	Remondelli, P (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy.	premondelli@unisa.it	Remondelli, Paolo/X-7805-2019; faraonio, raffaella/K-3802-2018; Cardinali, Giorgia/H-1814-2016	Cardinali, Giorgia/0000-0002-7527-9451; REMONDELLI, Paolo/0000-0002-3698-3497; Faraonio, Raffaella/0000-0002-7040-6781				Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; CONWAY EM, 1995, J BIOL CHEM, V270, P17011, DOI 10.1074/jbc.270.28.17011; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Erra MC, 1999, CELL BIOL INT, V23, P571, DOI 10.1006/cbir.1999.0420; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hauri HP, 2000, J CELL SCI, V113, P587; Hauri HP, 2000, FEBS LETT, V476, P32, DOI 10.1016/S0014-5793(00)01665-3; Herrmann JM, 1999, TRENDS CELL BIOL, V9, P5, DOI 10.1016/S0962-8924(98)01414-7; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kim YK, 2002, BIOCHEM BIOPH RES CO, V297, P224, DOI 10.1016/S0006-291X(02)02154-X; Klumperman J, 1998, J CELL SCI, V111, P3411; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Marra P, 2001, NAT CELL BIOL, V3, P1101, DOI 10.1038/ncb1201-1101; MIGLIACCIO G, 1990, EUR J CELL BIOL, V52, P291; Morimoto RI, 1997, ESSAYS BIOCHEM, V32, P17; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Mottola G, 2000, J BIOL CHEM, V275, P24070, DOI 10.1074/jbc.M910400199; Moussalli M, 1999, J BIOL CHEM, V274, P32539, DOI 10.1074/jbc.274.46.32539; NAGAI N, 1995, BIOCHEM BIOPH RES CO, V208, P1099, DOI 10.1006/bbrc.1995.1447; Neerman-Arbez M, 1999, BLOOD, V93, P2253; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Nyfeler B, 2003, BIOCHEM BIOPH RES CO, V304, P599, DOI 10.1016/S0006-291X(03)00634-X; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Santoro MG, 2000, BIOCHEM PHARMACOL, V59, P55, DOI 10.1016/S0006-2952(99)00299-3; SARASTE J, 1991, J CELL SCI, V100, P415; Sarnataro S, 1999, BBA-GENE STRUCT EXPR, V1447, P334, DOI 10.1016/S0167-4781(99)00177-3; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Stornaiuolo M, 2003, MOL BIOL CELL, V14, P889, DOI 10.1091/mbc.E02-08-0468; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Yueh A, 2000, GENE DEV, V14, P414; Zhang B, 2003, NAT GENET, V34, P220, DOI 10.1038/ng1153; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	47	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42535	42544		10.1074/jbc.M401860200	http://dx.doi.org/10.1074/jbc.M401860200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292203	hybrid			2022-12-27	WOS:000224226400025
J	Sun, JJ; Barbieri, JT				Sun, JJ; Barbieri, JT			ExoS Rho GTPase-activating protein activity stimulates reorganization of the actin cytoskeleton through rho GTPase guanine nucleotide disassociation inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; AERUGINOSA EXOENZYME S; PSEUDOMONAS-AERUGINOSA; BINDING PROTEIN; INTRACELLULAR-LOCALIZATION; CDC42 GTPASES; IN-VIVO; RAC; DOMAIN; CELLS	ExoS is a bifunctional Type III cytotoxin of Pseudomonas aeruginosa with N-terminal Rho GTPase-activating protein ( RhoGAP) and C-terminal ADP-ribosyltransferase domains. Although the ExoS RhoGAP inactivates Cdc42, Rac, and RhoA in vivo, the relationship between ExoS RhoGAP and the eukaryotic regulators of Rho GTPases is not clear. The present study investigated the roles of Rho GTPase guanine nucleotide disassociation inhibitor ( RhoGDI) in the reorganization of actin cytoskeleton mediated by ExoS RhoGAP. A green fluorescent protein-RhoGDI fusion protein was engineered and found to elicit actin reorganization through the inactivation of Rho GTPases. Green fluorescent protein-RhoGDI and ExoS RhoGAP cooperatively stimulated actin reorganization and translocation of Cdc42 from membrane to cytosol, and a RhoGDI mutant, RhoGDI( I177D), that is defective in extracting Rho GTPases off the membrane inhibited the actions of RhoGDI and ExoS RhoGAP on the translocation of Cdc42 from membrane to cytosol. A human RhoGDI small interfering RNA was transfected into HeLa cells to knock down 90% of the endogenous RhoGDI expression. HeLa cells with knockdown RhoGDI were resistant to the reorganization of the actin cytoskeleton elicited by type III-delivered ExoS RhoGAP. This indicates that ExoS RhoGAP and RhoGDI function in series to inactivate Rho GTPases, in which RhoGDI extracting GDP-bound Rho GTPases off the membrane and sequestering them in cytosol is the rate-limiting step in Rho GTPase inactivation. A eukaryotic GTPase-activating protein, p50RhoGAP, showed a similar cooperativity with RhoGDI on actin reorganization, suggesting that ExoS RhoGAP functions as a molecular mimic of eukaryotic RhoGAPs to inactivate Rho GTPases through RhoGDI.	Med Coll Wisconsin, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Barbieri, JT (corresponding author), Med Coll Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jtb01@mcw.edu	Sun, Jianjun/B-1525-2009		NIAID NIH HHS [AI-030162] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030162] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; Aepfelbacher M, 2003, J BIOL CHEM, V278, P33217, DOI 10.1074/jbc.M303349200; Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; Andor A, 2001, CELL MICROBIOL, V3, P301, DOI 10.1046/j.1462-5822.2001.00114.x; Barbieri JT, 2002, ANNU REV CELL DEV BI, V18, P315, DOI 10.1146/annurev.cellbio.18.012502.134748; Barbieri JT, 2000, INT J MED MICROBIOL, V290, P381; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Black DS, 2000, MOL MICROBIOL, V37, P515, DOI 10.1046/j.1365-2958.2000.02021.x; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CHUANG TH, 1993, J BIOL CHEM, V268, P775; Faure J, 2001, BIOCHIMIE, V83, P409, DOI 10.1016/S0300-9084(01)01263-9; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Genth H, 1999, J BIOL CHEM, V274, P29050, DOI 10.1074/jbc.274.41.29050; Genth H, 2003, J BIOL CHEM, V278, P28523, DOI 10.1074/jbc.M301915200; Giamarellou H, 2000, INT J ANTIMICROB AG, V16, P103, DOI 10.1016/S0924-8579(00)00212-0; Goehring UM, 1999, J BIOL CHEM, V274, P36369, DOI 10.1074/jbc.274.51.36369; Golovanov AP, 2001, EUR J BIOCHEM, V268, P2253, DOI 10.1046/j.1432-1327.2001.02100.x; Goranson J, 1997, J BACTERIOL, V179, P1646, DOI 10.1128/jb.179.5.1646-1654.1997; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Krall R, 2002, INFECT IMMUN, V70, P360, DOI 10.1128/IAI.70.1.360-367.2002; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEFFERS H, 1993, EXP CELL RES, V209, P165, DOI 10.1006/excr.1993.1298; LEONARD D, 1992, J BIOL CHEM, V267, P22860; Lian LY, 2000, STRUCT FOLD DES, V8, P47, DOI 10.1016/S0969-2126(00)00080-0; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MIURA Y, 1993, J BIOL CHEM, V268, P510; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Nomanbhoy TK, 1999, BIOCHEMISTRY-US, V38, P1744, DOI 10.1021/bi982198u; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; Pederson KJ, 1998, MOL MICROBIOL, V30, P751, DOI 10.1046/j.1365-2958.1998.01106.x; Pederson KJ, 2002, MOL MICROBIOL, V46, P1381, DOI 10.1046/j.1365-2958.2002.03256.x; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; SASAKI T, 1993, J BIOL CHEM, V268, P23959; Shao F, 2003, P NATL ACAD SCI USA, V100, P904, DOI 10.1073/pnas.252770599; Sivars U, 2003, NATURE, V425, P856, DOI 10.1038/nature02057; Wurtele M, 2001, FEBS LETT, V491, P26, DOI 10.1016/S0014-5793(01)02105-6; Wurtele M, 2001, NAT STRUCT BIOL, V8, P23; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045	52	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42936	42944		10.1074/jbc.M406493200	http://dx.doi.org/10.1074/jbc.M406493200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292224	hybrid			2022-12-27	WOS:000224226400073
J	Perrier, E; Perrier, R; Richard, S; Benitah, JP				Perrier, E; Perrier, R; Richard, S; Benitah, JP			Ca2+ controls functional expression of the cardiac K+ transient outward current via the calcineurin pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL GENE-EXPRESSION; KINASE-II; INTRACELLULAR CALCIUM; CURRENT-DENSITY; CALMODULIN; MYOCYTES; HYPERTROPHY; MODULATION; KV4.2; OVEREXPRESSION	The transient outward K+ current (I-to) modulates transmembrane Ca2+ influx into cardiomyocytes, which, in turn, might act on I-to. Here, we investigated whether Ca2+ modifies functional expression of Ito. Whole-cell I-to were recorded using the patch clamp technique in single right ventricular myocytes isolated from adult rats and incubated for 24 h at 37 degreesC in a serum-free medium containing various Ca2+ concentrations ([Ca2+](o)). Increasing the [Ca2+](o) from 0.5 to 1.0 and 2.5 mM produced a gradual decrease in I-to density without change in current kinetics. Quantitative reverse transcriptase-PCR showed that a decrease of the Kv4.2 mRNA could account for this decrease. In the acetoxymethyl ester form of 1,2-bis(2-aminophenoxy)ethane-N, N,N',N'-tetraacetic acid (BAPTA-AM)-loaded myocytes (a permeant Ca2+ chelator), I-to density increased significantly when cells were exposed for 24 h to either 1 or 2.5 mM [Ca2+](o). Moreover, 24-h exposure to the Ca2+ channel agonist, Bay K8644, in 1 mM [Ca2+](o) induced a decrease in Ito density, whereas the Ca2+ channel antagonist, nifedipine, blunted I-to decrease in 2.5 mM [Ca2+](o). The decrease of Ito in 2.5 mM [Ca2+](o) was also prevented by co-incubation with either the calmodulin inhibitor W7 or the calcineurin inhibitors FK506 or cyclosporin A. Furthermore, in myocytes incubated for 24 h with 2.5 mM [Ca2+](o), calcineurin activity was significantly increased compared with 1 mM [Ca2+](o). Our data suggest that modulation of [Ca2+](i) via L-type Ca2+ channels, which appears to involve the Ca2+/calmodulin-regulated protein phosphatase calcineurin, down-regulates the functional expression of I-to. This effect might be involved in many physiological and pathological modulations of I-to channel expression in cardiac cells, as well other cell types.	CHU A de Vlleneuve, INSERM, U637, F-34295 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Benitah, JP (corresponding author), CHU A de Vlleneuve, INSERM, U637, F-34295 Montpellier, France.	benitah@montp.inserm.fr	Benitah, Jean-Pierre/L-6060-2018; Richard, Sylvain/C-9695-2016	Benitah, Jean-Pierre/0000-0002-9866-9081; Richard, Sylvain/0000-0001-9460-6705; Perrier, Romain/0000-0003-2229-4700				Armoundas AA, 2001, PHARMACOL THERAPEUT, V92, P213, DOI 10.1016/S0163-7258(01)00171-1; BARRY WH, 1993, CIRCULATION, V87, P1806, DOI 10.1161/01.CIR.87.6.1806; Bassel-Duby R, 2003, BIOCHEM BIOPH RES CO, V311, P1133, DOI 10.1016/j.bbrc.2003.09.020; BENITAH JP, 1993, J PHYSIOL-LONDON, V469, P111, DOI 10.1113/jphysiol.1993.sp019807; Benitah JP, 2003, J MUSCLE RES CELL M, V24, P275; Benitah JP, 2001, J PHYSIOL-LONDON, V537, P151, DOI 10.1111/j.1469-7793.2001.0151k.x; CHIAMVIMONVAT N, 1995, J PHYSIOL-LONDON, V483, P307, DOI 10.1113/jphysiol.1995.sp020587; Chien KR, 2000, J CLIN INVEST, V105, P1339, DOI 10.1172/JCI10079; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Davidoff AJ, 1997, J MOL CELL CARDIOL, V29, P1791, DOI 10.1006/jmcc.1997.0406; Deng LL, 2001, J CARDIOVASC ELECTR, V12, P1055, DOI 10.1046/j.1540-8167.2001.01055.x; DOLMETSCH R, 2003, SCI STKE; Dong D, 2003, CARDIOVASC RES, V57, P320, DOI 10.1016/S0008-6363(02)00661-2; duBell WH, 1998, AM J PHYSIOL-HEART C, V275, pH2041, DOI 10.1152/ajpheart.1998.275.6.H2041; DUKES ID, 1991, J PHYSIOL-LONDON, V435, P395, DOI 10.1113/jphysiol.1991.sp018516; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Guia A, 2001, BIOPHYS J, V80, P2742, DOI 10.1016/S0006-3495(01)76242-X; Guo WN, 1997, CARDIOVASC RES, V33, P139, DOI 10.1016/S0008-6363(96)00191-5; Guo WN, 2002, J BIOL CHEM, V277, P26436, DOI 10.1074/jbc.M201431200; Harrison DC, 2000, MOL BRAIN RES, V75, P143, DOI 10.1016/S0169-328X(99)00305-8; Hidaka H, 1996, Adv Pharmacol, V36, P193, DOI 10.1016/S1054-3589(08)60583-9; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; Le Bouter S, 2003, CIRC RES, V92, P234, DOI 10.1161/01.RES.0000053185.75505.8E; Levitan ES, 1998, J NEUROBIOL, V37, P60, DOI 10.1002/(SICI)1097-4695(199810)37:1<60::AID-NEU5>3.0.CO;2-6; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Maier LS, 2002, J MOL CELL CARDIOL, V34, P919, DOI 10.1006/jmcc.2002.2038; MATSUBARA H, 1993, J CLIN INVEST, V92, P1659, DOI 10.1172/JCI116751; McKinsey TA, 1999, CURR OPIN GENET DEV, V9, P267, DOI 10.1016/S0959-437X(99)80040-9; Nerbonne JM, 2001, CIRC RES, V89, P944, DOI 10.1161/hh2301.100349; Nerbonne JM, 2000, J PHYSIOL-LONDON, V525, P285, DOI 10.1111/j.1469-7793.2000.t01-1-00285.x; Oudit GY, 2001, J MOL CELL CARDIOL, V33, P851, DOI 10.1006/jmcc.2001.1376; Patel SP, 2002, J PHYSIOL-LONDON, V545, P5, DOI 10.1113/jphysiol.2002.031856; Petrashevskaya NN, 2002, CARDIOVASC RES, V54, P117, DOI 10.1016/S0008-6363(02)00241-9; Sah R, 2002, CIRC RES, V90, P165, DOI 10.1161/hh0202.103315; Shimoni Y, 2003, AM J PHYSIOL-HEART C, V284, pH1168, DOI 10.1152/ajpheart.00748.2002; Sugden PH, 2002, J CARD FAIL, V8, pS359, DOI 10.1054/jcaf.2002.129282; Suzuki YJ, 1999, CELL CALCIUM, V25, P191, DOI 10.1054/ceca.1998.0019; Tessier S, 1999, CIRC RES, V85, P810, DOI 10.1161/01.RES.85.9.810; Tkatch T, 2000, J NEUROSCI, V20, P579, DOI 10.1523/JNEUROSCI.20-02-00579.2000; Varga AW, 2004, J NEUROSCI, V24, P3643, DOI 10.1523/JNEUROSCI.0154-04.2004; Wickenden AD, 1997, J PHYSIOL-LONDON, V504, P271, DOI 10.1111/j.1469-7793.1997.271be.x; Wilkins BJ, 2002, J PHYSIOL-LONDON, V541, P1, DOI 10.1113/jphysiol.2002.017129; YUE DT, 1990, J GEN PHYSIOL, V95, P911, DOI 10.1085/jgp.95.5.911; Zobel C, 2002, CIRCULATION, V106, P2385, DOI 10.1161/01.CIR.0000033970.22130.93	44	41	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40634	40639		10.1074/jbc.M407470200	http://dx.doi.org/10.1074/jbc.M407470200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15280354	hybrid			2022-12-27	WOS:000223916800052
J	Salnikow, K; Donald, SP; Bruick, RK; Zhitkovich, A; Phang, JM; Kasprzak, KS				Salnikow, K; Donald, SP; Bruick, RK; Zhitkovich, A; Phang, JM; Kasprzak, KS			Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-C; INDUCIBLE FACTOR; ERYTHROPOIETIN GENE; HIF-ALPHA; OXYGEN; ACID; TRANSPORT; FAMILY; 2-OXOGLUTARATE; TRANSFORMATION	Exposure of cells to carcinogenic compounds of nickel( II) and cobalt( II) causes activation of the HIF-1 transcription factor and up-regulates a battery of hypoxia-inducible genes. However, the mechanism of HIF-1 activation by these metals is not known. It was shown recently that hydroxylation of prolines in the HIFalpha subunit of HIF-1 is required for its binding with the von Hippel-Lindau tumor suppressor protein and the subsequent proteasomal destruction. Here we show that responsible prolyl hydroxylases are targets for both nickel( II) and cobalt( II) because degradation of a reporter protein containing the oxygen-dependent degradation domain (Pro-402/564) of HIFalpha was abolished in a von Hippel-Lindau-dependent manner in cells exposed to nickel( II) or cobalt( II). The enzymatic activity of prolyl hydroxylases depends on iron as the activating metal, 2-oxoglutarate as a co-substrate, and ascorbic acid as a cofactor. Hydroxylase activity can be impaired by the depletion of any of these factors. We found that exposure of cells to nickel( II) or cobalt( II) did not affect the level of intracellular iron. Instead, nickel( II) or cobalt( II) exposure greatly depleted intracellular ascorbate. Co-exposure of cells to metals and ascorbate resulted in the increase of intracellular ascorbate and reversed both metal-induced stabilization of HIF-1alpha and HIF-1-dependent gene transcription. Because ascorbate is essential for maintaining iron in prolyl hydroxylases in the active iron( II) state, we suggest that the observed depletion of ascorbate by nickel( II) or cobalt( II) favors iron oxidation and thus inactivation of the enzyme.	NCI, NIH, Frederick, MD 21702 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Brown Univ, Dept Pathol & Lab Med, Providence, RI 02912 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Brown University	Salnikow, K (corresponding author), NCI, NIH, Bldg 538,Rm 205 E, Frederick, MD 21702 USA.	salnikow@ncifcrf.gov			NIEHS NIH HHS [R01 ES008786, ES008786] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC000157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008786] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Acker T, 2002, J MOL MED-JMM, V80, P562, DOI 10.1007/s00109-002-0355-1; BENNETT BG, 1994, IARC SCI PUBL, V53, P487; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; DEJONG L, 1982, BIOCHIM BIOPHYS ACTA, V704, P326, DOI 10.1016/0167-4838(82)90162-5; Deutsch JC, 1998, ANAL BIOCHEM, V265, P238, DOI 10.1006/abio.1998.2940; Deutsch JC, 1998, ANAL BIOCHEM, V260, P223, DOI 10.1006/abio.1998.2700; DOLL R, 1990, SCAND J WORK ENV HEA, V16, P1; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FRIDMAN YD, 1979, ZH NEORG KHIM+, V24, P3325; FRIDMAN YD, 1981, ZH NEORG KHIM+, V26, P2443; Gavett SH, 1997, ENVIRON RES, V72, P162, DOI 10.1006/enrs.1997.3732; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOLDENBERG H, 1994, J BIOENERG BIOMEMBR, V26, P359, DOI 10.1007/BF00762776; GRUENERT DC, 1995, AM J PHYSIOL-LUNG C, V268, pL347, DOI 10.1152/ajplung.1995.268.3.L347; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HELBIG H, 1989, AM J PHYSIOL, V256, pC44, DOI 10.1152/ajpcell.1989.256.1.C44; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Huang LE, 1997, KIDNEY INT, V51, P548, DOI 10.1038/ki.1997.76; INT AGCY RES CANC, 1990, IARC MONOG EVAL CARC, V49, P257; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kasprzak KS, 2003, MUTAT RES-FUND MOL M, V533, P67, DOI 10.1016/j.mrfmmm.2003.08.021; KAULE G, 1990, ANAL BIOCHEM, V184, P291, DOI 10.1016/0003-2697(90)90683-Z; Kelleher P, 2000, ENVIRON HEALTH PERSP, V108, P685, DOI 10.2307/3454405; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; Knowles HJ, 2003, CANCER RES, V63, P1764; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; MAJAMAA K, 1986, J BIOL CHEM, V261, P7819; Martin R. B., 1986, MET IONS BIOL SYST, V20, P21; Maxwell P, 2004, CANCER BIOL THER, V3, P29, DOI 10.4161/cbt.3.1.547; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; National Toxicology Program, 1998, Natl Toxicol Program Tech Rep Ser, V471, P1; Nualart FJ, 2003, J BIOL CHEM, V278, P10128, DOI 10.1074/jbc.M210686200; Padayatty SJ, 2003, J AM COLL NUTR, V22, P18, DOI 10.1080/07315724.2003.10719272; Prescott AG, 2000, NAT PROD REP, V17, P367, DOI 10.1039/a902197c; PUPLIKOVA ON, 1967, ZH FIZ KHIM, V41, P1204; Quievryn G, 2002, BIOCHEMISTRY-US, V41, P3156, DOI 10.1021/bi011942z; ROSE RC, 1988, BIOCHIM BIOPHYS ACTA, V947, P335, DOI 10.1016/0304-4157(88)90014-7; Salnikow K, 2003, CANCER RES, V63, P3524; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; Salnikow K, 2004, TOXICOL APPL PHARM, V196, P258, DOI 10.1016/j.taap.2004.01.003; Salnikow K, 2002, ENVIRON HEALTH PERSP, V110, P831, DOI 10.1289/ehp.02110s5831; Salnikow K, 1999, CARCINOGENESIS, V20, P1819, DOI 10.1093/carcin/20.9.1819; Salnikow K, 2000, CANCER RES, V60, P38; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Takanaga H, 2004, PFLUG ARCH EUR J PHY, V447, P677, DOI 10.1007/s00424-003-1104-1; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WELCH RW, 1993, BIOCHEM J, V294, P505, DOI 10.1042/bj2940505	49	247	263	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40337	40344		10.1074/jbc.M403057200	http://dx.doi.org/10.1074/jbc.M403057200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15271983	hybrid			2022-12-27	WOS:000223916800015
J	Shapiro, MJ; Powell, P; Ndubuizu, A; Nzerem, C; Shapiro, VS				Shapiro, MJ; Powell, P; Ndubuizu, A; Nzerem, C; Shapiro, VS			The ALX Src homology 2 domain is both necessary and sufficient to inhibit T cell receptor/CD28-mediated up-regulation of RE/AP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; GROWTH-FACTOR; SH2 DOMAIN; IL-2 GENE; BINDING; RECEPTOR; REQUIREMENT; ACTIVATION; CLONING; TSAD	Activation of naive T cells occurs when two signals are received. The first signal is received through the T cell antigen receptor (TCR), and a second costimulatory signal is primarily provided by CD28. We have recently identified a novel adaptor molecule, ALX, which is expressed exclusively in hematopoietic cells. ALX contains several sites for potential protein-protein interaction, including an Src homology 2 (SH2) domain, four PXXP polyproline sequences, and two likely sites of tyrosine phosphorylation. Overexpression of ALX inhibits the transcriptional activation of the interleukin 2 promoter during T cell activation, specifically affecting CD28-mediated activation of the RE/AP element of the interleukin 2 promoter. To understand how ALX functions downstream of CD28, we generated a panel of site-directed mutants as well as truncations in which potential protein-binding sites were mutated or absent. We found that the ALX SH2 domain is both necessary and sufficient to mediate inhibition of RE/AP activation. Mutation of the SH2 domain did not affect ALX expression, relative localization in the cytoplasm and nucleus, phosphorylation, or a mobility shift in response to TCR signaling alone. However, an activation-induced mobility shift triggered by CD28 was reduced in the ALX SH2 domain mutant. In addition, the isolated ALX SH2 domain was found to associate with a phosphoprotein from Jurkat T cells on TCR/CD28 stimulation. Therefore, the ALX SH2 domain plays a critical role in ALX function downstream of CD28.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Shapiro, VS (corresponding author), Univ Penn, Dept Pathol & Lab Med, 288 John Morgan Bldg,3620 Hmilton Walk, Philadelphia, PA 19104 USA.	shapirov@mail.med.upenn.edu						Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; Choi YB, 1999, J IMMUNOL, V163, P5242; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Drappa J, 2003, J EXP MED, V198, P809, DOI 10.1084/jem.20021358; Greene TA, 2003, J BIOL CHEM, V278, P45128, DOI 10.1074/jbc.M306283200; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Latour S, 2003, NAT CELL BIOL, V5, P149, DOI 10.1038/ncb919; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; Marti F, 2001, J EXP MED, V193, P1425, DOI 10.1084/jem.193.12.1425; Mustelin T, 2002, FRONT BIOSCI-LANDMRK, V7, pD918, DOI 10.2741/musteli1; Rajagopal K, 1999, J EXP MED, V190, P1657, DOI 10.1084/jem.190.11.1657; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shapiro VS, 1998, J IMMUNOL, V161, P6455; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; Spurkland A, 1998, J BIOL CHEM, V273, P4539, DOI 10.1074/jbc.273.8.4539; Sun WY, 2003, MOL CELL BIOL, V23, P2298, DOI 10.1128/MCB.23.7.2298-2308.2003; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; UMLAUF SW, 1993, IMMUNOL REV, V133, P177, DOI 10.1111/j.1600-065X.1993.tb01516.x; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059	23	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40647	40652		10.1074/jbc.M404198200	http://dx.doi.org/10.1074/jbc.M404198200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15284240	hybrid			2022-12-27	WOS:000223916800054
J	Xiong, JP; Stehle, T; Goodman, SL; Arnaout, MA				Xiong, JP; Stehle, T; Goodman, SL; Arnaout, MA			A novel adaptation of the integrin PSI domain revealed from its crystal structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR SEGMENT; RISK-FACTOR; POLYMORPHISM; SUBUNIT; COMPLEX; GPIIIA; LIGAND; ALPHA-V-BETA-3; ACTIVATION; RECEPTOR	Integrin beta-subunits contain an N-terminal PSI (for plexin-semaphorin-integrin) domain that contributes to integrin activation and harbors the PI(A) alloantigen associated with immune thrombocytopenias and susceptibility to sudden cardiac death. Here we report the crystal structure of PSI in the context of the crystallized alpha(V)beta(3) ectodomain. The integrin PSI forms a two-stranded antiparallel beta-sheet flanked by two short helices; its long interstrand loop houses Pl(A) and may face the EGF2 domain. The integrin PSI contains four cysteine pairs connected in a 1-4, 2-8, 3-6, 5-7 pattern. An unexpected feature of the structure is that the final, eighth cysteine is located C-terminal to the Ig-like hybrid domain and is thus separated by the hybrid domain from the other seven cysteines of PSI. This architecture may be relevant to the evolution of integrins and should help refine the current models of integrin activation.	Massachusetts Gen Hosp, Renal Unit, Leukocyte Biol & Inflammat Program, Struct Biol Program, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Lab Dev Immunol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Merck KGaA, Oncol Res, D-64271 Darmstadt, Germany	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Merck KGaA	Arnaout, MA (corresponding author), Massachusetts Gen Hosp, Renal Unit, Leukocyte Biol & Inflammat Program, Struct Biol Program, 149 13th St, Charlestown, MA 02129 USA.	arnaout@receptor.mgh.harvard.edu		Goodman, Simon L./0000-0002-3480-1346	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048549] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL70219] Funding Source: Medline; NIDDK NIH HHS [DK48549] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnaout MA, 2002, IMMUNOL REV, V186, P125, DOI 10.1034/j.1600-065X.2002.18612.x; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; Brunger AT, 2002, ACCOUNTS CHEM RES, V35, P404, DOI 10.1021/ar010034r; Bussel James B., 2000, Hematology Am Soc Hematol Educ Program, P222; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, STRUCTURE, V2, P1241, DOI 10.1016/S0969-2126(94)00125-1; Love CA, 2003, NAT STRUCT BIOL, V10, P843, DOI 10.1038/nsb977; Peterson JA, 2003, BLOOD, V101, P937, DOI 10.1182/blood-2002-07-2336; Salido E, 1999, J AM SOC NEPHROL, V10, P2599; Stamos J, 2004, EMBO J, V23, P2325, DOI 10.1038/sj.emboj.7600243; Sun QH, 2002, BLOOD, V100, P2094, DOI 10.1182/blood-2002-02-0418; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Undas A, 2001, CIRCULATION, V104, P2666, DOI 10.1161/hc4701.099787; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2003, BLOOD, V102, P1155, DOI 10.1182/blood-2003-01-0334; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Zang Q, 2001, J BIOL CHEM, V276, P6922, DOI 10.1074/jbc.M005868200	21	79	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40252	40254		10.1074/jbc.C400362200	http://dx.doi.org/10.1074/jbc.C400362200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15299032	hybrid			2022-12-27	WOS:000223916800002
J	Wang, J; Sergina, N; Ko, TC; Gong, JG; Brattain, MG				Wang, J; Sergina, N; Ko, TC; Gong, JG; Brattain, MG			Autocrine and exogenous transforming growth factor beta control cell cycle inhibition through pathways with different sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA CELLS; DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR ACTIVITY; TGF-BETA; CDK INHIBITOR; CANCER CELLS; I RECEPTOR; MICROSATELLITE INSTABILITY; G1 PHASE; ARREST	Human colon carcinoma cells HCT116 that lack transforming growth factor beta (TGF-beta) type II receptor (RII) demonstrated restoration of autocrine TGF-beta activity upon reexpression of RII without restoring inhibitory responses to exogenous TGF-beta treatment. RII transfectants (designated RII Cl 37) had a longer lag phase relative to NEO-transfected control cells (designated NEO pool) before entering exponential growth in tissue culture. The prolonged growth arrest of RII Cl 37 cells was associated with markedly reduced cyclin-dependent kinase (CDK) 2 activity. Our results demonstrate that p21 induction by autocrine TGF-beta is responsible for reduced CDK2 activity, which at least partially contributes to prolonged growth arrest and reduced cell proliferation in RII Cl 37 cells. In contrast to RII transfectants, HCT116 cells transfected with chromosome 3 (designated HCT116Ch3), which bears the RII gene, restored the response to exogenous TGF-beta as well as autocrine TGF-beta activity. Autocrine TGF-beta activity in HCT116Ch3 cells induced p21 expression as seen in RII Cl 37 cells; however, in addition to autocrine activity, HCT116Ch3 cells responded to exogenous TGF-beta as decreased CDK4 expression and reduced pRb phosphorylation mediated a TGF-beta inhibitory response in these cells. These results indicate that autocrine TGF-beta regulates the cell cycle through a pathway different from exogenous TGF-beta in the sense that p21 is a more sensitive effector of the TGF-beta signaling pathway, which can be induced and saturated by autocrine TGF-beta, whereas CDK4 inhibition is a less sensitive effector, which can only be activated by high levels of exogenous TGF-beta.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14226 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA	Roswell Park Cancer Institute; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Medical Branch Galveston	Brattain, MG (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, GCDC Elm & Carlton St, Buffalo, NY 14226 USA.	michael.brattain@roswellpark.org			NATIONAL CANCER INSTITUTE [R01CA050457, R01CA038173, R37CA038173] Funding Source: NIH RePORTER; NCI NIH HHS [CA50457, CA38173] Funding Source: Medline; PHS HHS [16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOYD DD, 1988, CANCER RES, V48, P2469; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN YQ, 1995, CANCER RES, V55, P4536; DALY MC, 1993, ONCOGENE, V8, P1721; Dasgupta S, 2002, ORAL ONCOL, V38, P6, DOI 10.1016/S1368-8375(00)00131-7; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Iavarone A, 1997, NATURE, V387, P417; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KO TC, 1995, ONCOGENE, V10, P177; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOI M, 1994, CANCER RES, V54, P4308; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Miyafuji Y, 2001, J CELL PHYSIOL, V187, P356, DOI 10.1002/jcp.1084; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; Schoecklmann HO, 1997, KIDNEY INT, V51, P1228, DOI 10.1038/ki.1997.168; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yoo YD, 1999, INT J CANCER, V83, P512, DOI 10.1002/(SICI)1097-0215(19991112)83:4<512::AID-IJC13>3.0.CO;2-Z; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	67	21	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40237	40244		10.1074/jbc.M401665200	http://dx.doi.org/10.1074/jbc.M401665200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15271980	hybrid			2022-12-27	WOS:000223791500123
J	Tanimura, A; Nezu, A; Morita, T; Turner, RJ; Tojyo, Y				Tanimura, A; Nezu, A; Morita, T; Turner, RJ; Tojyo, Y			Fluorescent biosensor for quantitative real-time measurements of inositol 1,4,5-trisphosphate in single living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITE; CALCIUM-RELEASE; RECEPTOR; CA2+; PROTEIN; TRISPHOSPHATE; VISUALIZATION; TRANSDUCTION; INDICATORS; MECHANISM	The second messenger inositol 1,4,5-trisphosphate (IP3) plays a central role in the generation of a variety of spatiotemporally complex intracellular Ca2+ signals involved in the regulation of many essential physiological processes. Here we describe the development of "LIBRA", a novel ratiometric fluorescent IP3 biosensor that allows for the quantitative monitoring of intracellular IP3 concentrations in single living cells in real time. LIBRA consists of the IP3-binding domain of the rat type 3 IP3 receptor fused between the fluorescence resonance energy transfer pair cyan fluorescent protein and yellow fluorescent protein and preceded by a membrane-targeting signal. We show that the LIBRA fluorescent signal is highly selective for IP3 and unaffected by concentrations of Ca2+ and ATP in the physiological range. In addition, LIBRA can be calibrated in situ. We demonstrate the utility of LIBRA by monitoring the temporal relationship between the responses intracellular IP3 and Ca2+ concentrations in SH-SY5Y cells following acetylcholine stimulation.	Hlth Sci Univ Hokkaido, Sch Dent, Dept Dent Pharmacol, Ishikari, Hokkaido 0610293, Japan; NIDCR, Membrane Biol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA	Health Sciences University of Hokkaido; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Tanimura, A (corresponding author), Hlth Sci Univ Hokkaido, Sch Dent, Dept Dent Pharmacol, Ishikari, Hokkaido 0610293, Japan.	tanimura@hoku-iryo-u.ac.jp			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000415, ZIADE000415] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; Miyakawa T, 2001, EMBO J, V20, P1674, DOI 10.1093/emboj/20.7.1674; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Miyawaki A, 2003, DEV CELL, V4, P295, DOI 10.1016/S1534-5807(03)00060-1; Morita T, 2002, CELL CALCIUM, V31, P59, DOI 10.1054/ceca.2001.0262; MUALLEM S, 1989, J BIOL CHEM, V264, P205; Nash MS, 2001, NATURE, V413, P381, DOI 10.1038/35096643; PARKER I, 1992, AM J PHYSIOL, V263, pC154, DOI 10.1152/ajpcell.1992.263.1.C154; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Shin DM, 2003, J CELL BIOL, V162, P293, DOI 10.1083/jcb.200210109; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; TAKAHASHI M, 1994, J BIOL CHEM, V269, P369; Tanimura A, 1996, J CELL BIOL, V132, P607, DOI 10.1083/jcb.132.4.607; Tanimura A, 1996, J BIOL CHEM, V271, P30904, DOI 10.1074/jbc.271.48.30904; Taylor CW, 2001, CURR BIOL, V11, pR352, DOI 10.1016/S0960-9822(01)00192-0; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Xu C, 2003, J CELL BIOL, V161, P779, DOI 10.1083/jcb.200301070; Yoshikawa F, 1999, BIOCHEM BIOPH RES CO, V257, P792, DOI 10.1006/bbrc.1999.0498	30	86	93	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38095	38098		10.1074/jbc.C400312200	http://dx.doi.org/10.1074/jbc.C400312200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15272011	hybrid			2022-12-27	WOS:000223684100005
J	Ikehara, Y; Ikehara, SK; Paulson, JC				Ikehara, Y; Ikehara, SK; Paulson, JC			Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; MYELIN-ASSOCIATED GLYCOPROTEIN; NATURAL-KILLER-CELLS; IMMUNOGLOBULIN SUPERFAMILY; INHIBITORY RECEPTOR; AXONAL REGENERATION; BINDING; EXPRESSION; IDENTIFICATION; SIALOADHESIN	Siglec-7 (p70/AIRM) and Siglec-9 are "CD33"-related siglecs expressed on natural killer (NK) cells and subsets of peripheral T cells. Like other inhibitory NK cell receptors, they contain immunoglobulin receptor family tyrosine-based inhibitory motifs in their cytoplasmic domains, and Siglec-7 has been demonstrated to negatively regulate NK cell activation. Based on reports of the presence of these siglecs on T cells, we sought to determine if they are capable of modulating T cell receptor (TCR) signaling using Jurkat T cells stably and transiently transfected with Siglec-7 or Siglec-9. Following either pervanadate stimulation or TCR engagement, both Siglecs exhibited increased tyrosine phosphorylation and recruitment of SHP-1. Effects of Siglec-7 and -9 were also evident in downstream events in the signaling pathway. Both siglecs reduced phosphorylation of Tyr(319) on ZAP-70, known to play a pivotal role in up-regulation of gene transcription following TCR stimulation. There was also a corresponding decreased transcriptional activity of nuclear factor of activated T cells ( NFAT) as determined using a luciferase reporter gene. Like all siglecs, Siglec-7 and -9 recognize sialic acid-containing glycans of glycoproteins and glycolipids as ligands. Mutation of the conserved Arg in the ligand binding site of Siglec-7 (Arg(124)) or Siglec-9 (Arg(120)) resulted in reduced inhibitory function in the NFAT/luciferase transcription assay, suggesting that ligand binding is required for optimal inhibition of TCR signaling. The combined results demonstrate that both Siglec-7 and Siglec-9 are capable of negative regulation of TCR signaling and that ligand binding is required for optimal activity.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Paulson, JC (corresponding author), Scripps Res Inst, Dept Mol Biol, Mail Drop MEM L71,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jpaulson@scripps.edu	Paulson, James/AAG-3565-2019; Ikehara, yuzuru/L-7696-2018; Ikehara, yuzuru/R-2239-2019; Ikehara, Sanae/N-3622-2018	Ikehara, yuzuru/0000-0002-1915-9172; Ikehara, yuzuru/0000-0002-1915-9172; Ikehara, Sanae/0000-0001-7123-4777	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050143] Funding Source: NIH RePORTER; NIAID NIH HHS [AI050143, R01 AI050143] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alphey MS, 2003, J BIOL CHEM, V278, P3372, DOI 10.1074/jbc.M210602200; Angata T, 2000, J BIOL CHEM, V275, P22127, DOI 10.1074/jbc.M002775200; Angata T, 2000, GLYCOBIOLOGY, V10, P431, DOI 10.1093/glycob/10.4.431; Angata T, 2002, BBA-GEN SUBJECTS, V1572, P294, DOI 10.1016/S0304-4165(02)00316-1; Battistini L, 1997, J IMMUNOL, V159, P3723; Blixt O, 2003, J BIOL CHEM, V278, P31007, DOI 10.1074/jbc.M304331200; Braud VM, 2003, TRENDS IMMUNOL, V24, P162, DOI 10.1016/S1471-4906(03)00064-4; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; Cornall RJ, 1999, CURR TOP MICROBIOL, V244, P57; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; Dietrich J, 2001, J IMMUNOL, V166, P2514, DOI 10.4049/jimmunol.166.4.2514; Erickson-Miller CL, 2003, EXP HEMATOL, V31, P382, DOI 10.1016/S0301-472X(03)00046-8; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Farag SS, 2002, BLOOD, V100, P1935, DOI 10.1182/blood-2002-02-0350; FERRINI S, 1994, EUR J IMMUNOL, V24, P2294, DOI 10.1002/eji.1830241005; FILBIN MT, 1995, CURR OPIN NEUROBIOL, V5, P588, DOI 10.1016/0959-4388(95)80063-8; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Gong Q, 2001, J EXP MED, V194, P507, DOI 10.1084/jem.194.4.507; Ito A, 2001, FEBS LETT, V498, P116, DOI 10.1016/S0014-5793(01)02476-0; Jin L, 2002, J EXP MED, V195, P1199, DOI 10.1084/jem.20011796; Kelm S, 2002, J EXP MED, V195, P1207, DOI 10.1084/jem.20011783; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Magnan A, 2001, J EXP MED, V194, P491, DOI 10.1084/jem.194.4.491; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; McQueen KL, 2002, CURR OPIN IMMUNOL, V14, P615, DOI 10.1016/S0952-7915(02)00380-1; MINGARI MC, 1995, INT IMMUNOL, V7, P697, DOI 10.1093/intimm/7.4.697; Mingari MC, 1996, P NATL ACAD SCI USA, V93, P12433, DOI 10.1073/pnas.93.22.12433; Neilson J, 2001, CURR OPIN IMMUNOL, V13, P346, DOI 10.1016/S0952-7915(00)00225-9; Nicoll G, 2003, EUR J IMMUNOL, V33, P1642, DOI 10.1002/eji.200323693; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; Nikolova M, 2002, BLOOD, V100, P1019, DOI 10.1182/blood-2001-12-0303; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; Sathish JG, 2001, J IMMUNOL, V166, P1763, DOI 10.4049/jimmunol.166.3.1763; Spencer T, 2003, CURR OPIN NEUROBIOL, V13, P133, DOI 10.1016/S0959-4388(03)00012-6; Ugolini S, 2001, NAT IMMUNOL, V2, P430, DOI 10.1038/87740; Ugolini S, 2000, CURR OPIN IMMUNOL, V12, P295, DOI 10.1016/S0952-7915(00)00090-X; Uhrberg M, 2001, J IMMUNOL, V166, P3923, DOI 10.4049/jimmunol.166.6.3923; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; Vilches C, 2002, ANNU REV IMMUNOL, V20, P217, DOI 10.1146/annurev.immunol.20.092501.134942; Vitale C, 2001, P NATL ACAD SCI USA, V98, P5764, DOI 10.1073/pnas.091097198; Vitale C, 1999, P NATL ACAD SCI USA, V96, P15091, DOI 10.1073/pnas.96.26.15091; Vivier E, 2004, NAT REV IMMUNOL, V4, P190, DOI 10.1038/nri1306; Williams BL, 1999, EMBO J, V18, P1832, DOI 10.1093/emboj/18.7.1832; Yamaji T, 2002, J BIOL CHEM, V277, P6324, DOI 10.1074/jbc.M110146200; Yousef GM, 2002, GENE, V286, P259, DOI 10.1016/S0378-1119(02)00432-8; Zaccai NR, 2003, STRUCTURE, V11, P557, DOI 10.1016/S0969-2126(03)00073-X; Zhang JQ, 2000, J BIOL CHEM, V275, P22121, DOI 10.1074/jbc.M002788200	51	134	147	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43117	43125		10.1074/jbc.M403538200	http://dx.doi.org/10.1074/jbc.M403538200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292262	hybrid			2022-12-27	WOS:000224226400096
J	Lejon, S; Frick, IM; Bjorck, L; Wikstrom, M; Svensson, S				Lejon, S; Frick, IM; Bjorck, L; Wikstrom, M; Svensson, S			Crystal structure and biological implications of a bacterial albumin binding module in complex with human serum albumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCAL PROTEIN-G; ELECTRON-DENSITY MAPS; IDENTIFICATION; SPECIFICITY; RECEPTORS; REVEALS; PAB	Many bactericide species express surface proteins that interact with human serum albumin (HSA). Protein PAB from the anaerobic bacterium Finegoldia magna ( formerly Peptostreptococcus magnus) represents one of these proteins. Protein PAB contains a domain of 53 amino acid residues known as the GA module. GA homologs are also found in protein G of group C and G streptococci. Here we report the crystal structure of HSA in complex with the GA module of protein PAB. The model of the complex was refined to a resolution of 2.7 Angstrom and reveals a novel binding epitope located in domain II of the albumin molecule. The GA module is composed of a left-handed three-helix bundle, and residues from the second helix and the loops surrounding it were found to be involved in HSA binding. Furthermore, the presence of HSA-bound fatty acids seems to influence HSA-GA complex formation. F. magna has a much more restricted host specificity compared with C and G streptococci, which is also reflected in the binding of different animal albumins by proteins PAB and G. The structure of the HSA-GA complex offers a molecular explanation to this unusually clear example of bacterial adaptation.	Uppsala Univ, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden; Lund Univ, Dept Cell & Mol Biol, Sect Mol Pathogenesis, SE-22100 Lund, Sweden; Biovitrum, Dept Struct Chem, SE-11276 Stockholm, Sweden	Uppsala University; Lund University	Lejon, S (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden.	sara@xray.bmc.uu.se						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bhattacharya AA, 2000, J MOL BIOL, V303, P721, DOI 10.1006/jmbi.2000.4158; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; BJORCK L, 1987, MOL IMMUNOL, V24, P1113, DOI 10.1016/0161-5890(87)90080-0; BJORCK L, 1984, J IMMUNOL, V133, P969; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; deChateau M, 1996, P NATL ACAD SCI USA, V93, P8490, DOI 10.1073/pnas.93.16.8490; DECHATEAU M, 1994, J BIOL CHEM, V269, P12147; deChateau M, 1996, J BIOL CHEM, V271, P26609, DOI 10.1074/jbc.271.43.26609; DeLano WL, 2004, PYMOL MOL GRAPHICS S; FALKENBERG C, 1992, BIOCHEMISTRY-US, V31, P1451, DOI 10.1021/bi00120a023; FORSGREN A, 1966, J IMMUNOL, V97, P822; Hogbom M, 2003, P NATL ACAD SCI USA, V100, P3191, DOI 10.1073/pnas.0436100100; Johansson MU, 1997, J MOL BIOL, V266, P859, DOI 10.1006/jmbi.1996.0856; Johansson MU, 2002, J BIOL CHEM, V277, P8114, DOI 10.1074/jbc.M109943200; Johansson MU, 2002, J MOL BIOL, V316, P1083, DOI 10.1006/jmbi.2002.5398; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KRONVALL G, 1979, INFECT IMMUN, V25, P1; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Murdoch DA, 1998, CLIN MICROBIOL REV, V11, P81, DOI 10.1128/CMR.11.1.81; Mushudov G. N., 1997, ACTA CRYSTALLOGR D, V53, P240; MYHRE EB, 1984, J MED MICROBIOL, V18, P189, DOI 10.1099/00222615-18-2-189; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peters T., 1996, ALL ALBUMIN; REIS KJ, 1984, J IMMUNOL, V132, P3091; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wardell M, 2002, BIOCHEM BIOPH RES CO, V291, P813, DOI 10.1006/bbrc.2002.6540; ZUNSZAIN B, 2003, BMC STRUCT BIOL	31	91	100	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42924	42928		10.1074/jbc.M406957200	http://dx.doi.org/10.1074/jbc.M406957200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15269208	hybrid			2022-12-27	WOS:000224226400071
J	Liu, JL; Rigolet, P; Dou, SX; Wang, PY; Xi, XG				Liu, JL; Rigolet, P; Dou, SX; Wang, PY; Xi, XG			The zinc finger motif of Escherichia coli RecQ is implicated in both DNA binding and protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOMS-SYNDROME GENE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURES; FAMILY HELICASES; DOMAIN; MUTATIONS; MECHANISM; RECOMBINATION; REPLICATION; NUCLEOTIDES	The RecQ family of DNA helicases has been shown to be important for the maintenance of genomic integrity. Mutations in human RecQ genes lead to genomic instability and cancer. Several RecQ family of helicases contain a putative zinc finger motif of the C-4 type at the C terminus that has been identified in the crystalline structure of RecQ helicase from Escherichia coli. To better understand the role of this motif in helicase from E. coli, we constructed a series of single mutations altering the conserved cysteines as well as other highly conserved residues. All of the resulting mutant proteins exhibited a high level of susceptibility to degradation, making functional analysis impossible. In contrast, a double mutant protein in which both cysteine residues Cys(397) and Cys(400) in the zinc finger motif were replaced by asparagine residues was purified to homogeneity. Slight local conformational changes were detected, but the rest of the mutant protein has a well defined tertiary structure. Furthermore, the mutant enzyme displayed ATP binding affinity similar to the wild-type enzyme but was severely impaired in DNA binding and in subsequent ATPase and helicase activities. These results revealed that the zinc finger binding motif is involved in maintaining the integrity of the whole protein as well as DNA binding. We also showed that the zinc atom is not essential to enzymatic activity.	Ecole Normale Super, CNRS, UMR 8113, Lab Biotechnol & Pharmacol Genet Appl, F-94235 Cachan, France; Chinese Acad Sci, Inst Phys, Beijing Natl Lab Condensed Matter Phys, Lab Soft Matter Phys, Beijing 100080, Peoples R China	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; Chinese Academy of Sciences; Institute of Physics, CAS	Xi, XG (corresponding author), Ecole Normale Super, CNRS, UMR 8113, Lab Biotechnol & Pharmacol Genet Appl, 61 Ave President Wilson, F-94235 Cachan, France.	xi@lbpa.ens-cachan.fr	Xi, Xu Guang/AAK-4511-2020; Rigolet, Pascal/S-8602-2018; 王, 鹏业/A-9811-2012	Rigolet, Pascal/0000-0001-6868-4953; Dou, Shuo-Xing/0000-0002-7201-2081; Wang, Peng-Ye/0000-0002-9765-0610				Bahr A, 1998, ONCOGENE, V17, P2565, DOI 10.1038/sj.onc.1202389; Banci L, 2003, BIOCHEMISTRY-US, V42, P9543, DOI 10.1021/bi034324m; Bennett RJ, 2004, CRIT REV BIOCHEM MOL, V39, P79, DOI 10.1080/10409230490460756; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Betterton MD, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.258103; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Chakraverty RK, 1999, BIOESSAYS, V21, P286; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; Dessinges MN, 2004, P NATL ACAD SCI USA, V101, P6439, DOI 10.1073/pnas.0306713101; Dou SX, 2004, J BIOL CHEM, V279, P6354, DOI 10.1074/jbc.M311272200; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Foucault F, 1997, HUM MOL GENET, V6, P1427, DOI 10.1093/hmg/6.9.1427; Furuichi Y, 2001, ANN NY ACAD SCI, V928, P121; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Hanada K, 2000, P NATL ACAD SCI USA, V97, P5989, DOI 10.1073/pnas.100101297; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; HIRATSUKA T, 1982, BIOCHIM BIOPHYS ACTA, V719, P509, DOI 10.1016/0304-4165(82)90240-9; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; Iwaasa M, 2002, J NEUROCHEM, V82, P30, DOI 10.1046/j.1471-4159.2002.00996.x; Janscak P, 2003, J MOL BIOL, V330, P29, DOI 10.1016/S0022-2836(03)00534-5; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Levin MK, 2003, J BIOL CHEM, V278, P23311, DOI 10.1074/jbc.M301283200; Liu Z, 1999, STRUCTURE, V7, P1557, DOI 10.1016/S0969-2126(00)88346-X; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Mullen JR, 2000, GENETICS, V154, P1101; Onoda F, 2000, MUTAT RES-DNA REPAIR, V459, P203, DOI 10.1016/S0921-8777(99)00071-3; Simpson RJY, 2003, J BIOL CHEM, V278, P28011, DOI 10.1074/jbc.M211146200; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Singleton MR, 2002, P NATL ACAD SCI USA, V99, P13492, DOI 10.1073/pnas.212449899; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Xu HQ, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng070; Xu HQ, 2003, J BIOL CHEM, V278, P34925, DOI 10.1074/jbc.M303581200; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	40	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42794	42802		10.1074/jbc.M405008200	http://dx.doi.org/10.1074/jbc.M405008200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292213				2022-12-27	WOS:000224226400055
J	Wang, JL; Niemevz, F; Lad, L; Huang, LS; Alvarez, DE; Buldain, G; Poulos, TL; de Montellano, PRO				Wang, JL; Niemevz, F; Lad, L; Huang, LS; Alvarez, DE; Buldain, G; Poulos, TL; de Montellano, PRO			Human heme oxygenase oxidation of 5-and 15-phenylhemes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ACTIVE-SITE; REACTION REGIOSPECIFICITY; ELECTRONIC CONTROL; PROTEIN; INFLAMMATION; BILIVERDIN; BILIRUBIN; COMPLEX; IX	Human heme oxygenase-1 (hHO-1) catalyzes the O-2-dependent oxidation of heme to biliverdin, CO, and free iron. Previous work indicated that electrophilic addition of the terminal oxygen of the ferric hydroperoxo complex to the alpha-meso-carbon gives 5-hydroxyheme. Earlier efforts to block this reaction with a 5-methyl substituent failed, as the reaction still gave biliverdin IXalpha. Surprisingly, a 15-methyl substituent caused exclusive cleavage at the gamma-meso- rather than at the normal, unsubstituted alpha-meso-carbon. No CO was formed in these reactions, but the fragment cleaved from the porphyrin eluded identification. We report here that hHO-1 cleaves 5-phenylheme to biliverdin IXalpha and oxidizes 15-phenylheme at the alpha-meso position to give 10-phenylbiliverdin IXalpha. The fragment extruded in the oxidation of 5-phenylheme is benzoic acid, one oxygen of which comes from O-2 and the other from water. The 2.29- and 2.11-Angstrom crystal structures of the hHO-1 complexes with 1- and 15-phenylheme, respectively, show clear electron density for both the 5- and 15-phenyl rings in both molecules of the asymmetric unit. The overall structure of 15-phenylheme-hHO-1 is similar to that of heme-hHO-1 except for small changes in distal residues 141 - 150 and in the proximal Lys(18) and Lys(22). In the 5-phenylheme-hHO1 structure, the phenyl-substituted heme occupies the same position as heme in the heme-HO-1 complex but the 5- phenyl substituent disrupts the rigid hydrophobic wall of residues Met(34), Phe(214), and residues 26 - 42 near the alpha-meso carbon. The results provide independent support for an electrophilic oxidation mechanism and support a role for stereochemical control of the reaction regiospecificity.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Sci, Irvine, CA 92697 USA; Univ Buenos Aires, Fac Farm & Bioquim, Dept Quim Organ, RA-1113 Buenos Aires, DF, Argentina	University of California System; University of California San Francisco; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Buenos Aires	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, Genentech Hall,600 16th St,N572D, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu			NIDDK NIH HHS [DK30297] Funding Source: Medline; NIGMS NIH HHS [GM33688] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033688] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINI E, 1965, PHYSIOL REV, V45, P123, DOI 10.1152/physrev.1965.45.1.123; AUCLAIR K, 2002, PORPHYRIN HDB, V12, P183; BARKIGIA KM, 1990, J AM CHEM SOC, V112, P8851, DOI 10.1021/ja00180a029; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Clark JE, 2000, BIOCHEM J, V348, P615, DOI 10.1042/0264-6021:3480615; Crusats J, 1998, J ORG CHEM, V63, P602, DOI 10.1021/jo9714728; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; De Montellano PRO, 1998, ACCOUNTS CHEM RES, V31, P543; Ding Y, 1999, EUR J BIOCHEM, V264, P854, DOI 10.1046/j.1432-1327.1999.00677.x; Dolphin, 1979, PORPHYRINS, VVI, P257; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Friedman J, 2004, BIOCHEMISTRY-US, V43, P5239, DOI 10.1021/bi049687g; HANSCH C, 1995, EXPLORING QSAR HYDRO, P231; Hanselmann C, 2001, BIOCHEM J, V353, P459, DOI 10.1042/0264-6021:3530459; Ishikawa K, 2001, CIRC RES, V88, P506, DOI 10.1161/01.RES.88.5.506; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lad L, 2004, BIOCHEMISTRY-US, V43, P3793, DOI 10.1021/bi035451l; Lad L, 2003, J MOL BIOL, V330, P527, DOI 10.1016/S0022-2836(03)00578-3; Lad L, 2003, J BIOL CHEM, V278, P7834, DOI 10.1074/jbc.M211450200; LAD L, 2004, IN PRESS J INORG BIO; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li YM, 2002, J BIOL CHEM, V277, P33018, DOI 10.1074/jbc.M204216200; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Liu Y, 2000, J BIOL CHEM, V275, P5297, DOI 10.1074/jbc.275.8.5297; Liu Y, 1997, J BIOL CHEM, V272, P6909, DOI 10.1074/jbc.272.11.6909; Maines M.D., 1992, HEME OXYGENASE CLIN; McCarter SD, 2003, GENE THER, V10, P1629, DOI 10.1038/sj.gt.3302063; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MEDFORTH CJ, 1992, J AM CHEM SOC, V114, P9859, DOI 10.1021/ja00051a019; Nath KA, 2001, KIDNEY INT, V59, P106, DOI 10.1046/j.1523-1755.2001.00471.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Niemevz F, 2002, HETEROCYCLES, V57, P697; NIEMEVZ F, 2004, IN PRESS J PORPHYRIN; OCARRA P, 1975, PORPHYRINS METALLOPO, P123; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ratliff M, 2001, J BACTERIOL, V183, P6394, DOI 10.1128/JB.183.21.6394-6403.2001; Robinsohn AE, 2000, HETEROCYCLES, V53, P2127; Sass G, 2003, HEPATOLOGY, V38, P909, DOI 10.1053/jhep.2003.50386; Schuller DJ, 1998, PROTEIN SCI, V7, P1836, DOI 10.1002/pro.5560070820; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; SENGE MO, 1995, J CHEM SOC CHEM COMM, P733, DOI 10.1039/c39950000733; SHEN AL, 1991, J BIOL CHEM, V266, P19976; Soares MP, 2001, IMMUNOL REV, V184, P275, DOI 10.1034/j.1600-065x.2001.1840124.x; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Sugishima M, 2003, J BIOL CHEM, V278, P32352, DOI 10.1074/jbc.M303682200; Syvitski RT, 2002, J AM CHEM SOC, V124, P14296, DOI 10.1021/ja028108x; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Torpey J, 1997, J BIOL CHEM, V272, P22008, DOI 10.1074/jbc.272.35.22008; Torpey J, 1996, J BIOL CHEM, V271, P26067, DOI 10.1074/jbc.271.42.26067; Uzel C, 1998, SEMIN HEMATOL, V35, P27; Visner GA, 2003, TRANSPLANTATION, V76, P650, DOI 10.1097/01.TP.0000080069.61917.18; Wilks A, 1998, BIOCHEMISTRY-US, V37, P2889, DOI 10.1021/bi972720x; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; WILKS A, 1994, J BIOL CHEM, V269, P29553; Zhou H, 2000, J AM CHEM SOC, V122, P8311, DOI 10.1021/ja0002868	57	18	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42593	42604		10.1074/jbc.M406346200	http://dx.doi.org/10.1074/jbc.M406346200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15297453	hybrid, Green Published			2022-12-27	WOS:000224226400032
J	Aittaleb, M; Visone, T; Fenley, MO; Li, H				Aittaleb, M; Visone, T; Fenley, MO; Li, H			Structural and thermodynamic evidence for a stabilizing role of Nop5p in S-adenosyl-L-methionine binding to fibrillarin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNAS; METHYLTRANSFERASE; METHYLATION; ARCHAEA; PROTEIN; MODELS	In Archaea, fibrillarin and Nop5p form the core complex of box C/D small ribonucleoprotein particles, which are responsible for site-specific 2'-hydroxyl methylation of ribosomal and transfer RNAs. Fibrillarin has a conserved methyltransferase fold and employs S-adenosyl-L-methionine (AdoMet) as the cofactor in methyl transfer reactions. Comparison between recently determined crystal structures of free fibrillarin and fibrillarin-Nop5p-AdoMet tertiary complex revealed large conformational differences at the cofactor-binding site in fibrillarin. To identify the structural elements responsible for these large conformational differences, we refined a crystal structure of Archaeoglobus fulgidus fibrillarin-Nop5p binary complex at 3.5. This structure exhibited a pre-formed backbone geometry at the cofactor binding site similar to that when the cofactor is bound, suggesting that binding of Nop5p alone to fibrillarin is sufficient to stabilize the AdoMet-binding pocket. Calorimetry studies of cofactor binding to fibrillarin alone and to fibrillarin-Nop5p binary complex provided further support for this role of Nop5p. Mutagenesis and thermodynamic data showed that a cation-pi bridge formed between Tyr-89 of fibrillarin and Arg-169 of Nop5p, although dispensable for in vitro methylation activity, could partially account for the enhanced binding of cofactor to fibrillarin by Nop5p. Finally, assessment of cofactor-binding thermodynamics and catalytic activities of enzyme mutants identified three additional fibrillarin residues (Thr-70, Glu-88, and Asp-133) to be important for cofactor binding and for catalysis.	Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University	Li, H (corresponding author), Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA.	hongli@sb.fsu.edu		Li, Hong/0000-0003-2046-9861	NIGMS NIH HHS [R01 GM66958, R01 GM099604] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066958] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aittaleb M, 2003, NAT STRUCT BIOL, V10, P256, DOI 10.1038/nsb905; Boschitsch AH, 2004, J COMPUT CHEM, V25, P935, DOI 10.1002/jcc.20000; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavaille J, 2001, J BIOL CHEM, V276, P26374, DOI 10.1074/jbc.M103544200; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; Deng L, 2004, BIOCHEM BIOPH RES CO, V315, P726, DOI 10.1016/j.bbrc.2004.01.114; Dennis PP, 2001, MOL MICROBIOL, V40, P509, DOI 10.1046/j.1365-2958.2001.02381.x; Feder M, 2003, GENE, V302, P129, DOI 10.1016/S0378-1119(02)01097-1; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Hager J, 2002, J BIOL CHEM, V277, P41978, DOI 10.1074/jbc.M205423200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; Maravic G, 2003, J MOL BIOL, V332, P99, DOI 10.1016/S0022-2836(03)00863-5; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; Omer AD, 2003, MOL MICROBIOL, V48, P617, DOI 10.1046/j.1365-2958.2003.03483.x; Omer AD, 2002, P NATL ACAD SCI USA, V99, P5289, DOI 10.1073/pnas.082101999; Rashid R, 2003, J MOL BIOL, V333, P295, DOI 10.1016/j.jmb.2003.08.012; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SEGAL DM, 1989, ARCH BIOCHEM BIOPHYS, V275, P334, DOI 10.1016/0003-9861(89)90380-9; Shi XN, 1996, RNA, V2, P88; SITKOFF D, 1994, J PHYS CHEM-US, V98, P1978, DOI 10.1021/j100058a043; Terns MP, 2002, GENE EXPRESSION, V10, P17; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; WALSH CT, 1979, ENZYMATIC REACTION M; Wang HM, 2000, EMBO J, V19, P317, DOI 10.1093/emboj/19.3.317; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	28	25	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41822	41829		10.1074/jbc.M406209200	http://dx.doi.org/10.1074/jbc.M406209200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15286083	hybrid			2022-12-27	WOS:000224075500072
J	Papaiahgari, S; Kleeberger, SR; Cho, HY; Kalvakolanu, DV; Reddy, SP				Papaiahgari, S; Kleeberger, SR; Cho, HY; Kalvakolanu, DV; Reddy, SP			NADPH oxidase and ERK signaling regulates hyperoxia-induced Nrf2-ARE transcriptional response in pulmonary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED LUNG INJURY; PROTEIN-KINASE-C; HUMAN NEUROBLASTOMA-CELLS; OXIDATIVE STRESS; GENE-EXPRESSION; NF-E2-RELATED FACTOR-2; SUPEROXIDE-DISMUTASE; MOLECULAR MECHANISMS; CELLULAR-RESPONSE; HEME OXYGENASE-1	Oxidative stress plays a major role in hyperoxia-induced acute lung injury. We have shown previously that mice lacking the Nrf2 are more susceptible to hyperoxia than are wild-type mice. Nrf2 activates antioxidant response element (ARE)-mediated gene expression involved in cellular protection against toxic insults. The present study was designed to investigate the mechanisms that control the activation of Nrf2 by hyperoxia using a non-malignant murine alveolar epithelial cell line, C10. No significant alteration in the levels of Nrf2 mRNA and protein was found following exposure to hyperoxia. In contrast, hyperoxia caused the translocation of Nrf2 from the cytoplasm to the nucleus within 30-60 min of exposure. Consistent with these observations, gel shift and reporter analyses demonstrated a correlation between the hyperoxia-enhanced ARE DNA-binding activity of Nrf2 and an up-regulation of ARE-driven transcription. Inhibition of NADPH oxidase with diphenyleneiodonium (DPI) blocked both Nrf2 translocation and ARE-mediated transcription. Inhibition of the MEK/ERK pathway caused a similar effect. Consistent with this finding, hyperoxia stimulated ERK-1 and ERK-2 phosphorylation, whereas DPI or N-acetyl-L-cysteine blocked such activation. Hyperoxia stimulated the phosphorylation of endogenous Nrf2, but not in the presence of U0126, suggesting a critical role for ERK signaling in the activation of Nrf2. Consistent with this notion, hyperoxia did not stimulate the phosphorylation of Nrf2 in fibroblasts lacking the ERK-1. Collectively, our findings suggest that hyperoxia-induced, ARE-driven, Nrf2-dependent transcription is controlled by NADPH oxidase and ERK-1 signaling.	Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; NIEHS, NIH, Res Triangle Pk, NC 27709 USA; Univ Maryland, Maryland Greenbaum Canc Ctr, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University System of Maryland; University of Maryland Baltimore	Reddy, SP (corresponding author), Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Bloomberg Sch Publ Hlth, Rm W7006,615 N Wolfe St, Baltimore, MD 21205 USA.	sreddy@jhsph.edu	Kleeberger, Steven R/F-1807-2019	Kleeberger, Steven R/0000-0003-2948-8452; Papaiahgari, Srinivas/0000-0002-1110-7562	NATIONAL CANCER INSTITUTE [R01CA078282, R01CA105005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL073996, R01HL066109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES100513] Funding Source: NIH RePORTER; NCI NIH HHS [CA105005, CA78282] Funding Source: Medline; NHLBI NIH HHS [HL66109, P50 HL073996] Funding Source: Medline; NIEHS NIH HHS [ES30819] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adiseshaiah P, 2003, J BIOL CHEM, V278, P47423, DOI 10.1074/jbc.M303505200; Alam J, 2000, J BIOL CHEM, V275, P27694; Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Buckley S, 1999, AM J PHYSIOL-LUNG C, V277, pL159, DOI 10.1152/ajplung.1999.277.1.L159; Camhi S L, 1995, New Horiz, V3, P170; Chan D, 2000, AUSTRALAS J AGEING, V19, P26; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chang FM, 2003, INT J ONCOL, V22, P469; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Cho HY, 2002, AM J RESP CELL MOL, V26, P42, DOI 10.1165/ajrcmb.26.1.4536; CLERCH LB, 1993, J CLIN INVEST, V91, P499, DOI 10.1172/JCI116228; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; CRAPO JD, 1986, ANNU REV PHYSIOL, V48, P721; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Danel C, 1998, HUM GENE THER, V9, P1487, DOI 10.1089/hum.1998.9.10-1487; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Dos Santos CC, 2000, J APPL PHYSIOL, V89, P1645, DOI 10.1152/jappl.2000.89.4.1645; Fahey JW, 1999, FOOD CHEM TOXICOL, V37, P973, DOI 10.1016/S0278-6915(99)00082-4; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; Ho YS, 1998, AM J RESP CELL MOL, V18, P538, DOI 10.1165/ajrcmb.18.4.2959; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Ishii T, 2002, METHOD ENZYMOL, V348, P182, DOI 10.1016/S0076-6879(02)48637-5; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jones N, 2003, J CELL PHYSIOL, V196, P326, DOI 10.1002/jcp.10308; Keum YS, 2003, PHARM RES-DORDR, V20, P1351, DOI 10.1023/A:1025737622815; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; Lee PJ, 2003, FREE RADICAL BIO MED, V35, P341, DOI 10.1016/S0891-5849(03)00279-X; Leung L, 2003, J BIOL CHEM, V278, P48021, DOI 10.1074/jbc.M308439200; Li N, 2002, J IMMUNOL, V169, P4531, DOI 10.4049/jimmunol.169.8.4531; Malkinson AM, 1997, TOXICOLOGY, V123, P53, DOI 10.1016/S0300-483X(97)00108-X; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matthay MA, 2002, AM J PHYSIOL-LUNG C, V283, pL678, DOI 10.1152/ajplung.00154.2002; Moehlenkamp JD, 1999, ARCH BIOCHEM BIOPHYS, V363, P98, DOI 10.1006/abbi.1998.1046; Morito N, 2003, ONCOGENE, V22, P9275, DOI 10.1038/sj.onc.1207024; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Numazawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC334, DOI 10.1152/ajpcell.00043.2003; OBRIEN PJ, 1991, CHEM-BIOL INTERACT, V80, P1, DOI 10.1016/0009-2797(91)90029-7; Otterbein LE, 2003, AM J PATHOL, V163, P2555, DOI 10.1016/S0002-9440(10)63610-3; Otterbein LE, 2002, AM J RESP CELL MOL, V26, P161, DOI 10.1165/ajrcmb.26.2.f226; Parinandi NL, 2003, AM J PHYSIOL-LUNG C, V284, pL26, DOI 10.1152/ajplung.00123.2002; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Ryter SW, 2002, ANTIOXID REDOX SIGN, V4, P625, DOI 10.1089/15230860260220120; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sekhar KR, 2003, CANCER RES, V63, P5636; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tsan MF, 1998, AM J RESP CELL MOL, V19, P114, DOI 10.1165/ajrcmb.19.1.3066; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Whitehead T, 2002, THORAX, V57, P635, DOI 10.1136/thorax.57.7.635; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang J, 2003, P NATL ACAD SCI USA, V100, P9342, DOI 10.1073/pnas.1633516100; ZHANG Q, 2003, AM J PHYSIOL, V286, pL427; Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC; Zipper LM, 2000, BIOCHEM BIOPH RES CO, V278, P484, DOI 10.1006/bbrc.2000.3830; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	62	145	148	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42302	42312		10.1074/jbc.M408275200	http://dx.doi.org/10.1074/jbc.M408275200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292179	hybrid			2022-12-27	WOS:000224075500122
J	Saville, MK; Sparks, A; Xirodimas, DP; Wardrop, J; Stevenson, LF; Bourdon, JC; Woods, YL; Lane, DP				Saville, MK; Sparks, A; Xirodimas, DP; Wardrop, J; Stevenson, LF; Bourdon, JC; Woods, YL; Lane, DP			Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; NEGATIVE REGULATOR; RAPID DEGRADATION; PROTEIN LIGASE; TARGETS P53; MDM2; PATHWAY; IDENTIFICATION	p53 levels are regulated by ubiquitination and 26 S proteasome-mediated degradation. p53 is a substrate for the E3 ligase Mdm2, however, the ubiquitin-conjugating enzymes (E2s) involved in p53 ubiquitination in intact cells have not been defined previously. To investigate the E2 specificity of Mdm2 we carried out an in vitro screen using a panel of ubiquitin E2s. Of the E2s tested only UbcH5A, -B, and -C and E2-25K support Mdm2-mediated ubiquitination of p53. The same E2s also support Mdm2 auto-ubiquitination. Small interfering RNA-mediated knockdown of UbcH5B/C causes accumulation of Mdm2 and p53 in unstressed cells. We show that suppression of UbcH5B/C inhibits p53 ubiquitination and degradation. Despite up-regulating the level of nuclear p53, UbcH5B/C knockdown does not on its own result in an increase in p53 transcriptional activity or sensitize p53 to activation by the therapeutic drugs doxorubicin and actinomycin D. We provide evidence that Mdm2 is responsible, at least in part, for repression of the transcriptional activity of the accumulated p53. In MCF7 cells levels of UbcH5B/C are reduced by doxorubicin and actinomycin D. This observation and the sensitivity of p53 expression to levels of UbcH5B/C raise the possibility that E2 regulation could be involved in signaling pathways that control the stability of p53. Our data indicate that UbcH5B/C are physiological E2s for Mdm2, which make a significant contribution to the maintenance of low levels of p53 and Mdm2 in unstressed cells and that inhibition of p53 ubiquitination and degradation by targeting UbcH5B/C is not sufficient to up-regulate p53 transcriptional activity.	Univ Dundee, Ninewells Hosp & Med Sch, Cell Transformat Res Grp, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee	Saville, MK (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Cell Transformat Res Grp, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland.	m.k.saville@dundee.ac.uk	JC, Bourdon/A-4439-2008; Lane, David P/C-4920-2008	JC, Bourdon/0000-0003-4623-9386; Lane, David/0000-0003-0551-3545; Xirodimas, Dimitris/0000-0001-9275-1140				Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Bloom J, 2004, CELL CYCLE, V3, P138; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Finch RA, 2002, CANCER RES, V62, P3221; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Gonen H, 1999, J BIOL CHEM, V274, P14823, DOI 10.1074/jbc.274.21.14823; Gu HD, 2003, P NATL ACAD SCI USA, V100, P8963, DOI 10.1073/pnas.1533420100; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; Hansen S, 1996, J BIOL CHEM, V271, P3917; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Jones D, 2002, GENOME BIOL, V3; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KAISER P, 1994, J BIOL CHEM, V269, P8797; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kikuchi J, 2000, ARTERIOSCL THROM VAS, V20, P128, DOI 10.1161/01.ATV.20.1.128; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lai ZH, 2002, P NATL ACAD SCI USA, V99, P14734, DOI 10.1073/pnas.212428599; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; Lain S, 2003, EUR J CANCER, V39, P1053, DOI 10.1016/S0959-8049(03)00063-7; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Lara PN, 2004, SEMIN ONCOL, V31, P40, DOI 10.1053/j.seminoncol.2003.12.013; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liu Q, 2004, EXP EYE RES, V78, P197, DOI 10.1016/j.exer.2003.11.009; LUNA RMD, 1995, NATURE, V378, P203; Lyakhovich A, 2003, MOL CELL BIOL, V23, P2463, DOI 10.1128/MCB.23.7.2463-2475.2003; Ma Yongxian, 2000, Molecular Cell Biology Research Communications, V3, P122, DOI 10.1006/mcbr.2000.0201; Meek DW, 2003, MOL CANCER RES, V1, P1017; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Mimnaugh EG, 1999, ELECTROPHORESIS, V20, P418, DOI 10.1002/(SICI)1522-2683(19990201)20:2<418::AID-ELPS418>3.0.CO;2-N; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nyman TA, 2000, EUR J BIOCHEM, V267, P4011, DOI 10.1046/j.1432-1327.2000.01433.x; Ochs RL, 1998, METHOD CELL BIOL, V53, P303; Okamoto Y, 2003, CANCER RES, V63, P4167; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rajapurohitam V, 1999, DEV BIOL, V212, P217, DOI 10.1006/dbio.1999.9342; Rajapurohitam V, 2002, AM J PHYSIOL-ENDOC M, V282, pE739, DOI 10.1152/ajpendo.00511.2001; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sarcevic B, 2002, EMBO J, V21, P2009, DOI 10.1093/emboj/21.8.2009; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Semplici F, 2002, ONCOGENE, V21, P3978, DOI 10.1038/sj.onc.1205574; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Song S, 2003, MOL CELL, V12, P553, DOI 10.1016/j.molcel.2003.08.005; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Tongaonkar P, 1998, ANAL BIOCHEM, V260, P135, DOI 10.1006/abio.1998.2697; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316; Wing SS, 1996, BIOCHEM J, V319, P455, DOI 10.1042/bj3190455; WING SS, 1994, AM J PHYSIOL, V267, pE39, DOI 10.1152/ajpendo.1994.267.1.E39; Woods Yvonne L, 2003, Hematol J, V4, P233, DOI 10.1038/sj.thj.6200260; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411	81	108	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42169	42181		10.1074/jbc.M403362200	http://dx.doi.org/10.1074/jbc.M403362200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280377	hybrid			2022-12-27	WOS:000224075500109
J	Hobson, RP; Munro, CA; Bates, S; MacCallum, DM; Cutler, JE; Heinsbroek, SEM; Brown, GD; Odds, FC; Gow, NAR				Hobson, RP; Munro, CA; Bates, S; MacCallum, DM; Cutler, JE; Heinsbroek, SEM; Brown, GD; Odds, FC; Gow, NAR			Loss of cell wall mannosylphosphate in Candida albicans does not influence macrophage recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTABLE MARKER URA3; BETA-1,2-LINKED OLIGOMANNOSIDES; ADHESIN ACTIVITY; YEAST MANNAN; HOST-DEFENSE; MNN4 GENE; DECTIN-1; EXPRESSION; VIRULENCE; STRAINS	The outer layer of the cell wall of the human pathogenic fungus Candida albicans is enriched with heavily mannosylated glycoproteins that are the immediate point of contact between the fungus and cells of the host, including phagocytes. Previous work had identified components of the acid-labile fraction of N-linked mannan, comprising beta-1,2-linked mannose residues attached via a phosphodiester bond, as potential ligands for macrophage receptors and modulators of macrophage function. We therefore isolated and disrupted the CaMNN4 gene, which is required for mannosyl phosphate transfer and hence the attachment of beta-1,2 mannose oligosaccharides to the acid-labile N-mannan side chains. With the mannosylphosphate eliminated, the mnn4Delta null mutant was unable to bind the charged cationic dye Alcian Blue and was devoid of acid-labile beta-1,2-linked oligomannosaccharides. The mnn4Delta mutant was unaffected in cell growth and morphogenesis in vitro and in virulence in a murine model of systemic C. albicans infection. The null mutant was also not affected in its interaction with macrophages. Mannosylphosphate is therefore not required for macrophage interactions or for virulence of C. albicans.	Univ Aberdeen, Inst Med Sci, Sch Med Sci, Aberdeen AB25 2ZD, Scotland; Childrens Hosp, Res Inst Children, New Orleans, LA 70118 USA; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Aberdeen; Children's Hospital of New Orleans; University of Oxford	Gow, NAR (corresponding author), Univ Aberdeen, Inst Med Sci, Sch Med Sci, Aberdeen AB25 2ZD, Scotland.	n.gow@abdn.ac.uk	GOW, Neil/AAS-5323-2021; Munro, Carol A/A-5175-2011; MacCallum, Donna M./D-7897-2011	GOW, Neil/0000-0002-2776-5850; MacCallum, Donna M./0000-0003-4833-0378; Munro, Carol/0000-0003-0761-1755; Hobson, Richard/0000-0001-6222-7487; Bates, Steven/0000-0003-0489-5705; brown, gordon/0000-0002-0287-5383	PHS HHS [R01 24912] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alonso-Monge R, 1999, J BACTERIOL, V181, P3058, DOI 10.1128/JB.181.10.3058-3068.1999; Bain JM, 2001, FEMS MICROBIOL LETT, V204, P323, DOI 10.1111/j.1574-6968.2001.tb10905.x; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU CE, 1973, J BIOL CHEM, V248, P4667; BOTLZNITULESCU G, 1987, J LEUKOCYTE BIOL, V41, P83; Brand A, 2004, EUKARYOT CELL, V3, P900, DOI 10.1128/EC.3.4.900-909.2004; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Chinen T, 1999, CLIN EXP IMMUNOL, V115, P491; Cutler JE, 2001, MED MYCOL, V39, P75, DOI 10.1080/714030992; Cutler JE, 1998, RES IMMUNOL, V149, P299, DOI 10.1016/S0923-2494(98)80754-2; Dalle F, 2003, INFECT IMMUN, V71, P7061, DOI 10.1128/IAI.71.12.7061-7068.2003; Erwig LP, 1998, J IMMUNOL, V161, P1983; FONZI WA, 1993, GENETICS, V134, P717; Fradin C, 2000, INFECT IMMUN, V68, P4391, DOI 10.1128/IAI.68.8.4391-4398.2000; Fradin C, 1996, J LEUKOCYTE BIOL, V60, P81, DOI 10.1002/jlb.60.1.81; Fradin C, 2003, MOL MICROBIOL, V47, P1523, DOI 10.1046/j.1365-2958.2003.03396.x; Goins TL, 2000, J CLIN MICROBIOL, V38, P2862, DOI 10.1128/JCM.38.8.2862-2869.2000; Han Y, 1997, INFECT IMMUN, V65, P4100, DOI 10.1128/IAI.65.10.4100-4107.1997; HAN YM, 1995, INFECT IMMUN, V63, P2714, DOI 10.1128/IAI.63.7.2714-2719.1995; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; Hazen KC, 2001, INFECT IMMUN, V69, P779, DOI 10.1128/IAI.69.2.779-786.2001; Herre J, 2004, MOL IMMUNOL, V40, P869, DOI 10.1016/j.molimm.2003.10.007; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; Ibata-Ombetta S, 2003, J BIOL CHEM, V278, P13086, DOI 10.1074/jbc.M210680200; Jigami Y, 1999, BBA-GEN SUBJECTS, V1426, P335, DOI 10.1016/S0304-4165(98)00134-2; JOUAULT T, 1995, INFECT IMMUN, V63, P2378, DOI 10.1128/IAI.63.6.2378-2381.1995; Jouault T, 2000, INFECT IMMUN, V68, P965, DOI 10.1128/IAI.68.2.965-968.2000; KANBE T, 1994, INFECT IMMUN, V62, P1662, DOI 10.1128/IAI.62.5.1662-1668.1994; KANBE T, 1993, INFECT IMMUN, V61, P2578, DOI 10.1128/IAI.61.6.2578-2584.1993; Kanbe T, 1998, INFECT IMMUN, V66, P5812, DOI 10.1128/IAI.66.12.5812-5818.1998; Kaposzta R, 1999, J CELL SCI, V112, P3237; Kaposzta R, 1998, INFECT IMMUN, V66, P1708; KARSON EM, 1978, J BIOL CHEM, V253, P6484; Lay J, 1998, INFECT IMMUN, V66, P5301, DOI 10.1128/IAI.66.11.5301-5306.1998; Lefkowitz SS, 1996, J INFECT DIS, V173, P1202, DOI 10.1093/infdis/173.5.1202; Levitz SM, 1998, ASM NEWS, V64, P693; LI RK, 1993, J BIOL CHEM, V268, P18293; LI RK, 1993, J BIOL CHEM, V273, P26078; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594; Munro CA, 2001, MOL MICROBIOL, V39, P1414, DOI 10.1046/j.1365-2958.2001.02347.x; Murad AMA, 2000, YEAST, V16, P325, DOI 10.1002/1097-0061(20000315)16:4&lt;325::AID-YEA538&gt;3.0.CO;2-#; Nakayama K, 1998, BBA-GEN SUBJECTS, V1425, P255, DOI 10.1016/S0304-4165(98)00078-6; Navarro-Garcia F, 2001, FEMS MICROBIOL REV, V25, P245, DOI 10.1016/S0168-6445(00)00066-8; Newman SL, 1999, TRENDS MICROBIOL, V7, P67, DOI 10.1016/S0966-842X(98)01431-0; Nitz M, 2002, J BIOL CHEM, V277, P3440, DOI 10.1074/jbc.M109274200; Odani T, 1996, GLYCOBIOLOGY, V6, P805, DOI 10.1093/glycob/6.8.805; Odani T, 1997, FEBS LETT, V420, P186, DOI 10.1016/S0014-5793(97)01513-5; Pappas PG, 2003, CLIN INFECT DIS, V37, P634, DOI 10.1086/376906; RIESSELMAN MH, 1991, J IMMUNOL METHODS, V145, P153, DOI 10.1016/0022-1759(91)90321-6; Romani Luigina, 2002, P223; Sandven Per, 2000, Revista Iberoamericana de Micologia, V17, P73; SHIBATA N, 1992, INFECT IMMUN, V60, P4100, DOI 10.1128/IAI.60.10.4100-4110.1992; Steele C, 2003, J EXP MED, V198, P1677, DOI 10.1084/jem.20030932; Sundstrom P, 2002, INFECT IMMUN, V70, P3281, DOI 10.1128/IAI.70.6.3281-3283.2002; Suzuki Shigeo, 2002, P29; Taylor PR, 2004, J IMMUNOL, V172, P1157, DOI 10.4049/jimmunol.172.2.1157; Timpel C, 2000, J BACTERIOL, V182, P3063, DOI 10.1128/JB.182.11.3063-3071.2000; Trinel PA, 1997, FEBS LETT, V416, P203, DOI 10.1016/S0014-5793(97)01205-2; Trinel PA, 2002, J BIOL CHEM, V277, P37260, DOI 10.1074/jbc.M202295200; Wang XH, 1997, J BIOL CHEM, V272, P18117, DOI 10.1074/jbc.272.29.18117; WHELAN WL, 1990, INFECT IMMUN, V58, P1552, DOI 10.1128/IAI.58.6.1552-1557.1990; Willment JA, 2001, J BIOL CHEM, V276, P43818, DOI 10.1074/jbc.M107715200	63	99	102	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39628	39635		10.1074/jbc.M405003200	http://dx.doi.org/10.1074/jbc.M405003200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15271989	hybrid			2022-12-27	WOS:000223791500053
J	Mohler, PJ; Yoon, W; Bennett, V				Mohler, PJ; Yoon, W; Bennett, V			Ankyrin-B targets beta(2)-spectrin to an intracellular compartment in neonatal cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-ASSOCIATED PROTEIN; HUMAN-ERYTHROCYTE SPECTRIN; AXON INITIAL SEGMENTS; BETA-II-SPECTRIN; BINDING-SITES; INOSITOL 1,4,5-TRISPHOSPHATE; HEREDITARY SPHEROCYTOSIS; CARDIAC-ARRHYTHMIA; ATTACHMENT SITE; DOMAIN	Ankyrin-B is a spectrin-binding protein that is required for localization of inositol 1,4,5-trisphosphate receptor and ryanodine receptor in neonatal cardiomyocytes. This work addresses the interaction between ankyrin-B and beta(2)-spectrin in these cells. Ankyrin-B and beta(2)-spectrin are colocalized in an intracellular striated compartment overlying the M-line and distinct from T-tubules, sarcoplasmic reticulum, Golgi, endoplasmic reticulum, lysosomes, and endosomes. beta(2)-Spectrin is absent in ankyrin-B-null cardiomyocytes and is restored to a normal striated pattern by rescue with green fluorescent protein-220-kDa ankyrin-B. We identified two mutants (A1000P and DAR976AAA) located in the ZU5 domain which eliminate spectrin binding activity of ankyrin-B. Ankyrin-B mutants lacking spectrin binding activity are normally targeted but do not reestablish beta(2)-spectrin in ankyrin-B+/- cardiomyocytes. However, both mutant forms of ankyrin-B are still capable of restoring inositol 1,4,5-trisphosphate receptor localization and normal contraction frequency of cardiomyocytes. Therefore, direct binding of beta(2)-spectrin to ankyrin-B is required for the normal targeting of beta(2)-spectrin in neonatal cardiomyocytes. In contrast, ankyrin-B localization and function are independent of beta(2)-spectrin. In summary, this work demonstrates that interaction between members of the ankyrin and beta-spectrin families previously established in erythrocytes and axon initial segments also occurs in neonatal cardiomyocytes with ankyrin-B and beta(2)-spectrin. This work also establishes a functional hierarchy in which ankyrin-B determines the localization of beta(2)-spectrin and operates independently of beta(2)-spectrin in its role in organizing membrane-spanning proteins.	Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurosci, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Mohler, PJ (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst, Box 3892, Durham, NC 27710 USA.	p.mohler@cellbio.duke.edu; v.bennett@cellbio.duke.edu						Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Apel ED, 2000, J BIOL CHEM, V275, P31986, DOI 10.1074/jbc.M004775200; Beck KA, 1998, BBA-MOL CELL RES, V1404, P153, DOI 10.1016/S0167-4889(98)00054-8; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; BENNETT V, 1979, J BIOL CHEM, V254, P2533; BENNETT V, 1978, J BIOL CHEM, V253, P2292; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BODINE DM, 1984, CELL, V37, P721, DOI 10.1016/0092-8674(84)90408-2; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; DE M, 2000, J CELL SCI, V113, P2331; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; Eber SW, 1996, NAT GENET, V13, P214, DOI 10.1038/ng0696-214; Gough LL, 2003, MOL BIOL CELL, V14, P2410, DOI 10.1091/mbc.E02-07-0446; Hammarlund M, 2000, J CELL BIOL, V149, P931, DOI 10.1083/jcb.149.4.931; HANSPAL M, 1991, BLOOD, V77, P165; Hayes NVL, 2000, J CELL SCI, V113, P2023; HU RJ, 1995, J CELL BIOL, V128, P1069, DOI 10.1083/jcb.128.6.1069; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; Kizhatil K, 2004, J BIOL CHEM, V279, P16706, DOI 10.1074/jbc.M314296200; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; LUNA EJ, 1979, J BIOL CHEM, V254, P2526; Mohler PJ, 2004, P NATL ACAD SCI USA, V101, P9137, DOI 10.1073/pnas.0402546101; Mohler PJ, 2004, J BIOL CHEM, V279, P25798, DOI 10.1074/jbc.M401296200; Mohler PJ, 2004, J BIOL CHEM, V279, P12980, DOI 10.1074/jbc.M313979200; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Mohler PJ, 2002, J CELL SCI, V115, P1565; Mohler PJ, 2002, J BIOL CHEM, V277, P10599, DOI 10.1074/jbc.M110958200; Moorthy S, 2000, J CELL BIOL, V149, P915, DOI 10.1083/jcb.149.4.915; Pradhan D, 2001, J BIOL CHEM, V276, P4175, DOI 10.1074/jbc.M009259200; Stankewich MC, 1998, P NATL ACAD SCI USA, V95, P14158, DOI 10.1073/pnas.95.24.14158; STEINER JP, 1988, J BIOL CHEM, V263, P14417; STEINER JP, 1989, J BIOL CHEM, V264, P2783; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; Wang DS, 1995, BIOCHEM BIOPH RES CO, V217, P608, DOI 10.1006/bbrc.1995.2818; WOODS CM, 1988, ANNU REV MED, V39, P107, DOI 10.1146/annurev.med.39.1.107; YU J, 1979, P NATL ACAD SCI USA, V76, P2340, DOI 10.1073/pnas.76.5.2340; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	43	77	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40185	40193		10.1074/jbc.M406018200	http://dx.doi.org/10.1074/jbc.M406018200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262991	hybrid			2022-12-27	WOS:000223791500117
J	Immormino, RM; Dollins, DE; Shaffer, PL; Soldano, KL; Walker, MA; Gewirth, DT				Immormino, RM; Dollins, DE; Shaffer, PL; Soldano, KL; Walker, MA; Gewirth, DT			Ligand-induced conformational shift in the N-terminal domain of GRP94, an Hsp90 chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAIN; SHOCK-PROTEIN 90; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; ATPASE ACTIVITY; CLIENT PROTEIN; GELDANAMYCIN; DIMERIZATION; INHIBITION; IDENTIFICATION	GRP94 is the endoplasmic reticulum paralog of cytoplasmic Hsp90. Models of Hsp90 action posit an ATP-dependent conformational switch in the N-terminal ligand regulatory domain of the chaperone. However, crystal structures of the isolated N-domain of Hsp90 in complex with a variety of ligands have yet to demonstrate such a conformational change. We have determined the structure of the N-domain of GRP94 in complex with ATP, ADP, and AMP. Compared with the N-ethylcarboxamidoadenosine and radicicol-bound forms, these structures reveal a large conformational rearrangement in the protein. The nucleotide-bound form exposes new surfaces that interact to form a biochemically plausible dimer that is reminiscent of those seen in structures of MutL and DNA gyrase. Weak ATP binding and a conformational change in response to ligand identity are distinctive mechanistic features of GRP94 and suggest a model for how GRP94 functions in the absence of cochaperones and ATP hydrolysis.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Gewirth, DT (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	gewirth@duke.edu						Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Brino L, 2000, J BIOL CHEM, V275, P9468, DOI 10.1074/jbc.275.13.9468; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; Hu T, 2002, J BIOL CHEM, V277, P5944, DOI 10.1074/jbc.M111394200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Maruya M, 1999, J MOL BIOL, V285, P903, DOI 10.1006/jmbi.1998.2349; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; RICHARDS FM, 1988, PROTEINS, V3, P71, DOI 10.1002/prot.340030202; Richardson JS, 2003, METHOD ENZYMOL, V374, P385, DOI 10.1016/S0076-6879(03)74018-X; Richter K, 2002, J BIOL CHEM, V277, P44905, DOI 10.1074/jbc.M208457200; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Rosser MFN, 2000, J BIOL CHEM, V275, P22798, DOI 10.1074/jbc.M001477200; Rosser MFN, 2004, BIOCHEMISTRY-US, V43, P8835, DOI 10.1021/bi049539q; Scheibel T, 1999, P NATL ACAD SCI USA, V96, P1297, DOI 10.1073/pnas.96.4.1297; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Soldano KL, 2003, J BIOL CHEM, V278, P48330, DOI 10.1074/jbc.M308661200; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wassenberg JJ, 2000, J BIOL CHEM, V275, P22806, DOI 10.1074/jbc.M001476200; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	47	88	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46162	46171		10.1074/jbc.M405253200	http://dx.doi.org/10.1074/jbc.M405253200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15292259	hybrid			2022-12-27	WOS:000224694900103
J	Noda, M; Matoba, Y; Kumagai, T; Sugiyama, M				Noda, M; Matoba, Y; Kumagai, T; Sugiyama, M			Structural evidence that alanine racemase from a D-cycloserine-producing microorganism exhibits resistance to its own product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-STEAROTHERMOPHILUS; SALMONELLA-TYPHIMURIUM; FACTOR REFINEMENT; SEQUENCE; PURIFICATION; MECHANISM; DNA; ENZYMES; CLONING; LIGASE	Alanine racemase (ALR), an enzyme that catalyzes the interconversion of Ala enantiomers, is essential for the synthesis of the bacterial cell wall. We have shown that it is harder to inhibit the catalytic activity of ALR from D-cycloserine (DCS)-producing Streptomyces lavendulae than that from Escherichia coli by DCS. To obtain structural evidence for the fact that Streptomyces ALR displays resistance to DCS, we determined the precise nature of the x-ray crystal structures of the cycloserine-free and cycloserine enantiomer-bound forms of Streptomyces ALR at high resolutions. Streptomyces ALR takes a dimer structure, which is formed by interactions between the N-terminal domain of one monomer with the C-terminal domain of its partner. Each of the two active sites of ALR, which is generated as a result of the formation of the dimer structure, is composed of pyridoxal 5'-phosphate (PLP), the PLP-binding residue Lys(38), and the amino acids in the immediate environment of the pyridoxal cofactor. The current model suggests that each active site of Streptomyces ALR maintains a larger space and takes a more rigid conformation than that of Bacillus stearothermophilus ALR determined previously. Furthermore, we show that Streptomyces ALR results in a slow conversion to a final form of a pyridoxal derivative arising from either isomer of cycloserine, which inhibits the catalytic activity noncompetitively. In fact, the slow conversion is confirmed by the fact that each enzyme-bound cycloserine derivative, which is bound to PLP, takes an asymmetric structure.	Hiroshima Univ, Dept Mol Microbiol & Biotechnol, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan	Hiroshima University	Sugiyama, M (corresponding author), Hiroshima Univ, Dept Mol Microbiol & Biotechnol, Grad Sch Biomed Sci, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.	sugi@hiroshima-u.ac.jp						BADET B, 1985, BIOCHEMISTRY-US, V24, P1333, DOI 10.1021/bi00327a010; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER A, 1993, X PLOR VERSION 3 1 M; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Caceres NE, 1997, J BACTERIOL, V179, P5046, DOI 10.1128/jb.179.16.5046-5055.1997; DAVID HL, 1969, AM REV RESPIR DIS, V100, P579; DIVEN WF, 1964, BIOCHIM BIOPHYS ACTA, V85, P322, DOI 10.1016/0926-6569(64)90253-6; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Feng ZY, 2003, ANTIMICROB AGENTS CH, V47, P283, DOI 10.1128/AAC.47.1.283-291.2003; Fenn TD, 2003, BIOCHEMISTRY-US, V42, P5775, DOI 10.1021/bi027022d; GALAKATOS NG, 1986, BIOCHEMISTRY-US, V25, P3255, DOI 10.1021/bi00359a026; JANSKI AM, 1981, BIOCHEM J, V194, P1027, DOI 10.1042/bj1941027; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; LAMBERT MP, 1972, J BACTERIOL, V110, P978, DOI 10.1128/JB.110.3.978-987.1972; LILLEY PE, 1993, GENE, V129, P9; LOBOCKA M, 1994, J BACTERIOL, V176, P1500, DOI 10.1128/jb.176.5.1500-1510.1994; MCPHERSON A, 1982, PREPARATION ANAL PRO, P96; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Morollo AA, 1999, BIOCHEMISTRY-US, V38, P3293, DOI 10.1021/bi9822729; Neuhaus F. C., 1967, ANTIBIOTICS-BASEL, V1, P40; Noda M, 2004, J BIOL CHEM, V279, P46143, DOI 10.1074/jbc.M404603200; Peisach D, 1998, BIOCHEMISTRY-US, V37, P4958, DOI 10.1021/bi972884d; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; *RIG MOL STRUCT CO, 2001, CRYSTALCLEAR; Shaw JP, 1997, BIOCHEMISTRY-US, V36, P1329, DOI 10.1021/bi961856c; Stamper CGF, 1998, BIOCHEMISTRY-US, V37, P10438, DOI 10.1021/bi980692s; TANIZAWA K, 1988, BIOCHEMISTRY-US, V27, P1311, DOI 10.1021/bi00404a033; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALSH CT, 1989, J BIOL CHEM, V264, P2393; WANG E, 1978, BIOCHEMISTRY-US, V17, P1313, DOI 10.1021/bi00600a028; WASSERMAN SA, 1984, BIOCHEMISTRY-US, V23, P5182, DOI 10.1021/bi00317a015; Watanabe A, 2002, J BIOL CHEM, V277, P19166, DOI 10.1074/jbc.M201615200; YEW WW, 1993, CLIN INFECT DIS, V17, P288, DOI 10.1093/clinids/17.2.288	34	36	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46153	46161		10.1074/jbc.M404605200	http://dx.doi.org/10.1074/jbc.M404605200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15302886	hybrid			2022-12-27	WOS:000224694900102
J	Kumar, N; Tomar, A; Parrill, AL; Khurana, S				Kumar, N; Tomar, A; Parrill, AL; Khurana, S			Functional dissection and molecular characterization of calcium-sensitive actin-capping and actin-depolymerizing sites in villin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; GELSOLIN ACTIVITY; DOMAIN-STRUCTURE; PLASMA GELSOLIN; CA2+ REGULATION; BINDING SITES; F-ACTIN; IDENTIFICATION; CYTOSKELETON; PROTEINS	All proteins of the villin superfamily, which includes the actin-capping and - severing proteins such as gelsolin, scinderin, and severin, are calcium-regulated actin-modifying proteins. Like some of these proteins, villin has morphologically distinct effects on actin assembly depending on the free calcium concentrations. At physiological calcium (Ca2+) villin nucleates and bundles actin, whereas at higher concentrations it caps (> 50 muM) and severs (> 200 muM) actin filaments. Although Ca2+-binding sites have been described in villin, the functional characterization of these sites has not been done previously. In the present study we functionally dissect the calcium-dependent actin-capping and - depolymerizing sites in villin. Our analysis reveals that villin binds Ca2+ with a K-d of 80.5 muM, a stoichiometry of 5.97, and a Hill's coefficient of 1.2. Using the NMR structure of villin 14T and the gelsolin-actin/Ca2+ crystal structure, six putative sites that result in Ca2+-induced conformational changes were identified in human villin and confirmed by mutational analysis. Molecular dynamics studies support the mutational analysis and provide a model for structural difference in the A93G mutant that prevents the calcium-induced conformational changes in the S1 domain of villin. Furthermore, we determined that villin expresses at least two types of Ca2+-sensitive sites that determine separate functional properties; site 1 (Glu-25, Asp-44, and Glu-74) regulates actin-capping, whereas sites 1 and 2 (Asp-86, Ala-93, and Asp-61), together with the intra-domain calcium-sensitive sites in villin, regulate actin depolymerization by villin. This is the first study that employs sequential mutagenesis to biochemically and functionally characterize the calcium-sensitive sites in villin. Such mutational analysis and functional characterization of the actin-capping and - depolymerizing sites are unknown for other proteins of the villin family.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Memphis, Dept Chem, Memphis, TN 38152 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Memphis	Khurana, S (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave,Nash 402, Memphis, TN 38163 USA.	skhurana@utmem.edu		Parrill, Abby/0000-0003-1658-8497; Kumar, Narendra/0000-0002-1193-0954; Khurana, Seema/0000-0002-6884-810X	NIDDK NIH HHS [DK-65006, DK-54755] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054755, R01DK065006] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; BURTNICK LD, 2004, EMBO J; Choe H, 2002, J MOL BIOL, V324, P691, DOI 10.1016/S0022-2836(02)01131-2; COUE M, 1985, J BIOL CHEM, V260, P5033; EICHINGER L, 1991, J CELL BIOL, V112, P665, DOI 10.1083/jcb.112.4.665; FINIDORI J, 1992, J CELL BIOL, V116, P1145, DOI 10.1083/jcb.116.5.1145; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; GLENNEY JR, 1980, P NATL ACAD SCI-BIOL, V77, P6458, DOI 10.1073/pnas.77.11.6458; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; HELLWEG T, 1993, BIOPHYS J, V65, P799, DOI 10.1016/S0006-3495(93)81121-4; HESTERBERG LK, 1983, J BIOL CHEM, V258, P365; HESTERBERG LK, 1983, J BIOL CHEM, V258, P359; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Irobi E, 2003, FEBS LETT, V552, P86, DOI 10.1016/S0014-5793(03)00934-7; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; Kinosian HJ, 1998, BIOPHYS J, V75, P3101, DOI 10.1016/S0006-3495(98)77751-3; Kumar N, 2004, J BIOL CHEM, V279, P24915, DOI 10.1074/jbc.C400110200; Kumar N, 2004, J BIOL CHEM, V279, P3096, DOI 10.1074/jbc.M308878200; Lin KM, 2000, J BIOL CHEM, V275, P27746; Louvard RAD, 2003, MOL BIOL CELL, V14, P4641, DOI 10.1091/mbc.E03-02-0091; MARKUS MA, 1994, PROTEIN SCI, V3, P70; Markus MA, 1997, PROTEIN SCI, V6, P1197; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; POPE B, 1991, FEBS LETT, V280, P70, DOI 10.1016/0014-5793(91)80206-I; POPE B, 1995, BIOCHEMISTRY-US, V34, P1583, DOI 10.1021/bi00005a014; SAKURAI T, 1991, J BIOL CHEM, V266, P15979; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; SUN HQ, 1994, J BIOL CHEM, V269, P9473; WALSH TP, 1984, BIOCHEMISTRY-US, V23, P2613, DOI 10.1021/bi00307a012; WALSH TP, 1984, BIOCHEMISTRY-US, V23, P6099, DOI 10.1021/bi00320a030; WEEDS AG, 1995, FEBS LETT, V360, P227, DOI 10.1016/0014-5793(95)00109-M; Zhai LW, 2002, BIOCHEMISTRY-US, V41, P11750, DOI 10.1021/bi0263762; Zhai LW, 2001, J BIOL CHEM, V276, P36163, DOI 10.1074/jbc.C100418200	35	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45036	45046		10.1074/jbc.M405424200	http://dx.doi.org/10.1074/jbc.M405424200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15272027	hybrid			2022-12-27	WOS:000224505600096
J	Dong, TC; Cutting, SM				Dong, TC; Cutting, SM			The PDZ domain of the SpoIVB transmembrane signaling protein enables cis-trans interactions involving multiple partners leading to the activation of the pro-sigma(K) processing complex in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MOTHER-CELL; TRANSCRIPTION FACTOR; SPORE FORMATION; SIGMA-K; SPORULATION; FORESPORE; FAMILY; RECOGNITION; PROTEOLYSIS	In sporulating cells of Bacillus subtilis, the serine peptidase SpoIVB is the essential component of a transmembrane signaling cascade between the two intracellular compartments (forespore and mother cell) that leads to activation of the sigma(K) transcription factor in the mother cell chamber. This regulatory process, referred to as the sigma(K) checkpoint, is essential for ensuring proper development of the spore and introduces an appropriate level of fidelity to the developmental process. This work unravels the signaling process and establishes how SpoIVB interacts with other protein partners in the sigma(K) checkpoint. SpoIVB is synthesized as a zymogen that is autoproteolytically activated and carries a PDZ domain that is responsible for at least three distinct binding reactions, a phenomenon not previously demonstrated for an individual PDZ domain. First, binding to the SpoIVB NH2 terminus to maintain the protein in its zymogen form. Second, following secretion across a spore membrane, binding in trans to the COOH terminus of another SpoIVB molecule. Binding in trans facilitates the first cleavage event of SpoIVB near the NH2 terminus releasing it from the inner forespore membrane. We show that at least two further cis cleavage events occur at specific sites near the NH2 terminus after which the PDZ domain targets SpoIVB to the pro-sigma(K) processing complex in the outer forespore membrane. Specifically, SpoIVB binds to the COOH terminus of BofA. In turn, this allows SpoIVB to cleave the COOH terminus of SpoIVFA an event pivotal to activating the SpoIVFB zinc metalloprotease by disruption of the heteroligomeric pro-sigma(K) complex.	Royal Holloway Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England	University of London; Royal Holloway University London	Cutting, SM (corresponding author), Royal Holloway Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England.	s.cutting@rhul.ac.uk						Beebe KD, 2000, BIOCHEMISTRY-US, V39, P3149, DOI 10.1021/bi992709s; CUTTING S, 1991, J MOL BIOL, V221, P1237; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; Cutting S., 1990, MOL BIOL METHODS BAC; Dong TC, 2003, MOL MICROBIOL, V49, P1425, DOI 10.1046/j.1365-2958.2003.03651.x; Gomez M, 1996, MICROBIOL-UK, V142, P3453, DOI 10.1099/13500872-142-12-3453; Gomez M, 1997, MICROBIOL-UK, V143, P157, DOI 10.1099/00221287-143-1-157; GOMEZ M, 1995, J BACTERIOL, V177, P4825, DOI 10.1128/jb.177.16.4825-4827.1995; Green DH, 1999, APPL ENVIRON MICROB, V65, P4288; Harris BZ, 2001, J CELL SCI, V114, P3219; Harwood C.R., 1990, MOL BIOL METHODS BAC; Hoa NT, 2002, J BACTERIOL, V184, P191, DOI 10.1128/JB.184.1.191-199.2002; Hoa NT, 2001, J BACTERIOL, V183, P4364, DOI 10.1128/JB.183.14.4364-4373.2001; HOA NT, 2004, HDB PROTEOLYTIC ENZY, P2043; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Lewis AP, 1999, PROTEIN SCI, V8, P439; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; LOSICK R, 1993, SCIENCE, V262, P1227, DOI 10.1126/science.8235653; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; Nicholson WL., 1990, MOL BIOL METHODS BAC, P391, DOI DOI 10.1111/J.1751-1097.1991.TB02087.X; Oke V, 1997, MOL MICROBIOL, V23, P223, DOI 10.1046/j.1365-2958.1997.2091573.x; Pallen MJ, 1997, MOL MICROBIOL, V26, P411, DOI 10.1046/j.1365-2958.1997.5591911.x; Pan Q, 2003, J BACTERIOL, V185, P6051, DOI 10.1128/JB.185.20.6051-6056.2003; Ponting CP, 1997, PROTEIN SCI, V6, P464; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Resnekov O, 1996, GENES CELLS, V1, P529, DOI 10.1046/j.1365-2443.1996.d01-262.x; RICCA E, 1992, J BACTERIOL, V174, P3177, DOI 10.1128/jb.174.10.3177-3184.1992; Rudner DZ, 1999, P NATL ACAD SCI USA, V96, P14765, DOI 10.1073/pnas.96.26.14765; Rudner DZ, 2002, GENE DEV, V16, P1007, DOI 10.1101/gad.977702; Sambrook J., 2001, MOL CLONING LAB MANU; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wakeley P, 2000, MOL MICROBIOL, V36, P1415, DOI 10.1046/j.1365-2958.2000.01962.x; Wakeley PR, 2000, MOL MICROBIOL, V36, P1336, DOI 10.1046/j.1365-2958.2000.01946.x; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; YOUNGMAN P, 1984, PLASMID, V12, P1, DOI 10.1016/0147-619X(84)90061-1; Yu YTN, 2000, J BACTERIOL, V182, P3305, DOI 10.1128/JB.182.11.3305-3309.2000	40	13	14	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43468	43478		10.1074/jbc.M407048200	http://dx.doi.org/10.1074/jbc.M407048200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292188	hybrid			2022-12-27	WOS:000224383100016
J	Lorenzon, NM; Haarmann, CS; Norris, EE; Papadopoulos, S; Beam, KG				Lorenzon, NM; Haarmann, CS; Norris, EE; Papadopoulos, S; Beam, KG			Metabolic biotinylation as a probe of supramolecular structure of the triad junction in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-III-LOOP; GREEN FLUORESCENT PROTEIN; RECEPTOR BETA-1A SUBUNIT; DIHYDROPYRIDINE RECEPTOR; CALCIUM-CHANNEL; CA2+ CHANNEL; RYANODINE RECEPTOR; ALPHA(1S) SUBUNIT; CHARGE MOVEMENTS; TERMINUS	Excitation-contraction coupling in skeletal muscle involves conformational coupling between dihydropyridine receptors (DHPRs) in the plasma membrane and ryanodine receptors (RyRs) in the sarcoplasmic reticulum. However, it remains uncertain what regions, if any, of the two proteins interact with one another. Toward this end, it would be valuable to know the spatial interrelationships of DHPRs and RyRs within plasma membrane/sarcoplasmic reticulum junctions. Here we describe a new approach based on metabolic incorporation of biotin into targeted sites of the DHPR. To accomplish this, cDNAs were constructed with a biotin acceptor domain (BAD) fused to selected sites of the DHPR, with fluorescent protein (XFP) attached at a second site. All of the BAD-tagged constructs properly targeted to junctions (as indicted by small puncta of XFP) and were functional for excitation-contraction coupling. To determine whether the introduced BAD was biotinylated and accessible to avidin (similar to60 kDa), myotubes were fixed, permeablized, and exposed to fluorescently labeled avidin. Upon expression in beta(1)-null or dysgenic (alpha(1S)-null) myotubes, punctate avidin fluorescence co-localized with the XFP puncta for BAD attached to the beta(1a) N- or C-terminals, or the alpha(1S) N-terminal or II-III loop. However, BAD fused to the alpha(1S) C-terminal was inaccessible to avidin in dysgenic myotubes (containing RyR1). In contrast, this site was accessible to avidin when the identical construct was expressed in dyspedic myotubes lacking RyR1. These results indicate that avidin has access to a number of sites of the DHPR within fully assembled (RyR1-containing) junctions, but not to the alpha(1S) C-terminal, which appears to be occluded by the presence of RyR1.	Colorado State Univ, Dept Biomed Sci, Anat Sect, Ft Collins, CO 80523 USA	Colorado State University	Beam, KG (corresponding author), Colorado State Univ, Dept Biomed Sci, Anat Sect, 1617 Campus Delivery, Ft Collins, CO 80523 USA.	kbeam@lamar.colostate.edu			NIAMS NIH HHS [AR44750] Funding Source: Medline; NINDS NIH HHS [NS24444] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR044750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024444] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahern CA, 2001, P NATL ACAD SCI USA, V98, P6935, DOI 10.1073/pnas.111001898; Beam KG, 1997, METHOD CELL BIOL, V52, P283, DOI 10.1016/S0091-679X(08)60384-2; Beurg M, 1999, BIOPHYS J, V77, P2953, DOI 10.1016/S0006-3495(99)77128-6; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; Casarotto MG, 2000, J BIOL CHEM, V275, P11631, DOI 10.1074/jbc.275.16.11631; Cheng WJ, 2002, BIOPHYS J, V82, p78A; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; Dirksen RT, 1999, J GEN PHYSIOL, V114, P393, DOI 10.1085/jgp.114.3.393; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; Flucher BE, 2000, J CELL BIOL, V151, P467, DOI 10.1083/jcb.151.2.467; Flucher BE, 2000, FEBS LETT, V474, P93, DOI 10.1016/S0014-5793(00)01583-0; Flucher BE, 2002, P NATL ACAD SCI USA, V99, P10167, DOI 10.1073/pnas.122345799; FRANZINIARMSTRONG C, 1995, J MUSCLE RES CELL M, V16, P319, DOI 10.1007/BF00121140; GARCIA J, 1994, J GEN PHYSIOL, V103, P125, DOI 10.1085/jgp.103.1.125; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; Haarmann CS, 2004, BIOPHYS J, V86, p219A; Hulme JT, 2002, J BIOL CHEM, V277, P4079, DOI 10.1074/jbc.M109814200; Kugler G, 2004, J BIOL CHEM, V279, P4721, DOI 10.1074/jbc.M307538200; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Papadopoulos S, 2004, J BIOL CHEM, V279, P44046, DOI 10.1074/jbc.M405317200; Parrott MB, 2000, MOL THER, V1, P96, DOI 10.1006/mthe.1999.0011; Proenza C, 2000, J BIOL CHEM, V275, P23169, DOI 10.1074/jbc.M003389200; Proenza C, 2002, J BIOL CHEM, V277, P6530, DOI 10.1074/jbc.M106471200; PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321; Reddy DV, 2000, BIOCHEMISTRY-US, V39, P2509, DOI 10.1021/bi9925367; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; Sencer S, 2001, J BIOL CHEM, V276, P38237; Sheridan DC, 2003, BIOPHYS J, V84, P220, DOI 10.1016/S0006-3495(03)74844-9; Slavik KJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1475, DOI 10.1152/ajpcell.1997.272.5.C1475; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Wilkens CM, 2001, P NATL ACAD SCI USA, V98, P5892, DOI 10.1073/pnas.101618098	39	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44057	44064		10.1074/jbc.M405318200	http://dx.doi.org/10.1074/jbc.M405318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15280388	hybrid			2022-12-27	WOS:000224383100085
J	Qu, JH; Kryukova, Y; Potapova, IA; Doronin, SV; Larsen, M; Krishnamurthy, G; Cohen, IS; Robinson, RB				Qu, JH; Kryukova, Y; Potapova, IA; Doronin, SV; Larsen, M; Krishnamurthy, G; Cohen, IS; Robinson, RB			MiRP1 modulates HCN2 channel expression and gating in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINK-RELATED PEPTIDE-1; PACEMAKER CHANNELS; VENTRICULAR MYOCYTES; BETA-SUBUNIT; K+ CHANNEL; HERG	MinK-related protein (MiRP1 or KCNE2) interacts with the hyperpolarization-activated, cyclic nucleotide-gated (HCN) family of pacemaker channels to alter channel gating in heterologous expression systems. Given the high expression levels of MiRP1 and HCN subunits in the cardiac sinoatrial node and the contribution of pacemaker channel function to impulse initiation in that tissue, such an interaction could be of considerable physiological significance. However, the functional evidence for MiRP1/HCN interactions in heterologous expression studies has been accompanied by inconsistencies between studies in terms of the specific effects on channel function. To evaluate the effect of MiRP1 on HCN expression and function in a physiological context, we used an adenovirus approach to overexpress a hemagglutinin (HA)-tagged MiRP1 (HA-MiRP1) and HCN2 in neonatal rat ventricular myocytes, a cell type that expresses both MiRP1 and HCN2 message at low levels. HA-MiRP1 co-expression with HCN2 resulted in a 4-fold increase in maximal conductance of pacemaker currents compared with HCN2 expression alone. HCN2 activation and deactivation kinetics also changed, being significantly more rapid for voltages between - 60 and - 95 mV when HA-MiRP1 was co-expressed with HCN2. However, the voltage dependence of activation was not affected. Co-immunoprecipitation experiments demonstrated that expressed HA-MiRP1 and HCN2, as well as endogenous MiRP1 and HCN2, co-assemble in ventricular myocytes. The results indicate that MiRP1 acts as a beta subunit for HCN2 pacemaker channel subunits and alters channel gating at physiologically relevant voltages in cardiac cells.	Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ, Dept Pediat, New York, NY 10032 USA; Columbia Univ, Ctr Mol Therapeut, New York, NY 10032 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Mol Cardiol, Stony Brook, NY 11794 USA	Columbia University; Columbia University; Columbia University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Robinson, RB (corresponding author), Columbia Univ, Dept Pharmacol, 630 W 168th St, New York, NY 10032 USA.	rbr1@columbia.edu			NHLBI NIH HHS [HL20558, HL-28958] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL020558, R01HL020558, P01HL028958] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott G W, 2001, Mol Interv, V1, P95; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Altomare C, 2003, J PHYSIOL-LONDON, V549, P347, DOI 10.1113/jphysiol.2002.027698; Altomare C, 2001, J GEN PHYSIOL, V117, P519, DOI 10.1085/jgp.117.6.519; Anantharam A, 2003, J BIOL CHEM, V278, P11739, DOI 10.1074/jbc.M212751200; Barbuti A, 2004, CIRC RES, V94, P1325, DOI 10.1161/01.RES.0000127621.54132.AE; Cerbai E, 1996, CIRCULATION, V94, P1674, DOI 10.1161/01.CIR.94.7.1674; Cerbai E, 2001, J MOL CELL CARDIOL, V33, P441, DOI 10.1006/jmcc.2000.1316; Cui J, 2001, J BIOL CHEM, V276, P17244, DOI 10.1074/jbc.M010904200; Cui J, 2000, CURR BIOL, V10, P671, DOI 10.1016/S0960-9822(00)00516-9; Decher N, 2003, PFLUG ARCH EUR J PHY, V446, P633, DOI 10.1007/s00424-003-1127-7; Jiang M, 2004, CIRCULATION, V109, P1783, DOI 10.1161/01.CIR.0000124225.43852.50; Krumerman A, 2004, AM J PHYSIOL-CELL PH, V286, pC1453, DOI 10.1152/ajpcell.00275.2003; Melman YF, 2002, TRENDS CARDIOVAS MED, V12, P182, DOI 10.1016/S1050-1738(02)00158-5; Moosmang S, 2001, EUR J BIOCHEM, V268, P1646, DOI 10.1046/j.1432-1327.2001.02036.x; Much B, 2003, J BIOL CHEM, V278, P43781, DOI 10.1074/jbc.M306958200; Plotnikov AN, 2004, CIRCULATION, V109, P506, DOI 10.1161/01.CIR.0000114527.10764.CC; Pourrier M, 2003, CIRC RES, V93, P189, DOI 10.1161/01.RES.0000084851.60947.B5; Proenza C, 2002, J BIOL CHEM, V277, P5101, DOI 10.1074/jbc.M106974200; Protas L, 1999, AM J PHYSIOL-HEART C, V277, pH940, DOI 10.1152/ajpheart.1999.277.3.H940; Qu JH, 2001, CIRC RES, V89, pE8, DOI 10.1161/hh1301.094395; Romey G, 1997, J BIOL CHEM, V272, P16713, DOI 10.1074/jbc.272.27.16713; Shi WM, 1999, CIRC RES, V85, pE1; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839	26	109	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43497	43502		10.1074/jbc.M405018200	http://dx.doi.org/10.1074/jbc.M405018200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292247	hybrid			2022-12-27	WOS:000224383100019
J	Ussar, S; Voss, T				Ussar, S; Voss, T			MEK1 and MEK2, different regulators of the G(1)/S transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE PATHWAY; CELL-CYCLE ARREST; ACTIVATION; SIGNAL; ERK; PROLIFERATION; PHOSPHORYLATION; SENESCENCE; PROTEINS; GENE	The ERK cascade is activated by hormones, cytokines, and growth factors that result in either proliferation or growth arrest depending on the duration and intensity of the ERK activation. Here we provide evidence that the MEK1/ERK module preferentially provides proliferative signals, whereas the MEK2/ERK module induces growth arrest at the G(1)/S boundary. Depletion of either MEK subtype by RNA interference generated a unique phenotype. The MEK1 knock down led to p21(cip1) induction and to the appearance of cells with a senescence-like phenotype. Permanent ablation of MEK1 resulted in reduced colony formation potential, indicating the importance of MEK1 for long term proliferation and survival. MEK2 deficiency, in contrast, was accompanied by a massive induction of cyclin D expression and, thus, CDK4/6 activation followed by nucleophosmin hyperphosphorylation and centrosome over-amplification. Our results suggest that the two MEK subtypes have distinct ways to contribute to a regulated ERK activity and cell cycle progression.	Boehringer Ingelheim Austria GmbH, A-1121 Vienna, Austria	Boehringer Ingelheim	Voss, T (corresponding author), Boehringer Ingelheim Austria GmbH, Dr Boehringer Gasse 5-11, A-1121 Vienna, Austria.	tilman.voss@vie.boehringer-ingelheim.com	Ussar, Siegfried/AAL-4331-2021	Ussar, Siegfried/0000-0001-7575-0920				Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Belanger LF, 2003, MOL CELL BIOL, V23, P4778, DOI 10.1128/MCB.23.14.4778-4787.2003; Cha H, 2004, BIOCHEM J, V378, P857, DOI 10.1042/BJ20031173; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Colanzi A, 2000, J CELL BIOL, V149, P331, DOI 10.1083/jcb.149.2.331; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; EL DW, 1993, CELL, V75, P817; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; O'Neill E, 2004, BRIT J CANCER, V90, P283, DOI 10.1038/sj.bjc.6601488; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Roninson IB, 2003, CANCER RES, V63, P2705; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Willard FS, 2001, CELL SIGNAL, V13, P653, DOI 10.1016/S0898-6568(01)00185-1; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xu SC, 1997, MOL ENDOCRINOL, V11, P1618, DOI 10.1210/me.11.11.1618	39	89	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43861	43869		10.1074/jbc.M406240200	http://dx.doi.org/10.1074/jbc.M406240200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15284233	hybrid			2022-12-27	WOS:000224383100063
J	Bennett, RL; Blalock, WL; May, WS				Bennett, RL; Blalock, WL; May, WS			Serine 18 phosphorylation of RAX, the PKR activator, is required for PKR activation and consequent translation inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PKR; CELLULAR ACTIVATOR; RNA; PACT; INTERFERON; INTERLEUKIN-3; SURVIVAL; BINDING; SITES; CELLS	It is now apparent that the double-stranded (ds) RNA-dependent protein kinase, PKR, is a regulator of diverse cellular responses to stress. Recently, the murine dsRNA-binding protein RAX and its human ortholog PACT were identified as cellular activators of PKR. Previous reports demonstrate that following stress, RAX/ PACT associates with and activates PKR resulting in eIF2alpha phosphorylation, consequent translation inhibition, and cell death via apoptosis. Although RAX/ PACT is phosphorylated during stress, any regulatory role for this post-translational modification has been uncertain. Now we have discovered that RAX is phosphorylated on serine 18 in both human and mouse cells. The non-phosphorylatable form of RAX, RAX(S18A), although still able to bind dsRNA and associate with PKR, fails to activate PKR following stress. Furthermore, stable expression of RAX( S18A) results in a dominant-negative effect characterized by deficiency of eukaryotic initiation factor 2 alpha subunit phosphorylation, delay of translation inhibition, and failure to undergo rapid apoptosis following removal of interleukin-3. We propose that the ability of RAX to activate PKR is regulated by a sequential mechanism featuring RAX association with PKR, RAX phosphorylation at serine 18, and activation of PKR.	Univ Florida, Coll Dent, Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	May, WS (corresponding author), 1600 SW Archer Rd,POB 100232, Gainesville, FL 32610 USA.	smay@ufscc.ufl.edu	Bennett, Richard/ABF-9211-2021; Blalock, William L/C-6959-2019	Blalock, William L/0000-0002-8045-4840; Bennett, Richard/0000-0002-0243-2443	NCI NIH HHS [CA09126-27] Funding Source: Medline; NHLBI NIH HHS [5R01HL054083-8, R01 HL054083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009126] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Baltzis D, 2002, J BIOL CHEM, V277, P38364, DOI 10.1074/jbc.M203564200; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Donze O, 2004, EMBO J, V23, P564, DOI 10.1038/sj.emboj.7600078; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Gunnery S, 1998, METHODS, V15, P189, DOI 10.1006/meth.1998.0623; HAPEL AJ, 1985, BLOOD, V65, P1453, DOI 10.1182/blood.V65.6.1453.bloodjournal6561453; Huang X, 2002, BIOCHEM J, V366, P175, DOI 10.1042/BJ20020204; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; KELVIN DJ, 1986, J CELL PHYSIOL, V127, P403, DOI 10.1002/jcp.1041270308; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; Li SD, 2003, J INTERF CYTOK RES, V23, P689, DOI 10.1089/107999003772084806; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; May W S Jr, 1997, Adv Pharmacol, V41, P219; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Peters GA, 2001, MOL CELL BIOL, V21, P1908, DOI 10.1128/MCB.21.6.1908-1920.2001; Ruvolo PP, 2001, J BIOL CHEM, V276, P11754, DOI 10.1074/jbc.M011400200; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Yang ML, 2003, J BIOL CHEM, V278, P38325, DOI 10.1074/jbc.M303420200; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x	33	52	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42687	42693		10.1074/jbc.M403321200	http://dx.doi.org/10.1074/jbc.M403321200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15299031	hybrid			2022-12-27	WOS:000224226400042
J	Reinhardt, TA; Lippolis, JD; Shull, GE; Horst, RL				Reinhardt, TA; Lippolis, JD; Shull, GE; Horst, RL			Null mutation in the gene encoding plasma membrane Ca2+-ATPase isoform 2 impairs calcium transport into milk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ PUMP; SPERM MOTILITY; MAMMARY-GLAND; EXPRESSION; SECRETION; PMCA; ATPASE; 2A	The means by which calcium is transported into the milk produced by mammary glands is a poorly understood process. One hypothesis is that it occurs during exocytosis of secretory products via the Golgi pathway, consistent with the observation that the SPCA1 Ca2+-ATPase, which is expressed in the Golgi, is induced in lactating mammary tissue. However, massive up-regulation of the PMCA2bw plasma membrane Ca2+-ATPase also occurs during lactation and is more strongly correlated with increases in milk calcium, suggesting that calcium may be secreted directly via this pump. To examine the physiological role of PMCA2bw in lactation we compared lactating PMCA2-null mice to heterozygous and wild-type mice. Relative expression levels of individual milk proteins were unaffected by genotype. However, milk from PMCA2-null mice had 60% less calcium than milk from heterozygous and wild-type mice, the total milk protein concentration was lower, and an indirect measure of milk production ( litter weights) suggested that the PMCA2-null mice produce significantly less milk. In contrast, lactose was higher in milk from PMCA2-null mice during early lactation, but by day 12 of lactation there were no differences in milk lactose between the three genotypes. These data demonstrate that the activity of PMCA2bw is required for secretion of much of the calcium in milk. This major secretory function represents a novel biological role for the plasma membrane Ca2+-ATPases, which are generally regarded as premier regulators of intracellular Ca2+.	USDA ARS, Periparturient Dis Cattle Res Unit, Natl Anim Dis Ctr, Ames, IA 50010 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	United States Department of Agriculture (USDA); University System of Ohio; University of Cincinnati	Reinhardt, TA (corresponding author), USDA ARS, Periparturient Dis Cattle Res Unit, Natl Anim Dis Ctr, Ames, IA 50010 USA.	treinhar@nadc.ars.usda.gov	Reinhardt, Timothy/A-7536-2009	Reinhardt, Timothy/0000-0001-5552-2509; Lippolis, John/0000-0003-2314-4384	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061974] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61974] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; BAUMRUCKER CR, 1978, LACTATION, V4, P463; Brini M, 2003, J BIOL CHEM, V278, P24500, DOI 10.1074/jbc.M300784200; Burgoyne RD, 1998, J MAMMARY GLAND BIOL, V3, P275, DOI 10.1023/A:1018763427108; Burgoyne RD, 1998, BIOCHEM SOC SYMP, P91; CAMERON IL, 1980, CYTOBIOS, V27, P89; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; Chicka MC, 2003, J BIOL CHEM, V278, P18464, DOI 10.1074/jbc.M301482200; Dumont RA, 2001, J NEUROSCI, V21, P5066, DOI 10.1523/JNEUROSCI.21-14-05066.2001; Duncan JS, 1996, BIOCHEM J, V317, P487, DOI 10.1042/bj3170487; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; ENYEDI A, 1994, J BIOL CHEM, V269, P41; Filoteo AG, 1997, J BIOL CHEM, V272, P23741, DOI 10.1074/jbc.272.38.23741; Guerini D, 1999, CALCIUM AS A CELLULAR REGULATOR, P249; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; Horst RL, 1997, J MAMMARY GLAND BIOL, V2, P253, DOI 10.1023/A:1026384421273; Kip SN, 2003, AM J PHYSIOL-RENAL, V284, pF122, DOI 10.1152/ajprenal.00161.2002; Kozel PJ, 1998, J BIOL CHEM, V273, P18693, DOI 10.1074/jbc.273.30.18693; NEVILLE MC, 1982, J PHYSIOL-LONDON, V323, P497, DOI 10.1113/jphysiol.1982.sp014088; NEVILLE MC, 1979, J PHYSIOL-LONDON, V290, P59, DOI 10.1113/jphysiol.1979.sp012759; NEVILLE MC, 1994, J DAIRY SCI, V77, P1964, DOI 10.3168/jds.S0022-0302(94)77142-3; Okunande GW, 2004, J BIOL CHEM, V279, P33742, DOI 10.1074/jbc.M404628200; Penniston JT, 1997, ANN NY ACAD SCI, V834, P56, DOI 10.1111/j.1749-6632.1997.tb52225.x; Reinhardt TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1595, DOI 10.1152/ajpcell.2000.279.5.C1595; Reinhardt TA, 2004, AM J PHYSIOL-CELL PH, V286, pC164, DOI 10.1152/ajpcell.00065.2003; REINHARDT TA, 1984, J CLIN ENDOCR METAB, V58, P91, DOI 10.1210/jcem-58-1-91; Reinhardt TA, 1999, AM J PHYSIOL-CELL PH, V276, pC796, DOI 10.1152/ajpcell.1999.276.4.C796; Schuh K, 2004, J BIOL CHEM, V279, P28220, DOI 10.1074/jbc.M312599200; Shennan DB, 1998, J MAMMARY GLAND BIOL, V3, P247, DOI 10.1023/A:1018759326200; Shennan DB, 2000, PHYSIOL REV, V80, P925, DOI 10.1152/physrev.2000.80.3.925; Shull GE, 2003, ANN NY ACAD SCI, V986, P453, DOI 10.1111/j.1749-6632.2003.tb07229.x; STINNAKRE MG, 1994, P NATL ACAD SCI USA, V91, P6544, DOI 10.1073/pnas.91.14.6544; Strehler EE, 2004, CURR MOL MED, V4, P323, DOI 10.2174/1566524043360735; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; VIRK SS, 1985, BIOCHEM J, V226, P741, DOI 10.1042/bj2260741; Wuytack F, 2003, PFLUG ARCH EUR J PHY, V446, P148, DOI 10.1007/s00424-003-1011-5; Wuytack F, 2002, CELL CALCIUM, V32, P279, DOI 10.1016/S0143416002001847	38	104	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42369	42373		10.1074/jbc.M407788200	http://dx.doi.org/10.1074/jbc.M407788200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15302868	hybrid			2022-12-27	WOS:000224226400006
J	Tam, EM; Moore, TR; Butler, GS; Overall, CM				Tam, EM; Moore, TR; Butler, GS; Overall, CM			Characterization of the distinct collagen binding, helicase and cleavage mechanisms of matrix metalloproteinase 2 and 14 (gelatinase A and MT1-MMP) - The differential roles of the MMP hemopexin C domains and the MMP-2 fibronectin type II modules in collagen triple helicase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; HUMAN-FIBROBLAST-COLLAGENASE; HUMAN NEUTROPHIL COLLAGENASE; HUMAN 72-KDA GELATINASE; DEGRADE TYPE-IV; TISSUE INHIBITOR; TERMINAL DOMAIN; SUBSTRATE-SPECIFICITY; EXTRACELLULAR-MATRIX; INTERSTITIAL COLLAGENASE	Matrix metalloproteinase-2 (MMP-2, gelatinase A) and membrane type (MT)1-MMP (MMP-14) are cooperative dynamic components of a cell surface proteolytic axis involved in regulating the cellular signaling environment and pericellular collagen homeostasis. Although MT1-MMP exhibits type I collagenolytic but poor gelatinolytic activities, MMP-2 is a potent gelatinase with weak type I collagenolytic behavior. Recombinant linker/hemopexin C domain (LCD) of MT1-MMP binds native type I collagen, blocks MT1-MMP collagenolytic activity in trans, and by circular dichroism spectroscopy, induces localized structural perturbation in the collagen. These changes were reflected by enhanced cleavage of the MT1-LCD- bound collagen by the collagenases MMP-1 and MMP-8 but not by trypsin or MMP-7. Thus, the MT1-LCD alone can initiate triple helicase activity. In contrast, the native and denatured collagen binding properties of MMP-2 reside in the fibronectin type II modules, accordingly termed the collagen binding domain (CBD). Recombinant CBD ( but not the MMP-2 LCD) also changed the circular dichroism spectra leading to increased MMP-1 and -8 cleavage of native collagen. However, recombinant CBD reduced gelatin and collagen cleavage by MMP-2 in trans as did CBD23, which comprises the second and third fibronectin type II modules, but not the CBD23 mutant W316A/W374A, which neither binds gelatin nor collagen. This indicates that MMP-2 and MT1-MMP bind collagen at a different site than MMP-1 and MMP-8. Thus, MMP-2 utilizes the CBD in cis for collagen binding and triple helicase activity, which compensates for the lack of collagen binding by the MMP-2 LCD. Hence, the MMP family has evolved two distinct mechanisms for collagen triple helicase activity using two structurally distinct domains, with triple helicase activity occurring independent of alpha-chain hydrolysis.	Univ British Columbia, Dept Biochem & Mol Biol, UBC Ctr Blood Res, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Oral Biol & Med Sci, UBC Ctr Blood Res, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Canadian Inst Hlth Res Grp Matrix Dynam, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Overall, CM (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, UBC Ctr Blood Res, 2199 Wesbrook Mall,JB Macdonald Bldg, Vancouver, BC V6T 1Z3, Canada.	chris.overall@ubc.ca	Butler, Georgina/GQP-7553-2022	Butler, Georgina/0000-0003-1172-1578				AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Al Aqeel A, 2000, AM J MED GENET, V93, P11, DOI 10.1002/1096-8628(20000703)93:1<11::AID-AJMG3>3.0.CO;2-3; Al-Mayouf SM, 2000, AM J MED GENET, V93, P5, DOI 10.1002/1096-8628(20000703)93:1<5::AID-AJMG2>3.0.CO;2-Y; ALLAN JA, 1995, BIOCHEM J, V309, P299, DOI 10.1042/bj3090299; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M009586200; Bigg HF, 2001, CANCER RES, V61, P3610; Briknarova K, 1999, STRUCTURE, V7, P1235, DOI 10.1016/S0969-2126(00)80057-X; Briknarova K, 2001, J BIOL CHEM, V276, P27613, DOI 10.1074/jbc.M101105200; Brinckmann J, 2001, J INVEST DERMATOL, V117, P269, DOI 10.1046/j.0022-202x.2001.01414.x; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; Chien CY, 2004, BIOCHEMISTRY-US, V43, P1950, DOI 10.1021/bi030176o; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DANIELSEN CC, 1987, BIOCHEM J, V247, P725, DOI 10.1042/bj2470725; DeSouza SJ, 1996, FASEB J, V10, P927, DOI 10.1096/fasebj.10.8.8666171; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; EMMERTBUCK MR, 1995, FEBS LETT, V364, P28, DOI 10.1016/0014-5793(95)00345-A; Gehrmann M, 2002, BIOL CHEM, V383, P137, DOI 10.1515/BC.2002.014; Gilles C, 1997, LAB INVEST, V76, P651; Gioia M, 2002, J BIOL CHEM, V277, P23123, DOI 10.1074/jbc.M110873200; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; KADLER K, 1994, EXTRACELLULAR MATRIX, V1; Kai HST, 2002, J BIOL CHEM, V277, P48696, DOI 10.1074/jbc.M209177200; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Knauper V, 1997, FEBS LETT, V405, P60, DOI 10.1016/S0014-5793(97)00158-0; KNAUPER V, 1993, BIOCHEM J, V291, P847; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Knott L, 1998, BONE, V22, P181, DOI 10.1016/S8756-3282(97)00279-2; Lauer-Fields JL, 2000, J BIOL CHEM, V275, P13282, DOI 10.1074/jbc.275.18.13282; Lauer-Fields JL, 2002, BIOPOLYMERS, V66, P19, DOI 10.1002/bip.10201; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; MACKAY AR, 1990, J BIOL CHEM, V265, P21929; Martignetti JA, 2001, NAT GENET, V28, P261, DOI 10.1038/90100; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1981, BIOCHEM J, V199, P807, DOI 10.1042/bj1990807; MURPHY G, 1980, BIOCHEM J, V192, P517, DOI 10.1042/bj1920517; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; Ottl J, 2000, CHEM BIOL, V7, P119, DOI 10.1016/S1074-5521(00)00077-6; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; OVERALL CM, 1987, J DENT RES, V66, P1271, DOI 10.1177/00220345870660071201; Parks WC, 1998, BIOL EXTRAC, P263; Patterson ML, 2001, FEBS LETT, V503, P158, DOI 10.1016/S0014-5793(01)02723-5; Shingleton WD, 1996, BIOCHEM CELL BIOL, V74, P759, DOI 10.1139/o96-083; Sodek J, 1992, Matrix Suppl, V1, P352; SODEK J, 1988, MECHANISMS TOOTH MOV, P303; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Tam EM, 2004, P NATL ACAD SCI USA, V101, P6917, DOI 10.1073/pnas.0305862101; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Tordai H, 1999, EUR J BIOCHEM, V259, P513, DOI 10.1046/j.1432-1327.1999.00070.x; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	74	139	142	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43336	43344		10.1074/jbc.M407186200	http://dx.doi.org/10.1074/jbc.M407186200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292230	hybrid			2022-12-27	WOS:000224226400118
J	Weiss-Haljiti, C; Pasquali, C; Ji, H; Gillieron, C; Chabert, C; Curchod, ML; Hirsch, E; Ridley, AJ; van Huijsduijnen, RH; Camps, M; Rommel, C				Weiss-Haljiti, C; Pasquali, C; Ji, H; Gillieron, C; Chabert, C; Curchod, ML; Hirsch, E; Ridley, AJ; van Huijsduijnen, RH; Camps, M; Rommel, C			Involvement of phosphoinositide 3-kinase gamma, Rac, and PAK signaling in chemokine-induced macrophage migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; P21-ACTIVATED PROTEIN-KINASE; NUCLEOTIDE EXCHANGE FACTOR; HUMAN NEUTROPHILS; RHO GTPASES; CELL-MIGRATION; 3-KINASE GAMMA; T-LYMPHOCYTES; GROWTH-FACTOR; ACTIVATION	In macrophages, chemotactic stimuli cause the activation of Rac and PAK, but little is known about the signaling pathways involved and their role in chemotactic gradient sensing. Herein, we report that in macrophages, the chemokine RANTES (regulated on activation normal T cell expressed and secreted)/CCL5 activates the small GTPase Rac and its downstream target PAK2 within seconds. This response depends on G(i) activation and largely on the subsequent triggering of phosphoinositide 3-kinase gamma (PI3Kgamma) and Rac. Retroviral transduction of tagged Rac1 and -2 indicates that RANTES/CCL5-mediated activation of PI3Kgamma triggers Rac1 but not Rac2. In agreement, silencing of Rac1 by shRNA blocks PAK2 activity and inhibits RANTES/CCL5-induced macrophage polarization and directional migration. On the other hand, the tyrosine kinase receptor agonist CSF-1 activates PAK2 independently of PI3Kgamma and Rac. Our results thus demonstrate a chemokine-specific signaling pathway in which Gi and PI3Kgamma coordinate to drive Rac1 and PAK2 activation that eventually controls the chemotactic response.	Serono Int SA, Serona Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Univ Turin, Dipartimento Genet Biol & Biochim, I-10126 Turin, Italy; UCL, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London W1W 7BS, England	Merck & Company; Serono International S.A.; University of Turin; Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Rommel, C (corresponding author), Serono Int SA, Serona Pharmaceut Res Inst, 14 Chemin Aulx, CH-1228 Geneva, Switzerland.	christian.rommel@serono.com	Hirsch, Emilio/F-4848-2013; Hooft van Huijsduijnen, Rob/B-3653-2009	Hirsch, Emilio/0000-0002-9073-6024; Ridley, Anne/0000-0001-8186-5708; Camps, Montserrat/0000-0002-9849-8657; Hooft van Huijsduijnen, Rob/0000-0002-2261-9424				Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Allen WE, 1997, J CELL SCI, V110, P707; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bowles NE, 1996, HUM GENE THER, V7, P1735, DOI 10.1089/hum.1996.7.14-1735; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN TO, 2001, SCI STKE; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; Clissi B, 2000, J IMMUNOL, V164, P3292, DOI 10.4049/jimmunol.164.6.3292; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; ENGLEN MD, 1995, J IMMUNOL METHODS, V184, P281, DOI 10.1016/0022-1759(95)00136-X; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Huang RY, 1998, MOL CELL BIOL, V18, P7130, DOI 10.1128/MCB.18.12.7130; Jones GE, 2003, EXP CELL RES, V290, P120, DOI 10.1016/S0014-4827(03)00318-5; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Ridley AJ, 2001, FEBS LETT, V498, P168, DOI 10.1016/S0014-5793(01)02481-4; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Stanley E R, 1997, Methods Mol Biol, V75, P301; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; THELEN M, 2001, SCI STKE; TURNER L, 1995, J IMMUNOL, V155, P2437; VAN AL, 1997, GENE DEV, V11, P2295; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Webb SE, 1996, J CELL SCI, V109, P793; Weiner OD, 2002, CURR BIOL, V12, pR429, DOI 10.1016/S0960-9822(02)00917-X; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Wymann MP, 2000, IMMUNOL TODAY, V21, P260, DOI 10.1016/S0167-5699(00)01649-2; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565	65	83	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43273	43284		10.1074/jbc.M402924200	http://dx.doi.org/10.1074/jbc.M402924200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292195	hybrid			2022-12-27	WOS:000224226400112
J	Jia, J; Chen, XL; Guo, LT; Yu, YD; Ding, JP; Jin, YX				Jia, J; Chen, XL; Guo, LT; Yu, YD; Ding, JP; Jin, YX			Residues Lys-149 and Glu-153 switch the aminoacylation of tRNA(Trp) in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; HIGH-LEVEL EXPRESSION; AMINO-ACID BINDING; SUBSTRATE RECOGNITION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GENETIC-CODE; ATP BINDING; CP1 DOMAIN; IDENTITY	Tryptophanyl-tRNA synthetase (TrpRS) consists of two identical subunits that induce the cross-subunit binding mode of tRNA(Trp). It has been shown that eubacterial and eukaryotic TrpRSs cannot efficiently cross-aminoacylate the corresponding tRNATrp. Although the identity elements in tRNA(Trp) that confer the species-specific recognition have been identified, the corresponding elements in TrpRS have not yet been reported. In this study two residues, Lys-149 and Glu-153, were identified as being crucial for the accurate recognition of tRNA(Trp). These residues reside adjacent to the binding pocket for Trp-AMP and show phylogenic diversities in the charge on their side chains between eubacteria and eukaryotes. Single mutagenesis at Lys-149 or Glu-153 reduced the activity of TrpRS in the activation of Trp. The reduction was less than that caused by the double mutant WBHA (K149D/E153R). It is unusual that E153G had no detectable activity in the activation of Trp unless tRNA(Trp) was added to the reaction. In addition, we successfully switched the species specificity of Bacillus subtilis TrpRS recognition of tRNATrp. The affinity of WBHA, K149E and E153K to human tRNA(Trp) was 31-, 13.5-, and 12.9-fold greater than that of wild type B. subtilis TrpRS, respectively. Indeed WBHA and E153K were found to prefer genuine human tRNA(Trp) to their cognate eubacteria tRNA(Trp).	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Jin, YX (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Yueyang Rd 320, Shanghai 200031, Peoples R China.	yxjin@sunm.shcnc.ac.cn	Guo, Li-Tao/C-3126-2014	Jia, Jie/0000-0002-9583-1055				Banerjee R, 2004, EUR J BIOCHEM, V271, P724, DOI 10.1111/j.1432-1033.2003.03976.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBAUM JJ, 1992, PROTEIN SCI, V1, P575, DOI 10.1002/pro.5560010503; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; DOUBLIE S, 1995, STRUCTURE, V3, P17, DOI 10.1016/S0969-2126(01)00132-0; ERIANI G, 1989, NUCLEIC ACIDS RES, V17, P5725, DOI 10.1093/nar/17.14.5725; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Fechter P, 2000, BIOCHEMISTRY-US, V39, P1725, DOI 10.1021/bi992276t; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; Freist W, 1997, BIOL CHEM, V378, P1313; Fukunaga R, 2004, J BIOL CHEM, V279, P8396, DOI 10.1074/jbc.M312830200; Guez V, 2000, BIOCHEMISTRY-US, V39, P1739, DOI 10.1021/bi992382v; Hou YM, 1997, CHEM BIOL, V4, P93, DOI 10.1016/S1074-5521(97)90252-0; Ibba M, 1999, NUCLEIC ACIDS RES, V27, P3631, DOI 10.1093/nar/27.18.3631; Ibba M, 1999, P NATL ACAD SCI USA, V96, P418, DOI 10.1073/pnas.96.2.418; Ilyin VA, 2000, PROTEIN SCI, V9, P218; Jia J, 2002, BIOCHEM J, V365, P749, DOI 10.1042/BJ20020141; Jorgensen R, 2000, J BIOL CHEM, V275, P16820, DOI 10.1074/jbc.275.22.16820; Kise Y, 2004, NAT STRUCT MOL BIOL, V11, P149, DOI 10.1038/nsmb722; Kobayashi T, 2003, NAT STRUCT BIOL, V10, P425, DOI 10.1038/nsb934; MCCLAIN WH, 1993, J MOL BIOL, V234, P257, DOI 10.1006/jmbi.1993.1582; Retailleau P, 2003, J MOL BIOL, V325, P39, DOI 10.1016/S0022-2836(02)01156-7; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; Salazar JC, 2001, FEBS LETT, V491, P257, DOI 10.1016/S0014-5793(01)02214-1; Sekine S, 2003, EMBO J, V22, P676, DOI 10.1093/emboj/cdg053; SHI W, 1990, BIOCHEM CELL BIOL, V68, P492, DOI 10.1139/o90-069; Szymanski M, 2001, NUCLEIC ACIDS RES, V29, P288, DOI 10.1093/nar/29.1.288; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wakasugi K, 1998, EMBO J, V17, P297, DOI 10.1093/emboj/17.1.297; Xu F, 2002, BIOCHEMISTRY-US, V41, P8087, DOI 10.1021/bi015881g; Xu F, 2001, PROTEIN EXPRES PURIF, V23, P296, DOI 10.1006/prep.2001.1500; Xu F, 2001, NUCLEIC ACIDS RES, V29, P4125, DOI 10.1093/nar/29.20.4125; XU ZJ, 1989, J BIOL CHEM, V264, P4304; XUE H, 1993, J BIOL CHEM, V268, P9316; Yang XL, 2003, P NATL ACAD SCI USA, V100, P15376, DOI 10.1073/pnas.2136794100; Yaremchuk A, 2002, EMBO J, V21, P3829, DOI 10.1093/emboj/cdf373; Yu YD, 2004, J BIOL CHEM, V279, P8378, DOI 10.1074/jbc.M311284200	39	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41960	41965		10.1074/jbc.M401937200	http://dx.doi.org/10.1074/jbc.M401937200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280378	hybrid			2022-12-27	WOS:000224075500088
J	Panse, VG; Hardeland, U; Werner, T; Kuster, B; Hurt, E				Panse, VG; Hardeland, U; Werner, T; Kuster, B; Hurt, E			A proteome-wide approach identifies sumoylated substrate proteins in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; TRANSFER-RNA; UBIQUITIN; SUMO; COHESION; SMT3P; TAGS	The ubiquitin-related protein SUMO-1 is covalently attached to proteins by SUMO-1 ligases. We have performed a proteome-wide analysis of sumoylated substrate proteins in yeast. Employing the powerful affinity purification of Protein A-Smt3 (Smt3 is the yeast homologue of SUMO-1) from yeast lysates in combination with tandem liquid chromatography mass spectrometry, we have isolated potential Smt3-carrying substrate proteins involved in DNA replication and repair, chromatin remodeling, transcription activation, Pol-I, Pol-II, and Pol-III transcription, 5' pre-mRNA capping, 3' pre-mRNA processing, proteasome function, and tubulin folding. Employing tandem affinity purifications or a rapid biochemical assay referred to as "SUMO fingerprint," we showed that several subunits of RNA polymerases I, II, and III, members of the transcription repression and chromatin remodeling machineries previously not known to be sumoylated, are modified by SUMO-1. Thus, the identification of a broad range of SUMO-1 substrate proteins is expected to lead to further insight into the regulatory aspects of sumoylation.	Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany; Cellzome AG, D-69117 Heidelberg, Germany	Ruprecht Karls University Heidelberg; GlaxoSmithKline; Cellzome GmbH	Hurt, E (corresponding author), Univ Heidelberg, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	cg5@ix.urz.uni-heidelberg.de	Kuster, Bernhard/Q-6031-2016; Ed Hurt, Dr./AAE-8874-2019	Kuster, Bernhard/0000-0002-9094-1677; Ed Hurt, Dr./0000-0002-4535-8255; Panse, Vikram/0000-0001-7950-5746				Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Li TW, 2004, P NATL ACAD SCI USA, V101, P8551, DOI 10.1073/pnas.0402889101; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Panse VG, 2003, NAT CELL BIOL, V5, P21, DOI 10.1038/ncb893; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Stead K, 2003, J CELL BIOL, V163, P729, DOI 10.1083/jcb.200305080; Vertegaal ACO, 2004, J BIOL CHEM, V279, P33791, DOI 10.1074/jbc.M404201200; Zhao YM, 2004, J BIOL CHEM, V279, P20999, DOI 10.1074/jbc.M401541200	21	208	217	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41346	41351		10.1074/jbc.M407950200	http://dx.doi.org/10.1074/jbc.M407950200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292183	hybrid			2022-12-27	WOS:000224075500014
J	Shirotani, K; Edbauer, D; Prokop, S; Haass, C; Steiner, H				Shirotani, K; Edbauer, D; Prokop, S; Haass, C; Steiner, H			Identification of distinct gamma-secretase complexes with different APH-1 variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; INTRAMEMBRANE PROTEOLYSIS; COORDINATED EXPRESSION; BETA-APP; PRESENILIN; NICASTRIN; PEN-2; NOTCH; ENDOPROTEOLYSIS	The gamma-secretase complex catalyzes the final intramembraneous cleavage of the beta-amyloid precursor protein, liberating the neurotoxic amyloid beta-peptide implicated in Alzheimer's disease. Apart from the catalytic subunit presenilin (PS), three additional subunits, nicastrin, APH-1, and PEN-2, have been identified. In mammals, two PS homologues, PS1 and PS2, which are part of distinct gamma-secretase complexes, exist. Likewise, two APH-1 homologues, APH-1a and APH-1b, have been identified. Furthermore, two APH-1a splice forms, APH-1aS and APH-1aL, have been reported. Here we show that both APH-1a splice forms and APH-1b are expressed in peripheral and neuronal cells. APH-1aS, APH-1aL, and APH-1b form separate, proteolytically active gamma-secretase complexes containing either one of the two PSs. Deficiency of APH-1a caused a decrease in nicastrin, PS, and PEN-2 levels and an increase in the levels of APH-1b, whereas deficiency of APH-1b did not affect the levels of APH-1a or the other complex components. Consistent with this finding, we found that deficiency of APH-1a was associated with reduced gamma-secretase activity, whereas deficiency of APH-1b was not. Thus, APH-1b gamma-secretase complexes may fulfill redundant functions. Taken together, our results suggest that, dependent on the tissue expression of the individual subunits, six distinct gamma-secretase complexes composed of the known subunits can exist in human cells.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany	University of Munich	Haass, C (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, Schillerstr 44, D-80336 Munich, Germany.	chaass@med.uni-muenchen.de; hsteiner@med.uni-muenchen.de	Edbauer, Dieter/M-9906-2019; Prokop, Stefan/Y-1257-2019	Edbauer, Dieter/0000-0002-7186-4653; Prokop, Stefan/0000-0002-5633-2149				Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Cervantes S, 2001, FEBS LETT, V505, P81, DOI 10.1016/S0014-5793(01)02785-5; Chen FS, 2003, J BIOL CHEM, V278, P19974, DOI 10.1074/jbc.M210049200; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; FARMERY MR, 1977, J BIOL CHEM, V278, P242; Fortna RR, 2004, J BIOL CHEM, V279, P3685, DOI 10.1074/jbc.M310505200; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Lai MT, 2003, J BIOL CHEM, V278, P22475, DOI 10.1074/jbc.M300974200; LaPointe CF, 2000, J BIOL CHEM, V275, P1502, DOI 10.1074/jbc.275.2.1502; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Li JH, 2003, J BIOL CHEM, V278, P33445, DOI 10.1074/jbc.M301288200; Li T, 2003, J NEUROSCI, V23, P3272; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marlow L, 2003, BIOCHEM BIOPH RES CO, V305, P502, DOI 10.1016/S0006-291X(03)00797-6; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Periz G, 2004, J NEUROSCI RES, V77, P309, DOI 10.1002/jnr.20203; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Saura CA, 1999, J BIOL CHEM, V274, P13818, DOI 10.1074/jbc.274.20.13818; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Shirotani K, 2004, J NEUROCHEM, V89, P1520, DOI 10.1111/j.1471-4159.2004.02447.x; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia XG, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng098; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	56	141	154	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41340	41345		10.1074/jbc.M405768200	http://dx.doi.org/10.1074/jbc.M405768200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15286082	hybrid			2022-12-27	WOS:000224075500013
J	Cooper, EM; Hudson, AW; Amos, J; Wagstaff, J; Howley, PM				Cooper, EM; Hudson, AW; Amos, J; Wagstaff, J; Howley, PM			Biochemical analysis of Angelman syndrome-associated mutations in the E3 ubiquitin ligase E6-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; E6 ONCOPROTEIN; E6-AP; UBE3A; RECEPTOR; GENE; P53; IDENTIFICATION; UBE3A/E6-AP; EXPRESSION	Angelman syndrome is a severe neurological disorder characterized by mental retardation, absent speech, ataxia, seizures, and hyperactivity. The gene affected in this disorder is UBE3A, the gene encoding the E6-associated protein (E6AP) ubiquitin-protein ligase. Most patients have chromosomal deletions that remove the entire maternal allele of UBE3A. However, a small subset of patients have E6AP point mutations that result in single amino acid changes or short in-frame deletions that still allow translation of a full-length protein. By studying these point mutations in E6AP, we found a strong correlation between Angelman-associated mutations and a loss of E3 ubiquitin ligase activity. Interestingly the point mutations affect E6AP activity in different ways. Some mutant proteins cannot form thiol ester intermediates with ubiquitin, others retain the thiol ester formation activity but cannot efficiently transfer ubiquitin to a substrate, and still others are unstable in cells. Our results suggest that the loss of E6AP catalytic activity and likely the improper regulation of E6AP substrate(s) are important in the development of Angelman syndrome.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Carolinas Med Ctr, Dept Pediat, Clin Genet Program, Charlotte, NC 28232 USA	Harvard University; Harvard Medical School; Carolinas Medical Center	Howley, PM (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur,New Res Bldg,Rm 952, Boston, MA 02115 USA.	peter_howley@hms.harvard.edu		Howley, Peter/0000-0002-8668-9579	NATIONAL CANCER INSTITUTE [R37CA064888] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA64888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albrecht U, 1997, NAT GENET, V17, P75, DOI 10.1038/ng0997-75; DeLorey TM, 1998, J NEUROSCI, V18, P8505; Fang P, 1999, HUM MOL GENET, V8, P129, DOI 10.1093/hmg/8.1.129; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Kao WH, 2000, J VIROL, V74, P6408, DOI 10.1128/JVI.74.14.6408-6417.2000; Kelley ML, 2000, MAR ENVIRON RES, V50, P289, DOI 10.1016/S0141-1136(00)00087-8; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Laan LAEM, 1999, CLIN NEUROL NEUROSUR, V101, P161, DOI 10.1016/S0303-8467(99)00030-X; Malzac P, 1998, AM J HUM GENET, V62, P1353, DOI 10.1086/301877; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Miura K, 2002, NEUROBIOL DIS, V9, P149, DOI 10.1006/nbdi.2001.0463; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Nuber U, 1998, EUR J BIOCHEM, V254, P643, DOI 10.1046/j.1432-1327.1998.2540643.x; Rougeulle C, 1997, NAT GENET, V17, P14, DOI 10.1038/ng0997-14; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Siepmann TJ, 2003, J BIOL CHEM, V278, P9448, DOI 10.1074/jbc.M211240200; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; Yarnasaki K, 2003, HUM MOL GENET, V12, P837, DOI 10.1093/hmg/ddg106; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200	30	74	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41208	41217		10.1074/jbc.M401302200	http://dx.doi.org/10.1074/jbc.M401302200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15263005	hybrid			2022-12-27	WOS:000223916800120
J	Kamei, Y; Miura, S; Suzuki, M; Kai, Y; Mizukami, J; Taniguchi, T; Mochida, K; Hata, T; Matsuda, J; Aburatani, H; Nishino, I; Ezaki, O				Kamei, Y; Miura, S; Suzuki, M; Kai, Y; Mizukami, J; Taniguchi, T; Mochida, K; Hata, T; Matsuda, J; Aburatani, H; Nishino, I; Ezaki, O			Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated type I (slow twitch/red muscle) fiber genes, and impaired glycemic control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR FKHR; ACTIVATED RECEPTOR-GAMMA; GROWTH-FACTOR-I; FACTORS INDUCE; MESSENGER-RNA; INSULIN; EXPRESSION; COACTIVATOR; ALPHA; GLUCOSE-6-PHOSPHATASE	FOXO1, a member of the FOXO forkhead type transcription factors, is markedly up-regulated in skeletal muscle in energy-deprived states such as fasting and severe diabetes, but its functions in skeletal muscle have remained poorly understood. In this study, we created transgenic mice specifically overexpressing FOXO1 in skeletal muscle. These mice weighed less than the wildtype control mice, had a reduced skeletal muscle mass, and the muscle was paler in color. Microarray analysis revealed that the expression of many genes related to the structural proteins of type I muscles (slow twitch, red muscle) was decreased. Histological analyses showed a marked decrease in size of both type I and type II fibers and a significant decrease in the number of type I fibers in the skeletal muscle of FOXO1 mice. Enhanced gene expression of a lysosomal proteinase, cathepsin L, which is known to be up-regulated during skeletal muscle atrophy, suggested increased protein degradation in the skeletal muscle of FOXO1 mice. Running wheel activity (spontaneous locomotive activity) was significantly reduced in FOXO1 mice compared with control mice. Moreover, the FOXO1 mice showed impaired glycemic control after oral glucose and intraperitoneal insulin administration. These results suggest that FOXO1 negatively regulates skeletal muscle mass and type I fiber gene expression and leads to impaired skeletal muscle function. Activation of FOXO1 may be involved in the pathogenesis of sarcopenia, the age-related decline in muscle mass in humans, which leads to obesity and diabetes.	Natl Inst Hlth & Nutr, Div Clin Nutr, Shinjuku Ku, Tokyo 1628636, Japan; Japan Sci & Technol Agcy, PRESTO, Tokyo 1628636, Japan; Tanabe Seiyaku Co Ltd, Lead Generat Res Lab, Yodogawa Ku, Osaka 5328505, Japan; Inst Phys & Chem Res, Bioresource Ctr, Tsukuba, Ibaraki 3050074, Japan; Natl Inst Infect Dis, Dept Vet Sci, Shinjuku Ku, Tokyo 1628640, Japan; Univ Tokyo, Res Ctr Adv Sci & Technol, Meguro Ku, Tokyo 1538904, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo 1878502, Japan	National Institute of Health & Nutrition - Japan; Japan Science & Technology Agency (JST); Mitsubishi Tanabe Pharma Corporation; RIKEN; National Institute of Infectious Diseases (NIID); University of Tokyo; National Center for Neurology & Psychiatry - Japan	Kamei, Y (corresponding author), Natl Inst Hlth & Nutr, Div Clin Nutr, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628636, Japan.	ykamei@nih.go.jp	Miura, Shinji/K-6516-2013; Nishino, Ichizo/G-2676-2010	Miura, Shinji/0000-0001-8806-9763; Nishino, Ichizo/0000-0001-9452-112X				ADAMS MD, 1995, NATURE, V377, P3; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Ayala JE, 1999, DIABETES, V48, P1885, DOI 10.2337/diabetes.48.9.1885; Barthel A, 2001, BIOCHEM BIOPH RES CO, V285, P897, DOI 10.1006/bbrc.2001.5261; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Bois PRJ, 2003, EMBO J, V22, P1147, DOI 10.1093/emboj/cdg116; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chakkalakal JV, 2003, P NATL ACAD SCI USA, V100, P7791, DOI 10.1073/pnas.0932671100; Chakravarthy MV, 2000, J APPL PHYSIOL, V89, P1365, DOI 10.1152/jappl.2000.89.4.1365; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; DEVOL DL, 1990, AM J PHYSIOL, V259, pE89, DOI 10.1152/ajpendo.1990.259.1.E89; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; Ezaki O, 1997, BIOCHEM BIOPH RES CO, V241, P1, DOI 10.1006/bbrc.1997.7587; Fitts RH, 2001, J EXP BIOL, V204, P3201; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Frost R A, 2003, Minerva Endocrinol, V28, P53; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Garry DJ, 1998, NATURE, V395, P905, DOI 10.1038/27681; Gaster M, 2001, DIABETES, V50, P1324, DOI 10.2337/diabetes.50.6.1324; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; HAHN CG, 1990, ANAL BIOCHEM, V190, P193, DOI 10.1016/0003-2697(90)90180-H; HICKEY MS, 1995, AM J PHYSIOL-ENDOC M, V268, pE453, DOI 10.1152/ajpendo.1995.268.3.E453; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; Kaestner KH, 2000, GENE DEV, V14, P142; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karasseva N, 2003, MOL CELL BIOL, V23, P5143, DOI 10.1128/MCB.23.15.5143-5164.2003; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Machida S, 2003, J CELL PHYSIOL, V196, P523, DOI 10.1002/jcp.10339; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Miura S, 2003, J BIOL CHEM, V278, P31385, DOI 10.1074/jbc.M304312200; Nadal A, 2002, BIOCHEM J, V366, P289, DOI 10.1042/BJ20020598; Nagy TR, 2000, OBES RES, V8, P392, DOI 10.1038/oby.2000.47; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; OGILVIE RW, 1990, STAIN TECHNOL, V65, P231, DOI 10.3109/10520299009105613; Proctor DN, 1998, J NUTR, V128, p351S, DOI 10.1093/jn/128.2.351S; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Schneider MR, 2002, J ENDOCRINOL, V172, P423, DOI 10.1677/joe.0.1720423; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Stull JT, 2001, J BIOL CHEM, V276, P2311, DOI 10.1074/jbc.R000030200; Takahashi M, 2002, AM J PHYSIOL-GASTR L, V282, pG338, DOI 10.1152/ajpgi.00376.2001; Tanner CJ, 2002, AM J PHYSIOL-ENDOC M, V282, pE1191, DOI 10.1152/ajpendo.00416.2001; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Yamanouchi K, 2000, J VET MED SCI, V62, P1213, DOI 10.1292/jvms.62.1213; Yan Z, 2001, J BIOL CHEM, V276, P17361, DOI 10.1074/jbc.M101251200; ZDANOWICZ MM, 1995, ENDOCRINOLOGY, V136, P4880, DOI 10.1210/en.136.11.4880; Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200; ZURLO F, 1990, J CLIN INVEST, V86, P1423, DOI 10.1172/JCI114857	63	419	455	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41114	41123		10.1074/jbc.M400674200	http://dx.doi.org/10.1074/jbc.M400674200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15272020	hybrid			2022-12-27	WOS:000223916800110
J	Wahrle, SE; Jiang, H; Parsadanian, M; Legleiter, J; Han, XL; Fryer, JD; Kowalewski, T; Holtzman, DM				Wahrle, SE; Jiang, H; Parsadanian, M; Legleiter, J; Han, XL; Fryer, JD; Kowalewski, T; Holtzman, DM			ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE TRANSPORTER 1; DENSITY-LIPOPROTEIN DEFICIENCY; APOLIPOPROTEIN-E EPSILON-4; ALZHEIMERS-DISEASE; TANGIER-DISEASE; CEREBROSPINAL-FLUID; MOUSE MODEL; AMYLOID DEPOSITION; CHOLESTEROL EFFLUX; TRANSGENIC MICE	ABCA1 is an ATP-binding cassette protein that transports cellular cholesterol and phospholipids onto high density lipoproteins (HDL) in plasma. Lack of ABCA1 in humans and mice causes abnormal lipidation and increased catabolism of HDL, resulting in very low plasma apoA-I, apoA-II, and HDL. Herein, we have used Abca1(-/-) mice to ask whether ABCA1 is involved in lipidation of HDL in the central nervous system (CNS). ApoE is the most abundant CNS apolipoprotein and is present in HDL-like lipoproteins in CSF. We found that Abca1(-/-) mice have greatly decreased apoE levels in both the cortex (80% reduction) and the CSF (98% reduction). CSF from Abca1(-/-) mice had significantly reduced cholesterol as well as small apoE-containing lipoproteins, suggesting abnormal lipidation of apoE. Astrocytes, the primary producer of CNS apoE, were cultured from Abca1(+/+), (+/+), and (+/+) mice, and nascent lipoprotein particles were collected. Abca1(-/-) astrocytes secreted lipoprotein particles that had markedly decreased cholesterol and apoE and had smaller apoE-containing particles than particles from Abca1(-/-) astrocytes. These findings demonstrate that ABCA1 plays a critical role in CNS apoE metabolism. Since apoE isoforms and levels strongly influence Alzheimer's disease pathology and risk, these data suggest that ABCA1 may be a novel therapeutic target.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Program Neurosci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alzheimers Dis Res Ctr, St Louis, MO 63110 USA; Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Carnegie Mellon University	Holtzman, DM (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.	holtzman@neuro.wustl.edu	Kowalewski, Tomasz/B-6785-2016	Kowalewski, Tomasz/0000-0002-3544-554X; Schindler, Suzanne/0000-0002-1680-1465; Legleiter, Justin/0000-0002-5262-1867	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034467, R01NS034467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013956, R37AG013956, P50AG005681] Funding Source: NIH RePORTER; NIA NIH HHS [AG13956, P50-AG05681] Funding Source: Medline; NINDS NIH HHS [NS034467] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BORGHINI I, 1995, BBA-LIPID LIPID MET, V1255, P192, DOI 10.1016/0005-2760(94)00232-N; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; DeMattos RB, 2001, NEUROCHEM INT, V39, P415, DOI 10.1016/S0197-0186(01)00049-3; Duerstock BS, 2004, J NEUROSCI METH, V134, P101, DOI 10.1016/j.jneumeth.2003.11.012; Fagan AM, 1999, J BIOL CHEM, V274, P30001, DOI 10.1074/jbc.274.42.30001; Fagan AM, 2000, ANN NEUROL, V48, P201, DOI 10.1002/1531-8249(200008)48:2<201::AID-ANA10>3.0.CO;2-X; Fryer JD, 2003, J NEUROSCI, V23, P7889; Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; Han BH, 2001, NAT MED, V7, P338, DOI 10.1038/85487; Han XL, 2004, ANAL BIOCHEM, V330, P317, DOI 10.1016/j.ab.2004.04.004; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8; HOLTZMAN DM, 1992, P NATL ACAD SCI USA, V89, P1383, DOI 10.1073/pnas.89.4.1383; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Holtzman DM, 2001, J MOL NEUROSCI, V17, P147, DOI 10.1385/JMN:17:2:147; Hong SH, 2002, BBA-MOL BASIS DIS, V1587, P60, DOI 10.1016/S0925-4439(02)00066-2; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Katzov H, 2004, HUM MUTAT, V23, P358, DOI 10.1002/humu.20012; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200; KRUL ES, 1988, J LIPID RES, V29, P1309; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Legleiter J, 2004, J MOL BIOL, V335, P997, DOI 10.1016/j.jmb.2003.11.019; LEGLEITER J, 2004, IN PRESS COLLOID INT; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; NEWMAN TC, 1985, J BIOL CHEM, V260, P2452; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; ROSE K, 1993, METHODS TOXICOLOGY, V1, P46; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHAEFER EJ, 1981, J LIPID RES, V22, P217; SCHAEFER EJ, 1978, NEW ENGL J MED, V299, P905, DOI 10.1056/NEJM197810262991701; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sun Y, 2003, J BIOL CHEM, V278, P27688, DOI 10.1074/jbc.M300760200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wisniewski T, 1997, NEUROBIOL DIS, V4, P313, DOI 10.1006/nbdi.1997.0147; Wollmer MA, 2003, NEUROBIOL AGING, V24, P421, DOI 10.1016/S0197-4580(02)00094-5	50	329	336	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40987	40993		10.1074/jbc.M407963200	http://dx.doi.org/10.1074/jbc.M407963200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15269217	hybrid			2022-12-27	WOS:000223916800096
J	Xu, Y; Liu, YJ; Yu, Q				Xu, Y; Liu, YJ; Yu, Q			Angiopoietin-3 is tethered on the cell surface via heparan sulfate proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; BLOOD-VESSEL FORMATION; EXTRACELLULAR-MATRIX; TUMOR ANGIOGENESIS; CARCINOMA CELLS; TIE2 RECEPTOR; GROWTH-FACTOR; IN-VITRO; EXPRESSION; LIGAND	Angiopoietins are a family of factors that play important roles in angiogenesis, and their receptor, Tie-2 receptor tyrosine kinase, is expressed primarily by endothelial cells. Three angiopoietins have been identified so far, angiopoietin-1 (Ang-1), angiopietin-2 (Ang-2), and angiopoietin-3 (Ang-3). It has been established that Ang-1 and Tie-2 play essential roles in embryonic angiogenesis. We have demonstrated recently that, unlike Ang-2, Ang-1 binds to the extracellular matrix, which regulates the availability and activity of Ang-1 (Xu, Y., and Yu, Q. (2001) J. Biol. Chem. 276, 34990-34998). However, the role and biochemical characteristics of Ang-3 are unknown. In our current study, we demonstrated that, unlike Ang-1 and Ang-2, Ang-3 is tethered on cell surface via heparan sulfate proteoglycans (HSPGs), especially perlecan. The cell surface-bound Ang-3 is capable of binding to its receptor, Tie-2; suggesting HSPGs concentrate Ang-3 on the cell surface and present Ang-3 to its receptor to elicit specific local reaction. Mutagenesis experiment revealed that the coiled-coil domain of Ang-3 is responsible for its binding to the cell surface. In addition, we demonstrated that the cell surface-bound Ang-3 but not soluble Ang-3 induces retraction and loss of integrity of endothelial monolayer, indicating the binding of Ang-3 to the cell surface via HSPGs is required for this bioactivity of Ang-3.	Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Yu, Q (corresponding author), Univ Penn, Sch Vet Med, Dept Pathobiol, 372E Old Vet,3800 Spruce St, Philadelphia, PA 19104 USA.	qyu@vet.upenn.edu			NHLBI NIH HHS [5R01HL074117, R01 HL074117] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074117] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATTAGLIA C, 1993, EUR J CELL BIOL, V61, P92; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; CHAKRAVARTI S, 1995, J BIOL CHEM, V270, P404, DOI 10.1074/jbc.270.1.404; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hayes AJ, 1999, MICROVASC RES, V58, P224, DOI 10.1006/mvre.1999.2179; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sanderson RD, 2001, SEMIN CELL DEV BIOL, V12, P89, DOI 10.1006/scdb.2000.0241; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SOUTHERN JA, 1991, J GEN VIROL, V72, P1551, DOI 10.1099/0022-1317-72-7-1551; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; Xu Y, 2001, J BIOL CHEM, V276, P34990, DOI 10.1074/jbc.M103661200; XU Y, 2004, IN PRESS CANC RES; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 2001, AM J PATHOL, V158, P563, DOI 10.1016/S0002-9440(10)63998-3; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35	44	25	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41179	41188		10.1074/jbc.M400292200	http://dx.doi.org/10.1074/jbc.M400292200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15280392	Green Accepted, hybrid			2022-12-27	WOS:000223916800117
J	Yamada, A; Yoshio, M; Nakamura, A; Kohama, K; Oiwa, K				Yamada, A; Yoshio, M; Nakamura, A; Kohama, K; Oiwa, K			Protein phosphatase 2B dephosphorylates twitchin, initiating the catch state of invertebrate smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLLUSCAN TWITCHIN; MINI-TITINS; PHOSPHORYLATION; CALCINEURIN; PARAMYOSIN; KINASE; INHIBITOR; POTENT	"Catch" is the state where some invertebrate muscles sustain high tension for long periods at low ATP hydrolysis rates. Physiological studies using muscle fibers have not yet fully provided the details of the initiation process of the catch state. The process was extensively studied by using an in vitro reconstitution assay with several phosphatase inhibitors. Actin filaments bound to thick filaments pretreated with the soluble protein fraction of muscle homogenate and Ca2+ (catch treatment) in the presence of MgATP at a low free Ca2+ concentration ( the catch state). Catch treatment with >50 muM okadaic acid, > 1 muM microcystin LR, 1 muM cyclosporin A, 1 muM FK506, or 0.2 mM calcineurin autoinhibitory peptide fragment produced almost no binding of the actin filaments, indicating protein phosphatase 2B (PP2B) was involved. Use of bovine calcineurin ( PP2B) and its activator calmodulin instead of the soluble protein fraction initiated the catch state, indicating that only PP2B and calmodulin in the soluble protein fraction are essential for the initiation process. The initiation was reproduced with purified actin, myosin, twitchin, PP2B, and calmodulin. P-32 autoradiography showed that only twitchin was dephosphorylated during the catch treatment with either the soluble protein fraction or bovine calcineurin and calmodulin. These results indicate that PP2B directly dephosphorylates twitchin and initiates the catch state and that no other component is required for the initiation process of the catch state.	Natl Inst Informat & Commun Technol, Kansai Adv Res Ctr, Kobe, Hyogo 6512492, Japan; Gunma Univ, Sch Med, Dept Pharmacol, Gunma 3718511, Japan	National Institute of Information & Communications Technology (NICT) - Japan; Gunma University	Yamada, A (corresponding author), Natl Inst Informat & Commun Technol, Kansai Adv Res Ctr, Kobe, Hyogo 6512492, Japan.	c2v@nict.go.jp	Oiwa, Kazuhiro/D-7721-2011	Oiwa, Kazuhiro/0000-0002-1281-113X				Benian GM, 1999, REV PHYSIOL BIOCH P, V138, P235, DOI 10.1007/BF02346665; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; CASTELLANI L, 1992, FEBS LETT, V309, P321, DOI 10.1016/0014-5793(92)80798-L; CHENG HC, 1986, J BIOL CHEM, V261, P989; Funabara D, 2003, J BIOL CHEM, V278, P29308, DOI 10.1074/jbc.M303272200; Funabara D, 2001, BIOCHEMISTRY-US, V40, P2087, DOI 10.1021/bi0022691; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HEIERHORST J, 1995, EUR J BIOCHEM, V233, P426, DOI 10.1111/j.1432-1033.1995.426_2.x; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RJC, 1976, J CELL BIOL, V71, P273, DOI 10.1083/jcb.71.1.273; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; PFITZER G, 1982, J COMP PHYSIOL, V147, P137, DOI 10.1007/BF00689302; PROBST WC, 1994, P NATL ACAD SCI USA, V91, P8487, DOI 10.1073/pnas.91.18.8487; RUEGG JC, 1971, PHYSIOL REV, V51, P201, DOI 10.1152/physrev.1971.51.1.201; SHARMA RK, 1995, MOL CELL BIOCHEM, V149, P241, DOI 10.1007/BF01076583; Siegman MJ, 1998, P NATL ACAD SCI USA, V95, P5383, DOI 10.1073/pnas.95.9.5383; SZENTGYORGYI AG, 1971, J MOL BIOL, V56, P239, DOI 10.1016/0022-2836(71)90462-1; TONKS NK, 1983, BIOCHIM BIOPHYS ACTA, V747, P191, DOI 10.1016/0167-4838(83)90140-1; TWAROG BM, 1954, J CELL COMPAR PHYSL, V44, P141, DOI 10.1002/jcp.1030440112; VIBERT P, 1993, J MUSCLE RES CELL M, V14, P598, DOI 10.1007/BF00141557; Vibert P, 1996, ADV BIOPHYS, V33, P199; WATABE S, 1990, COMP BIOCHEM PHYS B, V96, P639, DOI 10.1016/0305-0491(90)90207-A; Yamada A, 2000, J MOL BIOL, V295, P169, DOI 10.1006/jmbi.1999.3349; Yamada A, 2001, P NATL ACAD SCI USA, V98, P6635, DOI 10.1073/pnas.111585098	28	32	32	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40762	40768		10.1074/jbc.M405191200	http://dx.doi.org/10.1074/jbc.M405191200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15272026	hybrid			2022-12-27	WOS:000223916800069
J	Shen, MR; Lin, AC; Hsu, YM; Chang, TJ; Tang, MJ; Alper, SL; Ellory, JC; Chou, CY				Shen, MR; Lin, AC; Hsu, YM; Chang, TJ; Tang, MJ; Alper, SL; Ellory, JC; Chou, CY			Insulin-like growth factor 1 stimulates KCl cotransport, which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; GROWTH; VOLUME; EXPRESSION; PROTEINS; CLONING; KCC3	The mechanisms by which insulin-like growth factor 1 (IGF-1) cooperates with membrane ion transport system to modulate epithelial cell motility and proliferation remain poorly understood. Here, we investigated the role of electroneutral KCl cotransport (KCC), in IGF-1-dependent invasiveness and proliferation of cervical and ovarian cancer cells. IGF-1 increased KCC activity and mRNA expression in a dose- and time-dependent manner in parallel with the enhancement of regulatory volume decrease. IGF-1 treatment triggers phosphatidylinositol 3-kinase and mitogen-activated protein kinase cascades leading to the activation of Akt and extracellular signal-regulated kinase1/2 (Erk1/2), respectively. The activated Erk1/2 mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways are differentially required for IGF-1-stimulated biosynthesis of KCC polypeptides. Specific reduction of Erk1/2 protein levels with small interference RNA abolishes IGF-1-stimulated KCC activity. Pharmacological inhibition and genetic modification of KCC activity demonstrate that KCC is necessary for IGF-1-induced cancer cell invasiveness and proliferation. IGF-1 and KCC colocalize in the surgical specimens of cervical cancer ( n = 28) and ovarian cancer ( n = 35), suggesting autocrine or paracrine IGF-1 stimulation of KCC production. Taken together, our results indicate that KCC activation by IGF-1 plays an important role in IGF-1 signaling to promote growth and spread of gynecological cancers.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Obstet & Gynecol, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 704, Taiwan; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Mol & Vasc Med Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Renal Unit, Boston, MA 02215 USA; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Oxford	Chou, CY (corresponding author), 138 Sheng Li Rd, Tainan 704, Taiwan.	chougyn@mail.ncku.edu.tw		Tang, Ming-Jer/0000-0002-0883-4363				Aguado F, 2003, DEVELOPMENT, V130, P1267, DOI 10.1242/dev.00351; ALBINI A, 1987, CANCER RES, V47, P3239; Boettger T, 2003, EMBO J, V22, P5422, DOI 10.1093/emboj/cdg519; Casula S, 2001, J BIOL CHEM, V276, P41870, DOI 10.1074/jbc.M107155200; Clemmons DR, 2003, ENDOCRINOLOGY, V144, P1664, DOI 10.1210/en.2002-221102; Denker SP, 2002, CURR OPIN CELL BIOL, V14, P214, DOI 10.1016/S0955-0674(02)00304-6; Ellory JC, 1998, CONTRIB NEPHROL, V123, P220, DOI 10.1159/000059915; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; Kim B, 2004, ONCOGENE, V23, P130, DOI 10.1038/sj.onc.1206924; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lauf PK, 2000, CELL PHYSIOL BIOCHEM, V10, P341, DOI 10.1159/000016357; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Rivera C, 2004, J NEUROSCI, V24, P4683, DOI 10.1523/JNEUROSCI.5265-03.2004; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; ROSS PE, 1995, J GEN PHYSIOL, V106, P415, DOI 10.1085/jgp.106.3.415; Roussa E, 2002, HISTOCHEM CELL BIOL, V117, P335, DOI 10.1007/s00418-002-0393-3; Shen MR, 2000, PFLUG ARCH EUR J PHY, V440, P751, DOI 10.1007/s004240000338; Shen MR, 2003, J BIOL CHEM, V278, P39941, DOI 10.1074/jbc.M308232200; Shen MR, 2002, J BIOL CHEM, V277, P15592, DOI 10.1074/jbc.M111043200; Shen MR, 2001, P NATL ACAD SCI USA, V98, P14714, DOI 10.1073/pnas.251388798; Shen MR, 2001, J PHYSIOL-LONDON, V537, P347, DOI 10.1111/j.1469-7793.2001.00347.x; Zhang J, 2003, AM J PHYSIOL-CELL PH, V284, pC674, DOI 10.1152/ajpcell.00312.2002	24	66	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40017	40025		10.1074/jbc.M406706200	http://dx.doi.org/10.1074/jbc.M406706200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262997	hybrid			2022-12-27	WOS:000223791500099
J	Valton, J; Filisetti, L; Fontecave, M; Niviere, V				Valton, J; Filisetti, L; Fontecave, M; Niviere, V			A two-component flavin-dependent monooxygenase involved in actinorhodin biosynthesis in Streptomyces coelicolor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-CLUSTER; ANTIBIOTIC ACTINORHODIN; ESCHERICHIA-COLI; CHLOROPHENOL 4-MONOOXYGENASE; FUNCTIONAL-ANALYSIS; PHENOL HYDROXYLASE; RECOMBINANT ENZYME; PRISTINAMYCIN-IIB; REDUCTASE; OXIDOREDUCTASE	The two-component flavin-dependent monooxygenases belong to an emerging class of enzymes involved in oxidation reactions in a number of metabolic and biosynthetic pathways in microorganisms. One component is a NAD(P)H:flavin oxidoreductase, which provides a reduced flavin to the second component, the proper monooxygenase. There, the reduced flavin activates molecular oxygen for substrate oxidation. Here, we study the flavin reductase ActVB and ActVA-ORF5 gene product, both reported to be involved in the last step of biosynthesis of the natural antibiotic actinorhodin in Streptomyces coelicolor. For the first time we show that ActVA-ORF5 is a FMN-dependent monooxygenase that together with the help of the flavin reductase ActVB catalyzes the oxidation reaction. The mechanism of the transfer of reduced FMN between ActVB and ActVA-ORF5 has been investigated. Dissociation constant values for oxidized and reduced flavin (FMNox and FMNred) with regard to ActVB and ActVA-ORF5 have been determined. The data clearly demonstrate a thermodynamic transfer of FMNred from ActVB to ActVA-ORF5 without involving a particular interaction between the two protein components. In full agreement with these data, we propose a reaction mechanism in which FMNox binds to ActVB, where it is reduced, and the resulting FMNred moves to ActVA-ORF5, where it reacts with O-2 to generate a flavin-peroxide intermediate. A direct spectroscopic evidence for the formation of such species within ActVA-ORF5 is reported.	Univ Grenoble 1, CNRS, CEA, DRDC,Lab Chim Biochim Ctr Redox Biol, F-38054 Grenoble 9, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Fontecave, M (corresponding author), Univ Grenoble 1, CNRS, CEA, DRDC,Lab Chim Biochim Ctr Redox Biol, 17 Ave Martyrs, F-38054 Grenoble 9, France.	mfontecave@cea.fr; vniviere@cea.fr		Valton, Julien/0000-0003-0826-5401; Niviere, Vincent/0000-0002-5132-457X				Baik MH, 2003, CHEM REV, V103, P2385, DOI 10.1021/cr950244f; Beltrametti F, 1997, APPL ENVIRON MICROB, V63, P2232, DOI 10.1128/AEM.63.6.2232-2239.1997; BLANC V, 1995, J BACTERIOL, V177, P5206, DOI 10.1128/jb.177.18.5206-5214.1995; Bohuslavek J, 2001, APPL ENVIRON MICROB, V67, P688, DOI 10.1128/AEM.67.2.688-695.2001; BRIMBLE MA, 1990, J CHEM SOC P1, V4, P881; CABALLERO JL, 1991, MOL GEN GENET, V230, P401, DOI 10.1007/BF00280297; Chiu HJ, 2001, STRUCTURE, V9, P311, DOI 10.1016/S0969-2126(01)00589-5; COLE SP, 1987, J ANTIBIOT, V40, P340, DOI 10.7164/antibiotics.40.340; Eichhorn E, 1999, J BIOL CHEM, V274, P26639, DOI 10.1074/jbc.274.38.26639; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; Filisetti L, 2003, J BIOL CHEM, V278, P296, DOI 10.1074/jbc.M209689200; Galan B, 2000, J BACTERIOL, V182, P627, DOI 10.1128/JB.182.3.627-636.2000; Gisi MR, 2003, J BACTERIOL, V185, P2786, DOI 10.1128/JB.185.9.2786-2792.2003; Hefti MH, 2003, BBA-GEN SUBJECTS, V1619, P139, DOI 10.1016/S0304-4165(02)00474-9; Jeffers CE, 2001, BIOCHEMISTRY-US, V40, P1749, DOI 10.1021/bi0024310; KENDREW SG, 1995, J BIOL CHEM, V270, P17339, DOI 10.1074/jbc.270.29.17339; Kendrew SG, 1997, J BACTERIOL, V179, P4305, DOI 10.1128/jb.179.13.4305-4310.1997; KIM IC, 1995, APPL ENVIRON MICROB, V61, P1252, DOI 10.1128/AEM.61.4.1252-1256.1995; Kirchner U, 2003, J BIOL CHEM, V278, P47545, DOI 10.1074/jbc.M307397200; Konishi J, 2002, APPL MICROBIOL BIOT, V60, P128, DOI 10.1007/s00253-002-1096-3; MALPARTIDA F, 1986, MOL GEN GENET, V205, P66, DOI 10.1007/BF02428033; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; Palfey B. A., 1995, ACTIVE OXYGEN BIOCH, P37, DOI DOI 10.1007/978-94-011-0609-2_2; Panke S, 1998, APPL ENVIRON MICROB, V64, P2032; Parry RJ, 1997, J BIOL CHEM, V272, P23303, DOI 10.1074/jbc.272.37.23303; Sciara G, 2003, EMBO J, V22, P205, DOI 10.1093/emboj/cdg031; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; THIBAUT D, 1995, J BACTERIOL, V177, P5199, DOI 10.1128/jb.177.18.5199-5205.1995; TU SC, 1974, BIOCHEMISTRY-US, V13, P893, DOI 10.1021/bi00702a010; van den Heuvel RHH, 2004, J BIOL CHEM, V279, P12860, DOI 10.1074/jbc.M313765200; Xi L, 1997, BIOCHEM BIOPH RES CO, V230, P73, DOI 10.1006/bbrc.1996.5878; Xu YR, 1997, J BACTERIOL, V179, P1112, DOI 10.1128/jb.179.4.1112-1116.1997; Xun LY, 2004, J BIOL CHEM, V279, P6696, DOI 10.1074/jbc.M312072200; Xun LY, 1996, J BACTERIOL, V178, P2645, DOI 10.1128/jb.178.9.2645-2649.1996; Xun LY, 2000, APPL ENVIRON MICROB, V66, P481, DOI 10.1128/AEM.66.2.481-486.2000	36	48	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44362	44369		10.1074/jbc.M407722200	http://dx.doi.org/10.1074/jbc.M407722200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15297451	Green Submitted, hybrid			2022-12-27	WOS:000224505600018
J	Solyakov, L; Cain, K; Tracey, BM; Jukes, R; Riley, AM; Potter, BVL; Tobin, AB				Solyakov, L; Cain, K; Tracey, BM; Jukes, R; Riley, AM; Potter, BVL; Tobin, AB			Regulation of casein kinase-2 (CK2) activity by inositol phosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CEREBRAL-CORTEX; PROTEIN-KINASE; 1,3,4,5-TETRAKISPHOSPHATE MASS; BETA-SUBUNIT; DNA-PK; HEXAKISPHOSPHATE; BINDING; CELLS; POLYPHOSPHATES; DEPOLARIZATION	Casein kinase 2 (CK2) was one of the first protein kinases to be discovered and has been suggested to be responsible for as much as one-fifth of the eukaryotic phosphoproteome. Despite being responsible for the phosphorylation of a vast array of proteins central to numerous dynamic cellular processes, the activity of CK2 appears to be unregulated. In the current study, we identified a protein kinase activity in rat liver supernatant that is up-regulated by inositol 1,3,4,5-tetrakisphosphate (IP4) and inositol hexakisphosphate (IP6). The substrate for the inositol phosphate-regulated protein kinase was identified as a phosphatidylcholine transfer protein-like protein. Using the phosphorylation of this substrate in an assay, we purified the inositol phosphate-regulated protein kinase and determined it to be CK2. Bacterially expressed recombinant CK2, however, showed very high basal activity and was only modestly activated by IP6 and not regulated by IP4. We found that an endogenous component present in rat liver supernatant was able to inhibit both recombinant and liver-purified CK2 basal activity. Under these conditions, recombinant CK2 catalytic activity could be increased substantially by IP4, inositol 1,3,4,5,6-pentakisphosphate (IP5), and IP6. We concluded that, contrary to the previously held view, CK2 can exist in a state of low constitutive activity allowing for its regulation by inositol phosphates. The ability of the higher inositol phosphates to directly stimulate CK2 catalytic activity provides the first evidence that these signaling molecules can operate via a direct control of protein phosphorylation.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Univ Bath, Wolfson Lab Med Chem, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England; Univ Leicester, Med Res Council Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester; University of Bath; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Leicester	Tobin, AB (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	tba@le.ac.uk	Riley, Andrew M/F-3526-2013; Potter, Barry/AAX-4781-2020; Potter, Barry VL/A-1845-2012	Riley, Andrew M/0000-0001-9003-3540; 				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BURNETT G, 1954, J BIOL CHEM, V211, P969; CHALLISS RAJ, 1990, J NEUROCHEM, V54, P2138, DOI 10.1111/j.1471-4159.1990.tb04920.x; CHALLISS RAJ, 1991, J NEUROCHEM, V57, P1042, DOI 10.1111/j.1471-4159.1991.tb08255.x; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; FISHER SK, 1990, MOL PHARMACOL, V38, P54; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Graham KC, 2000, J BIOL CHEM, V275, P5003, DOI 10.1074/jbc.275.7.5003; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; Hilton JM, 2001, J BIOL CHEM, V276, P16341, DOI 10.1074/jbc.M011122200; Hoy M, 2002, P NATL ACAD SCI USA, V99, P6773, DOI 10.1073/pnas.102157499; Hughes P J, 1993, Curr Opin Neurobiol, V3, P383, DOI 10.1016/0959-4388(93)90132-I; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Larsson O, 1997, SCIENCE, V278, P471, DOI 10.1126/science.278.5337.471; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; OharaImaizumi M, 1997, P NATL ACAD SCI USA, V94, P287, DOI 10.1073/pnas.94.1.287; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PITTET D, 1989, J BIOL CHEM, V264, P18489; Riley AM, 1997, ANGEW CHEM INT EDIT, V36, P1472, DOI 10.1002/anie.199714721; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96	31	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43403	43410		10.1074/jbc.M403239200	http://dx.doi.org/10.1074/jbc.M403239200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15297462	hybrid			2022-12-27	WOS:000224383100009
J	Yoshimura, Y; Tani, M; Okino, N; Iida, H; Ito, M				Yoshimura, Y; Tani, M; Okino, N; Iida, H; Ito, M			Molecular cloning and functional analysis of zebrafish neutral ceramidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; SPHINGOSINE-1-PHOSPHATE; EXPRESSION; KINASE; INTERLEUKIN-1-BETA; PROLIFERATION; PROTEINS; HOMOLOG	Almost all observations on the functions of neutral ceramidase have been carried out at cellular levels but not at an individual level. Here, we report the molecular cloning of zebrafish neutral ceramidase (znCD) and its functional analysis during embryogenesis. We isolated a cDNA clone encoding znCD by 5' and 3' rapid amplification of cDNA ends-PCR. It possessed an open reading frame of 2,229 base pairs encoding 743 amino acids. A possible signal/anchor sequence near the N terminus and four potential O-glycosylation and eight potential N-glycosylation sites were found in the putative sequence. The enzyme activity at neutral pH increased markedly after transformation of Chinese hamster CHOP and zebrafish BRF41 cells with the cDNA. The overexpressed enzyme was found to be distributed in endoplasmic reticulum/Golgi compartments as well as the plasma membranes. The antisense morpholino oligonucleotide (AMO), which was designed based on the sequence of znCD mRNA, successfully blocked the translation of znCD in a wheat germ in vitro translation system. The knockdown of znCD with AMO led to an increase in the number of zebrafish embryos with severe morphological and cellular abnormalities such as abnormal morphogenesis in the head and tail, pericardiac edema, defect of blood cell circulation, and an increase of apoptotic cells, especially in the head and neural tube regions, at 36 h post-fertilization. The ceramide level in AMO-injected embryos increased significantly compared with that in control embryos. Simultaneous injection of both AMO and synthetic znCD mRNA into one-cell-stage embryos rescued znCD activity and blood cell circulation. These results indicate that znCD is essential for the metabolism of ceramide and the early development of zebrafish.	Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, Fukuoka 8128581, Japan; Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Appl Genet & Pest Management, Higashi Ku, Fukuoka 8128581, Japan	Kyushu University; Kyushu University	Ito, M (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	makotoi@agr.kyushu-u.ac.jp	Ito, Makoto/Q-6164-2019; Okino, Nozomu/AAY-2635-2021	ito, Makoto/0000-0003-3159-7818; Tani, Motohiro/0000-0003-4316-8260				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Acharya U, 2004, P NATL ACAD SCI USA, V101, P1922, DOI 10.1073/pnas.0308693100; Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549; Bektas M, 2003, ANAL BIOCHEM, V320, P259, DOI 10.1016/S0003-2697(03)00388-9; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; English D, 2001, CARDIOVASC RES, V49, P588, DOI 10.1016/S0008-6363(00)00230-3; Franzen R, 2002, J BIOL CHEM, V277, P46184, DOI 10.1074/jbc.M204034200; Franzen R, 2001, J BIOL CHEM, V276, P35382, DOI 10.1074/jbc.M102153200; HANNUN YA, 1993, ADV LIPID RES, V25, P43; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; LOTAN R, 1975, J BIOL CHEM, V250, P8518; MATHIAS S, 1993, ADV LIPID RES, V25, P65; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; Monjusho H, 2003, BIOCHEM J, V376, P473, DOI 10.1042/BJ20030652; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Okino N, 1998, J BIOL CHEM, V273, P14368, DOI 10.1074/jbc.273.23.14368; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Sugiura M, 2002, J BIOL CHEM, V277, P23294, DOI 10.1074/jbc.M201535200; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 2003, J BIOL CHEM, V278, P10523, DOI 10.1074/jbc.M207932200; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; Tani M, 1998, ANAL BIOCHEM, V263, P183, DOI 10.1006/abio.1998.2781; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Yoshimura Y, 2002, J BIOCHEM, V132, P229, DOI 10.1093/oxfordjournals.jbchem.a003215	34	38	39	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44012	44022		10.1074/jbc.M405598200	http://dx.doi.org/10.1074/jbc.M405598200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15271994	hybrid			2022-12-27	WOS:000224383100080
J	Zhang, XL; Li, J; Sejas, DP; Rathbun, KR; Bagby, GC; Pang, QS				Zhang, XL; Li, J; Sejas, DP; Rathbun, KR; Bagby, GC; Pang, QS			The Fanconi anemia proteins functionally interact with the protein kinase regulated by RNA (PKR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; NECROSIS-FACTOR-ALPHA; HEMATOPOIETIC-CELLS; INTERFERON-GAMMA; APOPTOSIS; GENE; ACTIVATION; CLONING; FANCG/XRCC9; DEFICIENT	Protein kinase regulated by RNA (PKR) plays critical roles in cell growth and apoptosis and is implicated as a potential pathogenic factor of Alzheimer's, Parkinson's, and Huntington's diseases. Here we report that this proapoptotic kinase is also involved in Fanconi anemia ( FA), a disease characterized by bone marrow (BM) failure and leukemia. We have used a BM extract to show that three FA proteins, FANCA, FANCC, and FANCG, functionally interact with the PKR kinase, which in turn regulates translational control. By using a combined immunoprecipitation and reconstituted kinase assay, in which an active PKR kinase complex was captured from a normal cell extract, we demonstrated functional interactions between the FA proteins and the PKR kinase. In primary human BM cells, mutations in the FANCA, FANCC, and FANCG genes markedly increase the amount of PKR bound to FANCC, and this PKR accumulation is correlated with elevated PKR activation and hypersensitivity of BM progenitor cells to growth repression mediated by the inhibitory cytokines interferon-gamma and tumor necrosis factor-alpha. Specific inhibition of PKR by 2-aminopurine in these FA BM cells attenuates PKR activation and apoptosis induction. In lymphoblasts derived from an FA-C patient, overexpression of a dominant negative mutant PKR (PKRK296R) suppressed PKR activation and apoptosis induced by interferon-gamma and tumor necrosis factor-alpha. Furthermore, by using genetically matched wild-type and PKR-null cells, we demonstrated that forced expression of a patient-derived FA-C mutant (FANCC(L554P)) augmented double-stranded RNA-induced PKR activation and cell death. Thus, inappropriate activation of PKR as a consequence of certain FA mutations might play a role in bone marrow failure that frequently occurred in FA.	Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA; Oregon Hlth & Sci Univ, Oregon Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Oregon Health & Science University	Pang, QS (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	qishen.pang@cchmc.org						ALTER B, 1998, HEMATOLOGY INFANCY C, V1, P27; Bagby GC, 2003, CURR OPIN HEMATOL, V10, P68, DOI 10.1097/00062752-200301000-00011; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; Dufour C, 2003, BLOOD, V102, P2053, DOI 10.1182/blood-2003-01-0114; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GAVISH H, 1993, HUM MOL GENET, V2, P123, DOI 10.1093/hmg/2.2.123; Gil J, 2001, ONCOGENE, V20, P385, DOI 10.1038/sj.onc.1204109; Haneline LS, 1998, BLOOD, V91, P4092; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; HU YH, 1993, J INTERFERON RES, V13, P323, DOI 10.1089/jir.1993.13.323; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Jeffrey IW, 2002, CANCER RES, V62, P2272; Kuhen KL, 1996, GENOMICS, V36, P197, DOI 10.1006/geno.1996.0446; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Onuki R, 2004, EMBO J, V23, P959, DOI 10.1038/sj.emboj.7600049; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Pang QS, 2002, J BIOL CHEM, V277, P49638, DOI 10.1074/jbc.M209386200; Pang QS, 2001, BLOOD, V97, P1644, DOI 10.1182/blood.V97.6.1644; Pang QS, 2001, EMBO J, V20, P4478, DOI 10.1093/emboj/20.16.4478; Peel AL, 2001, HUM MOL GENET, V10, P1531, DOI 10.1093/hmg/10.15.1531; Rathbun RK, 2000, BLOOD, V96, P4204; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x	37	39	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43910	43919		10.1074/jbc.M403884200	http://dx.doi.org/10.1074/jbc.M403884200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15299030	hybrid			2022-12-27	WOS:000224383100069
J	Maynes, JT; Perreault, KR; Cherney, MM; Luu, HA; James, MNG; Holmes, CFB				Maynes, JT; Perreault, KR; Cherney, MM; Luu, HA; James, MNG; Holmes, CFB			Crystal structure and mutagenesis of a protein phosphatase-1 : calcineurin hybrid elucidate the role of the beta 12-beta 13 loop in inhibitor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; MOLECULAR-CLONING; OKADAIC ACID; PHOSPHATASES; TOXIN; IDENTIFICATION; TYPE-1; SPECIFICITY; MUTATION; PROGRAM	Protein phosphatase-1 and protein phosphatase-2B ( calcineurin) are eukaryotic serine/threonine phosphatases that share 40% sequence identity in their catalytic subunits. Despite the similarities in sequence, these phosphatases are widely divergent when it comes to inhibition by natural product toxins, such as microcystin-LR and okadaic acid. The most prominent region of non-conserved sequence between these phosphatases corresponds to the beta12-beta13 loop of protein phosphatase-1, and the L7 loop of toxin-resistant calcineurin. In the present study, mutagenesis of residues 273-277 of the beta12-beta13 loop of the protein phosphatase-1 catalytic subunit (PP-1c) to the corresponding residues in calcineurin (312-316), resulted in a chimeric mutant that showed a decrease in sensitivity to microcystin-LR, okadaic acid, and the endogenous PP-1c inhibitor protein inhibitor-2. A crystal structure of the chimeric mutant in complex with okadaic acid was determined to 2.0-Angstrom resolution. The beta12-beta13 loop region of the mutant superimposes closely with that of wild-type PP-1c bound to okadaic acid. Systematic mutation of each residue in the beta12-beta13 loop of PP-1c showed that a single amino acid change (C273L) was the most influential in mediating sensitivity of PP-1c to toxins. Taken together, these data indicate that it is an individual amino acid residue substitution and not a change in the overall beta12-beta13 loop conformation of protein phosphatase-1 that contributes to disrupting important interactions with inhibitors such as microcystin-LR and okadaic acid.	Univ Alberta, Fac Med, Dept Biochem,Grp Prot Struct & Funct, Canadian Inst Hlth Res, Edmonton, AB T6G 2H7, Canada	Institute for Work & Health; University of Alberta	Holmes, CFB (corresponding author), Univ Alberta, Fac Med, Dept Biochem,Grp Prot Struct & Funct, Canadian Inst Hlth Res, Edmonton, AB T6G 2H7, Canada.	Charles.Holmes@ualberta.ca	Maynes, Jason/AAE-4344-2020					ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; Andrioli LPM, 2003, BIOCHEM J, V373, P703, DOI 10.1042/BJ20021964; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COHEN P, 1994, BIOESSAYS, V16, P583, DOI 10.1002/bies.950160812; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Craig M, 1996, BIOCHEM CELL BIOL, V74, P569, DOI 10.1139/o96-061; Dawson JF, 2000, BIOCHEM BIOPH RES CO, V270, P543, DOI 10.1006/bbrc.2000.2459; Dawson John F., 1999, Frontiers in Bioscience, V4, pd646, DOI 10.2741/Dawson; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Holmes CFB, 2002, CURR MED CHEM, V9, P1981, DOI 10.2174/0929867023368827; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Kita A, 2002, STRUCTURE, V10, P715, DOI 10.1016/S0969-2126(02)00764-5; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lin Q, 1998, PLANT MOL BIOL, V37, P471, DOI 10.1023/A:1005912413555; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MACKINTOSH C, 1989, BIOCHEM J, V262, P335, DOI 10.1042/bj2620335; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; MACKINTOSH RW, 1990, FEBS LETT, V276, P156, DOI 10.1016/0014-5793(90)80531-M; Maynes JT, 2001, J BIOL CHEM, V276, P44078, DOI 10.1074/jbc.M107656200; McCready TL, 2000, J BIOL CHEM, V275, P4192, DOI 10.1074/jbc.275.6.4192; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; SHIMA H, 1994, P NATL ACAD SCI USA, V91, P9267, DOI 10.1073/pnas.91.20.9267; Terrak M, 2004, NATURE, V429, P780, DOI 10.1038/nature02582; Watanabe T, 2001, P NATL ACAD SCI USA, V98, P3080, DOI 10.1073/pnas.051003898; Wei Q, 1997, BIOCHEMISTRY-US, V36, P7418, DOI 10.1021/bi962703s; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200; Zhang LF, 1996, BIOCHEMISTRY-US, V35, P1606, DOI 10.1021/bi9521396; ZHANG ZJ, 1994, J BIOL CHEM, V269, P16997; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; ZIMMERLIN A, 1995, PLANT MOL BIOL, V28, P363, DOI 10.1007/BF00020386	36	29	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43198	43206		10.1074/jbc.M407184200	http://dx.doi.org/10.1074/jbc.M407184200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15280359	hybrid			2022-12-27	WOS:000224226400104
J	Singh, R; Wiseman, B; Deemagarn, T; Donald, LJ; Duckworth, HW; Carpena, X; Fita, I; Loewen, PC				Singh, R; Wiseman, B; Deemagarn, T; Donald, LJ; Duckworth, HW; Carpena, X; Fita, I; Loewen, PC			Catalase-peroxidases (KatG) exhibit NADH oxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE-ADENINE-DINUCLEOTIDE; MYCOBACTERIUM-TUBERCULOSIS; HORSERADISH-PEROXIDASE; ESCHERICHIA-COLI; MOLECULAR CHARACTERIZATION; ISONIAZID OXIDATION; INHA INHIBITOR; SUPEROXIDE; PROTEINS; SENSITIVITY	Catalase-peroxidases (KatG) produced by Burkholderia pseudomallei, Escherichia coli, and Mycobacterium tuberculosis catalyze the oxidation of NADH to form NAD(+) and either H2O2 or superoxide radical depending on pH. The NADH oxidase reaction requires molecular oxygen, does not require hydrogen peroxide, is not inhibited by superoxide dismutase or catalase, and has a pH optimum of 8.75, clearly differentiating it from the peroxidase and catalase reactions with pH optima of 5.5 and 6.5, respectively, and from the NADH peroxidase-oxidase reaction of horseradish peroxidase. B. pseudomallei KatG has a relatively high affinity for NADH (K-m = 12 muM), but the oxidase reaction is slow (k(cat) = 0.54 min(-1)) compared with the peroxidase and catalase reactions. The catalase-peroxidases also catalyze the hydrazinolysis of isonicotinic acid hydrazide (INH) in an oxygen- and H2O2-independent reaction, and KatG-dependent radical generation from a mixture of NADH and INH is two to three times faster than the combined rates of separate reactions with NADH and INH alone. The major products from the coupled reaction, identified by high pressure liquid chromatography fractionation and mass spectrometry, are NAD(+) and isonicotinoyl-NAD, the activated form of isoniazid that inhibits mycolic acid synthesis in M. tuberculosis. Isonicotinoyl-NAD synthesis from a mixture of NAD(+) and INH is KatG-dependent and is activated by manganese ion. M. tuberculosis KatG catalyzes isonicotinoyl-NAD formation from NAD(+) and INH more efficiently than B. pseudomallei KatG.	Univ Manitoba, Dept Microbiol, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Dept Chem, Winnipeg, MB R3T 2N2, Canada; Consejo Super Invest Cient, Barcelona 08028, Spain	University of Manitoba; University of Manitoba; Consejo Superior de Investigaciones Cientificas (CSIC)	Loewen, PC (corresponding author), Univ Manitoba, Dept Microbiol, Winnipeg, MB R3T 2N2, Canada.	peter_loewen@umanitoba.ca	Fita, Ignasi/R-4515-2019; Carpena, Xavi/J-5877-2017; Deemagarn, Taweewat/AAR-4030-2020; Singh, Rahul/A-6891-2009	Fita, Ignasi/0000-0002-7521-2679; Carpena, Xavi/0000-0002-8646-0440; Singh, Rahul/0000-0002-1467-7915; Wiseman, Benjamin/0000-0002-2994-5839; Deemagarn, Taweewat/0000-0003-3368-1749				AKAZAWA T, 1958, J BIOL CHEM, V232, P403; ASHRAFUDDIN S, 1989, J BIOL CHEM, V264, P19856; Auclair C., 1985, CRC HDB METHODS OXYG, P123, DOI DOI 10.1201/9781351072922; Carpena X, 2003, J MOL BIOL, V327, P475, DOI 10.1016/S0022-2836(03)00122-0; CLARE DA, 1984, ANAL BIOCHEM, V140, P532, DOI 10.1016/0003-2697(84)90204-5; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Deretic V, 1996, NAT BIOTECHNOL, V14, P1557, DOI 10.1038/nbt1196-1557; Dunford H. B., 1999, HEME PEROXIDASES; GREGORY EM, 1974, ANAL BIOCHEM, V58, P57, DOI 10.1016/0003-2697(74)90440-0; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; Hillar A, 2000, BIOCHEMISTRY-US, V39, P5868, DOI 10.1021/bi0000059; HILLAR A, 1995, ARCH BIOCHEM BIOPHYS, V323, P438, DOI 10.1006/abbi.1995.0065; Jakopitsch C, 2003, BIOCHEMISTRY-US, V42, P5292, DOI 10.1021/bi026944d; Jakopitsch C, 2003, J BIOL CHEM, V278, P20185, DOI 10.1074/jbc.M211625200; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; Kengen SWM, 2003, EUR J BIOCHEM, V270, P2885, DOI 10.1046/j.1432-1033.2003.03668.x; Klotz MG, 2003, MOL BIOL EVOL, V20, P1098, DOI 10.1093/molbev/msg129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; Lei BF, 2000, J BIOL CHEM, V275, P2520, DOI 10.1074/jbc.275.4.2520; Loboda AV, 2000, RAPID COMMUN MASS SP, V14, P1047, DOI 10.1002/1097-0231(20000630)14:12<1047::AID-RCM990>3.0.CO;2-E; LOEWEN PC, 1990, BIOCHEM CELL BIOL, V68, P1037, DOI 10.1139/o90-153; Magliozzo RS, 1996, J AM CHEM SOC, V118, P11303, DOI 10.1021/ja962047j; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; MINISCI F, 1989, HETEROCYCLES, V28, P489, DOI 10.3987/REV-88-SR1; MITCHISON DA, 1956, AM REV TUBERC PULM, V74, P109; Regelsberger G, 2000, J BIOL CHEM, V275, P22854, DOI 10.1074/jbc.M002371200; Ro YT, 2003, FEMS MICROBIOL LETT, V226, P397, DOI 10.1016/S0378-1097(03)00644-X; RORTH M, 1967, BIOCHIM BIOPHYS ACTA, V139, P171, DOI 10.1016/0005-2744(67)90124-6; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRIGGSRAINE BL, 1987, GENE, V52, P121, DOI 10.1016/0378-1119(87)90038-2; Wang JY, 1998, ANTIMICROB AGENTS CH, V42, P709, DOI 10.1128/AAC.42.3.709; Weber K, 1972, Methods Enzymol, V26, P3; Wei CJ, 2003, ANTIMICROB AGENTS CH, V47, P670, DOI 10.1128/AAC.47.2.670-675.2003; Wilming M, 1999, ANGEW CHEM INT EDIT, V38, P2588, DOI 10.1002/(SICI)1521-3773(19990903)38:17<2588::AID-ANIE2588>3.0.CO;2-8; Xia RH, 2003, AM J PHYSIOL-CELL PH, V285, pC215, DOI 10.1152/ajpcell.00034.2002; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834; YOKOTA K, 1965, BIOCHIM BIOPHYS ACTA, V105, P301, DOI 10.1016/S0926-6593(65)80154-0; YOKOTA K, 1977, BIOCHEMISTRY-US, V16, P1913, DOI 10.1021/bi00628a024; YOUATT J, 1969, AM REV RESPIR DIS, V99, P729; Yu SW, 2003, J BIOL CHEM, V278, P44121, DOI 10.1074/jbc.M304757200; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; Zoldak G, 2003, EUR J BIOCHEM, V270, P4887, DOI 10.1046/j.1432-1033.2003.03889.x	45	69	74	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43098	43106		10.1074/jbc.M406374200	http://dx.doi.org/10.1074/jbc.M406374200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15280362	hybrid			2022-12-27	WOS:000224226400094
J	Tomoda, K; Yoneda-Kato, N; Fukumoto, A; Yamanaka, S; Kato, Y				Tomoda, K; Yoneda-Kato, N; Fukumoto, A; Yamanaka, S; Kato, Y			Multiple functions of Jab1 are required for early embryonic development and growth potential in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-1 EXPRESSION; COP9 SIGNALOSOME; CELL-CYCLE; FISSION YEAST; COP9/SIGNALOSOME SUBUNITS; INHIBITOR P27(KIP1); INVERSE EXPRESSION; POOR-PROGNOSIS; LIGHT CONTROL; COMPLEX	Jab1 interacts with a variety of signaling molecules and regulates their stability in mammalian cells. As the fifth component of the COP9 signalosome (CSN) complex, Jab1 (CSN5) plays a central role in the deneddylation of the cullin subunit of the Skp1-Cullin- F box protein ubiquitin ligase complex. In addition, a CSN-independent function of Jab1 is suggested but is less well characterized. To elucidate the function of Jab1, we targeted the Jab1 locus by homologous recombination in mouse embryonic stem cells. Jab1-null embryos died soon after implantation. Jab1-/- embryonic cells, which lacked other CSN components, expressed higher levels of p27, p53, and cyclin E, resulting in impaired proliferation and accelerated apoptosis. Jab1 heterozygous mice were healthy and fertile but smaller than their wild-type littermates. Jab1-/- mouse embryonic fibroblast cells, in which the amount of Jab1-containing small subcomplex, but not that of CSN, was selectively reduced, proliferated poorly, showed an inefficient down-regulation of p27 during G(1), and was delayed in the progression from G(0) to S phase by 3 h compared with the wild-type cells. Most interestingly, in Jab1-/- mouse embryonic fibroblasts, the levels of cyclin E and deneddylated Cul1 were unchanged, and p53 was not induced. Thus, Jab1 controls cell cycle progression and cell survival by regulating multiple cell cycle signaling pathways.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Nara Med Univ, Dept Surg 1, Kashihara, Nara 634, Japan; Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan	Nara Institute of Science & Technology; Nara Medical University; Nara Institute of Science & Technology	Kato, Y (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.	jkata@bs.naist.jp						Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bech-Otschir D, 2002, J CELL SCI, V115, P467; Bemis L, 2004, GENE DEV, V18, P739, DOI 10.1101/gad.1180104; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; Chamovitz DA, 2002, CURR BIOL, V12, pR232, DOI 10.1016/S0960-9822(02)00775-3; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Doronkin S, 2002, DEVELOPMENT, V129, P5053; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Esteva FJ, 2003, CLIN CANCER RES, V9, P5652; Freilich S, 1999, CURR BIOL, V9, P1187, DOI 10.1016/S0960-9822(00)80023-8; Fukumoto A, 2004, ONCOL REP, V11, P277; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Ito Y, 2003, ANTICANCER RES, V23, P4121; Ito Y, 2003, CANCER LETT, V196, P87, DOI 10.1016/S0304-3835(03)00129-0; Ivan D, 2004, MODERN PATHOL, V17, P811, DOI 10.1038/modpathol.3800123; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Kwok SF, 1998, PLANT CELL, V10, P1779, DOI 10.1105/tpc.10.11.1779; Liu C, 2003, GENE DEV, V17, P1130, DOI 10.1101/gad.1090803; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Lykke-Andersen K, 2003, MOL CELL BIOL, V23, P6790, DOI 10.1128/MCB.23.19.6790-6797.2003; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Maytal-Kivity V, 2002, EMBO REP, V3, P1215, DOI 10.1093/embo-reports/kvf235; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Mundt KE, 1999, CURR BIOL, V9, P1427, DOI 10.1016/S0960-9822(00)80091-3; Mundt KE, 2002, MOL BIOL CELL, V13, P493, DOI 10.1091/mbc.01-10-0521; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nielsen O, 2003, CURR BIOL, V13, pR565, DOI 10.1016/S0960-9822(03)00475-5; Oron E, 2002, DEVELOPMENT, V129, P4399; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Seeger M, 2001, CURR BIOL, V11, pR643, DOI 10.1016/S0960-9822(01)00382-7; Serino G, 2003, ANNU REV PLANT BIOL, V54, P165, DOI 10.1146/annurev.arplant.54.031902.134847; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shintani S, 2003, ONCOLOGY-BASEL, V65, P355, DOI 10.1159/000074649; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Smith P, 2002, DEV BIOL, V251, P333, DOI 10.1006/dbio.2002.0832; Sui L, 2001, CLIN CANCER RES, V7, P4130; Sun Y, 2002, J BIOL CHEM, V277, P45759, DOI 10.1074/jbc.M208709200; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tsuchida R, 2002, JPN J CANCER RES, V93, P1000, DOI 10.1111/j.1349-7006.2002.tb02476.x; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Wang XP, 2002, MOL BIOL CELL, V13, P646, DOI 10.1091/mbc.01-08-0427; Wang YS, 1999, CURR BIOL, V9, P1191, DOI 10.1016/S0960-9822(00)80024-X; Wee S, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-15; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Wolf DA, 2003, NAT CELL BIOL, V5, P1029, DOI 10.1038/ncb1203-1029; Yan J, 2003, MOL CELL BIOL, V23, P6798, DOI 10.1128/MCB.23.19.6798-6808.2003; Yang XM, 2002, CURR BIOL, V12, P667, DOI 10.1016/S0960-9822(02)00791-1; Zhou CS, 2003, MOL CELL, V11, P927, DOI 10.1016/S1097-2765(03)00136-9	67	131	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43013	43018		10.1074/jbc.M406559200	http://dx.doi.org/10.1074/jbc.M406559200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15299027	hybrid			2022-12-27	WOS:000224226400083
J	Traiffort, E; Dubourg, C; Faure, H; Rognan, D; Odent, S; Durou, MR; David, V; Ruat, M				Traiffort, E; Dubourg, C; Faure, H; Rognan, D; Odent, S; Durou, MR; David, V; Ruat, M			Functional characterization of sonic hedgehog mutations associated with holoprosencephaly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; GENE; SHH; PROTEIN; DOMAIN; IDENTIFICATION; EXPRESSION; INDUCTION; ZIC2; SEGREGATION	Mutations of the developmental gene Sonic hedgehog (SHH) and alterations of SHH signaling have been associated with holoprosencephaly (HPE), a rare disorder characterized by a large spectrum of brain and craniofacial anomalies. Based on the crystal structure of mouse N-terminal and Drosophila C-terminal hedgehog proteins, we have developed three-dimensional models of the corresponding human proteins (SHH-N, SHH-C) that have allowed us to identify within these two domains crucial regions associated with HPE missense mutations. We have further characterized the functional consequences linked to 11 of these mutations. In transfected HEK293 cells, the production of the active SHH-N fragment was dramatically impaired for eight mutants ( W117R, W117G, H140P, T150R, C183F, L271P, I354T, A383T). The supernatants from these cell cultures showed no significant SHH-signaling activity in a reporter cell-based assay. Two mutants (G31R, D222N) were associated with a lower production of SHH-N and signaling activity. Finally, one mutant harboring the A226T mutation displays an activity comparable with the wild-type protein. This work demonstrates that most of the HPE-associated SHH mutations analyzed have a deleterious effect on the availability of SHH-N and its biological activity. However, because of the lack of correlation between genotype and phenotype for SHH-associated mutations, our study suggests that other factors intervene in the development of the spectrum of HPE anomalies.	CNRS, UPR 9040, Inst Neurol Alfred Fessard, Lab Neurobiol Cellulaire & Mol,IFR CNRS 2118, F-91198 Gif Sur Yvette, France; Fac Med, UMR 6061, F-35043 Rennes, France; CNRS, UMR 7081, Lab Pharmacochim Commun Cellulaire, F-67401 Illkirch Graffenstaden, France; Hop Sud, Unite Genet Med, F-35023 Rennes, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CHU Rennes	Traiffort, E (corresponding author), CNRS, UPR 9040, Inst Neurol Alfred Fessard, Lab Neurobiol Cellulaire & Mol,IFR CNRS 2118, Batiment 33,1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	Elisabeth.Traiffort@nbcm.cnrs-gif.fr	Rognan, Didier/B-9939-2014; Ruat, Martial/E-5544-2016; FAURE, Helene/E-4641-2010; Traiffort, Elisabeth/B-2042-2019	Traiffort, Elisabeth/0000-0002-9645-6269; FAURE, Helene/0000-0002-0005-9331				Adato A, 1999, AM J HUM GENET, V65, P261, DOI 10.1086/302438; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; Bissantz C, 2003, PROTEINS, V50, P5, DOI 10.1002/prot.10237; Brown LY, 2001, HUM MOL GENET, V10, P791, DOI 10.1093/hmg/10.8.791; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; CASE DA, 1997, AMBER; Charytoniuk D, 2002, EUR J NEUROSCI, V16, P2351, DOI 10.1046/j.1460-9568.2002.02412.x; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Coulombe J, 2004, MOL CELL NEUROSCI, V25, P323, DOI 10.1016/j.mcn.2003.10.024; Day ES, 1999, BIOCHEMISTRY-US, V38, P14868, DOI 10.1021/bi9910068; de la Cruz JM, 2002, HUM GENET, V110, P422, DOI 10.1007/s00439-002-0709-3; Dubourg C, 2004, HUM MUTAT, V24, P43, DOI 10.1002/humu.20056; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; Gabriel SB, 2002, NAT GENET, V31, P89, DOI 10.1038/ng868; Goodrich LV, 1999, DEV BIOL, V211, P323, DOI 10.1006/dbio.1999.9311; Gripp KW, 2000, NAT GENET, V25, P205, DOI 10.1038/76074; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; Hardcastle Z, 1998, DEVELOPMENT, V125, P2803; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Kato M, 2000, ANN NEUROL, V47, P514, DOI 10.1002/1531-8249(200004)47:4<514::AID-ANA16>3.3.CO;2-8; Kawakami T, 2002, DEVELOPMENT, V129, P5753, DOI 10.1242/dev.00178; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma Y, 2002, CELL, V111, P63, DOI 10.1016/S0092-8674(02)00977-7; MARIGO V, 1995, GENOMICS, V28, P44, DOI 10.1006/geno.1995.1104; Marigo V, 1996, DEVELOPMENT, V122, P1225; Marini M, 2003, AM J MED GENET A, V117A, P112, DOI 10.1002/ajmg.a.10163; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Ming JE, 2002, AM J HUM GENET, V71, P1017, DOI 10.1086/344412; Ming JE, 2002, HUM GENET, V110, P297, DOI 10.1007/s00439-002-0695-5; Nanni L, 1999, HUM MOL GENET, V8, P2479, DOI 10.1093/hmg/8.13.2479; Nanni L, 2001, AM J MED GENET, V102, P1, DOI 10.1002/1096-8628(20010722)102:1<1::AID-AJMG1336>3.0.CO;2-U; Odent S, 1998, AM J MED GENET, V77, P139, DOI 10.1002/(SICI)1096-8628(19980501)77:2<139::AID-AJMG6>3.0.CO;2-N; Odent S, 1999, HUM MOL GENET, V8, P1683, DOI 10.1093/hmg/8.9.1683; Orioli IM, 2001, HUM GENET, V109, P1, DOI 10.1007/s004390100537; Parisi MA, 2000, CURR OPIN PEDIATR, V12, P610, DOI 10.1097/00008480-200012000-00017; Pepinsky RB, 2000, J BIOL CHEM, V275, P10995, DOI 10.1074/jbc.275.15.10995; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Roessler E, 2003, HUM MOL GENET, V12, pR15, DOI 10.1093/hmg/ddg058; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Roessler E, 2003, P NATL ACAD SCI USA, V100, P13424, DOI 10.1073/pnas.2235734100; Roessler E, 1997, HUM MOL GENET, V6, P1847, DOI 10.1093/hmg/6.11.1847; Savage DB, 2002, NAT GENET, V31, P379, DOI 10.1038/ng926; Schell-Apacik C, 2003, HUM GENET, V113, P170, DOI 10.1007/s00439-003-0950-4; Smyth I, 1999, HUM MOL GENET, V8, P291, DOI 10.1093/hmg/8.2.291; Song JW, 1999, DEV BIOL, V213, P157, DOI 10.1006/dbio.1999.9370; Taylor FR, 2001, BIOCHEMISTRY-US, V40, P4359, DOI 10.1021/bi002487u; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Traiffort E, 2001, EUR J NEUROSCI, V14, P839, DOI 10.1046/j.0953-816x.2001.01708.x; Varlet I, 1997, COLD SPRING HARB SYM, V62, P105; Verlinsky Y, 2003, NEW ENGL J MED, V348, P1449, DOI 10.1056/NEJMoa022652; Wallis DE, 1999, MOL GENET METAB, V68, P126, DOI 10.1006/mgme.1999.2895; Zaphiropoulos PG, 1999, CANCER RES, V59, P787; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648; Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3	59	57	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42889	42897		10.1074/jbc.M405161200	http://dx.doi.org/10.1074/jbc.M405161200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292211	hybrid			2022-12-27	WOS:000224226400067
J	Kim, JH; Singvall, J; Schwarz-Linek, U; Johnson, BJB; Potts, JR; Hook, M				Kim, JH; Singvall, J; Schwarz-Linek, U; Johnson, BJB; Potts, JR; Hook, M			BBK32, a fibronectin binding MSCRAMM from Borrelia burgdorferi, contains a disordered region that undergoes a conformational change on ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYME-DISEASE SPIROCHETE; STAPHYLOCOCCUS-AUREUS INFECTIONS; SURFACE PROTEIN-A; STREPTOCOCCUS-PYOGENES; DECORIN-BINDING; BACTERIAL ADHERENCE; CRYSTAL-STRUCTURE; EPITHELIAL-CELLS; EXPRESSION; HOST	BBK32 is a fibronectin-binding lipoprotein on Borrelia burgdorferi, the causative agent of Lyme disease. Analysis using secondary structure prediction programs suggested that BBK32 is composed of two domains, an N-terminal segment lacking well defined secondary structure and a C-terminal segment composed largely of alpha-helices. Analysis of purified recombinant forms of the two domains by circular dichroism spectroscopy, gel permeation chromatography, and intrinsic viscosity determination were consistent with an N-terminal-extended, unstructured segment and a C-terminal globular domain in BBK32. Solid phase binding experiments suggest that the unstructured N-terminal domain binds fibronectin. Analysis of changes in circular dichroism spectra of the N-terminal segment of BBK32 upon binding of the N-terminal domain of fibronectin revealed an increase in beta-sheet content in the complex. Hence, BBK32, which belongs to a different family of proteins and shows no overall sequence similarity with the fibronectin binding MSCRAMMs (microbial surface components recognizing adhesive matrix molecules) of Gram-positive bacteria, binds fibronectin by a mechanism that is reminiscent of the "tandem beta-zipper" previously demonstrated for the fibronectin binding of streptococcal adhesins (Schwarz-Linek, U., Werner, J.M., Pickford, A. R., Gurusiddappa, S., Kim, J.H., Pilka, E. S., Briggs, J.A., Gough, T. S., Hook, M., Campbell, I. D., and Potts, J.R. (2003) Nature 423, 177-181).	Texas A&M Univ Syst Hlth Sci Ctr, Albert B Alkek Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Univ Oxford, Dept Biochem, Oxford OX1 2JD, England; Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO 80522 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Oxford; Centers for Disease Control & Prevention - USA	Hook, M (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Albert B Alkek Inst Biosci & Technol, Ctr Extracellular Matrix Biol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mhook@ibt.tamu.edu		Schwarz-Linek, Ulrich/0000-0003-0526-223X	NIAID NIH HHS [AI20624] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERS GK, 1967, J BIOL CHEM, V242, P3026; Anguita J, 2001, J IMMUNOL, V167, P3383, DOI 10.4049/jimmunol.167.6.3383; BORSI L, 1986, ANAL BIOCHEM, V155, P335, DOI 10.1016/0003-2697(86)90443-4; Brown EL, 1999, J BIOL CHEM, V274, P26272, DOI 10.1074/jbc.274.37.26272; Brown EL, 2001, J CLIN INVEST, V107, P845, DOI 10.1172/JCI11692; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; Casjens S, 2000, MOL MICROBIOL, V35, P490, DOI 10.1046/j.1365-2958.2000.01698.x; Casolini F, 1998, INFECT IMMUN, V66, P5433, DOI 10.1128/IAI.66.11.5433-5442.1998; Eicken C, 2002, J BIOL CHEM, V277, P21691, DOI 10.1074/jbc.M201547200; Fikrig E, 2000, J IMMUNOL, V164, P5344, DOI 10.4049/jimmunol.164.10.5344; Fikrig E, 1997, IMMUNITY, V6, P531, DOI 10.1016/S1074-7613(00)80341-6; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Fowler T, 2000, EUR J CELL BIOL, V79, P672, DOI 10.1078/0171-9335-00104; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Guo BP, 1998, MOL MICROBIOL, V30, P711, DOI 10.1046/j.1365-2958.1998.01103.x; Hanson LS, 2000, INFECT IMMUN, V68, P6457, DOI 10.1128/IAI.68.11.6457-6460.2000; HousePompeo K, 1996, J BIOL CHEM, V271, P1379, DOI 10.1074/jbc.271.3.1379; Joh D, 1998, EUR J BIOCHEM, V258, P897, DOI 10.1046/j.1432-1327.1998.2580897.x; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; JOH HJ, 1994, BIOCHEMISTRY-US, V33, P6086, DOI 10.1021/bi00186a007; Johansson S, 1997, FRONT BIOSCI, V2, P126; Katerov V, 1997, ADV EXP MED BIOL, V418, P741; Katerov V, 1998, MICROBIOL-UK, V144, P119, DOI 10.1099/00221287-144-1-119; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li H, 1997, P NATL ACAD SCI USA, V94, P3584, DOI 10.1073/pnas.94.8.3584; Liang FT, 2002, J EXP MED, V196, P275, DOI 10.1084/jem.20020770; Massey RC, 2001, CELL MICROBIOL, V3, P839, DOI 10.1046/j.1462-5822.2001.00157.x; MCGAVIN MJ, 1991, J BIOL CHEM, V266, P8343; Menzies BE, 2003, CURR OPIN INFECT DIS, V16, P225, DOI 10.1097/00001432-200306000-00007; Molinari G, 1997, INFECT IMMUN, V65, P1357, DOI 10.1128/IAI.65.4.1357-1363.1997; Mosher DF, 1989, FIBRONECTIN; Nadelman RB, 1998, LANCET, V352, P557, DOI 10.1016/S0140-6736(98)01146-5; Ozeri V, 1996, EMBO J, V15, P989, DOI 10.1002/j.1460-2075.1996.tb00435.x; Ozeri V, 1998, MOL MICROBIOL, V30, P625, DOI 10.1046/j.1365-2958.1998.01097.x; Penkett CJ, 1998, BIOCHEMISTRY-US, V37, P17054, DOI 10.1021/bi9814080; Ponnuraj K, 2002, BBA-PROTEIN STRUCT M, V1596, P173, DOI 10.1016/S0167-4838(01)00328-4; Potts JR, 1996, MATRIX BIOL, V15, P313, DOI 10.1016/S0945-053X(96)90133-X; Probert WS, 1998, MOL MICROBIOL, V30, P1003, DOI 10.1046/j.1365-2958.1998.01127.x; Probert WS, 2001, INFECT IMMUN, V69, P4129, DOI 10.1128/IAI.69.6.4129-4133.2001; Ramamoorthy R, 2001, INFECT IMMUN, V69, P2739, DOI 10.1128/IAI.69.4.2739-2742.2001; Revel AT, 2002, P NATL ACAD SCI USA, V99, P1562, DOI 10.1073/pnas.032667699; RIBEIRO JMC, 1987, J MED ENTOMOL, V24, P201, DOI 10.1093/jmedent/24.2.201; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; Schwarz-Linek U, 2001, FEBS LETT, V497, P137, DOI 10.1016/S0014-5793(01)02418-8; Schwarz-Linek U, 2004, MOL MICROBIOL, V52, P631, DOI 10.1111/j.1365-2958.2004.04027.x; Speziale P, 1996, J BIOL CHEM, V271, P1371, DOI 10.1074/jbc.271.3.1371; Steere AC, 2001, NEW ENGL J MED, V345, P115, DOI 10.1056/NEJM200107123450207; STEVENSON B, 1995, INFECT IMMUN, V63, P4535, DOI 10.1128/IAI.63.11.4535-4539.1995; Talay SR, 2000, CELL MICROBIOL, V2, P521, DOI 10.1046/j.1462-5822.2000.00076.x; Tilsta L., 1996, CIRCULAR DICHROISM C, P261; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; Wann ER, 2000, J BIOL CHEM, V275, P13863, DOI 10.1074/jbc.275.18.13863; Yang XF, 2001, INFECT IMMUN, V69, P4159, DOI 10.1128/IAI.69.6.4159-4163.2001	53	75	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41706	41714		10.1074/jbc.M401691200	http://dx.doi.org/10.1074/jbc.M401691200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292204	hybrid			2022-12-27	WOS:000224075500058
J	Tang, TS; Bezprozvanny, I				Tang, TS; Bezprozvanny, I			Dopamine receptor-mediated Ca2+ signaling in striatal medium spiny neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; INNERVATED BRAIN-REGIONS; PROTEIN-KINASE-A; AMP-DEPENDENT PHOSPHORYLATION; RAT-BRAIN; NMDA RECEPTOR; IMMUNOCYTOCHEMICAL LOCALIZATION; PHOSPHOINOSITIDE HYDROLYSIS; MUSCARINIC RECEPTORS; NEOSTRIATAL NEURONS	Inositol 1,4,5-trisphosphate (InsP(3)) and cAMP are the two second messengers that play an important role in neuronal signaling. Here, we investigated the interactions of InsP(3)- and cAMP-mediated signaling pathways activated by dopamine in striatal medium spiny neurons (MSN). We found that in similar to 40% of the MSN, application of dopamine elicited robust repetitive Ca2+ transients ( oscillations). In pharmacological experiments with specific agonists and antagonists, we found that the observed Ca2+ oscillations were triggered by activation of D1 class dopamine receptors (DARs). We further demonstrated that activation of phospholipase C was required for induction of dopamine-induced Ca2+ oscillations and that maintenance of dopamine-evoked Ca2+ oscillations required both Ca2+ influx and Ca2+ mobilization from internal Ca2+ stores. In "priming" experiments with a type 2 5-hydroxytryptamine receptor agonist, we have shown a likely role for calcyon in coupling D1 class DARs with Ca2+ oscillations in MSN. In experiments with the DAR-specific agonist SKF83959, we discovered that phospholipase C activation alone could not account for dopamine-induced Ca2+ oscillations. We further demonstrated that direct activation of protein kinase A by 8-bromo-cAMP or inhibition of protein phosphatase-1 (PP1) or calcineurin (PP2B) resulted in elevation of basal Ca2+ levels in MSN, but not in Ca2+ oscillations. In experiments with competitive peptides, we have shown an importance of type 1 InsP(3) receptor association with PP1alpha and with AKAP9 . protein kinase A for dopamine-induced Ca2+ oscillations. In experiments with MSN from DARPP-32 knock-out mice, we demonstrated a regulatory role of DARPP-32 in dopamine-induced Ca2+ oscillations. Our results indicate that, following D1 class DAR activation, InsP(3) and cAMP signaling pathways converge on the type 1 InsP(3) receptor, resulting in Ca2+ oscillations in MSN.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bezprozvanny, I (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd,K4-112, Dallas, TX 75390 USA.	Ilya.Bezprozvanny@UTSouthwestern.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038082] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS38082] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Bergson C, 2003, TRENDS PHARMACOL SCI, V24, P486, DOI 10.1016/S0165-6147(03)00232-3; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Blank T, 1997, P NATL ACAD SCI USA, V94, P14859, DOI 10.1073/pnas.94.26.14859; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; Cepeda C, 1998, J NEUROPHYSIOL, V79, P82, DOI 10.1152/jn.1998.79.1.82; Cepeda C, 1998, DEV NEUROSCI-BASEL, V20, P1, DOI 10.1159/000017294; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; Fienberg AA, 2000, BRAIN RES REV, V31, P313, DOI 10.1016/S0165-0173(99)00047-8; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Flores-Hernandez J, 2002, J NEUROPHYSIOL, V88, P3010, DOI 10.1152/jn.00361.2002; Friedman E, 1997, MOL PHARMACOL, V51, P6, DOI 10.1124/mol.51.1.6; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; Goslin K., 1998, CULTURING NERVE CELL, P339; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; GUSTAFSON EL, 1991, J COMP NEUROL, V310, P170, DOI 10.1002/cne.903100204; GUSTAFSON EL, 1990, EXP BRAIN RES, V79, P447; HARRISON JK, 1991, TRENDS PHARMACOL SCI, V12, P62, DOI 10.1016/0165-6147(91)90499-I; Haug LS, 1999, J BIOL CHEM, V274, P7467, DOI 10.1074/jbc.274.11.7467; Hernandez-Lopez S, 2000, J NEUROSCI, V20, P8987; HernandezLopez S, 1997, J NEUROSCI, V17, P3334; HOWE AR, 1995, J NEUROSCI, V15, P458; Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JACKSON DM, 1994, PHARMACOL THERAPEUT, V64, P291, DOI 10.1016/0163-7258(94)90041-8; Jin LQ, 2003, J NEUROCHEM, V85, P378, DOI 10.1046/j.1471-4159.2003.01698.x; KEIZER J, 1992, BIOPHYS J, V61, P649, DOI 10.1016/S0006-3495(92)81870-2; Kotecha SA, 2002, NEURON, V35, P1111, DOI 10.1016/S0896-6273(02)00859-0; Levine MS, 1996, J NEUROSCI, V16, P5870; Lezcano N, 2000, SCIENCE, V287, P1660, DOI 10.1126/science.287.5458.1660; Lezcano N, 2002, J NEUROPHYSIOL, V87, P2167, DOI 10.1152/jn.00541.2001; Mao LM, 2001, MOL BRAIN RES, V86, P125, DOI 10.1016/S0169-328X(00)00276-X; Maximov A, 2002, J NEUROSCI, V22, P6939; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Morikawa H, 2003, J NEUROSCI, V23, P149; NAKADE S, 1994, J BIOL CHEM, V269, P6735; Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185; NISENBAUM ES, 1995, J NEUROSCI, V15, P4449; OUIMET CC, 1984, J NEUROSCI, V4, P111; Pacheco MA, 1997, J NEUROCHEM, V69, P639; Panchalingam S, 2001, NEUROPHARMACOLOGY, V40, P826, DOI 10.1016/S0028-3908(01)00011-9; Pieper AA, 2001, NEUROSCIENCE, V102, P433, DOI 10.1016/S0306-4522(00)00470-X; Rajadhyaksha A, 1998, DEV NEUROSCI-BASEL, V20, P204, DOI 10.1159/000017314; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Snyder GL, 1998, J NEUROSCI, V18, P10297; Soulsby MD, 2004, FEBS LETT, V557, P181, DOI 10.1016/S0014-5793(03)01487-X; STOJILKOVIC SS, 1992, P NATL ACAD SCI USA, V89, P4081, DOI 10.1073/pnas.89.9.4081; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SURMEIER DJ, 1995, NEURON, V14, P385, DOI 10.1016/0896-6273(95)90294-5; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Tang TS, 2003, J NEUROSCI, V23, P403, DOI 10.1523/JNEUROSCI.23-02-00403.2003; Tu HP, 2004, J BIOL CHEM, V279, P19375, DOI 10.1074/jbc.M313476200; UNDIE AS, 1990, J PHARMACOL EXP THER, V253, P987; Vallone D, 2000, NEUROSCI BIOBEHAV R, V24, P125, DOI 10.1016/S0149-7634(99)00063-9; Wagner LE, 2003, J BIOL CHEM, V278, P45811, DOI 10.1074/jbc.M306270200; WALAAS SI, 1983, NATURE, V301, P69; WALAAS SI, 1984, J NEUROSCI, V4, P84; WALAAS SI, 1986, J NEUROSCI, V6, P954; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wilson CJ, 1996, J NEUROSCI, V16, P2397; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670	66	60	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42082	42094		10.1074/jbc.M407389200	http://dx.doi.org/10.1074/jbc.M407389200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292232	hybrid			2022-12-27	WOS:000224075500101
J	Jiang, YY; Saavedra, HI; Holloway, MP; Leone, G; Altura, RA				Jiang, YY; Saavedra, HI; Holloway, MP; Leone, G; Altura, RA			Aberrant regulation of survivin by the RB/E2F family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; WILD-TYPE P53; CELL-CYCLE; TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; APOPTOSIS; EXPRESSION; CANCER; RB; E2F	Survivin is a putative oncogene that is aberrantly expressed in cancer cells. It has been hypothesized to play a central role in cancer progression and resistance to therapy in diverse tumor types. Although some of the transcriptional processes regulating its expression have been established, the diversity of genes that may be controlling the levels of its expression in both normal cells as well as in cancer cells has not been fully explored. The most common genetically mutated pathways in human malignancies are the p53 tumor suppressor pathway and the RB/E2F pathway. Both of these pathways, when intact, provide essential checkpoints in the maintenance of normal cell growth and protect the cell from DNA damage. Using non-transformed embryonic fibroblasts, we provide evidence of a molecular link between the regulation of survivin transcription and the RB/E2F family of proteins. We demonstrate that both pRB and p130 can interact with the survivin promoter and can repress survivin transcription. We also show that the E2F activators (E2F1, E2F2, and E2F3) can bind to the survivin promoter and induce survivin transcription. Genetically modified cells that harbor deletions in various members of the RB/E2F family confirm our data from the wild-type cells. Our findings implicate several members of the RB/E2F pathway in an intricate mechanism of survivin gene regulation that, when genetically altered during the process of tumorigenesis, may function within cancer cells to aberrantly alter survivin levels and enhance tumor progression.	Ohio State Univ, Coll Med & Publ Hlth, Columbus Childrens Res Inst, Columbus, OH 43205 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Pediat, Columbus, OH 43205 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43205 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Genet, Columbus, OH 43205 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Altura, RA (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Columbus Childrens Res Inst, R II 5021,700 Childrens Dr, Columbus, OH 43205 USA.	Alturar@pediatrics.ohio-state.edu						Alevizopoulos K, 2000, ONCOGENE, V19, P2067, DOI 10.1038/sj.onc.1203534; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Altura RA, 2003, BRIT J CANCER, V89, P1743, DOI 10.1038/sj.bjc.6601334; *APPL BIOS, 2002, APPL BIOS US B, V2; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Conway EM, 2003, AM J PATHOL, V163, P935, DOI 10.1016/S0002-9440(10)63453-0; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Gianani R, 2001, HUM PATHOL, V32, P119, DOI 10.1053/hupa.2001.21897; Giet R, 1999, J CELL SCI, V112, P3591; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; NEVINS JR, 1992, SCIENCE, V258, P424; Otaki M, 2000, BBA-GENE STRUCT EXPR, V1493, P188, DOI 10.1016/S0167-4781(00)00142-1; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Saavedra HI, 2003, CANCER CELL, V3, P333, DOI 10.1016/S1535-6108(03)00083-7; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593	43	139	146	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40511	40520		10.1074/jbc.M404496200	http://dx.doi.org/10.1074/jbc.M404496200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15271987	hybrid			2022-12-27	WOS:000223916800038
J	Shin, J; Park, B; Cho, SL; Lee, S; Kim, Y; Lee, SO; Cho, K; Lee, S; Jin, BS; Ahn, JH; Choi, EJ; Ahn, K				Shin, J; Park, B; Cho, SL; Lee, S; Kim, Y; Lee, SO; Cho, K; Lee, S; Jin, BS; Ahn, JH; Choi, EJ; Ahn, K			Promyelocytic leukemia is a direct inhibitor of SAPK2/p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PML NUCLEAR-BODIES; FAS-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; CREB-BINDING-PROTEIN; RNA-POLYMERASE-II; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; RAR-ALPHA; HUMAN CYTOMEGALOVIRUS; TUMOR SUPPRESSION	The promyelocytic leukemia gene (PML) encodes a growth/tumor suppressor protein that is essential for the induction of apoptosis in response to various apoptotic signals. The mechanism by which PML plays a role in the regulation of cell death is still unknown. In the current study, we demonstrate that PML negatively regulated the SAPK2/p38 signaling pathway by sequestering p38 from its upstream kinases, MKK3, MKK4, and MKK6, whereas PML did not affect the SAPK1/c-Jun NH2-terminal kinase pathway. PML associated with p38 both in vitro and in vivo and the carboxyl terminus of PML mediated the interaction. In contrast to other studies of PML and PML-nuclear bodies ( NB), our study shows that the formation of PML-NBs was not required for PML to suppress p38 activity because PML was still able to bind and inhibit p38 activity under the conditions in which PML-NBs were disrupted. In addition, we show that the promotion of Fas-induced cell death by PML correlated with the extent of p38 inhibition by PML, suggesting that PML might regulate apoptosis through manipulating SAPK2/p38 pathways. Our findings define a novel function of PML as a negative regulator of p38 kinase and provide further understanding on the mechanism of how PML induces multiple pathways of apoptosis.	Korea Univ, Coll Life Sci & Biotechnol, Seoul 136701, South Korea; Sungkyunkwan Univ, Dept Mol Cell Biol, Sch Med, Suwon 440746, South Korea	Korea University; Sungkyunkwan University (SKKU)	Ahn, K (corresponding author), Seoul Natl Univ, Sch Biol Sci, San 56-1, Seoul 151742, South Korea.	ksahn3@hanmail.net	Lee, Sungwook/K-3697-2013; Shin, Jinwook/AAG-6004-2019	Shin, Jinwook/0000-0003-3476-7595; CHO, KWANGMIN/0000-0001-6764-1425				Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; Alvarado-Kristensson M, 2001, FASEB J, V15, P129, DOI 10.1096/fj.01-0817fje; Aoshiba K, 1999, J IMMUNOL, V162, P1692; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chan JYH, 1997, BIOCHEM BIOPH RES CO, V240, P640, DOI 10.1006/bbrc.1997.7692; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Charette SJ, 2000, ANN NY ACAD SCI, V926, P126; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; LAVAU C, 1995, ONCOGENE, V11, P871; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lim S, 2002, J BIOL CHEM, V277, P49438, DOI 10.1074/jbc.M206840200; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Maulik N, 1998, AM J PHYSIOL-HEART C, V275, pH1857, DOI 10.1152/ajpheart.1998.275.5.H1857; Merritt C, 2000, MOL CELL BIOL, V20, P936, DOI 10.1128/MCB.20.3.936-946.2000; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Ruggero D, 2000, BIOESSAYS, V22, P827, DOI 10.1002/1521-1878(200009)22:9<827::AID-BIES8>3.3.CO;2-T; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Seker H, 2003, ONCOGENE, V22, P1620, DOI 10.1038/sj.onc.1206140; Stadler M, 1995, ONCOGENE, V11, P2565; STUURMAN N, 1992, J CELL SCI, V101, P773; Takahashi Y, 2004, ONCOGENE, V23, P2819, DOI 10.1038/sj.onc.1207533; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	63	5	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40994	41003		10.1074/jbc.M407369200	http://dx.doi.org/10.1074/jbc.M407369200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15273249	hybrid			2022-12-27	WOS:000223916800097
J	Chen, GL; Raman, P; Bhonagiri, P; Strawbridge, AB; Pattar, GR; Elmendorf, JS				Chen, GL; Raman, P; Bhonagiri, P; Strawbridge, AB; Pattar, GR; Elmendorf, JS			Protective effect of phosphatidylinositol 4,5-bisphosphate against cortical filamentous actin loss and insulin resistance induced by sustained exposure of 3T3-L1 adipocytes to insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 TRANSLOCATION; SIGNALING PATHWAY; GLUCOSE-TRANSPORT; PLASMA-MEMBRANE; RAT ADIPOCYTES; HYPERINSULINEMIA; ENDOCYTOSIS; EXPRESSION; SECRETION; DISEASE	Muscle and fat cells develop insulin resistance when cultured under hyperinsulinemic conditions for sustained periods. Recent data indicate that early insulin signaling defects do not fully account for the loss of insulin action. Given that cortical filamentous actin (F-actin) represents an essential aspect of insulin regulated glucose transport, we tested to see whether cortical F-actin structure was compromised during chronic insulin treatment. The acute effect of insulin on GLUT4 translocation and glucose uptake was diminished in 3T3-L1 adipocytes exposed to a physiological level of insulin ( 5 nM) for 12 h. This insulin-induced loss of insulin responsiveness was apparent under both low (5.5 mM) and high ( 25 mM) glucose concentrations. Microscopic and biochemical analyses revealed that the hyperinsulinemic state caused a marked loss of cortical F-actin. Since recent data link phosphatidylinositol 4,5-bisphosphate (PIP2) to actin cytoskeletal mechanics, we tested to see whether the insulin-resistant condition affected PIP2 and found a noticeable loss of this lipid from the plasma membrane. Using a PIP2 delivery system, we replenished plasma membrane PIP2 in cells following the sustained insulin treatment and observed a restoration in cortical F-actin and insulin responsiveness. These data reveal a novel molecular aspect of insulin-induced insulin resistance involving defects in PIP2/actin regulation.	Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Ctr Diabet Res, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Ctr Diabet Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Elmendorf, JS (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Ctr Diabet Res, Indianapolis, IN 46202 USA.	jelmendo@iupui.edu			NCCIH NIH HHS [R01 AT001846, R01 AT001846-01A1, R01-AT001846] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001846] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Aschenbrenner L, 2004, MOL BIOL CELL, V15, P2253, DOI 10.1091/mbc.E04-01-0002; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; Chen GL, 2003, FEBS LETT, V534, P54, DOI 10.1016/S0014-5793(02)03774-2; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DELPRATO S, 1994, DIABETOLOGIA, V37, P1025, DOI 10.1007/BF00400466; Elmendorf JS, 2002, J MEMBRANE BIOL, V190, P167, DOI 10.1007/s00232-002-1035-3; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GARVEY WT, 1986, DIABETES, V35, P258, DOI 10.2337/diabetes.35.3.258; Henry RR, 1996, DIABETES, V45, P400, DOI 10.2337/diabetes.45.4.400; Hou JCQ, 2003, MOL BIOL CELL, V14, P3578, DOI 10.1091/mbc.E03-02-0012; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; Janez A, 2000, ENDOCRINOLOGY, V141, P4657, DOI 10.1210/en.141.12.4657; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; Kanzaki M, 2002, MOL BIOL CELL, V13, P2334, DOI 10.1091/mbc.01-10-0490; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kralik SF, 2002, ENDOCRINOLOGY, V143, P37, DOI 10.1210/en.143.1.37; Nelson BA, 2000, DIABETES, V49, P981, DOI 10.2337/diabetes.49.6.981; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; Pryor PR, 2000, BIOCHEM J, V348, P83, DOI 10.1042/0264-6021:3480083; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; RIZZA RA, 1985, DIABETOLOGIA, V28, P70; Ross SA, 2000, BIOCHEM BIOPH RES CO, V273, P1033, DOI 10.1006/bbrc.2000.3082; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Trifaro JM, 2002, NEUROCHEM RES, V27, P1371, DOI 10.1023/A:1021627800918; Tsakiridis T, 1998, J BIOL CHEM, V273, P28322, DOI 10.1074/jbc.273.43.28322; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	30	47	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39705	39709		10.1074/jbc.C400171200	http://dx.doi.org/10.1074/jbc.C400171200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15277534	Green Accepted, hybrid			2022-12-27	WOS:000223791500062
J	Fessler, MB; Arndt, PG; Frasch, SC; Lieber, JG; Johnson, CA; Murphy, RC; NickO, JA; Bratton, DL; Malcolm, KC; Worthen, GS				Fessler, MB; Arndt, PG; Frasch, SC; Lieber, JG; Johnson, CA; Murphy, RC; NickO, JA; Bratton, DL; Malcolm, KC; Worthen, GS			Lipid rafts regulate lipopolysaccharide-induced activation of Cdc42 and inflammatory functions of the human neutrophil	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-ACTIVATION; CHOLESTEROL DEPLETION; PLASMA-MEMBRANE; PROTEIN-KINASE; CUTTING EDGE; BACTERIAL LIPOPOLYSACCHARIDE; TYROSINE PHOSPHORYLATION; STIMULATED NEUTROPHILS; INDEPENDENT ACTIVATION; RHO PROTEINS	Lipid rafts are cholesterol-rich membrane microdomains that are thought to act as coordinated signaling platforms by regulating dynamic, agonist-induced translocation of signaling proteins. They have been described to play a role in multiple prototypical cascades, among them the lipopolysaccharide pathway, and to host multiple signaling proteins, including kinases and low molecular weight G-proteins. Here we report lipopolysaccharide-induced activation of the Rho family GTPase Cdc42, and we show its activation in the human neutrophil to be mediated by a p38 mitogen-activated protein kinase-dependent mechanism. Subcellular fractionation reveals that lipopolysaccharide induces translocation of Cdc42 to lipid rafts, where it and p38 are both found to be activated. By contrast, lipopolysaccharide causes translocation of Rac from the polymorphonuclear leukocyte (PMN) rafts and does not induce its activation. With the use of methyl-beta-cyclodextrin, a cholesterol-depleting agent that reversibly disrupts rafts, we confirm an important regulatory role for rafts in the activation state of p38 and Cdc42 and in the Rho GTPase-dependent functions superoxide anion production and actin polymerization. Methyl-beta-cyclodextrin induces activation of p38 and Cdc42, but not Rac, in the nonstimulated PMN, yet inhibits subsequent lipopolysaccharide-induced activation of p38 and Cdc42. In parallel, methyl-beta-cyclodextrin primes the human PMN for subsequent superoxide release triggered by the formylated bacterial tripeptide formyl-Met-Leu-Phe, and induces actin polymerization in a subcellular distribution distinct from that induced by lipopolysaccharide. In sum, these findings provide evidence for an important regulatory role of cholesterol in both transmission of the lipopolysaccharide signal and the inflammatory phenotype of the human neutrophil.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Med, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Fessler, MB (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St,D403, Denver, CO 80206 USA.	Michael.fessler@uchsc.edu	Fessler, Michael B/C-6323-2019	Fessler, Michael B/0000-0002-8262-8613	NHLBI NIH HHS [HL061407-05, HL67179, HL68743, HL34303] Funding Source: Medline; NIAID NIH HHS [AI58228] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303, R01HL061407, P01HL068743, K08HL067179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058228] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Amar S, 2001, J ENDOTOXIN RES, V7, P281, DOI 10.1179/096805101101532855; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Barabe F, 2002, J BIOL CHEM, V277, P13473, DOI 10.1074/jbc.M112149200; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chen X, 2001, J BIOL CHEM, V276, P34617, DOI 10.1074/jbc.M103995200; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Cheng PC, 2001, SEMIN IMMUNOL, V13, P107, DOI 10.1006/smim.2000.0302; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Chernow B, 1999, CHEST, V115, p71S, DOI 10.1378/chest.115.suppl_2.71S; Cottin V, 2002, J IMMUNOL, V168, P4095, DOI 10.4049/jimmunol.168.8.4095; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; Dinauer MC, 2003, CURR OPIN HEMATOL, V10, P8, DOI 10.1097/00062752-200301000-00003; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; Eggesbo JB, 1996, SCAND J CLIN LAB INV, V56, P199, DOI 10.3109/00365519609088609; ERZURUM SC, 1992, J IMMUNOL, V149, P154; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; GERLACH E, 1963, BIOCHEM Z, V337, P477; Gingras D, 1998, BIOCHEM BIOPH RES CO, V247, P888, DOI 10.1006/bbrc.1998.8885; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Hippenstiel S, 2000, BLOOD, V95, P3044; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Keresztes M, 1998, BIOCHEM BIOPH RES CO, V252, P723, DOI 10.1006/bbrc.1998.9730; Kindzelskii AL, 2004, J IMMUNOL, V172, P4681, DOI 10.4049/jimmunol.172.8.4681; MADDOX PH, 1987, J CLIN PATHOL, V40, P1256, DOI 10.1136/jcp.40.10.1256; Marwali MR, 2003, BLOOD, V102, P215, DOI 10.1182/blood-2002-10-3195; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; Nakamura M, 2003, EXP CELL RES, V290, P381, DOI 10.1016/S0014-4827(03)00343-4; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; OKAMURA N, 1980, J BIOCHEM-TOKYO, V88, P139; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; Schade AE, 2002, J IMMUNOL, V168, P2233, DOI 10.4049/jimmunol.168.5.2233; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sitrin RG, 2004, AM J RESP CELL MOL, V30, P233, DOI 10.1165/rcmb.2003-0079OC; Stokes KY, 2001, CIRC RES, V88, P499, DOI 10.1161/01.RES.88.5.499; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Triantafilou M, 2002, CRIT REV IMMUNOL, V22, P251; Triantafilou M, 2002, J CELL SCI, V115, P2603; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wang Ping-Yuan, 1995, Journal of Inflammation, V47, P126; Williams LM, 2000, J IMMUNOL, V164, P2028, DOI 10.4049/jimmunol.164.4.2028; Woo CH, 2002, MOL CELLS, V13, P470; WORTHEN GS, 1989, SCIENCE, V245, P183, DOI 10.1126/science.2749255; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zigmond SH, 1998, J CELL BIOL, V142, P1001, DOI 10.1083/jcb.142.4.1001	66	64	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39989	39998		10.1074/jbc.M401080200	http://dx.doi.org/10.1074/jbc.M401080200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262974	hybrid			2022-12-27	WOS:000223791500096
J	Voisin, S; Rognan, D; Gros, C; Ouimet, T				Voisin, S; Rognan, D; Gros, C; Ouimet, T			A three-dimensional model of the neprilysin 2 active site based on the x-ray structure of neprilysin - Identification of residues involved in substrate hydrolysis and inhibitor binding of neprilysin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEPTIDASE 24.11 ENKEPHALINASE; AMINO-ACID-SEQUENCE; MEMBRANE-BOUND METALLOPROTEASE; NEUTRAL ENDOPEPTIDASE; MOLECULAR-CLONING; EC 3.4.24.11; SUBSTANCE-P; CONVERTING ENZYME; KIDNEY; SPECIFICITY	Neprilysin 2 (NEP2), a recently identified member of the M13 subfamily of metalloproteases, shares the highest degree of homology with the prototypical member of the family neprilysin. Whereas the study of the in vitro enzymatic activity of NEP2 shows that it resembles that of NEP as it cleaves the same substrates often at the same amide bonds and binds the same inhibitory compounds albeit with different potencies, its physiological role remains elusive because of the lack of selective inhibitors. To aid in the design of these novel compounds and better understand the different inhibitory patterns of NEP and NEP2, the x-ray structure of NEP was used as a template to build a model of the NEP2 active site. The results of our modeling suggest that the overall structure of NEP2 closely resembles that of NEP. The model of the active site reveals a 97% sequence identity with that of NEP with differences located within the S-2' subsite of NEP2 where Ser(133) and Leu(739) replace two glycine residues in NEP. To validate the proposed model, site-directed mutagenesis was performed on a series of residues of NEP2, mutants expressed in AtT20 cells, and their ability to bind various substrates and inhibitory compounds was tested. The results confirm the involvement of the conserved Arg(131) and Asn(567) in substrate binding and catalytic activity of NEP2 and further show that the modifications in its S-2' pocket, particularly the presence therein of Leu739, account for a number of differences in inhibitor binding between NEP and NEP2.	INSERM, Unite Neurobiol & Pharmacol Mol, U573, Ctr Paul Broca, F-75014 Paris, France; Univ Louis Pasteur Strasbourg 1, Lab Pharmacochim Commun Cellulaire, CNRS, UMR 7081, F-67401 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Ouimet, T (corresponding author), INSERM, Unite Neurobiol & Pharmacol Mol, U573, Ctr Paul Broca, 2 Rue Dalesia, F-75014 Paris, France.	ouimet@broca.inserm.fr	Rognan, Didier/B-9939-2014					BATEMAN RC, 1989, J BIOL CHEM, V264, P6151; BAUMER P, 1992, GUT, V33, P753, DOI 10.1136/gut.33.6.753; BEAUMONT A, 1991, J BIOL CHEM, V266, P214; BENCHETRIT T, 1988, BIOCHEMISTRY-US, V27, P592, DOI 10.1021/bi00402a014; Bissantz C, 2000, J MED CHEM, V43, P4759, DOI 10.1021/jm001044l; Bralet J, 2001, TRENDS PHARMACOL SCI, V22, P106, DOI 10.1016/S0165-6147(00)01644-8; CASE DA, 1999, AMBER 6 0; Chothia C, 2003, SCIENCE, V300, P1701, DOI 10.1126/science.1085371; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; DION N, 1995, BIOCHEM J, V311, P623, DOI 10.1042/bj3110623; Dion N, 1997, FEBS LETT, V411, P140, DOI 10.1016/S0014-5793(97)00681-9; Du L, 1996, GENOMICS, V36, P22, DOI 10.1006/geno.1996.0421; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Facchinetti P, 2003, NEUROSCIENCE, V118, P627, DOI 10.1016/S0306-4522(02)01002-3; GAFFORD JT, 1983, BIOCHEMISTRY-US, V22, P3265, DOI 10.1021/bi00282a035; Ghaddar G, 2000, BIOCHEM J, V347, P419, DOI 10.1042/0264-6021:3470419; GROS C, 1989, P NATL ACAD SCI USA, V86, P7580, DOI 10.1073/pnas.86.19.7580; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HERSH LB, 1986, J BIOL CHEM, V261, P6433; Ikeda K, 1999, J BIOL CHEM, V274, P32469, DOI 10.1074/jbc.274.45.32469; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; KENNY AJ, 1988, FEBS LETT, V232, P1, DOI 10.1016/0014-5793(88)80375-2; KERR MA, 1974, BIOCHEM J, V137, P477, DOI 10.1042/bj1370477; KIM YA, 1992, J BIOL CHEM, V267, P12330; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; LEMAY G, 1989, J BIOL CHEM, V264, P15620; LLORENS C, 1981, EUR J PHARMACOL, V69, P113, DOI 10.1016/0014-2999(81)90609-9; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; MALFROY B, 1987, BIOCHEM BIOPH RES CO, V144, P59, DOI 10.1016/S0006-291X(87)80475-8; MALFROY B, 1978, NATURE, V276, P523, DOI 10.1038/276523a0; MALFROY B, 1984, J BIOL CHEM, V259, P4365; MATSAS R, 1983, P NATL ACAD SCI-BIOL, V80, P3111, DOI 10.1073/pnas.80.10.3111; MAUBORGNE A, 1991, NEUROSCI LETT, V123, P221, DOI 10.1016/0304-3940(91)90935-M; MAUBORGNE A, 1987, J PHARMACOL EXP THER, V243, P674; Oefner C, 2000, J MOL BIOL, V296, P341, DOI 10.1006/jmbi.1999.3492; Oefner C, 2004, ACTA CRYSTALLOGR D, V60, P392, DOI 10.1107/S0907444903027410; PATEY G, 1981, SCIENCE, V212, P113, DOI 10.1126/science.7015510; POLLARD H, 1987, NEUROSCI LETT, V77, P267, DOI 10.1016/0304-3940(87)90510-6; POZSGAY M, 1986, BIOCHEMISTRY-US, V25, P1292, DOI 10.1021/bi00354a015; Rognan D, 2001, J COMPUT AID MOL DES, V15, P103, DOI 10.1023/A:1008145813315; ROQUES BP, 1980, NATURE, V288, P286, DOI 10.1038/288286a0; ROQUES BP, 1993, PHARMACOL REV, V45, P87; Rose C, 2002, BIOCHEM J, V363, P697, DOI 10.1042/0264-6021:3630697; SCHWARTZ JC, 1990, LIFE SCI, V47, P1279, DOI 10.1016/0024-3205(90)90192-T; Tanja O, 2000, BIOCHEM BIOPH RES CO, V271, P565, DOI 10.1006/bbrc.2000.2664; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Turner AJ, 1998, HDB PROTEOLYTIC ENZY, P1080; Valdenaire O, 1999, MOL BRAIN RES, V64, P211, DOI 10.1016/S0169-328X(98)00321-0; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	50	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46172	46181		10.1074/jbc.M407333200	http://dx.doi.org/10.1074/jbc.M407333200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15294904	hybrid			2022-12-27	WOS:000224694900104
J	Lunn, JA; Rozengurt, E				Lunn, JA; Rozengurt, E			Hyperosmotic stress induces rapid focal adhesion kinase phosphorylation at tyrosines 397 and 577 - Role of Src family kinases and Rho family GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; IRRADIATION-INDUCED APOPTOSIS; INTACT SWISS 3T3-CELLS; HOG1 MAP KINASE; GROWTH-FACTOR; SIGNALING PATHWAYS; OSMOTIC-STRESS; LYSOPHOSPHATIDIC ACID; ACTIN CYTOSKELETON; ENDOTHELIAL-CELLS	Hyperosmotic stress induced by treatment of Swiss 3T3 cells with the non-permeant solutes sucrose or sorbitol, rapidly and robustly stimulated endogenous focal adhesion kinase (FAK) phosphorylation at Tyr-397, the major autophosphorylation site, and at Tyr-577, within the kinase activation loop. Hyperosmotic stress-stimulated FAK phosphorylation at Tyr-397 occurred via a Src-independent pathway, whereas Tyr-577 phosphorylation was completely blocked by exposure to the Src family kinase inhibitor PP-2. Inhibition of p38 MAP kinase or phosphatidylinositol 3-kinases did not prevent FAK phosphorylation stimulated by hyperosmotic stress. Overexpression of N17 RhoA did not reduce hyperosmotic stress-mediated localization of phosphorylated FAK to focal contacts and treatment with the Rho-associated kinase inhibitor Y-27632 did not prevent FAK translocation and tyrosine phosphorylation in response to hyperosmotic stress. Overexpression of N17 Rac only slightly altered the hyperosmotic stress-mediated localization of phosphorylated FAK to focal contacts. In contrast, overexpression of the N17 mutant of Cdc42 disrupted hyperosmotic stress-stimulated FAK Tyr-397 localization to focal contacts. Additionally, treatment of cells with Clostridium difficile toxin B potently inhibited hyperosmotic stress-induced FAK tyrosine phosphorylation. Furthermore, FAK null fibroblasts compared with their FAK containing controls show markedly increased sensitivity, manifest by subsequent apoptosis, to sustained hyperosmotic stress. Our results indicate that FAK plays a fundamental role in protecting cells from hyperosmotic stress, and that the pathway(s) that mediates FAK autophosphorylation at Tyr-397 in response to osmotic stress can be distinguished from the pathways utilized by many other stimuli, including neuropeptides and bioactive lipids (Rho- and Rho-associated kinase-dependent), tyrosine kinase receptor agonists (phosphatidylinositol 3-kinase-dependent), and integrins (Src-dependent).	Univ Calif Los Angeles, David Geffen Sch Med,CURE,Digest Dis Res Ctr, Dept Med,Div Digest Dis, Unite Signal Transduct & Gastrointestinal Canc, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med,CURE,Digest Dis Res Ctr, Dept Med,Div Digest Dis, Unite Signal Transduct & Gastrointestinal Canc, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu			NCI NIH HHS [P50 CA90388, K08CA104039-01] Funding Source: Medline; NIDDK NIH HHS [DK-41301, DK 55003, DK56930] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090388, K08CA104039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930, P30DK041301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aizawa H, 1999, GENES CELLS, V4, P311, DOI 10.1046/j.1365-2443.1999.00262.x; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Bell LM, 2000, J BIOL CHEM, V275, P25262, DOI 10.1074/jbc.M002076200; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Charlesworth A, 1996, ONCOGENE, V12, P1337; Clerk A, 1997, FEBS LETT, V403, P23, DOI 10.1016/S0014-5793(97)00020-3; Di Ciano C, 2002, AM J PHYSIOL-CELL PH, V283, pC850, DOI 10.1152/ajpcell.00018.2002; Di Ciano-Oliveira C, 2003, AM J PHYSIOL-CELL PH, V285, pC555, DOI 10.1152/ajpcell.00086.2003; Duzgun SA, 2000, J CELL BIOCHEM, V76, P567, DOI 10.1002/(SICI)1097-4644(20000315)76:4<567::AID-JCB5>3.0.CO;2-W; FLYNN DC, 1992, ONCOGENE, V7, P579; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Guay J, 1997, J CELL SCI, V110, P357; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HIRAYAMA T, 1995, MOL GEN GENET, V249, P127, DOI 10.1007/BF00290358; ILIC D, 1995, BIOCHEM BIOPH RES CO, V209, P300, DOI 10.1006/bbrc.1995.1503; Ilic D, 1998, J CELL BIOL, V143, P547; ILLC D, 1995, NATURE, V377, P539; Jekel J. F., 1996, EPIDEMIOLOGY BIOSTAT; Kapus A, 2000, J BIOL CHEM, V275, P32289, DOI 10.1074/jbc.M003172200; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KING CR, 1989, ONCOGENE, V4, P13; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Krump E, 1997, J BIOL CHEM, V272, P17303, DOI 10.1074/jbc.272.28.17303; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Lewis A, 2002, AM J PHYSIOL-CELL PH, V282, pC271, DOI 10.1152/ajpcell.00427.2001; Linseman DA, 2000, J NEUROCHEM, V74, P2010, DOI 10.1046/j.1471-4159.2000.0742010.x; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Malek AM, 1998, STROKE, V29, P2631, DOI 10.1161/01.STR.29.12.2631; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; Mattison CP, 2000, GENE DEV, V14, P1229; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Paemeleire K, 1999, EXP BRAIN RES, V126, P473, DOI 10.1007/s002210050755; PARK SS, 2004, ONCOGENE; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Raitt DC, 2000, EMBO J, V19, P4623, DOI 10.1093/emboj/19.17.4623; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Reiser V, 2000, NAT CELL BIOL, V2, P620, DOI 10.1038/35023568; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rizoli SB, 2000, AM J PHYSIOL-CELL PH, V279, pC619, DOI 10.1152/ajpcell.2000.279.3.C619; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schliess F, 1998, ARCH BIOCHEM BIOPHYS, V351, P35, DOI 10.1006/abbi.1997.0517; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Sinnett-Smith J, 2001, EXP CELL RES, V266, P292, DOI 10.1006/excr.2001.5219; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; TILLY BC, 1993, J BIOL CHEM, V268, P19919; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tsuda T, 1997, BIOCHEMISTRY-US, V36, P16328, DOI 10.1021/bi971448o; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	88	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45266	45278		10.1074/jbc.M314132200	http://dx.doi.org/10.1074/jbc.M314132200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302877	hybrid			2022-12-27	WOS:000224505600120
J	Deora, AB; Kreitzer, G; Jacovina, AT; Hajjar, KA				Deora, AB; Kreitzer, G; Jacovina, AT; Hajjar, KA			An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; FIBROBLAST-GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; MATRIX INVASION; PROTEIN-KINASE; FACTOR-I; EXPRESSION; RECEPTOR; MODULATION; EXOCYTOSIS	Annexin 2 is a profibrinolytic co-receptor for plasminogen and tissue plasminogen activator that stimulates activation of the major fibrinolysin, plasmin, at cell surfaces. In human subjects, overexpression of annexin 2 in acute promyelocytic leukemia leads to a bleeding diathesis reflective of excessive cell surface annexin 2-dependent generation of plasmin (Menell, J. S., Cesarman, G. M., Jacovina, A. T., McLaughlin, M. A., Lev, E. A., and Hajjar, K. A. ( 1999) N. Engl. J. Med. 340, 994 - 1004). In addition, mice completely deficient in annexin 2 display fibrin accumulation within blood vessels and impaired clearance of injury-induced thrombi ( Ling Q., Jacovina, A. T., Deora, A. B., Febbraio, M., Simantov, R., Silverstein, R. L., Hempstead, B. L., Mark, W., and Hajjar, K. A. ( 2004) J. Clin. Investig. 113, 38 - 48). Here, we show that endothelial cell annexin 2, a protein that lacks a typical signal peptide, translocates from the cytoplasm to the extracytoplasmic plasma membrane in response to brief temperature stress both in vitro and in vivo in the absence of cell death or cell lysis. This regulated response is independent of new protein or mRNA synthesis and does not require the classical endoplasmic reticulum-Golgi pathway. Temperature stress-induced annexin 2 translocation is dependent on both expression of protein p11 (S100A10) and tyrosine phosphorylation of annexin 2 because annexin 2 release is completely eliminated on depletion of p11, inactivation of tyrosine kinase, or mutation of tyrosine 23. Translocation of annexin 2 to the cell surface dramatically increases tissue plasminogen activator-dependent plasminogen activation potential and may represent a novel stress-induced protein secretion pathway.	Cornell Univ, Dept Cell & Dev Biol, Weill Med Coll, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Protein Ctr, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Hajjar, KA (corresponding author), Cornell Univ, Dept Cell & Dev Biol, Weill Med Coll, New York, NY 10021 USA.	khajjar@med.cornell.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058981, P01HL046403, R01HL042493, T32HL007423] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42493, HL 07423, HL 58981, HL 46403] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; Beaton AR, 2002, P NATL ACAD SCI USA, V99, P13154, DOI 10.1073/pnas.192432299; Bellagamba C, 1997, J BIOL CHEM, V272, P3195, DOI 10.1074/jbc.272.6.3195; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Brownstein C, 2004, BLOOD, V103, P317, DOI 10.1182/blood-2003-04-1304; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; ERIKSON E, 1980, CELL, V21, P829, DOI 10.1016/0092-8674(80)90446-8; Falcone DJ, 2001, BLOOD, V97, P777, DOI 10.1182/blood.V97.3.777; Gardella S, 2001, BLOOD, V98, P2152, DOI 10.1182/blood.V98.7.2152; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Girard C, 2002, EMBO J, V21, P4439, DOI 10.1093/emboj/cdf469; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; Hajjar KA, 1998, J BIOL CHEM, V273, P9987, DOI 10.1074/jbc.273.16.9987; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAJJAR KA, 1991, J BIOL CHEM, V266, P21962; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; Huang L, 2001, MOL CELL BIOL, V21, P8575, DOI 10.1128/MCB.21.24.8575-8591.2001; ISACKE CM, 1986, MOL CELL BIOL, V6, P2745, DOI 10.1128/MCB.6.7.2745; Isas JM, 2000, BIOCHEMISTRY-US, V39, P3015, DOI 10.1021/bi9922401; Ishii H, 2001, CIRC RES, V89, P1240, DOI 10.1161/hh2401.101066; Jacovina AT, 2001, J BIOL CHEM, V276, P49350, DOI 10.1074/jbc.M106289200; Katz AB, 1999, J INVEST DERMATOL, V112, P818, DOI 10.1046/j.1523-1747.1999.00572.x; KIANG JG, 1992, AM J PHYSIOL, V263, pC30, DOI 10.1152/ajpcell.1992.263.1.C30; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Kreitzer G, 2003, NAT CELL BIOL, V5, P126, DOI 10.1038/ncb917; Krishnan S, 2004, DEV BIOL, V265, P140, DOI 10.1016/j.ydbio.2003.08.026; Langen R, 1998, J BIOL CHEM, V273, P22453, DOI 10.1074/jbc.273.35.22453; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Ling Q, 2004, J CLIN INVEST, V113, P38, DOI 10.1172/JCI200419684; LU D, 1993, AM J PHYSIOL, V264, pC715, DOI 10.1152/ajpcell.1993.264.3.C715; MACH H, 1995, BIOCHEMISTRY-US, V34, P9913, DOI 10.1021/bi00031a013; Marmorstein AD, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P341; Menell JS, 1999, NEW ENGL J MED, V340, P994, DOI 10.1056/NEJM199904013401303; Montaville P, 2002, J BIOL CHEM, V277, P24684, DOI 10.1074/jbc.M109595200; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; Rammes A, 1997, J BIOL CHEM, V272, P9496; ROCHA V, 1990, BIOCHEM SOC T, V18, P1110, DOI 10.1042/bst0181110; Rubartelli A., 1997, UNUSUAL SECRETORY PA, P87, DOI [10.1007/978-3-662-22581-3_3, DOI 10.1007/978-3-662-22581-3_3]; Seko Y, 1999, BIOCHEM BIOPH RES CO, V262, P290, DOI 10.1006/bbrc.1999.1185; SHARP FR, 1993, STROKE S1, V24, P72; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; THIEL C, 1992, J CELL SCI, V103, P733; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; XU QB, 1993, ARTERIOSCLER THROMB, V13, P1763, DOI 10.1161/01.ATV.13.12.1763; XU QB, 1994, CIRC RES, V75, P1078, DOI 10.1161/01.RES.75.6.1078; ZHU W, 1994, BIOCHEM BIOPH RES CO, V200, P389, DOI 10.1006/bbrc.1994.1461	57	185	195	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43411	43418		10.1074/jbc.M408078200	http://dx.doi.org/10.1074/jbc.M408078200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15302870	hybrid			2022-12-27	WOS:000224383100010
J	Fujino, H; Vielhauer, GA; Regan, JW				Fujino, H; Vielhauer, GA; Regan, JW			Prostaglandin E-2 selectively antagonizes prostaglandin F-2 alpha-stimulated T-cell factor/beta-catenin signaling pathway by the FPB prostanoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLORECTAL CANCERS; COLON-CANCER; ACTIVATION; CLONING; EP2; STIMULATION; EXPRESSION; SUBTYPES; ISOFORMS; E(2)	FP prostanoid receptors are G-protein-coupled receptors ;that consist of two isoforms named FPA and FPB. Both isoforms activate inositol phosphate second messenger signaling pathways by their endogenous ligand prostaglandin F-2alpha (PGF(2alpha)). Previously we have shown that both isoforms undergo Rho-mediated cell rounding following treatment with PGF(2alpha). Following the removal of PGF(2alpha), however, FPA-expressing cells return to their original morphology, whereas FPB-expressing cells do not. It was also found that PGF(2alpha)-could activate T-cell factor (Tcf)/beta-catenin signaling in cells expressing the FPB isoform but not in cells expressing the FPA isoform. We now show that prostaglandin E-2 (PGE(2)) can induce cell rounding and stimulate the formation of inositol phosphates to the same extent as PGF(2alpha) in cells expressing either the FPA or FPB isoforms. However, PGE2 has much lower efficacy as compared with PGF(2alpha) for the activation of Tcf/beta-catenin signaling in FPB-expressing cells, and the cell rounding is reversible. Interestingly, pretreatment of FPB-expressing cells with PGE(2)-attenuated PGF(2alpha)-stimulated Tcf/beta-catenin signaling in a dose-dependent manner while having no effect on PGF(2alpha)-stimulated inositol phosphates formation. Thus, the ratio of endogenous PGE(2) and PGF(2alpha) has the potential to selectively regulate one signaling pathway over another. This represents a novel mechanism for the regulation of cell signaling that is distinct from regulation occurring at the level of the receptor and its effector pathways.	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA	University of Arizona	Regan, JW (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.	regan@pharmacy.arizona.edu			NATIONAL EYE INSTITUTE [R01EY011291] Funding Source: NIH RePORTER; NEI NIH HHS [EY11291] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Fujino H, 2000, J BIOL CHEM, V275, P29907, DOI 10.1074/jbc.M003467200; Fujino H, 2003, TRENDS PHARMACOL SCI, V24, P335, DOI 10.1016/S0165-6147(03)00162-7; Fujino H, 2003, EUR J PHARMACOL, V465, P39, DOI 10.1016/S0014-2999(03)01485-7; Fujino H, 2002, J BIOL CHEM, V277, P48786, DOI 10.1074/jbc.M209393200; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; Fujino H, 2000, MOL PHARMACOL, V57, P353; Fujino H, 2001, J BIOL CHEM, V276, P12489, DOI 10.1074/jbc.C100039200; GRAVES PE, 1995, ENDOCRINOLOGY, V136, P3430, DOI 10.1210/en.136.8.3430; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; Kobayashi T, 2002, PROSTAG OTH LIPID M, V68-9, P557, DOI 10.1016/S0090-6980(02)00055-2; Mariadason JM, 2001, CANCER RES, V61, P3465; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; OKA M, 1994, AM J SURG, V167, P264, DOI 10.1016/0002-9610(94)90089-2; Pierce KL, 1997, J BIOL CHEM, V272, P883, DOI 10.1074/jbc.272.2.883; Pierce KL, 1999, J BIOL CHEM, V274, P35944, DOI 10.1074/jbc.274.50.35944; PUGH S, 1994, GUT, V35, P675, DOI 10.1136/gut.35.5.675; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Srivastava S, 2001, CLIN CANCER RES, V7, P1118	23	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43386	43391		10.1074/jbc.M408276200	http://dx.doi.org/10.1074/jbc.M408276200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15280380	hybrid			2022-12-27	WOS:000224383100007
J	Zou, MH; Kirkpatrick, SS; Davis, BJ; Nelson, JS; Wiles, WG; Schlattner, U; Neumann, D; Brownlee, M; Freeman, MB; Goldman, MH				Zou, MH; Kirkpatrick, SS; Davis, BJ; Nelson, JS; Wiles, WG; Schlattner, U; Neumann, D; Brownlee, M; Freeman, MB; Goldman, MH			Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo - Role of mitochondrial reactive nitrogen species (Publication with Expression of Concern. See vol. 294, pg. 10024, 2019) (Withdrawn Publication. See vol. 294, pg. 13525, 2019)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Withdrawn Publication							NITRIC-OXIDE SYNTHASE; INSULIN-RESISTANCE; HYPOXIA-REOXYGENATION; SUPEROXIDE-PRODUCTION; TYROSINE NITRATION; CYTOCHROME-C; MALONYL-COA; COMPLEX; PHOSPHORYLATION; MUSCLE	Metformin, one of the most commonly used drugs for the treatment of type II diabetes, was recently found to exert its therapeutic effects, at least in part, by activating the AMP-activated protein kinase (AMPK). However, the site of its action, as well as the mechanism to activate AMPK, remains elusive. Here we report how metformin activates AMPK. In cultured bovine aortic endothelial cells, metformin dose-dependently activated AMPK in parallel with increased detection of reactive nitrogen species (RNS). Further, either depletion of mitochondria or adenoviral overexpression of superoxide dismutases, as well as inhibition of nitric-oxide synthase, abolished the metformin-enhanced phosphorylations and activities of AMPK, implicating that activation of AMPK by metformin might be mediated by the mitochondria-derived RNS. Furthermore, administration of metformin, which increased 3-nitrotyrosine staining in hearts of C57BL6, resulted in parallel activation of AMPK in the aorta and hearts of C57BL6 mice but not in those of endothelial nitric-oxide synthase (eNOS) knockout mice in which metformin had no effect on 3-nitrotyrosine staining. Because the eNOS knockout mice expressed normal levels of AMPK-alpha that was activated by 5-aminoimidazole-4-carboxamide riboside, an AMPK agonist, these data indicate that RNS generated by metformin is required for AMPK activation in vivo. In addition, metformin significantly increased the coimmunoprecipitation of AMPK and its upstream kinase, LKB1, in C57BL6 mice administered to metformin in vivo. Using pharmacological and genetic inhibitors, we found that inhibition of either c-Src or PI3K abolished AMPK that was enhanced by metformin. We conclude that activation of AMPK by metformin might be mediated by mitochondria-derived RNS, and activation of the c-Src/PI3K pathway might generate a metabolite or other molecule inside the cell to promote AMPK activation by the LKB1 complex.	Univ Tennessee, Grad Sch Med, Vasc Res Lab, Knoxville, TN 37920 USA; Univ Tennessee, Grad Sch Med, Dept Surg, Knoxville, TN 37920 USA; ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland; Albert Einstein Coll Med, Dept Med, Ctr Diabet Res, Bronx, NY 10461 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Swiss Federal Institutes of Technology Domain; ETH Zurich; Yeshiva University; Albert Einstein College of Medicine	Zou, MH (corresponding author), Univ Tennessee, Grad Sch Med, Vasc Res Lab, 1924 Alcoa Hwy, Knoxville, TN 37920 USA.	mzou@mc.utmck.edu	Schlattner, Uwe/D-1267-2009	Schlattner, Uwe/0000-0003-1159-5911				Alessi DR, 2001, BIOCHEM SOC T, V29, P1, DOI 10.1042/bst029a059; Beauloye C, 2002, FEBS LETT, V531, P324, DOI 10.1016/S0014-5793(02)03552-4; Brodsky SV, 2002, AM J PHYSIOL-HEART C, V283, pH2130, DOI 10.1152/ajpheart.00196.2002; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Buhl ES, 2002, DIABETES, V51, P2199, DOI 10.2337/diabetes.51.7.2199; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Choi SL, 2001, BIOCHEM BIOPH RES CO, V287, P92, DOI 10.1006/bbrc.2001.5544; D'Aurelio M, 2001, J BIOL CHEM, V276, P46925, DOI 10.1074/jbc.M106429200; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223; Frederich M, 2002, J BIOL CHEM, V277, P1928, DOI 10.1074/jbc.M107128200; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Ido Y, 2002, DIABETES, V51, pA396; Iglesias MA, 2002, DIABETES, V51, P2886, DOI 10.2337/diabetes.51.10.2886; Ishida M, 1998, CIRC RES, V82, P7; Katakam PVG, 2000, HYPERTENSION, V35, P108, DOI 10.1161/01.HYP.35.1.108; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Marfella R, 1996, DIABETES CARE, V19, P934, DOI 10.2337/diacare.19.9.934; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Momken I, 2002, BIOCHEM J, V368, P341, DOI 10.1042/BJ20020591; Moule SK, 1998, FEBS LETT, V439, P287, DOI 10.1016/S0014-5793(98)01392-1; Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Ruderman NB, 2003, BIOCHEM SOC T, V31, P202, DOI 10.1042/bst0310202; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Verma S, 2000, J HYPERTENS, V18, P1445, DOI 10.1097/00004872-200018100-00012; Viollet B, 2003, BIOCHEM SOC T, V31, P216, DOI 10.1042/bst0310216; Wick MJ, 2002, J BIOL CHEM, V277, P16632, DOI 10.1074/jbc.M112402200; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Xiao L, 2001, J MOL CELL CARDIOL, V33, P779, DOI 10.1006/jmcc.2001.1348; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zou MH, 1999, J EXP MED, V190, P135, DOI 10.1084/jem.190.1.135; Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200; Zou MH, 2002, DIABETES, V51, P198, DOI 10.2337/diabetes.51.1.198; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442; Zou MH, 2002, J BIOL CHEM, V277, P32552, DOI 10.1074/jbc.M204512200	51	393	411	22	56	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43940	43951		10.1074/jbc.M404421200	http://dx.doi.org/10.1074/jbc.M404421200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15265871	hybrid			2022-12-27	WOS:000224383100072
J	Angelov, D; Lenouvel, FO; Hans, F; Muller, CW; Bouvet, P; Bednar, J; Moudrianakis, EN; Cadet, J; Dimitrov, S				Angelov, D; Lenouvel, FO; Hans, F; Muller, CW; Bouvet, P; Bednar, J; Moudrianakis, EN; Cadet, J; Dimitrov, S			The histone octamer is invisible when NF-kappa B binds to the nucleosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWI/SNF COMPLEX; GENE ACTIVATION; DNA; CHROMATIN; TRANSCRIPTION; CORE; MECHANISM; ISWI; PURIFICATION; RECRUITMENT	The transcription factor NF-kappaB is involved in the transcriptional control of more than 150 genes, but the way it acts at the level of nucleosomal templates is not known. Here we report on a study examining the interaction of NF-kappaB p50 with its DNA recognition sequence in a positioned nucleosome. We demonstrate that NF-kappaB p50 was able to bind to the nucleosome with an apparent association constant close to that for free DNA. In agreement with this, the affinity of NF-kappaB p50 binding does not depend on the localization of its recognition sequence relative to the nucleosome dyad axis. In addition, the binding of NF-kappaB p50 does not induce eviction of histones and does not perturb the overall structure of the nucleosome. The NF-kappaB p50-nucleosome complex exhibits, however, local structural alterations within the NF-kappaB p50 recognition site. Importantly, these alterations were very similar to those found in the NF-kappaB p50-DNA complex. Our data suggest that NF-kappaB p50 can accommodate the distorted, bent DNA within the nucleosome. This peculiar property of NF-kappaB p50 might have evolved to meet the requirements for its function as a central switch for stress responses.	INSERM, U309, Lab Biol Mol & Cellulaire Differenciat, Inst Albert Bonniot, F-38706 La Tronche, France; European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France; Ecole Normale Super Lyon, CNRS, UMR 5161, F-69007 Lyon, France; CNRS, Spectrometrie Phys Lab, F-38402 St Martin Dheres, France; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Biophys, Baltimore, MD 21218 USA; CEA, Dept Rech Fondamentale Mat Condensee, SCIB LAN, F-38054 Grenoble 9, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); Johns Hopkins University; Johns Hopkins University; CEA	Dimitrov, S (corresponding author), INSERM, U309, Lab Biol Mol & Cellulaire Differenciat, Inst Albert Bonniot, Domaine Merci, F-38706 La Tronche, France.	stefan.dimitrov@ujf-grenoble.fr	dimitrov, stefan/M-7697-2013; Müller, Christoph W/I-7420-2012; Angelov, Dimitar/K-2004-2017; Bednar, Jan/K-2162-2012; Bednar, Jan/H-3648-2017; Cadet, Jean/M-2971-2018; , Bouvet/AAC-8779-2020	dimitrov, stefan/0000-0002-1326-3630; Müller, Christoph W/0000-0003-2176-8337; Angelov, Dimitar/0000-0002-5511-6647; Bednar, Jan/0000-0003-0879-6405; Cadet, Jean/0000-0003-2594-9485; Bouvet, Philippe/0000-0003-4524-2233				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; Anderson JD, 2000, J MOL BIOL, V296, P979, DOI 10.1006/jmbi.2000.3531; Angelov D, 1999, BIOCHEMISTRY-US, V38, P11333, DOI 10.1021/bi9905260; Angelov D, 2003, MOL CELL, V11, P1033, DOI 10.1016/S1097-2765(03)00100-X; Angelov D, 1999, METH MOL B, V119, P481; Angelov D, 2000, J MOL BIOL, V302, P315, DOI 10.1006/jmbi.2000.4069; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beato M, 1997, NUCLEIC ACIDS RES, V25, P3559, DOI 10.1093/nar/25.18.3559; BECKER MM, 1989, P NATL ACAD SCI USA, V86, P5315, DOI 10.1073/pnas.86.14.5315; Becker PB, 2002, EMBO J, V21, P4749, DOI 10.1093/emboj/cdf486; Bednar J, 1999, MOL CELL, V4, P377, DOI 10.1016/S1097-2765(00)80339-1; Bednar J, 1999, METHOD ENZYMOL, V304, P191; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Chafin DR, 2000, EMBO J, V19, P5492, DOI 10.1093/emboj/19.20.5492; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; Douki T, 2001, BIOCHEMISTRY-US, V40, P2495, DOI 10.1021/bi0022543; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Hassan AH, 2001, FRONT BIOSCI, V6, pD1054, DOI 10.2741/Hassan; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1992, TRENDS BIOCHEM SCI, V17, P250, DOI 10.1016/0968-0004(92)90403-V; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Langst G, 2001, J CELL SCI, V114, P2561; Lee KM, 1998, BIOCHEMISTRY-US, V37, P8622, DOI 10.1021/bi980499y; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1999, METH MOL B, V119, P1; Miller JA, 2003, MOL CELL BIOL, V23, P1623, DOI 10.1128/MCB.23.5.1623-1632.2003; MOUDRIANAKIS EN, 1993, COLD SPRING HARB SYM, V58, P273, DOI 10.1101/SQB.1993.058.01.032; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; NIKOGOSYAN DN, 1990, INT J RADIAT BIOL, V57, P233, DOI 10.1080/09553009014552411; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Peterson CL, 2000, J CELL BIOCHEM, V78, P179, DOI 10.1002/(SICI)1097-4644(20000801)78:2<179::AID-JCB1>3.0.CO;2-E; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Scrittori L, 2001, J BIOL CHEM, V276, P30002, DOI 10.1074/jbc.M102701200; Spassky A, 1997, BIOCHEMISTRY-US, V36, P6571, DOI 10.1021/bi962761d; Steger DJ, 1997, EMBO J, V16, P2463, DOI 10.1093/emboj/16.9.2463; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000	48	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42374	42382		10.1074/jbc.M407235200	http://dx.doi.org/10.1074/jbc.M407235200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15269206	hybrid			2022-12-27	WOS:000224226400007
J	De Felice, M; Esposito, L; Pucci, B; De Falco, M; Rossi, M; Pisani, FM				De Felice, M; Esposito, L; Pucci, B; De Falco, M; Rossi, M; Pisani, FM			A CDC6-like factor from the archaea Sulfolobus solfataricus promotes binding of the mini-chromosome maintenance complex to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION; HELICASE; PROTEIN; IDENTIFICATION; CHROMOSOME; INITIATION; RESIDUES; ORIGINS	The archaeal replication apparatus appears to be a simplified version of the eukaryotic one with fewer polypeptides and simpler protein complexes. Herein, we report evidence that a Cdc6-like factor from the hyperthermophilic crenarchaea Sulfolobus solfataricus stimulates binding of the homohexameric MCM-like complex to bubble- and fork-containing DNA oligonucleotides that mimic early replication intermediates. This function does not require the Cdc6 ATP and DNA binding activities. These findings may provide important clues to understanding how the DNA replication initiation process has evolved in the more complex eukaryotic organisms.	CNR, Ist Biochim Prot, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Pisani, FM (corresponding author), CNR, Ist Biochim Prot, Via P Castellino 111, I-80131 Naples, Italy.	fm.pisani@ibp.cnr.it	pucci, biagio/AAA-9268-2020; Pisani, Francesca M./AAX-4025-2020; Pucci, Biagio/AAS-7502-2021	pucci, biagio/0000-0003-4502-1748; 				Ahnert P, 2000, EMBO J, V19, P3418, DOI 10.1093/emboj/19.13.3418; Berquist BR, 2003, J BACTERIOL, V185, P5959, DOI 10.1128/JB.185.20.5959-5966.2003; Carpentieri F, 2002, J BIOL CHEM, V277, P12118, DOI 10.1074/jbc.M200091200; Davey MJ, 2003, CURR BIOL, V13, pR594, DOI 10.1016/S0960-9822(03)00523-2; Davey MJ, 2002, EMBO J, V21, P3148, DOI 10.1093/emboj/cdf308; De Felice M, 2004, BIOCHEM J, V381, P645, DOI 10.1042/BJ20040280; De Felice M, 2003, J BIOL CHEM, V278, P46424, DOI 10.1074/jbc.M306075200; DEAN FB, 1992, J BIOL CHEM, V267, P14129; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Grainge I, 2003, NUCLEIC ACIDS RES, V31, P4888, DOI 10.1093/nar/gkg662; Ishmael FT, 2002, J BIOL CHEM, V277, P20555, DOI 10.1074/jbc.M111951200; Kelman LM, 2003, MOL MICROBIOL, V48, P605, DOI 10.1046/j.1365-2958.2003.03369.x; Konieczny I, 2003, EMBO REP, V4, P37, DOI 10.1038/sj.embor.embor703; KORNBERG A, 1992, DNA REPLICATION, P355; Lundgren M, 2004, P NATL ACAD SCI USA, V101, P7046, DOI 10.1073/pnas.0400656101; Manco G, 2001, J BIOL CHEM, V276, P37482, DOI 10.1074/jbc.M103017200; Pisani FM, 1998, BIOCHEMISTRY-US, V37, P15005, DOI 10.1021/bi981127s; Robinson NP, 2004, CELL, V116, P25, DOI 10.1016/S0092-8674(03)01034-1; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Velten M, 2003, MOL CELL, V11, P1009, DOI 10.1016/S1097-2765(03)00130-8; Wadsworth RIM, 2001, NUCLEIC ACIDS RES, V29, P914, DOI 10.1093/nar/29.4.914	22	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43008	43012		10.1074/jbc.M406693200	http://dx.doi.org/10.1074/jbc.M406693200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292191	hybrid			2022-12-27	WOS:000224226400082
J	Mothe-Satney, I; Gautier, N; Hinault, C; Lawrence, JC; Van Obberghen, E				Mothe-Satney, I; Gautier, N; Hinault, C; Lawrence, JC; Van Obberghen, E			In rat hepatocytes glucagon increases mammalian target of rapamycin phosphorylation on serine 2448 but antagonizes the phosphorylation of its downstream targets induced by insulin and amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE B; PHAS-I; SIGNALING PATHWAYS; SKELETAL-MUSCLE; BINDING PARTNER; S6 KINASE; RAPTOR; MTOR; GROWTH; IDENTIFICATION	The major function of mammalian target of rapamycin ( mTOR) is the control of cell growth. Insulin and amino acids regulate the mTOR pathway, and both are needed to promote its maximal activation. To further understand mTOR regulation by insulin and amino acids, we have studied the enzyme in primary cultures of hepatocytes. We show that insulin increases mTOR phosphorylation on Ser(2448), a consensus phosphorylation site for protein kinase B (PKB). Ser(2448) phosphorylation is also increased by amino acids, although they do not activate PKB. Furthermore, insulin and amino acids have an additive effect, indicating that they act through distinct pathways. We also show that phosphorylation of Ser(2448) does not seem to modulate in vitro phosphorylation of eukaryotic initiation factor 4E-binding protein 1 by mTOR. However, stimulation of hepatocytes with insulin and amino acids leads to an increase in mTOR kinase activity. Rapamycin has no effect on insulin-, glucagon-, and 8-(4-chlorophenylthio) adenosine-cAMP-induced amino acid transport. Surprisingly, glucagon and 8-( 4-chlorophenylthio) adenosine-cAMP, which do not activate PKB, stimulate the phosphorylation on Ser(2448) of mTOR. However, glucagon inhibits amino acid- and insulin-induced activation of ribosomal S6 protein kinase 1 and phosphorylation of the translational repressor eukaryotic initiation factor 4E-binding protein 1. Our results demonstrate that glucagon, which is not able to activate but rather inhibits the mTOR pathways, stimulates the phosphorylation of mTOR on Ser(2448). This finding suggests that phosphorylation of this site might not be sufficient for mTOR kinase activity but is likely to be involved in other functions.	Fac Med, INSERM, U145, Inst Federatif Rech 50, F-06107 Nice 2, France; Univ Virginia Hlth Syst, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA 22908 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Virginia; University of Virginia	Mothe-Satney, I (corresponding author), Fac Med, INSERM, U145, Inst Federatif Rech 50, Ave Valombrose, F-06107 Nice 2, France.	satney@unice.fr	MOTHE-SATNEY, ISABELLE/Q-6377-2016; hinault, charlotte/P-6003-2016	MOTHE-SATNEY, ISABELLE/0000-0002-2693-8385; hinault, charlotte/0000-0002-3588-039X				Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; ALENGRIN F, 1987, DIABETES METAB, V13, P591; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anthony JC, 2001, J NUTR, V131, p856S, DOI 10.1093/jn/131.3.856S; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Cheng SWY, 2004, J BIOL CHEM, V279, P15719, DOI 10.1074/jbc.C300534200; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Edinger AL, 2003, CANCER RES, V63, P8451; FEHLMANN M, 1979, J BIOL CHEM, V254, P431; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; HARRIS TE, 2003, SCI STKE 2003, P1; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JC, 2003, CURR TOP MICROBIOL, V279, P199; Lawrence JC, 1997, ADV ENZYME REGUL, V37, P239, DOI 10.1016/S0065-2571(96)00016-7; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Oshiro N, 2004, GENES CELLS, V9, P359, DOI 10.1111/j.1356-9597.2004.00727.x; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Roh C, 2003, AM J PHYSIOL-ENDOC M, V284, pE322, DOI 10.1152/ajpendo.00230.2002; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Scott PH, 1998, J BIOL CHEM, V273, P34496, DOI 10.1074/jbc.273.51.34496; Sekulic A, 2000, CANCER RES, V60, P3504; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Yonezawa K, 2004, BIOCHEM BIOPH RES CO, V313, P437, DOI 10.1016/j.bbrc.2003.07.018	40	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42628	42637		10.1074/jbc.M405173200	http://dx.doi.org/10.1074/jbc.M405173200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292249	hybrid			2022-12-27	WOS:000224226400036
J	Calzada, MJ; Annis, DS; Zeng, BX; Marcinkiewicz, C; Banas, B; Lawler, J; Mosher, DF; Roberts, DD				Calzada, MJ; Annis, DS; Zeng, BX; Marcinkiewicz, C; Banas, B; Lawler, J; Mosher, DF; Roberts, DD			Identification of novel beta(1) integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; ARG-GLY-ASP; CELL ATTACHMENT; ALPHA-3-BETA-1 INTEGRIN; T-CELL; ALPHA(3)BETA(1) INTEGRIN; ALPHA-4-BETA-1 INTEGRIN; NEURITE OUTGROWTH; MESANGIAL CELLS; I REPEATS	In addition to the three known beta(1) integrin recognition sites in the N-module of thrombospondin-1 (TSP1), we found that beta(1) integrins mediate cell adhesion to the type 1 and type 2 repeats. The type 1 repeats of TSP1 differ from typical integrin ligands in that recognition is pan-beta(1)-specific. Adhesion of cells that express one dominant beta(1) integrin on immobilized type 1 repeats is specifically inhibited by antagonists of that integrin, whereas adhesion of cells that express several beta(1) integrins is partially inhibited by each alpha-subunit-specific antagonist and completely inhibited by combining the antagonists. beta(1) integrins recognize both the second and third type 1 repeats, and each type 1 repeat shows pan-beta(1) specificity and divalent cation dependence for promoting cell adhesion. Adhesion to the type 2 repeats is less sensitive to alpha-subunit antagonists, but a beta(1) blocking antibody and two disintegrins inhibit adhesion to immobilized type 2 repeats. beta(1) integrin expression is necessary for cell adhesion to the type 1 or type 2 repeats, and beta(1) integrins bind in a divalent cation-dependent manner to a type 1 repeat affinity column. The widely used TSP1 function blocking antibody A4.1 binds to a site in the third type 2 repeat. A4.1 proximally inhibits beta(1) integrin-dependent adhesion to the type 2 repeats and indirectly inhibits integrin-dependent adhesion mediated by the TSP1 type 1 repeats. Although antibody A4.1 is also an antagonist of CD36 binding to TSP1, these data suggest that some biological activities of A4.1 result from antagonism of these novel beta(1) integrin binding sites.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Temple Univ, Dept Biol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Univ Regensburg, Med Klin 2, D-93053 Regensburg, Germany; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Regensburg; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School	Roberts, DD (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Rm 2A33,10 Ctr Dr,MSC 1500, Bethesda, MD 20892 USA.	droberts@helix.nih.gov	Lawler, Jack/AAJ-1379-2020; Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981; Banas, Bernhard/0000-0003-2076-2195	NATIONAL CANCER INSTITUTE [Z01SC009172, ZIASC009172] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JC, 2000, DEV DYNAM, V218, P280; ADAMS JC, 1993, J CELL SCI, V104, P1061; Adams JC, 1998, EMBO J, V17, P4964, DOI 10.1093/emboj/17.17.4964; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AKIYAMA SK, 1995, CELL ADHES COMMUN, V3, P13, DOI 10.3109/15419069509081275; Anilkumar N, 2002, J CELL SCI, V115, P2357; Arnaout MA, 2002, CURR OPIN CELL BIOL, V14, P641, DOI 10.1016/S0955-0674(02)00371-X; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; Bamdad M, 2004, CELL TISSUE RES, V315, P15, DOI 10.1007/s00441-003-0793-2; Banas B, 1999, J AM SOC NEPHROL, V10, P2314; Barazi HO, 2002, CANCER RES, V62, P1541; Bocci G, 2003, P NATL ACAD SCI USA, V100, P12917, DOI 10.1073/pnas.2135406100; Calzada MJ, 2003, J BIOL CHEM, V278, P40679, DOI 10.1074/jbc.M302014200; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; Chen DH, 1999, AM J PHYSIOL-HEART C, V277, pH1100, DOI 10.1152/ajpheart.1999.277.3.H1100; Dawson DW, 1999, MOL PHARMACOL, V55, P332, DOI 10.1124/mol.55.2.332; Decker S, 2002, BIOCHEM BIOPH RES CO, V293, P86, DOI 10.1016/S0006-291X(02)00180-8; DEFREITAS MF, 1995, NEURON, V15, P333, DOI 10.1016/0896-6273(95)90038-1; DONG LJ, 1995, J BIOL CHEM, V270, P15838, DOI 10.1074/jbc.270.26.15838; Filleur S, 2001, GENE DEV, V15, P1373, DOI 10.1101/gad.193501; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hartner A, 1999, KIDNEY INT, V56, P1468, DOI 10.1046/j.1523-1755.1999.00662.x; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Hotchkiss KA, 1998, BBA-PROTEIN STRUCT M, V1388, P478, DOI 10.1016/S0167-4838(98)00211-8; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Keenan RM, 1997, J MED CHEM, V40, P2289, DOI 10.1021/jm970205r; Krukonis ES, 2000, CELL MICROBIOL, V2, P219, DOI 10.1046/j.1462-5822.2000.00048.x; Krutzsch HC, 1999, J BIOL CHEM, V274, P24080, DOI 10.1074/jbc.274.34.24080; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; Li ZQ, 2002, J CELL BIOL, V157, P509, DOI 10.1083/jcb.200109098; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; LONG MW, 1990, BLOOD, V75, P2311; Marcinkiewicz C, 2003, CANCER RES, V63, P2020; Miao WM, 2001, CANCER RES, V61, P7830; Misenheimer TM, 2000, J BIOL CHEM, V275, P40938, DOI 10.1074/jbc.M007022200; Moodley Y, 2003, AM J PATHOL, V162, P771, DOI 10.1016/S0002-9440(10)63874-6; Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3; OSTERHOUT DJ, 1992, DEV BIOL, V150, P256, DOI 10.1016/0012-1606(92)90240-H; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RISER BL, 1990, DERMATOLOGICA, V180, P60, DOI 10.1159/000247991; Roberts David D., 1994, Journal of Tissue Culture Methods, V16, P217, DOI 10.1007/BF01540654; Rofstad EK, 2001, J INVEST DERMATOL, V117, P1042, DOI 10.1046/j.0022-202x.2001.01552.x; Romzek NC, 1998, MOL BIOL CELL, V9, P2715, DOI 10.1091/mbc.9.10.2715; ROSSO GC, 1997, J BIOL CHEM, V272, P31447; SAELMAN EUM, 1994, BLOOD, V83, P1244; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SIPES JM, 1993, J CELL BIOL, V121, P469, DOI 10.1083/jcb.121.2.469; Sipes JM, 1999, J BIOL CHEM, V274, P22755, DOI 10.1074/jbc.274.32.22755; SOCHA SB, 2004, BIOCHEMISTRY-US, V43, P1639; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200; Tomczuk M, 2003, EXP CELL RES, V290, P68, DOI 10.1016/S0014-4827(03)00307-0; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; Yi XY, 1998, CELL ADHES COMMUN, V5, P237, DOI 10.3109/15419069809040294	63	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41734	41743		10.1074/jbc.M406267200	http://dx.doi.org/10.1074/jbc.M406267200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292271	hybrid			2022-12-27	WOS:000224075500061
J	Hirota, K; Fukuda, R; Takabuchi, S; Kizaka-Kondoh, S; Adachi, T; Fukuda, K; Semenza, GL				Hirota, K; Fukuda, R; Takabuchi, S; Kizaka-Kondoh, S; Adachi, T; Fukuda, K; Semenza, GL			Induction of hypoxia-inducible factor 1 activity by muscarinic acetylcholine receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; FACTOR 1-ALPHA HIF-1-ALPHA; ACTIVATED PROTEIN-KINASE; COLON-CANCER CELLS; TRANSCRIPTIONAL ACTIVITY; FACTOR EXPRESSION; MAP KINASE; ENOLASE 1; HIF-1; TRANSACTIVATION	Hypoxia-inducible factor-1 (HIF-1) is a master regulator of cellular adaptive responses to hypoxia. Levels of the HIF-1alpha subunit increase under hypoxic conditions. Exposure of cells to growth factors, prostaglandin, and certain nitric oxide donors also induces HIF-1alpha expression under non-hypoxic conditions. We demonstrate that muscarinic acetylcholine signals induce HIF-1alpha expression and transcriptional activity in a receptor subtype-specific manner using HEK293 cells transiently overexpressing each of M1-M4 muscarinic acetylcholine receptors. The muscarinic signaling pathways inhibited HIF-1alpha hydroxylation and degradation and induced HIF-1alpha protein synthesis that was confirmed by pulse labeling studies. Muscarinic signal-induced HIF-1alpha protein and HIF-1-dependent gene expression were blocked by treating cells with inhibitors of phosphatidylinositol 3-kinase, MAP kinase kinase, or tyrosine kinase signaling pathways. Dominant-negative forms of Ras and/or Rac-1 significantly suppressed HIF-1 activation by muscarinic signaling. Signaling via M1- and M3- but not M2- or M4-AchRs promote accumulation and transcriptional activation of HIF-1alpha. We conclude that muscarinic acetylcholine signals activate HIF-1 by both stabilization and synthesis of HIF-1alpha and by inducing the transcriptional activity of HIF-1alpha.	Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Anesthesia, Kita Ku, Osaka 5308480, Japan; Johns Hopkins Univ, Sch Med, Program Vasc Cell Engn, Baltimore, MD 21205 USA; Kyoto Univ, Kyoto Univ Hosp, Dept Anesthesia, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, COE Format Gen Anal Dis Model Anim Multiple Genet, Sakyo Ku, Kyoto 6068507, Japan	Kitano Hospital; Johns Hopkins University; Kyoto University; Kyoto University	Hirota, K (corresponding author), Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Anesthesia, Kita Ku, 2-4-20 Ohgimiachi, Osaka 5308480, Japan.	hif1@mac.com	Kondoh, Shinae/AAF-8745-2020; Kondoh, Shinae/C-6937-2015; Hirota, Kiichi/E-9181-2010	Kondoh, Shinae/0000-0003-3085-5782; Kondoh, Shinae/0000-0003-3085-5782; Hirota, Kiichi/0000-0003-1110-0827				Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Caulfield MP, 1998, PHARMACOL REV, V50, P279; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; FUKUDA K, 1987, NATURE, V327, P623, DOI 10.1038/327623a0; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Fukuda R, 2003, CANCER RES, V63, P2330; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; Hamilton SE, 2001, J BIOL CHEM, V276, P15850, DOI 10.1074/jbc.M011563200; Harada H, 2002, CANCER RES, V62, P2013; Hirota K, 2001, J BIOL CHEM, V276, P25953, DOI 10.1074/jbc.M011021200; Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Itoh T, 2001, FEBS LETT, V509, P225, DOI 10.1016/S0014-5793(01)03119-2; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; NAKAMURA K, 1994, J PHYSIOL-LONDON, V474, P35, DOI 10.1113/jphysiol.1994.sp020000; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Sodhi A, 2000, CANCER RES, V60, P4873; Soucek T, 2003, NEURON, V39, P43, DOI 10.1016/S0896-6273(03)00367-2; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zhong H, 2000, CANCER RES, V60, P1541	42	50	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41521	41528		10.1074/jbc.M405164200	http://dx.doi.org/10.1074/jbc.M405164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280370	hybrid			2022-12-27	WOS:000224075500035
J	Mason, JC; Steinberg, R; Lidington, EA; Kinderlerer, AR; Ohba, M; Haskard, DO				Mason, JC; Steinberg, R; Lidington, EA; Kinderlerer, AR; Ohba, M; Haskard, DO			Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2)- and protein kinase C-alpha/epsilon (PKC alpha/epsilon)-dependent cytoprotective signaling pathway and is inhibited by cyclosporin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; TISSUE FACTOR EXPRESSION; ACTIVATED T-CELLS; NUCLEAR-FACTOR; TYROSINE PHOSPHORYLATION; PROSTACYCLIN PRODUCTION; COMPLEMENT ACTIVATION; TRANSPLANT RECIPIENTS; FLK-1/KDR ACTIVATION; INDUCED ANGIOGENESIS	Decay-accelerating factor (DAF), a membrane-bound complement regulatory protein, is up-regulated on endothelial cells (ECs) following treatment with vascular endothelial growth factor ( VEGF), providing enhanced protection from complement-mediated injury. We explored the signaling pathways involved in this response. Incubation of human umbilical vein ECs with VEGF induced a 3-fold increase in DAF expression. Inhibition by flk-1 kinase inhibitor SU1498 and failure of placental growth factor (PlGF) to up-regulate DAF confirmed the role of VEGF-R2. The response was also blocked by pretreatment with phospholipase C-gamma (PLCgamma) inhibitor U71322 and protein kinase C (PKC) antagonist GF109203X. In contrast, no effect was seen with nitric oxide synthase inhibitor N-G-monomethyl-L-arginine (L-NMMA). Use of PKC agonists and isozyme-specific pseudosubstrate peptide antagonists suggested a role for PKCalpha and -epsilon in VEGF-mediated DAF up-regulation. This was confirmed by transfection of ECs with PKCalpha and -epsilon dominant-negative constructs, which in combination completely abrogated induction of DAF by VEGF. In contrast, LY290042, a phosphoinositide 3-kinase (PI3K) inhibitor, significantly augmented DAF expression, suggesting a negative regulatory role for phosphoinositide 3-kinase. The widely used immunosuppressive drug cyclosporin A (CsA) inhibited DAF induction by VEGF in a dose-dependent manner. The VEGF-induced DAF expression was functionally effective, significantly reducing complement-mediated EC lysis, and this cytoprotective effect was reversed by CsA. These data provide evidence for a VEGF-R2-, phospholipase C-gamma-, and PKCalpha/ epsilon-mediated cytoprotective pathway in ECs. This may represent an important mechanism for the maintenance of vascular integrity during chronic inflammation involving complement activation. Moreover, inhibition of this pathway by CsA may play a role in CsA-mediated vascular injury.	Univ London Imperial Coll Sci & Technol, Hammersmith Hosp, Eric Bywaters Ctr, Cardiovasc Med Unit,British Heart Fdn, London W12 0NN, England; Showa Univ, Inst Mol Oncol, Shinagawa Ku, Tokyo 1428555, Japan	Imperial College London; University of London; University College London; Showa University	Mason, JC (corresponding author), Univ London Imperial Coll Sci & Technol, Hammersmith Hosp, Eric Bywaters Ctr, Cardiovasc Med Unit,British Heart Fdn, Du Cane Rd, London W12 0NN, England.	justin.mason@imperial.ac.uk		Mason, Justin/0000-0001-7783-1660				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Ahmad SR, 2003, IMMUNOLOGY, V110, P258, DOI 10.1046/j.1365-2567.2003.01733.x; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Alvarez-Arroyo MV, 2002, CIRC RES, V91, P202, DOI 10.1161/01.RES.0000027562.91075.56; Armesilla AL, 1999, MOL CELL BIOL, V19, P2032; Asada A, 1998, J BIOL CHEM, V273, P28392, DOI 10.1074/jbc.273.43.28392; Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P1253, DOI 10.1038/sj.bjp.0704367; Blum S, 2001, J BIOL CHEM, V276, P33428, DOI 10.1074/jbc.M105474200; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Caramelo C, 2004, NEPHROL DIAL TRANSPL, V19, P285, DOI 10.1093/ndt/gfg516; Cheng JJ, 2001, J BIOL CHEM, V276, P31368, DOI 10.1074/jbc.M011317200; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FISHER GJ, 1988, J INVEST DERMATOL, V91, P142, DOI 10.1111/1523-1747.ep12464387; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gelinas DS, 2002, BRIT J PHARMACOL, V137, P1021, DOI 10.1038/sj.bjp.0704956; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Haller H, 1998, CIRC RES, V82, P157; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Holschermann H, 1996, BLOOD, V88, P3837, DOI 10.1182/blood.V88.10.3837.bloodjournal88103837; HRUBAN RH, 1990, AM J PATHOL, V137, P871; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; Kearney JB, 2004, BLOOD, V103, P4527, DOI 10.1182/blood-2003-07-2315; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Kou RQ, 2002, J BIOL CHEM, V277, P29669, DOI 10.1074/jbc.M204519200; KU DD, 1993, AM J PHYSIOL, V265, P586; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Li SH, 2004, CIRCULATION, V109, P833, DOI 10.1161/01.CIR.0000117087.27524.0E; Lidington EA, 2000, BLOOD, V96, P2784; Lin F, 2002, LAB INVEST, V82, P563, DOI 10.1038/labinvest.3780451; Liszewski MK, 1996, ADV IMMUNOL, V61, P201; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35; Mason JC, 1999, BLOOD, V94, P1673, DOI 10.1182/blood.V94.5.1673.417a05_1673_1682; Mason JC, 2002, AM J PHYSIOL-CELL PH, V282, pC578, DOI 10.1152/ajpcell.00339.2001; Mason JC, 2001, ARTHRITIS RHEUM, V44, P138, DOI 10.1002/1529-0131(200101)44:1<138::AID-ANR18>3.0.CO;2-G; Morris STW, 2000, KIDNEY INT, V57, P1100, DOI 10.1046/j.1523-1755.2000.00937.x; Murakami R, 2003, ARTERIOSCL THROM VAS, V23, P2034, DOI 10.1161/01.ATV.0000094234.60166.78; Murat A, 2000, J BIOL CHEM, V275, P40867, DOI 10.1074/jbc.M008071200; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Ostendorf T, 1999, J CLIN INVEST, V104, P913, DOI 10.1172/JCI6740; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Qian ZP, 2001, TRANSPLANTATION, V72, P900, DOI 10.1097/00007890-200109150-00027; Rafiee P, 2002, J BIOL CHEM, V277, P35605, DOI 10.1074/jbc.M205826200; Rafiee Parvaneh, 2004, Cell Commun Signal, V2, P3, DOI 10.1186/1478-811X-2-3; Reinders MEJ, 2003, J CLIN INVEST, V112, P1655, DOI 10.1172/JCI200317712; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Saito Y, 2002, J BIOL CHEM, V277, P23216, DOI 10.1074/jbc.M200605200; Scalia R, 1999, FASEB J, V13, P1039, DOI 10.1096/fasebj.13.9.1039; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Sogabe H, 2001, J IMMUNOL, V167, P2791, DOI 10.4049/jimmunol.167.5.2791; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 2001, J INVEST DERMATOL, V117, P605, DOI 10.1046/j.0022-202x.2001.01452.x; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; THOMAS DJ, 1993, J IMMUNOL, V150, P151; Torzewski J, 1997, ATHEROSCLEROSIS, V132, P131, DOI 10.1016/S0021-9150(97)00100-7; Tsopanoglou NE, 1999, J BIOL CHEM, V274, P23969, DOI 10.1074/jbc.274.34.23969; Wellner M, 1999, ARTERIOSCL THROM VAS, V19, P178, DOI 10.1161/01.ATV.19.1.178; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Zachary I, 2003, BIOCHEM SOC T, V31, P1171; Zachary I, 2001, AM J PHYSIOL-CELL PH, V280, pC1375, DOI 10.1152/ajpcell.2001.280.6.C1375; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.0.CO;2-A	75	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41611	41618		10.1074/jbc.M407981200	http://dx.doi.org/10.1074/jbc.M407981200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15284224	hybrid			2022-12-27	WOS:000224075500046
J	Rose, KM; Marin, M; Kozak, SL; Kabat, D				Rose, KM; Marin, M; Kozak, SL; Kabat, D			Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B MESSENGER-RNA; PROTEIN-KINASE-C; VIRAL VIF PROTEIN; HIV-1 VIF; ANTIVIRAL ACTIVITY; MOLECULAR-CLONING; ENZYME APOBEC3G; TYPE-1; EXPRESSION; INHIBITOR	Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G) is an antiretroviral deoxycytidine deaminase that lethally hypermutates human immunodeficiency virus type 1 (HIV-1) but is itself neutralized by the HIV-1-encoded viral infectivity factor. Accordingly, APOBEC3G occurs specifically in human T lymphocytic cell lines that contain this antiviral defense, including H9. Since the substrate specificities of related cytidine deaminases are strongly influenced by their intracellular quantities, we analyzed the factors that control APOBEC3G expression. The levels of APOBEC3G mRNA and protein were unaffected by treatment of proliferating H9 cells with interferons or tumor necrosis factor-alpha but were enhanced up to 20-fold by phorbol myristate acetate. This induction was mediated at the transcriptional level by a pathway that required activation of the protein kinase Calpha/betaI isozyme (PKC), mitogen-activated protein kinase kinase (MEK) 1 and 2, and extracellular signal-regulated kinase (ERK). Correspondingly, induction of APOBEC3G was blocked by multiple inhibitors that act at diverse steps of this pathway. The PKCalpha/betaI/MEK/ERK pathway also controlled basal levels of APOBEC3G mRNA and protein, which consequently declined when cells were treated with these inhibitors or arrested in the G(0) state of the cell cycle by serum starvation. We conclude that expression of the antiviral APOBEC3G editing enzyme is dynamically controlled by the PKCalpha/betaI/MEK/ERK protein kinase cascade in human T lymphocytes.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Kabat, D (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	kabat@ohsu.edu			NIAID NIH HHS [AI49729] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049729, R21AI049729] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anant S, 2001, AM J PHYSIOL-CELL PH, V281, pC1904, DOI 10.1152/ajpcell.2001.281.6.C1904; *APPL BIOSYST, 1997, ABI PRISM 7700 US B, V2; BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; BAXEVANIS AD, 2002, CURRENT PROTOCOLS BI; Besmer E, 2004, CURR OPIN IMMUNOL, V16, P241, DOI 10.1016/j.coi.2004.01.005; Bogerd HP, 2004, P NATL ACAD SCI USA, V101, P3770, DOI 10.1073/pnas.0307713101; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Dance GSC, 2002, J BIOL CHEM, V277, P12703, DOI 10.1074/jbc.M111337200; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Herbein G, 2000, P SOC EXP BIOL MED, V223, P241, DOI 10.1046/j.1525-1373.2000.22335.x; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu BD, 2004, J VIROL, V78, P2072, DOI 10.1128/JVI.78.4.2072-2081.2004; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Madsen P, 1999, J INVEST DERMATOL, V113, P162, DOI 10.1046/j.1523-1747.1999.00682.x; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; MANGEAT B, 2004, J BIOL CHEM; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2000, J VIROL, V74, P8085, DOI 10.1128/JVI.74.17.8085-8093.2000; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; MEHLE A, 2003, J BIOL CHEM; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RASMUSSEN HH, 1993, J INVEST DERMATOL, V101, P560, DOI 10.1111/1523-1747.ep12365986; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Schrofelbauer R, 2004, P NATL ACAD SCI USA, V101, P3927, DOI 10.1073/pnas.0307132101; SHAH RR, 1991, J BIOL CHEM, V266, P16301; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Sowden M, 1996, J BIOL CHEM, V271, P3011, DOI 10.1074/jbc.271.6.3011; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Tailor CS, 1999, P NATL ACAD SCI USA, V96, P927, DOI 10.1073/pnas.96.3.927; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WIEGAND HL, 2004, EMBO J; XU H, 2004, P NATL ACAD SCI US; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	62	70	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41744	41749		10.1074/jbc.M406760200	http://dx.doi.org/10.1074/jbc.M406760200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15297452	hybrid			2022-12-27	WOS:000224075500062
J	Arselin, G; Vaillier, J; Salin, B; Schaeffer, J; Giraud, MF; Dautant, A; Brethes, D; Velours, J				Arselin, G; Vaillier, J; Salin, B; Schaeffer, J; Giraud, MF; Dautant, A; Brethes, D; Velours, J			The modulation in subunits e and g amounts of yeast ATP synthase modifies mitochondrial cristae morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; POLYACRYLAMIDE-GEL ELECTROPHORESIS; BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; SACCHAROMYCES-CEREVISIAE; OUTER-MEMBRANE; MGM1P; PURIFICATION; DISRUPTION; F-1-ATPASE	Subunits e and g of Saccharomyces cerevisiae ATP synthase are required to maintain ATP synthase dimeric forms. Mutants devoid of these subunits display anomalous mitochondrial morphologies. An expression system regulated by doxycycline was used to modulate the expression of the genes encoding the subunits e and g. A decrease in the amount of subunit e induces a decrease in the amount of subunit g, but a decrease in the amount of subunit g does not affect subunit e. The loss of subunit e or g leads to the loss of supramolecular structures of ATP synthase, which is fully reversible upon removal of doxycycline. In the absence of doxycycline, mitochondria present poorly defined cristae. In the presence of doxycycline, onion-like structures are formed after five generations. When doxycycline is removed after five generations, cristae are mainly observed. The data demonstrate that the inner structure of mitochondria depends upon the ability of ATP synthase to make supramolecular structures.	Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Velours, J (corresponding author), Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	jean.velours@ibgc.u-bordeaux2.fr						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALLEN RD, 1995, PROTOPLASMA, V189, P1, DOI 10.1007/BF01280286; ALLEN RD, 1989, J CELL BIOL, V108, P2233, DOI 10.1083/jcb.108.6.2233; Amutha B, 2004, BIOCHEM J, V381, P19, DOI 10.1042/BJ20040566; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Arselin G, 2003, EUR J BIOCHEM, V270, P1875, DOI 10.1046/j.1432-1033.2003.03557.x; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; Belogrudov GI, 1996, J BIOL CHEM, V271, P20340, DOI 10.1074/jbc.271.34.20340; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Brunner S, 2002, J BIOL CHEM, V277, P48484, DOI 10.1074/jbc.M209382200; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; DECHATEAUBODEAU GA, 1976, BIOCHIMIE PARIS, V58, P601; EGNER R, 1995, MOL CELL BIOL, V15, P5879; Fillingame RH, 1999, SCIENCE, V286, P1687, DOI 10.1126/science.286.5445.1687; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gavin PD, 2004, J CELL SCI, V117, P2333, DOI 10.1242/jcs.01074; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GrandierVazeille X, 1996, ANAL BIOCHEM, V242, P248, DOI 10.1006/abio.1996.0460; Guerin B, 1979, Methods Enzymol, V55, P149; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; Hobbs AEA, 2001, J CELL BIOL, V152, P401, DOI 10.1083/jcb.152.2.401; Kondo-Okamoto N, 2003, J BIOL CHEM, V278, P48997, DOI 10.1074/jbc.M308436200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MUKHOPADHYAY A, 1994, FEBS LETT, V343, P160, DOI 10.1016/0014-5793(94)80310-2; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P325, DOI 10.1023/A:1005594800983; Pelloquin L, 1999, J CELL SCI, V112, P4151; Rubinstein JL, 2003, EMBO J, V22, P6182, DOI 10.1093/emboj/cdg608; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; Sesaki H, 2003, MOL BIOL CELL, V14, P2342, DOI 10.1091/mbc.E02-12-0788; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; Soubannier V, 2002, J BIOL CHEM, V277, P10739, DOI 10.1074/jbc.M111882200; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; Velours J, 2001, J BIOL CHEM, V276, P8602, DOI 10.1074/jbc.M008123200; Velours J, 2000, J BIOENERG BIOMEMBR, V32, P383, DOI 10.1023/A:1005580020547; Wong ED, 2003, J CELL BIOL, V160, P303, DOI 10.1083/jcb.200209015; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910	48	117	120	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40392	40399		10.1074/jbc.M404316200	http://dx.doi.org/10.1074/jbc.M404316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262977	hybrid			2022-12-27	WOS:000223916800023
J	Saarikettu, J; Sveshnikova, N; Grundstrom, T				Saarikettu, J; Sveshnikova, N; Grundstrom, T			Calcium/calmodulin inhibition of transcriptional activity of E-proteins by prevention of their binding to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; NUCLEAR CALCIUM; GENE-EXPRESSION; CALMODULIN; KINASE; DIFFERENTIATION; CELLS; PHOSPHORYLATION; RECOGNITION; MODULATION	The Ca2+ sensor protein calmodulin can interact with the DNA binding basic helix-loop-helix ( bHLH) domain of E12, E47, and SEF2-1 (E2-2), which belong to the E-protein subclass of bHLH transcription factors. This interaction inhibits the DNA binding of these bHLH proteins in vitro, and an ionophore that increases intracellular Ca2+ can inhibit transcriptional activation by the E-proteins. Here we have attempted to determine if these phenomena reflect a direct calmodulin-dependent inhibition of DNA binding by E-proteins in vivo. We show that calmodulin overexpression inhibits the transcriptional activity of E12, E47, and SEF2-1. We have compared calmodulin effects on DNA binding in vitro and on activation of transcription in vivo using a series of E12 mutants harboring defined alterations within the basic sequence of the bHLH domain that reduce their ability to bind calmodulin to varying degrees. We find a striking direct correlation between the ability of calmodulin to inhibit their DNA binding in vitro and the ability of overexpressed calmodulin or cellular Ca2+ mobilization to inhibit their transcriptional activity in vivo. Furthermore, E12 and overexpressed calmodulin were co-localized in the nucleus, and calmodulin pull-down experiments with cell extracts showed a Ca2+-dependent interaction between calmodulin and E12 but not with a calmodulin inhibition-deficient E12 mutant. Chromatin immunoprecipitation showed that calmodulin overexpression leads to decreased binding of E12 and E47, but not a calmodulin inhibition-deficient E12 mutant, to the DNA recognition sequence in vivo. The data suggest that Ca2+ signaling can inhibit the transcriptional activities of E-proteins through direct binding of Ca2+/calmodulin to the basic sequence of E-proteins, resulting in inhibition of their DNA binding.	Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden	Umea University	Grundstrom, T (corresponding author), Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden.	Thomas.Grundstrom@molbiol.umu.se						Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Hardingham GE, 1998, CELL CALCIUM, V23, P131, DOI 10.1016/S0143-4160(98)90111-7; Hardingham GE, 2001, NAT NEUROSCI, V4, P261, DOI 10.1038/85109; Hermann S, 1998, CELL CALCIUM, V23, P135, DOI 10.1016/S0143-4160(98)90112-9; Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200; Hughes K, 1998, FEBS LETT, V441, P132, DOI 10.1016/S0014-5793(98)01537-3; Hughes Kate, 2002, Methods Mol Biol, V173, P355; Larsson G, 2001, PROTEIN SCI, V10, P169, DOI 10.1110/ps.28401; Liao BR, 1999, P NATL ACAD SCI USA, V96, P6217, DOI 10.1073/pnas.96.11.6217; Liu H, 2002, MOL BIOL CELL, V13, P4497, DOI 10.1091/mbc.E02-03-0149; Markus M, 2002, J BIOL CHEM, V277, P6469, DOI 10.1074/jbc.M110659200; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Mellstrom B, 2001, CURR OPIN NEUROBIOL, V11, P312, DOI 10.1016/S0959-4388(00)00213-0; Onions J, 1997, J BIOL CHEM, V272, P23930, DOI 10.1074/jbc.272.38.23930; Onions J, 2000, BIOCHEMISTRY-US, V39, P4366, DOI 10.1021/bi992533u; PILON M, 1991, J IMMUNOL, V146, P1047; Porter GA, 2002, J BIOL CHEM, V277, P28942, DOI 10.1074/jbc.M203961200; SIDERAS P, 1992, J IMMUNOL, V149, P244; Teruel MN, 2000, CURR BIOL, V10, P86, DOI 10.1016/S0960-9822(00)00295-5; VANELDIK LJ, 1998, CALMODULIN SIGNAL TR; Zimmerman CM, 1998, J BIOL CHEM, V273, P677, DOI 10.1074/jbc.273.2.677	33	29	29	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41004	41011		10.1074/jbc.M408120200	http://dx.doi.org/10.1074/jbc.M408120200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15280352	hybrid			2022-12-27	WOS:000223916800098
J	Chen, LQ; DiGiammarino, E; Zhou, XYE; Wang, YJ; Toh, D; Hodge, TW; Meehan, EJ				Chen, LQ; DiGiammarino, E; Zhou, XYE; Wang, YJ; Toh, D; Hodge, TW; Meehan, EJ			High resolution crystal structure of human Rab9 GTPase - A novel antiviral drug target	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PROTEIN STRUCTURES; ENDOSOMES; BINDING; HYDROLYSIS; INSIGHTS; DOMAINS; REGIONS	Rab GTPases and their effectors facilitate vesicular transport by tethering donor vesicles to their respective target membranes. Rab9 mediates late endosome to trans-Golgi transport and has recently been found to be a key cellular component for human immunodeficiency virus-1, Ebola, Marburg, and measles virus replication, suggesting that it may be a novel target in the development of broad spectrum antiviral drugs. As part of our structure-based drug design program, we have determined the crystal structure of a C-terminally truncated human Rab9 (residues 1-177) to 1.25-Angstrom resolution. The overall structure shows a characteristic nucleotide binding fold consisting of a six-stranded beta-sheet surrounded by five alpha-helices with a tightly bound GDP molecule in the active site. Structure-based sequence alignment of Rab9 with other Rab proteins reveals that its active site consists of residues highly conserved in the Rab GTPase family, implying a common catalytic mechanism. However, Rab9 contains seven regions that are significantly different in conformation from other Rab proteins. Some of those regions coincide with putative effector-binding sites and switch I and switch II regions identified by structure/sequence alignments. The Rab9 structure at near atomic resolution provides an excellent model for structure-based antiviral drug design.	Univ Alabama, Dept Chem, Struct Biol Lab, Grad Programs Biotechnol Chem & Mat Sci, Huntsville, AL 35899 USA; Ctr Dis Control, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA	University of Alabama System; University of Alabama Huntsville; Centers for Disease Control & Prevention - USA	Meehan, EJ (corresponding author), Univ Alabama, Dept Chem, Struct Biol Lab, Grad Programs Biotechnol Chem & Mat Sci, Huntsville, AL 35899 USA.	meehane@uah.edu						Blot G, 2003, J VIROL, V77, P6931, DOI 10.1128/JVI.77.12.6931-6945.2003; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Constantinescu AT, 2002, STRUCTURE, V10, P569, DOI 10.1016/S0969-2126(02)00737-2; Diaz E, 1997, J CELL BIOL, V138, P283, DOI 10.1083/jcb.138.2.283; Dumas JJ, 1999, STRUCTURE, V7, P413, DOI 10.1016/S0969-2126(99)80054-9; Esters H, 2000, J MOL BIOL, V298, P111, DOI 10.1006/jmbi.2000.3645; Holm L, 1998, PROTEINS, V33, P88, DOI 10.1002/(SICI)1097-0134(19981001)33:1<88::AID-PROT8>3.0.CO;2-H; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Merithew E, 2001, J BIOL CHEM, V276, P13982, DOI 10.1074/jbc.M009771200; Pasqualato S, 2004, J BIOL CHEM, V279, P11480, DOI 10.1074/jbc.M310558200; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; Scheidig AJ, 1999, STRUCTURE, V7, P1311, DOI 10.1016/S0969-2126(00)80021-0; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; Stroupe C, 2000, J MOL BIOL, V304, P585, DOI 10.1006/jmbi.2000.4236; Zhu GY, 2003, J BIOL CHEM, V278, P2452, DOI 10.1074/jbc.M211042200	24	8	10	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40204	40208		10.1074/jbc.M407114200	http://dx.doi.org/10.1074/jbc.M407114200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15263003	hybrid			2022-12-27	WOS:000223791500119
J	Gupta, S; Singh, R; Datta, P; Zhang, ZJ; Orr, C; Lu, ZX; DuBois, G; Zervos, AS; Meisler, MH; Srinivasula, SM; Fernandes-Alnemri, T; Alnemri, ES				Gupta, S; Singh, R; Datta, P; Zhang, ZJ; Orr, C; Lu, ZX; DuBois, G; Zervos, AS; Meisler, MH; Srinivasula, SM; Fernandes-Alnemri, T; Alnemri, ES			The C-terminal tail of presenilin regulates Omi/HtrA2 protease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; NMDA RECEPTOR SUBUNITS; SERINE-PROTEASE; PDZ DOMAINS; MISSENSE MUTATIONS; APOPTOSIS PROTEINS; MULTIPLE MEMBERS; SODIUM-CHANNELS; HTRA FAMILY; CELL-DEATH	Presenilin mutations are responsible for most cases of autosomal dominant inherited forms of early onset Alzheimer disease. Presenilins play an important role in amyloid beta-precursor processing, NOTCH receptor signaling, and apoptosis. However, the molecular mechanisms by which presenilins regulate apoptosis are not fully understood. Here, we report that presenilin-1 (PS1) regulates the proteolytic activity of the serine protease Omi/HtrA2 through direct interaction with its regulatory PDZ domain. We show that a peptide corresponding to the cytoplasmic C-terminal tail of PS1 dramatically increases the proteolytic activity of Omi/HtrA2 toward the inhibitor of apoptosis proteins and beta-casein and induces cell death in an Omi/HtrA2-dependent manner. Consistent with these results, ectopic expression of full-length PS1, but not PS1 lacking the C-terminal PDZ binding motif, potentiated Omi/HtrA2-induced cell death. Our results suggest that the C terminus of PS1 is an activation peptide ligand for the PDZ domain of Omi/HtrA2 and may regulate the protease activity of Omi/HtrA2 after its release from the mitochondria during apoptosis. This mechanism of Omi/HtrA2 activation is similar to the mechanism of activation of the related bacterial DegS protease by the outer-membrane porins.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Univ Cent Florida, Biomol Sci Ctr, Orlando, FL 32826 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA	Jefferson University; Jefferson University; State University System of Florida; University of Central Florida; University of Michigan System; University of Michigan	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,Rm 904,233 S 10th St, Philadelphia, PA 19107 USA.	E_Alnemri@lac.jci.tju.edu	Gupta, Sanjeev/AAG-9749-2020; gupta, sanjeev/B-2824-2008; Alnemri, Emad S/B-4526-2010	Gupta, Sanjeev/0000-0002-4691-6853; gupta, sanjeev/0000-0002-4691-6853; 	NATIONAL CANCER INSTITUTE [Z01BC010629, P01CA078890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013487, R01AG014357] Funding Source: NIH RePORTER; NCI NIH HHS [CA78890] Funding Source: Medline; NIA NIH HHS [AG14357, AG13487] Funding Source: Medline; NIGMS NIH HHS [GM24872] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ankarcrona M, 2002, BIOCHEM BIOPH RES CO, V295, P766, DOI 10.1016/S0006-291X(02)00735-0; Bartke T, 2004, MOL CELL, V14, P801, DOI 10.1016/j.molcel.2004.05.018; BENZ R, 1985, CRC CR REV BIOCH MOL, V19, P145, DOI 10.3109/10409238509082542; BLASS JP, 1993, HIPPOCAMPUS, V3, P45; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Cruts M, 1998, HUM MUTAT, V11, P183, DOI 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO;2-M; Eckert A, 2003, BIOCHEM PHARMACOL, V66, P1627, DOI 10.1016/S0006-2952(03)00534-3; Faccio L, 2000, GENOMICS, V68, P343, DOI 10.1006/geno.2000.6263; Gee SH, 1998, J NEUROSCI, V18, P128; Guo Q, 1998, P NATL ACAD SCI USA, V95, P3227, DOI 10.1073/pnas.95.6.3227; Harris BZ, 2001, J CELL SCI, V114, P3219; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lau KF, 2000, MOL CELL NEUROSCI, V16, P557, DOI 10.1006/mcne.2000.0898; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Martins LM, 2003, J BIOL CHEM, V278, P49417, DOI 10.1074/jbc.M308659200; Medina M, 2003, CELL SIGNAL, V15, P829, DOI 10.1016/S0898-6568(03)00041-X; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Pellegrini L, 2001, J ALZHEIMERS DIS, V3, P181; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHELLENBERG GD, 1995, P NATL ACAD SCI USA, V92, P8552, DOI 10.1073/pnas.92.19.8552; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; Wilken C, 2004, CELL, V117, P483, DOI 10.1016/S0092-8674(04)00454-4; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Xu XM, 1999, J BIOL CHEM, V274, P32543, DOI 10.1074/jbc.274.46.32543; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903	42	75	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45844	45854		10.1074/jbc.M404940200	http://dx.doi.org/10.1074/jbc.M404940200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15294909	hybrid, Green Published			2022-12-27	WOS:000224694900069
J	Fouquet, S; Lugo-Martinez, VH; Faussat, AM; Renaud, F; Cardot, P; Chambaz, J; Pincon-Raymond, M; Thenet, S				Fouquet, S; Lugo-Martinez, VH; Faussat, AM; Renaud, F; Cardot, P; Chambaz, J; Pincon-Raymond, M; Thenet, S			Early loss of E-cadherin from cell-cell contacts is involved in the onset of Anoikis in enterocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; DETACHMENT-INDUCED APOPTOSIS; BETA-CATENIN; EXTRACELLULAR-MATRIX; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEOLYTIC CLEAVAGE; ADHERENS JUNCTIONS; DOWN-REGULATION; ADHESION; ACTIVATION	Anoikis, i.e. apoptosis induced by detachment from the extracellular matrix, is thought to be involved in the shedding of enterocytes at the tip of intestinal villi. Mechanisms controlling enterocyte survival are poorly understood. We investigated the role of E-cadherin, a key protein of cell-cell adhesion, in the control of anoikis of normal intestinal epithelial cells, by detaching murine villus epithelial cells from the underlying basement membrane while preserving cell-cell interactions. We show that upon the loss of anchorage, normal enterocytes execute a program of apoptosis within minutes, via a Bcl-2-regulated and caspase-9-dependent pathway. E-cadherin is lost early from cell-cell contacts. This process precedes the execution phase of detachment-induced apoptosis as it is only weakly modulated by Bcl-2 overexpression or caspase inhibition. E-cadherin loss, however, is efficiently prevented by lysosome and proteasome inhibitors. We also found that a blocking anti-E-cadherin antibody increases the rate of anoikis, whereas the activation of E-cadherin using E-cadherin-Fc chimera proteins reduces anoikis. In conclusion, our results stress the striking sensitivity of normal enterocytes to the loss of anchorage and the contribution of E-cadherin to the control of their survival/apoptosis balance. They open new perspectives on the key role of this protein, which is dysregulated in the intestinal epithelium in both inflammatory bowel disease and cancer.	EPHE, Pharmacol Cellulaire & Mol Lab, UMR INSERM UPMC 505, F-75006 Paris, France; IFR 58, INSERM, EPI9912, F-75006 Paris, France; Univ Versailles, Ecole Prat Hautes Etud, Lab Genet Mol & Physiol, CNRS,UPRESA 8087, F-78000 Versailles, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Thenet, S (corresponding author), EPHE, Pharmacol Cellulaire & Mol Lab, UMR INSERM UPMC 505, 15 Rue Ecole Med, F-75006 Paris, France.	Sophie.Thenet-u505@bhdc.jussieu.fr	Thenet, Sophie/GQY-5726-2022	Thenet, Sophie/0000-0002-0336-2942; Lugo Martinez, Veronica Haydee/0000-0002-0184-6417				Akhtar N, 2001, MOL BIOL CELL, V12, P847, DOI 10.1091/mbc.12.4.847; Beaulieu JF, 1997, PROG HISTOCHEM CYTOC, V31, P1; Bergin E, 2000, AM J PHYSIOL-RENAL, V278, pF758, DOI 10.1152/ajprenal.2000.278.5.F758; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gassler N, 2001, AM J PHYSIOL-GASTR L, V281, pG216, DOI 10.1152/ajpgi.2001.281.1.G216; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147; Grossmann J, 1998, AM J PHYSIOL-GASTR L, V274, pG1117, DOI 10.1152/ajpgi.1998.274.6.G1117; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Mayhew TM, 1999, HISTOL HISTOPATHOL, V14, P257, DOI 10.14670/HH-14.257; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nakagawa M, 2001, J CELL SCI, V114, P1829; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Pece S, 2002, NAT CELL BIOL, V4, pE72, DOI 10.1038/ncb0402-e72; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; Potten CS, 1997, AM J PHYSIOL-GASTR L, V273, pG253, DOI 10.1152/ajpgi.1997.273.2.G253; Rak Janusz, 1999, Neoplasia (New York), V1, P23, DOI 10.1038/sj.neo.7900001; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Schmeiser K, 1999, CELL DEATH DIFFER, V6, P377, DOI 10.1038/sj.cdd.4400504; Schreider C, 2002, J CELL SCI, V115, P543; SHIBAHARA T, 1995, ARCH HISTOL CYTOL, V58, P205, DOI 10.1679/aohc.58.205; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; Tsukamoto T, 1999, J BIOL CHEM, V274, P24579, DOI 10.1074/jbc.274.35.24579; Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072; Vallorosi CJ, 2000, J BIOL CHEM, V275, P3328, DOI 10.1074/jbc.275.5.3328; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; Walker PR, 1999, METHODS, V17, P329, DOI 10.1006/meth.1999.0747; Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200; Weaver VM, 1999, J MAMMARY GLAND BIOL, V4, P193, DOI 10.1023/A:1018781325716; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200; Zugasti O, 2001, MOL CELL BIOL, V21, P6706, DOI 10.1128/MCB.21.19.6706-6717.2001	57	109	114	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43061	43069		10.1074/jbc.M405095200	http://dx.doi.org/10.1074/jbc.M405095200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292248	hybrid, Green Published			2022-12-27	WOS:000224226400089
J	Lee, JH; Jeon, MH; Seo, YJ; Lee, YJ; Ko, JH; Tsujimoto, Y; Lee, JH				Lee, JH; Jeon, MH; Seo, YJ; Lee, YJ; Ko, JH; Tsujimoto, Y; Lee, JH			CA repeats in the 3 '-untranslated region of bcl-2 mRNA mediate constitutive decay of bcl-2 mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENT; DEPENDENT DEGRADATION; RESPONSE ELEMENT; DOWN-REGULATION; HNRNP L; BINDING; PROTEIN; EXPRESSION; APOPTOSIS; DESTABILIZATION	An AU-rich element ( ARE) in the 3'-untranslated region (UTR) of bcl-2 mRNA has previously been shown to be responsible for destabilizing bcl-2 mRNA during apoptosis through increasing AUF1 binding. In the present study, we investigated the effect of the region upstream of the ARE on bcl-2 mRNA stability using serial deletion constructs of the 3'-UTR of bcl-2. Deletion of 30 nucleotides mostly consisting of the CA repeats, located upstream of the ARE, resulted in the stabilization of bcl-2 mRNA abundance, in the absence or presence of the ARE. The specificity of the CA repeats in terms of destabilizing bcl-2 mRNA was proven by the substituting the CA repeats with other alternative repeats of purine/ pyriminine, but this had no effect on the stability of bcl-2 mRNA. CA repeats alone, however, failed to confer instability to bcl-2 or gfp reporter mRNAs, indicating a requirement for additional sequences in the upstream region of the 3'-UTR. Serial deletion and replacement of a part of the region upstream of the CA repeats revealed that the entire 131-nucleotide upstream region is an essential prerequisite for the CA repeat-dependent destabilization of bcl-2 mRNA. Unlike the ARE, CA repeat-mediated degradation of bcl-2 mRNA was not accelerated upon apoptotic stimulus. Moreover, the upstream sequences and CA repeats are conserved among mammals. Collectively, CA repeats contribute to the constitutive decay of bcl-2 mRNA in the steady states, thereby maintaining appropriate bcl-2 levels in mammalian cells.	Catholic Univ Korea, Dept Biochem, Coll Med, Seoul 137701, South Korea; Korea Res Inst Biosci & Biotechnol, Proteom Syst Res Ctr, Daijeon 305333, South Korea; Osaka Univ, Dept Postgenom & Dis, Sch Med, Osaka 5650871, Japan; Japan Sci & Technol Corp, Solut Oriented Res Sci & Technol, Sch Med, Osaka 5650871, Japan	Catholic University of Korea; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Osaka University; Japan Science & Technology Agency (JST)	Lee, JH (corresponding author), Catholic Univ Korea, Dept Biochem, Coll Med, 505 Banpo Dong, Seoul 137701, South Korea.	leejh@catholic.ac.kr	Ko, Jae-Hyeon/I-4133-2019	Ko, Jae-Hyeon/0000-0001-7766-2385				Agarwal AK, 2000, HYPERTENSION, V36, P187, DOI 10.1161/01.HYP.36.2.187; Bandyopadhyay S, 2003, BIOCHEM PHARMACOL, V66, P1151, DOI 10.1016/S0006-2952(03)00453-2; BETTAIEB A, 2003, ANTICANC AGENTS, V3, P307; Bevilacqua A, 2003, J BIOL CHEM, V278, P23451, DOI 10.1074/jbc.M210620200; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Del Bello B, 2001, ONCOGENE, V20, P4591, DOI 10.1038/sj.onc.1204618; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Donnini M, 2001, BIOCHEM BIOPH RES CO, V287, P1063, DOI 10.1006/bbrc.2001.5700; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Hui JY, 2003, RNA, V9, P931, DOI 10.1261/rna.5660803; Hui JY, 2003, NAT STRUCT BIOL, V10, P33, DOI 10.1038/nsb875; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lapucci A, 2002, J BIOL CHEM, V277, P16139, DOI 10.1074/jbc.M201377200; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; Luzi E, 2003, CANCER GENE THER, V10, P201, DOI 10.1038/sj.cgt.7700556; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; MIYASHITA T, 1994, CANCER RES, V54, P3131; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Pravica V, 1999, EUR J IMMUNOGENET, V26, P1, DOI 10.1046/j.1365-2370.1999.00122.x; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; Sengupta TK, 2004, J BIOL CHEM, V279, P10855, DOI 10.1074/jbc.M309111200; Sharma VK, 2003, J BIOMOL STRUCT DYN, V21, P303, DOI 10.1080/07391102.2003.10506926; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Thomson AM, 1999, BIOTECHNIQUES, V27, P1032, DOI 10.2144/99275rr03; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686	33	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42758	42764		10.1074/jbc.M407357200	http://dx.doi.org/10.1074/jbc.M407357200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15294893	hybrid			2022-12-27	WOS:000224226400051
J	Lei, S; Dubeykovskiy, A; Chakladar, A; Wojtukiewicz, L; Wang, TC				Lei, S; Dubeykovskiy, A; Chakladar, A; Wojtukiewicz, L; Wang, TC			The murine gastrin promoter is synergistically activated by transforming growth factor-beta/Smad and Wnt signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-EXTENDED GASTRIN; RECEPTOR GENE-EXPRESSION; BETA-CATENIN; TRANSCRIPTIONAL ACTIVATION; CRYPT FOCI; CANCER; PROGASTRIN; PROLIFERATION; PROTEIN; SMAD4	The transforming growth factor-beta (TGF-beta) and Wnt/wingless pathways play critical roles in the specification of cell fate during development and also contribute to cancer formation and progression. Whereas Wnt signaling is clearly pro-oncogenic, TGF-beta signaling is cell- and context-dependent, manifesting both inhibitory and proliferative effects. The growth factor, gastrin, has previously been shown to be a downstream target of the Wnt pathway and a promoter of gastrointestinal cancer. In this study, we show that the mouse gastrin promoter is regulated synergistically by TGF-beta/Smads and beta-catenin/T-cell factor (TCF). Co-transfection of Smad3/Smad4 and beta-catenin expression constructs synergistically activated mouse gastrin promoter activity 30-60-fold in AGS cells with minimal effect seen with either construct alone. This activation was further potentiated by TGF-beta1 treatment. Mutating either the TCF binding site or the Smad-binding element (SBE) diminished the activation of gastrin expression by Smad3/Smad4 and beta-catenin and led to a loss of gastrin promoter responsiveness to TGF-beta1 treatment. Wnt and TGF-beta regulated endogenous gastrin mRNA levels in AGS cells in a similar fashion, as revealed by small interference RNA studies or overexpression of Smads and TCF4/beta-catenin. Electrophoretic mobility shift assays and DNA affinity precipitation assays showed that the putative SBE and T- cell factor (TCF) sites were able to bind a complex containing Smads and beta-catenin/TCF4. In addition, the synergy between Smads and beta-catenin/ TCF4 was dependent on CREB-binding protein (CBP)/P300, as demonstrated by overexpression of CBP or E1A. Moreover, by using a heterogeneous promoter reporter system, we showed that this complex containing Smads/TCF4/beta-catenin complex was able to up-regulate transcription at isolated SBE or TCF sites. Thus, the Wnt signaling pathway is able to activate some target genes through its actions as a co-activator at non-TCF sites and has the potential to profoundly alter transcriptional responses to TGF-beta signaling.	Columbia Univ Coll Phys & Surg, Dept Med, Div Gastroenterol, New York, NY 10032 USA; Univ Massachusetts, Sch Med, Dept Med, Div Gastroenterol, Worcester, MA 01605 USA	Columbia University; University of Massachusetts System; University of Massachusetts Worcester	Wang, TC (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, Div Gastroenterol, New York, NY 10032 USA.	tcw21@columbia.edu		Wang, Timothy/0000-0001-5730-3019				Aly A, 2001, INT J CANCER, V94, P307, DOI 10.1002/ijc.1483; ASSOIAN RK, 1984, CELL, V36, P35, DOI 10.1016/0092-8674(84)90071-0; BALDWIN GS, 1994, BAILLIERE CLIN ENDOC, V8, P185, DOI 10.1016/S0950-351X(05)80231-9; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dockray GJ, 2001, ANNU REV PHYSIOL, V63, P119, DOI 10.1146/annurev.physiol.63.1.119; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eger A, 2004, ONCOGENE, V23, P2672, DOI 10.1038/sj.onc.1207416; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hori H, 2003, J LAB CLIN MED, V141, P335, DOI 10.1016/S0022-2143(03)00021-0; Hurlstone A, 2002, EMBO J, V21, P2303, DOI 10.1093/emboj/21.10.2303; Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200; Kanamaru Y, 2003, NEPHRON EXP NEPHROL, V95, pE36, DOI 10.1159/000073022; KOCHMAN ML, 1992, BIOCHEM BIOPH RES CO, V189, P1165, DOI 10.1016/0006-291X(92)92326-S; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Koh TJ, 1999, J CLIN INVEST, V103, P1119, DOI 10.1172/JCI4910; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Letamendia A, 2001, J BONE JOINT SURG AM, V83A, pS31; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MATSUSHIMA Y, 1994, JPN J CANCER RES, V85, P819, DOI 10.1111/j.1349-7006.1994.tb02953.x; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; Nakata H, 1998, GASTROENTEROLOGY, V115, P1144, DOI 10.1016/S0016-5085(98)70085-X; Natsume H, 2003, BIOCHEM BIOPH RES CO, V309, P408, DOI 10.1016/j.bbrc.2003.08.019; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Ottewell PD, 2003, GASTROENTEROLOGY, V124, P1348, DOI 10.1016/S0016-5085(03)00288-9; Oving IM, 2002, EUR J CLIN INVEST, V32, P448, DOI 10.1046/j.1365-2362.2002.01004.x; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Siddheshwar RK, 2001, GUT, V48, P47, DOI 10.1136/gut.48.1.47; Singh J, 2002, ONCOGENE, V21, P1812, DOI 10.1038/sj.onc.1205252; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Singh P, 1996, CANCER RES, V56, P4111; Singh P, 2000, AM J PHYSIOL-GASTR L, V278, pG390, DOI 10.1152/ajpgi.2000.278.3.G390; Stepan VM, 1999, MOL MED, V5, P147, DOI 10.1007/BF03402058; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Theil T, 2002, DEVELOPMENT, V129, P3045; Tian YC, 2003, AM J PHYSIOL-RENAL, V285, pF130, DOI 10.1152/ajprenal.00408.2002; Tian YC, 2002, AM J PATHOL, V160, P1619, DOI 10.1016/S0002-9440(10)61109-1; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Watson SA, 2001, CANCER RES, V61, P625; Wojtukiewicz LJ, 2003, GASTROENTEROLOGY, V124, pA105, DOI 10.1016/S0016-5085(03)80516-4; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200	51	74	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42492	42502		10.1074/jbc.M404025200	http://dx.doi.org/10.1074/jbc.M404025200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292219	hybrid			2022-12-27	WOS:000224226400021
J	Lievens, PMJ; Mutinelli, C; Baynes, D; Liboi, E				Lievens, PMJ; Mutinelli, C; Baynes, D; Liboi, E			The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSPLASIA TYPE-II; SKELETAL DYSPLASIA; BONE-DEVELOPMENT; FGFR3; PROTEIN; MICE; ACHONDROPLASIA; PROLIFERATION; PHENOTYPE; MECHANISM	Amino acid substitutions at the Lys-650 codon within the activation loop kinase domain of fibroblast growth factor receptor 3 (FGFR3) result in graded constitutive phosphorylation of the receptor. Accordingly, the Lys-650 mutants are associated with dwarfisms with graded clinical severity. To assess the importance of the phosphorylation level on FGFR3 maturation along the secretory pathway, hemagglutinin A-tagged derivatives were studied. The highly activated SADDAN (severe achondroplasia with developmental delay and acanthosis nigricans) mutant accumulates in its immature and phosphorylated form in the endoplasmic reticulum (ER), which fails to be degraded. Furthermore, the Janus kinase (Jak)/STAT pathway is activated from the ER by direct recruitment of Jak1. Abolishing the autocatalytic property of the mutated FGFR3 by replacing the critical Tyr-718 reestablishes the receptor full maturation and inhibits signaling. Differently, the low activated hypochondroplasia mutant is present as a mature phosphorylated form on the plasma membrane, although with a delayed transition in the ER, and is completely processed. Signaling does not occur in the presence of brefeldin A; instead, STAT1 is activated when protein secretion is blocked with monensin, suggesting that the hypochondroplasia receptor signals at the exit from the ER. Our results suggest that kinase activity affects FGFR3 trafficking and determines the spatial segregation of signaling pathways. Consequently, the defect in down-regulation of the highly activated receptors results in the increased signaling capacity from the intracellular compartments, and this may determine the severity of the diseases.	Univ Verona, Sch Med, Dept Neurol Sci, Div Biochem, I-37134 Verona, Italy	University of Verona	Liboi, E (corresponding author), Univ Verona, Sch Med, Dept Neurol Sci, Div Biochem, I-37134 Verona, Italy.	Elio.liboi@univr.it			Telethon [GP0164Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bellus GA, 2000, AM J HUM GENET, V67, P1411, DOI 10.1086/316892; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Cho JY, 2004, P NATL ACAD SCI USA, V101, P609, DOI 10.1073/pnas.2237184100; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Hart KC, 2001, MOL BIOL CELL, V12, P931, DOI 10.1091/mbc.12.4.931; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Iwata T, 2000, HUM MOL GENET, V9, P1603, DOI 10.1093/hmg/9.11.1603; Iwata T, 2001, HUM MOL GENET, V10, P1255, DOI 10.1093/hmg/10.12.1255; KEEGAN K, 1991, ONCOGENE, V6, P2229; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Lievens PMJ, 2003, J BIOL CHEM, V278, P17344, DOI 10.1074/jbc.M212710200; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Monsonego-Ornan E, 2000, MOL CELL BIOL, V20, P516, DOI 10.1128/MCB.20.2.516-522.2000; ORIT RR, 2001, J CELL SCI, V115, P553; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Webster MK, 1996, MOL CELL BIOL, V16, P4081	28	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43254	43260		10.1074/jbc.M405247200	http://dx.doi.org/10.1074/jbc.M405247200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292251	hybrid			2022-12-27	WOS:000224226400110
J	Antonyak, MA; Miller, AM; Jansen, JM; Boehm, JE; Balkman, CE; Wakshlag, JJ; Page, RL; Cerione, RA				Antonyak, MA; Miller, AM; Jansen, JM; Boehm, JE; Balkman, CE; Wakshlag, JJ; Page, RL; Cerione, RA			Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; RETINOIC ACID; CARCINOMA CELLS; SH-SY5Y CELLS; NIH3T3 CELLS; GTP-BINDING; ERK PATHWAY; DIFFERENTIATION; IDENTIFICATION; STIMULATION	Tissue transglutaminase ( TGase) exhibits both a GTP binding/hydrolytic capability and an enzymatic transamidation activity. Increases in TGase expression and activation often occur in response to stimuli that promote cellular differentiation and apoptosis, yet the signaling mechanisms used by these stimuli to regulate TGase expression and activation and the role of TGase in these cellular processes are not well understood. Retinoic acid ( RA) consistently induces TGase expression and activation, and it was shown recently that RA-induced TGase expression was inhibited in NIH3T3 mouse fibroblasts co-stimulated with epidermal growth factor (EGF). Here we investigate whether EGF also antagonized RA-induced TGase expression in breast cancer cells. We found that EGF stimulation affected TGase expression and activation very differently in these cancer cells. Not only did EGF fail to block RA-induced TGase expression, but also EGF alone was sufficient to potently up-regulate TGase expression and activation in SKBR3 cells, as well as MDAMB468 and BT-20 cells. Inhibiting phosphoinositide 3-kinase activity severely diminished the ability of EGF and RA to increase TGase protein levels, whereas a constitutively active form of phosphoinositide 3-kinase potentiated the induction of TGase expression by EGF in SKBR3 cells. Because EGF is an established antiapoptotic factor, we examined whether the protection afforded by EGF was dependent on its ability to up-regulate TGase activity in SKBR3 and BT-20 cells. Exposure of cells to a TGase inhibitor or expression of a dominant-negative form of TGase potently inhibited EGF-mediated protection from doxorubicin-induced apoptosis. Moreover, expression of exogenous TGase in SKBR3 cells mimicked the survival advantage of EGF, suggesting that TGase activation is necessary and sufficient for the antiapoptotic properties of EGF. These findings indicate for the first time that EGF can induce TGase expression and activation in human breast cancer cells and that this contributes to their oncogenic potential by promoting chemoresistance.	Cornell Univ, VMC, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Clin Sci, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, VMC, Dept Mol Med, Ithaca, NY 14853 USA.	rac1@cornell.edu-email						ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; Antonyak MA, 2003, J BIOL CHEM, V278, P15859, DOI 10.1074/jbc.M300037200; Antonyak MA, 2002, J BIOL CHEM, V277, P14712, DOI 10.1074/jbc.M112259200; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; Birckbichler PJ, 2000, CANCER-AM CANCER SOC, V89, P412, DOI 10.1002/1097-0142(20000715)89:2<412::AID-CNCR29>3.0.CO;2-O; Boehm JE, 2002, J BIOL CHEM, V277, P20127, DOI 10.1074/jbc.C200147200; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; Cerione RA, 2004, TRENDS CELL BIOL, V14, P127, DOI 10.1016/j.tcb.2004.01.008; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; Hebert SS, 2000, J BIOL CHEM, V275, P32482, DOI 10.1074/jbc.M006528200; Hettasch JM, 1996, LAB INVEST, V75, P637; Hilton DA, 1997, NEUROPATH APPL NEURO, V23, P507, DOI 10.1111/j.1365-2990.1997.tb01328.x; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jeon JH, 2002, BIOCHEM BIOPH RES CO, V294, P818, DOI 10.1016/S0006-291X(02)00582-X; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; KOSA K, 1993, BIOCHEM BIOPH RES CO, V196, P1025, DOI 10.1006/bbrc.1993.2354; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; MEHTA K, 1994, INT J CANCER, V58, P400, DOI 10.1002/ijc.2910580316; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Milakovic T, 2004, J BIOL CHEM, V279, P8715, DOI 10.1074/jbc.M308479200; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; Sapi E, 1999, CANCER RES, V59, P5578; Shin DM, 2004, J BIOL CHEM, V279, P15032, DOI 10.1074/jbc.M308734200; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SPORN MB, 1983, CANCER RES, V43, P3034; SUTO N, 1993, J BIOL CHEM, V268, P7469; Tucholski J, 2002, J NEUROCHEM, V81, P780, DOI 10.1046/j.1471-4159.2002.00859.x; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; WONG AJ, 1994, SEMIN ONCOL, V21, P39; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288; Zhang LF, 2002, LAB INVEST, V82, P71, DOI 10.1038/labinvest.3780396; Zhang RL, 2003, GLIA, V42, P194, DOI 10.1002/glia.10222	38	94	97	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41461	41467		10.1074/jbc.M404976200	http://dx.doi.org/10.1074/jbc.M404976200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15272014	hybrid			2022-12-27	WOS:000224075500028
J	Brennan, JP; Wait, R; Begum, S; Bell, JR; Dunn, MJ; Eaton, P				Brennan, JP; Wait, R; Begum, S; Bell, JR; Dunn, MJ; Eaton, P			Detection and mapping of widespread intermolecular protein disulfide formation during cardiac oxidative stress using proteomics with diagonal electrophoresis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; IDENTIFICATION; OXIDANTS; PURIFICATION; MECHANISMS; RADICALS; CELL	Regulation of protein function by reversible cysteine-targeted oxidation can be achieved by multiple mechanisms, such as S-glutathiolation, S-nitrosylation, sulfenic acid, sulfinic acid, and sulfenyl amide formation, as well as intramolecular disulfide bonding of vicinal thiols. Another cysteine oxidation state with regulatory potential involves the formation of intermolecular protein disulfides. We utilized two-dimensional sequential non-reducing/reducing SDS-PAGE (diagonal electrophoresis) to investigate intermolecular protein disulfide formation in adult cardiac myocytes subjected to a series of interventions (hydrogen peroxide, S-nitroso-N-acetylpenicillamine, doxorubicin, simulated ischemia, or metabolic inhibition) that alter the redox status of the cell. More detailed experiments were undertaken with the thiol-specific oxidant diamide (5 mM), a concentration that induces a mild non-injurious oxidative stress. This increase in cellular oxidation potential caused global intermolecular protein disulfide formation in cytosolic, membrane, and myofilament/cytoskeletal compartments. A large number of proteins that undergo these associations were identified using liquid chromatography-mass spectrometry/mass spectrometry. These associations, which involve metabolic and antioxidant enzymes, structural proteins, signaling molecules, and molecular chaperones, were confirmed by assessing "shifts" on non-reducing immunoblots. The observation of widespread protein-protein disulfides indicates that these oxidative associations are likely to be fundamental in how cells respond to redox changes.	Kings Coll London, Rayne Inst, Dept Cardiol, St Thomas Hosp,Cardiovasc Div, London SE1 7EH, England; Univ London Imperial Coll Sci Technol & Med, Kennedy Inst, Div Rheumatol, Fac Med, London W6 8LH, England; Kings Coll London, Inst Psychiat, Dept Neurosci, London SE5 8AF, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Imperial College London; University of Oxford; University of London; King's College London	Eaton, P (corresponding author), Kings Coll London, Rayne Inst, Dept Cardiol, St Thomas Hosp,Cardiovasc Div, London SE1 7EH, England.	philip.eaton@kcl.ac.uk	Eaton, Philip/I-5444-2015	Eaton, Philip/0000-0003-0748-2367				Baines CP, 2003, CIRC RES, V92, P873, DOI 10.1161/01.RES.0000069215.36389.8D; Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; Eaton P, 2003, J AM SOC NEPHROL, V14, pS290, DOI 10.1097/01.ASN.0000078024.50060.C6; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Eaton P, 2002, J BIOL CHEM, V277, P21189, DOI 10.1074/jbc.M200591200; Eaton P, 2001, CIRCULATION, V104, P61; Eaton P, 2001, CARDIOVASC RES, V51, P294, DOI 10.1016/S0008-6363(01)00303-0; EATON P, 2002, ANN NY ACAD SCI, V973, P1; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Gitler C, 1997, ANAL BIOCHEM, V252, P48, DOI 10.1006/abio.1997.2294; Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Humphries KM, 2002, J BIOL CHEM, V277, P43505, DOI 10.1074/jbc.M207088200; James AF, 2001, BIOCHEM BIOPH RES CO, V284, P1048, DOI 10.1006/bbrc.2001.5083; JENO P, 1995, ANAL BIOCHEM, V224, P75, DOI 10.1006/abio.1995.1010; Klein JA, 2003, J CLIN INVEST, V111, P785, DOI 10.1172/JCI200318182; Kono H, 2000, J CLIN INVEST, V106, P867, DOI 10.1172/JCI9020; Kuncewicz T, 2003, MOL CELL PROTEOMICS, V2, P156, DOI 10.1074/mcp.M300003-MCP200; Lind C, 2002, ARCH BIOCHEM BIOPHYS, V406, P229, DOI 10.1016/S0003-9861(02)00468-X; Lopez-Ongil S, 2000, J BIOL CHEM, V275, P26423, DOI 10.1074/jbc.M000767200; Mahadev K, 2001, J BIOL CHEM, V276, P48662, DOI 10.1074/jbc.M105061200; MARCELLA C, 2004, AM J PHYSIOL, V286, pH870; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; *NAT AC SCI, 1996, GUID CAR US LAB AN; Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735; Rhee S G, 2000, Sci STKE, V2000, ppe1; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Sahaf B, 2003, P NATL ACAD SCI USA, V100, P4001, DOI 10.1073/pnas.2628032100; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sies H., 1985, OXIDATIVE STRESS, V1, P73, DOI DOI 10.1016/B978-0-12-642760-8.50008-9; Soberman RJ, 2003, J CLIN INVEST, V111, P571, DOI 10.1172/JCI200318099; SOMMER A, 1974, P NATL ACAD SCI USA, V71, P3946, DOI 10.1073/pnas.71.10.3946; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Wait R, 2002, ELECTROPHORESIS, V23, P3418, DOI 10.1002/1522-2683(200210)23:19&lt;3418::AID-ELPS3418&gt;3.0.CO;2-7; Wait R, 2001, ELECTROPHORESIS, V22, P3043, DOI 10.1002/1522-2683(200108)22:14<3043::AID-ELPS3043>3.0.CO;2-M; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0	43	157	162	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41352	41360		10.1074/jbc.M403827200	http://dx.doi.org/10.1074/jbc.M403827200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292244	hybrid			2022-12-27	WOS:000224075500015
J	Yompakdee, C; Huberman, JA				Yompakdee, C; Huberman, JA			Enforcement of late replication origin firing by clusters of short G-rich DNA sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; RECOGNITION COMPLEX; FISSION YEAST; ALLELIC REPLICATION; ACTIVATION; TRANSFORMATION; LYMPHOCYTES; PLASMIDS; ELEMENTS; DOMAINS	Previous studies in budding yeast suggested that the default firing time of most DNA replication origins is early in S phase and that origins can be forced to fire later by proximity to certain cis-acting sequences. However, these cis-acting sequences were not well defined. We have attempted to characterize cis-acting sequences that affect replication timing in the fission yeast. We identified a stretch of 200 bp that was sufficient to compel nearby origins to fire late. The 200-bp stretch was able to force an origin to fire late whether adjacent to the origin or similar to800 bp away in opposite orientation. The stretch contains a cluster of three close matches to a G-rich, 10-bp late consensus sequence (LCS). The three LCS elements cooperate with each other and with other sequences within the 200-bp stretch to enforce late replication. Although only a few origins that fire in very late S phase have been identified in fission yeast, all of them are located close to a cluster of LCS elements.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Huberman, JA (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.	huberman@buffalo.edu		Yompakdee, Chulee/0000-0003-4690-4809	NCI NIH HHS [CA84302, P30 CA16056, CA95908] Funding Source: Medline; NIGMS NIH HHS [GM49294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095908, P30CA016056, R21CA084302] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aparicio JG, 2004, MOL CELL BIOL, V24, P4769, DOI 10.1128/MCB.24.11.4769-4780.2004; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; DeBeer MAP, 2003, GENE DEV, V17, P1817, DOI 10.1101/gad.1096703; Dotan ZA, 2004, INT J CANCER, V111, P60, DOI 10.1002/ijc.20237; Dotan ZA, 2000, GENE CHROMOSOME CANC, V27, P270, DOI 10.1002/(SICI)1098-2264(200003)27:3<270::AID-GCC7>3.3.CO;2-Z; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; Friedman KL, 1996, GENE DEV, V10, P1595, DOI 10.1101/gad.10.13.1595; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; Gomez M, 2004, P NATL ACAD SCI USA, V101, P6923, DOI 10.1073/pnas.0401854101; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Kim SM, 1998, MOL CELL BIOL, V18, P7294, DOI 10.1128/MCB.18.12.7294; Kim SM, 2003, GENE DEV, V17, P330, DOI 10.1101/gad.1046203; Kim SM, 2001, EMBO J, V20, P6115, DOI 10.1093/emboj/20.21.6115; Kong DC, 2001, MOL CELL BIOL, V21, P8095, DOI 10.1128/MCB.21.23.8095-8103.2001; Lee JK, 2001, P NATL ACAD SCI USA, V98, P13589, DOI 10.1073/pnas.251530398; LIMADEFARIA A, 1968, NATURE, V217, P138, DOI 10.1038/217138a0; Masukata H, 2003, MOLECULAR BIOLOGY OF SCHIZOSACCHAROMYCES POMBE, P73; MAUNDRELL K, 1988, EMBO J, V7, P2203, DOI 10.1002/j.1460-2075.1988.tb03059.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Sanchez JA, 1998, EXP CELL RES, V238, P220, DOI 10.1006/excr.1997.3835; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; SCHVARTZMAN JB, 1990, MOL CELL BIOL, V10, P3078, DOI 10.1128/MCB.10.6.3078; Sharma K, 2001, GENETICS, V159, P35; Stevenson JB, 1999, GENE DEV, V13, P146, DOI 10.1101/gad.13.2.146; Sugawara N, 1989, THESIS HARVARD U CAM; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Vujcic M, 1999, MOL CELL BIOL, V19, P6098; Zappulla DC, 2002, CURR BIOL, V12, P869, DOI 10.1016/S0960-9822(02)00871-0; Zhang JM, 2002, NATURE, V420, P198, DOI 10.1038/nature01150	31	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42337	42344		10.1074/jbc.M407552200	http://dx.doi.org/10.1074/jbc.M407552200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15294892	hybrid			2022-12-27	WOS:000224075500126
J	Gendreau, S; Voswinkel, S; Torres-Salazar, D; Lang, N; Heidtmann, H; Detro-Dassen, S; Schmalzing, G; Hidalgo, P; Fahlke, C				Gendreau, S; Voswinkel, S; Torres-Salazar, D; Lang, N; Heidtmann, H; Detro-Dassen, S; Schmalzing, G; Hidalgo, P; Fahlke, C			A trimeric quaternary structure is conserved in bacterial and human glutamate transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; SEROTONIN TRANSPORTER; CONDUCTING STATES; PLASMA-MEMBRANE; EXPRESSION; OLIGOMERIZATION; RECONSTITUTION; STOICHIOMETRY	Neuronal and glial glutamate transporters play a central role in the termination of synaptic transmission and in extracellular glutamate homeostasis in the mammalian central nervous system. They are known to be multimers; however, the number of subunits forming a functional transporter is controversial. We studied the subunit stoichiometry of two distantly related glutamate transporters, the human glial glutamate transporter hEAAT2 and a bacterial glutamate transporter from Escherichia coli, ecgltP. Using blue native polyacrylamide gel electrophoresis, analysis of concatenated transporters, and chemical cross-linking, we demonstrated that human and prokaryotic glutamate transporters expressed in Xenopus laevis oocytes or in mammalian cells are assembled as trimers composed of three identical subunits. In an inducible mammalian cell line expressing hEAAT2 the glutamate uptake currents correlate to the amount of trimeric transporters. Overexpression and purification of ecgltP in E. coli resulted in a homogenous population of trimeric transporters that were functional after reconstitution in lipid vesicles. Our results indicate that an evolutionarily conserved trimeric quaternary structure represents the sole native and functional state of glutamate transporters.	Rhein Westfal TH Aachen, Dept Physiol, D-52057 Aachen, Germany; Rhein Westfal TH Aachen, Dept Mol Pharmacol, D-52057 Aachen, Germany; Ctr Estudios Cient, Valdivia 509000, Chile	RWTH Aachen University; RWTH Aachen University	Fahlke, C (corresponding author), Rhein Westfal TH Aachen, Dept Physiol, PAuwelsstr 30, D-52057 Aachen, Germany.	chfahlke@physiology.rwth-aachen.de	Hidalgo, Patricia/I-7506-2013; Fahlke, Christoph/G-3635-2013	Hidalgo, Patricia/0000-0002-4162-6590; Fahlke, Christoph/0000-0001-8602-9952; Torres-Salazar, Delany/0000-0002-6789-9810				Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Billups B, 1996, J NEUROSCI, V16, P6722; BLAKELY RD, 1994, J EXP BIOL, V196, P263; Cammack JN, 1996, P NATL ACAD SCI USA, V93, P723, DOI 10.1073/pnas.93.2.723; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; Gaillard I, 1996, BIOCHEMISTRY-US, V35, P6150, DOI 10.1021/bi953005v; Galli A, 1999, J NEUROSCI, V19, P6290; Galli A, 1997, J NEUROSCI, V17, P3401; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Hastrup H, 2003, J BIOL CHEM, V278, P45045, DOI 10.1074/jbc.C300349200; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; Horiuchi M, 2001, P NATL ACAD SCI USA, V98, P1448, DOI 10.1073/pnas.041329498; Ingram SL, 2002, NAT NEUROSCI, V5, P971, DOI 10.1038/nn920; Jess U, 1996, FEBS LETT, V394, P44, DOI 10.1016/0014-5793(96)00916-7; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; Larsson HP, 1996, BIOPHYS J, V70, P733, DOI 10.1016/S0006-3495(96)79613-3; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Li XD, 2001, FEBS LETT, V494, P165, DOI 10.1016/S0014-5793(01)02334-1; Lin F, 1996, BIOPHYS J, V71, P3126, DOI 10.1016/S0006-3495(96)79506-1; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; Melzer N, 2003, J BIOL CHEM, V278, P50112, DOI 10.1074/jbc.M307990200; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Nicke A, 2003, MOL PHARMACOL, V63, P243, DOI 10.1124/mol.63.1.243; Otis TS, 2000, J NEUROSCI, V20, P2749; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Quick MW, 2003, NEURON, V40, P537, DOI 10.1016/S0896-6273(03)00605-6; Ramsey IS, 2002, J BIOL CHEM, V277, P14475, DOI 10.1074/jbc.M110783200; Sadtler S, 2003, J BIOL CHEM, V278, P16782, DOI 10.1074/jbc.M213077200; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Slotboom DJ, 1999, MICROBIOL MOL BIOL R, V63, P293, DOI 10.1128/MMBR.63.2.293-307.1999; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TOLNER B, 1992, J BACTERIOL, V174, P2391, DOI 10.1128/JB.174.7.2391-2393.1992; Trotti D, 1999, NAT NEUROSCI, V2, P427, DOI 10.1038/8091; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Yernool D, 2003, BIOCHEMISTRY-US, V42, P12981, DOI 10.1021/bi030161q; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	45	93	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39505	39512		10.1074/jbc.M408038200	http://dx.doi.org/10.1074/jbc.M408038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15265858	hybrid			2022-12-27	WOS:000223791500040
J	MacCorkle, RA; Tan, TH				MacCorkle, RA; Tan, TH			Inhibition of JNK2 disrupts anaphase and produces aneuploidy in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; JUN NH2-TERMINAL KINASE; SIGNAL-TRANSDUCTION; PROTEIN-KINASES; GAMMA-RADIATION; ACTIVATION; PATHWAY; APOPTOSIS; CYTOKINESIS; CYCLE	The JNK family members JNK1 and JNK2 regulate tumor growth and are essential for transformation by oncogenes such as constitutively activated Ras. The mechanisms downstream of JNK that regulate cell cycle progression and transformation are unclear. Here we show that inhibition of JNK2, but not JNK1, with either a dominant-negative mutant, a pharmacological inhibitor, or RNA interference caused an accumulation of mammalian cells with 4N DNA content. When observed by immunofluorescence, these cells progressed to metaphase without apparent defects in spindle formation or chromosome alignment to the metaphase plate, suggesting that the 4N accumulation is a result of postmetaphase defects. Consistent with this prediction, when JNK activity was suppressed, we observed defects in central spindle formation and chromosome segregation during anaphase. In contrast, cyclin-dependent kinase 1 activity, cyclin B1 protein, and Polo-like kinase 1 protein turnover remained intact when JNK was inhibited. In addition, continued inhibition of JNK activity did not block reentry into subsequent cell cycles but instead resulted in polyploidy. This evidence suggests that JNK2 functions in maintaining the genomic stability of mammalian cells by signaling that is independent of cyclin-dependent kinase 1/cyclin B1 down-regulation.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine	Tan, TH (corresponding author), Baylor Coll Med, Dept Immunol, 1 Baylor Plaza M929, Houston, TX 77030 USA.	ttan@bcm.tmc.edu	Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010; Hall, Rebecca/L-3432-2019; Hall, Rebecca/G-4929-2012	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Hall, Rebecca/0000-0002-5460-0090; 	NATIONAL CANCER INSTITUTE [R01CA087076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007495, R01AI042532] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA87076] Funding Source: Medline; NIAID NIH HHS [R01-AI42532, T32-AI07495] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Campbell KS, 1998, J IMMUNOL, V161, P1728; Chen NY, 2001, CANCER RES, V61, P3908; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Cimini D, 1998, CHROMOSOMA, V107, P479, DOI 10.1007/s004120050332; Dai W, 2003, FRONT BIOSCI-LANDMRK, V8, pD1128, DOI 10.2741/1129; Echard A, 2003, CURR BIOL, V13, P373, DOI 10.1016/S0960-9822(03)00127-1; Fan MY, 2000, CANCER RES, V60, P6403; HIME G, 1992, DEVELOPMENT, V114, P165; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Hollenbeck PJ, 2001, J CELL BIOL, V152, pF25, DOI 10.1083/jcb.152.5.F25; Hreniuk D, 2001, MOL PHARMACOL, V59, P867, DOI 10.1124/mol.59.4.867; Kaltschmidt JA, 2002, NAT CELL BIOL, V4, P937, DOI 10.1038/ncb882; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; LEHNER CF, 1992, J CELL SCI, V103, P1021; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; MacCorkle-Chosnek RA, 2001, BIOCHEM BIOPH RES CO, V289, P173, DOI 10.1006/bbrc.2001.5948; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Papachristou DJ, 2003, BONE, V32, P364, DOI 10.1016/S8756-3282(03)00026-7; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; She QB, 2002, CANCER RES, V62, P1343; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Tchou WW, 1999, ONCOGENE, V18, P6974, DOI 10.1038/sj.onc.1203195; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; Tsuiki H, 2003, CANCER RES, V63, P250; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Weston CR, 2002, SCIENCE, V296, P2345, DOI 10.1126/science.1073344; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yasunaga M, 1996, J CELL BIOL, V132, P91, DOI 10.1083/jcb.132.1.91	43	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40112	40121		10.1074/jbc.M405481200	http://dx.doi.org/10.1074/jbc.M405481200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262983	hybrid			2022-12-27	WOS:000223791500109
J	Salim, A; Nacamuli, RP; Morgan, EF; Giaccia, AJ; Longaker, MT				Salim, A; Nacamuli, RP; Morgan, EF; Giaccia, AJ; Longaker, MT			Transient changes in oxygen tension inhibit osteogenic differentiation and Runx2 expression in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; IN-VITRO; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; BONE-FORMATION; FACTOR-BETA; CELL-LINE; HYPOXIA; CBFA1; ANGIOGENESIS	Vascular disruption following bony injury results in a hypoxic gradient within the wound microenvironment. Nevertheless, the effects of low oxygen tension on osteogenic precursors remain to be fully elucidated. In the present study, we investigated in vitro osteoblast and mesenchymal stem cell differentiation following exposure to 21% O-2 ( ambient oxygen), 2% O-2 (hypoxia), and < 0.02% O-2 (anoxia). Hypoxia had little effect on osteogenic differentiation. In contrast, short-term anoxic treatment of primary osteoblasts and mesenchymal precursors inhibited in vitro bone nodule formation and extracellular calcium deposition. Cell viability assays revealed that this effect was not caused by immediate or delayed cell death. Microarray profiling implicated down-regulation of the key osteogenic transcription factor Runx2 as a potential mechanism for the anoxic inhibition of differentiation. Subsequent analysis revealed not only a short-term differential regulation of Runx2 and its targets by anoxia and hypoxia, but a long-term inhibition of Runx2 transcriptional and protein levels after only 12 - 24 h of anoxic insult. Furthermore, we present evidence that Runx2 inhibition may, at least in part, be because of anoxic repression of BMP2, and that restoring Runx2 levels during anoxia by pretreatment with recombinant BMP2 rescued the anoxic inhibition of differentiation. Taken together, our findings indicate that brief exposure to anoxia ( but not 2% hypoxia) downregulated BMP2 and Runx2 expression, thus inhibiting critical steps in the osteogenic differentiation of pluripotent mesenchymal precursors and committed osteoblasts.	Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA	Stanford University; Stanford University	Longaker, MT (corresponding author), Stanford Univ, Sch Med, Dept Surg, 257 Campus Dr, Stanford, CA 94305 USA.	Longaker@stanford.edu	Morgan, Elise F/L-1706-2013		NCI NIH HHS [R01 CA88480] Funding Source: Medline; NIDCR NIH HHS [R01 DE14526, R01 DE13028] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013028, R01DE014526] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Blaschke F, 2002, BIOCHEM BIOPH RES CO, V296, P890, DOI 10.1016/S0006-291X(02)02033-8; BRIGHTON CT, 1972, J BONE JOINT SURG AM, VA 54, P323, DOI 10.2106/00004623-197254020-00010; BRIGHTON CT, 1969, J BONE JOINT SURG AM, VA 51, P1383, DOI 10.2106/00004623-196951070-00018; De Jong DS, 2002, J BONE MINER RES, V17, P2119, DOI 10.1359/jbmr.2002.17.12.2119; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; GERRITSEN ME, 1993, FASEB J, V7, P523, DOI 10.1096/fasebj.7.6.8472891; Glowacki J, 1998, CLIN ORTHOP RELAT R, pS82, DOI 10.1097/00003086-199810001-00010; Gordillo GM, 2003, AM J SURG, V186, P259, DOI 10.1016/S0002-9610(03)00211-3; GRUNDNES O, 1992, ACTA ORTHOP SCAND, V63, P487, DOI 10.3109/17453679209154720; HEPPENSTALL RB, 1975, CLIN ORTHOP RELAT R, P357; HEPPENSTALL RB, 1976, J BONE JOINT SURG AM, V58, P1153, DOI 10.2106/00004623-197658080-00022; Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731; Karsenty G, 1999, BONE, V25, P107, DOI 10.1016/S8756-3282(99)00111-8; Kim W, 2003, FASEB J, V17, P1937, DOI 10.1096/fj.02-1209fje; KNIGHTON DR, 1981, SURGERY, V90, P262; KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Kubota M, 1989, Kokubyo Gakkai Zasshi, V56, P473; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; Liu F, 1997, EXP CELL RES, V232, P97, DOI 10.1006/excr.1997.3501; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151; MICHIELS C, 1994, EXP CELL RES, V213, P43, DOI 10.1006/excr.1994.1171; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; Nikitenko LL, 2003, FASEB J, V17, P1499, DOI 10.1096/fj.02-0993fje; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; OWEN ME, 1987, J CELL SCI, V87, P731; Park JH, 2002, MOL CELL ENDOCRINOL, V192, P197, DOI 10.1016/S0303-7207(02)00036-9; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; QUARLES LD, 1992, J BONE MINER RES, V7, P683; Saadeh PB, 2000, ENDOCRINOLOGY, V141, P2075, DOI 10.1210/en.141.6.2075; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Seymour IJ, 1999, MICROBIOL-SGM, V145, P231, DOI 10.1099/13500872-145-1-231; Sherlock G, 2001, NUCLEIC ACIDS RES, V29, P152, DOI 10.1093/nar/29.1.152; Shiffman D, 2000, J BIOL CHEM, V275, P37324, DOI 10.1074/jbc.M004732200; Steinbrech DS, 2000, ANN PLAS SURG, V44, P529, DOI 10.1097/00000637-200044050-00012; Steinbrech DS, 2000, AM J PHYSIOL-CELL PH, V278, pC853, DOI 10.1152/ajpcell.2000.278.4.C853; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TUNCAY OC, 1994, AM J ORTHOD DENTOFAC, V105, P457, DOI 10.1016/S0889-5406(94)70006-0; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	50	170	188	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40007	40016		10.1074/jbc.M403715200	http://dx.doi.org/10.1074/jbc.M403715200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15263007	hybrid			2022-12-27	WOS:000223791500098
J	Beriault, V; Clement, JF; Levesque, K; LeBel, C; Yong, X; Chabot, B; Cohen, EA; Cochrane, AW; Rigby, WFC; Mouland, AJ				Beriault, V; Clement, JF; Levesque, K; LeBel, C; Yong, X; Chabot, B; Cohen, EA; Cochrane, AW; Rigby, WFC; Mouland, AJ			A late role for the association of hnRNP A2 with the HIV-1 hnRNP A2 response elements in genomic RNA, Gag, and Vpr localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN MESSENGER-RNA; NUCLEAR EXPORT; BINDING PROTEIN; POSTTRANSCRIPTIONAL REGULATION; CYTOPLASMIC TRANSPORT; PLASMA-MEMBRANE; MATRIX PROTEIN; HIGH-AFFINITY; TYPE-1 HIV-1	Two cis-acting RNA trafficking sequences (heterogenous ribonucleoprotein A2 (hnRNP A2)-response elements 1 and 2 or A2RE-1 and A2RE-2) have been identified in HIV-1 vpr and gag mRNAs and were found to confer cytoplasmic RNA trafficking in a murine oligodendrocyte assay. Their activities were assessed during HIV-1 proviral gene expression in COS7 cells. Single point mutations that were shown to severely block RNA trafficking were introduced into each of the A2REs. In both cases, this resulted in a marked decrease in hnRNP A2 binding to HIV-1 genomic RNA in whole cell extracts and hnRNP A2-containing polysomes. This also resulted in an accumulation of HIV-1 genomic RNA in the nucleus and a significant reduction in genomic RNA encapsidation levels. Immunofluorescence analyses revealed altered expression patterns for pr55(Gag) and particularly that for Vpr. Vpr localization became almost completely nuclear and this was reflected in a significant reduction in virion-associated Vpr levels. These effects coincided with late steps of the viral replication cycle and were not seen at early time points post-transfection. Transcription, splicing, steady state RNA levels, and pr55Gag processing were not affected. On the other hand, viral replication was markedly compromised in A2RE-2 mutant viruses and this correlated with lowered genomic RNA encapsidation levels. These data reveal new insights into the virus-host interactions between hnRNP A2 and the HIV-1 A2REs and their influence on the patterns of HIV-1 gene expression and viral assembly.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, HIV1 RNA Trafficking Lab, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H3A 2B4, Canada; Univ Sherbrooke, Dept Microbiol & Infectiol, Sherbrooke, PQ J1H 5N4, Canada; Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3G 1J4, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Dartmouth Coll Sch Med, Dept Med, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Microbiol, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Immunol, Lebanon, NH 03756 USA	Lady Davis Institute; McGill University; McGill University; McGill University; University of Sherbrooke; Universite de Montreal; University of Toronto; Dartmouth College; Dartmouth College; Dartmouth College	Mouland, AJ (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, HIV1 RNA Trafficking Lab, Room 323A,3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	andrew.mouland@mcgill.ca	Chabot, Benoit/A-8943-2008	Chabot, Benoit/0000-0003-0994-0042				Abbink TEM, 2003, J BIOL CHEM, V278, P11601, DOI 10.1074/jbc.M210291200; Afonina E, 1997, J BIOL CHEM, V272, P2307, DOI 10.1074/jbc.272.4.2307; Basyuk E, 2003, DEV CELL, V5, P161, DOI 10.1016/S1534-5807(03)00188-6; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; Bilodeau PS, 1999, J VIROL, V73, P9764, DOI 10.1128/JVI.73.12.9764-9772.1999; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Blanchette M, 1997, RNA, V3, P405; Bounou S, 2002, J VIROL, V76, P1004, DOI 10.1128/JVI.76.3.1004-1014.2002; Brooks S A, 2000, Nucleic Acids Res, V28, pE49, DOI 10.1093/nar/28.10.e49; Brumwell C, 2002, EXP CELL RES, V279, P310, DOI 10.1006/excr.2002.5604; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Carson JH, 1997, CELL MOTIL CYTOSKEL, V38, P318, DOI 10.1002/(SICI)1097-0169(1997)38:4<318::AID-CM2>3.0.CO;2-#; Carson JH, 1998, CURR OPIN NEUROBIOL, V8, P607, DOI 10.1016/S0959-4388(98)80088-3; Carson JH, 2001, CURR OPIN NEUROBIOL, V11, P558, DOI 10.1016/S0959-4388(00)00249-X; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Chartrand P, 2002, MOL CELL, V10, P1319, DOI 10.1016/S1097-2765(02)00694-9; Chatel-Chaix L, 2004, MOL CELL BIOL, V24, P2637, DOI 10.1128/MCB.24.7.2637-2648.2004; Chen CYA, 2004, RNA, V10, P669, DOI 10.1261/rna.5269304; Clever JL, 1997, J VIROL, V71, P3407, DOI 10.1128/JVI.71.5.3407-3414.1997; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dimaano C, 2004, MOL CELL BIOL, V24, P3069, DOI 10.1128/MCB.24.8.3069-3076.2004; Dodon MD, 2002, J BIOL CHEM, V277, P18744, DOI 10.1074/jbc.M109087200; Dupont S, 1999, NATURE, V402, P681, DOI 10.1038/45272; Fischer U, 1999, NUCLEIC ACIDS RES, V27, P4128, DOI 10.1093/nar/27.21.4128; Forget J, 1998, J MOL BIOL, V284, P915, DOI 10.1006/jmbi.1998.2206; Forshey BM, 2002, J VIROL, V76, P5667, DOI 10.1128/JVI.76.11.5667-5677.2002; Gu W, 2002, J CELL BIOL, V156, P41, DOI 10.1083/jcb.200105133; Gupta K, 2000, J VIROL, V74, P11811, DOI 10.1128/JVI.74.24.11811-11824.2000; Hay DC, 2001, MOL CELL BIOL, V21, P3482, DOI 10.1128/MCB.21.10.3482-3490.2001; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; Hofmann W, 2001, J CELL BIOL, V152, P895, DOI 10.1083/jcb.152.5.895; Hrimech M, 1999, J VIROL, V73, P4101, DOI 10.1128/JVI.73.5.4101-4109.1999; Huang YQ, 1999, EMBO J, V18, P1642, DOI 10.1093/emboj/18.6.1642; HUTCHISON S, 2002, J BIOL CHEM, V11, P11; Jenkins Y, 2001, J VIROL, V75, P8348, DOI 10.1128/JVI.75.17.8348-8352.2001; Kamma H, 1999, EXP CELL RES, V246, P399, DOI 10.1006/excr.1998.4323; Kashima T, 2003, NAT GENET, V34, P460, DOI 10.1038/ng1207; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Kjems J, 2000, Adv Pharmacol, V48, P251; Knowles RB, 1996, J NEUROSCI, V16, P7812; Kondo E, 1996, J VIROL, V70, P159, DOI 10.1128/JVI.70.1.159-164.1996; Kwon S, 1999, J CELL BIOL, V147, P247, DOI 10.1083/jcb.147.2.247; Lall S, 1999, CELL, V98, P171, DOI 10.1016/S0092-8674(00)81012-0; Larocque D, 2002, NEURON, V36, P815, DOI 10.1016/S0896-6273(02)01055-3; LAVALLEE C, 1994, J VIROL, V68, P1926; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; Long RM, 2001, J CELL BIOL, V153, P307, DOI 10.1083/jcb.153.2.307; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; Ma ASW, 2002, J BIOL CHEM, V277, P18010, DOI 10.1074/jbc.M200050200; MALIM MH, 1992, J EXP MED, V176, P1197, DOI 10.1084/jem.176.4.1197; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Mandelkow E, 2002, TRENDS CELL BIOL, V12, P585, DOI 10.1016/S0962-8924(02)02400-5; Mazroui R, 2002, HUM MOL GENET, V11, P3007, DOI 10.1093/hmg/11.24.3007; McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150; Mouland AJ, 2000, J VIROL, V74, P5441, DOI 10.1128/JVI.74.12.5441-5451.2000; Mouland AJ, 2002, VIROLOGY, V292, P321, DOI 10.1006/viro.2001.1261; Mouland AJ, 2001, MOL CELL BIOL, V21, P2133, DOI 10.1128/MCB.21.6.2133-2143.2001; MOULAND AJ, 2003, CURR GENOMICS, V4, P196; Najera I, 1999, J MOL BIOL, V285, P1951, DOI 10.1006/jmbi.1998.2473; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; Nydegger S, 2003, TRAFFIC, V4, P902, DOI 10.1046/j.1600-0854.2003.00145.x; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; Ono A, 2004, J VIROL, V78, P1552, DOI 10.1128/JVI.78.3.1552-1563.2004; Paillart JC, 2002, J BIOL CHEM, V277, P5995, DOI 10.1074/jbc.M108972200; Pioli PA, 2001, J BIOL CHEM, V276, P40346, DOI 10.1074/jbc.M105391200; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; Purohit P, 2001, RNA, V7, P576, DOI 10.1017/S1355838201002023; Reddy B, 1999, AIDS RES HUM RETROV, V15, P273, DOI 10.1089/088922299311457; Reddy TR, 2000, ONCOGENE, V19, P3570, DOI 10.1038/sj.onc.1203676; RICE AP, 1990, J VIROL, V64, P6018, DOI 10.1128/JVI.64.12.6018-6026.1990; Russell RS, 2003, J VIROL, V77, P84, DOI 10.1128/JVI.77.1.84-96.2003; SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284; Saksena N. K., 1996, Annals Academy of Medicine Singapore, V25, P848; Sanchez-Velar N, 2004, GENE DEV, V18, P23, DOI 10.1101/gad.1149704; Schneider R, 1997, J VIROL, V71, P4892, DOI 10.1128/JVI.71.7.4892-4903.1997; Shan JG, 2000, J BIOL CHEM, V275, P38286, DOI 10.1074/jbc.M007642200; Sherman MP, 2003, J VIROL, V77, P7582, DOI 10.1128/JVI.77.13.7582-7589.2003; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Si ZH, 1997, NUCLEIC ACIDS RES, V25, P861, DOI 10.1093/nar/25.4.861; Singer RH, 1996, MOL MED TODAY, V2, P65, DOI 10.1016/1357-4310(96)88740-5; Soros VB, 2001, J VIROL, V75, P8203, DOI 10.1128/JVI.75.17.8203-8215.2001; Suh D, 2003, VIROLOGY, V310, P85, DOI 10.1016/S0042-6822(03)00073-4; Tang Y, 1999, J VIROL, V73, P10508, DOI 10.1128/JVI.73.12.10508-10513.1999; Tekotte H, 2002, TRENDS GENET, V18, P636, DOI 10.1016/S0168-9525(02)02819-6; Watts NR, 2000, J CELL BIOL, V150, P349, DOI 10.1083/jcb.150.2.349; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xu Yuan, 1996, Journal of Biomedical Science, V3, P82, DOI 10.1007/BF02255535; Yao XJ, 1998, J VIROL, V72, P4686, DOI 10.1128/JVI.72.6.4686-4693.1998; YAO XJ, 1995, J VIROL, V69, P7032, DOI 10.1128/JVI.69.11.7032-7044.1995; Zahler AM, 2004, J BIOL CHEM, V279, P10077, DOI 10.1074/jbc.M312743200; Zolotukhin AS, 2003, MOL CELL BIOL, V23, P6618, DOI 10.1128/MCB.23.18.6618-6630.2003	102	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44141	44153		10.1074/jbc.M404691200	http://dx.doi.org/10.1074/jbc.M404691200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15294897	hybrid			2022-12-27	WOS:000224383100094
J	Tiwari, S; Kishan, KVR; Chakrabarti, T; Chakraborti, PK				Tiwari, S; Kishan, KVR; Chakrabarti, T; Chakraborti, PK			Amino acid residues involved in autophosphorylation and phosphotransfer activities are distinct in nucleoside diphosphate kinase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; TRIPHOSPHATE SYNTHESIS; ESCHERICHIA-COLI; ACTIVE-SITE; MYXOCOCCUS-XANTHUS; PROTEINS; CELL; MECHANISM; SEQUENCE; BINDING	Nucleoside diphosphate kinase (NdK) is a ubiquitous enzyme in both prokaryotes and eukaryotes and is primarily involved in the maintenance of cellular nucleotide pools. We have cloned ndk from Mycobacterium tuberculosis strain H37Ra and expressed it in Escherichia coli as a fusion protein with glutathione S-transferase. The purified protein, following thrombin cleavage and gel permeation chromatography, was found to be hexameric with a monomeric unit molecular mass of similar to 16.5 kDa. The protein exhibited nucleotide binding, divalent cation-dependent autophosphorylation, and phosphate transfer ability from nucleoside triphosphate to nucleoside diphosphate. Although UDP inhibited the catalytic activity of the recombinant protein, the classic inhibitors, like cromoglycate, 5'-adenosine 3'-phosphate, and adenosine 3'-phosphate 5'-phosphosulfate, had no effect on the activity. Among three histidine residues in the protein, His-117 was found to be essential for autophosphorylation. However, in subsequent phosphate transfer, we observed that His-53 had a significant contribution. Consistent with this observation, substitution of His-53 with either Ala or Gln affected the ability of the recombinant protein to complement NdK function in Pseudomonas aeruginosa. Furthermore, mutational analysis established critical roles for Tyr-50 and Arg-86 of the M. tuberculosis protein in maintaining phosphotransfer ability.	Inst Microbial Technol, Chandigarh 160036, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Chakraborti, PK (corresponding author), Inst Microbial Technol, Sector 39A, Chandigarh 160036, India.	pradip@imtech.res.in						Andersen Ase Bengard, 1994, P307; ANOSTARIO M, 1990, ANAL BIOCHEM, V190, P60, DOI 10.1016/0003-2697(90)90133-T; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chaba R, 2002, EUR J BIOCHEM, V269, P1078, DOI 10.1046/j.1432-1033.2002.02778.x; Chakrabarty AM, 1998, MOL MICROBIOL, V28, P875, DOI 10.1046/j.1365-2958.1998.00846.x; Chen YX, 2002, PROTEINS, V47, P556, DOI 10.1002/prot.10113; Chopra P, 2003, EUR J BIOCHEM, V270, P625, DOI 10.1046/j.1432-1033.2003.03402.x; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Couch R, 2002, BIOTECHNIQUES, V32, P1230, DOI 10.2144/02326bm03; DIVER JM, 1990, ANAL BIOCHEM, V189, P75, DOI 10.1016/0003-2697(90)90046-C; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Gounaris K, 2001, INFECT IMMUN, V69, P3658, DOI 10.1128/IAI.69.6.3658-3662.2001; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; Hartsough MT, 2000, J BIOENERG BIOMEMBR, V32, P301, DOI 10.1023/A:1005597231776; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Janin J, 2000, J BIOENERG BIOMEMBR, V32, P215, DOI 10.1023/A:1005528811303; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIMURA N, 1988, J BIOL CHEM, V263, P4647; Kowluru A, 2002, BIOCHEM PHARMACOL, V63, P2091, DOI 10.1016/S0006-2952(02)01025-0; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LASCU I, 1993, ANAL BIOCHEM, V209, P6, DOI 10.1006/abio.1993.1075; Lascu I, 2000, J BIOENERG BIOMEMBR, V32, P237, DOI 10.1023/A:1005532912212; Lascu I, 2000, J BIOENERG BIOMEMBR, V32, P227, DOI 10.1023/A:1005580828141; Lefevre P, 1997, J BACTERIOL, V179, P2900, DOI 10.1128/jb.179.9.2900-2906.1997; Lu Q, 1996, J BIOL CHEM, V271, P32886, DOI 10.1074/jbc.271.51.32886; Min K, 2002, PROTEINS, V46, P340, DOI 10.1002/prot.10038; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2707; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; OKA A, 1981, J MOL BIOL, V147, P217, DOI 10.1016/0022-2836(81)90438-1; Postel EH, 2003, P NATL ACAD SCI USA, V100, P13247, DOI 10.1073/pnas.2333230100; Postel EH, 2002, BIOCHEMISTRY-US, V41, P6330, DOI 10.1021/bi025606+; Postel EH, 2000, J BIOENERG BIOMEMBR, V32, P277, DOI 10.1023/A:1005541114029; Postel EH, 2000, P NATL ACAD SCI USA, V97, P14194, DOI 10.1073/pnas.97.26.14194; Punj V, 2000, INFECT IMMUN, V68, P4930, DOI 10.1128/IAI.68.9.4930-4937.2000; Sambrook J., 2001, MOL CLONING LAB MANU; Sarin J, 2001, J BIOL CHEM, V276, P44590, DOI 10.1074/jbc.M105401200; Schneider B, 2001, EUR J BIOCHEM, V268, P1964, DOI 10.1046/j.1432-1327.2001.02070.x; Schneider B, 1998, J BIOL CHEM, V273, P28773, DOI 10.1074/jbc.273.44.28773; Shankar S, 1996, J BACTERIOL, V178, P1777, DOI 10.1128/jb.178.7.1777-1781.1996; Shankar S, 1997, MOL MICROBIOL, V24, P477, DOI 10.1046/j.1365-2958.1997.3491724.x; Sundin GW, 1996, MOL MICROBIOL, V20, P965, DOI 10.1111/j.1365-2958.1996.tb02538.x; TEPPER AD, 1994, J BIOL CHEM, V269, P32175; Zaborina O, 1999, MOL MICROBIOL, V31, P1333, DOI 10.1046/j.1365-2958.1999.01240.x	51	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43595	43603		10.1074/jbc.M401704200	http://dx.doi.org/10.1074/jbc.M401704200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15302878	hybrid			2022-12-27	WOS:000224383100032
J	Dahabada, HJL; Colin, C; Degaki, TL; de Sousa, ACV; Vieira, MNN; Sebollela, A; Martinez, AMB; Bloch, C; Ferreira, ST; Sogayar, MC				Dahabada, HJL; Colin, C; Degaki, TL; de Sousa, ACV; Vieira, MNN; Sebollela, A; Martinez, AMB; Bloch, C; Ferreira, ST; Sogayar, MC			Amyloidogenicity and cytotoxicity of recombinant mature human islet amyloid polypeptide (rhIAPP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 DIABETES-MELLITUS; IN-VITRO; GLUTATHIONE-REDUCTASE; EXPRESSION SYSTEM; ESCHERICHIA-COLI; AMYLIN; AGGREGATION; PEPTIDE; PROTEINS; TOXICITY	Pancreatic amyloid plaques formed by the pancreatic islet amyloid polypeptide ( IAPP) are present in more than 95% of type II diabetes mellitus patients, and their abundance correlates with the severity of the disease. IAPP is currently considered the most amyloidogenic peptide known, but the molecular bases of its aggregation are still incompletely understood. Detailed characterization of the mechanisms of amyloid formation requires large quantities of pure material. Thus, availability of recombinant IAPP in sufficient amounts for such studies constitutes an important step toward elucidation of the mechanisms of amyloidogenicity. Here, we report, for the first time, the successful expression, purification and characterization of the amyloidogenicity and cytotoxicity of recombinant human mature IAPP. This approach is likely to be useful for the production of other amyloidogenic peptides or proteins that are difficult to obtain by chemical synthesis.	Univ Sao Paulo, Inst Quim, BR-05513970 Sao Paulo, Brazil; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Cenargen EMBRAPA, Lab Espectrometria Massa, BR-70770900 Brasilia, DF, Brazil; LNLS, Lab Nacl Luz Sincrotron, BR-13084971 Campinas, SP, Brazil; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Histol & Embriol, BR-21941590 Rio De Janeiro, Brazil	Universidade de Sao Paulo; Universidade Federal do Rio de Janeiro; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Laboratorio Nacional de Luz Sincrotron (LNLS); Universidade Federal do Rio de Janeiro	Sogayar, MC (corresponding author), Univ Sao Paulo, Inst Quim, BR-05513970 Sao Paulo, Brazil.	mcsoga@iq.usp.br	Bloch, Carlos/S-8375-2019; Ferreira, Sergio/AAZ-1576-2020; Sebollela, Adriano/O-4385-2014; Martinez, Ana/C-6318-2014; Sogayar, Mari C/B-3980-2017	Ferreira, Sergio/0000-0001-7160-9866; Sebollela, Adriano/0000-0002-7444-9156; Sogayar, Mari C/0000-0003-4805-4609; , Dahabada/0000-0002-5411-9264; Bloch Jr, Carlos/0000-0003-2799-6883; Vieira, Marcelo/0000-0003-2178-9218				Badman MK, 1996, FEBS LETT, V378, P227, DOI 10.1016/0014-5793(95)01460-8; BURDICK D, 1992, J BIOL CHEM, V267, P546; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cooper G J, 1989, Prog Growth Factor Res, V1, P99, DOI 10.1016/0955-2235(89)90004-5; COOPER GJS, 1988, P NATL ACAD SCI USA, V85, P7763, DOI 10.1073/pnas.85.20.7763; DOBELI H, 1995, BIO-TECHNOL, V13, P988, DOI 10.1038/nbt0995-988; EDWARDS BJA, 1992, LIFE SCI, V51, P1899, DOI 10.1016/0024-3205(92)90106-Y; Fezoui Y, 2002, J BIOL CHEM, V277, P36948, DOI 10.1074/jbc.M204168200; Goldsbury C, 2000, J STRUCT BIOL, V130, P352, DOI 10.1006/jsbi.2000.4268; Goldsbury CS, 1997, J STRUCT BIOL, V119, P17, DOI 10.1006/jsbi.1997.3858; HAYDEN MR, 2001, J PANCREAS, V2, P129; Higham CE, 2000, EUR J BIOCHEM, V267, P4998, DOI 10.1046/j.1432-1327.2000.01548.x; Hollenbach B, 1999, PHILOS T ROY SOC B, V354, P991, DOI 10.1098/rstb.1999.0450; Janciauskiene S, 1998, BIOCHEM BIOPH RES CO, V251, P888, DOI 10.1006/bbrc.1998.9574; Janson J, 1999, DIABETES, V48, P491, DOI 10.2337/diabetes.48.3.491; Kapurniotu A, 2001, BIOPOLYMERS, V60, P438, DOI 10.1002/1097-0282(2001)60:6<438::AID-BIP10182>3.0.CO;2-A; Kapurniotu A, 2002, J MOL BIOL, V315, P339, DOI 10.1006/jmbi.2001.5244; Kayed R, 1999, J MOL BIOL, V287, P781, DOI 10.1006/jmbi.1999.2646; Krampert M, 2000, CHEM BIOL, V7, P855, DOI 10.1016/S1074-5521(00)00034-X; KULIOPULOS A, 1994, J AM CHEM SOC, V116, P4599, DOI 10.1021/ja00090a008; LaVallie Edward R, 2003, Methods Mol Biol, V205, P119; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LaVallie ER, 2000, METHOD ENZYMOL, V326, P322; LEVINE H, 1995, AMYLOID, V2, P1, DOI 10.3109/13506129509031881; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; Louzada PR, 2003, BIOPHYS J, V85, P3255, DOI 10.1016/S0006-3495(03)74743-2; Mazor Y, 2002, J MOL BIOL, V322, P1013, DOI 10.1016/S0022-2836(02)00887-2; Naiki H, 1996, LAB INVEST, V74, P374; Nilsson MR, 2001, ANAL BIOCHEM, V288, P76, DOI 10.1006/abio.2000.4887; Padrick SB, 2002, BIOCHEMISTRY-US, V41, P4694, DOI 10.1021/bi0160462; Ramos OHP, 2003, PROTEIN EXPRES PURIF, V28, P34, DOI 10.1016/S1046-5928(02)00644-7; RENDON JL, 1995, ARCH BIOCHEM BIOPHYS, V318, P264, DOI 10.1006/abbi.1995.1229; Rhoades E, 2000, BBA-PROTEIN STRUCT M, V1476, P230, DOI 10.1016/S0167-4838(99)00248-4; ROBERTS AN, 1989, P NATL ACAD SCI USA, V86, P9662, DOI 10.1073/pnas.86.24.9662; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Soeller WC, 1998, DIABETES, V47, P743, DOI 10.2337/diabetes.47.5.743; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Ueda EKM, 2003, J CHROMATOGR A, V988, P1, DOI 10.1016/S0021-9673(02)02057-5; Wang J, 2001, DIABETES, V50, P534, DOI 10.2337/diabetes.50.3.534; WESTERMARK P, 1987, P NATL ACAD SCI USA, V84, P3881, DOI 10.1073/pnas.84.11.3881; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40	44	13	14	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42803	42810		10.1074/jbc.M406108200	http://dx.doi.org/10.1074/jbc.M406108200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292167	hybrid			2022-12-27	WOS:000224226400056
J	Jin, L; Pluskey, S; Petrella, EC; Cantin, SM; Gora, JC; Rynkiewicz, MJ; Pandey, P; Strickler, JE; Babine, RE; Weaver, DT; Seidl, KJ				Jin, L; Pluskey, S; Petrella, EC; Cantin, SM; Gora, JC; Rynkiewicz, MJ; Pandey, P; Strickler, JE; Babine, RE; Weaver, DT; Seidl, KJ			The three-dimensional structure of the ZAP-70 kinase domain in complex with staurosporine - Implications for the design of selective inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CELL ANTIGEN RECEPTOR; CHRONIC LYMPHOCYTIC-LEUKEMIA; SEVERE COMBINED IMMUNODEFICIENCY; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; T-CELLS; PHOSPHORYLATION; ACTIVATION	The ZAP-70 tyrosine kinase plays a critical role in T cell activation and the immune response and therefore is a logical target for immunomodulatory therapies. Although the crystal structure of the tandem Src homology-2 domains of human ZAP-70 in complex with a peptide derived from the zeta subunit of the T cell receptor has been reported ( Hatada, M. H., Lu, X., Laird, E. R., Green, J., Morgenstern, J. P., Lou, M., Marr, C. S., Phillips, T. B., Ram, M. K., Theriault, K., Zoller, M. J., and Karas, J. L. ( 1995) Nature 377, 32 - 38), the structure of the kinase domain has been elusive to date. We crystallized and determined the three-dimensional structure of the catalytic subunit of ZAP-70 as a complex with staurosporine to 2.3 Angstrom resolution, utilizing an active kinase domain containing residues 327 - 606 identified by systematic N- and C-terminal truncations. The crystal structure shows that this ZAP-70 kinase domain is in an active-like conformation despite the lack of tyrosine phosphorylation in the activation loop. The unique features of the ATP-binding site, identified by structural and sequence comparison with other kinases, will be useful in the design of ZAP-70-selective inhibitors.	Daiichi Asubio Med Res Labs LLC, Cambridge, MA 02139 USA		Seidl, KJ (corresponding author), Daiichi Asubio Med Res Labs LLC, Cambridge, MA 02139 USA.	kathy.seidl@daiamed.com		Rynkiewicz, Michael/0000-0002-4717-5700				ADAMS JL, 2004, PROTEIN CRYSTALLOGRA, V20, P47; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Breitenlechner C, 2003, STRUCTURE, V11, P1595, DOI 10.1016/j.str.2003.11.002; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Chen LG, 2002, BLOOD, V100, P4609, DOI 10.1182/blood-2002-06-1683; Dumont F J, 2001, Curr Opin Investig Drugs, V2, P357; Dumont FJ, 2000, CURR MED CHEM, V7, P731, DOI 10.2174/0929867003374723; Dumont Francis J, 2002, Curr Opin Investig Drugs, V3, P1453; Dumont RJ, 2000, CLIN PHARMACOKINET, V38, P427, DOI 10.2165/00003088-200038050-00004; Durig J, 2003, LEUKEMIA, V17, P2426, DOI 10.1038/sj.leu.2403147; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HONMA T, 2004, PROTEIN CRYSTALLOGRA, V20, P147; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JIN L, 2004, PROTEIN CRYSTALLOGRA, V20, P209; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Lamers MBAC, 1999, J MOL BIOL, V285, P713, DOI 10.1006/jmbi.1998.2369; Lawrie AM, 1997, NAT STRUCT BIOL, V4, P796, DOI 10.1038/nsb1097-796; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; Magistrelli G, 1999, EUR J BIOCHEM, V266, P1166, DOI 10.1046/j.1432-1327.1999.00973.x; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Nagar B, 2002, CANCER RES, V62, P4236; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Nishikawa K, 2000, MOL CELL, V6, P969, DOI 10.1016/S1097-2765(05)00085-7; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; OMURA S, 1977, J ANTIBIOT, V30, P275, DOI 10.7164/antibiotics.30.275; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park YW, 1999, ANAL BIOCHEM, V269, P94, DOI 10.1006/abio.1999.4029; Prade L, 1997, STRUCTURE, V5, P1627, DOI 10.1016/S0969-2126(97)00310-9; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Samelson LE, 1995, ANN NY ACAD SCI, V766, P157, DOI 10.1111/j.1749-6632.1995.tb26659.x; SAMELSON LE, 1992, ADV EXP MED BIOL, V323, P9; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; Toledo LM, 1999, CURR MED CHEM, V6, P775; Toledo LM, 1997, STRUCTURE, V5, P1551, DOI 10.1016/S0969-2126(97)00304-3; Traxler P, 1999, PHARMACOL THERAPEUT, V82, P195, DOI 10.1016/S0163-7258(98)00044-8; Underwood KW, 2003, STRUCTURE, V11, P627, DOI 10.1016/S0969-2126(03)00092-3; Visco C, 2000, BIOCHEMISTRY-US, V39, P2784, DOI 10.1021/bi991840x; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; WATTS JD, 1994, J BIOL CHEM, V269, P29520; Wiestner A, 2003, BLOOD, V101, P4944, DOI 10.1182/blood-2002-10-3306; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200; Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0	57	52	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42818	42825		10.1074/jbc.M407096200	http://dx.doi.org/10.1074/jbc.M407096200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292186	hybrid			2022-12-27	WOS:000224226400058
J	Kim, HS; Hoja, U; Stolz, J; Sauer, G; Schweizer, E				Kim, HS; Hoja, U; Stolz, J; Sauer, G; Schweizer, E			Identification of the tRNA-binding protein Arc1p as a novel target of in vivo biotinylation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA-CARBOXYLASE; FATTY-ACID SYNTHESIS; POSTTRANSLATIONAL MODIFICATION; RECOMBINANT PROTEINS; ENZYMATIC BIOTINYLATION; BIOTIN; YEAST; GENE; COENZYME; DOMAIN	Biotin is an essential cofactor of cell metabolism serving as a protein-bound coenzyme in ATP-dependent carboxylation, in transcarboxylation, and certain decarboxylation reactions. The involvement of biotinylated proteins in other cellular functions has been suggested occasionally, but available data on this are limited. In the present study, a Saccharomyces cerevisiae protein was identified that reacts with streptavidin on Western blots and is not identical to one of the known biotinylated yeast proteins. After affinity purification on monomeric avidin, the biotinylated protein was identified as Arc1p. Using C-14-labeled biotin, the cofactor was shown to be incorporated into Arc1p by covalent and alkali-stable linkage. Similar to the known carboxylases, Arc1p biotinylation is mediated by the yeast biotin: protein ligase, Bpl1p. Mutational studies revealed that biotinylation occurs at lysine 86 within the N-terminal domain of Arc1p. In contrast to the known carboxylases, however, in vitro biotinylation of Arc1p is incomplete and increases with BPL1 overexpression. In accordance to this fact, Arc1p lacks the canonical consensus sequence of known biotin binding domains, and the bacterial biotin: protein ligase, BirA, is unable to use Arc1p as a substrate. Arc1p was shown previously to organize the association of MetRS and GluRS tRNA synthetases with their cognate tRNAs thereby increasing the substrate affinity and catalytic efficiency of these enzymes. Remarkably, not only biotinylated but also the biotin-free Arc1p obtained by replacement of lysine 86 with arginine were capable of restoring Arc1p function in both arc1Delta and arc1Deltalos1Delta mutants, indicating that biotinylation of Arc1p is not essential for activity.	Univ Erlangen Nurnberg, Lehrstuhl Biochem, D-91058 Erlangen, Germany; Univ Regensburg, Lerhstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany; GSF Munich, Inst Klin Mol Biol & Tumorgenet, D-81377 Munich, Germany	University of Erlangen Nuremberg; University of Regensburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Schweizer, E (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Biochem, Staudtstr 5, D-91058 Erlangen, Germany.	eschweiz@biologie.uni-erlangen.de						Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARKER DF, 1981, J MOL BIOL, V146, P451, DOI 10.1016/0022-2836(81)90042-5; BAYER EA, 1990, METHOD ENZYMOL, V184, P138; Beckett D, 1999, PROTEIN SCI, V8, P921, DOI 10.1110/ps.8.4.921; Beckett D, 1997, METHOD ENZYMOL, V279, P362; BREWSTER NK, 1994, ARCH BIOCHEM BIOPHYS, V311, P62, DOI 10.1006/abbi.1994.1209; Chapman-Smith A, 1999, TRENDS BIOCHEM SCI, V24, P359, DOI 10.1016/S0968-0004(99)01438-3; CHAUHAN J, 1991, J BIOL CHEM, V266, P10035; CRONAN JE, 1995, FEMS MICROBIOL LETT, V130, P221, DOI 10.1016/0378-1097(95)00210-V; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; CRONAN JE, 1989, CELL, V58, P427, DOI 10.1016/0092-8674(89)90421-2; Cronan JE, 2000, METHOD ENZYMOL, V326, P440; Cull MG, 2000, METHOD ENZYMOL, V326, P430; Deinert K, 2001, J BIOL CHEM, V276, P6000, DOI 10.1074/jbc.M008682200; Denis L, 2002, J BIOL CHEM, V277, P10435, DOI 10.1074/jbc.M111110200; Duffy S, 1998, ANAL BIOCHEM, V262, P122, DOI 10.1006/abio.1998.2770; Eakin RE, 1941, J BIOL CHEM, V140, P535; FRANTZ JD, 1995, J BIOL CHEM, V270, P20692, DOI 10.1074/jbc.270.35.20692; Galani K, 2001, EMBO J, V20, P6889, DOI 10.1093/emboj/20.23.6889; GENBAUFFE FS, 1991, DNA SEQUENCE, V36, P19; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; Gobom J, 2001, ANAL CHEM, V73, P434, DOI 10.1021/ac001241s; Grosshans H, 2000, J STRUCT BIOL, V129, P288, DOI 10.1006/jsbi.2000.4226; Grosshans H, 2000, GENE DEV, V14, P830; HASSLACHER M, 1993, J BIOL CHEM, V268, P10946; Hoja U, 2004, J BIOL CHEM, V279, P21779, DOI 10.1074/jbc.M401071200; Hoja U, 1998, EUR J BIOCHEM, V254, P520, DOI 10.1046/j.1432-1327.1998.2540520.x; Hymes J, 1999, J NUTR, V129, p485S, DOI 10.1093/jn/129.2.485S; HYMES J, 1995, BIOCHEM MOL MED, V56, P76, DOI 10.1006/bmme.1995.1059; KADOWAKI T, 1992, P NATL ACAD SCI USA, V89, P2312, DOI 10.1073/pnas.89.6.2312; KNAPPE J, 1961, BIOCHEM Z, V335, P168; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; Kogl F, 1936, H-S Z PHYSIOL CHEM, V242, P43; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LANE MD, 1964, J BIOL CHEM, V239, P2858; LEONDELRIO A, 1994, J BIOL CHEM, V269, P22964; LIM P, 1987, ARCH BIOCHEM BIOPHYS, V258, P219; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Parrott MB, 2000, MOL THER, V1, P96, DOI 10.1006/mthe.1999.0011; PETRELLI F, 1978, MOL BIOL REP, V4, P87, DOI 10.1007/BF00775966; Roberts EL, 1999, BIOCHEMISTRY-US, V38, P5045, DOI 10.1021/bi982466o; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; Schneiter R, 1997, CELL, V88, P431, DOI 10.1016/S0092-8674(00)81882-6; Schneiter R, 1996, MOL CELL BIOL, V16, P7161; Schneiter R, 1999, MOL CELL BIOL, V19, P3415; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; Skerra A, 2000, METHOD ENZYMOL, V326, P271; SRIMONTI S, 1998, MOL BIOL CELL, V9, P3041; Stolz J, 1998, FEBS LETT, V440, P213, DOI 10.1016/S0014-5793(98)01454-9; Stolz J, 1999, J BIOL CHEM, V274, P18741, DOI 10.1074/jbc.274.26.18741; TSARBOPOULOS A, 1994, ANAL CHEM, V66, P2062, DOI 10.1021/ac00085a022; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Yao X, 1997, BIOCHEMISTRY-US, V36, P15089, DOI 10.1021/bi971485f	61	29	30	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42445	42452		10.1074/jbc.M407137200	http://dx.doi.org/10.1074/jbc.M407137200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15272000	hybrid			2022-12-27	WOS:000224226400015
J	Rozenfeld, R; Muller, L; El Messari, S; Llorens-Cortes, C				Rozenfeld, R; Muller, L; El Messari, S; Llorens-Cortes, C			The C-terminal domain of aminopeptidase A is an intramolecular chaperone required for the correct folding, cell surface expression, and activity of this monozinc aminopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE PRO-REGION; VASOPRESSIN RELEASE; MOLECULAR-CLONING; ANGIOTENSIN-III; EXOPEPTIDASE SPECIFICITY; CATALYTIC-ACTIVITY; ESCHERICHIA-COLI; BP-1/6C3 ANTIGEN; CDNA CLONING; ENZYME	Aminopeptidase A (APA, EC 3.4.11.7) is a type II integral membrane glycoprotein responsible for the conversion of angiotensin II to angiotensin III in the brain. Previous site-directed mutagenesis studies and the recent molecular modeling of the APA zinc metallopeptidase domain have shown that all the amino acids involved in catalysis are located between residues 200 and 500. The APA ectodomain is cleaved in the kidney into an N-terminal fragment corresponding to the zinc metallopeptidase domain, and a C-terminal fragment of unknown function. We investigated the function of this C-terminal domain, by expressing truncated APAs in Chinese hamster ovary and AtT-20 cells. Deletion of the C-terminal domain abolished the maturation and enzymatic activity of the N-terminal domain, which was retained in the endoplasmic reticulum as an unfolded protein bound to calnexin. Expression in trans of the C-terminal domain resulted in association of the N- and C-terminal domains soon after biosynthesis, allowing folding rescue, maturation, cell surface expression, and activity of the N- terminal zinc metallopeptidase domain. We also show that the C-terminal domain is not required for the catalytic activity of APA but is essential for its activation. Moreover, we show that the C-terminal domain of aminopeptidase N (EC3.4.11.2, APN) also promotes maturation and cell surface expression of the N-terminal domain of APN, suggesting a common role of the C-terminal domain in the monozinc aminopeptidase family. Our data provide the first demonstration that the C-terminal domain of an eukaryotic exopeptidase acts as an intramolecular chaperone.	Coll France, INSERM, U36, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Llorens-Cortes, C (corresponding author), Coll France, INSERM, U36, 11 Pl Marcelin Berthelot, F-75005 Paris, France.	c.llorens-cortes@college-de-france.fr	Llorens-Cortès, catherine/AAL-3893-2021; muller, laurent/S-1990-2016; Llorens-Cortes, Catherine/E-5839-2016	Llorens-Cortès, catherine/0000-0002-7667-0401; muller, laurent/0000-0001-9634-4323; Llorens-Cortes, Catherine/0000-0002-7667-0401				Anderson ED, 2002, J BIOL CHEM, V277, P12879, DOI 10.1074/jbc.M108740200; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang YC, 1996, BIOCHEM BIOPH RES CO, V219, P463, DOI 10.1006/bbrc.1996.0256; CHAUVEL EN, 1994, J MED CHEM, V37, P2950, DOI 10.1021/jm00044a016; COLOMA MJ, 1992, J IMMUNOL METHODS, V152, P89, DOI 10.1016/0022-1759(92)90092-8; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; FURTH J, 1953, P SOC EXP BIOL MED, V84, P253; Hesp JR, 1997, BIOCHEMISTRY-US, V36, P3000, DOI 10.1021/bi962401q; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; HUSSAIN MM, 1981, BIOCHEM J, V199, P179, DOI 10.1042/bj1990179; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; Iturrioz X, 2000, BIOCHEMISTRY-US, V39, P3061, DOI 10.1021/bi9925726; Iturrioz X, 2001, BIOCHEMISTRY-US, V40, P14440, DOI 10.1021/bi011409j; Jacob R, 2002, J BIOL CHEM, V277, P32141, DOI 10.1074/jbc.M204116200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HJ, 2000, BBA-GENE STRUCT EXPR, V1493, P273, DOI 10.1016/S0167-4781(00)00183-4; LEJCZAK B, 1993, J ENZYM INHIB, V7, P97, DOI 10.3109/14756369309040752; Lesage G, 2000, MOL BIOL CELL, V11, P1947, DOI 10.1091/mbc.11.6.1947; LI L, 1993, GENOMICS, V17, P657, DOI 10.1006/geno.1993.1386; LODJA Z, 1980, HISTOCHEMISTRY, V67, P267; Marie-Claire C, 1999, J MOL BIOL, V285, P1911, DOI 10.1006/jmbi.1998.2449; Muller L, 2000, J BIOL CHEM, V275, P39213, DOI 10.1074/jbc.M003547200; NAGATSU I, 1970, BIOCHIM BIOPHYS ACTA, V198, P255, DOI 10.1016/0005-2744(70)90058-6; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; Ofner LD, 2002, BIOCHEM J, V362, P191, DOI 10.1042/0264-6021:3620191; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Pavlaki M, 2002, J BIOL CHEM, V277, P2740, DOI 10.1074/jbc.M108987200; Reaux A, 1999, NEUROENDOCRINOLOGY, V69, P370, DOI 10.1159/000054439; Reaux A, 2001, TRENDS ENDOCRIN MET, V12, P157, DOI 10.1016/S1043-2760(01)00381-2; Rozenfeld R, 2002, J BIOL CHEM, V277, P29242, DOI 10.1074/jbc.M204406200; SCHALK C, 1994, ARCH BIOCHEM BIOPHYS, V311, P42, DOI 10.1006/abbi.1994.1206; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SONG LJ, 1994, AM J PHYSIOL-RENAL, V267, pF546, DOI 10.1152/ajprenal.1994.267.4.F546; Thunnissen MMGM, 2001, NAT STRUCT BIOL, V8, P131, DOI 10.1038/84117; TIEKU S, 1992, BIOCHEM PHARMACOL, V44, P1725, DOI 10.1016/0006-2952(92)90065-Q; Troyanovskaya M, 2000, AM J PHYSIOL-REG I, V278, pR413, DOI 10.1152/ajpregu.2000.278.2.R413; VANDENHAZEL HB, 1993, J BIOL CHEM, V268, P18002; Vazeux G, 1996, J BIOL CHEM, V271, P9069, DOI 10.1074/jbc.271.15.9069; Vazeux G, 1998, BIOCHEM J, V334, P407, DOI 10.1042/bj3340407; Vazeux G, 1997, BIOCHEM J, V327, P883, DOI 10.1042/bj3270883; WANG JY, 1993, P NATL ACAD SCI USA, V90, P1222, DOI 10.1073/pnas.90.4.1222; WILK S, 1993, ADV NEUROIMMUNOL, V3, P195, DOI 10.1016/S0960-5428(05)80021-X; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0; Zini S, 1997, NEUROSCIENCE, V78, P1187, DOI 10.1016/S0306-4522(96)00660-4; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968	47	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43285	43295		10.1074/jbc.M404369200	http://dx.doi.org/10.1074/jbc.M404369200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15263000	hybrid			2022-12-27	WOS:000224226400113
J	Suormala, T; Baumgartner, MR; Coelho, D; Zavadakova, P; Kozich, V; Koch, HG; Berghauser, M; Wraith, JE; Burlina, A; Sewell, A; Herwig, J; Fowler, B				Suormala, T; Baumgartner, MR; Coelho, D; Zavadakova, P; Kozich, V; Koch, HG; Berghauser, M; Wraith, JE; Burlina, A; Sewell, A; Herwig, J; Fowler, B			The cblD defect causes either isolated or combined deficiency of methylcobalamin and adenosylcobalamin synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE SYNTHASE DEFICIENCY; METHYLMALONIC ACIDURIA; COBALAMIN METABOLISM; INTERALLELIC COMPLEMENTATION; GENETIC-HETEROGENEITY; ENZYME-ACTIVITY; INBORN ERROR; REDUCTASE; HOMOCYSTINURIA; FIBROBLASTS	Intracellular cobalamin is converted to adenosylcobalamin, coenzyme for methylmalonyl-CoA mutase and to methylcobalamin, coenzyme for methionine synthase, in an incompletely understood sequence of reactions. Genetic defects of these steps are defined as cbl complementation groups of which cblC, cblD ( described in only two siblings), and cblF are associated with combined homocystinuria and methylmalonic aciduria. Here we describe three unrelated patients belonging to the cblD complementation group but with distinct biochemical phenotypes different from that described in the original cblD siblings. Two patients presented with isolated homocystinuria and reduced formation of methionine and methylcobalamin in cultured fibroblasts, defined as cblD-variant 1, and one patient with isolated methylmalonic aciduria and deficient adenosylcobalamin synthesis in fibroblasts, defined as cblD-variant 2. Cell lines from the cblD-variant 1 patients clearly complemented reference lines with the same biochemical phenotype, i.e. cblE and cblG, and the cblD-variant 2 cell line complemented cells from the mutant classes with isolated deficiency of adenosylcobalamin synthesis, i.e. cblA and cblB. Also, no pathogenic sequence changes in the coding regions of genes associated with the respective biochemical phenotypes were found. These findings indicate heterogeneity within the previously defined cblD mutant class and point to further complexity of intracellular cobalamin metabolism.	Univ Childrens Hosp, Metab Unit, CH-4058 Basel, Switzerland; Charles Univ Prague, Inst Inherited Metab Dis, Fac Med 1, Prague 12808 2, Czech Republic; Univ Hosp, Dept Pediat, D-48149 Munster, Germany; Royal Manchester Childrens Hosp, Willink Biochem Genet Unit, Manchester M27 4HA, Lancs, England; Univ Padua, Dept Pediat, I-35128 Padua, Italy; Goethe Univ Frankfurt, Dept Pediat, D-60590 Frankfurt, Germany	Charles University Prague; University of Munster; Royal Manchester Children's Hospital; University of Padua; Goethe University Frankfurt	Fowler, B (corresponding author), Univ Childrens Hosp, Metab Unit, Romergasse 8, CH-4058 Basel, Switzerland.	Brian.Fowler@ukbb.ch	Coelho, David/AAE-9547-2020; Kozich, Viktor/A-7672-2008; Coelho, David/F-6680-2011; Baumgartner, Matthias/Q-2855-2017	Kozich, Viktor/0000-0001-5820-5277; Coelho, David/0000-0001-7010-5789; Baumgartner, Matthias/0000-0002-9270-0826				BAUMGARTNER R, 1983, COBALAMINS METHODS H, V10, P181; CARMEL R, 1982, BLOOD, V59, P306; COOPER BA, 1990, AM J HEMATOL, V34, P115, DOI 10.1002/ajh.2830340207; Dobson CM, 2002, P NATL ACAD SCI USA, V99, P15554, DOI 10.1073/pnas.242614799; DODSON CM, 2002, HUM MOL GENET, V26, P3361; FENTON WA, 1981, BIOCHEM BIOPH RES CO, V98, P283, DOI 10.1016/0006-291X(81)91900-8; FENTON WA, 1978, ANNU REV GENET, V12, P223, DOI 10.1146/annurev.ge.12.120178.001255; Fenton WA, 2001, METABOLIC MOL BASES, P2165; Fowler B, 1997, PEDIATR RES, V41, P145, DOI 10.1203/00006450-199701000-00023; Fowler B, 1998, EUR J PEDIATR, V157, pS88, DOI 10.1007/PL00014311; Fowler B, 1997, J INHERIT METAB DIS, V20, P270, DOI 10.1023/A:1005369109055; GIORDANO SJ, 1991, BIOCHEM BIOPH RES CO, V178, P38, DOI 10.1016/0006-291X(91)91776-9; GOODMAN SI, 1970, BIOCHEM MED METAB B, V4, P500, DOI 10.1016/0006-2944(70)90080-3; Gulati S, 1996, HUM MOL GENET, V5, P1859, DOI 10.1093/hmg/5.12.1859; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; MCINNES RR, 1984, P NATL ACAD SCI-BIOL, V81, P4480, DOI 10.1073/pnas.81.14.4480; MELLMAN I, 1979, J BIOL CHEM, V254, P1847; MELLMAN I, 1978, J CLIN INVEST, V62, P952, DOI 10.1172/JCI109224; Olteanu H, 2003, J BIOL CHEM, V278, P38310, DOI 10.1074/jbc.M306282200; PEZACKA EH, 1993, BIOCHIM BIOPHYS ACTA, V1157, P167, DOI 10.1016/0304-4165(93)90061-C; QURESHI AA, 1994, J CLIN INVEST, V93, P1812, DOI 10.1172/JCI117166; Rosenblatt D. S., 2001, METABOLIC MOL BASES, V8th, P3897; Suormala T, 2002, CLIN CHEM, V48, P835; Watanabe F, 1996, J NUTR, V126, P2947, DOI 10.1093/jn/126.12.2947; WATKINS D, 1986, AM J HUM GENET, V39, P404; Watkins D, 2000, J MED GENET, V37, P510, DOI 10.1136/jmg.37.7.510; Watkins D, 2002, AM J HUM GENET, V71, P143, DOI 10.1086/341354; WATKINS D, 1989, AM J MED GENET, V34, P427, DOI 10.1002/ajmg.1320340320; WATKINS D, 1988, J CLIN INVEST, V81, P1690, DOI 10.1172/JCI113507; WILLARD HF, 1978, AM J HUM GENET, V30, P1; WILLARD HF, 1976, HUM GENET, V34, P277, DOI 10.1007/BF00295291; Zavad'akova P, 2002, J INHERIT METAB DIS, V25, P461, DOI 10.1023/A:1021299117308	32	90	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42742	42749		10.1074/jbc.M407733200	http://dx.doi.org/10.1074/jbc.M407733200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292234	Green Accepted, hybrid			2022-12-27	WOS:000224226400049
J	Wang, XH; Huang, GJ; Luo, X; Penninger, JM; Muallem, S				Wang, XH; Huang, GJ; Luo, X; Penninger, JM; Muallem, S			Role of regulator of G protein signaling 2 (RGS2) in Ca2+ oscillations and adaptation of Ca2+ signaling to reduce excitability of RGS2(-/-) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; COUPLED RECEPTORS; PANCREATIC ACINI; EXPRESSION; ACTIVATION; RELEASE; PUMP; SPECIFICITY; INHIBITION; METABOLISM	Regulators of G protein signaling (RGS) proteins accelerate the GTPase activity of Galpha subunits to determine the duration of the stimulated state and control G protein-coupled receptor-mediated cell signaling. RGS2 is an RGS protein that shows preference toward Galpha(q). To better understand the role of RGS2 in Ca2+ signaling and Ca2+ oscillations, we characterized Ca2+ signaling in cells derived from RGS2(-/-) mice. Deletion of RGS2 modified the kinetic of inositol 1,4,5-trisphosphate (IP3) production without affecting the peak level of IP3, but rather increased the steady-state level of IP3 at all agonist concentrations. The increased steady-state level of IP3 led to an increased frequency of [Ca2+](i) oscillations. The cells were adapted to deletion of RGS2 by reducing Ca2+ signaling excitability. Reduced excitability was achieved by adaptation of all transporters to reduce Ca2+ influx into the cytosol. Thus, IP3 receptor 1 was down-regulated and IP3 receptor 3 was up-regulated in RGS2(-/-) cells to reduce the sensitivity for IP3 to release Ca2+ from the endoplasmic reticulum to the cytosol. Sarco/endoplasmic reticulum Ca2+ ATPase 2b was upregulated to more rapidly remove Ca2+ from the cytosol of RGS2(-/-) cells. Agonist-stimulated Ca2+ influx was reduced, and Ca2+ efflux by plasma membrane Ca2+ was up-regulated in RGS2(-/-) cells. The result of these adaptive mechanisms was the reduced excitability of Ca2+ signaling, as reflected by the markedly reduced response of RGS2(-/-) cells to changes in the endoplasmic reticulum Ca2+ load and to an increase in extracellular Ca2+. These findings highlight the central role of RGS proteins in [Ca2+](i) oscillations and reveal a prominent plasticity and adaptability of the Ca2+ signaling apparatus.	Univ Texas, SE Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA; Austrian Acad Sci, Inst Mol Biotechnol IMBA, A-1030 Vienna, Austria	University of Texas System; University of Texas Dallas; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Muallem, S (corresponding author), Univ Texas, SE Med Ctr Dallas, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	SHMUEL.MUALLEM@utsouthwestern.edu	Huang, Guojin/ABB-1091-2021; Penninger, Josef M/I-6860-2013	Huang, Guojin/0000-0001-7020-5528; Penninger, Josef M/0000-0002-8194-3777				Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; DOLMETSCH R, 2003, SCI STKE; Doupnik CA, 2001, BBA-GENE STRUCT EXPR, V1522, P97, DOI 10.1016/S0167-4781(01)00342-6; Haffner C, 2000, CURR BIOL, V10, P471, DOI 10.1016/S0960-9822(00)00446-2; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Kiselyov K, 2003, CELL SIGNAL, V15, P243, DOI 10.1016/S0898-6568(02)00074-8; Liu BF, 1996, J BIOL CHEM, V271, P5536, DOI 10.1074/jbc.271.10.5536; Luo X, 2004, METHOD ENZYMOL, V389, P119; Luo X, 2001, MOL CELL, V7, P651, DOI 10.1016/S1097-2765(01)00211-8; Muallem S, 1999, CELL CALCIUM, V26, P173, DOI 10.1054/ceca.1999.0077; MUALLEM S, 1986, J BIOL CHEM, V261, P2660; Nash MS, 2001, NATURE, V413, P381, DOI 10.1038/35096643; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Pattni K, 2004, CELL SIGNAL, V16, P643, DOI 10.1016/j.cellsig.2003.10.009; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; SANCHEZBUENO A, 1990, BIOCHEM J, V268, P627, DOI 10.1042/bj2680627; Shin DM, 2003, J CELL BIOL, V162, P293, DOI 10.1083/jcb.200210109; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; Wenk MR, 2004, P NATL ACAD SCI USA, V101, P8262, DOI 10.1073/pnas.0401874101; Woodring PJ, 1997, J BIOL CHEM, V272, P30447, DOI 10.1074/jbc.272.48.30447; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Xu X, 1996, J BIOL CHEM, V271, P11737, DOI 10.1074/jbc.271.20.11737; Young KW, 2003, J BIOL CHEM, V278, P20753, DOI 10.1074/jbc.M211555200; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHANG BX, 1992, J BIOL CHEM, V267, P15419; Zhao XS, 2001, EMBO J, V20, P2680, DOI 10.1093/emboj/20.11.2680	36	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41642	41649		10.1074/jbc.M406450200	http://dx.doi.org/10.1074/jbc.M406450200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292238	hybrid			2022-12-27	WOS:000224075500050
J	Weinglass, A; Whitelegge, JP; Faull, KF; Kaback, HR				Weinglass, A; Whitelegge, JP; Faull, KF; Kaback, HR			Monitoring conformational rearrangements in the substrate-binding site of a membrane transport protein by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYS-SCANNING MUTAGENESIS; ESCHERICHIA-COLI; LACTOSE PERMEASE; LAC PERMEASE; HELIX-VIII; MECHANISM; GLU126; ARG144; SUGAR; IV	Combined biochemical, biophysical, and crystallographic studies on the lactose permease of Escherichia coli suggest that Arg-144 (helix V) forms a salt bridge with Glu-126 (helix IV), which is broken during substrate binding, thereby permitting the guanidino group to form a bidentate H-bond with the C-4 and C-3 O atoms of the galactopyranosyl moiety and an H-bond with Glu-269 (helix VIII). To examine the relative interaction of Arg-144 with these two potential salt bridge partners (Glu-126 and Glu-269) in the absence of substrate, the covalent modification of the guanidino group was monitored with the Arg-specific reagent butane-2,3-dione using electrospray ionization mass spectrometry. In a functional background, the reactivity of Arg-144 with butane-2,3-dione is low (similar to25%) and is reduced by a factor of approximately 2 by preincubation with ligand. Interestingly, although replacement of Glu-126 with Ala results in a 3-fold increase in the reactivity of Arg-144, replacement of Glu-269 with Ala elicits virtually no effect. Taken together, these results suggest that in the absence of substrate the interaction between Arg-144 and Glu-126 is much stronger than the interaction with Glu-269, supporting the contention that sugar recognition leads to rearrangement of charge-paired residues essential for sugar binding.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Neuropsychiat, Dept Psychiat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Neuropsychiat, Dept Behav Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biochem, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Kaback, HR (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, 5-748 MacDonald Res Labs,Box 951662, Los Angeles, CA 90095 USA.	RonaldK@HHMI.UCLA.edu			NIDDK NIH HHS [DK51131-09] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051131] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; Frillingos S, 1997, PROTEIN SCI, V6, P431; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P14284, DOI 10.1021/bi972314d; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Guan L, 2003, BIOCHEMISTRY-US, V42, P1377, DOI 10.1021/bi027152m; He MM, 1997, BIOCHEMISTRY-US, V36, P13688, DOI 10.1021/bi9715324; Hirai T, 2003, J BACTERIOL, V185, P1712, DOI 10.1128/JB.185.5.1712-1718.2003; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Kaback H R, 1974, Methods Enzymol, V31, P698; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; KONINGS WN, 1996, HDB BIOL PHYS TRANSP, V2; Lundblad RL, 1995, TECHNIQUES PROTEIN M, V1, P187; OLSEN SG, 1989, J BIOL CHEM, V264, P15982; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Sahin-Toth M, 2000, P NATL ACAD SCI USA, V97, P10729, DOI 10.1073/pnas.200351797; Sahin-Toth M, 2002, BIOCHEMISTRY-US, V41, P13039, DOI 10.1021/bi0203076; Sahin-Toth M, 2000, BIOCHEMISTRY-US, V39, P5097, DOI 10.1021/bi0000263; Sahin-Toth M, 2001, BIOCHEMISTRY-US, V40, P13015, DOI 10.1021/bi011233l; Sahin-Toth M, 1999, BIOCHEMISTRY-US, V38, P813, DOI 10.1021/bi982200h; SAHINTOTH M, 1994, P NATL ACAD SCI USA, V91, P5421, DOI 10.1073/pnas.91.12.5421; Saier M H Jr, 1999, J Mol Microbiol Biotechnol, V1, P257; Saier MH, 2000, MOL MICROBIOL, V35, P699, DOI 10.1046/j.1365-2958.2000.01759.x; SANDERMANN H, 1977, EUR J BIOCHEM, V80, P507, DOI 10.1111/j.1432-1033.1977.tb11906.x; Smirnova IN, 2003, BIOCHEMISTRY-US, V42, P3025, DOI 10.1021/bi027329c; UJWAL ML, 1994, MOL MEMBR BIOL, V11, P9, DOI 10.3109/09687689409161024; Vazquez-Ibar JL, 2003, P NATL ACAD SCI USA, V100, P12706, DOI 10.1073/pnas.1835645100; Venkatesan P, 1998, P NATL ACAD SCI USA, V95, P9802, DOI 10.1073/pnas.95.17.9802; Weinglass AB, 2003, EMBO J, V22, P1467, DOI 10.1093/emboj/cdg145; Weinglass AB, 2002, J MOL BIOL, V315, P561, DOI 10.1006/jmbi.2001.5289; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Whitelegge JP, 1998, PROTEIN SCI, V7, P1423, DOI 10.1002/pro.5560070619; WHITELEGGE JP, 1992, EUR J BIOCHEM, V207, P1077, DOI 10.1111/j.1432-1033.1992.tb17144.x; WITKOP B, 1961, ADV PROTEIN CHEM, V16, P221; Wolin CD, 2000, BIOCHEMISTRY-US, V39, P6130, DOI 10.1021/bi0001269; WU JH, 1994, BIOCHEMISTRY-US, V33, P12166, DOI 10.1021/bi00206a020; Zhao M, 1999, BIOCHEMISTRY-US, V38, P15970, DOI 10.1021/bi991754x; Zhao M, 1999, BIOCHEMISTRY-US, V38, P7407, DOI 10.1021/bi9906524	42	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41858	41865		10.1074/jbc.M407555200	http://dx.doi.org/10.1074/jbc.M407555200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15272008	hybrid			2022-12-27	WOS:000224075500076
J	Hirsch-Reinshagen, V; Zhou, S; Burgess, BL; Bernier, L; McIsaac, SA; Chan, JY; Tansley, GH; Cohn, JS; Hayden, MR; Wellington, CL				Hirsch-Reinshagen, V; Zhou, S; Burgess, BL; Bernier, L; McIsaac, SA; Chan, JY; Tansley, GH; Cohn, JS; Hayden, MR; Wellington, CL			Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-X-RECEPTOR; AMYLOID-BETA DEPOSITION; CENTRAL-NERVOUS-SYSTEM; CHOLESTEROL EFFLUX; MOUSE MODEL; ALZHEIMERS-DISEASE; TANGIER-DISEASE; 9-CIS-RETINOIC ACID; CEREBROSPINAL-FLUID; TRANSPORTER ABCA1	ABCA1 is a cholesterol transporter that is widely expressed throughout the body. Outside the central nervous system (CNS), ABCA1 functions in the biogenesis of high-density lipoprotein (HDL), where it mediates the efflux of cholesterol and phospholipids to apolipoprotein (apo) A-I. Deficiency of ABCA1 results in lack of circulating HDL and greatly reduced levels of apoA-I. ABCA1 is also expressed in cells within the CNS, but its roles in brain lipid metabolism are not yet fully understood. In the brain, glia synthesize the apolipoproteins involved in CNS lipid metabolism. Here we demonstrate that glial ABCA1 is required for cholesterol efflux to apoA-I and plays a key role in facilitating cholesterol efflux to apoE, which is the major apolipoprotein in the brain. In both astrocytes and microglia, ABCA1 deficiency reduces lipid efflux to exogenous apoE. The impaired ability to efflux lipids in ABCA1-/- glia results in lipid accumulation in both astrocytes and microglia under normal culture conditions. Additionally, apoE secretion is compromised in ABCA1-/- astrocytes and microglia. In vivo, deficiency of ABCA1 results in a 65% decrease in apoE levels in whole brain, and a 75-80% decrease in apoE levels in hippocampus and striatum. Additionally, the effect of ABCA1 on apoE is selective, as apoJ levels are unchanged in brains of ABCA1-/- mice. Taken together, these results show that glial ABCA1 is a key influence on apoE metabolism in the CNS.	Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 4H4, Canada; Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada	University of British Columbia; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of British Columbia	Wellington, CL (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, 980 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	cheryl@cmmt.ubc.ca	Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419				Aleshkov S, 1997, BIOCHEMISTRY-US, V36, P10571, DOI 10.1021/bi9626362; Allayee H, 2003, ARTERIOSCL THROM VAS, V23, P1501, DOI 10.1161/01.ATV.0000090886.40027.DC; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Bales KR, 2000, NEUROBIOL AGING, V21, P427, DOI 10.1016/S0197-4580(00)00143-3; Bjorkhem I, 1998, J LIPID RES, V39, P1594; Bjorkhem I, 1997, J BIOL CHEM, V272, P30178, DOI 10.1074/jbc.272.48.30178; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Broccardo C, 1999, BBA-BIOMEMBRANES, V1461, P395, DOI 10.1016/S0005-2736(99)00170-4; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Carter DB, 2001, ANN NEUROL, V50, P468, DOI 10.1002/ana.1134; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Cole GM, 1999, J NEUROSCI RES, V57, P504, DOI 10.1002/(SICI)1097-4547(19990815)57:4<504::AID-JNR10>3.0.CO;2-H; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Costet P, 2000, J BIOL CHEM, V275, P28240; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; Dean M, 2001, J LIPID RES, V42, P1007; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; Fagan AM, 2000, MICROSC RES TECHNIQ, V50, P297, DOI 10.1002/1097-0029(20000815)50:4<297::AID-JEMT9>3.0.CO;2-C; Fazio S, 2000, TRENDS CARDIOVAS MED, V10, P23, DOI 10.1016/S1050-1738(00)00033-5; Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200; Hayden MR, 2000, CURR OPIN LIPIDOL, V11, P117, DOI 10.1097/00041433-200004000-00003; Heeren J, 2003, J BIOL CHEM, V278, P14370, DOI 10.1074/jbc.M209006200; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Hone E, 2003, J ALZHEIMERS DIS, V5, P1, DOI 10.3233/JAD-2003-5101; Huang ZH, 2001, ARTERIOSCL THROM VAS, V21, P2019, DOI 10.1161/hq1201.100242; Ignatius MJ, 1987, PROG BRAIN RES <D>, V71, P177; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Irizarry MC, 2000, ANN NY ACAD SCI, V920, P171; Katzov H, 2004, HUM MUTAT, V23, P358, DOI 10.1002/humu.20012; KOCH S, 2000, LIPIDS VASCULAR DIS, P51; Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Lakins JN, 2002, BIOCHEMISTRY-US, V41, P282, DOI 10.1021/bi0157666; Langmann T, 2003, J LIPID RES, V44, P968, DOI 10.1194/jlr.M300016-JLR200; Lawn RM, 2001, ARTERIOSCL THROM VAS, V21, P378, DOI 10.1161/01.ATV.21.3.378; Liang Y, 2004, J NEUROCHEM, V88, P623, DOI 10.1111/j.1471-4159.2004.02183.x; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Mabile L, 2003, J CELL BIOCHEM, V90, P766, DOI 10.1002/jcb.10697; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mak PA, 2002, J BIOL CHEM, V277, P31900, DOI 10.1074/jbc.M202993200; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Michikawa M, 2000, J NEUROCHEM, V74, P1008, DOI 10.1046/j.1471-4159.2000.0741008.x; Naidu A, 2002, BRAIN RES, V958, P100, DOI 10.1016/S0006-8993(02)03480-7; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Poon S, 2002, FEBS LETT, V513, P259, DOI 10.1016/S0014-5793(02)02326-8; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Singaraja RR, 2002, J CLIN INVEST, V110, P35, DOI 10.1172/JCI200215748; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sun Y, 2003, J BIOL CHEM, V278, P27688, DOI 10.1074/jbc.M300760200; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Van Eck M, 2002, P NATL ACAD SCI USA, V99, P6298, DOI 10.1073/pnas.092327399; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; WAHRLE S, 2004, IN PRESS J BIOL CHEM; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wellington CL, 2002, J LIPID RES, V43, P1939, DOI 10.1194/jlr.M200277-JLR200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Wollmer MA, 2003, NEUROBIOL AGING, V24, P421, DOI 10.1016/S0197-4580(02)00094-5; ZLOKOVIC BV, 1994, BIOCHEM BIOPH RES CO, V205, P1431, DOI 10.1006/bbrc.1994.2825; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	84	288	292	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41197	41207		10.1074/jbc.M407962200	http://dx.doi.org/10.1074/jbc.M407962200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15269218	hybrid			2022-12-27	WOS:000223916800119
J	Shinohara, H; Udagawa, J; Morishita, R; Ueda, H; Otani, H; Semba, R; Kato, K; Asano, T				Shinohara, H; Udagawa, J; Morishita, R; Ueda, H; Otani, H; Semba, R; Kato, K; Asano, T			G(i2) signaling enhances proliferation of neural progenitor cells in the developing brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; FIBROBLAST-GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; BETA-GAMMA-SUBUNITS; ADULT-RAT BRAIN; STEM-CELLS; IMMUNOHISTOCHEMICAL LOCALIZATION; PERTUSSIS-TOXIN; MESSENGER-RNA; CORTICAL NEUROGENESIS	Our previous study showed that the pertussis toxin-sensitive G protein, G(i2), is selectively localized in the ventricular zone of embryonic brains, where the neuroepithelial cells undergo active proliferation. In order to clarify the role of G(i2) in this site, we first administered pertussis toxin by an exo-utero manipulation method into the lateral ventricle of mouse brain at embryonic day 14.5. Examination at embryonic day 18.5 revealed that pertussis toxin-injected embryos had brains with thinner cerebral cortices, made up of fewer constituent cells. Bromodeoxyuridine labeling revealed fewer numbers of bromodeoxyuridine-positive cells in the cerebral cortices of pertussis toxin-injected embryos, suggesting impaired proliferation of neuroepithelial cells. Next we cultured neural progenitor cells from rat embryonic brains and evaluated the mitogenic effects of agonists for several G(i)-coupled receptors that are known to be expressed in the ventricular zone. Among agonists tested, endothelin most effectively stimulated the incorporation of [H-3]thymidine in the presence of fibronectin, via the endothelin-B receptor. This was associated with phosphorylation of extracellular signal-regulated kinase, and pertussis toxin partially inhibited both endothelin-stimulated DNA synthesis and phosphorylation of extracellular signal-regulated kinase. Injection of endothelin-3 into the ventricle of embryonic brains increased numbers of bromodeoxyuridine-positive cells in the cerebral cortex, whereas injection of an endothelin-B receptor antagonist decreased them. These findings indicate that G(i2) mediates signaling from receptors such as the endothelin-B receptor to maintain mitogenic activity in the neural progenitor cells of developing brain.	Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, Kasugai, Aichi 4800392, Japan; Mie Univ, Sch Med, Dept Anat, Tsu, Mie 5148507, Japan; Shimane Univ, Fac Med, Dept Dev Biol, Izumo, Shimane 6938501, Japan	Mie University; Shimane University	Asano, T (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, Kasugai, Aichi 4800392, Japan.	toasano@inst-hsc.jp						Asano T, 2001, J NEUROCHEM, V79, P1129, DOI 10.1046/j.1471-4159.2001.00662.x; ASANO T, 1995, J NEUROCHEM, V64, P1267; ASANO T, 1988, J NEUROCHEM, V50, P1164, DOI 10.1111/j.1471-4159.1988.tb10588.x; ASANO T, 1990, J BIOCHEM-TOKYO, V108, P988, DOI 10.1093/oxfordjournals.jbchem.a123326; Cazaubon S, 1997, J NEUROSCI, V17, P6203; Chan TSK, 1995, EUR J BIOCHEM, V234, P819, DOI 10.1111/j.1432-1033.1995.819_a.x; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Diaz J, 1997, J NEUROSCI, V17, P4282; DOUGLAS SA, 1994, TRENDS PHARMACOL SCI, V15, P313, DOI 10.1016/0165-6147(94)90019-1; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hatta T, 2002, J NEUROSCI, V22, P5516; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kitamura K, 1999, AM J PHYSIOL-CELL PH, V276, pC930, DOI 10.1152/ajpcell.1999.276.4.C930; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahav R, 1996, P NATL ACAD SCI USA, V93, P3892, DOI 10.1073/pnas.93.9.3892; Leslie FM, 1998, CAN J PHYSIOL PHARM, V76, P284, DOI 10.1139/cjpp-76-3-284; Li BS, 2001, J NEUROSCI, V21, P1569, DOI 10.1523/JNEUROSCI.21-05-01569.2001; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; Maric D, 2003, J NEUROSCI, V23, P240; Morishita R, 1999, J NEUROCHEM, V73, P2369, DOI 10.1046/j.1471-4159.1999.0732369.x; MORISHITA R, 1988, EUR J BIOCHEM, V174, P87, DOI 10.1111/j.1432-1033.1988.tb14066.x; MUNEOKA K, 1986, J EXP ZOOL, V239, P289, DOI 10.1002/jez.1402390216; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Oishi K, 2002, J PHYSIOL-LONDON, V540, P139, DOI 10.1113/jphysiol.2001.013278; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; POWELL PP, 1991, MOL BRAIN RES, V11, P71, DOI 10.1016/0169-328X(91)90023-Q; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SCHMIDT CJ, 1994, J NEUROSCI RES, V38, P182, DOI 10.1002/jnr.490380208; Sheppard AM, 1995, DEV BIOL, V172, P504, DOI 10.1006/dbio.1995.8034; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; TEMPLE S, 1995, NEURON, V15, P249, DOI 10.1016/0896-6273(95)90030-6; Torii MA, 1999, DEVELOPMENT, V126, P443; Tsai RYL, 2000, J NEUROSCI, V20, P3725, DOI 10.1523/JNEUROSCI.20-10-03725.2000; Tsaur ML, 1997, FEBS LETT, V417, P208, DOI 10.1016/S0014-5793(97)01295-7; VANDERPLOEG I, 1991, NEUROSCIENCE, V44, P205, DOI 10.1016/0306-4522(91)90261-L; WEISE B, 1993, J NEUROSCI RES, V34, P442, DOI 10.1002/jnr.490340409; WORLEY PF, 1986, P NATL ACAD SCI USA, V83, P4561, DOI 10.1073/pnas.83.12.4561; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Zhu GF, 1999, DEV BIOL, V215, P118, DOI 10.1006/dbio.1999.9431	45	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41141	41148		10.1074/jbc.M406721200	http://dx.doi.org/10.1074/jbc.M406721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15272018	hybrid			2022-12-27	WOS:000223916800113
J	Aubert-Jousset, E; Sbarra, V; Lombardo, D				Aubert-Jousset, E; Sbarra, V; Lombardo, D			Site-directed mutagenesis of the distal basic cluster of pancreatic bile salt-dependent lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYLIC ESTER HYDROLASE; CHOLESTEROL ESTERASE; ACTIVATED LIPASE; SUBSTRATE-SPECIFICITY; STIMULATED LIPASE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; BINDING-SITE; HUMAN-MILK; SECRETION	Previous studies have postulated the presence of two bile salt-binding sites regulating the activity of the pancreatic bile salt-dependent lipase. One of these sites, located in an N-terminal basic cluster, has been identified as the specific bile salt-binding site. Interaction of primary bile salts with this proximal site induces the formation of a micellar binding site from a pre-existing nonspecific or pre-micellar bile salt-binding site. Here we have investigated the functional significance of another basic cluster comprised of amino acid residues Arg(423), Lys(429), Arg(454), Arg(458), and Lys(462), distal from the catalytic site. For this purpose these residues were mutagenized in Ile or Ala residues. The mutagenized enzyme lost activity on both soluble and emulsified substrates in the presence of bile salts. However, in the absence of bile salts, the mutagenized enzyme displayed the same activity on soluble substrate as the wild-type recombinant enzyme. Consequently, the distal basic cluster may represent the nonspecific ( or pre-micellar) bile salt-binding site susceptible to accommodate primary and secondary bile salts. According to the literature, tyrosine residue(s) should participate in this site. Therefore, two tyrosine residues, Tyr(427) and Tyr(453), associated with the distal basic cluster were also mutagenized. Each tyrosine substitution to serine did not inhibit the enzyme activity on soluble substrate, independently of the presence of primary or secondary bile salts. However, the enzyme activity on cholesteryl oleate solubilized in primary bile salt micelles was decreased by mutations substantiating that these residues are part of the nonspecific bile salt-binding site.	Fac Med Timone, INSERM, U559, Unite Rech Physiopathol Cellules Epitheliales, F-13385 Marseille 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Lombardo, D (corresponding author), Fac Med Timone, INSERM, U559, Unite Rech Physiopathol Cellules Epitheliales, 27 Blvd Jean Moulin, F-13385 Marseille 05, France.	dominique.lombardo@medecine.univ-mrs.fr						ABOUAKIL N, 1993, J BIOL CHEM, V268, P25755; Ansaldi M, 1996, ANAL BIOCHEM, V234, P110, DOI 10.1006/abio.1996.0060; Aubert E, 2002, J BIOL CHEM, V277, P34987, DOI 10.1074/jbc.M202893200; Aubert-Jousset E, 2004, STRUCTURE, V12, P1437, DOI 10.1016/j.str.2004.05.016; Auge N, 2003, CIRCULATION, V108, P86, DOI 10.1161/01.CIR.0000079101.69806.47; BLACKBERG L, 1993, FEBS LETT, V323, P207, DOI 10.1016/0014-5793(93)81340-6; Bruneau N, 1997, J BIOL CHEM, V272, P27353, DOI 10.1074/jbc.272.43.27353; CAMPESE D, 1984, BIOCHIM BIOPHYS ACTA, V784, P147, DOI 10.1016/0167-4838(84)90121-3; Chen JCH, 1998, BIOCHEMISTRY-US, V37, P5107, DOI 10.1021/bi972989g; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; DIPERSIO LP, 1993, J BIOL CHEM, V268, P300; DIPERSIO LP, 1991, J BIOL CHEM, V266, P4033; GJELLESVIK DR, 1992, BIOCHIM BIOPHYS ACTA, V1124, P123, DOI 10.1016/0005-2760(92)90088-D; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; Hui DY, 2002, J LIPID RES, V43, P2017, DOI 10.1194/jlr.R200013-JLR200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Petit-Thevenin J, 2001, BBA-MOL CELL BIOL L, V1530, P184, DOI 10.1016/S1388-1981(00)00181-5; Liang Y, 2000, J BIOL CHEM, V275, P24040, DOI 10.1074/jbc.M003187200; LOMBARDO D, 1983, EUR J BIOCHEM, V133, P327, DOI 10.1111/j.1432-1033.1983.tb07466.x; LOMBARDO D, 1980, BIOCHIM BIOPHYS ACTA, V611, P136, DOI 10.1016/0005-2744(80)90049-2; LOMBARDO D, 1980, BIOCHIM BIOPHYS ACTA, V611, P147, DOI 10.1016/0005-2744(80)90050-9; Lombardo D, 2001, BBA-MOL CELL BIOL L, V1533, P1, DOI 10.1016/S1388-1981(01)00130-5; Loomes KM, 1997, FEBS LETT, V405, P369, DOI 10.1016/S0014-5793(97)00215-9; Moore SA, 2001, J MOL BIOL, V312, P511, DOI 10.1006/jmbi.2001.4979; Nganga A, 2000, BIOCHEM J, V352, P865, DOI 10.1042/0264-6021:3520865; Sbarra V, 1998, BBA-LIPID LIPID MET, V1393, P80, DOI 10.1016/S0005-2760(98)00067-8; Terzyan S, 2000, PROTEIN SCI, V9, P1783, DOI 10.1110/ps.9.9.1783; VERINE A, 1982, AM J PHYSIOL, V243, pE175, DOI 10.1152/ajpendo.1982.243.3.E175; Verine A, 1999, BIOCHEM J, V342, P179, DOI 10.1042/0264-6021:3420179; WANG CS, 1981, J BIOL CHEM, V256, P198; Wang XQ, 1997, STRUCTURE, V5, P1209, DOI 10.1016/S0969-2126(97)00271-2	31	6	8	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39697	39704		10.1074/jbc.M407646200	http://dx.doi.org/10.1074/jbc.M407646200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15265857	hybrid			2022-12-27	WOS:000223791500061
J	Morales-Johansson, H; Jenoe, P; Cooke, FT; Hall, MN				Morales-Johansson, H; Jenoe, P; Cooke, FT; Hall, MN			Negative regulation of phosphatidylinositol 4,5-bisphosphate levels by the INP51-associated proteins TAX4 and IRS4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL INTEGRITY; GTP-BINDING PROTEIN; KINASE SUBSTRATE EPS15; EXCHANGE FACTOR ROM2; 170 KDA ISOFORM; SACCHAROMYCES-CEREVISIAE; ACTIN CYTOSKELETON; EH-DOMAIN; 4-PHOSPHATE 5-KINASE; PLASMA-MEMBRANE	Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P(2)) is an important second messenger in signaling pathways in organisms ranging from yeast to mammals, but the regulation of PI(4,5) P(2) levels remains unclear. Here we present evidence that PI(4,5) P(2) levels in Saccharomyces cerevisiae are down-regulated by the homologous and functionally redundant proteins TAX4 and IRS4. The EPS15 homology domain-containing proteins TAX4 and IRS4 bind and activate the PI(4,5) P(2) 5-phosphatase INP51 via an Asn-Pro-Phe motif in INP51. Furthermore, the INP51-TAX4/IRS4 complex negatively regulates the cell integrity pathway. Thus, TAX4 and IRS4 are novel regulators of PI(4,5) P(2) and PI(4,5)P(2)-dependent signaling. The interaction between TAX4/IRS4 and INP51 is analogous to the association of EPS15 with the 5-phosphatase synaptojanin 1 in mammalian cells, suggesting that EPS15 is an activator of synaptojanin 1.	Univ Basel, Biozentrum, Div Biochem, CH-4056 Basel, Switzerland; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of Basel; University of London; University College London	Hall, MN (corresponding author), Univ Basel, Biozentrum, Div Biochem, Klingelbergstr 70, CH-4056 Basel, Switzerland.	m.hall@unibas.ch		Hall, Michael N/0000-0002-2998-0757				ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; Audhya A, 2002, DEV CELL, V2, P593, DOI 10.1016/S1534-5807(02)00168-5; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Cremona O, 2001, J CELL SCI, V114, P1041; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; DENOBEL JG, 1991, YEAST, V7, P589, DOI 10.1002/yea.320070606; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; Faucherre A, 2003, HUM MOL GENET, V12, P2449, DOI 10.1093/hmg/ddg250; Gagny B, 2000, J CELL SCI, V113, P3309; Garcia-Rodriguez LJ, 2000, FEBS LETT, V478, P84, DOI 10.1016/S0014-5793(00)01835-4; GASCARD P, 1993, BIOCHEMISTRY-US, V32, P5941, DOI 10.1021/bi00074a004; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; Haffner C, 2000, CURR BIOL, V10, P471, DOI 10.1016/S0960-9822(00)00446-2; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Helliwell SB, 1998, GENETICS, V148, P99; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; HILGEMANN DW, 2001, SCI STKE; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Kaiser CA, 2002, METHOD ENZYMOL, V351, P325; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Loovers HM, 2003, J BIOL CHEM, V278, P5652, DOI 10.1074/jbc.M208396200; Malecz N, 2000, CURR BIOL, V10, P1383, DOI 10.1016/S0960-9822(00)00778-8; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Morinaka K, 1999, ONCOGENE, V18, P5915, DOI 10.1038/sj.onc.1202974; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; Philip B, 2001, MOL CELL BIOL, V21, P271, DOI 10.1128/MCB.21.1.271-280.2001; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Schmelzle T, 2002, MOL CELL BIOL, V22, P1329, DOI 10.1128/MCB.22.5.1329-1339.2002; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Smith JS, 1999, MOL CELL BIOL, V19, P3184; Song W, 2003, NEURON, V40, P665, DOI 10.1016/S0896-6273(03)00726-8; Stefan CJ, 2002, MOL BIOL CELL, V13, P542, DOI 10.1091/mbc.01-10-0476; Stolz LE, 1998, GENETICS, V148, P1715; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; SUCHY SF, 1995, HUM MOL GENET, V4, P2245, DOI 10.1093/hmg/4.12.2245; Tang HY, 1996, MOL CELL BIOL, V16, P4897; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Weernink PAO, 2004, J BIOL CHEM, V279, P7840, DOI 10.1074/jbc.M312737200; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	71	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39604	39610		10.1074/jbc.M405589200	http://dx.doi.org/10.1074/jbc.M405589200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15265867	hybrid, Green Accepted			2022-12-27	WOS:000223791500050
J	Serrato, AJ; Perez-Ruiz, JM; Spinola, MC; Cejudo, FJ				Serrato, AJ; Perez-Ruiz, JM; Spinola, MC; Cejudo, FJ			A novel NADPH thioredoxin reductase, localized in the chloroplast, which deficiency causes hypersensitivity to abiotic stress in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-CYSTEINE PEROXIREDOXIN; EXPRESSION; IDENTIFICATION; SYSTEM; PHOTOSYNTHESIS; SEQUENCE; PROTEIN; CLONING	Plants contain three thioredoxin systems. Chloroplast thioredoxins are reduced by ferredoxin-thioredoxin reductase, whereas the cytosolic and mitochondrial thioredoxins are reduced by NADPH thioredoxin reductase (NTR). There is high similarity among NTRs from plants, lower eukaryotes, and bacteria, which are different from mammal NTR. Here we describe the OsNTRC gene from rice encoding a novel NTR with a thioredoxin-like domain at the C terminus, hence, a putative NTR/thioredoxin system in a single polypeptide. Orthologous genes were found in other plants and cyanobacteria, but not in bacteria, yeast, or mammals. Full-length OsNTRC and constructs with truncated NTR and thioredoxin domains were expressed in Escherichia coli as His-tagged polypeptides, and a polyclonal antibody specifically cross-reacting with the OsNTRC enzyme was raised. An in vitro activity assay showed that OsNTRC is a bifunctional enzyme with both NTR and thioredoxin activity but is not an NTR/thioredoxin system. Although the OsNTRC gene was expressed in roots and shoots of rice seedlings, the protein was exclusively found in shoots and mature leaves. Moreover, fractionation experiments showed that OsNTRC is localized to the chloroplast. An Arabidopsis NTRC knock-out mutant showed growth inhibition and hypersensitivity to methyl viologen, drought, and salt stress. These results suggest that the NTRC gene is involved in plant protection against oxidative stress.	Ctr Invest Cient Isla Cartuja, Inst Bioquim Vegetal & Fotosintesis, Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF)	Cejudo, FJ (corresponding author), Ctr Invest Cient Isla Cartuja, Inst Bioquim Vegetal & Fotosintesis, Avda Amer Vespucio 49, Seville, Spain.	fjcejudo@us.es	Serrato, Antonio Jesús/H-1861-2015; Ruiz, Juan Manuel Perez/K-9238-2017; Serrato, Antonio Jesús/AAD-5008-2021; Cejudo, Francisco Javier/M-2749-2014	Serrato, Antonio Jesús/0000-0002-9570-9746; Ruiz, Juan Manuel Perez/0000-0002-9992-497X; Cejudo, Francisco Javier/0000-0002-3936-5491				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; BABBS CF, 1989, PLANT PHYSIOL, V90, P1267, DOI 10.1104/pp.90.4.1267; Baier M, 1999, TRENDS PLANT SCI, V4, P166, DOI 10.1016/S1360-1385(99)01398-9; Baier M, 1999, PLANT PHYSIOL, V119, P1407, DOI 10.1104/pp.119.4.1407; Baier M, 1997, PLANT J, V12, P179, DOI 10.1046/j.1365-313X.1997.12010179.x; Balmer Y, 2003, P NATL ACAD SCI USA, V100, P370, DOI 10.1073/pnas.232703799; Balmer Y, 2002, TRENDS PLANT SCI, V7, P191, DOI 10.1016/S1360-1385(02)02263-X; Broin M, 2002, PLANT CELL, V14, P1417, DOI 10.1105/tpc.001644; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; Collin V, 2003, J BIOL CHEM, V278, P23747, DOI 10.1074/jbc.M302077200; Dai SD, 1996, J MOL BIOL, V264, P1044, DOI 10.1006/jmbi.1996.0695; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; JACQUOT JP, 1994, J MOL BIOL, V235, P1357, DOI 10.1006/jmbi.1994.1091; Konig J, 2002, P NATL ACAD SCI USA, V99, P5738, DOI 10.1073/pnas.072644999; Laloi C, 2001, P NATL ACAD SCI USA, V98, P14144, DOI 10.1073/pnas.241340898; LEVINGS CS, 1995, SCIENCE, V268, P695, DOI 10.1126/science.268.5211.695; Mestres-Ortega D, 1999, GENE, V240, P307, DOI 10.1016/S0378-1119(99)00448-5; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Motohashi K, 2001, P NATL ACAD SCI USA, V98, P11224, DOI 10.1073/pnas.191282098; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; PRICE CA, 1994, PLANT MOL BIOL MANUA, P1; Ruelland E, 1999, TRENDS PLANT SCI, V4, P136, DOI 10.1016/S1360-1385(99)01391-6; Sanchez R, 2003, PLANT PHYSIOL, V132, P949, DOI 10.1104/pp.102.019653; Schurmann P, 2000, ANNU REV PLANT PHYS, V51, P371, DOI 10.1146/annurev.arplant.51.1.371; Serrato A. J., 2002, BIOCHEM J, V217, P392, DOI [10.1042/BJ20020103, DOI 10.1042/BJ20020103]; Serrato AJ, 2001, PLANT MOL BIOL, V46, P361, DOI 10.1023/A:1010697331184; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; WIELES B, 1995, J BIOL CHEM, V270, P25604, DOI 10.1074/jbc.270.43.25604; WIELES B, 1995, MOL MICROBIOL, V16, P921, DOI 10.1111/j.1365-2958.1995.tb02318.x; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x	34	268	276	3	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43821	43827		10.1074/jbc.M404696200	http://dx.doi.org/10.1074/jbc.M404696200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292215	hybrid			2022-12-27	WOS:000224383100058
J	Bordelon, T; Montegudo, SK; Pakhomova, S; Oldham, ML; Newcomer, ME				Bordelon, T; Montegudo, SK; Pakhomova, S; Oldham, ML; Newcomer, ME			A disorder to order transition accompanies catalysis in retinaldehyde dehydrogenase type II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ALDEHYDE DEHYDROGENASE; RETINOIC ACID SYNTHESIS; SITE-DIRECTED MUTAGENESIS; ANGSTROM RESOLUTION; ORIENTAL SUBUNIT; ACTIVE-SITE; INVOLVEMENT; MOUSE; RAT; SPECIFICITY	Retinaldehyde dehydrogenase II (RalDH2) converts retinal to the transcriptional regulator retinoic acid in the developing embryo. The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel. We asked whether this disordered loop might order during the course of catalysis and provide a means for an enzyme that requires a large substrate access channel to restrict access to the catalytic machinery by smaller compounds that might potentially enter the active site and be metabolized. Our experiments, a combination of kinetic, spectroscopic, and crystallographic techniques, suggest that a disorder to order transition is linked to catalytic activity.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Newcomer, ME (corresponding author), Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA.	newcomer@lsu.edu			NIGMS NIH HHS [GM 55420] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Bateman OA, 2003, BIOCHEMISTRY-US, V42, P4349, DOI 10.1021/bi027367w; FARRES J, 1995, BIOCHEMISTRY-US, V34, P2592, DOI 10.1021/bi00008a025; FARRES J, 1994, J BIOL CHEM, V269, P13854; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Gagnon I, 2002, BBA-PROTEIN STRUCT M, V1596, P156, DOI 10.1016/S0167-4838(02)00213-3; Hammen PK, 2002, BIOCHEMISTRY-US, V41, P7156, DOI 10.1021/bi012197t; Hurley TD, 2001, CHEM-BIOL INTERACT, V130, P3, DOI 10.1016/S0009-2797(00)00217-9; Johansson K, 1998, PROTEIN SCI, V7, P2106, DOI 10.1002/pro.5560071007; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Lamb AL, 1999, BIOCHEMISTRY-US, V38, P6003, DOI 10.1021/bi9900471; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; Mark M, 1999, P NUTR SOC, V58, P609, DOI 10.1017/S0029665199000798; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7194, DOI 10.1073/pnas.91.15.7194; McCaffery PJ, 2003, EUR J NEUROSCI, V18, P457, DOI 10.1046/j.1460-9568.2003.02765.x; Moore SA, 1998, STRUCTURE, V6, P1541, DOI 10.1016/S0969-2126(98)00152-X; Moss JB, 1998, DEV BIOL, V199, P55, DOI 10.1006/dbio.1998.8911; Ni L, 1997, J BIOL CHEM, V272, P18823, DOI 10.1074/jbc.272.30.18823; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; OTWINOWSKI Z, 1993, CCP4 STUDY WEEKEND D, P56; Perez-Miller SJ, 2003, BIOCHEMISTRY-US, V42, P7100, DOI 10.1021/bi034182w; ROUT UK, 1994, BIOCHEMISTRY-US, V33, P8955, DOI 10.1021/bi00196a013; Sheikh S, 1997, J BIOL CHEM, V272, P18817, DOI 10.1074/jbc.272.30.18817; STEINBERG IZ, 1971, ANNU REV BIOCHEM, V40, P83, DOI 10.1146/annurev.bi.40.070171.000503; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; WANG XP, 1995, BIOCHEMISTRY-US, V34, P237, DOI 10.1021/bi00001a028; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; WEINER H, 1976, J BIOL CHEM, V251, P3853; Weiner H, 2001, CHEM-BIOL INTERACT, V130, P47, DOI 10.1016/S0009-2797(00)00221-0; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x; Zhou JZ, 2000, BIOCHEMISTRY-US, V39, P12019, DOI 10.1021/bi001221k	32	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43085	43091		10.1074/jbc.M406139200	http://dx.doi.org/10.1074/jbc.M406139200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15299009	Green Published, hybrid			2022-12-27	WOS:000224226400092
J	Lundmark, R; Carlsson, SR				Lundmark, R; Carlsson, SR			Regulated membrane recruitment of dynamin-2 mediated by sorting nexin 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; PROTEIN INTERACTIONS; AXONAL GUIDANCE; F-ACTIN; CLATHRIN; BINDING; DOMAIN; ALDOLASE; RECEPTOR; PLASMODIUM	The endocytic proteins sorting nexin 9 (SNX9) and dynamin-2 (Dyn2) assemble in the cytosol as a resting complex, together with a 41-kDa protein. We show here that the complex can be activated for membrane binding of SNX9 and Dyn2 by incubation of cytosol in the presence of ATP. SNX9 was essential for Dyn2 recruitment, whereas the reverse was not the case. RNA interference experiments confirmed that SNX9 functions as a mediator of Dyn2 recruitment to membranes in cells. The 41-kDa component was identified as the glycolytic enzyme aldolase. Aldolase bound with high affinity to a tryptophan-containing acidic sequence in SNX9 located close to its Phox homology domain, thereby blocking the membrane binding activity of SNX9. Phosphorylation of SNX9 released aldolase from the native cytosolic complex and rendered SNX9 competent for membrane binding. The results suggest that SNX9-dependent recruitment of Dyn2 to the membrane is regulated by an interaction between SNX9 and aldolase.	Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden	Umea University	Carlsson, SR (corresponding author), Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden.	sven.carlsson@medkem.umu.se		Carlsson, Sven R/0000-0001-5123-135X				Buscaglia CA, 2003, MOL BIOL CELL, V14, P4947, DOI 10.1091/mbc.E03-06-0355; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Habermann B, 2004, EMBO REP, V5, P250, DOI 10.1038/sj.embor.7400105; Hill E, 2001, J CELL BIOL, V152, P309, DOI 10.1083/jcb.152.2.309; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742; Kim H, 1998, BIOCHEMISTRY-US, V37, P4388, DOI 10.1021/bi972233h; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Kusakabe T, 1997, ARCH BIOCHEM BIOPHYS, V344, P184, DOI 10.1006/abbi.1997.0204; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Leprince C, 2003, J CELL SCI, V116, P1937, DOI 10.1242/jcs.00403; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; Lundmark R, 2003, J BIOL CHEM, V278, P46772, DOI 10.1074/jbc.M307334200; Lundmark R, 2002, BIOCHEM J, V362, P597, DOI 10.1042/0264-6021:3620597; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; Miele AE, 2004, NAT STRUCT MOL BIOL, V11, P242, DOI 10.1038/nsmb736; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Schafer DA, 2004, TRAFFIC, V5, P463, DOI 10.1111/j.1600-0854.2004.00199.x; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schulze WX, 2004, J BIOL CHEM, V279, P10756, DOI 10.1074/jbc.M309909200; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; STECK TL, 1978, J SUPRAMOL STR CELL, V8, P311, DOI 10.1002/jss.400080309; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Szaszak M, 2002, J BIOL CHEM, V277, P21650, DOI 10.1074/jbc.M200778200; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Volker KW, 1997, ARCH BIOCHEM BIOPHYS, V338, P237, DOI 10.1006/abbi.1996.9819; Wang JA, 1996, J BIOL CHEM, V271, P6861, DOI 10.1074/jbc.271.12.6861; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Worby CA, 2002, J BIOL CHEM, V277, P9422, DOI 10.1074/jbc.M110172200; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Worby CA, 2001, J BIOL CHEM, V276, P41782, DOI 10.1074/jbc.M107080200; Zhang PJ, 2001, NAT CELL BIOL, V3, P922, DOI 10.1038/ncb1001-922	43	79	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42694	42702		10.1074/jbc.M407430200	http://dx.doi.org/10.1074/jbc.M407430200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15299020	hybrid			2022-12-27	WOS:000224226400043
J	Clarke, TA; Dennison, V; Seward, HE; Burlat, B; Cole, JA; Hemmings, AM; Richardson, DJ				Clarke, TA; Dennison, V; Seward, HE; Burlat, B; Cole, JA; Hemmings, AM; Richardson, DJ			Purification and spectropotentiometric characterization of Escherichia coli NrfB, a decaheme homodimer that transfers electrons to the decaheme periplasmic nitrite reductase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; CYTOCHROME-C; WOLINELLA-SUCCINOGENES; FUMARATE REDUCTASE; NITRATE REDUCTION; RESOLUTION; TRANSPORT; PRODUCTS; GENES; EPR	Escherichia coli can reduce nitrite to ammonium via a 120-kDa decaheme homodimeric periplasmic nitrite reductase (NrfA) complex. Recent structure-based spectropotentiometric studies are shedding light on the catalytic mechanism of NrfA; however, electron input into the enzyme has not been addressed biochemically. This study reports the first purification of NrfB, a novel 20-kDa pentaheme c-type cytochrome encoded by the nrfB gene that follows the nrfA gene in many bacterial nrf operons. Analyses by gel filtration demonstrated that NrfB purifies as a decaheme homodimer. Analysis of NrfB by UV-visible and magnetic circular dichroism spectroscopy demonstrates that all five NrfB ferric heme irons are low spin and are most likely coordinated by two axial histidine ligands. Spectropotentiometry revealed that the midpoint redox potentials of five ferric hemes were in the low potential range of 0 to -400 mV. Analysis by low temperature EPR spectroscopy revealed signals that arise from two classes of bis-His ligated low spin hemes, namely a rhombic trio at g(1,2,3)=2.99, 2.27, and 1.5 that arises from two hemes in which the planes of histidine imidazole rings are near-parallel and a large g(max) signal at g=3.57 that arises from three hemes in which the planes of the histidine imidazole rings are near-perpendicular. NrfB was also overexpressed as a recombinant protein, which had similar spectropotentiometric properties as the native protein. Reconstitution experiments demonstrated that the reduced decaheme NrfB dimer could serve as a direct electron donor to the oxidized decaheme NrfA dimer, thus forming a transient 20-heme [NrfB](2)[NrfA](2) electron transfer complex.	Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Chem Sci, Norwich NR4 7TJ, Norfolk, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of East Anglia; University of East Anglia; University of Birmingham	Richardson, DJ (corresponding author), Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.	d.richardson@uea.ac.uk	clarke, tom/D-1837-2009; HEMMINGS, ANDREW MICHAEL/E-5517-2011; Richardson, David J/E-2275-2011	clarke, tom/0000-0002-6234-1914; HEMMINGS, ANDREW MICHAEL/0000-0003-3053-3134; 	Biotechnology and Biological Sciences Research Council [B18695] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bamford V, 1999, NAT STRUCT BIOL, V6, P1104; Bamford VA, 2002, BIOCHEMISTRY-US, V41, P2921, DOI 10.1021/bi015765d; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BLACKMORE RS, 1987, FEBS LETT, V219, P244, DOI 10.1016/0014-5793(87)81225-5; BLACKMORE RS, 1990, FEBS LETT, V264, P257, DOI 10.1016/0014-5793(90)80262-H; DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P334; Eaves DJ, 1998, MOL MICROBIOL, V28, P205, DOI 10.1046/j.1365-2958.1998.00792.x; Einsle O, 2000, J BIOL CHEM, V275, P39608, DOI 10.1074/jbc.M006188200; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; Einsle O, 2002, J AM CHEM SOC, V124, P11737, DOI 10.1021/ja0206487; Leys D, 2002, J BIOL CHEM, V277, P35703, DOI 10.1074/jbc.M203866200; MOORE G, 1990, SPRINGER SERIES MOL, P316; Pitts KE, 2003, J BIOL CHEM, V278, P27758, DOI 10.1074/jbc.M302582200; Poock SR, 2002, J BIOL CHEM, V277, P23664, DOI 10.1074/jbc.M200731200; Potter L, 2001, ADV MICROB PHYSIOL, V45, P51, DOI 10.1016/S0065-2911(01)45002-8; Potter LC, 1999, BIOCHEM J, V344, P69, DOI 10.1042/0264-6021:3440069; Potter LC, 1999, BIOCHEM J, V344, P77, DOI 10.1042/0264-6021:3440077; Roldan MD, 1998, J BIOL CHEM, V273, P28785, DOI 10.1074/jbc.273.44.28785; Simon J, 2000, MOL MICROBIOL, V35, P686, DOI 10.1046/j.1365-2958.2000.01742.x; Simon J, 2002, FEMS MICROBIOL REV, V26, P285, DOI 10.1111/j.1574-6976.2002.tb00616.x; Taylor P, 1999, NAT STRUCT BIOL, V6, P1108; THOMSON AJ, 1993, METHOD ENZYMOL, V226, P199, DOI 10.1016/0076-6879(93)26011-W; TYSON KL, 1994, MOL MICROBIOL, V13, P1045, DOI 10.1111/j.1365-2958.1994.tb00495.x; Walker FA, 1999, COORDIN CHEM REV, V185-6, P471, DOI 10.1016/S0010-8545(99)00029-6	24	29	31	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41333	41339		10.1074/jbc.M407604200	http://dx.doi.org/10.1074/jbc.M407604200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280383	hybrid			2022-12-27	WOS:000224075500012
J	Denis, M; Haidar, B; Marcil, M; Bouvier, M; Krimbou, L; Genest, J				Denis, M; Haidar, B; Marcil, M; Bouvier, M; Krimbou, L; Genest, J			Characterization of oligomeric human ATP binding cassette transporter A1 - Potential implications for determining the structure of nascent high density lipoprotein particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL EFFLUX; ABCA1 TRANSPORTER; TANGIER-DISEASE; PROTEIN; GENE; PHOSPHORYLATION; DEFICIENCY; MUTATIONS; PLASMA; LIPIDATION	The oligomeric structure of ABCA1 transporter and its function related to the biogenesis of nascent apoA-I-containing particles (LpA-I) were investigated. Using n-dodecylmaltoside and perfluoro-octanoic acid combined with non-denaturing gel, the majority of ABCA1 was found as a tetramer in ABCA1-induced human fibroblasts. Furthermore, using chemical cross-linking and SDS-PAGE, ABCA1 dimers but not the tetramers were found covalently linked. Oligomeric ABCA1 was present in isolated plasma membranes as well as in intracellular compartments. Interestingly, apoA-I was found to be associated with both dimeric and tetrameric, but not monomeric, forms of ABCA1. Neither apoA-I nor lipid molecules did affect ABCA1 oligomerization. Immunoprecipitation analysis showed that oligomeric ABCA1 did not contain other associated proteins. We next investigated the relationship between the oligomeric ABCA1 complex and the structure of LpA-I. Lipid-free apoA-I incubated with normal cells generated LpA-I with diameters between 9.5 and 20 nm. Subsequent isolation of LpA-I followed by cross-linking revealed the presence of four and eight apoA-I molecules per particle, whereas apoA-I incubated with ABCA1 mutant (Q597R) cells was unable to form such particles and remained in the monomeric form. These results demonstrate that: 1) ABCA1 exists as an oligomeric complex; and 2) ABCA1 oligomerization was independent of apoA-I binding and lipid molecules. The findings that the majority of ABCA1 exists as a tetramer that binds apoA-I, together with the observation that LpA-I contains at least four molecules of apoA-I per particle, support the concept that the homotetrameric ABCA1 complex constitutes the minimum functional unit required for the biogenesis of high density lipoprotein particles.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Cardiol,Cardiovasc Genet Lab, Montreal, PQ H3A 1A1, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada	McGill University; Royal Victoria Hospital; Universite de Montreal	Genest, J (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Cardiol,Cardiovasc Genet Lab, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	jacques.genest@muhc.mcgill.ca	Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100				Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Bennett KL, 2000, PROTEIN SCI, V9, P1503, DOI 10.1110/ps.9.8.1503; Brewer HB, 2003, AM J CARDIOL, V91, p3E, DOI 10.1016/S0002-9149(02)03382-9; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Croop JM, 1998, METHOD ENZYMOL, V292, P101; DAVIDSON WS, 1994, J BIOL CHEM, V269, P8959; Davidson WS, 2003, J BIOL CHEM, V278, P27199, DOI 10.1074/jbc.M302764200; Denis M, 2004, J BIOL CHEM, V279, P7384, DOI 10.1074/jbc.M306963200; Gursky O, 1996, P NATL ACAD SCI USA, V93, P2991, DOI 10.1073/pnas.93.7.2991; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; Haidar B, 2004, J BIOL CHEM, V279, P9963, DOI 10.1074/jbc.M313487200; Krimbou L, 1998, J LIPID RES, V39, P861; Krimbou L, 2004, J LIPID RES, V45, P839, DOI 10.1194/jlr.M300418-JLR200; Krimbou L, 2001, J BIOL CHEM, V276, P33241, DOI 10.1074/jbc.M100326200; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Marcil M, 2003, CIRCULATION, V107, P1366, DOI 10.1161/01.CIR.0000056764.53152.F9; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; Neufeld EB, 2004, J BIOL CHEM, V279, P15571, DOI 10.1074/jbc.M314160200; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Ramjeesingh M, 2001, BIOCHEMISTRY-US, V40, P10700, DOI 10.1021/bi0108195; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; SARKADI B, 1992, J BIOL CHEM, V267, P4854; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; Singaraja RR, 2003, ARTERIOSCL THROM VAS, V23, P1322, DOI 10.1161/01.ATV.0000078520.89539.77; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; TALL AR, 1993, J LIPID RES, V34, P1255; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Witting SR, 2003, J BIOL CHEM, V278, P40121, DOI 10.1074/jbc.M305193200; Xu JK, 2004, J BIOL CHEM, V279, P19781, DOI 10.1074/jbc.M310785200	36	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41529	41536		10.1074/jbc.M406881200	http://dx.doi.org/10.1074/jbc.M406881200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280376	hybrid			2022-12-27	WOS:000224075500036
J	Metge, B; Ofori-Acquah, S; Stevens, T; Balczon, R				Metge, B; Ofori-Acquah, S; Stevens, T; Balczon, R			Stat3 activity is required for centrosome duplication in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASES; PHOSPHOLIPASE-C; GAMMA-TUBULIN; AMPLIFICATION; PHOSPHORYLATION; TRANSDUCER; BINDING	The centrosome is the major microtubule organizing center in mammalian cells. During interphase, the single centrosome is duplicated and the progeny centrosomes then serve as the spindle poles during mitosis. Little is known about the signals that drive centrosome doubling. In these studies, various inhibitors and molecular approaches were used to demonstrate a role for the Stat pathway in regulating the events of centrosome doubling. Both piceatannol and a dominant negative behaving Stat3 adenovirus were able to disrupt centrosome duplication in hydroxyurea-arrested Chinese hamster ovary cells, demonstrating that Stat3 is a key signaling molecule in the events of centrosome duplication. Investigation into the role of Stat3 signaling during centrosome production demonstrated that Stat3 does not directly regulate the transcription of the centrosome genes encoding gamma-tubulin and PCM-1. Instead, Stat3 apparently regulated gamma-tubulin levels through post-transcriptional mechanisms whereas PCM-1 levels actually increased when Stat3 was inhibited, suggesting more complex mechanisms for regulating PCM-1 production. These studies demonstrate that Stat3 plays a vital role in centrosome duplication events, although the downstream targets of Stat3 activation leading to centrosome production remain to be established. The proposed signaling pathway utilizes Stat3 as a fundamental signaling molecule that directs the production of the various centrosome proteins indirectly.	Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA; Univ S Alabama, Dept Pharmacol, Mobile, AL 36688 USA; Univ S Alabama, Ctr Lung Biol, Mobile, AL 36688 USA	University of South Alabama; University of South Alabama; University of South Alabama	Balczon, R (corresponding author), Univ S Alabama, Dept Cell Biol & Neurosci, MSB 1201, Mobile, AL 36688 USA.	balczonr@sungcg.usouthal.edu		Ofori-Acquah, Solomon/0000-0001-5000-3048				Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Balczon R, 2002, CELL MOTIL CYTOSKEL, V52, P183, DOI 10.1002/cm.10043; Balczon R, 2001, CHROMOSOMA, V110, P381, DOI 10.1007/s004120100157; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; DeArmond D, 2003, ONCOGENE, V22, P7781, DOI 10.1038/sj.onc.1206966; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Dumontet C, 1996, CELL MOTIL CYTOSKEL, V35, P49, DOI 10.1002/(SICI)1097-0169(1996)35:1<49::AID-CM4>3.0.CO;2-D; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GERGEL JR, 1994, BIOCHEMISTRY-US, V33, P14671, DOI 10.1021/bi00253a004; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kubo A, 2003, J CELL SCI, V116, P919, DOI 10.1242/jcs.00282; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Maritano D, 2004, NAT IMMUNOL, V5, P401, DOI 10.1038/ni1052; MASCARDO RN, 1984, DIABETES, V33, P1099, DOI 10.2337/diabetes.33.11.1099; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Scholz A, 2003, GASTROENTEROLOGY, V125, P891, DOI 10.1016/S0016-5085(03)01064-3; SELVA E, 1993, J BIOL CHEM, V268, P2250; SHERLINE P, 1982, J CELL BIOL, V95, P316, DOI 10.1083/jcb.95.1.316; SHU HB, 1995, J CELL BIOL, V130, P1137, DOI 10.1083/jcb.130.5.1137; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Toyonaga T, 2003, CANCER LETT, V201, P107, DOI 10.1016/S0304-3835(03)00482-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wiese C, 2000, NAT CELL BIOL, V2, P358, DOI 10.1038/35014051; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	39	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41801	41806		10.1074/jbc.M407094200	http://dx.doi.org/10.1074/jbc.M407094200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15294906	hybrid			2022-12-27	WOS:000224075500069
J	Newman, RM; Mobascher, A; Mangold, U; Koike, C; Diah, S; Schmidt, M; Finley, D; Zetter, BR				Newman, RM; Mobascher, A; Mangold, U; Koike, C; Diah, S; Schmidt, M; Finley, D; Zetter, BR			Antizyme targets cyclin D1 for degradation - A novel mechanism for cell growth repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE-DECARBOXYLASE ANTIZYME; RETINOBLASTOMA PROTEIN; PROTEASOME PATHWAY; NUCLEAR EXPORT; EXPRESSION; INHIBITOR; POLYAMINES; INDUCTION; PHOSPHORYLATION; CARCINOGENESIS	Overproduction of the ornithine decarboxylase (ODC) regulatory protein ODC-antizyme has been shown to correlate with cell growth inhibition in a variety of different cell types. Although the exact mechanism of this growth inhibition is not known, it has been attributed to the effect of antizyme on polyamine metabolism. Antizyme binds directly to ODC, targeting ODC for ubiquitin-independent degradation by the 26 S proteasome. We now show that antizyme induction also leads to degradation of the cell cycle regulatory protein cyclin D1. We demonstrate that antizyme is capable of specific, noncovalent association with cyclin D1 and that this interaction accelerates cyclin D1 degradation in vitro in the presence of only antizyme, cyclin D1, purified 26 S proteasomes, and ATP. In vivo, antizyme up-regulation induced either by the polyamine spermine or by antizyme overexpression causes reduction of intracellular cyclin D1 levels. The antizyme-mediated pathway for cyclin D1 degradation is independent of the previously characterized phosphorylation- and ubiquitination-dependent pathway, because antizyme up-regulation induces the degradation of a cyclin D1 mutant (T286A) that abrogates its ubiquitination. We propose that antizyme-mediated degradation of cyclin D1 by the proteasome may provide an explanation for the repression of cell growth following antizyme up-regulation.	Childrens Hosp, Program Vasc Biol, Boston, MA 02115 USA; Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Zetter, BR (corresponding author), Childrens Hosp, Program Vasc Biol, Karp Bldg,Rm 11-125,300 Longwood Ave, Boston, MA 02115 USA.	Bruce.Zetter@childrens.harvard.edu	Loizides-Mangold, Ursula/I-9061-2014	Loizides-Mangold, Ursula/0000-0001-9233-2974	NCI NIH HHS [CA37393] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA037393, R01CA037393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RD, 1987, AM J REPROD IMMUNOL, V13, P4; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Bettuzzi S, 1999, FEBS LETT, V446, P18, DOI 10.1016/S0014-5793(99)00182-9; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; BRUNTON VG, 1991, BIOCHEM J, V280, P193, DOI 10.1042/bj2800193; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Coffino P, 2001, BIOCHIMIE, V83, P319, DOI 10.1016/S0300-9084(01)01252-4; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Feith DJ, 2001, CANCER RES, V61, P6073; Fong LYY, 2003, CANCER RES, V63, P3945; FREDLUND JO, 1995, EXP CELL RES, V216, P86, DOI 10.1006/excr.1995.1011; Gritli-Linde A, 2001, DEV DYNAM, V220, P259, DOI 10.1002/1097-0177(20010301)220:3<259::AID-DVDY1100>3.0.CO;2-#; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; Ivanov IP, 2000, EMBO J, V19, P1907, DOI 10.1093/emboj/19.8.1907; Iwata S, 1999, ONCOGENE, V18, P165, DOI 10.1038/sj.onc.1202275; KATO J, 1993, GENE DEV, V7, P331; KITANI T, 1989, BIOCHIM BIOPHYS ACTA, V991, P44, DOI 10.1016/0304-4165(89)90026-3; Koguchi K, 1997, BBA-GENE STRUCT EXPR, V1353, P209, DOI 10.1016/S0167-4781(97)00106-1; Koike C, 1999, CANCER RES, V59, P6109; Lin Y, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-15; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; Mitchell JLA, 2002, BIOCHEM J, V366, P663, DOI 10.1042/BJ20011612; Murai N, 2003, J BIOL CHEM, V278, P44791, DOI 10.1074/jbc.M308059200; MURAKAMI Y, 1994, BIOCHEM J, V304, P183, DOI 10.1042/bj3040183; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; Nilsson J, 2000, BIOCHEM J, V346, P699, DOI 10.1042/0264-6021:3460699; Oredsson SM, 2003, BIOCHEM SOC T, V31, P366, DOI 10.1042/BST0310366; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; SMITH RC, 1995, NAT MED, V1, P1040, DOI 10.1038/nm1095-1040; Tsuji T, 2001, ONCOGENE, V20, P24, DOI 10.1038/sj.onc.1204051; Tsuji T, 1998, ONCOGENE, V16, P3379, DOI 10.1038/sj.onc.1201887; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; WEBBER MM, 1980, CELL BIOL INT REP, V4, P185, DOI 10.1016/0309-1651(80)90073-9	41	120	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41504	41511		10.1074/jbc.M407349200	http://dx.doi.org/10.1074/jbc.M407349200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15277517	hybrid			2022-12-27	WOS:000224075500033
J	Srinivasan, B; Roque, CH; Hempstead, BL; Al-Ubaidi, MR; Roque, RS				Srinivasan, B; Roque, CH; Hempstead, BL; Al-Ubaidi, MR; Roque, RS			Microglia-derived pronerve growth factor promotes photoreceptor cell death via p75 neurotrophin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; RAT RETINA; IN-VITRO; HIPPOCAMPAL-NEURONS; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; MESSENGER-RNA; NGF RECEPTOR; EXPRESSION; APOPTOSIS	Reports implicating microglia-derived nerve growth factor (NGF) during programmed cell death in the developing chick retina led us to investigate its possible role in degenerative retinal disease. Freshly isolated activated retinal microglia expressed high molecular weight forms of neurotrophins including that of nerve growth factor (NGF), brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4. Conditioned media from cultured retinal microglia (MGCM) consistently yielded a similar to32-kDa NGF-reactive band when supplemented with bovine serum albumin (BSA) or protease inhibitors (PI); and promoted cell death that was suppressed by NGF immunodepletion in a mouse photoreceptor cell line (661w). The similar to32 kDa protein was partially purified (MGCM/p32) and was highly immunoreactive with a polyclonal anti-pro-NGF antibody. Both MGCM/p32 and recombinant pro-NGF protein promoted cell death in 661w cultures. Increased levels of pro-NGF mRNA and protein were observed in the RCS rat model of retinal dystrophy. MGCM-mediated cell death was reversed by p75NTR antiserum in p75NTR(+)/trkA(-) 661w cells. Our study shows that a similar to32 kDa pro-NGF protein released by activated retinal microglia promoted degeneration of cultured photoreceptor cells. Moreover, our study suggests that defective post-translational processing of NGF might be involved in photoreceptor cell loss in retinal dystrophy.	Univ N Texas, Hlth Sci Ctr, Dept Cell Biol & Genet, Ft Worth, TX 76107 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA	University of North Texas System; University of North Texas Health Science Center; Cornell University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Roque, RS (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Cell Biol & Genet, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	rroque@hsc.unt.edu			NEI NIH HHS [EY10766] Funding Source: Medline; NINDS NIH HHS [NS30687] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY010766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030687] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allington C, 2001, CELL DEATH DIFFER, V8, P451, DOI 10.1038/sj.cdd.4400831; ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Brann AB, 1999, J NEUROSCI, V19, P8199; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; CARMIGNOTO G, 1991, EXP NEUROL, V111, P302, DOI 10.1016/0014-4886(91)90097-V; Carter BD, 1997, NEURON, V18, P187, DOI 10.1016/S0896-6273(00)80259-7; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; Coulson EJ, 2000, CLIN EXP PHARMACOL P, V27, P537, DOI 10.1046/j.1440-1681.2000.03295.x; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; Elkabes S, 1996, J NEUROSCI, V16, P2508; Fahnestock M, 2001, MOL CELL NEUROSCI, V18, P210, DOI 10.1006/mcne.2001.1016; Frade JM, 2000, J CELL SCI, V113, P1139; Frade JM, 1998, NEURON, V20, P35, DOI 10.1016/S0896-6273(00)80432-8; Frade JM, 1996, NATURE, V383, P166; Friedman WJ, 2000, J NEUROSCI, V20, P6340, DOI 10.1523/JNEUROSCI.20-17-06340.2000; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Hallbook F, 1996, J COMP NEUROL, V364, P664; Harada T, 2000, NEURON, V26, P533, DOI 10.1016/S0896-6273(00)81185-X; Heese K, 1997, NEUROSCI LETT, V231, P83, DOI 10.1016/S0304-3940(97)00545-4; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HETIER E, 1988, J NEUROSCI RES, V21, P391, DOI 10.1002/jnr.490210230; Hu B, 1998, GLIA, V24, P187, DOI 10.1002/(SICI)1098-1136(199810)24:2<187::AID-GLIA4>3.3.CO;2-Z; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; HUBER LJ, 1995, DEV BIOL, V167, P227, DOI 10.1006/dbio.1995.1019; Jingjing Liu, 2001, Angiogenesis, V4, P103, DOI 10.1023/A:1012214931986; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Krishnamoorthy RR, 1999, J BIOL CHEM, V274, P3734, DOI 10.1074/jbc.274.6.3734; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Liu JJ, 1999, INVEST OPHTH VIS SCI, V40, P752; Llamosas MM, 1997, ANAT EMBRYOL, V195, P337, DOI 10.1007/s004290050053; MALLAT M, 1989, DEV BIOL, V133, P309, DOI 10.1016/0012-1606(89)90322-9; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Ng TF, 2001, INVEST OPHTH VIS SCI, V42, P3301; Nichols A, 1998, APOPTOSIS, V3, P289, DOI 10.1023/A:1009617426753; RICKMAN DW, 1995, VISUAL NEUROSCI, V12, P215, DOI 10.1017/S0952523800007896; Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X; ROQUE RS, 1993, CURR EYE RES, V12, P285, DOI 10.3109/02713689308999475; Roque RS, 1996, INVEST OPHTH VIS SCI, V37, P196; Rosales AA, 1997, BRAIN RES, V748, P195, DOI 10.1016/S0006-8993(96)01301-7; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; Sheedlo HJ, 2002, MOL BRAIN RES, V103, P71, DOI 10.1016/S0169-328X(02)00185-7; Soilu-Hanninen M, 1999, J NEUROSCI, V19, P4828; Syroid DE, 2000, J NEUROSCI, V20, P5741, DOI 10.1523/JNEUROSCI.20-15-05741.2000; Tan E, 2004, INVEST OPHTH VIS SCI, V45, P764, DOI 10.1167/iovs.03-1114; Taylor S, 2003, MOL BRAIN RES, V111, P189, DOI 10.1016/S0169-328X(03)00030-5; THANOS S, 1992, BRAIN RES, V588, P21, DOI 10.1016/0006-8993(92)91340-K; Ugolini G, 1995, BRAIN RES, V704, P121, DOI 10.1016/0006-8993(95)01191-9; Vecino E, 1998, GEN PHARMACOL-VASC S, V30, P305, DOI 10.1016/S0306-3623(97)00361-3; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9; Yoon SO, 1998, J NEUROSCI, V18, P3273; ZUPAN AA, 1989, J BIOL CHEM, V264, P11714	63	82	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41839	41845		10.1074/jbc.M402872200	http://dx.doi.org/10.1074/jbc.M402872200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15277529	hybrid			2022-12-27	WOS:000224075500074
J	Ueda, K; Kosako, H; Fukui, Y; Hattori, S				Ueda, K; Kosako, H; Fukui, Y; Hattori, S			Proteomic identification of Bcl2-associated athanogene 2 as a novel MAPK-activated protein kinase 2 substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS; DEATH DOMAINS; HEAT-SHOCK; KINASE 2; PROTEIN; P38; PHOSPHORYLATION; BINDING; CASCADE; STRESS	The p38 MAPK cascade is activated by various stresses or cytokines. Downstream of p38 MAPKs, there are diversification and extensive branching of signaling pathways. Fluorescent two-dimensional difference gel electrophoresis of phosphoprotein-enriched samples from HeLa cells in which p38 MAPK activity was either suppressed or activated enabled us to detect similar to90 candidate spots for factors involved in p38-dependent pathways. Among these candidates, here we identified four proteins including Bcl-2-associated athanogene 2 (BAG2) by peptide mass fingerprintings. BAG family proteins are highly conserved throughout eukaryotes and regulate Hsc/Hsp70-mediated molecular chaperone activities and apoptosis. The results of two-dimensional immunoblots suggested that the phosphorylation of BAG2 was specifically controlled in a p38 MAPK-dependent manner. Furthermore, BAG2 was directly phosphorylated at serine 20 in vitro by MAPK-activated protein kinase 2 (MAPKAP kinase 2), which is known as a primary substrate of p38 MAPK and mediates several p38 MAPK-dependent processes. We confirmed that MAPKAP kinase 2 is also required for phosphorylation of BAG2 in vivo. Thus, p38 MAPK-MAPKAP kinase 2-BAG2 phosphorylation cascade may be a novel signaling pathway for response to extracellular stresses.	Univ Tokyo, Inst Med Sci, Div Cellular Proteom BML, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Fac Agr & Life Sci, Dept Appl Biol Chem, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo	Kosako, H (corresponding author), Univ Tokyo, Inst Med Sci, Div Cellular Proteom BML, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	kosako@ims.u-tokyo.ac.jp; hattoris@ims.u-tokyo.ac.jp	Fukui, Yasuhisa/E-8806-2010					Antoku K, 2001, BIOCHEM BIOPH RES CO, V286, P1003, DOI 10.1006/bbrc.2001.5512; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bonelli P, 2004, LEUKEMIA, V18, P358, DOI 10.1038/sj.leu.2403219; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chrestensen CA, 2004, J BIOL CHEM, V279, P10176, DOI 10.1074/jbc.M310486200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DeSilva DR, 1998, J IMMUNOL, V160, P4175; HAN JH, 1994, J BIOL CHEM, V269, P8172; Hannigan MO, 2001, J IMMUNOL, V167, P3953, DOI 10.4049/jimmunol.167.7.3953; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LANDRY J, 1992, J BIOL CHEM, V267, P794; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sette C, 1999, J BIOL CHEM, V274, P33571, DOI 10.1074/jbc.274.47.33571; Singh S, 2003, J BIOL CHEM, V278, P36410, DOI 10.1074/jbc.M306428200; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Undevia NS, 2004, AM J PHYSIOL-LUNG C, V287, pL515, DOI 10.1152/ajplung.00044.2004; Varghese J, 2001, J IMMUNOL, V166, P6570, DOI 10.4049/jimmunol.166.11.6570; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Zu YL, 1996, BLOOD, V87, P5287, DOI 10.1182/blood.V87.12.5287.bloodjournal87125287	33	44	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41815	41821		10.1074/jbc.M406049200	http://dx.doi.org/10.1074/jbc.M406049200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15271996	hybrid			2022-12-27	WOS:000224075500071
J	Yamagishi, N; Ishihara, K; Hatayama, T				Yamagishi, N; Ishihara, K; Hatayama, T			Hsp105 alpha suppresses Hsc70 chaperone activity by inhibiting Hsc70 ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; PEPTIDE-BINDING DOMAIN; COGNATE PROTEIN; REACTION CYCLE; HSP70; EXPRESSION; IDENTIFICATION; HSC70/HSP40; NUCLEOTIDE; HYDROLYSIS	Hsp105alpha is a mammalian member of the HSP105/110 family, a diverged subgroup of the HSP70 family. Hsp105alpha associates with Hsp70/Hsc70 as complexes in vivo and regulates the chaperone activity of Hsp70/Hsc70 negatively in vitro and in vivo. In this study, we examined the mechanisms by which Hsp105alpha regulates Hsc70 chaperone activity. Using a series of deletion mutants of Hsp105alpha and Hsc70, we found that the interaction between Hsp105alpha and Hsc70 was necessary for the suppression of Hsc70 chaperone activity by Hsp105alpha. Furthermore, Hsp105alpha and deletion mutants of Hsp105alpha that interacted with Hsc70 suppressed the ATPase activity of Hsc70, with the concomitant appearance of ATPase activity of Hsp105alpha. As the ATPase activity of Hsp70/Hsc70 is essential for the efficient folding of non-native protein substrates, Hsp105alpha is suggested to regulate the substrate binding cycle of Hsp70/Hsc70 by inhibiting the ATPase activity of Hsp70/Hsc70, thereby functioning as a negative regulator of the Hsp70/Hsc70 chaperone system.	Kyoto Pharmaceut Univ, Dept Biochem, Yamashina Ku, Kyoto 6078414, Japan	Kyoto Pharmaceutical University	Hatayama, T (corresponding author), Kyoto Pharmaceut Univ, Dept Biochem, Yamashina Ku, 5 Nakauchi Cho, Kyoto 6078414, Japan.	hatayama@mb.kyoto-phu.ac.jp						Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; Hatayama T, 1998, BIOCHEM BIOPH RES CO, V248, P395, DOI 10.1006/bbrc.1998.8979; HATAYAMA T, 1986, BIOCHEM BIOPH RES CO, V137, P957, DOI 10.1016/0006-291X(86)90318-9; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOHFELD J, 1995, CELL, V83, P589; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; Ishihara K, 2003, BIOCHEM J, V371, P917, DOI 10.1042/BJ20021331; Ishihara K, 1999, BBA-GENE STRUCT EXPR, V1444, P138, DOI 10.1016/S0167-4781(98)00254-1; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; MELANIE C, 1996, J BIOL CHEM, V271, P15874; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; MINAMI Y, 1996, J BIOL CHEM, V271, P18617; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Wakatsuki T, 1998, BIOL PHARM BULL, V21, P905; WANG TF, 1993, J BIOL CHEM, V268, P26049; Yamagishi N, 2000, BIOCHEM BIOPH RES CO, V272, P850, DOI 10.1006/bbrc.2000.2864; Yamagishi N, 2003, FEBS LETT, V555, P390, DOI 10.1016/S0014-5793(03)01292-4; YASUDA K, 1995, J BIOL CHEM, V270, P29718, DOI 10.1074/jbc.270.50.29718	27	45	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41727	41733		10.1074/jbc.M407947200	http://dx.doi.org/10.1074/jbc.M407947200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292236	hybrid			2022-12-27	WOS:000224075500060
J	Zhao, Q; Cumming, H; Cerruti, L; Cunningham, JM; Jane, SM				Zhao, Q; Cumming, H; Cerruti, L; Cunningham, JM; Jane, SM			Site-specific acetylation of the fetal globin activator NF-E4 prevents its ubiquitination and regulates its interaction with the histone deacetylase, HDAC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; TRANSCRIPTION FACTOR GATA-1; HUMAN GAMMA-GLOBIN; NUCLEAR RECEPTOR REPRESSION; REMODELING COMPLEX; BETA-THALASSEMIA; GENE-EXPRESSION; DNA-BINDING; FACTOR EKLF; N-COR	Acetylation provides one mechanism by which the functional diversity of individual transcription factors can be expanded. This is valuable in the setting of complex multigene loci that are regulated by a limited number of proteins, such as the human beta-globin locus. We have studied the role of acetylation in the regulation of the transcription factor NF-E4, a component of a protein complex that facilitates the preferential expression of the human gamma-globin genes in fetal erythroid cells. We have shown that NF-E4 interacts directly with, and serves as a substrate for, the acetyltransferase co-activator PCAF. Acetylation of NF-E4 is restricted to a single residue (Lys(43)) in the amino-terminal domain of the protein and results in two important functional consequences. Acetylation of NF-E4 prolongs the protein half-life by preventing ubiquitin-mediated degradation. This stabilization is PCAF-dependent, since enforced expression in fetal/erythroid cells of a mutant form of PCAF lacking the histone acetyltransferase domain (PCAFDeltaHAT) decreases NF-E4 stability. Acetylation of Lys43 also reduces the interaction between NF-E4 and HDAC1, potentially maximizing the activating ability of the factor at the gamma-promoter. These results provide further demonstration that co-activators, such as PCAF, can influence individual transcription factor properties at multiple levels to alter their effects on gene expression.	Royal Melbourne Hosp, Rotary Bone Marrow Res Lab, Parkville, Vic 3050, Australia; St Jude Childrens Res Hosp, Div Expt Hematol, Memphis, TN 38101 USA	Royal Melbourne Hospital; St Jude Children's Research Hospital	Jane, SM (corresponding author), PO Royal Melbourne Hosp, Rotary Bone Marrow Res Lab, Grattan St, Parkville, Vic 3050, Australia.	jane@wehi.edu.au	Jane, Stephen/D-6659-2011; Zhao, Quan/E-9147-2011	Zhao, Quan/0000-0002-8533-1938; Jane, Stephen Marsden/0000-0002-1045-0481	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069232, P01HL053749] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NHLBI NIH HHS [R01 HL69232-01, P01 HL53749-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brown RC, 2002, MOL CELL BIOL, V22, P161, DOI 10.1128/MCB.22.1.161-170.2002; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Cao H, 2004, BLOOD, V103, P701, DOI 10.1182/blood-2003-02-0478; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; FENG WC, 1994, J BIOL CHEM, V269, P1493; Giandomenico V, 2003, MOL CELL BIOL, V23, P2587, DOI 10.1128/MCB.23.7.2587-2599.2003; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Hung HL, 2001, J BIOL CHEM, V276, P10715, DOI 10.1074/jbc.M007846200; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; LHERNAULT SW, 1985, BIOCHEMISTRY-US, V24, P473, DOI 10.1021/bi00323a034; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; McCaffrey PG, 1997, BLOOD, V90, P2075, DOI 10.1182/blood.V90.5.2075; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PERKINS AC, 1995, NATURE, V375, P318; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Song CZ, 2002, J BIOL CHEM, V277, P7029, DOI 10.1074/jbc.M108826200; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DIS; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang WJ, 2001, MOL CELL BIOL, V21, P2413, DOI 10.1128/MCB.21.7.2413-2422.2001; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zhou WL, 2000, MOL CELL BIOL, V20, P7662, DOI 10.1128/MCB.20.20.7662-7672.2000	54	25	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41477	41486		10.1074/jbc.M405129200	http://dx.doi.org/10.1074/jbc.M405129200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15273251	hybrid			2022-12-27	WOS:000224075500030
J	Mathew, S; Mascareno, E; Siddiqui, MAQ				Mathew, S; Mascareno, E; Siddiqui, MAQ			A ternary complex of transcription factors, Nished and NFATc4, and co-activator p300 bound to an intronic sequence, intronic regulatory element, is pivotal for the up-regulation of myosin light chain-2v gene in cardiac hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC TRANSCRIPTION; ALPHA-B-CRYSTALLIN; ACTIVATED T-CELLS; ACETYL-TRANSFERASE-ACTIVITY; ATRIAL-NATRIURETIC-FACTOR; ANGIOTENSIN-II RECEPTOR; RAT MYOCARDIAL-CELLS; BINDING PROTEIN CBP; TRANSGENIC MICE; NUCLEAR FACTOR	Transcriptional up-regulation of the myosin light chain-2 (MLC-2v) gene is an established marker for hypertrophic response in cardiomyocytes. Despite the documentation on the role of several cis-elements in the MLC-2v gene and their cognate proteins in transcription, the mechanism that dictates the preferential increase in MLC-2v gene expression during myocardial hypertrophy has not been delineated. Here we describe the properties of a cardiac specific intronic activator element ( IRE) that shares sequence homology with the repressor element, the cardiac specific sequence, in the chicken MLC-2v gene. The transcription factor, Nished, that recognizes both IRE and the cardiac specific sequence potentiates the transcription of the MLC-2v gene via interaction with another transcription factor, nuclear factor of activated T cells, and the co-activator p300 at the IRE site. Angiotensin II (Ang II), a potent agonist of hypertrophy, causes induction of the MLC-2v gene transcription, which correlates well with the enhanced binding of Nished-nuclear factor of the activated T cells-p300 complex to IRE in the gel mobility shift assay. Losartan, an antagonist of Ang II receptor (AT(1)), abolishes the agonist-dependent stimulation of IRE/protein interaction and the consequent increase in MLC-2v gene transcription. These results together have thus established a transcriptional role of IRE as a direct target sequence of Ang II-mediated signaling that appears to be pivotal in the mechanism underlying the up-regulation of the MLC-2v gene during cardiac hypertrophy.	SUNY Downstate Med Ctr, Dept Anat & Cell Biol, Ctr Cardiovasc & Muscle Res, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Siddiqui, MAQ (corresponding author), SUNY Downstate Med Ctr, Dept Anat & Cell Biol, Ctr Cardiovasc & Muscle Res, Box 5,450 Clarkson Ave, Brooklyn, NY 11203 USA.	siddiqui@downstate.edu						Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; ARNOLD HH, 1988, NUCLEIC ACIDS RES, V16, P2411, DOI 10.1093/nar/16.6.2411; BAKER KM, 1990, AM J PHYSIOL, V259, pH610, DOI 10.1152/ajpheart.1990.259.2.H610; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; Braz JC, 2003, J CLIN INVEST, V111, P1475, DOI 10.1172/JCI200317295; Bueno OF, 2004, CIRC RES, V94, P91, DOI 10.1161/01.RES.0000107197.99679.77; Chan HM, 2001, J CELL SCI, V114, P2363; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Chung SW, 2003, MOL PHARMACOL, V64, P1169, DOI 10.1124/mol.64.5.1169; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Dhar M, 1997, J BIOL CHEM, V272, P18490, DOI 10.1074/jbc.272.29.18490; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; FRANZ WM, 1993, CIRC RES, V73, P629, DOI 10.1161/01.RES.73.4.629; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; GOPALSRIVASTAVA R, 1995, MOL CELL BIOL, V15, P7081; GOSWAMI S, 1994, MOL CELL BIOL, V14, P5130, DOI 10.1128/MCB.14.8.5130; Griscelli F, 1998, HUM GENE THER, V9, P1919, DOI 10.1089/hum.1998.9.13-1919; Gusterson RJ, 2003, J BIOL CHEM, V278, P6838, DOI 10.1074/jbc.M211762200; Haase D, 2002, EUR J HEART FAIL, V4, P23, DOI 10.1016/S1388-9842(01)00226-4; Hasegawa K, 1997, CIRCULATION, V96, P3943; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Hoover HE, 2000, J BIOL CHEM, V275, P23825, DOI 10.1074/jbc.M003864200; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; Kakita T, 2001, CIRC RES, V88, P1239, DOI 10.1161/hh1201.091794; Kempf H, 1999, MECH DEVELOP, V84, P177, DOI 10.1016/S0925-4773(99)00071-4; King KL, 1998, ENDOCRINE, V9, P45, DOI 10.1385/ENDO:9:1:45; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; Kobayashi N, 2002, J PHARMACOL EXP THER, V301, P459, DOI 10.1124/jpet.301.2.459; Kwiatkowska-Patzer B, 1983, Adv Myocardiol, V4, P183; Lakshmanan G, 1999, MOL CELL BIOL, V19, P1558; LEE HR, 1988, J BIOL CHEM, V263, P7352; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; LENOBLE FAC, 1991, EUR J PHARMACOL, V195, P305, DOI 10.1016/0014-2999(91)90552-2; MILLER JS, 1983, METHOD ENZYMOL, V101, P650; MIYATA S, 1994, AM J PHYSIOL, V266, pH2443, DOI 10.1152/ajpheart.1994.266.6.H2443; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; OPARIL S, 1985, J AM COLL CARDIOL, V5, pB57, DOI 10.1016/S0735-1097(85)80528-3; Pikkarainen S, 2003, J BIOL CHEM, V278, P23807, DOI 10.1074/jbc.M302719200; Pu WT, 2003, CIRC RES, V92, P725, DOI 10.1161/01.RES.0000069211.82346.46; QASBA P, 1992, MOL CELL BIOL, V12, P1107, DOI 10.1128/MCB.12.3.1107; Qasba Pankaj, 1992, Cellular and Molecular Biology (Noisy-Le-Grand), V38, P561; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; Schulz RA, 2004, DEV BIOL, V266, P1, DOI 10.1016/j.ydbio.2003.10.008; SHEN RQ, 1991, MOL CELL BIOL, V11, P1676, DOI 10.1128/MCB.11.3.1676; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; Slepak TI, 2001, J BIOL CHEM, V276, P7575, DOI 10.1074/jbc.M004625200; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Suzuki E, 2002, CIRC RES, V90, P1004, DOI 10.1161/01.RES.0000017629.70769.CC; Suzuki YJ, 1999, CELL CALCIUM, V25, P401, DOI 10.1054/ceca.1999.0037; Suzuki YJ, 1999, ANTIOXID REDOX SIGN, V1, P233, DOI 10.1089/ars.1999.1.2-233; van Rooij E, 2002, J BIOL CHEM, V277, P48617, DOI 10.1074/jbc.M206532200; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; WINTER BB, 1987, J BIOL CHEM, V262, P13750; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; Yanazume T, 2003, MOL CELL BIOCHEM, V248, P115, DOI 10.1023/A:1024132217870; Yanazume T, 2003, MOL CELL BIOL, V23, P3593, DOI 10.1128/MCB.23.10.3593-3606.2003; Yui MA, 2001, J IMMUNOL, V166, P1730, DOI 10.4049/jimmunol.166.3.1730; ZARRAGA AM, 1986, J BIOL CHEM, V261, P3852; ZHOU MD, 1993, MOL CELL BIOL, V13, P1222, DOI 10.1128/MCB.13.2.1222; Zhou Ming-Dong, 1992, Gene Expression, V2, P127; ZHU H, 1993, MOL CELL BIOL, V13, P4432, DOI 10.1128/MCB.13.7.4432; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	74	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41018	41027		10.1074/jbc.M403578200	http://dx.doi.org/10.1074/jbc.M403578200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15272022	hybrid			2022-12-27	WOS:000223916800100
J	Sato, T; Furukawa, K				Sato, T; Furukawa, K			Transcriptional regulation of the human beta-1,4-galactosyltransferase V gene in cancer cells - Essential role of transcription factor Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; ENDOTHELIAL GROWTH-FACTOR; HAMSTER-KIDNEY CELLS; LINKED SUGAR CHAINS; BOX-BINDING-PROTEINS; MEMBRANE-GLYCOPROTEINS; MOLECULAR-CLONING; MURINE BETA-1,4-GALACTOSYLTRANSFERASE; STRUCTURAL DETERMINANTS; FUNCTIONAL-ANALYSIS	beta-1,4-Galactosyltransferase (beta-1,4-GalT) V is a constitutively expressed enzyme that can effectively galactosylate the GlcNAcbeta1-->6Man group of the highly branched N-glycans that are characteristic of tumor cells. Upon malignant transformation of cells, the expression of the beta-1,4-GalT V gene increases in accordance with the increase in the amounts of highly branched N-glycans. Lectin blot analysis showed that the galactosylation of highly branched N-glycans is inhibited significantly in SH-SY5Y human neuroblastoma cells by the transfection of the antisense beta-1,4-GalT V cDNA, indicating the biological importance of the beta-1,4-GalT V for the functions of highly branched N-glycans. We cloned the 2.3-kb 5'-flanking region of the human beta-1,4-GalT V gene, and we identified the region -116/-18 relative to the transcription start site as that having promoter activity. The region was found to contain several putative binding sites for transcription factors, including AP2, AP4, N-Myc, Sp1, and upstream stimulatory factor. Electrophoretic mobility shift assay showed that Sp1 binds to nucleotide positions -81/-69 of the promoter region. Mutations induced in the Sp1-binding site showed that the promoter activity of the beta-1,4-GalT V gene is impaired completely in cancer cells. In contrast, the promoter activity increased significantly by the transfection of the Sp1 cDNA into A549 human lung carcinoma cells. Mithramycin A, which inhibits the binding of Sp1 to its binding site, reduced the promoter activation and expression of the beta-1,4-GalT V gene in A549 cells. These results indicate that Sp1 plays an essential role in the transcriptional activity of the beta-1,4-GalT V gene in cancer cells.	Tokyo Metropolitan Inst Gerontol, Dept Biosignal Res, Itabashi Ku, Tokyo 1730015, Japan	Tokyo Metropolitan Institute of Gerontology	Sato, T (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Biosignal Res, Itabashi Ku, Sakaecho 35-2, Tokyo 1730015, Japan.	taksato@tmig.or.jp						Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; ARANGO J, 1988, J CELL BIOCHEM, V37, P225, DOI 10.1002/jcb.240370209; Asada M, 1997, CANCER RES, V57, P1073; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BUCK CA, 1971, SCIENCE, V172, P169, DOI 10.1126/science.172.3979.169; Buckhaults P, 1997, J BIOL CHEM, V272, P19575, DOI 10.1074/jbc.272.31.19575; Charron M, 1999, MOL CELL BIOL, V19, P5823; Chen GY, 2001, GENE, V275, P253, DOI 10.1016/S0378-1119(01)00657-6; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Fan YX, 2002, DNA SEQUENCE, V13, P1, DOI 10.1080/10425170290019838; Furukawa K, 1999, BBA-GEN SUBJECTS, V1473, P54, DOI 10.1016/S0304-4165(99)00169-5; FURUKAWA K, 1986, J BIOL CHEM, V261, P7755; Guo S, 2001, GLYCOBIOLOGY, V11, P813, DOI 10.1093/glycob/11.10.813; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; Harrison SM, 2000, DEV BIOL, V227, P358, DOI 10.1006/dbio.2000.9878; HIRAIZUMI S, 1990, ARCH BIOCHEM BIOPHYS, V280, P9, DOI 10.1016/0003-9861(90)90511-V; HIRAIZUMI S, 1992, JPN J CANCER RES, V83, P1063, DOI 10.1111/j.1349-7006.1992.tb02723.x; Hoppe KL, 1998, J LIPID RES, V39, P969; Ishibashi H, 2000, CANCER RES, V60, P6531; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kim YJ, 1996, GENE, V170, P281, DOI 10.1016/0378-1119(95)00818-7; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KITADAI Y, 1992, BIOCHEM BIOPH RES CO, V189, P1342, DOI 10.1016/0006-291X(92)90221-6; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; Kobata A., 1984, BIOL CARBOHYDRATES, V2, P87; Kumar AP, 1999, CANCER LETT, V137, P159, DOI 10.1016/S0304-3835(98)00351-6; Lietard J, 1997, AM J PATHOL, V151, P1663; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MEEZAN E, 1969, BIOCHEMISTRY-US, V8, P2518, DOI 10.1021/bi00834a039; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; Nicolas M, 2001, J BIOL CHEM, V276, P22126, DOI 10.1074/jbc.M010740200; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; PIERCE M, 1986, J BIOL CHEM, V261, P772; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rajput B, 1996, J BIOL CHEM, V271, P5131, DOI 10.1074/jbc.271.9.5131; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; Rundlof AK, 2001, J BIOL CHEM, V276, P30542, DOI 10.1074/jbc.M101452200; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTER UV, 1984, CANCER RES, V44, P3730; Sato T, 2000, BIOCHEM BIOPH RES CO, V276, P1019, DOI 10.1006/bbrc.2000.3594; SATO T, 1993, J BIOCHEM-TOKYO, V114, P890, DOI 10.1093/oxfordjournals.jbchem.a124273; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; Sato T, 2001, BIOCHIMIE, V83, P719, DOI 10.1016/S0300-9084(01)01304-9; Sato T., 1999, RECENT RES DEV CANC, V1, P105; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; SEGAWA K, 1986, VIROLOGY, V155, P334, DOI 10.1016/0042-6822(86)90197-2; SHAPER NL, 1994, J BIOL CHEM, V269, P25165; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; Shi Q, 2001, CANCER RES, V61, P4143; Shirane K, 1999, BIOCHEM BIOPH RES CO, V265, P434, DOI 10.1006/bbrc.1999.1684; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Taniguchi A, 2000, GLYCOBIOLOGY, V10, P623, DOI 10.1093/glycob/10.6.623; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Yamamoto S, 2002, J BIOCHEM, V131, P337, DOI 10.1093/oxfordjournals.jbchem.a003108; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; Yip B, 1997, BIOCHEM J, V321, P465, DOI 10.1042/bj3210465; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167; Zhu GH, 2002, ONCOGENE, V21, P8477, DOI 10.1038/sj.onc.1206030	77	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39574	39583		10.1074/jbc.M405805200	http://dx.doi.org/10.1074/jbc.M405805200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15263012	hybrid			2022-12-27	WOS:000223791500047
J	Shen, WF; Chrobak, D; Krishnan, K; Lawrence, HJ; Largman, C				Shen, WF; Chrobak, D; Krishnan, K; Lawrence, HJ; Largman, C			HOXB6 protein is bound to CREB-binding protein and represses globin expression in a DNA binding-dependent, PBX interaction-independent process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; HUMAN HEMATOPOIETIC-CELLS; HOMEOBOX GENES; HOMEODOMAIN PROTEINS; HISTONE ACETYLTRANSFERASES; ERYTHROID-DIFFERENTIATION; DROSOPHILA EMBRYOS; RESTRICTED EXPRESSION; MYELOID-LEUKEMIA; CBP	Although HOXB6 and other HOX genes have previously been associated with hematopoiesis and leukemias, the precise mechanism of action of their protein products remains unclear. Here we use a biological model in which HOXB6 represses alpha- and gamma-globin mRNA levels to perform a structure/function analysis for this homeodomain protein. HOXB6 protein represses globin transcript levels in stably transfected K562 cells in a DNA-binding dependent fashion. However, the capacity to form cooperative DNA-binding complexes with the PBX co-factor protein is not required for HOXB6 biological activity. Neither the conserved extreme N-terminal region, a polyglutamic acid region at the protein C terminus, nor the Ser(214) CKII phosphorylation site was required for DNA binding or activity in this model. We have previously reported that HOX proteins can inhibit CREB-binding protein (CBP)-histone acetyltransferase-mediated potentiation of reporter gene transcription. We now show that endogenous CBP is co-precipitated with exogenous HOXB6 from nuclear and cytoplasmic compartments of transfected K562 cells. Furthermore, endogenous CBP co-precipitates with endogenous HOXB6 in day 14.5 murine fetal liver cells during active globin gene expression in this tissue. The CBP interaction motif was localized to the homeodomain but does not require the highly conserved helix 3. Our data suggest that the homeodomain contains most or all of the important structures required for HOXB6 activity in blood cells.	Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Largman, C (corresponding author), Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Med, 4150 Clement St, San Francisco, CA 94121 USA.	largman@cgl.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA080029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055814] Funding Source: NIH RePORTER; NCI NIH HHS [CA80029] Funding Source: Medline; NIGMS NIH HHS [GM55814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Burglin Thomas R., 1994, P25; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Care A, 1996, MOL CELL BIOL, V16, P4842; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CELETTI A, 1993, INT J CANCER, V53, P237, DOI 10.1002/ijc.2910530211; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; COLIGAN JE, 1998, CURRENT PROTOCOLS IM; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Fienberg AA, 1999, J EXP ZOOL, V285, P76, DOI 10.1002/(SICI)1097-010X(19990415)285:1<76::AID-JEZ9>3.0.CO;2-K; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; Giampaolo A, 2002, LEUKEMIA, V16, P1293, DOI 10.1038/sj.leu.2402532; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; Gould A, 1997, GENE DEV, V11, P900, DOI 10.1101/gad.11.7.900; Graba Y, 1997, BIOESSAYS, V19, P379, DOI 10.1002/bies.950190505; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HICKS DG, 1985, EXP HEMATOL, V13, P273; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Ito T, 2000, GENE DEV, V14, P1899; Kappen C, 2000, AM J HEMATOL, V65, P111, DOI 10.1002/1096-8652(200010)65:2<111::AID-AJH4>3.0.CO;2-Z; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Komuves LG, 2000, DEV DYNAM, V218, P636; Komuves LG, 2003, DEV DYNAM, V227, P192, DOI 10.1002/dvdy.10290; Komuves LG, 2002, DEV DYNAM, V224, P58, DOI 10.1002/dvdy.10085; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 2003, IMMUNITY, V18, P561, DOI 10.1016/S1074-7613(03)00090-6; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAWRENCE HJ, 1994, ANN NY ACAD SCI, V718, P165; Lohmann I, 2002, CELL, V110, P457, DOI 10.1016/S0092-8674(02)00871-1; LU QA, 1995, MOL CELL BIOL, V15, P3786; Lutz B, 1996, GENE DEV, V10, P176, DOI 10.1101/gad.10.2.176; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; Maizel A, 2002, DEVELOPMENT, V129, P3545; Maizel A, 1999, DEVELOPMENT, V126, P3183; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; MANN RS, 1995, BIOESSAYS, V17, P855, DOI 10.1002/bies.950171007; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MATHEWS CHE, 1991, BLOOD, V78, P2248; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Pinsonneault J, 1997, EMBO J, V16, P2032, DOI 10.1093/emboj/16.8.2032; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Raman V, 2000, J BIOL CHEM, V275, P26551, DOI 10.1074/jbc.C000324200; Saleh M, 2000, MOL CELL BIOL, V20, P8623, DOI 10.1128/MCB.20.22.8623-8633.2000; Schnabel CA, 2000, ONCOGENE, V19, P608, DOI 10.1038/sj.onc.1203371; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; Shen WF, 1999, MOL CELL BIOL, V19, P3051; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; SHEN WF, 1991, NUCLEIC ACIDS RES, V19, P539, DOI 10.1093/nar/19.3.539; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Shen WF, 2001, MOL CELL BIOL, V21, P7509, DOI 10.1128/MCB.21.21.7509-7522.2001; SHEN WF, 1992, EMBO J, V11, P983, DOI 10.1002/j.1460-2075.1992.tb05137.x; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; VIEILLEGROSJEAN I, 1992, BIOCHEM BIOPH RES CO, V183, P1124, DOI 10.1016/S0006-291X(05)80307-9; Vijapurkar U, 2004, MOL CELL BIOL, V24, P3827, DOI 10.1128/MCB.24.9.3827-3837.2004; WALTER J, 1994, GENE DEV, V8, P1678, DOI 10.1101/gad.8.14.1678; WINSLOW GM, 1989, CELL, V57, P1017, DOI 10.1016/0092-8674(89)90340-1; Yaron Y, 2001, J IMMUNOL, V166, P5058, DOI 10.4049/jimmunol.166.8.5058; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x; Zhao F, 2003, MOL CELL BIOL, V23, P3837, DOI 10.1128/MCB.23.11.3837-3846.2003; Zimmermann F, 1997, BLOOD, V89, P2723, DOI 10.1182/blood.V89.8.2723	76	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39895	39904		10.1074/jbc.M404132200	http://dx.doi.org/10.1074/jbc.M404132200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15269212	hybrid			2022-12-27	WOS:000223791500086
J	Xie, ZL; Singh, M; Singh, K				Xie, ZL; Singh, M; Singh, K			Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NF-KAPPA-B; MATRIX-METALLOPROTEINASE ACTIVITY; CONGESTIVE-HEART-FAILURE; MYOCARDIAL-INFARCTION; GENE-EXPRESSION; VENTRICULAR MYOCYTES; MEDIATED INDUCTION; TISSUE INHIBITOR; MAP KINASE	Matrix metalloproteinases (MMPs), a family of endoproteinases, are implicated in cardiac remodeling. Interleukin-1beta (IL-1beta), which is increased in the heart following myocardial infarction, increases expression and activity of MMP-2 (gelatinase A) and -9 (gelatinase B) in cardiac fibroblasts. Previously, we have shown that IL-1beta activates ERK1/2, JNKs, and protein kinase C (PKC). However, signaling pathways involved in the regulation of MMP-2 and -9 expression and activity are not yet well understood. Using adult rat cardiac fibroblasts, we show that inhibition of ERK1/2 and JNKs inhibits IL-1beta-stimulated increases in MMP-9, not MMP-2, expression and activity. Chelerythrine, an inhibitor of PKC, inhibited activation of ERK1/2 and JNKs and expression and activity of both MMPs. Selective inhibition of PKC-alpha/beta1 using Go6976 inhibited JNKs activation and the expression and activity of MMP-9, not MMP-2. Inhibition of PKC-theta and PKC-zeta using pseudosubstrates inhibited IL-1beta-stimulated activation of ERK1/2 and JNKs and the expression and activity of MMP-2 and -9. Inhibition of PKC-epsilon had no effect. IL-1beta activated NF-kappaB pathway as measured by increased phosphorylation of IKKalpha/beta and IkappaB-alpha. Inhibition of ERK1/2, JNKs, and PKC-alpha/beta1 had no effect on NF-kappaB activation, whereas inhibition of PKC-theta and PKC-zeta inhibited IL-1beta-stimulated activation of NF-kappaB. SN50, NF-kappaB inhibitor peptide, inhibited IL-1beta-stimulated increases in MMP-2 and -9 expression and activity. These observations suggest that 1) activation of ERK1/2 and JNKs plays a critical role in the regulation of MMP-9, not MMP-2, expression and activity; 2) PKC-alpha/beta1 act upstream of JNKs, not ERK1/2; 3) PKC-zeta and -theta, not PKC-epsilon, act upstream of JNKs, ERK1/2, and NF-kappaB; and 4) activation of NF-kappaB stimulates expression and activity of MMP-2 and -9.	E Tennessee State Univ, James H Quillen Coll Med, Dept Physiol, James H Quillen Vet Affairs Med Ctr, Johnson City, TN 37614 USA	East Tennessee State University	Singh, K (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Physiol, James H Quillen Vet Affairs Med Ctr, POB 70576, Johnson City, TN 37614 USA.	singhk@mail.etsu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071519] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071519, HL-071519] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Chang YC, 2002, J ENDODONT, V28, P90, DOI 10.1097/00004770-200202000-00010; Clerk A, 2001, CIRC RES, V89, P847, DOI 10.1161/res.89.10.847; Coker ML, 1998, AM J PHYSIOL-HEART C, V274, pH1516, DOI 10.1152/ajpheart.1998.274.5.H1516; Creemers EEJM, 2001, CIRC RES, V89, P201, DOI 10.1161/hh1501.094396; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ducharme A, 2000, J CLIN INVEST, V106, P55, DOI 10.1172/JCI8768; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; FINI ME, 1994, J BIOL CHEM, V269, P28620; Frantz S, 2003, CARDIOVASC RES, V57, P749, DOI 10.1016/S0008-6363(02)00723-X; Gurjar MV, 2001, J APPL PHYSIOL, V91, P1380, DOI 10.1152/jappl.2001.91.3.1380; Han YP, 2001, J CELL SCI, V114, P131; Heidkamp MC, 2001, CIRC RES, V89, P882, DOI 10.1161/hh2201.099434; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Hussain S, 2002, J BIOL CHEM, V277, P27345, DOI 10.1074/jbc.M111890200; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Li YY, 2000, CARDIOVASC RES, V46, P214, DOI 10.1016/S0008-6363(00)00003-1; Libby P, 2000, CIRCULATION, V102, P1874, DOI 10.1161/01.CIR.102.16.1874; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; MACKAY AR, 1992, INVAS METAST, V12, P168; Mackay K, 2001, J MOL CELL CARDIOL, V33, P1301, DOI 10.1006/jmcc.2001.1400; Mifflin RC, 2002, AM J PHYSIOL-CELL PH, V282, pC824, DOI 10.1152/ajpcell.00388.2001; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Naruse K, 2000, CIRC RES, V86, P1104; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; Ono K, 1998, CIRCULATION, V98, P149, DOI 10.1161/01.CIR.98.2.149; Peterson JT, 2000, CARDIOVASC RES, V46, P307, DOI 10.1016/S0008-6363(00)00029-8; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ReifelMiller AE, 1996, J BIOL CHEM, V271, P21666, DOI 10.1074/jbc.271.35.21666; SATO H, 1993, ONCOGENE, V8, P395; Simonis G, 2002, BASIC RES CARDIOL, V97, P223, DOI 10.1007/s003950200015; Siwik DA, 2000, CIRC RES, V86, P1259, DOI 10.1161/01.RES.86.12.1259; Spinale FG, 2000, CIRCULATION, V102, P1944, DOI 10.1161/01.CIR.102.16.1944; Spinale FG, 1998, CIRC RES, V82, P482, DOI 10.1161/01.RES.82.4.482; Spinale FG, 2002, CIRC RES, V90, P520, DOI 10.1161/01.RES.0000013290.12884.A3; Spinale FG, 1999, CIRC RES, V85, P364, DOI 10.1161/01.RES.85.4.364; Strait JB, 2001, AM J PHYSIOL-HEART C, V280, pH756, DOI 10.1152/ajpheart.2001.280.2.H756; Tao ZY, 2004, LIFE SCI, V74, P1561, DOI 10.1016/j.lfs.2003.09.042; Ukimura A, 2003, J CARDIAC SURG, V18, pS101, DOI 10.1046/j.1540-8191.18.s2.8.x; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xie ZL, 2004, J CELL PHYSIOL, V198, P399, DOI 10.1002/jcp.10419; Xie ZL, 2003, J BIOL CHEM, V278, P48546, DOI 10.1074/jbc.M302727200; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V111, P74, DOI 10.1093/oxfordjournals.jbchem.a123721; Yue P, 1998, AM J PHYSIOL-HEART C, V275, pH250, DOI 10.1152/ajpheart.1998.275.1.H250	49	136	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39513	39519		10.1074/jbc.M405844200	http://dx.doi.org/10.1074/jbc.M405844200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15269222	Green Published, hybrid			2022-12-27	WOS:000223791500041
J	Raymond, CK; Castle, J; Garrett-Engele, P; Armour, CD; Kan, ZY; Tsinoremas, N; Johnson, JM				Raymond, CK; Castle, J; Garrett-Engele, P; Armour, CD; Kan, ZY; Tsinoremas, N; Johnson, JM			Expression of alternatively spliced sodium channel alpha-subunit genes - Unique splicing patterns are observed in dorsal root ganglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPATHIC PAIN; RAT-BRAIN; MOUSE; NEURONS; MODEL; MICROARRAYS; TRANSCRIPTS; EVOLUTION; CURRENTS; ISOFORMS	Molecular medicine requires the precise definition of drug targets, and tools are now in place to provide genome-wide information on the expression and alternative splicing patterns of any known gene. DNA microarrays were used to monitor transcript levels of the nine well-characterized alpha-subunit sodium channel genes across a broad range of tissues from cynomolgus monkey, a non-human primate model. Alternative splicing of human transcripts for a subset of the genes that are expressed in dorsal root ganglia, SCN8A (Na(v)1.6), SCN9A (Na(v)1.7), and SCN11A (Na(v)1.9) was characterized in detail. Genomic sequence analysis among gene family paralogs and between cross-species orthologs suggested specific alternative splicing events within transcripts of these genes, all of which were experimentally confirmed in human tissues. Quantitative PCR revealed that certain alternative splice events are uniquely expressed in dorsal root ganglia. In addition to characterization of human transcripts, alternatively spliced sodium channel transcripts were monitored in a rat model for neuropathic pain. Consistent down-regulation of all transcripts was observed, as well as significant changes in the splicing patterns of SCN8A and SCN9A.	Rosetta Inpharmat LLC, Seattle, WA 98109 USA	Merck & Company	Raymond, CK (corresponding author), Rosetta Inpharmat LLC, 401 Terry Ave N, Seattle, WA 98109 USA.	christopher_raymond@merck.com						AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; BELCHER SM, 1995, P NATL ACAD SCI USA, V92, P11034, DOI 10.1073/pnas.92.24.11034; Bell TJ, 2004, NEURON, V41, P127, DOI 10.1016/S0896-6273(03)00801-8; Castle J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r66; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Dib-Hajj SD, 2002, MOL NEUROBIOL, V26, P235, DOI 10.1385/MN:26:2-3:235; Dib-Hajj SD, 1999, PAIN, V83, P591, DOI 10.1016/S0304-3959(99)00169-4; DibHajj S, 1996, P NATL ACAD SCI USA, V93, P14950, DOI 10.1073/pnas.93.25.14950; Dietrich PS, 1998, J NEUROCHEM, V70, P2262; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; GUSTAFSON TA, 1993, J BIOL CHEM, V268, P18648; He YDD, 2003, BIOINFORMATICS, V19, P956, DOI 10.1093/bioinformatics/btg126; Hsiao LL, 2001, PHYSIOL GENOMICS, V7, P97, DOI 10.1152/physiolgenomics.00040.2001; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; KAN Z, P S BIOC, P4204; Kan ZY, 2002, GENOME RES, V12, P1837, DOI 10.1101/gr.764102; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; Miyahara T, 2003, INVEST OPHTH VIS SCI, V44, P4347, DOI 10.1167/iovs.02-1032; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; Plummer NW, 1998, GENOMICS, V54, P287, DOI 10.1006/geno.1998.5550; Plummer NW, 1999, GENOMICS, V57, P323, DOI 10.1006/geno.1998.5735; Plummer NW, 1997, J BIOL CHEM, V272, P24008, DOI 10.1074/jbc.272.38.24008; Sangameswaran L, 1997, J BIOL CHEM, V272, P14805, DOI 10.1074/jbc.272.23.14805; SARAO R, 1991, NUCLEIC ACIDS RES, V19, P5673, DOI 10.1093/nar/19.20.5673; SCHALLER KL, 1992, J NEUROSCI, V12, P1370; Sleeper AA, 2000, J NEUROSCI, V20, P7279; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Tan JG, 2002, J NEUROSCI, V22, P5300; Thanaraj TA, 2003, NUCLEIC ACIDS RES, V31, P2544, DOI 10.1093/nar/gkg355; Wang H, 2002, NEUROSCIENCE, V114, P529, DOI 10.1016/S0306-4522(02)00341-X; Waxman SG, 2000, J REHABIL RES DEV, V37, P517; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207; Zimmer T, 2002, AM J PHYSIOL-HEART C, V282, pH1007, DOI 10.1152/ajpheart.00644.2001; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	35	97	120	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46234	46241		10.1074/jbc.M406387200	http://dx.doi.org/10.1074/jbc.M406387200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15302875	Green Submitted, hybrid			2022-12-27	WOS:000224694900110
J	Zietkiewicz, S; Krzewska, J; Liberek, K				Zietkiewicz, S; Krzewska, J; Liberek, K			Successive and synergistic action of the Hsp70 and Hsp100 chaperones in protein disaggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; NEWLY SYNTHESIZED PROTEINS; ESCHERICHIA-COLI PROTEINS; GREEN FLUORESCENT PROTEIN; ATP-BINDING-SITES; MOLECULAR CHAPERONE; DNAK CHAPERONE; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL HSP78; RNA-POLYMERASE	Proteins belonging to the B-subtype of the Hsp100/Clp chaperone family execute a crucial role in cellular thermotolerance. They cooperate with the Hsp70 chaperones in reactivation of thermally aggregated protein substrates. We investigated the initial events of the disaggregation reaction in real time using denatured, aggregated green fluorescent protein (GFP) as a substrate. Bacterial Hsp70 (DnaK), its co-chaperones (DnaJ and GrpE), and Hsp100 (ClpB) were incubated with aggregated GFP, and the increase in GFP fluorescence was monitored. Incubation of aggregated GFP with DnaK/DnaJ/GrpE but not with ClpB resulted in the rapid initiation of the disaggregation reaction. Under the same conditions a complex between DnaK, DnaJ, and GFP, but not ClpB, was formed as demonstrated by sedimentation analysis and light scattering experiments. Chaperone-dependent disaggregation of chemically denatured aggregated luciferase showed that, similar to GFP disaggregation, incubation with Hsp70 results in the rapid start of the reactivation reaction. For both aggregated GFP and luciferase, incubation with Hsp70 chaperones changes the initial rate but not the overall efficiency or rate of the refolding reaction. Our results clearly demonstrate that the interaction of DnaK and its co-chaperones with aggregated substrate is the rate-limiting reaction at the initial steps of disaggregation.	Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland	Fahrenheit Universities; University of Gdansk	Liberek, K (corresponding author), Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, Kladki 24, PL-80822 Gdansk, Poland.	liberek@biotech.univ.gda.pl	Liberek, Krzysztof/F-5812-2011; Ziętkiewicz, Szymon/L-5259-2014	Zietkiewicz, Szymon/0000-0002-3435-4603; Liberek, Krzysztof/0000-0002-7532-9279; Wolak, Joanna/0000-0003-1068-1770				Banecki B, 1998, BBA-GENE STRUCT EXPR, V1442, P39, DOI 10.1016/S0167-4781(98)00118-3; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; BLASZCZAK A, 1995, EMBO J, V14, P5085, DOI 10.1002/j.1460-2075.1995.tb00190.x; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Germaniuk A, 2002, J BIOL CHEM, V277, P27801, DOI 10.1074/jbc.M201756200; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; HWANG DS, 1990, J BIOL CHEM, V265, P19244; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; Krzewska J, 2001, J MOL BIOL, V314, P901, DOI 10.1006/jmbi.2001.5190; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; KUCHARCZYK K, 1991, MOL MICROBIOL, V5, P2935, DOI 10.1111/j.1365-2958.1991.tb01853.x; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laskowska E, 1996, MOL MICROBIOL, V22, P555, DOI 10.1046/j.1365-2958.1996.1231493.x; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Makino Y, 1997, J BIOL CHEM, V272, P12468, DOI 10.1074/jbc.272.19.12468; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Mogk A, 2004, CURR BIOL, V14, pR78, DOI 10.1016/j.cub.2003.12.051; Mogk A, 2003, J BIOL CHEM, V278, P31033, DOI 10.1074/jbc.M303587200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schlee S, 2004, J MOL BIOL, V336, P275, DOI 10.1016/j.jmb.2003.12.013; Schlieker C, 2004, NAT STRUCT MOL BIOL, V11, P607, DOI 10.1038/nsmb787; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schmitt M, 1996, J CELL BIOL, V134, P1375, DOI 10.1083/jcb.134.6.1375; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WEIZBEZAHN J, 2003, J BIOL CHEM, V278, P32608; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WOO KM, 1992, J BIOL CHEM, V267, P20429; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	53	115	116	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44376	44383		10.1074/jbc.M402405200	http://dx.doi.org/10.1074/jbc.M402405200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302880	hybrid			2022-12-27	WOS:000224505600020
J	Bulina, ME; Lukyanov, KA; Yampolsky, IV; Chudakov, DM; Staroverov, DB; Shcheglov, AS; Gurskaya, NG; Lukyanov, S				Bulina, ME; Lukyanov, KA; Yampolsky, IV; Chudakov, DM; Staroverov, DB; Shcheglov, AS; Gurskaya, NG; Lukyanov, S			New class of blue animal pigments based on Frizzled and Kringle protein domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN; BINDING; RECEPTOR; FAMILY	The nature of coloration in many marine animals remains poorly investigated. Here we studied the blue pigment of a scyfoid jellyfish Rhizostoma pulmo and determined it to be a soluble extracellular 30-kDa chromoprotein with a complex absorption spectrum peaking at 420, 588, and 624 nm. Furthermore, we cloned the corresponding cDNA and confirmed its identity by immunoblotting and mass spectrometry experiments. The chromoprotein, named rpulFKz1, consists of two domains, a Frizzled cysteine-rich domain and a Kringle domain, inserted into one another. Generally, Frizzleds are members of a basic Wnt signal transduction pathway investigated intensely with regard to development and cancerogenesis. Kringles are autonomous structural domains found throughout the blood clotting and fibrinolytic proteins. Neither Frizzled and Kringle domains association with any type of coloration nor Kringle intrusion into Frizzled sequence was ever observed. Thus, rpulFKz1 represents a new class of animal pigments, whose chromogenic group remains undetermined. The striking homology between a chromoprotein and members of the signal transduction pathway provides a novel node in the evolution track of growth factor-mediated morphogenesis compounds.	Russian Acad Sci, Inst Bioorgan Chem, Moscow 117997, Russia; Evrogen JSC, Moscow 117997, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Lukyanov, KA (corresponding author), Russian Acad Sci, Inst Bioorgan Chem, Miklukho Maklaya 16-10, Moscow 117997, Russia.	kluk@ibch.ru	Lukyanov, Sergey/F-9140-2014; Gurskaya, Nadya G/Q-1750-2016; Lukyanov, Sergey/HIU-0305-2022; Yampolsky, Ilia V/R-6798-2016; Lukyanov, Konstantin A/D-4030-2013; Boulina, Maria/F-3124-2013; Chudakov, Dmitriy M/G-7741-2014	Gurskaya, Nadya G/0000-0002-8028-8176; Yampolsky, Ilia V/0000-0003-2558-2476; Lukyanov, Konstantin A/0000-0001-9845-2088; Chudakov, Dmitriy M/0000-0003-0430-790X; Staroverov, Dmitry/0000-0001-6789-9442				Angles-Cano E, 2002, BIOL CHEM, V383, P93, DOI 10.1515/BC.2002.009; BLANQUET RS, 1987, MAR BIOL, V94, P423, DOI 10.1007/BF00428249; Britton G, 1983, BIOCH NATURAL PIGMEN; Chang Y, 1998, BIOCHEMISTRY-US, V37, P3258, DOI 10.1021/bi972284e; Cianci M, 2002, P NATL ACAD SCI USA, V99, P9795, DOI 10.1073/pnas.152088999; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; Gonzalez-Gronow M, 2003, J BIOL CHEM, V278, P27312, DOI 10.1074/jbc.M303172200; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Matz M, 1999, NUCLEIC ACIDS RES, V27, P1558, DOI 10.1093/nar/27.6.1558; Matz MV, 2002, BIOESSAYS, V24, P953, DOI 10.1002/bies.10154; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; THEWES T, 1990, J BIOL CHEM, V265, P3906; Yoda A, 2003, J RECEPT SIG TRANSD, V23, P1, DOI 10.1081/RRS-120018757	13	13	13	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43367	43370		10.1074/jbc.C400337200	http://dx.doi.org/10.1074/jbc.C400337200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15297465	hybrid			2022-12-27	WOS:000224383100002
J	Marcyjaniak, M; Odintsov, SG; Sabala, I; Bochtler, M				Marcyjaniak, M; Odintsov, SG; Sabala, I; Bochtler, M			Peptidoglycan amidase MepA is a LAS metallopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; AUTOLYSINS; PROTEINS; DOMAIN; ENDOPEPTIDASE; SUBSTITUTION; BACTERIAL; PROTEASE; ENZYMES; MUREIN	LAS enzymes are a group of metallopeptidases that share an active site architecture and a core folding motif and have been named according to the group members (l) under bar ysostaphin, D-(A) under bar la-D-Ala carboxypeptidase and (s) under bar onic hedgehog. Escherichia coli MepA is a periplasmic, penicillin-insensitive murein endopeptidase that cleaves the D-alanyl-meso-2,6-diamino-pimelyl amide bond in E. coli peptidoglycan. The enzyme lacks sequence similarity with other peptidases, and is currently classified as a peptidase of unknown fold and catalytic class in all major data bases. Here, we build on our observation that two motifs, characteristic of the newly described LAS group of metallopeptidases, are conserved in MepA-type sequences. We demonstrate that recombinant E. coli MepA is sensitive to metal chelators and that mutations in the predicted Zn2+ ligands His-113, Asp-120, and His-211 inactivate the enzyme. Moreover, we present the crystal structure of MepA. The active site of the enzyme is most similar to the active sites of lysostaphin and D-Ala-D-Ala carboxypeptidase, and the fold is most closely related to the N-domain of sonic hedgehog. We conclude that MepA-type peptidases are LAS enzymes.	Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; Max Planck Inst Mol Cell Biol & Genet, D-01309 Dresden, Germany	Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Max Planck Society	Bochtler, M (corresponding author), Int Inst Mol & Cell Biol, Ul Trojdena 4, PL-02109 Warsaw, Poland.	MBochtler@iimcb.gov.pl	Bochtler, Matthias/A-4514-2010; Sabała, Izabela/HGB-4142-2022	Firczuk, Malgorzata/0000-0002-1719-5233; Sabala, Izabela/0000-0002-5481-8671; Bochtler, Matthias/0000-0001-7884-4463				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Anantharaman V, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r11; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bateman A, 2003, TRENDS BIOCHEM SCI, V28, P234, DOI 10.1016/S0968-0004(03)00061-6; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; BERNADSKY G, 1994, J BACTERIOL, V176, P5225, DOI 10.1128/JB.176.17.5225-5232.1994; Bochtler M, 2004, PROTEIN SCI, V13, P854, DOI 10.1110/ps.03515704; Bricogne G, 2002, ACTA CRYSTALLOGR A, V58, pC239, DOI 10.1107/S0108767302094576; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; Bussiere DE, 1998, MOL CELL, V2, P75, DOI 10.1016/S1097-2765(00)80115-X; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GOODELL EW, 1983, J BACTERIOL, V156, P136, DOI 10.1128/JB.156.1.136-140.1983; Gustin JK, 1996, J BACTERIOL, V178, P6608, DOI 10.1128/jb.178.22.6608-6617.1996; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Holtje JV, 2001, BIOCHIMIE, V83, P103, DOI 10.1016/S0300-9084(00)01226-8; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kessler E, 1997, J BIOL CHEM, V272, P9884; KITANO K, 1986, J BACTERIOL, V167, P759, DOI 10.1128/jb.167.3.759-765.1986; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Odintsov SG, 2004, J MOL BIOL, V335, P775, DOI 10.1016/j.jmb.2003.11.009; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; Richardson JS, 2002, P NATL ACAD SCI USA, V99, P2754, DOI 10.1073/pnas.052706099; RICHARDSON JS, 1977, NATURE, V268, P495, DOI 10.1038/268495a0; Rigden DJ, 2003, TRENDS BIOCHEM SCI, V28, P230, DOI 10.1016/S0968-0004(03)00062-8; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Smith TJ, 2000, MICROBIOL-UK, V146, P249, DOI 10.1099/00221287-146-2-249; TOMIOKA S, 1978, BIOCHEM BIOPH RES CO, V84, P978, DOI 10.1016/0006-291X(78)91679-0; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780	33	38	39	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43982	43989		10.1074/jbc.M406735200	http://dx.doi.org/10.1074/jbc.M406735200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292190	hybrid			2022-12-27	WOS:000224383100076
J	Perret, D; Guillet, C; Elson, G; Froger, J; Plun-Favreau, H; Rousseau, F; Chabbert, M; Gauchat, JF; Gascan, H				Perret, D; Guillet, C; Elson, G; Froger, J; Plun-Favreau, H; Rousseau, F; Chabbert, M; Gauchat, JF; Gascan, H			Two different contact sites are recruited by cardiotrophin-like cytokine (CLC) to generate the CLC/CLF and CLC/sCNTFR alpha composite cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; INHIBITORY FACTOR RECEPTOR; IL-6 SIGNAL TRANSDUCER; HUMAN INTERLEUKIN-11; CRYSTAL-STRUCTURE; CNTF RECEPTOR; MOLECULAR-CLONING; LIGAND-BINDING; GP130; EXPRESSION	The cytokines of the interleukin-6 family are multifunctional proteins that regulate cell growth, differentiation, and other cell functions in a variety of biological systems including the immune, inflammatory, hematopoietic, and nervous systems. One member of this family, ciliary neurotrophic factor (CNTF), displays biological functions more restricted to the neuromuscular axis. We have recently identified two additional ligands for the CNTF receptor complex. Both are composite cytokines formed by cardiotrophin-like cytokine (CLC) associated to either the soluble type I cytokine receptor CLF or the soluble form of CNTF receptor alpha (CNTFRalpha). The present study was aimed at analyzing the interactions between the cytokine CLC and its different receptor chains. For this purpose, we modeled CLC/receptor interactions to define the residues potentially involved in the contact sites. We then performed site-directed mutagenesis on these residues and analyzed the biological interactions between mutants and receptor chains. Importantly, we found that CLC interacts with the soluble forms of CNTFRalpha and CLF via sites 1 and 3, respectively. For site 1, the most crucial residues involved in the interaction are Trp(67), Arg(170), and Asp(174), which interact with CNTFRalpha. Surprisingly, the residues that are important for the interaction of CLC with CLF are part of the conserved FXXK motif of site 3 known to be the interaction site of LIFRbeta. Obtained results show that the Phe(151) and Lys(154) residues are effectively involved in the interaction of CLC with LIFRbeta. This study establishes the molecular details of the interaction of CLC with CLF, CNTFRalpha, and LIFRbeta and helps to define the precise role of each protein in this functional receptor complex.	CHU Angers, INSERM, U564, F-49033 Angers 01, France; Ctr Immunol Pierre Fabre, F-74164 St Julien En Genevois, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Centre d'Immunologie Pierre Fabre	Gascan, H (corresponding author), CHU Angers, INSERM, U564, 4 Rue Larrey, F-49033 Angers 01, France.	gascan@univ-angers.fr	PLUN-FAVREAU, Helene/C-8513-2009; Plun-Favreau, Helene/Q-4111-2016; Chabbert, Marie/K-1245-2015	Plun-Favreau, Helene/0000-0002-1401-9656; 				ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; Barton VA, 2000, J BIOL CHEM, V275, P36197, DOI 10.1074/jbc.M004648200; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; Boulanger MJ, 2003, MOL CELL, V12, P577, DOI 10.1016/S1097-2765(03)00365-4; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Brombacher F, 2003, TRENDS IMMUNOL, V24, P207, DOI 10.1016/S1471-4906(03)00067-X; CURTIS R, 1993, NATURE, V365, P253, DOI 10.1038/365253a0; Dahmen H, 1998, BIOCHEM J, V331, P695, DOI 10.1042/bj3310695; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Deleage G, 1997, BIOCHIMIE, V79, P681, DOI 10.1016/S0300-9084(97)83524-9; Derouet D, 2004, P NATL ACAD SCI USA, V101, P4827, DOI 10.1073/pnas.0306178101; Devergne O, 1997, P NATL ACAD SCI USA, V94, P12041, DOI 10.1073/pnas.94.22.12041; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUAN JB, 1995, SCI CHINA SER B, V38, P1321; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Grotzinger J, 1999, BIOL CHEM, V380, P803, DOI 10.1515/BC.1999.100; Guillet C, 1999, J NEUROSCI, V19, P1257; Guillet C, 2002, EUR J BIOCHEM, V269, P1932, DOI 10.1046/j.1432-1033.2002.02850.x; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; Kallen KJ, 1999, J BIOL CHEM, V274, P11859, DOI 10.1074/jbc.274.17.11859; Kurth I, 1999, J IMMUNOL, V162, P1480; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lelievre E, 2001, J BIOL CHEM, V276, P22476, DOI 10.1074/jbc.M101681200; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Neddermann P, 1996, J BIOL CHEM, V271, P30986, DOI 10.1074/jbc.271.48.30986; Nicholas KB, 1997, EMBNEW NEWS, V4, P14; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; PANAYOTATOS N, 1995, J BIOL CHEM, V270, P14007, DOI 10.1074/jbc.270.23.14007; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Peters M, 1998, BLOOD, V92, P3495, DOI 10.1182/blood.V92.10.3495.422k47_3495_3504; Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2; Pflanz S, 2004, J IMMUNOL, V172, P2225, DOI 10.4049/jimmunol.172.4.2225; Plun-Favreau H, 2003, J BIOL CHEM, V278, P27169, DOI 10.1074/jbc.M303168200; Plun-Favreau H, 2001, EMBO J, V20, P1692, DOI 10.1093/emboj/20.7.1692; Robledo O, 1997, J BIOL CHEM, V272, P4855, DOI 10.1074/jbc.272.8.4855; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schleinkofer K, 2001, J MOL BIOL, V306, P263, DOI 10.1006/jmbi.2000.4387; Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; Shi Y, 1999, BIOCHEM BIOPH RES CO, V262, P132, DOI 10.1006/bbrc.1999.1181; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; Tacken I, 1999, EUR J BIOCHEM, V265, P645, DOI 10.1046/j.1432-1327.1999.00755.x; TAKAHASHI R, 1994, NAT GENET, V7, P79, DOI 10.1038/ng0594-79; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; Yoon C, 2000, EMBO J, V19, P3530, DOI 10.1093/emboj/19.14.3530; Zhang J, 1997, GENE THER, V4, P367, DOI 10.1038/sj.gt.3300409	58	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43961	43970		10.1074/jbc.M407686200	http://dx.doi.org/10.1074/jbc.M407686200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15272019	hybrid			2022-12-27	WOS:000224383100074
J	Bachelor, MA; Bowden, GT				Bachelor, MA; Bowden, GT			Ultraviolet A-induced modulation of Bcl-X-L by p38 MAPK in human Keratinocytes - Post-transcriptional regulation through the 3 '-untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; NECROSIS-FACTOR-ALPHA; CELL-SURVIVAL; CYCLOOXYGENASE-2 EXPRESSION; UNTRANSLATED REGION; INDUCED APOPTOSIS; GENE-EXPRESSION; ACTIVATION; KINASE; UVA	We examined the effect of inhibiting p38 MAPK on UVA-irradiated HaCaT cells, a spontaneously immortalized human keratinocyte cell line. Recent work from our laboratory has shown that UVA ( 250 kJ/m(2)) induces a rapid phosphorylation of p38 MAPK in the HaCaT cell line. Inhibition of p38 MAPK activity through the use of a specific inhibitor, SB202190, in combination with UVA treatment induced a rapid cleavage of caspase-9, caspase-8, and caspase-3, whereas UVA irradiation alone had no effect. Similarly, cleavage of the caspase substrate poly( ADPribose) polymerase was observed in UVA-irradiated HaCaT cells treated with SB202190 or in cells expressing a dominant-negative p38 MAPK. No effect of p38 MAPK inhibition upon caspase cleavage was observed in mock-irradiated HaCaT cells. In addition, increases in apoptosis were observed in UVA-irradiated cells treated with SB202190 by morphological analysis with no significant apoptosis occurring from UVA irradiation alone. Similar results were obtained by using normal human epidermal keratinocytes. UVA induced expression of the anti-apoptotic Bcl-2 family member, Bcl-X-L, with abrogation of expression by using the p38 MAPK inhibitor SB202190. Overexpression of Bcl-X-L prevented poly(ADP-ribose) polymerase cleavage induced by the combination of UVA and p38 MAPK inhibition. UVA enhanced the stability of Bcl-X-L mRNA through increases in p38 MAPK activity. We determined that increases in UVA-induced expression of Bcl-X-L occur through a posttranscriptional mechanism mediated by the 3'-untranslated region (UTR). We used Bcl-X-L 3'-UTR luciferase constructs to determine the mechanism by which UVA increased Bcl-X-L mRNA stability. Additionally, RNA binding studies indicate that UVA increases the binding of RNA-binding proteins to Bcl-X-L 3'-UTR mRNA, which can be decreased by using SB202190. In conclusion, p38 MAPK and Bcl-X-L expression play critical roles in the survival of UVA-irradiated HaCaT cells.	Univ Arizona, Arizona Canc Ctr, Dept Cell Biol & Anat, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Bowden, GT (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Cell Biol & Anat, 1515 N Campbell Ave,Rm 4999, Tucson, AZ 85724 USA.	tbowden@azcc.arizona.edu			NATIONAL CANCER INSTITUTE [P30CA023074, P01CA027502] Funding Source: NIH RePORTER; NCI NIH HHS [CA23074, CA27502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachelor MA, 2002, ONCOGENE, V21, P7092, DOI 10.1038/sj.onc.1205855; Bernerd F, 1998, CELL DEATH DIFFER, V5, P792, DOI 10.1038/sj.cdd.4400413; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; CERRONI L, 1994, J CUTAN PATHOL, V21, P398, DOI 10.1111/j.1600-0560.1994.tb00279.x; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; Chouinard N, 2002, BIOCHEM J, V365, P133, DOI 10.1042/BJ20020072; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; de Gruijl FR, 2000, METHOD ENZYMOL, V319, P359; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Didier C, 1999, FASEB J, V13, P1817, DOI 10.1096/fasebj.13.13.1817; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Grillot DAM, 1997, J IMMUNOL, V158, P4750; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; Jost M, 2001, J INVEST DERMATOL, V116, P860, DOI 10.1046/j.1523-1747.2001.01356.x; KAMB A, 1994, NATURE, V372, P730, DOI 10.1038/372730a0; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; MATSUI MS, 1991, CANCER CELL-MON REV, V3, P8; MORALESDUCRET CRJ, 1995, ARCH DERMATOL, V131, P909, DOI 10.1001/archderm.131.8.909; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Nickoloff BJ, 2002, J INVEST DERM SYMP P, V7, P27, DOI 10.1046/j.1523-1747.2002.19633.x; Obata T, 2000, CRIT CARE MED, V28, pN67, DOI 10.1097/00003246-200004001-00008; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; Pourzand C, 1997, CANCER RES, V57, P1405; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Silvers AL, 2003, NEOPLASIA, V5, P319, DOI 10.1016/S1476-5586(03)80025-8; Silvers AL, 2002, PHOTOCHEM PHOTOBIOL, V75, P302, DOI 10.1562/0031-8655(2002)075<0302:UIIAOA>2.0.CO;2; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wrone-Smith T, 1999, J DERMATOL SCI, V19, P53, DOI 10.1016/S0923-1811(98)00052-8; Zhuang LH, 2000, J INTERF CYTOK RES, V20, P445, DOI 10.1089/10799900050023852; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	52	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42658	42668		10.1074/jbc.M406626200	http://dx.doi.org/10.1074/jbc.M406626200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292226	hybrid			2022-12-27	WOS:000224226400039
J	Pingle, SC; Mishra, S; Marcuzzi, A; Bhat, SG; Sekino, Y; Rybak, LP; Ramkumar, V				Pingle, SC; Mishra, S; Marcuzzi, A; Bhat, SG; Sekino, Y; Rybak, LP; Ramkumar, V			Osmotic diuretics induce adenosine A(1) receptor expression and protect renal proximal tubular epithelial cells against cisplatin-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HIGH-DOSE CISPLATIN; OVARIAN-CANCER; RAT-KIDNEY; HYPEROSMOTIC STRESS; REPERFUSION INJURY; HYPERTONIC STRESS; ISCHEMIC-INJURY; CARCINOMA-CELLS; MANNITOL	Osmotic diuretics are used successfully to alleviate acute tubular necrosis (ATN) produced by chemotherapeutic agents and aminoglycoside antibiotics. The beneficial action of these agents likely involves rapid elimination of the nephrotoxic agents from the kidney by promoting diuresis. Adenosine A(1) receptor (A(1)AR) subtype present on renal proximal tubular epithelial and cortical collecting duct cells mediates the antidiuretic and cytoprotective actions of adenosine. These receptors are induced by activation of nuclear factor (NF)-kappaB, a transcription factor reported to mediate hyperosmotic stress-induced cytoprotection in renal medullary cells. In this study, we tested the hypothesis that induction of the A(1)AR in renal proximal tubular cells by NF-kappaB contributes to the cytoprotection afforded by osmotic diuretics. Exposure of porcine renal proximal tubular epithelial (LLC-PK1) cells to mannitol or NaCl produced a significant increase in A(1)AR. This increase was preceded by adenosine release and NF-kappaB activation. Expression of an IkappaB-alpha mutant, which acts as a superrepressor of NF-kappaB, abrogated the increase in A(1)AR. Cells exposed to mannitol demonstrated increased reactive oxygen species (ROS) generation, which was attenuated by inhibiting xanthine oxidase with allopurinol. Allopurinol attenuated both the increase in A(1)AR expression and NF-kappaB activation produced by osmotic diuretics, indicating a role of adenosine metabolites in these processes. Treatment of LLC-PK1 cells with cisplatin ( 8 muM) resulted in apoptosis, which was attenuated by mannitol but exacerbated by selective A(1)AR blockade. Administration of mannitol to mice increases A(1)AR expression and activation of NF-kappaB in renal cortical sections. Taken together, these data provide novel mechanisms of nephroprotection by osmotic diuretics, involving both activation and induction of the A(1)AR, the latter mediated through activation of a xanthine oxidase pathway leading to ROS generation and promoting activation of NF-kappaB.	So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62702 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Gunma Univ, Sch Med, Dept Neurobiol & Behav, Maebashi, Gumma 3718511, Japan	Southern Illinois University System; Southern Illinois University; Oregon Health & Science University; Gunma University	Ramkumar, V (corresponding author), SIU Sch Med, Box 19230, Springfield, IL 62974 USA.	vramkumar@siumed.edu			NHLBI NIH HHS [HL-56316-01] Funding Source: Medline; NIDCD NIH HHS [DC-02936, R01 DC002396] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL056316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002396] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AMBROSIO G, 1992, CARDIOVASC DRUG THER, V6, P623, DOI 10.1007/BF00052564; ANAND AJ, 1993, ANN PHARMACOTHER, V27, P1519, DOI 10.1177/106002809302701219; BALAKRISHNAN VS, 1993, AM J PHYSIOL, V265, pF504, DOI 10.1152/ajprenal.1993.265.4.F504; Behnia R, 1996, ANESTH ANALG, V82, P902, DOI 10.1097/00000539-199605000-00002; Bhat SG, 2002, EUR J PHARMACOL, V442, P251, DOI 10.1016/S0014-2999(02)01510-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Caro A, 1996, BBA-GEN SUBJECTS, V1291, P245, DOI 10.1016/S0304-4165(96)00071-2; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; COULSON R, 1991, AM J PHYSIOL, V260, pF921, DOI 10.1152/ajprenal.1991.260.6.F921; Coulson R, 1996, AM J PHYSIOL-RENAL, V270, pF263, DOI 10.1152/ajprenal.1996.270.2.F263; DAUGAARD G, 1988, CLIN PHARMACOL THER, V44, P164, DOI 10.1038/clpt.1988.132; DAVIS GD, 1986, METHOD MOL BIOL, P139; Dmitrieva N, 2000, J BIOL CHEM, V275, P18243, DOI 10.1074/jbc.M000522200; Dmitrieva N, 2001, AM J PHYSIOL-RENAL, V281, pF522, DOI 10.1152/ajprenal.2001.281.3.F522; DOBYAN DC, 1980, J PHARMACOL EXP THER, V213, P551; Eastman A., 1999, CISPLATIN CHEM BIOCH, P111, DOI [DOI 10.1002/9783906390420.CH4, 10.1002/9783906390420.ch4]; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; FRICK GA, 1979, CANCER TREAT REP, V63, P13; Gonzalez VM, 2001, MOL PHARMACOL, V59, P657, DOI 10.1124/mol.59.4.657; Hammond LC, 2004, BIOCHEM PHARMACOL, V67, P421, DOI 10.1016/j.bcp.2003.09.003; HANDLER JS, 1989, ANNU REV PHYSIOL, V51, P729, DOI 10.1146/annurev.ph.51.030189.003501; Hao CM, 2000, J CLIN INVEST, V106, P973, DOI 10.1172/JCI9956; Henkels KM, 1999, CANCER RES, V59, P3077; Jones NA, 1998, MOL PHARMACOL, V53, P819; KNIGHT RJ, 1993, BRIT J PHARMACOL, V109, P271, DOI 10.1111/j.1476-5381.1993.tb13564.x; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kuhlmann MK, 1997, NEPHROL DIAL TRANSPL, V12, P2478, DOI 10.1093/ndt/12.12.2478; Lee HT, 2004, AM J PHYSIOL-RENAL, V286, pF298, DOI 10.1152/ajprenal.00185.2003; Lee HT, 2004, J AM SOC NEPHROL, V15, P102, DOI 10.1097/01.ASN.0000102474.68613.AE; Lee HT, 2002, J AM SOC NEPHROL, V13, P2753, DOI 10.1097/01.ASN.0000032421.79225.6E; LEVIER DG, 1992, AM J PHYSIOL, V263, pC729, DOI 10.1152/ajpcell.1992.263.4.C729; MAGOVERN GJ, 1984, CIRCULATION, V70, P91; Malek AM, 1998, STROKE, V29, P2631, DOI 10.1161/01.STR.29.12.2631; MCCOY DE, 1993, SEMIN NEPHROL, V13, P31; Nie ZZ, 1998, MOL PHARMACOL, V53, P663, DOI 10.1124/mol.53.4.663; Ochiishi T, 1999, NEUROSCIENCE, V93, P955, DOI 10.1016/S0306-4522(99)00179-7; OLAH ME, 1994, MOL PHARMACOL, V45, P978; OZOLS RF, 1985, SEMIN ONCOL, V12, P21; Paczynski RP, 1997, STROKE, V28, P1437, DOI 10.1161/01.STR.28.7.1437; PerezGarcia F, 1996, LIFE SCI, V59, P2033, DOI 10.1016/S0024-3205(96)00556-5; Pingle SC, 2003, MOL PHARMACOL, V63, P1238, DOI 10.1124/mol.63.6.1238; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; Reed E DM, 1996, PLATINUM ANALOGUES C; Reed JC, 1997, APOPTOSIS AND CANCER, P64; Ren HZ, 1995, MOL PHARMACOL, V48, P975; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; SAFIRSTEIN R, 1984, KIDNEY INT, V25, P753, DOI 10.1038/ki.1984.86; Santoso JT, 2003, CANCER CHEMOTH PHARM, V52, P13, DOI 10.1007/s00280-003-0620-1; SCHWIEBERT EM, 1992, J CLIN INVEST, V89, P834, DOI 10.1172/JCI115662; Seki K, 2000, CANCER CHEMOTH PHARM, V45, P199, DOI 10.1007/s002800050030; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Sprague GF, 1998, GENE DEV, V12, P2817, DOI 10.1101/gad.12.18.2817; SUGIHARA K, 1987, JPN J PHARMACOL, V44, P71, DOI 10.1254/jjp.44.71; TAKEDA M, 1993, AM J PHYSIOL, V265, pF511, DOI 10.1152/ajprenal.1993.265.4.F511; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; VANDERHEIDE RS, 1987, J MOL CELL CARDIOL, V19, P615, DOI 10.1016/S0022-2828(87)80367-X; Wojtaszek PA, 1998, J BIOL CHEM, V273, P800, DOI 10.1074/jbc.273.2.800	59	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43157	43167		10.1074/jbc.M405666200	http://dx.doi.org/10.1074/jbc.M405666200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15272017	hybrid			2022-12-27	WOS:000224226400100
J	Stolze, IP; Tian, YM; Appelhoff, RJ; Turley, H; Wykoff, CC; Gleadle, JM; Ratcliffe, PJ				Stolze, IP; Tian, YM; Appelhoff, RJ; Turley, H; Wykoff, CC; Gleadle, JM; Ratcliffe, PJ			Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL HYDROXYLATION/; STRUCTURAL BASIS; MAMMALIAN-CELLS; OXYGEN; HIF-1-ALPHA; EXPRESSION; PROTEIN; VHL; FACTOR-1-ALPHA; FAMILY	Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor that directs a broad range of cellular responses to hypoxia. Recent studies have defined a set of 2-oxoglutarate and Fe(II)-dependent dioxygenases that modify HIF-alpha subunits by prolyl and asparaginyl hydroxylation. These processes potentially provide a dual system of control, down-regulating both HIF-alpha stability and transcriptional activity. Although genetic analyses in both primitive organisms and mammalian cells have demonstrated a critical role for the prolyl hydroxylase pathway in the regulation of HIF, analogous studies have not been performed on the HIF asparaginyl hydroxylase pathway, and its role in directing the expression of endogenous HIF transcriptional targets has not yet been clearly defined. Here we demonstrate, using small interfering RNA-mediated FIH suppression and controlled overexpression by a doxycycline-inducible system, that alterations in FIH expression in both directions have reciprocal effects on the expression of a range of HIF target genes. These effects were observed in normoxic and severely hypoxic cells but not anoxic cells. Evidence for FIH activity in severely hypoxic cells contrasted with results for the prolyl hydroxylase PHD2, suggesting that these enzymes display different oxygen dependence in vivo, with PHD2 requiring higher levels of oxygen for biological activity. Our results demonstrate an important physiological role for FIH in regulating HIF-dependent target genes over a wide range of oxygen tensions and indicate that inhibition of FIH has the potential to augment HIF target gene expression even in severe hypoxia.	Univ Oxford, Oxford OX3 7BN, England; Univ Oxford, John Radcliffe Hosp, Canc Res United Kingdom,Tumor Pathol Grp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England; John Radcliffe Hosp, CRUK, Mol Oncol Grp, Weatherall Inst Mol Med, Oxford OX3 9DU, England	University of Oxford; Cancer Research UK; University of Oxford; University of Oxford	Ratcliffe, PJ (corresponding author), Univ Oxford, Henry Wellcome Bldg Genom Med,Roosevelt Dr, Oxford OX3 7BN, England.	pjr@well.ox.ac.uk	Gleadle, Jonathan M/K-4188-2012	Gleadle, Jonathan M/0000-0002-5215-7208; Ratcliffe, Peter/0000-0002-2853-806X				Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; DEUSCHLE U, 1995, MOL CELL BIOL, V15, P1907; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Linke S, 2004, J BIOL CHEM, V279, P14391, DOI 10.1074/jbc.M313614200; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McNeill LA, 2002, BIOCHEM J, V367, P571, DOI 10.1042/BJ20021162; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Park SK, 2003, MOL CELL BIOL, V23, P4959, DOI 10.1128/MCB.23.14.4959-4971.2003; PASTOREKOVA S, 1992, VIROLOGY, V187, P620, DOI 10.1016/0042-6822(92)90464-Z; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sowter HM, 2003, CANCER RES, V63, P6130; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wykoff CC, 2000, CANCER RES, V60, P7075; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	34	132	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42719	42725		10.1074/jbc.M406713200	http://dx.doi.org/10.1074/jbc.M406713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15302861	hybrid			2022-12-27	WOS:000224226400046
J	Arbeloa, A; Hugonnet, JE; Sentilhes, AC; Josseaume, N; Dubost, L; Monsempes, C; Blanot, D; Brouard, JP; Arthur, M				Arbeloa, A; Hugonnet, JE; Sentilhes, AC; Josseaume, N; Dubost, L; Monsempes, C; Blanot, D; Brouard, JP; Arthur, M			Synthesis of mosaic peptidoglycan cross-bridges by hybrid peptidoglycan assembly pathways in gram-positive bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM RESISTANCE; PENICILLIN-BINDING PROTEIN-5; STAPHYLOCOCCUS-AUREUS; ENTEROCOCCUS-FAECIUM; STREPTOCOCCUS-FAECALIS; AMPICILLIN RESISTANCE; ESCHERICHIA-COLI; CELL-WALLS; EXPRESSION; TRANSPEPTIDATION	The peptidoglycan cross-bridges of Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium consist of the sequences Gly(5), L-Ala(2), and D-Asx, respectively. Expression of the fmhB, femA, and femB genes of S. aureus in E. faecalis led to the production of peptidoglycan precursors substituted by mosaic side chains that were efficiently used by the penicillin-binding proteins for cross-bridge formation. The Fem transferases were specific for incorporation of glycyl residues at defined positions of the side chains in the absence of any additional S. aureus factors such as tRNAs used for amino acid activation. The PBPs of E. faecalis displayed a broad substrate specificity because mosaic side chains containing from 1 to 5 residues and Gly instead of L-Ala at the N-terminal position were used for peptidoglycan cross-linking. Low affinity PBP2a of S. aureus conferred beta-lactam resistance in E. faecalis and E. faecium, thereby indicating that there was no barrier to heterospecific expression of resistance caused by variations in the structure of peptidoglycan precursors. Thus, conservation of the structure of the peptidoglycan cross-bridges in members of the same species reflects the high specificity of the enzymes for side chain synthesis, although this is not essential for the activity of the PBPs.	Univ Paris 06, LRMA, INSERM, F-75270 Paris 06, France; CNRS, Museum Natl Hist Nat, F-75005 Paris, France; CNRS, UMR 8619, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS)	Arthur, M (corresponding author), Univ Paris 06, LRMA, INSERM, E0004,15 Rue Ecole Med, F-75270 Paris 06, France.	michel.arthur@bhdc.jussieu.fr	HUGONNET, Jean-Emmanuel/H-3581-2014; Arthur, Michel/G-3680-2013; HUGONNET, Jean-Emmanuel/ABC-7914-2021	HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; Arthur, Michel/0000-0003-1007-636X; HUGONNET, Jean-Emmanuel/0000-0003-4150-0944				Anderson JW, 2003, BIOCHEM J, V373, P949, DOI 10.1042/BJ20030217; Arbeloa A, 2004, J BACTERIOL, V186, P1221, DOI 10.1128/JB.186.5.1221-1228.2004; Bouhss A, 2002, J BIOL CHEM, V277, P45935, DOI 10.1074/jbc.M207449200; Bouhss A, 2001, J BACTERIOL, V183, P5122, DOI 10.1128/JB.183.17.5122-5127.2001; Filipe SR, 2000, J BIOL CHEM, V275, P27768; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; GREEN CJ, 1993, J BACTERIOL, V175, P5091, DOI 10.1128/JB.175.16.5091-5096.1993; Hegde SS, 2001, J BIOL CHEM, V276, P6998, DOI 10.1074/jbc.M008591200; Hegde SS, 2003, J BIOL CHEM, V278, P22861, DOI 10.1074/jbc.M301565200; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; JACOB AE, 1974, J BACTERIOL, V117, P360, DOI 10.1128/JB.117.2.360-372.1974; JAMIN M, 1995, ESSAYS BIOCHEM, V29, P1; KLAIC B, 1985, CARBOHYD RES, V138, P65, DOI 10.1016/0008-6215(85)85223-X; Kopp U, 1996, MICROB DRUG RESIST, V2, P29, DOI 10.1089/mdr.1996.2.29; Mainard JL, 2002, J BIOL CHEM, V277, P35801, DOI 10.1074/jbc.M204319200; Mainardi JL, 2000, J BIOL CHEM, V275, P16490, DOI 10.1074/jbc.M909877199; Rice LB, 2001, ANTIMICROB AGENTS CH, V45, P1480, DOI 10.1128/AAC.45.5.1480-1486.2001; ROBERTS RJ, 1974, J BIOL CHEM, V249, P4781; Rohrer S, 1999, P NATL ACAD SCI USA, V96, P9351, DOI 10.1073/pnas.96.16.9351; Rohrer S, 2003, ANTIMICROB AGENTS CH, V47, P837, DOI 10.1128/AAC.47.3.837-846.2003; RYFFEL C, 1994, ANTIMICROB AGENTS CH, V38, P724, DOI 10.1128/AAC.38.4.724; Sauvage E, 2002, CELL MOL LIFE SCI, V59, P1223, DOI 10.1007/s00018-002-8500-0; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Sifaoui F, 2001, ANTIMICROB AGENTS CH, V45, P2594, DOI 10.1128/AAC.45.9.2594-2597.2001; SIGNORETTO C, 1994, FEMS MICROBIOL LETT, V123, P99; STAUDENBAUER W, 1972, J BIOL CHEM, V247, P5289; Stranden AM, 1997, J BACTERIOL, V179, P9, DOI 10.1128/jb.179.1.9-16.1997; TOMASZ A, 1991, ANTIMICROB AGENTS CH, V35, P124, DOI 10.1128/AAC.35.1.124; Tschierske M, 1999, FEMS MICROBIOL LETT, V171, P97, DOI 10.1016/S0378-1097(98)00586-2; van Heijenoort J, 2001, GLYCOBIOLOGY, V11, p25R; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; Wu SW, 2001, J BACTERIOL, V183, P2417, DOI 10.1128/JB.183.8.2417-2424.2001	33	61	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41546	41556		10.1074/jbc.M407149200	http://dx.doi.org/10.1074/jbc.M407149200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280360	hybrid			2022-12-27	WOS:000224075500038
J	Castagnola, M; Inzitari, R; Rossetti, DV; Olmi, C; Cabras, T; Piras, V; Nicolussi, P; Sanna, MT; Pellegrini, M; Giardina, B; Messana, I				Castagnola, M; Inzitari, R; Rossetti, DV; Olmi, C; Cabras, T; Piras, V; Nicolussi, P; Sanna, MT; Pellegrini, M; Giardina, B; Messana, I			A cascade of 24 histatins (histatin 3 fragments) in human saliva - Suggestions for a pre-secretory sequential cleavage pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-RICH POLYPEPTIDES; PEPTIDES; GENES	The systematic search by tandem mass spectrometry of human saliva from four different subjects, of 136 possible fragments originated from histatin 3, allowed the detection of 24 different peptides. They include, with the exception of histatin 4, all the known histatin 3 fragments, namely histatins 5-12 and the peptides corresponding to 15-24, 26-32, 29-32 residues, and 13 new fragments corresponding to 1-11, 1-12, 1-13, 5-13, 6-11, 6-13, 7-11, 7-12, 7-13, 14-24, 14-25, 15-25, and 28-32 residues of histatin 3. On the contrary, none of 119 possible fragments of histatin 1, including histatin 2, was detected. The results suggest that the genesis of histatin 3-related peptides, being under the principal action of trypsin-like activities, is probably not a random process but rather follows a sequential fragmentation pathway. Lack of detection of C-terminal fragments, with the exception of 26-32, 28-32, and 29-32 fragments, suggested that arginine 25 should be the first cleavage site, generating histatin 6 and 26-32 fragments. The genesis of 28-32 and 29-32 fragments and histatin 5 should implicate a subsequent exo-protease action. Similarly, lack of detection of fragments having Lys-5 and Arg-6 at the N terminus and Arg-25 at the C terminus strongly suggested that sequences KRKF (11-14 residues) and AKR (4-6 residues) should be the second and the third cleavage sites, respectively. Lys-17 and Arg-22 are not cleaved at all.	Univ Cattolica, Ist Biochim & Biochim Clin, Fac Med, I-00168 Rome, Italy; CNR, Ist Chim Riconoscimento Mol, I-00168 Rome, Italy; Univ Cagliari, Dipartimento Sci Applicate Biosistemi, I-09100 Cagliari, Italy; Univ Cagliari, Dipartimento Sci Odontostomatol, I-09100 Cagliari, Italy; Ist Zooprofilattico Sardegna G Pegreffi, I-07100 Sassari, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR); University of Cagliari; University of Cagliari; IZS Della Sardegna	Castagnola, M (corresponding author), Univ Cattolica, Ist Biochim & Biochim Clin, Fac Med, Largo F Vito 1, I-00168 Rome, Italy.	massimo.castagnola@icrm.cnr.it	Messana, Irene/L-2478-2019; Cabras, Tiziana/AAF-6231-2020; Castagnola, Massimo/AAM-6355-2021; Castagnola, Massimo/AAB-2825-2019	Messana, Irene/0000-0002-1436-6105; Castagnola, Massimo/0000-0002-0959-7259; Piras, Vincenzo/0000-0003-4499-5567				Basak A, 1997, J PEPT RES, V49, P596; Brewer D, 2002, BIOCHEMISTRY-US, V41, P5526, DOI 10.1021/bi015926d; Castagnola M, 2001, J CHROMATOGR B, V751, P153, DOI 10.1016/S0378-4347(00)00466-7; Chan M, 2001, EUR J BIOCHEM, V268, P3423, DOI 10.1046/j.1432-1327.2001.02241.x; Gusman H, 2004, ARCH ORAL BIOL, V49, P11, DOI 10.1016/S0003-9969(03)00182-1; Helmerhorst EJ, 1999, J BIOL CHEM, V274, P7286, DOI 10.1074/jbc.274.11.7286; Helmerhorst EJ, 1997, BIOCHEM J, V326, P39, DOI 10.1042/bj3260039; MACKAY BJ, 1984, INFECT IMMUN, V44, P688, DOI 10.1128/IAI.44.3.688-694.1984; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; PERINPANAYAGAM HER, 1995, J DENT RES, V74, P345, DOI 10.1177/00220345950740011001; Rothstein DM, 2001, ANTIMICROB AGENTS CH, V45, P1367, DOI 10.1128/AAC.45.5.1367-1373.2001; SABATINI LM, 1993, MOL BIOL EVOL, V10, P497; TROXLER RF, 1990, J DENT RES, V69, P2, DOI 10.1177/00220345900690010101; Tsai H, 1997, ANTIMICROB AGENTS CH, V41, P2224, DOI 10.1128/AAC.41.10.2224; Tsai H, 1998, CRIT REV ORAL BIOL M, V9, P480, DOI 10.1177/10454411980090040601; VANDERSPEK JC, 1989, AM J HUM GENET, V45, P381; XU L, 1993, ARCH ORAL BIOL, V38, P277, DOI 10.1016/0003-9969(93)90133-7; XU L, 1992, ORAL MICROBIOL IMMUN, V7, P127, DOI 10.1111/j.1399-302X.1992.tb00524.x; XU T, 1991, INFECT IMMUN, V59, P2549, DOI 10.1128/IAI.59.8.2549-2554.1991; Yousef GM, 2000, GENOMICS, V63, P88, DOI 10.1006/geno.1999.6072; Zhang ZQ, 1998, J AM SOC MASS SPECTR, V9, P225, DOI 10.1016/S1044-0305(97)00284-5; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	22	91	94	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41436	41443		10.1074/jbc.M404322200	http://dx.doi.org/10.1074/jbc.M404322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15272024	hybrid			2022-12-27	WOS:000224075500025
J	Kulartz, M; Knippers, R				Kulartz, M; Knippers, R			The replicative regulator protein geminin on chromatin in the HeLa cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME MAINTENANCE PROTEINS; RECOGNITION COMPLEX PROTEIN-1; LICENSING FACTOR CDT1; DNA-REPLICATION; S-PHASE; MAMMALIAN-CELLS; MCM PROTEINS; BINDING; ORIGIN; INHIBITION	Geminin is believed to have a major function in the regulation of genome replication and cell proliferation. Published evidence shows that geminin specifically interacts with Cdt1 to block its function in the assembly of prereplication complexes. However, in proliferating HeLa cells geminin and Cdt1 are co-expressed during a relatively short time at the G(1)-to-S phase transition. Under these conditions, nearly all Cdt1 and a major part of geminin are bound to chromatin and reside at the same or closely adjacent sites as shown here by chromatin immunoprecipitation. Cdt1 is rapidly degraded early in S phase, but geminin remains bound to the chromatin sites. One function that chromatin-bound geminin could perform is to prevent access to Cdt1 that may escape S phase-dependent degradation or is synthesized in excess. Indeed, Cdt1 continues to be synthesized in HeLa cells in S phase but never accumulates because of the efficient degradation. Therefore, geminin can be eliminated by RNA interference without detectable effects on cell cycle parameters.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Kulartz, M (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	monika.kulartz@uni-konstanz.de						Ballabeni A, 2004, EMBO J, V23, P3122, DOI 10.1038/sj.emboj.7600314; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Cook JG, 2004, J BIOL CHEM, V279, P9625, DOI 10.1074/jbc.M311933200; Del Bene F, 2004, NATURE, V427, P745, DOI 10.1038/nature02292; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; Hansel DE, 2003, AM J PATHOL, V163, P217, DOI 10.1016/S0002-9440(10)63645-0; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; Johnson R. T., 1993, CELL CYCLE PRACTICAL, P1; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Krude T, 1996, J CELL SCI, V109, P309; Kulartz M, 2003, BIOCHEM BIOPH RES CO, V305, P412, DOI 10.1016/S0006-291X(03)00773-3; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li A, 2004, NAT CELL BIOL, V6, P260, DOI 10.1038/ncb1100; Li X, 2004, NATURE, V427, P687, DOI 10.1038/427687a; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Luo LF, 2004, NATURE, V427, P749, DOI 10.1038/nature02305; Maiorano D, 2004, EXP CELL RES, V295, P138, DOI 10.1016/j.yexcr.2003.11.018; Markey M, 2004, J BIOL CHEM, V279, P29255, DOI 10.1074/jbc.M313482200; McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Nishitani H, 2004, J BIOL CHEM, V279, P30807, DOI 10.1074/jbc.M312644200; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Richter A, 1998, BIOL CHEM, V379, P1181; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; Saxena S, 2004, MOL CELL, V15, P245, DOI 10.1016/j.molcel.2004.06.045; Schaarschmidt D, 2002, NUCLEIC ACIDS RES, V30, P4176, DOI 10.1093/nar/gkf532; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Yoshida K, 2004, ONCOGENE, V23, P3802, DOI 10.1038/sj.onc.1207488; Yoshida K, 2004, ONCOGENE, V23, P58, DOI 10.1038/sj.onc.1206987	41	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41686	41694		10.1074/jbc.M405798200	http://dx.doi.org/10.1074/jbc.M405798200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15284237	hybrid			2022-12-27	WOS:000224075500056
J	Kumar, JK; Chiu, ET; Tabor, S; Richardson, CC				Kumar, JK; Chiu, ET; Tabor, S; Richardson, CC			A unique region in bacteriophage T7 DNA polymerase important for exonucleolytic hydrolysis of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID POLYMERASE; ESCHERICHIA-COLI; PROOFREADING EXONUCLEASE; CONFERS PROCESSIVITY; REPLICATION FORK; GENE-5 PROTEIN; RNA PRIMER; T7; THIOREDOXIN; SEQUENCE	A crystal structure of the bacteriophage T7 gene 5 protein/Escherichia coli thioredoxin complex reveals a region in the exonuclease domain ( residues 144 - 157) that is not present in other members of the E. coli DNA polymerase I family. To examine the role of this region, a genetically altered enzyme that lacked residues 144 157 ( T7 polymerase (pol) Delta144 - 157) was purified and characterized biochemically. The polymerase activity and processivity of T7 pol Delta144 - 157 on primed M13 DNA are similar to that of wild-type T7 DNA polymerase implying that these residues are not important for DNA synthesis. The ability of T7 pol Delta144 - 157 to catalyze the hydrolysis of a phosphodiester bond, as judged from the rate of hydrolysis of a p-nitrophenyl ester of thymidine monophosphate, also remains unaffected. However, the 3'-5' exonuclease activity on polynucleotide substrates is drastically reduced; exonuclease activity on single-stranded DNA is 10-fold lower and that on double-stranded DNA is 20-fold lower as compared with wild-type T7 DNA polymerase. Taken together, our results suggest that residues 144 - 157 of gene 5 protein, although not crucial for polymerase activity, are important for DNA binding during hydrolysis of polynucleotides.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	ccr@hms.harvard.edu			NIGMS NIH HHS [GM 54397] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054397] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bambara RA, 1995, METHOD ENZYMOL, V262, P270; Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breyer WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/ps.10301; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; Chowdhury K, 2000, P NATL ACAD SCI USA, V97, P12469, DOI 10.1073/pnas.230448397; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; GRIPPO P, 1971, J BIOL CHEM, V246, P6867; Hamdan S, 2002, BIOCHEMISTRY-US, V41, P5266, DOI 10.1021/bi0159480; HORI K, 1979, J BIOL CHEM, V254, P1598; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; Kumar JK, 2001, J BIOL CHEM, V276, P46151, DOI 10.1074/jbc.M106319200; Kumar JK, 2001, J BIOL CHEM, V276, P34905, DOI 10.1074/jbc.M104151200; Kusakabe T, 1997, J BIOL CHEM, V272, P12446, DOI 10.1074/jbc.272.19.12446; LECHNER RL, 1983, J BIOL CHEM, V258, P1174; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; LEHMAN IR, 1964, J BIOL CHEM, V239, P233; Miller H, 1996, BIOCHEMISTRY-US, V35, P12919, DOI 10.1021/bi960326d; NAKAI H, 1986, J BIOL CHEM, V261, P5217; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; Yang XM, 1997, J BIOL CHEM, V272, P6599, DOI 10.1074/jbc.272.10.6599	33	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42018	42025		10.1074/jbc.M406103200	http://dx.doi.org/10.1074/jbc.M406103200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292168	hybrid			2022-12-27	WOS:000224075500095
J	Lebowitz, J; Edinger, RS; An, B; Perry, CJ; Onate, S; Kleyman, TR; Johnson, JP				Lebowitz, J; Edinger, RS; An, B; Perry, CJ; Onate, S; Kleyman, TR; Johnson, JP			I kappa B kinase-beta (IKK beta) modulation of epithelial sodium channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; TNF-ALPHA; GENE-EXPRESSION; GAMMA-SUBUNITS; ENAC; ACTIVATION; TRANSPORT; MECHANISMS; RAT; CELLS	Using the yeast two-hybrid system, we identified a number of proteins that interacted with the carboxyl termini of murine epithelial sodium channel ( ENaC) subunits. Initial screens indicated an interaction between the carboxyl terminus of beta-ENaC and IkappaB kinase-beta ( IKKbeta), the kinase that phosphorylates Ikappabeta and results in nuclear targeting of NF-kappaB. A true two-hybrid reaction employing full-length IKKbeta and the carboxyl termini of all three subunits confirmed a strong interaction with beta-ENaC, a weak interaction with gamma-ENaC, and no interaction with alpha-ENaC. Co-immunoprecipitation studies for IKKbeta were performed in a murine cortical collecting duct cell line that endogenously expresses ENaC. Immunoprecipitation with beta-ENaC, but not gamma-ENaC, resulted in co-immunoprecipitation of IKKbeta. To examine the direct effects of IKKbeta on ENaC activity, co-expression studies were performed using the two-electrode voltage clamp technique in Xenopus oocytes. Oocytes were injected with cRNAs for alphabetagamma-ENaC with or without cRNA for IKKbeta. Co-injection of IKKbeta significantly increased the amiloride-sensitive current above controls. Using cell surface ENaC labeling, we determined that an increase of ENaC in the plasma membrane accounted for the increase in current. The injection of kinase-dead IKKbeta (K44A) in ENaC-expressing oocytes resulted in a significant decrease in current. Treatment of mpkCCD(c14) cells with aldosterone increased whole cell amounts of IKKbeta. Because this result suggested that aldosterone might activate NF-kappaB, mpkCCD(c14) cells were transiently transfected with a luciferase reporter gene responsive to NF-kappaB activation. Both aldosterone and tumor necrosis factor-alpha (TNFalpha) stimulation caused a similar and significant increase in luciferase activity as compared with controls. We conclude that IKKbeta interacts with ENaC by up-regulating ENaC at the plasma membrane and that the presence of IKKbeta is at very least permissive to ENaC function. These studies also suggest a previously unexpected interaction between the NF-kappaB transcription pathway and steroid regulatory pathways in epithelial cells.	Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Ctr Res Reprod Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lebowitz, J (corresponding author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, A915 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	Lebowitzj@msx.dept-med.pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354, R01DK047874, K08DK067143] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 54354, DK 067143, DK 047874] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arai K, 1999, J CLIN ENDOCR METAB, V84, P2434, DOI 10.1210/jc.84.7.2434; Baines DL, 2001, J PHYSIOL-LONDON, V532, P105, DOI 10.1111/j.1469-7793.2001.0105g.x; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Biasio W, 2004, J BIOL CHEM, V279, P5429, DOI 10.1074/jbc.M311155200; Borjesson A, 2000, AM J PHYSIOL-LUNG C, V278, pL3, DOI 10.1152/ajplung.2000.278.1.L3; Bruns JB, 2003, AM J PHYSIOL-RENAL, V285, pF600, DOI 10.1152/ajprenal.00095.2003; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1995, KIDNEY INT, V48, P950, DOI 10.1038/ki.1995.376; Cao CC, 2001, PEDIATR NEPHROL, V16, P790, DOI 10.1007/s004670100632; Carattino MD, 2004, J BIOL CHEM, V279, P4120, DOI 10.1074/jbc.M311783200; Carter KB, 2000, J BIOL CHEM, V275, P27858; *CLONT, 2001, YEAST PROT HDB; *CLONT, 1999, PT32471 CLONT; Condliffe SB, 2003, J BIOL CHEM, V278, P12796, DOI 10.1074/jbc.M210772200; Dagenais A, 2004, AM J PHYSIOL-LUNG C, V286, pL301, DOI 10.1152/ajplung.00326.2002; de Haij S, 2003, J BIOL CHEM, V278, P5091, DOI 10.1074/jbc.M209836200; de Haij S, 2002, BRIT J PHARMACOL, V137, P197, DOI 10.1038/sj.bjp.0704866; DiPetrillo K, 2004, KIDNEY INT, V65, P1676, DOI 10.1111/j.1523-1755.2004.00606.x; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; Fiebeler A, 2001, HYPERTENSION, V37, P787, DOI 10.1161/01.HYP.37.2.787; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Fukuda N, 2001, AM J PHYSIOL-LUNG C, V280, pL1258, DOI 10.1152/ajplung.2001.280.6.L1258; Funder JW, 1997, ANNU REV MED, V48, P231, DOI 10.1146/annurev.med.48.1.231; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Galietta LJV, 2000, AM J PHYSIOL-LUNG C, V278, pL1186, DOI 10.1152/ajplung.2000.278.6.L1186; Ganesh L, 2003, NATURE, V426, P853, DOI 10.1038/nature02171; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gormley K, 2003, BIOCHEM J, V371, P1, DOI 10.1042/BJ20021375; Gougat C, 2002, J MOL MED-JMM, V80, P309, DOI 10.1007/s00109-001-0302-6; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Kolla V, 2000, ARCH BIOCHEM BIOPHYS, V383, P38, DOI 10.1006/abbi.2000.2045; Lebowitz J, 2003, AM J PHYSIOL-RENAL, V285, pF524, DOI 10.1152/ajprenal.00366.2001; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; OBrodovich HM, 1996, P ASSOC AM PHYSICIAN, V108, P345; PALMER LG, 1986, FASEB J, V45, P2708; Rafii B, 1998, AM J PHYSIOL-LUNG C, V275, pL764, DOI 10.1152/ajplung.1998.275.4.L764; RENARD S, 1995, PFLUG ARCH EUR J PHY, V430, P299, DOI 10.1007/BF00373903; Rezaiguia S, 1997, J CLIN INVEST, V99, P325, DOI 10.1172/JCI119161; Rocha R, 2002, AM J PHYSIOL-HEART C, V283, pH1802, DOI 10.1152/ajpheart.01096.2001; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; Rotin D, 2000, CURR OPIN NEPHROL HY, V9, P529, DOI 10.1097/00041552-200009000-00012; Sahali D, 2001, J AM SOC NEPHROL, V12, P1648, DOI 10.1681/ASN.V1281648; Schaaf MJM, 2002, J STEROID BIOCHEM, V83, P37, DOI 10.1016/S0960-0760(02)00263-7; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Shi HK, 2002, EUR J BIOCHEM, V269, P4551, DOI 10.1046/j.1432-1033.2002.03154.x; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Sun Y, 2002, AM J PATHOL, V161, P1773, DOI 10.1016/S0002-9440(10)64454-9; Ten RM, 1999, J IMMUNOL, V163, P3851; Valanciute A, 2004, J IMMUNOL, V172, P688, DOI 10.4049/jimmunol.172.1.688; Vuagniaux G, 2002, J GEN PHYSIOL, V120, P191, DOI 10.1085/jgp.20028598; Wallach D, 2002, ARTHRITIS RES THER, V4, pS189, DOI 10.1186/ar585; Webster JC, 2001, P NATL ACAD SCI USA, V98, P6865, DOI 10.1073/pnas.121455098; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	55	18	18	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41985	41990		10.1074/jbc.M403923200	http://dx.doi.org/10.1074/jbc.M403923200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292220	hybrid			2022-12-27	WOS:000224075500091
J	Yu, JD; He, S; Friedman, JS; Akimoto, M; Ghosh, D; Mears, AJ; Hicks, D; Swaroop, A				Yu, JD; He, S; Friedman, JS; Akimoto, M; Ghosh, D; Mears, AJ; Hicks, D; Swaroop, A			Altered expression of genes of the Bmp/Smad and Wnt/calcium signaling pathways in the cone-only Nrl(-/-) mouse retina, revealed by gene profiling using custom cDNA microarrays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BZIP TRANSCRIPTION FACTOR; LEUCINE-ZIPPER; FACTOR-BINDING; SUBUNIT GENE; FACTOR NRL; ROD; PROTEIN; IDENTIFICATION; DIFFERENTIATION; NORMALIZATION	Many mammalian retinas are rod-dominant, and hence our knowledge of cone photoreceptor biology is relatively limited. To gain insights into the molecular differences between rods and cones, we compared the gene expression profile of the rod-dominated retina of wild type mouse with that of the cone-only retina of Nrl(-/-) (Neural retina leucine zipper knockout) mouse. Our analysis, using custom microarrays of eye-expressed genes, provided equivalent data using either direct or reference-based experimental designs, confirmed differential expression of rod- and cone-specific genes in the Nrl(-/-) retina and identified novel genes that could serve as candidates for retinopathies or for functional studies. In addition, we detected altered expression of several genes that encode cell signaling or structural proteins. Prompted by these findings, additional real-time PCR analysis revealed that genes belonging to the Bmp/Smad and Wnt/Ca2+ signaling pathways are expressed in the mature wild type retina and that their expression is significantly altered in the Nrl(-/-) retina. Chromatin immunoprecipitation analysis of adult retina identified Bmp4 and Smad4, which are down-regulated in the Nrl(-/-) retina, as possible direct transcriptional targets of Nrl. Consistent with these studies, Bmp4 and Smad4 are expressed in the mature rod photoreceptors of mouse retina. Modulation of Bmp4 and/or Smad4 by Nrl may provide a mechanism for integrating diverse cell signaling networks in rods. We hypothesize that Bmp/Smad and Wnt/Ca2+ pathways participate in cell-cell communication in the mature retina, and expression changes observed in the Nrl(-/-) retina reflect their biased utilization in rod versus cone homeostasis.	Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA; Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48015 USA; Univ Michigan, Dept Biostat, Ann Arbor, MI 48015 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48015 USA; Kyoto Univ Hosp, Translat Res Ctr, Sakyo Ku, Kyoto 6068507, Japan; INSERM, Lab Physiopathol Cellulaire & Mol Retine, U 592, F-67091 Strasbourg, France	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Kyoto University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Swaroop, A (corresponding author), Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.	swaroop@umich.edu	Akimoto, Masayuki/AAP-3676-2020	Swaroop, Anand/0000-0002-1975-1141; Ghosh, Debashis/0000-0001-6618-1316; Akimoto, Masayuki/0000-0002-5899-2925	NATIONAL EYE INSTITUTE [R01EY011115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072007] Funding Source: NIH RePORTER; NEI NIH HHS [EY07003, EY11115] Funding Source: Medline; NIGMS NIH HHS [GM72007, R01 GM072007-01, R01 GM072007] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; Belecky-Adams TL, 1999, DEV BIOL, V210, P107, DOI 10.1006/dbio.1999.9268; Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678; Blackshaw S, 2001, CELL, V107, P579, DOI 10.1016/S0092-8674(01)00574-8; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Cheng H, 2004, HUM MOL GENET, V13, P1563, DOI 10.1093/hmg/ddh173; Chowers I, 2003, INVEST OPHTH VIS SCI, V44, P3732, DOI 10.1167/iovs.02-1080; Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015; DeAngelis MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P369; DeRyckere D, 2002, METHODS, V26, P57, DOI 10.1016/S1046-2023(02)00008-7; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dowling J. E., 1987, RETINA APPROACHABLE; Ebrey T, 2001, PROG RETIN EYE RES, V20, P49, DOI 10.1016/S1350-9462(00)00014-8; Faber SC, 2002, DEVELOPMENT, V129, P3727; Farjo R, 2002, VISION RES, V42, P463, DOI 10.1016/S0042-6989(01)00219-X; Furuta Y, 1998, GENE DEV, V12, P3764, DOI 10.1101/gad.12.23.3764; Hendrickson A, 2002, EXP EYE RES, V74, P435, DOI 10.1006/exer.2002.1181; Hicks D, 1999, INVEST OPHTH VIS SCI, V40, P3071; HICKS D, 1986, EXP EYE RES, V42, P55, DOI 10.1016/0014-4835(86)90017-5; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Jones SE, 2000, NEUROREPORT, V11, P3963, DOI 10.1097/00001756-200012180-00012; Jones SE, 2000, INVEST OPHTH VIS SCI, V41, P1297; Kameya S, 2002, HUM MOL GENET, V11, P1879, DOI 10.1093/hmg/11.16.1879; Krizaj D, 2002, FRONT BIOSCI-LANDMRK, V7, pD2023, DOI 10.2741/krizaj; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Lerner LE, 2001, J BIOL CHEM, V276, P34999, DOI 10.1074/jbc.M103301200; Leskov IB, 2000, NEURON, V27, P525, DOI 10.1016/S0896-6273(00)00063-5; Liu Q, 1996, ONCOGENE, V12, P207; Liu XX, 1999, P NATL ACAD SCI USA, V96, P14383, DOI 10.1073/pnas.96.25.14383; Livesey FJ, 2000, CURR BIOL, V10, P301, DOI 10.1016/S0960-9822(00)00379-1; Lonnstedt I, 2002, STAT SINICA, V12, P31; Marc RE, 2003, MOL NEUROBIOL, V28, P139, DOI 10.1385/MN:28:2:139; Masland RH, 2001, CURR OPIN NEUROBIOL, V11, P431, DOI 10.1016/S0959-4388(00)00230-0; Mathura JR, 2000, INVEST OPHTH VIS SCI, V41, P592; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; Mitton KP, 2003, HUM MOL GENET, V12, P365, DOI 10.1093/hmg/ddg035; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; MJU, 2004, DEVELOPMENT, V131, P1197; Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493; Nathans J, 1999, NEURON, V24, P299, DOI 10.1016/S0896-6273(00)80845-4; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; PAN W, 2002, GENOME BIOL; Pittler SJ, 2004, J BIOL CHEM, V279, P19800, DOI 10.1074/jbc.M401864200; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Rebrik TI, 1998, J GEN PHYSIOL, V112, P537, DOI 10.1085/jgp.112.5.537; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Sakuta H, 2001, SCIENCE, V293, P111, DOI 10.1126/science.1058379; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Strettoi E, 2004, J NEUROSCI, V24, P7576, DOI 10.1523/JNEUROSCI.2245-04.2004; Swain PK, 2001, J BIOL CHEM, V276, P36824, DOI 10.1074/jbc.M105855200; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Swaroop A, 2002, GENOME BIOL, V3; Tseng GC, 2001, NUCLEIC ACIDS RES, V29, P2549, DOI 10.1093/nar/29.12.2549; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yang RB, 1997, J BIOL CHEM, V272, P13738, DOI 10.1074/jbc.272.21.13738; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yang YH, 2002, NAT REV GENET, V3, P579, DOI 10.1038/nrg863; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yoshida S, 2004, HUM MOL GENET, V13, P1487, DOI 10.1093/hmg/ddh160; Yoshida S, 2002, INVEST OPHTH VIS SCI, V43, P2554; Yu JD, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r65; Yu JD, 2002, MOL VIS, V8, P130; Zhu XM, 2003, J NEUROSCI, V23, P6152, DOI 10.1523/JNEUROSCI.23-14-06152.2003	71	49	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42211	42220		10.1074/jbc.M408223200	http://dx.doi.org/10.1074/jbc.M408223200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292180	hybrid			2022-12-27	WOS:000224075500113
J	Jones, ML; Craik, JD; Gibbins, JM; Poole, AW				Jones, ML; Craik, JD; Gibbins, JM; Poole, AW			Regulation of SHP-1 tyrosine phosphatase in human platelets by serine phosphorylation at its C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HEMATOPOIETIC-CELL PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; THROMBIN RECEPTOR; NEGATIVE REGULATION; CRYSTAL-STRUCTURE; T-CELLS; ACTIVATION; SH-PTP1; ASSOCIATION	SHP-1 is a Src homology 2 (SH2) domain-containing tyrosine phosphatase that plays an essential role in negative regulation of immune cell activity. We describe here a new model for regulation of SHP-1 involving phosphorylation of its C-terminal Ser(591) by associated protein kinase Calpha. In human platelets, SHP-1 was found to constitutively associate with its substrate Vav1 and, through its SH2 domains, with protein kinase Calpha. Upon activation of either PAR1 or PAR4 thrombin receptors, the association between the three proteins was retained, and Vav1 became phosphorylated on tyrosine and SHP-1 became phosphorylated on Ser(591). Phosphorylation of SHP-1 was mediated by protein kinase C and negatively regulated the activity of SHP-1 as demonstrated by a decrease in the in vitro ability of SHP-1 to dephosphorylate Vav1 on tyrosine. Protein kinase Calpha therefore critically and negatively regulates SHP-1 function, forming part of a mechanism to retain SHP-1 in a basal active state through interaction with its SH2 domains, and phosphorylating its C-terminal Ser(591) upon cellular activation leading to inhibition of SHP-1 activity and an increase in the tyrosine phosphorylation status of its substrates.	Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England; Univ Reading, Sch Anim & Microbial Sci, Reading, Berks, England	University of Bristol; University of Reading	Poole, AW (corresponding author), Univ Bristol, Sch Med Sci, Dept Pharmacol, Univ Walk, Bristol BS8 1TD, Avon, England.	a.poole@bris.ac.uk		Gibbins, Jonathan/0000-0002-0372-5352; Poole, Alastair/0000-0002-0868-297X				Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; Brumell JH, 1997, J BIOL CHEM, V272, P875, DOI 10.1074/jbc.272.2.875; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; Crosby D, 2003, J BIOL CHEM, V278, P24533, DOI 10.1074/jbc.M301847200; Crosby D, 2002, J BIOL CHEM, V277, P9958, DOI 10.1074/jbc.M108965200; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; Gaits F, 1996, J BIOL CHEM, V271, P20151; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Miyakawa Y, 1997, BLOOD, V89, P2789, DOI 10.1182/blood.V89.8.2789; Mizuno K, 1996, J EXP MED, V184, P457, DOI 10.1084/jem.184.2.457; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Pasquet JM, 2000, J BIOL CHEM, V275, P28526, DOI 10.1074/jbc.M001531200; Pearce AC, 2002, BLOOD, V100, P3561, DOI 10.1182/blood.V100.10.3561; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Sathish JG, 2001, J IMMUNOL, V166, P1763, DOI 10.4049/jimmunol.166.3.1763; Stebbins CC, 2003, MOL CELL BIOL, V23, P6291, DOI 10.1128/MCB.23.17.6291-6299.2003; Strack V, 2002, BIOCHEMISTRY-US, V41, P603, DOI 10.1021/bi011327v; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; Yoshida K, 2001, MOL PHARMACOL, V60, P1431, DOI 10.1124/mol.60.6.1431; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223; Zhang ZS, 2003, J BIOL CHEM, V278, P4668, DOI 10.1074/jbc.M210028200	33	51	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40475	40483		10.1074/jbc.M402970200	http://dx.doi.org/10.1074/jbc.M402970200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15269224	hybrid			2022-12-27	WOS:000223916800034
J	Muhlethaler-Mottet, A; Krawczyk, M; Masternak, K; Spilianakis, C; Kretsovali, A; Papamatheakis, J; Reith, W				Muhlethaler-Mottet, A; Krawczyk, M; Masternak, K; Spilianakis, C; Kretsovali, A; Papamatheakis, J; Reith, W			The S box of major histocompatibility complex class II promoters is a key determinant for recruitment of the transcriptional co-activator CIITA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARE-LYMPHOCYTE-SYNDROME; HLA-DRA GENE; CREB BINDING-PROTEIN; IN-VIVO RECRUITMENT; NF-Y; X-BOX; COOPERATIVE BINDING; REGULATORY REGIONS; EXPRESSION; TRANSACTIVATOR	Tightly regulated expression of major histocompatibility complex (MHC) class II genes is critical for the immune system. A conserved regulatory module consisting of four cis-acting elements, the W, X, X2 and Y boxes, controls transcription of MHC class II genes. The X, X2, and Y boxes are bound, respectively, by RFX, CREB, and NF-Y to form a MHC class II-specific enhanceosome complex. The latter constitutes a landing pad for recruitment of the transcriptional co-activator CIITA. In contrast to the well defined roles of the X, X2, and Y boxes, the role of the W region has remained controversial. In vitro binding studies have suggested that it might contain a second RFX-binding site. We demonstrate here by means of promoter pull-down assays that the most conserved subsequence within the W region, called the S box, is a critical determinant for tethering of CIITA to the enhanceosome complex. Binding of CIITA to the enhanceosome requires both integrity of the S box and a remarkably stringent spacing between the S and X boxes. Even a 1-2-base pair change in the native S-X distance is detrimental for CIITA recruitment and promoter function. In contrast to current models, binding of RFX to a putative duplicated binding site in the W box is thus not required for either CIITA recruitment or promoter activity. This paves the way for the identification of novel factors mediating the contribution of the S box to the activation of MHC class II promoters.	Univ Geneva, Sch Med, CMU, Dept Pathol & Immunol, CH-1211 Geneva, Switzerland; Fdn Res & Technol, Inst Mol Biol & Biotechnol, Iraklion 71110, Crete, Greece	University of Geneva	Reith, W (corresponding author), Univ Geneva, Sch Med, CMU, Dept Pathol & Immunol, 1 Rue Michel Servet, CH-1211 Geneva, Switzerland.	walter.reith@medecine.unige.ch	Spilianakis, Charalampos G/C-9893-2011; Mühlethaler-Mottet, Annick/H-2848-2019; Krawczyk, Michal/W-2538-2018	Spilianakis, Charalampos G/0000-0003-0921-1923; Mühlethaler-Mottet, Annick/0000-0001-8274-0907; Krawczyk, Michal/0000-0001-9646-3779				ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; Alfonso C, 2000, ANNU REV IMMUNOL, V18, P113, DOI 10.1146/annurev.immunol.18.1.113; ANDERSEN LC, 1991, J EXP MED, V173, P181, DOI 10.1084/jem.173.1.181; BASTA PV, 1988, P NATL ACAD SCI USA, V85, P8618, DOI 10.1073/pnas.85.22.8618; Beaty JS, 1999, MICROBES INFECT, V1, P919, DOI 10.1016/S1286-4579(99)00225-7; BEATY JS, 1995, MOL CELL BIOL, V15, P4771; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; BOSS JM, 1986, P NATL ACAD SCI USA, V83, P9139, DOI 10.1073/pnas.83.23.9139; BROWN AM, 1993, J BIOL CHEM, V268, P26328; Brown JA, 1998, NUCLEIC ACIDS RES, V26, P4128, DOI 10.1093/nar/26.18.4128; COGSWELL JP, 1991, J IMMUNOL, V146, P1361; COGSWELL JP, 1990, P NATL ACAD SCI USA, V87, P7703, DOI 10.1073/pnas.87.19.7703; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DeSandro A, 1999, AM J HUM GENET, V65, P279, DOI 10.1086/302519; DeSandro AM, 2000, MOL CELL BIOL, V20, P6587, DOI 10.1128/MCB.20.17.6587-6599.2000; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; Fontes JD, 1997, J MOL BIOL, V270, P336, DOI 10.1006/jmbi.1997.1121; Fontes JD, 1999, MOL CELL BIOL, V19, P941; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; Hake SB, 2000, MOL CELL BIOL, V20, P7716, DOI 10.1128/MCB.20.20.7716-7725.2000; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; Jabrane-Ferrat N, 2003, INT IMMUNOL, V15, P467, DOI 10.1093/intimm/dxg048; JabraneFerrat N, 1996, MOL CELL BIOL, V16, P4683; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARA CJ, 1993, J IMMUNOL, V150, P4934; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; LeibundGut-Landmann S, 2004, EUR J IMMUNOL, V34, P1513, DOI 10.1002/eji.200424964; LouisPlence P, 1997, J IMMUNOL, V159, P3899; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Masternak K, 2000, GENE DEV, V14, P1156; Masternak K, 2003, NAT IMMUNOL, V4, P132, DOI 10.1038/ni883; Masternak K, 2002, EMBO J, V21, P1379, DOI 10.1093/emboj/21.6.1379; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; Masternak K, 2000, Rev Immunogenet, V2, P267; MORENO CS, 1995, J IMMUNOL, V155, P4313; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Nagarajan UM, 2002, J IMMUNOL, V168, P1780, DOI 10.4049/jimmunol.168.4.1780; Nagarajan UM, 1999, IMMUNITY, V10, P153, DOI 10.1016/S1074-7613(00)80016-3; Nekrep N, 2003, IMMUNITY, V18, P453, DOI 10.1016/S1074-7613(03)00086-4; REITH W, 1994, J BIOL CHEM, V269, P20020; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; SERVENIUS B, 1987, J BIOL CHEM, V262, P8759; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Spilianakis C, 2003, EMBO J, V22, P5125, DOI 10.1093/emboj/cdg496; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; SUGAWARA M, 1995, J EXP MED, V182, P175, DOI 10.1084/jem.182.1.175; Taxman DJ, 2000, J IMMUNOL, V165, P1410, DOI 10.4049/jimmunol.165.3.1410; Ting JPY, 1997, J IMMUNOL, V159, P5457; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; van den Elsen PJ, 1998, IMMUNOL TODAY, V19, P308, DOI 10.1016/S0167-5699(98)01287-0; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; VILEN BJ, 1992, J BIOL CHEM, V267, P23728; Westerheide SD, 1997, J IMMUNOL, V158, P4812; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000	62	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40529	40535		10.1074/jbc.M406585200	http://dx.doi.org/10.1074/jbc.M406585200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15271997	hybrid			2022-12-27	WOS:000223916800040
J	Song, YL; Sonawane, ND; Salinas, D; Qian, LM; Pedemonte, N; Galietta, LJV; Verkman, AS				Song, YL; Sonawane, ND; Salinas, D; Qian, LM; Pedemonte, N; Galietta, LJV; Verkman, AS			Evidence against the rescue of defective Delta F508-CFTR cellular processing by curcumin in cell culture and mouse models	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; FIBROSIS EPITHELIAL-CELLS; CYSTIC-FIBROSIS; DIETARY CURCUMIN; FLUID SECRETION; CFTR INHIBITOR; ACTIVATION; MICE; CARCINOGENESIS; MECHANISM	Curcumin, the yellow colored component of the spice turmeric, has been reported to rescue defective DeltaF508-cystic fibrosis transmembrane conductance regulator (CFTR) cellular processing in homozygous mutant mice, restoring nasal potential differences and improving survival (Egan, M. E., Pearson, M., Weiner, S. A., Rajendran, V., Rubin, D., Glockner-Pagel, J., Canny, S., Du, K., Lukacs, G. L., and Caplan, M. J. (2004) Science 304, 600-602). Because of the implied potential use of curcumin or similar compounds in the therapy of cystic fibrosis caused by the DeltaF508 mutation, we tried to reproduce and extend the pre-clinical data of Egan et al. Fluorometric measurements of iodide influx in Fischer rat thyroid cells expressing DeltaF508-CFTR showed no effect of curcumin (1-40 muM) when added for up to 24 h prior to assay in cells grown at 37degreesC. Controls, including 27degreesC rescue and 4 mM phenylbutyrate at 37degreesC, were strongly positive. Also, curcumin did not increase short circuit current in primary cultures of a human airway epithelium homozygous for DeltaF508-CFTR with a 27degreesC rescue-positive control. Nasal potential differences in mice were measured in response to topical perfusion with serial solutions containing amiloride, low Cl-, and forskolin. Robust low Cl- and forskolin-induced hyperpolarization of 22+/-3 mV was found in wild type mice, with 2.1+/-0.4 mV hyperpolarization in DeltaF508 homozygous mutant mice. No significant increase in Cl-/forskolin hyperpolarization was seen in any of the 22 DeltaF508 mice studied using different curcumin preparations and administration regimens, including that used by Egan et al. Assay of serum curcumin by ethyl acetate extraction followed by liquid chromatography/mass spectrometry indicated a maximum serum concentration of 60 nM, well below that of 5-15 muM, where cellular effects by sarcoplasmic/endoplasmic reticulum calcium pump inhibition are proposed to occur. Our results do not support further evaluation of curcumin for cystic fibrosis therapy.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Genoa; IRCCS Istituto Giannina Gaslini	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu	Pedemonte, Nicoletta/B-3607-2010; Galietta, Luis JV/HCG-8692-2022	Pedemonte, Nicoletta/0000-0002-5161-1720; 	NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER; NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Nakkash L, 2001, J PHARMACOL EXP THER, V296, P464; Araujo CAC, 2001, MEM I OSWALDO CRUZ, V96, P723, DOI 10.1590/S0074-02762001000500026; Bobadilla JL, 2002, HUM MUTAT, V19, P575, DOI 10.1002/humu.10041; Busquets S, 2001, CANCER LETT, V167, P33, DOI 10.1016/S0304-3835(01)00456-6; Chainani-Wu N, 2003, J ALTERN COMPLEM MED, V9, P161, DOI 10.1089/107555303321223035; Clarke LL, 1996, LAB ANIM SCI, V46, P612; COLLEDGE WH, 1995, NAT GENET, V10, P445, DOI 10.1038/ng0895-445; Cooper T.H., 1994, FOOD PHYTOCHEMICALS, P231; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Egan ME, 2004, SCIENCE, V304, P600, DOI 10.1126/science.1093941; Egan ME, 2002, NAT MED, V8, P485, DOI 10.1038/nm0502-485; Garcea G, 2004, BRIT J CANCER, V90, P1011, DOI 10.1038/sj.bjc.6601623; Haws CM, 1996, AM J PHYSIOL-CELL PH, V270, pC1544, DOI 10.1152/ajpcell.1996.270.5.C1544; Iqbal M, 2003, PHARMACOL TOXICOL, V92, P33, DOI 10.1034/j.1600-0773.2003.920106.x; Ireson CR, 2002, CANCER EPIDEM BIOMAR, V11, P105; Kim HY, 2003, J IMMUNOL, V171, P6072, DOI 10.4049/jimmunol.171.11.6072; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; Muanprasat C, 2004, J GEN PHYSIOL, V124, P125, DOI 10.1085/jgp.200409059; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; RAO CV, 1995, CANCER RES, V55, P259; Riordan JR, 1999, AM J HUM GENET, V64, P1499, DOI 10.1086/302429; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; SALINAS DB, 2004, IN PRESS AM J PHYSL; Sharma RA, 2001, CLIN CANCER RES, V7, P1894; Sharma RA, 2001, CLIN CANCER RES, V7, P1452; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Thiagarajah JR, 2004, GASTROENTEROLOGY, V126, P511, DOI 10.1053/j.gastro.2003.11.005; Verkman AS, 2004, AM J PHYSIOL-CELL PH, V286, pC465, DOI 10.1152/ajpcell.00397.2003; Yang H, 2003, J BIOL CHEM, V278, P35079, DOI 10.1074/jbc.M303098200	32	88	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40629	40633		10.1074/jbc.M407308200	http://dx.doi.org/10.1074/jbc.M407308200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15280357	hybrid			2022-12-27	WOS:000223916800051
J	Yamaguchi, H; Chen, JD; Bhalla, K; Wang, HG				Yamaguchi, H; Chen, JD; Bhalla, K; Wang, HG			Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY-MEMBER BIM; BCL-2 FAMILY; CONFORMATIONAL CHANGE; BH3-ONLY PROTEINS; CELL-SURVIVAL; PACLITAXEL; PUMA; ABSENCE; TAXOL; MITOCHONDRIA	Microtubule-damaging agents (MDA) are potent antineoplastic drugs that are widely used in clinical treatment for a variety of cancers. However, the precise mechanisms underlying MDA-induced cell death are largely unknown. Here, we report that both p53 and Bax are central participants in the MDA-mediated cell death machinery in HCT116 human colon cancer cells. MDA, including epothilone B analogue (BMS-247550) and vinblastine, induced apoptosis of Bax-positive HCT116 cells in a p53-dependent manner; p53 was required for MDA-induced Bax conformational change. In response to MDA treatment, the BH3-only proapoptotic protein PUMA was up-regulated in p53-positive but not in p53 knockout HCT116 cells. Moreover, PUMA knockout HCT116 cells were resistant to MDA-induced Bax conformational change and apoptosis. In addition, introducing p53 plasmid DNA into p53-deficient HCT116 cells restored PUMA expression and apoptotic response to MDA treatment. However, ectopic expression of the p53 point mutation L22Q/W23S, but not the proline-rich domain deletion mutants 83-393 and DeltaProAE, could also sensitize p53 knockout HCT116 cells to MDA-induced Bax activation and apoptosis, although all mutants failed to restore PUMA expression. Together, these findings suggest that p53 acts upstream of Bax to promote MDA-mediated cell death in a proline-rich domain-dependent manner through both transcription-dependent (by up-regulating PUMA expression) and -independent mechanisms in human colon cancer HCT116 cells.	Univ S Florida, Coll Med, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr, Expt Therapeut Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Wang, HG (corresponding author), Univ S Florida, Coll Med, Drug Discovery Program, Tampa, FL 33612 USA.	wanghg@moffitt.usf.edu	Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Bhalla, Kapil/0000-0001-5209-5126				Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Crown J, 2000, LANCET, V355, P1176, DOI 10.1016/S0140-6736(00)02074-2; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Galmarini CM, 2001, BRIT J CANCER, V85, P902, DOI 10.1054/bjoc.2001.2017; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jordan MA, 1996, CANCER RES, V56, P816; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Ngan VK, 2000, CANCER RES, V60, P5045; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tan GL, 2002, INT J CANCER, V97, P168, DOI 10.1002/ijc.1591; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yamaguchi H, 2002, CANCER RES, V62, P466; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang H, 2002, J BIOL CHEM, V277, P43648, DOI 10.1074/jbc.M203214200; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	56	106	109	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39431	39437		10.1074/jbc.M401530200	http://dx.doi.org/10.1074/jbc.M401530200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262986	hybrid			2022-12-27	WOS:000223791500031
J	Kayser, EB; Sedensky, MM; Morgan, PG; Hoppel, CL				Kayser, EB; Sedensky, MM; Morgan, PG; Hoppel, CL			Mitochondrial oxidative phosphorylation is defective in the long-lived mutant clk-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; COENZYME-Q; LIFE-SPAN; COMPLEX-I; UBIQUINONE; EXPRESSION; GENE; DEHYDROGENASE; BIOSYNTHESIS; SPECIFICITY	The long-lived mutant of Caenorhabditis elegans, clk-1, is unable to synthesize ubiquinone, CoQ(9). Instead, the mutant accumulates demethoxyubiquinone(9) and small amounts of rhodoquinone(9) as well as dietary CoQ(8). We found a profound defect in oxidative phosphorylation, a test of integrated mitochondrial function, in clk-1 mitochondria fueled by NADH-linked electron donors, i.e. complex I-dependent substrates. Electron transfer from complex I to complex III, which requires quinones, is severely depressed, whereas the individual complexes are fully active. In contrast, oxidative phosphorylation initiated through complex II, which also requires quinones, is completely normal. Here we show that complexes I and II differ in their ability to use the quinone pool in clk-1. This is the first direct demonstration of a differential interaction of complex I and complex II with the endogenous quinone pool. This study uses the combined power of molecular genetics and biochemistry to highlight the role of quinones in mitochondrial function and aging.	Univ Hosp, Dept Anesthesiol, Cleveland, OH 44106 USA; Univ Hosp, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Anesthesiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Vet Affairs Med Ctr, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Vet Affairs Med Ctr, Dept Med, Cleveland, OH 44106 USA	University Hospitals of Cleveland; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Hoppel, CL (corresponding author), Louis Stokes Vet Affairs Med Ctr, Med Res Serv 151W, 10701 East Blvd, Cleveland, OH 44106 USA.	charles.hoppel@case.edu			NIA NIH HHS [P01 AG15885] Funding Source: Medline; NIGMS NIH HHS [GM58881] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015885] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Braeckman BP, 2002, AGING CELL, V1, P82, DOI 10.1046/j.1474-9728.2002.00021.x; Braeckman BP, 2002, MECH AGEING DEV, V123, P1447, DOI 10.1016/S0047-6374(02)00085-4; Braeckman BP, 1999, CURR BIOL, V9, P493, DOI 10.1016/S0960-9822(99)80216-4; Brass EP, 2001, AM J PHYSIOL-HEART C, V280, pH603, DOI 10.1152/ajpheart.2001.280.2.H603; BRENNER S, 1974, GENETICS, V77, P71; CHAPPELL JB, 1969, CELL RES, P335; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Fiermonte G, 1998, J BIOL CHEM, V273, P24754, DOI 10.1074/jbc.273.38.24754; Genova Maria Luisa, 2003, Ital J Biochem, V52, P58; Hihi AK, 2003, J BIOL CHEM, V278, P41013, DOI 10.1074/jbc.M305034200; Hihi AK, 2002, J BIOL CHEM, V277, P2202, DOI 10.1074/jbc.M109034200; HINKLE PC, 1991, BIOCHEMISTRY-US, V30, P3576, DOI 10.1021/bi00228a031; HOPPEL C, 1979, J BIOL CHEM, V254, P4164; HOPPEL CL, 1987, J CLIN INVEST, V80, P71, DOI 10.1172/JCI113066; Jonassen T, 2003, J BIOL CHEM, V278, P51735, DOI 10.1074/jbc.M308760200; Jonassen T, 2002, J BIOL CHEM, V277, P45020, DOI 10.1074/jbc.M204758200; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Kayser EB, 2001, J BIOL CHEM, V276, P20551, DOI 10.1074/jbc.M011066200; KRAHENBUHL S, 1994, CLIN CHIM ACTA, V230, P177, DOI 10.1016/0009-8981(94)90270-4; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; Lenaz G, 1998, BBA-BIOENERGETICS, V1364, P207, DOI 10.1016/S0005-2728(98)00028-0; LENAZ G, 1968, ARCH BIOCHEM BIOPHYS, V123, P539, DOI 10.1016/0003-9861(68)90175-6; Lenaz G, 2001, FEBS LETT, V509, P151, DOI 10.1016/S0014-5793(01)03172-6; Liu FZ, 1997, BIOCHEMISTRY-US, V36, P255, DOI 10.1021/bi9623800; LIU FZ, 1995, DEV BIOL, V169, P399, DOI 10.1006/dbio.1995.1156; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; Poon WW, 2000, J BACTERIOL, V182, P5139, DOI 10.1128/JB.182.18.5139-5146.2000; Rea S, 2003, DEV CELL, V5, P197, DOI 10.1016/S1534-5807(03)00242-9; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; SNEDECOR GW, 1968, STAT METHODS, P271; Van Voorhies WA, 2002, AGING CELL, V1, P91, DOI 10.1046/j.1474-9728.2002.00022.x; WONG A, 1995, GENETICS, V139, P1247	34	78	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54479	54486		10.1074/jbc.M403066200	http://dx.doi.org/10.1074/jbc.M403066200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15269213	hybrid			2022-12-27	WOS:000225793600071
J	Curran, SP; Leuenberger, D; Leverich, EP; Hwang, DK; Beverly, KN; Koehler, CM				Curran, SP; Leuenberger, D; Leverich, EP; Hwang, DK; Beverly, KN; Koehler, CM			The role of Hot13p and redox chemistry in the mitochondrial TIM22 import pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAFNESS DYSTONIA SYNDROME; ADP ATP CARRIER; PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; INNER MEMBRANE; COMPLEX; TIM10; TRANSLOCATION; INSERTION	The small Tim proteins in the mitochondrial intermembrane space participate in the TIM22 import pathway for assembly of the inner membrane. Assembly of the small TIM complexes requires the conserved "twin CX3C" motif that forms juxtapositional intramolecular disulfide bonds. Here we identify a new intermembrane space protein, Hot13p, as the first component of a pathway that mediates assembly of the small TIM complexes. The small Tim proteins require Hot13p for assembly into a 70-kDa complex in the intermembrane space. Once assembled the small TIM complexes escort hydrophobic inner membrane proteins en route to the TIM22 complex. The mechanism by which the small Tim proteins bind and release substrate is not understood, and we investigated the affect of oxidant/reductant treatment on the TIM22 import pathway. With in organello import studies, oxidizing agents arrest the ADP/ATP carrier (AAC) bound to the Tim9p-Tim10p complex in the intermembrane space; this productive intermediate can be chased into the inner membrane upon subsequent treatment with reductant. Moreover, AAC import is markedly decreased by oxidant treatment in Deltahot13 mitochondria and improved when Hot13p is overexpressed, suggesting Hot13p may function to remodel the small TIM complexes during import. Together these results suggest that the small TIM complexes have a specialized assembly pathway in the intermembrane space and that the local redox state of the TIM complexes may mediate translocation of inner membrane proteins.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Koehler, CM (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.	koehler@chem.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM070415, R01GM061721, F31GM070404] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07185, 1R01GM61721, GM070415, GM070404] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; Allen S, 2003, J BIOL CHEM, V278, P38505, DOI 10.1074/jbc.M306027200; [Anonymous], 1991, Methods Enzymol, V194, P1; Bauer MF, 1999, FEBS LETT, V464, P41, DOI 10.1016/S0014-5793(99)01665-8; Curran SP, 2002, J CELL BIOL, V158, P1017, DOI 10.1083/jcb.200205124; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Davis AJ, 2000, J CELL BIOL, V150, P1271, DOI 10.1083/jcb.150.6.1271; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200; Ghezzi P, 2003, PROTEOMICS, V3, P1145, DOI 10.1002/pmic.200300435; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; Kadokura H, 2001, NAT CELL BIOL, V3, pE247, DOI 10.1038/ncb1101-e247b; Koehler CM, 2004, TRENDS BIOCHEM SCI, V29, P1, DOI 10.1016/j.tibs.2003.11.003; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Koehler CM, 2000, MOL CELL BIOL, V20, P1187, DOI 10.1128/MCB.20.4.1187-1193.2000; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; Kovermann P, 2002, MOL CELL, V9, P363, DOI 10.1016/S1097-2765(02)00446-X; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; Lee JE, 2000, FEBS LETT, V477, P62, DOI 10.1016/S0014-5793(00)01767-1; Leuenberger D, 2003, TRAFFIC, V4, P144, DOI 10.1034/j.1600-0854.2003.00095.x; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lu H, 2004, J BIOL CHEM, V279, P18952, DOI 10.1074/jbc.M313045200; Lu H, 2004, J BIOL CHEM, V279, P18959, DOI 10.1074/jbc.M313046200; Luciano P, 2001, EMBO J, V20, P4099, DOI 10.1093/emboj/20.15.4099; Lutz T, 2003, EMBO J, V22, P4400, DOI 10.1093/emboj/cdg421; Matthews JM, 2002, IUBMB LIFE, V54, P351, DOI 10.1080/15216540216035; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; Murphy MP, 2001, MOL CELL BIOL, V21, P6132, DOI 10.1128/MCB.21.18.6132-6138.2001; Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392; Paschen SA, 2001, IUBMB LIFE, V52, P101, DOI 10.1080/15216540152845894; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477; Rospert S, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P277; Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619; Senkevich TG, 2002, P NATL ACAD SCI USA, V99, P6667, DOI 10.1073/pnas.062163799; SIKORSKI RS, 1989, GENETICS, V122, P19; Vial S, 2002, J BIOL CHEM, V277, P36100, DOI 10.1074/jbc.M202310200; Wheeler GL, 2004, PHYSIOL PLANTARUM, V120, P12, DOI 10.1111/j.0031-9317.2004.0193.x	46	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43744	43751		10.1074/jbc.M404878200	http://dx.doi.org/10.1074/jbc.M404878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15294910	hybrid			2022-12-27	WOS:000224383100049
J	Ducreux, S; Zorzato, F; Muller, C; Sewry, C; Muntoni, F; Quinlivan, R; Restagno, G; Girard, T; Treves, S				Ducreux, S; Zorzato, F; Muller, C; Sewry, C; Muntoni, F; Quinlivan, R; Restagno, G; Girard, T; Treves, S			Effect of ryanodine receptor mutations on interleukin-6 release and intracellular calcium homeostasis in human myotubes from malignant hyperthermia-susceptible individuals and patients affected by central core disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SARCOPLASMIC-RETICULUM; CA2+; CELLS; ACTIVATION; DOMAIN; RODS; LOOP	In this study we report for the first time the functional properties of human myotubes isolated from patients harboring the native RYR1 I4898T and R4893W mutations linked to central core disease. We examined two aspects of myotube physiology, namely excitation-contraction and excitation-secretion coupling. Our results show that upon activation of the ryanodine receptor (RYR), myotubes release interleukin-6 (IL-6); this was dependent on de novo protein synthesis and could be blocked by dantrolene and cyclosporine. Myotubes from the two patients affected by central core disease showed a 4-fold increase in the release of the inflammatory cytokine IL-6, compared with cells derived from control or malignant hyperthermia susceptible individuals. All tested myotubes released calcium from intracellular stores upon stimulation via surface membrane depolarization or direct RYR activation by 4-chloro-m-cresol. The functional impact on calcium release of RYR1 mutations linked to central core disease or malignant hyperthermia is different: human myotubes carrying the malignant hyperthermia-linked RYR1 mutation V2168M had a shift in their sensitivity to the RYR agonist 4-chloro-m-cresol to lower concentrations, whereas human myotubes harboring C-terminal mutations linked to central core disease exhibited reduced [Ca2+](i) increase in response to 4-chloro-m-cresol, caffeine, and KCl. Taken together, these results suggest that abnormal release of calcium via mutated RYR enhances the production of the inflammatory cytokine IL-6, which may in turn affect signaling pathways responsible for the trophic status of muscle fibers.	Kantonsspital, Dept Anaesthesia, CH-4031 Basel, Switzerland; Kantonsspital, Dept Res, CH-4031 Basel, Switzerland; Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, I-44100 Ferrara, Italy; Univ Wurzburg, Biozentrum, Inst Humangenet, D-97074 Wurzburg, Germany; Dubowitz Neuromuscular Ctr, London W12 0NN, England; Robert Jones & Agnes Hunt Orthopaed Hosp NHS Trus, Neuromuscular Ctr, Oswestry SY10 7AG, Shrops, England; Azienda Osped S Anna, Dipartimento Patol Clin, SC Genet Mol, I-10126 Turin, Italy	Kantonsspital Aarau AG (KSA); University of Basel; Kantonsspital Aarau AG (KSA); University of Basel; University of Ferrara; University of Wurzburg; University of London; University College London	Treves, S (corresponding author), Kantonsspital, Dept Anaesthesia, CH-4031 Basel, Switzerland.	susan.treves@unibas.ch	DUCREUX, SYLVIE/D-6257-2013	DUCREUX, SYLVIE/0000-0003-3207-9537; Quinlivan, Rosaline/0000-0002-2306-4782; Treves, Susan/0000-0002-0007-9631				Avila G, 2003, J GEN PHYSIOL, V121, P277, DOI 10.1085/jgp.200308791; Avila G, 2001, P NATL ACAD SCI USA, V98, P4215, DOI 10.1073/pnas.071048198; Balciunaite G, 2002, NAT IMMUNOL, V3, P1102, DOI 10.1038/ni850; Benacquista BL, 2000, BIOPHYS J, V78, P1349, DOI 10.1016/S0006-3495(00)76689-6; Censier K, 1998, J CLIN INVEST, V101, P1233, DOI 10.1172/JCI993; Chen SRW, 2002, BIOPHYS J, V82, P2436, DOI 10.1016/S0006-3495(02)75587-2; Constantin B, 1996, CELL CALCIUM, V19, P365, DOI 10.1016/S0143-4160(96)90109-8; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Denborough M, 1998, LANCET, V352, P1131, DOI 10.1016/S0140-6736(98)03078-5; Du GG, 2002, P NATL ACAD SCI USA, V99, P16725, DOI 10.1073/pnas.012688999; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Fischer-Lougheed J, 2001, J CELL BIOL, V153, P677, DOI 10.1083/jcb.153.4.677; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; Friday BB, 2001, J CELL SCI, V114, P303; GALLANT EM, 1992, AM J PHYSIOL, V262, pC422, DOI 10.1152/ajpcell.1992.262.2.C422; Gao L, 2000, BIOPHYS J, V79, P828, DOI 10.1016/S0006-3495(00)76339-9; Gelfand J.A., 2001, HARRISONS PRINCIPLES, P90; Girard T, 2001, Hum Mutat, V18, P357, DOI 10.1002/humu.1203; Girard T, 2001, J BIOL CHEM, V276, P48077, DOI 10.1074/jbc.M107134200; GONCHAROVA EJ, 1992, DEVELOPMENT, V114, P173; Gonzalez E, 2003, J PHYSIOL-LONDON, V552, P833, DOI 10.1113/jphysiol.2003.048165; GREENFIELD JG, 1958, BRAIN, V81, P461, DOI 10.1093/brain/81.4.461; HAYASHI K, 1989, MUSCLE NERVE, V12, P95, DOI 10.1002/mus.880120203; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HerrmannFrank A, 1996, BIOCHEM PHARMACOL, V52, P149, DOI 10.1016/0006-2952(96)00175-X; Horsley V, 2003, CELL, V113, P483, DOI 10.1016/S0092-8674(03)00319-2; ISAACS H, 1975, J NEUROL NEUROSUR PS, V38, P1177, DOI 10.1136/jnnp.38.12.1177; Jurkat-Rott K, 2000, MUSCLE NERVE, V23, P4, DOI 10.1002/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D; Kamdar SJ, 1997, EXP CELL RES, V232, P439, DOI 10.1006/excr.1997.3551; Kami K, 2000, J HISTOCHEM CYTOCHEM, V48, P1203, DOI 10.1177/002215540004800904; LARACH MG, 1994, ANESTHESIOLOGY, V80, P771, DOI 10.1097/00000542-199404000-00008; Lynch PJ, 1999, P NATL ACAD SCI USA, V96, P4164, DOI 10.1073/pnas.96.7.4164; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; Monnier N, 2000, HUM MOL GENET, V9, P2599, DOI 10.1093/hmg/9.18.2599; Reid MB, 2001, ACTA PHYSIOL SCAND, V171, P225, DOI 10.1046/j.1365-201x.2001.00824.x; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Santana LF, 2002, J PHYSIOL-LONDON, V544, P57, DOI 10.1113/jphysiol.2002.020552; Scacheri PC, 2000, NEUROLOGY, V55, P1689, DOI 10.1212/WNL.55.11.1689; Sewry CA, 2002, NEUROMUSCULAR DISORD, V12, P930, DOI 10.1016/S0960-8966(02)00135-9; SHUAIB A, 1987, MEDICINE, V66, P389, DOI 10.1097/00005792-198709000-00004; SHY GM, 1956, BRAIN, V79, P610, DOI 10.1093/brain/79.4.610; Sugiura T, 2002, INT IMMUNOL, V14, P917, DOI 10.1093/intimm/dxf062; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tilgen N, 2001, HUM MOL GENET, V10, P2879, DOI 10.1093/hmg/10.25.2879; Tong JF, 1999, J BIOL CHEM, V274, P693, DOI 10.1074/jbc.274.2.693; Treves S, 2002, CELL CALCIUM, V31, P1, DOI 10.1054/ceca.2001.0252; Wehner M, 2003, CELL CALCIUM, V34, P163, DOI 10.1016/S0143-4160(03)00072-1; WIETZERBIN J, 1989, ANN NY ACAD SCI, V557, P162; Yang TZ, 2003, J BIOL CHEM, V278, P25722, DOI 10.1074/jbc.M302165200; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200; Zorzato F, 2003, HUM MOL GENET, V12, P379, DOI 10.1093/hmg/ddg032; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; Zumwalt JW, 1999, ENDOCRINOLOGY, V140, P888, DOI 10.1210/en.140.2.888	55	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43838	43846		10.1074/jbc.M403612200	http://dx.doi.org/10.1074/jbc.M403612200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15299003	Green Accepted, hybrid			2022-12-27	WOS:000224383100060
J	Errico, M; Riccioni, T; Iyer, S; Pisano, C; Acharya, KR; Persico, MG; De Falco, S				Errico, M; Riccioni, T; Iyer, S; Pisano, C; Acharya, KR; Persico, MG; De Falco, S			Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; CRYSTAL-STRUCTURE; FACTOR-I; PATHOLOGICAL CONDITIONS; VASCULAR-PERMEABILITY; ANGSTROM RESOLUTION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; HUMAN TROPHOBLAST; VEGF RECEPTORS	Placenta growth factor (PlGF) belongs to the vascular endothelial growth factor (VEGF) family and represents a key regulator of angiogenic events in pathological conditions. PlGF exerts its biological function through the binding and activation of the seven immunoglobulin-like domain receptor Flt-1, also known as VEGFR-1. Here, we report the first detailed mutagenesis studies that provide a basis for understanding molecular recognition between PlGF-1 and Flt-1, highlighting some of the residues that are critical for receptor recognition. Mutagenesis analysis, performed on the basis of a structural model of interaction between PlGF and the minimal binding domain of Flt-1, has led to the identification of several PlGF-1 residues involved in Flt-1 recognition. The two negatively charged residues, Asp-72 and Glu-73, located in the beta3-beta4 loop, are critical for Flt-1 binding. Other mutations, which bring about a significant decrease in PlGF binding activity, are Gln-27, located in the N-terminal alpha-helix, and Pro-98 and Tyr-100 on the beta6 strand. The mutation of one of the two glycosylated residues of PlGF, Asn-84, generates a PlGF variant with reduced binding activity. This indicates that, unlike in VEGF, glycosylation plays an important role in Flt-1 binding. The double mutation of residues Asp-72 and Glu-73 generates a PlGF variant unable to bind and activate the receptor molecules on the cell surface. This variant failed to induce in vitro capillary-like tube formation of primary endothelial cells or neo-angiogenesis in an in vivo chorioallantoic membrane assay.	CNR, Inst Genet & Biophys Adriano Buzzati Traverso, I-80131 Naples, Italy; Sigma Tau Pharmaceut Co, Ind Farmaceut Riunite, Res & Dev, I-00040 Pomezia, Rome, Italy; Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Leadiant Biosciences; University of Bath	De Falco, S (corresponding author), CNR, Inst Genet & Biophys Adriano Buzzati Traverso, Via P Castellino 111, I-80131 Naples, Italy.	defalco@igb.cnr.it	De Falco, Sandro/P-6724-2015	pisano, claudio/0000-0001-8624-2980; Acharya, K. Ravi/0000-0002-3009-4058; De Falco, Sandro/0000-0002-6501-1697				Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069; Cao YH, 1997, BIOCHEM BIOPH RES CO, V235, P493, DOI 10.1006/bbrc.1997.6813; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Christinger HW, 2004, J BIOL CHEM, V279, P10382, DOI 10.1074/jbc.M313237200; Davis-Smyth T, 1998, J BIOL CHEM, V273, P3216, DOI 10.1074/jbc.273.6.3216; De Falco S, 2002, TRENDS CARDIOVAS MED, V12, P241, DOI 10.1016/S1050-1738(02)00168-8; Desai J, 1999, BIOL REPROD, V60, P887, DOI 10.1095/biolreprod60.4.887; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; Epstein SE, 2001, CIRCULATION, V104, P115, DOI 10.1161/01.CIR.104.1.115; Eriksson A, 2002, CANCER CELL, V1, P99, DOI 10.1016/S1535-6108(02)00028-4; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; Isner JM, 2001, CIRC RES, V89, P389, DOI 10.1161/hh1701.096259; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Luttun A, 2002, ANN NY ACAD SCI, V979, P80, DOI 10.1111/j.1749-6632.2002.tb04870.x; Luttun A, 2002, BIOCHEM BIOPH RES CO, V295, P428, DOI 10.1016/S0006-291X(02)00677-0; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MAGLIONE D, 1993, GROWTH FACTORS, V8, P141, DOI 10.3109/08977199309046934; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; PARK JE, 1994, J BIOL CHEM, V269, P25646; Pipp F, 2003, CIRC RES, V92, P378, DOI 10.1161/01.RES.0000057997.77714.72; Ribatti D, 2001, J VASC RES, V38, P389, DOI 10.1159/000051070; Sato Y, 2000, ANN NY ACAD SCI, V902, P201; Selvaraj SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood-2002-11-3423; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang W, 2003, J REPROD IMMUNOL, V60, P53, DOI 10.1016/S0165-0378(03)00082-2; Ziche M, 1997, LAB INVEST, V76, P517	36	42	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43929	43939		10.1074/jbc.M401418200	http://dx.doi.org/10.1074/jbc.M401418200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15272021	hybrid			2022-12-27	WOS:000224383100071
J	Giovedi, S; Darchen, F; Valtorta, F; Greengard, P; Benfenati, F				Giovedi, S; Darchen, F; Valtorta, F; Greengard, P; Benfenati, F			Synapsin is a novel Rab3 effector protein on small synaptic vesicles - II. Functional effects of the Rab3A-synapsin I interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ACTIVE ZONE; SMG P25A; F-ACTIN; RABPHILIN-3A; PHOSPHORYLATION; IDENTIFICATION; RECRUITMENT; DISSOCIATION; TRANSPORT	Synapsins, a family of neuron-specific phosphoproteins that play an important role in the regulation of synaptic vesicle trafficking and neurotransmitter release, were recently demonstrated to interact with the synaptic vesicle-associated small G protein Rab3A within nerve terminals (Giovedi`, S., Vaccaro, P., Valtorta, F., Darchen, F., Greengard, P., Cesareni, G., and Benfenati, F. (2004) J. Biol. Chem. 279, 43760 - 43768). We have analyzed the functional consequences of this interaction on the biological activities of both proteins and on their subcellular distribution within nerve terminals. The presence of synapsin I stimulated GTP binding and GTPase activity of both purified and endogenous synaptic vesicle-associated Rab3A. Conversely, Rab3A inhibited synapsin I binding to F-actin, as well as synapsin-induced actin bundling and vesicle clustering. Moreover, the amount of Rab3A associated with synaptic vesicles was decreased in synapsin knockout mice, and the presence of synapsin I prevented RabGDI-induced Rab3A dissociation from synaptic vesicles. The results indicate that an interaction between synapsin I and Rab3A exists on synaptic vesicles that modulates the functional properties of both proteins. Given the well recognized importance of both synapsins and Rab3A in synaptic vesicles exocytosis, this interaction is likely to play a major role in the modulation of neurotransmitter release.	Univ Genoa, Dept Expt Med, Sect Human Physiol, I-16132 Genoa, Italy; Inst Biol Physicochim, CNRS, UPR 1929, F-75005 Paris, France; S Raffaele Vita Salute Univ, Dept Neurosci, I-20132 Milan, Italy; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	University of Genoa; Centre National de la Recherche Scientifique (CNRS); Vita-Salute San Raffaele University; Rockefeller University	Benfenati, F (corresponding author), Univ Genoa, Dept Expt Med, Sect Human Physiol, Via Benedetto XV 3, I-16132 Genoa, Italy.	benfenat@unige.it	Giovedì, Silvia/AAB-7614-2019; Flavia, Valtorta/F-3450-2012	Flavia, Valtorta/0000-0001-9556-4746; GIOVEDI', SILVIA/0000-0001-7949-4274	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039327, R01MH039327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015072] Funding Source: NIH RePORTER; NIA NIH HHS [AG15072] Funding Source: Medline; NIMH NIH HHS [MH39327] Funding Source: Medline; Telethon [1131] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Telethon(Fondazione Telethon)		ARAKI S, 1990, J BIOL CHEM, V265, P13007; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BENFENATI F, 1993, J CELL BIOL, V123, P1845, DOI 10.1083/jcb.123.6.1845; BENFENATI F, 1992, NEURON, V8, P377, DOI 10.1016/0896-6273(92)90303-U; Bloom O, 2003, J CELL BIOL, V161, P737, DOI 10.1083/jcb.200212140; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; CECCALDI PE, 1995, J CELL BIOL, V128, P905, DOI 10.1083/jcb.128.5.905; Cheetham JJ, 2001, BIOCHEM J, V354, P57, DOI 10.1042/0264-6021:3540057; Chi P, 2003, NEURON, V38, P69, DOI 10.1016/S0896-6273(03)00151-X; Chi P, 2001, NAT NEUROSCI, V4, P1187, DOI 10.1038/nn756; Chou JH, 2000, J BIOL CHEM, V275, P9433, DOI 10.1074/jbc.275.13.9433; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; Clabecq A, 2000, J BIOL CHEM, V275, P31786, DOI 10.1074/jbc.M003705200; Darchen F, 2000, BIOCHIMIE, V82, P375, DOI 10.1016/S0300-9084(00)00219-4; Desnos C, 2003, J CELL BIOL, V163, P559, DOI 10.1083/jcb.200302157; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; Doussau F, 1998, J NEUROSCI, V18, P3147; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; FISCHER V, 1991, NATURE, V349, P79; Foletti DL, 2001, J NEUROSCI, V21, P5473, DOI 10.1523/JNEUROSCI.21-15-05473.2001; FYKSE EM, 1995, J NEUROSCI, V15, P2385, DOI 10.1523/JNEUROSCI.15-03-02385.1995; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Giovedi S, 2004, J BIOL CHEM, V279, P43760, DOI 10.1074/jbc.M403293200; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hales CM, 2002, J BIOL CHEM, V277, P50415, DOI 10.1074/jbc.M209270200; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; Hilfiker S, 1998, NAT NEUROSCI, V1, P29, DOI 10.1038/229; Hosaka M, 1999, J BIOL CHEM, V274, P16747, DOI 10.1074/jbc.274.24.16747; Humeau Y, 2001, J NEUROSCI, V21, P4195, DOI 10.1523/JNEUROSCI.21-12-04195.2001; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Johannes L, 1996, J CELL SCI, V109, P2875; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; Jordens I, 2001, CURR BIOL, V11, P1680, DOI 10.1016/S0960-9822(01)00531-0; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; KIKUCHI A, 1995, METHOD ENZYMOL, V257, P57; KISHIDA S, 1993, J BIOL CHEM, V268, P22259; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leenders AGM, 2001, MOL BIOL CELL, V12, P3095, DOI 10.1091/mbc.12.10.3095; LI L, 1995, P NATL ACAD SCI USA, V92, P9235, DOI 10.1073/pnas.92.20.9235; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; Schluter OM, 2002, J BIOL CHEM, V277, P40919, DOI 10.1074/jbc.M203704200; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; Senbonmatsu T, 1996, BIOCHEM BIOPH RES CO, V228, P567, DOI 10.1006/bbrc.1996.1699; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; Sivars U, 2003, NATURE, V425, P856, DOI 10.1038/nature02057; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; Wang XL, 2001, J BIOL CHEM, V276, P32480, DOI 10.1074/jbc.M103337200; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	62	51	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43769	43779		10.1074/jbc.M404168200	http://dx.doi.org/10.1074/jbc.M404168200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15265868	hybrid			2022-12-27	WOS:000224383100052
J	Ingham, KC; Brew, S; Vaz, D; Sauder, DN; McGavin, MJ				Ingham, KC; Brew, S; Vaz, D; Sauder, DN; McGavin, MJ			Interaction of Staphylococcus aureus fibronectin-binding protein with fibronectin - Affinity, stoichiometry, and modular requirements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; STREPTOCOCCUS-DYSGALACTIAE; NUCLEOTIDE-SEQUENCE; EPITHELIAL-CELLS; SURFACE PROTEIN; PHAGE DISPLAY; D MOTIFS; DOMAINS; GENE; RECEPTORS	The repetitive D1, D2, and D3 elements of Staphylococcus aureus fibronectin-binding protein FnBPA each bind the N-terminal 29-kDa fragment (N29) of fibronectin with low micromolar dissociation constants (K-d), but in tandem they compose a high affinity domain, D1 - 3. An additional seven Fn-binding segments have been predicted in FnBPA in a region N-terminal of the D-repeats (Schwarz-Linek, U., Werner, J. M., Pickford, A. R., Gurusiddappa, S., Kim, J. H., Pilka, E. S., Briggs, J. A., Gough, T. S., Hook, M., Campbell, I. D., and Potts, J. R. ( 2003) Nature 423, 177 - 181). We have evaluated the requirements for high affinity binding of N29 to the D-repeat domain and determined the affinity and stoichiometry of N29 binding to segments that are N-terminal of the D-repeats in the related FnBPB adhesin. We confirmed that D1 - 3 has two equivalent high affinity sites (K-d, similar to 1 nM) and provided evidence for one or more lower affinity sites (K-d, similar to 0.5 muM). Bimodular D1 - 2 and D2 - 3 exhibit intermediate affinity sites with respective Kd values of 0.25 and 0.044 muM, as well as a low affinity site with a K-d value of 2.2 - 2.5 muM. We also identified two binding domains that are N-terminal of the D-repeats, designated DuB and DuA. Segments internal to these domains individually bound N29 with similar Kd values of similar to2 muM, whereas the DuBA polypeptide possessing both segments and other intervening sites bound four molecules of N29 with much higher affinity (K-d, similar to 10 nM). DuBAD, a larger polypeptide harboring all of the known or predicted binding motifs in FnBPB, bound seven to eight molecules of N29, with a K-d of similar to 7 nM. Because most of the isolated binding segments display low affinity for N29 and lack motifs for binding of one or both of the (1)F1 and (5)F1 modules in the N-terminal domain of Fn, we propose that high affinity is achieved in part as a consequence of self-interaction between bound molecules of N29.	Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Microbiol, Toronto, ON M4N 3M5, Canada; Amer Red Cross, Holland Lab, Dept Biochem, Rockville, MD 20855 USA; Johns Hopkins Univ, Dept Dermatol, Baltimore, MD 21287 USA; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; American Red Cross; Johns Hopkins University; University of Toronto	McGavin, MJ (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Microbiol S112, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	martin.mcgavin@sw.ca		McGavin, Martin/0000-0001-5955-0689				BORSI L, 1986, ANAL BIOCHEM, V155, P335, DOI 10.1016/0003-2697(86)90443-4; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; HousePompeo K, 1996, J BIOL CHEM, V271, P1379, DOI 10.1074/jbc.271.3.1379; Huesca M, 2000, INFECT IMMUN, V68, P1156, DOI 10.1128/IAI.68.3.1156-1163.2000; Huesca M, 2002, J INFECT DIS, V185, P1285, DOI 10.1086/340123; HUFF S, 1994, J BIOL CHEM, V269, P15563; INGHAM KC, 1981, BIOCHIM BIOPHYS ACTA, V670, P181, DOI 10.1016/0005-2795(81)90007-6; JACOBSSON K, 1995, BIOTECHNIQUES, V18, P878; Jacobsson K, 1996, BIOTECHNIQUES, V20, P1070; Joh D, 1998, EUR J BIOCHEM, V258, P897, DOI 10.1046/j.1432-1327.1998.2580897.x; JONSSON K, 1991, EUR J BIOCHEM, V202, P1041, DOI 10.1111/j.1432-1033.1991.tb16468.x; KONDO S, 1993, J INVEST DERMATOL, V101, P690, DOI 10.1111/1523-1747.ep12371677; LINDGREN PE, 1993, EUR J BIOCHEM, V214, P819, DOI 10.1111/j.1432-1033.1993.tb17985.x; Lindmark H, 1996, INFECT IMMUN, V64, P3993, DOI 10.1128/IAI.64.10.3993-3999.1996; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; MCGAVIN MJ, 1993, J BIOL CHEM, V268, P23946; McGavin MJ, 1997, INFECT IMMUN, V65, P2621, DOI 10.1128/IAI.65.7.2621-2628.1997; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; Molinari G, 1999, J INFECT DIS, V179, P1049, DOI 10.1086/314681; Papakyriacou H, 2000, J INFECT DIS, V181, P990, DOI 10.1086/315342; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; Penkett CJ, 2000, BIOCHEMISTRY-US, V39, P2887, DOI 10.1021/bi992267k; Potts JR, 1999, BIOCHEMISTRY-US, V38, P8304, DOI 10.1021/bi990202b; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; SHEAGREN JN, 1984, NEW ENGL J MED, V310, P1368, DOI 10.1056/NEJM198405243102107; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; TALAY SR, 1992, INFECT IMMUN, V60, P3837, DOI 10.1128/IAI.60.9.3837-3844.1992; Weigel LM, 2003, SCIENCE, V302, P1569, DOI 10.1126/science.1090956; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; Zhang LH, 1998, MICROBIOL-UK, V144, P985, DOI 10.1099/00221287-144-4-985	31	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42945	42953		10.1074/jbc.M406984200	http://dx.doi.org/10.1074/jbc.M406984200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15294899	hybrid			2022-12-27	WOS:000224226400074
J	Zheng, G; Yang, YC				Zheng, G; Yang, YC			ZNF76, a novel transcriptional repressor targeting TATA-binding protein, is modulated by sumoylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUMO E3 LIGASE; GENE-EXPRESSION; POLYMERASE-III; DNA-BINDING; IN-VIVO; P53; TBP; ACTIVATION; PIAS1; COMPLEX	Direct interaction of positive and negative regulators with the general transcription machinery modulates transcription. The TATA-binding protein (TBP) is one target for transcriptional regulators. In this study, we identified ZNF76 as a novel transcriptional repressor that targets TBP. ZNF76 interacts with TBP through both its N and C termini, and both regions are required for ZNF76 to exert its inhibitory function on p53-mediated transactivation. The inhibitory effect of ZNF76 on p53 activity was demonstrated by reporter assays and endogenous target gene expression. We mapped the TBP-interacting region in the C terminus of ZNF76 to a glutamic acid-rich domain, which acts in a dominant negative manner to enhance p53-mediated transactivation in reporter assays. Mutagenesis study for ZNF76 suggests a correlation between interaction with TBP and effect on p53-mediated transactivation, supporting the conclusion that ZNF76 targets TBP for transcriptional repression. Chromatin immunoprecipitation experiments suggest that ZNF76 prevents TBP from occupying the endogenous p21 promoter. ZNF76 is sumoylated by PIAS1 at lysine 411, which is in the minimal TBP-interacting region. Overexpression of PIAS1 and SUMO-1 abolishes the interaction between ZNF76 and TBP and partially relieves the repressive effect of ZNF76. These results suggest that ZNF76 functions as a transcriptional repressor through its interaction with TBP and that sumoylation modulates its transcriptional repression activity.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Canc, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Yang, YC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 2109 Adelbert Rd,W353, Cleveland, OH 44106 USA.	yxy36@cwru.edu		Zheng, Gang/0000-0003-0276-9430	NCI NIH HHS [CA78433] Funding Source: Medline; NHLBI NIH HHS [HL48819] Funding Source: Medline; NIDDK NIH HHS [DK50570] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078433] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050570] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; Comerford KM, 2003, P NATL ACAD SCI USA, V100, P986, DOI 10.1073/pnas.0337412100; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; Darst RP, 2003, J BIOL CHEM, V278, P13216, DOI 10.1074/jbc.M211445200; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Jackson-Fisher AJ, 1999, MOL CELL, V3, P717, DOI 10.1016/S1097-2765(01)80004-6; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; Kim S, 1997, P NATL ACAD SCI USA, V94, P820, DOI 10.1073/pnas.94.3.820; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kubota H, 2000, J BIOL CHEM, V275, P28641, DOI 10.1074/jbc.M005009200; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Massimi P, 1997, VIROLOGY, V227, P255, DOI 10.1006/viro.1996.8315; Mauser A, 2002, J VIROL, V76, P12503, DOI 10.1128/JVI.76.24.12503-12512.2002; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; NILBERT M, 1990, HUM GENET, V85, P605; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Qadri I, 2002, BBA-MOL CELL RES, V1592, P193, DOI 10.1016/S0167-4889(02)00315-4; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Song CZ, 1997, MOL CELL BIOL, V17, P2186, DOI 10.1128/MCB.17.4.2186; Tripodis N, 1998, GENOME RES, V8, P631, DOI 10.1101/gr.8.6.631; UM M, 1995, MOL CELL BIOL, V15, P5007; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764	42	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42410	42421		10.1074/jbc.M407287200	http://dx.doi.org/10.1074/jbc.M407287200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15280358	hybrid			2022-12-27	WOS:000224226400011
J	Majumdar, S; Ramachandran, S; Cerione, RA				Majumdar, S; Ramachandran, S; Cerione, RA			Perturbing the linker regions of the alpha-subunit of transducin - A new class of constitutively active GTP-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; CRYSTAL-STRUCTURE; BETA-GAMMA; STRUCTURAL DETERMINANTS; ADENYLATE-CYCLASE; EFFECTOR-BINDING; 2.0 ANGSTROM; ACTIVATION; PHOSPHODIESTERASE; EXCHANGE	The GDP-GTP exchange activity of the retinal G protein, transducin, is markedly accelerated by the photoreceptor rhodopsin in the first step of visual transduction. The x-ray structures for the alpha subunits of transducin (alpha(T)) and other G proteins suggest that the nucleotide-binding (Ras-like) domain and a large helical domain form a "clam shell" that buries the GDP molecule. Thus, receptor-promoted G protein activation may involve "opening the clam shell" to facilitate GDP dissociation. In this study, we have examined whether perturbing the linker regions connecting the Ras-like and helical domains of Galpha subunits gives rise to a more readily exchangeable state. The sole glycine residues in linkers 1 and 2 were individually changed to proline residues within an alpha(T)/alpha(i1) chimera (designated alpha(T)*). Both alpha(T)* linker mutants showed significant increases in their basal rates of GDP-GTP exchange when compared either to retinal alpha(T) or recombinant alpha(T)(*). The alpha(T)(*) linker mutants were responsive to aluminum fluoride, which binds to alpha-GDP complexes and induces changes in Switch 2. Although both linker mutants were further activated by light-activated rhodopsin together with the betagamma complex, their activation was not influenced by betagamma alone, arguing against the idea that the betagamma complex helps to pry apart the helical and Ras-like domains of Galpha subunits. Once activated, the alpha(T)* linker mutants were able to stimulate the cyclic GMP phosphodiesterase. Overall, these findings highlight a new class of activated Galpha mutants that constitutively exchange GDP for GTP and should prove valuable in studying different G protein-signaling systems.	Cornell Univ, Dept Mol Med, Ctr Vet Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem & Chem Biol, Baker Lab, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Dept Mol Med, Ctr Vet Med, Ithaca, NY 14853 USA.	rac1@cornell.edu	Ramachandran, Sekar/AAP-2287-2020	Ramachandran, Sekar/0000-0002-2243-1368	NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER; NEI NIH HHS [EY06429] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BRANDT DR, 1985, J BIOL CHEM, V260, P266; Cherfils J, 2003, TRENDS BIOCHEM SCI, V28, P13, DOI 10.1016/S0968-0004(02)00006-3; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GIERSCHIK P, 1984, FEBS LETT, V172, P321, DOI 10.1016/0014-5793(84)81149-7; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Li QB, 1997, J BIOL CHEM, V272, P21673, DOI 10.1074/jbc.272.35.21673; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Liu W, 1998, P NATL ACAD SCI USA, V95, P12878, DOI 10.1073/pnas.95.22.12878; Marin EP, 2001, J BIOL CHEM, V276, P23873, DOI 10.1074/jbc.M101197200; Mello LV, 1998, BIOCHEMISTRY-US, V37, P3137, DOI 10.1021/bi971402v; Mello LV, 2002, J PROTEIN CHEM, V21, P29, DOI 10.1023/A:1014127015042; Min KC, 2000, PROTEIN EXPRES PURIF, V20, P514, DOI 10.1006/prep.2000.1326; Muradov KG, 2000, BIOCHEMISTRY-US, V39, P3937, DOI 10.1021/bi992156l; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PINES M, 1985, P NATL ACAD SCI USA, V82, P4095, DOI 10.1073/pnas.82.12.4095; Rondard P, 2001, P NATL ACAD SCI USA, V98, P6150, DOI 10.1073/pnas.101136198; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WITTINGHOFER A, 1994, CELL, V76, P201, DOI 10.1016/0092-8674(94)90327-1	36	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40137	40145		10.1074/jbc.M405420200	http://dx.doi.org/10.1074/jbc.M405420200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15271992	hybrid			2022-12-27	WOS:000223791500112
J	Ferrer-Orta, C; Arias, A; Perez-Luque, R; Escarmis, C; Domingo, E; Verdaguer, N				Ferrer-Orta, C; Arias, A; Perez-Luque, R; Escarmis, C; Domingo, E; Verdaguer, N			Structure of foot-and-mouth disease virus RNA-dependent RNA polymerase and its complex with a template-primer RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DNA-POLYMERASES; MUTAGENESIS; EXTINCTION; RIBAVIRIN; 3D(POL); REVEALS; CELLS	Genome replication in picornaviruses is catalyzed by a virally encoded RNA-dependent RNA polymerase, termed 3D. The enzyme performs this operation, together with other viral and probably host proteins, in the cytoplasm of their host cells. The crystal structure of the 3D polymerase of foot-and-mouth disease virus, one of the most important animal pathogens, has been determined unliganded and bound to a template-primer RNA decanucleotide. The enzyme folds in the characteristic fingers, palm and thumb subdomains, with the presence of an NH2-terminal segment that encircles the active site. In the complex, several conserved amino acid side chains bind to the template-primer, likely mediating the initiation of RNA synthesis. The structure provides essential information for studies on RNA replication and the design of antiviral compounds.	CSIC, Inst Biol Mol Barcelona, E-08028 Barcelona, Spain; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Verdaguer, N (corresponding author), CSIC, Inst Biol Mol Barcelona, Parc Cient Barcelona,Josep Samitier 1-5, E-08028 Barcelona, Spain.	nvmcri@ibmb.csic.es	Arias, Armando/E-1393-2016; Domingo, Esteban/K-3937-2014	Arias, Armando/0000-0002-4138-4608; Verdaguer, Nuria/0000-0001-8826-7129; Ferrer Orta, Cristina/0000-0002-1072-8463; Domingo, Esteban/0000-0002-0573-1676; Perez Luque, Rosa/0000-0003-0759-0608				Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Airaksinen A, 2003, VIROLOGY, V311, P339, DOI 10.1016/S0042-6822(03)00144-2; Arnold JJ, 2000, J BIOL CHEM, V275, P5329, DOI 10.1074/jbc.275.8.5329; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bruenn JA, 2003, NUCLEIC ACIDS RES, V31, P1821, DOI 10.1093/nar/gkg277; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Cameron Craig E., 2002, P255; Choi KH, 2004, P NATL ACAD SCI USA, V101, P4425, DOI 10.1073/pnas.0400660101; DELATORRE JC, 1987, J VIROL, V61, P233, DOI 10.1128/JVI.61.1.233-235.1987; Domingo Esteban, 2002, P285; Escarmis C, 1996, J MOL BIOL, V264, P255, DOI 10.1006/jmbi.1996.0639; Gohara DW, 2000, J BIOL CHEM, V275, P25523, DOI 10.1074/jbc.M002671200; Graci JD, 2002, VIROLOGY, V298, P175, DOI 10.1006/viro.2002.1487; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Hobson SD, 2001, EMBO J, V20, P1153, DOI 10.1093/emboj/20.5.1153; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Knowles NJ, 2003, VIRUS RES, V91, P65, DOI 10.1016/S0168-1702(02)00260-5; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Leveque VJP, 2003, J VIROL, V77, P9020, DOI 10.1128/JVI.77.16.9020-9028.2003; Lyle JM, 2002, SCIENCE, V296, P2218, DOI 10.1126/science.1070585; Menendez-Arias L, 2002, PROG NUCLEIC ACID RE, V71, P91, DOI 10.1016/S0079-6603(02)71042-8; Murray KE, 2003, J VIROL, V77, P4739, DOI 10.1128/JVI.77.8.4739-4750.2003; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Ng KKS, 2004, J BIOL CHEM, V279, P16638, DOI 10.1074/jbc.M400584200; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; O'Farrell D, 2003, J MOL BIOL, V326, P1025, DOI 10.1016/S0022-2836(02)01439-0; O'Reilly EK, 1998, VIROLOGY, V252, P287, DOI 10.1006/viro.1998.9463; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pariente N, 2003, J VIROL, V77, P7131, DOI 10.1128/JVI.77.12.7131-7138.2003; Pariente N, 2001, J VIROL, V75, P9723, DOI 10.1128/JVI.75.20.9723-9730.2001; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Ranjith-Kumar CT, 2003, J MOL BIOL, V330, P675, DOI 10.1016/S0022-2836(03)00613-2; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Rowlands DJ, 2003, VIRUS RES, V91, P1, DOI 10.1016/S0168-1702(02)00264-2; Salt J, 2004, FOOT AND MOUTH DISEASE: CURRENT PERSPECTIVES, P103; Sierra S, 2000, J VIROL, V74, P8316, DOI 10.1128/JVI.74.18.8316-8323.2000; Snell N J, 2001, Expert Opin Pharmacother, V2, P1317, DOI 10.1517/14656566.2.8.1317; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Sobrino F., 2004, FOOT MOUTH DIS; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Sutmoller P, 2003, VIRUS RES, V91, P101, DOI 10.1016/S0168-1702(02)00262-9; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P45, DOI 10.1107/S0907444902018048; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Thompson D, 2002, REV SCI TECH OIE, V21, P675, DOI 10.20506/rst.21.3.1353; van Dijk AA, 2004, J GEN VIROL, V85, P1077, DOI 10.1099/vir.0.19731-0; WECKBECKER G, 1991, PHARMACOL THERAPEUT, V50, P367, DOI 10.1016/0163-7258(91)90051-M; Wilke H, 2000, MED KLIN, V95, P3; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	53	183	190	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47212	47221		10.1074/jbc.M405465200	http://dx.doi.org/10.1074/jbc.M405465200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15294895	hybrid			2022-12-27	WOS:000224832400109
J	Qiao, FY; Mi, J; Wilson, JB; Zhi, G; Bucheimer, NR; Jones, NJ; Kupfer, GM				Qiao, FY; Mi, J; Wilson, JB; Zhi, G; Bucheimer, NR; Jones, NJ; Kupfer, GM			Phosphorylation of Fanconi anemia (FA) complementation group G protein, FANCG, at serine 7 is important for function of the FA pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-D GENE; NUCLEAR ACCUMULATION; HEMATOPOIETIC-CELLS; GAMMA-INTERFERON; COMPLEX; APOPTOSIS; FANCG/XRCC9; EXPRESSION; BINDS; POLYPEPTIDE	Fanconi anemia ( FA) is an autosomal recessive disease of cancer susceptibility. FA cells exhibit a characteristic hypersensitivity to DNA cross-linking agents. The molecular mechanism for the disease is unknown as few of the FA proteins have functional motifs. Several post-translational modifications of the proteins have been described. We and others (Qiao, F., Moss, A., and Kupfer, G. M. (2001) J. Biol. Chem. 276, 23391-23396 and Futaki, M., Watanabe, S., Kajigaya, S., and Liu, J. M. (2001) Biochem. Biophys. Res. Commun. 281, 347-351) have reported that the FANCG protein ( Fanconi complementation group G) is phosphorylated. We show that in an in vitro kinase reaction FANCG is radioactively labeled. Mass spectrometry analysis detected a peptide containing phosphorylation of serine 7. Using PCR-mediated site-directed mutagenesis we mutated serine 7 to alanine. Only wild-type FANCG cDNA fully corrected FA-G mutant cells. We also tested the effect of human wild-type FANCG in Chinese hamster ovary cells in which the FANCG homologue is mutant. Human FANCG complemented these cells, whereas human FANCG(S7A) did not. Unexpectedly, FANCG( S7A) bound to and stabilized the endogenous forms of the FANCA and FANCC proteins in the FA-G cells. FANCG(S7A) aberrantly localized to globules in chromatin and did not abrogate the internuclear bridges seen in the FA-G mutant cells. Phosphorylation of serine 7 in FANCG is functionally important in the FA pathway.	Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Pediat, Charlottesville, VA 22908 USA; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	University of Virginia; University of Virginia; University of Liverpool	Kupfer, GM (corresponding author), Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA.	gk9@virginia.edu	Jones, Nigel J/D-1997-2010		NHLBI NIH HHS [HL-063776] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063776] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi D, 2002, HUM MOL GENET, V11, P3125, DOI 10.1093/hmg/11.25.3125; Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; ALTER BP, 1993, HEMATOLOGY INFANCY C, V1, P216; Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; AUERBACH AD, 1997, GENETIC BASIS HUMAN, P317; Blom E, 2004, DNA REPAIR, V3, P77, DOI 10.1016/j.dnarep.2003.09.007; Blower MD, 2002, DEV CELL, V2, P319, DOI 10.1016/S1534-5807(02)00135-1; Christianson TA, 2000, BLOOD, V95, P725, DOI 10.1182/blood.V95.2.725; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; Cumming RC, 1996, BLOOD, V88, P4558, DOI 10.1182/blood.V88.12.4558.bloodjournal88124558; Cutts SM, 1999, HUM MOL GENET, V8, P1145, DOI 10.1093/hmg/8.7.1145; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; DUTRILLAUX B, 1982, HUM GENET, V62, P327, DOI 10.1007/BF00304549; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FANCONI G., 1967, SEMINARS HAMATOL, V4, P233; Fanconi G., 1927, JAHRB KINDERHEILK, V117, P257; Futaki M, 2001, BIOCHEM BIOPH RES CO, V281, P347, DOI 10.1006/bbrc.2001.4359; Garcia-Higuera I, 2000, BLOOD, V96, P3224, DOI 10.1182/blood.V96.9.3224.h8003224_3224_3230; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Haneline LS, 1998, BLOOD, V91, P4092; HEAD DR, 1989, CANCER-AM CANCER SOC, V64, P2199, DOI 10.1002/1097-0142(19891201)64:11<2199::AID-CNCR2820641102>3.0.CO;2-3; Hejna JA, 2000, AM J HUM GENET, V66, P1540, DOI 10.1086/302896; Joenje H, 2000, AM J HUM GENET, V67, P759, DOI 10.1086/303067; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; KAISER TN, 1982, CYTOMETRY, V2, P291; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; Kupfer GM, 1996, BLOOD, V88, P1019; Lamerdin JE, 2004, MUTAGENESIS, V19, P237, DOI 10.1093/mutage/geh019; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; Liu N, 1997, P NATL ACAD SCI USA, V94, P9232, DOI 10.1073/pnas.94.17.9232; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; Marathi UK, 1996, BLOOD, V88, P2298, DOI 10.1182/blood.V88.6.2298.bloodjournal8862298; McCleland ML, 2003, GENE DEV, V17, P101, DOI 10.1101/gad.1040903; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; MI J, 2004, IN PRESS BLOOD; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Naf D, 1998, MOL CELL BIOL, V18, P5952; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Pang QS, 2000, MOL CELL BIOL, V20, P4724, DOI 10.1128/MCB.20.13.4724-4735.2000; Qiao FY, 2001, J BIOL CHEM, V276, P23391, DOI 10.1074/jbc.M101855200; Rathbun RK, 1997, BLOOD, V90, P974, DOI 10.1182/blood.V90.3.974.974_974_985; Ridet A, 1997, CANCER RES, V57, P1722; Schroeder MJ, 2004, ANAL CHEM, V76, P3590, DOI 10.1021/ac0497104; Shevchenko A, 2001, ANAL BIOCHEM, V296, P279, DOI 10.1006/abio.2001.5321; STONESIFER KJ, 1987, ACTA CYTOL, V31, P125; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Taniguchi T, 2002, BLOOD, V100, P2457, DOI 10.1182/blood-2002-03-0860; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Thomashevski A, 2004, J BIOL CHEM, V279, P26201, DOI 10.1074/jbc.M400091200; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; van de Vrugt HJ, 2002, GENES CELLS, V7, P333, DOI 10.1046/j.1365-2443.2002.00518.x; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; WHITNEY M, 1995, NAT GENET, V11, P341, DOI 10.1038/ng1195-341; Whitney MA, 1996, BLOOD, V88, P49; Wilson JB, 2001, CARCINOGENESIS, V22, P1939, DOI 10.1093/carcin/22.12.1939; Yagasaki H, 2001, BLOOD, V98, P3650, DOI 10.1182/blood.V98.13.3650; Yamashita T, 1998, P NATL ACAD SCI USA, V95, P13085, DOI 10.1073/pnas.95.22.13085; Yamashita T, 1996, BLOOD, V87, P4424, DOI 10.1182/blood.V87.10.4424.bloodjournal87104424; Zarling AL, 2000, J EXP MED, V192, P1755, DOI 10.1084/jem.192.12.1755	64	36	38	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46035	46045		10.1074/jbc.M408323200	http://dx.doi.org/10.1074/jbc.M408323200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15299017	hybrid			2022-12-27	WOS:000224694900089
J	Miyazaki, T; Shen, M; Fujikura, D; Tosa, N; Kim, HR; Kon, S; Uede, T; Reed, JC				Miyazaki, T; Shen, M; Fujikura, D; Tosa, N; Kim, HR; Kon, S; Uede, T; Reed, JC			Functional role of death-associated protein 3 (DAP3) in anoikis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; APOPTOSIS; SURVIVAL; PATHWAY; MEDIATOR; IDENTIFICATION; MITOCHONDRIA; INTEGRINS; RECEPTORS; CANCER	Detachment of adherent epithelial cells from the extracellular matrix induces apoptosis, known as anoikis. Integrin stimulation protects cells from anoikis, but the responsible mechanisms are not well known. Here, we demonstrated that a pro-apoptotic GTP-binding protein, DAP3 (death-associated protein 3), is critical for induction of anoikis. Down-regulation of DAP3 expression by antisense oligonucleotides inhibited anoikis. Conversely, overexpression of DAP3 augmented cell death and caspase activation induced by cell detachment. Furthermore, the association of DAP3 with FADD and the activation of caspase-8 were induced by cell detachment. We also showed that DAP3 is phosphorylated by kinase Akt (PKB), and active Akt can nullify apoptosis induction by DAP3. Mutation of a consensus Akt phosphorylation site in DAP3 renders it resistant to suppression by active Akt in cells. Integrin ligation stimulates Akt activation and phosphorylation of DAP3 in intact cells, as well as suppresses the ability of DAP3 overexpression to augment anoikis. Involvement of DAP3 in anoikis signaling demonstrates a novel role for this GTP-binding protein in apoptosis induction caused by cell detachment.	Burnham Inst, La Jolla, CA 92037 USA; Hokkaido Univ, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Sanford Burnham Prebys Medical Discovery Institute; Hokkaido University	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reedoffice@burnham.org	Miyazaki, Tadaaki/D-9368-2012; Tosa, Noriko/E-1602-2012; Kon, Shigeyuki/A-3809-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061694] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-61694] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Berger T, 2000, J CELL SCI, V113, P3603; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Danielsen AJ, 2002, GROWTH FACTORS, V20, P1, DOI 10.1080/08977190290022185; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kimchi A, 1998, BBA-REV CANCER, V1377, pF13, DOI 10.1016/S0304-419X(98)00002-X; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; Kissil JL, 1998, MOL MED TODAY, V4, P268, DOI 10.1016/S1357-4310(98)01263-5; Kissil JL, 1999, EMBO J, V18, P353, DOI 10.1093/emboj/18.2.353; Koc EC, 2001, FEBS LETT, V492, P166, DOI 10.1016/S0014-5793(01)02250-5; Lawlor MA, 2001, J CELL SCI, V114, P2903; Liu W, 2000, APOPTOSIS, V5, P323, DOI 10.1023/A:1009679307513; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Miyazaki T, 2002, NAT IMMUNOL, V3, P4, DOI 10.1038/ni0102-4; Miyazaki T, 2001, NAT IMMUNOL, V2, P493, DOI 10.1038/88684; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Morgan CJ, 2001, BIOCHEM BIOPH RES CO, V280, P177, DOI 10.1006/bbrc.2000.4119; Mukamel Z, 2004, J BIOL CHEM, V279, P36732, DOI 10.1074/jbc.M400041200; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Screaton RA, 2003, P NATL ACAD SCI USA, V100, P5211, DOI 10.1073/pnas.0431215100; Suzuki T, 2001, J BIOL CHEM, V276, P33181, DOI 10.1074/jbc.M103236200; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553	32	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44667	44672		10.1074/jbc.M408101200	http://dx.doi.org/10.1074/jbc.M408101200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302871	hybrid			2022-12-27	WOS:000224505600053
J	van der Wijk, T; Overvoorde, J; den Hertog, J				van der Wijk, T; Overvoorde, J; den Hertog, J			H2O2-induced intermolecular disulfide bond formation between receptor protein-tyrosine phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSIBLE INACTIVATION; REDOX REGULATION; IN-VIVO; NEGATIVE REGULATION; HYDROGEN-PEROXIDE; ALPHA; 1B; DIMERIZATION; INHIBITION; MECHANISM	Receptor protein-tyrosine phosphatase alpha (RPTPalpha) belongs to the subfamily of receptor-like protein-tyrosine phosphatases that are characterized by two catalytic domains of which only the membrane-proximal one (D1) exhibits appreciable catalytic activity. The C-terminal catalytic domain (D2) regulates RPTPalpha catalytic activity by controlling rotational coupling within RPTPalpha dimers. RPTPalpha-D2 changes conformation and thereby rotational coupling within RPTPalpha dimers in response to changes in the cellular redox state. Here we report a decrease in motility of RPTPalpha from cells treated with H2O2 on non-reducing SDS-polyacrylamide gels to a position that corresponds to RPTPalpha dimers, indicating intermolecular disulfide bond formation. Using mutants of all individual cysteines in RPTPalpha and constructs encoding the individual protein-tyrosine phosphatase domains, we located the intermolecular disulfide bond to the catalytic Cys-723 in D2. Disulfide bond formation and dimer stabilization showed similar levels of concentration and time dependence. However, treatment of lysates with dithiothreitol abolished intermolecular disulfide bonds but not stable dimer formation. Intermolecular disulfide bond formation and rotational coupling were also found using a chimera of the extracellular domain of RPTPalpha fused to the transmembrane and intracellular domain of the leukocyte common antigen-related protein ( LAR). These results suggest that H2O2 treatment leads to oxidation of the catalytic Cys in D2, which then rapidly forms a disulfide bond with the D2 catalytic Cys of the dyad-related monomer, rendering an inactive RPTP dimer. Recovery from oxidative stress first leads to the reduction of the disulfide bond followed by a slower refolding of the protein to the active conformation.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	den Hertog, J (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	hertog@niob.knaw.nl						Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Blanchetot C, 2002, J BIOL CHEM, V277, P47263, DOI 10.1074/jbc.M205810200; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; Blanchetot C, 2002, EMBO J, V21, P493, DOI 10.1093/emboj/21.4.493; Buist A, 2000, BIOCHEM BIOPH RES CO, V267, P96, DOI 10.1006/bbrc.1999.1901; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; DENHERTOG J, 2004, IN PRESS ARCH BIOCH; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Persson C, 2004, P NATL ACAD SCI USA, V101, P1886, DOI 10.1073/pnas.0304403101; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Tertoolen LGJ, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-8; van der Wijk T, 2003, J BIOL CHEM, V278, P13968, DOI 10.1074/jbc.M300632200; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; Xu Z, 2002, NAT IMMUNOL, V3, P764, DOI 10.1038/ni822	30	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44355	44361		10.1074/jbc.M407483200	http://dx.doi.org/10.1074/jbc.M407483200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15294898	hybrid			2022-12-27	WOS:000224505600017
J	Baronas-Lowell, D; Lauer-Fields, JL; Borgia, JA; Sferrazza, GF; Al-Ghoul, M; Minond, D; Fields, GB				Baronas-Lowell, D; Lauer-Fields, JL; Borgia, JA; Sferrazza, GF; Al-Ghoul, M; Minond, D; Fields, GB			Differential modulation of human melanoma cell metalloproteinase expression by alpha(2)beta(1) integrin and CD44 triple-helical ligands derived from type IV collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DEGRADATION SEQUENCE-ANALYSIS; BASEMENT-MEMBRANE COLLAGEN; MATRIX-METALLOPROTEINASE; INTEGRINS ALPHA(1)BETA(1); MOLECULAR ARCHITECTURE; PEPTIDE-AMPHIPHILES; DOWN-REGULATION; TUMOR-GROWTH; BINDING; ADHESION	Tumor cell binding to components of the basement membrane is well known to trigger intracellular signaling pathways. Signaling ultimately results in the modulation of gene expression, facilitating metastasis. Type IV collagen is the major structural component of the basement membrane and is known to be a polyvalent ligand, possessing sequences bound by the alpha(1)beta(1), alpha(2)beta(1), and alpha(3)beta(1) integrins, as well as cell surface proteoglycan receptors, such as CD44/chondroitin sulfate proteoglycan (CSPG). The role of alpha(2)beta(1) integrin and CD44/CSPG receptor binding on human melanoma cell activation has been evaluated herein using triple-helical peptide ligands incorporating the alpha1( IV) 382 - 393 and alpha1( IV) 1263 - 1277 sequences, respectively. Gene expression and protein production of matrix metalloproteinases-1 (MMP-1), - 2, - 3, - 13, and - 14 were modulated with the alpha(2)beta(1)-specific sequence, whereas the CD44-specific sequence yielded significant stimulation of MMP-8 and lower levels of modulation of MMP-1, - 2, - 13, and - 14. Analysis of enzyme activity confirmed different melanoma cell proteolytic potentials based on engagement of either the alpha(2)beta(1) integrin or CD44/CSPG. These results are indicative of specific activation events that tumor cells undergo upon binding to select regions of basement membrane collagen. Based on the present study, triple-helical peptide ligands provide a general approach for monitoring the regulation of proteolysis in cellular systems.	Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA	State University System of Florida; Florida Atlantic University	Fields, GB (corresponding author), Florida Atlantic Univ, Dept Chem & Biochem, 777 Glades Rd, Boca Raton, FL 33431 USA.	fieldsg@fau.edu		Minond, Dmitriy/0000-0003-2473-5944	NATIONAL CANCER INSTITUTE [R01CA077402, R01CA098799] Funding Source: NIH RePORTER; NCI NIH HHS [CA98799, CA77402] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahrens T, 2001, J INVEST DERMATOL, V116, P93, DOI 10.1046/j.1523-1747.2001.00236.x; Alessandro R, 2002, CLIN EXP METASTAS, V19, P265, DOI 10.1023/A:1015547804511; Baronas-Lowell D, 2004, J BIOL CHEM, V279, P952, DOI 10.1074/jbc.M305989200; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; Berditchevski F, 2001, J CELL SCI, V114, P4143; Bockers TM, 2001, J BIOL CHEM, V276, P40104, DOI 10.1074/jbc.M102454200; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Bogenrieder T, 2002, CRIT REV ONCOL HEMAT, V44, P1, DOI 10.1016/S1040-8428(01)00196-2; BORGIA J, 2002, T 48 ANN M ORTH RES, P763; CAMPER L, 1989, J BIOL CHEM, V273, P20382; Cichy J, 2002, J BIOL CHEM, V277, P44440, DOI 10.1074/jbc.M207437200; CROWTER JR, 1995, METHOD MOL BIOL, P42; Dillow AK, 2001, BIOMATERIALS, V22, P1493, DOI 10.1016/S0142-9612(00)00304-5; Dori Y, 2000, J BIOMED MATER RES, V50, P75, DOI 10.1002/(SICI)1097-4636(200004)50:1<75::AID-JBM11>3.0.CO;2-A; Eliaz RE, 2001, CANCER RES, V61, P2592; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; ETOH T, 1993, J INVEST DERMATOL, V100, P640, DOI 10.1111/1523-1747.ep12472299; FAASSEN AE, 1992, ADV PATHOLOGY LABORA, V5, P229; FIELDS CG, 1993, PEPTIDE RES, V6, P39; FIELDS CG, 1995, ANAL BIOCHEM, V231, P57, DOI 10.1006/abio.1995.1503; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; Fields GB, 1998, BIOPOLYMERS, V47, P143, DOI 10.1002/(SICI)1097-0282(1998)47:2<143::AID-BIP3>3.0.CO;2-U; Giambernardi TA, 2001, MATRIX BIOL, V20, P577, DOI 10.1016/S0945-053X(01)00166-4; Griffioen AW, 1997, BLOOD, V90, P1150, DOI 10.1182/blood.V90.3.1150.1150_1150_1159; Heino J, 1996, INT J CANCER, V65, P717, DOI 10.1002/(SICI)1097-0215(19960315)65:6<717::AID-IJC1>3.3.CO;2-P; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; Hsu MY, 2002, DIFFERENTIATION, V70, P522, DOI 10.1046/j.1432-0436.2002.700906.x; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Iida J, 1998, J BIOL CHEM, V273, P5955, DOI 10.1074/jbc.273.10.5955; Iida J, 1996, SEMIN CANCER BIOL, V7, P155, DOI 10.1006/scbi.1996.0021; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Knutson JR, 1996, MOL BIOL CELL, V7, P383, DOI 10.1091/mbc.7.3.383; KNUTZ T, 1995, SEA TECHNOL, V36, P68; KOHN EC, 1994, J BIOL CHEM, V269, P21505; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; Lauer JL, 1998, BIOCHEMISTRY-US, V37, P5279, DOI 10.1021/bi972958l; Lauer-Fields JL, 2000, J CHROMATOGR A, V890, P117, DOI 10.1016/S0021-9673(00)00396-4; Lauer-Fields JL, 2003, J BIOL CHEM, V278, P18140, DOI 10.1074/jbc.M211330200; Lauer-Fields JL, 2003, J BIOL CHEM, V278, P14321, DOI 10.1074/jbc.M212246200; Lauer-Fields JL, 2002, BIOL CHEM, V383, P1095, DOI 10.1515/BC.2002.118; Lauer-Fields JL, 2001, BIOCHEMISTRY-US, V40, P5795, DOI 10.1021/bi0101190; LAUERFIELDS JL, 2004, IN PRESS J BIOMOL TE, V15; Leigh CJ, 1996, HUM PATHOL, V27, P1288, DOI 10.1016/S0046-8177(96)90339-1; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; Li G, 2003, ONCOGENE, V22, P3162, DOI 10.1038/sj.onc.1206455; Liu DF, 2002, P NATL ACAD SCI USA, V99, P568, DOI 10.1073/pnas.012578299; LOHI J, 1995, J BIOL CHEM, V270, P17602, DOI 10.1074/jbc.270.29.17602; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Malkar NB, 2003, BIOMACROMOLECULES, V4, P518, DOI 10.1021/bm0256597; Malkar NB, 2002, BIOCHEMISTRY-US, V41, P6054, DOI 10.1021/bi012071w; MICKELSON DJ, 1991, J CELL BIOL, V115, P287; MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047; MINOND D, 2004, IN PRESS BIOCHEMISTR, V43; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; Mott JD, 1997, KIDNEY INT, V52, P1302, DOI 10.1038/ki.1997.455; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Nickoloff BJ, 2001, METH MOLEC MED, V61, P3, DOI 10.1385/1-59259-145-0:3; Ntayi C, 2001, EXP CELL RES, V270, P110, DOI 10.1006/excr.2001.5306; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Pakalns T, 1999, BIOMATERIALS, V20, P2265, DOI 10.1016/S0142-9612(99)00157-X; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Park MJ, 2002, CANCER RES, V62, P6318; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Ranuncolo SM, 2002, ONCOL REP, V9, P51; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; SAVARESE DMF, 1992, J BIOL CHEM, V267, P21928; Schon M, 1996, J INVEST DERMATOL, V106, P1175, DOI 10.1111/1523-1747.ep12347929; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Shimaoka M, 2003, NAT REV DRUG DISCOV, V2, P703, DOI 10.1038/nrd1174; Singh A, 2000, ARCH ORAL BIOL, V45, P431, DOI 10.1016/S0003-9969(00)00020-0; Stricker TP, 2001, J BIOL CHEM, V276, P29375, DOI 10.1074/jbc.M102217200; Takagaki K, 2002, J BIOL CHEM, V277, P8882, DOI 10.1074/jbc.M106479200; Takahashi K, 1999, INT J CANCER, V80, P387, DOI 10.1002/(SICI)1097-0215(19990129)80:3<387::AID-IJC9>3.3.CO;2-K; Tanimura S, 2003, BIOCHEM BIOPH RES CO, V304, P801, DOI 10.1016/S0006-291X(03)00670-3; Teriete P, 2004, MOL CELL, V13, P483, DOI 10.1016/S1097-2765(04)00080-2; Thorne RF, 2004, J CELL SCI, V117, P373, DOI 10.1242/jcs.00954; Tiger CF, 2001, DEV BIOL, V237, P116, DOI 10.1006/dbio.2001.0363; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Vachhani BV, 1998, MOL BIOL CELL, V9, p56A; Valentino LA, 1996, BBA-MOL BASIS DIS, V1316, P19, DOI 10.1016/0925-4439(95)00092-5; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Vo HP, 1998, INT J ONCOL, V13, P1127; Vogel WF, 2001, EUR J DERMATOL, V11, P506; Wald M, 2001, CANCER CHEMOTH PHARM, V47, pS16, DOI 10.1007/s002800170004; Weber GF, 2002, CANCER RES, V62, P2281; Woessner J.F., 2000, PROTEIN PROFILE SER; Wong H, 2000, METH MOL B, V151, P305, DOI 10.1385/1-59259-046-2:305; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; YOSHINAGA IG, 1993, MELANOMA RES, V3, P435, DOI 10.1097/00008390-199311000-00006; Yu YC, 1998, J AM CHEM SOC, V120, P9979, DOI 10.1021/ja981654z; Yu YC, 1997, METHOD ENZYMOL, V289, P571; Yu YC, 1996, J AM CHEM SOC, V118, P12515, DOI 10.1021/ja9627656; Zigrino P, 2001, EUR J CELL BIOL, V80, P68, DOI 10.1078/0171-9335-00134	106	43	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43503	43513		10.1074/jbc.M405979200	http://dx.doi.org/10.1074/jbc.M405979200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292257	hybrid			2022-12-27	WOS:000224383100020
J	Papadopoulos, S; Leuranguer, V; Bannister, RA; Beam, KG				Papadopoulos, S; Leuranguer, V; Bannister, RA; Beam, KG			Mapping sites of potential proximity between the dihydropyridine receptor and RyR1 in muscle using a cyan fluorescent protein-yellow fluorescent protein tandem as a fluorescence resonance energy transfer probe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-III-LOOP; SKELETAL-MUSCLE; RYANODINE RECEPTOR; SARCOPLASMIC-RETICULUM; CALCIUM-CHANNELS; ALPHA(1) SUBUNIT; CA2+ CHANNELS; BETA-SUBUNIT; EXCITATION; REGIONS	Excitation-contraction coupling in skeletal muscle involves conformational coupling between the dihydropyridine receptor ( DHPR) and the type 1 ryanodine receptor (RyR1) at junctions between the plasma membrane and sarcoplasmic reticulum. In an attempt to find which regions of these proteins are in close proximity to one another, we have constructed a tandem of cyan and yellow fluorescent proteins (CFP and YFP, respectively) linked by a 23-residue spacer, and measured the fluorescence resonance energy transfer (FRET) of the tandem either in free solution or after attachment to sites of the alpha(1S) and beta(1a) subunits of the DHPR. For all of the sites examined, attachment of the CFP-YFP tandem did not impair function of the DHPR as a Ca2+ channel or voltage sensor for excitation-contraction coupling. The free tandem displayed a 27.5% FRET efficiency, which decreased significantly after attachment to the DHPR subunits. At several sites examined for both alpha(1S) (N-terminal, proximal II-III loop of a two fragment construct) and beta(1a) (C-terminal), the FRET efficiency was similar after expression in either dysgenic (alpha(1S)-null) or dyspedic (RyR1-null) myotubes. However, compared with dysgenic myotubes, the FRET efficiency in dyspedic myotubes increased from 9.9 to 16.7% for CFP-YFP attached to the N-terminal of beta(1a), and from 9.5 to 16.8% for CFP-YFP at the C-terminal of alpha(1S). Thus, the tandem reporter suggests that the C terminus of alpha(1S) and the N terminus of beta(1a) may be in close proximity to the ryanodine receptor.	Colorado State Univ, Dept Biomed Sci, Anat Sect, Ft Collins, CO 80523 USA	Colorado State University	Beam, KG (corresponding author), Colorado State Univ, Dept Biomed Sci, Anat Sect, 1617 Campus Delivery, Ft Collins, CO 80523 USA.	kbeam@lamar.colostate.edu	Tuluc, Petronel/C-2527-2011		NIAMS NIH HHS [AR44750] Funding Source: Medline; NINDS NIH HHS [NS24444] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR044750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024444] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahern CA, 2001, P NATL ACAD SCI USA, V98, P6935, DOI 10.1073/pnas.111001898; Ahern CA, 2001, BIOPHYS J, V81, P3294, DOI 10.1016/S0006-3495(01)75963-2; BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; Beam KG, 1997, METHOD CELL BIOL, V52, P283, DOI 10.1016/S0091-679X(08)60384-2; Beurg M, 1999, BIOPHYS J, V77, P2953, DOI 10.1016/S0006-3495(99)77128-6; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; Brejc K, 1997, P NATL ACAD SCI USA, V94, P2306, DOI 10.1073/pnas.94.6.2306; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; Casarotto MG, 2000, J BIOL CHEM, V275, P11631, DOI 10.1074/jbc.275.16.11631; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; Cheng W, 2003, BIOPHYS J, V84, p109A; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; DOSREMEDIOS CG, 1995, J STRUCT BIOL, V115, P175, DOI 10.1006/jsbi.1995.1042; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; Flucher BE, 2002, P NATL ACAD SCI USA, V99, P10167, DOI 10.1073/pnas.122345799; FLUCHER BE, 1994, MOL BIOL CELL, V5, P1105, DOI 10.1091/mbc.5.10.1105; GLOSSMANN H, 1988, VITAM HORM, V44, P155; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KNUDSON CM, 1989, J BIOL CHEM, V264, P1345; Leong P, 1998, J BIOL CHEM, V273, P29958, DOI 10.1074/jbc.273.45.29958; Liu Z, 2002, J BIOL CHEM, V277, P46712, DOI 10.1074/jbc.M208124200; Lorenzon NM, 2004, J BIOL CHEM, V279, P44057, DOI 10.1074/jbc.M405318200; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; Neuhuber B, 1998, P NATL ACAD SCI USA, V95, P5015, DOI 10.1073/pnas.95.9.5015; Proenza C, 2000, J BIOL CHEM, V275, P29935, DOI 10.1074/jbc.C000464200; Proenza C, 2002, J BIOL CHEM, V277, P6530, DOI 10.1074/jbc.M106471200; RIOS E, 1991, J MUSCLE RES CELL M, V12, P127, DOI 10.1007/BF01774031; Sencer S, 2001, J BIOL CHEM, V276, P38237; Siegel R. M., 2000, SCI STKE, V2000, ppl1; TAKEKURA H, 1995, P NATL ACAD SCI USA, V92, P3381, DOI 10.1073/pnas.92.8.3381; Takekura H, 1999, DEV DYNAM, V214, P372, DOI 10.1002/(SICI)1097-0177(199904)214:4<372::AID-AJA9>3.0.CO;2-Q; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; van der Meer B W, 2002, J Biotechnol, V82, P181, DOI 10.1016/S1389-0352(01)00037-X; Wilkens CM, 2001, P NATL ACAD SCI USA, V98, P5892, DOI 10.1073/pnas.101618098; Zhang J, 2003, J BIOL CHEM, V278, P14211, DOI 10.1074/jbc.M213164200	43	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44046	44056		10.1074/jbc.M405317200	http://dx.doi.org/10.1074/jbc.M405317200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15280389	hybrid			2022-12-27	WOS:000224383100084
J	Cornah, JE; Germain, V; Ward, JL; Beale, MH; Smith, SM				Cornah, JE; Germain, V; Ward, JL; Beale, MH; Smith, SM			Lipid utilization, gluconeogenesis, and seedling growth in Arabidopsis mutants lacking the glyoxylate cycle enzyme malate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOCITRATE LYASE; THALIANA; METABOLISM; LEAVES; TISSUE; PLANTS; CONSTITUENTS; TRANSITION; OILSEEDS; PATHWAY	The aim of this research was to test the role of the glyoxylate cycle enzyme malate synthase (MLS) in lipid utilization, gluconeogenesis, and seedling growth in Arabidopsis. We hypothesized that in the absence of MLS, succinate produced by isocitrate lyase (ICL) could still feed into the tricarboxylic acid cycle, whereas glyoxylate could be converted to sugars using enzymes of the photorespiratory pathway. To test this hypothesis we isolated knock-out mls mutants and studied their growth and metabolism in comparison to wild type and icl mutant seedlings. In contrast to icl seedlings, which grow slowly and are unable to convert lipid into sugars (Eastmond, P. J., Germain, V., Lange, P. R., Bryce, J. H., Smith, S. M. & Graham, I. A. ( 2000) Proc. Natl. Acad. Sci. U. S. A. 97, 5669 5674), mls seedlings grow faster, use their lipid more rapidly, and are better able to establish as plantlets. Transcriptome and metabolome analyses show that icl seedlings exhibit many features characteristic of carbohydrate starvation, whereas mls seedlings differ relatively little from wild type. In the light mls seedlings generate more sugars than icl seedlings, and when fed with [C-14] acetate, C-14-labeling of sugars is three times greater than in icl seedlings and more than half that in wild type seedlings. The mls seedlings also accumulate more glycine and serine than icl or wild type seedlings, consistent with a diversion of glyoxylate into these intermediates of the photorespiratory pathway. We conclude that, in contrast to bacteria and fungi in which MLS is essential for gluconeogenesis from acetate or fatty acids, MLS is partially dispensable for lipid utilization and gluconeogenesis in Arabidopsis seedlings.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JH, Midlothian, Scotland; Inst Natl Rech Agron Bordeaux, Ctr Rech, Inst Biol Vegetale Bourleaux, UMR Physiol & Biotechnol Vegetales, F-33883 Villenave Dornon, France; Rothamsted Res, Crop Performance & Improvement Div, Harpenden AL5 2JQ, Herts, England	University of Edinburgh; INRAE; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Smith, SM (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Mayfield Rd, Edinburgh EH9 3JH, Midlothian, Scotland.	s.smith@ed.ac.uk	Smith, Steven M/G-7183-2015; Smith, Steven/HDM-9496-2022	Smith, Steven M/0000-0001-5661-9994; GERMAIN, Veronique/0000-0001-6322-1204	Biotechnology and Biological Sciences Research Council [MET20482, G18889] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BEEVERS H, 1961, NATURE, V191, P433, DOI 10.1038/191433a0; BOUCHEZ D, 1993, CR ACAD SCI III-VIE, V316, P1188; Boyes DC, 2001, PLANT CELL, V13, P1499, DOI 10.1105/tpc.13.7.1499; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUQUISSE R, 1992, PLANTA, V188, P384, DOI 10.1007/BF00192806; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; CANVIN DT, 1961, J BIOL CHEM, V236, P988; COOPER TG, 1969, J BIOL CHEM, V244, P3507; Cornah JE, 2002, PLANT PEROXISOMES, P57; Eastmond PJ, 2000, P NATL ACAD SCI USA, V97, P5669, DOI 10.1073/pnas.97.10.5669; Eastmond PJ, 2001, TRENDS PLANT SCI, V6, P72, DOI 10.1016/S1360-1385(00)01835-5; GODAVARI HR, 1973, PLANT PHYSIOL, V51, P863, DOI 10.1104/pp.51.5.863; HARTIG A, 1992, NUCLEIC ACIDS RES, V20, P5677, DOI 10.1093/nar/20.21.5677; HUNT L, 1977, PLANT SCI LETT, V10, P243, DOI 10.1016/0304-4211(77)90135-3; Kornberg HL, 2003, J BIOL CHEM, V278, P9993, DOI 10.1074/jbc.X200008200; KORNBERG HL, 1957, NATURE, V179, P988, DOI 10.1038/179988a0; Liu JQ, 2003, APPL MICROBIOL BIOT, V62, P53, DOI 10.1007/s00253-003-1238-2; Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NAKAMURA Y, 1983, J BIOL CHEM, V258, P7631; NIELSEN TH, 1991, PHYSIOL PLANTARUM, V82, P311, DOI 10.1034/j.1399-3054.1991.820227.x; NISHIMURA M, 1986, PLANT PHYSIOL, V80, P313; Pellicer MT, 1999, J BIOL CHEM, V274, P1745, DOI 10.1074/jbc.274.3.1745; SAUTTER C, 1986, PLANTA, V167, P491, DOI 10.1007/BF00391225; Sherson SM, 2000, PLANT J, V24, P849, DOI 10.1046/j.1365-313x.2000.00935.x; TITUS DE, 1985, J CELL BIOL, V101, P1288, DOI 10.1083/jcb.101.4.1288; Ward JL, 2003, PHYTOCHEMISTRY, V62, P949, DOI 10.1016/S0031-9422(02)00705-7; ZELITCH I, 1988, PLANT PHYSIOL, V86, P463, DOI 10.1104/pp.86.2.463	31	86	94	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42916	42923		10.1074/jbc.M407380200	http://dx.doi.org/10.1074/jbc.M407380200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15272001	Green Published, hybrid			2022-12-27	WOS:000224226400070
J	Hanson, CL; Videler, H; Santos, C; Ballesta, JPG; Robinson, CV				Hanson, CL; Videler, H; Santos, C; Ballesta, JPG; Robinson, CV			Mass spectrometry of ribosomes from Saccharomyces cerevisiae - Implications for assembly of the stalk complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC PHOSPHOPROTEINS; PROTEINS P1; MONOCLONAL-ANTIBODIES; ANGSTROM RESOLUTION; SUBUNIT; P2; P0; PHOSPHORYLATION; TRANSLOCATION; COMPONENTS	The acidic ribosomal P proteins form a distinct protuberance on the 60 S subunit of eukaryotic ribosomes. In yeast this structure is composed of two heterodimers (P1alpha-P2beta and P1beta-P2alpha) attached to the ribosome via P0. Although for prokaryotic ribosomes the isolation of a pentameric stalk complex comprising the analogous proteins is well established, its observation has not been reported for eukaryotic ribosomes. We used mass spectrometry to examine the composition of the stalk proteins on ribosomes from Saccharomyces cerevisiae. The resulting mass spectra reveal a noncovalent complex of mass 77,291 +/- 7 Da assigned to the pentameric stalk. Tandem mass spectrometry confirms this assignment and is consistent with the location of the P2 proteins on the periphery of the stalk complex, shielding the P1 proteins, which in turn interact with P0. No other oligomers are observed, confirming the specificity of the pentameric complex. At lower m/z values the spectra are dominated by individual proteins, largely from the stalk complex, giving rise to many overlapping peaks. To define the composition of the stalk proteins in detail we compared spectra of ribosomes from strains in which genes encoding either or both of the interacting stalk proteins P1alpha or P2beta are deleted. This enables us to define novel post-translational modifications at very low levels, including a population of P2alpha molecules with both phosphorylation and trimethylation. The deletion mutants also reveal interactions within the heterodimers, specifically that the absence of P1alpha or P2beta destabilizes binding of the partner protein on the ribosome. This implies that assembly of the stalk complex is not governed solely by interactions with P0 but is a cooperative process involving binding to partner proteins for additional stability on the ribosome.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Autonoma Madrid, Ctr Biol Mol, Madrid 28040, Spain	University of Cambridge; Autonomous University of Madrid	Robinson, CV (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cvr24@cam.ac.uk	Santos, Cruz/ABG-3054-2020	Videler, Hortense/0000-0002-6369-5984; Santos, Cruz/0000-0001-5164-5050; robinson, carol/0000-0001-7829-5505				Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Aquilina JA, 2003, P NATL ACAD SCI USA, V100, P10611, DOI 10.1073/pnas.1932958100; Ballesta JPG, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P115; Ballesta JPG, 1996, PROG NUCLEIC ACID RE, V55, P157, DOI 10.1016/S0079-6603(08)60193-2; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Benjamin DR, 1998, P NATL ACAD SCI USA, V95, P7391, DOI 10.1073/pnas.95.13.7391; CHOWDHURY SK, 1990, BIOCHEM BIOPH RES CO, V173, P927, DOI 10.1016/S0006-291X(05)80874-5; Guarinos E, 2003, MOL MICROBIOL, V50, P703, DOI 10.1046/j.1365-2958.2003.03733.x; Ilag LL, 2004, STRUCTURE, V12, P269, DOI 10.1016/j.str.2004.01.007; Lalioti VS, 2002, MOL MICROBIOL, V46, P719, DOI 10.1046/j.1365-2958.2002.03179.x; Lee SW, 2002, P NATL ACAD SCI USA, V99, P5942, DOI 10.1073/pnas.082119899; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; Nettleton EJ, 1998, J MOL BIOL, V281, P553, DOI 10.1006/jmbi.1998.1937; Nusspaumer G, 2000, EMBO J, V19, P6075, DOI 10.1093/emboj/19.22.6075; Remacha M, 1995, BIOCHEM CELL BIOL, V73, P959, DOI 10.1139/o95-103; REMACHA M, 1992, J BIOL CHEM, V267, P12061; Rodriguez-Gabriel MA, 2000, J BIOL CHEM, V275, P2130, DOI 10.1074/jbc.275.3.2130; Rodriguez-Gabriel MA, 1998, BIOCHEMISTRY-US, V37, P16620, DOI 10.1021/bi981396i; Rostom AA, 2000, P NATL ACAD SCI USA, V97, P5185, DOI 10.1073/pnas.97.10.5185; SAENZROBLES MT, 1990, BIOCHIM BIOPHYS ACTA, V1050, P51, DOI 10.1016/0167-4781(90)90140-W; SANTOS C, 1993, BIOCHEMISTRY-US, V32, P4231, DOI 10.1021/bi00067a010; SANTOS C, 1995, J BIOL CHEM, V270, P20608, DOI 10.1074/jbc.270.35.20608; Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552; Spahn CMT, 2004, EMBO J, V23, P1008, DOI 10.1038/sj.emboj.7600102; Spahn CMT, 1999, STRUCT FOLD DES, V7, P1567, DOI 10.1016/S0969-2126(00)88347-1; Tchorzewski M, 2003, BIOCHEMISTRY-US, V42, P3399, DOI 10.1021/bi0206006; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; VILELLA MD, 1991, EUR J BIOCHEM, V196, P407, DOI 10.1111/j.1432-1033.1991.tb15831.x; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Zabrouskov V, 2003, MOL CELL PROTEOMICS, V2, P1253, DOI 10.1074/mcp.M300069-MCP200; Zambrano R, 1997, BIOCHEMISTRY-US, V36, P14439, DOI 10.1021/bi971494o; Zurdo J, 2000, BIOCHEMISTRY-US, V39, P8929, DOI 10.1021/bi000362j; Zurdo J, 2000, BIOCHEMISTRY-US, V39, P8935, DOI 10.1021/bi000363b	34	39	39	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42750	42757		10.1074/jbc.M405718200	http://dx.doi.org/10.1074/jbc.M405718200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15294894	hybrid			2022-12-27	WOS:000224226400050
J	Wajih, N; Borras, T; Xue, W; Hutson, SM; Wallin, R				Wajih, N; Borras, T; Xue, W; Hutson, SM; Wallin, R			Processing and transport of matrix gamma-carboxyglutamic acid protein and bone morphogenetic protein-2 in cultured human vascular smooth muscle cells - Evidence for an uptake mechanism for serum fetuin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRABECULAR MESHWORK; GLA PROTEIN; ALPHA-FETOPROTEIN; IN-VITRO; GENE-TRANSFER; CALCIFICATION; RAT; MINERALIZATION; EXPRESSION; BINDING	Matrix gamma-carboxyglutamic acid protein (MGP) is a member of the vitamin K-dependent protein family with unique structural and physical properties. MGP has been shown to be an inhibitor of arterial wall and cartilage calcification. One inhibitory mechanism is thought to be binding of bone morphogenetic protein-2. Binding has been shown to be dependent upon the vitamin K-dependent gamma-carboxylation modification of MGP. Since MGP is an insoluble matrix protein, this work has focused on intracellular processing and transport of MGP to become an extracellular binding protein for bone morphogenetic protein-2. Human vascular smooth muscle cells (VSMCs) were infected with an adenovirus carrying the MGP construct, which produced non-gamma-carboxylated MGP and fully gamma-carboxylated MGP. Both forms of MGP were found in the cytosolic and microsomal fractions obtained from the cells by differential centrifugation. The crude microsomal fraction was shown to contain an additional, more acidic Ser-phosphorylated form of MGP believed to be the product of Golgi casein kinase. The data suggest that phosphorylation of MGP dictates different transport routes for MGP in VSMCs. A proteomic approach failed to identify a larger soluble precursor of MGP or an intracellular carrier protein for MGP. Evidence is presented for a receptor-mediated uptake mechanism for fetuin by cultured human VSMCs. Fetuin, shown by mass spectrometry not to contain MGP, was found to be recognized by anti-MGP antibodies. Fetuin uptake and secretion by proliferating and differentiating cells at sites of calcification in the arterial wall may represent an additional protective mechanism against arterial calcification.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Rheumatol Sect, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Univ N Carolina, Sch Med, Dept Ophthalmol, Chapel Hill, NC 27599 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Wallin, R (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Rheumatol Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.	rwallin@wfubmc.edu	Wajih, Nadeem/GMW-6625-2022		NATIONAL EYE INSTITUTE [R01EY013126] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069331] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY013126] Funding Source: Medline; NHLBI NIH HHS [R01HL069331] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Annes JP, 2004, J CELL BIOL, V165, P723, DOI 10.1083/jcb.200312172; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; Borras T, 1999, GENE THER, V6, P515, DOI 10.1038/sj.gt.3300860; Borras T, 1996, INVEST OPHTH VIS SCI, V37, P1282; BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391; BOSTROM K, 1995, AM J CARDIOL, V75, pB88, DOI 10.1016/0002-9149(95)80020-S; Demer LL, 2003, ARTERIOSCL THROM VAS, V23, P1739, DOI 10.1161/01.ATV.0000093547.63630.0F; FRASER JD, 1988, J BIOL CHEM, V263, P911; FURIE B, 1990, BLOOD, V75, P1753; Garimella R, 2004, BONE, V34, P961, DOI 10.1016/j.bone.2004.02.010; GEUSKENS M, 1986, J CELL PHYSIOL, V128, P389, DOI 10.1002/jcp.1041280307; Gonzalez P, 2000, INVEST OPHTH VIS SCI, V41, P3678; Hackeng TM, 2001, PROTEIN SCI, V10, P864, DOI 10.1110/ps.44701; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; Israel DI, 1992, GROWTH FACTORS, V7, P139, DOI 10.3109/08977199209046403; JahnenDechent W, 1997, J BIOL CHEM, V272, P31496, DOI 10.1074/jbc.272.50.31496; Jono S, 2004, THROMB HAEMOSTASIS, V91, P790, DOI 10.1160/TH03-08-0572; Ketteler M, 2003, LANCET, V361, P827, DOI 10.1016/S0140-6736(03)12710-9; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; Kulman JD, 2001, P NATL ACAD SCI USA, V98, P1370, DOI 10.1073/pnas.98.4.1370; LOESER R, 1992, BIOCHEM J, V282, P1; Lorenzo HC, 1996, TUMOR BIOL, V17, P251, DOI 10.1159/000217986; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MEGGIO F, 1988, EUR J BIOCHEM, V177, P281, DOI 10.1111/j.1432-1033.1988.tb14374.x; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Murshed M, 2004, J CELL BIOL, V165, P625, DOI 10.1083/jcb.200402046; NAVAL J, 1985, P NATL ACAD SCI USA, V82, P3301, DOI 10.1073/pnas.82.10.3301; OHNISHI T, 1991, J BIOL CHEM, V266, P14636; Pedersen KO, 1944, NATURE, V154, P575, DOI 10.1038/154575a0; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; Price PA, 2003, J BIOL CHEM, V278, P22153, DOI 10.1074/jbc.M300739200; Price PA, 1998, ARTERIOSCL THROM VAS, V18, P1400, DOI 10.1161/01.ATV.18.9.1400; PRICE PA, 1994, PROTEIN SCI, V3, P822; Procino G, 2003, FASEB J, V17, P1886, DOI 10.1096/fj.02-0870fje; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; Shanahan CM, 1999, CIRCULATION, V100, P2168, DOI 10.1161/01.CIR.100.21.2168; Simon JP, 1996, J BIOL CHEM, V271, P16952, DOI 10.1074/jbc.271.28.16952; STANTON C, 1991, BIOCHEM J, V277, P59, DOI 10.1042/bj2770059; Suttie J. W., 1978, Handbook of lipid research. Volume 2. The fat-soluble vitamins, P211; Sweatt A, 2003, J THROMB HAEMOST, V1, P178, DOI 10.1046/j.1538-7836.2003.00023.x; URIEL J, 1981, NEUROSCI LETT, V27, P171, DOI 10.1016/0304-3940(81)90263-9; VILLACAMPA MJ, 1984, DEV BRAIN RES, V12, P77, DOI 10.1016/0165-3806(84)90177-9; Wajih N, 2004, J BIOL CHEM, V279, P25276, DOI 10.1074/jbc.M401645200; Wallin R, 1999, THROMB HAEMOSTASIS, V82, P1764; Wallin R, 2000, THROMB HAEMOSTASIS, V84, P1039; Wallin R, 2001, MED RES REV, V21, P274, DOI 10.1002/med.1010.abs; WILLINGHAM MC, 1984, P NATL ACAD SCI-BIOL, V81, P175, DOI 10.1073/pnas.81.1.175; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	50	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43052	43060		10.1074/jbc.M407180200	http://dx.doi.org/10.1074/jbc.M407180200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15280384	hybrid			2022-12-27	WOS:000224226400088
J	Parrella, E; Gianni', M; Cecconi, V; Nigro, E; Barzago, MM; Rambaldi, A; Rochette-Egly, C; Terao, M; Garattini, E				Parrella, E; Gianni', M; Cecconi, V; Nigro, E; Barzago, MM; Rambaldi, A; Rochette-Egly, C; Terao, M; Garattini, E			Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells - Cross-talk between the cAMP and the retinoic acid signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; ELEMENT-BINDING-PROTEIN; LEUKOCYTE ALKALINE-PHOSPHATASE; MONOCYTE-CHEMOTACTIC PROTEIN-1; CYCLIC-AMP; KINASE-A; RECEPTOR-ALPHA; GROWTH ARREST; RAR-ALPHA; GRANULOCYTIC DIFFERENTIATION	Inhibition of phosphodiesterase IV by N-(3,5-dichloropyrid-4- yl) -3-cyclopentyloxy-4-methoxybenzamide (piclamilast) enhances the myeloid differentiation induced by all-trans-retinoic acid ( ATRA), retinoic acid receptor alpha (RARalpha), or retinoic acid receptor X agonists in NB4 and other retinoid-sensitive myeloid leukemia cell types. ATRA-resistant NB4.R2 cells are also partially responsive to the action of piclamilast and retinoic acid receptor X agonists. Treatment of NB4 cells with piclamilast or ATRA results in activation of the cAMP signaling pathway and nuclear translocation of cAMP-dependent protein kinase. This causes a transitory increase in cAMP-responsive element-binding protein phosphorylation, which is followed by down-modulation of the system. ATRA + piclamilast have no additive effects on the modulation of the cAMP pathway, and the combination has complex effects on cAMP-regulated genes. Piclamilast potentiates the ligand-dependent transactivation and degradation of RARalpha through a cAMP-dependent protein kinase-dependent phosphorylation. Enhanced transactivation is also observed in the case of PML-RARalpha. In NB4 cells, increased transactivation is likely to be at the basis of enhanced myeloid maturation and enhanced expression of many retinoid-dependent genes. Piclamilast and/or ATRA exert major effects on the expression of cEBP and STAT1, two types of transcription factors involved in myeloid maturation. Induction and activation of STAT1 correlates directly with enhanced cytodifferentiation. Finally, ERK and the cAMP target protein, Epac, do not participate in the maturation program activated by ATRA + piclamilast. Initial in vivo studies conducted in severe combined immunodeficiency mice transplanted with NB4 leukemia cells indicate that the enhancing effect of piclamilast on ATRA-induced myeloid maturation translates into a therapeutic benefit.	Mario Negri Inst Pharmacol Res, Ctr Catullo & Daniela Borgomainerio, Mol Biol Lab, I-20157 Milan, Italy; Inst Genet & Biol Mol, F-67404 Illkirch Graffenstaden, France; Osped Riuniti Bergamo, Div Hematol, I-24100 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Institut National de la Sante et de la Recherche Medicale (Inserm); Ospedali Riuniti di Bergamo	Garattini, E (corresponding author), Mario Negri Inst Pharmacol Res, Ctr Catullo & Daniela Borgomainerio, Mol Biol Lab, Via Eritrea 62, I-20157 Milan, Italy.	egarattini@marionegri.it	Rambaldi, Alessandro/P-2603-2018; Garattini, Enrico/AAI-1998-2019; Rambaldi, Alessandro/M-6172-2019; terao, mineko/AAU-8089-2020; Terao, Mineko/AAA-6415-2020; Barzago, Maria Monica/AAA-6402-2020; Nigro, Elisa Agnese/Z-5679-2019; Gianni, Maurizio/ABG-6322-2020	Rambaldi, Alessandro/0000-0002-3739-7502; Rambaldi, Alessandro/0000-0002-3739-7502; Terao, Mineko/0000-0002-9976-9869; Barzago, Maria Monica/0000-0002-6952-0069; Gianni, Maurizio/0000-0002-6945-708X; Nigro, Elisa Agnese/0000-0002-5806-9495; Garattini, Enrico/0000-0001-8983-886X; Parrella, Edoardo/0000-0003-0365-5144				Barnette M S, 1999, Prog Drug Res, V53, P193; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; BIESALSKI HK, 1989, TOXICOLOGY, V57, P117, DOI 10.1016/0300-483X(89)90161-3; Bundschuh DS, 2001, J PHARMACOL EXP THER, V297, P280; Camacho LH, 2000, J CLIN ONCOL, V18, P2620, DOI 10.1200/JCO.2000.18.13.2620; Charrad RS, 2002, BLOOD, V99, P290, DOI 10.1182/blood.V99.1.290; Chomienne C, 1996, FASEB J, V10, P1025, DOI 10.1096/fasebj.10.9.8801163; Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200; Cote S, 2002, BLOOD, V100, P2586, DOI 10.1182/blood-2002-02-0614; COX DR, 1972, J R STAT SOC B, V34, P187; D'Alo F, 2003, BLOOD, V102, P3163, DOI 10.1182/blood-2003-02-0479; Davis MI, 2003, J BIOL CHEM, V278, P48973, DOI 10.1074/jbc.M305697200; DellaFazia MA, 1997, FEBS LETT, V410, P22, DOI 10.1016/S0014-5793(97)00445-6; DERMIME S, 1995, LEUKEMIA LYMPHOMA, V16, P289, DOI 10.3109/10428199509049768; Dimberg A, 2000, BLOOD, V96, P2870; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fanelli M, 2004, J BIOL CHEM, V279, P5374, DOI 10.1074/jbc.M306407200; Fenaux P, 1999, BLOOD, V94, P1192, DOI 10.1182/blood.V94.4.1192.416k07_1192_1200; Gallagher RE, 2002, LEUKEMIA, V16, P1940, DOI 10.1038/sj.leu.2402719; Garattini E, 1996, LEUKEMIA LYMPHOMA, V23, P493, DOI 10.3109/10428199609054858; Garattini E, 2004, BLOOD, V103, P194, DOI 10.1182/blood-2003-05-1577; Garattini E, 1998, LEUKEMIA LYMPHOMA, V30, P467, DOI 10.3109/10428199809057559; Garattini Enrico, 2001, Current Opinion in Pharmacology, V1, P358, DOI 10.1016/S1471-4892(01)00062-5; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; GIANNI M, 1995, EUR CYTOKINE NETW, V6, P157; Gianni M, 2000, CELL DEATH DIFFER, V7, P447, DOI 10.1038/sj.cdd.4400673; Gianni M, 1996, BLOOD, V87, P1520, DOI 10.1182/blood.V87.4.1520.bloodjournal8741520; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; GIANNI M, 1994, BLOOD, V83, P1909; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Gianni M, 1996, INT J CANCER, V68, P75, DOI 10.1002/(SICI)1097-0215(19960927)68:1<75::AID-IJC14>3.0.CO;2-5; Gianni' M, 2001, BLOOD, V97, P3234, DOI 10.1182/blood.V97.10.3234; Guillemin MC, 2002, J EXP MED, V196, P1373, DOI 10.1084/jem.20021129; KOYAMA T, 1994, BLOOD, V84, P3001; LANOTTE M, 1991, BLOOD, V77, P1080; LARRICK JW, 1980, J IMMUNOL, V125, P6; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LEVY J, 1989, INFECT IMMUN, V57, P1632, DOI 10.1128/IAI.57.5.1632-1634.1989; MacKenzie SJ, 2000, BIOCHEM J, V347, P571, DOI 10.1042/0264-6021:3470571; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; Matikainen S, 1996, BLOOD, V88, P114; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Miranda MB, 2002, LEUKEMIA, V16, P683, DOI 10.1038/sj.leu.2402400; Moon EY, 2003, BLOOD, V101, P4122, DOI 10.1182/blood-2002-10-3208; Nervi C, 1998, BLOOD, V92, P2244; Nesterova M, 2000, CLIN CANCER RES, V6, P3434; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; PERI G, 1994, J IMMUNOL METHODS, V174, P249, DOI 10.1016/0022-1759(94)90029-9; Pisano C, 2002, BLOOD, V100, P3719, DOI 10.1182/blood-2002-03-0720; Post SR, 1996, J BIOL CHEM, V271, P895, DOI 10.1074/jbc.271.2.895; Quenech'Du N, 1998, LEUKEMIA, V12, P1829, DOI 10.1038/sj.leu.2401171; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Roussel MJS, 2001, ONCOGENE, V20, P7287, DOI 10.1038/sj.onc.1204863; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Sironi M, 1997, INT J CLIN LAB RES, V27, P118, DOI 10.1007/BF02912445; Truong BTH, 2003, BLOOD, V101, P1141, DOI 10.1182/blood-2002-05-1374; Tucholski J, 2003, J BIOL CHEM, V278, P26838, DOI 10.1074/jbc.M303683200; WARRELL RP, 1994, SEMIN HEMATOL, V31, P1; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yen A, 1998, CANCER RES, V58, P3163; Yoshida H, 1996, CANCER RES, V56, P2945; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173; Zhao Q, 2004, LEUKEMIA, V18, P285, DOI 10.1038/sj.leu.2403226; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	68	36	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42026	42040		10.1074/jbc.M406530200	http://dx.doi.org/10.1074/jbc.M406530200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292163	hybrid			2022-12-27	WOS:000224075500096
J	Riley, BE; Xu, YF; Zoghbi, HY; Orr, HT				Riley, BE; Xu, YF; Zoghbi, HY; Orr, HT			The effects of the polyglutamine repeat protein ataxin-1 on the UbL-UBA protein A1Up	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							26 S PROTEASOME; UBIQUITIN-MEDIATED PROTEOLYSIS; MULTIUBIQUITIN-CHAIN-BINDING; DAMAGE-INDUCIBLE PROTEINS; DNA-REPAIR; SUBUNIT S5A; EXPANDED POLYGLUTAMINE; POLYUBIQUITIN CHAINS; GEL ELECTROPHORESIS; MOLECULAR-WEIGHTS	The ataxin-1 interacting ubiquitin-like protein (A1Up) contains an amino-terminal ubiquitin-like (UbL) region, four stress-inducible, heat shock chaperonin-binding motifs (STI1), and an ubiquitin-associated domain (UBA) at the carboxyl terminus of A1Up. Although proteins that have both an UbL and UBA domain are thought to play a crucial role in proteasome-mediated activities, few are characterized, except for hHR23A/B. Similar to other UbL-containing proteins, the UbL of A1Up is essential for the interaction of A1Up with the S5a subunit of the 19S proteasome. Importantly, the interaction with the 19S proteasome was disrupted in the presence of the polyglutamine repeat protein, ataxin-1. The UbL domain of A1Up is ubiquitinated by both Lys(48)-linked and Lys(63)-linked chains. Intact A1Up is stable, suggesting that ubiquitination of A1Up is important for degradation-independent targeting of A1Up to the 19S proteasome. The UBA domain of A1Up binds polyubiquitin chains and has a role in the stability of A1Up and in the subcellular localization of A1Up. When the UBA domain was deleted, the localization of A1Up was entirely cytoplasmic, and it co-localized with the proteasome. Interestingly, the interaction between A1Up and mutant ataxin-1-(82Q) increased the half- life of A1Up, whereas nonpathogenic wild- type ataxin-1-(30Q) or ataxin-1(82Q)-A776 did not.	Univ Minnesota, Dept Lab Med & Pathol, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Biochem, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Mol Biol, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Biophys, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Lab Med & Pathol, Inst Human Genet, Minneapolis, MN 55455 USA; Baylor Coll Med, Dept Mol & Human Genet, Howard Hughes Med Inst, Houston, TX 77030 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine; Howard Hughes Medical Institute	Orr, HT (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Inst Human Genet, MMC 206, Minneapolis, MN 55455 USA.	orrxx002@umn.edu		Zoghbi, Huda/0000-0002-0700-3349; Orr, Harry/0000-0001-6118-741X				Alberti S, 2002, J BIOL CHEM, V277, P45920, DOI 10.1074/jbc.M204196200; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bertolaet BL, 2001, J MOL BIOL, V313, P955, DOI 10.1006/jmbi.2001.5105; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Clarke DJ, 2001, MOL CELL BIOL, V21, P1997, DOI 10.1128/MCB.21.6.1997-2007.2001; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davidson JD, 2000, HUM MOL GENET, V9, P2305, DOI 10.1093/oxfordjournals.hmg.a018922; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; Donaldson KM, 2003, P NATL ACAD SCI USA, V100, P8892, DOI 10.1073/pnas.1530212100; Doss-Pepe EW, 2003, MOL CELL BIOL, V23, P6469, DOI 10.1128/MCB.23.18.6469-6483.2003; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Funakoshi M, 1999, EMBO J, V18, P5009, DOI 10.1093/emboj/18.18.5009; GALLAGHER SR, 1995, CURRENT PROTOCOLS PR; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Matsuda M, 2001, BIOCHEM BIOPH RES CO, V280, P535, DOI 10.1006/bbrc.2000.4149; Mueller TD, 2003, EMBO J, V22, P4634, DOI 10.1093/emboj/cdg467; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; Sakata E, 2003, EMBO REP, V4, P301, DOI 10.1038/sj.embor.embor764; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Tsai YC, 2003, J BIOL CHEM, V278, P22044, DOI 10.1074/jbc.M212235200; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Walters KJ, 2003, P NATL ACAD SCI USA, V100, P12694, DOI 10.1073/pnas.1634989100; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang GH, 2000, HUM MOL GENET, V9, P1795, DOI 10.1093/hmg/9.12.1795; Wang QH, 2003, BIOCHEMISTRY-US, V42, P13529, DOI 10.1021/bi035391j; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	54	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42290	42301		10.1074/jbc.M406284200	http://dx.doi.org/10.1074/jbc.M406284200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280365	hybrid			2022-12-27	WOS:000224075500121
J	Ichimura, Y; Imamura, Y; Emoto, K; Umeda, M; Noda, T; Ohsumi, Y				Ichimura, Y; Imamura, Y; Emoto, K; Umeda, M; Noda, T; Ohsumi, Y			In vivo and in vitro reconstitution of Atg8 conjugation essential for autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TRANSPORT MODULATOR; MAMMALIAN HOMOLOG; YEAST; GATE-16; GABARAP; PROTEINS; ENZYME; AUT7P; APG7P/CVT2P; DISSECTION	In an analogous manner to protein ubiquitination, The C terminus of Atg8p, a yeast protein essential for autophagy, conjugates to a head group of phosphatidylethanolamine via an amide bond. Though physiological role of this reaction is assigned to membrane organization during autophagy, its molecular details are still unknown. Here, we show that Escherichia coli cells coexpressed Atg8p, Atg7p (E1), and Atg3p (E2) allowed to form conjugate of Atg8p with endogenous PE. Further, we established an in vitro Atg8p-PE reconstitution system using purified Atg8p(G116), Atg7p, Atg3p, and PE-containing liposomes, demonstrating that the Atg7p and the Atg3p are minimal catalysts for Atg8p-PE conjugate reaction. Efficiency of this lipidation reaction depends on the state of the substrate, PE (phospholipid bilayer and its lipid composition). It is also suggested that the lipidation induces a conformational change in the N-terminal region of Atg8p. In vitro system developed here will provide a powerful system for further understanding the precise role of lipidation and interaction of two ubiquitin-like systems essential for autophagy.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Kyoto Univ, Inst Chem Sci, Div Mol Biol & Informat, Kyoto 6110011, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kyoto University	Ohsumi, Y (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.	yohsumi@nibb.ac.jp	Ohsumi, Yoshinori/C-6449-2009; EMOTO, KAZUO/G-4992-2014; Noda, Takeshi/B-7240-2008	Ohsumi, Yoshinori/0000-0003-2384-2166; Noda, Takeshi/0000-0003-3581-7961				Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; BARTLETT GR, 1958, ANN NY ACAD SCI, V75, P110, DOI 10.1111/j.1749-6632.1958.tb36855.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Coyle JE, 2002, NEURON, V33, P63, DOI 10.1016/S0896-6273(01)00558-X; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200; Hemelaar J, 2003, J BIOL CHEM, V278, P51841, DOI 10.1074/jbc.M308762200; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Komatsu M, 2001, J BIOL CHEM, V276, P9846, DOI 10.1074/jbc.M007737200; Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Legesse-Miller A, 2000, J BIOL CHEM, V275, P32966, DOI 10.1074/jbc.M000917200; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Saha SK, 1996, BIOSCI BIOTECH BIOCH, V60, P111; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Stangler T, 2002, J BIOL CHEM, V277, P13363, DOI 10.1074/jbc.C200050200; Sugawara K, 2004, GENES CELLS, V9, P611, DOI 10.1111/j.1356-9597.2004.00750.x; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Tanida I, 2003, BIOCHEM BIOPH RES CO, V300, P637, DOI 10.1016/S0006-291X(02)02907-8; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tuller G, 1999, YEAST, V15, P1555, DOI 10.1002/(SICI)1097-0061(199910)15:14<1555::AID-YEA479>3.0.CO;2-Z; Verkleij AJ, 2000, J MEMBRANE BIOL, V178, P1, DOI 10.1007/s002320010009; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264	37	164	173	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40584	40592		10.1074/jbc.M405860200	http://dx.doi.org/10.1074/jbc.M405860200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15277523	hybrid			2022-12-27	WOS:000223916800046
J	Lin, CF; Chen, CL; Chang, WT; Jan, MS; Hsu, LJ; Wu, RH; Tang, MJ; Chang, WC; Lin, YS				Lin, CF; Chen, CL; Chang, WT; Jan, MS; Hsu, LJ; Wu, RH; Tang, MJ; Chang, WC; Lin, YS			Sequential caspase-2 and caspase-8 activation upstream of mitochondria during ceramide- and etoposide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; STRESS-INDUCED APOPTOSIS; NEURONAL APOPTOSIS; CELL-DEATH; SIGNAL-TRANSDUCTION; FAS; PATHWAY; PROTEIN; CLEAVAGE; RECEPTOR	Recently, caspase-2 was shown to act upstream of mitochondria in stress-induced apoptosis. Activation of caspase-8, a key event in death receptor-mediated apoptosis, also has been demonstrated in death receptor-independent apoptosis. The regulation of these initiator caspases, which trigger the mitochondrial apoptotic pathway, is unclear. Here we report a potential regulatory role of caspase-2 on caspase-8 during ceramide-induced apoptosis. Our results demonstrate the sequential events of initiator caspase-2 and caspase-8 activation, Bid cleavage and translocation, and mitochondrial damage followed by downstream caspase-9 and -3 activation and cell apoptosis after ceramide induction in T cell lines. The expression of truncated Bid (tBid) and the reduction in mitochondrial transmembrane potential were blocked by caspase-2 or caspase-8, but not caspase-3, knockdown using an RNA interference technique. Ceramide-induced caspase-8 activation, mitochondrial damage, and apoptosis were blocked in caspase-2 short interfering RNA-expressing cells. Therefore, caspase-2 acts upstream of caspase-8 during ceramide-induced mitochondrial apoptosis. Similarly, sequential caspase-2 and caspase-8 activation upstream of mitochondria was also observed in etoposide-induced apoptosis. These data suggest sequential initiator caspase-2 and caspase-8 activation in the mitochondrial apoptotic pathway induced by ceramide or etoposide.	Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 701, Taiwan; Chung Shan Med Univ, Dept Microbiol & Immunol, Taichung 402, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Chung Shan Medical University	Lin, YS (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 701, Taiwan.	yslin1@mail.ncku.edu.tw	Hsu, Li-Jin/G-7822-2011	Tang, Ming-Jer/0000-0002-0883-4363				Adam D, 2002, TRENDS IMMUNOL, V23, P1, DOI 10.1016/S1471-4906(01)02091-9; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004; Cock JGRBD, 1998, APOPTOSIS, V3, P17, DOI 10.1023/A:1009603001888; Darios F, 2003, J NEUROCHEM, V84, P643, DOI 10.1046/j.1471-4159.2003.01590.x; Dirsch VM, 2004, ONCOGENE, V23, P1586, DOI 10.1038/sj.onc.1207281; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; LAI MZ, 1987, J IMMUNOL, V139, P3973; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Movsesyan VA, 2002, BIOCHEM BIOPH RES CO, V299, P201, DOI 10.1016/S0006-291X(02)02593-7; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Petit PX, 2001, BIOCHEM J, V353, P357, DOI 10.1042/0264-6021:3530357; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Schweizer A, 2003, J BIOL CHEM, V278, P42441, DOI 10.1074/jbc.M304895200; Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3; Swanton E, 1999, ONCOGENE, V18, P1781, DOI 10.1038/sj.onc.1202490; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Watts JD, 1999, TRENDS BIOCHEM SCI, V24, P228, DOI 10.1016/S0968-0004(99)01411-5; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wurzer WJ, 2003, EMBO J, V22, P2717, DOI 10.1093/emboj/cdg279; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	43	103	107	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40755	40761		10.1074/jbc.M404726200	http://dx.doi.org/10.1074/jbc.M404726200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262979	hybrid			2022-12-27	WOS:000223916800068
J	Ma, LM; Song, LH; Radoi, GE; Harrison, NL				Ma, LM; Song, LH; Radoi, GE; Harrison, NL			Transcriptional regulation of the mouse gene encoding the alpha-4 subunit of the GABA(A) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL GENE; AMINOBUTYRIC ACID(A) RECEPTORS; NEURAL-SPECIFIC EXPRESSION; TATA-LESS PROMOTER; GABA(A)-RECEPTOR SUBTYPES; RAT-BRAIN; FUNCTIONAL-ANALYSIS; SP-FAMILY; PHARMACOLOGY; BINDING	The gamma-aminobutyric acid type A receptors (GABA(A)-Rs) mediate fast inhibitory synaptic transmission in the brain. The alpha4 subunit of the GABA(A)-R confers distinct pharmacological properties on the receptor and its expression pattern exhibits plasticity in response to physiological and pharmacological stimuli, including withdrawal from progesterone and alcohol. We have analyzed the promoter region of the mouse GABRA4 gene that encodes the alpha4 subunit and found that the promoter has multiple transcriptional initiation sites and lacks a TATA box. The minimal promoter for GABRA4 spans the region between -444 to -19 bp relative to the coding ATG and shows high activity in cultured mouse cortical neurons. Both Sp3 and Sp4 transcription factors can interact with the two Sp1 binding sites within the minimal promoter and are critical for maximal activity of the promoter in neurons.	Cornell Univ, Weill Med Coll, Dept Anesthesiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	Cornell University; Cornell University	Harrison, NL (corresponding author), 525 E 68th St,A-1040, New York, NY 10021 USA.	neh2001@med.cornell.edu			NIAAA NIH HHS [AA13646] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013646] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Akk G, 2004, J PHYSIOL-LONDON, V556, P387, DOI 10.1113/jphysiol.2003.058230; Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; Barnard EA, 1998, PHARMACOL REV, V50, P291; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brown N, 2002, BRIT J PHARMACOL, V136, P965, DOI 10.1038/sj.bjp.0704795; Chew LJ, 2001, J BIOL CHEM, V276, P42162, DOI 10.1074/jbc.M101895200; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Clark M, 1998, NEUROSCI LETT, V250, P17, DOI 10.1016/S0304-3940(98)00422-4; Devaud LL, 1997, J NEUROCHEM, V69, P126; Devaud LL, 1998, BRAIN RES, V796, P222, DOI 10.1016/S0006-8993(98)00357-6; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; Fritschy JM, 2003, PHARMACOL THERAPEUT, V98, P299, DOI 10.1016/S0163-7258(03)00037-8; Fuchs K, 2002, J NEUROCHEM, V82, P1512, DOI 10.1046/j.1471-4159.2002.01098.x; Gulinello M, 2001, BRAIN RES, V910, P55, DOI 10.1016/S0006-8993(01)02565-3; Gulinello M, 2002, NEUROPHARMACOLOGY, V43, P701, DOI 10.1016/S0028-3908(02)00171-5; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Harris RA, 2004, P NATL ACAD SCI USA, V101, P2, DOI 10.1073/pnas.0307281101; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; Jones A, 1996, J NEUROCHEM, V67, P907; Kang MH, 1996, BRAIN RES, V709, P221, DOI 10.1016/0006-8993(95)01274-5; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Krainc D, 1998, J BIOL CHEM, V273, P26218, DOI 10.1074/jbc.273.40.26218; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; Kunig G, 2000, ANN NEUROL, V47, P644; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Liu AG, 2003, J BIOL CHEM, V278, P26423, DOI 10.1074/jbc.M211165200; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Mahmoudi M, 1997, J NEUROCHEM, V68, P2485; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; McLean PJ, 2000, J NEUROCHEM, V74, P1858, DOI 10.1046/j.1471-4159.2000.0741858.x; MOHLER H, 1992, ADV BIOCHEM PSYCHOPH, V47, P41; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; Morrow A L, 1994, Alcohol Alcohol Suppl, V2, P89; MOTEJLEK K, 1994, J BIOL CHEM, V269, P15265; Myers SJ, 1998, J NEUROSCI, V18, P6723; Myers SJ, 2004, J NEUROSCI, V24, P3489, DOI 10.1523/JNEUROSCI.4127-03.2004; Nishikawa K, 2002, NEUROPHARMACOLOGY, V42, P337, DOI 10.1016/S0028-3908(01)00189-7; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Parks CL, 1996, J BIOL CHEM, V271, P4417; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Pirker S, 2000, NEUROSCIENCE, V101, P815, DOI 10.1016/S0306-4522(00)00442-5; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Redecker C, 2002, J CEREBR BLOOD F MET, V22, P1463, DOI 10.1097/01.WCB.0000034149.72481.BD; Russek SJ, 2000, P NATL ACAD SCI USA, V97, P8600, DOI 10.1073/pnas.97.15.8600; Sanna E, 2003, J NEUROSCI, V23, P11711; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SIEGHART W, 1992, TRENDS PHARMACOL SCI, V13, P446, DOI 10.1016/0165-6147(92)90142-S; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smith SS, 1998, NATURE, V392, P926, DOI 10.1038/31948; Sundstrom-Poromaa I, 2002, NAT NEUROSCI, V5, P721, DOI 10.1038/nn888; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Wafford KA, 1996, MOL PHARMACOL, V50, P670; Wallner M, 2003, P NATL ACAD SCI USA, V100, P15218, DOI 10.1073/pnas.2435171100; Whiting PJ, 1999, ANN NY ACAD SCI, V868, P645, DOI 10.1111/j.1749-6632.1999.tb11341.x; WISDEN W, 1992, J NEUROSCI, V12, P1040	60	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40451	40461		10.1074/jbc.M406827200	http://dx.doi.org/10.1074/jbc.M406827200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15265862	hybrid			2022-12-27	WOS:000223916800031
J	Norris-Cervetto, E; Callaghan, R; Platt, FM; Dwek, RA; Butters, TD				Norris-Cervetto, E; Callaghan, R; Platt, FM; Dwek, RA; Butters, TD			Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAUNORUBICIN-INDUCED APOPTOSIS; CERAMIDE GLYCANASE DIGESTION; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; GLYCOSPHINGOLIPID BIOSYNTHESIS; ANTICANCER DRUGS; N-BUTYLDEOXYGALACTONOJIRIMYCIN; GLYCOLIPID BIOSYNTHESIS; ADRIAMYCIN RESISTANCE; NEUROBLASTOMA-CELLS	The multidrug-resistant cancer cell lines NCI/AdR(RES) and MES-SA/DX-5 have higher glycolipid levels and higher P-glycoprotein expression than the chemosensitive cell lines MCF7-wt and MES-SA. Inhibiting glycolipid biosynthesis by blocking glucosylceramide synthase has been proposed to reverse drug resistance in MDR cells by causing an increased accumulation of proapoptotic ceramide during treatment of cells with cytotoxic drugs. We treated both multidrug-resistant cell lines with the glucosylceramide synthase inhibitors PDMP (D-threo-1-phenyl-2-decanoylamino-3-morpholino-1- propanol), C(9)DGJ (N-nonyl-deoxygalactonojirimycin) or C(4)DGJ (N-butyl-deoxygalactonojirimycin). PDMP achieved a significant reversal of drug resistance in agreement with previous reports. However, the N-alkylated iminosugars C(9)DGJ and C(4)DGJ, which are more selective glucosylceramide synthase inhibitors than PDMP, failed to cause any reversal of drug resistance despite depleting glycolipids to the same extent as PDMP. Our results suggest that ( a) inhibition of glucosylceramide synthase does not reverse multidrug resistance and (b) the chemosensitization achieved by PDMP cannot be caused by inhibition of glucosylceramide synthase alone.	Univ Oxford, Oxford Glycobiol Inst, Oxford OX1 3QU, England; John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Butters, TD (corresponding author), Univ Oxford, Oxford Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.	terry.butters@bioch.ox.ac.uk	Callaghan, Richard/ABG-1638-2020; Callaghan, Richard/B-7032-2012; Platt, Frances/G-1004-2010	Callaghan, Richard/0000-0001-6136-3532; Callaghan, Richard/0000-0001-6136-3532; Platt, Frances/0000-0001-7614-0403				Andersson U, 2000, BIOCHEM PHARMACOL, V59, P821, DOI 10.1016/S0006-2952(99)00384-6; BATIST G, 1986, J BIOL CHEM, V261, P5544; Bieberich E, 1999, J NEUROCHEM, V72, P1040, DOI 10.1046/j.1471-4159.1999.0721040.x; Bleicher RJ, 2002, BBA-MOL CELL BIOL L, V1585, P172, DOI 10.1016/S1388-1981(02)00338-4; Bodennec J, 2000, J LIPID RES, V41, P1524; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Butters TD, 2000, TETRAHEDRON-ASYMMETR, V11, P113, DOI 10.1016/S0957-4166(99)00468-1; BUTTERS TD, 1980, IN VITRO, V17, P831; Claudio JA, 1996, BREAST CANCER RES TR, V41, P111, DOI 10.1007/BF01807156; Come MG, 1999, INT J CANCER, V81, P580, DOI 10.1002/(SICI)1097-0215(19990517)81:4<580::AID-IJC13>3.0.CO;2-T; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GRAZIDE S, 2004, J BIOL CHEM; HARKER WG, 1985, CANCER RES, V45, P4091; HARKER WG, 1983, CANCER RES, V43, P4943; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Krishna R, 2000, EUR J PHARM SCI, V11, P265, DOI 10.1016/S0928-0987(00)00114-7; Lala P, 2000, J BIOL CHEM, V275, P6246, DOI 10.1074/jbc.275.9.6246; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Liour SS, 2002, NEUROCHEM RES, V27, P1507, DOI 10.1023/A:1021652506370; Liu YY, 2000, J BIOL CHEM, V275, P7138, DOI 10.1074/jbc.275.10.7138; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Liu YY, 2001, FASEB J, V15, P719, DOI 10.1096/fj.00-0223com; LIU YY, 2004, J LIPID RES; Lucci A, 1998, ANTICANCER RES, V18, P475; Martin C, 1999, BRIT J PHARMACOL, V128, P403, DOI 10.1038/sj.bjp.0702807; Mellor HR, 2003, BIOCHEM J, V374, P307, DOI 10.1042/BJ20030348; Morjani H, 2001, INT J CANCER, V94, P157, DOI 10.1002/ijc.1449; Neville DCA, 2004, ANAL BIOCHEM, V331, P275, DOI 10.1016/j.ab.2004.03.051; Olshefski RS, 2001, INT J CANCER, V93, P131, DOI 10.1002/ijc.1301; Pirnia F, 2000, J NATL CANCER I, V92, P1535, DOI 10.1093/jnci/92.18.1535; PLATT FM, 1994, J BIOL CHEM, V269, P27108; PLATT FM, 1992, EUR J BIOCHEM, V208, P187, DOI 10.1111/j.1432-1033.1992.tb17173.x; PLUMB JA, 1990, BIOCHEM PHARMACOL, V39, P787, DOI 10.1016/0006-2952(90)90160-M; Radin NS, 2003, BIOORGAN MED CHEM, V11, P2123, DOI 10.1016/S0968-0896(02)00609-0; Radin NS, 1999, BIOCHEM PHARMACOL, V57, P589; Radin NS, 2001, EUR J BIOCHEM, V268, P193, DOI 10.1046/j.1432-1033.2001.01845.x; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; Scudiero DA, 1998, J NATL CANCER I, V90, P862, DOI 10.1093/jnci/90.11.862; Shabbits JA, 2002, MOL CANCER THER, V1, P205; Sietsma H, 2000, CLIN CANCER RES, V6, P942; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; Tepper AD, 2000, J BIOL CHEM, V275, P34810, DOI 10.1074/jbc.M005142200; Veldman RJ, 2003, FASEB J, V17, P1144, DOI 10.1096/fj.02-1053fje; Walker J, 2004, EUR J CANCER, V40, P594, DOI 10.1016/j.ejca.2003.09.036; Wing DR, 2001, ANAL BIOCHEM, V298, P207, DOI 10.1006/abio.2001.5393	49	46	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40412	40418		10.1074/jbc.M404466200	http://dx.doi.org/10.1074/jbc.M404466200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15263008	hybrid			2022-12-27	WOS:000223916800026
J	Spafford, JD; van Minnen, J; Larsen, P; Smit, AB; Syed, NI; Zamponi, GW				Spafford, JD; van Minnen, J; Larsen, P; Smit, AB; Syed, NI; Zamponi, GW			Uncoupling of calcium channel alpha(1) and beta subunits in developing neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; SYNAPTIC-TRANSMISSION; FUNCTIONAL-INTEGRATION; PROTEIN-SYNTHESIS; GROWTH CONES; NERVE GROWTH; EXPRESSION; MOUSE; GENE; ORGANIZATION	Calcium channel beta subunits are key modulators of calcium channel function and membrane targeting of the pore-forming alpha(1) subunit. Here we show that an invertebrate (Lymnaea stagnalis) homolog of P/Q- and N-type calcium channels (LCa(v)2), although colocalized with beta subunits in synapses of mature neurons, is physically uncoupled from the beta subunits in the leading edge of growth cones of outgrowing neurons. Moreover, LCa(v)2 channels that mediate transmitter release in mature synapses also participate in neuronal outgrowth in growth cones. The differential association of beta subunits with synaptic calcium channels and those expressed in emergent neuronal growth suggests that beta subunits may play a role in the transformation of Ca(v)2 calcium channel function in immature neurons and mature synapses.	Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada; Vrije Univ Amsterdam, Neurosci Res Inst, Dept Mol & Cellular Neurobiol, NL-1081 HV Amsterdam, Netherlands	University of Calgary; University of Calgary; Vrije Universiteit Amsterdam	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	Zamponi@ucalgary.ca	Smit, August B/E-8410-2011	Zamponi, Gerald W./0000-0002-0644-9066				Altier C, 2002, J BIOL CHEM, V277, P33598, DOI 10.1074/jbc.M202476200; Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Berrow NS, 1997, EUR J NEUROSCI, V9, P739, DOI 10.1111/j.1460-9568.1997.tb01422.x; BERROW NS, 1995, J PHYSIOL-LONDON, V482, P481, DOI 10.1113/jphysiol.1995.sp020534; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Biederer T, 2001, J BIOL CHEM, V276, P47869, DOI 10.1074/jbc.M105287200; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; BRIDGMAN PC, 1989, J CELL BIOL, V108, P95, DOI 10.1083/jcb.108.1.95; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; Burgess DL, 1999, MOL CELL NEUROSCI, V13, P293, DOI 10.1006/mcne.1999.0748; CAMPBELL V, 1995, J PHYSIOL-LONDON, V485, P365, DOI 10.1113/jphysiol.1995.sp020735; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DIATCHENKO L, 1996, GENE CLONING ANAL, P213; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Escayg A, 1998, GENOMICS, V50, P14, DOI 10.1006/geno.1998.5311; Feng ZP, 1997, J NEUROSCI, V17, P7839; Giuditta A, 2002, TRENDS NEUROSCI, V25, P400, DOI 10.1016/S0166-2236(02)02188-4; Hanlon MR, 1999, FEBS LETT, V445, P366, DOI 10.1016/S0014-5793(99)00156-8; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; Kawasaki F, 2000, J NEUROSCI, V20, P4885; LETOURNEAU PC, 1983, J CELL BIOL, V97, P963, DOI 10.1083/jcb.97.4.963; Ludwig A, 1997, J NEUROSCI, V17, P1339; LUEBKE JI, 1993, NEURON, V11, P895, DOI 10.1016/0896-6273(93)90119-C; Maximov A, 2002, J NEUROSCI, V22, P6939; Miller RJ, 2001, TRENDS NEUROSCI, V24, P445, DOI 10.1016/S0166-2236(00)01859-2; Namkung Y, 1998, P NATL ACAD SCI USA, V95, P12010, DOI 10.1073/pnas.95.20.12010; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; Piddini E, 2001, EMBO J, V20, P4076, DOI 10.1093/emboj/20.15.4076; Richter JD, 2002, CURR OPIN NEUROBIOL, V12, P300, DOI 10.1016/S0959-4388(02)00318-5; Rieckhof GE, 2003, J BIOL CHEM, V278, P41099, DOI 10.1074/jbc.M306417200; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Spafford JD, 2003, CURR OPIN NEUROBIOL, V13, P308, DOI 10.1016/S0959-4388(03)00061-8; Spafford JD, 2003, J BIOL CHEM, V278, P21178, DOI 10.1074/jbc.M302212200; Spafford JD, 2003, J BIOL CHEM, V278, P4258, DOI 10.1074/jbc.M211076200; Spencer GE, 2000, J NEUROBIOL, V44, P72, DOI 10.1002/1097-4695(200007)44:1<72::AID-NEU7>3.0.CO;2-#; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; Stotz SC, 2004, J BIOL CHEM, V279, P3793, DOI 10.1074/jbc.M308991200; SYED NI, 1992, NEURON, V8, P767, DOI 10.1016/0896-6273(92)90097-W; Takahashi SX, 2003, BIOPHYS J, V84, P3007, DOI 10.1016/S0006-3495(03)70027-7; Tang FJ, 2003, J NEUROSCI, V23, P927; Timmermann DB, 2002, J NEUROSCI RES, V67, P48, DOI 10.1002/jnr.10074; TSUI HCT, 1984, J NEUROSCI, V4, P3002; van Kesteren RE, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0004.2001; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; WITCHER DR, 1995, J BIOL CHEM, V270, P18088, DOI 10.1074/jbc.270.30.18088; Yasuda T, 2004, EUR J NEUROSCI, V20, P1, DOI 10.1111/j.1460-9568.2004.03434.x; Zwingman TA, 2001, J NEUROSCI, V21, P1169	55	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41157	41167		10.1074/jbc.M403781200	http://dx.doi.org/10.1074/jbc.M403781200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15265869	hybrid, Green Published			2022-12-27	WOS:000223916800115
J	Umejiego, NN; Li, C; Riera, T; Hedstrom, L; Striepen, B				Umejiego, NN; Li, C; Riera, T; Hedstrom, L; Striepen, B			Cryptosporidium parvum IMP dehydrogenase - Identification of functional, structural, and dynamic properties that can be exploited for drug design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSINE 5'-MONOPHOSPHATE DEHYDROGENASE; TRANSITION-STATE ANALOG; MYCOPHENOLIC-ACID; MONOPHOSPHATE DEHYDROGENASE; TRITRICHOMONAS-FETUS; CRYSTAL-STRUCTURE; INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE; BORRELIA-BURGDORFERI; KINETIC MECHANISM; HYDRIDE TRANSFER	The protozoan parasite Cryptosporidium parvum causes severe enteritis with substantial morbidity and mortality among AIDS patients and young children. No fully effective treatment is available. C. parvum relies on inosine 5'-monophosphate dehydrogenase (IMPDH) to produce guanine nucleotides and is highly susceptible to IMPDH inhibition. Furthermore, C. parvum obtained its IMPDH gene by lateral transfer from an epsilon-proteobacterium, suggesting that the parasite enzyme might have very different characteristics than the human counterpart. Here we describe the expression of recombinant C. parvum IMPDH in an Escherichia coli strain lacking the bacterial homolog. Expression of the parasite gene restores growth of this mutant on minimal medium, confirming that the protein has IMPDH activity. The recombinant protein was purified to homogeneity and used to probe the enzyme's mechanism, structure, and inhibition profile in a series of kinetic experiments. The mechanism of the C. parvum enzyme involves the random addition of substrates and ordered release of products with rate-limiting hydrolysis of a covalent enzyme intermediate. The pronounced resistance of C. parvum IMPDH to mycophenolic acid inhibition is in strong agreement with its bacterial origin. The values of K-m for NAD and K-i for mycophenolic acid as well as the synergistic interaction between tiazofurin and ADP differ significantly from those of the human enzymes. These data suggest that the structure and dynamic properties of the NAD binding site of C. parvum IMPDH can be exploited to develop parasite-specific inhibitors.	Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA; Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA; Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Brandeis University	Striepen, B (corresponding author), Univ Georgia, Dept Cellular Biol, 724 Biol Sci Bldg, Athens, GA 30602 USA.	striepen@cb.uga.edu		Riera, Thomas/0000-0001-7427-2728; Striepen, Boris/0000-0002-7426-432X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048475] Funding Source: NIH RePORTER; NIAID NIH HHS [AI48475, AI55268] Funding Source: Medline; NIGMS NIH HHS [GM54403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON AC, 1993, IMMUNOL REV, V136, P5, DOI 10.1111/j.1600-065X.1993.tb00652.x; Arkin MR, 2003, P NATL ACAD SCI USA, V100, P1603, DOI 10.1073/pnas.252756299; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; Colby TD, 1999, P NATL ACAD SCI USA, V96, P3531, DOI 10.1073/pnas.96.7.3531; Digits JA, 1999, BIOCHEMISTRY-US, V38, P15388, DOI 10.1021/bi991558q; Digits JA, 2000, BIOCHEMISTRY-US, V39, P1771, DOI 10.1021/bi992288e; Digits JA, 1999, BIOCHEMISTRY-US, V38, P2295, DOI 10.1021/bi982305k; DUPONT HL, 1995, NEW ENGL J MED, V332, P855, DOI 10.1056/NEJM199503303321304; Farazi T, 1997, J BIOL CHEM, V272, P961, DOI 10.1074/jbc.272.2.961; Franchetti P, 1999, CURR MED CHEM, V6, P599; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; Gan L, 2003, BIOCHEMISTRY-US, V42, P857, DOI 10.1021/bi0271401; Gan L, 2002, BIOCHEMISTRY-US, V41, P13309, DOI 10.1021/bi0203785; HAGER PW, 1995, BIOCHEM PHARMACOL, V49, P1323, DOI 10.1016/0006-2952(95)00026-V; Hedstrom L, 1999, CURR MED CHEM, V6, P545; HEDSTROM L, 1990, BIOCHEMISTRY-US, V29, P849, DOI 10.1021/bi00456a001; HEYDE E, 1976, BIOCHIM BIOPHYS ACTA, V429, P645, DOI 10.1016/0005-2744(76)90314-4; HOLMES EW, 1974, BIOCHIM BIOPHYS ACTA, V364, P209, DOI 10.1016/0005-2744(74)90006-0; Huang JL, 2004, INT J PARASITOL, V34, P265, DOI 10.1016/j.ijpara.2003.11.025; Hunter PR, 2002, CLIN MICROBIOL REV, V15, P145, DOI 10.1128/CMR.15.1.145-154.2002; IKEGAMI T, 1987, LIFE SCI, V40, P2277, DOI 10.1016/0024-3205(87)90064-6; Ishikawa H, 1999, CURR MED CHEM, V6, P575; Kerr KM, 2000, BIOCHEMISTRY-US, V39, P9804, DOI 10.1021/bi0005409; Kerr KM, 1997, BIOCHEMISTRY-US, V36, P13365, DOI 10.1021/bi9714161; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LEE HJ, 1985, CANCER RES, V45, P5512; MACKENZIE WR, 1995, CLIN INFECT DIS, V21, P57, DOI 10.1093/clinids/21.1.57; McMillan FM, 2000, BIOCHEMISTRY-US, V39, P4533, DOI 10.1021/bi992645l; Mead JR, 2002, DRUG RESIST UPDATE, V5, P47, DOI 10.1016/S1368-7646(02)00011-0; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; Schlippe YVG, 2004, BIOCHEMISTRY-US, V43, P4511, DOI 10.1021/bi035823q; Sintchak MD, 2000, IMMUNOPHARMACOLOGY, V47, P163, DOI 10.1016/S0162-3109(00)00193-4; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; Striepen B, 2004, P NATL ACAD SCI USA, V101, P3154, DOI 10.1073/pnas.0304686101; Striepen B, 2002, P NATL ACAD SCI USA, V99, P6304, DOI 10.1073/pnas.092525699; STRIEPEN B, 2004, IN PRESS TRENDS PARA; TIEDEMAN AA, 1985, NUCLEIC ACIDS RES, V13, P1303, DOI 10.1093/nar/13.4.1303; VERHAM R, 1987, MOL BIOCHEM PARASIT, V24, P1, DOI 10.1016/0166-6851(87)90110-1; Wang W, 1996, BIOCHEMISTRY-US, V35, P95, DOI 10.1021/bi951499q; Wang W, 1997, BIOCHEMISTRY-US, V36, P8479, DOI 10.1021/bi970226n; Whitby FG, 1997, BIOCHEMISTRY-US, V36, P10666, DOI 10.1021/bi9708850; Woods KM, 1998, FEMS MICROBIOL LETT, V168, P59, DOI 10.1111/j.1574-6968.1998.tb13255.x; Xiang BS, 1997, ARCH BIOCHEM BIOPHYS, V348, P378, DOI 10.1006/abbi.1997.0439; Zhang RG, 1999, BIOCHEMISTRY-US, V38, P4691, DOI 10.1021/bi982858v; Zhou X, 1997, J BIOL CHEM, V272, P21977, DOI 10.1074/jbc.272.35.21977	45	77	85	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40320	40327		10.1074/jbc.M407121200	http://dx.doi.org/10.1074/jbc.M407121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15269207	hybrid			2022-12-27	WOS:000223916800013
J	Wang, J; Wiltshire, T; Wang, YT; Mikell, C; Burks, J; Cunningham, C; Van Laar, ES; Waters, SJ; Reed, E; Wang, WX				Wang, J; Wiltshire, T; Wang, YT; Mikell, C; Burks, J; Cunningham, C; Van Laar, ES; Waters, SJ; Reed, E; Wang, WX			ATM-dependent CHK2 activation induced by anticancer agent, irofulven	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							S-PHASE CHECKPOINT; DNA-DAMAGE CHECKPOINT; ENHANCED ANTITUMOR-ACTIVITY; LUNG-CARCINOMA XENOGRAFT; MGI 114 6-HYDROXYMETHYLACYLFULVENE; EARLY EMBRYONIC LETHALITY; CELL-CYCLE ARREST; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; PROTEIN-KINASE	Irofulven (6- hydroxymethylacylfulvene, HMAF, MGI 114) is one of a new class of anticancer agents that are semisynthetic derivatives of the mushroom toxin illudin S. Preclinical studies and clinical trials have demonstrated that irofulven is effective against several tumor types. Mechanisms of action studies indicate that irofulven induces DNA damage, MAPK activation, and apoptosis. In this study we found that in ovarian cancer cells, CHK2 kinase is activated by irofulven while CHK1 kinase is not activated even when treated at higher concentrations of the drug. By using GM00847 human fibroblast expressing tetracycline-controlled, FLAG-tagged kinase-dead ATR (ATR.kd), it was demonstrated that ATR kinase does not play a major role in irofulven-induced CHK2 activation. Results from human fibroblasts proficient or deficient in ATM function (GM00637 and GM05849) indicated that CHK2 activation by irofulven is mediated by the upstream ATM kinase. Phosphorylation of ATM on Ser(1981), which is critical for kinase activation, was observed in ovarian cancer cell lines treated with irofulven. RNA interference results confirmed that CHK2 activation was inhibited after introducing siRNA for ATM. Finally, experiments done with human colon cancer cell line HCT116 and its isogenic CHK2 knockout derivative; and experiments done by expressing kinase-dead CHK2 in an ovarian cancer cell line demonstrated that CHK2 activation contributes to irofulven-induced S phase arrest. In addition, it was shown that NBS1, SMC1, and p53 were phosphorylated in an ATM-dependent manner, and p53 phosphorylation on serine 20 is dependent on CHK2 after irofulven treatment. In summary, we found that the anticancer agent, irofulven, activates the ATM-CHK2 DNA damage-signaling pathway, and CHK2 activation contributes to S phase cell cycle arrest induced by irofulven.	W Virginia Univ, May Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; MGI Pharma Inc, Bloomington, MN 55437 USA	West Virginia University; West Virginia University	Wang, WX (corresponding author), W Virginia Univ, May Babb Randolph Canc Ctr, Morgantown, WV 26506 USA.	wwang@hsc.wvu.edu						Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Ahn JY, 2000, CANCER RES, V60, P5934; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Boddy MN, 2003, MOL CELL BIOL, V23, P5939, DOI 10.1128/MCB.23.16.5939-5946.2003; Britten CD, 1999, CANCER RES, V59, P1049; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown EJ, 2000, GENE DEV, V14, P397; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Busby EC, 2000, CANCER RES, V60, P2108; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen ZH, 2003, MOL CANCER THER, V2, P543; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Eckhardt SG, 2000, J CLIN ONCOL, V18, P4086, DOI 10.1200/JCO.2000.18.24.4086; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Friedman HS, 2001, CANCER CHEMOTH PHARM, V48, P413, DOI 10.1007/s002800100358; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Giles F, 2001, INVEST NEW DRUG, V19, P13, DOI 10.1023/A:1006432012394; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hammond LA, 2000, EUR J CANCER, V36, P2430, DOI 10.1016/S0959-8049(00)00302-6; Hidalgo M, 1999, ANTI-CANCER DRUG, V10, P837, DOI 10.1097/00001813-199910000-00007; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jaspers NGJ, 2002, DNA REPAIR, V1, P1027, DOI 10.1016/S1568-7864(02)00166-0; Kelner MJ, 2000, ANTI-CANCER DRUG, V11, P217, DOI 10.1097/00001813-200003000-00010; Kelner MJ, 2002, INVEST NEW DRUG, V20, P271, DOI 10.1023/A:1016201807796; Kelner MJ, 2002, CANCER CHEMOTH PHARM, V49, P412, DOI 10.1007/s00280-001-0410-6; Kelner MJ, 1998, EUR J CANCER, V34, P908, DOI 10.1016/S0959-8049(98)00033-1; KELNER MJ, 1990, JNCI-J NATL CANCER I, V82, P1562, DOI 10.1093/jnci/82.19.1562; KELNER MJ, 1987, CANCER RES, V47, P3186; Kelner MJ, 1996, INVEST NEW DRUG, V14, P161; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee SA, 1998, J BIOL CHEM, V273, P32889, DOI 10.1074/jbc.273.49.32889; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu QH, 2000, GENE DEV, V14, P1448; MacDonald JR, 1997, CANCER RES, V57, P279; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; MURGO A, 1999, ONCOLOGY HUNTINGT, V13, P237; Pearce AK, 2001, TRENDS CELL BIOL, V11, P426, DOI 10.1016/S0962-8924(01)02119-5; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Poindessous V, 2003, CLIN CANCER RES, V9, P2817; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sato Y, 2001, EUR J CANCER, V37, P1419, DOI 10.1016/S0959-8049(01)00135-6; Seiden M V, 2001, Oncologist, V6, P327, DOI 10.1634/theoncologist.6-4-327; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Sherr CJ, 2000, CANCER RES, V60, P3689; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang WX, 2001, ANTICANCER RES, V21, P1789; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Woynarowski JM, 1997, BIOCHEM PHARMACOL, V54, P1181, DOI 10.1016/S0006-2952(97)00321-3; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu JH, 2001, FEBS LETT, V508, P394, DOI 10.1016/S0014-5793(01)03103-9; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; YAGINUMA Y, 1992, CANCER RES, V52, P4196; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou XY, 2002, CANCER RES, V62, P1598; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	106	37	37	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39584	39592		10.1074/jbc.M400015200	http://dx.doi.org/10.1074/jbc.M400015200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15269203	hybrid, Green Published			2022-12-27	WOS:000223791500048
J	Yang, XH; Kovalenko, D; Nadeau, RJ; Harkins, LK; Mitchell, J; Zubanova, O; Chen, PY; Friesel, R				Yang, XH; Kovalenko, D; Nadeau, RJ; Harkins, LK; Mitchell, J; Zubanova, O; Chen, PY; Friesel, R			Sef interacts with TAK1 and mediates JNK activation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPROUTY; GENE; ERK	Sef was recently identified as a negative regulator of fibroblast growth factor (FGF) signaling in a genetic screen of zebrafish and subsequently in mouse and humans. By inhibiting FGFR1 tyrosine phosphorylation and/or Ras downstream events, Sef inhibits FGF-mediated ERK activation and cell proliferation as well as PC12 cell differentiation. Here we show that Sef and a deletion mutant of Sef lacking the extracellular domain (SefIC) physically interact with TAK1 ( transforming growth factor-beta-associated kinase) and activate JNK through a TAK1-MKK4-JNK pathway. Sef and SefIC overexpression also resulted in apoptotic cell death, while dominant negative forms of MKK4 and TAK1 blocked Sef-mediated JNK activation and attendant 293T cell apoptosis. These investigations reveal a novel activating function of Sef that is distinct from its inhibitory effect on FGF receptor signaling and ERK activation.	Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA; Univ Maine, Cooperat Grad Program, Orono, ME 04469 USA; Maine Med Ctr Res, Ctr Regenerat Med, Scarborough, ME 04074 USA; Maine Med Ctr Res, Hematol Res Lab, Scarborough, ME 04074 USA	Maine Medical Center; University of Maine System; University of Maine Orono	Friesel, R (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.	friesr@mmc.org	Chen, Pei-Yu/H-1669-2013		NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015555] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013248] Funding Source: NIH RePORTER; NCRR NIH HHS [RR15555] Funding Source: Medline; NHLBI NIH HHS [HL65301] Funding Source: Medline; NIDCR NIH HHS [DE13248] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Cabrita MA, 2003, THROMB HAEMOSTASIS, V90, P586, DOI 10.1160/TH03-04-0217; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Friesel R, 1999, THROMB HAEMOSTASIS, V82, P748; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Konopleva M, 1999, ADV EXP MED BIOL, V457, P217; Kovalenko D, 2003, J BIOL CHEM, V278, P14087, DOI 10.1074/jbc.C200606200; Lin W, 2002, MECH DEVELOP, V113, P163, DOI 10.1016/S0925-4773(02)00018-7; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; Preger E, 2004, P NATL ACAD SCI USA, V101, P1229, DOI 10.1073/pnas.0307952100; Rebay I, 2002, DEV BIOL, V251, P1, DOI 10.1006/dbio.2002.0806; Robertson SC, 2000, TRENDS GENET, V16, P368, DOI 10.1016/S0168-9525(00)02077-1; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; TSANG M, 2004, SCI STKE; Xiong SQ, 2003, J BIOL CHEM, V278, P50273, DOI 10.1074/jbc.M306936200; Yang RB, 2003, J BIOL CHEM, V278, P33232, DOI 10.1074/jbc.M305022200	20	32	35	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38099	38102		10.1074/jbc.C400318200	http://dx.doi.org/10.1074/jbc.C400318200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15277532	hybrid			2022-12-27	WOS:000223684100006
J	Hall, BS; Pal, A; Goulding, D; Field, MC				Hall, BS; Pal, A; Goulding, D; Field, MC			Rab4 is an essential regulator of lysosomal trafficking in trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; VARIANT SURFACE GLYCOPROTEIN; PROTEIN; BRUCEI; ENDOSOMES; KINETOPLASTIDA; TRANSFERRIN; TRANSPORT; APPARATUS; EFFECTOR	Rapid endocytosis and recycling of surface proteins are important processes common to most nucleated eukaryotic cells. The best characterized membrane recycling routes are mediated by the small GTPases Rab4 and Rab11, but the precise roles that these pathways play have not been fully elucidated. The protozoan Trypanosoma brucei has a highly developed endocytic system that is similar to that found in metazoans, albeit with an accelerated rate of membrane turnover. We have used this organism to investigate the function of the trypanosome orthologue of Rab4 (TbRAB4) by a combination of RNA interference, microscopy, and quantitative trafficking assays. RNA interference-mediated suppression of TbRAB4 expression inhibited the growth of trypanosomes without affecting receptor-mediated endocytosis or ligand recycling. Ultrastructural analysis indicated a major defect in membrane transport events. The accumulation of fluorescent dextran, a fluid-phase marker, was blocked in cells lacking TbRAB4 protein. Since most fluid-phase markers are transported to the lysosome in T. brucei, the effects of TbRAB4 RNA interference on lysosomal function were investigated. By immunofluorescence, the major lysosomal protein p67 became progressively dispersed in cells lacking the TbRAB4 protein. Pulse-chase analysis demonstrated that initial proteolytic cleavage and glycan processing of p67 were unaffected but that cells failed to accumulate the later p67 proteolyzed products associated with the lysosome. To confirm the role of TbRAB4 in lysosomal trafficking, a constitutively active mutant, TbRAB4(QL), was expressed. TbRAB4(QL) was closely associated with an enlarged multivesicular body that contained p67. In addition, cells expressing TbRAB4(QL) showed increased fluid-phase uptake when compared with the parental line. Taken together, these data suggest that TbRAB4 is involved in regulation of fluid-phase traffic to the lysosome in T. brucei but not in receptor-mediated endocytosis or recycling. These data have implications for the role of Rab4 in other cell systems.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AY, England	Imperial College London	Field, MC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AY, England.	mfield@mac.com	Field, Mark/AAD-6455-2021; Hall, Belinda/AGU-6214-2022	Hall, Belinda/0000-0002-3753-1978; Field, Mark/0000-0002-4866-2885				ACKERS JP, 2004, IN PRESS MOL BIOCH P; Alexander DL, 2002, J CELL SCI, V115, P3253; Allen CL, 2003, EMBO J, V22, P4991, DOI 10.1093/emboj/cdg481; BANGS JD, 1993, J CELL SCI, V105, P1101; Cormont M, 2003, TRAFFIC, V4, P97, DOI 10.1034/j.1600-0854.2003.40205.x; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Engstler M, 2004, J CELL SCI, V117, P1105, DOI 10.1242/jcs.00938; Field H, 1998, J BIOL CHEM, V273, P32102, DOI 10.1074/jbc.273.48.32102; Fouraux MA, 2004, MOL BIOL CELL, V15, P611, DOI 10.1091/mbc.E03-05-0343; Garcia-Salcedo JA, 2004, EMBO J, V23, P780, DOI 10.1038/sj.emboj.7600094; Grunfelder CG, 2003, MOL BIOL CELL, V14, P2029, DOI 10.1091/mbc.E02-10-0640; HALL B, 2004, IN PRESS MOL BIOCH P; Imamura T, 2003, MOL CELL BIOL, V23, P4892, DOI 10.1128/MCB.23.14.4892-4900.2003; Jeffries TR, 2001, J CELL SCI, V114, P2617; Kelley RJ, 1995, MOL BIOCHEM PARASIT, V74, P167, DOI 10.1016/0166-6851(95)02493-X; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Landfear SM, 2001, MOL BIOCHEM PARASIT, V115, P1, DOI 10.1016/S0166-6851(01)00262-6; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; McCaffrey MW, 2001, FEBS LETT, V495, P21, DOI 10.1016/S0014-5793(01)02359-6; Morgan GW, 2002, TRENDS PARASITOL, V18, P540, DOI 10.1016/S1471-4922(02)02392-9; Morgan GW, 2002, TRENDS PARASITOL, V18, P491, DOI 10.1016/S1471-4922(02)02391-7; Morgan GW, 2001, J CELL SCI, V114, P2605; Pal A, 2003, BIOCHEM J, V374, P443, DOI 10.1042/BJ20030469; Pal A, 2002, J BIOL CHEM, V277, P9529, DOI 10.1074/jbc.M110055200; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Shirakawa R, 2000, J BIOL CHEM, V275, P33844, DOI 10.1074/jbc.M002834200; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STEVERDING D, 1995, J CELL BIOL, V131, P1173, DOI 10.1083/jcb.131.5.1173; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wallace DM, 2002, BIOCHEM BIOPH RES CO, V292, P909, DOI 10.1006/bbrc.2002.6736; Wissel H, 2001, AM J PHYSIOL-LUNG C, V281, pL345, DOI 10.1152/ajplung.2001.281.2.L345; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	35	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45047	45056		10.1074/jbc.M407271200	http://dx.doi.org/10.1074/jbc.M407271200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15284229	hybrid			2022-12-27	WOS:000224505600097
J	Vanacore, RM; Shanmugasundararaj, S; Friedman, DB; Bondar, O; Hudson, BG; Sundaramoorthy, M				Vanacore, RM; Shanmugasundararaj, S; Friedman, DB; Bondar, O; Hudson, BG; Sundaramoorthy, M			The alpha 1.alpha 2 network of collagen IV - Reinforced stabilization of the noncollagenous domain-1 by noncovalent forces and the absence of Met-Lys cross-links	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; CRYSTAL-STRUCTURE; DISULFIDE BONDS; CHAIN; CLEAVAGE; ALPHA-5	Collagen IV networks are present in all metazoa and underlie epithelia as a component of basement membranes. The networks are essential for tissue function and are defective in disease. They are assembled by the oligomerization of triple-helical protomers that are linked end-to-end. At the C terminus, two protomers are linked head-to-head by interactions of their trimeric noncollagenous domains, forming a hexamer structure. This linkage in the alpha1.alpha2 network is stabilized by a putative covalent Met-Lys cross-link between the trimer-trimer interface (Than, M. E., Henrich, S., Huber, R., Ries, A., Mann, K., Kuhn, K., Timpl, R., Bourenkov, G. P., Bartunik, H. D., and Bode, W. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 6607-6612) forming a nonreducible dimer that connects the hexamer. In the present study, this cross-link was further investigated by: (a) comparing the 1.5-Angstrom resolution crystal structures of the alpha1.alpha2 hexamers from bovine placenta and lens capsule basement membranes, (b) mass spectrometric analysis of monomer and nonreducible dimer subunits of placenta basement membrane hexamers, and (c) hexamer dissociation/re-association studies. The findings rule out the novel Met-Lys cross-link, as well as other covalent cross-links, but establish that the nonreducible dimer is an inherent structural feature of a subpopulation of hexamers. The dimers reflect the reinforced stabilization, by noncovalent forces, of the connection between two adjoining protomers of a network. The reinforcement extends to other types of collagen IV networks, and it underlies the cryptic nature of a B-cell epitope of the alpha3.alpha4.alpha5 hexamer, implicating the stabilization event in the etiology and pathogenesis of Goodpasture autoimmune disease.	Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Mass Spectrometry Res Ctr, Nashville, TN 37232 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Matrix Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; University of Kansas; University of Kansas Medical Center; Vanderbilt University; Vanderbilt University	Sundaramoorthy, M (corresponding author), Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA.	m.sundaramoorthy@vanderbilt.edu	Vanacore, Roberto/C-9763-2012; Vanacore, Roberto/AAD-6399-2020	Vanacore, Roberto/0000-0002-2886-0606; Vanacore, Roberto/0000-0002-2886-0606; Hudson, Billy/0000-0002-5420-4100	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062524, R37DK018381, R01DK018381, P01DK065123] Funding Source: NIH RePORTER; NCRR NIH HHS [RR017806] Funding Source: Medline; NIDDK NIH HHS [DK62524, DK065123, DK18381] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Borza DB, 2003, J AM SOC NEPHROL, V14, p632A; Borza DB, 2002, J BIOL CHEM, V277, P40075, DOI 10.1074/jbc.M207769200; Borza DB, 2001, J BIOL CHEM, V276, P28532, DOI 10.1074/jbc.M103690200; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fowler SJ, 2000, J BIOL CHEM, V275, P39589, DOI 10.1074/jbc.M005871200; GUNWAR S, 1991, J BIOL CHEM, V266, P14088; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037; SARRAS MP, 1991, DEV BIOL, V148, P481, DOI 10.1016/0012-1606(91)90266-6; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; Sundaramoorthy M, 2002, J BIOL CHEM, V277, P31142, DOI 10.1074/jbc.M201740200; Than ME, 2002, P NATL ACAD SCI USA, V99, P6607, DOI 10.1073/pnas.062183499; WEBER S, 1984, EUR J BIOCHEM, V139, P401, DOI 10.1111/j.1432-1033.1984.tb08019.x; WEBER S, 1988, EUR J BIOCHEM, V175, P229, DOI 10.1111/j.1432-1033.1988.tb14188.x	27	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44723	44730		10.1074/jbc.M406344200	http://dx.doi.org/10.1074/jbc.M406344200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15299013	hybrid			2022-12-27	WOS:000224505600060
J	Wang, DJ; Park, JS; Chu, JSF; Krakowski, A; Luo, KX; Chen, DJ; Li, S				Wang, DJ; Park, JS; Chu, JSF; Krakowski, A; Luo, KX; Chen, DJ; Li, S			Proteomic profiling of bone marrow mesenchymal stem cells upon transforming growth factor beta 1 stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-DIMENSIONAL GEL-ELECTROPHORESIS; TGF-BETA; ACTIN EXPRESSION; STROMAL CELLS; IN-VIVO; DIFFERENTIATION; GELSOLIN	Bone marrow mesenchymal stem cells (MSCs) can differentiate into different types of cells and have tremendous potential for cell therapy and tissue engineering. Transforming growth factor beta1 (TGF-beta) plays an important role in cell differentiation and vascular remodeling. We showed that TGF-beta induced cell morphology change and an increase in actin fibers in MSCs. To determine the global effects of TGF-beta on MSCs, we employed a proteomic strategy to analyze the effect of TGF-beta on the human MSC proteome. By using two-dimensional gel electrophoresis and electrospray ionization coupled to quadrupole/time-of-flight tandem mass spectrometers, we have generated a proteome reference map of MSCs, and we identified similar to30 proteins with an increase or decrease in expression or phosphorylation in response to TGF-beta. The proteins regulated by TGF-beta included cytoskeletal proteins, matrix synthesis proteins, membrane proteins, metabolic enzymes, etc. TGF-beta increased the expression of smooth muscle alpha-actin and decreased the expression of gelsolin. Overexpression of gelsolin inhibited TGF-beta-induced assembly of smooth muscle alpha-actin; on the other hand, knocking down gelsolin expression enhanced the assembly of alpha-actin and actin filaments without significantly affecting alpha-actin expression. These results suggest that TGF-beta coordinates the increase of alpha-actin and the decrease of gelsolin to promote MSC differentiation. This study demonstrates that proteomic tools are valuable in studying stem cell differentiation and elucidating the underlying molecular mechanisms.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Wang, DJ (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd,MS 84-171, Berkeley, CA 94720 USA.	djwang@lbl.gov; songli@socrates.berkeley.edu		Li, Song/0000-0002-4760-8828; Krakowski, Ari/0000-0003-0554-1669	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL079419] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL079419] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; ARPIN M, 1994, J CELL BIOL, V127, P1995, DOI 10.1083/jcb.127.6.1995; Blackstock WP, 1999, TRENDS BIOTECHNOL, V17, P121, DOI 10.1016/S0167-7799(98)01245-1; Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471-4914(01)02016-0; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; FATH KR, 1995, CURR BIOL, V5, P591, DOI 10.1016/S0960-9822(95)00117-5; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; GALMICHE MC, 1993, BLOOD, V82, P66, DOI 10.1182/blood.V82.1.66.bloodjournal82166; GLENNEY JR, 1981, J BIOL CHEM, V256, P9283; Gojo S, 2003, EXP CELL RES, V288, P51, DOI 10.1016/S0014-4827(03)00132-0; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Hirschi KK, 2002, ANN NY ACAD SCI, V961, P223, DOI 10.1111/j.1749-6632.2002.tb03090.x; Hirschi KK, 2002, J BIOL CHEM, V277, P6287, DOI 10.1074/jbc.M106649200; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858; Kinner B, 2002, EXP CELL RES, V278, P72, DOI 10.1006/excr.2002.5561; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; LANDRY J, 1992, J BIOL CHEM, V267, P794; Lilley KS, 2002, CURR OPIN CHEM BIOL, V6, P46, DOI 10.1016/S1367-5931(01)00275-7; Liu Y, 2003, J BIOL CHEM, V278, P48004, DOI 10.1074/jbc.M301902200; MacCoss MJ, 2001, CURR OPIN CLIN NUTR, V4, P369, DOI 10.1097/00075197-200109000-00006; Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Miao H, 2002, FASEB J, V16, pA464; Mo WJ, 2002, CURR OPIN CHEM BIOL, V6, P666, DOI 10.1016/S1367-5931(02)00379-4; Moustakas A, 2001, J CELL SCI, V114, P4359; Patterson SD, 2003, NAT GENET, V33, P311, DOI 10.1038/ng1106; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Rabilloud T, 2002, PROTEOMICS, V2, P3, DOI 10.1002/1615-9861(200201)2:1<3::AID-PROT3>3.3.CO;2-I; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Srinivas PR, 2002, CLIN CHEM, V48, P1160; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Topper JN, 2000, TRENDS CARDIOVAS MED, V10, P132, DOI 10.1016/S1050-1738(00)00061-X; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212; Witzmann FA, 2002, AM J PHYSIOL-GASTR L, V282, pG735, DOI 10.1152/ajpgi.00510.2001; Yarmush ML, 2002, ANNU REV BIOMED ENG, V4, P349, DOI 10.1146/annurev.bioeng.4.020702.153443	42	201	222	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43725	43734		10.1074/jbc.M407368200	http://dx.doi.org/10.1074/jbc.M407368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15302865	hybrid			2022-12-27	WOS:000224383100047
J	Esseiva, AC; Naguleswaran, A; Hemphill, A; Schneider, A				Esseiva, AC; Naguleswaran, A; Hemphill, A; Schneider, A			Mitochondrial tRNA import in Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; LEISHMANIA-TARENTOLAE; ELONGATOR TRNA(MET); APICOMPLEXAN; DNA; INITIATOR; GENE; ATOVAQUONE; EXPRESSION; SYNTHETASE	Apicomplexan parasites have the smallest known mitochondrial genome. It consists of a repeated element of similar to6-7 kb in length and encodes three mitochondrial proteins, a number of rRNA fragments, but no tRNAs. It has therefore been postulated that in apicomplexans all tRNAs required for mitochondrial translation are imported from the cytosol. To provide direct evidence for this process we have established a cell fractionation procedure allowing the isolation of defined organellar RNA fractions from the apicomplexan Toxoplasma gondii. Analysis of T. gondii total and organellar RNA by Northern hybridization showed that except for the cytosol-specific initiator tRNA(Met) all nucleus-encoded tRNAs tested were present in the cytosol and in the mitochondrion but not in the plastid. Thus, these results provide the first experimental evidence for mitochondrial tRNA import in apicomplexans. The only other taxon that imports the whole set of mitochondrial tRNAs are the trypanosomatids. Interestingly, the initiator tRNA(Met) is the only cytosol-specific tRNA in trypanosomatids, indicating that the import specificity is identical in both groups. In agreement with this, the T. gondii initiator tRNA(Met) remained in the cytosol when expressed in Trypanosoma brucei. However, in contrast to trypanosomatids, no thio- modifications were detected in the tRNA(Gln) of T. gondii indicating that, unlike what is suggested in Leishmania, they are not involved in regulating import.	Univ Fribourg, Dept Biol Zool, CH-1700 Fribourg, Switzerland; Univ Bern, Inst Parasitol, CH-3012 Bern, Switzerland	University of Fribourg; University of Bern	Schneider, A (corresponding author), Univ Fribourg, Dept Biol Zool, Chemin Musee 10, CH-1700 Fribourg, Switzerland.	andre.schneider@unifr.ch		Hemphill, Andrew/0000-0002-0622-2128	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045806, Z01AI005093] Funding Source: NIH RePORTER; NIAID NIH HHS [AI05093, 1R01AI045806-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beverley S M, 1993, Methods Mol Biol, V21, P333; Biebinger S, 1997, MOL BIOCHEM PARASIT, V85, P99, DOI 10.1016/S0166-6851(96)02815-0; Black MW, 2000, MICROBIOL MOL BIOL R, V64, P607, DOI 10.1128/MMBR.64.3.607-623.2000; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crain PF, 2002, RNA, V8, P752, DOI 10.1017/S1355838202022045; Drabkin HJ, 1998, MOL CELL BIOL, V18, P1459, DOI 10.1128/MCB.18.3.1459; Esseiva AC, 2004, MOL BIOL CELL, V15, P2750, DOI 10.1091/mbc.E03-11-0821; FEAGIN JE, 1992, MOL BIOCHEM PARASIT, V52, P145, DOI 10.1016/0166-6851(92)90046-M; Feagin JE, 2000, INT J PARASITOL, V30, P371, DOI 10.1016/S0020-7519(99)00190-3; FEAGIN JE, 1994, ANNU REV MICROBIOL, V48, P81, DOI 10.1146/annurev.mi.48.100194.000501; GUAY JM, 1992, GENE, V114, P165, DOI 10.1016/0378-1119(92)90570-F; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HAUSER R, 1995, EMBO J, V14, P4212, DOI 10.1002/j.1460-2075.1995.tb00095.x; Hemphill A, 1996, PARASITOLOGY, V112, P183, DOI 10.1017/S0031182000084754; IGLOI GL, 1992, ANAL BIOCHEM, V206, P363, DOI 10.1016/0003-2697(92)90379-L; Kaneko T, 2003, EMBO J, V22, P657, DOI 10.1093/emboj/cdg066; Kim K, 2004, INT J PARASITOL, V34, P423, DOI 10.1016/j.ijpara.2003.12.009; Martin NC, 2002, P NATL ACAD SCI USA, V99, P1110, DOI 10.1073/pnas.042011199; McFadden DC, 2000, MOL BIOCHEM PARASIT, V108, P1, DOI 10.1016/S0166-6851(00)00184-5; McFadden GI, 1999, TRENDS MICROBIOL, V7, P328, DOI 10.1016/S0966-842X(99)01547-4; Menand B, 1998, P NATL ACAD SCI USA, V95, P11014, DOI 10.1073/pnas.95.18.11014; Nabholz CE, 1997, P NATL ACAD SCI USA, V94, P7903, DOI 10.1073/pnas.94.15.7903; OSSORIO PN, 1991, J MOL BIOL, V222, P525, DOI 10.1016/0022-2836(91)90494-Q; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; Schneider A, 2000, TRENDS CELL BIOL, V10, P509, DOI 10.1016/S0962-8924(00)01854-7; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; Srivastava IK, 1997, J BIOL CHEM, V272, P3961, DOI 10.1074/jbc.272.7.3961; Tan THP, 2002, P NATL ACAD SCI USA, V99, P1152, DOI 10.1073/pnas.022522299; Tan THP, 2002, MOL CELL BIOL, V22, P3707, DOI 10.1128/MCB.22.11.3707-3716.2002; Vercesi AE, 1998, J BIOL CHEM, V273, P31040, DOI 10.1074/jbc.273.47.31040; Williamson DH, 2001, J MOL BIOL, V306, P159, DOI 10.1006/jmbi.2000.4385	31	64	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42363	42368		10.1074/jbc.M404519200	http://dx.doi.org/10.1074/jbc.M404519200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15280394	Green Published, hybrid			2022-12-27	WOS:000224226400005
J	Harman, CA; Rieke, CJ; Garavito, RM; Smith, WL				Harman, CA; Rieke, CJ; Garavito, RM; Smith, WL			Crystal structure of arachidonic acid bound to a mutant of prostaglandin endoperoxide H synthase-1 that forms predominantly 11-hydroperoxyeicosatetraenoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOOXYGENASE ACTIVE-SITE; BINDING; OXYGENATION	Kinetic studies and analysis of the products formed by native and mutant forms of ovine prostaglandin endoperoxide H synthase-1 (oPGHS-1) have suggested that arachidonic acid ( AA) can exist in the cyclooxygenase active site of the enzyme in three different, catalytically competent conformations that lead to prostaglandin G(2) (PGG(2)), 11R-hydroperoxyeicosatetraenoic acid (HPETE), and 15R, S-HPETE, respectively. We have identified an oPGHS-1 mutant (V349A/W387F) that forms predominantly 11R-HPETE. Thus, the preferred catalytically competent arrangement of AA in the cyclooxygenase site of this double mutant must be one that leads to 11-HPETE. The crystal structure of Co3+-protoporphyrin IX V349A/W387F oPGHS-1 in a complex with AA was determined to 3.1 Angstrom. Significant differences are observed in the positions of atoms C-3, C-4, C-5, C-6, C-10, C-11, and C-12 of bound AA between native and V349A/W387F oPGHS-1; in comparison, the positions of the side chains of cyclooxygenase active site residues are unchanged. The structure of the double mutant presented here provides structural insight as to how Val(349) and Trp(387) help position C-9 and C-11 of AA so that the incipient 11-peroxyl radical intermediate is able to add to C-9 to form the 9,11 endoperoxide group of PGG2. In the V349A/W387F oPGHS-1 . AA complex the locations of C-9 and C-11 of AA with respect to one another make it difficult to form the endoperoxide group from the 11-hydroperoxyl radical. Therefore, the reaction apparently aborts yielding 11R-HPETE instead of PGG(2). In addition, the observed differences in the positions of carbon atoms of AA bound to this mutant provides indirect support for the concept that the conformer of AA shown previously to be bound within the cyclooxygenase active site of native oPGHS-1 is the one that leads to PGG(2).	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	University of Michigan System; University of Michigan; Michigan State University	Smith, WL (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 5416 Med Sci Bldg 1,1301 E Catherine St, Ann Arbor, MI 48109 USA.	smithww@umich.edu			NHLBI NIH HHS [R01 HL56773] Funding Source: Medline; NIGMS NIH HHS [R01 GM68848, P01 GM57323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057323, R01GM068848] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; EVANS SV, 1993, J MOL GRAPHICS, V11, P127; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; Malkowski MG, 2001, J BIOL CHEM, V276, P37547, DOI 10.1074/jbc.M105982200; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Schneider C, 2002, J BIOL CHEM, V277, P13354; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936; Thuresson ED, 2000, J BIOL CHEM, V275, P8501, DOI 10.1074/jbc.275.12.8501; Thuresson ED, 2001, J BIOL CHEM, V276, P10358, DOI 10.1074/jbc.M009378200; Thuresson ED, 2001, J BIOL CHEM, V276, P10347, DOI 10.1074/jbc.M009377200; van der Donk WA, 2002, BIOCHEMISTRY-US, V41, P15451, DOI 10.1021/bi026938h	22	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42929	42935		10.1074/jbc.M403013200	http://dx.doi.org/10.1074/jbc.M403013200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292194	hybrid			2022-12-27	WOS:000224226400072
J	Masuda, Y; Shima, G; Aiuchi, T; Horie, M; Hori, K; Nakajo, S; Kajimoto, S; Shibayama-Imazu, T; Nakaya, K				Masuda, Y; Shima, G; Aiuchi, T; Horie, M; Hori, K; Nakajo, S; Kajimoto, S; Shibayama-Imazu, T; Nakaya, K			Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; POLO-LIKE KINASE; ABL TYROSINE KINASE; CYTOCHROME-C; LEUKEMIA-CELLS; BCL-2 FAMILY; HSP90; INHIBITOR; MITOCHONDRIA; MECHANISM	beta- Hydroxyisovalerylshikonin (beta-HIVS), a compound isolated from the traditional oriental medicinal herb Lithospermum radix, is an ATP non-competitive inhibitor of protein-tyrosine kinases, such as v-Src and EGFR, and it induces apoptosis in various lines of human tumor cells. However, the way in which beta-HIVS induces apoptosis remains to be clarified. In this study, we performed cDNA array analysis and found that beta-HIVS suppressed the expression of the gene for tumor necrosis factor receptor-associated protein 1 (TRAP1), which is a member of the heat-shock family of proteins. When human leukemia HL60 cells and human lung cancer DMS114 cells were treated with beta-HIVS, the amount of TRAP1 in mitochondria decreased in a time-dependent manner during apoptosis. A similar reduction in the level of TRAP1 was also observed upon exposure of cells to VP16. Treatment of DMS114 cells with TRAP1-specific siRNA sensitized the cells to beta-HIVS-induced apoptosis. Moreover, the reduction in the level of expression of TRAP1 by TRAP1-specific siRNA enhanced the release of cytochrome c from mitochondria when DMS114 cells were treated with either beta-HIVS or VP16. The suppression of the level of TRAP1 by either beta-HIVS or VP16 was blocked by N-acetyl-cysteine, indicating the involvement of reactive oxygen species (ROS) in the regulation of the expression of TRAP1. These results suggest that suppression of the expression of TRAP1 in mitochondria might play an important role in the induction of apoptosis caused via formation of ROS.	Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, Tokyo 1428555, Japan	Showa University	Masuda, Y (corresponding author), Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	masuda@pharm.showa-u.ac.jp	堀, 孝一/K-5102-2019	堀, 孝一/0000-0002-0530-181X				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Al-Obeidi FA, 2000, ONCOGENE, V19, P5690, DOI 10.1038/sj.onc.1203926; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Chen CF, 1996, MOL CELL BIOL, V16, P4691; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; De Maio A, 1999, SHOCK, V11, P1, DOI 10.1097/00024382-199901000-00001; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Fabbro D, 2002, PHARMACOL THERAPEUT, V93, P79, DOI 10.1016/S0163-7258(02)00179-1; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FONG TA, CANC RES, V59, P99; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; Gottlieb RA, 2000, METHOD ENZYMOL, V322, P213; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; GUPTA RS, 1995, MOL BIOL EVOL, V12, P1063; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hashimoto S, 1999, J BIOCHEM-TOKYO, V125, P17, DOI 10.1093/oxfordjournals.jbchem.a022255; Hashimoto S, 2002, JPN J CANCER RES, V93, P944, DOI 10.1111/j.1349-7006.2002.tb01341.x; Heussler VT, 1999, CELL DEATH DIFFER, V6, P342, DOI 10.1038/sj.cdd.4400501; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; Koren R, 2001, CANCER RES, V61, P1439; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Machida K, 2002, J BIOL CHEM, V277, P31243, DOI 10.1074/jbc.M204564200; MAILHOS C, 1993, NEUROSCIENCE, V55, P621, DOI 10.1016/0306-4522(93)90428-I; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Masuda Y, 2003, ONCOGENE, V22, P1012, DOI 10.1038/sj.onc.1206200; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; MOSSER DD, 1992, J CELL PHYSIOL, V151, P561, DOI 10.1002/jcp.1041510316; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nakaya K, 2003, ANTI-CANCER DRUG, V14, P683, DOI 10.1097/01.cad.0000092781.37568.df; Noonberg SB, 2000, DRUGS, V59, P753, DOI 10.2165/00003495-200059040-00003; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Toft DO, 1998, TRENDS ENDOCRIN MET, V9, P238, DOI 10.1016/S1043-2760(98)00060-5; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Vantieghem A, 1998, FEBS LETT, V440, P19, DOI 10.1016/S0014-5793(98)01416-1; Wakeling AE, 2002, CANCER RES, V62, P5749; Wolf BB, 2002, CURR BIOL, V12, pR177, DOI 10.1016/S0960-9822(02)00736-4; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	69	123	127	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42503	42515		10.1074/jbc.M404256200	http://dx.doi.org/10.1074/jbc.M404256200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292218	hybrid			2022-12-27	WOS:000224226400022
J	Munoz, I; Ruiz, A; Marquina, M; Barcelo, A; Albert, A; Arino, J				Munoz, I; Ruiz, A; Marquina, M; Barcelo, A; Albert, A; Arino, J			Functional characterization of the yeast Ppz1 phosphatase inhibitory subunit Hal3 - A mutagenesis study.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; REGULATORY SUBUNIT; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; SALT TOLERANCE; MOLECULAR CHARACTERIZATION; STRUCTURAL BASIS; EXPRESSION; GENE	Saccharomyces cerevisiae Hal3 is a conserved protein that binds the carboxyl-terminal catalytic domain of the PP1c ( protein phosphatase 1)-related phosphatase Ppz1 and potently inhibits its activity, thus modulating all of the characterized functions so far of the phosphatase. It is unknown how Hal3 binds to Ppz1 and inhibits its activity. Although it contains a putative protein phosphatase 1c binding-like sequence ((KLHVLF268)-K-263), mutagenesis analysis suggests that this motif is not required for Ppz1 binding and inhibition. The mutation of the conserved His(378) ( possibly involved in dehydrogenase catalytic activity) did not impair Hal3 functions or Ppz1 binding. Random mutagenesis of the 228 residue-conserved central region of Hal3 followed by a loss-of-function screen allowed the identification of nine residues important for Ppz1-related Hal3 functions. Seven of these residues cluster in a relatively small region spanning from amino acid 446 to 480. Several mutations affected Ppz1 binding and inhibition in vitro, whereas changes in Glu(460) and Val(462) did not alter binding but resulted in Hal3 versions unable to inhibit the phosphatase. Therefore, there are independent Hal3 structural elements required for Ppz1 binding and inhibition. S. cerevisiae encodes a protein (Vhs3) structurally related to Hal3. Recent evidence suggests that both mutations are synthetically lethal. Surprisingly, versions of Hal3 carrying mutations that strongly affected Ppz1 binding or inhibitory capacity were able to complement lethality. In contrast, the mutation of His(378) did not. This finding suggests that Hal3 may have both Ppz1-dependent and independent functions involving different structural elements.	Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Vet, E-08193 Barcelona, Spain; CSIC, Grp Cristalog Macromol & Biol Estruct, Inst Quim Fis Rocasolano, CSIC, Madrid 28006, Spain	Autonomous University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Arino, J (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Vet, E-08193 Barcelona, Spain.		Albert, Armando/J-2373-2012; barcelo, anna/K-2383-2014; Zhang, Ning/F-1387-2014; Ruiz, Amparo/AAZ-2317-2021; Arino, Joaquin/D-3756-2011	Albert, Armando/0000-0002-0026-6816; Ruiz, Amparo/0000-0002-3947-4540; Arino, Joaquin/0000-0002-6774-2987; Munoz Munoz, Ivan/0000-0002-1606-5445; Arino Carmona, Joaquin/0000-0002-0390-4270; Marquina Rodriguez, Maribel/0000-0002-7798-5528				Albert A, 2000, STRUCTURE, V8, P961, DOI 10.1016/S0969-2126(00)00187-8; Arino J, 2002, EUR J BIOCHEM, V269, P1072, DOI 10.1046/j.0014-2956.2002.02753.x; Blaesse M, 2000, EMBO J, V19, P6299, DOI 10.1093/emboj/19.23.6299; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Cohen PTW, 2002, J CELL SCI, V115, P241; de Nadal E, 1998, P NATL ACAD SCI USA, V95, P7357, DOI 10.1073/pnas.95.13.7357; de Nadal E, 2001, J BIOL CHEM, V276, P14829, DOI 10.1074/jbc.M010824200; DICOMO CJ, 1995, GENETICS, V139, P95; Dombek KM, 1999, MOL CELL BIOL, V19, P6029; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Espinosa-Ruiz A, 1999, PLANT J, V20, P529, DOI 10.1046/j.1365-313X.1999.00626.x; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; Garcia-Gimeno MA, 2003, J BIOL CHEM, V278, P47744, DOI 10.1074/jbc.M306157200; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Hernandez-Acosta P, 2002, J BIOL CHEM, V277, P20490, DOI 10.1074/jbc.M201557200; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kupke T, 2001, J BIOL CHEM, V276, P19190, DOI 10.1074/jbc.M100776200; Munoz I, 2003, YEAST, V20, P157, DOI 10.1002/yea.938; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; POSAS F, 1992, J BIOL CHEM, V267, P11734; Ruiz A, 2004, J BIOL CHEM, V279, P34421, DOI 10.1074/jbc.M400572200; Ruiz A, 2003, EUKARYOT CELL, V2, P937, DOI 10.1128/EC.2.5.937-948.2003; Sambrook J., 2002, MOL CLONING LAB MANU; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Simon E, 2001, J BIOL CHEM, V276, P29740, DOI 10.1074/jbc.M101992200; Steinbacher S, 2003, J MOL BIOL, V327, P193, DOI 10.1016/S0022-2836(03)00092-5; Treco DA, 1990, CURRENT PROTOCOLS MO; Vissi E, 2001, YEAST, V18, P115, DOI 10.1002/1097-0061(20010130)18:2<115::AID-YEA653>3.0.CO;2-G; Wu X, 2001, MOL GENET GENOMICS, V265, P622, DOI 10.1007/s004380100455; Yenush L, 2002, EMBO J, V21, P920, DOI 10.1093/emboj/21.5.920; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	35	27	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42619	42627		10.1074/jbc.M405656200	http://dx.doi.org/10.1074/jbc.M405656200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292171	hybrid			2022-12-27	WOS:000224226400035
J	Cavaldesi, M; Caruso, M; Sthandier, O; Amati, P; Garcia, MI				Cavaldesi, M; Caruso, M; Sthandier, O; Amati, P; Garcia, MI			Conformational changes of murine polyomavirus capsid proteins induced by sialic acid binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYLOLIGOSACCHARIDE RECEPTORS; RESOLUTION STRUCTURE; ENVELOPE PROTEIN; MEMBRANE-FUSION; VIRAL ENTRY; CELL ENTRY; VIRUS; POLIOVIRUS; MUTATION; VP1	Murine polyomavirus (Py) infection initiates by the recognition of cell membrane molecules containing terminal sialic acid ( SA) residues through specific binding pockets formed at the major capsid protein VP1 surface. VP1 Pockets 1, 2, and 3 bind terminal SA, Gal, and second branched SA, respectively. The consequence of recognition on viral cell entry remains elusive. In this work, we show that preincubation of Py with soluble compounds within Pocket 1 (N-acetyl or N-glycolyl neuraminic acids) increases Py cell binding and infectivity in murine 3T6 fibroblasts. In contrast, Gal does not significantly alter Py binding nor infectivity, whereas sialyllactose, in Pockets 1 and 2, decreases cell binding and infectivity. Binding experiments with Py virus-like particles confirmed the direct involvement of VP1 in this effect. To determine whether such results could reflect VP1 conformational changes induced by SA binding, protease digestion assays were performed after pretreatment of Py or virus-like particles with soluble receptor fragments. Binding of SA with the VP1 Pocket 1, but not of compounds interacting with Pocket 2, was associated with a transition of this protein from a protease-sensitive to a protease-resistant state. This effect was transmitted to the minor capsid proteins VP2 and VP3 in virus particles. Attachment of Py to cell monolayers similarly led to a VP1 trypsin-resistant pattern. Taken together, these data present evidence that initial binding of Py to terminal SA induces conformational changes in the viral capsid, which may influence subsequent virus cell entry steps.	Univ Roma La Sapienza, Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, Ist Pasteur,Fdn Cenci Bolognetti, I-00161 Rome, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome	Amati, P (corresponding author), Univ Roma La Sapienza, Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, Ist Pasteur,Fdn Cenci Bolognetti, Viale Regina Elena 324, I-00161 Rome, Italy.	amati@bce.uniroma1.it; garcia@bce.uniroma1.it	Garcia, Marie Isabelle/E-9164-2011	Garcia, Marie Isabelle/0000-0003-2147-7003				Arnberg N, 2002, J VIROL, V76, P8834, DOI 10.1128/JVI.76.17.8834-8841.2002; Barnett AL, 2001, J VIROL, V75, P9096, DOI 10.1128/JVI.75.19.9096-9105.2001; BAROUCH DH, 1994, J VIROL, V68, P3982, DOI 10.1128/JVI.68.6.3982-3989.1994; Bauer PH, 1999, J VIROL, V73, P5826, DOI 10.1128/JVI.73.7.5826-5832.1999; Belnap DM, 2000, J VIROL, V74, P1342, DOI 10.1128/JVI.74.3.1342-1354.2000; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; CAHAN LD, 1983, VIROLOGY, V130, P281, DOI 10.1016/0042-6822(83)90083-1; Caruso M, 2003, J GEN VIROL, V84, P2927, DOI 10.1099/vir.0.19369-0; Caruso M, 2003, J VIROL, V77, P3913, DOI 10.1128/JVI.77.7.3913-3921.2003; Chen XJS, 1998, EMBO J, V17, P3233, DOI 10.1093/emboj/17.12.3233; FERNANDES J, 1994, J BIOL CHEM, V269, P17043; FORSTOVA J, 1993, J VIROL, V67, P1405; FRICKS CE, 1990, J VIROL, V64, P1934, DOI 10.1128/JVI.64.5.1934-1945.1990; FRIED H, 1981, VIROLOGY, V109, P188, DOI 10.1016/0042-6822(81)90485-2; Garcia ML, 2000, VIROLOGY, V272, P293, DOI 10.1006/viro.2000.0351; GRIPON P, 1995, VIROLOGY, V213, P292, DOI 10.1006/viro.1995.0002; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; Liu CK, 1998, J VIROL, V72, P4643, DOI 10.1128/JVI.72.6.4643-4649.1998; Lu CW, 2003, J VIROL, V77, P10841, DOI 10.1128/JVI.77.20.10841-10849.2003; Mannova P, 2002, J GEN VIROL, V83, P2309, DOI 10.1099/0022-1317-83-9-2309; Matsuyama S, 2002, J VIROL, V76, P11819, DOI 10.1128/JVI.76.23.11819-11826.2002; MOSCUFO N, 1993, J VIROL, V67, P5075, DOI 10.1128/JVI.67.8.5075-5078.1993; SAHLI R, 1993, VIROLOGY, V192, P142, DOI 10.1006/viro.1993.1016; Selinka HC, 2003, J VIROL, V77, P12961, DOI 10.1128/JVI.77.24.12961-12967.2003; Stehle T, 1996, STRUCTURE, V4, P183, DOI 10.1016/S0969-2126(96)00021-4; Stehle T, 1997, EMBO J, V16, P5139, DOI 10.1093/emboj/16.16.5139; STEHLE T, 1994, NATURE, V369, P160, DOI 10.1038/369160a0; Takimoto T, 2002, J VIROL, V76, P13028, DOI 10.1128/JVI.76.24.13028-13033.2002; Tsai B, 2003, EMBO J, V22, P4346, DOI 10.1093/emboj/cdg439; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3	30	18	18	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41573	41579		10.1074/jbc.M405995200	http://dx.doi.org/10.1074/jbc.M405995200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292169	hybrid			2022-12-27	WOS:000224075500041
J	Krol, J; Sobczak, K; Wilczynska, U; Drath, M; Jasinska, A; Kaczynska, D; Krzyzosiak, WJ				Krol, J; Sobczak, K; Wilczynska, U; Drath, M; Jasinska, A; Kaczynska, D; Krzyzosiak, WJ			Structural features of MicroRNA (miRNA) precursors and their relevance to miRNA biogenesis and small interfering RNA/Short hairpin RNA design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SECONDARY STRUCTURE; METAL-IONS; CLEAVAGES; IDENTIFICATION; RIBONUCLEASE	We have established the structures of 10 human microRNA (miRNA) precursors using biochemical methods. Eight of these structures turned out to be different from those that were computer-predicted. The differences localized in the terminal loop region and at the opposite side of the precursor hairpin stem. We have analyzed the features of these structures from the perspectives of miRNA biogenesis and active strand selection. We demonstrated the different thermodynamic stability profiles for pre-miRNA hairpins harboring miRNAs at their 5'- and 3'-sides and discussed their functional implications. Our results showed that miRNA prediction based on predicted precursor structures may give ambiguous results, and the success rate is significantly higher for the experimentally determined structures. On the other hand, the differences between the predicted and experimentally determined structures did not affect the stability of termini produced through "conceptual dicing." This result confirms the value of thermodynamic analysis based on mfold as a predictor of strand section by RNAi-induced silencing complex (RISC).	Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, PL-61704 Poznan, Poland	Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Krzyzosiak, WJ (corresponding author), Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, Noskowskiego 12-14, PL-61704 Poznan, Poland.	wlodkrzy@ibch.poznan.pl		Jasinska, Anna/0000-0002-1897-4570; Sobczak, Krzysztof/0000-0001-8352-9812				Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernal JJ, 1997, RNA, V3, P1052; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; BROWN RS, 1983, NATURE, V303, P543, DOI 10.1038/303543a0; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; Carmell MA, 2004, NAT STRUCT MOL BIOL, V11, P214, DOI 10.1038/nsmb729; Ciesiolka J, 1998, J MOL BIOL, V275, P211, DOI 10.1006/jmbi.1997.1462; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; FAVOROVA OO, 1981, BIOCHEMISTRY-US, V20, P1006, DOI 10.1021/bi00507a055; GIEGE R, 2001, RNA, P71; GORNICKI P, 1989, J BIOMOL STRUCT DYN, V6, P971, DOI 10.1080/07391102.1989.10506525; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kierzek R, 1999, BIOCHEMISTRY-US, V38, P14214, DOI 10.1021/bi991186l; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; KRZYZOSIAK WJ, 1988, BIOCHEMISTRY-US, V27, P5771, DOI 10.1021/bi00415a056; Kulinski T, 2003, J BIOL CHEM, V278, P38892, DOI 10.1074/jbc.M301939200; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r42; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lentzen G, 1996, RNA, V2, P244; Leontis NB, 2001, RNA, V7, P499, DOI 10.1017/S1355838201002515; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; LOCKARD RE, 1981, NUCLEIC ACIDS RES, V9, P5125, DOI 10.1093/nar/9.19.5125; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; MARCINIEC T, 1989, FEBS LETT, V243, P293, DOI 10.1016/0014-5793(89)80148-6; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Michalowski D, 1996, BIOCHEMISTRY-US, V35, P10727, DOI 10.1021/bi9530393; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Pyle AM, 1996, MET IONS BIOL SYST, V32, P479; Reinhart BJ, 2002, SCIENCE, V297, P1831, DOI 10.1126/science.1077183; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Streicher B, 1996, EMBO J, V15, P2556, DOI 10.1002/j.1460-2075.1996.tb00613.x; Walczak R, 1996, RNA, V2, P367; WRZESINSKI J, 1995, FEBS LETT, V374, P62, DOI 10.1016/0014-5793(95)01077-R; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	44	140	171	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42230	42239		10.1074/jbc.M404931200	http://dx.doi.org/10.1074/jbc.M404931200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292246	hybrid			2022-12-27	WOS:000224075500115
J	Nielsen, AL; Jorgensen, AL				Nielsen, AL; Jorgensen, AL			Self-assembly of the cytoskeletal glial fibrillary acidic protein is inhibited by an isoform-specific C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-FILAMENTS; ALEXANDER-DISEASE; ALZHEIMERS-DISEASE; GFAP; MUTATIONS; VIMENTIN; EXPRESSION; CLONING; ABSENCE; CELLS	The predominant isoform of glial fibrillary acidic protein (GFAP), GFAPalpha, is the characteristic building block of the cytoskeletal intermediate filaments in astrocytes. Isoform GFAPepsilon, produced by alternative splicing of the GFAP gene, includes a new tail domain that confers a presenilin binding capacity. We here show that the GFAPepsilon tail prevents GFAPepsilon homodimerization and homomeric filament formation, whereas the ability to form heterodimers and filaments with GFAPalpha is retained. Furthermore, GFAPepsilon shows decreased affinity for several GFAPalpha-interacting proteins. A GFAPepsilon tail mutation that results in gain of GFAPepsilon dimerization and filament formation abolishes presenilin binding. This mutation also abolishes interaction between the tail and the coiled-coil domain of GFAPepsilon. Together, this indicates that direct interaction between the coiled-coil and tail domains may serve as an inhibitory mechanism for homomeric dimerization and filament formation. We propose that the GFAPepsilon isoform represents a new functionally distinct component of GFAP intermediate filaments.	Univ Aarhus, Dept Human Genet, DK-8000 Aarhus C, Denmark	Aarhus University	Nielsen, AL (corresponding author), Univ Aarhus, Dept Human Genet, Bartholin Bldg, DK-8000 Aarhus C, Denmark.	aln@humgen.au.dk	Nielsen, Anders Lade L/Q-9604-2016	Nielsen, Anders Lade L/0000-0003-4372-9961				BONGCAMRUDLOFF E, 1991, CANCER RES, V51, P1553; Brenner M, 2001, NAT GENET, V27, P117, DOI 10.1038/83679; CHEN WJ, 1994, J CELL SCI, V107, P2299; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Fuchs E, 1996, ANNU REV GENET, V30, P197, DOI 10.1146/annurev.genet.30.1.197; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; Hol EM, 2003, MOL PSYCHIATR, V8, P786, DOI 10.1038/sj.mp.4001379; Isaacs A, 1998, GENOMICS, V51, P152, DOI 10.1006/geno.1998.5360; JOHNSON AB, 2002, INT J DEV NEUROSCI, V759, P1; Kazerounian S, 2002, EXP DERMATOL, V11, P428, DOI 10.1034/j.1600-0625.2002.110506.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Leem JY, 2002, NEUROBIOL DIS, V11, P64, DOI 10.1006/nbdi.2002.0546; Leung CL, 1996, J BIOL CHEM, V271, P14041, DOI 10.1074/jbc.271.24.14041; MCCORMICK MB, 1993, J CELL BIOL, V122, P395, DOI 10.1083/jcb.122.2.395; Messing A, 2001, J NEUROPATH EXP NEUR, V60, P563, DOI 10.1093/jnen/60.6.563; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Nielsen AL, 2002, J NEUROGENET, V16, P175, DOI 10.1080/01677060215305; Nielsen AL, 2002, J BIOL CHEM, V277, P29983, DOI 10.1074/jbc.M112121200; Porchet R, 2003, PROTEOMICS, V3, P1476, DOI 10.1002/pmic.200300456; REEVES SA, 1989, P NATL ACAD SCI USA, V86, P5178, DOI 10.1073/pnas.86.13.5178; Rose MD., 1990, METHODS YEAST GENETI; SARRIA AJ, 1994, J CELL SCI, V107, P1593; Singh R, 2003, GENOMICS, V82, P185, DOI 10.1016/S0888-7543(03)00106-X; Strelkov SV, 2003, BIOESSAYS, V25, P243, DOI 10.1002/bies.10246; Takemura M, 2002, J NEUROSCI, V22, P6972; Tandon Anurag, 2000, Current Opinion in Neurology, V13, P377, DOI 10.1097/00019052-200008000-00003; Thinakaran G, 1999, J CLIN INVEST, V104, P1321, DOI 10.1172/JCI8728	29	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41537	41545		10.1074/jbc.M406601200	http://dx.doi.org/10.1074/jbc.M406601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15284230	hybrid			2022-12-27	WOS:000224075500037
J	Ouameur, AA; Tajmir-Riahi, HA				Ouameur, AA; Tajmir-Riahi, HA			Structural analysis of DNA interactions with biogenic polyamines and cobalt(III) hexamine studied by Fourier transform infrared and capillary electrophoresis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALF THYMUS DNA; B-DNA; CONFORMATIONAL TRANSITION; CIRCULAR-DICHROISM; CRYSTAL-STRUCTURE; STRAND BREAKS; SHIFT ASSAY; A-DNA; SPERMINE; BINDING	Biogenic polyamines, such as putrescine, spermidine, and spermine are small organic polycations involved in numerous diverse biological processes. These compounds play an important role in nucleic acid function due to their binding to DNA and RNA. It has been shown that biogenic polyamines cause DNA condensation and aggregation similar to that of inorganic cobalt( III) hexamine cation, which has the ability to induce DNA conformational changes. However, the nature of the polyamine . DNA binding at the molecular level is not clearly established and is the subject of much controversy. In the present study the effects of spermine, spermidine, putrescine, and cobalt( III) hexamine on the solution structure of calf-thymus DNA were investigated using affinity capillary electrophoresis, Fourier transform infrared, and circular dichroism spectroscopic methods. At low polycation concentrations, putrescine binds preferentially through the minor and major grooves of double strand DNA, whereas spermine, spermidine, and cobalt( III) hexamine bind to the major groove. At high polycation concentrations, putrescine interaction with the bases is weak, whereas strong base binding occurred for spermidine in the major and minor grooves of DNA duplex. However, major groove binding is preferred by spermine and cobalt( III) hexamine cations. Electrostatic attractions between polycation and the backbone phosphate group were also observed. No major alterations of B-DNA were observed for biogenic polyamines, whereas cobalt( III) hexamine induced a partial B 3 A transition. DNA condensation was also observed for cobalt( III) hexamine cation, whereas organic polyamines induced duplex stabilization. The binding constants calculated for biogenic polyamines are K-Spm = 2.3 x 10(5) M-1, K-Spd = 1.4 x 10(5) M-1, and K-Put = 1.02 x 10(5) M-1. Two binding constants have been found for cobalt( III) hexamine with K-1 = 1.8 x 10(5) M-1 and K-2 = 9.2 x 10(4) M-1. The Hill coefficients indicate a positive cooperativity binding for biogenic polyamines and a negative cooperativity for cobalt( III) hexamine.	Univ Quebec Trois Rivieres, Dept Biol Chem, Trois Rivieres, PQ G9A 5H7, Canada	University of Quebec; University of Quebec Trois Rivieres	Tajmir-Riahi, HA (corresponding author), Univ Quebec Trois Rivieres, Dept Biol Chem, CP 500, Trois Rivieres, PQ G9A 5H7, Canada.	tajmirri@uqtr.ca						ALEX S, 1989, INORG CHIM ACTA, V157, P271, DOI 10.1016/S0020-1693(00)80552-6; Arakawa H, 2000, J BIOL CHEM, V275, P10150, DOI 10.1074/jbc.275.14.10150; BANCROFT D, 1994, BIOCHEMISTRY-US, V33, P1073, DOI 10.1021/bi00171a005; Bloomfield VA, 1997, BIOPOLYMERS, V44, P269, DOI 10.1002/(SICI)1097-0282(1997)44:3<269::AID-BIP6>3.0.CO;2-T; Bryson K, 2000, J BIOMOL STRUCT DYN, V18, P393, DOI 10.1080/07391102.2000.10506676; Casero RA, 2001, J MED CHEM, V44, P1, DOI 10.1021/jm000084m; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; D'Agostino L, 2002, EUR J BIOCHEM, V269, P4317, DOI 10.1046/j.1432-1033.2002.03128.x; Deng H, 2000, NUCLEIC ACIDS RES, V28, P3379, DOI 10.1093/nar/28.17.3379; DIRICO DE, 1985, NUCLEIC ACIDS RES, V13, P251, DOI 10.1093/nar/13.1.251; Douki T, 2000, RADIAT RES, V153, P29, DOI 10.1667/0033-7587(2000)153[0029:PARIDO]2.0.CO;2; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; FEUERSTEIN BG, 1986, P NATL ACAD SCI USA, V83, P5948, DOI 10.1073/pnas.83.16.5948; FEUERSTEIN BG, 1990, NUCLEIC ACIDS RES, V18, P1271, DOI 10.1093/nar/18.5.1271; Foulds GJ, 1998, NUCLEIC ACIDS RES, V26, P4304, DOI 10.1093/nar/26.18.4304; GOSULE LC, 1976, NATURE, V259, P333, DOI 10.1038/259333a0; Guanzler H., 2002, IR SPECTROSCOPY INTR; Guszczynski T, 1998, ANAL BIOCHEM, V260, P212, DOI 10.1006/abio.1998.2694; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; Ha HC, 1998, BIOCHEM BIOPH RES CO, V244, P298, DOI 10.1006/bbrc.1998.8258; HASAN R, 1995, FEBS LETT, V368, P27, DOI 10.1016/0014-5793(95)00591-V; HEBY O, 1981, DIFFERENTIATION, V19, P1, DOI 10.1111/j.1432-0436.1981.tb01123.x; Hou MH, 2001, NUCLEIC ACIDS RES, V29, P5121, DOI 10.1093/nar/29.24.5121; HOUGAARD DM, 1987, HISTOCHEM J, V19, P643, DOI 10.1007/BF01676170; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; JACK RC, 1995, BASIC BIOCH LAB PROC, P147; JAIN S, 1989, BIOCHEMISTRY-US, V28, P2360, DOI 10.1021/bi00432a002; Kankia BI, 2001, NUCLEIC ACIDS RES, V29, P2795, DOI 10.1093/nar/29.13.2795; KLOTZ IM, 1982, SCIENCE, V217, P1247, DOI 10.1126/science.6287580; Korolev N, 2002, BIOPHYS J, V82, P2860, DOI 10.1016/S0006-3495(02)75628-2; Korolev N, 2001, J MOL BIOL, V308, P907, DOI 10.1006/jmbi.2001.4642; Kypr J, 2002, BIOPOLYMERS, V67, P275, DOI 10.1002/bip.10112; Laitinen J, 1998, J CELL BIOCHEM, V68, P200, DOI 10.1002/(SICI)1097-4644(19980201)68:2<200::AID-JCB7>3.0.CO;2-Z; Li CZ, 1998, ANAL BIOCHEM, V263, P72, DOI 10.1006/abio.1998.2791; Lin Z, 1998, NUCLEIC ACIDS RES, V26, P3228, DOI 10.1093/nar/26.13.3228; LIQUORI AM, 1967, J MOL BIOL, V24, P113, DOI 10.1016/0022-2836(67)90094-0; LOPRETE DM, 1993, BIOCHEMISTRY-US, V32, P4077, DOI 10.1021/bi00066a032; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; Marques MPM, 2000, EUR COMMISS SCI RES, P122; MARQUET R, 1986, J BIOMOL STRUCT DYN, V4, P205, DOI 10.1080/07391102.1986.10506340; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; Marty R, 2004, DNA CELL BIOL, V23, P135, DOI 10.1089/104454904322964724; MINYAT EE, 1978, J MOL BIOL, V128, P379; MORGAN DML, 1990, BIOCHEM SOC T, V18, P1080, DOI 10.1042/bst0181080; Nunn CM, 1996, J MOL BIOL, V256, P340, DOI 10.1006/jmbi.1996.0090; Oh TJ, 1998, BIOTECHNOL TECH, V12, P755, DOI 10.1023/A:1008864618091; Ouameur AA, 2003, J BIOMOL STRUCT DYN, V20, P561, DOI 10.1080/07391102.2003.10506872; PATTABIRAMAN N, 1984, J BIOMOL STRUCT DYN, V1, P1525, DOI 10.1080/07391102.1984.10507536; Pavia DL., 1979, INTRO SPECTROSCOPY; PEGG AE, 1988, CANCER RES, V48, P759; Pelta J, 1996, J BIOL CHEM, V271, P5656, DOI 10.1074/jbc.271.10.5656; REICHMANN ME, 1954, J AM CHEM SOC, V76, P3047, DOI 10.1021/ja01640a067; Ruiz-Chica J, 2003, BBA-GENE STRUCT EXPR, V1628, P11, DOI 10.1016/S0167-4781(03)00098-8; Ruiz-Chica J, 2001, BIOCHEM BIOPH RES CO, V285, P437, DOI 10.1006/bbrc.2001.5192; Ruiz-Chica J, 2001, BIOPHYS J, V80, P443, DOI 10.1016/S0006-3495(01)76027-4; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; SCHMID N, 1991, BIOCHEMISTRY-US, V30, P4357, DOI 10.1021/bi00231a035; SEN D, 1986, BIOCHEMISTRY-US, V25, P1495, DOI 10.1021/bi00355a004; Shimura K, 1997, ANAL BIOCHEM, V251, P1, DOI 10.1006/abio.1997.2212; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR H, 1962, BIOCHEMISTRY-US, V1, P496, DOI 10.1021/bi00909a021; TAILLANDIER E, 1992, METHOD ENZYMOL, V211, P307; TAILLANDIER E, 1984, BIOCHEMISTRY-US, V23, P5703, DOI 10.1021/bi00319a007; Taillandier E., 1985, ADV INFRARED RAMAN S, P65; TAILLANDIER E, 1984, SPECTROSCOPY BIOL MO, P171; THEOPHANIDES T, 1985, J BIOMOL STRUCT DYN, V2, P995, DOI 10.1080/07391102.1985.10507615; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; THOMAS TJ, 1984, BIOPOLYMERS, V23, P1295, DOI 10.1002/bip.360230713; THOMAS TJ, 1991, J BIOL CHEM, V266, P6137; Tkachenko A, 2001, ARCH MICROBIOL, V176, P155, DOI 10.1007/s002030100301; TSUBOI M, 1964, B CHEM SOC JPN, V37, P1514, DOI 10.1246/bcsj.37.1514; Vijayalakshmi R, 2000, BIOCHEM BIOPH RES CO, V271, P731, DOI 10.1006/bbrc.2000.2707; WATANABE S, 1991, J BIOL CHEM, V266, P20803; WEMMER DE, 1985, J MOL BIOL, V185, P457, DOI 10.1016/0022-2836(85)90418-8; WIDOM J, 1980, J MOL BIOL, V144, P431, DOI 10.1016/0022-2836(80)90330-7; WILLIAMS LD, 1990, NUCLEIC ACIDS RES, V18, P5533, DOI 10.1093/nar/18.18.5533; Xian J, 1996, P NATL ACAD SCI USA, V93, P86, DOI 10.1073/pnas.93.1.86; Zimmerman SB, 1996, FEBS LETT, V390, P245, DOI 10.1016/0014-5793(96)00725-9	78	255	260	2	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42041	42054		10.1074/jbc.M406053200	http://dx.doi.org/10.1074/jbc.M406053200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15284235	hybrid			2022-12-27	WOS:000224075500097
J	Davoodi, J; Lin, L; Kelly, J; Liston, P; MacKenzie, AE				Davoodi, J; Lin, L; Kelly, J; Liston, P; MacKenzie, AE			Neuronal apoptosis-inhibitory protein does not interact with Smac and requires ATP to bind caspase-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED INHIBITOR; CELL-DEATH; GENOMIC ORGANIZATION; REGULATES APOPTOSIS; STRUCTURAL BASIS; SERINE-PROTEASE; CYTOCHROME-C; IAP GENES; XIAP; SMAC/DIABLO	The (n) under bar euronal (a) under bar poptosis- (i) under bar nhibitory (p) under bar rotein (NAIP) is the founding member of the mammalian family of (i) under bar nhibitor of (ap) under bar optosis (IAP) proteins (also known as BIRC proteins) and has been shown to be antiapoptotic both in vivo and in vitro. The 160-kDa NAIP contains three distinct regions: an amino-terminal cluster of three (b) under bar aculoviral (i) under bar nhibitory (r) under bar epeat (BIR) domains, a central (n) under bar ucleotide binding (o) under bar ligomerization (d) under bar omain (NOD), and a carboxyl-terminal (l) under bar eucine-(r) under bar ich (r) under bar epeat (LRR) domain. The presence of the NOD and LRR domains renders NAIP unique among the IAPs and suggests that NAIP activity is regulated in a manner distinct from that of other members of the family. In this report, we examined the interaction of various regions of NAIP with caspase-9 and Smac. Recombinant NAIPs with truncations of the carboxyl-terminal LRR or NOD-LRR regions bound to caspase-9. In contrast, the full-length protein did not, suggesting some form of structural autoregulation. However, the association of the wild type full-length protein with caspase-9 was observed when interaction analysis was performed in the presence of ATP. Furthermore, mutation of the NAIP ATP binding pocket allowed full-length protein to interact with caspase-9. Thus, we conclude that NAIP binds to caspase-9 with a structural requirement for ATP and that in the absence of ATP the LRR domain negatively regulates the caspase-9-inhibiting activity of the BIR domains. Interestingly, and in contrast to the X-chromosome-linked inhibitor of apoptosis protein (XIAP), NAIP-mediated inhibition of caspase-9 was not countered by a peptide containing an amino-terminal (I) under bar AP (b) under bar inding (m) under bar otif (IBM). Consistent with this observation was the failure of Smac protein to interact with the NAIP BIR domains. These results demonstrate that NAIP is distinct from the other IAPs, both in demonstrating a ligand-dependent caspase-9 interaction and in demonstrating a distinct mechanism of inhibition.	Childrens Hosp Eastern Ontario, Res Inst, Solange Gauthier Karsh Lab, Ottawa, ON K1H 8L1, Canada; Natl Res Council Canada, Ottawa, ON K1A 0R6, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; National Research Council Canada	Davoodi, J (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Solange Gauthier Karsh Lab, Ottawa, ON K1H 8L1, Canada.	jamshid@mgcheo.med.uottawa.ca; alex@mgcheo.med.uottawa.ca						Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; Chaudhary D, 1998, J BIOL CHEM, V273, P17708, DOI 10.1074/jbc.273.28.17708; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Farahani R, 1997, GENOMICS, V42, P514, DOI 10.1006/geno.1997.4742; Hegde R, 2003, J BIOL CHEM, V278, P38699, DOI 10.1074/jbc.M303179200; Hunter AM, 2003, J BIOL CHEM, V278, P7494, DOI 10.1074/jbc.C200695200; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Inohara N, 2001, ONCOGENE, V20, P6473, DOI 10.1038/sj.onc.1204787; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Lagace M, 2001, GENOMICS, V77, P181, DOI 10.1006/geno.2001.6635; Linhoff MW, 2001, MOL CELL BIOL, V21, P3001, DOI 10.1128/MCB.21.9.3001-3011.2001; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Martin SJ, 2002, CELL, V109, P793, DOI 10.1016/S0092-8674(02)00802-4; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Matsumoto K, 1999, MOL REPROD DEV, V54, P103, DOI 10.1002/(SICI)1098-2795(199910)54:2&lt;103::AID-MRD1&gt;3.0.CO;2-V; Mercer EA, 2000, EMBO J, V19, P3597, DOI 10.1093/emboj/19.14.3597; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; RajcanSeparovic E, 1996, GENOMICS, V37, P404, DOI 10.1006/geno.1996.0579; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Richter BWM, 2001, MOL CELL BIOL, V21, P4292, DOI 10.1128/MCB.21.13.4292-4301.2001; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, J BIOL CHEM, V276, P27058, DOI 10.1074/jbc.M102415200; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zou H, 2003, J BIOL CHEM, V278, P8091, DOI 10.1074/jbc.M204783200	41	62	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40622	40628		10.1074/jbc.M405963200	http://dx.doi.org/10.1074/jbc.M405963200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15280366	hybrid			2022-12-27	WOS:000223916800050
J	Kanamaru, S; Kondabagil, K; Rossmann, MG; Rao, VB				Kanamaru, S; Kondabagil, K; Rossmann, MG; Rao, VB			The functional domains of bacteriophage T4 terminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA PACKAGING MACHINE; PROTEIN GP17; LAMBDA TERMINASE; ATPASE ACTIVITY; LARGE SUBUNIT; PORTAL PROTEIN; BINDING; PROHEAD; ENZYME; ENDONUCLEASE	The packaging of double-stranded genomic DNA into some viral and all bacteriophage capsids is driven by powerful molecular motors. In bacteriophage T4, the motor consists of the portal protein assembly composed of twelve copies of gene product 20 (gp20, 61 kDa) and an oligomeric terminase complex composed of gp16 ( 18 kDa) and gp17 ( 70 kDa). The packaging motor drives the 171-kbp T4 DNA into the capsid utilizing the free energy of ATP hydrolysis. Evidence suggests that gp17 is the key component of the motor; it exhibits ATPase, nuclease, and in vitro DNA-packaging activities. The N- and C-terminal halves of gp17 were expressed and purified to homogeneity and found to have ATPase and nuclease activities, respectively. The N- terminal domain exhibited 2-3-fold higher K-cat values for gp16-stimulated ATPase than the full-length gp17. Neither of the domains, individually or together, exhibited in vitro DNA-packaging activity, suggesting that communication between the domains is essential for DNA packaging. The domains, in particular the C-terminal domain or a mixture of both the N- and C-terminal domains, inhibited in vitro DNA packaging that is catalyzed by full-length gp17. In conjunction with genetic evidence, these data suggest that the domains compete with the full-length gp17 for binding sites on the portal protein. A model for the assembly of the T4 DNA-packaging machine is presented.	Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Catholic University of America; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Rao, VB (corresponding author), Catholic Univ Amer, Dept Biol, 103 McCort Ward Hall,620 Michigan Ave NE, Washington, DC 20064 USA.	rao@cua.edu	Kanamaru, Shuji/R-4049-2017	Kanamaru, Shuji/0000-0002-2765-531X; Rao, Venigalla/0000-0002-0777-6587	NIAID NIH HHS [R01 AI011676, R56 AI081726, R01 AI011219, R01 AI081726] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baumann RG, 2003, J BIOL CHEM, V278, P4618, DOI 10.1074/jbc.M208574200; BHATTACHARYYA SP, 1994, GENE, V146, P67, DOI 10.1016/0378-1119(94)90834-6; BHATTACHARYYA SP, 1993, VIROLOGY, V196, P34, DOI 10.1006/viro.1993.1452; Black LW, 1988, BACTERIOPHAGES, P321; DAVIDSON AR, 1992, VIROLOGY, V189, P21, DOI 10.1016/0042-6822(92)90677-H; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; GLERT JA, 1993, NUCLEASES, P1; Goetzinger KR, 2003, J MOL BIOL, V331, P139, DOI 10.1016/S0022-2836(03)00636-3; GOLTZ S, 1999, J MOL BIOL, V285, P1131; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; Hang JQ, 2000, J MOL BIOL, V302, P777, DOI 10.1006/jmbi.2000.4086; Hwang Y, 2000, VIROLOGY, V277, P204, DOI 10.1006/viro.2000.0591; Kindt J, 2001, P NATL ACAD SCI USA, V98, P13671, DOI 10.1073/pnas.241486298; Kuebler D, 1998, J MOL BIOL, V281, P803, DOI 10.1006/jmbi.1998.1952; Leffers G, 2000, J BIOL CHEM, V275, P37127, DOI 10.1074/jbc.M003357200; Lin H, 1997, J BIOL CHEM, V272, P3495, DOI 10.1074/jbc.272.6.3495; Lin HC, 1999, J MOL BIOL, V289, P249, DOI 10.1006/jmbi.1999.2781; Mitchell MS, 2004, VIROLOGY, V321, P217, DOI 10.1016/j.virol.2003.11.006; Mitchell MS, 2002, NUCLEIC ACIDS RES, V30, P4009, DOI 10.1093/nar/gkf524; MORITA M, 1995, J MOL BIOL, V245, P635, DOI 10.1006/jmbi.1994.0052; MORITA M, 1993, VIROLOGY, V193, P748, DOI 10.1006/viro.1993.1183; POWELL D, 1990, NUCLEIC ACIDS RES, V18, P4005, DOI 10.1093/nar/18.13.4005; Przech AJ, 2003, J VIROL, V77, P9613, DOI 10.1128/JVI.77.17.9613-9621.2003; RAO VB, 1988, J MOL BIOL, V200, P475, DOI 10.1016/0022-2836(88)90537-2; Rao VB, 2001, J MOL BIOL, V314, P401, DOI 10.1006/jmbi.2001.5169; Rentas FJ, 2003, J MOL BIOL, V334, P37, DOI 10.1016/j.jmb.2003.09.028; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; YEO A, 1995, J MOL BIOL, V245, P141, DOI 10.1006/jmbi.1994.0013	30	67	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40795	40801		10.1074/jbc.M403647200	http://dx.doi.org/10.1074/jbc.M403647200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15265872	hybrid			2022-12-27	WOS:000223916800073
J	Levenson, JM; O'Riordan, KJ; Brown, KD; Trinh, MA; Molfese, DL; Sweatt, JD				Levenson, JM; O'Riordan, KJ; Brown, KD; Trinh, MA; Molfese, DL; Sweatt, JD			Regulation of histone acetylation during memory formation in the hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM-MEMORY; ACTIVATED PROTEIN-KINASE; ELEMENT-BINDING PROTEIN; GENE-EXPRESSION; NEURONAL GENES; LATE-PHASE; SYNAPTIC PLASTICITY; RNA-SYNTHESIS; IN-VITRO; POTENTIATION	Formation of long term memory begins with the activation of many disparate signaling pathways that ultimately impinge on the cellular mechanisms regulating gene expression. We investigated whether mechanisms regulating chromatin structure were activated during the early stages of long term memory formation in the hippocampus. Specifically, we investigated hippocampal histone acetylation during the initial stages of consolidation of long term association memories in a contextual fear conditioning paradigm. Acetylation of histone H3 in area CA1 of the hippocampus was regulated in contextual fear conditioning, an effect dependent on activation of N-methyl-D-aspartic acid (NMDA) receptors and ERK, and blocked using a behavioral latent inhibition paradigm. Activation of NMDA receptors in area CA1 in vitro increased acetylation of histone H3, and this effect was blocked by inhibition of ERK signaling. Moreover, activation of ERK in area CA1 in vitro through either the protein kinase C or protein kinase A pathways, biochemical events known to be involved in long term memory formation, also increased histone H3 acetylation. Furthermore, we observed that elevating levels of histone acetylation through the use of the histone deacetylase inhibitors trichostatin A or sodium butyrate enhanced induction of long term potentiation at Schaffer-collateral synapses in area CA1 of the hippocampus, a candidate mechanism contributing to long term memory formation in vivo. In concert with our findings in vitro, injection of animals with sodium butyrate prior to contextual fear conditioning enhanced formation of long term memory. These results indicate that histone-associated heterochromatin undergoes changes in structure during the formation of long term memory. Mimicking memory-associated changes in heterochromatin enhances a cellular process thought to underlie long term memory formation, hippocampal long term potentiation, and memory formation itself.	Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Baylor College of Medicine	Sweatt, JD (corresponding author), Baylor Coll Med, Div Neurosci, 1 Baylor Plaza, Houston, TX 77030 USA.	jsweatt@bcm.tmc.edu	O'Riordan, Kenneth J./H-6467-2019	O'Riordan, Kenneth J./0000-0003-0081-6010; Sweatt, J. David/0000-0003-3567-485X; Molfese, David/0000-0002-1839-9262	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057014] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24064] Funding Source: Medline; NIMH NIH HHS [MH57014] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Abel T, 1998, BRAIN RES REV, V26, P360, DOI 10.1016/S0165-0173(97)00050-7; ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; Adams JP, 2002, ANNU REV PHARMACOL, V42, P135, DOI 10.1146/annurev.pharmtox.42.082701.145401; Angus-Hill ML, 1999, J MOL BIOL, V294, P1311, DOI 10.1006/jmbi.1999.3338; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bartsch D, 1998, CELL, V95, P211, DOI 10.1016/S0092-8674(00)81752-3; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Blum S, 1999, J NEUROSCI, V19, P3535; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Calderone A, 2003, J NEUROSCI, V23, P2112; Casadesus J, 2002, BIOESSAYS, V24, P512, DOI 10.1002/bies.10102; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Crosio C, 2000, NAT NEUROSCI, V3, P1241, DOI 10.1038/81767; Crosio C, 2003, J CELL SCI, V116, P4905, DOI 10.1242/jcs.00804; Davis S, 2000, J NEUROSCI, V20, P4563, DOI 10.1523/JNEUROSCI.20-12-04563.2000; DINGLEDINE R, 1983, FED PROC, V42, P2881; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; FANSELOW MS, 1994, BEHAV NEUROSCI, V108, P235, DOI 10.1037/0735-7044.108.2.235; Fleischmann A, 2003, J NEUROSCI, V23, P9116; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; FREY U, 1989, NEUROSCI LETT, V97, P135, DOI 10.1016/0304-3940(89)90152-3; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; Frey U, 1996, J PHYSIOL-LONDON, V490, P703, DOI 10.1113/jphysiol.1996.sp021179; Guan ZH, 2003, J NEUROSCI, V23, P7317; Guan ZH, 2002, CELL, V111, P483, DOI 10.1016/S0092-8674(02)01074-7; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; Huang YF, 2002, J NEUROSCI, V22, P8422; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Igaz LM, 2002, J NEUROSCI, V22, P6781; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones MW, 2001, NAT NEUROSCI, V4, P289, DOI 10.1038/85138; Levenson JM, 2004, J NEUROSCI, V24, P3933, DOI 10.1523/JNEUROSCI.5646-03.2004; LUBOW RE, 1973, PSYCHOL BULL, V79, P398, DOI 10.1037/h0034425; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110; Merienne K, 2001, MOL CELL BIOL, V21, P7089, DOI 10.1128/MCB.21.20.7089-7096.2001; Muller C, 2001, CURR OPIN GENET DEV, V11, P167, DOI 10.1016/S0959-437X(00)00175-1; Murray HJ, 2003, NEUROPHARMACOLOGY, V44, P374, DOI 10.1016/S0028-3908(02)00375-1; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; PARO R, 1995, TRENDS GENET, V11, P295, DOI 10.1016/S0168-9525(00)89081-2; Sananbenesi F, 2002, MOL CELL NEUROSCI, V21, P463, DOI 10.1006/mcne.2002.1188; Selcher JC, 1999, LEARN MEMORY, V6, P478, DOI 10.1101/lm.6.5.478; STANTON PK, 1984, J NEUROSCI, V4, P3080; Taubenfeld SM, 2001, J NEUROSCI, V21, P84, DOI 10.1523/JNEUROSCI.21-01-00084.2001; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; VanLint C, 1996, GENE EXPRESSION, V5, P245; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; Weeber EJ, 2000, J NEUROSCI, V20, P5906, DOI 10.1523/JNEUROSCI.20-16-05906.2000; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	55	823	889	2	76	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40545	40559		10.1074/jbc.M402229200	http://dx.doi.org/10.1074/jbc.M402229200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15273246	hybrid			2022-12-27	WOS:000223916800042
J	Martin, SW; Konopka, JB				Martin, SW; Konopka, JB			SUMO modification of septin-interacting proteins in Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; TRANSCRIPTIONAL CONTROL; YEAST SEPTINS/; BUDDING YEAST; BUD NECK; MORPHOGENESIS; GENE; UBIQUITIN; FAMILY	The initiation of bud and hyphal growth in the opportunistic fungal pathogen Candida albicans both involve polarized morphogenesis. However, there are many differences including the function of the septin proteins, a family of proteins involved in membrane organization in a wide range of organisms. Septins form a characteristic ring on the inner surface of the plasma membrane at the bud neck, whereas the septins are diffusely localized across emerging hyphal tips. In addition, septin rings are maintained at sites of septum formation in hyphae rather than being disassembled immediately after cytokinesis. The possibility that C. albicans septins are regulated by the small ubiquitin-like protein SUMO was examined in this study because the Saccharomyces cerevisiae septins were shown previously to be modified by SUMO (Smt3p). However, SUMO conjugation to septins was not detected during budding or hyphal morphogenesis in C. albicans. These results are supported by the lack of conserved SUMO consensus motifs between septins from the two organisms even after adjusting the predicted Cdc3p and Cdc12p septin sequences to account for mRNA splicing in C. albicans. Interestingly, a homolog of the Smt3p SUMO was identified in the C. albicans genome, and an epitope tagged version of Smt3p was conjugated to a variety of proteins. Immunofluorescence analysis showed prominent Smt3p SUMO localization at bud necks and sites of septum formation in hyphae similar to the septins. However, Smt3p was primarily detected on the mother cell side of the septin ring. A subset of these Smt3p-modified proteins co-immunoprecipitated with the septin Cdc11p. These results indicate that septin-associated proteins and not the septins themselves are the key target of SUMO modification at the bud neck in C. albicans.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Program Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Konopka, JB (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	james.konopka@sunysb.edu		Konopka, James/0000-0001-5989-4086	NIAID NIH HHS [R01 AI47837] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047837] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Barral Y, 2000, MOL CELL, V5, P841, DOI 10.1016/S1097-2765(00)80324-X; Berman J, 2002, NAT REV GENET, V3, P918, DOI 10.1038/nrg948; Brown AJP, 1999, TRENDS MICROBIOL, V7, P333, DOI 10.1016/S0966-842X(99)01556-5; DeVirgilio C, 1996, MICROBIOL-SGM, V142, P2897, DOI 10.1099/13500872-142-10-2897; Ernst JF, 2000, MICROBIOL-SGM, V146, P1763, DOI 10.1099/00221287-146-8-1763; Fares H, 1996, J CELL BIOL, V132, P399, DOI 10.1083/jcb.132.3.399; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; FORD SK, 1991, DEV GENET, V12, P281, DOI 10.1002/dvg.1020120405; Frazier JA, 1998, J CELL BIOL, V143, P737, DOI 10.1083/jcb.143.3.737; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Gale C, 2001, MOL BIOL CELL, V12, P3538, DOI 10.1091/mbc.12.11.3538; Gerami-Nejad M, 2001, YEAST, V18, P859, DOI 10.1002/yea.738; Giot L, 1997, MOL BIOL CELL, V8, P987, DOI 10.1091/mbc.8.6.987; Gladfelter AS, 2001, CURR OPIN MICROBIOL, V4, P681, DOI 10.1016/S1369-5274(01)00269-7; Gow Neil A. R., 2002, P145; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kartmann B, 2001, J CELL SCI, V114, P839; Liu HP, 2001, CURR OPIN MICROBIOL, V4, P728, DOI 10.1016/S1369-5274(01)00275-2; Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Mitchell AP, 1998, CURR OPIN MICROBIOL, V1, P687, DOI 10.1016/S1369-5274(98)80116-1; Mortensen EM, 2002, MOL BIOL CELL, V13, P2091, DOI 10.1091/mbc.01-10-0500; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; OHAMA T, 1993, NUCLEIC ACIDS RES, V21, P4039, DOI 10.1093/nar/21.17.4039; OZSARAC N, 1995, GENE, V164, P157, DOI 10.1016/0378-1119(95)00438-C; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; SANTOS MAS, 1995, NUCLEIC ACIDS RES, V23, P1481, DOI 10.1093/nar/23.9.1481; Sudbery PE, 2001, MOL MICROBIOL, V41, P19, DOI 10.1046/j.1365-2958.2001.02459.x; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Takizawa PA, 2000, SCIENCE, V290, P341, DOI 10.1126/science.290.5490.341; Tang CSL, 2002, CELL CYCLE, V1, P42, DOI 10.4161/cc.1.1.99; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519; Versele M, 2004, J CELL BIOL, V164, P701, DOI 10.1083/jcb.200312070; Warenda AJ, 2002, MOL BIOL CELL, V13, P2732, DOI 10.1091/mbc.E02-01-0013; Whiteway M, 2000, CURR OPIN MICROBIOL, V3, P582, DOI 10.1016/S1369-5274(00)00144-2; Wilson RB, 1999, J BACTERIOL, V181, P1868, DOI 10.1128/JB.181.6.1868-1874.1999; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	45	26	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40861	40867		10.1074/jbc.M406422200	http://dx.doi.org/10.1074/jbc.M406422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15277521	hybrid			2022-12-27	WOS:000223916800081
J	Paul, S; Karle, S; Planque, S; Taguchi, H; Salas, M; Nishiyama, Y; Handy, B; Hunter, R; Edmundson, A; Hanson, C				Paul, S; Karle, S; Planque, S; Taguchi, H; Salas, M; Nishiyama, Y; Handy, B; Hunter, R; Edmundson, A; Hanson, C			Naturally occurring proteolytic antibodies - Selective immunoglobulin M-catalyzed hydrolysis of HIV gp120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPERANTIGEN-BINDING-SITE; IRREVERSIBLE INHIBITORS; MONOCLONAL-ANTIBODIES; RHEUMATOID-ARTHRITIS; SERINE PROTEASES; CD4 RECEPTOR; LIGHT-CHAIN; NEUTRALIZATION; ANTIGEN; PEPTIDE	We report the selective catalytic cleavage of the HIV coat protein gp120, a B cell superantigen, by IgM antibodies (Abs) from uninfected humans and mice that had not been previously exposed to gp120. The rate of IgM-catalyzed gp120 cleavage was greater than of other polypeptide substrates, including the bacterial superantigen protein A. The kinetic parameters of gp120 cleavage varied over a broad range depending on the source of the IgMs, and turnover numbers as great as 2.1/min were observed, suggesting that different Abs possess distinct gp120 recognition properties. IgG Abs failed to cleave gp120 detectably. The Fab fragment of a monoclonal IgM cleaved gp120, suggesting that the catalytic activity belongs to the antibody combining site. The electrophoretic profile of gp120 incubated with a monoclonal human IgM suggested hydrolysis at several sites. One of the cleavage sites was identified as the Lys(432)-Ala(433) peptide bond, located within the region thought to be the Ab-recognizable superantigenic determinant. A covalently reactive peptide analog (CRA) corresponding to gp120 residues 421-431 with a C-terminal amidino phosphonate diester mimetic of the Lys(432)-Ala(433) bond was employed to probe IgM nucleophilic reactivity. The peptidyl CRA inhibited the IgM-catalyzed cleavage of gp120 and formed covalent IgM adducts at levels exceeding a control hapten CRA devoid of the peptide sequence. These observations suggest that IgMs can selectively cleave gp120 by a nucleophilic mechanism and raise the possibility of their role as defense enzymes.	Univ Texas, Hlth Sci Ctr,Houston Med Sch, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Oklahoma Med Res Fdn, Crystallog Program, Oklahoma City, OK 73104 USA; Calif Dept Hlth Serv, Viral & Rickettsial Dis Lab, Richmond, CA 94804 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; Oklahoma Medical Research Foundation; California Department of Health Care Services	Paul, S (corresponding author), Univ Texas, Hlth Sci Ctr,Houston Med Sch, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, Med Sci Bld,Rm 2-250, Houston, TX 77030 USA.	Sudhir.Paul@uth.tmc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046029, R21AI031268, R01AI031268] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31268, AI46029] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERBERIAN L, 1993, SCIENCE, V261, P1588, DOI 10.1126/science.7690497; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; CHAVIN SI, 1969, J BIOL CHEM, V244, P1345; CORNISHBOWDEN AJ, 1969, BIOCHEM J, V113, P353, DOI 10.1042/bj1130353; GAO QS, 1995, J MOL BIOL, V253, P658, DOI 10.1006/jmbi.1995.0580; Gololobov G, 1999, MOL IMMUNOL, V36, P1215, DOI 10.1016/S0161-5890(99)00141-8; GOODGLICK L, 1995, J IMMUNOL, V155, P5151; Hatiuchi K, 2003, IMMUNOL LETT, V86, P249, DOI 10.1016/S0165-2478(03)00030-0; He YX, 2002, J IMMUNOL, V169, P595, DOI 10.4049/jimmunol.169.1.595; Juompan L, 1998, FASEB J, V12, P1473, DOI 10.1096/fasebj.12.14.1473; KALAGA R, 1995, J IMMUNOL, V155, P2695; Karle S, 2004, AIDS, V18, P329, DOI 10.1097/00002030-200401230-00026; Karle S, 2003, VACCINE, V21, P1213, DOI 10.1016/S0264-410X(02)00504-2; Karray S, 1997, P NATL ACAD SCI USA, V94, P1356, DOI 10.1073/pnas.94.4.1356; Karray S, 1998, J IMMUNOL, V161, P6681; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lacroix-Desmazes S, 1999, NAT MED, V5, P1044, DOI 10.1038/12483; MACKENZIE MR, 1978, J IMMUNOL, V7, P367; Marangoni AG, 2003, ENZYME KINETICS MODE, P50; Matsuura K, 1998, IMMUNOLOGY, V95, P26; Matsuura K, 1996, BIOL CHEM, V377, P587, DOI 10.1515/bchm3.1996.377.9.587; Moore J, 1997, AIDS RES HUM RETROV, V13, P733, DOI 10.1089/aid.1997.13.733; MORELOCK MM, 1994, J BIOL CHEM, V269, P13048; MORROW WJW, 1992, IMMUNOLOGY, V75, P557; Neshat MN, 2000, INT IMMUNOL, V12, P305, DOI 10.1093/intimm/12.3.305; Nishiyama Y, 2002, ARCH BIOCHEM BIOPHYS, V402, P281, DOI 10.1016/S0003-9861(02)00087-5; OLEKSYSZYN J, 1994, METHOD ENZYMOL, V244, P423; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; Paul S, 2003, J BIOL CHEM, V278, P20429, DOI 10.1074/jbc.M300870200; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; Paul S, 2001, J BIOL CHEM, V276, P28314, DOI 10.1074/jbc.M102530200; Planque S, 2004, J BIOL CHEM, V279, P14024, DOI 10.1074/jbc.M312152200; Planque S, 2003, J BIOL CHEM, V278, P20436, DOI 10.1074/jbc.M301468200; POLLARD SR, 1991, P NATL ACAD SCI USA, V88, P11320, DOI 10.1073/pnas.88.24.11320; Powers JC, 2002, CHEM REV, V102, P4639, DOI 10.1021/cr010182v; Richieri SP, 1998, VACCINE, V16, P119, DOI 10.1016/S0264-410X(97)00196-5; Roux KH, 1998, J IMMUNOL, V161, P4083; SAMPSON NS, 1991, BIOCHEMISTRY-US, V30, P2255, DOI 10.1021/bi00222a031; Shaw DC, 2002, J MOL RECOGNIT, V15, P341, DOI 10.1002/jmr.596; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; Siliciano RF, 1996, CURR TOP MICROBIOL, V205, P159; SILVERMAN GJ, 1993, J IMMUNOL, V151, P5840; Sun M, 1997, J MOL BIOL, V271, P374, DOI 10.1006/jmbi.1997.1196; Taguchi H, 2002, BIOORG MED CHEM LETT, V12, P3167, DOI 10.1016/S0960-894X(02)00640-6; TownsleyFuchs J, 1996, J CLIN INVEST, V98, P1794, DOI 10.1172/JCI118979; VANERP R, 1991, J IMMUNOL METHODS, V140, P235, DOI 10.1016/0022-1759(91)90376-Q; Wentworth AD, 2000, P NATL ACAD SCI USA, V97, P10930, DOI 10.1073/pnas.97.20.10930	49	70	81	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39611	39619		10.1074/jbc.M406719200	http://dx.doi.org/10.1074/jbc.M406719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15269209	hybrid			2022-12-27	WOS:000223791500051
J	Pike, BL; Tenis, N; Heierhorst, J				Pike, BL; Tenis, N; Heierhorst, J			Rad53 kinase activation-independent replication checkpoint function of the N-terminal forkhead-associated (FHA1) domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; S-PHASE CHECKPOINT; CELL-CYCLE PROGRESSION; DOUBLE-STRAND BREAK; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; BUDDING YEAST; CDC7P-DBF4P KINASE; TUMOR-SUPPRESSOR; PHOSPHORYLATION	Saccharomyces cerevisiae Rad53 has crucial functions in many aspects of the cellular response to DNA damage and replication blocks. To coordinate these diverse roles, Rad53 has two forkhead-associated (FHA) phosphothreonine-binding domains in addition to a kinase domain. Here, we show that the conserved N-terminal FHA1 domain is essential for the function of Rad53 to prevent the firing of late replication origins in response to replication blocks. However, the FHA1 domain is not required for Rad53 activation during S phase, and as a consequence of defective downstream signaling, Rad53 containing an inactive FHA1 domain is hyperphosphorylated in response to replication blocks. The FHA1 mutation dramatically hypersensitizes strains with defects in the cell cycle-wide checkpoint pathways (rad9Delta and rad17Delta) to DNA damage, but it is largely epistatic with defects in the replication checkpoint (mrc1Delta). Altogether, our data indicate that the FHA1 domain links activated Rad53 to downstream effectors in the replication checkpoint. The results reveal an important mechanistic difference to the homologous Schizosaccharomyces pombe FHA domain that is required for Mrc1-dependent activation of the corresponding Cds1 kinase. Surprisingly, despite the severely impaired replication checkpoint and also G(2)/M checkpoint functions, the FHA1 mutation by itself leads to only moderate viability defects in response to DNA damage, highlighting the importance of functionally redundant pathways.	Univ Melbourne, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research; University of Melbourne; University of Melbourne	Pike, BL (corresponding author), Univ Melbourne, St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.	bpike@svi.edu.au	Pike, Brietta L./H-5317-2019	Pike, Brietta L./0000-0002-4763-1729				Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Bashkirov VI, 2000, MOL CELL BIOL, V20, P4393, DOI 10.1128/MCB.20.12.4393-4404.2000; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Chen XB, 2001, MOL CELL, V8, P1117, DOI 10.1016/S1097-2765(01)00375-6; Clarke DJ, 2001, NAT CELL BIOL, V3, P619, DOI 10.1038/35083009; de la Torre-Ruiz MA, 1998, EMBO J, V17, P2687, DOI 10.1093/emboj/17.9.2687; Duncker BP, 2002, P NATL ACAD SCI USA, V99, P16087, DOI 10.1073/pnas.252093999; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Foiani M, 2000, MUTAT RES-FUND MOL M, V451, P187, DOI 10.1016/S0027-5107(00)00049-X; Foiani M, 1997, TRENDS BIOCHEM SCI, V22, P424; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Hammet A, 2000, FEBS LETT, V471, P141, DOI 10.1016/S0014-5793(00)01392-2; Hammet A, 2003, IUBMB LIFE, V55, P23, DOI 10.1080/1521654031000070636; Hammet A, 2002, J BIOL CHEM, V277, P22469, DOI 10.1074/jbc.M202473200; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Jares P, 2000, EMBO REP, V1, P319, DOI 10.1093/embo-reports/kvd076; Kihara M, 2000, J BIOL CHEM, V275, P35051, DOI 10.1074/jbc.M003491200; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kondo T, 1999, MOL CELL BIOL, V19, P1136; Lee SJ, 2003, MOL CELL BIOL, V23, P6300, DOI 10.1128/MCB.23.17.6300-6314.2003; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Liao H, 2000, J MOL BIOL, V304, P941, DOI 10.1006/jmbi.2000.4291; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; McGowan CH, 2002, CELL CYCLE, V1, P401, DOI 10.4161/cc.1.6.264; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Muzi-Falconi M, 2003, CELL CYCLE, V2, P564, DOI 10.4161/cc.2.6.553; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Paciotti V, 2001, MOL CELL BIOL, V21, P3913, DOI 10.1128/MCB.21.12.3913-3925.2001; Pasero P, 1999, GENE DEV, V13, P2159, DOI 10.1101/gad.13.16.2159; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Pike BL, 2004, MOL CELL BIOL, V24, P2779, DOI 10.1128/MCB.24.7.2779-2788.2004; Pike BL, 2003, J BIOL CHEM, V278, P30421, DOI 10.1074/jbc.C300227200; Pike BL, 2001, J BIOL CHEM, V276, P14019, DOI 10.1074/jbc.M009558200; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Schwartz MF, 2003, CELL CYCLE, V2, P384, DOI 10.4161/cc.2.4.457; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Shimada K, 2002, GENE DEV, V16, P3236, DOI 10.1101/gad.239802; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tanaka K, 2004, J BIOL CHEM, V279, P32079, DOI 10.1074/jbc.M404834200; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	68	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39636	39644		10.1074/jbc.M405080200	http://dx.doi.org/10.1074/jbc.M405080200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15271990	hybrid			2022-12-27	WOS:000223791500054
J	Boldt, HB; Kjaer-Sorensen, K; Overgaard, MT; Weyer, K; Poulsen, CB; Sottrup-Jensen, L; Conover, CA; Giudice, LC; Oxvig, C				Boldt, HB; Kjaer-Sorensen, K; Overgaard, MT; Weyer, K; Poulsen, CB; Sottrup-Jensen, L; Conover, CA; Giudice, LC; Oxvig, C			The Lin12-Notch repeats of pregnancy-associated plasma protein-A bind calcium and determine its proteolytic specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR BASIC-PROTEIN; PHYSIOLOGICAL INHIBITOR; HUMAN NOTCH1; PAPP-A; GROWTH; EXPRESSION; MODULE; IGF; IDENTIFICATION; TRANSDUCTION	The Lin12-Notch repeat (LNR) module of about 35 residues is a hallmark of the Notch receptor family. Three copies, arranged in tandem, are invariably present in the extracellular portion of the Notch receptors. Although their function is unknown, genetic and biochemical data indicate that the LNR modules participate in the regulation of ligand-induced proteolytic cleavage of the Notch receptor, a prerequisite to intramembrane cleavage and Notch signaling. Outside the Notch receptor family, the LNR module is present only in the metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) and its homologue PAPP-A2, which also contain three copies. Curiously, LNR modules 1 and 2 are present within the proteolytic domain of PAPP-A/A2, but LNR3 is separated from LNR2 by more than 1000 amino acids. The growth factor antagonists insulin-like growth factor-binding protein (IGFBP)-4 and -5 are both substrates of PAPP- A. We provide here evidence that the PAPP- A LNR modules function together to determine the proteolytic specificity of PAPP- A. Analysis of C-terminally truncated PAPP- A mutants followed by the analysis of LNR deletion mutants demonstrated that each of the three PAPP- A LNR modules is strictly required for proteolytic activity against IGFBP-4 but not for proteolytic activity against IGFBP-5. Individual substitution of conserved LNR residues predicted to participate in calcium coordination caused elimination (D341A, D356A, D389A, D1484A, D1499A, and D1502A) or a significant reduction (D359A and E392A) of IGFBP-4 proteolysis, whereas IGFBP-5 proteolysis was unaffected. The activity of the latter mutants against IGFBP-4 could be partially rescued by calcium, and the addition of the calcium-binding protein calbindin D9k to wild-type PAPP- A eliminated activity against IGFBP-4 but not against IGFBP-5, demonstrating that the PAPP- A LNR modules bind calcium ions. We propose a model in which LNR3 is spatially localized in proximity to LNR1 and -2, forming a single functional unit.	Univ Aarhus, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Mayo Clin & Mayo Fdn, Endocrine Res Unit, Rochester, MN 55905 USA; Stanford Univ, Dept Gynecol & Obstet, Stanford, CA 94305 USA	Aarhus University; Mayo Clinic; Stanford University	Oxvig, C (corresponding author), Univ Aarhus, Dept Mol Biol, Sci Pk,Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	co@mb.au.dk	Kjaer-Sorensen, Kasper/AAF-1457-2020; Overgaard, Michael Toft/E-1354-2011	Overgaard, Michael Toft/0000-0002-1423-2481; Oxvig, Claus/0000-0002-4715-9719; Weyer, Kathrin/0000-0002-8473-7987	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031579] Funding Source: NIH RePORTER; NICHD NIH HHS [HD31579-07] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1999, BIOCHEMISTRY-US, V38, P4736, DOI 10.1021/bi982713o; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; Bayes-Genis A, 2001, NEW ENGL J MED, V345, P1022, DOI 10.1056/NEJMoa003147; Boldt HB, 2001, BIOCHEM J, V358, P359, DOI 10.1042/0264-6021:3580359; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Bunn RC, 2003, TRENDS ENDOCRIN MET, V14, P176, DOI 10.1016/S1043-2760(03)00049-3; Chen BK, 2003, J CLIN ENDOCR METAB, V88, P4465, DOI 10.1210/jc.2003-030193; Conover CA, 2004, DEVELOPMENT, V131, P1187, DOI 10.1242/dev.00997; Conover CA, 2001, ENDOCRINOLOGY, V142, P2155, DOI 10.1210/en.142.5.2155; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Giudice LC, 2002, J CLIN ENDOCR METAB, V87, P2359, DOI 10.1210/jc.87.5.2359; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHANSSON C, 1990, EUR J BIOCHEM, V187, P455, DOI 10.1111/j.1432-1033.1990.tb15325.x; Kimble J, 1998, TRENDS BIOCHEM SCI, V23, P353, DOI 10.1016/S0968-0004(98)01263-8; KRISTENSEN T, 1994, BIOCHEMISTRY-US, V33, P1592, DOI 10.1021/bi00172a040; Laursen LS, 2002, J BIOL CHEM, V277, P47225, DOI 10.1074/jbc.M209155200; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; LINSE S, 1991, BIOCHEMISTRY-US, V30, P154, DOI 10.1021/bi00215a023; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nam Y, 2002, CURR OPIN CHEM BIOL, V6, P501, DOI 10.1016/S1367-5931(02)00346-0; Ortiz CO, 2003, J BONE MINER RES, V18, P1066, DOI 10.1359/jbmr.2003.18.6.1066; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Overgaard MT, 2000, J BIOL CHEM, V275, P31128, DOI 10.1074/jbc.M001384200; Overgaard MT, 1999, BIOL REPROD, V61, P1083, DOI 10.1095/biolreprod61.4.1083; Overgaard MT, 2003, J BIOL CHEM, V278, P2106, DOI 10.1074/jbc.M208777200; Overgaard MT, 2001, J BIOL CHEM, V276, P21849, DOI 10.1074/jbc.M102191200; OXVIG C, 1994, BBA-GEN SUBJECTS, V1201, P415, DOI 10.1016/0304-4165(94)90071-X; OXVIG C, 2004, HDB PROTEOLYTIC ENZY, V1, P754; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Qin QP, 1997, CLIN CHEM, V43, P2323; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; Raya A, 2004, NATURE, V427, P121, DOI 10.1038/nature02190; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Smith GCS, 2002, NATURE, V417, P916, DOI 10.1038/417916a; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; STOCKER W, 1995, PROTEIN SCI, V4, P823; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Vardar D, 2003, BIOCHEMISTRY-US, V42, P7061, DOI 10.1021/bi034156y; Weyer K, 2004, EUR J BIOCHEM, V271, P1525, DOI 10.1111/j.1432-1033.2004.04061.x	47	45	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38525	38531		10.1074/jbc.M405222200	http://dx.doi.org/10.1074/jbc.M405222200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15262980	hybrid			2022-12-27	WOS:000223684100058
J	Cardenas, C; Muller, M; Jaimovich, E; Perez, F; Buchuk, D; Quest, AFG; Carrasco, MA				Cardenas, C; Muller, M; Jaimovich, E; Perez, F; Buchuk, D; Quest, AFG; Carrasco, MA			Depolarization of skeletal muscle cells induces phosphorylation of cAMP response element binding protein via calcium and protein kinase C alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ACETYLCHOLINE-RECEPTOR; PHOSPHOLIPASE-C; CA2+ SIGNALS; TRANSIENTS; CREB; SLOW; LOCALIZATION; CONTRACTION; ACTIVATION	Membrane depolarization of skeletal muscle cells induces slow inositol trisphosphate-mediated calcium signals that regulate the activity of transcription factors such as the cAMP-response element-binding protein (CREB), jun, and fos. Here we investigated whether such signals regulate CREB phosphorylation via protein kinase C (PKC)-dependent pathways. Western blot analysis revealed the presence of seven isoforms (PKCalpha, -betaI, -betaII, -delta, -epsilon, -theta, and -zeta) in rat primary myotubes. The PKC inhibitors bisindolymaleimide I and Go6976, blocked CREB phosphorylation. Chronic exposure to phorbol ester triggered complete down-regulation of several isoforms, but reduced PKCalpha levels to only 40%, and did not prevent CREB phosphorylation upon myotube depolarization. Immunocytochemical analysis revealed selective and rapid PKCalpha translocation to the nucleus following depolarization, which was blocked by 2-amino-ethoxydiphenyl borate, an inositol trisphosphate receptor inhibitor, and by the phospholipase C inhibitor U73122. In C2C12 cells, which expressed PKCalpha, -epsilon, and -zeta, CREB phosphorylation also depended on PKCalpha. These results strongly implicate nuclear PKCalpha translocation in CREB phosphorylation induced by skeletal muscle membrane depolarization.	Univ Chile, Fac Med, Ctr Estudios Mol celula, Inst Ciencias Biomed, Santiago 7, Chile	Universidad de Chile	Quest, AFG (corresponding author), Univ Chile, Fac Med, Ctr Estudios Mol celula, Inst Ciencias Biomed, Independencia 1027, Santiago 7, Chile.	aquest@med.uchile.cl; mcarras@med.uchile.cl	Jaimovich, Enrique/AAY-7632-2020; Muller, Marioly/J-5420-2014					Altiok N, 2001, FEBS LETT, V487, P333, DOI 10.1016/S0014-5793(00)02311-5; Araya R, 2003, J GEN PHYSIOL, V121, P3, DOI 10.1085/jgp.20028671; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Boczan J, 2000, ACTA NEUROPATHOL, V99, P96, DOI 10.1007/PL00007429; Boczan J, 2001, ACTA NEUROPATHOL, V102, P55; Braiman L, 1999, DIABETES, V48, P1922, DOI 10.2337/diabetes.48.10.1922; Braz JC, 2002, J CELL BIOL, V156, P905, DOI 10.1083/jcb.200108062; Buchner K, 2000, J CANCER RES CLIN, V126, P1, DOI 10.1007/PL00008458; Buitrago CG, 2003, J BIOL CHEM, V278, P2199, DOI 10.1074/jbc.M205732200; Capiati DA, 2000, J CELL BIOCHEM, V77, P200, DOI 10.1002/(SICI)1097-4644(20000501)77:2<200::AID-JCB4>3.0.CO;2-5; Carrasco MA, 2003, AM J PHYSIOL-CELL PH, V284, pC1438, DOI 10.1152/ajpcell.00117.2002; Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200; DIKES AC, 2003, AM J PHYSIOL, V285, pC76; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Estrada M, 2001, J BIOL CHEM, V276, P22868, DOI 10.1074/jbc.M100118200; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hardingham GE, 2001, NAT NEUROSCI, V4, P261, DOI 10.1038/85109; IMPEY S, 2001, SCI STKE, V82, pPE1; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P1; Jaimovich E, 2002, BIOL RES, V35, P195, DOI 10.4067/S0716-97602002000200010; JAIMOVICH E, 1994, CELL CALCIUM, V15, P356, DOI 10.1016/0143-4160(94)90011-6; Jaimovich E, 2000, AM J PHYSIOL-CELL PH, V278, pC998, DOI 10.1152/ajpcell.2000.278.5.C998; Jordan T, 2003, J CELL BIOL, V162, P843, DOI 10.1083/jcb.200303164; LI E, 2002, ACTA PHYSL SCAND, V173, P237; Luo B, 2003, J BIOL CHEM, V278, P39542, DOI 10.1074/jbc.M307153200; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Macpherson P, 2002, J BIOL CHEM, V277, P15638, DOI 10.1074/jbc.M109864200; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; Neri LM, 1998, J BIOL CHEM, V273, P29738, DOI 10.1074/jbc.273.45.29738; POHORSKA A, 2003, J NEUROCHEM, V84, P447; Powell JA, 1996, J CELL BIOL, V134, P375, DOI 10.1083/jcb.134.2.375; Powell JA, 2001, J CELL SCI, V114, P3673; Quest AFG, 1996, ENZYME PROTEIN, V49, P231, DOI 10.1159/000468635; QUEST AFG, 2000, RRD BIOCHEM, V2, P171; RICHTER EA, 1987, FEBS LETT, V217, P232, DOI 10.1016/0014-5793(87)80669-5; Roberson ED, 1999, J NEUROSCI, V19, P4337; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Wu GY, 2001, NAT NEUROSCI, V4, P151, DOI 10.1038/83976; Xu AM, 2001, J BIOL CHEM, V276, P14980, DOI 10.1074/jbc.M009144200	48	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39122	39131		10.1074/jbc.M401044200	http://dx.doi.org/10.1074/jbc.M401044200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15262987	hybrid			2022-12-27	WOS:000223684100128
J	Amini, S; Saunders, M; Kelley, K; Khalili, K; Sawaya, BE				Amini, S; Saunders, M; Kelley, K; Khalili, K; Sawaya, BE			Interplay between HIV-1 Vpr and Sp1 modulates p21(WAF1) gene expression in human astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSCRIPTION FACTOR SP1; TUMOR-SUPPRESSOR PROTEIN; ELEMENT-BINDING PROTEIN; LONG TERMINAL REPEAT; KRUPPEL-LIKE FACTOR; GROWTH-FACTOR-BETA; CELL-CYCLE; SYNERGISTIC ACTIVATION; FUNCTIONAL INTERACTION	The Vpr (viral protein R) of human immunodeficiency virus, type 1, which is expressed during the late stage of the viral infection, has received special attention because of its ability to control transcription of the human immunodeficiency virus, type 1, long terminal repeat and to influence cell cycle progression. Here we demonstrate that Vpr has the ability to regulate transcription of the cyclin-dependent kinase inhibitor, p21(WAF1) (p21), one of the key regulators of the cell cycle, in human astrocytic cells. The results from transcription assays demonstrated that Vpr augments promoter activity of p21 through the GC-rich region located between nucleotides -84 and -74 with respect to the + 1 transcription start site. Activation of p21 by Vpr required cooperativity of Sp1, which binds to the DNA sequence spanning -84 to -74. Results from bandshift assay revealed an increased level of Sp1 DNA binding activity in the presence of Vpr. Furthermore, Vpr was able to associate with Sp1 via the zinc finger domain located in the C-terminal region of Sp1. Functional studies revealed that the cooperativity between Vpr and Sp1 requires the zinc finger domain at the C terminus and the glutamine-rich domain at the N terminus of Sp1. Expression of p53 further enhanced the level of Vpr-Sp1-mediated transcription activation of p21 through the sequence spanning -84 to -74 and increased the DNA binding activity of Sp1 in the presence of Vpr. Results from glutathione S-transferase pull-down assay showed the association of Vpr with p53 in extracts containing Sp1. Altogether, the outcome of our functional and binding studies suggested that the physical interaction of Vpr with Sp1 and p53 could modulate transcriptional activity of p21.	Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Sawaya, BE (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, 1900 N 12th St 015-96, Philadelphia, PA 19122 USA.	sawaya@temple.edu			NINDS NIH HHS [R01 NS040673-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040673] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amini S, 2002, ONCOGENE, V21, P5797, DOI 10.1038/sj.onc.1205754; Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Chang YC, 2001, MOL CELL BIOL, V21, P1121, DOI 10.1128/MCB.21.4.1121-1131.2001; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Darbinian N, 2001, J NEUROIMMUNOL, V121, P3, DOI 10.1016/S0165-5728(01)00372-1; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dovat S, 2002, GENE DEV, V16, P2985, DOI 10.1101/gad.1040502; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Esposito F, 1997, EUR J BIOCHEM, V245, P730, DOI 10.1111/j.1432-1033.1997.00730.x; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; Hasleton MD, 2003, BIOCHEM J, V373, P925, DOI 10.1042/BJ20030388; Hilton TL, 2003, J BIOL CHEM, V278, P12992, DOI 10.1074/jbc.M300412200; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kim BJ, 2002, CARCINOGENESIS, V23, P1411, DOI 10.1093/carcin/23.9.1411; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Lu XH, 2003, CELL CYCLE, V2, P59, DOI 10.4161/cc.2.1.273; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; Sawaya BE, 2000, J BIOL CHEM, V275, P35209, DOI 10.1074/jbc.M005197200; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN JM, 1993, FEBS LETT, V331, P141, DOI 10.1016/0014-5793(93)80313-J; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; Wang Z, 2000, CANCER RES, V60, P5376; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; Zhang XL, 2003, J BIOL CHEM, V278, P21474, DOI 10.1074/jbc.M212098200; Zhou YH, 2002, CANCER INVEST, V20, P348, DOI 10.1081/CNV-120001180; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	59	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46046	46056		10.1074/jbc.M403792200	http://dx.doi.org/10.1074/jbc.M403792200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15302882	hybrid			2022-12-27	WOS:000224694900090
J	Ohnishi, H; Nakahara, T; Furuse, K; Sasaki, H; Tsukita, S; Furuse, M				Ohnishi, H; Nakahara, T; Furuse, K; Sasaki, H; Tsukita, S; Furuse, M			JACOP, a novel plaque protein localizing at the apical junctional complex with sequence similarity to cingulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNDERCOAT-CONSTITUTIVE PROTEIN; TIGHT JUNCTION; ADHESION MOLECULE; EPITHELIAL-CELLS; PARACELLULAR PERMEABILITY; ADHERENS JUNCTIONS; MEMBRANE-PROTEIN; ACTIN-FILAMENTS; DIRECT BINDING; ZO-1	The apical junctional complex is composed of various cell adhesion molecules and cytoplasmic plaque proteins. Using a monoclonal antibody that recognizes a chicken 155-kDa cytoplasmic antigen (p155) localizing at the apical junctional complex, we have cloned a cDNA of its mouse homologue. The full-length cDNA of mouse p155 encoded a 148-kDa polypeptide containing a coiled-coil domain with sequence similarity to cingulin, a tight junction (TJ)-associated plaque protein. We designated this protein JACOP (junction-associated coiled-coil protein). Immunofluorescence staining showed that JACOP was concentrated in the junctional complex in various types of epithelial and endothelial cells. Furthermore, in the liver and kidney, JACOP was also distributed along nonjunctional actin filaments. Upon immunoelectron microscopy, JACOP was found to be localized to the undercoat of TJs in the liver, but in some tissues, its distribution was not restricted to TJs but extended to the area of adherens junctions. Overexpression studies have revealed that JACOP was recruited to the junctional complex in epithelial cells and to cell-cell contacts and stress fibers in fibroblasts. These findings suggest that JACOP is involved in anchoring the apical junctional complex, especially TJs, to actin-based cytoskeletons.	Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan; KAN Res Inst, Kyoto 6068507, Japan; Jikei Univ, Sch Med, Inst DNA Med, Dept Mol Cell Biol,Minato Ku, Tokyo 105, Japan	Kyoto University; KAN Research Institute; Jikei University	Furuse, M (corresponding author), Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan.	furuse@mfour.med.kyoto-u.ac.jp		Ohnishi, Hiroe/0000-0003-3437-680X; Furuse, Mikio/0000-0003-2847-8156; Sasaki, Hiroyuki/0000-0002-5358-5853; Furuse, Kyoko/0000-0003-4304-6204				ANDERSON JM, 1995, AM J PHYSIOL, V269, P467; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; Benais-Pont G, 2003, J CELL BIOL, V160, P729, DOI 10.1083/jcb.200211047; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; Cordenonsi M, 1999, J CELL BIOL, V147, P1569, DOI 10.1083/jcb.147.7.1569; DARTI F, 2001, FEBS LETT, V507, P21; DARTI F, 2002, J BIOL CHEM, V277, P27757; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hecht G, 1996, AM J PHYSIOL-CELL PH, V271, pC1678, DOI 10.1152/ajpcell.1996.271.5.C1678; Hirase T, 1997, EUR J CELL BIOL, V72, P174; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Kawabe H, 2001, J BIOL CHEM, V276, P48350, DOI 10.1074/jbc.M107335200; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laura RP, 2002, EXP CELL RES, V275, P155, DOI 10.1006/excr.2002.5475; MADARA JL, 1987, AM J PHYSIOL, V253, P171; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1235, DOI 10.1006/bbrc.1994.2063; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; Nishimura M, 2002, J BIOL CHEM, V277, P5583, DOI 10.1074/jbc.M110154200; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; RODEWALD R, 1976, J CELL BIOL, V70, P541, DOI 10.1083/jcb.70.3.541; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Schneeberger EE, 1992, AM J PHYSIOL, V262, P647; STEVENSON BR, 1989, AM J PHYSIOL, V257, pC621, DOI 10.1152/ajpcell.1989.257.4.C621; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STEVENSON BR, 1994, J CELL SCI, V107, P367; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Turner JR, 1997, AM J PHYSIOL-CELL PH, V273, pC1378, DOI 10.1152/ajpcell.1997.273.4.C1378; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477; [No title captured]	51	63	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46014	46022		10.1074/jbc.M402616200	http://dx.doi.org/10.1074/jbc.M402616200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15292197	hybrid			2022-12-27	WOS:000224694900087
J	Hynes, TR; Mervine, SM; Yost, EA; Sabo, JL; Berlot, CH				Hynes, TR; Mervine, SM; Yost, EA; Sabo, JL; Berlot, CH			Live cell imaging of G(s) and the beta(2)-adrenergic receptor demonstrates that both alpha(s) and beta(1)gamma(7) internalize upon stimulation and exhibit similar trafficking patterns that differ from that of the beta(2)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; INDUCED SUBCELLULAR REDISTRIBUTION; BETA-GAMMA-SUBUNIT; BIMOLECULAR FLUORESCENCE COMPLEMENTATION; PLASMA-MEMBRANE; LIVING CELLS; ADENYLYL-CYCLASE; MEDIATED ENDOCYTOSIS; ADENOSINE RECEPTORS; CRYSTAL-STRUCTURE	To visualize and investigate the regulation of the localization patterns of G(s) and an associated receptor during cell signaling, we produced functional fluorescent fusion proteins and imaged them in HEK-293 cells. alpha(s)-CFP, with cyan fluorescent protein (CFP) inserted into an internal loop of alpha(s), localized to the plasma membrane and exhibited similar receptor-mediated activity to that of alpha(s). Functional fluorescent beta(1)gamma(7) dimers were produced by fusing an amino-terminal yellow fluorescent protein (YFP) fragment to beta(1) (YFP-N-beta(1)) and a carboxyl-terminal YFP fragment to gamma(7) (YFP-C-gamma(7)). When expressed together, YFP-N-beta(1) and YFP-C-gamma(7) produced fluorescent signals in the plasma membrane that were not seen when the subunits were expressed separately. Isoproterenol stimulation of cells co-expressing alpha(s)-CFP, YFP-N-beta(1)/YFP-C-gamma(7), and the beta(2)-adrenergic receptor (beta(2)AR) resulted in internalization of both fluorescent signals from the plasma membrane. Initially, alpha(s)-CFP and YFP-N-beta(1)/YFP-C-gamma(7) stained the cytoplasm diffusely, and subsequently they co-localized on vesicles that exhibited minimal overlap with beta(2)AR-labeled vesicles. Moreover, internalization of beta(2)AR-GFP, but not alphas-CFP or YFP-N-beta(1)/YFP-C-gamma(7), was inhibited by a fluorescent dominant negative dynamin 1 mutant, Dyn1(K44A)-mRFP, indicating that the G(s) subunits and beta(2)AR utilize different internalization mechanisms. Subsequent trafficking of the G(s) subunits and beta(2)AR also differed in that vesicles labeled with the G(s) subunits exhibited less overlap with RhoB-labeled endosomes and greater overlap with Rab11-labeled endosomes. Because Rab11 regulates traffic through recycling endosomes, colocalization of alpha(s) and beta(1)gamma(7) on these endosomes may indicate a means of recycling specific alpha(s)betagamma combinations to the plasma membrane.	Geisinger Med Clin, Weis Ctr Res, Danville, PA 17822 USA	Geisinger Medical Center	Berlot, CH (corresponding author), Geisinger Med Clin, Weis Ctr Res, 100 N Acad Ave, Danville, PA 17822 USA.	chberlot@geisinger.edu			NIGMS NIH HHS [GM50369] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050369, R01GM050369] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; COLOMBO MI, 1994, J BIOL CHEM, V269, P14919; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; Evanko DS, 2001, J BIOL CHEM, V276, P23945, DOI 10.1074/jbc.M101154200; Fan GH, 2003, BLOOD, V101, P2115, DOI 10.1182/blood-2002-07-1965; Figler RA, 1997, BIOCHEMISTRY-US, V36, P16288, DOI 10.1021/bi972000q; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HARAGUCHI K, 1991, P NATL ACAD SCI USA, V88, P5964, DOI 10.1073/pnas.88.14.5964; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hou YM, 2001, J BIOL CHEM, V276, P19982, DOI 10.1074/jbc.M010424200; Hou YM, 2000, J BIOL CHEM, V275, P38961, DOI 10.1074/jbc.C000604200; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Hurowitz EH, 2000, DNA RES, V7, P111, DOI 10.1093/dnares/7.2.111; Hynes TR, 2004, J BIOL CHEM, V279, P30279, DOI 10.1074/jbc.M401432200; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; JONES DT, 1987, J BIOL CHEM, V262, P14241; Kleuss C, 2003, EMBO J, V22, P826, DOI 10.1093/emboj/cdg095; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Kreuzer OJ, 2001, J NEUROENDOCRINOL, V13, P279, DOI 10.1046/j.1365-2826.2001.00630.x; LIU YC, 1994, J NEUROSCI, V14, P5807; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; Marra P, 2001, NAT CELL BIOL, V3, P1101, DOI 10.1038/ncb1201-1101; McIntire WE, 2001, J BIOL CHEM, V276, P15801, DOI 10.1074/jbc.M011233200; Medina R, 1996, J BIOL CHEM, V271, P24720, DOI 10.1074/jbc.271.40.24720; Michaelson D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/mbc.E02-02-0095; Mirshahi T, 2002, J BIOL CHEM, V277, P7348, DOI 10.1074/jbc.M109999200; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Moore RH, 1999, J CELL SCI, V112, P329; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NOVOTNY J, 1995, ARCH PHYSIOL BIOCHEM, V103, P202, DOI 10.3109/13813459508996134; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Ostrom RS, 2002, MOL PHARMACOL, V61, P473, DOI 10.1124/mol.61.3.473; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; ROBERTSON D, 1995, J HISTOCHEM CYTOCHEM, V43, P471, DOI 10.1177/43.5.7537292; Schwindinger WF, 2003, J BIOL CHEM, V278, P6575, DOI 10.1074/jbc.M211132200; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; Sheridan DL, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-7; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Thiyagarajan MM, 2002, BIOCHEMISTRY-US, V41, P9470, DOI 10.1021/bi025533u; UEDA N, 1994, J BIOL CHEM, V269, P4388; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; URBE S, 1993, FEBS LETT, V334, P175, DOI 10.1016/0014-5793(93)81707-7; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wang Q, 1999, J BIOL CHEM, V274, P17365, DOI 10.1074/jbc.274.24.17365; Wang Q, 1997, J BIOL CHEM, V272, P26040, DOI 10.1074/jbc.272.41.26040; Wang Q, 2001, J BIOL CHEM, V276, P39386, DOI 10.1074/jbc.M104981200; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Wedegaertner PB, 1996, MOL BIOL CELL, V7, P1225, DOI 10.1091/mbc.7.8.1225; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170; Yi TM, 2003, P NATL ACAD SCI USA, V100, P10764, DOI 10.1073/pnas.1834247100; Yu JZ, 2002, MOL PHARMACOL, V61, P352, DOI 10.1124/mol.61.2.352; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	81	83	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44101	44112		10.1074/jbc.M405151200	http://dx.doi.org/10.1074/jbc.M405151200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15297467	hybrid			2022-12-27	WOS:000224383100090
J	Lyon, M; Deakin, JA; Lietha, D; Gherardi, E; Gallagher, JT				Lyon, M; Deakin, JA; Lietha, D; Gherardi, E; Gallagher, JT			The interactions of hepatocyte growth factor/scatter factor and its NK1 and NK2 variants with glycosaminoglycans using a modified gel mobility shift assay - Elucidation of the minimal size of binding and activatory oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; MITOGENIC ACTIVITY; CRYSTAL-STRUCTURE; RECEPTOR-BINDING; SPLICE VARIANT; IN-VIVO; C-MET; HIGH-AFFINITY; DOMAIN	Full-length hepatocyte growth factor/scatter factor interacts with both heparan and dermatan sulfates and is critically dependent upon them as cofactors for activation of the tyrosine kinase receptor Met. Two C-terminally truncated variants (NK1 and NK2) of this growth factor also occur naturally. Their glycosaminoglycan binding properties are not clear. We have undertaken a comparative study of the heparan/dermatan sulfate binding characteristics of all three proteins. This has entailed the development of a modified gel mobility shift assay, utilizing fluorescence end-tagged oligosaccharides, that is also widely applicable to the analysis of many glycosaminoglycan-protein interactions. Using this we have shown that all three hepatocyte growth factor/scatter factor variants share identical heparan/ dermatan sulfate binding properties and that both glycosaminoglycans occupy the same binding site. The minimal size of the oligosaccharide that binds with high affinity in all cases is a tetrasaccharide from heparan sulfate but a hexasaccharide from dermatan sulfate. These findings demonstrate that functional glycosaminoglycan binding is restricted to a binding site situated solely within the small N-terminal domain. The same minimal size fractions are also able to promote hepatocyte growth factor/scatter factor-mediated activation of Met and consequent downstream signaling in the glycosaminoglycan-deficient Chinese hamster ovary pgsA-745 cells. A covalent complex of heparan sulfate tetrasaccharide with monovalent growth factor is also active. The binding and activity of tetrasaccharides put constraints upon the possible interactions and molecular geometry within the ternary signaling complex.	Christie Hosp Natl Hlth Serv Trust, Dept Med Oncol, CRUK Res Ctr, Manchester M20 4BX, Lancs, England; MRC Ctr, Growth Factor Grp, Cambridge CB2 2QH, England	Christie NHS Foundation Trust; Christie Hospital; MRC Laboratory Molecular Biology	Lyon, M (corresponding author), Christie Hosp Natl Hlth Serv Trust, Dept Med Oncol, CRUK Res Ctr, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	MLyon@picr.man.ac.uk	Gherardi, Ermanno/AAB-9608-2022; Lietha, Daniel/AAD-1952-2022; Lietha, Daniel/L-8041-2014	Lietha, Daniel/0000-0002-6133-6486; Lietha, Daniel/0000-0002-6133-6486; GHERARDI, ERMANNO/0000-0002-0016-2945; Lyon, Malcolm/0000-0001-9575-6879				Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Blackhall FH, 2003, BIOCHEM J, V375, P131, DOI 10.1042/BJ20030730; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Chirgadze DY, 1999, NAT STRUCT BIOL, V6, P72; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; Date K, 1997, FEBS LETT, V420, P1, DOI 10.1016/S0014-5793(97)01475-0; Deakin JA, 1999, J CELL SCI, V112, P1999; Delehedde M, 2002, J BIOL CHEM, V277, P12456, DOI 10.1074/jbc.M111345200; Gallagher JT, 2000, PROTEOGLYCANS STRUCT, P27; Gherardi E, 2003, P NATL ACAD SCI USA, V100, P12039, DOI 10.1073/pnas.2034936100; Hartmann G, 1998, CURR BIOL, V8, P125, DOI 10.1016/S0960-9822(98)70059-4; JACKSON P, 1994, METHOD ENZYMOL, V230, P250; Jakubczak JL, 1998, MOL CELL BIOL, V18, P1275, DOI 10.1128/MCB.18.3.1275; Lietha D, 2001, EMBO J, V20, P5543, DOI 10.1093/emboj/20.20.5543; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 2000, J BIOL CHEM, V275, P4599, DOI 10.1074/jbc.275.7.4599; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Lyon M, 2002, J BIOL CHEM, V277, P1040, DOI 10.1074/jbc.M107506200; Mahoney DJ, 2001, GLYCOBIOLOGY, V11, P1025, DOI 10.1093/glycob/11.12.1025; MARK MR, 1992, J BIOL CHEM, V267, P26166; Matsumoto K, 2001, KIDNEY INT, V59, P2023, DOI 10.1046/j.1523-1755.2001.00717.x; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; Otsuka T, 2000, MOL CELL BIOL, V20, P2055, DOI 10.1128/MCB.20.6.2055-2065.2000; Rahmoune H, 1998, BIOCHEMISTRY-US, V37, P6003, DOI 10.1021/bi972468t; Rubin JS, 2001, J BIOL CHEM, V276, P32977, DOI 10.1074/jbc.M105486200; Sakata H, 1997, J BIOL CHEM, V272, P9457; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; Sergeant N, 2000, J BIOL CHEM, V275, P17094, DOI 10.1074/jbc.M000237200; Stamos J, 2004, EMBO J, V23, P2325, DOI 10.1038/sj.emboj.7600243; Ultsch M, 1998, STRUCT FOLD DES, V6, P1383, DOI 10.1016/S0969-2126(98)00138-5; van der Voort R, 1999, J BIOL CHEM, V274, P6499, DOI 10.1074/jbc.274.10.6499; Watanabe K, 2002, J MOL BIOL, V319, P283, DOI 10.1016/S0022-2836(02)00199-7; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; Wu ZLL, 2002, FASEB J, V16, P539, DOI 10.1096/fj.01-0807com; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	43	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43560	43567		10.1074/jbc.M408510200	http://dx.doi.org/10.1074/jbc.M408510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292253	hybrid			2022-12-27	WOS:000224383100027
J	Montigny, C; Jaxel, C; Shainskaya, A; Vinh, J; Labas, V; Moller, JV; Karlish, SJD; le Maire, M				Montigny, C; Jaxel, C; Shainskaya, A; Vinh, J; Labas, V; Moller, JV; Karlish, SJD; le Maire, M			Fe2+-catalyzed oxidative cleavages of Ca2+-ATPase reveal novel features of its pumping mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; ENERGY TRANSDUCTION MECHANISM; SITE-DIRECTED MUTAGENESIS; P-TYPE ATPASES; CALCIUM-PUMP; TRANSPORT SITES; CA2+ OCCLUSION; SEGMENT M3; NA+,K+-ATPASE; NA,K-ATPASE	We have analyzed the Fe2+-catalyzed oxidative cleavages of Ca2+-ATPase in the presence of Ca2+, with or without the ATP analog 5'-adenylyl-beta,gamma-imidodiphosphate (AMP-PNP) or in the presence of the inhibitor thapsigargin. To identify the positions of cleavages as precisely as possible, we have used previously identified proteinase K and tryptic fragments as a standard, advanced mass spectrometry techniques, as well as specific antibodies. A number of cleavages are similar to those described for Na+,K+-ATPase or other P-type pumps and are expected on the basis of the putative Mg2+ binding residues near the phosphorylated Asp(351) in E1 or E2P conformations. However, intriguing new features have also been observed. These include a Fe2+ site near M3, which cannot be due to the presence of histidine residues as it was postulated in the case of Na+,K+-ATPase and H+,K+-ATPase. This site could represent a Ca2+ binding zone between M1 and M3, preceding Ca2+ occlusion within M4, 5, 6, and 8. In addition, we present evidence that, in the non-crystalline state, the N- and P-domain may approach each other, at least temporarily, in the presence of Ca2+ (E1Ca(2) conformation), whereas the presence of Mg.ATP stabilizes the N to P interaction (E1.Mg.ATP conformation).	CEA Saclay, CNRS, Unite Rech Associee 2096, F-91191 Gif Sur Yvette, France; CEA Saclay, Dept Biol Joliot Curie, Serv Biophys Fonct Membranaires, F-91191 Gif Sur Yvette, France; Weizmann Inst Sci, Biol Mass Spectrometry Facil, IL-76100 Rehovot, Israel; Univ Paris 11, Lab Rech Associe 17V, Orsay, France; Univ Paris Sud, Inst Federatif Rech 46, Paris, France; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Ecole Super Phys & Chim Ind Ville Paris, CNRS, UMR 7637, Neurobiol Lab, F-75231 Paris 05, France; Aarhus Univ, Dept Biophys, DK-8000 Aarhus C, Denmark	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; Weizmann Institute of Science; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Aarhus University	Karlish, SJD (corresponding author), CEA Saclay, CNRS, Unite Rech Associee 2096, F-91191 Gif Sur Yvette, France.	lemairem@dsvidf.cea.fr	Vinh, Joelle/K-1347-2015	Vinh, Joelle/0000-0001-7184-2668; JAXEL, CHRISTINE/0000-0002-1387-4458				Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BIGELOW DJ, 1992, BIOCHIM BIOPHYS ACTA, V1113, P323, DOI 10.1016/0304-4157(92)90005-U; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; Castilho RF, 1996, MOL CELL BIOCHEM, V159, P105, DOI 10.1007/BF00420912; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; Clausen JD, 2003, BIOCHEMISTRY-US, V42, P2585, DOI 10.1021/bi0271897; Eckstein-Ludwig U, 2003, NATURE, V424, P957, DOI 10.1038/nature01813; Einholm AP, 2004, J BIOL CHEM, V279, P15888, DOI 10.1074/jbc.M400158200; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; Goldshleger R, 1999, J BIOL CHEM, V274, P16213, DOI 10.1074/jbc.274.23.16213; Green NM, 2002, NATURE, V418, P598, DOI 10.1038/418598b; HENAO F, 1992, J BIOL CHEM, V267, P10302; Hua SM, 2002, BIOCHEMISTRY-US, V41, P11405, DOI 10.1021/bi026181u; IMAMURA Y, 1989, J BIOCHEM-TOKYO, V105, P775, DOI 10.1093/oxfordjournals.jbchem.a122743; Inesi G, 2004, J BIOL CHEM, V279, P31629, DOI 10.1074/jbc.M403211200; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; Jorgensen PL, 2001, J BIOENERG BIOMEMBR, V33, P367, DOI 10.1023/A:1010611322024; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; Karlish SJD, 2003, ANN NY ACAD SCI, V986, P39, DOI 10.1111/j.1749-6632.2003.tb07137.x; Lee AG, 2002, BBA-BIOMEMBRANES, V1565, P246, DOI 10.1016/S0005-2736(02)00573-4; Lee AG, 2001, BIOCHEM J, V356, P665, DOI 10.1042/0264-6021:3560665; LEMAIRE M, 1993, ANAL BIOCHEM, V214, P50, DOI 10.1006/abio.1993.1455; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LESNIAK W, 1994, BIOCHEMISTRY-US, V33, P13678, DOI 10.1021/bi00250a018; Liu M, 2003, J BIOL CHEM, V278, P10112, DOI 10.1074/jbc.M212403200; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; MEHLMAN T, 2002, P 50 C AM SOC MASS S; MEIS LD, 1971, J BIOL CHEM, V246, P4759; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; Moller JV, 1997, J BIOL CHEM, V272, P29015, DOI 10.1074/jbc.272.46.29015; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; Patchornik G, 2002, BIOCHEMISTRY-US, V41, P11740, DOI 10.1021/bi026334d; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; Scarborough GA, 2002, J BIOENERG BIOMEMBR, V34, P235, DOI 10.1023/A:1020211016696; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shin JM, 2001, J BIOL CHEM, V276, P48440, DOI 10.1074/jbc.M106864200; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Stokes DL, 2003, ANNU REV BIOPH BIOM, V32, P445, DOI 10.1146/annurev.biophys.32.110601.142433; Strugatsky D, 2003, J BIOL CHEM, V278, P46064, DOI 10.1074/jbc.M308303200; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Valiakhmetov A, 2003, J BIOL CHEM, V278, P6330, DOI 10.1074/jbc.M208927200; Vanmolkot KRJ, 2003, ANN NEUROL, V54, P360, DOI 10.1002/ana.10674; VILSEN B, 1995, ACTA PHYSIOL SCAND, V154, P1; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330	54	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43971	43981		10.1074/jbc.M407142200	http://dx.doi.org/10.1074/jbc.M407142200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15262996	Green Published, hybrid			2022-12-27	WOS:000224383100075
J	Theodossis, A; Walden, H; Westwick, EJ; Connaris, H; Lamble, HJ; Hough, DW; Danson, MJ; Taylor, GL				Theodossis, A; Walden, H; Westwick, EJ; Connaris, H; Lamble, HJ; Hough, DW; Danson, MJ; Taylor, GL			The structural basis for substrate promiscuity in 2-keto-3-deoxygluconate aldolase from the Entner-Doudoroff pathway in Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLNEURAMINATE LYASE; DIHYDRODIPICOLINATE SYNTHASE; ESCHERICHIA-COLI; GLUCOSE; CRYSTALLOGRAPHY; METABOLISM; SUBFAMILY; MECHANISM	The hyperthermophilic Archaea Sulfolobus solfataricus grows optimally above 80degreesC and metabolizes glucose by a non-phosphorylative variant of the Entner-Doudoroff pathway. In this pathway glucose dehydrogenase and gluconate dehydratase catalyze the oxidation of glucose to gluconate and the subsequent dehydration of gluconate to D-2-keto-3-deoxygluconate (KDG). KDG aldolase (KDGA) then catalyzes the cleavage of KDG to D-glyceraldehyde and pyruvate. It has recently been shown that all the enzymes of this pathway exhibit a catalytic promiscuity that also enables them to be used for the metabolism of galactose. This phenomenon, known as metabolic pathway promiscuity, depends crucially on the ability of KDGA to cleave KDG and D-2-keto-3-deoxygalactonate (KDGal), in both cases producing pyruvate and D-glyceraldehyde. In turn, the aldolase exhibits a remarkable lack of stereoselectivity in the condensation reaction of pyruvate and D-glyceraldehyde, forming a mixture of KDG and KDGal. We now report the structure of KDGA, determined by multi-wavelength anomalous diffraction phasing, and confirm that it is a member of the tetrameric N-acetylneuraminate lyase superfamily of Schiff base-forming aldolases. Furthermore, by soaking crystals of the aldolase at more than 80 C below its temperature activity optimum, we have been able to trap Schiff base complexes of the natural substrates pyruvate, KDG, KDGal, and pyruvate plus D-glyceraldehyde, which have allowed rationalization of the structural basis of promiscuous substrate recognition and catalysis. It is proposed that the active site of the enzyme is rigid to keep its thermostability but incorporates extra functionality to be promiscuous.	Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Univ Bath, Ctr Extremophile Res, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of St Andrews; University of Bath	Taylor, GL (corresponding author), Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.	glt2@st-andrews.ac.uk	Theodossis, Alexander/A-1091-2009; Taylor, Garry/G-3017-2014	Westwick, Elaine/0000-0003-1149-2242; Taylor, Garry/0000-0001-9486-566X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barbosa JARG, 2000, J MOL BIOL, V303, P405, DOI 10.1006/jmbi.2000.4138; Blickling S, 1997, BIOCHEMISTRY-US, V36, P24, DOI 10.1021/bi962272d; Blickling S, 1997, J MOL BIOL, V274, P608, DOI 10.1006/jmbi.1997.1393; Breuer M, 2003, CURR OPIN BIOTECH, V14, P570, DOI 10.1016/j.copbio.2003.10.004; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchanan CL, 1999, BIOCHEM J, V343, P563, DOI 10.1042/0264-6021:3430563; BUDGEN N, 1986, FEBS LETT, V196, P207, DOI 10.1016/0014-5793(86)80247-2; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; DEROSA M, 1984, BIOCHEM J, V224, P407, DOI 10.1042/bj2240407; ELZAINY TA, 1973, J BACTERIOL, V114, P457, DOI 10.1128/JB.114.1.457-459.1973; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GROGAN DW, 1989, J BACTERIOL, V171, P6710, DOI 10.1128/jb.171.12.6710-6719.1989; Hendry EJ, 2000, ACTA CRYSTALLOGR D, V56, P1437, DOI 10.1107/S0907444900009859; IZARD T, 1994, STRUCTURE, V2, P361, DOI 10.1016/S0969-2126(00)00038-1; KUO DJ, 1985, BIOCHEMISTRY-US, V24, P3947, DOI 10.1021/bi00336a022; Lamble HJ, 2003, J BIOL CHEM, V278, P34066, DOI 10.1074/jbc.M305818200; Lawrence MC, 1997, J MOL BIOL, V266, P381, DOI 10.1006/jmbi.1996.0769; MIRWALDT C, 1995, J MOL BIOL, V246, P227, DOI 10.1006/jmbi.1994.0078; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schoemaker HE, 2003, SCIENCE, V299, P1694, DOI 10.1126/science.1079237; Selig M, 1997, ARCH MICROBIOL, V167, P217, DOI 10.1007/BF03356097; Smith BJ, 1999, J ORG CHEM, V64, P945, DOI 10.1021/jo981960v; Straathof AJJ, 2002, CURR OPIN BIOTECH, V13, P548, DOI 10.1016/S0958-1669(02)00360-9; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839	25	62	66	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43886	43892		10.1074/jbc.M407702200	http://dx.doi.org/10.1074/jbc.M407702200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15265860	hybrid			2022-12-27	WOS:000224383100066
J	Viladevall, L; Serrano, R; Ruiz, A; Domenech, G; Giraldo, J; Barcelo, A; Arino, J				Viladevall, L; Serrano, R; Ruiz, A; Domenech, G; Giraldo, J; Barcelo, A; Arino, J			Characterization of the calcium-mediated response to alkaline stress in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ANALYSIS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CA2+ INFLUX; YEAST; CALCINEURIN; PROTEIN; HOMOLOG; TOLERANCE; PATHWAY	Exposure of the yeast Saccharomyces cerevisiae to alkaline stress resulted in adaptive changes that involved remodeling the gene expression. Recent evidence suggested that the calcium-activated protein phosphatase calcineurin could play a role in alkaline stress signaling. By using an aequorin luminescence reporter, we showed that alkaline stress resulted in a sharp and transient rise in cytoplasmic calcium. This increase was largely abolished by addition of EGTA to the medium or in cells lacking Mid1 or Cch1, components of the high affinity cell membrane calcium channel. Under these circumstances, the alkaline response of different calcineurin-sensitive transcriptional promoters was also blocked. Therefore, exposure to alkali resulted in entry of calcium from the external medium, and this triggered a calcineurin-mediated response. The involvement of calcineurin and Crz1/Tcn1, the transcription factor activated by the phosphatase, in the transcriptional response triggered by alkalinization has been globally assessed by DNA microarray analysis in a time course experiment using calcineurin-deficient (cnb1) and crz1 mutants. We found that exposure to pH 8.0 increased at least 2-fold the mRNA levels of 266 genes. In many cases (60%) the response was rather early ( peak after 10 min). The transcriptional response of 27 induced genes (10%) was reduced or fully abolished in cnb1 cells. In general, the response of crz1 mutants was similar to that of calcineurin-deficient cells. By analysis of a systematic deletion library, we found 48 genes whose mutation resulted in increased sensitivity to the calcineurin inhibitor FK506. Twenty of these mutations (42%) also provoked alkaline pH sensitivity. In conclusion, our results demonstrated that calcium signaling and calcineurin activation represented a significant component of the yeast response to environmental alkalinization.	Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Vet, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Grp Modelitzacio Estruct & Func Sistemes Biol, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Inst Neurociencies, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Unit Bioestadist, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Serv DNA Microxips & Sequenciacio, E-08193 Barcelona, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona; Autonomous University of Barcelona; Autonomous University of Barcelona; Autonomous University of Barcelona	Arino, J (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Vet, E-08193 Barcelona, Spain.	Joaquin.Arino@uab.es	Giraldo, Jesus/F-9881-2011; Ruiz, Amparo/AAZ-2317-2021; Arino, Joaquin/D-3756-2011; barcelo, anna/K-2383-2014	Giraldo, Jesus/0000-0001-7082-4695; Ruiz, Amparo/0000-0002-3947-4540; Arino, Joaquin/0000-0002-6774-2987; Arino Carmona, Joaquin/0000-0002-0390-4270				Adams A, 1997, METHODS YEAST GENETI; ALBEROLA TM, 2004, IN PRESS INT MICROBI; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Birchwood CJ, 2001, J BIOL CHEM, V276, P11712, DOI 10.1074/jbc.M010221200; Bonilla M, 2003, MOL BIOL CELL, V14, P4296, DOI 10.1091/mbc.E03-02-0113; Cabiscol E, 2002, J BIOL CHEM, V277, P44531, DOI 10.1074/jbc.M206525200; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Courchesne WE, 2003, MOL MICROBIOL, V47, P223, DOI 10.1046/j.1365-2958.2003.03291.x; Cui XQ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-210; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; de Nadal E, 1998, P NATL ACAD SCI USA, V95, P7357, DOI 10.1073/pnas.95.13.7357; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; Ezaki B, 1998, FEMS MICROBIOL LETT, V159, P99, DOI 10.1016/S0378-1097(97)00554-5; Fischer M, 1997, FEBS LETT, V419, P259, DOI 10.1016/S0014-5793(97)01466-X; Garcia R, 2004, J BIOL CHEM, V279, P15183, DOI 10.1074/jbc.M312954200; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gorlach J, 2000, EMBO J, V19, P3618, DOI 10.1093/emboj/19.14.3618; HALACHMI D, 1989, FEBS LETT, V256, P55, DOI 10.1016/0014-5793(89)81717-X; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Hilioti Z, 2004, TOP CURR GENET, V5, P73; Hilioti Z, 2004, GENE DEV, V18, P35, DOI 10.1101/gad.1159204; Hilioti Z, 2003, BIOCHEM BIOPH RES CO, V311, P1089, DOI 10.1016/S0006-291X(03)01515-8; IIDA H, 1990, J BIOL CHEM, V265, P13391; Issel-Tarver L, 2002, METHOD ENZYMOL, V350, P329, DOI 10.1016/S0076-6879(02)50972-1; Kafadar KA, 2003, GENE DEV, V17, P2698, DOI 10.1101/gad.1140603; Kapteyn JC, 2001, MOL MICROBIOL, V39, P469, DOI 10.1046/j.1365-2958.2001.02242.x; Kingsbury TJ, 2000, GENE DEV, V14, P1595; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Lamb TM, 2003, MOL CELL BIOL, V23, P677, DOI 10.1128/MCB.23.2.677-686.2003; Lamb TM, 2001, J BIOL CHEM, V276, P1850, DOI 10.1074/jbc.M008381200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Locke EG, 2000, MOL CELL BIOL, V20, P6686, DOI 10.1128/MCB.20.18.6686-6694.2000; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Matsumoto TK, 2002, J BIOL CHEM, V277, P33075, DOI 10.1074/jbc.M205037200; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Mewes HW, 2000, NUCLEIC ACIDS RES, V28, P37, DOI 10.1093/nar/28.1.37; Monteiro G, 2002, FREE RADICAL BIO MED, V32, P278, DOI 10.1016/S0891-5849(01)00801-2; Muller EM, 2003, J BIOL CHEM, V278, P38461, DOI 10.1074/jbc.M304089200; Muller EM, 2001, GENETICS, V159, P1527; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; Paidhungat M, 1997, MOL CELL BIOL, V17, P6339, DOI 10.1128/MCB.17.11.6339; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Rodrigues-Pousada CA, 2004, FEBS LETT, V567, P80, DOI 10.1016/j.febslet.2004.03.119; Serrano R, 2002, MOL MICROBIOL, V46, P1319, DOI 10.1046/j.1365-2958.2002.03246.x; Serrano R, 2004, J BIOL CHEM, V279, P19698, DOI 10.1074/jbc.M313746200; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Strayle J, 1999, EMBO J, V18, P4733, DOI 10.1093/emboj/18.17.4733; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200	56	158	166	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43614	43624		10.1074/jbc.M403606200	http://dx.doi.org/10.1074/jbc.M403606200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15299026	hybrid			2022-12-27	WOS:000224383100034
J	Gohil, VM; Hayes, P; Matsuyama, S; Schagger, H; Schlame, M; Greenberg, ML				Gohil, VM; Hayes, P; Matsuyama, S; Schagger, H; Schlame, M; Greenberg, ML			Cardiolipin biosynthesis and mitochondrial respiratory chain function are interdependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; BEEF-HEART MITOCHONDRIA; CYTOCHROME-C REDUCTASE; RAT-LIVER MITOCHONDRIA; ACETYL-L-CARNITINE; SACCHAROMYCES-CEREVISIAE; YEAST MITOCHONDRIA; CARRIER PROTEIN; PHOSPHATIDYLGLYCEROLPHOSPHATE SYNTHASE; BOUND CARDIOLIPIN	Cardiolipin (CL) is an acidic phospholipid present almost exclusively in membranes harboring respiratory chain complexes. We have previously shown that, in Saccharomyces cerevisiae, CL provides stability to respiratory chain supercomplexes and CL synthase enzyme activity is reduced in several respiratory complex assembly mutants. In the current study, we investigated the interdependence of the mitochondrial respiratory chain and CL biosynthesis. Pulse-labeling experiments showed that in vivo CL biosynthesis was reduced in respiratory complexes III ( ubiquinol: cytochrome c oxidoreductase) and IV ( cytochrome c oxidase) and oxidative phosphorylation complex V (ATP synthase) assembly mutants. CL synthesis was decreased in the presence of CCCP, an inhibitor of oxidative phosphorylation that reduces the pH gradient but not by valinomycin or oligomycin, both of which reduce the membrane potential and inhibit ATP synthase, respectively. The inhibitors had no effect on phosphatidylglycerol biosynthesis or CRD1 gene expression. These results are consistent with the hypothesis that in vivo CL biosynthesis is regulated at the level of CL synthase activity by the DeltapH component of the proton-motive force generated by the functional electron transport chain. This is the first report of regulation of phospholipid biosynthesis by alteration of subcellular compartment pH.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA; Med Coll Wisconsin, Blood Ctr SE Wisconsin, Blood Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Blood Ctr SE Wisconsin, Blood Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Frankfurt Klinikum, Zentrum Biol Chem, D-60590 Frankfurt, Germany; NYU, Sch Med, Dept Anesthesiol, New York, NY 10016 USA	Wayne State University; Medical College of Wisconsin; Versiti Blood Center of Wisconsin; Medical College of Wisconsin; Versiti Blood Center of Wisconsin; Medical College of Wisconsin; Goethe University Frankfurt; Goethe University Frankfurt Hospital; New York University	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.	MLGREEN@sun.science.wayne.edu		Gohil, Vishal/0000-0002-9920-2563				Anderson MS, 1996, J BIOL CHEM, V271, P26596, DOI 10.1074/jbc.271.43.26596; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BEYER K, 1985, BIOCHEMISTRY-US, V24, P3821, DOI 10.1021/bi00336a001; Beyer K, 1996, BIOCHEMISTRY-US, V35, P15784, DOI 10.1021/bi9610055; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; COLLART MA, 1994, CURRENT PROTOCOLS MO; DREES M, 1988, BIOCHEMISTRY-US, V27, P8584, DOI 10.1021/bi00423a012; Dzugasova V, 1998, CURR GENET, V34, P297, DOI 10.1007/s002940050399; EBLE KS, 1990, J BIOL CHEM, V265, P19434; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRENTZEN M, 1994, PLANT PHYSIOL, V106, P1527, DOI 10.1104/pp.106.4.1527; FRY M, 1981, J BIOL CHEM, V256, P1874; Gallet PF, 1997, BIOCHEM J, V324, P627, DOI 10.1042/bj3240627; GALLET PF, 1995, EUR J BIOCHEM, V228, P113, DOI 10.1111/j.1432-1033.1995.tb20238.x; GAYNOR PM, 1991, J BACTERIOL, V173, P6124, DOI 10.1128/jb.173.19.6124-6131.1991; Gomez B, 1999, BIOCHEMISTRY-US, V38, P9031, DOI 10.1021/bi990603r; Hagen TM, 1998, P NATL ACAD SCI USA, V95, P9562, DOI 10.1073/pnas.95.16.9562; Hardy S, 2003, J BIOL CHEM, V278, P31861, DOI 10.1074/jbc.M300190200; HAYERHARTL M, 1992, EUR J BIOCHEM, V209, P423, DOI 10.1111/j.1432-1033.1992.tb17305.x; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; JAKOVCIC S, 1971, J CELL BIOL, V48, P490, DOI 10.1083/jcb.48.3.490; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; Jiang F, 1999, MOL MICROBIOL, V31, P373, DOI 10.1046/j.1365-2958.1999.01181.x; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; KADENBACH B, 1982, FEBS LETT, V139, P109, DOI 10.1016/0014-5793(82)80498-5; Kirkland RA, 2002, NEUROSCIENCE, V115, P587, DOI 10.1016/S0306-4522(02)00512-2; Koshkin V, 2002, BIOCHEM J, V364, P317, DOI 10.1042/bj3640317; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; KOVAC L, 1982, BIOCHIM BIOPHYS ACTA, V721, P341, DOI 10.1016/0167-4889(82)90088-X; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; LECOCQ J, 1964, BIOCHEMISTRY-US, V3, P976, DOI 10.1021/bi00895a023; LERAY C, 1987, J CHROMATOGR-BIOMED, V420, P411, DOI 10.1016/0378-4347(87)80198-6; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; McAuley KE, 1999, P NATL ACAD SCI USA, V96, P14706, DOI 10.1073/pnas.96.26.14706; Paradies G, 1999, FEBS LETT, V454, P207, DOI 10.1016/S0014-5793(99)00809-1; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; ROBINSON NC, 1990, BIOCHEMISTRY-US, V29, P8962, DOI 10.1021/bi00490a012; RYTOMAA M, 1994, J BIOL CHEM, V269, P1770; SCHAGGER H, 1990, EUR J BIOCHEM, V190, P123, DOI 10.1111/j.1432-1033.1990.tb15554.x; SCHLAME M, 1993, J BIOL CHEM, V268, P74; Schlame M, 1997, BBA-LIPID LIPID MET, V1348, P207, DOI 10.1016/S0005-2760(97)00119-7; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SCHLAME M, 1991, J BIOL CHEM, V266, P22398; Sedlak E, 1999, BIOCHEMISTRY-US, V38, P14966, DOI 10.1021/bi9914053; TAMAI KT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P214, DOI 10.1016/0005-2760(90)90192-Z; Tuller G, 1998, FEBS LETT, V421, P15, DOI 10.1016/S0014-5793(97)01525-1; VELOURS J, 1989, BIOCHIMIE, V71, P903, DOI 10.1016/0300-9084(89)90073-4; Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952; YOTSUYANAGI Y, 1962, J ULTRA MOL STRUCT R, V7, P121, DOI 10.1016/S0022-5320(62)80031-8; YU CA, 1980, BIOCHEMISTRY-US, V19, P5715, DOI 10.1021/bi00566a008; Zhao M, 1998, J BIOL CHEM, V273, P2402, DOI 10.1074/jbc.273.4.2402; Zhong Q, 2003, J BIOL CHEM, V278, P33978, DOI 10.1074/jbc.M305242200	56	110	115	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42612	42618		10.1074/jbc.M402545200	http://dx.doi.org/10.1074/jbc.M402545200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292198	hybrid			2022-12-27	WOS:000224226400034
J	Koszewski, NJ; Alimov, AP; Park-Sarge, OK; Malluche, HH				Koszewski, NJ; Alimov, AP; Park-Sarge, OK; Malluche, HH			Suppression of the human parathyroid hormone promoter by vitamin D involves displacement of NF-Y binding to the vitamin D response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID ELEMENT; D-RECEPTOR INTERACTIONS; DNA-BINDING; TRANSCRIPTIONAL REPRESSION; 1,25-DIHYDROXYVITAMIN D-3; GENE-REGULATION; GLANDS; IDENTIFICATION; EXPRESSION; THYMUS	An earlier report in the literature indicated the vitamin D response element (VDRE) in the human parathyroid hormone ( hPTH) promoter could be specifically bound by an unidentified transcription factor in addition to the vitamin D receptor (VDR) complex. We confirmed that OK and HeLa cell nuclear extracts formed a specific complex with the hPTH VDRE that was insensitive to competition with other VDRE sequences. However, this factor could be competed for by a consensus NF-Y DNA-binding site, and an anti-NF-Y antibody was able to supershift the bound band. Mutational analysis indicated that the NF-Y-binding site partially overlapped the 3' portion of the VDRE. Transfection studies using an hPTH promoter construct in Drosophila SL2 cells demonstrated strong synergistic transactivation by NF-Y interactions with both the VDRE site and a previously described distal NF-Y-binding site. Finally, mobility shift studies indicated that the VDR heterodimer competed with NF-Y for binding to the VDRE sequence, and NF-Y-stimulated activity of the hPTH promoter could be suppressed in a hormone-dependent manner when the VDR heterodimer complex was co-expressed in SL2 cells. In summary, these findings establish the presence of a proximal NF-Y-binding site in the hPTH promoter and highlight the potential for synergism between distal and proximal NF-Y DNA elements to strongly enhance transcription. Furthermore, findings suggest that the repressive effects of vitamin D on hPTH gene transcription may involve displacement of NF-Y binding to the proximal site by the VDR heterodimer, which subsequently attenuates synergistic transactivation.	Univ Kentucky, Med Ctr, Div Nephrol Bone & Mineral Metab, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Koszewski, NJ (corresponding author), Univ Kentucky, Med Ctr, Div Nephrol Bone & Mineral Metab, Rm MN562,800 Rose St, Lexington, KY 40536 USA.	njhosz0@uky.edu			NICHD NIH HHS [HD41609] Funding Source: Medline; NIDDK NIH HHS [DK51530, DK54276] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054276, R01DK051530] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alimov AP, 2004, ENDOCRINOLOGY, V145, P2713, DOI 10.1210/en.2003-1763; Alimov AP, 2003, ENDOCRINOLOGY, V144, P3138, DOI 10.1210/en.2003-0119; Bhakat KK, 2003, EMBO J, V22, P6299, DOI 10.1093/emboj/cdg595; Bonfanti M, 1999, ANTI-CANCER DRUG DES, V14, P179; BROWN AJ, 1995, ENDOCRINOLOGY, V136, P1419, DOI 10.1210/en.136.4.1419; BROWN AJ, 1989, KIDNEY INT, V35, P19, DOI 10.1038/ki.1989.3; Carling T, 2000, J CLIN ENDOCR METAB, V85, P2000, DOI 10.1210/jc.85.5.2000; Darwish HM, 1996, ARCH BIOCHEM BIOPHYS, V334, P223, DOI 10.1006/abbi.1996.0450; Darwish HM, 1999, ARCH BIOCHEM BIOPHYS, V365, P123, DOI 10.1006/abbi.1999.1160; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; Ding CL, 2001, J CLIN INVEST, V108, P1215, DOI 10.1172/JCI13180; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Drissi H, 2002, EXP CELL RES, V274, P323, DOI 10.1006/excr.2002.5474; FUKUDA N, 1993, J CLIN INVEST, V92, P1436, DOI 10.1172/JCI116720; Ge YB, 2002, BBA-GENE STRUCT EXPR, V1579, P73, DOI 10.1016/S0167-4781(02)00509-2; Ge YB, 2001, BIOCHEM J, V357, P97, DOI 10.1042/0264-6021:3570097; Gordon J, 2001, MECH DEVELOP, V103, P141, DOI 10.1016/S0925-4773(01)00333-1; Gunther T, 2000, NATURE, V406, P199, DOI 10.1038/35018111; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Hawa NS, 1996, BIOCHEM BIOPH RES CO, V228, P352, DOI 10.1006/bbrc.1996.1665; He B, 2002, J MOL ENDOCRINOL, V29, P193, DOI 10.1677/jme.0.0290193; Joshi AA, 2003, MOL PHARMACOL, V63, P359, DOI 10.1124/mol.63.2.359; Kim JS, 1998, P NATL ACAD SCI USA, V95, P12364, DOI 10.1073/pnas.95.21.12364; Kim RH, 1996, BIOCHEM J, V318, P219, DOI 10.1042/bj3180219; KORKOR AB, 1987, NEW ENGL J MED, V316, P1573, DOI 10.1056/NEJM198706183162504; Koszewski NJ, 1998, ARCH BIOCHEM BIOPHYS, V349, P388, DOI 10.1006/abbi.1997.0481; Koszewski NJ, 2000, J STEROID BIOCHEM, V72, P125, DOI 10.1016/S0960-0760(00)00022-4; Koszewski NJ, 2003, STEROIDS, V68, P307, DOI 10.1016/S0039-128X(03)00038-2; Liu SM, 1996, MOL ENDOCRINOL, V10, P206, DOI 10.1210/me.10.2.206; Lok CN, 2002, BIOCHEM J, V368, P741, DOI 10.1042/BJ20020791; Luo D, 2003, BIOCHEM BIOPH RES CO, V303, P609, DOI 10.1016/S0006-291X(03)00397-8; Mackey SL, 1996, MOL ENDOCRINOL, V10, P298, DOI 10.1210/me.10.3.298; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; RUPP E, 1990, NUCLEIC ACIDS RES, V18, P5677, DOI 10.1093/nar/18.19.5677; Russell J, 1999, J BONE MINER RES, V14, P1828, DOI 10.1359/jbmr.1999.14.11.1828; Salsi V, 2003, J BIOL CHEM, V278, P6642, DOI 10.1074/jbc.M210065200; Su DM, 2001, DEV BIOL, V236, P316, DOI 10.1006/dbio.2001.0342; Suske G, 2000, Methods Mol Biol, V130, P175; Towers TL, 1999, MOL CELL BIOL, V19, P4191; Valimaki S, 2001, KIDNEY INT, V60, P1666, DOI 10.1046/j.1523-1755.2001.00986.x; Xu PX, 2002, DEVELOPMENT, V129, P3033; Yamada K, 2000, J BIOL CHEM, V275, P18129, DOI 10.1074/jbc.M001543200; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822	44	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42431	42437		10.1074/jbc.M407742200	http://dx.doi.org/10.1074/jbc.M407742200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15297458	hybrid			2022-12-27	WOS:000224226400013
J	Gomez, D; Paterski, R; Lemarteleur, T; Shin-ya, K; Mergny, JL; Riou, JF				Gomez, D; Paterski, R; Lemarteleur, T; Shin-ya, K; Mergny, JL; Riou, JF			Interaction of telomestatin with the telomeric single-strand overhang	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-QUADRUPLEX LIGAND-12459; SMALL-MOLECULE; MASS-SPECTROMETRY; HUMAN-CHROMOSOMES; DNA; INHIBITOR; CELLS; SENESCENCE; DUPLEX; RESISTANCE	The extremities of chromosomes end in a G-rich single-stranded overhang that has been implicated in the onset of the replicative senescence. The repeated sequence forming a G-overhang is able to adopt a peculiar four-stranded DNA structure in vitro called a G-quadruplex, which is a poor substrate for telomerase. Small molecule ligands that selectively stabilize the telomeric G-quadruplex induce telomere shortening and a delayed growth arrest. Here we show that the G-quadruplex ligand telomestatin has a dramatic effect on the conformation of intracellular G-overhangs. Competition experiments indicate that telomestatin strongly binds in vitro and in vivo to the telomeric overhang and impairs its single-stranded conformation. Long-term treatment of cells with telomestatin greatly reduces the G-overhang size, as evidenced by specific hybridization or telomeric oligonucleotide ligation assay experiments, with a concomitant delayed loss of cell viability. In vivo protection experiments using dimethyl sulfate also indicate that telomestatin treatment alters the dimethyl sulfate effect on G-overhangs, a result compatible with the formation of a local quadruplex structure at telomeric overhang. Altogether these experiments strongly support the hypothesis that the telomeric G-overhang is an intracellular target for the action of telomestatin.	Univ Reims, UFR Pharm, Lab Oncopharmacol, F-51096 Reims, France; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; CNRS, INSERM, U565,UMR 5153, Lab Biophys,Museum Natl Hist Nat, F-75005 Paris, France	Universite de Reims Champagne-Ardenne; University of Tokyo; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN)	Riou, JF (corresponding author), Univ Reims, UFR Pharm, Lab Oncopharmacol, JE 2428 Oncopharmacol,51 Rue Cognacq Jay, F-51096 Reims, France.	jf.riou@univ-reims.fr	Gomez Zamorano, Dennis Gomez/AAX-5182-2021; Mergny, Jean-Louis/E-2860-2013	Gomez Zamorano, Dennis Gomez/0000-0001-9942-1451; Mergny, Jean-Louis/0000-0003-3043-8401; riou, jean-francois/0000-0002-0055-6506; Boujemaa-Paterski, Rajaa/0000-0001-9645-387X				Alberti P, 2001, J BIOMOL STRUCT DYN, V19, P505, DOI 10.1080/07391102.2001.10506758; Alberti P, 2003, P NATL ACAD SCI USA, V100, P1569, DOI 10.1073/pnas.0335459100; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Cimino-Reale G, 2003, J BIOL CHEM, V278, P2136, DOI 10.1074/jbc.M208939200; Cimino-Reale G, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e35; Cloutier JF, 2001, J MOL BIOL, V306, P169, DOI 10.1006/jmbi.2000.4371; Darby RAJ, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e39; Davis JT, 2004, ANGEW CHEM INT EDIT, V43, P668, DOI 10.1002/anie.200300589; de Lange T, 2004, NAT REV MOL CELL BIO, V5, P323, DOI 10.1038/nrm1359; Gomez D, 2004, NUCLEIC ACIDS RES, V32, P371, DOI 10.1093/nar/gkh181; Gomez D, 2003, J BIOL CHEM, V278, P50554, DOI 10.1074/jbc.M308440200; Gomez D, 2003, CANCER RES, V63, P6149; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Gowan SM, 2001, MOL PHARMACOL, V60, P981, DOI 10.1124/mol.60.5.981; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hemann MT, 1999, NUCLEIC ACIDS RES, V27, P3964, DOI 10.1093/nar/27.20.3964; Jacob NK, 2003, MOL CELL, V11, P1021, DOI 10.1016/S1097-2765(03)00131-X; Kim MY, 2003, CANCER RES, V63, P3247; Kim MY, 2002, J AM CHEM SOC, V124, P2098, DOI 10.1021/ja017308q; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949; Neidle S, 2002, NAT REV DRUG DISCOV, V1, P383, DOI 10.1038/nrd793; Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755; Phan AT, 2002, NUCLEIC ACIDS RES, V30, P4618, DOI 10.1093/nar/gkf597; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Rosu F, 2003, CHEM COMMUN, P2702, DOI 10.1039/b309394h; Rosu F, 2003, BIOCHEMISTRY-US, V42, P10361, DOI 10.1021/bi034531m; Shammas MA, 2004, CLIN CANCER RES, V10, P770, DOI 10.1158/1078-0432.CCR-0793-03; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q; Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9; Wright WE, 1999, EXP CELL RES, V251, P492, DOI 10.1006/excr.1999.4602; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	41	120	127	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41487	41494		10.1074/jbc.M406123200	http://dx.doi.org/10.1074/jbc.M406123200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15277522	hybrid			2022-12-27	WOS:000224075500031
J	Kidd, JF; Ramjeesingh, M; Stratford, F; Huan, LJ; Bear, CE				Kidd, JF; Ramjeesingh, M; Stratford, F; Huan, LJ; Bear, CE			A heteromeric complex of the two nucleotide binding domains of cystic fibrosis transmembrane conductance regulator (CFTR) mediates ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN; ADENYLATE KINASE; CL-CHANNEL; FOLD; GENE; MUTATIONS; 2ND; EXPRESSION; HYDROLYSIS; MECHANISM	The cystic fibrosis transmembrane conductance regulator ( CFTR) protein is a member of the ABC superfamily of transporter proteins. Recently, crystal structures of intact, prokaryotic members of this family have been described. These structures suggested that ATP binding and hydrolysis occurs at two sites formed at the interface between their nucleotide binding domains (NBDs). In contrast to the prokaryotic family members, the NBDs of CFTR are asymmetric ( both structurally and functionally), and previous to the present studies, it was not clear whether both NBDs are required for ATP hydrolysis. In order to assess the relative roles of the two NBDs of human CFTR, we purified and reconstituted NBD1 and NBD2, separately and together. We found that NBD1 and NBD2 by themselves exhibited relatively low ATPase activity. Co-assembly of NBD1 and NBD2 exhibited a 2-3-fold enhancement in catalytic activity relative to the isolated domains and this increase reflected enhanced ATP turnover (V-max). These data provide the first direct evidence that heterodimerization of the NBD1 and NBD2 domains of CFTR is required to generate optimal catalytic activity.	Univ Toronto, Hosp Sick Children, Res Inst,Fac Med, Programme Struct Biol & Biochem,Physiol Dept, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Res Inst,Fac Med, Programme Struct Biol & Biochem,Biochem Dept, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Bear, CE (corresponding author), Univ Toronto, Hosp Sick Children, Res Inst,Fac Med, Programme Struct Biol & Biochem,Physiol Dept, Toronto, ON M5G 1X8, Canada.	bear@sickkids.on.ca						Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Aleksandrov L, 2001, J BIOL CHEM, V276, P12918, DOI 10.1074/jbc.M100515200; Annereau JP, 2003, BIOCHEM J, V371, P451, DOI 10.1042/BJ20021318; Basso C, 2003, J GEN PHYSIOL, V122, P333, DOI 10.1085/jgp.200308798; Callebaut I, 2004, CELL MOL LIFE SCI, V61, P230, DOI 10.1007/s00018-003-3386-z; Carrier I, 2003, BIOCHEMISTRY-US, V42, P12875, DOI 10.1021/bi034257w; Cotten JF, 1996, J BIOL CHEM, V271, P21279, DOI 10.1074/jbc.271.35.21279; Duffieux F, 2000, EUR J BIOCHEM, V267, P5306, DOI 10.1046/j.1432-1327.2000.01614.x; GARBOCZI DN, 1990, J BIOL CHEM, V265, P14632; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Howell LD, 2000, BIOCHEM BIOPH RES CO, V271, P518, DOI 10.1006/bbrc.2000.2659; Howell LD, 2004, BIOCHEM J, V378, P151, DOI 10.1042/BJ20021428; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; Kartner N, 1998, METHOD ENZYMOL, V292, P629; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; Kogan I, 2001, J BIOL CHEM, V276, P11575, DOI 10.1074/jbc.M010403200; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Li CH, 1996, J BIOL CHEM, V271, P11623, DOI 10.1074/jbc.271.20.11623; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Lu NT, 2000, ARCH BIOCHEM BIOPHYS, V375, P7, DOI 10.1006/abbi.1999.1656; Moncalian G, 2004, J MOL BIOL, V335, P937, DOI 10.1016/j.jmb.2003.11.026; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Neville DCA, 1998, BIOCHEMISTRY-US, V37, P2401, DOI 10.1021/bi972021k; Ostedgaard LS, 2001, J BIOL CHEM, V276, P7689, DOI 10.1074/jbc.R100001200; Ramjeesingh M, 1999, BIOCHEMISTRY-US, V38, P1463, DOI 10.1021/bi982243y; Ramjeesingh M, 1999, Methods Enzymol, V294, P227; Randak C, 1997, FEBS LETT, V410, P180, DOI 10.1016/S0014-5793(97)00574-7; Randak C, 1999, BIOCHEM J, V340, P227, DOI 10.1042/0264-6021:3400227; RANDAK C, 1995, FEBS LETT, V363, P189, DOI 10.1016/0014-5793(95)00314-Y; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Tombline G, 2004, J BIOL CHEM, V279, P5363, DOI 10.1074/jbc.M311964200; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; Vergani P, 2003, J GEN PHYSIOL, V121, P17, DOI 10.1085/jgp.20028673; Yike I, 1996, PROTEIN SCI, V5, P89	43	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41664	41669		10.1074/jbc.M407666200	http://dx.doi.org/10.1074/jbc.M407666200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15284228	hybrid			2022-12-27	WOS:000224075500053
J	Qing, YL; Stark, GR				Qing, YL; Stark, GR			Alternative activation of STAT1 and STAT3 in response to interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; IFN-GAMMA; SIGNAL TRANSDUCER; KINASE INHIBITOR; PROTEIN-KINASE; DNA-BINDING; TRANSCRIPTIONAL RESPONSES; TARGETED DISRUPTION; B-LYMPHOPOIESIS; GENE-EXPRESSION	Interferon-gamma (IFNgamma) is a pluripotent cytokine whose major biological effects are mediated through a pathway in which STAT1 is the predominant and essential transcription factor. STAT3 can also be activated weakly by IFNgamma, but the mechanism of activation and function of STAT3 as a part of the interferon response are not known. Here we show that STAT3 activation is much stronger and more prolonged in STAT1-null mouse embryo fibroblasts than in wild-type cells. In response to IFNgamma, SRC-family kinases are required to activate STAT3 (but not STAT1) through tyrosine phosphorylation, whereas the receptor-bound kinases JAK1 and JAK2 are required to activate both STATs. Tyrosine 419 of the IFNgamma receptor subunit 1 (IFNGR1) is required to activate both STATs, suggesting that STAT1 and STAT3 compete with each other for the same receptor phosphotyrosine motif. Activated STAT3 can replace STAT1 in STAT1-null cells to drive the transcription of certain genes, for example, socs-3 and c/ebpdelta, which have gamma-activated sequence motifs in their promoters. Work from Ian Kerr's laboratory reveals that the gp130-linked interleukin-6 receptor, which usually activates STAT3 predominantly, activates STAT1 efficiently when STAT3 is absent (Costa-Pereira, A. P., Tininini, S., Strobl, B., Alonzi, T., Schlaak, J. F., Is'harc, H., Gesualdo, I., Newman, S. J., Kerr, I. M., and Poli, V. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 8043-8047). Because STAT1 and STAT3 have opposing biological effects (STAT3 is an oncogene, and STAT1 is a tumor suppressor), the reciprocal activation of these two transcription factors in response to IFNgamma or interleukin-6 suggests that their relative abundance, which may vary substantially in different normal cell types, under different conditions or in tumors is likely to have a major impact on how cells behave in response to different cytokines.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	starkg@ccf.org			NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NCI NIH HHS [CA062220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Auernhammer CJ, 2000, ANN NY ACAD SCI, V917, P658; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Chang YJ, 2002, J BIOL CHEM, V277, P7118, DOI 10.1074/jbc.M109924200; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Choudhury GG, 1998, J CLIN INVEST, V101, P2751, DOI 10.1172/JCI1044; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deb DK, 2003, J IMMUNOL, V171, P267, DOI 10.4049/jimmunol.171.1.267; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Gongora R, 2000, J IMMUNOL, V165, P2362, DOI 10.4049/jimmunol.165.5.2362; Gongora R, 2001, IMMUNITY, V14, P727, DOI 10.1016/S1074-7613(01)00152-2; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; He B, 2003, BIOCHEM BIOPH RES CO, V301, P386, DOI 10.1016/S0006-291X(02)03071-1; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; Herrero C, 2003, J IMMUNOL, V171, P5034, DOI 10.4049/jimmunol.171.10.5034; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kerr IM, 2003, FEBS LETT, V546, P1, DOI 10.1016/S0014-5793(03)00411-3; Kincaid EZ, 2003, J IMMUNOL, V171, P2042, DOI 10.4049/jimmunol.171.4.2042; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; Lee DK, 1999, BIOCHEM J, V337, P59, DOI 10.1042/0264-6021:3370059; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Majumder S, 1998, J NEUROSCI RES, V54, P169, DOI 10.1002/(SICI)1097-4547(19981015)54:2<169::AID-JNR5>3.0.CO;2-C; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Nguyen KB, 2000, NAT IMMUNOL, V1, P70, DOI 10.1038/76940; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Peilot H, 2000, J BIOL CHEM, V275, P22895, DOI 10.1074/jbc.M002783200; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Russello SV, 2003, FRONT BIOSCI-LANDMRK, V8, pS1068, DOI 10.2741/1138; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schindler CW, 2002, J CLIN INVEST, V109, P1133, DOI 10.1172/JCI200215644; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Sizemore N, 2004, P NATL ACAD SCI USA, V101, P7994, DOI 10.1073/pnas.0401593101; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; Wang JP, 2002, P NATL ACAD SCI USA, V99, P16209, DOI 10.1073/pnas.252454799; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wiederkehr-Adam M, 2003, J BIOL CHEM, V278, P16117, DOI 10.1074/jbc.M300261200; Woldman I, 2001, J BIOL CHEM, V276, P45722, DOI 10.1074/jbc.M105320200; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	67	240	251	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41679	41685		10.1074/jbc.M406413200	http://dx.doi.org/10.1074/jbc.M406413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15284232	hybrid			2022-12-27	WOS:000224075500055
J	Subramanian, V; Rothenberg, A; Gomez, C; Cohen, AW; Garcia, A; Bhattacharyya, S; Shapiro, L; Dolios, G; Wang, R; Lisanti, MP; Brasaemle, DL				Subramanian, V; Rothenberg, A; Gomez, C; Cohen, AW; Garcia, A; Bhattacharyya, S; Shapiro, L; Dolios, G; Wang, R; Lisanti, MP; Brasaemle, DL			Perilipin A mediates the reversible binding of CGI-58 to lipid droplets in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; CHANARIN-DORFMAN-SYNDROME; STORAGE DROPLET; STIMULATED LIPOLYSIS; ADIPOSE-TISSUE; PROTEIN; TRIACYLGLYCEROLS; TRANSLOCATION; SURFACE; OBESITY	Perilipins, the major structural proteins coating the surfaces of mature lipid droplets of adipocytes, play an important role in the regulation of triacylglycerol storage and hydrolysis. We have used proteomic analysis to identify CGI-58, a member of the alpha/beta-hydrolase fold family of enzymes, as a component of lipid droplets of 3T3-L1 adipocytes. CGI-58 mRNA is highly expressed in adipose tissue and testes, tissues that also express perilipins, and at lower levels in liver, skin, kidney, and heart. Both endogenous CGI-58 and an ectopic CGI-58-GFP chimera show diffuse cytoplasmic localization in 3T3-L1 preadipocytes, but localize almost exclusively to the surfaces of lipid droplets in differentiated 3T3-L1 adipocytes. The localization of endogenous CGI-58 was investigated in 3T3-L1 cells stably expressing mutated forms of perilipin using microscopy. CGI-58 binds to lipid droplets coated with perilipin A or mutated forms of perilipin with an intact C-terminal sequence from amino acid 382 to 429, but not to lipid droplets coated with perilipin B or mutated perilipin A lacking this sequence. Immunoprecipitation studies confirmed these findings, but also showed co-precipitation of perilipin B and CGI-58. Remarkably, activation of cAMP-dependent protein kinase by the incubation of 3T3-L1 adipocytes with isoproterenol and isobutylmethylxanthine disperses CGI-58 from the surfaces of lipid droplets to a cytoplasmic distribution. This shift in subcellular localization can be reversed by the addition of propanolol to the culture medium. Thus, CGI-58 binds to perilipin A-coated lipid droplets in a manner that is dependent upon the metabolic status of the adipocyte and the activity of cAMP-dependent protein kinase.	Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	Rutgers State University New Brunswick; Columbia University; Yeshiva University; Albert Einstein College of Medicine; Icahn School of Medicine at Mount Sinai	Brasaemle, DL (corresponding author), Rutgers State Univ, Dept Nutr Sci, 96 Lipman Dr, New Brunswick, NJ 08901 USA.	Brasaemle@AESOP.Rutgers.edu	Wang, Rong/A-8721-2009; Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Brasaemle, Dawn/0000-0002-8553-8285	NATIONAL CANCER INSTITUTE [R24CA088325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NCI NIH HHS [CA88325] Funding Source: Medline; NIDDK NIH HHS [DK54797] Funding Source: Medline; NIGMS NIH HHS [T32 GM07288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; Brasaemle DL, 2004, J BIOL CHEM; Caldas H, 2003, HUM MOL GENET, V12, P2981, DOI 10.1093/hmg/ddg321; Dias DC, 2002, P NATL ACAD SCI USA, V99, P16601, DOI 10.1073/pnas.252646399; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; Fujimoto Y, 2004, BBA-MOL CELL RES, V1644, P47, DOI 10.1016/j.bbamcr.2003.10.018; Garcia A, 2004, J BIOL CHEM, V279, P8409, DOI 10.1074/jbc.M311198200; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; HILAIRE N, 1995, J BIOL CHEM, V270, P27027, DOI 10.1074/jbc.270.45.27027; Igal RA, 1997, J PEDIATR GASTR NUTR, V25, P541, DOI 10.1097/00005176-199711000-00011; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; Igal RA, 1996, J BIOL CHEM, V271, P16644, DOI 10.1074/jbc.271.28.16644; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Lefevre C, 2001, AM J HUM GENET, V69, P1002, DOI 10.1086/324121; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Srebrnik A, 1998, AM J DERMATOPATH, V20, P79, DOI 10.1097/00000372-199802000-00016; SU CL, 2003, J BIOL CHEM; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Wolins NE, 2003, J BIOL CHEM, V278, P37713, DOI 10.1074/jbc.M304025200; Yamaguchi T, 2004, J BIOL CHEM, V279, P30490, DOI 10.1074/jbc.M403920200; Zhang HH, 2003, J BIOL CHEM, V278, P51535, DOI 10.1074/jbc.M309591200	40	244	262	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42062	42071		10.1074/jbc.M407462200	http://dx.doi.org/10.1074/jbc.M407462200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292255	hybrid			2022-12-27	WOS:000224075500099
J	Tanaka, M; Nanba, D; Mori, S; Shiba, F; Ishiguro, H; Yoshino, K; Matsuura, N; Higashiyama, S				Tanaka, M; Nanba, D; Mori, S; Shiba, F; Ishiguro, H; Yoshino, K; Matsuura, N; Higashiyama, S			ADAM binding protein Eve-1 is required for ectodomain shedding of epidermal growth factor receptor ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST GROWTH-FACTOR-2; RIBOSOME ENTRY SITE; EGF-RECEPTOR; ALTERNATIVE TRANSLATION; CYTOPLASMIC DOMAIN; ADAPTER PROTEIN; GENE-EXPRESSION; C2C12 CELLS; SH3 DOMAIN; SRC	A disintegrin and metalloproteases (ADAMs) are implicated in the ectodomain shedding of epidermal growth factor receptor (EGFR) ligands in EGFR transactivation. However, the activation mechanisms of ADAMs remain elusive. To analyze the regulatory mechanisms of ADAM activation, we performed yeast two-hybrid screening using the cytoplasmic domain of ADAM12 as bait, and identified a protein that we designated Eve-1. Two cDNAs were cloned and characterized. They encode alternatively spliced isoforms of Eve-1, called Eve-1a and Eve-1b, that have four and five tandem Src homology 3 (SH3) domains in the carboxylterminal region, respectively, and seven proline-rich SH3 domain binding motifs in the amino-terminal region. The short forms of Eve-1, Eve-1c and Eve-1d, translated at Met-371 are human counterparts of mouse Sh3d19. Northern blot analysis demonstrated that Eve-1 is abundantly expressed in skeletal muscle and heart. Western blot analysis revealed the dominant production of Eve-1c in human cancer cell lines. Knockdown of Eve-1 by small interfering RNA in HT1080 cells reduced the shedding of proHB-EGF induced by angiotensin II and 12-O-tetradecanoylphorbol-13-acetate, as well as the shedding of pro-transforming growth factor-alpha, promphiregulin, and proepiregulin by 12-O-tetradecanoylphorbol-13- acetate, suggesting that Eve-1 plays a role in positively regulating the activity of ADAMs in the signaling of EGFR-ligand shedding.	Ehime Univ, Sch Med, Dept Mol & Cellular Biol, Div Biochem & Mol Genet, Shigenobu, Ehime 7910295, Japan; Osaka Univ, Sch Allied Hlth Sci, Dept Mol Pathol, Suita, Osaka 5650871, Japan; Carna Biosci Inc, Chuou Ku, Kobe, Hyogo 6508543, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Tokyo 1028666, Japan	Ehime University; Osaka University; Japan Science & Technology Agency (JST)	Higashiyama, S (corresponding author), Ehime Univ, Sch Med, Dept Mol & Cellular Biol, Div Biochem & Mol Genet, Shigenobu, Ehime 7910295, Japan.	shigeki@m.ehime-u.ac.jp						Abram CL, 2003, J BIOL CHEM, V278, P16844, DOI 10.1074/jbc.M300267200; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bonnal S, 2003, J BIOL CHEM, V278, P39330, DOI 10.1074/jbc.M305580200; Bonnal S, 2003, NUCLEIC ACIDS RES, V31, P427, DOI 10.1093/nar/gkg003; FENG S, 1994, SCIENCE, V266, P1242; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Kang Q, 2001, J BIOL CHEM, V276, P24466, DOI 10.1074/jbc.M101162200; Kang Q, 2000, BIOCHEM J, V352, P883, DOI 10.1042/0264-6021:3520883; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Mori S, 2003, J BIOL CHEM, V278, P46029, DOI 10.1074/jbc.M306393200; Nanba D, 2004, CYTOKINE GROWTH F R, V15, P13, DOI 10.1016/j.cytogfr.2003.10.002; Poghosyan Z, 2002, J BIOL CHEM, V277, P4999, DOI 10.1074/jbc.M107430200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shimomura Y, 2003, J DERMATOL SCI, V31, P43, DOI 10.1016/S0923-1811(02)00140-8; Suzuki A, 2000, ONCOGENE, V19, P5842, DOI 10.1038/sj.onc.1203986; TANABE Y, 1988, MOL CELL BIOL, V8, P466; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Umata T, 2001, J BIOL CHEM, V276, P30475, DOI 10.1074/jbc.M103673200; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	34	65	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41950	41959		10.1074/jbc.M400086200	http://dx.doi.org/10.1074/jbc.M400086200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280379	hybrid			2022-12-27	WOS:000224075500087
J	Zhang, GM; Schmidt, O; Asgari, S				Zhang, GM; Schmidt, O; Asgari, S			A novel venom peptide from an endoparasitoid wasp is required for expression of polydnavirus genes in host hemocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDALETIA-SEPARATA WALKER; APANTELES-KARIYAI WATANABE; MANDUCA-SEXTA LARVAE; HELIOTHIS-VIRESCENS; COTESIA-RUBECULA; PIERIS-RAPAE; MICROPLITIS-CROCEIPES; LACANOBIA-OLERACEA; PARASITOID WASP; CALYX FLUID	Maternal factors introduced into host insects by endoparasitoid wasps are usually essential for successful parasitism. This includes polydnaviruses (PDVs) that are produced in the reproductive organ of female hymenopteran endoparasitoids and are injected, together with venom proteins, into the host hemocoel at oviposition. Inside the host, PDVs enter various tissue cells and hemocytes where viral genes are expressed, leading to developmental and physiological alterations in the host, including the suppression of the host immune system. Although several studies have shown that some PDVs are only effective when accompanied by venom proteins, there is no report of an active venom ingredient(s) facilitating PDV infection and/or gene expression. In this study, we describe a novel peptide (Vn1.5) isolated from Cotesia rubecula venom that is required for the expression of C. rubecula bracoviruses (CrBVs) in host hemocytes (Pieris rapae), although it is not essential for CrBV entry into host cells. The peptide consists of 14 amino acids with a molecular mass of 1598 Da. In the absence of Vn1.5 or total venom proteins, CrBV genes are not expressed in host cells and did not cause inactivation of host hemocytes.	Univ Queensland, Sch Life Sci, Dept Zool & Entomol, St Lucia, Qld 4072, Australia; Univ Adelaide, Dept Plant & Pest Sci, Insect Mol Biol Lab, Glen Osmond, SA 5064, Australia	University of Queensland; University of Adelaide	Asgari, S (corresponding author), Univ Queensland, Sch Life Sci, Dept Zool & Entomol, St Lucia, Qld 4072, Australia.	s.asgari@uq.edu.au	Asgari, Sassan/G-2678-2011	Asgari, Sassan/0000-0001-7885-6544				ASGARI S, 1994, J INSECT PHYSIOL, V40, P789, DOI 10.1016/0022-1910(94)90008-6; Asgari S, 1996, J GEN VIROL, V77, P2653, DOI 10.1099/0022-1317-77-10-2653; Asgari S, 2003, INSECT BIOCHEM MOLEC, V33, P1017, DOI 10.1016/S0965-1748(03)00116-4; Asgari S, 2003, ARCH INSECT BIOCHEM, V53, P92, DOI 10.1002/arch.10088; Asgari S, 1997, J GEN VIROL, V78, P3061, DOI 10.1099/0022-1317-78-11-3061; Asgari S, 1998, P NATL ACAD SCI USA, V95, P3690, DOI 10.1073/pnas.95.7.3690; Ausubel F. M., 1993, CURRENT PROTOCOLS MO, V1; AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V2; BECKAGE NE, 1990, INSECT BIOCHEM, V20, P285, DOI 10.1016/0020-1790(90)90046-W; BECKAGE NE, 1994, ARCH INSECT BIOCHEM, V26, P165, DOI 10.1002/arch.940260209; Digilio MC, 2000, J INSECT PHYSIOL, V46, P1041, DOI 10.1016/S0022-1910(99)00216-4; EDSON KM, 1981, SCIENCE, V211, P582, DOI 10.1126/science.7455695; FLEMING JAGW, 1983, J VIROL, V48, P74, DOI 10.1128/JVI.48.1.74-78.1983; FLEMING JAGW, 1991, P NATL ACAD SCI USA, V88, P9770, DOI 10.1073/pnas.88.21.9770; Glatz R, 2004, J GEN VIROL, V85, P2873, DOI 10.1099/vir.0.80307-0; Glatz R, 2003, J BIOL CHEM, V278, P19743, DOI 10.1074/jbc.M301396200; Gupta P, 1998, J INSECT PHYSIOL, V44, P713, DOI 10.1016/S0022-1910(98)00004-3; HARWOOD SH, 1994, INSECT BIOCHEM MOLEC, V24, P685, DOI 10.1016/0965-1748(94)90056-6; Jones Davy, 1993, P227; KITANO H, 1986, J INSECT PHYSIOL, V32, P369, DOI 10.1016/0022-1910(86)90050-8; Kroemer JA, 2004, ANNU REV ENTOMOL, V49, P431, DOI 10.1146/annurev.ento.49.072103.120132; Richards EH, 1999, INSECT BIOCHEM MOLEC, V29, P557, DOI 10.1016/S0965-1748(99)00031-4; Richards EH, 2000, J INVERTEBR PATHOL, V76, P33, DOI 10.1006/jipa.2000.4948; Stoltz D B, 1979, Adv Virus Res, V24, P125, DOI 10.1016/S0065-3527(08)60393-0; STOLTZ DB, 1988, J GEN VIROL, V69, P903, DOI 10.1099/0022-1317-69-4-903; STOLTZ DB, 1986, J INSECT PHYSIOL, V32, P377, DOI 10.1016/0022-1910(86)90051-X; STRAND MR, 1995, ANNU REV ENTOMOL, V40, P31, DOI 10.1146/annurev.en.40.010195.000335; STRAND MR, 1992, J GEN VIROL, V73, P1627, DOI 10.1099/0022-1317-73-7-1627; TANAKA T, 1987, J INSECT PHYSIOL, V33, P413, DOI 10.1016/0022-1910(87)90020-5; THEILMANN DA, 1986, J GEN VIROL, V67, P1061; WAGO H, 1989, ZOOL SCI, V6, P691; WEBB BA, 1994, ARCH INSECT BIOCHEM, V26, P147, DOI 10.1002/arch.940260208; WEBB BA, 1985, ARCH INSECT BIOCHEM, V2, P131, DOI 10.1002/arch.940020203; Zhang GM, 2004, INSECT BIOCHEM MOLEC, V34, P477, DOI 10.1016/j.ibmb.2004.02.009	34	41	46	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41580	41585		10.1074/jbc.M406865200	http://dx.doi.org/10.1074/jbc.M406865200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292189	hybrid			2022-12-27	WOS:000224075500042
J	Gonzalez, E; Nagiel, A; Lin, AJ; Golan, DE; Michel, T				Gonzalez, E; Nagiel, A; Lin, AJ; Golan, DE; Michel, T			Small interfering RNA-mediated down-regulation of caveolin-1 differentially modulates signaling pathways in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; P42/44 MAP KINASE; SPHINGOSINE 1-PHOSPHATE; TYROSINE KINASE; LIPID RAFTS; PLASMALEMMAL CAVEOLAE; ACTIN CYTOSKELETON; INSULIN-RECEPTOR; MEMBRANE DOMAINS	Caveolin-1 is a scaffolding/regulatory protein that interacts with diverse signaling molecules in endothelial cells. To explore the role of this protein in receptor-modulated signaling pathways, we transfected bovine aortic endothelial cells (BAEC) with small interfering RNA (siRNA) duplexes to down-regulate caveolin-1 expression. Transfection of BAEC with duplex siRNA targeted against caveolin-1 mRNA selectively "knocked-down" the expression of caveolin-1 by similar to90%, as demonstrated by immunoblot analyses of BAEC lysates. We used discontinuous sucrose gradients to purify caveolin-containing lipid rafts from siRNA-treated endothelial cells. Despite the near-total down-regulation of caveolin-1 expression, the lipid raft targeting of diverse signaling proteins (including the endothelial isoform of nitric-oxide synthase, Src-family tyrosine kinases, Galphaq and the insulin receptor) was unchanged. We explored the consequences of caveolin-1 knockdown on kinase pathways modulated by the agonists sphingosine-1 phosphate (S1P) and vascular endothelial growth factor (VEGF). siRNA-mediated caveolin-1 knockdown enhanced basal as well as S1P- and VEGF-induced phosphorylation of the protein kinase Akt and did not modify the basal or agonist-induced phosphorylation of extracellular signal-regulated kinases 1/2. Caveolin-1 knockdown also significantly enhanced the basal and agonist-induced activity of the small GTPase Rac. We used siRNA to down-regulate Rac expression in BAEC, and we observed that Rac knockdown significantly reduced basal, S1P-, and VEGF-induced Akt phosphorylation, suggesting a role for Rac activation in the caveolin siRNA-mediated increase in Akt phosphorylation. By using siRNA to knockdown caveolin-1 and Rac expression in cultured endothelial cells, we have found that caveolin-1 does not seem to be required for the targeting of signaling molecules to caveolae/lipid rafts and that caveolin-1 differentially modulates specific kinase pathways in endothelial cells.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, West Roxbury, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Michel, T (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	tmichel@rics.bwh.harvard.edu	Nagiel, Aaron/AAT-8886-2020	Nagiel, Aaron/0000-0001-7275-6980	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032854, R29HL046457, U54HL070819, R37HL032854, R01HL046457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036259, R37GM036259] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL070819, HL46457, HL32854] Funding Source: Medline; NIEHS NIH HHS [T32-ES07155] Funding Source: Medline; NIGMS NIH HHS [GM36259] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V284, pC457, DOI 10.1152/ajpcell.00380.2002; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Ge SJ, 2004, J BIOL CHEM, V279, P6688, DOI 10.1074/jbc.M311769200; Griffoni C, 2000, BIOCHEM BIOPH RES CO, V276, P756, DOI 10.1006/bbrc.2000.3484; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Haasemann M, 1998, J CELL SCI, V111, P917; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Kawamura S, 2003, J BIOL CHEM, V278, P31111, DOI 10.1074/jbc.M300725200; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Liu J, 2001, AM J PHYSIOL-CELL PH, V280, pC823, DOI 10.1152/ajpcell.2001.280.4.C823; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Minshall RD, 2003, AM J PHYSIOL-LUNG C, V285, pL1179, DOI 10.1152/ajplung.00242.2003; Minshall RD, 2000, J CELL BIOL, V150, P1057, DOI 10.1083/jcb.150.5.1057; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Parton RG, 2003, NAT REV MOL CELL BIO, V4, P162, DOI 10.1038/nrm1017; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; Razani B, 2001, J BIOL CHEM, V276, P38121; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; Razani B, 2000, J CELL SCI, V113, P2103; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Scheel J, 1999, NAT CELL BIOL, V1, P127, DOI 10.1038/10100; Schubert W, 2001, J BIOL CHEM, V276, P48619, DOI 10.1074/jbc.C100613200; Shack S, 2003, MOL CELL BIOL, V23, P2407, DOI 10.1128/MCB.23.7.2407-2414.2003; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1997, CELL MOL BIOL, V43, P293; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Tiruppathi C, 1997, J BIOL CHEM, V272, P25968, DOI 10.1074/jbc.272.41.25968; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	66	123	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40659	40669		10.1074/jbc.M407051200	http://dx.doi.org/10.1074/jbc.M407051200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15292187	hybrid			2022-12-27	WOS:000223916800056
J	Jansson, A; Koskiniemi, H; Mantsala, P; Niemi, J; Schneider, G				Jansson, A; Koskiniemi, H; Mantsala, P; Niemi, J; Schneider, G			Crystal structure of a ternary complex of DnrK, a methyltransferase in daunorubicin biosynthesis, with bound products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARMINOMYCIN 4-O-METHYLTRANSFERASE; STREPTOMYCES-PURPURASCENS; IN-VITRO; ANTHRACYCLINES; EXPRESSION; MECHANISM; GENES; ACLACINOMYCIN-10-HYDROXYLASE; PEUCETIUS; ALIGNMENT	One of the final steps in the biosynthesis of the widely used anti-tumor drug daunorubicin in Streptomyces peucetius is the methylation of the 4-hydroxyl group of the tetracyclic ring system. This reaction is catalyzed by the S-adenosyl-L-methionine-dependent carminomycin 4-O-methyltransferase DnrK. The crystal structure of the ternary complex of this enzyme with the bound products S-adenosyl-L-homocysteine and 4-methoxy-epsilon-rhodomycin T has been determined to a 2.35-Angstrom resolution. DnrK is a homodimer, and the subunit displays the typical fold of small molecule O-methyltransferases. The structure provides insights into the recognition of the anthracycline substrate and also suggests conformational changes as part of the catalytic cycle of the enzyme. The position and orientation of the bound ligands are consistent with an S(N)2 mechanism of methyl transfer. Mutagenesis experiments on a putative catalytic base confirm that DnrK most likely acts as an entropic enzyme in that rate enhancement is mainly due to orientational and proximity effects. This contrasts the mechanism of DnrK with that of other O-methyltransferases where acid/base catalysis has been demonstrated to be an essential contribution to rate enhancement.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Univ Turku, Dept Biochem & Food Chem, FIN-20014 Turku, Finland	Karolinska Institutet; University of Turku	Niemi, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	jarnie@utu.fi; gunter.schneider@mbb.ki.se		Schneider, Gunter/0000-0003-0622-5713				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARCAMONE F, 1969, TETRAHEDRON LETT, P1007; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blow D, 2000, STRUCT FOLD DES, V8, pR77, DOI 10.1016/S0969-2126(00)00125-8; CONNORS NC, 1990, J GEN MICROBIOL, V136, P1895, DOI 10.1099/00221287-136-9-1895; CONNORS NC, 1993, J GEN MICROBIOL, V139, P1353, DOI 10.1099/00221287-139-6-1353; CONNORS NC, 1990, J GEN MICROBIOL, V136, P1887, DOI 10.1099/00221287-136-9-1887; Coward J. K., 1977, BIOCH ADENOSYLMETHIO, P127; DeLano W.L, PYMOL MOL GRAPHICS S; Dickens ML, 1997, J BACTERIOL, V179, P2641, DOI 10.1128/jb.179.8.2641-2650.1997; DIMARCO A, 1964, NATURE, V201, P706, DOI 10.1038/201706a0; Dong AP, 2001, NUCLEIC ACIDS RES, V29, P439, DOI 10.1093/nar/29.2.439; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fabrega C, 2004, MOL CELL, V13, P77, DOI 10.1016/S1097-2765(03)00522-7; Fu ZJ, 1996, BIOCHEMISTRY-US, V35, P11985, DOI 10.1021/bi961068n; GAUZE GF, 1973, ANTIBIOT MED BIOTEK, V18, P675; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; Horton JR, 2001, STRUCTURE, V9, P837, DOI 10.1016/S0969-2126(01)00643-8; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jansson A, 2003, J MOL BIOL, V334, P269, DOI 10.1016/j.jmb.2003.09.061; Jansson A, 2003, J BIOL CHEM, V278, P39006, DOI 10.1074/jbc.M304008200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Komoto J, 2002, J MOL BIOL, V320, P223, DOI 10.1016/S0022-2836(02)00448-5; Korolev S, 2002, NAT STRUCT BIOL, V9, P27, DOI 10.1038/nsb737; Kwon T, 2003, EMBO J, V22, P292, DOI 10.1093/emboj/cdg025; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Lim K, 2001, PROTEINS, V45, P397, DOI 10.1002/prot.10004; Lu GG, 1999, J APPL CRYSTALLOGR, V32, P365, DOI 10.1107/S0021889898015052; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; MADDURI K, 1993, J BACTERIOL, V175, P3900, DOI 10.1128/JB.175.12.3900-3904.1993; Martin JL, 2002, CURR OPIN STRUC BIOL, V12, P783, DOI 10.1016/S0959-440X(02)00391-3; Martin JL, 2001, STRUCTURE, V9, P977, DOI 10.1016/S0969-2126(01)00662-1; MATSUZAWA Y, 1981, J ANTIBIOT, V34, P1596, DOI 10.7164/antibiotics.34.1596; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Niemi J, 1999, BBA-PROTEIN STRUCT M, V1430, P57, DOI 10.1016/S0167-4838(98)00265-9; NIEMI J, 1995, J BACTERIOL, V177, P2942, DOI 10.1128/jb.177.10.2942-2945.1995; NIEMI J, 1994, MICROBIOL-UK, V140, P1351, DOI 10.1099/00221287-140-6-1351; OTTEN SL, 1990, J BACTERIOL, V172, P3427, DOI 10.1128/jb.172.6.3427-3434.1990; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Shen B, 1996, P NATL ACAD SCI USA, V93, P6600, DOI 10.1073/pnas.93.13.6600; STUTZMANENGWALL KJ, 1989, P NATL ACAD SCI USA, V86, P3135, DOI 10.1073/pnas.86.9.3135; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wang YL, 2000, BBA-PROTEIN STRUCT M, V1480, P191, DOI 10.1016/S0167-4838(00)00089-3; Wang YL, 2002, FEMS MICROBIOL LETT, V208, P117, DOI 10.1016/S0378-1097(01)00591-2; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509; Zubieta C, 2001, NAT STRUCT BIOL, V8, P271, DOI 10.1038/85029	48	48	51	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41149	41156		10.1074/jbc.M407081200	http://dx.doi.org/10.1074/jbc.M407081200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15273252	hybrid			2022-12-27	WOS:000223916800114
J	Kuwabara, N; Inoue, H; Tsuboi, Y; Nakamura, N; Kanazawa, H				Kuwabara, N; Inoue, H; Tsuboi, Y; Nakamura, N; Kanazawa, H			The fourth transmembrane domain of the Helicobacter pylori Na(+)/H(+) antiporter NhaA faces a water-filled channel required for ion transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SCANNING MUTAGENESIS; AMINO-ACID; GENE; RESIDUES; CLONING; SITE; IDENTIFICATION; OVERPRODUCTION; EXPRESSION	Cysteine-scanning mutagenesis was performed from Ser-130 to Leu-160 in the fourth transmembrane domain (TM4) of the Na(+)/H(+) antiporter NhaA from Helicobacter pylori to determine the topology of each residue and to identify functionally important residues. All of the mutants were based on cysteine-less NhaA (Cys-less NhaA), which functions very similarly to the wild-type protein, and were expressed at a level similar to Cys-less NhaA. Discontinuity of [(14)C] N-ethylmaleimide (NEM)-reactive residues suggested that TM4 comprises residues Gly-135 to Val-156. Even within TM4, NEM reactivity was high for I136C, D141C to A143C, L146C, M150C, and G153C to R155C. These residues are thought to be located on one side of the alpha-helical structure of TM4 and to face a putative water-filled channel. Pretreatment of intact cells with membrane-impermeable maleimide did not inhibit [(14)C] NEM binding to the NEM-reactive residues within TM4, suggesting that the putative channel opens toward the cytoplasm. NEM reactivity of the A143C mutant was significantly inhibited by Li(+). The T140C and D141C mutants showed lower affinity for Na(+) and Li(+) as transport substrates, but their maximal antiporter velocities (V(max)) were relatively unaffected. Whereas the I142C and F144C mutants completely lost their Li(+)/H(+) antiporter activity, I142C had a lower V(max) for the Na(+)/H(+) antiporter. F144C exhibited a markedly lower V(max) and a partially reduced affinity for Na(+). These results suggest that Thr-140, Asp-141, and Phe-144 are located in the end portion of a putative water-filled channel and may provide the binding site for Na(+), Li(+,) and/or H(+). Furthermore, residues Ile-142 to Phe-144 may be important for the conformational change that accompanies ion transport in NhaA.	Osaka Univ, Grad Sch Sci, Dept Biol Sci, Toyonaka, Osaka 5600043, Japan	Osaka University	Kanazawa, H (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol Sci, Machikaneyama Cho 1-1, Toyonaka, Osaka 5600043, Japan.	kanazawa@bio.sci.osaka-u.ac.jp		Kuwabara, Naoyuki/0000-0002-1659-323X				Burnay M, 2003, J BIOL CHEM, V278, P19237, DOI 10.1074/jbc.M300946200; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Galili L, 2002, BIOCHEMISTRY-US, V41, P609, DOI 10.1021/bi011655v; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; HASHIMOTOGOTOH T, 1995, GENE, V152, P271, DOI 10.1016/0378-1119(94)00750-M; INOUE H, 1995, FEBS LETT, V363, P264, DOI 10.1016/0014-5793(95)00331-3; Inoue H, 1998, BIOL PHARM BULL, V21, P1128; Inoue H, 1999, FEBS LETT, V443, P11, DOI 10.1016/S0014-5793(98)01652-4; Inoue S, 2001, J BIOCHEM, V129, P569, DOI 10.1093/oxfordjournals.jbchem.a002892; IVEY DM, 1993, J BIOL CHEM, V268, P11296; Iwaki S, 2000, J BIOL CHEM, V275, P22704, DOI 10.1074/jbc.M910354199; KANAZAWA H, 1979, P NATL ACAD SCI USA, V76, P1126, DOI 10.1073/pnas.76.3.1126; KARPEL R, 1988, J BIOL CHEM, V263, P10408; Kimura-Someya T, 1998, J BIOL CHEM, V273, P32806, DOI 10.1074/jbc.273.49.32806; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MIKI J, 1994, J BIOL CHEM, V269, P4227; MUSVETEAU I, 1995, BIOCHEMISTRY-US, V34, P6775, DOI 10.1021/bi00020a024; Noumi T, 1997, J BIOCHEM-TOKYO, V121, P661; Nozaki K, 1996, BIOCHEM BIOPH RES CO, V222, P774, DOI 10.1006/bbrc.1996.0820; Ostroumov E, 2002, BBA-BIOMEMBRANES, V1564, P99, DOI 10.1016/S0005-2736(02)00407-8; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; Padan E, 1998, MICR EXTREM UNUSUAL, P163; PADAN E, 1992, ALKALI CATION TRANSP, P3; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1994, J BIOL CHEM, V269, P26274; Rimon A, 1998, J BIOL CHEM, V273, P26470, DOI 10.1074/jbc.273.41.26470; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; Schuldiner S., 1992, ALKALI CATION TRANSP, P25; Soh H, 2002, BIOPHYS J, V83, P2528, DOI 10.1016/S0006-3495(02)75264-8; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; Tsuboi Y, 2003, J BIOL CHEM, V278, P21467, DOI 10.1074/jbc.M301932200; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	36	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40567	40575		10.1074/jbc.M401132200	http://dx.doi.org/10.1074/jbc.M401132200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15263004	hybrid			2022-12-27	WOS:000223916800044
J	Leimkuhler, S; Stockert, AL; Igarashi, K; Nishino, T; Hille, R				Leimkuhler, S; Stockert, AL; Igarashi, K; Nishino, T; Hille, R			The role of active site glutamate residues in catalysis of Rhodobacter capsulatus xanthine dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTIVE HALF-REACTION; MOLYBDENUM ENZYMES; CRYSTAL-STRUCTURES; MOLECULAR-OXYGEN; OXIDASE; MECHANISM; PURIFICATION; CONVERSION; INHIBITION; REACTIVITY	Xanthine dehydrogenase (XDH) from the bacterium Rhodobacter capsulatus catalyzes the hydroxylation of xanthine to uric acid with NAD(+) as the electron acceptor. R. capsulatus XDH forms an (alphabeta)(2) heterotetramer and is highly homologous to homodimeric eukaryotic xanthine oxidoreductases. Here we first describe reductive titration and steady state kinetics on recombinant wild-type R. capsulatus XDH purified from Escherichia coli, and we then proceed to evaluate the catalytic importance of the active site residues Glu-232 and Glu-730. The steady state and rapid reaction kinetics of an E232A variant exhibited a significant decrease in both k(cat) and k(red) as well as increased K-m and K-d values as compared with the wild-type protein. No activity was determined for the E730A, E730Q, E730R, and E730D variants in either the steady state or rapid reaction experiments, indicating at least a 10(7) decrease in catalytic effectiveness for this variant. This result is fully consistent with the proposed role of this residue as an active site base that initiates catalysis.	Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Univ Tokyo, Dept Biomat Sci, Bunkyo Ku, Tokyo 1138657, Japan; Nippon Med Coll, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan	Braunschweig University of Technology; University System of Ohio; Ohio State University; University of Tokyo; Nippon Medical School	Leimkuhler, S (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany.	S.Leimkuehler@tu-bs.de	Igarashi, Kiyohiko/E-6799-2016	Igarashi, Kiyohiko/0000-0001-5152-7177; Leimkuhler, Silke/0000-0003-3238-2122	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059953] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59953] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Harris CM, 1997, J BIOL CHEM, V272, P8370, DOI 10.1074/jbc.272.13.8370; HILLE R, 1984, J BIOL CHEM, V259, P1570; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; HUNT J, 1994, J BIOL CHEM, V269, P18904; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; Kim JH, 1996, J BIOL CHEM, V271, P6771, DOI 10.1074/jbc.271.12.6771; Leimkuhler S, 1998, MOL MICROBIOL, V27, P853, DOI 10.1046/j.1365-2958.1998.00733.x; Leimkuhler S, 2003, J BIOL CHEM, V278, P20802, DOI 10.1074/jbc.M303091200; Massey V, 1970, Vitam Horm, V28, P505; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; NISHINO T, 1981, FEBS LETT, V131, P369, DOI 10.1016/0014-5793(81)80406-1; NISHINO T, 1989, J BIOL CHEM, V264, P2518; NISHINO T, 1989, J BIOL CHEM, V264, P6075; NISHINO T, 1989, J BIOL CHEM, V264, P60775; Okamoto K, 2004, P NATL ACAD SCI USA, V101, P7931, DOI 10.1073/pnas.0400973101; OLSON JS, 1974, J BIOL CHEM, V249, P4363; RAJAGOPALAN KV, 1967, J BIOL CHEM, V242, P4097; RUBBO H, 1991, BIOCHIM BIOPHYS ACTA, V1074, P386, DOI 10.1016/0304-4165(91)90089-Y; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; STIRPE F, 1969, J BIOL CHEM, V244, P3855; Truglio JJ, 2002, STRUCTURE, V10, P115, DOI 10.1016/S0969-2126(01)00697-9; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6; Westley J, 1981, Methods Enzymol, V77, P285; Williams C H Jr, 1979, Methods Enzymol, V62, P185; Xiang Q, 1996, BIOCHEMISTRY-US, V35, P5441, DOI 10.1021/bi952880d	27	57	58	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40437	40444		10.1074/jbc.M405778200	http://dx.doi.org/10.1074/jbc.M405778200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15265866	hybrid			2022-12-27	WOS:000223916800029
J	Morinobu, A; Kanno, Y; O'Shea, JJ				Morinobu, A; Kanno, Y; O'Shea, JJ			Discrete roles for histone acetylation in human T helper 1 cell-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-GAMMA-PRODUCTION; CD4(+) T-CELLS; INTERFERON-GAMMA; CHROMATIN-STRUCTURE; LINEAGE COMMITMENT; CUTTING EDGE; IMMUNE-RESPONSES; TH1 DEVELOPMENT; IL-18 RECEPTOR; BET	To better understand the control of T helper (T-H) 1-expressed genes, we compared and contrasted acetylation and expression for three key genes, IFNG, TBET, and IL18RAP and found them to be distinctly regulated. The TBET and the IFNG genes, but not the IL18RAP gene, showed preferential acetylation of histones H3 and H4 during T(H)1 differentiation. Analysis of acetylation of specific histone residues revealed that H3(Lys-9), H4(Lys-8), and H4(Lys-12) were preferentially modified in T(H)1 cells, suggesting a possible contribution of acetylation of these residues for induction of these genes. On the other hand, the acetylation of IL18RAP gene occurred both in T(H)1 and T(H)2 cells with the similar kinetics and on the same residues, demonstrating that selective histone acetylation was not universally the case for all T(H)1-expressed genes. Histone H3 acetylation of IFNG and TBET genes occurred with different kinetics, however, and was distinctively regulated by cytokines. Interleukin (IL)-12 and IL-18 enhanced the histone acetylation of the IFNG gene. By contrast, histone acetylation of the TBET gene was markedly suppressed by IL-4, whereas IL-12 and IL-18 had only modest effects suggesting that histone acetylation during T(H)1 differentiation is a process that is regulated by various factors at multiple levels. By treating Th2 cells with a histone deacetylase inhibitor, we restored histone acetylation of the IFNG and TBET genes, but it did not fully restore their expression in T(H)2 cells, again suggesting that histone acetylation explains one but not all the aspects of T(H)1-specific gene expression.	NIAMS, Lymphocyte Cell Biol Sect, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	O'Shea, JJ (corresponding author), NIAMS, Lymphocyte Cell Biol Sect, Mol Immunol & Inflammat Branch, NIH, Bldg 10,Rm 9N252,10 Ctr Dr,MSC-1820, Bethesda, MD 20892 USA.	morinobu@med.kobe-u.ac.jp; osheajo@mail.nih.gov	Kanno, Yuka/B-5802-2013	Kanno, Yuka/0000-0001-5668-9319	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041106, ZIAAR041106] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Agnello D, 2003, J CLIN IMMUNOL, V23, P147, DOI 10.1023/A:1023381027062; AVNI O, 2002, NAT IMMUNOL, V10, P10; Barbulescu K, 1998, J IMMUNOL, V160, P3642; BRINKMANN V, 1993, J EXP MED, V178, P1655, DOI 10.1084/jem.178.5.1655; Bulger M, 2002, CURR OPIN GENET DEV, V12, P170, DOI 10.1016/S0959-437X(02)00283-6; Chan WL, 2001, J IMMUNOL, V167, P1238, DOI 10.4049/jimmunol.167.3.1238; Chen Q, 2000, NATURE, V407, P916, DOI 10.1038/35038103; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Frucht DM, 2001, TRENDS IMMUNOL, V22, P556, DOI 10.1016/S1471-4906(01)02005-1; Glimcher LH, 2000, GENE DEV, V14, P1693; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; Morinobu A, 2002, P NATL ACAD SCI USA, V99, P12281, DOI 10.1073/pnas.182618999; Mullen AC, 2001, SCIENCE, V292, P1907, DOI 10.1126/science.1059835; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Nakahira M, 2001, J IMMUNOL, V167, P1306, DOI 10.4049/jimmunol.167.3.1306; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nguyen KB, 2002, SCIENCE, V297, P2063, DOI 10.1126/science.1074900; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; PARRONCHI P, 1992, J IMMUNOL, V149, P2977; Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2; Recillas-Targa F, 2002, P NATL ACAD SCI USA, V99, P6883, DOI 10.1073/pnas.102179399; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; Robinson DS, 2002, IMMUNITY, V16, P755, DOI 10.1016/S1074-7613(02)00331-X; Rogge L, 2000, NAT GENET, V25, P96, DOI 10.1038/75671; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Smale ST, 2002, ANNU REV IMMUNOL, V20, P427, DOI 10.1146/annurev.immunol.20.100301.064739; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; Takeda A, 2003, J IMMUNOL, V170, P4886, DOI 10.4049/jimmunol.170.10.4886; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Xu DM, 1998, J EXP MED, V188, P1485, DOI 10.1084/jem.188.8.1485; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yoshida H, 2001, IMMUNITY, V15, P569, DOI 10.1016/S1074-7613(01)00206-0; Zhang YK, 2001, J EXP MED, V194, P165, DOI 10.1084/jem.194.2.165	46	60	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40640	40646		10.1074/jbc.M407576200	http://dx.doi.org/10.1074/jbc.M407576200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15280353	hybrid			2022-12-27	WOS:000223916800053
J	Gaertner, TR; Putkey, JA; Waxham, MN				Gaertner, TR; Putkey, JA; Waxham, MN			RC3/neurogranin and Ca2+/calmodulin-dependent protein kinase II produce opposing effects on the affinity of calmodulin for calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; STOPPED-FLOW FLUORESCENCE; CA2+ BINDING; DENDRITIC SPINES; AUTOPHOSPHORYLATION SITES; TRYPTIC FRAGMENTS; CAM-KINASE; IQ MOTIF; NEUROGRANIN; BRAIN	The interaction of calmodulin with its target proteins is known to affect the kinetics and affinity of Ca2+ binding to calmodulin. Based on thermodynamic principles, proteins that bind to Ca2+-calmodulin should increase the affinity of calmodulin for Ca2+, while proteins that bind to apo-calmodulin should decrease its affinity for Ca2+. We quantified the effects on Ca2+-calmodulin interaction of two neuronal calmodulin targets: RC3, which binds both Ca2+- and apo-calmodulin, and alphaCaM kinase II, which binds selectively to Ca2+-calmodulin. RC3 was found to decrease the affinity of calmodulin for Ca2+, whereas CaM kinase II increases the calmodulin affinity for Ca2+. Specifically, RC3 increases the rate of Ca2+ dissociation from the C-terminal sites of calmodulin up to 60-fold while having little effect on the rate of Ca2+ association. Conversely, CaM kinase II decreases the rates of dissociation of Ca2+ from both lobes of calmodulin and autophosphorylation of CaM kinase II at Thr(286) induces a further decrease in the rates of Ca2+ dissociation. RC3 dampens the effects of CaM kinase II on Ca2+ dissociation by increasing the rate of dissociation from the C-terminal lobe of calmodulin when in the presence of CaM kinase II. This effect is not seen with phosphorylated CaM kinase II. The results are interpreted according to a kinetic scheme in which there are competing pathways for dissociation of the Ca2+-calmodulin target complex. This work indicates that the Ca2+ binding properties of calmodulin are highly regulated and reveals a role for RC3 in accelerating the dissociation of Ca2+-calmodulin target complexes at the end of a Ca2+ signal.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; University of Texas System	Waxham, MN (corresponding author), 6431 Fannin St, Houston, TX 77030 USA.	m.n.waxham@uth.tmc.edu		Waxham, M. Neal/0000-0003-4801-1190	NINDS NIH HHS [NS26086] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS026086, R01NS026086] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAYLEY P, 1984, BIOCHEM BIOPH RES CO, V120, P185, DOI 10.1016/0006-291X(84)91431-1; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; BENNETT MK, 1983, J BIOL CHEM, V258, P2735; Bradshaw JM, 2002, J BIOL CHEM, V277, P20991, DOI 10.1074/jbc.M202154200; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; Cui YF, 2003, ANAL BIOCHEM, V315, P175, DOI 10.1016/S0003-2697(03)00007-1; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Gaertner TR, 2004, J BIOL CHEM, V279, P12484, DOI 10.1074/jbc.M313597200; GERENDASY DD, 1994, J BIOL CHEM, V269, P22420; Gerendasy DD, 1997, MOL NEUROBIOL, V15, P131, DOI 10.1007/BF02740632; GERENDASY DD, 1994, J MOL NEUROSCI, V5, P133, DOI 10.1007/BF02736729; IKEDA A, 1991, J BIOL CHEM, V266, P11582; JOB D, 1981, P NATL ACAD SCI-BIOL, V78, P4679, DOI 10.1073/pnas.78.8.4679; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; KELLER CH, 1982, BIOCHEMISTRY-US, V21, P156, DOI 10.1021/bi00530a027; Krucker T, 2002, J NEUROSCI, V22, P5525; LINSE S, 1991, J BIOL CHEM, V266, P8050; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOU LL, 1989, J NEUROSCI, V9, P2020; MARTIN SR, 1985, EUR J BIOCHEM, V151, P543, DOI 10.1111/j.1432-1033.1985.tb09137.x; MARTZEN MR, 1995, J NEUROCHEM, V64, P92; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; NeunerJehle M, 1996, BRAIN RES, V733, P149, DOI 10.1016/0006-8993(96)00786-X; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; OLWIN BB, 1984, J BIOL CHEM, V259, P949; Pak JH, 2000, P NATL ACAD SCI USA, V97, P11232, DOI 10.1073/pnas.210184697; Peersen OB, 1997, PROTEIN SCI, V6, P794; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; Persechini A, 1996, J BIOL CHEM, V271, P62, DOI 10.1074/jbc.271.1.62; Persechini A, 2000, J BIOL CHEM, V275, P4199, DOI 10.1074/jbc.275.6.4199; PETROZZINO JJ, 1995, NEURON, V14, P1223, DOI 10.1016/0896-6273(95)90269-4; Putkey JA, 1996, J BIOL CHEM, V271, P29619, DOI 10.1074/jbc.271.47.29619; Putkey JA, 2003, J BIOL CHEM, V278, P49667, DOI 10.1074/jbc.C300372200; Ran XY, 2003, BIOCHEMISTRY-US, V42, P5143, DOI 10.1021/bi0271751; SHARMA RK, 1980, J BIOL CHEM, V255, P5916; Shen K, 1998, NEURON, V21, P593, DOI 10.1016/S0896-6273(00)80569-3; Singla SI, 2001, J BIOL CHEM, V276, P29353, DOI 10.1074/jbc.M101744200; SOBUE K, 1981, FEBS LETT, V132, P137, DOI 10.1016/0014-5793(81)80447-4; TELEMAN A, 1986, BIOCHIM BIOPHYS ACTA, V873, P204, DOI 10.1016/0167-4838(86)90047-6; Torok K, 2001, BIOCHEMISTRY-US, V40, P14878, DOI 10.1021/bi010920+; van Dalen JJW, 2003, EUR J NEUROSCI, V18, P13, DOI 10.1046/j.1460-9568.2003.02720.x; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; Waxham MN, 1998, J BIOL CHEM, V273, P17579, DOI 10.1074/jbc.273.28.17579; Wu JF, 2002, J BIOL CHEM, V277, P19498, DOI 10.1074/jbc.M109082200; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	49	74	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39374	39382		10.1074/jbc.M405352200	http://dx.doi.org/10.1074/jbc.M405352200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262982	hybrid			2022-12-27	WOS:000223791500023
J	Zisoulis, DG; Kansas, GS				Zisoulis, DG; Kansas, GS			H-Ras and phosphoinositide 3-kinase cooperate to induce alpha(1,3)-fucosyltransferase VII expression in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; E-SELECTIN; K-RAS; T-HELPER-2 CELLS; GOLGI-APPARATUS; GENE-EXPRESSION; P-SELECTIN; FUCT-VII; TRANSFORMATION; LIGANDS	The alpha(1,3)-fucosyltransferase FucT-VII is essential for the biosynthesis of selectin ligands, but the signaling pathways mediating FucT-VII induction in T cells and other lymphocytes are poorly understood. We have shown previously that sustained activation of Ras in Jurkat T cells induces FucT-VII transcription, which requires the Raf-MEK-ERK pathway. In this study we report that FucT-VII induction is specific to the H-Ras isoform. Jurkat T cells retrovirally transduced with constitutively active H-Ras but not N- or K-Ras up-regulated expression of FucT-VII. Pharmacological inhibition studies also revealed that phosphoinositide 3-kinase (PI3K) activity is required for H-Ras-mediated FucT-VII induction. However, the ability of H-Ras to selectively induce FucT-VII is not a function of the inability of the N- or K-Ras isoforms to activate Raf or PI3K pathways. The use of effector-loop domain mutants of H-Ras, which are impaired for their ability to interact selectively with individual effectors alone or in combination with active Raf, indicated that induction of FucT-VII requires the concomitant activation of at least three signaling pathways. These studies show that H-Ras mediates FucT-VII induction in Jurkat T cells via the activation of the Raf, PI3K, and a distinct, H-Ras-specific effector signaling pathway.	Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Kansas, GS (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, 303 E Chicago Ave, Chicago, IL 60611 USA.	gsk@northwestern.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050837] Funding Source: NIH RePORTER; NIAID NIH HHS [AI50837] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham RT, 2004, NAT REV IMMUNOL, V4, P301, DOI 10.1038/nri1330; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; Barry SM, 2003, BLOOD, V102, P1771, DOI 10.1182/blood-2002-11-3551; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; Borges E, 1997, J EXP MED, V185, P573, DOI 10.1084/jem.185.3.573; BOS JL, 1989, CANCER RES, V49, P4682; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Czyzyk J, 2003, P NATL ACAD SCI USA, V100, P6003, DOI 10.1073/pnas.1031494100; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; Knibbs RN, 1998, J IMMUNOL, V161, P6305; Kranenburg O, 2001, CURR BIOL, V11, P1880, DOI 10.1016/S0960-9822(01)00582-6; Ley K, 2004, NAT REV IMMUNOL, V4, P325, DOI 10.1038/nri1351; Lim YC, 1999, J IMMUNOL, V162, P3193; Lowe JB, 2002, IMMUNOL REV, V186, P19, DOI 10.1034/j.1600-065X.2002.18603.x; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Lucas JA, 2003, IMMUNOL REV, V191, P119, DOI 10.1034/j.1600-065X.2003.00029.x; MAHER J, 1995, ONCOGENE, V11, P1639; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Millan O, 2003, ONCOGENE, V22, P477, DOI 10.1038/sj.onc.1206179; Perez de Castro I, 2004, MOL CELL BIOL, V24, P3485, DOI 10.1128/MCB.24.8.3485-3496.2004; Porter CM, 2002, J IMMUNOL, V168, P4936, DOI 10.4049/jimmunol.168.10.4936; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rubiol I, 1999, EUR J BIOCHEM, V266, P70, DOI 10.1046/j.1432-1327.1999.00815.x; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Smithson G, 2001, J EXP MED, V194, P601, DOI 10.1084/jem.194.5.601; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; Tu L, 1999, J EXP MED, V189, P241, DOI 10.1084/jem.189.2.241; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Van Parijs L, 1999, IMMUNITY, V11, P763, DOI 10.1016/S1074-7613(00)80150-8; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wagers AJ, 2000, J IMMUNOL, V165, P5011, DOI 10.4049/jimmunol.165.9.5011; Wagers AJ, 1997, J IMMUNOL, V159, P1917; Wagers AJ, 1998, J EXP MED, V188, P2225, DOI 10.1084/jem.188.12.2225; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1	56	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39495	39504		10.1074/jbc.M407904200	http://dx.doi.org/10.1074/jbc.M407904200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262995	hybrid			2022-12-27	WOS:000223791500039
J	Campobasso, N; Patel, M; Wilding, IE; Kallender, H; Rosenberg, M; Gwynn, MN				Campobasso, N; Patel, M; Wilding, IE; Kallender, H; Rosenberg, M; Gwynn, MN			Staphylococcus aureus 3-hydroxy-3-methylglutaryl-CoA synthase - Crystal structure and mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; BIOSYNTHETIC THIOLASE; ZOOGLOEA-RAMIGERA; PROTEIN; ENZYME; ESSENTIALITY; MOLSCRIPT; RESIDUES; CYS-378	3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase, a member of the family of acyl-condensing enzymes, catalyzes the first committed step in the mevalonate pathway and is a potential target for novel antibiotics and cholesterol-lowering agents. The Staphylococcus aureus mvaS gene product (43.2 kDa) was overexpressed in Escherichia coli, purified to homogeneity, and shown biochemically to be an HMG-CoA synthase. The crystal structure of the full-length enzyme was determined at 2.0-Angstrom resolution, representing the first structure of an HMG-CoA synthase from any organism. HMG-CoA synthase forms a homodimer. The monomer, however, contains an important core structure of two similar alpha/beta motifs, a fold that is completely conserved among acyl-condensing enzymes. This common fold provides a scaffold for a catalytic triad made up of Cys, His, and Asn required by these enzymes. In addition, a crystal structure of HMG-CoA synthase with acetoacetyl-CoA was determined at 2.5-Angstrom resolution. Together, these structures provide the structural basis for an understanding of the mechanism of HMG-CoA synthase.	GlaxoSmithKline, Computat Analyt & Struct Sci, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Microbial Musculoskeletal & Proliferat Dis Ctr Ex, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Assay Dev & Compound Profiling, King Of Prussia, PA 19406 USA; Promega Corp, Res & Dev, Madison, WI 53711 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Promega Corporation	Campobasso, N (corresponding author), GlaxoSmithKline, Computat Analyt & Struct Sci, King Of Prussia, PA 19406 USA.	Nino.2.Campobasso@gsk.com	ID, IMCACAT/D-5867-2014	Campobasso, Nino/0000-0003-3419-2840				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chun KY, 2000, BIOCHEMISTRY-US, V39, P14670, DOI 10.1021/bi001805m; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; DeLano W. L., 2002, PYMOL MOL GRAPHICS S; EISENBERG DA, 1998, AM J MED, V104, P25; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Ferrer JL, 1999, NAT STRUCT BIOL, V6, P775, DOI 10.1038/11553; Hedl M, 2002, J BACTERIOL, V184, P2116, DOI 10.1128/JB.184.8.2116-2122.2002; Huang WJ, 1998, EMBO J, V17, P1183, DOI 10.1093/emboj/17.5.1183; Istvan ES, 2000, EMBO J, V19, P819, DOI 10.1093/emboj/19.5.819; Johnson E A, 1996, Adv Biochem Eng Biotechnol, V53, P119; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE CM, 1995, SCIENCE, V268, P1758, DOI 10.1126/science.7792601; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MATHIEU M, 1994, STRUCTURE, V2, P797, DOI 10.1016/S0969-2126(94)00081-6; MEGANATHAN R, 2000, ESCHERICHIA COLI SAL, P642; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MISRA I, 1995, BBA-PROTEIN STRUCT M, V1247, P253, DOI 10.1016/0167-4838(94)00223-4; MISRA I, 1993, J BIOL CHEM, V268, P12129; Misra I, 2003, J BIOL CHEM, V278, P26443, DOI 10.1074/jbc.M300244200; MIZIORKO HM, 1985, METHOD ENZYMOL, V110, P19; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Olsen JG, 1999, FEBS LETT, V460, P46, DOI 10.1016/S0014-5793(99)01303-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALMER MAJ, 1991, J BIOL CHEM, V266, P8369; Qiu XY, 1999, J BIOL CHEM, V274, P36465, DOI 10.1074/jbc.274.51.36465; REUSCH VM, 1984, CRC CR REV MICROBIOL, V11, P129, DOI 10.3109/10408418409105475; Rohmer M., 1999, COMPR NAT PROD CHEM, V2, P45, DOI 10.1016/B978-0-08-091283-7.00036-9; ROHMER M, 2002, BIOCHEM J, V295, P517; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Vinarov DA, 2000, BIOCHEMISTRY-US, V39, P3360, DOI 10.1021/bi9922897; Wilding EI, 2000, J BACTERIOL, V182, P4319, DOI 10.1128/JB.182.15.4319-4327.2000; Wilding EI, 2000, J BACTERIOL, V182, P5147, DOI 10.1128/JB.182.18.5147-5152.2000; WILLIAMS SF, 1992, J BIOL CHEM, V267, P16041	37	47	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44883	44888		10.1074/jbc.M407882200	http://dx.doi.org/10.1074/jbc.M407882200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15292254	hybrid			2022-12-27	WOS:000224505600078
J	Gingis-Velitski, S; Zetser, A; Kaplan, V; Ben-Zaken, O; Cohen, E; Levy-Adam, F; Bashenko, Y; Flugelman, MY; Vlodavsky, I; Ilan, N				Gingis-Velitski, S; Zetser, A; Kaplan, V; Ben-Zaken, O; Cohen, E; Levy-Adam, F; Bashenko, Y; Flugelman, MY; Vlodavsky, I; Ilan, N			Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX DEGRADATIVE ENZYMES; EXTRACELLULAR-MATRIX; MAMMALIAN HEPARANASE; BASEMENT-MEMBRANE; KEY ENZYME; EXPRESSION; INTERNALIZATION; INVOLVEMENT; SYNDECAN-4; RECEPTOR	Heparanase is a mammalian endoglycosidase that degrades heparan sulfate (HS) at specific intrachain sites, an activity that is strongly implicated in cell dissemination associated with metastasis and inflammation. In addition to its structural role in extracellular matrix assembly and integrity, HS sequesters a multitude of polypeptides that reside in the extracellular matrix as a reservoir. A variety of growth factors, cytokines, chemokines, and enzymes can be released by heparanase activity and profoundly affect cell and tissue function. Thus, heparanase bioavailability, accessibility, and activity should be kept tightly regulated. We provide evidence that HS is not only a substrate for, but also a regulator of, heparanase. Addition of heparin or xylosides to cell cultures resulted in a pronounced accumulation of, heparanase in the culture medium, whereas sodium chlorate had no such effect. Moreover, cellular uptake of heparanase was markedly reduced in HS-deficient CHO-745 mutant cells, heparan sulfate proteoglycan-deficient HT-29 colon cancer cells, and heparinase-treated cells. We also studied the heparanase biosynthetic route and found that the half-life of the active enzyme is similar to30 h. This and previous localization studies suggest that heparanase resides in the endosomal/lysosomal compartment for a relatively long period of time and is likely to play a role in the normal turnover of HS. Co-localization studies and cell fractionation following heparanase addition have identified syndecan family members as candidate molecules responsible for heparanase uptake, providing an efficient mechanism that limits extracellular accumulation and function of heparanase.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; Lady Davies Carmel Med Ctr, Dept Cardiol, IL-34632 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Clalit Health Services; Carmel Medical Center	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Fac Med, Canc & Vasc Biol Res Ctr, POB 9649, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il			NCI NIH HHS [R01 CA106456-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrami L, 2001, J BIOL CHEM, V276, P30729, DOI 10.1074/jbc.M102039200; BARTLETT MR, 1995, IMMUNOL CELL BIOL, V73, P113, DOI 10.1038/icb.1995.19; Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Bernard D, 2001, J INVEST DERMATOL, V117, P1266, DOI 10.1046/j.1523-1747.2001.15401.x; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Chen GP, 2004, BIOCHEMISTRY-US, V43, P4971, DOI 10.1021/bi0356552; de Mestre AM, 2003, J BIOL CHEM, V278, P50377, DOI 10.1074/jbc.M310154200; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Egeberg M, 2001, BBA-MOL CELL RES, V1541, P135, DOI 10.1016/S0167-4889(01)00132-X; El-Assal ON, 2001, CLIN CANCER RES, V7, P1299; Elkin M, 2003, CANCER RES, V63, P8821; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Freissler E, 2000, CELL MICROBIOL, V2, P69, DOI 10.1046/j.1462-5822.2000.00036.x; Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Goldshmidt O, 2002, EXP CELL RES, V281, P50, DOI 10.1006/excr.2002.5651; Gotte M, 2003, FASEB J, V17, P575, DOI 10.1096/fj.02-0739rev; Ho YY, 2000, BIOCHEMISTRY-US, V39, P4746, DOI 10.1021/bi992294a; Katz A, 2002, ISRAEL MED ASSOC J, V4, P996; Koliopanos A, 2001, CANCER RES, V61, P4655; Kramer KL, 2003, ANNU REV GENET, V37, P461, DOI 10.1146/annurev.genet.37.061103.090226; Levidiotis V, 2001, KIDNEY INT, V60, P1287, DOI 10.1046/j.1523-1755.2001.00934.x; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; Liu BY, 2003, ONCOGENE, V22, P9243, DOI 10.1038/sj.onc.1207217; Lu WC, 2003, ONCOGENE, V22, P919, DOI 10.1038/sj.onc.1206201; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Mollinedo F, 1997, BIOCHEM J, V327, P917, DOI 10.1042/bj3270917; Nadav L, 2002, J CELL SCI, V115, P2179; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Parish CR, 1998, IMMUNOL CELL BIOL, V76, P104, DOI 10.1046/j.1440-1711.1998.00722.x; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Rohloff J, 2002, BRIT J CANCER, V86, P1270, DOI 10.1038/sj.bjc.6600232; Safaiyan F, 1999, J BIOL CHEM, V274, P36267, DOI 10.1074/jbc.274.51.36267; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Schroter CJ, 1999, J IMMUNOL METHODS, V227, P161, DOI 10.1016/S0022-1759(99)00079-4; Seo T, 1997, J LIPID RES, V38, P765; Seo T, 2000, J BIOL CHEM, V275, P30355, DOI 10.1074/jbc.M910327199; Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056; Vaday GG, 2000, J LEUKOCYTE BIOL, V67, P149, DOI 10.1002/jlb.67.2.149; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253; Xiao Y, 2003, HEPATOL RES, V26, P192, DOI 10.1016/S1386-6346(03)00107-4; Yang YJ, 2003, WORLD J GASTROENTERO, V9, P1707, DOI 10.3748/wjg.v9.i8.1707; Zeng BJ, 1998, J LIPID RES, V39, P845; Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068; Zetser A, 2003, CANCER RES, V63, P7733	59	141	154	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44084	44092		10.1074/jbc.M402131200	http://dx.doi.org/10.1074/jbc.M402131200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292202	hybrid			2022-12-27	WOS:000224383100088
J	Kiefer, HLB; Hanley, TM; Marcello, JE; Karthik, AG; Viglianti, GA				Kiefer, HLB; Hanley, TM; Marcello, JE; Karthik, AG; Viglianti, GA			Retinoic acid inhibition of chromatin remodeling at the human immunodeficiency virus type 1 promoter - Uncoupling of histone acetylation and chromatin remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A-DEFICIENCY; THYROID-HORMONE RECEPTOR; LIGATION-MEDIATED PCR; CREB-BINDING-PROTEIN; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; PHORBOL ESTER; CO-REPRESSOR; HIV-1 TAT	All-trans retinoic acid (RA) represses HIV-1 transcription and replication in cultured monocytic cells and in primary monocyte-derived macrophages. Here we examine the role of histone acetylation and chromatin remodeling in RA-mediated repression. RA pretreatment of latently infected U1 promonocytes inhibits HIV-1 expression in response to the histone deacetylase ( HDAC) inhibitor, trichostatin A (TSA). TSA is thought to activate HIV-1 transcription by inducing histone hyperacetylation within a regulatory nucleosome, nuc-1, positioned immediately downstream from the transcription start site. Acetylation of nuc-1 is thought to be a critical step in activation that precedes nuc-1 remodeling and, subsequently, transcriptional initiation. Here we demonstrate that TSA treatment induces H3 and H4 hyperacetylation and nuc-1 remodeling. Although RA pretreatment inhibits nuc-1 remodeling and HIV-1 transcription, it has no effect on histone acetylation. This suggests that acetylation and remodeling are not obligatorily coupled. We also show that growth of U1 cells in retinoid-deficient medium induces nuc-1 remodeling and HIV-1 expression but does not induce histone hyperacetylation. These findings suggest that remodeling, not histone hyperacetylation, is the limiting step in transcriptional activation in these cells. Together, these data suggest that RA signaling maintains the chromatin structure of the HIV-1 promoter in a transcriptionally non-permissive state that may contribute to the establishment of latency in monocyte/macrophages.	Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA	Boston University	Viglianti, GA (corresponding author), Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.	gviglian@bu.edu	Hanley, Timothy/AAG-7547-2020	Hanley, Timothy/0000-0002-6253-6850; Viglianti, Gregory/0000-0002-0244-8293	NHLBI NIH HHS [HL57882] Funding Source: Medline; NIAID NIH HHS [AI49098] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049098] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Brown XQ, 2002, AIDS RES HUM RETROV, V18, P649, DOI 10.1089/088922202760019347; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COUTSOUDIS A, 1995, AM J PUBLIC HEALTH, V85, P1076, DOI 10.2105/AJPH.85.8_Pt_1.1076; El Kharroubi A, 1998, MOL CELL BIOL, V18, P2535, DOI 10.1128/MCB.18.5.2535; Fawzi W, 2003, CLIN INFECT DIS, V37, pS112, DOI 10.1086/375882; Fawzi WW, 2000, J PEDIATR-US, V137, P660, DOI 10.1067/mpd.2000.110136; Fawzi WW, 1999, PEDIATR INFECT DIS J, V18, P127, DOI 10.1097/00006454-199902000-00009; FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; Hanley TM, 2004, J VIROL, V78, P2819, DOI 10.1128/JVI.78.6.2819-2830.2004; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Henderson A, 2004, MOL CELL BIOL, V24, P389, DOI 10.1128/MCB.24.1.389-397.2004; Hill DA, 2000, BIOCHEMISTRY-US, V39, P11649, DOI 10.1021/bi001330z; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Hsia SCV, 2002, MOL CELL BIOL, V22, P4043, DOI 10.1128/MCB.22.12.4043-4052.2002; KARTER DL, 1995, J ACQ IMMUN DEF SYND, V8, P199; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; LINNEY E, 1992, CURR TOP DEV BIOL, V27, P309, DOI 10.1016/S0070-2153(08)60538-4; Lusic M, 2003, EMBO J, V22, P6550, DOI 10.1093/emboj/cdg631; Lusser A, 2003, BIOESSAYS, V25, P1192, DOI 10.1002/bies.10359; Maciaszek JW, 1998, J VIROL, V72, P5862, DOI 10.1128/JVI.72.7.5862-5869.1998; MACIASZEK JW, 1994, J VIROL, V68, P6598, DOI 10.1128/JVI.68.10.6598-6604.1994; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Melikian G, 2001, NUTRITION, V17, P567, DOI 10.1016/S0899-9007(01)00567-6; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Neely KE, 2002, MOL GENET METAB, V76, P1, DOI 10.1016/S1096-7192(02)00014-8; Peterson CL, 2000, J CELL BIOCHEM, V78, P179, DOI 10.1002/(SICI)1097-4644(20000801)78:2<179::AID-JCB1>3.0.CO;2-E; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; POLI G, 1992, P NATL ACAD SCI USA, V89, P2689, DOI 10.1073/pnas.89.7.2689; SEMBA RD, 1993, ARCH INTERN MED, V153, P2149, DOI 10.1001/archinte.153.18.2149; SEMBA RD, 1995, J INFECT DIS, V171, P1196, DOI 10.1093/infdis/171.5.1196; SEMBA RD, 1994, LANCET, V343, P1593, DOI 10.1016/S0140-6736(94)93056-2; Sheridan PL, 1997, GENE DEV, V11, P3327, DOI 10.1101/gad.11.24.3327; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; TANG AM, 1993, AM J EPIDEMIOL, V138, P937, DOI 10.1093/oxfordjournals.aje.a116814; TOWERS G, 1995, AIDS, V9, P129, DOI 10.1097/00002030-199509020-00003; TURPIN JA, 1992, J IMMUNOL, V148, P2539; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VERDIN E, 1991, J VIROL, V65, P6790, DOI 10.1128/JVI.65.12.6790-6799.1991; Villamor E, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e6; Villamor E, 2000, J INFECT DIS, V182, pS122, DOI 10.1086/315921; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YAMAGUCHI K, 1994, AIDS, V8, P1675, DOI 10.1097/00002030-199412000-00006	49	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43604	43613		10.1074/jbc.M408069200	http://dx.doi.org/10.1074/jbc.M408069200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15299018	hybrid			2022-12-27	WOS:000224383100033
J	Davis, KE; Moldes, M; Farmer, SR				Davis, KE; Moldes, M; Farmer, SR			The forkhead transcription factor FoxC2 inhibits white adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; MITOTIC CLONAL EXPANSION; BROWN ADIPOSE-TISSUE; PPAR-GAMMA; UNCOUPLING PROTEIN; C/EBP-ALPHA; 3T3-L1 PREADIPOCYTES; INSULIN-RESISTANCE; GENE-EXPRESSION; MESSENGER-RNA	In this study, we show that expression of FoxC2 blocks the capacity of 3T3-L1 preadipocytes to undergo adipogenesis in the presence of dexamethasone, isobutylmethylxanthine, and insulin. This block is characterized by an extensive decrease in the expression of proteins associated with the function of the mature fat cell, most notably C/EBPalpha, adiponectin, perilipin, and the adipose-specific fatty acid-binding protein, FABP4/aP2. Since the expression of these proteins lies downstream of PPARgamma, we overexpressed PPARgamma in Swiss mouse fibroblasts to promote adipocyte differentiation. We show that FoxC2 blocks the ability of PPARgamma to induce adipogenic gene expression in response to exposure of the cells to dexamethasone, isobutylmethylxanthine, insulin, and a PPARgamma ligand. Interestingly, the expression of aP2 escapes the inhibitory action of FoxC2 under conditions that promote maximum PPARgamma activity. In contrast, FoxC2 inhibits the expression of C/EBPalpha, perilipin, and adiponectin even in the presence of potent PPARgamma ligands. Finally, we show that FoxC2 does not affect the ability of PPARgamma to bind to or transactivate from a PPARgamma response element. These data suggest that FoxC2 blocks adipogenesis by inhibiting the capacity of PPARgamma to promote the expression of a subset of adipogenic genes.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Farmer, SR (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	farmer@biochem.bumc.bu.edu	Moldes-Garnaud, Marthe/E-4817-2017	Moldes-Garnaud, Marthe/0000-0002-9950-2267; Farmer, Stephen/0000-0003-2483-2795	NIDDK NIH HHS [DK51586, DK58825] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK051586, R01DK051586, R01DK058825, R56DK058825] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Bergman RN, 2001, J INVEST MED, V49, P119, DOI 10.2310/6650.2001.34108; Boney CM, 1996, ENDOCRINOLOGY, V137, P2923, DOI 10.1210/en.137.7.2923; BOUILLAUD F, 1988, CLIN SCI, V75, P21, DOI 10.1042/cs0750021; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; Dixon TM, 2001, J BIOL CHEM, V276, P722, DOI 10.1074/jbc.M008440200; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Farmer SR, 2003, MOL CELL, V11, P6, DOI 10.1016/S1097-2765(03)00003-0; Floyd ZE, 2002, J BIOL CHEM, V277, P4062, DOI 10.1074/jbc.M108473200; FoellmiAdams LA, 1996, BIOCHEM PHARMACOL, V52, P693, DOI 10.1016/0006-2952(96)00345-0; GARRUTI G, 1992, INT J OBESITY, V16, P383; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Gronning LM, 2002, MOL ENDOCRINOL, V16, P873, DOI 10.1210/me.16.4.873; Gustafson B, 2003, BIOCHEM BIOPH RES CO, V308, P933, DOI 10.1016/S0006-291X(03)01518-3; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Han JR, 2002, J NUTR, V132, P904, DOI 10.1093/jn/132.5.904; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Himms-Hagen J, 2000, AM J PHYSIOL-CELL PH, V279, pC670, DOI 10.1152/ajpcell.2000.279.3.C670; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Koza RA, 2000, J BIOL CHEM, V275, P34486, DOI 10.1074/jbc.M002136200; Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Oberkofler H, 1997, J LIPID RES, V38, P2125; PARK BH, 2004, IN PRESS MOL CELL BI; Prins JB, 1997, CLIN SCI, V92, P3, DOI 10.1042/cs0920003; Rajala MW, 2003, ENDOCRINOLOGY, V144, P3765, DOI 10.1210/en.2003-0580; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; Wolfrum C, 2003, J CLIN INVEST, V112, P345, DOI 10.1172/JCI18698; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Yang XL, 2003, OBES RES, V11, P1182, DOI 10.1038/oby.2003.163; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang JW, 2004, P NATL ACAD SCI USA, V101, P43, DOI 10.1073/pnas.0307229101	52	63	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42453	42461		10.1074/jbc.M402197200	http://dx.doi.org/10.1074/jbc.M402197200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15277530	hybrid			2022-12-27	WOS:000224226400016
J	Li, ZY; Zhang, GY; Marjanovic, JA; Ruan, CG; Du, XP				Li, ZY; Zhang, GY; Marjanovic, JA; Ruan, CG; Du, XP			A platelet secretion pathway mediated by cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN IB; CYCLIC-GMP; RELEASE REACTION; NITRIC-OXIDE; GUANOSINE 3',5'-MONOPHOSPHATE; INTEGRIN ALPHA(IIB)BETA(3); VONWILLEBRAND-FACTOR; MONOCLONAL-ANTIBODY; THROMBOXANE A(2); AGGREGATION	Platelet secretion (exocytosis) is critical in amplifying platelet activation, in stabilizing thrombi, and in arteriosclerosis and vascular remodeling. The signaling mechanisms leading to secretion have not been well defined. We have shown previously that cGMP-dependent protein kinase (PKG) plays a stimulatory role in platelet activation via the glycoprotein Ib-IX pathway. Here we show that PKG also plays an important stimulatory role in mediating aggregation-dependent platelet secretion and secretion-dependent second wave platelet aggregation, particularly those induced via G(q)-coupled agonist receptors, the thromboxane A2 (TXA2) receptor, and protease-activated receptors (PARs). PKG I knock-out mouse platelets and PKG inhibitor-treated human platelets showed diminished aggregation-dependent secretion and also showed a diminished secondary wave of platelet aggregation induced by a TXA2 analog and thrombin receptor-activating peptides that were rescued by the granule content ADP. Low dose collagen-induced platelet secretion and aggregation were also reduced by PKG inhibitors. Furthermore PKG I knockout and PKG inhibitors significantly attenuated activation of the G(i) pathway that is mediated by secreted ADP. These data unveil a novel PKG-dependent platelet secretion pathway and a mechanism by which PKG promotes platelet activation.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Suzhou 215006, Peoples R China	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Soochow University - China	Du, XP (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.	xdu@uic.edu			NHLBI NIH HHS [R01 HL068819, HL62350, HL68819, R01 HL062350] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068819, R01HL062350] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Butt E, 1995, BRIT J PHARMACOL, V116, P3110, DOI 10.1111/j.1476-5381.1995.tb15112.x; BUTT E, 1994, EUR J PHARM-MOLEC PH, V269, P265, DOI 10.1016/0922-4106(94)90095-7; Chen JH, 2004, BLOOD, V104, P1703, DOI 10.1182/blood-2003-10-3428; CHIANG TM, 1975, J BIOL CHEM, V250, P6916; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Feil R, 2003, CIRC RES, V93, P907, DOI 10.1161/01.RES.0000100390.68771.CC; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; GOLDBERG ND, 1977, ANNU REV BIOCHEM, V46, P823, DOI 10.1146/annurev.bi.46.070177.004135; Greco NJ, 1996, BIOCHEMISTRY-US, V35, P906, DOI 10.1021/bi951503y; Gu MY, 1999, J CELL BIOL, V147, P1085, DOI 10.1083/jcb.147.5.1085; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; Haslam RJ, 1999, THROMB HAEMOSTASIS, V82, P412; HASLAM RJ, 1975, NATURE, V253, P455, DOI 10.1038/253455a0; HOLMSEN H, 1968, NATURE, V219, P760, DOI 10.1038/219760a0; Hou YL, 2003, J BIOL CHEM, V278, P16706, DOI 10.1074/jbc.M300045200; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; Li ZY, 2003, J BIOL CHEM, V278, P30725, DOI 10.1074/jbc.M301838200; Li ZY, 2003, BLOOD, V101, P4423, DOI 10.1182/blood-2002-10-3210; Li ZY, 2003, CELL, V112, P77, DOI 10.1016/S0092-8674(02)01254-0; Massberg S, 1999, J EXP MED, V189, P1255, DOI 10.1084/jem.189.8.1255; MELLION BT, 1981, BLOOD, V57, P946; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; PACKHAM MA, 1977, BLOOD, V50, P915; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; Ramakrishnan V, 2001, P NATL ACAD SCI USA, V98, P1823, DOI 10.1073/pnas.98.4.1823; Rao AK, 2003, J THROMB HAEMOST, V1, P671, DOI 10.1046/j.1538-7836.2003.00129.x; Reed GL, 2000, BLOOD, V96, P3334; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SPAET TH, 1964, AM J PHYSIOL, V206, P1267, DOI 10.1152/ajplegacy.1964.206.6.1267; Thomas DW, 1998, J CLIN INVEST, V102, P1994, DOI 10.1172/JCI5116; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wegener JW, 2002, CIRC RES, V90, P18, DOI 10.1161/hh0102.103222; Woulfe D, 2004, J CLIN INVEST, V113, P441, DOI 10.1172/JCI200420267; WU G, 1990, NOUV REV FR HEMATOL, V32, P231; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; YAMAMOTO N, 1985, THROMB RES, V39, P751, DOI 10.1016/0049-3848(85)90259-2	51	58	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42469	42475		10.1074/jbc.M401532200	http://dx.doi.org/10.1074/jbc.M401532200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15280395	hybrid			2022-12-27	WOS:000224226400018
J	Soutourina, O; Soutourina, J; Blanquet, S; Plateau, P				Soutourina, O; Soutourina, J; Blanquet, S; Plateau, P			Formation of D-tyrosyl-tRNA(Tyr) accounts for the toxicity of D-tyrosine toward Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA HYDROLASE; RIBONUCLEIC ACID SYNTHETASES; AMINOACYL-TRANSFER-RNAS; SACCHAROMYCES-CEREVISIAE; BACILLUS-SUBTILIS; D-TYR-TRNA(TYR) DEACYLASE; PROTEIN-SYNTHESIS; SITE; HYDROLYSIS; BINDING	D-Tyr-tRNA(Tyr) deacylase cleaves the ester bond between a tRNA molecule and a D-amino acid. In Escherichia coli, inactivation of the gene (dtd) encoding this deacylase increases the toxicity of several D-amino acids including D-tyrosine, D-tryptophan, and D-aspartic acid. Here, we demonstrate that, in a Deltadtd cell grown in the presence of 2.4 mM D-tyrosine, similar to40% of the total tRNA(Tyr) pool is converted into D-Tyr-tRNA(Tyr). No D-Tyr-tRNA(Tyr) is observed in dtd(+) cells. In addition, we observe that overproduction of tRNA(Tyr), tRNA(Trp), or tRNA(Asp) protects a Deltadtd mutant strain against the toxic effect of D-tyrosine, D-tryptophan, or D-aspartic acid, respectively. In the case of D-tyrosine, we show that the protection is accounted for by an increase in the concentration of L-Tyr-tRNA(Tyr) proportional to that of overproduced tRNA(Tyr). Altogether, these results indicate that, by accumulating in vivo, high amounts of D-Tyr-tRNA(Tyr) cause a starvation for L-Tyr-tRNA(Tyr). The deacylase prevents the starvation by hydrolyzing D-Tyr-tRNA(Tyr). Overproduction of tRNA(Tyr) also relieves the starvation by increasing the amount of cellular L-Tyr-tRNA(Tyr) available for translation.	Ecole Polytech, Biochim Lab, UMR 7654, CNRS, F-91128 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Polytechnique de Paris	Plateau, P (corresponding author), Ecole Polytech, Biochim Lab, UMR 7654, CNRS, F-91128 Palaiseau, France.	plateau@botrytis.polytechnique.fr	Soutourina, Julie/F-8305-2014; Soutourina, Olga/F-2042-2015	Soutourina, Julie/0000-0001-5218-2350; Soutourina, Olga/0000-0001-6439-7228				BAIN JD, 1991, BIOCHEMISTRY-US, V30, P5411, DOI 10.1021/bi00236a013; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1690, DOI 10.1021/bi00869a034; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1681, DOI 10.1021/bi00869a033; CALENDAR R, 1967, J MOL BIOL, V26, P39, DOI 10.1016/0022-2836(67)90259-8; CHAMPNEY WS, 1970, J BACTERIOL, V104, P107, DOI 10.1128/JB.104.1.107-116.1970; COSTE H, 1987, J BIOL CHEM, V262, P12096; CUZIN F, 1967, P NATL ACAD SCI USA, V58, P2079, DOI 10.1073/pnas.58.5.2079; Dedkova LM, 2003, J AM CHEM SOC, V125, P6616, DOI 10.1021/ja035141q; Friedman M, 1999, J AGR FOOD CHEM, V47, P3457, DOI 10.1021/jf990080u; Fromant M, 2003, NUCLEIC ACIDS RES, V31, P3227, DOI 10.1093/nar/gkg428; GARTLAND WJ, 1966, P NATL ACAD SCI USA, V55, P948, DOI 10.1073/pnas.55.4.948; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; HECKLER TG, 1988, BIOCHEMISTRY-US, V27, P7254, DOI 10.1021/bi00419a012; KEMKHADZE KS, 1981, FEBS LETT, V125, P10, DOI 10.1016/0014-5793(81)80985-4; KOSSEL H, 1968, J MOL BIOL, V35, P539, DOI 10.1016/S0022-2836(68)80013-0; LINDAHL T, 1966, P NATL ACAD SCI USA, V55, P941, DOI 10.1073/pnas.55.4.941; MARSH L, 1987, J BACTERIOL, V169, P1818, DOI 10.1128/jb.169.5.1818-1823.1987; MEINNEL T, 1988, NUCLEIC ACIDS RES, V16, P8095, DOI 10.1093/nar/16.16.8095; MENNINGER JR, 1976, J BIOL CHEM, V251, P3392; MILLER HI, 1980, CELL, V20, P711, DOI 10.1016/0092-8674(80)90317-7; RHEINBERGER HJ, 1986, J BIOL CHEM, V261, P9133; ROESSER JR, 1989, BIOCHEMISTRY-US, V28, P5185, DOI 10.1021/bi00438a041; Rosas-Sandoval G, 2002, P NATL ACAD SCI USA, V99, P16707, DOI 10.1073/pnas.222659199; Schmitt E, 1997, EMBO J, V16, P4760, DOI 10.1093/emboj/16.15.4760; SCHOFIEL.P, 1968, BIOCHIM BIOPHYS ACTA, V155, P410, DOI 10.1016/0005-2787(68)90185-8; Soutourina J, 2000, J BIOL CHEM, V275, P32535, DOI 10.1074/jbc.M005166200; Soutourina J, 1999, J BIOL CHEM, V274, P19109, DOI 10.1074/jbc.274.27.19109; Soutourina J, 2000, J BIOL CHEM, V275, P11626, DOI 10.1074/jbc.275.16.11626; Soutourina J, 2001, J BIOL CHEM, V276, P40864, DOI 10.1074/jbc.M102375200; YAMANE T, 1981, BIOCHEMISTRY-US, V20, P7059, DOI 10.1021/bi00528a001; Yang HB, 2003, FEBS LETT, V552, P95, DOI 10.1016/S0014-5793(03)00858-5	32	53	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42560	42565		10.1074/jbc.M402931200	http://dx.doi.org/10.1074/jbc.M402931200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292242	Green Published, hybrid			2022-12-27	WOS:000224226400028
J	Vallet-Erdtmann, V; Tavernier, G; Contreras, JA; Mairal, A; Rieu, C; Touzalin, AM; Holm, C; Jegou, B; Langin, D				Vallet-Erdtmann, V; Tavernier, G; Contreras, JA; Mairal, A; Rieu, C; Touzalin, AM; Holm, C; Jegou, B; Langin, D			The testicular form of hormone-sensitive lipase HSLtes confers rescue of male infertility in HSL-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; TESTIS; PROMOTER; ORGANIZATION; TISSUES; CELL	Inactivation of the hormone-sensitive lipase gene (HSL) confers male sterility with a major defect in spermatogenesis. Several forms of HSL are expressed in testis. HSLtes mRNA and protein are found in early and elongated spermatids, respectively. The other forms are expressed in diploid germ cells and interstitial cells of the testis. To determine whether the absence of the testis-specific form of HSL, HSLtes, was responsible for the infertility in HSL-null mice, we generated transgenic mice expressing HSLtes under the control of its own promoter. The transgenic animals were crossed with HSL-null mice to produce mice deficient in HSL in non-gonadal tissues but expressing HSLtes in haploid germ cells. Cholesteryl ester hydrolase activity was almost completely blunted in HSL-deficient testis. Mice with one allele of the transgene showed an increase in enzymatic activity and a small elevation in the production of spermatozoa. The few fertile hemizygous male mice produced litters of very small to small size. The presence of the two alleles led to a doubling in cholesteryl ester hydrolase activity, which represented 25% of the wild type values associated with a qualitatively normal spermatogenesis and a partial restoration of sperm reserves. The fertility of these mice was totally restored with normal litter sizes. In line with the importance of the esterase activity, HSLtes transgene expression reversed the cholesteryl ester accumulation observed in HSL-null mice. Therefore, expression of HSLtes and cognate cholesteryl ester hydrolase activity leads to a rescue of the infertility observed in HSL-deficient male mice.	Univ Rennes 1, INSERM, U625, Team 1,Grp Etud Reprod Homme & Mammiferes, F-35042 Rennes, France; Univ Rennes 1, INSERM, U625, Team 2,Grp Etud Reprod Homme & Mammiferes, F-35042 Rennes, France; Univ Toulouse 3, CHU Toulouse, Inst Louis Bugnard, INSERM,U586,Unite Rech Obes, F-31059 Toulouse 9, France; Lund Univ, Dept Cell & Mol Biol, Sect Mol Signalling, SE-22184 Lund, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Lund University	Jegou, B (corresponding author), CHU Rangueil, INSERM,U586, UPS, Inst Louis Bugnard, Batiment L3,TSA 50032, F-31059 Toulouse 9, France.	jegou@rennes.inserm.fr; langin@toulouse.inserm.fr	Jégou, Bernard/I-4742-2015	Langin, Dominique/0000-0002-2669-7825; Tavernier, Genevieve/0000-0002-0214-0344; JEGOU, Bernard/0000-0003-0623-3609				Arenas MI, 2004, HUM PATHOL, V35, P34, DOI 10.1016/j.humpath.2003.08.015; BARRANS A, 1994, J BIOL CHEM, V269, P11572; Blaise R, 1999, J BIOL CHEM, V274, P9327, DOI 10.1074/jbc.274.14.9327; Blaise R, 2001, J BIOL CHEM, V276, P5109, DOI 10.1074/jbc.M009103200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chung SR, 2001, ENDOCRINOLOGY, V142, P4272, DOI 10.1210/en.142.10.4272; GRISWOLD MD, 1989, P NATL ACAD SCI USA, V90, P154; Grober J, 1997, BIOCHEM J, V328, P453, DOI 10.1042/bj3280453; Grober J, 2003, J BIOL CHEM, V278, P6510, DOI 10.1074/jbc.M208513200; Haemmerle G, 2003, CURR OPIN LIPIDOL, V14, P289, DOI 10.1097/00041433-200306000-00009; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; Holm C, 2000, METH MOL B, V155, P97; Holst LS, 1996, GENOMICS, V35, P441, DOI 10.1006/geno.1996.0383; Kabbaj O, 2001, BIOL REPROD, V65, P601, DOI 10.1095/biolreprod65.2.601; KRAEMER FB, 1993, J LIPID RES, V34, P609; Kraemer FB, 2002, J LIPID RES, V43, P1585, DOI 10.1194/jlr.R200009-JLR200; Ladha S, 1998, J MEMBRANE BIOL, V165, P1, DOI 10.1007/s002329900415; LANGIN D, 1993, P NATL ACAD SCI USA, V90, P4897, DOI 10.1073/pnas.90.11.4897; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Mairal A, 2002, BIOCHEM BIOPH RES CO, V291, P286, DOI 10.1006/bbrc.2002.6427; Mulder H, 2003, J BIOL CHEM, V278, P36380, DOI 10.1074/jbc.M213032200; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PELLETIER RM, 1983, AM J ANAT, V167, P119, DOI 10.1002/aja.1001670110; Tiraby C, 2003, J BIOL CHEM, V278, P33370, DOI 10.1074/jbc.M305235200; Wei SH, 1997, J BIOL CHEM, V272, P14159, DOI 10.1074/jbc.272.22.14159	28	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42875	42880		10.1074/jbc.M403495200	http://dx.doi.org/10.1074/jbc.M403495200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292223	hybrid			2022-12-27	WOS:000224226400065
J	Agrotis, A; Kanellakis, P; Kostolias, G; Di Vitto, G; Wei, C; Hannan, R; Jennings, G; Bobik, A				Agrotis, A; Kanellakis, P; Kostolias, G; Di Vitto, G; Wei, C; Hannan, R; Jennings, G; Bobik, A			Proliferation of neointimal smooth muscle cells after arterial injury - Dependence on interactions between fibroblast growth factor receptor-2 and fibroblast growth factor-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE LOOP; MATRIX-METALLOPROTEINASE; DIFFERENTIAL EXPRESSION; FGF; LOCALIZATION; IDENTIFICATION; SPECIFICITY; ATTENUATION; MECHANISMS; INHIBITION	The growth factor signaling mechanisms responsible for neointimal smooth muscle cell (SMC) proliferation and accumulation, a characteristic feature of many vascular pathologies that can lead to restenosis after angioplasty, remain to be identified. Here, we examined the contribution of fibroblast growth factor receptors (FGFRs) 2 and 3 as well as novel fibroblast growth factors (FGFs) to such proliferation. Balloon catheter injury to the rat carotid artery stimulated the expression of two distinctly spliced FGFR-2 isoforms, differing only by the presence or absence of the acidic box, and two distinctly spliced FGFR-3 isoforms containing the acidic box and differing only by the presence of either the IIIb or IIIc exon. Post-injury arterial administration of recombinant adenoviruses expressing dominant negative mutant forms of these FGFRs were used to assess the roles of the endogenous FGFR isoforms in neointimal SMC proliferation. Dominant negative FGFR-2 containing the acidic box inhibited such proliferation by 40%, whereas the dominant negative FGFR-3 forms had little effect. Expression of FGF-9, known to be capable of binding to all four neointimal FGFR-2/-3 isoforms, was abundant within the neointima. FGF-9 markedly stimulated both the proliferation of neointimal SMCs and the activation of extracellular signal-related kinases 1/2, effects which were abrogated by the administration of antisense FGF-9 oligonucleotides to injured arteries and the expression of the dominant negative FGFR-2 adenovirus in cultured neointimal SMCs. These studies demonstrate that, although multiple FGFRs are induced in neointimal SMCs following arterial injury, specific interactions between distinctly spliced FGFR-2 isoforms and FGF-9 contribute to the proliferation of these SMCs.	Baker Heart Res Inst, Cell Biol Lab, Melbourne, Vic 8008, Australia; Monash Univ, Alfred Hosp, Melbourne, Vic 3181, Australia; Peter MacCallum Canc Inst, Growth Control Lab, Melbourne, Vic 3002, Australia	Baker Heart and Diabetes Institute; Florey Institute of Neuroscience & Mental Health; Monash University; Peter Maccallum Cancer Center	Agrotis, A (corresponding author), Baker Heart Res Inst, Cell Biol Lab, St Kilda Rd Cent,POB 6492, Melbourne, Vic 8008, Australia.	alex.agrotis@baker.edu.au	Jennings, Garry/B-3914-2009	Jennings, Garry/0000-0002-7865-5483; Hannan, Ross/0000-0002-2166-4493				AGROTIS A, 1994, HYPERTENSION, V23, P593, DOI 10.1161/01.HYP.23.5.593; Agrotis A, 2000, FEBS LETT, V467, P128, DOI 10.1016/S0014-5793(00)01132-7; Bochaton-Piallat ML, 2001, ARTERIOSCL THROM VAS, V21, P949, DOI 10.1161/01.ATV.21.6.949; BochatonPiallat ML, 1996, ARTERIOSCL THROM VAS, V16, P815, DOI 10.1161/01.ATV.16.6.815; Colvin JS, 2001, CELL, V104, P875, DOI 10.1016/S0092-8674(01)00284-7; Dailey L, 2003, J CELL BIOL, V161, P1053, DOI 10.1083/jcb.200302075; Frid MG, 1999, ARTERIOSCL THROM VAS, V19, P2884, DOI 10.1161/01.ATV.19.12.2884; Garofalo S, 1999, J BONE MINER RES, V14, P1909, DOI 10.1359/jbmr.1999.14.11.1909; Gennaro G, 2003, ARTERIOSCL THROM VAS, V23, P204, DOI 10.1161/01.ATV.0000053182.58636.BE; Govindarajan V, 2001, DEVELOPMENT, V128, P1617; Granerus M, 2003, ANTICANCER RES, V23, P1313; Hart AW, 2000, NATURE, V408, P864, DOI 10.1038/35048589; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hughes SE, 1996, CARDIOVASC RES, V32, P557, DOI 10.1016/S0008-6363(96)00102-2; Jenkins GM, 1998, CIRCULATION, V97, P82, DOI 10.1161/01.CIR.97.1.82; Kalinina N, 2002, ARTERIOSCL THROM VAS, V22, P2037, DOI 10.1161/01.ATV.0000040222.02255.0F; Kanai M, 1997, AM J PHYSIOL-GASTR L, V272, pG885, DOI 10.1152/ajpgi.1997.272.4.G885; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; Kanda T, 2000, BRAIN RES, V876, P22, DOI 10.1016/S0006-8993(00)02563-4; Koyama H, 1997, CIRC RES, V80, P408, DOI 10.1161/01.res.0000435857.23307.bd; Lee SH, 2000, J BIOL CHEM, V275, P33679, DOI 10.1074/jbc.M004994200; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Miller DL, 2000, MOL CELL BIOL, V20, P2260, DOI 10.1128/MCB.20.6.2260-2268.2000; MILLER MJ, 1993, AM J CARDIOL, V71, P652, DOI 10.1016/0002-9149(93)91005-3; MURGUE B, 1994, CANCER RES, V54, P5206; Olson NE, 2000, J BIOL CHEM, V275, P11270, DOI 10.1074/jbc.275.15.11270; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sakaguchi K, 1999, MOL CELL BIOL, V19, P6754; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Schmahl J, 2004, DEVELOPMENT, V131, P3627, DOI 10.1242/dev.01239; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; Thomas WG, 2002, CIRC RES, V90, P135, DOI 10.1161/hh0202.104109; Tsai SJ, 2002, ENDOCRINOLOGY, V143, P2715, DOI 10.1210/en.143.7.2715; VENTURA HO, 1995, AM HEART J, V129, P791, DOI 10.1016/0002-8703(95)90331-3; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; Ward MR, 2001, ARTERIOSCL THROM VAS, V21, P208, DOI 10.1161/01.ATV.21.2.208; Ward MR, 1997, ARTERIOSCL THROM VAS, V17, P2461, DOI 10.1161/01.ATV.17.11.2461; Wong J, 1997, CIRCULATION, V96, P1631, DOI 10.1161/01.CIR.96.5.1631; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; Yeh BK, 2003, P NATL ACAD SCI USA, V100, P2266, DOI 10.1073/pnas.0436500100; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	45	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42221	42229		10.1074/jbc.M408121200	http://dx.doi.org/10.1074/jbc.M408121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292181	hybrid			2022-12-27	WOS:000224075500114
J	Dail, M; Kalo, MS; Seddon, JA; Cote, JF; Vuori, K; Pasquale, EB				Dail, M; Kalo, MS; Seddon, JA; Cote, JF; Vuori, K; Pasquale, EB			SHEP1 function in cell migration is impaired by a single amino acid mutation that disrupts association with the scaffolding protein Cas but not with Ras GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; GDP EXCHANGE FACTOR; ADAPTER PROTEIN; ANTIESTROGEN RESISTANCE; COMPLEX-FORMATION; MOLECULAR SWITCH; STRUCTURAL BASIS; EPHB2 RECEPTOR; R-RAS; SRC	SHEP1 is a signaling protein that contains a guanine nucleotide exchange factor-like domain, which binds Ras family GTPases and also forms a stable complex with the scaffolding protein Crk-associated substrate ( Cas). SHEP1 and Cas have several common functions, such as increasing c-Jun N-terminal kinase activity, promoting T cell activation, and regulating the actin cytoskeleton. However, it is unclear whether a physical association between SHEP1 and Cas is required for these activities. We reported previously that SHEP1 is tyrosine-phosphorylated downstream of the EphB2 receptor; in this study, we further demonstrate that activated EphB2 inhibits SHEP1 association with Cas. To investigate whether phosphorylation negatively regulates the SHEP1-Cas complex, we have identified by mass spectrometry several SHEP1 tyrosine phosphorylation sites downstream of EphB2; of particular interest among them is tyrosine 635 in the Cas association/exchange factor domain. Mutation of this tyrosine to glutamic acid, but not to phenylalanine, disrupts Cas binding to SHEP1 without inhibiting Ras GTPase binding. The glutamic acid mutation also makes SHEP1 unable to promote Cas-Crk association, membrane ruffling, and cell migration toward epidermal growth factor (EGF), implying that these activities of SHEP1 depend upon a physical interaction with Cas. Association with Cas also seems to be necessary for EGF-induced SHEP1 tyrosine phosphorylation, which is mediated by a Src family kinase. It is noteworthy that EGF stimulation does not cause dissociation of SHEP1 from Cas. These data show that SHEP1 regulates membrane ruffling and cell migration and that binding to Cas is probably critical for these functions. Furthermore, the SHEP1-Cas complex may have different roles downstream of EphB2 and the EGF receptor.	Burnham Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Pasquale, EB (corresponding author), 10901 N Torrey Pine Rd, La Jolla, CA 92037 USA.	elenap@burnham.org						Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Arold ST, 2002, STRUCTURE, V10, P319, DOI 10.1016/S0969-2126(02)00717-7; BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Cai DP, 1999, J IMMUNOL, V163, P2104; Cai DP, 2003, CANCER RES, V63, P6802; Cai DP, 2003, J IMMUNOL, V170, P969, DOI 10.4049/jimmunol.170.2.969; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; De Corte V, 1999, PROTEIN SCI, V8, P234; DeMali KA, 2003, J CELL SCI, V116, P2389, DOI 10.1242/jcs.00605; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Girardin SE, 2001, EMBO J, V20, P3437, DOI 10.1093/emboj/20.13.3437; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Harte MT, 2000, BBA-MOL CELL RES, V1499, P34, DOI 10.1016/S0167-4889(00)00104-X; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; Hayashi I, 2002, NAT STRUCT BIOL, V9, P101, DOI 10.1038/nsb755; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Law SF, 1999, EXP CELL RES, V252, P224, DOI 10.1006/excr.1999.4609; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Ohba Y, 2000, MOL CELL BIOL, V20, P6074, DOI 10.1128/MCB.20.16.6074-6083.2000; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riggins RB, 2003, J BIOL CHEM, V278, P28264, DOI 10.1074/jbc.M303535200; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sakakibara A, 2000, J BIOL CHEM, V275, P6404, DOI 10.1074/jbc.275.9.6404; Sakakibara A, 2003, J BIOL CHEM, V278, P6012, DOI 10.1074/jbc.M207942200; Sakakibara A, 2002, J CELL SCI, V115, P4915, DOI 10.1242/jcs.00207; Salomon AR, 2003, P NATL ACAD SCI USA, V100, P443, DOI 10.1073/pnas.2436191100; Soans C, 1996, J CELL BIOL, V135, P781, DOI 10.1083/jcb.135.3.781; Stover DR, 1996, J BIOL CHEM, V271, P12481, DOI 10.1074/jbc.271.21.12481; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Yang LT, 2002, J BIOL CHEM, V277, P17406, DOI 10.1074/jbc.M111902200; Yu HH, 2001, ONCOGENE, V20, P3995, DOI 10.1038/sj.onc.1204524; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	58	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41892	41902		10.1074/jbc.M402929200	http://dx.doi.org/10.1074/jbc.M402929200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15272013	hybrid			2022-12-27	WOS:000224075500080
J	Gao, L; Macara, IG				Gao, L; Macara, IG			Isoforms of the polarity protein Par6 have distinct functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS EMBRYOS; CELL-POLARITY; EPITHELIAL TIGHT; PDZ DOMAIN; KINASE-C; CDC42; COMPLEX; MORPHOGENESIS; DROSOPHILA; JUNCTIONS	PAR-6 is essential for asymmetric division of the Caenorhabditis elegans zygote. It is also critical for cell polarization in many other contexts throughout the Metazoa. The Par6 protein contains a PDZ domain and a partial CRIB ( Cdc42/Rac interactive binding) domain, which mediate interactions with other polarity proteins such as Par3, Cdc42, Pals1, and Lgl. A family of mammalian Par6 isoforms (Par6A-D) has been described, but the significance of this diversification has been unclear. Here we demonstrate that Par6 family members localize differently when expressed in Madin-Darby canine kidney epithelial cells and have distinct effects on tight junction (TJ) assembly. Par6B localizes to the cytosol and inhibits TJ formation, but Par6A co-localizes predominantly with the TJ marker ZO-1 at cell-cell contacts and does not affect junctions. These functional differences correlate with differences in Pals1 binding; Par6B interacts strongly with Pals1, whereas Par6A binds weakly to Pals1 even in the presence of active Cdc42. Pals1 has a low affinity for the isolated CRIB-PDZ domain of Par6A, but analysis of chimeras showed that in addition Pals1 binding is blocked by an inhibitory property of the N terminus of Par6A. Unexpectedly, the localization of Par6A to cell-cell contacts is Cdc42-independent.	Univ Virginia, Ctr Cell Signaling, HSC, Sch Med, Charlottesville, VA 22908 USA	University of Virginia	Macara, IG (corresponding author), Univ Virginia, Ctr Cell Signaling, HSC, Sch Med, Box 800577, Charlottesville, VA 22908 USA.	imacara@virginia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070902] Funding Source: NIH RePORTER; NCI NIH HHS [CA40042] Funding Source: Medline; NIGMS NIH HHS [GM070902] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Garrard SM, 2003, EMBO J, V22, P1125, DOI 10.1093/emboj/cdg110; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Hung TJ, 1999, DEVELOPMENT, V126, P127; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Lemmers C, 2004, MOL BIOL CELL, V15, P1324, DOI 10.1091/mbc.E03-04-0235; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Nam SC, 2003, DEVELOPMENT, V130, P4363, DOI 10.1242/dev.00648; Peterson FC, 2004, MOL CELL, V13, P665, DOI 10.1016/S1097-2765(04)00086-3; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Straight SW, 2004, MOL BIOL CELL, V15, P1981, DOI 10.1091/mbc.E03-08-0620; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Watts JL, 1996, DEVELOPMENT, V122, P3133; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6	21	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41557	41562		10.1074/jbc.M403723200	http://dx.doi.org/10.1074/jbc.M403723200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292221	hybrid			2022-12-27	WOS:000224075500039
J	Sanishvili, R; Beasley, S; Skarina, T; Glesne, D; Joachimiak, A; Edwards, A; Savchenko, A				Sanishvili, R; Beasley, S; Skarina, T; Glesne, D; Joachimiak, A; Edwards, A; Savchenko, A			The crystal structure of Escherichia coli MoaB suggests a probable role in molybdenum cofactor synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; BIOSYNTHESIS; MOLYBDOPTERIN; GEPHYRIN; INSIGHTS; LOCUS; MOEA; MOBA	The crystal structure of Escherichia coli MoaB was determined by multiwavelength anomalous diffraction phasing and refined at 1.6-Angstrom resolution. The molecule displayed a modified Rossman fold. MoaB is assembled into a hexamer composed of two trimers. The monomers have high structural similarity with two proteins, MogA and MoeA, from the molybdenum cofactor synthesis pathway in E. coli, as well as with domains of mammalian gephyrin and plant Cnx1, which are also involved in molybdopterin synthesis. Structural comparison between these proteins and the amino acid conservation patterns revealed a putative active site in MoaB. The structural analysis of this site allowed to advance several hypothesis that can be tested in further studies.	Argonne Natl Lab, Biosci Struct Biol Ctr, Midwest Ctr Struct Genom, Argonne, IL 60439 USA; Univ Hlth Network, Clin Genom Ctr Proteom, Toronto, ON M5G 1L7, Canada; Argonne Natl Lab, Div Energy Syst, Argonne, IL 60439 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	United States Department of Energy (DOE); Argonne National Laboratory; University of Toronto; University Toronto Affiliates; University Health Network Toronto; United States Department of Energy (DOE); Argonne National Laboratory; University of Toronto	Joachimiak, A (corresponding author), Argonne Natl Lab, Biosci Struct Biol Ctr, Midwest Ctr Struct Genom, 9700 S Cass Ave, Argonne, IL 60439 USA.	andrzejj@anl.gov	Beasley, Steven/B-8106-2019	Edwards, Aled/0000-0002-4782-6016; Beasley, Steven/0000-0002-8702-5651	NIGMS NIH HHS [P50 GM062414, P50 GM062414-05] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Evans G, 2001, J APPL CRYSTALLOGR, V34, P82, DOI 10.1107/S0021889800014655; Hille R, 1999, ESSAYS BIOCHEM, V34, P125, DOI 10.1042/bse0340125; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamdar KP, 1997, BIOCHEM SOC T, V25, P778, DOI 10.1042/bst0250778; Kozmin SG, 2000, J BACTERIOL, V182, P3361, DOI 10.1128/JB.182.12.3361-3367.2000; Lake MW, 2000, J BIOL CHEM, V275, P40211, DOI 10.1074/jbc.M007406200; LEIMKUHLER S, 2001, J BIOL CHEM, V4, P4; Liu MTW, 2000, J BIOL CHEM, V275, P1814, DOI 10.1074/jbc.275.3.1814; Magalon A, 2002, J BIOL CHEM, V277, P48199, DOI 10.1074/jbc.M205806200; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McLuskey K, 2003, J BIOL CHEM, V278, P23706, DOI 10.1074/jbc.M301485200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALMER T, 1994, EUR J BIOCHEM, V222, P687, DOI 10.1111/j.1432-1033.1994.tb18913.x; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; RAJAGOPALAN KV, 1996, ESCHERICHIA COLI SAL, P674; Ramming M, 2000, P NATL ACAD SCI USA, V97, P10266, DOI 10.1073/pnas.97.18.10266; Reiss J, 2000, HUM GENET, V106, P157, DOI 10.1007/s004390051023; Romao MJ, 1997, PROG BIOPHYS MOL BIO, V68, P121, DOI 10.1016/S0079-6107(97)00022-9; Rothery RA, 2001, J MOL MICROB BIOTECH, V3, P273; Rubio LM, 1998, J BACTERIOL, V180, P1200, DOI 10.1128/JB.180.5.1200-1206.1998; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Scheffers DJ, 2002, MOL MICROBIOL, V43, P1517, DOI 10.1046/j.1365-2958.2002.02828.x; Schrag JD, 2001, J MOL BIOL, V310, P419, DOI 10.1006/jmbi.2001.4771; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; Schwarz G, 2001, J MOL BIOL, V312, P405, DOI 10.1006/jmbi.2001.4952; Sola M, 2001, J BIOL CHEM, V276, P25294, DOI 10.1074/jbc.M101923200; STALLMEYER B, 1995, PLANT J, V8, P751, DOI 10.1046/j.1365-313X.1995.08050751.x; Stevenson CEM, 2000, STRUCTURE, V8, P1115, DOI 10.1016/S0969-2126(00)00518-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Westbrook EM, 1997, METHOD ENZYMOL, V276, P244, DOI 10.1016/S0076-6879(97)76063-4; Wuebbens MM, 2000, STRUCTURE, V8, P709, DOI 10.1016/S0969-2126(00)00157-X; Xiang S, 2001, STRUCTURE, V9, P299, DOI 10.1016/S0969-2126(01)00588-3; Zhang RG, 2001, STRUCTURE, V9, P1095, DOI 10.1016/S0969-2126(01)00675-X	45	12	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42139	42146		10.1074/jbc.M407694200	http://dx.doi.org/10.1074/jbc.M407694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15269205	hybrid, Green Accepted			2022-12-27	WOS:000224075500106
J	Wertheim, N; Cai, ZJ; McGraw, TE				Wertheim, N; Cai, ZJ; McGraw, TE			The transcription factor CCAAT/enhancer-binding protein alpha is required for the intracellular retention of GLUT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; REGULATED MEMBRANE AMINOPEPTIDASE; RAT ADIPOSE-CELLS; C/EBP-ALPHA; PPAR-GAMMA; 3T3-L1 ADIPOCYTES; RECYCLING COMPARTMENT; SUBCELLULAR-DISTRIBUTION; INSULIN; TRAFFICKING	Insulin modulates glucose uptake into adipocytes by regulating the trafficking of the GLUT4 glucose transporter. GLUT4 is mostly excluded from the surface of unstimulated cells because it is much more slowly exocytosed than it is endocytosed. GLUT4 traffics through an adipocyte-specific, specialized endosomal recycling pathway that only partially overlaps with compartments of the general endosomal recycling pathway. Insulin stimulates GLUT4 exocytosis and partially inhibits its endocytosis, resulting in GLUT4 redistribution to the cell surface. Insulin does not stimulate glucose uptake into adipocytes lacking the CCAAT/enhancer-binding protein alpha( C/EBPalpha) transcription factor. Here we show that these adipocytes do not properly traffic GLUT4. In these adipocytes, GLUT4 was rapidly exocytosed in basal conditions, resulting in an accumulation of GLUT4 on the plasma membrane. Although the kinetics of GLUT4 trafficking were altered, GLUT4 was still targeted to specialized intracellular compartments in adipocytes lacking C/EBPalpha, demonstrating an uncoupling of the targeting of GLUT4 to a specialized, adipocyte-specific insulin-regulated pathway from the regulation of the movement of GLUT4 through this pathway. Re-expression of C/EBPalpha in adipocytes lacking C/EBPalpha restored normal GLUT4 trafficking. We propose that C/EBPalpha controls the expression of the proteins that determine the basal, slow exocytosis of GLUT4, but not the proteins required to make the adipocyte-specific compartments through which GLUT4 traffics. Furthermore, these data support a model in which insulin stimulates GLUT4 exocytosis by releasing an inhibitor of GLUT4 movement to the cell surface, and it is this clamp on basal exocytosis that is missing in adipocytes lacking C/EBPalpha.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Cornell University	McGraw, TE (corresponding author), 1300 York Ave, New York, NY 10021 USA.	temcgraw@med.cornell.edu			NIDDK NIH HHS [DK52852, DK57689] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052852, R01DK057689] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aledo JC, 1997, BIOCHEM J, V325, P727, DOI 10.1042/bj3250727; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Chen XL, 2003, J CELL SCI, V116, P3511, DOI 10.1242/jcs.00675; Dawson K, 2001, BIOCHEM BIOPH RES CO, V287, P445, DOI 10.1006/bbrc.2001.5620; El-Jack AK, 1999, MOL BIOL CELL, V10, P1581, DOI 10.1091/mbc.10.5.1581; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; Garza LA, 2000, J BIOL CHEM, V275, P2560, DOI 10.1074/jbc.275.4.2560; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; Hamm JK, 1999, ANN NY ACAD SCI, V892, P134, DOI 10.1111/j.1749-6632.1999.tb07792.x; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Johnson AO, 1996, J CELL BIOL, V135, P1749, DOI 10.1083/jcb.135.6.1749; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; Keller SR, 2002, J BIOL CHEM, V277, P17677, DOI 10.1074/jbc.M202037200; Lampson MA, 2001, MOL BIOL CELL, V12, P3489, DOI 10.1091/mbc.12.11.3489; Lampson MA, 2000, J CELL SCI, V113, P4065; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Rosen ED, 2002, ANN ENDOCRINOL-PARIS, V63, P79; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Ross SA, 1997, BIOCHEM BIOPH RES CO, V239, P247, DOI 10.1006/bbrc.1997.7459; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; YEH JI, 1995, BIOCHEMISTRY-US, V34, P15523, DOI 10.1021/bi00047a018; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071	33	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41468	41476		10.1074/jbc.M405088200	http://dx.doi.org/10.1074/jbc.M405088200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15277525	hybrid			2022-12-27	WOS:000224075500029
J	Fethiere, J; Venzke, D; Diepholz, M; Seybert, A; Geerlof, A; Gentzel, M; Wilm, M; Bottcher, B				Fethiere, J; Venzke, D; Diepholz, M; Seybert, A; Geerlof, A; Gentzel, M; Wilm, M; Bottcher, B			Building the stator of the yeast vacuolar-ATPase - Specific interaction between subunits E and G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; ESCHERICHIA-COLI F1F0-ATPASE; HELICAL COILED-COILS; H+-ATPASE; V-ATPASE; CROSS-LINKING; B-SUBUNIT; 3-DIMENSIONAL STRUCTURE; NEUROSPORA-CRASSA; 13-KDA SUBUNIT	The vacuolar (H+)-ATPase (or V-ATPase) is a membrane protein complex that is structurally related to F-1 and F-0 ATP synthases. The V-ATPase is composed of an integral domain (V-0) and a peripheral domain (V-1) connected by a central stalk and up to three peripheral stalks. The number of peripheral stalks and the proteins that comprise them remain controversial. We have expressed subunits E and G in Escherichia coli as maltose binding protein fusion proteins and detected a specific interaction between these two subunits. This interaction was specific for subunits E and G and was confirmed by co-expression of the subunits from a bicistronic vector. The EG complex was characterized using size exclusion chromatography, cross-linking with short length chemical cross-linkers, circular dichroism spectroscopy, and electron microscopy. The results indicate a tight interaction between subunits E and G and revealed interacting helices in the EG complex with a length of about 220 Angstrom. We propose that the V-ATPase EG complex forms one of the peripheral stators similar to the one formed by the two copies of subunit b in F-ATPase.	European Mol Biol Lab, Struct & Computat Biol Programme, D-69117 Heidelberg, Germany; European Mol Biol Lab, Protein Express & Purificat Core Facil, D-69117 Heidelberg, Germany; European Mol Biol Lab, Bioanalyt Res Grp, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)	Fethiere, J (corresponding author), European Mol Biol Lab, Struct & Computat Biol Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.	fethiere@embl.de; boettcher@embl.de	Bottcher, Bettina/E-9397-2010	Bottcher, Bettina/0000-0002-7962-4849; Wilm, Matthias/0000-0002-5461-6834; Venzke, David/0000-0001-8180-9562; Gentzel, Marc/0000-0002-4482-6010				ADACHI I, 1990, J BIOL CHEM, V265, P967; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ARAI H, 1988, J BIOL CHEM, V263, P8796; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Armbruster A, 2003, FEBS LETT, V546, P395, DOI 10.1016/S0014-5793(03)00643-4; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; Crider BP, 1997, J BIOL CHEM, V272, P10721; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Domgall I, 2002, J BIOL CHEM, V277, P13115, DOI 10.1074/jbc.M112011200; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Futai M, 2000, J EXP BIOL, V203, P107; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; GOGARTEN JP, 1992, J EXP BIOL, V172, P137; Golas MM, 2003, SCIENCE, V300, P980, DOI 10.1126/science.1084155; Gruber G, 2002, BIOCHEM BIOPH RES CO, V298, P383, DOI 10.1016/S0006-291X(02)02468-3; Gruber G, 2000, BIOCHEMISTRY-US, V39, P8609, DOI 10.1021/bi000103u; Harrison M, 2003, J BIOENERG BIOMEMBR, V35, P337, DOI 10.1023/A:1025728915565; HENDERSON R, 1995, Q REV BIOPHYS, V28, P171, DOI 10.1017/S003358350000305X; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; Hunt IE, 1997, J BIOENERG BIOMEMBR, V29, P533, DOI 10.1023/A:1022474816665; Kawasaki-Nishi S, 2003, FEBS LETT, V545, P76, DOI 10.1016/S0014-5793(03)00396-X; LAU SYM, 1984, J BIOL CHEM, V259, P3253; Lepier A, 1996, J BIOL CHEM, V271, P8502, DOI 10.1074/jbc.271.14.8502; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; McCarty RE, 2000, ANNU REV PLANT PHYS, V51, P83, DOI 10.1146/annurev.arplant.51.1.83; McLachlin DT, 1997, J BIOL CHEM, V272, P21233, DOI 10.1074/jbc.272.34.21233; Nelson N, 2000, J EXP BIOL, V203, P89; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Supekova L, 1996, J EXP BIOL, V199, P1147; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Tomashek JJ, 1997, J BIOL CHEM, V272, P16618, DOI 10.1074/jbc.272.26.16618; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	49	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40670	40676		10.1074/jbc.M407086200	http://dx.doi.org/10.1074/jbc.M407086200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15292229	hybrid			2022-12-27	WOS:000223916800057
J	Kerschbaumer, RJ; Riedrich, K; Kral, M; Varadi, K; Dorner, F; Rosing, J; Scheiflinger, F				Kerschbaumer, RJ; Riedrich, K; Kral, M; Varadi, K; Dorner, F; Rosing, J; Scheiflinger, F			An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-VIII; CATALYTIC-ACTIVITY; HEMOPHILIA-A; THROMBIN; CELLS; PURIFICATION; INHIBITORS; RECEPTOR; SUBUNIT; VARIANT	During hemostasis the zymogen factor X (FX) is converted into its enzymatically active form factor Xa by the intrinsic FX-activating complex. This complex consists of the protease factor IXa (FIXa) that assembles, together with its cofactor, factor VIIIa, on a phospholipid surface. We have studied the functional properties of a FIXa-specific monoclonal antibody, 224AE3, which has the potential to enhance intrinsic FX activation. Binding of the antibody to FIXa improved the catalytic properties of the intrinsic FX-activating complex in two ways: (i) factor VIIIa bound to the FIXa-antibody complex with a more than 18-fold higher affinity than to FIXa, and (ii) the turnover number (k(cat)) of the enzyme complex increased 2- to 3-fold whereas the K-m for FX remained unaffected. The ability of 224AE3 to increase the FXa-generation potential (called the "booster effect") was confirmed in factor VIII (FVIII)-depleted plasma, which was supplemented with different amounts of recombinant FVIII. In the presence of antibody 224AE3 the coagulant activity was increased 2- fold at physiological FVIII concentration and up to 15-fold at low FVIII concentrations. The booster effect that we describe demonstrates the ability of antibodies to function as an additional cofactor in an enzymatic reaction and might open up a new principle for improving the treatment of hemophilia.	Baxter Biosci, Biomed Res Ctr, Preclin Prod Dev, A-2304 Orth, Austria; Baxter Biosci, Vasc Biol, A-1220 Vienna, Austria; Baxter Biosci, Global R&D, A-1220 Vienna, Austria; Maastricht Univ, Cardiovasc Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands	Maastricht University	Scheiflinger, F (corresponding author), Baxter Biosci, Biomed Res Ctr, Preclin Prod Dev, Uferstr 15, A-2304 Orth, Austria.	scheiff@baxter.com	Scheiflinger, Friedrich/AAO-6307-2020					Ando T, 2002, J CLIN INVEST, V110, P1667, DOI 10.1172/JCI200216991; Bolton-Maggs PHB, 2003, LANCET, V361, P1801, DOI 10.1016/S0140-6736(03)13405-8; Brettler DB, 1996, BAILLIERE CLIN HAEM, V9, P319, DOI 10.1016/S0950-3536(96)80066-7; Chang JL, 1998, J BIOL CHEM, V273, P12089, DOI 10.1074/jbc.273.20.12089; Chang JY, 1997, J CLIN INVEST, V100, P886, DOI 10.1172/JCI119604; Deng BJ, 1998, BLOOD, V92, P1981, DOI 10.1182/blood.V92.6.1981.418k15_1981_1988; DONATH MJSH, 1995, BIOCHEM J, V312, P49, DOI 10.1042/bj3120049; HEMKER HC, 1995, THROMB HAEMOSTASIS, V74, P134; Jenkins PV, 2002, BLOOD, V100, P501, DOI 10.1182/blood-2001-12-0361; JUNGBAUER A, 1989, J CHROMATOGR, V476, P257, DOI 10.1016/S0021-9673(01)93874-9; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; Kaufman RJ, 1998, HAEMOPHILIA, V4, P370, DOI 10.1046/j.1365-2516.1998.440370.x; Khaldoyanidi S, 2002, BLOOD, V99, P3955, DOI 10.1182/blood.V99.11.3955; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Lapan KA, 1997, J BIOL CHEM, V272, P2082; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; Mace G, 1999, J BIOL CHEM, V274, P20079, DOI 10.1074/jbc.274.29.20079; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; MANN KG, 1990, BLOOD, V76, P1; Penner JA, 2001, HAEMOPHILIA, V7, P103, DOI 10.1046/j.1365-2516.2001.00473.x; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; ROSING J, 1985, BLOOD, V65, P319; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VANDIEIJEN G, 1985, THROMB HAEMOSTASIS, V53, P396	26	9	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40445	40450		10.1074/jbc.M405966200	http://dx.doi.org/10.1074/jbc.M405966200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15265864	hybrid			2022-12-27	WOS:000223916800030
J	Liu, ZM; Dronadula, N; Rao, GN				Liu, ZM; Dronadula, N; Rao, GN			A novel role for nuclear factor of activated T cells in receptor tyrosine kinase and G protein-coupled receptor agonist-induced vascular smooth muscle cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; NF-ATC; GROWTH; PROLIFERATION; INHIBITION; MECHANISMS; MIGRATION; ANTIBODY; NFATC3; RNA	In addition to their role in cytokine gene regulation in T cells, nuclear factors of activated T cells (NFATs) have been shown to be involved in cardiac development and hypertrophy. We have reported previously that NFATs play an important role in the regulation of vascular smooth muscle cell (VSMC) proliferation by receptor tyrosine kinase (RTK) and G protein-coupled receptor ( GPCR) agonists, platelet-derived growth factor-BB (PDGF-BB) and thrombin, respectively. To understand the role of NFATs in vascular disease and development, we have now studied the role of these transcriptional factors in VSMC motility. PDGF-BB and thrombin induced VSMC motility in a dose-dependent manner. Blockade of NFAT activation resulted in substantial reduction in PDGF-BB- and thrombin-induced VSMC motility. PDGF-BB and thrombin also induced interleukin-6 (IL-6) expression in NFAT-dependent manner. Furthermore, IL-6 dose-dependently caused VSMC motility. A neutralizing anti-rat IL-6 antibody inhibited VSMC motility induced by IL-6, PDGF-BB, and thrombin. In addition, exogenous addition of IL-6 rescued both PDGF-BB- and thrombin-induced VSMC motility from inhibition by the blockade of NFAT activation. Together, these results for the first time demonstrate that NFATs mediate both RTK and GPCR agonist-induced VSMC motility via induction of expression of IL-6.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Rao, GN (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	grao@physiol.utmem.edu			NHLBI NIH HHS [HL 1R01069908-03, HL2R01064165-06] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott KL, 2000, MOL PHARMACOL, V58, P946, DOI 10.1124/mol.58.5.946; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Bushdid PB, 2003, CIRC RES, V92, P1305, DOI 10.1161/01.RES.0000077045.84609.9F; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Decker EL, 2003, NUCLEIC ACIDS RES, V31, P911, DOI 10.1093/nar/gkg186; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duan C, 2000, CIRC RES, V86, P15, DOI 10.1161/01.RES.86.1.15; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Goetze S, 1999, HYPERTENSION, V33, P183, DOI 10.1161/01.HYP.33.1.183; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Hedin KE, 1997, J IMMUNOL, V159, P5431; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; Horsley V, 2001, J CELL BIOL, V153, P329, DOI 10.1083/jcb.153.2.329; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kegley KM, 2001, DEV BIOL, V232, P115, DOI 10.1006/dbio.2001.0179; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Regan CP, 2000, J CLIN INVEST, V106, P1139, DOI 10.1172/JCI10522; RODRIGUEZ C, 1999, P NATL ACAD SCI USA, V96, P7214; RODRIGUEZ CL, 2001, IMMUNITY, V15, P47; RODRIGUEZ CL, 2003, P NATL ACAD SCI USA, V101, P2392; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Trama J, 2000, J IMMUNOL, V165, P4884, DOI 10.4049/jimmunol.165.9.4884; van Rooij E, 2002, J BIOL CHEM, V277, P48617, DOI 10.1074/jbc.M206532200; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; Yellaturu CR, 2002, BIOCHEM J, V368, P183, DOI 10.1042/BJ20020347; Zhuang DM, 2004, AM J PHYSIOL-HEART C, V286, pH2103, DOI 10.1152/ajpheart.01118.2003	40	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41218	41226		10.1074/jbc.M406917200	http://dx.doi.org/10.1074/jbc.M406917200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15272006	hybrid			2022-12-27	WOS:000223916800121
J	Torrelles, JB; Khoo, KH; Sieling, PA; Modlin, RL; Zhang, NN; Marques, AM; Treumann, A; Rithner, CD; Brennan, PJ; Chatterjee, D				Torrelles, JB; Khoo, KH; Sieling, PA; Modlin, RL; Zhang, NN; Marques, AM; Treumann, A; Rithner, CD; Brennan, PJ; Chatterjee, D			Truncated structural variants of lipoarabinomannan in Mycobacterium leprae and an ethambutol-resistant strain of Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL HEXAARABINOFURANOSYL MOTIF; BOVIS BCG; LIPOGLYCAN ANTIGENS; ATTENUATED STRAINS; CELL-WALL; T-CELLS; LEPROSY; RECOGNITION; ARABINOGALACTAN; LOCALIZATION	Current knowledge on the structure of lipoarabinomannan ( LAM) has resulted primarily from detailed studies on a few selected laboratory strains of Mycobacterium tuberculosis, Mycobacterium bovis BCG, and Mycobacterium smegmatis. Our previous work was the first to report on the salient structural features of M. tuberculosis clinical isolates and demonstrated significant structural variations. A prime effort is to correlate a particular structural characteristic with observed differences in eliciting an immunobiological response, especially in the context of CD1-restricted presentation of LAM to T cells. T cell clones derived from the cutaneous lesions of leprosy patients have been shown to recognize specifically LAM from Mycobacterium leprae and not from M. tuberculosis Erdman or H37Rv. Herein we provide further fine structural data on LAM from M. leprae (LepLAM) and a tuberculosis clinical isolate, CSU20 (CSU20LAM), which was unexpectedly recognized by the supposedly LepLAM-specific CD1-restricted T cell clones. In comparison with the de facto laboratory LAM standard from M. tuberculosis H37Rv (RvLAM), LepLAM derived from in vivo grown M. leprae is apparently simpler in its arabinan architecture with a high degree of exposed, non-mannose-capped termini. On the other hand, CSU20, an ethambutol-resistant clinical isolate, makes a vastly heterogeneous population of LAM ranging from rather small and non-mannose-capped to full-length and fully capped variants. LepLAM and CSU20LAM contain a higher level of succinylation than RvLAM, which, in the context of truncated or less elaborated arabinan, may contribute to selective recognition by T cells. LAM from all species could be resolved into discrete forms by isoelectric focusing based apparently on their arabinan heterogeneity. In the light of our current and more recent findings, we reason that all immunobiological data should be cautiously interpreted and that the actual LAM variants that may be present in vivo during infection and pathogenesis need to be taken into consideration.	Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Immunol, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Pathol, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England; Univ Calif Los Angeles, Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA; Univ Autonoma Barcelona, E-08193 Barcelona, Spain	Colorado State University; Colorado State University; Colorado State University; Colorado State University; Academia Sinica - Taiwan; University of Leeds; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Autonomous University of Barcelona	Chatterjee, D (corresponding author), Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA.	delphi@lamar.colostate.edu	Torrelles, Jordi/E-4204-2011; Khoo, Kay-Hooi/E-1989-2019; Modlin, Robert L/M-7941-2014; Treumann, Achim/H-1295-2013	Khoo, Kay-Hooi/0000-0003-2906-406X; Modlin, Robert L/0000-0003-4720-031X; de Mello Marques, Maria Angela/0000-0002-4680-2653; Treumann, Achim/0000-0002-9417-3505	PHS HHS [N01 AL 55262, AL-22553, AL-47197, AL-37139] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beckman EM, 1996, J IMMUNOL, V157, P2795; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brennan PJ, 2001, LEPROSY REV, V72, P415; Chan ED, 2001, AM J RESP CELL MOL, V25, P606, DOI 10.1165/ajrcmb.25.5.4487; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Cole ST, 2000, LEPROSY REV, V71, pS162; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Curtiss R, 2001, LEPROSY REV, V72, P8; Delmas C, 1997, GLYCOBIOLOGY, V7, P811, DOI 10.1093/glycob/7.6.811; Draper P, 1984, Acta Leprol, P99; DRAPER P, 1980, 5 M SCI WORK GROUP I; Escuyer VE, 2001, J BIOL CHEM, V276, P48854, DOI 10.1074/jbc.M102272200; Gilleron M, 1997, J BIOL CHEM, V272, P117; Guerardel Y, 2003, J BIOL CHEM, V278, P36637, DOI 10.1074/jbc.M305427200; Guerardel Y, 2002, J BIOL CHEM, V277, P30635, DOI 10.1074/jbc.M204398200; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; Kaur D, 2002, MICROBIOL-SGM, V148, P3049, DOI 10.1099/00221287-148-10-3049; Khoo HH, 2001, J BIOL CHEM, V276, P3863, DOI 10.1074/jbc.M004010200; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; MCNEIL M, 1989, METHOD ENZYMOL, V179, P215; MCNEIL MR, 1994, GLYCOBIOLOGY, V4, P165, DOI 10.1093/glycob/4.2.165; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; Prigozy TI, 1997, IMMUNITY, V6, P187, DOI 10.1016/S1074-7613(00)80425-2; PRINZIS S, 1993, J GEN MICROBIOL, V139, P2649, DOI 10.1099/00221287-139-11-2649; SANSONETTI P, 1981, REV INFECT DIS, V3, P422; Schlesinger LS, 1996, J IMMUNOL, V157, P4568; SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920; Severn WB, 1997, J MICROBIOL METH, V28, P123, DOI 10.1016/S0167-7012(97)00985-8; Sidobre S, 2000, J BIOL CHEM, V275, P2415, DOI 10.1074/jbc.275.4.2415; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Strohmeier GR, 1999, MICROBES INFECT, V1, P709, DOI 10.1016/S1286-4579(99)80072-0; Treumann A, 2002, J MOL BIOL, V316, P89, DOI 10.1006/jmbi.2001.5317; Turnbull WB, 2004, ANGEW CHEM INT EDIT, V43, P3918, DOI 10.1002/anie.200454119; VENISSE A, 1993, J BIOL CHEM, V268, P12401; Vissa V. D., 2001, Genome Biology, V2, P1023, DOI 10.1186/gb-2001-2-8-reviews1023; Zhang N, 2003, MOL MICROBIOL, V50, P69, DOI 10.1046/j.1365-2958.2003.03681.x	40	60	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41227	41239		10.1074/jbc.M405180200	http://dx.doi.org/10.1074/jbc.M405180200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15263002	hybrid			2022-12-27	WOS:000223916800122
J	Daelemans, D; Costes, SV; Cho, EH; Erwin-Cohen, RA; Lockett, S; Pavlakis, GN				Daelemans, D; Costes, SV; Cho, EH; Erwin-Cohen, RA; Lockett, S; Pavlakis, GN			In vivo HIV-1 rev multimerization in the nucleolus and cytoplasm identified by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR EXPORT SIGNAL; VIRAL MESSENGER-RNA; TYPE-1 REV; LIVING CELLS; RESPONSE ELEMENT; GENE-PRODUCT; INTRACELLULAR TRAFFICKING; PHOTOBLEACHING RECOVERY; FUNCTIONAL-ANALYSIS	Nuclear export of intron-containing human immunodeficiency virus type 1 RNA is mediated by the viral Rev protein. Rev is a nucleocytoplasmic transport protein that directly binds to its cis-acting Rev-responsive element RNA. Rev function depends on its ability to multimerize. The in vivo dynamics and the subcellular dependence of this process are still largely unexplored. To visualize and quantitatively analyze the mechanism of Rev multimeric assembly in live cells, we used high resolution in vivo fluorescence resonance energy transfer ( FRET) and fluorescence recovery after photobleaching. By using two different dynamic FRET approaches ( acceptor photobleaching and donor bleaching time measurements), we observed a strong Rev-Rev interaction in the nucleoli of living cells. Most interestingly, we could also detect Rev multimerization in the cytoplasm; however, FRET efficiency in the cytoplasm was significantly lower than in the nucleolus. By using fluorescence recovery after photobleaching, we investigated the mobility of Rev within the nucleolus. Mathematical modeling of the fluorescence recovery after photobleaching recoveries enabled us to extract relative association and dissociation constants and the diffusion coefficient of Rev in the nucleolus. Our results show that Rev multimerizes in the nucleolus of living cells, suggesting an important role of the nucleolus in nucleocytoplasmic transport.	NCI, Human Retrovirus Sect, Basic Res Lab, Frederick, MD 21702 USA; NCI, Image Anal Lab, Sci Applicat Int Corp, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Daelemans, D (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.	dirk.daelemans@uz.kuleuven.ac.be	Daelemans, Dirk/P-7923-2017; Cho, Edward/B-3727-2012; Costes, Sylvain V/D-2522-2013	Daelemans, Dirk/0000-0001-7092-1153; Cho, Edward/0000-0002-0278-334X; Costes, Sylvain V/0000-0002-8542-2389	NCI NIH HHS [N01-CO-12400] Funding Source: Medline; DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUER M, 1994, BIOCHEMISTRY-US, V33, P2988, DOI 10.1021/bi00176a031; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; Bastiaens PIH, 1996, P NATL ACAD SCI USA, V93, P8407, DOI 10.1073/pnas.93.16.8407; Carrero G, 2003, METHODS, V29, P14, DOI 10.1016/S1046-2023(02)00288-8; Chen DY, 2001, J CELL BIOL, V153, P169, DOI 10.1083/jcb.153.1.169; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577; Day RN, 1998, MOL ENDOCRINOL, V12, P1410, DOI 10.1210/me.12.9.1410; Demart S, 2003, EXP CELL RES, V291, P484, DOI 10.1016/j.yexcr.2003.07.011; EDIDIN M, 1976, SCIENCE, V191, P466, DOI 10.1126/science.1246629; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; Houtsmuller AB, 1999, SCIENCE, V284, P958, DOI 10.1126/science.284.5416.958; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; Jain C, 2001, MOL CELL, V7, P603, DOI 10.1016/S1097-2765(01)00207-6; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; KUBOTA S, 1992, J VIROL, V66, P2510, DOI 10.1128/JVI.66.4.2510-2513.1992; Li HY, 2001, J CELL BIOCHEM, V80, P293, DOI 10.1002/1097-4644(20010301)80:3<293::AID-JCB10>3.3.CO;2-L; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; MADORE SJ, 1994, VIROLOGY, V202, P186, DOI 10.1006/viro.1994.1334; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Marcello A, 2001, J BIOL CHEM, V276, P39220, DOI 10.1074/jbc.M104830200; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; Michienzi A, 2000, P NATL ACAD SCI USA, V97, P8955, DOI 10.1073/pnas.97.16.8955; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Ng EKO, 2002, J CELL BIOCHEM, V84, P556, DOI 10.1002/jcb.10041.abs; OLSEN HS, 1991, J ACQ IMMUN DEF SYND, V4, P558; PERKINS A, 1989, J ACQ IMMUN DEF SYND, V2, P256; Phair RD, 2001, NAT REV MOL CELL BIO, V2, P898, DOI 10.1038/35103000; Philipps B, 2003, J MOL BIOL, V327, P239, DOI 10.1016/S0022-2836(03)00077-9; Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615; Siegel R. M., 2000, SCI STKE, V2000, ppl1; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; Stauber RH, 1998, VIROLOGY, V251, P38, DOI 10.1006/viro.1998.9295; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Szilvay AM, 1997, VIROLOGY, V235, P73, DOI 10.1006/viro.1997.8671; TERWILLIGER E, 1988, J VIROL, V62, P655, DOI 10.1128/JVI.62.2.655-658.1988; Thomas SL, 1998, J VIROL, V72, P2935, DOI 10.1128/JVI.72.4.2935-2944.1998; Thomas SL, 1997, PROTEIN ENG, V10, P103, DOI 10.1093/protein/10.2.103; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; VENKATESH LK, 1990, VIROLOGY, V176, P39, DOI 10.1016/0042-6822(90)90228-J; Wouters FS, 1998, EMBO J, V17, P7179, DOI 10.1093/emboj/17.24.7179; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Zolotukhin AS, 1999, J VIROL, V73, P120, DOI 10.1128/JVI.73.1.120-127.1999	63	45	48	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50167	50175		10.1074/jbc.M407713200	http://dx.doi.org/10.1074/jbc.M407713200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15294891	Green Accepted, Green Published, hybrid			2022-12-27	WOS:000225229500076
J	Gardai, SJ; Whitlock, BB; Xiao, YQ; Bratton, DB; Henson, PM				Gardai, SJ; Whitlock, BB; Xiao, YQ; Bratton, DB; Henson, PM			Oxidants inhibit ERK/MAPK and prevent its ability to delay neutrophil apoptosis downstream of mitochondrial changes and at the level of XIAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; X-LINKED INHIBITOR; PROTEIN-KINASE; CYTOCHROME-C; INFLAMMATORY CYTOKINES; SELECTIVE SUPPRESSION; ACTIVATION; P38; ERK; PATHWAY	Normal spontaneous apoptosis in neutrophils is enhanced by "stress" stimuli such as tumor necrosis factor-alpha, Fas ligand, and oxidants, and this effect is inhibited by anti-apoptotic stimuli including granulocyte-macrophage colony-stimulating factor, lipopolysaccharide, and formylmethionine-leucine- phenylalanine. In this report we demonstrate that anti-apoptotic stimuli protect neutrophils from stress-induced apoptosis via activation of the ERK/MAPK pathway. The protection occurs downstream of mitochondrial alterations assessed as a decrease in membrane potential concomitant with enhanced cytochrome c release. ERK activation was shown to inhibit apoptosis by maintaining levels of XIAP, which is normally decreased in the presence of the pro-apoptotic/stress stimuli. This report also demonstrates that potent intra- and extracellular oxidants inhibit the protective effect of ERK. Oxidant-dependent inhibition of ERK was because of activation of p38 MAPK and activation of the protein phosphatases PP1 and PP2A. Our data suggest that ERK suppresses stress-induced apoptosis downstream of mitochondrial alterations by maintaining XIAP levels and that oxidants block this effect through activation of p38 and protein phosphatases.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; W Virginia Wesleyan Coll, Dept Biol, Buckhannon, WV USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Henson, PM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, D508,1400 Jackson St, Denver, CO 80206 USA.	hensonp@NJC.org						Alvarado-Kristensson M, 2001, FASEB J, V15, P129, DOI 10.1096/fj.01-0817fje; Aoshiba K, 1999, J IMMUNOL, V162, P1692; Asselin E, 2001, CANCER RES, V61, P1862; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Gardai S, 2002, J BIOL CHEM, V277, P5236, DOI 10.1074/jbc.M110005200; Hanada M, 1998, FEBS LETT, V437, P172, DOI 10.1016/S0014-5793(98)01229-0; HASLETT C, 1985, AM J PATHOL, V119, P101; Kasahara Y, 1997, BLOOD, V89, P1748, DOI 10.1182/blood.V89.5.1748.1748_1748_1753; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V275, pF691, DOI 10.1152/ajprenal.1998.275.5.F691; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Lin H, 2002, EXP CELL RES, V272, P192, DOI 10.1006/excr.2001.5417; Lin H, 2001, BIOCHEM J, V353, P299, DOI 10.1042/0264-6021:3530299; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Sweeney JF, 1999, J SURG RES, V81, P108, DOI 10.1006/jsre.1998.5471; TAKEDA Y, 1993, INT IMMUNOL, V5, P691, DOI 10.1093/intimm/5.6.691; Tashker JS, 2002, MOL BIOL CELL, V13, P393, DOI 10.1091/mbc.01-06-0291; Tudan C, 2000, J IMMUNOL, V165, P5798, DOI 10.4049/jimmunol.165.10.5798; Underwood DC, 2000, AM J PHYSIOL-LUNG C, V279, pL895, DOI 10.1152/ajplung.2000.279.5.L895; VOWELLS SJ, 1995, J IMMUNOL METHODS, V178, P89, DOI 10.1016/0022-1759(94)00247-T; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Watson RWG, 1997, J IMMUNOL, V158, P945; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; Whitlock BB, 2000, J CELL BIOL, V151, P1305, DOI 10.1083/jcb.151.6.1305; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Yang YL, 1999, J CLIN IMMUNOL, V19, P337, DOI 10.1023/A:1020594531159; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200	41	49	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44695	44703		10.1074/jbc.M405313200	http://dx.doi.org/10.1074/jbc.M405313200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15292176	hybrid			2022-12-27	WOS:000224505600057
J	Han, C; Demetris, AJ; Liu, YH; Shelhamer, JH; Wu, T				Han, C; Demetris, AJ; Liu, YH; Shelhamer, JH; Wu, T			Transforming growth factor-beta (TGF-beta) activates cytosolic phospholipase A(2)alpha (cPLA(2)alpha)-mediated prostaglandin E-2 (PGE(2))/EP1 and peroxisome proliferator-activated receptor-gamma (PPAR-gamma)/Smad signaling pathways in human liver cancer cells - A novel mechanism for subversion of TGF-beta-induced mitoinhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; ARACHIDONIC-ACID RELEASE; PPAR-GAMMA; EPITHELIAL-CELLS; TRANSGENIC MICE; MAMMARY-GLAND; INTESTINAL POLYPOSIS; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; NUCLEAR-ENVELOPE	Transforming growth factor-beta(TGF-beta) potently inhibits the growth of human epithelial cells. However, neoplastic epithelial cells become resistant to TGF-beta-mediated mitoinhibition, and the mechanisms for this alteration during tumorigenesis are not fully understood. This study was designed to determine whether there is an association between the cytosolic phospholipase A(2)alpha (cPLA(2)alpha)-controlled eicosanoid metabolism and the growth response to TGF-beta in human liver cancer cells. TGF-beta treatment induced simultaneous Smad-mediated gene transcription and phosphorylation of cPLA(2)alpha. Whereas Smad activation inhibited tumor cell growth, phosphorylation of cPLA(2)alpha promoted growth and counteracted Smad-mediated mitoinhibition. TGF-beta1 failed to prevent the growth of cells with high basal expression of cPLA(2)alpha, but inhibition of cPLA(2)alpha, cyclooxygenase-2 (COX-2), or EP1 receptor restored mitoinhibition by TGF-beta1 in these cells. These results suggest that resistance of tumor cells to TGF-beta-mediated mitoinhibition involves activation of cPLA(2)alpha/COX-2/EP1 signaling. Furthermore, the TGF-beta1-induced Smad transcriptional activity and mitoinhibition were blocked by overexpression of cPLA(2)alpha or peroxisome proliferator-activated receptor-gamma (PPAR-gamma) but enhanced by depletion of cPLA(2)alpha or PPAR-gamma. These findings, along with the observations that cPLA(2)alpha activates PPAR-gamma and that PPAR-gamma binds Smad3, illustrate novel cPLA(2)alpha/COX-2/EP1 and cPLA(2)alpha/PPAR-gamma/Smad signaling pathways that counteract the mitoinhibition by TGF-beta in human cancer cells.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Wu, T (corresponding author), Univ Pittsburgh, Presbyterian Univ Hosp C902, Sch Med, Dept Pathol, 200 Lothrop St, Pittsburgh, PA 15213 USA.	wut@upmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049615] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49615] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Bottinger EP, 1997, CANCER RES, V57, P5564; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Clay CE, 2001, J INVEST MED, V49, P413, DOI 10.2310/6650.2001.33786; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Dixon M, 1999, HEPATOLOGY, V29, P1418, DOI 10.1002/hep.510290516; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Engle SJ, 1999, CANCER RES, V59, P3379; Fitzpatrick FA, 2001, J CLIN INVEST, V107, P1347, DOI 10.1172/JCI13241; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fosslien E, 2000, ANN CLIN LAB SCI, V30, P3; Fournier DB, 2000, J CELL BIOCHEM, P97; Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007; Fu MG, 2001, J BIOL CHEM, V276, P45888, DOI 10.1074/jbc.M105490200; Gately S, 2000, CANCER METAST REV, V19, P19, DOI 10.1023/A:1026575610124; Gavrilova O, 2003, J BIOL CHEM, V278, P34268, DOI 10.1074/jbc.M300043200; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Gonzalez FJ, 1997, ADV EXP MED BIOL, V422, P109; Gorska AE, 1998, CELL GROWTH DIFFER, V9, P229; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Han C, 2004, CANCER RES, V64, P1369, DOI 10.1158/0008-5472.CAN-03-1086; Han C, 2002, AM J PHYSIOL-GASTR L, V282, pG586, DOI 10.1152/ajpgi.00305.2001; Han C, 2003, HEPATOLOGY, V38, P167, DOI 10.1053/jhep.2003.50296; Hong KH, 2001, P NATL ACAD SCI USA, V98, P3935, DOI 10.1073/pnas.051635898; Ikezoe T, 2001, CANCER RES, V61, P5307; Jong HS, 2002, BIOCHEM BIOPH RES CO, V292, P383, DOI 10.1006/bbrc.2002.6666; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Leng J, 2003, HEPATOLOGY, V38, P756, DOI 10.1053/jhep.2003.50380; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Meyer AM, 2004, CARCINOGENESIS, V25, P1517, DOI 10.1093/carcin/bgh150; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; MIYAGIWA M, 1989, IN VITRO CELL DEV B, V25, P503; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pawliczak R, 2002, J BIOL CHEM, V277, P33153, DOI 10.1074/jbc.M200246200; PetersGolden M, 1996, BIOCHEM J, V318, P797, DOI 10.1042/bj3180797; PIERCE DF, 1993, GENE DEV, V7, P2308, DOI 10.1101/gad.7.12a.2308; Pineda Torra I., 1999, CURR OPIN LIPIDOL, V10, P151; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rumi MAK, 2001, BRIT J CANCER, V84, P1640, DOI 10.1054/bjoc.2001.1821; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Saez E, 2004, GENE DEV, V18, P528, DOI 10.1101/gad.1167804; Sapirstein A, 2000, BBA-MOL CELL BIOL L, V1488, P139, DOI 10.1016/S1388-1981(00)00116-5; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHIMIZU Y, 1992, INT J CANCER, V52, P252, DOI 10.1002/ijc.2910520217; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Spiegelman B M, 1997, Eur J Med Res, V2, P457; STORTO PD, 1990, GENE CHROMOSOME CANC, V2, P300, DOI 10.1002/gcc.2870020408; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Suruga K, 1999, EUR J BIOCHEM, V262, P70, DOI 10.1046/j.1432-1327.1999.00330.x; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wu T, 2004, CYTOKINE, V25, P11, DOI 10.1016/j.cyto.2003.08.013; Wu T, 2002, HEPATOLOGY, V36, P363, DOI 10.1053/jhep.2002.34743; Wu T, 1997, AM J PHYSIOL-LUNG C, V273, pL331, DOI 10.1152/ajplung.1997.273.2.L331; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yokomuro S, 2000, HEPATOLOGY, V32, P26, DOI 10.1053/jhep.2000.8535; Yoo HY, 1999, GENE, V234, P87, DOI 10.1016/S0378-1119(99)00176-6; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	79	60	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44344	44354		10.1074/jbc.M404852200	http://dx.doi.org/10.1074/jbc.M404852200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15294900	hybrid			2022-12-27	WOS:000224505600016
J	Ibrahim, FBM; Pang, SJ; Melendez, AJ				Ibrahim, FBM; Pang, SJ; Melendez, AJ			Anaphylatoxin signaling in human neutrophils - A key role for sphingosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; N-METHYL DERIVATIVES; LEUKEMIC HL-60 CELLS; TRANSENDOTHELIAL MIGRATION; IN-VITRO; RECEPTOR; C5A; INDUCTION; SPHINGOSINE-1-PHOSPHATE; INTERLEUKIN-1	Anaphylatoxins activate immune cells to trigger the release of proinflammatory mediators that can lead to the pathology of several immune-inflammatory diseases. However, the intracellular signaling pathways triggered by anaphylatoxins are not well understood. Here we report for the first time that sphingosine kinase (SPHK) plays a key role in C5a-triggered signaling, leading to physiological responses of human neutrophils. We demonstrate that C5a rapidly stimulates SPHK activity in neutrophils and differentiated HL-60 cells. Using the SPHK inhibitor N,N-dimethylsphingosine (DMS), we show that inhibition of SPHK abolishes the Ca2+ release from internal stores without inhibiting phospholipase C or protein kinase C activation triggered by C5a but has no effect on calcium signals triggered by other stimuli (FcgammaRII). We also show that DMS inhibits degranulation, activation of the NADPH oxidase, and chemotaxis triggered by C5a. Moreover, an antisense oligonucleotide against SPHK1, in neutrophil-differentiated HL-60 cells, had similar inhibitory properties as DMS, suggesting that the SPHK utilized by C5a is SPHK1. Our data indicate that C5a stimulation decreases cellular sphingosine levels and increases the formation of sphingosine-1-phosphate. Exogenously added sphingosine has a dual effect on C5a-stimulated oxidative burst: it has a priming effect at lower concentrations but a dose-dependent inhibitory effect at higher concentrations; however, C5a-triggered protein kinase C activity was only reduced at high concentration of sphingosine. In contrast, C5a-triggered Ca2+ signals, chemotaxis, and degranulation were not affected by sphingosine at all. Exogenous sphingosine-1-phosphate, by itself, did not induce degranulation or chemotaxis, but it did marginally induce Ca2+ signals and oxidative burst and had a priming effect, enhancing all the C5a-triggered responses. Taken together, these results suggest that SPHK plays an important role in the immune-inflammatory pathologies triggered by anaphylatoxins in human neutrophils and point out SPHK as a potential therapeutic target for the treatment of diseases associated with neutrophil hyperactivation.	Natl Univ Singapore, Fac Med, Dept Physiol, Singapore 117597, Singapore	National University of Singapore	Melendez, AJ (corresponding author), Natl Univ Singapore, Fac Med, Dept Physiol, 2 Med Dr,MD 01-05, Singapore 117597, Singapore.	phsmraj@nus.edu.sg						Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994; AREND WP, 1989, J IMMUNOL, V142, P173; Bless NM, 1998, AM J PATHOL, V153, P1113, DOI 10.1016/S0002-9440(10)65655-6; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; CAVAILLON JM, 1990, EUR J IMMUNOL, V20, P253, DOI 10.1002/eji.1830200204; Choi OH, 1996, NATURE, V380, P634; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; DeVries ME, 1999, SEMIN IMMUNOL, V11, P95, DOI 10.1006/smim.1999.0165; DiScipio RG, 1999, J IMMUNOL, V162, P1127; Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HARKIN DG, 1994, CELL BIOL INT, V18, P177, DOI 10.1006/cbir.1994.1059; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; Heller T, 1999, J IMMUNOL, V163, P985; Heringdorf DMZ, 1997, FEBS LETT, V410, P34, DOI 10.1016/S0014-5793(97)00320-7; Hill GR, 1999, J CLIN INVEST, V104, P459, DOI 10.1172/JCI6896; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; KELLER HU, 1983, CELL MOTIL CYTOSKEL, V3, P47, DOI 10.1002/cm.970030105; KHAN WA, 1990, BIOCHEM BIOPH RES CO, V172, P683, DOI 10.1016/0006-291X(90)90728-6; KIMURA S, 1992, BIOCHEM PHARMACOL, V44, P1585; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Matsumoto K, 1999, CLIN EXP IMMUNOL, V117, P361, DOI 10.1046/j.1365-2249.1999.00975.x; Melendez A, 1998, CURR BIOL, V8, P210, DOI 10.1016/S0960-9822(98)70085-5; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; Mohr M, 1998, EUR J CLIN INVEST, V28, P227; Niwa M, 1999, LIFE SCI, V66, P245, DOI 10.1016/S0024-3205(99)00587-1; OHTA H, 1995, CANCER RES, V55, P691; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; OKUSAWA S, 1987, J IMMUNOL, V139, P2635; OKUSAWA S, 1988, J EXP MED, V168, P443, DOI 10.1084/jem.168.1.443; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pellas TC, 1998, J IMMUNOL, V160, P5616; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Sakakura C, 1996, FEBS LETT, V379, P177, DOI 10.1016/0014-5793(95)01508-6; Short A, 1999, BRIT J PHARMACOL, V126, P551, DOI 10.1038/sj.bjp.0702338; SMEDEGARD G, 1989, AM J PATHOL, V135, P489; SMITH WB, 1991, IMMUNOLOGY, V72, P65; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; STEVENS JH, 1986, J CLIN INVEST, V77, P1812, DOI 10.1172/JCI112506; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; Wong AK, 1998, J MED CHEM, V41, P3417, DOI 10.1021/jm9800651	44	64	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44802	44811		10.1074/jbc.M403977200	http://dx.doi.org/10.1074/jbc.M403977200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302883	hybrid			2022-12-27	WOS:000224505600069
J	Mareeva, T; Lebedeva, T; Anikeeva, N; Manser, T; Sykulev, Y				Mareeva, T; Lebedeva, T; Anikeeva, N; Manser, T; Sykulev, Y			Antibody specific for the peptide center dot major histocompatibility complex - Is it T cell receptor-like?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RECOMBINANT ANTIBODIES; PROTEIN-PROTEIN INTERACTIONS; POSITIVE SELECTION; RESTRICTED SPECIFICITY; MONOCLONAL-ANTIBODY; BINDING-SITES; HIGH-AFFINITY; MHC; ANTIGEN; RECOGNITION	Antibodies recognizing peptide bound to a major histocompatability complex (MHC) protein usually have a higher affinity for the composite peptide.MHC (pMHC) ligand than T cell receptors (TCR) with the same specificity. Because the solvent-accessible peptide area constitutes only a small portion of the contacting pMHC surface, we hypothesized that the contribution of the MHC moiety to the TCR-pMHC complex stability is limited, ensuring a small increment of the binding energy delivered by the peptide to be distinguishable by the TCR or the peptide-specific antibody. This suggests that the gain in affinity of the antibody-pMHC interaction can be achieved through an increase in the on-rate without a significant change in the off-rate of the interaction. To test the hypothesis, we have analyzed the binding of an ovalbumin peptide (pOV8) and its variants associated with soluble H-2K(b) protein to the 25-D1.16 monoclonal antibody and compared it with the binding of the same pMHC complexes to the OT-1 TCR. This comparison revealed a substantially higher on-rate of the antibody-pMHC interaction compared with the TCR-pMHC interaction. In contrast, both the antibody and the TCR-pMHC complexes exhibited comparably fast off-rates. Sequencing of the 25-D1.16 V-H and V-L genes showed that they have very few somatic mutations and those occur mainly in framework regions. We propose that the above features constitute a signature of the recognition of MHC-bound peptide antigens by TCR and TCR-like antibodies, which could explain why the latter are rarely produced in vivo.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Sykulev, Y (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Bluemle Life Sci Bldg 650, Philadelphia, PA 19107 USA.	ysykulev@lac.jci.tju.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039966, R01AI043254, R21AI043254] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43254, AI39966] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHARONI R, 1991, NATURE, V351, P147, DOI 10.1038/351147a0; Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; Alam SM, 1999, IMMUNITY, V10, P227, DOI 10.1016/S1074-7613(00)80023-0; AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; ALRAMADI BK, 1995, J IMMUNOL, V155, P662; Andersen PS, 1996, P NATL ACAD SCI USA, V93, P1820, DOI 10.1073/pnas.93.5.1820; Anikeeva N, 2003, J IMMUNOL METHODS, V277, P75, DOI 10.1016/S0022-1759(03)00179-0; Anikeeva N, 2003, BIOCHEMISTRY-US, V42, P4709, DOI 10.1021/bi026864+; Baker BM, 2001, J EXP MED, V193, P551, DOI 10.1084/jem.193.5.551; Biddison WE, 2003, J IMMUNOL, V171, P3064, DOI 10.4049/jimmunol.171.6.3064; Boniface JJ, 1999, P NATL ACAD SCI USA, V96, P11446, DOI 10.1073/pnas.96.20.11446; BRUNMARK A, 1998, MHC, V2, P53; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; Cohen CJ, 2003, J MOL RECOGNIT, V16, P324, DOI 10.1002/jmr.640; Denkberg G, 2002, P NATL ACAD SCI USA, V99, P9421, DOI 10.1073/pnas.132285699; EISENBERG D, 1979, PHYS CHEM APPL LIFE, P242; England P, 1997, BIOCHEMISTRY-US, V36, P164, DOI 10.1021/bi961419y; FOOTE J, 1991, NATURE, V352, P530, DOI 10.1038/352530a0; Gakamsky DM, 2004, P NATL ACAD SCI USA, V101, P9063, DOI 10.1073/pnas.0402840101; Garcia KC, 2001, P NATL ACAD SCI USA, V98, P6818, DOI 10.1073/pnas.111161198; Hogquist KA, 1997, IMMUNITY, V6, P389, DOI 10.1016/S1074-7613(00)80282-4; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Holler PD, 2003, NAT IMMUNOL, V4, P55, DOI 10.1038/ni863; Holler PD, 2001, J EXP MED, V194, P1043, DOI 10.1084/jem.194.8.1043; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; JANIN J, 1978, BIOCHEMISTRY-US, V17, P2943, DOI 10.1021/bi00608a001; Kabat EA, 1991, SEQUENCES PROTEINS I; Lee PUY, 2000, J EXP MED, V191, P1355, DOI 10.1084/jem.191.8.1355; Lev A, 2002, CANCER RES, V62, P3184; Manning TC, 1999, IMMUNOL TODAY, V20, P417, DOI 10.1016/S0167-5699(99)01508-X; Manning TC, 1998, IMMUNITY, V8, P413, DOI 10.1016/S1074-7613(00)80547-6; Markvicheva EA, 2000, APPL BIOCHEM BIOTECH, V88, P145, DOI 10.1385/ABAB:88:1-3:145; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; Mozdzanowski J, 1998, ANAL BIOCHEM, V260, P183, DOI 10.1006/abio.1998.2690; MURPHY DB, 1992, J IMMUNOL, V148, P3483; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Reay PA, 2000, J IMMUNOL, V164, P5626, DOI 10.4049/jimmunol.164.11.5626; Robinson RA, 1996, J IMMUNOL, V156, P4266; Rudolph MG, 2002, CURR OPIN IMMUNOL, V14, P52, DOI 10.1016/S0952-7915(01)00298-9; Schreiber G, 2002, CURR OPIN STRUC BIOL, V12, P41, DOI 10.1016/S0959-440X(02)00287-7; Shusta EV, 2000, NAT BIOTECHNOL, V18, P754, DOI 10.1038/77325; Sinha N, 2002, BIOPHYS J, V83, P2946, DOI 10.1016/S0006-3495(02)75302-2; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; Udaka K, 1996, J IMMUNOL, V157, P670; Wang ZC, 2002, J IMMUNOL, V169, P3146, DOI 10.4049/jimmunol.169.6.3146; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920; Zarutskie JA, 2001, P NATL ACAD SCI USA, V98, P12450, DOI 10.1073/pnas.211439398; Zhang C, 1999, PROTEINS, V34, P255, DOI 10.1002/(SICI)1097-0134(19990201)34:2<255::AID-PROT10>3.3.CO;2-F; Zhu YR, 2003, J MOL BIOL, V326, P1157, DOI 10.1016/S0022-2836(02)01437-7	52	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44243	44249		10.1074/jbc.M407021200	http://dx.doi.org/10.1074/jbc.M407021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302863	hybrid			2022-12-27	WOS:000224505600004
J	Kitazawa, H; Nishihara, T; Nambu, T; Nishizawa, H; Iwaki, M; Fukuhara, A; Kitamura, T; Matsuda, M; Shimomuraa, I				Kitazawa, H; Nishihara, T; Nambu, T; Nishizawa, H; Iwaki, M; Fukuhara, A; Kitamura, T; Matsuda, M; Shimomuraa, I			Intectin, a novel small intestine-specific glycosylphosphatidylinositol-anchored protein, accelerates apoptosis of intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; GASTROINTESTINAL-TRACT; EXPRESSION; ACTIVATION; ADHESION; INHIBITION; RESISTANCE; ADAPTATION; PATHWAYS; RECEPTOR	Intestinal epithelial cells undergo rapid turnover and exfoliation especially at the villus tips. This process is modulated by various nutrients especially fat. Apoptosis is one of the important regulatory mechanisms of this turnover. Therefore, identification of the factors that control epithelial cell apoptosis should help us understand the mechanism of intestinal mucosal turnover. Here, we report the identification of a novel small intestine-specific member of the Ly-6 family, intectin, by signal sequence trap method. Intectin mRNA expression was exclusively identified in the intestine and localized at the villus tips of intestinal mucosa, which is known to undergo apoptosis. Intectin mRNA expression was modulated by nutrition. Intestinal epithelial cells expressing intectin were more sensitive to palmitate-induced apoptosis, compared with control intestinal epithelial cells, and such effect was accompanied by increased activity of caspase-3. Intectin expression also reduced cell-cell adhesion of intestinal epithelial cells.	Osaka Univ, Grad Sch Med, Grad Sch Frontier Biosci, Dept Med & Pathophysiol, Suita, Osaka 5650871, Japan; Banyu Pharmaceut Co Ltd, Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan; Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Japan Soc Promot Sci, Century Ctr Excellence Program 21, Tokyo 1028471, Japan	Osaka University; Merck & Company; Novartis; Osaka University; University of Tokyo; Japan Science & Technology Agency (JST); Japan Society for the Promotion of Science	Shimomuraa, I (corresponding author), Osaka Univ, Grad Sch Med, Grad Sch Frontier Biosci, Dept Med & Pathophysiol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ichi@imed2.med.osaka-u.ac.jp	Fukuhara, Atsunori/A-9601-2018; Kitamura, Toshio/AAA-2071-2021	Fukuhara, Atsunori/0000-0002-6289-3778; 				BAMEZAI A, 1995, P NATL ACAD SCI USA, V92, P4294, DOI 10.1073/pnas.92.10.4294; BAMEZAI A, 1995, J IMMUNOL, V154, P4233; Brodsky RA, 1997, P NATL ACAD SCI USA, V94, P8756, DOI 10.1073/pnas.94.16.8756; FLOOD PM, 1990, J EXP MED, V172, P115, DOI 10.1084/jem.172.1.115; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Groos S, 2003, ANAT REC PART A, V272A, P503, DOI 10.1002/ar.a.10063; Groos S, 2003, J SURG RES, V109, P74, DOI 10.1016/S0022-4804(02)00094-X; HALL PA, 1994, J CELL SCI, V107, P3569; Hanninen A, 1997, P NATL ACAD SCI USA, V94, P6898, DOI 10.1073/pnas.94.13.6898; Horikawa K, 1997, BLOOD, V90, P2716, DOI 10.1182/blood.V90.7.2716.2716_2716_2722; Hyoh Y, 2002, GUT, V50, P71, DOI 10.1136/gut.50.1.71; Hyoh Y, 1999, PARASITOLOGY, V119, P199, DOI 10.1017/S003118209900462X; JOHNSON R, 1993, J IMMUNOL, V151, P2986; Jones BA, 1997, AM J PHYSIOL-GASTR L, V273, pG1174, DOI 10.1152/ajpgi.1997.273.6.G1174; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; Kojima T, 1999, NAT BIOTECHNOL, V17, P487, DOI 10.1038/8666; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LECLAIR KP, 1987, P NATL ACAD SCI USA, V84, P1638, DOI 10.1073/pnas.84.6.1638; LEE SK, 1994, EMBO J, V13, P2167, DOI 10.1002/j.1460-2075.1994.tb06493.x; Moss SF, 1996, GUT, V39, P811, DOI 10.1136/gut.39.6.811; Nishizawa H, 2002, DIABETES, V51, P2734, DOI 10.2337/diabetes.51.9.2734; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; POTTEN CS, 1977, J ULTRA MOL STRUCT R, V60, P272, DOI 10.1016/S0022-5320(77)80071-3; Potten CS, 1997, STEM CELLS, V15, P82, DOI 10.1002/stem.150082; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Potten CS, 1997, AM J PHYSIOL-GASTR L, V273, pG253, DOI 10.1152/ajpgi.1997.273.2.G253; Raab S, 1998, METABOLISM, V47, P1105, DOI 10.1016/S0026-0495(98)90285-2; ROSSE WF, 1995, BLOOD, V86, P3277, DOI 10.1182/blood.V86.9.3277.bloodjournal8693277; Ruemmele FM, 2002, J PEDIATR GASTR NUTR, V34, P254, DOI 10.1097/00005176-200203000-00005; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Sparagna GC, 2001, ANTIOXID REDOX SIGN, V3, P71, DOI 10.1089/152308601750100524; Stuber E, 1999, GUT, V45, P229, DOI 10.1136/gut.45.2.229; Sukhotnik I, 2003, J PEDIATR SURG, V38, P1182, DOI 10.1016/S0022-3468(03)00264-1; Uchida E, 2002, BIOL PHARM BULL, V25, P891, DOI 10.1248/bpb.25.891; Whittard JD, 2001, EXP CELL RES, V263, P65, DOI 10.1006/excr.2000.5099; WILLIAMSON RCN, 1978, NEW ENGL J MED, V298, P1444, DOI 10.1056/NEJM197806292982604	37	14	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42867	42874		10.1074/jbc.M408047200	http://dx.doi.org/10.1074/jbc.M408047200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292182	hybrid			2022-12-27	WOS:000224226400064
J	Ledin, J; Staatz, W; Li, JP; Gotte, M; Selleck, S; Kjellen, L; Spillmann, D				Ledin, J; Staatz, W; Li, JP; Gotte, M; Selleck, S; Kjellen, L; Spillmann, D			Heparan sulfate structure in mice with genetically modified heparan sulfate production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDURONIC ACID; TARGETED DISRUPTION; DOMAIN-STRUCTURE; LIGAND-BINDING; FINE-STRUCTURE; SYNDECAN-1; GLYCOSAMINOGLYCANS; DEPOLYMERIZATION; PROTEOGLYCANS; IDENTIFICATION	Using a high throughput heparan sulfate (HS) isolation and characterization protocol, we have analyzed HS structure in several tissues from mice/mouse embryos deficient in HS biosynthesis enzymes (N-deacetylase/ N-sulfotransferase (NDST)-1, NDST-2, and C5-epimerase, respectively) and in mice lacking syndecan-1. The results have given us new information regarding HS biosynthesis with implications on the role of HS in embryonic development. Our main conclusions are as follows. 1) The HS content, disaccharide composition, and the overall degree of N- and O-sulfation as well as domain organization are characteristic for each individual mouse tissue. 2) Removal of a key biosynthesis enzyme (NDST-1 or C5-epimerase) results in similar structural alterations in all of the tissues analyzed. 3) Essentially no variation in HS tissue structure is detected when individuals of the same genotype are compared. 4) NDST-2, although generally expressed, does not contribute significantly to tissue-specific HS structures. 5) No change in HS structure could be detected in syndecan-1- deficient mice.	Uppsala Univ, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Univ Minnesota, Ctr Dev Biol, Dept Pediat & Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Univ Hosp, Dept Obstet & Gynecol, D-48149 Munster, Germany	Uppsala University; University of Minnesota System; University of Minnesota Twin Cities; University of Munster	Spillmann, D (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden.	dorothe.spillmann@imbim.uu.se	Götte, Martin/G-2254-2018; Gotte, M/Z-5878-2019; Kjellen, Lena/F-1362-2011	Götte, Martin/0000-0003-2360-2496; Gotte, M/0000-0003-2360-2496; Ledin, Johan/0000-0002-7319-7735				Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; BAME KJ, 1989, J BIOL CHEM, V264, P8059; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BRAUKER JH, 1991, DEV BIOL, V147, P285, DOI 10.1016/0012-1606(91)90286-C; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; CASU B, 1994, CARBOHYD RES, V263, P271, DOI 10.1016/0008-6215(94)00172-3; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P221, DOI 10.1016/0968-0004(88)90088-6; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Gotte M, 2002, INVEST OPHTH VIS SCI, V43, P1135; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; Grobe K, 2002, J BIOL CHEM, V277, P30699, DOI 10.1074/jbc.M111904200; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; Jenniskens GJ, 2003, J CELL SCI, V116, P2187, DOI 10.1242/jcs.00447; Kariya Y, 2000, J BIOL CHEM, V275, P25949, DOI 10.1074/jbc.M004140200; KATO M, 1994, J BIOL CHEM, V269, P18881; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Kramer KL, 2003, ANNU REV GENET, V37, P461, DOI 10.1146/annurev.genet.37.061103.090226; Kreuger J, 2002, EMBO J, V21, P6303, DOI 10.1093/emboj/cdf638; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Lin XH, 2002, GLYCOCONJUGATE J, V19, P363, DOI 10.1023/A:1025329323438; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; Liu BY, 2003, ONCOGENE, V22, P9243, DOI 10.1038/sj.onc.1207217; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; LYON M, 1994, J BIOL CHEM, V269, P11208; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Pikas DS, 2000, BIOCHEMISTRY-US, V39, P4552, DOI 10.1021/bi992524l; Razi N, 1995, GLYCOBIOLOGY, V5, P807, DOI 10.1093/glycob/5.8.807; RIESENFELD J, 1990, ANAL BIOCHEM, V188, P383, DOI 10.1016/0003-2697(90)90624-I; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Safaiyan F, 2000, BIOCHEMISTRY-US, V39, P10823, DOI 10.1021/bi000411s; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; Selleck SB, 2001, SEMIN CELL DEV BIOL, V12, P127, DOI 10.1006/scdb.2000.0242; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; Staatz W D, 2001, Methods Mol Biol, V171, P41; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Tumova S, 2000, J BIOL CHEM, V275, P9410, DOI 10.1074/jbc.275.13.9410; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; Zako M, 2003, J BIOL CHEM, V278, P13561, DOI 10.1074/jbc.M209658200	61	198	204	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42732	42741		10.1074/jbc.M405382200	http://dx.doi.org/10.1074/jbc.M405382200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292174	hybrid			2022-12-27	WOS:000224226400048
J	Nakajima, H; Nagaso, H; Kakui, N; Ishikawa, M; Hiranuma, T; Hoshiko, S				Nakajima, H; Nagaso, H; Kakui, N; Ishikawa, M; Hiranuma, T; Hoshiko, S			Critical role of the automodification of poly(ADP-ribose) polymerase-1 in nuclear factor-kappa B-dependent gene expression in primary cultured mouse glial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSE POLYMERASE; ASTROCYTE-ENRICHED CULTURES; DNA-BINDING; TRANSCRIPTION FACTOR; NITRIC-OXIDE; ENDOTOXIC-SHOCK; MIXED GLIA; RAT-BRAIN; ACTIVATION; SYNTHETASE	Synthesis of ADP-ribose polymers catalyzed by poly( ADP-ribose) polymerase-1 (PARP-1) has been implicated in transcriptional regulation. Recent studies with PARP-1 null mice and PARP-1 inhibitors have also demonstrated that PARP-1 has an essential role in nuclear factor-kappaB (NF-kappaB)-dependent gene expression induced by various inflammatory stimuli. In this study, we used primary cultured mouse glial cells to investigate the role of poly( ADP-ribosyl) ation by PARP-1 in NF-kappaB-dependent gene expression. PARP-1 inhibitors and the antisense RNA for PARP-1 mRNA suppressed lipopolysaccharide (LPS)-induced expression of tumor necrosis factor-alpha and inducible nitric-oxide synthase, suggesting that PARP-1 activity has a critical role in synthesis. Western blotting with anti-poly( ADP-ribose) antibody revealed that PARP-1 itself was mainly poly( ADP-ribosyl) ated in glial cells, i.e. automodified PARP-1 (AM-PARP). The amounts of AM-PARP were not affected by LPS treatment, but were decreased by PARP-1 inhibitors. Electrophoretic mobility shift assay revealed that PARP-1 inhibitors and the antisense RNA for PARP-1 mRNA reduced the LPS-induced DNA binding of NF-kappaB. Non-modified PARP-1 also reduced the DNA binding of NF-kappaB via its physical association with NF-kappaB, whereas AM-PARP had no effect. On the other hand, enhancement of the automodification of PARP-1 by the addition of NAD(+), its substrate, promoted the DNA binding of NF-kappaB. Furthermore, in in vitro transcription assay, the addition of AM-PARP or NAD(+) to nuclear extracts promoted NF-kappaB p50-dependent transcription. These results indicate that automodification of PARP-1 positively up-regulates formation of the NF-kappaB . DNA complex and enhances transcriptional activation. Therefore, AM-PARP may be critical for the NF-kappaB-dependent gene expression of some inflammatory mediators in glial cells.	Meiji Seika Kaisha Ltd, Pharmaceut Res Ctr, Kohoku Ku, Yokohama, Kanagawa 2228567, Japan	Meiji Holdings Co., Ltd.	Nakajima, H (corresponding author), Meiji Seika Kaisha Ltd, Pharmaceut Res Ctr, Kohoku Ku, 760 Moro Oka Cho, Yokohama, Kanagawa 2228567, Japan.	hidemitsu_nakajima@meiji.co.jp		Nakajima, Hidemitsu/0000-0002-0441-1929				Akiyama T, 2001, P NATL ACAD SCI USA, V98, P48, DOI 10.1073/pnas.240458597; BANASIK M, 1992, J BIOL CHEM, V267, P1569; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Chiarugi A, 2002, BRIT J PHARMACOL, V137, P761, DOI 10.1038/sj.bjp.0704934; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; FERRO AM, 1982, J BIOL CHEM, V257, P15990; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; GINER H, 1992, GENE, V114, P279, DOI 10.1016/0378-1119(92)90588-G; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hasko G, 2002, MOL MED, V8, P283, DOI 10.1007/BF03402154; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hassa PO, 2003, J BIOL CHEM, V278, P45145, DOI 10.1074/jbc.M307957200; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; Kong LY, 1996, BRAIN RES, V729, P102, DOI 10.1016/0006-8993(96)00417-9; Kong LY, 1997, NEUROCHEM INT, V30, P491, DOI 10.1016/S0197-0186(96)00086-1; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LUKASIUK K, 1995, NEUROCHEM INT, V26, P173, DOI 10.1016/0197-0186(94)00121-A; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mendoza-Alvarez H, 2001, J BIOL CHEM, V276, P36425, DOI 10.1074/jbc.M105215200; NAKAJIMA K, 1989, BIOMED RES-TOKYO, V10, P411; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Oei SL, 1998, BIOCHEMISTRY-US, V37, P1465, DOI 10.1021/bi9727390; Oei SL, 2001, BIOCHEM BIOPH RES CO, V285, P27, DOI 10.1006/bbrc.2001.5115; OGATA N, 1981, J BIOL CHEM, V256, P4135; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; Scott GS, 2001, J NEUROIMMUNOL, V117, P78, DOI 10.1016/S0165-5728(01)00329-0; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; TANUMA S, 1982, J BIOL CHEM, V257, P6565; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375	50	85	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42774	42786		10.1074/jbc.M407923200	http://dx.doi.org/10.1074/jbc.M407923200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15302869	hybrid			2022-12-27	WOS:000224226400053
J	Zhang, XM; Ellis, S; Sriratana, A; Mitchell, CA; Rowe, T				Zhang, XM; Ellis, S; Sriratana, A; Mitchell, CA; Rowe, T			Sec15 is an effector for the Rab11 GTPase in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; BINDING PROTEIN RAB4; EXOCYST COMPLEX; MEMBRANE-TRANSPORT; ENDOCYTIC PATHWAY; SEC6/8 COMPLEX; EXOCYTOSIS; FAMILY; YEAST; TRANSFERRIN	Rab/Ypt GTPases play key roles in the regulation of vesicular trafficking. They perform most of their functions in a GTP-bound form by interacting with specific downstream effectors. The exocyst is a complex of eight polypeptides involved in constitutive secretion and functions as an effector for multiple Ras-related small GTPases, including the Rab protein Sec4p in yeast. In this study, we have examined the localization and function of the Sec15 exocyst subunit in mammalian cells. Overexpressed Sec15 associated with clusters of tubular/vesicular elements that were concentrated in the perinuclear region. The tubular/vesicular clusters were dispersed throughout the cytoplasm upon treatment with the microtubule-depolymerizing agent nocodazole and were accessible to endocytosed transferrin, but not exocytic cargo (vesicular stomatitis virus glycoprotein). Consistent with these observations, Sec15 colocalized selectively with the recycling endosome marker Rab11 and exhibited a GTP-dependent interaction with the Rab11 GTPase, but not with Rab4, Rab6, or Rab7. These findings provide the first evidence that the exocyst functions as a Rab effector complex in mammalian cells.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Peter MacCallum Canc Ctr, Melbourne, Vic 3002, Australia	Monash University; Peter Maccallum Cancer Center	Rowe, T (corresponding author), Biogen IDEC Inc, 3010 Sci Pk Rd, San Diego, CA 92121 USA.	Tony.Rowe@biogenidec.com		Mitchell, Christina A/0000-0001-9372-3192; Ellis, Sarah/0000-0002-5772-6051				Andrews HK, 2002, TRAFFIC, V3, P906, DOI 10.1034/j.1600-0854.2002.31206.x; Brown DL, 2001, TRAFFIC, V2, P336, DOI 10.1034/j.1600-0854.2001.002005336.x; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; Hales CM, 2002, J BIOL CHEM, V277, P50415, DOI 10.1074/jbc.M209270200; HARSAY E, 1995, J CELL BIOL, V131, P297, DOI 10.1083/jcb.131.2.297; Harsay E, 2002, J CELL BIOL, V156, P271, DOI 10.1083/jcb.200109077; Hsu SC, 2004, INT REV CYTOL, V233, P243, DOI 10.1016/S0074-7696(04)33006-8; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; Lipschutz JH, 2002, CURR BIOL, V12, pR212, DOI 10.1016/S0960-9822(02)00753-4; Matern HT, 2001, P NATL ACAD SCI USA, V98, P9648, DOI 10.1073/pnas.171317898; McCaffrey MW, 2001, FEBS LETT, V495, P21, DOI 10.1016/S0014-5793(01)02359-6; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Novick P, 2002, TRENDS CELL BIOL, V12, P247, DOI 10.1016/S0962-8924(02)02293-6; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; SALMINEN A, 1989, J CELL BIOL, V109, P1023, DOI 10.1083/jcb.109.3.1023; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; Vega IE, 2001, J NEUROSCI, V21, P3839, DOI 10.1523/JNEUROSCI.21-11-03839.2001; Wallace DM, 2002, BIOCHEM BIOPH RES CO, V292, P909, DOI 10.1006/bbrc.2002.6736; Wang S, 2003, HYBRIDOMA HYBRIDOM, V22, P159, DOI 10.1089/153685903322286575; Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Yeaman C, 2001, J CELL BIOL, V155, P593, DOI 10.1083/jcb.200107088	40	177	187	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43027	43034		10.1074/jbc.M402264200	http://dx.doi.org/10.1074/jbc.M402264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292201	hybrid			2022-12-27	WOS:000224226400085
J	Chander, M; Demple, B				Chander, M; Demple, B			Functional analysis of SoxR residues affecting transduction of oxidative stress signals into gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSCRIPTIONAL ACTIVATION; 2FE-2S CLUSTERS; IN-VIVO; OXIDIZED FORM; MERR HOMOLOG; SWISS-MODEL; PROTEIN; CENTERS; REGULON	SoxR protein, a member of the MerR family of transcriptional activators, mediates a global oxidative stress response in Escherichia coli. Upon oxidation or nitrosylation of its [2Fe-2S] centers SoxR activates its target gene, soxS, by mediating a structural transition in the promoter DNA that stimulates initiation by RNA polymerase. We explored the molecular basis of this signal transduction by analyzing mutant SoxR proteins defective in responding to oxidative stress signals in vivo. We have confirmed that the DNA binding domain of SoxR is highly conserved compared with other MerR family proteins and functions in a similar manner to activate transcription. Several mutations in the dimerization domain of SoxR disrupted intersubunit communication, and the resulting proteins were unable to propagate redox signals to the soxS promoter. Mutations scattered throughout the polypeptide yielded proteins that were underresponsive to in vivo redox signals, which indicates that the redox properties of the [2Fe-2S] centers are influenced by global protein structure. These findings indicate that SoxR functions as a redox-responsive molecular switch in which subunit interactions transduce a subtle alteration in oxidation state into a profound change in DNA structure.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	bdemple@hsph.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA037831] Funding Source: NIH RePORTER; NCI NIH HHS [CA37831] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED M, 1994, J BIOL CHEM, V269, P28506; Baranova NN, 1999, MOL MICROBIOL, V31, P1549, DOI 10.1046/j.1365-2958.1999.01301.x; Bradley TM, 1997, NUCLEIC ACIDS RES, V25, P1469, DOI 10.1093/nar/25.8.1469; Brown NL, 2003, FEMS MICROBIOL REV, V27, P145, DOI 10.1016/S0168-6445(03)00051-2; Caguiat JJ, 1999, J BACTERIOL, V181, P3462, DOI 10.1128/JB.181.11.3462-3471.1999; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chander M, 2003, J BACTERIOL, V185, P2441, DOI 10.1128/JB.185.8.2441-2450.2003; Changela A, 2003, SCIENCE, V301, P1383, DOI 10.1126/science.1085950; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dawson M. C., 1986, DATA BIOCH RES; Ding HG, 2000, P NATL ACAD SCI USA, V97, P5146, DOI 10.1073/pnas.97.10.5146; Ding HG, 1997, P NATL ACAD SCI USA, V94, P8445, DOI 10.1073/pnas.94.16.8445; Ding HG, 1996, J BIOL CHEM, V271, P33173, DOI 10.1074/jbc.271.52.33173; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; Gaudu P, 1997, J BIOL CHEM, V272, P5082, DOI 10.1074/jbc.272.8.5082; Godsey MH, 2001, J BIOL CHEM, V276, P47178, DOI 10.1074/jbc.M105819200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; Hidalgo E, 1998, EMBO J, V17, P2629, DOI 10.1093/emboj/17.9.2629; Hidalgo E, 1997, EMBO J, V16, P1056, DOI 10.1093/emboj/16.5.1056; Hidalgo E, 1997, CELL, V88, P121, DOI 10.1016/S0092-8674(00)81864-4; Hidalgo E, 1996, J BIOL CHEM, V271, P7269, DOI 10.1074/jbc.271.13.7269; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; HIDALGO E, 1996, REGULATION GENE EXPR; KAPPUS H, 1981, EXPERIENTIA, V37, P1233, DOI 10.1007/BF01948335; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Koo MS, 2003, EMBO J, V22, P2614, DOI 10.1093/emboj/cdg252; Newberry KJ, 2004, J BIOL CHEM, V279, P20356, DOI 10.1074/jbc.M400960200; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; Outten CE, 1999, J BIOL CHEM, V274, P37517, DOI 10.1074/jbc.274.53.37517; Outten FW, 2000, J BIOL CHEM, V275, P31024, DOI 10.1074/jbc.M006508200; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Pomposiello PJ, 2001, TRENDS BIOTECHNOL, V19, P109, DOI 10.1016/S0167-7799(00)01542-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sies H., 1991, OXIDATIVE STRESS OXI, pxv; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P3673; WU J, 1995, J BIOL CHEM, V270, P10323, DOI 10.1074/jbc.270.17.10323; ZHELEZNOVAHELDW.EE, 2001, NATURE, V409, P378	41	20	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41603	41610		10.1074/jbc.M405512200	http://dx.doi.org/10.1074/jbc.M405512200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292172	hybrid			2022-12-27	WOS:000224075500045
J	Karlsson, M; Mathers, J; Dickinson, RJ; Mandl, M; Keyse, SM				Karlsson, M; Mathers, J; Dickinson, RJ; Mandl, M; Keyse, SM			Both nuclear-cytoplasmic shuttling of the dual specificity phosphatase MKP-3 and its ability to anchor MAP kinase in the cytoplasm are mediated by a conserved nuclear export signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; AMINO-ACID-SEQUENCE; CATALYTIC ACTIVATION; TYROSINE-PHOSPHATASE; BINDING; TRANSLOCATION; TRANSPORT; PYST1; INACTIVATION; RECOGNITION	MAP kinase phosphatase (MKP)-3 is a cytoplasmic dual specificity protein phosphatase that specifically binds to and inactivates the ERK1/2 MAP kinases in mammalian cells. However, the molecular basis of the cytoplasmic localization of MKP-3 or its physiological significance is unknown. We have used MKP-3-green fluorescent protein fusions in conjunction with leptomycin B to show that the cytoplasmic localization of MKP-3 is mediated by a chromosome region maintenance-1 (CRM1)-dependent nuclear export pathway. Furthermore, the nuclear translocation of MKP-3 seen in the presence of leptomycin B is mediated by an active process, indicating that MKP-3 shuttles between the nucleus and cytoplasm. The amino-terminal noncatalytic domain of MKP-3 is both necessary and sufficient for nuclear export of the phosphatase and contains a single functional leucine-rich nuclear export signal (NES). Even though this domain of the protein also mediates the binding of MKP-3 to MAP kinase, we show that mutations of the kinase interaction motif which abrogate ERK2 binding do not affect MKP-3 localization. Conversely, mutation of the NES does not affect either the binding or phosphatase activity of MKP-3 toward ERK2, indicating that the kinase interaction motif and NES function independently. Finally, we demonstrate that the ability of MKP-3 to cause the cytoplasmic retention of ERK2 requires both a functional kinase interaction motif and NES. We conclude that in addition to its established function in the regulated dephosphorylation and inactivation of MAP kinase, MKP-3 may also play a role in determining the subcellular localization of its substrate. Our results reinforce the idea that regulatory proteins such as MKP-3 may play a key role in the spatio-temporal regulation of MAP kinase activity.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Canc Res UK Mol Pharmacol Unit, Dundee DD1 9SY, Scotland	University of Dundee	Keyse, SM (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Canc Res UK Mol Pharmacol Unit, Level 5, Dundee DD1 9SY, Scotland.	Stephen.Keyse@cancer.org.uk	Keyse, Stephen M./B-9575-2009	Keyse, Stephen M./0000-0002-5150-8221				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Allen TD, 2000, J CELL SCI, V113, P1651; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; Dickinson RJ, 2002, BIOCHEM J, V364, P145, DOI 10.1042/bj3640145; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; Dowd S, 1998, J CELL SCI, V111, P3389; Eblaghie MC, 2003, CURR BIOL, V13, P1009, DOI 10.1016/S0960-9822(03)00381-6; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Kawakami Y, 2003, NAT CELL BIOL, V5, P513, DOI 10.1038/ncb989; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kim SH, 2002, BIOCHEM J, V361, P143, DOI 10.1042/bj3610143; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Rigas JD, 2001, BIOCHEMISTRY-US, V40, P4398, DOI 10.1021/bi002951v; Satou Y, 2003, DEV GENES EVOL, V213, P254, DOI 10.1007/s00427-003-0317-9; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; Theodosiou A, 2002, GENOME BIOL, V3; Volmat V, 2001, J CELL SCI, V114, P3433; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200	45	107	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41882	41891		10.1074/jbc.M406720200	http://dx.doi.org/10.1074/jbc.M406720200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15269220	hybrid			2022-12-27	WOS:000224075500079
J	Dilly, KW; Kurokawa, J; Terrenoire, C; Reiken, S; Lederer, WJ; Marks, AR; Kass, RS				Dilly, KW; Kurokawa, J; Terrenoire, C; Reiken, S; Lederer, WJ; Marks, AR; Kass, RS			Overexpression of beta(2)-adrenergic receptors cAMP-dependent protein kinase phosphorylates and modulates slow delayed rectifier potassium channels expressed in murine heart - Evidence for receptor/channel co-localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RYANODINE RECEPTOR; I-KS; VENTRICULAR MYOCYTES; MEMBRANE PATCHES; FAILING HEARTS; CELLS; ISOPROTERENOL; PROLONGATION; REQUIREMENT; MECHANISM	The cardiac slow delayed rectifier potassium channel (I-Ks), comprised of alpha (KCNQ1) and beta (KCNE1) subunits, is regulated by sympathetic nervous stimulation, with activation of beta-adrenergic receptors PKA phosphorylating IKs channels. We examined the effects of beta(2)-adrenergic receptors (beta(2)-AR) on I-Ks in cardiac ventricular myocytes from transgenic mice expressing fusion proteins of I-Ks subunits and hbeta(2)-ARs. KCNQ1 and beta(2)-ARs were localized to the same subcellular regions, sharing intimate localization within nanometers of each other. In I-Ks/B-2-AR myocytes, I-Ks density was increased, and activation shifted in the hyperpolarizing direction; I-Ks was not further modulated by exposure to isoproterenol, and KCNQ1 was found to be PKA-phosphorylated. Conversely, beta(2)-AR overexpression did not affect L-type calcium channel current (I-CaL) under basal conditions with ICaL remaining responsive to cAMP. These data indicate intimate association of KCNQ1 and beta(2)-ARs and that beta(2)-AR signaling can modulate the function of I-Ks channels under conditions of increased beta(2)-AR expression, even in the absence of exogenous beta(2)-AR agonist.	Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Physiol & Cellular Biophys, Ctr Mol Cardiol, New York, NY 10032 USA; Univ Maryland, Maryland Biotechnol Inst, Ctr Med Biotechnol, Inst Mol Cardiol, Baltimore, MD 21201 USA	Columbia University; Columbia University; University System of Maryland; University of Maryland Baltimore	Kass, RS (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pharmacol, 630 W 168th St PH 7W 318, New York, NY 10032 USA.	rsk20@columbia.edu	Kurokawa, Junko/Q-6287-2017; Lederer, William/B-1285-2010; Kurokawa, Junko/ABF-7557-2021	Kurokawa, Junko/0000-0002-9098-0908; Kurokawa, Junko/0000-0002-9098-0908	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067849, R01HL044365] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL044365-13, R01 HL44365, P01 HL67849, R01 HL044365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An RH, 1999, J PHYSIOL-LONDON, V516, P19, DOI 10.1111/j.1469-7793.1999.019aa.x; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Kaab S, 1996, CIRC RES, V78, P262, DOI 10.1161/01.RES.78.2.262; Kaczmarek LK, 1997, PHYSIOL REV, V77, P627, DOI 10.1152/physrev.1997.77.3.627; Kass RS, 2003, TRENDS CARDIOVAS MED, V13, P52, DOI 10.1016/S1050-1738(02)00211-6; KASS RS, 1982, J PHYSIOL-LONDON, V322, P541, DOI 10.1113/jphysiol.1982.sp014054; Kathofer S, 2003, N-S ARCH PHARMACOL, V368, P119, DOI 10.1007/s00210-003-0772-x; Kurokawa J, 2003, P NATL ACAD SCI USA, V100, P2122, DOI 10.1073/pnas.0434935100; Marks AR, 2000, BIOPHYS J, V78, p16A; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 2002, SCIENCE, V295, P496, DOI 10.1126/science.1066843; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; Nabauer M, 1998, CARDIOVASC RES, V37, P324, DOI 10.1016/S0008-6363(97)00274-5; POWELL T, 1980, J PHYSIOL-LONDON, V302, P131; Reiken S, 2003, J BIOL CHEM, V278, P444, DOI 10.1074/jbc.M207028200; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1991, CIRC RES, V68, P77, DOI 10.1161/01.RES.68.1.77; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; Volders PGA, 2003, CIRCULATION, V107, P2753, DOI 10.1161/01.CIR.0000068344.54010.B3; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; WALSH KB, 1991, AM J PHYSIOL, V260, pH1390, DOI 10.1152/ajpheart.1991.260.4.H1390; Wehrens XHT, 2003, CELL, V113, P829, DOI 10.1016/S0092-8674(03)00434-3; Ye CI, 2000, BIOPHYS J, V79, P2547, DOI 10.1016/S0006-3495(00)76495-2; Zhou YY, 2000, MOL PHARMACOL, V58, P887, DOI 10.1124/mol.58.5.887	29	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40778	40787		10.1074/jbc.M406010200	http://dx.doi.org/10.1074/jbc.M406010200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15272004	hybrid			2022-12-27	WOS:000223916800071
J	Sneeden, JL; Loeb, LA				Sneeden, JL; Loeb, LA			Mutations in the R2 subunit of ribonucleotide reductase that confer resistance to hydroxyurea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; FETAL-HEMOGLOBIN; PROTEIN R2; IRON; MECHANISM; INHIBITORS; INDUCTION; HAMSTER; CLUSTER	Ribonucleotide reductase is an essential enzyme that catalyzes the reduction of ribonucleotides to deoxyribonucleotides for use in DNA synthesis. Ribonucleotide reductase from Escherichia coli consists of two subunits, R1 and R2. The R2 subunit contains an unusually stable radical at tyrosine 122 that participates in catalysis. Buried deep within a hydrophobic pocket, the radical is inaccessible to solvent although subject to inactivation by radical scavengers. One such scavenger, hydroxyurea, is a highly specific inhibitor of ribonucleotide reductase and therefore of DNA synthesis; thus it is an important anticancer and antiviral agent. The mechanism of radical access remains to be established; however, small molecules may be able to access Tyr-122 directly via channels from the surface of the protein. We used random oligonucleotide mutagenesis to create a library of 200,000 R2 mutants containing random substitutions at five contiguous residues (Ile-74, Ser-75, Asn-76, Leu-77, Lys-78) that partially comprise one side of a channel where Tyr-122 is visible from the protein surface. We subjected this library to increasing concentrations of hydroxyurea and identified mutants that enhance survival more than 1000-fold over wild-type R2 at high drug concentrations. Repetitive selections yielded S75T as the predominant R2 mutant in our library. Purified S75TR2 exhibits a radical half-life that is 50% greater than wild-type R2 in the presence of hydroxyurea. These data represent the first demonstration of R2 protein mutants in E. coli that are highly resistant to hydroxyurea; elucidation of their mechanism of resistance may provide valuable insight into the development of more effective inhibitors.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Dept Biochem, K-056 HSB 1959 NE Pacific, Seattle, WA 98195 USA.	laloeb@u.washington.edu			NATIONAL CANCER INSTITUTE [R01CA078885] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA78885] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMARA FM, 1995, CANCER RES, V55, P4503; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BAKER CH, 1991, J MED CHEM, V34, P1879, DOI 10.1021/jm00110a019; Baliga BS, 2000, AM J HEMATOL, V65, P227, DOI 10.1002/1096-8652(200011)65:3<227::AID-AJH9>3.0.CO;2-V; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; Burton TR, 2003, INT J ONCOL, V22, P21; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; Fontecave M, 1998, CELL MOL LIFE SCI, V54, P684, DOI 10.1007/s000180050195; FUCHS JA, 1976, J BACTERIOL, V128, P810, DOI 10.1128/JB.128.3.810-814.1976; Gerez C, 1997, EUR J BIOCHEM, V249, P401, DOI 10.1111/j.1432-1033.1997.t01-2-00401.x; GEREZ C, 1992, BIOCHEMISTRY-US, V31, P780, DOI 10.1021/bi00118a020; GRASLUND A, 1982, J BIOL CHEM, V257, P5711; Guzman EC, 2002, MOL MICROBIOL, V43, P487, DOI 10.1046/j.1365-2958.2002.02761.x; Ho JA, 2003, EXP HEMATOL, V31, P586, DOI 10.1016/S0301-472X(03)00086-9; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; LARSEN IK, 1982, EUR J BIOCHEM, V125, P75; LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634; Lye LF, 1997, MOL BIOCHEM PARASIT, V90, P353, DOI 10.1016/S0166-6851(97)00159-X; Martz E, 2002, TRENDS BIOCHEM SCI, V27, P107, DOI 10.1016/S0968-0004(01)02008-4; Mayhew CN, 1999, STEM CELLS, V17, P345, DOI 10.1002/stem.170345; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Parkin SE, 1998, BIOCHEMISTRY-US, V37, P1124, DOI 10.1021/bi9723717; REGNSTROM K, 1994, J BIOL CHEM, V269, P6355; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; SALOWE SP, 1986, J BACTERIOL, V165, P363, DOI 10.1128/jb.165.2.363-366.1986; Sambrook J., 2001, MOL CLONING LAB MANU; Sneeden Jessica L, 2003, Methods Mol Biol, V231, P65; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; Stubbe J, 2000, CURR OPIN STRUC BIOL, V10, P731, DOI 10.1016/S0959-440X(00)00153-6; Suzuki M, 1996, MOL DIVERS, V2, P111, DOI 10.1007/BF01718708; TAGGER AY, 1988, INT J CANCER, V42, P760, DOI 10.1002/ijc.2910420522; Thelander L, 1978, Methods Enzymol, V51, P227; WRIGHT JA, 1987, SOMAT CELL MOLEC GEN, V13, P155, DOI 10.1007/BF01534695	35	28	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40723	40728		10.1074/jbc.M402699200	http://dx.doi.org/10.1074/jbc.M402699200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262976	hybrid			2022-12-27	WOS:000223916800064
J	Cho, HDD; Weiner, AM				Cho, HDD; Weiner, AM			A single catalytically active subunit in the multimeric Sulfolobus shibatae CCA-adding enzyme can carry out all three steps of CCA addition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA NUCLEOTIDYLTRANSFERASE; MAMMALIAN POLY(A) POLYMERASE; CRYSTAL-STRUCTURE; CLASS-I; POLYMERIZATION; SUPERFAMILY; ATP; DNA; MECHANISM; SUBSTRATE	The CCA-adding enzyme ATP(CTP): tRNA nucleotidyltransferase builds and repairs the 3'-terminal CCA sequence of tRNA. Although this unusual RNA polymerase has no nucleic acid template, it can construct the CCA sequence one nucleotide at a time using CTP and ATP as substrates. We found previously that tRNA does not translocate along the enzyme during CCA addition (Yue, D., Weiner, A.M., and Maizels, N. (1998) J. Biol. Chem. 273, 29693-29700) and that a single nucleotidyltransferase motif adds all three nucleotides (Shi, P.-Y., Maizels, N., and Weiner, A. M. (1998) EMBO J. 17, 3197-3206). Intriguingly, the CCA-adding enzyme from the archaeon Sulfolobus shibatae is a homodimer that forms a tetramer upon binding two tRNAs. We therefore asked whether the active form of the S. shibatae enzyme might have two quasi-equivalent active sites, one adding CTP and the other ATP. Using an intersubunit complementation approach, we demonstrate that the dimer is active and that a single catalytically active subunit can carry out all three steps of CCA addition. We also locate one UV light-induced tRNA cross-link on the enzyme structure and provide evidence suggesting the location of another. Our data rule out shuttling models in which the 3'-end of the tRNA shuttles from one quasi-equivalent active site to another, demonstrate that tRNA-induced tetramerization is not required for CCA addition, and support a role for the tail domain of the enzyme in tRNA binding.	Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Weiner, AM (corresponding author), Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA.	amweiner@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059804] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59804] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1990, J BIOL CHEM, V265, P16216; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; Ast G, 1997, RNA, V3, P371; Augustin MA, 2003, J MOL BIOL, V328, P985, DOI 10.1016/S0022-2836(03)00381-4; Cho HD, 2003, RNA, V9, P970, DOI 10.1261/rna.2110903; Cho HDD, 2002, J BIOL CHEM, V277, P3447, DOI 10.1074/jbc.M109559200; DEUTSCHER MP, 1972, J BIOL CHEM, V247, P469; DEUTSCHER MP, 1982, ENZYMES, V15, P182; GOTT JM, 1991, BIOCHEMISTRY-US, V30, P6290, DOI 10.1021/bi00239a030; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; Li F, 2002, CELL, V111, P815, DOI 10.1016/S0092-8674(02)01115-7; LIU MS, 1994, P NATL ACAD SCI USA, V91, P10389, DOI 10.1073/pnas.91.22.10389; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; Martin G, 2000, EMBO J, V19, P4193, DOI 10.1093/emboj/19.16.4193; Okabe M, 2003, EMBO J, V22, P5918, DOI 10.1093/emboj/cdg563; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Shi PY, 1998, RNA, V4, P276; Sprinzl M, 1979, Prog Nucleic Acid Res Mol Biol, V22, P1, DOI 10.1016/S0079-6603(08)60798-9; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; Tomari Y, 2000, GENES CELLS, V5, P689, DOI 10.1046/j.1365-2443.2000.00360.x; Tomita K, 2002, J BIOL CHEM, V277, P48192, DOI 10.1074/jbc.M207527200; Tomita K, 2001, SCIENCE, V294, P1334, DOI 10.1126/science.1063816; WILLIS MC, 1994, NUCLEIC ACIDS RES, V22, P4947, DOI 10.1093/nar/22.23.4947; Xiong Y, 2003, MOL CELL, V12, P1165, DOI 10.1016/S1097-2765(03)00440-4; Yue DX, 1996, RNA, V2, P895; ZHU LQ, 1987, EMBO J, V6, P2473, DOI 10.1002/j.1460-2075.1987.tb02528.x	33	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40130	40136		10.1074/jbc.M405518200	http://dx.doi.org/10.1074/jbc.M405518200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15265870	hybrid			2022-12-27	WOS:000223791500111
J	Spehr, M; Schwane, K; Riffell, JA; Barbour, J; Zimmer, RK; Nauhaus, EM; Hatt, H				Spehr, M; Schwane, K; Riffell, JA; Barbour, J; Zimmer, RK; Nauhaus, EM; Hatt, H			Particulate adenylate cyclase plays a key role in human sperm olfactory receptor-mediated chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IDENTIFICATION TECHNOLOGY; MALE GERM-CELLS; MOUSE SPERM; MAMMALIAN SPERMATOZOA; CALCIUM-CHANNEL; MOLECULAR-BASIS; ZONA-PELLUCIDA; EGG ZP3; CAPACITATION; INHIBITION	Human sperm chemotaxis is a critical component of the fertilization process, but the molecular basis for this behavior remains unclear. Recent evidence shows that chemotactic responses depend on activation of the sperm olfactory receptor, hOR17-4. Certain floral scents, including bourgeonal, activate hOR17-4, trigger pronounced Ca2+ fluxes, and evoke chemotaxis. Here, we provide evidence that hOR17-4 activation is coupled to a cAMP-mediated signaling cascade. Multidimensional protein identification technology was used to identify potential components of a G-protein-coupled cAMP transduction pathway in human sperm. These products included various membrane-associated adenylate cyclase (mAC) isoforms and the G(olf)-subunit. Using immunocytochemistry, specific mAC isoforms were localized to particular cell regions. Whereas mAC III occurred in the sperm head and midpiece, mAC VIII was distributed predominantly in the flagellum. In contrast, G(olf) was found mostly in the flagellum and midpiece. The observed spatial distribution patterns largely correspond to the spatiotemporal character of hOR17-4-induced Ca2+ changes. Behavioral and Ca2+ signaling responses of human sperm to bourgeonal were bioassayed in the presence, or absence, of the adenylate cyclase antagonist SQ22536. This specific agent inhibits particulate AC, but not soluble AC, activation. Upon incubation with SQ22536, cells ceased to exhibit Ca2+ signaling, chemotaxis, and hyperactivation (faster swim speed and flagellar beat rate) in response to bourgeonal. Particulate AC is therefore required for induction of hOR17-4-mediated human sperm behavior and represents a promising target for future design of contraceptive drugs.	Univ Maryland, Dept Anat & Neurobiol, Sch Med, Baltimore, MD 21201 USA; Ruhr Univ Bochum, Lst Zellphysiol, D-44780 Bochum, Germany; Univ Calif Los Angeles, Dept Ecol & Evolut Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Dept Neurosci, Los Angeles, CA 90024 USA	University System of Maryland; University of Maryland Baltimore; Ruhr University Bochum; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Spehr, M (corresponding author), Univ Maryland, Dept Anat & Neurobiol, Sch Med, 685 W Baltimore St, Baltimore, MD 21201 USA.	mspeh001@umaryland.edu	Spehr, Marc/B-3140-2011; Spehr, Marc/AAK-3162-2021; Neuhaus, Eva/L-1428-2015	Spehr, Marc/0000-0001-6616-4196; Spehr, Marc/0000-0001-6616-4196; Neuhaus, Eva/0000-0003-3363-1231				Arnoult C, 1999, P NATL ACAD SCI USA, V96, P6757, DOI 10.1073/pnas.96.12.6757; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; Baxendale RW, 2003, MOL REPROD DEV, V66, P181, DOI 10.1002/mrd.10344; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Chen S, 2000, J NEUROPHYSIOL, V84, P575, DOI 10.1152/jn.2000.84.1.575; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; COHENDAYAG A, 1995, P NATL ACAD SCI USA, V92, P11039, DOI 10.1073/pnas.92.24.11039; CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453; Crank J., 1975, MATH DIFFUSION; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; Defer N, 1998, FEBS LETT, V424, P216, DOI 10.1016/S0014-5793(98)00178-1; Defer N, 2000, AM J PHYSIOL-RENAL, V279, pF400, DOI 10.1152/ajprenal.2000.279.3.F400; Diez-Sanchez C, 2003, FEBS LETT, V553, P205, DOI 10.1016/S0014-5793(03)01013-5; Eisenbach M, 1999, DEV GENET, V25, P87, DOI 10.1002/(SICI)1520-6408(1999)25:2&lt;87::AID-DVG2&gt;3.0.CO;2-4; Firestein S, 2001, NATURE, V413, P211, DOI 10.1038/35093026; Gautier-Courteille C, 1998, ENDOCRINOLOGY, V139, P2588, DOI 10.1210/en.139.5.2588; Gu C, 1999, J BIOL CHEM, V274, P8012, DOI 10.1074/jbc.274.12.8012; Harrison RAP, 2003, REPROD DOMEST ANIM, V38, P102, DOI 10.1046/j.1439-0531.2003.00400.x; Hurley JH, 1999, J BIOL CHEM, V274, P7599, DOI 10.1074/jbc.274.12.7599; Inaba K, 2003, ZOOL SCI, V20, P1043, DOI 10.2108/zsj.20.1043; Jaiswal BS, 2003, P NATL ACAD SCI USA, V100, P10676, DOI 10.1073/pnas.1831008100; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kobori H, 2000, BIOL REPROD, V63, P113, DOI 10.1095/biolreprod63.1.113; Leclerc P, 1999, J ANDROL, V20, P126; LECLERC P, 1995, BIOL REPROD, V52, P1227, DOI 10.1095/biolreprod52.6.1227; Luconi M, 2003, CELL MOL BIOL, V49, P357; MEIZEL S, 1993, MOL REPROD DEV, V34, P457, DOI 10.1002/mrd.1080340416; MENCO BPM, 1992, NEURON, V8, P441, DOI 10.1016/0896-6273(92)90272-F; Miller R.L., 1985, P275; NaabyHansen S, 1997, BIOL REPROD, V56, P771, DOI 10.1095/biolreprod56.3.771; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; Quill TA, 2001, P NATL ACAD SCI USA, V98, P12527, DOI 10.1073/pnas.221454998; Regnauld KL, 2002, AM J PHYSIOL-REG I, V282, pR870, DOI 10.1152/ajpregu.00374.2001; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Riffell JA, 2004, P NATL ACAD SCI USA, V101, P4501, DOI 10.1073/pnas.0304594101; Riffell JA, 2002, J EXP BIOL, V205, P1439; Schaefer ML, 2000, J NEUROSCI, V20, P4809; Spehr M, 2003, SCIENCE, V299, P2054, DOI 10.1126/science.1080376; Spehr M, 2002, NEURON, V33, P731, DOI 10.1016/S0896-6273(02)00610-4; Tesmer JJG, 2000, BIOCHEMISTRY-US, V39, P14464, DOI 10.1021/bi0015562; Travis AJ, 2002, J CLIN INVEST, V110, P731, DOI [10.1172/JCI200216392, 10.1172/JCI0216392]; Vacquier VD, 1998, SCIENCE, V281, P1995, DOI 10.1126/science.281.5385.1995; VANDERHAEGHEN P, 1993, J CELL BIOL, V123, P1441, DOI 10.1083/jcb.123.6.1441; Vanderhaeghen P, 1997, GENOMICS, V39, P239, DOI 10.1006/geno.1996.4490; Visconti PE, 1997, DEV BIOL, V192, P351, DOI 10.1006/dbio.1997.8768; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Wennemuth G, 2000, J BIOL CHEM, V275, P21210, DOI 10.1074/jbc.M002068200; Westenbroek RE, 1999, DEV BIOL, V207, P457, DOI 10.1006/dbio.1998.9172; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; *WHO, 1993, LAB METH EX HUM SER; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X; Wuttke M S, 2001, JOP, V2, P154; XIA ZG, 1992, NEUROSCI LETT, V144, P169, DOI 10.1016/0304-3940(92)90742-P	60	119	123	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40194	40203		10.1074/jbc.M403913200	http://dx.doi.org/10.1074/jbc.M403913200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15271985	hybrid			2022-12-27	WOS:000223791500118
J	Chakrabarti, PP; Suveyzdis, Y; Wittinghofer, A; Gerwert, K				Chakrabarti, PP; Suveyzdis, Y; Wittinghofer, A; Gerwert, K			Fourier transform infrared spectroscopy on the Rap center dot RapGAP reaction, GTPase activation without an arginine finger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN MOTOR DOMAIN; TIME-RESOLVED FTIR; CRYSTAL-STRUCTURE; BETA-PHOSPHATE; MECHANISM; PROTEIN; HYDROLYSIS; COMPLEX; GAP; P21	(G) under bar TPase (a) under bar ctivating (p) under bar roteins (GAPs) down-regulate Ras-like proteins by stimulating their GTP hydrolysis, and a malfunction of this reaction leads to disease formation. In most cases, the molecular mechanism of activation involves stabilization of a catalytic Gln and insertion of a catalytic Arg into the active site by GAP. Rap1 neither possesses a Gln nor does its cognate RapGAP employ an Arg. Recently it was proposed that RapGAP provides a catalytic Asn, which substitutes for the Gln found in all other Ras-like proteins (Daumke, O., Weyand, M., Chakrabarti, P. P., Vetter, I. R., and Wittinghofer, A. (2004) Nature 429, 197-201). Here, RapGAP-mediated activation has been investigated by time-resolved Fourier transform infrared spectroscopy. Although the intrinsic hydrolysis reactions of Rap and Ras are very similar, the GAP-catalyzed reaction shows unique features. RapGAP binding induces a GTP* conformation in which the three phosphate groups are oriented such that they are vibrationally coupled to each other, in contrast to what was seen in the intrinsic and the Ras.RasGAP reactions. However, the charge shift toward beta-phosphate observed with RasGAP was also observed for RapGAP. A GDP.P-i intermediate accumulates in the GAP-catalyzed reaction, because the release of P-i is eight times slower than the cleavage reaction, and significant GTP synthesis from GDP.P-i was observed. Partial steps of the cleavage reaction are correlated with structural changes of protein side groups and backbone. Thus, the Rap.RapGAP catalytic machinery compensates for the absence of a cis-Gln by a trans-Asn and for the catalytic Arg by inducing a different GTP conformation that is more prone to be attacked by a water molecule.	Ruhr Univ Bochum, Lehrstuhl Biophys, D-44780 Bochum, Germany; Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44227 Dortmund, Germany	Ruhr University Bochum; Max Planck Society	Gerwert, K (corresponding author), Ruhr Univ Bochum, Lehrstuhl Biophys, Postfach 102148,Univ Str 150, D-44780 Bochum, Germany.	gerwert@bph.rub.de	Gerwert, Klaus/G-7311-2015					Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Albert S, 1999, EMBO J, V18, P5216, DOI 10.1093/emboj/18.19.5216; Allin C, 2001, P NATL ACAD SCI USA, V98, P7754, DOI 10.1073/pnas.131549798; Allin C, 2001, BIOCHEMISTRY-US, V40, P3037, DOI 10.1021/bi0017024; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Brinkmann T, 2002, J BIOL CHEM, V277, P12525, DOI 10.1074/jbc.M109176200; Cepus V, 1998, Methods Enzymol, V291, P223; Cepus V, 1998, BIOCHEMISTRY-US, V37, P10263, DOI 10.1021/bi973183j; Cherfils J, 1997, EMBO J, V16, P5582, DOI 10.1093/emboj/16.18.5582; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Daumke O, 2004, NATURE, V429, P197, DOI 10.1038/nature02505; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FEUERSTEIN J, 1989, J BIOL CHEM, V264, P6188; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GERWERT K, 1990, P NATL ACAD SCI USA, V87, P9774, DOI 10.1073/pnas.87.24.9774; GERWERT K, 1993, CURR OPIN STRUC BIOL, V3, P769, DOI 10.1016/0959-440X(93)90062-P; GERWERT K, 1989, P NATL ACAD SCI USA, V86, P4943, DOI 10.1073/pnas.86.13.4943; Graham DL, 1999, BIOCHEMISTRY-US, V38, P985, DOI 10.1021/bi9821770; HESSLING B, 1993, BIOPHYS J, V65, P1929, DOI 10.1016/S0006-3495(93)81264-5; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kraemer A, 2002, J MOL BIOL, V324, P763, DOI 10.1016/S0022-2836(02)01136-1; Leonard DA, 1998, J BIOL CHEM, V273, P16210, DOI 10.1074/jbc.273.26.16210; LEVY HM, 1959, J BIOL CHEM, V234, P1102; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NIXON AE, 1995, BIOCHEMISTRY-US, V34, P15592, DOI 10.1021/bi00047a026; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Phillips RA, 2003, BIOCHEMISTRY-US, V42, P3956, DOI 10.1021/bi027316z; Rayment I, 1996, J BIOL CHEM, V271, P15850, DOI 10.1074/jbc.271.27.15850; Sasaki N, 1998, ADV BIOPHYS, V35, P1; Seewald MJ, 2002, NATURE, V415, P662, DOI 10.1038/415662a; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wang JP, 2004, CHEM PHYS, V297, P195, DOI 10.1016/j.chemphys.2003.10.013; Wittinghofer A, 2000, ANGEW CHEM INT EDIT, V39, P4193, DOI 10.1002/1521-3773(20001201)39:23<4192::AID-ANIE4192>3.0.CO;2-Y	39	25	25	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46226	46233		10.1074/jbc.M405603200	http://dx.doi.org/10.1074/jbc.M405603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15292263	hybrid			2022-12-27	WOS:000224694900109
J	Huang, J; Chen, J; Chesla, SE; Yago, T; Mehta, P; McEver, RP; Zhu, C; Long, M				Huang, J; Chen, J; Chesla, SE; Yago, T; Mehta, P; McEver, RP; Zhu, C; Long, M			Quantifying the effects of molecular orientation and length on two-dimensional receptor-ligand binding kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIN GLYCOPROTEIN LIGAND-1; P-SELECTIN; CELL-ADHESION; CONCURRENT BINDING; MEMBRANE; FLOW; NEUTROPHILS; FIBRONECTIN; AFFINITY; IDENTIFICATION	Surface presentation of adhesion receptors influences cell adhesion, although the mechanisms underlying these effects are not well understood. We used a micropipette adhesion frequency assay to quantify how the molecular orientation and length of adhesion receptors on the cell membrane affected two-dimensional kinetic rates of interactions with surface ligands. Interactions of P-selectin, E-selectin, and CD16A with their respective ligands or antibody were used to demonstrate such effects. Randomizing the orientation of the adhesion receptor or lowering its ligand- and antibody-binding domain above the cell membrane lowered two-dimensional affinities of the molecular interactions by reducing the forward rates but not the reverse rates. In contrast, the soluble antibody bound with similar three-dimensional affinities to cell-bound P-selectin constructs regardless of their orientation and length. These results demonstrate that the orientation and length of an adhesion receptor influences its rate of encountering and binding a surface ligand but does not subsequently affect the stability of binding.	Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA; Chinese Acad Sci, Inst Mech, Natl Micrograv Lab, Beijing 100080, Peoples R China; Georgia Inst Technol, Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	University System of Georgia; Georgia Institute of Technology; Chinese Academy of Sciences; Institute of Mechanics, CAS; University System of Georgia; Georgia Institute of Technology; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Zhu, C (corresponding author), Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA.	cheng.zhu@me.gatech.edu; mlong@imech.ac.cn	Huang, Jun/E-8472-2010; Zhu, Cheng/A-5724-2011		FOGARTY INTERNATIONAL CENTER [R03TW005774] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038282, R29AI038282, R01AI044902, R21AI044902] Funding Source: NIH RePORTER; FIC NIH HHS [TW 05774-01] Funding Source: Medline; NHLBI NIH HHS [HL 65631] Funding Source: Medline; NIAID NIH HHS [AI38282, AI 44902] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHAN PY, 1992, MOL BIOL CELL, V3, P157, DOI 10.1091/mbc.3.2.157; Chesla SE, 2000, J BIOL CHEM, V275, P10235, DOI 10.1074/jbc.275.14.10235; Chesla SE, 1998, BIOPHYS J, V75, P1553, DOI 10.1016/S0006-3495(98)74074-3; Dustin ML, 2001, ANNU REV CELL DEV BI, V17, P133, DOI 10.1146/annurev.cellbio.17.1.133; Dwir O, 2000, J BIOL CHEM, V275, P18682, DOI 10.1074/jbc.M001103200; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Keselowsky BG, 2003, J BIOMED MATER RES A, V66A, P247, DOI 10.1002/jbm.a.10537; KOFLER R, 1977, J IMMUNOL METHODS, V16, P201, DOI 10.1016/0022-1759(77)90198-3; LI SH, 1994, J BIOL CHEM, V269, P4431; Long M, 2001, ANN BIOMED ENG, V29, P935, DOI 10.1114/1.1415529; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; Mehta P, 1997, BLOOD, V90, P2381, DOI 10.1182/blood.V90.6.2381.2381_2381_2389; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; Michael KE, 2003, LANGMUIR, V19, P8033, DOI 10.1021/la034810a; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NAGARAJAN S, 1995, J BIOL CHEM, V270, P25762, DOI 10.1074/jbc.270.43.25762; Patel KD, 1995, J CELL BIOL, V131, P1893, DOI 10.1083/jcb.131.6.1893; PATEL KD, 1995, J CLIN INVEST, V96, P1887, DOI 10.1172/JCI118234; Riper JW, 1998, BIOPHYS J, V74, P492, DOI 10.1016/S0006-3495(98)77807-5; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Williams TE, 2000, BIOPHYS J, V79, P1858, DOI 10.1016/S0006-3495(00)76435-6; Williams TE, 2001, J BIOL CHEM, V276, P13283, DOI 10.1074/jbc.M010427200; Wong JY, 1997, SCIENCE, V275, P820, DOI 10.1126/science.275.5301.820; Yago T, 2002, J CELL BIOL, V158, P787, DOI 10.1083/jcb.200204041; Zhu C, 2000, BIOPHYS J, V79, P1850, DOI 10.1016/S0006-3495(00)76434-4	34	92	100	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44915	44923		10.1074/jbc.M407039200	http://dx.doi.org/10.1074/jbc.M407039200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15299021	hybrid			2022-12-27	WOS:000224505600082
J	Tang, ZZ; Liang, MC; Lu, SQ; Yu, DJ; Yu, CY; Yue, DT; Soong, TW				Tang, ZZ; Liang, MC; Lu, SQ; Yu, DJ; Yu, CY; Yue, DT; Soong, TW			Transcript scanning reveals novel and extensive splice variations in human L-type voltage-gated calcium channel, Ca(v)1.2 alpha(1) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; VASCULAR SMOOTH-MUSCLE; DEPENDENT K+ CHANNEL; CA2+ CHANNEL; MOLECULAR DIVERSITY; FUNCTIONAL EXPRESSION; CA2+-DEPENDENT INACTIVATION; GATING KINETICS; CURRENT-DENSITY; N-TERMINUS	The L-type (Ca(v)1.2) voltage-gated calcium channels play critical roles in membrane excitability, gene expression, and muscle contraction. The generation of splice variants by the alternative splicing of the pore-forming Ca(v)1.2 alpha(1)-subunit (alpha(1)1.2) may thereby provide potent means to enrich functional diversity. To date, however, no comprehensive scan of alpha(1)1.2 splice variation has been performed, particularly in the human context. Here we have undertaken such a screen, exploiting recently developed "transcript scanning" methods to probe the human gene. The degree of variation turns out to be surprisingly large; 19 of the 55 exons comprising the human alpha(1)1.2 gene were subjected to alternative splicing. Two of these are previously unrecognized exons and two others were not known to be spliced. Comparisons of fetal and adult heart and brain uncovered a large IVS3-S4 variability resulting from combinatorial utilization of exons 31-33. Electrophysiological characterization of such IVS3-S4 variation revealed unmistakable shifts in the voltage dependence of activation, according to an interesting correlation between increased IVS3-S4 linker length and activation at more depolarized potentials. Steady-state inactivation profiles remained unaltered. This systematic portrait of splice variation furnishes a reference library for comprehending combinatorial arrangements of Ca(v)1.2 splice exons, especially as they impact development, physiology, and disease.	Natl Univ Singapore, Fac Med, Dept Physiol, Singapore 117597, Singapore; Natl Inst Neurosci, Singapore 308433, Singapore; Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	National University of Singapore; National Neuroscience Institute (NNI); Johns Hopkins University; Johns Hopkins University	Soong, TW (corresponding author), Natl Univ Singapore, Fac Med, Dept Physiol, Blk Md9,2 Med Dr, Singapore 117597, Singapore.	phsstw@nus.edu.sg	Tuluc, Petronel/C-2527-2011	Soong, Tuck Wah/0000-0002-0876-0325; Liang, Mui Cheng/0000-0003-1208-0733	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052307] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL52307-10] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abernethy DR, 2002, J PHARMACOL EXP THER, V300, P724, DOI 10.1124/jpet.300.3.724; Alseikhan BA, 2002, P NATL ACAD SCI USA, V99, P17185, DOI 10.1073/pnas.262372999; Bell TJ, 2004, NEURON, V41, P127, DOI 10.1016/S0896-6273(03)00801-8; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; Bielefeldt K, 1999, J LAB CLIN MED, V133, P469, DOI 10.1016/S0022-2143(99)90024-0; Blumenstein Y, 2002, J BIOL CHEM, V277, P3419, DOI 10.1074/jbc.C100642200; Bonci A, 1998, J NEUROSCI, V18, P6693; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chaudhuri D, 2004, J NEUROSCI, V24, P6334, DOI 10.1523/JNEUROSCI.1712-04.2004; Dai BS, 2002, BIOCHEM BIOPH RES CO, V296, P429, DOI 10.1016/S0006-291X(02)00894-X; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Fearon IM, 2000, CIRC RES, V87, P537, DOI 10.1161/01.RES.87.7.537; FERON O, 1994, EUR J BIOCHEM, V222, P195, DOI 10.1111/j.1432-1033.1994.tb18857.x; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gerzanich V, 2003, CIRC RES, V93, P805, DOI 10.1161/01.RES.0000097872.69043.A0; Gonzalez C, 2000, J GEN PHYSIOL, V115, P193, DOI 10.1085/jgp.115.2.193; Gonzalez C, 2001, P NATL ACAD SCI USA, V98, P9617, DOI 10.1073/pnas.171306298; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Hans M, 1999, BIOPHYS J, V76, P1384, DOI 10.1016/S0006-3495(99)77300-5; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; Lacinova L, 2000, PFLUG ARCH EUR J PHY, V440, P50, DOI 10.1007/s004240051021; Lin ZX, 1999, J NEUROSCI, V19, P5322; Lin ZX, 1997, NEURON, V18, P153, DOI 10.1016/S0896-6273(01)80054-4; Lipscombe D, 2002, MOL NEUROBIOL, V26, P21, DOI 10.1385/MN:26:1:021; MA WJ, 1992, J BIOL CHEM, V267, P22728; McRory JE, 2004, J NEUROSCI, V24, P1707, DOI 10.1523/JNEUROSCI.4846-03.2004; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Mittman S, 1999, NEUROSCI LETT, V274, P143, DOI 10.1016/S0304-3940(99)00716-8; Neves G, 2004, NAT GENET, V36, P240, DOI 10.1038/ng1299; Pang L, 2003, FEBS LETT, V546, P349, DOI 10.1016/S0014-5793(03)00629-X; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Raghib A, 2001, J NEUROSCI, V21, P8495, DOI 10.1523/JNEUROSCI.21-21-08495.2001; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; Shistik E, 1999, J BIOL CHEM, V274, P31145, DOI 10.1074/jbc.274.44.31145; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOLDATOV NM, 1992, P NATL ACAD SCI USA, V89, P4628, DOI 10.1073/pnas.89.10.4628; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; Soong TW, 2002, J NEUROSCI, V22, P10142; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; Takahashi SX, 2003, BIOPHYS J, V84, P3007, DOI 10.1016/S0006-3495(03)70027-7; Ule J, 2003, SCIENCE, V302, P1212, DOI 10.1126/science.1090095; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Welling A, 1997, CIRC RES, V81, P526, DOI 10.1161/01.RES.81.4.526; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492; Yang YB, 2000, J MOL CELL CARDIOL, V32, P973, DOI 10.1006/jmcc.2000.1138; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	61	120	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44335	44343		10.1074/jbc.M407023200	http://dx.doi.org/10.1074/jbc.M407023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15299022	hybrid			2022-12-27	WOS:000224505600015
J	Umeda, K; Matsui, T; Nakayama, M; Furuse, K; Sasaki, H; Furuse, M; Tsukita, S				Umeda, K; Matsui, T; Nakayama, M; Furuse, K; Sasaki, H; Furuse, M; Tsukita, S			Establishment and characterization of cultured epithelial cells lacking expression of ZO-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION PROTEIN; TUMOR-SUPPRESSOR PROTEIN; INTERCELLULAR-JUNCTIONS; ADHESION MOLECULE; DIFFERENTIAL BEHAVIOR; DIRECT BINDING; MAGUK PROTEIN; OCCLUDIN; ACTIN; CADHERIN	In well polarized epithelial cells, closely related ZO-1 and ZO-2 are thought to function as scaffold proteins at tight junctions (TJs). In epithelial cells at the initial phase of polarization, these proteins are recruited to cadherin-based spotlike adherens junctions (AJs). As a first step to clarify the function of ZO-1, we successfully generated mouse epithelial cell clones lacking ZO-1 expression (ZO-1-/- cells) by homologous recombination. Unexpectedly, in confluent cultures, ZO-1-/- cells were highly polarized with well organized AJs/TJs, which were indistinguishable from those in ZO-1+/+ cells by electron microscopy. In good agreement, by immunofluorescence microscopy, most TJ proteins including claudins and occludin appeared to be normally concentrated at TJs of ZO-1-/- cells with the exception that a ZO-1 deficiency significantly up- or down-regulated the recruitment of ZO-2 and cingulin, another TJ scaffold protein, respectively, to TJs. When the polarization of ZO-1-/- cells was initiated by a Ca2+ switch, the initial AJ formation did not appear to be affected; however, the subsequent TJ formation ( recruitment of claudins/occludin to junctions and barrier establishment) was markedly retarded. This retardation as well as the disappearance of cingulin were rescued completely by exogenous ZO-1 but not by ZO-2 expression. Quantitative evaluation of ZO-1/ZO-2 expression levels led to the conclusion that ZO-1 and ZO-2 would function redundantly to some extent in junction formation/epithelial polarization but that they are not functionally identical. Finally, we discussed advantageous aspects of the gene knockout system with cultured epithelial cells in epithelial cell biology.	Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan; KAN Res Inst Inc, Kyoto Res Pk, Shimogyo Ku, Kyoto 6008815, Japan; Jikei Univ, Sch Med, Inst DNA Med, Dept Mol Cell Biol,Minato Ku, Tokyo 1058461, Japan	Kyoto University; KAN Research Institute; Jikei University	Tsukita, S (corresponding author), Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Yoshida Konoe, Kyoto 6068501, Japan.	htsukita@mfour.med.kyoto-u.ac.jp		Furuse, Mikio/0000-0003-2847-8156; Sasaki, Hiroyuki/0000-0002-5358-5853; Furuse, Kyoko/0000-0003-4304-6204				Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; ANDERSON JM, 1995, AM J PHYSIOL, V269, P467; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Balda MS, 1998, J CELL SCI, V111, P541; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; Benais-Pont G, 2003, J CELL BIOL, V160, P729, DOI 10.1083/jcb.200211047; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; Cordenonsi M, 1999, J CELL BIOL, V147, P1569, DOI 10.1083/jcb.147.7.1569; D'Atri F, 2002, J BIOL CHEM, V277, P27757, DOI 10.1074/jbc.M203717200; D'Atri F, 2002, MOL MEMBR BIOL, V19, P103, DOI 10.1080/09687680210129236; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hayashi K, 1999, J CELL SCI, V112, P1149; Inoko A, 2003, GENES CELLS, V8, P837, DOI 10.1046/j.1365-2443.2003.00681.x; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Nelson WJ, 2003, NEWS PHYSIOL SCI, V18, P143, DOI 10.1152/nips.01435.2002; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; Roh MH, 2003, AM J PHYSIOL-RENAL, V285, pF377, DOI 10.1152/ajprenal.00086.2003; Ryeom SW, 2000, MOL BIOL CELL, V11, P1687, DOI 10.1091/mbc.11.5.1687; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Schneeberger EE, 1992, AM J PHYSIOL, V262, P647; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; YONEMURA S, 1995, J CELL SCI, V108, P127; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	49	201	208	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44785	44794		10.1074/jbc.M406563200	http://dx.doi.org/10.1074/jbc.M406563200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15292177	hybrid, Green Submitted			2022-12-27	WOS:000224505600067
J	Heilman-Miller, SL; Wu, TY; Levin, JG				Heilman-Miller, SL; Wu, TY; Levin, JG			Alteration of nucleic acid structure and stability modulates the efficiency of minus-strand transfer mediated by the HIV-1 nucleocapsid protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMER BINDING-SITE; STRONG-STOP DNA; ZINC-FINGER STRUCTURES; RNASE-H ACTIVITY; IMMUNODEFICIENCY-VIRUS; REVERSE TRANSCRIPTION; IN-VITRO; SECONDARY STRUCTURE; CHAPERONE ACTIVITY; GENOMIC RNA	During human immunodeficiency virus type 1 minus-strand transfer, the nucleocapsid protein (NC) facilitates annealing of the complementary repeat regions at the 3'-ends of acceptor RNA and minus-strand strong-stop DNA ((-) SSDNA). In addition, NC destabilizes the highly structured complementary trans-activation response element (TAR) stem-loop (TAR DNA) at the 3'-end of (-) SSDNA and inhibits TAR-induced self-priming, a dead-end reaction that competes with minus-strand transfer. To investigate the relationship between nucleic acid secondary structure and NC function, a series of truncated (-) SSDNA and acceptor RNA constructs were used to assay minus-strand transfer and self-priming in vitro. The results were correlated with extensive enzymatic probing and mFold analysis. As the length of (-) SSDNA was decreased, self-priming increased and was highest when the DNA contained little more than TAR DNA, even if NC and acceptor were both present; in contrast, truncations within TAR DNA led to a striking reduction or elimination of self-priming. However, destabilization of TAR DNA was not sufficient for successful strand transfer: the stability of acceptor RNA was also crucial, and little or no strand transfer occurred if the RNA was highly stable. Significantly, NC may not be required for in vitro strand transfer if (-) SSDNA and acceptor RNA are small, relatively unstructured molecules with low thermodynamic stabilities. Collectively, these findings demonstrate that for efficient NC-mediated minus-strand transfer, a delicate thermodynamic balance between the RNA and DNA reactants must be maintained.	NICHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Levin, JG (corresponding author), NICHD, Mol Genet Lab, NIH, Bldg 6B,Rm 216, Bethesda, MD 20892 USA.	levinju@mail.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000069] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000069] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; Auxilien S, 1999, J BIOL CHEM, V274, P4412, DOI 10.1074/jbc.274.7.4412; Azoulay J, 2003, J MOL BIOL, V326, P691, DOI 10.1016/S0022-2836(02)01430-4; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; Beltz H, 2004, J MOL BIOL, V338, P711, DOI 10.1016/j.jmb.2004.03.019; Beltz H, 2003, J MOL BIOL, V328, P95, DOI 10.1016/S0022-2836(03)00244-4; BERKHOUT B, 1995, J MOL BIOL, V252, P59, DOI 10.1006/jmbi.1994.0475; BERKHOUT B, 1991, NUCLEIC ACIDS RES, V19, P6169, DOI 10.1093/nar/19.22.6169; Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035; Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2002.5429; Brule F, 2000, NUCLEIC ACIDS RES, V28, P634, DOI 10.1093/nar/28.2.634; Cen S, 1999, J VIROL, V73, P4485, DOI 10.1128/JVI.73.5.4485-4488.1999; Chan BD, 1999, P NATL ACAD SCI USA, V96, P459, DOI 10.1073/pnas.96.2.459; Chen Y, 2003, J BIOL CHEM, V278, P38368, DOI 10.1074/jbc.M305700200; Chen Y, 2003, J BIOL CHEM, V278, P8006, DOI 10.1074/jbc.M210959200; Coffin J, 1997, RETROVIRUSES; Cristofari G, 2002, PROG NUCLEIC ACID RE, V72, P223, DOI 10.1016/S0079-6603(02)72071-0; Dang Q, 2001, J VIROL, V75, P809, DOI 10.1128/JVI.75.2.809-820.2001; DARLIX JL, 1993, CR ACAD SCI III-VIE, V316, P763; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; Davis WR, 1998, BIOCHEMISTRY-US, V37, P14213, DOI 10.1021/bi9814890; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; Derebail SS, 2003, J BIOL CHEM, V278, P15702, DOI 10.1074/jbc.M211701200; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1995, ARCH VIROL, V140, P1775, DOI 10.1007/BF01384341; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; Driscoll MD, 2000, J VIROL, V74, P8785, DOI 10.1128/JVI.74.19.8785-8792.2000; Driscoll MD, 2001, J VIROL, V75, P672, DOI 10.1128/JVI.75.2.672-686.2001; Drummond JE, 1997, AIDS RES HUM RETROV, V13, P533, DOI 10.1089/aid.1997.13.533; Feng YX, 1999, J VIROL, V73, P4251, DOI 10.1128/JVI.73.5.4251-4256.1999; Fisher RJ, 1998, J VIROL, V72, P1902, DOI 10.1128/JVI.72.3.1902-1909.1998; Golinelli MP, 2003, BIOCHEMISTRY-US, V42, P8153, DOI 10.1021/bi027039w; Golinelli MP, 2001, VIROLOGY, V285, P278, DOI 10.1006/viro.2001.0970; GREEN LM, 1990, P NATL ACAD SCI USA, V87, P6403, DOI 10.1073/pnas.87.16.6403; GUO JH, 1995, BIOCHEMISTRY-US, V34, P5018, DOI 10.1021/bi00015a013; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; Guo JH, 2002, J VIROL, V76, P4370, DOI 10.1128/JVI.76.9.4370-4378.2002; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Guo JH, 1998, J VIROL, V72, P6716, DOI 10.1128/JVI.72.8.6716-6724.1998; Hargittai MRS, 2004, J MOL BIOL, V337, P951, DOI 10.1016/j.jmb.2004.01.054; Hargittai MRS, 2001, J MOL BIOL, V312, P985, DOI 10.1006/jmbi.2001.5021; Heath MJ, 2003, J BIOL CHEM, V278, P30755, DOI 10.1074/jbc.M303819200; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Hong MK, 2003, J MOL BIOL, V325, P1, DOI 10.1016/S0022-2836(02)01177-4; Iwatani Y, 2003, J BIOL CHEM, V278, P14185, DOI 10.1074/jbc.M211618200; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; Johnson PE, 2000, BIOCHEMISTRY-US, V39, P9084, DOI 10.1021/bi000841i; KHAN R, 1992, J BIOL CHEM, V267, P6689; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; Lee N, 2003, NUCLEIC ACIDS RES, V31, P4847, DOI 10.1093/nar/gkg679; Li XG, 1996, J VIROL, V70, P4996, DOI 10.1128/JVI.70.8.4996-5004.1996; Lorsch JR, 2002, CELL, V109, P797, DOI 10.1016/S0092-8674(02)00804-8; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Morellet N, 1998, J MOL BIOL, V283, P419, DOI 10.1006/jmbi.1998.2098; Moscardini M, 2002, J MOL BIOL, V318, P149, DOI 10.1016/S0022-2836(02)00092-X; Moumen A, 2003, J BIOL CHEM, V278, P15973, DOI 10.1074/jbc.M212306200; Muthuswami R, 2002, J MOL BIOL, V315, P311, DOI 10.1006/jmbi.2001.5205; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; Negroni M, 1999, J MOL BIOL, V286, P15, DOI 10.1006/jmbi.1998.2460; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; Pfeiffer JK, 2001, J VIROL, V75, P11263, DOI 10.1128/JVI.75.23.11263-11274.2001; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Roda RH, 2003, J BIOL CHEM, V278, P31536, DOI 10.1074/jbc.M304608200; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Rong LW, 1998, J VIROL, V72, P9353, DOI 10.1128/JVI.72.11.9353-9358.1998; Rong LW, 2001, J BIOL CHEM, V276, P47725, DOI 10.1074/jbc.M105124200; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; SOUTH TL, 1990, BIOCHEMISTRY-US, V29, P7786, DOI 10.1021/bi00486a002; SOUTH TL, 1993, PROTEIN SCI, V2, P3; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; Tisne C, 2003, BIOCHIMIE, V85, P557, DOI 10.1016/S0300-9084(03)00034-8; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Urbaneja MA, 2002, J MOL BIOL, V318, P749, DOI 10.1016/S0022-2836(02)00043-8; Vuilleumier C, 1999, BIOCHEMISTRY-US, V38, P16816, DOI 10.1021/bi991145p; Williams MC, 2002, P NATL ACAD SCI USA, V99, P8614, DOI 10.1073/pnas.132128999; Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198; Wu TY, 1999, J VIROL, V73, P4794, DOI 10.1128/JVI.73.6.4794-4805.1999; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; YOU JC, 1994, J BIOL CHEM, V269, P31491; Zhang WH, 2002, J VIROL, V76, P7473, DOI 10.1128/JVI.76.15.7473-7484.2002; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	91	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44154	44165		10.1074/jbc.M401646200	http://dx.doi.org/10.1074/jbc.M401646200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15271979	hybrid			2022-12-27	WOS:000224383100095
J	Wu, LJ; Duan, B; Mei, YD; Gao, J; Chen, JG; Zhuo, M; Xu, L; Wu, MA; Xu, TL				Wu, LJ; Duan, B; Mei, YD; Gao, J; Chen, JG; Zhuo, M; Xu, L; Wu, MA; Xu, TL			Characterization of acid-sensing ion channels in dorsal horn neurons of rat spinal cord	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED NA+ CHANNEL; MUTATIONS CAUSING NEURODEGENERATION; MAMMALIAN DEGENERIN MDEG; ROOT GANGLION-CELLS; CAENORHABDITIS-ELEGANS; HIPPOCAMPAL-NEURONS; ACTIVATED CURRENTS; PAIN; H+; EXPRESSION	Acid-sensing ion channels (ASICs) are ligand-gated cation channels activated by extracellular protons. In periphery, they contribute to sensory transmission, including that of nociception and pain. Here we characterized ASIC-like currents in dorsal horn neurons of the rat spinal cord and their functional modulation in pathological conditions. Reverse transcriptase-nested PCR and Western blotting showed that three ASIC isoforms, ASIC1a, ASIC2a, and ASIC2b, are expressed at a high level in dorsal horn neurons. Electrophysiological and pharmacological properties of the proton-gated currents suggest that homomeric ASIC1a and/or heteromeric ASIC1a + 2b channels are responsible for the proton-induced currents in the majority of dorsal horn neurons. Acidification-induced action potentials in these neurons were compatible in a pH-dependent manner with the pH dependence of ASIC-like current. Furthermore, peripheral complete Freund's adjuvant-induced inflammation resulted in increased expression of both ASIC1a and ASIC2a in dorsal horn. These results support the idea that the ASICs of dorsal horn neurons participate in central sensory transmission/modulation under physiological conditions and may play important roles in inflammation-related persistent pain.	Chinese Acad Sci, Inst Neurosci, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Peoples R China; Huazhong Univ Sci & Technol, Dept Pharmacol, Tongji Med Coll, Wuhan 430030, Peoples R China; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A1, Canada; Chinese Acad Sci, Lab Learning & Memory, Kunming Inst Zool, Kunming 650223, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Huazhong University of Science & Technology; University of Toronto; Chinese Academy of Sciences; Kunming Institute of Zoology	Xu, TL (corresponding author), Chinese Acad Sci, Inst Neurosci, Shanghai Inst Biol Sci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	tlxu@ion.ac.cn	Mei, Yide/M-4468-2013; Wu, Long-Jun/E-2684-2012; Xu, Lin/T-5531-2017; Wu, Long-Jun/AAK-7113-2020; Zhuo, Min/A-2072-2008	Xu, Lin/0000-0002-2710-3507; Wu, Long-Jun/0000-0001-8019-3380; Zhuo, Min/0000-0001-9062-3241; Wu, Mian/0000-0002-2714-0500				AKAIKE N, 1990, J NEUROPHYSIOL, V63, P805, DOI 10.1152/jn.1990.63.4.805; Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; Askwith CC, 2004, J BIOL CHEM, V279, P18296, DOI 10.1074/jbc.M312145200; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Biagini G, 2001, NEUROBIOL DIS, V8, P45, DOI 10.1006/nbdi.2000.0331; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; CHVATAL A, 1988, PHYSIOL BOHEMOSLOV, V37, P203; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; Ettaiche M, 2004, J NEUROSCI, V24, P1005, DOI 10.1523/JNEUROSCI.4698-03.2004; Grunder S, 2000, NEUROREPORT, V11, P1607; Hesselager M, 2004, J BIOL CHEM, V279, P11006, DOI 10.1074/jbc.M313507200; Immke DC, 2003, NEURON, V37, P75, DOI 10.1016/S0896-6273(02)01130-3; Johnson MB, 2001, J CEREBR BLOOD F MET, V21, P734, DOI 10.1097/00004647-200106000-00011; Li YF, 2003, J PHYSIOL-LONDON, V552, P73, DOI 10.1113/jphysiol.2003.047324; Li YX, 1997, DEV BRAIN RES, V102, P261, DOI 10.1016/S0165-3806(97)00102-8; Lin WH, 2002, J NEUROPHYSIOL, V88, P133, DOI 10.1152/jn.2002.88.1.133; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Mamet J, 2002, J NEUROSCI, V22, P10662; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; RANDIC M, 1993, J NEUROSCI, V13, P5228, DOI 10.1523/JNEUROSCI.13-12-05228.1993; Reeh P W, 2001, Curr Opin Pharmacol, V1, P45, DOI 10.1016/S1471-4892(01)00014-5; Reeh PW, 1996, PROG BRAIN RES, V113, P143, DOI 10.1016/S0079-6123(08)61085-7; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; Ugawa S, 2003, J NEUROSCI, V23, P3616; Varming T, 1999, NEUROPHARMACOLOGY, V38, P1875, DOI 10.1016/S0028-3908(99)00079-9; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Woolf CJ, 1999, P NATL ACAD SCI USA, V96, P7723, DOI 10.1073/pnas.96.14.7723; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; Wu LJ, 2001, J NEUROSCI METH, V108, P199, DOI 10.1016/S0165-0270(01)00404-6; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100; Zhuo M, 2002, DRUG DISCOV TODAY, V7, P259, DOI 10.1016/S1359-6446(01)02138-9	47	141	149	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43716	43724		10.1074/jbc.M403557200	http://dx.doi.org/10.1074/jbc.M403557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15302881	hybrid			2022-12-27	WOS:000224383100046
J	Bederman, IR; Reszko, AE; Kasumov, T; David, F; Wasserman, DH; Kelleher, JK; Brunengraber, H				Bederman, IR; Reszko, AE; Kasumov, T; David, F; Wasserman, DH; Kelleher, JK; Brunengraber, H			Zonation of labeling of lipogenic acetyl-CoA across the liver - Implications for studies of lipogenesis by mass isotopomer analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; FATTY-ACID; GLYCEROL PRODUCTION; ZONAL DISTRIBUTION; IN-VIVO; METABOLISM; GLUCONEOGENESIS; SPECTROMETRY; GLUCOKINASE; CHOLESTEROL	Measurement of fractional lipogenesis by condensation polymerization methods assumes constant enrichment of lipogenic acetyl-CoA in all hepatocytes. mass isotopomer distribution analysis (MIDA) and isotopomer spectral analysis (ISA) represent such methods and are based on the combinatorial analyses of mass isotopomer distributions (MIDs) of fatty acids and sterols. We previously showed that the concentration and enrichment of [C-13]acetate decrease markedly across the dog liver because of the simultaneous uptake and production of acetate. To test for zonation of the enrichment of lipogenic acetyl-CoA, conscious dogs, prefitted with transhepatic catheters, were infused with glucose and [1,2-C-13(2)]acetate in a branch of the portal vein. Analyses of MIDs of fatty acids and sterols isolated from liver, bile, and plasma very low density lipoprotein by a variant of ISA designed to detect gradients in precursor enrichment revealed marked zonation of enrichment of lipogenic acetyl-CoA. As control experiments where no zonation of acetyl-CoA enrichment would be expected, isolated rat livers were perfused with 10 mM [1,2-C-13(2)] acetate. The ISA analyses of MIDs of fatty acids and sterols from liver and bile still revealed a zonation of acetyl-CoA enrichment. We conclude that zonation of hepatic acetyl-CoA enrichment occurs under a variety of animal models and physiological conditions. Failure to consider gradients of precursor enrichment can lead to underestimations of fractional lipogenesis calculated from the mass isotopomer distributions. The degree of such underestimation was modeled in vitro, and the data are reported in the companion paper (Bederman, I. R., Kasumov, T., Reszko, A. E., David, F., Brunengraber, H., and Kelleher, J. K. (2004) J. Biol. Chem. 279, 43217- 43226).	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; MIT, Dept Chem Engn, Cambridge, MA 01239 USA	Case Western Reserve University; Case Western Reserve University; Vanderbilt University; Massachusetts Institute of Technology (MIT)	Brunengraber, H (corresponding author), Case Western Reserve Univ, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.	hxb8@cwru.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07319, DK35543] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bederman IR, 2004, J BIOL CHEM, V279, P43217, DOI 10.1074/jbc.M403837200; BRUNENGRABER H, 1981, J LIPID RES, V22, P916; Brunengraber H, 1997, ANNU REV NUTR, V17, P559, DOI 10.1146/annurev.nutr.17.1.559; BRUNENGRABER H, 1973, J BIOL CHEM, V248, P2656; Chinkes DL, 1996, AM J PHYSIOL-ENDOC M, V271, pE373, DOI 10.1152/ajpendo.1996.271.2.E373; CRABTREE B, 1990, BIOCHEM J, V270, P219, DOI 10.1042/bj2700219; FISCHER W, 1982, H-S Z PHYSIOL CHEM, V363, P375, DOI 10.1515/bchm2.1982.363.1.375; Glantz S., 1990, PRIMER APPL REGRESSI; GUZMAN M, 1989, BIOCHEM J, V264, P107, DOI 10.1042/bj2640107; Hellerstein MK, 1999, AM J PHYSIOL-ENDOC M, V276, pE1146, DOI 10.1152/ajpendo.1999.276.6.E1146; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; HELLERSTEIN MK, 1991, AM J PHYSIOL, V261, pE479, DOI 10.1152/ajpendo.1991.261.4.E479; Irtun O, 2001, METABOLISM, V50, P189, DOI 10.1053/meta.2001.20167; Jungermann K, 1996, ANNU REV NUTR, V16, P179, DOI 10.1146/annurev.nu.16.070196.001143; JUNGERMANN K, 1986, ENZYME, V35, P161, DOI 10.1159/000469338; KATZ N, 1989, EUR J BIOCHEM, V180, P185, DOI 10.1111/j.1432-1033.1989.tb14631.x; KATZ N, 1977, FEBS LETT, V83, P272, DOI 10.1016/0014-5793(77)81021-1; KATZ NR, 1983, EUR J BIOCHEM, V130, P297, DOI 10.1111/j.1432-1033.1983.tb07151.x; KATZ NR, 1983, EUR J BIOCHEM, V135, P103, DOI 10.1111/j.1432-1033.1983.tb07623.x; KELLEHER JK, 1994, AM J PHYSIOL, V266, pE384, DOI 10.1152/ajpendo.1994.266.3.E384; KELLEHER JK, 1992, AM J PHYSIOL, V262, pE118, DOI 10.1152/ajpendo.1992.262.1.E118; KELLER U, 1978, AM J PHYSIOL, V235, pE238, DOI 10.1152/ajpendo.1978.235.2.E238; KNUDSEN CT, 1992, EUR J BIOCHEM, V204, P359, DOI 10.1111/j.1432-1033.1992.tb16644.x; LANDAU BR, 1995, AM J PHYSIOL-ENDOC M, V269, pE18, DOI 10.1152/ajpendo.1995.269.1.E18; Landau BR, 1996, AM J PHYSIOL-ENDOC M, V271, pE1110, DOI 10.1152/ajpendo.1996.271.6.E1110; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; MATTHEWS DE, 1976, ANAL CHEM, V48, P1375, DOI 10.1021/ac50003a028; MIETHKE H, 1985, BIOL CHEM H-S, V366, P493, DOI 10.1515/bchm3.1985.366.1.493; Mittendorfer B, 1998, AM J PHYSIOL-ENDOC M, V274, pE978, DOI 10.1152/ajpendo.1998.274.6.E978; Ostlund RE, 1996, J MASS SPECTROM, V31, P1291, DOI 10.1002/(SICI)1096-9888(199611)31:11<1291::AID-JMS424>3.0.CO;2-5; POWERS L, 1995, J MASS SPECTROM, V30, P747, DOI 10.1002/jms.1190300514; PRASS RL, 1980, J BIOL CHEM, V255, P5215; PREVIS SF, 1995, J BIOL CHEM, V270, P19806, DOI 10.1074/jbc.270.34.19806; Previs SF, 1996, AM J PHYSIOL-ENDOC M, V271, pE1118, DOI 10.1152/ajpendo.1996.271.6.E1118; Previs SF, 1999, AM J PHYSIOL-ENDOC M, V277, pE154, DOI 10.1152/ajpendo.1999.277.1.E154; Puchowicz MA, 1999, AM J PHYSIOL-ENDOC M, V277, pE1022, DOI 10.1152/ajpendo.1999.277.6.E1022; ROBINS SJ, 1982, J LIPID RES, V23, P604; TRUS M, 1980, J HISTOCHEM CYTOCHEM, V28, P579, DOI 10.1177/28.6.7391551; Yang DW, 2000, AM J PHYSIOL-ENDOC M, V278, pE469, DOI 10.1152/ajpendo.2000.278.3.E469; Yang DW, 1996, AM J PHYSIOL-ENDOC M, V270, pE882, DOI 10.1152/ajpendo.1996.270.5.E882	40	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43207	43216		10.1074/jbc.M403838200	http://dx.doi.org/10.1074/jbc.M403838200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15284242	hybrid			2022-12-27	WOS:000224226400105
J	Parathath, S; Connelly, MA; Rieger, RA; Klein, SM; Abumrad, NA; de la Llera-Moya, M; Iden, CR; Rothblat, GH; Williams, DL				Parathath, S; Connelly, MA; Rieger, RA; Klein, SM; Abumrad, NA; de la Llera-Moya, M; Iden, CR; Rothblat, GH; Williams, DL			Changes in plasma membrane properties and phosphatidylcholine subspecies of insect Sf9 cells due to expression of scavenger receptor class B, type I, and CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; MICROVILLAR CHANNEL FORMATION; CELLULAR CHOLESTEROL EFFLUX; ESTER SELECTIVE UPTAKE; APOPROTEIN-A-I; SR-BI; SPODOPTERA-FRUGIPERDA; ADRENOCORTICAL-CELLS; CATALYZED OXIDATION; GRANULOSA-CELLS	In mammalian cells scavenger receptor class B, type I (SR-BI), mediates the selective uptake of high density lipoprotein (HDL) cholesteryl ester into hepatic and steroidogenic cells. In addition, SR-BI has a variety of effects on plasma membrane properties including stimulation of the bidirectional flux of free cholesterol (FC) between cells and HDL and changes in the organization of plasma membrane FC as indicated by increased susceptibility to exogenous cholesterol oxidase. Recent studies in SR-BI-deficient mice and in SR-BI-expressing Sf9 insect cells showed that SR-BI has significant effects on plasma membrane ultrastructure. The present study was designed to test the range of SR-BI effects in Sf9 insect cells that typically have very low cholesterol content and a different phospholipid profile compared with mammalian cells. The results showed that, as in mammalian cells, SR-BI expression increased HDL cholesteryl ester selective uptake, cellular cholesterol mass, FC efflux to HDL, and the sensitivity of membrane FC to cholesterol oxidase. These activities were diminished or absent upon expression of the related scavenger receptor CD36. Thus, SR-BI has fundamental effects on cholesterol flux and membrane properties that occur in cells of evolutionarily divergent origins. Profiling of phospholipid species by electrospray ionization mass spectrometry showed that scavenger receptor expression led to the accumulation of phosphatidylcholine species with longer mono- or polyunsaturated acyl chains. These changes would be expected to decrease phosphatidylcholine/cholesterol interactions and thereby enhance cholesterol desorption from the membrane. Scavenger receptor-mediated changes in membrane phosphatidylcholine may contribute to the increased flux of cholesterol and other lipids elicited by these receptors.	SUNY Stony Brook, Dept Pharmacol Sci, Univ Med Ctr, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Univ Med Ctr, Stony Brook, NY 11794 USA; Childrens Hosp Philadelphia, Dept Pediat, Div Gastroenterol & Nutr, Philadelphia, PA 19104 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Parathath, S (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Univ Med Ctr, Stony Brook, NY 11794 USA.	parathath@pharm.sunysb.edu	Parathath, Saj/ABE-2183-2021	Parathath, Sajesh/0000-0003-3431-297X	NHLBI NIH HHS [HL22633, HL58012, HL63768] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058012, R01HL063768, P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Ahn KW, 2004, BIOCHEMISTRY-US, V43, P827, DOI 10.1021/bi035697q; Azhar S, 1998, J CLIN ENDOCR METAB, V83, P983, DOI 10.1210/jc.83.3.983; AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; Briand O, 2003, BBA-MOL CELL BIOL L, V1631, P42, DOI 10.1016/S1388-1981(02)00354-2; Brinkmann JFF, 2002, BIOCHEM J, V367, P561, DOI 10.1042/BJ20020747; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; Connelly MA, 2003, J LIPID RES, V44, P331, DOI 10.1194/jlr.M200186-JLR200; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; Connelly MA, 2001, BIOCHEMISTRY-US, V40, P5249, DOI 10.1021/bi002825r; Covey SD, 2003, ARTERIOSCL THROM VAS, V23, P1589, DOI 10.1161/01.ATV.0000083343.19940.A0; DANIELS C, 1985, BIOCHEMISTRY-US, V24, P3286, DOI 10.1021/bi00334a032; de la Llera-Moya M, 2001, J LIPID RES, V42, P1969; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; Francone OL, 1997, J LIPID RES, V38, P813; FUGLER L, 1985, J BIOL CHEM, V260, P4098; Gerbal M, 2000, IN VITRO CELL DEV-AN, V36, P117, DOI 10.1290/1071-2690(2000)036<0117:AOAICL>2.0.CO;2; GIMPL G, 1995, BIOCHEMISTRY-US, V34, P13794, DOI 10.1021/bi00042a010; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDBERG DI, 1991, J CLIN INVEST, V87, P331, DOI 10.1172/JCI114991; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GRONBERG L, 1990, BIOCHEMISTRY-US, V29, P3173, DOI 10.1021/bi00465a003; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; GWYNNE JT, 1980, J BIOL CHEM, V255, P875; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marheineke K, 1998, FEBS LETT, V441, P49, DOI 10.1016/S0014-5793(98)01523-3; MATTJUS P, 1994, CHEM PHYS LIPIDS, V71, P73, DOI 10.1016/0009-3084(94)02306-9; MATTJUS P, 1994, CHEM PHYS LIPIDS, V74, P195, DOI 10.1016/0009-3084(94)90060-4; MCLEAN LR, 1982, BIOCHEMISTRY-US, V21, P4053, DOI 10.1021/bi00260a022; MILLER GJ, 1975, LANCET, V1, P16; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Patel SN, 2004, J INFECT DIS, V189, P204, DOI 10.1086/380764; Peng Y, 2004, MOL BIOL CELL, V15, P384, DOI 10.1091/mbc.e03-06-0445; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Ramstedt B, 1999, BIOPHYS J, V76, P908, DOI 10.1016/S0006-3495(99)77254-1; REAVEN E, 1989, J LIPID RES, V30, P1551; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; Reaven E, 2001, P NATL ACAD SCI USA, V98, P1613, DOI 10.1073/pnas.98.4.1613; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; RINNINGER F, 1988, J LIPID RES, V29, P1179; Rothblat GH, 1999, J LIPID RES, V40, P781; Silver DL, 2001, CURR OPIN LIPIDOL, V12, P497, DOI 10.1097/00041433-200110000-00004; Slotte JP, 1999, CHEM PHYS LIPIDS, V102, P13, DOI 10.1016/S0009-3084(99)00071-7; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Thomas RM, 2002, BIOCHEMISTRY-US, V41, P1591, DOI 10.1021/bi011555p; Van Eck M, 2003, J BIOL CHEM, V278, P23699, DOI 10.1074/jbc.M211233200; VOELKER DR, 2002, BIOCH LIPIDS LIPOPRO, P449; Williams DL, 2002, J LIPID RES, V43, P544; Williams DL, 1999, CURR OPIN LIPIDOL, V10, P329, DOI 10.1097/00041433-199908000-00007; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986; Zhang FL, 1996, BIOCHEMISTRY-US, V35, P16055, DOI 10.1021/bi961685b; Zhang WW, 2003, CIRCULATION, V108, P2258, DOI 10.1161/01.CIR.0000093189.97429.9D	67	39	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41310	41318		10.1074/jbc.M404952200	http://dx.doi.org/10.1074/jbc.M404952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280390	hybrid			2022-12-27	WOS:000224075500010
J	Hayashi, K; Shibata, K; Morita, T; Iwasaki, K; Watanabe, M; Sobue, K				Hayashi, K; Shibata, K; Morita, T; Iwasaki, K; Watanabe, M; Sobue, K			Insulin receptor substrate-1/SHP-2 interaction, a phenotype-dependent switching machinery of insulin-like growth factor-I signaling in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INTEGRIN-ASSOCIATED PROTEIN; TYROSINE-PHOSPHATASE SHP-2; RAS ACTIVATION; FACTOR-BB; PATHWAYS; PROLIFERATION; DIFFERENTIATION; INVOLVEMENT; EXPRESSION	Insulin-like growth factor-I (IGF-I) plays a role in mutually exclusive processes such as proliferation and differentiation in a variety of cell types. IGF-I is a potent mitogen and motogen for dedifferentiated vascular smooth muscle cells (VSMCs) in vivo and in vitro. However, in differentiated VSMCs, IGF-I is only required for maintaining the differentiated phenotype. Here we investigated the VSMC phenotype-dependent signaling and biological processes triggered by IGF-I. In differentiated VSMCs, IGF-I activated a protein-tyrosine phosphatase, SHP-2, recruited by insulin receptor substrate-1 (IRS-1). The activated SHP-2 then dephosphorylated IRS-1 Tyr(P)-895, resulting in blockade of the pathways from IRS-1/Grb2/Sos to the ERK and p38 MAPK. Conversely, such negative regulation was silent in dedifferentiated VSMCs, where IGF-I activated both MAPKs via IRS-1/Grb2/Sos interaction-linked Ras activation, leading to proliferation and migration. Thus, our present results demonstrate that the IRS-1/SHP-2 interaction acts as a switch controlling VSMC phenotype-dependent IGF-I-induced signaling pathways and biological processes, and this mechanism is likely to be applicable to other cells.	Osaka Univ, Grad Sch Med, Dept Neurosci D13, Suita, Osaka 5650871, Japan	Osaka University	Sobue, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Neurosci D13, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	sobue@nbiochem.med.osaka-u.ac.jp						Avena R, 1999, AM J SURG, V178, P156, DOI 10.1016/S0002-9610(99)00150-6; Bayes-Genis A, 2000, CIRC RES, V86, P125, DOI 10.1161/01.RES.86.2.125; Boney CM, 1998, ENDOCRINOLOGY, V139, P1638, DOI 10.1210/en.139.4.1638; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; CASE RD, 1994, J BIOL CHEM, V269, P10467; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Chen Y, 1998, GROWTH HORM IGF RES, V8, P299, DOI 10.1016/S1096-6374(98)80125-1; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; DU J, 1995, CIRC RES, V76, P963, DOI 10.1161/01.RES.76.6.963; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hayashi K, 1998, J BIOL CHEM, V273, P28860, DOI 10.1074/jbc.273.44.28860; Hayashi K, 2001, CIRC RES, V89, P251, DOI 10.1161/hh1501.094265; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; Huang QH, 2002, J BIOL CHEM, V277, P29330, DOI 10.1074/jbc.M112450200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Maile LA, 2003, CIRC RES, V93, P925, DOI 10.1161/01.RES.0000101754.33652.B7; Maile LA, 2002, J BIOL CHEM, V277, P8955, DOI 10.1074/jbc.M109258200; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Pukac L, 1998, EXP CELL RES, V242, P548, DOI 10.1006/excr.1998.4138; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sajid M, 2001, J INVEST MED, V49, P398, DOI 10.2310/6650.2001.33784; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SIMONS M, 1995, AM J PHYSIOL-CELL PH, V268, pC856, DOI 10.1152/ajpcell.1995.268.4.C856; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; Takahashi M, 2003, CIRCULATION, V108, P2524, DOI 10.1161/01.CIR.0000096482.02567.8C; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Ward CW, 1996, J BIOL CHEM, V271, P5603, DOI 10.1074/jbc.271.10.5603; XIAO S, 1994, J BIOL CHEM, V269, P21244; Yeh LCC, 1997, ENDOCRINOLOGY, V138, P4181, DOI 10.1210/en.138.10.4181; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Yoshida K, 2003, CIRCULATION, V108, P1746, DOI 10.1161/01.CIR.0000089374.35455.F3; Zhu BH, 2001, ENDOCRINOLOGY, V142, P3598, DOI 10.1210/en.142.8.3598; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	42	58	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40807	40818		10.1074/jbc.M405100200	http://dx.doi.org/10.1074/jbc.M405100200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15272025	hybrid			2022-12-27	WOS:000223916800075
J	Yamaguchi, T; Wallace, DP; Magenheimer, BS; Hempson, SJ; Grantham, JJ; Calvet, JP				Yamaguchi, T; Wallace, DP; Magenheimer, BS; Hempson, SJ; Grantham, JJ; Calvet, JP			Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CAPACITATIVE CA2+ ENTRY; CYST EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; NEGATIVE REGULATION; ADENYLYL CYCLASES; CYCLIC-AMP; PROLIFERATION; POLYCYSTIN-1; CHANNEL	cAMP can be either mitogenic or anti-mitogenic, depending on the cell type. We demonstrated previously that cAMP inhibited the proliferation of normal renal epithelial cells and stimulated the proliferation of cells derived from the cysts of polycystic kidney disease (PKD) patients. The protein products of the genes causing PKD, polycystin-1 and polycystin-2, are thought to regulate intracellular calcium levels, suggesting that abnormal polycystin function may affect calcium signaling and thus cause a switch to the cAMP growth-stimulated phenotype. To test this hypothesis, we disrupted intracellular calcium mobilization by treating immortalized mouse M-1 collecting duct cells and primary cultures of human kidney epithelial cells with calcium channel blockers and by lowering extracellular calcium with EGTA. Calcium restriction for 3 - 5 h converted both cell types from a normal cAMP growth-inhibited phenotype to an abnormal cAMP growth-stimulated phenotype, characteristic of PKD. In M-1 cells, we showed that calcium restriction was associated with an elevation in B-Raf protein levels and cAMP-stimulated, Ras-dependent activation of B-Raf and ERK. Moreover, the activity of Akt, a negative regulator of B-Raf, was decreased by calcium restriction. Inhibition of Akt or phosphatidylinositol 3-kinase also allowed cAMP-dependent activation of B-Raf and ERK in normal calcium. These results suggest that calcium restriction causes an inhibition of the phosphatidylinositol 3-kinase/Akt pathway, which relieves the inhibition of B-Raf to allow the cAMP growth-stimulated phenotypic switch. Finally, M-1 cells stably overexpressing an inducible polycystin-1 C-terminal cytosolic tail construct were shown to exhibit a cAMP growth-stimulated phenotype involving B-Raf and ERK activation, which was reversed by the calcium ionophore A23187. We conclude that disruption of calcium mobilization in cells that are normally growth-inhibited by cAMP can derepress the B-Raf/ERK pathway, thus converting these cells to a phenotype that is growth-stimulated by cAMP.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Calvet, JP (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, MS3030, Kansas City, KS 66160 USA.	jcalvet@kumc.edu		Wallace, Darren/0000-0003-4616-7669	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK057301, P01DK053763, R21DK064756] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK064756, DK57301, DK53763] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abernethy DR, 1999, NEW ENGL J MED, V341, P1447, DOI 10.1056/NEJM199911043411907; Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Anderson KA, 1998, BIOMETALS, V11, P331, DOI 10.1023/A:1009276932076; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; Blanc A, 2004, ANTIOXID REDOX SIGN, V6, P353, DOI 10.1089/152308604322899422; Boletta Alessandra, 2001, Journal of the American Society of Nephrology, V12, p531A; Brose MS, 2002, CANCER RES, V62, P6997; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Calvet JP, 2001, SEMIN NEPHROL, V21, P107, DOI 10.1053/snep.2001.20929; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; Chabardes D, 1999, CELL SIGNAL, V11, P651, DOI 10.1016/S0898-6568(99)00031-5; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; Chodniewicz D, 2003, BLOOD, V101, P1181, DOI 10.1182/blood-2002-05-1435; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Cruzalegui FH, 2000, CELL MOL LIFE SCI, V57, P402, DOI 10.1007/PL00000702; Cruzalegui FH, 1999, EMBO J, V18, P1335, DOI 10.1093/emboj/18.5.1335; Danciu TE, 2003, FEBS LETT, V536, P193, DOI 10.1016/S0014-5793(03)00055-3; Delmas P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/jbc.M110483200; Delmas P, 2004, FASEB J, V18, P740, DOI 10.1096/fj.03-0319fje; Dousa TP, 1999, KIDNEY INT, V55, P29, DOI 10.1046/j.1523-1755.1999.00233.x; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; Gattone VH, 2003, NAT MED, V9, P1323, DOI 10.1038/nm935; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Guan KL, 2000, J BIOL CHEM, V275, P27354; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Hanaoka K, 2000, J AM SOC NEPHROL, V11, P1179, DOI 10.1681/ASN.V1171179; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hardingham GE, 1998, BIOMETALS, V11, P345, DOI 10.1023/A:1009257909785; Hoffman S, 1998, EXP EYE RES, V67, P45, DOI 10.1006/exer.1998.0491; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Ichikawa J, 2001, CELL BIOCHEM FUNCT, V19, P213, DOI 10.1002/cbf.914; Igarashi P, 2002, J AM SOC NEPHROL, V13, P2384, DOI 10.1097/01.ASN.0000028643.17901.42; Ikeda M, 2002, CURR OPIN NEPHROL HY, V11, P539, DOI 10.1097/00041552-200209000-00010; Johnson CM, 1997, J NEUROSCI, V17, P6189; Kizer JR, 2001, ARCH INTERN MED, V161, P1145, DOI 10.1001/archinte.161.9.1145; Klinger M, 2002, J BIOL CHEM, V277, P32490, DOI 10.1074/jbc.M200556200; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Maier LS, 2002, J MOL CELL CARDIOL, V34, P919, DOI 10.1006/jmcc.2002.2038; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Mosior M, 1997, MOL MEMBR BIOL, V14, P65, DOI 10.3109/09687689709068436; Munaron L, 2002, INT J MOL MED, V10, P671; Ono T, 2002, AM J NEPHROL, V22, P581, DOI 10.1159/000065266; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; Perez-Garcia MJ, 2004, J BIOL CHEM, V279, P6132, DOI 10.1074/jbc.M308367200; Perkinton MS, 2002, J NEUROCHEM, V80, P239, DOI 10.1046/j.0022-3042.2001.00699.x; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Sallese M, 2000, BBA-MOL CELL RES, V1498, P112, DOI 10.1016/S0167-4889(00)00088-4; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schaefer A, 1998, BIOCHEM J, V335, P505, DOI 10.1042/bj3350505; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Smith-Thomas L, 1998, CURR EYE RES, V17, P813, DOI 10.1080/02713689808951263; Somlo S, 2001, CURR BIOL, V11, pR356, DOI 10.1016/S0960-9822(01)00193-2; Spitzer NC, 2000, BIOESSAYS, V22, P811; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Sullivan LP, 1998, PHYSIOL REV, V78, P1165, DOI 10.1152/physrev.1998.78.4.1165; Sutters M, 2001, KIDNEY INT, V60, P484, DOI 10.1046/j.1523-1755.2001.060002484.x; Sutton G, 2002, J NEUROCHEM, V82, P1097, DOI 10.1046/j.1471-4159.2002.01031.x; Tang XW, 2002, J BIOL CHEM, V277, P338, DOI 10.1074/jbc.M108927200; Torres VE, 2004, NAT MED, V10, P363, DOI 10.1038/nm1004; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xu GM, 2003, J BIOL CHEM, V278, P1457, DOI 10.1074/jbc.M209996200; Yamaguchi T, 2003, KIDNEY INT, V63, P1983, DOI 10.1046/j.1523-1755.2003.00023.x; Yamaguchi T, 2000, KIDNEY INT, V57, P1460, DOI 10.1046/j.1523-1755.2000.00991.x; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200; Zhang MIN, 1996, J MEMBRANE BIOL, V154, P259, DOI 10.1007/s002329900150; Zhang R, 2003, J BIOL CHEM, V278, P51267, DOI 10.1074/jbc.M310678200; Zhao PL, 2002, KIDNEY INT, V61, P1393, DOI 10.1046/j.1523-1755.2002.00267.x	76	258	272	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40419	40430		10.1074/jbc.M405079200	http://dx.doi.org/10.1074/jbc.M405079200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15263001	hybrid			2022-12-27	WOS:000223916800027
J	Cezanne, L; Lecat, S; Lagane, B; Millot, C; Vollmer, JY; Matthes, H; Galzi, JL; Lopez, A				Cezanne, L; Lecat, S; Lagane, B; Millot, C; Vollmer, JY; Matthes, H; Galzi, JL; Lopez, A			Dynamic confinement of NK2 receptors in the plasma membrane - Improved frap analysis and biological relevance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SINGLE-PARTICLE TRACKING; CLATHRIN-COATED PITS; LIPID LATERAL DIFFUSION; HAMSTER OVARY CELLS; SUBSTANCE-P; INDUCED INTERNALIZATION; NEUROKININ RECEPTORS; MEDIATED ENDOCYTOSIS; PHASE ENDOCYTOSIS	A functional fluorescent neurokinin NK2 receptor, EGFP-NK2, was previously used to follow, by fluorescence resonance energy transfer measurements in living cells, the binding of its fluorescently labeled agonist, bodipy-neurokinin A (NKA). Local agonist application suggested that the activation and desensitization of the NK2 receptors were compartmentalized at the level of the plasma membrane. In this study, fluorescence recovery after photobleaching experiments are carried out at variable observation radius (vrFRAP) to probe EGFP-NK2 receptor mobility and confinement. Experiments are carried out at 20 degreesC to maintain the number of receptors constant at the cell surface during recordings. In the absence of agonist, 35% EGFP-NK2 receptors diffuse within domains of 420 +/- 80 nm in radius with the remaining 65% of receptors able to diffuse with a long range lateral diffusion coefficient between the domains. When cells are incubated with a saturating concentration of NKA, 30% EGFP-NK2 receptors become immobilized in small domains characterized by a radius equal to 170 +/- 50 nm. Biochemical experiments show that the confinement of EGFP-NK2 receptor is not due to its association with rafts at any given time. Colocalization of the receptor with beta-arrestin and transferrin supports that the small domains, containing 30% of activated EGFP-NK2, correspond to clathrin-coated pre-pits. The similar amount of confined EGFP-NK2 receptors found before and after activation ( 30 - 35%) is discussed in term of putative transient interactions of the receptors with preexisting scaffolds of signaling molecules.	IPBS, CNRS, F-31062 Toulouse, France; Ecole Super Biotechnol Strasbourg, CNRS, UPR9050, F-67400 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Cezanne, L (corresponding author), IPBS, CNRS, 205 Route Narbonne, F-31062 Toulouse, France.	laurence.cezanne@ipbs.fr	Lagane, Bernard/AAA-2205-2019; Lagane, Bernard/K-8446-2016	Lagane, Bernard/0000-0002-3459-7867; 				Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Chidiac P, 1998, BIOCHEM PHARMACOL, V55, P549, DOI 10.1016/S0006-2952(97)00361-4; Choquet D, 2003, NAT REV NEUROSCI, V4, P251, DOI 10.1038/nrn1077; CUPERS P, 1994, J CELL BIOL, V127, P725, DOI 10.1083/jcb.127.3.725; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; Daumas F, 2003, BIOPHYS J, V84, P356, DOI 10.1016/S0006-3495(03)74856-5; DUPOU L, 1988, EUR J BIOCHEM, V171, P669, DOI 10.1111/j.1432-1033.1988.tb13838.x; EDIDIN M, 1991, J CELL BIOL, V112, P1143, DOI 10.1083/jcb.112.6.1143; Edidin M, 1997, CURR OPIN STRUC BIOL, V7, P528, DOI 10.1016/S0959-440X(97)80117-0; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Garland AM, 1996, MOL PHARMACOL, V49, P438; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; Ge MT, 1999, BIOPHYS J, V77, P925, DOI 10.1016/S0006-3495(99)76943-2; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; Gurevich VV, 2003, STRUCTURE, V11, P1037, DOI 10.1016/S0969-2126(03)00184-9; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Horvat RD, 2001, MOL ENDOCRINOL, V15, P534, DOI 10.1210/me.15.4.534; Horvat RD, 2001, MOL ENDOCRINOL, V15, P695, DOI 10.1210/me.15.5.695; Horvat RD, 1999, BIOCHEM BIOPH RES CO, V255, P382, DOI 10.1006/bbrc.1999.0185; JOHANSSON B, 1993, J CELL BIOL, V121, P1281, DOI 10.1083/jcb.121.6.1281; Kajino S, 2000, ONCOGENE, V19, P2233, DOI 10.1038/sj.onc.1203560; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Lecat S, 2000, J CELL SCI, V113, P2607; Lecat S, 2002, J BIOL CHEM, V277, P42034, DOI 10.1074/jbc.M203606200; LOPEZ A, 1988, BIOPHYS J, V53, P963, DOI 10.1016/S0006-3495(88)83177-1; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000; Nelson S, 1999, ENDOCRINOLOGY, V140, P950, DOI 10.1210/en.140.2.950; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Palanche T, 2001, J BIOL CHEM, V276, P34853, DOI 10.1074/jbc.M104363200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pearse BMF, 2000, CURR OPIN STRUC BIOL, V10, P220, DOI 10.1016/S0959-440X(00)00071-3; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Rappoport JZ, 2003, TRAFFIC, V4, P460, DOI 10.1034/j.1600-0854.2003.00100.x; Rappoport JZ, 2003, J CELL SCI, V116, P847, DOI 10.1242/jcs.00289; Rappoport JZ, 2003, J BIOL CHEM, V278, P47357, DOI 10.1074/jbc.C300390200; Roettger BF, 1999, AM J PHYSIOL-CELL PH, V276, pC539, DOI 10.1152/ajpcell.1999.276.3.C539; SAKO Y, 1994, J CELL BIOL, V125, P1251, DOI 10.1083/jcb.125.6.1251; SAKO Y, 1995, J CELL BIOL, V129, P1559, DOI 10.1083/jcb.129.6.1559; Salome L, 1998, EUR BIOPHYS J BIOPHY, V27, P391, DOI 10.1007/s002490050146; Santini F, 2002, J CELL BIOL, V156, P665, DOI 10.1083/jcb.200110132; SAXTON MJ, 1990, BIOPHYS J, V57, P1167, DOI 10.1016/S0006-3495(90)82636-9; Saxton MJ, 1997, ANNU REV BIOPH BIOM, V26, P373, DOI 10.1146/annurev.biophys.26.1.373; Schmidlin F, 2002, P NATL ACAD SCI USA, V99, P3324, DOI 10.1073/pnas.052161299; SCHRAM V, 1994, EUR BIOPHYS J, V23, P337; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; Scott MGH, 2002, J BIOL CHEM, V277, P3552, DOI 10.1074/jbc.M106586200; Severini C, 2002, PHARMACOL REV, V54, P285, DOI 10.1124/pr.54.2.285; Sheets ED, 1997, BIOCHEMISTRY-US, V36, P12449, DOI 10.1021/bi9710939; SIMSON R, 1995, BIOPHYS J, V69, P989, DOI 10.1016/S0006-3495(95)79972-6; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smith PR, 1999, BIOPHYS J, V76, P3331, DOI 10.1016/S0006-3495(99)77486-2; STRUCK DK, 1980, J BIOL CHEM, V255, P5404; TOCANNE JF, 1994, PROG LIPID RES, V33, P203, DOI 10.1016/0163-7827(94)90027-2; TOCANNE JF, 1989, FEBS LETT, V257, P10, DOI 10.1016/0014-5793(89)81774-0; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Vergne I, 1999, EUR J BIOCHEM, V264, P369, DOI 10.1046/j.1432-1327.1999.00651.x; Vollmer JY, 1999, J BIOL CHEM, V274, P37915, DOI 10.1074/jbc.274.53.37915; YECHIEL E, 1987, J CELL BIOL, V105, P755, DOI 10.1083/jcb.105.2.755; Young SH, 2001, EXP CELL RES, V267, P37, DOI 10.1006/excr.2001.5245	70	40	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45057	45067		10.1074/jbc.M404811200	http://dx.doi.org/10.1074/jbc.M404811200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15294896	hybrid			2022-12-27	WOS:000224505600098
J	Benard, M; Gonzalez, BJ; Schouft, MT; Falluel-Morel, A; Vaudry, D; Chan, P; Vaudry, H; Fontaine, M				Benard, M; Gonzalez, BJ; Schouft, MT; Falluel-Morel, A; Vaudry, D; Chan, P; Vaudry, H; Fontaine, M			Characterization of C3a and C5a receptors in rat cerebellar granule neurons during maturation - Neuroprotective effect of C5a against apoptotic cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT ANAPHYLATOXIN C5A; GROWTH-FACTOR-I; ALZHEIMERS-DISEASE; EXPRESSION; ACTIVATION; SURVIVAL; POTASSIUM; NEURODEGENERATION; CLONING; BCL-2	There is now clear evidence that the Complement anaphylatoxin C3a and C5a receptors (C3aR and C5aR) are expressed in glial cells, notably in astrocytes and microglia. In contrast, very few data are available concerning the possible expression of these receptors in neurons. Here, we show that transient expression of C3aR and C5aR occurs in cerebellar granule neurons in vivo with a maximal density in 12-day-old rat, suggesting a role of these receptors during development of the cerebellum. Expression of C3aR and C5aR mRNAs and proteins was also observed in vitro in cultured cerebellar granule cells. Quantification of the mRNAs by real-time reverse transcription-PCR showed a peak of expression at day 2 in vitro (DIV 2); the C3aR and C5aR proteins were detected by Western blot analysis at DIV 4 and by flow cytometry and immunocytochemistry in differentiating neurons with a maximum density at DIV 4 - 9. Apoptosis of granule cells plays a crucial role for the harmonious development of the cerebellar cortex. We found that, in cultured granule neurons in which apoptosis was induced by serum deprivation and low potassium concentration, a C5aR agonist promoted cell survival and inhibited caspase-3 activation and DNA fragmentation. The neuroprotective effect of the C5aR agonist was associated with a marked inhibition of caspase-9 activity and partial restoration of mitochondrial integrity. Our results provide the first evidence that C3aR and C5aR are both expressed in cerebellar granule cells during development and that C5a, but not C3a, is a potent inhibitor of apoptotic cell death in cultured granule neurons.	Univ Rouen, INSERM, U519, European Inst Peptide Res IFRMP 23, F-76183 Rouen, France; Univ Rouen, INSERM, U413, F-76821 Mont St Aignan, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Benard, M (corresponding author), Univ Rouen, INSERM, U519, European Inst Peptide Res IFRMP 23, 22 Blvd Gambetta, F-76183 Rouen, France.	magalie.benard@univ-rouen.fr	VAUDRY, David/M-1454-2018; Gonzalez, Bruno/E-6103-2016	VAUDRY, David/0000-0003-3567-7452; Gonzalez, Bruno/0000-0002-7176-1320; Anthony, FALLUEL-MOREL/0000-0002-4081-6704				ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; Ames RS, 1996, J BIOL CHEM, V271, P20231, DOI 10.1074/jbc.271.34.20231; Armstrong RC, 1997, J NEUROSCI, V17, P553; BALAZS R, 1988, NEUROSCI LETT, V87, P80, DOI 10.1016/0304-3940(88)90149-8; BUHL AM, 1995, J BIOL CHEM, V270, P19828, DOI 10.1074/jbc.270.34.19828; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Crass T, 1996, EUR J IMMUNOL, V26, P1944, DOI 10.1002/eji.1830260840; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davoust N, 1999, GLIA, V26, P201, DOI 10.1002/(SICI)1098-1136(199905)26:3<201::AID-GLIA2>3.0.CO;2-M; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; Farkas I, 2003, J IMMUNOL, V170, P5764, DOI 10.4049/jimmunol.170.11.5764; Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; GALLI C, 1995, J NEUROSCI, V15, P1172; GALLO V, 1987, J NEUROSCI, V7, P2203; GASQUE P, 1993, J BIOL CHEM, V268, P25068; GASQUE P, 1995, J IMMUNOL, V155, P4882; Gasque P, 1997, AM J PATHOL, V150, P31; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD NP, 1989, J BIOL CHEM, V264, P1760; Gerhardt E, 2001, MOL CELL NEUROSCI, V17, P717, DOI 10.1006/mcne.2001.0962; Ginham R, 2001, NEUROSCI LETT, V302, P113, DOI 10.1016/S0304-3940(01)01687-1; Gleichmann M, 1998, CELL PHYSIOL BIOCHEM, V8, P194, DOI 10.1159/000016282; GONZALEZ B, 1992, P NATL ACAD SCI USA, V89, P9627, DOI 10.1073/pnas.89.20.9627; HAVILAND DL, 1995, J IMMUNOL, V154, P1861; Ischenko A, 1998, J NEUROCHEM, V71, P2487; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jauneau AC, 2003, FEBS LETT, V537, P17, DOI 10.1016/S0014-5793(03)00060-7; Karp CL, 2001, MICROBES INFECT, V3, P109, DOI 10.1016/S1286-4579(00)01358-7; LACY M, 1995, J NEUROIMMUNOL, V61, P71, DOI 10.1016/0165-5728(95)00075-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafon-Cazal M, 2002, EUR J NEUROSCI, V16, P575, DOI 10.1046/j.1460-9568.2002.02124.x; Linseman DA, 2002, J NEUROSCI, V22, P9287; Mastellos D, 2002, TRENDS IMMUNOL, V23, P485, DOI 10.1016/S1471-4906(02)02287-1; Miller TM, 1996, J NEUROSCI, V16, P7487; Monsinjon T, 2001, FEBS LETT, V487, P339, DOI 10.1016/S0014-5793(00)02320-6; Mukherjee P, 2001, J NEUROCHEM, V77, P43, DOI 10.1046/j.1471-4159.2001.00167.x; Mukherjee P, 2000, J NEUROIMMUNOL, V105, P124, DOI 10.1016/S0165-5728(99)00261-1; MullerLadner U, 1996, J NEUROL SCI, V144, P135, DOI 10.1016/S0022-510X(96)00217-1; Nataf S, 1998, J NEUROIMMUNOL, V91, P147, DOI 10.1016/S0165-5728(98)00169-6; NORGAUER J, 1993, EUR J BIOCHEM, V217, P289, DOI 10.1111/j.1432-1033.1993.tb18245.x; O'Barr SA, 2001, J IMMUNOL, V166, P4154, DOI 10.4049/jimmunol.166.6.4154; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; Osaka H, 1999, J CELL BIOCHEM, V73, P303, DOI 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.0.CO;2-2; Pasinetti GM, 1996, NEUROBIOL AGING, V17, P707, DOI 10.1016/0197-4580(96)00113-3; Perianayagam MC, 2002, KIDNEY INT, V61, P456, DOI 10.1046/j.1523-1755.2002.00139.x; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; ROLLINS TE, 1991, P NATL ACAD SCI USA, V88, P971, DOI 10.1073/pnas.88.3.971; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sayah S, 1999, J NEUROCHEM, V72, P2426, DOI 10.1046/j.1471-4159.1999.0722426.x; Sayah S, 1997, MOL BRAIN RES, V48, P215, DOI 10.1016/S0169-328X(97)00094-6; Shimoke K, 1999, DEV BRAIN RES, V112, P245, DOI 10.1016/S0165-3806(98)00172-2; Slagsvold HH, 2003, BRAIN RES, V984, P111, DOI 10.1016/S0006-8993(03)03119-6; Stahel PF, 1997, J IMMUNOL, V159, P861; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; Stark M, 2001, J CHROMATOGR B, V754, P357, DOI 10.1016/S0378-4347(00)00628-9; Thomas A, 2000, INT IMMUNOL, V12, P1015, DOI 10.1093/intimm/12.7.1015; van Beek J, 2001, NEUROREPORT, V12, P289, DOI 10.1097/00001756-200102120-00022; Van Beek J, 2000, EXP NEUROL, V161, P373, DOI 10.1006/exnr.1999.7273; Vaudry D, 2003, SCIENCE, V300, P1532, DOI 10.1126/science.1085260; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yasojima K, 1999, AM J PATHOL, V154, P927, DOI 10.1016/S0002-9440(10)65340-0; Zhong J, 2004, J NEUROSCI RES, V75, P794, DOI 10.1002/jnr.20024; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	71	79	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43487	43496		10.1074/jbc.M404124200	http://dx.doi.org/10.1074/jbc.M404124200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292245	hybrid			2022-12-27	WOS:000224383100018
J	Zaidi, SK; Young, DW; Choi, JY; Pratap, J; Javed, A; Montecino, M; Stein, JL; Lian, JB; van Wijnen, AJ; Stein, GS				Zaidi, SK; Young, DW; Choi, JY; Pratap, J; Javed, A; Montecino, M; Stein, JL; Lian, JB; van Wijnen, AJ; Stein, GS			Intranuclear trafficking: Organization and assembly of regulatory machinery for combinatorial biological control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MATRIX TARGETING SIGNAL; RNA-POLYMERASE-II; NUCLEAR-MATRIX; TRANSCRIPTION FACTORS; GLUCOCORTICOID-RECEPTOR; CHROMOSOME TERRITORIES; OSTEOCALCIN GENE; MITOTIC CHROMOSOMES; SUBNUCLEAR DOMAINS; REPLICATION SITES	The molecular logistics of nuclear regulatory processes necessitate temporal and spatial regulation of protein-protein and protein-DNA interactions in response to physiological cues. Biochemical, in situ, and in vivo genetic evidence demonstrates the requirement for intranuclear localization of regulatory complexes that functionally couple cellular responses to signals that mediate combinatorial control of gene expression. We have summarized evidence that subnuclear targeting of transcription factors mechanistically links gene expression with architectural organization and assembly of nuclear regulatory machinery for biological control. The compromised intranuclear targeting of regulatory proteins under pathological conditions provides options for the diagnosis and treatment of disease.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA; Univ Concepcion, Dept Mol Biol, Concepcion 4079100, Chile; Kyungpook Natl Univ, Dept Biochem, Sch Med, Taegu 700422, South Korea	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Universidad de Concepcion; Kyungpook National University	Stein, GS (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	gary.stein@umassmed.edu	Zaidi, Sayyed Kaleem/I-5596-2019; van Wijnen, Andre J./AAG-3578-2019	Zaidi, Sayyed Kaleem/0000-0001-6664-5168; van Wijnen, Andre J./0000-0002-4458-0946; Javed, Amjad/0000-0002-0847-8266	NATIONAL CANCER INSTITUTE [P01CA082834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR048818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA82834] Funding Source: Medline; NIAMS NIH HHS [P01 AR48818] Funding Source: Medline; NIDDK NIH HHS [5P30 DK32520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Barseguian K, 2002, P NATL ACAD SCI USA, V99, P15434, DOI 10.1073/pnas.242588499; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Berezney R, 1996, J CELL BIOCHEM, V62, P223, DOI 10.1002/(SICI)1097-4644(199608)62:2<223::AID-JCB10>3.3.CO;2-M; Berube NG, 2002, HUM MOL GENET, V11, P253, DOI 10.1093/hmg/11.3.253; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Casolari JM, 2004, CELL, V117, P427, DOI 10.1016/S0092-8674(04)00448-9; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Chen DY, 2002, MOL BIOL CELL, V13, P276, DOI 10.1091/mbc.01-10-0523; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; CIEJEK EM, 1983, NATURE, V306, P607, DOI 10.1038/306607a0; Clevers H, 2004, CANCER CELL, V5, P5, DOI 10.1016/S1535-6108(03)00339-8; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Davie JK, 2004, CURR TOP DEV BIOL, V59, P145, DOI 10.1016/S0070-2153(04)59006-3; DeFranco DB, 2002, MOL ENDOCRINOL, V16, P1449, DOI 10.1210/me.16.7.1449; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Ennas MG, 1997, CANCER RES, V57, P2035; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Francastel C, 2001, P NATL ACAD SCI USA, V98, P12120, DOI 10.1073/pnas.211444898; Gasser SM, 2002, SCIENCE, V296, P1412, DOI 10.1126/science.1067703; GebraneYounes J, 1997, J CELL SCI, V110, P2429; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; Harrington KS, 2002, J CELL SCI, V115, P4167, DOI 10.1242/jcs.00095; Hieronymus H, 2003, NAT GENET, V33, P155, DOI 10.1038/ng1080; HOZAK P, 1994, J CELL SCI, V107, P2191; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Javed A, 2000, J CELL SCI, V113, P2221; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Kimura H, 1999, MOL CELL BIOL, V19, P5383; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Leonhardt H, 1998, J CELL BIOCHEM, P243, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<243::AID-JCB30>3.0.CO;2-6; Ma H, 1999, J CELL BIOL, V146, P531, DOI 10.1083/jcb.146.3.531; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; McNeil S, 1998, J CELL BIOCHEM, V68, P500, DOI 10.1002/(SICI)1097-4644(19980315)68:4<500::AID-JCB9>3.3.CO;2-T; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; McNeil S, 2000, J CELL BIOCHEM, V79, P103, DOI 10.1002/1097-4644(2000)79:1<103::AID-JCB100>3.3.CO;2-2; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; Misteli T, 2000, J CELL SCI, V113, P1841; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nicoll JB, 2003, MOL CELL ENDOCRINOL, V205, P65, DOI 10.1016/S0303-7207(03)00199-0; North T, 1999, DEVELOPMENT, V126, P2563; Olson MOJ, 2002, INT REV CYTOL, V219, P199; Parada LA, 2002, CURR BIOL, V12, P1692, DOI 10.1016/S0960-9822(02)01166-1; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Pompetti F, 1996, J CELL BIOCHEM, V63, P37; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Sachs RK, 1997, INT J RADIAT BIOL, V71, P1, DOI 10.1080/095530097144364; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Smith KP, 1999, J CELL BIOL, V144, P617, DOI 10.1083/jcb.144.4.617; Stachowiak MK, 2003, J CELL BIOCHEM, V90, P662, DOI 10.1002/jcb.10606; Stein GS, 2000, J CELL SCI, V113, P2527; Stein GS, 2000, CANCER RES, V60, P2067; Stenoien D, 1998, J CELL BIOCHEM, V70, P213, DOI 10.1002/(SICI)1097-4644(19980801)70:2<213::AID-JCB7>3.0.CO;2-R; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Tang L, 1999, J BIOL CHEM, V274, P33580, DOI 10.1074/jbc.274.47.33580; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tseng H, 1999, J CELL SCI, V112, P3039; VANSTEENSEL B, 1995, J CELL BIOCHEM, V57, P465, DOI 10.1002/jcb.240570312; Verschure PJ, 1999, J CELL BIOL, V147, P13, DOI 10.1083/jcb.147.1.13; Wagner S, 2003, P NATL ACAD SCI USA, V100, P3269, DOI 10.1073/pnas.0438055100; Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo-reports/kvf193; Wei XY, 1998, SCIENCE, V281, P1502, DOI 10.1126/science.281.5382.1502; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zaidi SK, 2001, J CELL SCI, V114, P3093; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zaidi SK, 2003, P NATL ACAD SCI USA, V100, P14852, DOI 10.1073/pnas.2533076100; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746	79	22	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43363	43366		10.1074/jbc.R400020200	http://dx.doi.org/10.1074/jbc.R400020200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15277516	hybrid, Green Published			2022-12-27	WOS:000224383100001
J	Goforth, RL; Peterson, EC; Yuan, JG; Moore, MJ; Kight, AD; Lohse, MB; Sakon, J; Henry, RL				Goforth, RL; Peterson, EC; Yuan, JG; Moore, MJ; Kight, AD; Lohse, MB; Sakon, J; Henry, RL			Regulation of the GTPase cycle in post-translational signal recognition particle-based protein targeting involves cpSRP43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANES; ENDOPLASMIC-RETICULUM; CHLOROPLAST HOMOLOG; BINDING; INTEGRATION; TRANSPORT; RIBOSOME; SRP; RECEPTOR; DOMAIN	The chloroplast signal recognition particle consists of a conserved 54-kDa GTPase and a novel 43-kDa chromo-domain protein (cpSRP43) that together bind light-harvesting chlorophyll a/b-binding protein (LHCP) to form a soluble targeting complex that is subsequently directed to the thylakoid membrane. Homology-based modeling of cpSRP43 indicates the presence of two previously identified chromodomains along with a third N-terminal chromodomain. Chromodomain deletion constructs were used to examine the role of each chromodomain in mediating distinct steps in the LHCP localization mechanism. The C-terminal chromodomain is completely dispensable for LHCP targeting/integration in vitro. The central chromodomain is essential for both targeting complex formation and integration because of its role in binding the M domain of cpSRP54. The N-terminal chromodomain (CD1) is unnecessary for targeting complex formation but is required for integration. This correlates with the ability of CD1 along with the ankyrin repeat region of cpSRP43 to regulate the GTPase cycle of the cpSRP-receptor complex.	Univ Arkansas, Dept Biol Sci, SCEN 601, Fayetteville, AR 72701 USA; Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA	University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas System; University of Arkansas Fayetteville	Henry, RL (corresponding author), Univ Arkansas, Dept Biol Sci, SCEN 601, Fayetteville, AR 72701 USA.	Ralph.Henry@uark.edu	Peterson, Eric/I-3082-2013; Sakon, Joshua/N-2289-2014; Lohse, Martin J/A-7160-2012	Sakon, Joshua/0000-0002-8373-969X; Lohse, Martin J/0000-0002-0599-3510	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015569] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR15569] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1989, J BIOL CHEM, V264, P14225; de Leeuw E, 2000, EMBO J, V19, P531, DOI 10.1093/emboj/19.4.531; DeLille J, 2000, P NATL ACAD SCI USA, V97, P1926, DOI 10.1073/pnas.030395197; Egea PF, 2004, NATURE, V427, P215, DOI 10.1038/nature02250; Eichacker LA, 2001, BBA-MOL CELL RES, V1541, P120, DOI 10.1016/S0167-4889(01)00151-3; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Focia PJ, 2004, SCIENCE, V303, P373, DOI 10.1126/science.1090827; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; Fulga TA, 2001, EMBO J, V20, P2338, DOI 10.1093/emboj/20.9.2338; GONZALEZROMO P, 1992, ANAL BIOCHEM, V200, P235, DOI 10.1016/0003-2697(92)90458-J; Groves MR, 2001, J BIOL CHEM, V276, P27778, DOI 10.1074/jbc.M103470200; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; Horton R M, 1997, Methods Mol Biol, V67, P141; Jarvis P, 2002, BBA-MOL CELL RES, V1590, P177, DOI 10.1016/S0167-4889(02)00176-3; Jonas-Straube E, 2001, J BIOL CHEM, V276, P24654, DOI 10.1074/jbc.M100153200; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Klimyuk VI, 1999, PLANT CELL, V11, P87, DOI 10.1105/tpc.11.1.87; Kogata N, 1999, FEBS LETT, V447, P329, DOI 10.1016/S0014-5793(99)00305-1; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; Mandon EC, 2003, J CELL BIOL, V162, P575, DOI 10.1083/jcb.200303143; Moore M, 2003, J CELL BIOL, V162, P1245, DOI 10.1083/jcb.200307067; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Schnell DJ, 2000, ESSAYS BIOCHEM, V36, P47, DOI 10.1042/bse0360047; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schwede T, 2000, RES MICROBIOL, V151, P107, DOI 10.1016/S0923-2508(00)00121-2; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Song WQ, 2000, CELL, V100, P333, DOI 10.1016/S0092-8674(00)80669-8; Tu CJ, 2000, J BIOL CHEM, V275, P13187, DOI 10.1074/jbc.C000108200; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; Yuan J, 2002, J BIOL CHEM, V277, P32400, DOI 10.1074/jbc.M206192200	42	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43077	43084		10.1074/jbc.M401600200	http://dx.doi.org/10.1074/jbc.M401600200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292240	hybrid			2022-12-27	WOS:000224226400091
J	Sawada, K; Yang, Z; Horton, JR; Collins, RE; Zhang, X; Cheng, XD				Sawada, K; Yang, Z; Horton, JR; Collins, RE; Zhang, X; Cheng, XD			Structure of the conserved core of the yeast Dot1p, a nucleosomal histone H3 lysine 79 methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SET DOMAIN; CATALYTIC MECHANISM; ELECTRON-DENSITY; CRYSTAL-STRUCTURE; METHYLATION; PROTEIN; H3; DNA; CHROMATIN; COMPLEX	Methylation of Lys(79) on histone H3 by Dot1p is important for gene silencing. The elongated structure of the conserved core of yeast Dot1p contains an N-terminal helical domain and a seven-stranded catalytic domain that harbors the binding site for the methyl-donor and an active site pocket sided with conserved hydrophobic residues. The S-adenosyl-L-homocysteine exhibits an extended conformation distinct from the folded conformation observed in structures of SET domain histone lysine methyltransferases. A catalytic asparagine (Asn(479)), located at the bottom of the active site pocket, suggests a mechanism similar to that employed for amino methylation in DNA and protein glutamine methylation. The acidic, concave cleft between the two domains contains two basic residue binding pockets that could accommodate the outwardly protruding basic side chains around Lys(79) of histone H3 on the disk-like nucleosome surface. Biochemical studies suggest that recombinant Dot1 proteins are active on recombinant nucleosomes, free of any modifications.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Cheng, XD (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.	xcheng@emory.edu	Horton, John R/ABB-4770-2020; Horton, John/F-2375-2010; Hu, Ruogu/B-2203-2008	Collins, Robert/0000-0002-4580-5991; Horton, John/0000-0001-9749-8068	NIGMS NIH HHS [GM61355, T32 GM008367, R01 GM061355-04S1, GM49245, R01 GM049245, R01 GM061355] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367, R01GM049245, R01GM061355] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; Dlakic M, 2001, TRENDS BIOCHEM SCI, V26, P405, DOI 10.1016/S0968-0004(01)01856-4; Dong AP, 2001, NUCLEIC ACIDS RES, V29, P439, DOI 10.1093/nar/29.2.439; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Goedecke K, 2001, NAT STRUCT BIOL, V8, P121, DOI 10.1038/84104; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; Jacobs SA, 2002, NAT STRUCT BIOL, V9, P833, DOI 10.1038/nsb861; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; Kwon T, 2003, EMBO J, V22, P292, DOI 10.1093/emboj/cdg025; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Min JR, 2003, CELL, V112, P711, DOI 10.1016/S0092-8674(03)00114-4; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Park JH, 2002, NAT GENET, V32, P273, DOI 10.1038/ng982; Pilizota T, 2004, J CHEM INF COMP SCI, V44, P113, DOI 10.1021/ci034037p; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; Schubert HL, 2003, BIOCHEMISTRY-US, V42, P5592, DOI 10.1021/bi034026p; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Singer MS, 1998, GENETICS, V150, P613; SLILATY SN, 1991, PROTEIN ENG, V4, P919, DOI 10.1093/protein/4.8.919; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Trievel RC, 2003, NAT STRUCT BIOL, V10, P545, DOI 10.1038/nsb946; Trievel RC, 2002, CELL, V111, P91, DOI 10.1016/S0092-8674(02)01000-0; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; WESTHEIMER FH, 1995, TETRAHEDRON, V51, P3, DOI 10.1016/0040-4020(94)00865-R; Xiao B, 2003, NATURE, V421, P652, DOI 10.1038/nature01378; Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6; Zhang X, 2002, CELL, V111, P117, DOI 10.1016/S0092-8674(02)00999-6; Zhang X, 2003, MOL CELL, V12, P177, DOI 10.1016/S1097-2765(03)00224-7; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhao KH, 2003, NAT STRUCT BIOL, V10, P864, DOI 10.1038/nsb978	63	93	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43296	43306		10.1074/jbc.M405902200	http://dx.doi.org/10.1074/jbc.M405902200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292170	Green Accepted, hybrid			2022-12-27	WOS:000224226400114
J	Yan, Q; Kamura, T; Cai, Y; Jin, JJ; Ivan, M; Mushegian, A; Conaway, RC; Conaway, JW				Yan, Q; Kamura, T; Cai, Y; Jin, JJ; Ivan, M; Mushegian, A; Conaway, RC; Conaway, JW			Identification of Elongin C and Skp1 sequences that determine Cullin selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; UBIQUITIN-LIGASE COMPLEX; HYPOXIA-INDUCIBLE FACTOR; KAPPA-B-ALPHA; SOCS-BOX MOTIF; F-BOX; PROTEASOME PATHWAY; FACTOR 1-ALPHA; HIF-ALPHA; SCF	The multiprotein von Hippel-Lindau (VHL) tumor suppressor and Skp1-Cul1-F-box protein (SCF) complexes belong to families of structurally related E3 ubiquitin ligases. In the VHL ubiquitin ligase, the VHL protein serves as the substrate recognition subunit, which is linked by the adaptor protein Elongin C to a heterodimeric Cul2/Rbx1 module that activates ubiquitylation of target proteins by the E2 ubiquitin-conjugating enzyme Ubc5. In SCF ubiquitin ligases, F-box proteins serve as substrate recognition subunits, which are linked by the Elongin C-like adaptor protein Skp1 to a Cul1/Rbx1 module that activates ubiquitylation of target proteins, in most cases by the E2 Cdc34. In this report, we investigate the functions of the Elongin C and Skp1 proteins in reconstitution of VHL and SCF ubiquitin ligases. We identify Elongin C and Skp1 structural elements responsible for selective interaction with their cognate Cullin/Rbx1 modules. In addition, using altered specificity Elongin C and F-box protein mutants, we investigate models for the mechanism underlying E2 selection by VHL and SCF ubiquitin ligases. Our findings provide evidence that E2 selection by VHL and SCF ubiquitin ligases is determined not solely by the Cullin/Rbx1 module, the target protein, or the integrity of the substrate recognition subunit but by yet to be elucidated features of these macromolecular complexes.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 8128582, Japan; Tufts New England Med Ctr, Dept Med, Mol Oncol Res Inst, Boston, MA 02111 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	Stowers Institute for Medical Research; University of Oklahoma System; University of Oklahoma Health Sciences Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Kyushu University; Tufts Medical Center; University of Kansas; University of Kansas Medical Center	Conaway, JW (corresponding author), Stowers Inst Med Res, Kansas City, MO 64110 USA.	jlc@stowers-institute.org	Yan, Qin/E-8893-2012; Mushegian, Arcady/ABF-5387-2021; Ivan, Mircea/A-8109-2012	Yan, Qin/0000-0003-4077-453X; Mushegian, Arcady/0000-0002-6809-9225; Conaway, Joan/0000-0002-2786-0663; Ivan, Mircea/0000-0003-3424-6642	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM041628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 2002, J BIOL CHEM, V277, P30388, DOI 10.1074/jbc.M203344200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Oh KJ, 2004, J VIROL, V78, P5338, DOI 10.1128/JVI.78.10.5338-5346.2004; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Pause A, 1999, P NATL ACAD SCI USA, V96, P9533, DOI 10.1073/pnas.96.17.9533; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Strack P, 2000, ONCOGENE, V19, P3529, DOI 10.1038/sj.onc.1203647; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	49	10	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43019	43026		10.1074/jbc.M408018200	http://dx.doi.org/10.1074/jbc.M408018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15280393	hybrid			2022-12-27	WOS:000224226400084
J	Evans, SR; Thoreson, WB; Beck, CL				Evans, SR; Thoreson, WB; Beck, CL			Molecular and functional analyses of two new calcium-activated chloride channel family members from mouse eye and intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED CL-CHANNEL; BETA(4) INTEGRIN; SMOOTH-MUSCLE; BREAST-CANCER; CELLS; CURRENTS; CLONING; CONDUCTANCE; EPITHELIUM; EXPRESSION	Two new calcium-activated chloride channel (CLCA) family members, mCLCA5 and mCLCA6, have been cloned from mouse eye and intestine, respectively. mCLCA5 is highly homologous to hCLCA2, and mCLCA6 is highly homologous to hCLCA4. mCLCA5 is widely expressed with strong expression in eye and spleen, whereas mCLCA6 is primarily expressed in intestine and stomach. mCLCA6 is also expressed as a splice variant lacking exon 8 and part of exon 10 in intestine and stomach. Transfection of tsA201 cells with enhanced green fluorescent protein-tagged versions of the three cDNAs reveals protein products of 155 and 65 kDa for mCLCA5 and mCLCA6 and 145 and 65 kDa for the mCLCA6 splice variant. In vitro translation of mCLCA5 generates a 90-kDa protein that does not appear to be glycosylated. mCLCA6 also generates a 90-kDa protein that is glycosylated to a 110-kDa product, whereas the mCLCA6 splice variant generates an 80-kDa product that is 100 kDa after glycosylation. Treatment of enhanced green fluorescent protein-tagged mCLCA6 with PNGase F (peptide: N-glycosidase F) to remove N-linked glycosyl groups shows a reduction in size of the 65 kDa product to 60 kDa. Consistent with the hypothesis that mCLCA5, mCLCA6, and its splice variant encode calcium-activated chloride channels, in HEK293 cells expressing CLCAs ionomycin-evoked increases in intracellular calcium stimulated a current that reversed near Cl- equilibrium potential, E-Cl. Furthermore, these currents were inhibited by the chloride channel blocker niflumic acid. Given the prominent role of hCLCA2 in cancer cell adhesion and the unique high level of expression of hCLCA4 in brain, the identification of their murine counterparts presents the opportunity to clarify the role of CLCAs in disease and normal cell physiology.	Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Univ Nebraska, Med Ctr, Dept Ophthalmol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pharmacol, Omaha, NE 68198 USA	Jefferson University; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Beck, CL (corresponding author), Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, 233 S 10th St,Rm 302 B BLSB, Philadelphia, PA 19107 USA.	carol.beck@jefferson.edu	Thoreson, Wallace B./F-6172-2010	Thoreson, Wallace B./0000-0001-7104-042X	NATIONAL EYE INSTITUTE [R55EY010542, R01EY010542, R29EY010542] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10542, R01 EY010542] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abdel-Ghany M, 2003, J BIOL CHEM, V278, P49406, DOI 10.1074/jbc.M309086200; Abdel-Ghany M, 2002, J BIOL CHEM, V277, P34391, DOI 10.1074/jbc.M205307200; Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; Agnel M, 1999, FEBS LETT, V455, P295, DOI 10.1016/S0014-5793(99)00891-1; AMEDEE T, 1990, J PHYSIOL-LONDON, V428, P501, DOI 10.1113/jphysiol.1990.sp018224; Arreola J, 1996, J PHYSIOL-LONDON, V490, P351, DOI 10.1113/jphysiol.1996.sp021149; Atherton H, 2003, N-S ARCH PHARMACOL, V367, P214, DOI 10.1007/s00210-002-0668-1; BARNES S, 1989, J GEN PHYSIOL, V94, P719, DOI 10.1085/jgp.94.4.719; Bustin SA, 2001, DNA CELL BIOL, V20, P331, DOI 10.1089/10445490152122442; Clapp LH, 1996, AM J PHYSIOL-HEART C, V270, pH1577, DOI 10.1152/ajpheart.1996.270.5.H1577; CLARKE LL, 1994, P NATL ACAD SCI USA, V91, P464; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; Connon CJ, 2004, J HISTOCHEM CYTOCHEM, V52, P415, DOI 10.1177/002215540405200313; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; Elble RC, 1997, J BIOL CHEM, V272, P27853, DOI 10.1074/jbc.272.44.27853; Elble RC, 2002, J BIOL CHEM, V277, P18586, DOI 10.1074/jbc.M200829200; Elble RC, 2001, J BIOL CHEM, V276, P40510, DOI 10.1074/jbc.M104821200; EVANS MG, 1986, J PHYSIOL-LONDON, V378, P437, DOI 10.1113/jphysiol.1986.sp016229; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; Greenwood IA, 2002, J BIOL CHEM, V277, P22119, DOI 10.1074/jbc.C200215200; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1999, CANCER RES, V59, P5488; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Gruber AD, 1999, BBA-GENE STRUCT EXPR, V1444, P418, DOI 10.1016/S0167-4781(99)00008-1; Hallani M, 1998, J MEMBRANE BIOL, V161, P163, DOI 10.1007/s002329900323; Hoshino M, 2002, AM J RESP CRIT CARE, V165, P1132, DOI 10.1164/ajrccm.165.8.2107068; HUANG SJ, 1993, AM J PHYSIOL, V264, pC794, DOI 10.1152/ajpcell.1993.264.4.C794; HUME RI, 1989, J PHYSIOL-LONDON, V417, P241, DOI 10.1113/jphysiol.1989.sp017799; Ji HL, 1998, AM J PHYSIOL-CELL PH, V274, pC455, DOI 10.1152/ajpcell.1998.274.2.C455; Leverkoehne I, 2002, J HISTOCHEM CYTOCHEM, V50, P829, DOI 10.1177/002215540205000609; Loewen ME, 2002, BIOCHEM BIOPH RES CO, V298, P531, DOI 10.1016/S0006-291X(02)02498-1; Loewen ME, 2003, AM J PHYSIOL-CELL PH, V285, pC1314, DOI 10.1152/ajpcell.00210.2003; PAULI BU, 1997, ENCY CANC; PAULI BU, 1995, ADHESION MOL LUNG, P211; Qu ZQ, 2004, J GEN PHYSIOL, V123, P327, DOI 10.1085/jgp.200409031; Qu ZQ, 2003, J BIOL CHEM, V278, P49563, DOI 10.1074/jbc.M308414200; RITZKA M, 2003, GENOME LETT, V2, P149; Rozmahel R, 1996, NAT GENET, V12, P280, DOI 10.1038/ng0396-280; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999; Toda M, 2002, J ALLERGY CLIN IMMUN, V109, P246, DOI 10.1067/mai.2002.121555; Tsunenari T, 2003, J BIOL CHEM, V278, P41114, DOI 10.1074/jbc.M306150200; WANG Q, 1992, J PHYSIOL-LONDON, V451, P525, DOI 10.1113/jphysiol.1992.sp019177; Zhou YH, 2001, AM J RESP CELL MOL, V25, P486, DOI 10.1165/ajrcmb.25.4.4578	44	35	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41792	41800		10.1074/jbc.M408354200	http://dx.doi.org/10.1074/jbc.M408354200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15284223	Green Accepted, hybrid			2022-12-27	WOS:000224075500068
J	Goto, M; Eddy, EM				Goto, M; Eddy, EM			Speriolin is a novel spermatogenic cell-specific centrosomal protein associated with the seventh WD motif of Cdc20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; SPINDLE CHECKPOINT; MOUSE SPERMATOCYTES; MITOTIC REGULATOR; CRYSTAL-STRUCTURE; GENE-EXPRESSION; FISSION YEAST; IDENTIFICATION; MAD2; DESTRUCTION	The fundamental mechanisms of mitosis are conserved throughout evolution in eukaryotes, including ubiquitin-mediated proteolysis of cell cycle regulators by the anaphase-promoting complex/cyclosome. The spindle checkpoint protein Cdc20 activates the anaphase-promoting complex/cyclosome in a substrate-specific manner. It is present in the cytoplasm and concentrated in the centrosomes throughout the cell cycle, accumulates at the kinetochores in metaphase, and is no longer detected following anaphase. However, it is unknown whether Cdc20 has the same activities and distribution during meiosis in male germ cells. We found that in mice, Cdc20 accumulates in the cytoplasm of pachytene spermatocytes during meiosis I, is distributed throughout spermatocytes undergoing meiotic division, and is present in the cytoplasm of postmeiotic spermatids. Several proteins bind to and regulate the function of Cdc20 during mitosis. We identified speriolin and determined that it is a novel spermatogenic cell-specific Cdc20-binding protein, is present in the cytoplasm, and is concentrated at the centrosomes of spermatocytes and spermatids and that a leucine zipper domain is required to target speriolin to the centrosome. The seven tandem WD motifs of Cdc20 probably fold into a seven-blade beta-propeller structure, and we determined that they are required for speriolin binding and for localization of Cdc20 to the centrosomes and nucleus, suggesting that speriolin might regulate or stabilize the folding of Cdc20 during meiosis in spermatogenic cells.	NIEHS, LRDT, NIH, Gamete Biol Sect,Lab Reprod & Dev Toxicol, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	Eddy, EM (corresponding author), NIEHS, LRDT, NIH, Gamete Biol Sect,Lab Reprod & Dev Toxicol, C4-01,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	eddy@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES070076, ZIAES070076] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alsheimer M, 1996, EXP CELL RES, V228, P181, DOI 10.1006/excr.1996.0315; Baker SC, 1997, J MOL BIOL, V269, P440, DOI 10.1006/jmbi.1997.1070; Eaker S, 2002, DEV BIOL, V249, P85, DOI 10.1006/dbio.2002.0708; Eaker S, 2001, J CELL SCI, V114, P2953; Eddy EM, 1995, REPROD FERT DEVELOP, V7, P695, DOI 10.1071/RD9950695; Eddy EM, 1998, CURR TOP DEV BIOL, V37, P141; ESPONDA P, 1972, CHROMOSOMA, V38, P405, DOI 10.1007/BF00320159; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; FURUKAWA K, 1994, EXP CELL RES, V212, P426, DOI 10.1006/excr.1994.1164; FURUKAWA K, 1993, EMBO J, V12, P97, DOI 10.1002/j.1460-2075.1993.tb05635.x; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kallio MJ, 2002, J CELL BIOL, V158, P841, DOI 10.1083/jcb.200201135; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Liebe B, 2004, MOL BIOL CELL, V15, P827, DOI 10.1091/mbc.E03-07-0524; Lin M, 2003, EXP MOL PATHOL, V74, P123, DOI 10.1016/S0014-4800(02)00021-7; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Manandhar G, 1998, DEV BIOL, V203, P424, DOI 10.1006/dbio.1998.8947; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Miki E, 1998, J BIOL CHEM, V273, P34384, DOI 10.1074/jbc.273.51.34384; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; OBRIEN DA, 1993, METHODS TOXICOL, V3, P246; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Prieto I, 2001, NAT CELL BIOL, V3, P761, DOI 10.1038/35087082; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; SMITH A, 1992, DIFFERENTIATION, V52, P55, DOI 10.1111/j.1432-0436.1992.tb00499.x; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; VESTER B, 1993, J CELL SCI, V104, P557; Vodermaier HC, 2001, CURR BIOL, V11, pR834, DOI 10.1016/S0960-9822(01)00498-5; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wassmann K, 2003, CURR BIOL, V13, P1596, DOI 10.1016/j.cub.2003.08.052; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; Woods LM, 1999, J CELL BIOL, V145, P1395, DOI 10.1083/jcb.145.7.1395; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001	51	29	34	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42128	42138		10.1074/jbc.M403190200	http://dx.doi.org/10.1074/jbc.M403190200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280373	hybrid, Green Published			2022-12-27	WOS:000224075500105
J	Bream, JH; Hodge, DL; Gonsky, R; Spolski, R; Leonard, WJ; Krebs, S; Targan, S; Morinobu, A; O'Shea, JJ; Young, HA				Bream, JH; Hodge, DL; Gonsky, R; Spolski, R; Leonard, WJ; Krebs, S; Targan, S; Morinobu, A; O'Shea, JJ; Young, HA			A distal region in the interferon-gamma gene is a site of epigenetic remodeling and transcriptional regulation by interleukin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; IFN-GAMMA; T-CELLS; CUTTING EDGE; LINEAGE COMMITMENT; SELECTIVE EXPRESSION; HISTONE ACETYLATION; PROMOTER ELEMENTS; TOXOPLASMA-GONDII; DNA-BINDING	Interferon-gamma (IFN-gamma) is a multifunctional cytokine that defines the development of Th1 cells and is critical for host defense against intracellular pathogens. IL-2 is another key immunoregulatory cytokine that is involved in T helper differentiation and is known to induce IFN-gamma expression in natural killer (NK) and T cells. Despite concerted efforts to identify the one or more transcriptional control mechanisms by which IL-2 induces IFN-gamma mRNA expression, no such genomic regulatory regions have been described. We have identified a DNase I hypersensitivity site similar to3.5-4.0 kb upstream of the transcriptional start site. Using chromatin immunoprecipitation assays we found constitutive histone H3 acetylation in this distal region in primary human NK cells, which is enhanced by IL-2 treatment. This distal region is also preferentially acetylated on histones H3 and H4 in primary Th1 cells as compared with Th2 cells. Within this distal region we found a Stat5-like motif, and in vitro DNA binding assays as well as in vivo chromosomal immunoprecipitation assays showed IL-2-induced binding of both Stat5a and Stat5b to this distal element in the IFNG gene. We examined the function of this Stat5-binding motif by transfecting human peripheral blood mononuclear cells with -3.6 kb of IFNG-luciferase constructs and found that phorbol 12-myristate 13-acetate/ionomycin-induced transcription was augmented by IL-2 treatment. The effect of IL-2 was lost when the Stat5 motif was disrupted. These data led us to conclude that this distal region serves as both a target of chromatin remodeling in the IFNG locus as well as an IL-2-induced transcriptional enhancer that binds Stat5 proteins.	NCI, Cellular & Mol Immunol Sect, Expt Immunol Lab, NIH, Frederick, MD 21702 USA; NIAMSD, Lymphocyte & Cell Biol Sect, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD 20892 USA; Cedars Sinai Med Ctr, Dept Gastroenterol, Los Angeles, CA 90048 USA; NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; Kobe Univ, Grad Sch Med, Dept Clin Pathol & Immunol, Chuo Ku, Kobe, Hyogo 6500017, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Cedars Sinai Medical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Kobe University	Bream, JH (corresponding author), NCI, Cellular & Mol Immunol Sect, Expt Immunol Lab, NIH, Frederick, MD 21702 USA.	youngh@ncifcrf.gov	Young, Howard/A-6350-2008; Leonard, Warren/AAA-1397-2022	Young, Howard/0000-0002-3118-5111; Bream, Jay/0000-0002-9149-7643	NATIONAL CANCER INSTITUTE [Z01BC009283] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043211, R37DK043211] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43211] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE E, 1992, P NATL ACAD SCI USA, V89, P2864, DOI 10.1073/pnas.89.7.2864; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Agnello D, 2003, J CLIN IMMUNOL, V23, P147, DOI 10.1023/A:1023381027062; Aune TM, 1997, MOL CELL BIOL, V17, P199, DOI 10.1128/MCB.17.1.199; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Barbulescu K, 1998, J IMMUNOL, V160, P3642; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Bream JH, 2002, GENES IMMUN, V3, P165, DOI 10.1038/sj.gene.6363870; Bream JH, 2000, IMMUNOGENETICS, V51, P50, DOI 10.1007/s002510050008; Bream JH, 2003, BLOOD, V102, P207, DOI 10.1182/blood-2002-08-2602; Cerwenka A, 2001, NAT REV IMMUNOL, V1, P41, DOI 10.1038/35095564; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; COUSENS LP, 1995, J IMMUNOL, V155, P5690; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; FARRAR WL, 1985, J IMMUNOL, V135, P1551; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Fitzpatrick DR, 1999, J IMMUNOL, V162, P5053; GAZZINELLI RT, 1991, J IMMUNOL, V146, P286; Glimcher LH, 2000, GENE DEV, V14, P1693; Gonsky R, 2003, EUR J IMMUNOL, V33, P1152, DOI 10.1002/eji.200322875; Gonsky R, 2000, J IMMUNOL, V164, P1399, DOI 10.4049/jimmunol.164.3.1399; HARDY KJ, 1985, P NATL ACAD SCI USA, V82, P8173, DOI 10.1073/pnas.82.23.8173; HARDY KJ, 1987, J IMMUNOL, V138, P2353; Ho IC, 2002, CELL, V109, pS109, DOI 10.1016/S0092-8674(02)00705-5; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Kaiser P, 1998, GENE, V207, P25, DOI 10.1016/S0378-1119(97)00600-8; KASAHARA T, 1983, J IMMUNOL, V130, P1784; Kim HP, 2001, IMMUNITY, V15, P159, DOI 10.1016/S1074-7613(01)00167-4; Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X; Lee DU, 2004, J BIOL CHEM, V279, P4802, DOI 10.1074/jbc.M307904200; Lee GR, 2003, IMMUNITY, V19, P145, DOI 10.1016/S1074-7613(03)00179-1; Lee GR, 2001, IMMUNITY, V14, P447, DOI 10.1016/S1074-7613(01)00125-X; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Mikovits JA, 1998, MOL CELL BIOL, V18, P5166, DOI 10.1128/MCB.18.9.5166; Mohrs M, 2001, NAT IMMUNOL, V2, P842, DOI 10.1038/ni0901-842; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Nakahira M, 2002, J IMMUNOL, V168, P1146, DOI 10.4049/jimmunol.168.3.1146; Nguyen KB, 2002, SCIENCE, V297, P2063, DOI 10.1126/science.1074900; Pearce EL, 2003, SCIENCE, V302, P1041, DOI 10.1126/science.1090148; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; Penix LA, 1996, J BIOL CHEM, V271, P31964, DOI 10.1074/jbc.271.50.31964; REEM GH, 1984, SCIENCE, V225, P429, DOI 10.1126/science.6429853; Reiner SL, 2003, IMMUNOL RES, V27, P463, DOI 10.1385/IR:27:2-3:463; Rincon M, 1997, CURR BIOL, V7, pR729, DOI 10.1016/S0960-9822(06)00368-X; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; Soutto M, 2002, J IMMUNOL, V169, P6664, DOI 10.4049/jimmunol.169.12.6664; Stetson DB, 2003, J EXP MED, V198, P1069, DOI 10.1084/jem.20030630; Sweetser MT, 1998, J BIOL CHEM, V273, P34775, DOI 10.1074/jbc.273.52.34775; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; Villegas EN, 1999, J IMMUNOL, V163, P3344; Villegas EN, 2002, INFECT IMMUN, V70, P4757, DOI 10.1128/IAI.70.9.4757-4761.2002; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Young HA, 1997, BLOOD, V89, P583, DOI 10.1182/blood.V89.2.583; YOUNG HA, 1988, J INTERFERON RES, V8, P527, DOI 10.1089/jir.1988.8.527; YOUNG HA, 1994, J IMMUNOL, V153, P3603; Zhang F, 1998, J IMMUNOL, V161, P6105; Zhu H, 2001, J IMMUNOL, V167, P855, DOI 10.4049/jimmunol.167.2.855; Zhu JF, 2003, IMMUNITY, V19, P739, DOI 10.1016/S1074-7613(03)00292-9	66	60	61	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41249	41257		10.1074/jbc.M401168200	http://dx.doi.org/10.1074/jbc.M401168200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15271977	hybrid			2022-12-27	WOS:000223916800124
J	Carriere, A; Carmona, MC; Fernandez, Y; Rigoulet, M; Wenger, RH; Penicaud, L; Casteilla, L				Carriere, A; Carmona, MC; Fernandez, Y; Rigoulet, M; Wenger, RH; Penicaud, L; Casteilla, L			Mitochondrial reactive oxygen species control the transcription factor CHOP-10/GADD153 and adipocyte differentiation - A mechanism for hypoxia-dependent effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEINS; OXIDATIVE CAPACITY; HYDROGEN-PEROXIDE; STRESS-RESPONSE; MAMMALIAN-CELLS; ADIPOGENESIS; INHIBITION; INDUCTION; GADD153; CHOP	Recent reports emphasize the importance of mitochondria in white adipose tissue biology. In addition to their crucial role in energy homeostasis, mitochondria are the main site of reactive oxygen species generation. When moderately produced, they function as physiological signaling molecules. Thus, mitochondrial reactive oxygen species trigger hypoxia-dependent gene expression. Therefore the present study tested the implication of mitochondrial reactive oxygen species in adipocyte differentiation and their putative role in the hypoxia-dependent effect on this differentiation. Pharmacological manipulations of mitochondrial reactive oxygen species generation demonstrate a very strong and negative correlation between changes in mitochondrial reactive oxygen species and adipocyte differentiation of 3T3- F442A preadipocytes. Moreover, mitochondrial reactive oxygen species positively and specifically control expression of the adipogenic repressor CHOP-10/GADD153. Hypoxia (1% O-2) strongly increased reactive oxygen species generation, hypoxia-inducible factor-1 and CHOP-10/GADD153 expression, and inhibited adipocyte differentiation. All of these hypoxia-dependent effects were partly prevented by antioxidants. By using hypoxia-inducible factor-1alpha (HIF-1alpha)-deficient mouse embryonic fibroblasts, HIF-1alpha was shown not to be required for hypoxia-mediated CHOP-10/GADD153 induction. Moreover, the comparison of hypoxia and CoCl2 effects on adipocyte differentiation of wild type or HIF-1alpha deficient mouse embryonic fibroblasts suggests the existence of at least two pathways dependent or not on the presence of HIF-1alpha. Together, these data demonstrate that mitochondrial reactive oxygen species control CHOP-10/GADD153 expression, are antiadipogenic signaling molecules, and trigger hypoxia-dependent inhibition of adipocyte differentiation.	Univ Toulouse 3, CNRS, Unite Mixte Rech 5018, F-31059 Toulouse 9, France; CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; Univ Zurich Irchel, Inst Physiol, CH-8057 Zurich, Switzerland	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Zurich	Casteilla, L (corresponding author), Univ Toulouse 3, CNRS, Unite Mixte Rech 5018, IFR31,Bat L1,Complexe Hosp Univ Rangueil, F-31059 Toulouse 9, France.	casteil@toulouse.inserm.fr	Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839; Casteilla, Louis/0000-0001-9647-3248; Carriere, Audrey/0000-0002-4277-7905; Carmona Orozco, Mamen/0000-0001-5911-6938				AILHAUD G, 1995, ANN ENDOCRINOL, V562, P93; Ameri K, 2004, BLOOD, V103, P1876, DOI 10.1182/blood-2003-06-1859; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carriere A, 2003, FEBS LETT, V550, P163, DOI 10.1016/S0014-5793(03)00862-7; Casteilla L, 2001, IUBMB LIFE, V52, P181, DOI 10.1080/15216540152845984; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Entingh AJ, 2001, ENDOCRINOLOGY, V142, P221, DOI 10.1210/en.142.1.221; Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955-0674(98)80138-5; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; Genbacev O, 1997, SCIENCE, V277, P1669, DOI 10.1126/science.277.5332.1669; GREEN TR, 1994, TOXICOL APPL PHARM, V129, P163, DOI 10.1006/taap.1994.1240; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; IIUANG LE, 2003, J BIOL CHEM, V278, P19575; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; Liebermann DA, 2002, LEUKEMIA, V16, P527, DOI 10.1038/sj.leu.2402477; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Negre-Salvayre A, 2002, METHOD ENZYMOL, V352, P62; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; PRICE BD, 1992, CANCER RES, V52, P3814; Prunet-Marcassus B, 1999, FEBS LETT, V464, P184, DOI 10.1016/S0014-5793(99)01710-X; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Schrauwen P, 2004, DIABETES, V53, P1412, DOI 10.2337/diabetes.53.6.1412; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Wilson-Fritch L, 2003, MOL CELL BIOL, V23, P1085, DOI 10.1128/MCB.23.3.1085-1094.2003; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445	34	173	181	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40462	40469		10.1074/jbc.M407258200	http://dx.doi.org/10.1074/jbc.M407258200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15265861	Green Accepted, hybrid			2022-12-27	WOS:000223916800032
J	Cummings, R; Zhao, YT; Jacoby, D; Spannhake, EW; Ohba, M; Garcia, JGN; Watkins, T; He, DH; Saatian, B; Natarajan, V				Cummings, R; Zhao, YT; Jacoby, D; Spannhake, EW; Ohba, M; Garcia, JGN; Watkins, T; He, DH; Saatian, B; Natarajan, V			Protein kinase C delta mediates lysophosphatidic acid-induced NF-kappa B activation and interleukin-8 secretion in human bronchial epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY SMOOTH-MUSCLE; BRONCHOALVEOLAR LAVAGE FLUID; OVARIAN-CANCER CELLS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; RECEPTOR; TRANSCRIPTION; GROWTH; ALPHA; IL-8	Lysophosphatidic acid (LPA), a potent bioactive lipid, elicits many of its biological actions via the specific G-protein-coupled receptors LPA(1), LPA(2), LPA(3), and LPA(4). Recently, we have shown that LPA-induced trans-activation of platelet-derived growth factor receptor-beta is regulated by phospholipase D-2 in human bronchial epithelial cells (HBEpCs) (Wang, L., Cummings, R. J., Zhao, Y., Kazlauskas, A., Sham, J., Morris, A., Brindley, D. N., Georas, S., and Natarajan, V. ( 2003) J. Biol. Chem. 278, 39931-39940). Here, we report that protein kinase Cdelta (PKCdelta) mediates LPA-induced NF-kappaB transcription and interleukin-8 (IL-8) secretion in HBEpCs. Treatment of HBEpCs with LPA increased both IL-8 gene and protein expression, which was coupled to G(i) and G(12/13) proteins. LPA caused a marked activation of NF-kappaB in HBEpCs as determined by IkappaB phosphorylation and of NF-kappaB nuclear translocation and a strong induction of NF-kappaB promoter-mediated luciferase activity. Furthermore, LPA-activated PKCdelta and the LPA-mediated activation of NF-kappaB and IL-8 production were attenuated by overexpression of dominant-negative PKCdelta and rottlerin. Intratracheal administration of LPA in mice resulted in elevated levels of macrophage inflammatory protein-2, a murine homolog of IL-8, and an influx of neutrophils in the bronchoalveolar lavage fluid. These results demonstrate for the first time that LPA is a potent stimulator of IL-8 production in HBEpCs, which involves PKCdelta/NF-kappaB signaling pathways.	Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21224 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97239 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Showa Univ, Inst Mol Oncol, Tokyo 1428555, Japan	Johns Hopkins University; Oregon Health & Science University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Showa University	Natarajan, V (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, MFL 675,Ctr Tower,5200 Eastern Ave, Baltimore, MD 21224 USA.	vnataraj@jhmi.edu	Garcia, Joe GN/E-8862-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054659, R01HL061013] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54659, HL71121, HL61013] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abul H, 2001, MOL CELL BIOCHEM, V217, P107, DOI 10.1023/A:1007264411006; Allen GL, 2000, AM J PHYSIOL-LUNG C, V278, pL253, DOI 10.1152/ajplung.2000.278.2.L253; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; CAR BD, 1994, AM J RESP CRIT CARE, V149, P655, DOI 10.1164/ajrccm.149.3.8118632; CHOI AM, 1992, FEBS LETT, V390, P327; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Cummings RJ, 2002, J BIOL CHEM, V277, P30227, DOI 10.1074/jbc.M111078200; DEVLIN RB, 1994, AM J PHYSIOL, V266, P612; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Ediger TL, 2003, EUR RESPIR J, V21, P759, DOI 10.1183/09031936.03.00075702; Ediger TL, 2001, BBA-MOL CELL BIOL L, V1531, P59, DOI 10.1016/S1388-1981(01)00084-1; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Folkard SG, 1997, EUR RESPIR J, V10, P2097, DOI 10.1183/09031936.97.10092097; Gilmour PS, 2001, AM J PHYSIOL-LUNG C, V281, pL598, DOI 10.1152/ajplung.2001.281.3.L598; Goetzl EJ, 2000, J BIOL CHEM, V275, P14573, DOI 10.1074/jbc.275.19.14573; Goodman RB, 1996, AM J RESP CRIT CARE, V154, P602, DOI 10.1164/ajrccm.154.3.8810593; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; Hashimoto T, 2003, J PHARMACOL SCI, V91, P8, DOI 10.1254/jphs.91.8; Hashimoto T, 2001, LIFE SCI, V70, P199, DOI 10.1016/S0024-3205(01)01382-0; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Kuroki T, 1999, J INVEST DERM SYMP P, V4, P153, DOI 10.1038/sj.jidsp.5640200; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Li N, 2002, J IMMUNOL, V169, P4531, DOI 10.4049/jimmunol.169.8.4531; Matsumoto K, 1998, J ALLERGY CLIN IMMUN, V101, P825, DOI 10.1016/S0091-6749(98)70311-2; Minami T, 2003, J BIOL CHEM, V278, P6976, DOI 10.1074/jbc.M208974200; Mio T, 1997, AM J RESP CRIT CARE, V155, P1770, DOI 10.1164/ajrccm.155.5.9154890; Mukaida N, 2003, AM J PHYSIOL-LUNG C, V284, pL566, DOI 10.1152/ajplung.00233.2002; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Page K, 2003, J IMMUNOL, V170, P5681, DOI 10.4049/jimmunol.170.11.5681; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; Postma FR, 1996, EMBO J, V15, P63, DOI 10.1002/j.1460-2075.1996.tb00334.x; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Reynaud-Gaubert M, 2002, J HEART LUNG TRANSPL, V21, P721, DOI 10.1016/S1053-2498(02)00392-3; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Toews ML, 1997, J APPL PHYSIOL, V83, P1216, DOI 10.1152/jappl.1997.83.4.1216; Wang LX, 2003, J BIOL CHEM, V278, P39931, DOI 10.1074/jbc.M302896200; WU R, 1985, AM REV RESPIR DIS, V132, P311; Wyatt TA, 1999, AM J RESP CELL MOL, V21, P283, DOI 10.1165/ajrcmb.21.2.3636; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu YJ, 2003, J CARDIOVASC PHARM, V41, P381, DOI 10.1097/00005344-200303000-00006	44	106	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41085	41094		10.1074/jbc.M404045200	http://dx.doi.org/10.1074/jbc.M404045200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15280372	hybrid			2022-12-27	WOS:000223916800107
J	Nair, KS; Hanson, SM; Kennedy, MJ; Hurley, JB; Gurevich, VV; Slepak, VZ				Nair, KS; Hanson, SM; Kennedy, MJ; Hurley, JB; Gurevich, VV; Slepak, VZ			Direct binding of visual arrestin to microtubules determines the differential subcellular localization of its splice variants in rod photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN KINASE; OUTER SEGMENTS; IN-VIVO; MULTIPLE PHOSPHORYLATION; DEPENDENT TRANSLOCATION; 48-KDA PROTEIN; RETINAL RODS; LIGHT; TUBULIN; TRANSDUCIN	Proper function of visual arrestin is indispensable for rapid signal shut-off in rod photoreceptors. Dramatic light dependent changes in its subcellular localization are believed to play an important role in light adaptation of photoreceptor cells. Here we show that visual arrestin binds microtubules. The truncated splice variant of visual arrestin, p44, demonstrates dramatically higher affinity for microtubules than the full-length protein (p48). Enhanced microtubule binding of p44 underlies its earlier reported preferential localization to detergent-resistant membranes, where it is anchored via membrane-associated microtubules in a rhodopsin-independent fashion. Experiments with purified proteins demonstrate that arrestin interaction with microtubules is direct and does not require any additional protein partners. Most importantly, arrestin interactions with microtubules and light-activated phosphorylated rhodopsin are mutually exclusive, suggesting that microtubule interaction may play a role in keeping p44 arrestin away from rhodopsin in dark-adapted photoreceptors.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Program Neurosci, Miami, FL 33136 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Miami; University of Miami; Vanderbilt University; University of Washington; University of Washington Seattle	Slepak, VZ (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, R-189,1600 NW 10th Ave, Miami, FL 33136 USA.	vslepak@newssun.med.miami.edu	Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NEI NIH HHS [R01 EY006641, EY06641, EY11500] Funding Source: Medline; NIGMS NIH HHS [R01 GM060019-02, R01 GM060019-02S1, R01 GM060019-03S1, R01 GM060019-04, R01 GM060019-03, GM07628, R01 GM060019, GM060019] Funding Source: Medline; PHS HHS [EI012982] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006641, R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060019, T32GM007628] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZARIAN SM, 1995, J BIOL CHEM, V270, P24375, DOI 10.1074/jbc.270.41.24375; Bifulco M, 2002, P NATL ACAD SCI USA, V99, P1807, DOI 10.1073/pnas.042678799; BINDER BM, 1990, J BIOL CHEM, V265, P15333; Binder BM, 1996, J BIOL CHEM, V271, P19826, DOI 10.1074/jbc.271.33.19826; BROEKHUYSE RM, 1985, CURR EYE RES, V4, P613, DOI 10.3109/02713688508999993; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; Eckmiller MS, 2000, VISUAL NEUROSCI, V17, P711, DOI 10.1017/S0952523800175054; FLEISCHMAN D, 1980, BIOCHIM BIOPHYS ACTA, V630, P176, DOI 10.1016/0304-4165(80)90419-5; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 2003, STRUCTURE, V11, P1037, DOI 10.1016/S0969-2126(03)00184-9; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HORST CJ, 1987, J CELL BIOL, V105, P2973, DOI 10.1083/jcb.105.6.2973; Kennedy MJ, 2001, NEURON, V31, P87, DOI 10.1016/S0896-6273(01)00340-3; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; Langlois G, 1996, P NATL ACAD SCI USA, V93, P4677, DOI 10.1073/pnas.93.10.4677; Lee KA, 2002, PROTEIN SCI, V11, P862, DOI 10.1110/ps.3870102; MATESIC DF, 1992, J CELL SCI, V103, P157; McGinnis JF, 2002, J NEUROSCI RES, V67, P290, DOI 10.1002/jnr.10120; Mendez A, 2000, NEURON, V28, P153, DOI 10.1016/S0896-6273(00)00093-3; Mendez A, 2003, J NEUROSCI, V23, P3124; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; Ozols J, 1997, MOL BIOL CELL, V8, P637, DOI 10.1091/mbc.8.4.637; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PHILP NJ, 1987, FEBS LETT, V225, P127, DOI 10.1016/0014-5793(87)81144-4; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; Pulvermuller A, 1997, BIOCHEMISTRY-US, V36, P9253, DOI 10.1021/bi970772g; Rim J, 1997, BIOCHEMISTRY-US, V36, P7064, DOI 10.1021/bi970470e; Schroder K, 2002, J BIOL CHEM, V277, P43987, DOI 10.1074/jbc.M206211200; SMITH WC, 1994, J BIOL CHEM, V269, P15407; Vishnivetskiy SA, 2002, J BIOL CHEM, V277, P43961, DOI 10.1074/jbc.M206951200; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068; Zambito AM, 2001, BIOCHEM BIOPH RES CO, V283, P42, DOI 10.1006/bbrc.2001.4735; Zhang HB, 2003, MOL VIS, V9, P231	45	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41240	41248		10.1074/jbc.M406768200	http://dx.doi.org/10.1074/jbc.M406768200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15272005	hybrid			2022-12-27	WOS:000223916800123
J	Fago, A; Hundahl, C; Dewilde, S; Gilany, K; Moens, L; Weber, RE				Fago, A; Hundahl, C; Dewilde, S; Gilany, K; Moens, L; Weber, RE			Allosteric regulation and temperature dependence of oxygen binding in human neuroglobin and cytoglobin - Molecular mechanisms and physiological significance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; MURINE NEUROGLOBIN; REDOX STATE; GLOBIN; HEMOGLOBIN; PROTEIN; CELL; ENVIRONMENT; AFFINITY; BRAIN	Two new globin proteins have recently been discovered in vertebrates, neuroglobin in neurons and cytoglobin in all tissues, both showing heme hexacoordination by the distal His(E7) in the absence of gaseous ligands. In analogy to hemoglobin and myoglobin, neuroglobin and cytoglobin are supposedly involved in O-2 storage and delivery, although their physiological role remains to be solved. Here we report O-2 equilibria of recombinant human neuroglobin (NGB) and cytoglobin (CYGB) measured under close to physiological conditions and at varying temperature and pH ranges. NGB shows both alkaline and acid Bohr effects (pH-dependent O-2 affinity) and temperature-dependent enthalpy of oxygenation. O-2 and CO binding equilibrium studies on neuroglobin mutants strongly suggest that the bound O-2 is stabilized by interactions with His(E7) and that this residue functions as a major Bohr group in the presence of Lys(E10). As shown by the titration of free thiols with 4,4'-dithiodipyridine and by mass spectrometry, this mechanism of modulating O-2 affinity is independent of formation of an internal disulfide bond under the experimental conditions used, which stabilize thiols in the reduced form. In CYGB, O-2 binding is cooperative, consistent with its proposed dimeric structure. Similar to myoglobin but in contrast to NGB, O-2 binding to CYGB is pH-independent and exothermic throughout the temperature range investigated. Our data support the hypothesis that CYGB may be involved in O-2-requiring metabolic processes. In contrast, the lower O-2 affinity in NGB does not appear compatible with a physiological role involving mitochondrial O-2 supply at the low O-2 tensions found within neurons.	Aarhus Univ, Inst Biol Sci, Dept Zoophysiol, DK-8000 Aarhus C, Denmark; Univ Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium	Aarhus University; University of Antwerp	Fago, A (corresponding author), Aarhus Univ, Inst Biol Sci, Dept Zoophysiol, CF Mollers Alle 131, DK-8000 Aarhus C, Denmark.	angela.fago@biology.au.dk	Hundahl, Christian Ansgar/H-3938-2015; Gilany, Kambiz/F-3271-2017; Fago, Angela/J-5946-2013	Gilany, Kambiz/0000-0003-2916-7245; Fago, Angela/0000-0001-7315-2628; Gilany, Kambiz/0000-0002-6729-5566				Alayash AI, 2001, ANTIOXID REDOX SIGN, V3, P313, DOI 10.1089/152308601300185250; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BERG JM, 2002, BIOCHEMISTRY-US, P686; Bonaventura C, 1998, BIOCHEMISTRY-US, V37, P496, DOI 10.1021/bi971574s; BRIEHL RW, 1963, J BIOL CHEM, V238, P2361; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; CHIANCONE E, 1981, J MOL BIOL, V152, P577, DOI 10.1016/0022-2836(81)90270-9; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Creighton T. E., 1993, PROTEINS STRUCTURES; de Sanctis D, 2004, BIOCHEM BIOPH RES CO, V316, P1217, DOI 10.1016/j.bbrc.2004.03.007; de Sanctis D, 2004, J MOL BIOL, V336, P917, DOI 10.1016/j.jmb.2003.12.063; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Du WH, 2003, J AM CHEM SOC, V125, P8080, DOI 10.1021/ja034584r; Fago A, 1997, COMP BIOCHEM PHYS B, V118, P319, DOI 10.1016/S0305-0491(97)00160-0; Fago A, 2001, J BIOL CHEM, V276, P27415, DOI 10.1074/jbc.M100759200; GERSONDE K, 1986, EUR J BIOCHEM, V157, P393, DOI 10.1111/j.1432-1033.1986.tb09681.x; Geuens E, 2003, J BIOL CHEM, V278, P30417, DOI 10.1074/jbc.C300203200; Gladwin MT, 2002, J BIOL CHEM, V277, P27818, DOI 10.1074/jbc.M203236200; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hamdane D, 2003, J BIOL CHEM, V278, P51713, DOI 10.1074/jbc.M309396200; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; Herold S, 2004, J BIOL CHEM, V279, P22841, DOI 10.1074/jbc.M313732200; Hochachka P. W., 2002, BIOCH ADAPTATION MEC, DOI 10.1002/bmb.2002.494030030071; KRAUS DW, 1986, SCIENCE, V232, P90, DOI 10.1126/science.232.4746.90; Kriegl JM, 2002, P NATL ACAD SCI USA, V99, P7992, DOI 10.1073/pnas.082244399; Kussmann M, 1997, J MASS SPECTROM, V32, P483; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Lodish H, 2000, MOL CELL BIOL; Mammen PPA, 2002, J HISTOCHEM CYTOCHEM, V50, P1591, DOI 10.1177/002215540205001203; Nienhaus K, 2004, J BIOL CHEM, V279, P22944, DOI 10.1074/jbc.M401561200; PERUTZ MF, 1979, ANNU REV BIOCHEM, V48, P327, DOI 10.1146/annurev.bi.48.070179.001551; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Royer WE, 2001, TRENDS BIOCHEM SCI, V26, P297, DOI 10.1016/S0968-0004(01)01811-4; Sawai H, 2003, BIOCHEMISTRY-US, V42, P5133, DOI 10.1021/bi027067e; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Schmidt M, 2004, J BIOL CHEM, V279, P8063, DOI 10.1074/jbc.M310540200; SUGIMOTO H, IN PRESS J MOL BIOL; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; Uno T, 2004, J BIOL CHEM, V279, P5886, DOI 10.1074/jbc.M311748200; UZAN J, IN PRESS BIOPHYS J; Vallone B, 2004, PROTEINS, V56, P85, DOI 10.1002/prot.20113; Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547; WEBER RE, 1981, NATURE, V292, P386, DOI 10.1038/292386a0; WEBER RE, 1992, J APPL PHYSIOL, V72, P1611, DOI 10.1152/jappl.1992.72.4.1611; Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	54	157	169	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44417	44426		10.1074/jbc.M407126200	http://dx.doi.org/10.1074/jbc.M407126200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15299006	hybrid			2022-12-27	WOS:000224505600025
J	Miyanaga, A; Koseki, T; Matsuzawa, H; Wakagi, T; Shoun, H; Fushinobu, S				Miyanaga, A; Koseki, T; Matsuzawa, H; Wakagi, T; Shoun, H; Fushinobu, S			Crystal structure of a family 54 alpha-L-arabinofuranosidase reveals a novel carbohydrate-binding module that can bind arabinose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOPROTEIN METHANOL DEHYDROGENASE; GEOBACILLUS-STEAROTHERMOPHILUS T-6; ACTIVE-SITE; 3-DIMENSIONAL STRUCTURE; CELLOBIOHYDROLASE-I; TRICHODERMA-REESEI; XYLAN-BINDING; CLASSIFICATION; EXPRESSION; SEQUENCE	As the first known structures of a glycoside hydrolase family 54 (GH54) enzyme, we determined the crystal structures of free and arabinose-complex forms of Aspergillus kawachii IFO4308 alpha-L-arabinofuranosidase (AkAbfB). AkAbfB comprises two domains: a catalytic domain and an arabinose-binding domain (ABD). The catalytic domain has a beta-sandwich fold similar to those of clan-B glycoside hydrolases. ABD has a beta-trefoil fold similar to that of carbohydrate-binding module (CBM) family 13. However, ABD shows a number of characteristics distinctive from those of CBM family 13, suggesting that it could be classified into a new CBM family. In the arabinose-complex structure, one of three arabinofuranose molecules is bound to the catalytic domain through many interactions. Interestingly, a disulfide bond formed between two adjacent cysteine residues recognized the arabinofuranose molecule in the active site. From the location of this arabinofuranose and the results of a mutational study, the nucleophile and acid/ base residues were determined to be Glu(221) and Asp(297), respectively. The other two arabinofuranose molecules are bound to ABD. The O-1 atoms of the two arabinofuranose molecules bound at ABD are both pointed toward the solvent, indicating that these sites can both accommodate an arabinofuranose side-chain moiety linked to decorated arabinoxylans.	Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Natl Res Inst Brewing, Higashihiroshima 7390046, Japan; Aomori Univ, Dept Biosci & Biotechnol, Aomori 0300943, Japan	University of Tokyo	Fushinobu, S (corresponding author), Univ Tokyo, Dept Biotechnol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	asfushi@mail.ecc.u-tokyo.ac.jp	Miyanaga, Akimasa/C-1472-2015; Wakagi, Takayoshi/AAJ-4145-2021; Fushinobu, Shinya/E-4987-2011	Miyanaga, Akimasa/0000-0003-2219-6051; Fushinobu, Shinya/0000-0003-1346-6435				Afolabi PR, 2001, BIOCHEMISTRY-US, V40, P9799, DOI 10.1021/bi002932l; Amaya MF, 2003, J MOL BIOL, V325, P773, DOI 10.1016/S0022-2836(02)01306-2; AVEZOUX A, 1995, BIOCHEM J, V307, P735, DOI 10.1042/bj3070735; BELDMAN G, 1993, CARBOHYD POLYM, V20, P159, DOI 10.1016/0144-8617(93)90146-U; Bianchet MA, 2002, NAT STRUCT BIOL, V9, P628, DOI 10.1038/nsb817; BLAKE CCF, 1994, NAT STRUCT BIOL, V1, P102, DOI 10.1038/nsb0294-102; BORASTON AB, 2004, IN PRESS BIOCH J; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Christopher JA, 1998, J MOL GRAPH MODEL, V16, P285; De Ioannes P, 2000, J BIOTECHNOL, V76, P253, DOI 10.1016/S0168-1656(99)00190-X; Divne C, 1998, J MOL BIOL, V275, P309, DOI 10.1006/jmbi.1997.1437; DIVNE C, 1994, SCIENCE, V265, P524, DOI 10.1126/science.8036495; Fujimoto Z, 2004, J BIOL CHEM, V279, P9606, DOI 10.1074/jbc.M312293200; Fujimoto Z, 2002, J MOL BIOL, V316, P65, DOI 10.1006/jmbi.2001.5338; Fushinobu S, 1998, PROTEIN ENG, V11, P1121, DOI 10.1093/protein/11.12.1121; Gilbert HJ, 2002, ROY SOC CH, P89, DOI 10.1039/9781847550323-00089; Gilbert HJ, 2003, STRUCTURE, V11, P609, DOI 10.1016/S0969-2126(03)00103-5; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hirabayashi J, 1998, J BIOL CHEM, V273, P14450, DOI 10.1074/jbc.273.23.14450; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Hovel K, 2003, EMBO J, V22, P4922, DOI 10.1093/emboj/cdg494; Kaneko S, 1998, APPL ENVIRON MICROB, V64, P4021; Kim BM, 1999, PROTEIN SCI, V8, P430; Koseki T, 2003, J BIOSCI BIOENG, V96, P232, DOI 10.1016/S1389-1723(03)80187-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuno A, 1998, J FERMENT BIOENG, V86, P434, DOI 10.1016/S0922-338X(98)80147-5; MargollesClark E, 1996, APPL ENVIRON MICROB, V62, P3840, DOI 10.1128/AEM.62.10.3840-3846.1996; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Michel G, 2001, STRUCTURE, V9, P513, DOI 10.1016/S0969-2126(01)00612-8; Miyanaga A, 2004, ACTA CRYSTALLOGR D, V60, P1286, DOI 10.1107/S0907444904010108; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nogawa M, 1999, APPL ENVIRON MICROB, V65, P3964; Notenboom V, 2001, J MOL BIOL, V314, P797, DOI 10.1006/jmbi.2001.5153; Notenboom V, 2002, BIOCHEMISTRY-US, V41, P4246, DOI 10.1021/bi015865j; Nurizzo D, 2002, NAT STRUCT BIOL, V9, P665, DOI 10.1038/nsb835; OGASAWARA H, 1991, J BREW SOC JPN, V86, P304; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pitson SM, 1996, FEBS LETT, V398, P7, DOI 10.1016/S0014-5793(96)01153-2; PULS J, 1993, PORT PR R M, V4, P1; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; Saha BC, 2000, BIOTECHNOL ADV, V18, P403, DOI 10.1016/S0734-9750(00)00044-6; Shallom D, 2002, FEBS LETT, V514, P163, DOI 10.1016/S0014-5793(02)02343-8; Shallom D, 2002, J BIOL CHEM, V277, P43667, DOI 10.1074/jbc.M208285200; Szabo L, 2001, J BIOL CHEM, V276, P49061, DOI 10.1074/jbc.M109558200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; Varghese JN, 1999, STRUCTURE, V7, P179, DOI 10.1016/S0969-2126(99)80024-0	53	72	75	2	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44907	44914		10.1074/jbc.M405390200	http://dx.doi.org/10.1074/jbc.M405390200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15292273	hybrid			2022-12-27	WOS:000224505600081
J	Zen, K; Utech, M; Liu, Y; Soto, I; Nusrat, A; Parkos, CA				Zen, K; Utech, M; Liu, Y; Soto, I; Nusrat, A; Parkos, CA			Association of BAP31 with CD11b/CD18 - Potential role in intracellular trafficking of CD11b/CD18 in neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; INTEGRIN MAC-1 CD11B/CD18; POLYMORPHONUCLEAR LEUKOCYTES; ENDOPLASMIC-RETICULUM; INTESTINAL EPITHELIUM; JUNCTION STRUCTURE; HUMAN-GRANULOCYTES; ADHESION RECEPTOR; LIGAND; EXPRESSION	The beta(2) integrin CD11b/CD18 is an integral membrane protein that is present in the plasma membrane and secondary granules of neutrophils and functions as a major adhesion molecule. Upon cellular activation, there is translocation of intracellular pools of CD11b/ CD18 to the plasma membrane in concert with enhanced cellular adhesion. Although much is known about the function of CD11b/ CD18, how this protein is transported within the cell is less well defined. Here we report that CD11b/ CD18 specifically binds to BAP31, a member of a novel class of sorting proteins regulating cellular anterograde transport. Through experiments aimed at identifying CD11b/CD18-binding proteins, we produced a monoclonal antibody termed E1B2 that recognizes a 28-kDa membrane protein that co-precipitates with CD11b/ CD18. Microsequence analysis of the E1B2 antigen revealed that it is BAP31. Co-association of CD11b/ CD18 and BAP31 was confirmed in co-immunoprecipitation and protein binding assays. Additional experiments revealed that the binding of BAP31 to CD11b/ CD18 was not dependent on divalent cations nor mediated by the I-domain of CD11b. Using glutathione S-transferase fusion chimeras, we determined that binding of CD11b/ CD18 to BAP31 is mediated through interactions with the cytoplasmic tail of BAP31. Immunolocalization studies revealed colocalization of BAP31 and CD11b/ CD18 within neutrophil secondary granules. Subcellular fractionation studies in polymorphonuclear leukocytes (PMN) revealed similar patterns of redistribution of BAP31 and CD11b/ CD18 from fractions enriched in secondary granules to the plasma membrane following stimulation with formylmethionylleucylphenylalanine ( fMLP). Given the known sorting properties of BAP31, these findings suggest that BAP31 may play a role in regulating intracellular trafficking of CD11b/ CD18 in neutrophils.	Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA; Univ Munster, Dept Gen Surg, D-48149 Munster, Germany	Emory University; University of Munster	Zen, K (corresponding author), Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Whitehead Biomed Bldg,Rm 115,615 Michael St, Atlanta, GA 30322 USA.	kzen@emory.edu	Parkos, Charles a/B-3896-2009; Nusrat, Asma/B-3887-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054229, R01HL072124, R01HL054229] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL72124, HL54229] Funding Source: Medline; NIDDK NIH HHS [DK277640] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi T, 1996, EMBO J, V15, P1534, DOI 10.1002/j.1460-2075.1996.tb00497.x; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; Annaert WG, 1997, J CELL BIOL, V139, P1397, DOI 10.1083/jcb.139.6.1397; Balsam LB, 1998, J IMMUNOL, V160, P5058; Bax DV, 2004, J BIOL CHEM, V279, P22377, DOI 10.1074/jbc.M400180200; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BORREGAARD N, 1987, SCIENCE, V237, P1204, DOI 10.1126/science.3629236; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Cai TQ, 1996, J EXP MED, V184, P1213, DOI 10.1084/jem.184.4.1213; CALAFAT J, 1993, BLOOD, V81, P3122; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; DiScipio RG, 1998, J IMMUNOL, V160, P4057; Ducret A, 2003, EUR J BIOCHEM, V270, P342, DOI 10.1046/j.1432-1033.2003.03395.x; Gahmberg CG, 1997, CURR OPIN CELL BIOL, V9, P643, DOI 10.1016/S0955-0674(97)80117-2; Hopkins AM, 2003, J CELL SCI, V116, P725, DOI 10.1242/jcs.00300; Issekutz AC, 1999, J LEUKOCYTE BIOL, V65, P117, DOI 10.1002/jlb.65.1.117; JESAITIS AJ, 1990, J CLIN INVEST, V85, P821, DOI 10.1172/JCI114509; KAOUTZANI P, 1993, AM J PHYSIOL, V264, pC1327, DOI 10.1152/ajpcell.1993.264.5.C1327; KIM KM, 1994, EMBO J, V13, P3793, DOI 10.1002/j.1460-2075.1994.tb06690.x; Kjeldsen L, 1999, J IMMUNOL METHODS, V232, P131, DOI 10.1016/S0022-1759(99)00171-4; KOTOVUORI P, 1993, GLYCOBIOLOGY, V3, P131, DOI 10.1093/glycob/3.2.131; Lambert G, 2001, J BIOL CHEM, V276, P20340, DOI 10.1074/jbc.M011209200; Liu Y, 2002, J BIOL CHEM, V277, P10028, DOI 10.1074/jbc.M109720200; Liu Y, 2001, J BIOL CHEM, V276, P40156, DOI 10.1074/jbc.M104138200; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; Manley HA, 2001, J HISTOCHEM CYTOCHEM, V49, P1235, DOI 10.1177/002215540104901005; MILLER JL, 1982, BLOOD, V60, P790; MONBOISSE JC, 1991, J LEUKOCYTE BIOL, V50, P373, DOI 10.1002/jlb.50.4.373; MOYLE M, 1994, J BIOL CHEM, V269, P10008; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; Paquet ME, 2004, J IMMUNOL, V172, P7548, DOI 10.4049/jimmunol.172.12.7548; PARKOS CA, 1995, AM J PHYSIOL-CELL PH, V268, pC472, DOI 10.1152/ajpcell.1995.268.2.C472; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; PARKOS CA, 1985, J BIOL CHEM, V260, P6541; PARKOS CA, 1991, J CLIN INVEST, V88, P1605, DOI 10.1172/JCI115473; Parkos CA, 1996, MOL MED, V2, P489, DOI 10.1007/BF03401908; Repo H, 1997, J IMMUNOL, V159, P943; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Schamel WWA, 2003, P NATL ACAD SCI USA, V100, P9861, DOI 10.1073/pnas.1633363100; Schober JM, 2002, BLOOD, V99, P4457, DOI 10.1182/blood.V99.12.4457; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; SMOLEN JE, 1986, AM J PATHOL, V124, P281; STACKER SA, 1991, J IMMUNOL, V146, P648; THOMPSON HL, 1992, CLIN EXP IMMUNOL, V90, P280; WALZOG B, 1995, EXP CELL RES, V218, P28, DOI 10.1006/excr.1995.1127; Zen K, 2004, MOL BIOL CELL, V15, P3926, DOI 10.1091/mbc.E04-04-0317; Zen K, 2002, J IMMUNOL, V169, P5270, DOI 10.4049/jimmunol.169.9.5270; Zimmer KP, 2000, GASTROENTEROLOGY, V118, P128, DOI 10.1016/S0016-5085(00)70421-5	53	46	46	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44924	44930		10.1074/jbc.M402115200	http://dx.doi.org/10.1074/jbc.M402115200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15294914	hybrid			2022-12-27	WOS:000224505600083
J	Gerges, NZ; Backos, DS; Esteban, JA				Gerges, NZ; Backos, DS; Esteban, JA			Local control of AMPA receptor trafficking at the postsynaptic terminal by a small GTPase of the Rab family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; POLARIZED MEMBRANE-TRANSPORT; PLASMA-MEMBRANE; SYNAPTIC-TRANSMISSION; EARLY ENDOSOMES; NEUROTRANSMITTER RELEASE; EXCITATORY SYNAPSES; PROTEIN-KINASE; GOLGI NETWORK; LIVING CELLS	The delivery of neurotransmitter receptors into the synaptic membrane is essential for synaptic function and plasticity. However, the molecular mechanisms of these specialized trafficking events and their integration with the intracellular membrane transport machinery are virtually unknown. Here, we have investigated the role of the Rab family of membrane sorting proteins in the late stages of receptor trafficking into the postsynaptic membrane. We have identified Rab8, a vesicular transport protein associated with trans-Golgi network membranes, as a critical component of the cellular machinery that delivers AMPA-type glutamatergic receptors (AMPARs) into synapses. Using electron microscopic techniques, we have found that Rab8 is localized in close proximity to the synaptic membrane, including the postsynaptic density. Electrophysiological studies indicated that Rab8 is necessary for the synaptic delivery of AMPARs during plasticity (long-term potentiation) and during constitutive receptor cycling. In addition, Rab8 is required for AMPAR delivery into the spine surface, but not for receptor transport from the dendritic shaft into the spine compartment or for delivery into the dendritic surface. Therefore, Rab8 specifically drives the local delivery of AMPARs into synapses. These results demonstrate a new role for the cellular secretory machinery in the control of synaptic function and plasticity directly at the postsynaptic membrane.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Esteban, JA (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	estebanj@umich.edu	Backos, Donald/Q-4791-2018; Backos, Donald/N-5265-2019; Esteban, Jose/L-4944-2014	Backos, Donald/0000-0001-6735-6210; Backos, Donald/0000-0001-6735-6210; Esteban, Jose/0000-0002-3759-3300				Ang AL, 2003, J CELL BIOL, V163, P339, DOI 10.1083/jcb.200307046; Barbero P, 2002, J CELL BIOL, V156, P511, DOI 10.1083/jcb.200109030; Barbieri MA, 1998, J BIOL CHEM, V273, P25850, DOI 10.1074/jbc.273.40.25850; Barry MF, 2002, CURR OPIN NEUROBIOL, V12, P279, DOI 10.1016/S0959-4388(02)00329-X; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; D'Adamo P, 1998, NAT GENET, V19, P134, DOI 10.1038/487; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; DERETIC D, 1995, J CELL SCI, V108, P215; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; El-Hussein AE, 2000, SCIENCE, V290, P1364; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; Fan GH, 2003, BLOOD, V101, P2115, DOI 10.1182/blood-2002-07-1965; FISCHER V, 1990, P NATL ACAD SCI USA, V87, P1988; Folsch H, 2003, J CELL BIOL, V163, P351, DOI 10.1083/jcb.200309020; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Gerges NZ, 2004, J NEUROSCI, V24, P4758, DOI 10.1523/JNEUROSCI.0594-04.2004; Hattula K, 2002, MOL BIOL CELL, V13, P3268, DOI 10.1091/mbc.E02-03-0143; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Horton AC, 2003, J NEUROSCI, V23, P6188; HUBER LA, 1993, J CELL BIOL, V123, P47, DOI 10.1083/jcb.123.1.47; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; HUBER LA, 1995, MOL CELL BIOL, V15, P918; Lee SH, 2001, NEUROPHARMACOLOGY, V41, P680, DOI 10.1016/S0028-3908(01)00124-1; LO DC, 1994, NEURON, V13, P1263, DOI 10.1016/0896-6273(94)90412-X; Lonart G, 1998, NEURON, V21, P1141, DOI 10.1016/S0896-6273(00)80631-5; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; MALINOW R, 1999, IMAGING LIVING NEURO; McCaffrey MW, 2001, FEBS LETT, V495, P21, DOI 10.1016/S0014-5793(01)02359-6; Mohrmann K, 2002, J BIOL CHEM, V277, P10474, DOI 10.1074/jbc.M111237200; Moritz OL, 2001, MOL BIOL CELL, V12, P2341, DOI 10.1091/mbc.12.8.2341; Murthy VN, 2003, ANNU REV NEUROSCI, V26, P701, DOI 10.1146/annurev.neuro.26.041002.131445; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; PHEND KD, 1995, J HISTOCHEM CYTOCHEM, V43, P283, DOI 10.1177/43.3.7532656; Piccini A, 2002, J NEUROSCI, V22, P5387; Pierce JP, 2001, CURR BIOL, V11, P351, DOI 10.1016/S0960-9822(01)00077-X; Poncer JC, 2002, J NEUROSCI, V22, P4406, DOI 10.1523/JNEUROSCI.22-11-04406.2002; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Roberts RL, 1999, J CELL SCI, V112, P3667; Roosterman D, 2003, AM J PHYSIOL-CELL PH, V284, pC1319, DOI 10.1152/ajpcell.00540.2002; SCHLESINGER S, 1993, TRENDS BIOTECHNOL, V11, P18, DOI 10.1016/0167-7799(93)90070-P; Schluter OM, 2004, J NEUROSCI, V24, P6629, DOI 10.1523/JNEUROSCI.1610-04.2004; Schluter OM, 2002, J BIOL CHEM, V277, P40919, DOI 10.1074/jbc.M203704200; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; Sheng M, 2001, CELL, V105, P825, DOI 10.1016/S0092-8674(01)00406-8; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shirakawa R, 2000, J BIOL CHEM, V275, P33844, DOI 10.1074/jbc.M002834200; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Song I, 2002, TRENDS NEUROSCI, V25, P578, DOI 10.1016/S0166-2236(02)02270-1; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Stein V, 2003, J NEUROSCI, V23, P5503; Steiner P, 2002, J CELL BIOL, V157, P1197, DOI 10.1083/jcb.200202022; Stenmark H, 2001, GENOME BIOL, V2; Sudhof TC, 2000, NEURON, V28, P317, DOI 10.1016/S0896-6273(00)00109-4; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Volpicelli LA, 2002, J NEUROSCI, V22, P9776, DOI 10.1523/jneurosci.22-22-09776.2002; Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhu JJ, 2000, NAT NEUROSCI, V3, P1098, DOI 10.1038/80614	74	105	109	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43870	43878		10.1074/jbc.M404982200	http://dx.doi.org/10.1074/jbc.M404982200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15297461	hybrid, Green Submitted			2022-12-27	WOS:000224383100064
J	Utomo, A; Jiang, XZ; Furuta, S; Yun, J; Levin, DS; Wang, YCJ; Desai, KV; Green, JE; Chen, PL; Lee, WH				Utomo, A; Jiang, XZ; Furuta, S; Yun, J; Levin, DS; Wang, YCJ; Desai, KV; Green, JE; Chen, PL; Lee, WH			Identification of a novel putative non-selenocysteine containing phospholipid hydroperoxide glutathione peroxidase (NPGPx) essential for alleviating oxidative stress generated from polyunsaturated fatty acids in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-COUPLED REPAIR; RETINOBLASTOMA GENE-PRODUCT; RETRACTED ARTICLE. SEE; EICOSAPENTAENOIC ACID; ANTIOXIDANT ENZYMES; LIPID-PEROXIDATION; FREE-RADICALS; HIGH-TITER; BRCA1; EXPRESSION	A dramatic reduction in the expression of a novel phospholipid hydroperoxide glutathione peroxidase ( PHGPx), which incorporates cysteine instead of selenocysteine in the conserved catalytic motif was observed in a microarray analysis using cDNAs amplified from mRNA of Brca1-null mouse embryonic fibroblasts. This non-selenocysteine PHGPx named NPGPx is a cytoplasmic protein with molecular mass of similar to 22 kDa and has little detectable glutathione peroxidase activity in vitro. Ectopic expression of NPGPx in Brca1-null cells that were sensitive to oxidative stress induced by hydrogen peroxide conferred a similar resistance level to that of the wild-type cells, suggesting the importance of this protein in reducing oxidative stress. Expression of NPGPx was found in many tissues, including developing mammary gland. However, the majority of breast cancer cell lines studied ( 11 of 12) expressed very low or undetectable levels of NPGPx irrespective of BRCA1 status. Re-expression of NPGPx in breast cancer lines, MCF-7 and HCC1937, which have very little or no endogenous NPGPx, induced resistance to eicosapentaenoic acid ( an omega-3 type of polyunsaturated fatty acid)-mediated cell death. Conversely, inhibition of the expression of NPGPx by the specific small interfering RNA in HS578T breast cancer cells that originally express substantial amounts of endogenous NPGPx increased their sensitivity to eicosapentaenoic acid-mediated cell death. Thus, NPGPx plays an essential role in breast cancer cells in alleviating oxidative stress generated from polyunsaturated fatty acid metabolism.	Univ Calif Irvine, Dept Biol Chem, Sch Med, Irvine, CA 92697 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA; GenTex Inc, San Antonio, TX 78245 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	University of California System; University of California Irvine; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lee, WH (corresponding author), Univ Calif Irvine, Dept Biol Chem, Sch Med, Irvine, CA 92697 USA.	whlee@uci.edu	utomo, ahmad/CAF-9546-2022; Furuta, Saori/P-9677-2018; Utomo, Ahmad Rusdan Handoyo/CAJ-0570-2022; Utomo, Ahmad Rusdan H/GPW-8717-2022; Desai, Kartiki/ABF-3538-2021; Utomo, Ahmad/AAO-5605-2020; Jiang, Xianzhi/A-5427-2013	Furuta, Saori/0000-0003-1121-0487; Utomo, Ahmad Rusdan H/0000-0003-3092-3714; Jiang, Xianzhi/0000-0002-4645-154X; Chen, Phang-Lang/0000-0002-0357-9017; Desai, Kartiki V/0000-0001-8974-0707	NCI NIH HHS [CA94170, CA81020] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC005740, P01CA081020, R01CA094170, Z01BC005740] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARSLAND A, 1990, LIPIDS, V25, P546, DOI 10.1007/BF02537162; AbdiDezfuli F, 1997, BREAST CANCER RES TR, V45, P229, DOI 10.1023/A:1005818917479; Ambrosone CB, 2000, ANTIOXID REDOX SIGN, V2, P903, DOI 10.1089/ars.2000.2.4-903; Avery AM, 2001, J BIOL CHEM, V276, P33730, DOI 10.1074/jbc.M105672200; Avis I, 2001, FASEB J, V15, P2007, DOI 10.1096/fj.00-0866fje; Bardon S, 1996, CANCER LETT, V99, P51, DOI 10.1016/0304-3835(95)04037-4; Bartsch H, 1999, CARCINOGENESIS, V20, P2209, DOI 10.1093/carcin/20.12.2209; Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6; Bieche I, 1999, GENE CHROMOSOME CANC, V24, P255, DOI 10.1002/(SICI)1098-2264(199903)24:3<255::AID-GCC11>3.0.CO;2-2; Brigelius-Flohe R, 2000, ATHEROSCLEROSIS, V152, P307, DOI 10.1016/S0021-9150(99)00486-4; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen YM, 1996, CANCER RES, V56, P3168; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; DEMOZ A, 1992, LIPIDS, V27, P968, DOI 10.1007/BF02535573; Deng CX, 2000, BIOESSAYS, V22, P728; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; DOROSHOW JH, 1990, PHARMACOL THERAPEUT, V47, P359, DOI 10.1016/0163-7258(90)90062-7; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; El-Rifai W, 1999, CANCER GENET CYTOGEN, V112, P169, DOI 10.1016/S0165-4608(98)00274-X; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; ESWORTHY RS, 1995, CANCER RES, V55, P957; ESWORTHY RS, 1994, GENE, V144, P317, DOI 10.1016/0378-1119(94)90400-6; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; Gouaze V, 2001, MOL PHARMACOL, V60, P488; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HARRIS AL, 1992, ACTA ONCOL, V31, P205, DOI 10.3109/02841869209088904; Herbette S, 2002, EUR J BIOCHEM, V269, P2414, DOI 10.1046/j.1432-1033.2002.02905.x; Hough CD, 2001, CANCER RES, V61, P3869; IMAI H, 1995, J BIOCHEM-TOKYO, V118, P1061, DOI 10.1093/jb/118.5.1061; Imai H, 2003, FREE RADICAL BIO MED, V34, P145, DOI 10.1016/S0891-5849(02)01197-8; Iscan M, 1998, EUR J DRUG METAB PH, V23, P497, DOI 10.1007/BF03190001; Kirschmann DA, 2002, CANCER RES, V62, P4478; Kuhn H, 2002, FREE RADICAL BIO MED, V33, P154, DOI 10.1016/S0891-5849(02)00855-9; Le Page F, 2000, CANCER RES, V60, P5548; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lusini L, 2001, INT J CANCER, V91, P55, DOI 10.1002/1097-0215(20010101)91:1<55::AID-IJC1006>3.0.CO;2-4; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mork H, 2000, NUTR CANCER, V37, P108, DOI 10.1207/S15327914NC3701_14; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Pavelic K, 2001, J MOL MED, V79, P566, DOI 10.1007/s001090100256; Perquin M, 2001, J CANCER RES CLIN, V127, P368, DOI 10.1007/s004320000228; Perquin M, 2000, CANCER LETT, V158, P7, DOI 10.1016/S0304-3835(00)00481-X; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; Rose DP, 1998, INT J ONCOL, V13, P1179; ROSE DP, 1990, MED ONCOL TUMOR PHAR, V7, P121; ROSE DP, 1993, JNCI-J NATL CANCER I, V85, P1743, DOI 10.1093/jnci/85.21.1743; Shackelford RE, 2001, J BIOL CHEM, V276, P21951, DOI 10.1074/jbc.M011303200; Stoll BA, 2002, BRIT J NUTR, V87, P193, DOI [10.1079/BJN2001512, 10.1079/BJNBJN2001512]; Sztajer H, 2001, J BIOL CHEM, V276, P7397, DOI 10.1074/jbc.M008631200; Tan MJ, 1999, J BIOL CHEM, V274, P12061, DOI 10.1074/jbc.274.17.12061; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vernet P, 1999, MOL REPROD DEV, V54, P362, DOI 10.1002/(SICI)1098-2795(199912)54:4&lt;362::AID-MRD6&gt;3.0.CO;2-#; Wang HP, 2001, FREE RADICAL BIO MED, V30, P825, DOI 10.1016/S0891-5849(01)00469-5; WELSCH CW, 1992, CANCER RES, V52, pS2040; Welt C, 2002, EXP BIOL MED, V227, P724, DOI 10.1177/153537020222700905; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	69	87	101	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43522	43529		10.1074/jbc.M407141200	http://dx.doi.org/10.1074/jbc.M407141200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15294905	hybrid			2022-12-27	WOS:000224383100022
J	Brown, RJ; Gauthier, A; Parks, RJ; McPherson, R; Sparks, DL; Schultz, JR; Yao, ZM				Brown, RJ; Gauthier, A; Parks, RJ; McPherson, R; Sparks, DL; Schultz, JR; Yao, ZM			Severe hypoalphalipoproteinemia in mice expressing human hepatic lipase deficient in binding to heparan sulfate proteoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; ESTER TRANSFER PROTEIN; TRIGLYCERIDE LIPASE; PLASMA-LIPOPROTEINS; SELECTIVE UPTAKE; HDL METABOLISM; SCAVENGER RECEPTOR; POSTHEPARIN PLASMA; LIPOLYTIC-ACTIVITY	Unlike human hepatic lipase (hHL) that is mainly cell surface-anchored via binding to heparan sulfate proteoglycans (HSPG), mouse HL (mHL) has a low affinity to HSPG and thus is largely blood-borne. The reduced HSPG binding of mHL is attributable to the C-terminal amino acids. To determine the functions of HSPG binding of hHL in vivo, we created adenovirus vectors encoding hHL or a chimeric protein (designated hHLmt) in which the C-terminal HSPG-binding sequences were replaced with the corresponding mouse sequences. Injecting hHLmt-expressing virus into C57BL/6J mice (1.8 x 1010 virus particles/mouse) resulted in a 3-fold increase in pre-heparin HL activity, whereas infection with an identical dose of hHL virus did not change pre-heparin HL activity. In hHLmt-expressing mice, the concentration of total cholesterol and phospholipids was inversely related to the hHL activity in pre-heparin plasma in a dose- and time-dependent manner, and the decrease was mainly attributable to high density lipoproteins (HDL) cholesterol and HDL phospholipids. The expression of hHL exhibited no change in plasma total cholesterol or phospholipid levels as compared with control mice infected with luciferase or injected with saline. The reduced HDL lipids in the hHLmt-expressing mice were accompanied by markedly decreased plasma and hepatic apolipoprotein (apo) A-I. In primary hepatocytes isolated from hHLmt-expressing mice, the concentration of cell-associated and secreted apoA-I was decreased by 2-3-fold as compared with hepatocytes isolated from control mice, whereas the levels of apoB and apoE were unaltered. Infection of primary hepatocytes with hHLmt virus ex vivo also resulted in reduced apoA-I secretion but had no effect on cell-associated apoA-I. These results suggest that expression of HSPG binding-deficient hHL has a profound HDL-lowering effect.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Ottawa, ON K1Y 4W7, Canada; Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa	Yao, ZM (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Ottawa, ON K1Y 4W7, Canada.	zyao@ottawaheart.ca		Brown, Robert/0000-0002-1875-1537				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Amar MJA, 1998, J LIPID RES, V39, P2436; ApplebaumBowden D, 1996, J CLIN INVEST, V97, P799, DOI 10.1172/JCI118479; Barter PJ, 2003, ARTERIOSCL THROM VAS, V23, P160, DOI 10.1161/01.ATV.0000054658.91146.64; BLADES B, 1993, ARTERIOSCLER THROMB, V13, P1227, DOI 10.1161/01.ATV.13.8.1227; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brown RJ, 2003, J LIPID RES, V44, P1306, DOI 10.1194/jlr.M200374-JLR200; Brundert M, 2003, J LIPID RES, V44, P1020, DOI 10.1194/jlr.M300058-JLR200; Burris TP, 2002, MOL GENET METAB, V77, P13, DOI 10.1016/S1096-7192(02)00144-0; BUSCH SJ, 1994, J BIOL CHEM, V269, P16376; Choi SY, 1998, J BIOL CHEM, V273, P20456, DOI 10.1074/jbc.273.32.20456; Clee SM, 1997, J LIPID RES, V38, P2079; Conde-Knape K, 2002, J LIPID RES, V43, P2136, DOI 10.1194/jlr.M200210-JLR200; CONNELLY PW, 1990, ARTERIOSCLEROSIS, V10, P40, DOI 10.1161/01.ATV.10.1.40; DATTA S, 1988, J BIOL CHEM, V263, P1107; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DICHEK HL, 1993, J LIPID RES, V34, P1393; Dichek HL, 1998, J BIOL CHEM, V273, P1896, DOI 10.1074/jbc.273.4.1896; Ehnholm C, 1986, Methods Enzymol, V129, P716; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; FIELDING CJ, 1995, J LIPID RES, V36, P211; GLASER DS, 1992, J LIPID RES, V33, P209; HEGELE RA, 1993, ARTERIOSCLER THROMB, V13, P720, DOI 10.1161/01.ATV.13.5.720; HIDE WA, 1992, J LIPID RES, V33, P167; Hill JS, 1996, J BIOL CHEM, V271, P22931, DOI 10.1074/jbc.271.37.22931; Hirata K, 1999, J BIOL CHEM, V274, P14170, DOI 10.1074/jbc.274.20.14170; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; HUFF MW, 1993, ARTERIOSCLER THROMB, V13, P1282, DOI 10.1161/01.ATV.13.9.1282; Huuskonen J, 2001, ATHEROSCLEROSIS, V155, P269, DOI 10.1016/S0021-9150(01)00447-6; Jansen H, 2002, J LIPID RES, V43, P1352, DOI 10.1194/jlr.R200008-JLR200; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; JENSEN GL, 1982, BIOCHIM BIOPHYS ACTA, V710, P464, DOI 10.1016/0005-2760(82)90130-8; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Jin WJ, 2002, GENOMICS, V80, P268, DOI 10.1006/geno.2002.6837; Jin WJ, 2002, TRENDS ENDOCRIN MET, V13, P174, DOI 10.1016/S1043-2760(02)00589-1; Kuivenhoven JA, 1997, J LIPID RES, V38, P191; Lambert G, 1999, J LIPID RES, V40, P1294; Lutz EP, 2001, J CLIN INVEST, V107, P1183, DOI 10.1172/JCI11774; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; MARTIN GA, 1988, J BIOL CHEM, V263, P10907; McCoy MG, 2002, J LIPID RES, V43, P921; Mezdour H, 1997, J BIOL CHEM, V272, P13570, DOI 10.1074/jbc.272.21.13570; PETERSON J, 1986, BIOCHIM BIOPHYS ACTA, V878, P65, DOI 10.1016/0005-2760(86)90344-9; Qin SC, 2000, J LIPID RES, V41, P269; Ramsamy TA, 2003, J LIPID RES, V44, P733, DOI 10.1194/jlr.M200339-JLR200; Ransamy TA, 2000, J BIOL CHEM, V275, P33480, DOI 10.1074/jbc.M005436200; Santamarina-Fojo S, 2000, CURR OPIN LIPIDOL, V11, P267, DOI 10.1097/00041433-200006000-00007; Santamarina-Fojo S, 1998, CURR OPIN LIPIDOL, V9, P211, DOI 10.1097/00041433-199806000-00005; SHAFI S, 1994, J LIPID RES, V35, P709; STAHNKE G, 1987, DIFFERENTIATION, V35, P45, DOI 10.1111/j.1432-0436.1987.tb00150.x; SUBRAHMANYAN L, 1988, SCAND J IMMUNOL, V27, P251, DOI 10.1111/j.1365-3083.1988.tb02345.x; THOMAS SS, 1995, BBA-MOL BASIS DIS, V1272, P37, DOI 10.1016/0925-4439(95)00065-C; Tretjakovs P, 2000, Med Sci Monit, V6, P507; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; Weng W, 1999, J LIPID RES, V40, P1064; Zambon A, 2000, J LIPID RES, V41, P2094	57	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42403	42409		10.1074/jbc.M407748200	http://dx.doi.org/10.1074/jbc.M407748200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292235	hybrid			2022-12-27	WOS:000224226400010
J	Chang, WZ; Rewari, A; Centrella, M; McCarthy, TL				Chang, WZ; Rewari, A; Centrella, M; McCarthy, TL			Fos-related antigen 2 controls protein kinase A-induced CCAAT/enhancer-binding protein beta expression in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT BONE; GROWTH-FACTOR-BETA; DELTA-GENE-EXPRESSION; JUN-RELATED GENES; TRANSCRIPTION FACTOR; C/EBP-BETA; CELL-CULTURES; DEOXYRIBONUCLEIC-ACID; SIGNAL-TRANSDUCTION; COLLAGEN-SYNTHESIS	Transcription factor CCAAT/enhancer-binding protein beta (C/EBPbeta) plays an important role in hormone-dependent gene expression. In osteoblasts C/EBPbeta can increase insulin-like growth factor I (IGF-I) transcription following treatment with hormones that activate protein kinase A, but little is known as yet about the expression of C/EBPbeta itself in these cells. We initially showed that prostaglandin E-2 (PGE(2)) rapidly enhances C/EBPbeta mRNA and protein expression, and in this study we identified a 3'-proximal region of the C/EBPbeta promoter containing a 541-bp upstream sequence that could account for this effect. PGE(2)-dependent activation of C/EBPbeta was blocked by expression of a mutated regulatory subunit of protein kinase A or by mutation of two previously identified cAMP-sensitive cis-acting regulatory elements within the promoter between bp -111 and -61. Nuclear protein binding to these elements was induced by PGE(2), required new protein synthesis, and was sensitive to antibody to the transcription factor termed Fos-related antigen 2 (Fra-2). Fra-2 cDNA generated from rat osteoblasts by reverse transcriptase PCR was 95% homologous to human Fra-2, and PGE(2) rapidly induced Fra-2 mRNA and protein expression. Consistent with these findings, over-expression of Fra-2 significantly increased C/EBPbeta promoter activity in PGE(2)-induced osteoblasts, whereas expression of Fra-2 lacking its activation domain had a dominant negative inhibitory effect. Together, these results reveal a significant, hormone-dependent role for Fra-2 in osteoblast function, both directly, through its ability to increase new C/EBPbeta gene expression, and indirectly, through downstream C/EBP sensitive genes.	Yale Univ, Sch Med, Dept Surg, Sect Plast Surg, New Haven, CT 06520 USA	Yale University	McCarthy, TL (corresponding author), Yale Univ, Sch Med, Dept Surg, Sect Plast Surg, POB 208041, New Haven, CT 06520 USA.	thomas.mccarthy@yale.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039201, R01AR039201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056310] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39201] Funding Source: Medline; NIDDK NIH HHS [DK56310] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banerjee C, 1996, ENDOCRINOLOGY, V137, P1991, DOI 10.1210/en.137.5.1991; Billiard J, 2001, J BIOL CHEM, V276, P15354, DOI 10.1074/jbc.M009973200; Buck M, 2003, HEPATOLOGY, V37, P731, DOI 10.1053/jhep.2003.50155; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Carpenter TO, 1998, ENDOCRINOLOGY, V139, P35, DOI 10.1210/en.139.1.35; CARRASCO D, 1995, ONCOGENE, V10, P1069; CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; Centrella M, 1996, ANN NY ACAD SCI, V785, P224, DOI 10.1111/j.1749-6632.1996.tb56267.x; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; FOLETTA VC, 1994, ONCOGENE, V9, P3305; Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Galien R, 1996, MOL ENDOCRINOL, V10, P713, DOI 10.1210/me.10.6.713; Granet C, 2002, CELL SIGNAL, V14, P679, DOI 10.1016/S0898-6568(02)00008-6; GRUDA MC, 1994, ONCOGENE, V9, P2537; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Harrison JR, 2000, J BONE MINER RES, V15, P1138, DOI 10.1359/jbmr.2000.15.6.1138; Ji CH, 1999, ENDOCRINOLOGY, V140, P4564, DOI 10.1210/en.140.10.4564; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Ji CH, 2003, MOL ENDOCRINOL, V17, P1834, DOI 10.1210/me.2002-0235; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Lewinson D, 2003, J HISTOCHEM CYTOCHEM, V51, P1161, DOI 10.1177/002215540305100906; MCCABE LR, 1995, EXP CELL RES, V218, P255, DOI 10.1006/excr.1995.1154; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; McCarthy TL, 2000, ENDOCRINOLOGY, V141, P127, DOI 10.1210/en.141.1.127; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; McCarthy TL, 2000, J BIOL CHEM, V275, P21746, DOI 10.1074/jbc.M002291200; McCarthy TL, 2003, J BIOL CHEM, V278, P43121, DOI 10.1074/jbc.M306531200; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; McCauley LK, 2001, ENDOCRINOLOGY, V142, P1975, DOI 10.1210/en.142.5.1975; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Niehof M, 2001, J MOL BIOL, V309, P855, DOI 10.1006/jmbi.2001.4708; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; SCHILLING AF, 2003, J BONE MIN RES S2, V18, pS3; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Smith M, 2001, MOL CELL BIOL, V21, P3704, DOI 10.1128/MCB.21.11.3704-3713.2001; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Tanabe A, 2000, BIOL PHARM BULL, V23, P1424, DOI 10.1248/bpb.23.1424; Tierney EP, 2003, PHYSIOL GENOMICS, V16, P47, DOI 10.1152/physiolgenomics.00066.2003; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Varghese S, 2000, ENDOCRINOLOGY, V141, P2185, DOI 10.1210/en.141.6.2185; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; Yamada T, 1998, BIOCHEM BIOPH RES CO, V242, P88, DOI 10.1006/bbrc.1997.7915; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A	61	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42438	42444		10.1074/jbc.M405549200	http://dx.doi.org/10.1074/jbc.M405549200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15299028	hybrid			2022-12-27	WOS:000224226400014
J	Perez, E; Constant, P; Lemassu, A; Laval, F; Daffe, M; Guilhot, C				Perez, E; Constant, P; Lemassu, A; Laval, F; Daffe, M; Guilhot, C			Characterization of three glycosyltransferases involved in the biosynthesis of the phenolic glycolipid antigens from the Mycobacterium tuberculosis complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOCEROSIC ACID SYNTHASE; PHTHIOCEROL DIMYCOCEROSATE; GENE-CLUSTER; VIRULENCE; LEPRAE; MUTAGENESIS; GENERATION; MUTATIONS; FAMILY; UNIQUE	Mycobacterium tuberculosis and Mycobacterium leprae, the two main mycobacterial pathogens in humans, produce highly specific long chain beta-diols, the dimycocerosates of phthiocerol, and structurally related phenolic glycolipid (PGL) antigens, which are important virulence factors. In addition, M. tuberculosis also secretes glycosylated p-hydroxybenzoic acid methyl esters (p-HBAD) that contain the same carbohydrate moiety as the species-specific PGL of M. tuberculosis (PGL-tb). The genes involved in the biosynthesis of these compounds in M. tuberculosis are grouped on a 70-kilobase chromosomal fragment containing three genes encoding putative glycosyltransferases: Rv2957, Rv2958c, and Rv2962c. To determine the functions of these genes, three recombinant M. tuberculosis strains, in which these genes were individually inactivated, were constructed and biochemically characterized. Our results demonstrated that (i) the biosynthesis of PGL-tb and p-HBAD involves common enzymatic steps, (ii) the Rv2957, Rv2958c, and Rv2962c genes are involved in the formation of the glycosyl moiety of the two classes of molecules, and (iii) the product of Rv2962c catalyzes the transfer of a rhamnosyl residue onto p-hydroxybenzoic acid ethyl ester or phenolphthiocerol dimycocerosates, whereas the products of Rv2958c and Rv2957 add a second rhamnosyl unit and a fucosyl residue to form the species-specific triglycosyl appendage of PGL-tb and p-HBAD. The recombinant strains produced provide the tools to study the role of the carbohydrate domain of PGL-tb and p-HBAD in M. tuberculosis pathogenesis.	Inst Pharmacol & Biol Struct, Dept Mecanismes Mol Infect Mycobacteriennes, CNRS, F-31077 Toulouse, France; Univ Toulouse 3, Unite Mixte Rech 5089, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Daffe, M (corresponding author), Inst Pharmacol & Biol Struct, Dept Mecanismes Mol Infect Mycobacteriennes, CNRS, 205 Route Narbonne, F-31077 Toulouse, France.	Mamadou.Daffe@ipbs.fr; Christophe.Guilhot@ipbs.fr	LAUZERAL-VIZCAINO, Françoise/W-8898-2019	LAUZERAL-VIZCAINO, Françoise/0000-0002-9741-3252; Lemassu, Anne/0000-0002-9323-2497				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; Azad AK, 1996, P NATL ACAD SCI USA, V93, P4787, DOI 10.1073/pnas.93.10.4787; BARRY CE, 2003, KEYST S TUB INT HOST; Belisle JT, 1998, METH MOL B, V101, P31, DOI 10.1385/0-89603-471-2:31; Bifani PJ, 2002, TRENDS MICROBIOL, V10, P45, DOI 10.1016/S0966-842X(01)02277-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P203; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CHO SN, 1992, J CLIN MICROBIOL, V30, P3065, DOI 10.1128/JCM.30.12.3065-3069.1992; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Constant P, 2002, J BIOL CHEM, V277, P38148, DOI 10.1074/jbc.M206538200; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; DAFFE M, 1988, BIOCHIM BIOPHYS ACTA, V958, P443, DOI 10.1016/0005-2760(88)90230-5; DAFFE M, 1987, EUR J BIOCHEM, V167, P155, DOI 10.1111/j.1432-1033.1987.tb13317.x; DAFFE M, 1991, J INFECT DIS, V163, P161, DOI 10.1093/infdis/163.1.161; DAFFE M, 1988, J GEN MICROBIOL, V134, P2049; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Daffe M, 2000, GLYCOMICROBIOLOGY, P225, DOI DOI 10.1007/0-306-46821-2_8; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; FOURNIE JJ, 1989, INFECT IMMUN, V57, P3653, DOI 10.1128/IAI.57.11.3653-3659.1989; GOREN MB, 1974, INFECT IMMUN, V9, P150, DOI 10.1128/IAI.9.1.150-158.1974; Jackson M, 1999, INFECT IMMUN, V67, P2867, DOI 10.1128/IAI.67.6.2867-2873.1999; Laval F, 2001, ANAL CHEM, V73, P4537, DOI 10.1021/ac0105181; Malaga W, 2003, FEMS MICROBIOL LETT, V219, P261, DOI 10.1016/S0378-1097(03)00003-X; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998; MATHUR M, 1992, J BIOL CHEM, V267, P19388; MEHRA V, 1984, NATURE, V308, P194, DOI 10.1038/308194a0; NEILL MA, 1988, J EXP MED, V167, P30, DOI 10.1084/jem.167.1.30; Ng V, 2000, CELL, V103, P511, DOI 10.1016/S0092-8674(00)00142-2; Pelicic V, 1996, MOL MICROBIOL, V20, P919, DOI 10.1111/j.1365-2958.1996.tb02533.x; Pelicic V, 1997, P NATL ACAD SCI USA, V94, P10955, DOI 10.1073/pnas.94.20.10955; PRTSCH E, 1985, TABLAS ELUCIDACION E; SCHLESINGER LS, 1991, J EXP MED, V174, P1031, DOI 10.1084/jem.174.5.1031; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THURMAN PF, 1993, EUR J BIOCHEM, V212, P705, DOI 10.1111/j.1432-1033.1993.tb17708.x; WATANABE M, 1994, BBA-LIPID LIPID MET, V1210, P174, DOI 10.1016/0005-2760(94)90118-X	42	59	71	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42574	42583		10.1074/jbc.M406246200	http://dx.doi.org/10.1074/jbc.M406246200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292272	hybrid			2022-12-27	WOS:000224226400030
J	Adachi, K; Lakka, V; Zhao, Y; Surrey, S				Adachi, K; Lakka, V; Zhao, Y; Surrey, S			Ubiquitylation of nascent globin chains in a cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; DEPENDENT PROTEOLYSIS; PROTEIN-DEGRADATION; ALPHA-GLOBIN; BIOGENESIS; CFTR	The ubiquitin/proteasome pathway for degradation of completed and nascent globin chains was evaluated using a cell-free in vitro coupled transcription/translation assay. No decrease in radiolabeled globin chains was observed when ubiquitin, energy regenerating source (or ATP), and E1 and E2 enzymes were added 30 min after the start of translation when globin chain synthesis had plateaued. In contrast, the addition of these components prior to the start of translation resulted in no radiolabeled globin chains after 30 min. The loss of radiolabeled globin chains was dependent on ATP concentration; the higher the concentration, the less the radiolabeled globin chains formed. Prior to the initiation of transcription/translation, cell extract was preincubated with the proteasomal inhibitor MG132 in the absence of globin chain expression vector after which ubiquitin-protein isopeptidase inhibitor, Ubal, and expression vector were added in the presence of 1.5 mM ATP. Thereafter, radiolabeled monoubiquitylated and multiubiquitylated globin chains with few unmodified globin chains were formed. Our results suggest that polyubiquitylated globin chains are localized to the polysomal fractions. These results suggest that nascent globin chains are potential targets for ubiquitylation and deubiquitylation during or soon after translation and that ATP levels play a role in the balance between polypeptide synthesis and degradation.	Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Jefferson Med Coll, Cardeza Fdn Hematol Res, Dept Med, Philadelphia, PA 19107 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Jefferson University	Adachi, K (corresponding author), Childrens Hosp Philadelphia, Div Hematol, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	adachi@email.chop.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069256, R01HL058879, P60HL038632] Funding Source: NIH RePORTER; NHLBI NIH HHS [P60 HL38632, HL69256, HL58879] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi K, 2003, ARCH BIOCHEM BIOPHYS, V413, P99, DOI 10.1016/S0003-9861(03)00089-4; Adachi K, 2002, J BIOL CHEM, V277, P13415, DOI 10.1074/jbc.M200857200; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; FEDOROV AN, 1997, J BIOL CHEM, V272, P32175; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1982, ANNU REV BIOCHEM, V51, P335, DOI 10.1146/annurev.bi.51.070182.002003; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Komar AA, 1997, J BIOL CHEM, V272, P10646; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; NAKANO H, 1994, BIOSCI BIOTECH BIOCH, V58, P631, DOI 10.1271/bbb.58.631; Persons DA, 2000, P NATL ACAD SCI USA, V97, P5022, DOI 10.1073/pnas.97.10.5022; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; Shaeffer JR, 1997, BLOOD, V90, P1300, DOI 10.1182/blood.V90.3.1300.1300_1300_1308; SHAEFFER JR, 1983, J BIOL CHEM, V258, P3172; SHAEFFER JR, 1995, BIOCHEMISTRY-US, V34, P4015, DOI 10.1021/bi00012a020; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEFES I, 1995, P NATL ACAD SCI USA, V92, P4982, DOI 10.1073/pnas.92.11.4982; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WILKINSON KD, 1980, J BIOL CHEM, V255, P7529	26	6	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41767	41774		10.1074/jbc.M405059200	http://dx.doi.org/10.1074/jbc.M405059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15297454	hybrid			2022-12-27	WOS:000224075500065
J	Catena, R; Tiveron, C; Ronchi, A; Porta, S; Ferri, A; Tatangelo, L; Cavallaro, M; Favaro, R; Ottolenghi, S; Reinbold, R; Scholer, H; Nicolis, SK				Catena, R; Tiveron, C; Ronchi, A; Porta, S; Ferri, A; Tatangelo, L; Cavallaro, M; Favaro, R; Ottolenghi, S; Reinbold, R; Scholer, H; Nicolis, SK			Conserved POU binding DNA sites in the Sox2 upstream enhancer regulate gene expression in embryonic and neural stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; CHICKEN SOX2; SELF-RENEWAL; DIFFERENTIATION; PROTEINS; OCT-4; REGIONALIZATION; NEUROGENESIS; REQUIREMENT; ACTIVATION	The Sox2 transcription factor is expressed early in the stem cells of the blastocyst inner cell mass and, later, in neural stem cells. We previously identified a Sox2 5'-regulatory region directing transgene expression to the inner cell mass and, later, to neural stem cells and precursors of the forebrain. Here, we identify a core enhancer element able to specify transgene expression in forebrain neural precursors of mouse embryos, and we show that the same core element efficiently activates transcription in inner cell mass-derived embryonic stem (ES) cells. Mutation of POU factor binding sites, able to recognize the neural factors Brn1 and Brn2, shows that these sites contribute to transgene activity in neural cells. The same sites are also essential for activity in ES cells, where they bind different members of the POU family, including Oct4, as shown by gel shift assays and chromatin immunoprecipitation with anti-Oct4 antibodies. Our findings indicate a role for the same POU binding motifs in Sox2 transgene regulation in both ES and neural precursor cells. Oct4 might play a role in the regulation of Sox2 in ES (inner cell mass) cells and, possibly, at the transition between inner cell mass and neural cells, before recruitment of neural POU factors such as Brn1 and Brn2.	Univ Milano Bicocca, Dept Biosci & Biotechnol, I-20126 Milan, Italy; Ist Regina Elena, Ctr Ric Sperimentale, Transgen Mice Serv Ctr, I-00158 Rome, Italy; Univ Penn, Sch Vet Med, Ctr Anim Transgenesis & Germ Cell Res, New Bolton Ctr,Germline Dev Grp, Kennett Sq, PA 19348 USA	University of Milano-Bicocca; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Pennsylvania	Nicolis, SK (corresponding author), Univ Milano Bicocca, Dept Biosci & Biotechnol, Piazza Sci 2, I-20126 Milan, Italy.	silvia.nicolis@unimib.it	reinbold, rolland/AAW-8940-2020; , HS/AAB-4434-2019; Favaro, Rebecca/HHZ-8978-2022; Ferri, Luca Angelo/AAC-5890-2022	, HS/0000-0003-2643-5136; Favaro, Rebecca/0000-0002-6195-5711; Ferri, Luca Angelo/0000-0001-9031-6284; NICOLIS, SILVIA KIRSTEN/0000-0003-0378-3808; RONCHI, ANTONELLA ELLENA/0000-0002-3905-1038	Telethon [D.127] Funding Source: Medline	Telethon(Fondazione Telethon)		ALVAREZBOLADO G, 1995, J COMP NEUROL, V355, P237, DOI 10.1002/cne.903550207; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Burgess S, 2002, DEVELOPMENT, V129, P905; Bylund M, 2003, NAT NEUROSCI, V6, P1162, DOI 10.1038/nn1131; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Ferri ALM, 2004, DEVELOPMENT, V131, P3805, DOI 10.1242/dev.01204; Fuhrmann G, 2001, DEV CELL, V1, P377, DOI 10.1016/S1534-5807(01)00038-7; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; Hitoshi S, 2002, DEVELOPMENT, V129, P233; Josephson R, 1998, DEVELOPMENT, V125, P3087; Katsuoka F, 2000, EMBO J, V19, P2980, DOI 10.1093/emboj/19.12.2980; Kishi M, 2000, DEVELOPMENT, V127, P791; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Miyagi S, 2004, MOL CELL BIOL, V24, P4207, DOI 10.1128/MCB.24.10.4207-4220.2004; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Pfeffer PL, 2002, DEVELOPMENT, V129, P307; RONCHI A, 1989, NUCLEIC ACIDS RES, V17, P10231, DOI 10.1093/nar/17.24.10231; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Schier AF, 1996, DEVELOPMENT, V123, P165; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shimozaki K, 2003, DEVELOPMENT, V130, P2505, DOI 10.1242/dev.00476; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Tomioka M, 2002, NUCLEIC ACIDS RES, V30, P3202, DOI 10.1093/nar/gkf435; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Uchikawa M, 2003, DEV CELL, V4, P509, DOI 10.1016/S1534-5807(03)00088-1; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; van der Kooy D, 2000, SCIENCE, V287, P1439, DOI 10.1126/science.287.5457.1439; Wood HB, 1999, MECH DEVELOP, V86, P197, DOI 10.1016/S0925-4773(99)00116-1; Yamagishi H, 2003, GENE DEV, V17, P269, DOI 10.1101/gad.1048903; Yeom YI, 1996, DEVELOPMENT, V122, P881; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zappone MV, 2000, DEVELOPMENT, V127, P2367	41	117	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41846	41857		10.1074/jbc.M405514200	http://dx.doi.org/10.1074/jbc.M405514200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15262984	hybrid			2022-12-27	WOS:000224075500075
J	Dere, R; Napierala, M; Ranum, LPW; Wells, RD				Dere, R; Napierala, M; Ranum, LPW; Wells, RD			Hairpin structure-forming propensity of the (CCTG center dot CAGG) tetranucleotide repeats contributes to the genetic instability associated with myotonic dystrophy type 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							INTRAMOLECULAR DNA TRIPLEXES; DOUBLE-STRAND BREAK; ORIENTATION-DEPENDENT MANNER; TRINUCLEOTIDE REPEAT; ESCHERICHIA-COLI; MISMATCH REPAIR; CTG REPEATS; IN-VITRO; HOMOLOGOUS RECOMBINATION; SUPERCOILED PLASMIDS	The genetic instabilities of (CCTG.CAGG)(n) tetranucleotide repeats were investigated to evaluate the molecular mechanisms responsible for the massive expansions found in myotonic dystrophy type 2 (DM2) patients. DM2 is caused by an expansion of the repeat from the normal allele of 26 to as many as 11,000 repeats. Genetic expansions and deletions were monitored in an African green monkey kidney cell culture system (COS-7 cells) as a function of the length (30, 114, or 200 repeats), orientation, or proximity of the repeat tracts to the origin (SV40) of replication. As found for CTG.CAG repeats related to DM1, the instabilities were greater for the longer tetranucleotide repeat tracts. Also, the expansions and deletions predominated when cloned in orientation II (CAGG on the leading strand template) rather than I and when cloned proximal rather than distal to the replication origin. Biochemical studies on synthetic d(CAGG)(26) and d( CCTG)(26) as models of unpaired regions of the replication fork revealed that d(CAGG)(26) has a marked propensity to adopt a defined base paired hairpin structure, whereas the complementary d(CCTG)(26) lacks this capacity. The effect of orientation described above differs from all previous results with three triplet repeat sequences ( including CTG.CAG), which are also involved in the etiologies of other hereditary neurological diseases. However, similar to the triplet repeat sequences, the ability of one of the two strands to form a more stable folded structure, in our case the CAGG strand, explains this unorthodox "reversed" behavior.	Texas A&M Univ, Hlth Sci Ctr, Ctr Genome Res, Inst Biosci & Technol, Houston, TX 77030 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; University of Minnesota System; University of Minnesota Twin Cities	Wells, RD (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Ctr Genome Res, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamushsc.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035870, R01NS037554] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES11347] Funding Source: Medline; NINDS NIH HHS [NS37554, NS35870] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; Allawi HT, 1998, BIOCHEMISTRY-US, V37, P2170, DOI 10.1021/bi9724873; Allawi HT, 1998, NUCLEIC ACIDS RES, V26, P2694, DOI 10.1093/nar/26.11.2694; AMIRHAERI S, 1988, J VIROL, V62, P922, DOI 10.1128/JVI.62.3.922-931.1988; ANDERSON S, 1979, J BIOL CHEM, V254, P1495; Balakumaran BS, 2000, HUM MOL GENET, V9, P93, DOI 10.1093/hmg/9.1.93; Beilina A, 2004, HUM MOL GENET, V13, P543, DOI 10.1093/hmg/ddh053; Bichara M, 2000, GENETICS, V154, P533; Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Bowater RP, 2001, PROG NUCLEIC ACID RE, V66, P159; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; Cemal CK, 1999, GENE, V236, P53, DOI 10.1016/S0378-1119(99)00273-5; CHAN HW, 1974, NATURE, V252, P205, DOI 10.1038/252205a0; CHAN HW, 1977, BIOCHEMISTRY-US, V16, P2356, DOI 10.1021/bi00630a008; Cleary JD, 2003, CYTOGENET GENOME RES, V100, P25, DOI 10.1159/000072837; Cleary JD, 2002, NAT GENET, V31, P37, DOI 10.1038/ng870; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Cummings CJ, 2000, ANNU REV GENOM HUM G, V1, P281, DOI 10.1146/annurev.genom.1.1.281; DARLOW JM, 1995, GENETICS, V141, P825; Darlow JM, 1998, J MOL BIOL, V275, P3, DOI 10.1006/jmbi.1997.1453; DAVISON A, 1994, NUCLEIC ACIDS RES, V22, P4361, DOI 10.1093/nar/22.21.4361; Day JW, 2003, NEUROLOGY, V60, P657, DOI 10.1212/01.WNL.0000054481.84978.F9; DEB S, 1986, MOL CELL BIOL, V6, P1663, DOI 10.1128/MCB.6.5.1663; DUTCH RE, 1995, J VIROL, V69, P3084, DOI 10.1128/JVI.69.5.3084-3089.1995; Finsterer J, 2002, EUR J NEUROL, V9, P441, DOI 10.1046/j.1468-1331.2002.00453.x; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Gacy AM, 1998, MOL CELL, V1, P583, DOI 10.1016/S1097-2765(00)80058-1; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; Hebert ML, 2004, J MOL BIOL, V336, P655, DOI 10.1016/j.jmb.2003.12.038; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; Henricksen LA, 2002, J BIOL CHEM, V277, P22361, DOI 10.1074/jbc.M201765200; Huertas D, 1996, BIOCHEMISTRY-US, V35, P13125, DOI 10.1021/bi961020+; HUERTAS D, 1993, EMBO J, V12, P4029, DOI 10.1002/j.1460-2075.1993.tb06081.x; Iyer RR, 1999, J BIOL CHEM, V274, P3865, DOI 10.1074/jbc.274.6.3865; Jakupciak JP, 2000, J BIOL CHEM, V275, P40003, DOI 10.1074/jbc.M007153200; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; Jankowski C, 2000, P NATL ACAD SCI USA, V97, P2134, DOI 10.1073/pnas.040460297; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; Ji JP, 1996, NUCLEIC ACIDS RES, V24, P2835, DOI 10.1093/nar/24.14.2835; JIANG H, 1991, NUCLEIC ACIDS RES, V19, P6943, DOI 10.1093/nar/19.24.6943; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1992, J BIOL CHEM, V267, P20887; KANG S, 1992, J BIOL CHEM, V267, P19435; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KOHWISHIGEMATSU T, 1992, METHOD ENZYMOL, V212, P155; Kramer PR, 1996, HUM GENET, V98, P151, DOI 10.1007/s004390050179; Krasilnikov AS, 1997, NUCLEIC ACIDS RES, V25, P1339, DOI 10.1093/nar/25.7.1339; Krasilnikova MM, 2004, MOL CELL BIOL, V24, P2286, DOI 10.1128/MCB.24.6.2286-2295.2004; Lahue RS, 2003, FRONT BIOSCI-LANDMRK, V8, pS653, DOI 10.2741/1107; Lalioti MD, 1997, NATURE, V386, P847, DOI 10.1038/386847a0; LASPADA AR, 1994, ANN NEUROL, V36, P814, DOI 10.1002/ana.410360604; LaSpada AR, 1997, BRAIN PATHOL, V7, P943; Lee S, 2002, EXP MOL MED, V34, P313, DOI 10.1038/emm.2002.44; LI Y, 1991, BIOCHEMISTRY-US, V30, P7566, DOI 10.1021/bi00244a028; LI Y, 1995, BIOCHEMISTRY-US, V34, P10056, DOI 10.1021/bi00031a030; Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125; Mankodi A, 2002, CURR OPIN NEUROL, V15, P545, DOI 10.1097/00019052-200210000-00005; Marcadier JL, 2003, J BIOL CHEM, V278, P33848, DOI 10.1074/jbc.M304284200; Matsuura T, 2000, NAT GENET, V26, P191, DOI 10.1038/79911; Maurer DJ, 1998, MOL CELL BIOL, V18, P4597, DOI 10.1128/MCB.18.8.4597; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; McMurray CT, 1999, P NATL ACAD SCI USA, V96, P1823, DOI 10.1073/pnas.96.5.1823; Miret JJ, 1998, P NATL ACAD SCI USA, V95, P12438, DOI 10.1073/pnas.95.21.12438; Miret JJ, 1997, MOL CELL BIOL, V17, P3382, DOI 10.1128/MCB.17.6.3382; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; MOXLEY RT, 1995, MUSCLE NERVE, V18, P557, DOI 10.1002/mus.880180516; Napierala M, 1997, J BIOL CHEM, V272, P31079, DOI 10.1074/jbc.272.49.31079; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Napierala M, 2004, J BIOL CHEM, V279, P6444, DOI 10.1074/jbc.M309596200; Nasar F, 2000, MOL CELL BIOL, V20, P3449, DOI 10.1128/MCB.20.10.3449-3458.2000; Nenguke T, 2003, HUM MOL GENET, V12, P1021, DOI 10.1093/hmg/ddg111; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16784, DOI 10.1074/jbc.271.28.16784; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Ohshima K, 1999, NEUROLOGY, V53, P1854, DOI 10.1212/WNL.53.8.1854; Oussatcheva EA, 2001, J BIOL CHEM, V276, P30878, DOI 10.1074/jbc.M104697200; PALECEK E, 1992, METHOD ENZYMOL, V212, P139; PANYUTIN IG, 1992, J BIOL CHEM, V267, P5495; Parniewski P, 1999, NUCLEIC ACIDS RES, V27, P616, DOI 10.1093/nar/27.2.616; Parsons MA, 1998, J BIOL CHEM, V273, P26998, DOI 10.1074/jbc.273.41.26998; Pearson CE, 1997, HUM MOL GENET, V6, P1117, DOI 10.1093/hmg/6.7.1117; Pearson CE, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P585; Pearson CE, 2002, NUCLEIC ACIDS RES, V30, P4534, DOI 10.1093/nar/gkf572; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; Pelletier R, 2003, MOL CELL BIOL, V23, P1349, DOI 10.1128/MCB.23.4.1349-1357.2003; Petruska J, 1998, J BIOL CHEM, V273, P5204, DOI 10.1074/jbc.273.9.5204; Peyret N, 1999, BIOCHEMISTRY-US, V38, P3468, DOI 10.1021/bi9825091; Pluciennik A, 2002, J BIOL CHEM, V277, P34074, DOI 10.1074/jbc.M202127200; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; Ranum LPW, 2004, AM J HUM GENET, V74, P793, DOI 10.1086/383590; Richard GF, 1999, MOL GEN GENET, V261, P871, DOI 10.1007/s004380050031; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; Savouret C, 2004, MOL CELL BIOL, V24, P629, DOI 10.1128/MCB.24.2.629-637.2004; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; Schumacher S, 1998, J MOL BIOL, V279, P1101, DOI 10.1006/jmbi.1998.1827; Schweitzer JK, 1997, HUM MOL GENET, V6, P349, DOI 10.1093/hmg/6.3.349; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; SHIMIZU M, 1990, BIOCHEMISTRY-US, V29, P4704, DOI 10.1021/bi00471a027; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; Sinden RR, 2002, J BIOSCIENCES, V27, P53, DOI 10.1007/BF02703683; Sinden RR, 2001, NATURE, V411, P757, DOI 10.1038/35081234; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; TIBANYENDA N, 1984, EUR J BIOCHEM, V139, P19, DOI 10.1111/j.1432-1033.1984.tb07970.x; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; Van Craenenbroeck K, 2000, EUR J BIOCHEM, V267, P5665, DOI 10.1046/j.1432-1327.2000.01645.x; Veeraraghavan J, 2003, J BIOL CHEM, V278, P42854, DOI 10.1074/jbc.M305137200; Vispe S, 2003, J BIOL CHEM, V278, P35279, DOI 10.1074/jbc.M303448200; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wells R D, 1998, Results Probl Cell Differ, V21, P133; Wells R.D., 1998, GENETIC INSTABILITIE; Wells RD, 1998, J BIOL CHEM, V273, P19532, DOI 10.1074/jbc.273.31.19532; WOHLRAB F, 1992, METHOD ENZYMOL, V212, P294; YU A, 1995, NUCLEIC ACIDS RES, V23, P4055, DOI 10.1093/nar/23.20.4055; Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P8326, DOI 10.1073/pnas.151008498	126	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41715	41726		10.1074/jbc.M406415200	http://dx.doi.org/10.1074/jbc.M406415200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292165	hybrid			2022-12-27	WOS:000224075500059
J	Larsen, MB; Elfving, B; Wiborg, O				Larsen, MB; Elfving, B; Wiborg, O			The chicken serotonin transporter discriminates between serotonin-selective reuptake inhibitors - A species-scanning mutagenesis study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECOGNITION; TRANSMEMBRANE DOMAIN; NEUROTRANSMITTER TRANSPORTERS; MOLECULAR-CLONING; EXPRESSION; COCAINE; ANTIDEPRESSANTS; RESIDUES; OLIGOMERIZATION; LOCALIZATION	The serotonin transporter (SERT) belongs to a family of sodium chloride-dependent transporters responsible for uptake of amino acids and biogenic amines from extracellular spaces. SERT represents the main pharmacological target in the treatment of several clinical conditions, including depression and anxiety. Serotonin-selective reuptake inhibitors and tricyclic antidepressants are the most predominantly prescribed drugs in the treatment of depression. In addition to antidepressants also psychostimulants, like cocaine and amphetamines, are important SERT antagonists. In the present study, we report the cloning and characterization of chicken SERT. Although the uptake kinetic was very similar to human SERT, the pharmacological profiles differed considerably for the two species. We find that chicken SERT is capable of discriminating between different serotonin-selective reuptake inhibitors; thus, the potency of S-citalopram and paroxetine is reduced more than 40-fold. A cross-species chimera strategy was undertaken and followed by species-scanning mutagenesis. Differences in pharmacological profiles were tracked to amino acid residues 169, 172, and 586 in human SERT. Structure-activity studies on structurally related compounds indicated that species divergences in drug sensitivity between human and chicken SERT were arising from differences in coordination or recognition of an important aminomethyl pharmacophoric substructure, which is shared by all high affinity antidepressants. Consequently, we suggest that Ala(169) and Ile(172) of human SERT are important residues in sensing the N-methylation state of SERT antagonists.	Aarhus Psychiat Univ Hosp, Mol Neurobiol Lab, Dept Biol Psychiat, Risskov 8240, Denmark	Aarhus University	Wiborg, O (corresponding author), Aarhus Psychiat Univ Hosp, Mol Neurobiol Lab, Dept Biol Psychiat, Skovagervej 2, Risskov 8240, Denmark.	owiborg@post.tele.dk	Elfving, Betina/H-2814-2019	Elfving, Betina/0000-0001-6939-5088				Barker EL, 1999, J NEUROSCI, V19, P4705; Barker EL, 1996, MOL PHARMACOL, V50, P957; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; BARKER EL, 1994, MOL PHARMACOL, V46, P799; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Chang AS, 1996, MOL BRAIN RES, V43, P185, DOI 10.1016/S0169-328X(96)00172-6; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JX, 1998, AM J PHYSIOL-GASTR L, V275, pG433, DOI 10.1152/ajpgi.1998.275.3.G433; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COREY JL, 1994, P NATL ACAD SCI USA, V91, P1188, DOI 10.1073/pnas.91.3.1188; DEMCHYSHYN LL, 1994, P NATL ACAD SCI USA, V91, P5158, DOI 10.1073/pnas.91.11.5158; Feighner JP, 1999, J CLIN PSYCHIAT, V60, P18; FULLER RW, 1990, ANN NY ACAD SCI, V600, P68, DOI 10.1111/j.1749-6632.1990.tb16873.x; Galli A, 1997, J NEUROSCI, V17, P3401; Gorman JM, 2002, CNS SPECTRUMS, V7, P40, DOI 10.1017/S1092852900028595; GUNDERTOFTE K, 1996, COMPUTER ASSISTED LE, P443; HOFFMAN BJ, 1994, PHARMACOPSYCHIATRY, V27, P16, DOI 10.1055/s-2007-1014268; Jess U, 1996, FEBS LETT, V394, P44, DOI 10.1016/0014-5793(96)00916-7; Kamdar G, 2001, J BIOL CHEM, V276, P4038, DOI 10.1074/jbc.M008483200; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; Kristensen AS, 2004, EUR J NEUROSCI, V19, P1513, DOI 10.1111/j.1460-9568.2004.03202.x; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; Melikian HE, 1996, MOL PHARMACOL, V50, P266; Miller GM, 2001, MOL BRAIN RES, V87, P124, DOI 10.1016/S0169-328X(00)00288-6; Mortensen OV, 2001, J NEUROCHEM, V79, P237, DOI 10.1046/j.1471-4159.2001.00587.x; Mortensen OV, 1999, MOL BRAIN RES, V71, P120, DOI 10.1016/S0169-328X(99)00178-3; Nelson N, 1998, J NEUROCHEM, V71, P1785; OWENS MJ, 1994, CLIN CHEM, V40, P288; Owens MJ, 2001, BIOL PSYCHIAT, V50, P345, DOI 10.1016/S0006-3223(01)01145-3; Padbury JF, 1997, MOL BRAIN RES, V45, P163, DOI 10.1016/S0169-328X(96)00309-9; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Ranganathan R, 2001, J NEUROSCI, V21, P5871, DOI 10.1523/JNEUROSCI.21-16-05871.2001; Ravna AW, 2003, J PHARMACOL EXP THER, V307, P34, DOI 10.1124/jpet.103.054593; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; Sandhu SK, 2002, EUR J BIOCHEM, V269, P3934, DOI 10.1046/j.1432-1033.2002.03084.x; Schmid JA, 2001, BIOCHEM SOC T, V29, P732, DOI 10.1042/0300-5127:0290732; Sur C, 1997, P NATL ACAD SCI USA, V94, P7639, DOI 10.1073/pnas.94.14.7639; TATE CG, 1994, J BIOL CHEM, V269, P26303; Tatsumi M, 1997, EUR J PHARMACOL, V340, P249, DOI 10.1016/S0014-2999(97)01393-9; White FJ, 1998, NATURE, V393, P118, DOI 10.1038/30105	44	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42147	42156		10.1074/jbc.M405579200	http://dx.doi.org/10.1074/jbc.M405579200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15271993	hybrid			2022-12-27	WOS:000224075500107
J	Wright, AM; Gong, XD; Verdon, B; Linsdell, P; Mehta, A; Riordan, JR; Argent, BE; Gray, MA				Wright, AM; Gong, XD; Verdon, B; Linsdell, P; Mehta, A; Riordan, JR; Argent, BE; Gray, MA			Novel regulation of cystic fibrosis transmembrane conductance regulator (CFTR) channel gating by external chloride	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BICARBONATE SECRETION; SALIVARY MUCINS; CL-CHANNEL; WILD-TYPE; PHOSPHORYLATION; PH; CELLS; VISCOSITY; BINDING; ATP	The cystic fibrosis transmembrane conductance regulator ( CFTR) is vital for Cl- and HCO3- transport in many epithelia. As the HCO3- concentration in epithelial secretions varies and can reach as high as 140 mM, the lumen-facing domains of CFTR are exposed to large reciprocal variations in Cl- and HCO3- levels. We have investigated whether changes in the extracellular anionic environment affects the activity of CFTR using the patch clamp technique. In fast whole cell current recordings, the replacement of 100 mM external Cl- (Cl-o(-)) with HCO3-, Br-, NO3-, or aspartate(-) inhibited inward CFTR current (Cl- efflux) by similar to50% in a reversible manner. Lowering Cl-o(-) alone by iso-osmotic replacement with mannitol also reduced Cl- efflux to a similar extent. The maximal inhibition of CFTR current was similar to 70%. Raising cytosolic calcium shifted the Cl- dose-inhibition curve to the left but did not alter the maximal current inhibition observed. In contrast, a reduction in the internal [Cl-] neither inhibited CFTR nor altered the block caused by reduced Cl-o(-). Single channel recordings from outside-out patches showed that lowering Cl-o(-) markedly reduced channel open probability with little effect on unitary conductance. Together, these results indicate that alterations in Cl-o(-) alone and not the Cl-/ HCO3- ratio regulate the gating of CFTR. Physiologically, our data have implications for current models of epithelial HCO3- secretion and for the control of pH at epithelial cell surfaces.	Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Dalhousie Univ, Dept Physiol & Biophys, Halifax, NS B3H 1X5, Canada; Univ Dundee, Ninewells Hosp & Med Sch, Div Maternal & Child Hlth Sci, Dundee DD1 9SY, Scotland; Mayo Clin Scottsdale, SC Johnson Med Res Ctr, Mayo Clin & Mayo Fdn, Scottsdale, AZ 85259 USA	Newcastle University - UK; Dalhousie University; University of Dundee; Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Gray, MA (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	m.a.gray@ncl.ac.uk		Linsdell, Paul/0000-0001-6257-6273; GRAY, MICHAEL/0000-0002-6774-6283				ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; Argent B. E., 1994, P1473; Argent B.E., 1997, BILIARY PANCREATIC D, P349; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; BHASKAR KR, 1991, AM J PHYSIOL, V261, pG827, DOI 10.1152/ajpgi.1991.261.5.G827; CARNOY C, 1993, AM J RESP CELL MOL, V9, P323, DOI 10.1165/ajrcmb/9.3.323; CARSON MR, 1995, J BIOL CHEM, V270, P20466, DOI 10.1074/jbc.270.35.20466; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; Coakley RD, 2003, P NATL ACAD SCI USA, V100, P16083, DOI 10.1073/pnas.2634339100; FOSKETT JK, 1990, AM J PHYSIOL, V259, pC998; GONG X, 2003, J PHYSIOL-LONDON, P387; Gong XD, 2003, J GEN PHYSIOL, V122, P673, DOI 10.1085/jgp.200308889; Grimard V, 2004, J BIOL CHEM, V279, P5528, DOI 10.1074/jbc.M311014200; IROKAWA T, 2004, IN PRESS AM J PHYSL; Ishiguro H, 2002, J GEN PHYSIOL, V120, P617, DOI 10.1085/jgp.20028631; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; KOPELMAN H, 1988, GASTROENTEROLOGY, V95, P349, DOI 10.1016/0016-5085(88)90490-8; Luo JX, 1998, AM J PHYSIOL-CELL PH, V274, pC1397, DOI 10.1152/ajpcell.1998.274.5.C1397; O'Reilly CM, 2000, GASTROENTEROLOGY, V118, P1187, DOI 10.1016/S0016-5085(00)70372-6; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; RICHARD EA, 1990, SCIENCE, V247, P1208, DOI 10.1126/science.2156338; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBINSON PJ, 1990, DIGEST DIS SCI, V35, P1299, DOI 10.1007/BF01536423; Shcheynikov N, 2004, J BIOL CHEM, V279, P21857, DOI 10.1074/jbc.M313323200; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; Sheppard DN, 1999, PHYSIOL REV, V79, P23; SMITH JJ, 1992, J CLIN INVEST, V89, P1148, DOI 10.1172/JCI115696; Tabcharani JA, 1997, J GEN PHYSIOL, V110, P341, DOI 10.1085/jgp.110.4.341; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VEERMAN ECI, 1989, J BIOL BUCCALE, V17, P297; Wang XF, 2003, NAT CELL BIOL, V5, P902, DOI 10.1038/ncb1047; WANKE CA, 1990, INFECT IMMUN, V58, P794, DOI 10.1128/IAI.58.3.794-800.1990; Zsembery A, 2002, HEPATOLOGY, V35, P95, DOI 10.1053/jhep.2002.30423	39	39	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41658	41663		10.1074/jbc.M405517200	http://dx.doi.org/10.1074/jbc.M405517200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15286085	hybrid			2022-12-27	WOS:000224075500052
J	Stensman, H; Raghunath, A; Larsson, C				Stensman, H; Raghunath, A; Larsson, C			Autophosphorylation suppresses whereas kinase inhibition augments the translocation of protein kinase C alpha in response to diacylglycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY DOMAINS; CATALYTIC DOMAIN; PHOSPHOLIPASE D1; DOWN-REGULATION; PKC-EPSILON; BETA-II; PHOSPHORYLATION; ACTIVATION; MEMBRANE; DEPHOSPHORYLATION	We have seen that protein kinase Calpha (PKCalpha) is transiently translocated to the plasma membrane by carbachol stimulation of neuroblastoma cells. This is induced by the Ca2+ increase, and PKCalpha does not respond to diacylglycerol (DAG). The unresponsiveness is dependent on structures in the catalytic domain of PKCalpha. This study was designed to investigate if and how the kinase activity and autophosphorylation are involved in regulating the translocation. PKCalpha enhanced green fluorescent protein translocation was studied in living neuroblastoma cells by confocal microscopy. Carbachol stimulation induced a transient translocation of PKCalpha to the plasma membrane and a sustained translocation of kinase-dead PKCalpha. In cells treated with the PKC inhibitor GF109203X, wild-type PKCalpha also showed a sustained translocation. The same effects were seen with PKCbetaI, PKCbetaII, and PKCdelta. Only kinase-dead and not wild-type PKCalpha translocated in response to 1,2-dioctanoylglycerol. To examine whether autophosphorylation regulates relocation to the cytosol, the autophosphorylation sites in PKCalpha were mutated to glutamate, to mimic phosphorylation, or alanine, to mimic the nonphosphorylated protein. After stimulation with carbachol, glutamate mutants behaved like wild-type PKCalpha, whereas alanine mutants behaved like kinase-dead PKCalpha. When the alanine mutants were treated with 1,2-dioctanoylglycerol, all cells showed a sustained translocation of the protein. However, neither carbachol nor GF109203X had any major effects on the level of autophosphorylation, and GF109203X potentiated the translocation of the glutamate mutants. We, therefore, hypothesize that 1) autophosphorylation of PKCalpha limits its sensitivity to DAG and 2) that kinase inhibitors augment the DAG sensitivity of PKCalpha, perhaps by destabilizing the closed conformation.	Lund Univ, Malmo Univ Hosp, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Larsson, C (corresponding author), Lund Univ, Malmo Univ Hosp, Entrance 78,3rd Floor, S-20502 Malmo, Sweden.	christer.larsson@molmed.mas.lu.se						Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; Banci L, 2002, J BIOL CHEM, V277, P12988, DOI 10.1074/jbc.M106875200; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Chen JS, 2004, J BIOL CHEM, V279, P22076, DOI 10.1074/jbc.M311033200; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; Gysin S, 1997, EUR J BIOCHEM, V249, P156, DOI 10.1111/j.1432-1033.1997.t01-2-00156.x; Gysin S, 1996, EUR J BIOCHEM, V240, P747, DOI 10.1111/j.1432-1033.1996.0747h.x; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Hu TH, 2004, J BIOL CHEM, V279, P35702, DOI 10.1074/jbc.M402372200; Lee JY, 2000, J BIOL CHEM, V275, P29290, DOI 10.1074/jbc.M000170200; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Ling M, 2004, EXP CELL RES, V292, P135, DOI 10.1016/j.yexcr.2003.08.013; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oka M, 2003, FEBS LETT, V554, P179, DOI 10.1016/S0014-5793(03)01158-X; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Raghunath A, 2003, BIOCHEM J, V370, P901, DOI 10.1042/BJ20021420; Schultz A, 2003, CELL DEATH DIFFER, V10, P662, DOI 10.1038/sj.cdd.4401235; Sivasankaran R, 2004, NAT NEUROSCI, V7, P261, DOI 10.1038/nn1193; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Svensson K, 2000, CELL GROWTH DIFFER, V11, P641; Tanimura A, 2002, J BIOL CHEM, V277, P29054, DOI 10.1074/jbc.M201130200; Upla P, 2004, MOL BIOL CELL, V15, P625, DOI 10.1091/mbc.E03-08-0588; Zeidman R, 1999, J CELL BIOL, V145, P713, DOI 10.1083/jcb.145.4.713	34	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40576	40583		10.1074/jbc.M405560200	http://dx.doi.org/10.1074/jbc.M405560200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15277524	hybrid			2022-12-27	WOS:000223916800045
J	Buevich, AV; Silva, T; Brodsky, B; Baum, J				Buevich, AV; Silva, T; Brodsky, B; Baum, J			Transformation of the mechanism of triple-helix peptide folding in the absence of a C-terminal nucleation domain and its implications for mutations in collagen disorders	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERIZATION; OSTEOGENESIS IMPERFECTA; SEQUENCE; PROTEIN; ACID; TRIMERIZATION; SUBSTITUTIONS; FIBRILS; CHAIN	Folding abnormalities of the triple helix have been demonstrated in collagen diseases such as osteogenesis imperfecta in which the mutation leads to the substitution of a single Gly in the (Gly-X-Y)(n) sequence pattern by a larger residue. Model peptides can be used to clarify the details of normal collagen folding and the consequences of the interruption of that folding by a Gly substitution. NMR and CD studies show that placement of a (GPO)(4) nucleation domain at the N terminus rather than the C terminus of a native collagen sequence allows the formation of a stable triple helix but alters the folding mechanism. Although C- to N-terminal directional folding occurs when the nucleation domain is at the C terminus, there is no preferential folding direction when the nucleation domain is at the N terminus. The lack of zipper-like directional folding does not interfere with triple-helix formation, and when a Gly residue is replaced by Ser to model an osteogenesis imperfecta mutation, the peptide with the N-terminal (GPO)(4) domain can still form a good triple helix N-terminal to the mutation site. These peptide studies raise the possibility that mutant collagen could fold in a C to N direction in a zipper-like manner up to the mutation site and that completion of the triple helix N-terminal to the mutation would involve an alternative mechanism.	Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Brodsky, B (corresponding author), Rutgers State Univ, Dept Chem & Biol Chem, 610 TAylor Rd, Piscataway, NJ 08854 USA.	brodsky@umdnj.edu; baum@rutchem.rutgers.edu			NIGMS NIH HHS [GM60048, GM45302] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045302, R01GM045302, R01GM060048] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Areida SK, 2001, J BIOL CHEM, V276, P1594, DOI 10.1074/jbc.M008709200; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BACHINGER HP, 1978, EUR J BIOCHEM, V90, P605, DOI 10.1111/j.1432-1033.1978.tb12641.x; Barth D, 2003, CHEM-EUR J, V9, P3703, DOI 10.1002/chem.200304918; BAUM J, 2000, PROTEIN FOLDING FRON, P330; Baum Jean, 1999, Current Opinion in Structural Biology, V9, P122, DOI 10.1016/S0959-440X(99)80016-5; Boudko S, 2002, J MOL BIOL, V317, P459, DOI 10.1006/jmbi.2002.5439; Buevich AV, 2000, BIOCHEMISTRY-US, V39, P4299, DOI 10.1021/bi992584r; Byers P, 2002, CONNECTIVE TISSUE IT, P385, DOI DOI 10.1002/0471221929.CH8; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; CULBERT AA, 1995, BIOCHEM J, V311, P815, DOI 10.1042/bj3110815; Dobson CM, 2001, BIOCHEM SOC SYMP, V68, P1; Frank S, 2003, J BIOL CHEM, V278, P7747, DOI 10.1074/jbc.C200698200; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; Liu XY, 1998, BIOCHEMISTRY-US, V37, P15528, DOI 10.1021/bi981147u; Mazzorana M, 2001, J BIOL CHEM, V276, P27989, DOI 10.1074/jbc.M101633200; McAlinden A, 2003, J BIOL CHEM, V278, P42200, DOI 10.1074/jbc.M302429200; McAlinden A, 2002, J BIOL CHEM, V277, P41274, DOI 10.1074/jbc.M202257200; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; RAGHUNATH M, 1994, J MOL BIOL, V236, P940, DOI 10.1006/jmbi.1994.1199; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Yang W, 1997, BIOCHEMISTRY-US, V36, P6930, DOI 10.1021/bi970051h	24	28	28	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46890	46895		10.1074/jbc.M407061200	http://dx.doi.org/10.1074/jbc.M407061200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15299012	hybrid			2022-12-27	WOS:000224832400071
J	Song, RP; Zhou, ZH; Kim, PKM; Shapiro, RA; Liu, F; Ferran, C; Choi, AMK; Otterbein, LE				Song, RP; Zhou, ZH; Kim, PKM; Shapiro, RA; Liu, F; Ferran, C; Choi, AMK; Otterbein, LE			Carbon monoxide promotes Fas/CD95-induced apoptosis in Jurkat cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; HEME OXYGENASE-1 INDUCTION; REPERFUSION LUNG INJURY; RENAL-ALLOGRAFTS; GRAFT-REJECTION; SUPPRESSES; EXPRESSION; DEATH; INHIBITION; SURVIVAL	A properly functioning immune system is dependent on programmed cell death/apoptosis at virtually every stage of lymphocyte development and activity. Carbon monoxide (CO), an enzymatic product of heme oxyenase-1, has been shown to possess anti-apoptotic effects in a number of different model systems. The purpose of the present study was to expand on this knowledge to determine the role of CO in the well established model of Fas/CD95-induced apoptosis in Jurkat cells, and to determine the mechanism by which CO can modulate T-cell apoptosis. Exposure of Jurkat cells to CO resulted in augmentation in Fas/CD95-induced apoptosis, which correlated with CO-induced up-regulation of the pro-apoptotic protein FADD as well as activation of caspase-8, -9, and -3 while simultaneously down-regulating the anti-apoptotic protein BCL-2. These effects of CO were lost with overexpression of the small interfering RNA of FADD. CO, as demonstrated previously in endothelial cells, was also anti-apoptotic in Jurkat cells against tumor necrosis factor and etoposide. We further demonstrate that this pro-apoptotic effect of CO was independent of reactive oxygen species production and involved inhibition in Fas/CD95-induced activation of the pro-survival ERK MAPK. We conclude that in contrast to other studies showing the anti-apoptotic effects of CO, Fas/CD95-induced cell death in Jurkat cells is augmented by exposure to CO and that this occurs in part via inhibition in the activation of ERK MAPK. These data begin to elucidate specific differences with regard to the effects of CO and cell death pathways and provide important and valuable insight into potential mechanisms of action.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Immunobiol Res Ctr, Boston, MA 02215 USA; Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Otterbein, LE (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Immunobiol Res Ctr, 99 Brookline Ave, Boston, MA 02215 USA.	lotterbe@bidmc.harvard.edu	Zhou, Z Hong/HDN-0747-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060234, R01HL071797] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60234, HL-071797] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Avihingsanon Y, 2002, TRANSPLANTATION, V73, P1079, DOI 10.1097/00007890-200204150-00011; Badrichani AZ, 1999, J CLIN INVEST, V103, P543, DOI 10.1172/JCI2517; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Coito AJ, 2002, LAB INVEST, V82, P61, DOI 10.1038/labinvest.3780395; DeBruyne LA, 2000, TRANSPLANTATION, V69, P120, DOI 10.1097/00007890-200001150-00021; FERRARI G, 1995, J NEUROSCI, V15, P2857; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Grambihler A, 2003, J BIOL CHEM, V278, P26831, DOI 10.1074/jbc.M303229200; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Ingi T, 1996, NEURON, V16, P835, DOI 10.1016/S0896-6273(00)80103-8; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; Morse D, 2003, J BIOL CHEM, V278, P36993, DOI 10.1074/jbc.M302942200; Nakao A, 2003, GUT, V52, P1278, DOI 10.1136/gut.52.9.1278; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Petit PX, 2001, BIOCHEM J, V353, P357, DOI 10.1042/0264-6021:3530357; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; Piantadosi CA, 2002, ANTIOXID REDOX SIGN, V4, P259, DOI 10.1089/152308602753666316; PRABHAKAR NR, 1995, P NATL ACAD SCI USA, V92, P1994, DOI 10.1073/pnas.92.6.1994; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sharma K, 2000, PHARMACOL THERAPEUT, V88, P333, DOI 10.1016/S0163-7258(00)00096-6; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; SONG R, 2003, AM J PATHOL; Song RP, 2002, AM J RESP CELL MOL, V27, P603, DOI 10.1165/rcmb.4851; Thom SR, 2000, P NATL ACAD SCI USA, V97, P1305, DOI 10.1073/pnas.97.3.1305; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tullius SG, 2001, TRANSPLANT P, V33, P1286, DOI 10.1016/S0041-1345(00)02480-5; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0; Zuckerbraun BS, 2003, J EXP MED, V198, P1707, DOI 10.1084/jem.20031003	38	65	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44327	44334		10.1074/jbc.M406105200	http://dx.doi.org/10.1074/jbc.M406105200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15280387	hybrid			2022-12-27	WOS:000224505600014
J	Ehlers, I; Horke, S; Reumann, K; Rang, A; Grosse, F; Will, H; Heise, T				Ehlers, I; Horke, S; Reumann, K; Rang, A; Grosse, F; Will, H; Heise, T			Functional characterization of the interaction between human La and hepatitis B virus RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-MEDIATED TRANSLATION; CYTOTOXIC T-LYMPHOCYTES; ALBUMIN MESSENGER-RNA; INTERFERON-ALPHA; GENE-EXPRESSION; ENDORIBONUCLEASE ACTIVITY; 3'-UNTRANSLATED REGION; RIBONUCLEASE-ACTIVITY; BINDING PROTEINS; TRANSGENIC MICE	The La protein is a multifunctional RNA-binding protein and has also been suggested to be involved in the stabilization of hepatitis B virus (HBV) RNA. Here we demonstrate that antibodies against the human La protein specifically precipitate HBV RNA from HBV ribonucleoprotein-containing mammalian cell extracts, providing evidence for the association between human La and HBV RNA. Moreover, we report that the turnover of HBV RNA depends on structural features and less on the primary sequence of the La-binding site on the viral RNA. In addition we show that the interaction between human La and HBV RNA in vitro is modulated by accessory factor(s) in a phosphorylation-dependent manner. Taken together these data indicate that both structural features, the composition of La/HBV ribonucleoprotein particles as well as interacting cellular factors, are critical determinants in the regulation of the stability of the HBV RNA.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20206 Hamburg, Germany; Biochem Abt, Inst Mol Biotechnol, D-07745 Jena, Germany	Heinrich Pette Institute; University of Hamburg	Heise, T (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Postfac 201652,Martinistr 52, D-20206 Hamburg, Germany.	heise@hpi.uni-hamburg.de						Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; BACHMANN M, 1989, J GEN VIROL, V70, P881, DOI 10.1099/0022-1317-70-4-881; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Chen CY, 2000, GENE DEV, V14, P1236; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chernokalskaya E, 1997, NUCLEIC ACIDS RES, V25, P735, DOI 10.1093/nar/25.4.735; Chisari FV, 1997, J CLIN INVEST, V99, P1472, DOI 10.1172/JCI119308; Cunningham KS, 2000, P NATL ACAD SCI USA, V97, P12498, DOI 10.1073/pnas.220425497; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; GUIDOTTI LG, 1994, P NATL ACAD SCI USA, V91, P3764, DOI 10.1073/pnas.91.9.3764; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; Heise T, 2001, J VIROL, V75, P6874, DOI 10.1128/JVI.75.15.6874-6883.2001; Heise T, 1999, J VIROL, V73, P474, DOI 10.1128/JVI.73.1.474-481.1999; Heise T, 1999, J VIROL, V73, P5767, DOI 10.1128/JVI.73.7.5767-5776.1999; Heise T, 1998, BIOL CHEM, V379, P875, DOI 10.1515/bchm.1998.379.7.875; Heise TD, 2000, CHRONIC HEPATITIS NE, P23; Horke S, 2002, J BIOL CHEM, V277, P34949, DOI 10.1074/jbc.M201911200; Intine RV, 2003, MOL CELL, V12, P1301, DOI 10.1016/S1097-2765(03)00429-5; Jensen TH, 2003, MOL CELL, V11, P1129, DOI 10.1016/S1097-2765(03)00191-6; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Klocker U, 2000, J VIROL, V74, P5525, DOI 10.1128/JVI.74.12.5525-5533.2000; Kracht M, 2002, CYTOKINE, V20, P91, DOI 10.1006/cyto.2002.0895; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; MALTER JS, 1991, J BIOL CHEM, V266, P3167; McLaren RS, 1997, MOL CELL BIOL, V17, P3028, DOI 10.1128/MCB.17.6.3028; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; PASTORI RL, 1991, BIOCHEMISTRY-US, V30, P10490, DOI 10.1021/bi00107a018; Pudi R, 2003, J BIOL CHEM, V278, P12231, DOI 10.1074/jbc.M210287200; Rang A, 1999, J HEPATOL, V31, P791, DOI 10.1016/S0168-8278(99)80279-7; Rang A, 2000, NUCLEIC ACIDS RES, V28, P1120, DOI 10.1093/nar/28.5.1120; Rang A, 2002, J BIOL CHEM, V277, P7645, DOI 10.1074/jbc.C100729200; Robek MD, 2004, P NATL ACAD SCI USA, V101, P1743, DOI 10.1073/pnas.0308340100; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Schultz U, 1999, J VIROL, V73, P5459, DOI 10.1128/JVI.73.7.5459-5465.1999; Schultz UA, 1999, J VIROL, V73, P3162, DOI 10.1128/JVI.73.4.3162-3168.1999; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; Sela-Brown A, 2000, J BIOL CHEM, V275, P7424, DOI 10.1074/jbc.275.10.7424; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shim J, 2002, MOL CELLS, V14, P323; Shimazaki T, 2002, HEPATOLOGY, V35, P199, DOI 10.1053/jhep.2002.30202; Shiroki K, 1999, J VIROL, V73, P2193, DOI 10.1128/JVI.73.3.2193-2200.1999; Spangberg K, 2001, J GEN VIROL, V82, P113, DOI 10.1099/0022-1317-82-1-113; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang ZR, 2000, MOL CELL BIOL, V20, P6334, DOI 10.1128/MCB.20.17.6334-6341.2000; Wang ZR, 2000, EMBO J, V19, P295, DOI 10.1093/emboj/19.2.295; Wieland SF, 2003, J VIROL, V77, P1227, DOI 10.1128/JVI.77.2.1227-1236.2003	53	36	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43437	43447		10.1074/jbc.M402227200	http://dx.doi.org/10.1074/jbc.M402227200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15302879	hybrid			2022-12-27	WOS:000224383100013
J	Hermansson, M; Sawaji, Y; Bolton, M; Alexander, S; Wallace, A; Begum, S; Wait, R; Saklatvala, J				Hermansson, M; Sawaji, Y; Bolton, M; Alexander, S; Wallace, A; Begum, S; Wait, R; Saklatvala, J			Proteomic analysis of articular cartilage shows increased type II collagen synthesis in osteoarthritis and expression of inhibin beta A (activin A), a regulatory molecule for chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; SIGNAL-TRANSDUCTION; IN-VITRO; PROTEINS; IDENTIFICATION; LOCALIZATION; INJURY; SERUM; GENE; DIFFERENTIATION	We show that proteomic analysis can be applied to study cartilage pathophysiology. Proteins secreted by articular cartilage were analyzed by two-dimensional SDS-PAGE and mass spectrometry. Cartilage explants were cultured in medium containing [S-35] methionine/cysteine to radiolabel newly synthesized proteins. To resolve the cartilage proteins by two-dimensional electrophoresis, it was necessary to remove the proteoglycan aggrecan by precipitation with cetylpyridinium chloride. 50 - 100 radiolabeled protein spots were detected on two-dimensional gels of human cartilage cultures. Of 170 silver-stained proteins identified, 19 were radiolabeled, representing newly synthesized gene products. Most of these were known cartilage constituents. Several nonradiolabeled cartilage proteins were also detected. The secreted protein pattern of explants from 12 osteoarthritic joints ( knee, hip, and shoulder) and 14 nonosteoarthritic adult joints were compared. The synthesis of type II collagen was strongly up-regulated in osteoarthritic cartilage. Normal adult cartilage synthesized little or no type II collagen in contrast to infant and juvenile cartilage. Potential regulatory molecules novel to cartilage were identified; pro-inhibin betaA and processed inhibin betaA ( which dimerizes to activin A) were produced by all the osteoarthritic samples and half of the normals. Connective tissue growth factor and cytokine-like protein C17 ( previously only identified as an mRNA) were also found. Activin induced the tissue inhibitor for metalloproteinases-1 in human chondrocytes. Its expression was induced in isolated chondrocytes by growth factors or interleukin-1. We conclude that type II collagen synthesis in articular cartilage is down-regulated at skeletal maturity and reactivated in osteoarthritis in attempted repair and that activin A may be an anabolic factor in cartilage.	Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol, Fac Med, London W6 8LH, England; Charing Cross Hosp, Dept Musculoskeletal Surg, Div Surg Anaesthet & Intens Care, Fac Med, London W6 8RF, England	Imperial College London; University of Oxford; Imperial College London	Wait, R (corresponding author), Karolinska Hosp, Dept Rheumatol, S-10401 Stockholm, Sweden.	r.wait@imperial.ac.uk						Aigner T, 2001, ARTHRITIS RHEUM-US, V44, P2777, DOI 10.1002/1529-0131(200112)44:12<2777::AID-ART465>3.0.CO;2-H; AIGNER T, 1993, J CLIN INVEST, V91, P829, DOI 10.1172/JCI116303; Bau B, 2002, ARTHRITIS RHEUM, V46, P2648, DOI 10.1002/art.10531; Bernard DJ, 2001, RECENT PROG HORM RES, V56, P417, DOI 10.1210/rp.56.1.417; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; DeBleser PJ, 1997, HEPATOLOGY, V26, P905; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; Gruber J, 2004, ARTHRITIS RHEUM-US, V50, P2539, DOI 10.1002/art.20369; GUNTHER M, 1994, ARTHRITIS RHEUM, V37, P395, DOI 10.1002/art.1780370314; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Hubner G, 1996, EXP CELL RES, V228, P106, DOI 10.1006/excr.1996.0305; Hubner G, 1997, LAB INVEST, V77, P311; Hubner G, 1996, DEV BIOL, V173, P490, DOI 10.1006/dbio.1996.0042; Kumar S, 2001, OSTEOARTHR CARTILAGE, V9, P641, DOI 10.1053/joca.2001.0421; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1964, NATURE, V202, P661, DOI 10.1038/202661a0; LAWRENCE RC, 1989, J RHEUMATOL, V16, P427; LIPPIELLO L, 1977, J CLIN INVEST, V59, P593, DOI 10.1172/JCI108676; Liu X, 2000, GENOMICS, V65, P283, DOI 10.1006/geno.2000.6170; Lohmander LS, 1999, ARTHRITIS RHEUM, V42, P534, DOI 10.1002/1529-0131(199904)42:3<534::AID-ANR19>3.0.CO;2-J; LUYTEN FP, 1994, EXP CELL RES, V210, P224, DOI 10.1006/excr.1994.1033; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; Nakata E, 2002, BONE, V31, P441, DOI 10.1016/S8756-3282(02)00846-3; Pangas SA, 2000, TRENDS ENDOCRIN MET, V11, P309, DOI 10.1016/S1043-2760(00)00294-0; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; POOLE AR, 1986, BIOCHEM J, V236, P1; Saha N, 1999, ARTHRITIS RHEUM, V42, P1577, DOI 10.1002/1529-0131(199908)42:8<1577::AID-ANR3>3.0.CO;2-Z; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Tetlow LC, 2001, ARTHRITIS RHEUM-US, V44, P585, DOI 10.1002/1529-0131(200103)44:3<585::AID-ANR107>3.0.CO;2-C; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VANSAASE JLCM, 1989, ANN RHEUM DIS, V48, P271, DOI 10.1136/ard.48.4.271; Vincent T, 2002, P NATL ACAD SCI USA, V99, P8259, DOI 10.1073/pnas.122033199; Wait R, 2002, ELECTROPHORESIS, V23, P3418, DOI 10.1002/1522-2683(200210)23:19&lt;3418::AID-ELPS3418&gt;3.0.CO;2-7; Wait R, 2001, ELECTROPHORESIS, V22, P3043, DOI 10.1002/1522-2683(200108)22:14<3043::AID-ELPS3043>3.0.CO;2-M; Westbrook JA, 2001, PROTEOMICS, V1, P370; Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35; Yu EW, 1998, CLIN EXP IMMUNOL, V112, P126	41	139	144	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43514	43521		10.1074/jbc.M407041200	http://dx.doi.org/10.1074/jbc.M407041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292256	hybrid			2022-12-27	WOS:000224383100021
J	Li, WW; Walus, L; Rabacchi, SA; Jirik, A; Chang, E; Schauer, J; Zheng, BH; Benedetti, NJ; Liu, BP; Choi, E; Worley, D; Silvian, L; Mo, WJ; Mullen, C; Yang, WX; Strittmatter, SM; Sah, DWY; Pepinsky, B; Lee, DHS				Li, WW; Walus, L; Rabacchi, SA; Jirik, A; Chang, E; Schauer, J; Zheng, BH; Benedetti, NJ; Liu, BP; Choi, E; Worley, D; Silvian, L; Mo, WJ; Mullen, C; Yang, WX; Strittmatter, SM; Sah, DWY; Pepinsky, B; Lee, DHS			A neutralizing anti-Nogo66 receptor monoclonal antibody reverses inhibition of neurite outgrowth by central nervous system myelin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOGO-66 RECEPTOR; GLYCOPROTEIN; GROWTH; IDENTIFICATION; REGENERATION; INTERACTS; PROTEINS; LIGAND	The Nogo66 receptor (NgR1) is a neuronal, leucine-rich repeat (LRR) protein that binds three central nervous system (CNS) myelin proteins, Nogo, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein, and mediates their inhibitory effects on neurite growth. Although the LRR domains on NgR1 are necessary for binding to the myelin proteins, the exact epitope(s) involved in ligand binding is unclear. Here we report the generation and detailed characterization of an anti-NgR1 monoclonal antibody, 7E11. The 7E11 monoclonal antibody blocks Nogo, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein binding to NgR1 with IC50 values of 120, 14, and 4.5 nM, respectively, and effectively promotes neurite outgrowth of P3 rat dorsal root ganglia neurons cultured on a CNS myelin substrate. Further, we have defined the molecular epitope of 7E11 to be DNAQLR located in the third LRR domain of rat NgR1. Our data demonstrate that anti-NgR1 antibodies recognizing this epitope, such as 7E11, can neutralize CNS myelin-dependent inhibition of neurite outgrowth. Thus, specific anti-NgR1 antibodies may represent a useful therapeutic approach for promoting CNS repair after injury.	Biogen Idec Inc, Cambridge, MA 02142 USA; Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06150 USA	Biogen; Yale University	Lee, DHS (corresponding author), Biogen Idec Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA.	Daniel_Lee@biogenidec.com	Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092; Silvian, Laura/0000-0002-5299-5201; /0000-0003-0575-6475				Barton WA, 2003, EMBO J, V22, P3291, DOI 10.1093/emboj/cdg325; Brezinsky SCG, 2003, J IMMUNOL METHODS, V277, P141, DOI 10.1016/S0022-1759(03)00108-X; Cajal RS., 1928, DEGENERATION REGENER; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; Filbin MT, 2003, NAT REV NEUROSCI, V4, P1019, DOI 10.1038/nrn1288; Fournier AE, 2002, J NEUROSCI, V22, P8876; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; HARLOW E, 1998, USING ANTIBODIES LAB; He XLL, 2003, NEURON, V38, P177, DOI 10.1016/S0896-6273(03)00232-0; Huber AB, 2000, BIOL CHEM, V381, P407, DOI 10.1515/BC.2000.053; Jin Z, 1997, J NEUROSCI, V17, P6256; JIRIK AM, 2003, 34 ANN M SOC NEUR NE; Lee DHS, 2003, NAT REV DRUG DISCOV, V2, P872, DOI 10.1038/nrd1228; Li M, 1996, J NEUROSCI RES, V46, P404, DOI 10.1002/(SICI)1097-4547(19961115)46:4<404::AID-JNR2>3.3.CO;2-W; Li SX, 2003, J NEUROSCI, V23, P4219; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; McGee AW, 2003, TRENDS NEUROSCI, V26, P193, DOI 10.1016/S0166-2236(03)00062-6; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MONTAG D, 1994, NEURON, V13, P229, DOI 10.1016/0896-6273(94)90472-3; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Pignot V, 2003, J NEUROCHEM, V85, P717, DOI 10.1046/j.1471-4159.2003.01710.x; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHNELL L, 1993, EUR J NEUROSCI, V5, P1156, DOI 10.1111/j.1460-9568.1993.tb00970.x; Sivasankaran R, 2004, NAT NEUROSCI, V7, P261, DOI 10.1038/nn1193; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Wang XX, 2002, J NEUROSCI, V22, P5505; Wong ST, 2002, NAT NEUROSCI, V5, P1302, DOI 10.1038/nn975; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Yiu G, 2003, CURR OPIN NEUROBIOL, V13, P545, DOI 10.1016/j.conb.2003.09.006	34	49	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43780	43788		10.1074/jbc.M401803200	http://dx.doi.org/10.1074/jbc.M401803200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15297463	hybrid			2022-12-27	WOS:000224383100053
J	Arosio, D; Costantini, S; Kong, Y; Vindigni, A				Arosio, D; Costantini, S; Kong, Y; Vindigni, A			Fluorescence anisotropy studies on the Ku-DNA interaction - Anion and cation effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEIC-ACID INTERACTIONS; DEPENDENT PROTEIN-KINASE; STRAND BINDING-PROTEIN; DIMENSIONAL HOMOGENEOUS LATTICE; LAMBDA-CI REPRESSOR; SINGLE-STRAND; BREAK REPAIR; V(D)J RECOMBINATION; EQUILIBRIUM BINDING; COOPERATIVE BINDING	DNA non-homologous end joining starts with the binding of Ku heterodimers to double strand breaks. In this work, we characterized the thermodynamics of the Ku-DNA interaction by fluorescence anisotropy of the probe-labeled DNA. We determined that the microscopic dissociation constant (k(d)) for the binding of Ku to a DNA binding site of the proper length (> 20 bp) ranges from 22 to 29 nM at 300 mM NaCl. The binding isotherms for DNA duplexes with two or three heterodimers were analyzed with two independent models considering the presence and absence of overlapping binding sites. This analysis demonstrated that there is no or very weak nearest-neighbor cooperativity among the Ku molecules. These models can most likely be applied to study the interaction of Ku with duplexes of any length. Furthermore, our salt dependence studies indicated that electrostatic interactions play a major role in the binding of Ku to DNA and that the k(d) decreases similar to 60-fold as the salt concentration is lowered from 300 to 200 mM. The slope (Gamma(salt)) of the plot of log k(d) versus log[NaCl] is 12.4 +/- 0.1. This value is among the highest reported in the literature for a protein-DNA interaction and suggests that similar to 12 ions are released upon formation of the Ku-DNA complex. In addition, comparison of the slope values measured upon varying the type of cation and anion indicated that approximately nine cations and three anions are released from DNA and Ku, respectively, when the complex is formed.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; CuraGen Corp, Life Sci 454, Branford, CT 06405 USA	International Center for Genetic Engineering & Biotechnology (ICGEB)	Vindigni, A (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	vindigni@icgeb.org	arosio, daniele/B-3160-2012; Kong, Yong/B-5105-2014	Kong, Yong/0000-0002-2881-5274				ANDERSON CF, 1995, ANNU REV PHYS CHEM, V46, P657, DOI 10.1146/annurev.physchem.46.1.657; ANDERSON CF, 1978, BIOPHYS CHEM, V7, P301, DOI 10.1016/0301-4622(78)85007-8; Arosio D, 2002, J BIOL CHEM, V277, P9741, DOI 10.1074/jbc.M111916200; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BUJALOWSKI W, 1989, J MOL BIOL, V207, P269, DOI 10.1016/0022-2836(89)90455-5; BUJALOWSKI W, 1989, BIOPOLYMERS, V28, P1637, DOI 10.1002/bip.360280912; BUJALOWSKI W, 1987, J MOL BIOL, V195, P897, DOI 10.1016/0022-2836(87)90493-1; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DiCera E, 1996, BIOPHYS CHEM, V61, P107, DOI 10.1016/S0301-4622(96)02178-3; Dou SX, 2004, J BIOL CHEM, V279, P6354, DOI 10.1074/jbc.M311272200; Dragan AI, 2003, J MOL BIOL, V331, P795, DOI 10.1016/S0022-2836(03)00785-X; FALZON M, 1993, J BIOL CHEM, V268, P10546; FERRARI ME, 1994, J MOL BIOL, V236, P106, DOI 10.1006/jmbi.1994.1122; FRIEDMAN RAG, 1984, BIOPOLYMERS, V23, P2671, DOI 10.1002/bip.360231202; HA JH, 1992, J MOL BIOL, V228, P252, DOI 10.1016/0022-2836(92)90504-D; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Jones JM, 2001, STRUCTURE, V9, P881, DOI 10.1016/S0969-2126(01)00658-X; Kong Y, 2001, J PHYS CHEM B, V105, P10111, DOI 10.1021/jp011758n; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KUIL ME, 1989, BIOCHEMISTRY-US, V28, P9795, DOI 10.1021/bi00451a038; Kysela B, 2003, J BIOL CHEM, V278, P22466, DOI 10.1074/jbc.M303273200; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lohman TM, 1996, BIOCHEMISTRY-US, V35, P5272, DOI 10.1021/bi9527606; LOHMAN TM, 1992, METHOD ENZYMOL, V212, P400; LOHMAN TM, 1991, METHOD ENZYMOL, V208, P258; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Ma YM, 2001, BIOCHEMISTRY-US, V40, P9638, DOI 10.1021/bi010932v; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MISRA VK, 1994, J MOL BIOL, V238, P264, DOI 10.1006/jmbi.1994.1286; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; OVERMAN LB, 1994, J MOL BIOL, V236, P165, DOI 10.1006/jmbi.1994.1126; OVERMAN LB, 1988, BIOCHEMISTRY-US, V27, P456, DOI 10.1021/bi00401a067; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; SENEAR DF, 1991, BIOCHEMISTRY-US, V30, P6677, DOI 10.1021/bi00241a007; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Von Hippel PH, 1969, STRUCTURE STABILITY, P417; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; WOODBURY CP, 1981, BIOPOLYMERS, V20, P2225, DOI 10.1002/bip.1981.360201015; Zhao JK, 1999, BIOCHEMISTRY-US, V38, P2152, DOI 10.1021/bi9825246	44	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42826	42835		10.1074/jbc.M406529200	http://dx.doi.org/10.1074/jbc.M406529200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15284231	hybrid			2022-12-27	WOS:000224226400059
J	Gao, C; Wang, LM; Milgrom, E; Shen, WCW				Gao, C; Wang, LM; Milgrom, E; Shen, WCW			On the mechanism of constitutive Pdr1 activator-mediated PDR5 transcription in Saccharomyces cerevisiae - Evidence for enhanced recruitment of coactivators and altered nucleosome structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; HISTONE ACETYLTRANSFERASE COMPLEXES; TATA-BINDING PROTEIN; RNA-POLYMERASE-II; IN-VIVO TARGET; MULTIDRUG-RESISTANCE; FUNCTIONAL-ORGANIZATION; PROMOTER NUCLEOSOMES; CRYSTAL-STRUCTURE; STRESS-RESPONSE	Drug resistance as a result of overexpression of drug transporter genes presents a major obstacle in the treatment of cancers and infections. The molecular mechanisms underlying transcriptional up-regulation of drug transporter genes remains elusive. Employing Saccharomyces cerevisiae as a model, we analyzed here transcriptional regulation of the drug transporter gene PDR5 in a drug-resistant pdr1-3 strain. This mutant bears a gain-of-function mutation in PDR1, which encodes a transcriptional activator for PDR5. Similar to the well studied model gene GAL1, we provide evidence showing that PDR5 belongs to a group of genes whose transcription requires the Spt-Ada-Gcn5 acetyltransferase (SAGA) complex. We also show that the drug-independent PDR5 transcription is associated with enhanced promoter occupancy of coactivator complexes, including SAGA, Mediator, chromatin remodeling SWI/ SNF complex, and TATA-binding protein. Analyzed by chromatin immunoprecipitations, loss of contacts between histones and DNA occurs at both promoter and coding sequences of PDR5. Consistently, micrococcal nuclease susceptibility analysis revealed altered chromatin structure at the promoter and coding sequences of PDR5. Our data provide molecular description of the changes associated with constitutive PDR5 transcription, and reveal the molecular mechanism underlying drug-independent transcriptional up-regulation of PDR5.	SUNY Upstate Med Ctr, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Shen, WCW (corresponding author), SUNY Upstate Med Ctr, Dept Biochem & Mol Biol, 750 E Adams St,Rm 4821 WHA, Syracuse, NY 13210 USA.	shenw@upstate.edu						Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Akache B, 2002, J BIOL CHEM, V277, P21254, DOI 10.1074/jbc.M202566200; An WJ, 2004, METHOD ENZYMOL, V377, P460; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; Barbaric S, 2003, MOL CELL BIOL, V23, P3468, DOI 10.1128/MCB.23.10.3468-3476.2003; Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; Bash R, 2001, PROG NUCLEIC ACID RE, V65, P197; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; Bhaumik SR, 2004, GENE DEV, V18, P333, DOI 10.1101/gad.1148404; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Boeger H, 2004, MOL CELL, V14, P667, DOI 10.1016/j.molcel.2004.05.013; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; Fleming AB, 2001, EMBO J, V20, P5219, DOI 10.1093/emboj/20.18.5219; GANSHEROFF LJ, 1995, GENETICS, V139, P523; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hellauer K, 2002, J BIOL CHEM, V277, P17671, DOI 10.1074/jbc.M201637200; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Jackson V, 1999, METHODS, V17, P125, DOI 10.1006/meth.1998.0724; Kang JS, 2001, J BIOL CHEM, V276, P42003, DOI 10.1074/jbc.M105961200; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; Keener J, 1997, P NATL ACAD SCI USA, V94, P13458, DOI 10.1073/pnas.94.25.13458; KENT NA, 1993, NUCLEIC ACIDS RES, V21, P4653, DOI 10.1093/nar/21.19.4653; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; Kolaczkowski M, 1998, MICROB DRUG RESIST, V4, P143, DOI 10.1089/mdr.1998.4.143; Kren A, 2003, MOL CELL BIOL, V23, P1775, DOI 10.1128/MCB.23.5.1775-1785.2003; Kuras L, 2003, P NATL ACAD SCI USA, V100, P13887, DOI 10.1073/pnas.2036346100; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Labialle S, 2002, BIOCHEM PHARMACOL, V64, P943, DOI 10.1016/S0006-2952(02)01156-5; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mamnun YM, 2002, MOL MICROBIOL, V46, P1429, DOI 10.1046/j.1365-2958.2002.03262.x; Martens JA, 1996, J BIOL CHEM, V271, P15884, DOI 10.1074/jbc.271.27.15884; Moye-Rowley WS, 2003, PROG NUCLEIC ACID RE, V73, P251, DOI 10.1016/S0079-6603(03)01008-0; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nourani A, 1997, MOL GEN GENET, V256, P397, DOI 10.1007/s004380050583; Piper P, 1998, EMBO J, V17, P4257, DOI 10.1093/emboj/17.15.4257; Poch O, 1997, GENE, V184, P229, DOI 10.1016/S0378-1119(96)00602-6; Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Scotto KW, 2003, ONCOGENE, V22, P7496, DOI 10.1038/sj.onc.1206950; Shen WC, 2003, EMBO J, V22, P3395, DOI 10.1093/emboj/cdg336; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sterner DE, 2002, P NATL ACAD SCI USA, V99, P11622, DOI 10.1073/pnas.182021199; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Wolfger H, 1997, FEBS LETT, V418, P269, DOI 10.1016/S0014-5793(97)01382-3; Wolfger H, 2001, RES MICROBIOL, V152, P375, DOI 10.1016/S0923-2508(01)01209-8	67	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42677	42686		10.1074/jbc.M406363200	http://dx.doi.org/10.1074/jbc.M406363200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15294907	hybrid			2022-12-27	WOS:000224226400041
J	Gotting, C; Muller, S; Schottler, M; Schon, S; Prante, C; Brinkmann, T; Kuhn, J; Kleesiek, K				Gotting, C; Muller, S; Schottler, M; Schon, S; Prante, C; Brinkmann, T; Kuhn, J; Kleesiek, K			Analysis of the DXD motifs in human xylosyltransferase I required for enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-D-XYLOSYLTRANSFERASE; UDP-D-XYLOSE; CHONDROITIN SULFATE PROTEOGLYCAN; HERPES-SIMPLEX VIRUS; SPINAL-CORD-INJURY; HEPARAN-SULFATE; SERUM XYLOSYLTRANSFERASE; EXPRESSION CLONING; SYSTEMIC-SCLEROSIS; KEY ENZYME	Human xylosyltransferase I (XT-I) is the initial enzyme involved in the biosynthesis of the glycosaminoglycan linker region in proteoglycans. Here, we tested the importance of the DXD motifs at positions 314 - 316 and 745 - 747 for enzyme activity and the nucleotide binding capacity of human XT-I. Mutations of the (DED316)-D-314 motif did not have any effect on enzyme activity, whereas alterations of the (DWD747)-D-745 motif resulted in reduced XT-I activity. Loss of function was observed after exchange of the highly conserved aspartic acid at position 745 with glycine. However, mutation of Asp(745) to glutamic acid retained full enzyme activity, indicating the importance of an acidic amino acid at this position. Reduced substrate affinity was observed for mutants D747G (K-m = 6.9 muM) and D747E (K-m = 4.4 muM) in comparison with the wild-type enzyme (K-m = 0.9 muM). Changing the central tryptophan to a neutral, basic, or acidic amino acid resulted in a 6-fold lower V-max, with K-m values comparable with those of the wild-type enzyme. Despite the major effect of the DWD motif on XT-I activity, nucleotide binding was not abolished in the D745G and D747G mutants, as revealed by UDP-bead binding assays. K-i values for inhibition by UDP were determined to be 1.9 - 24.6 muM for the XT-I mutants. The properties of binding of XT-I to heparin-beads, the K-i constants for noncompetitive inhibition by heparin, and the activation by protamine were not altered by the generated mutations.	Ruhr Univ Bochum, Inst Lab & Transfus Med, Herz & Diabet Zentrum Nordehein Westfalen, Univ Klin, D-32545 Bad Oeynhausen, Germany	Ruhr University Bochum	Gotting, C (corresponding author), Ruhr Univ Bochum, Inst Lab & Transfus Med, Herz & Diabet Zentrum Nordehein Westfalen, Univ Klin, Georg Str 11, D-32545 Bad Oeynhausen, Germany.	cgoetting@hdz-nrw.de						Belting M, 2002, P NATL ACAD SCI USA, V99, P371, DOI 10.1073/pnas.012346499; Blackhall FH, 2001, BRIT J CANCER, V85, P1094, DOI 10.1054/bjoc.2001.2054; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Breton C, 1998, J BIOCHEM, V123, P1000; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Chai WG, 2002, J BIOL CHEM, V277, P22438, DOI 10.1074/jbc.M111401200; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Frevert U, 1996, MOL BIOCHEM PARASIT, V76, P257, DOI 10.1016/0166-6851(95)02563-4; Fukuda M, 1996, GLYCOBIOLOGY, V6, P683, DOI 10.1093/glycob/6.7.683; Gotting C, 1998, J PROTEIN CHEM, V17, P295, DOI 10.1023/A:1022549121672; Gotting C, 1999, J INVEST DERMATOL, V112, P919, DOI 10.1046/j.1523-1747.1999.00590.x; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Gotting C, 2002, MOL HUM REPROD, V8, P1079, DOI 10.1093/molehr/8.12.1079; Gotting C, 2000, ACTA DERM-VENEREOL, V80, P60; Grancharov K, 2001, PHARMACOL THERAPEUT, V89, P171, DOI 10.1016/S0163-7258(00)00109-1; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; Hennig L, 1999, BIOTECHNIQUES, V26, P1170, DOI 10.2144/99266bc02; HEROLD BC, 1994, J GEN VIROL, V75, P1211, DOI 10.1099/0022-1317-75-6-1211; HOFFMANN HP, 1984, CONNECT TISSUE RES, V12, P151, DOI 10.3109/03008208408992780; Hwang HY, 2003, J BIOL CHEM, V278, P11735, DOI 10.1074/jbc.C200518200; Jiang XN, 2003, J HISTOCHEM CYTOCHEM, V51, P1393, DOI 10.1177/002215540305101101; Jones LL, 2003, J NEUROSCI, V23, P9276; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KEARNS AE, 1991, BIOCHEMISTRY-US, V30, P7477, DOI 10.1021/bi00244a016; Keusch JJ, 2000, J BIOL CHEM, V275, P25308, DOI 10.1074/jbc.M002629200; Keusch JJ, 2000, J BIOL CHEM, V275, P25315, DOI 10.1074/jbc.M002630200; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLEESIEK K, 1987, J CLIN CHEM CLIN BIO, V25, P473; Kleineidam RG, 1997, GLYCOCONJUGATE J, V14, P57, DOI 10.1023/A:1018560931389; Kuhn J, 2003, BIOCHEM BIOPH RES CO, V312, P537, DOI 10.1016/j.bbrc.2003.10.157; Kuhn J, 2001, J BIOL CHEM, V276, P4940, DOI 10.1074/jbc.M005111200; KUHN J, 2002, J LAB MED, V26, P514; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Li JG, 2001, GLYCOBIOLOGY, V11, P217, DOI 10.1093/glycob/11.3.217; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Pradel G, 2002, MOL MICROBIOL, V45, P637, DOI 10.1046/j.1365-2958.2002.03057.x; RODEN L, 1980, BIOCH GLYCOPROTEINS, P269; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SCHWARTZ NB, 1977, J BIOL CHEM, V252, P6316; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Silbert JE, 1995, BBA-REV BIOMEMBRANES, V1241, P371, DOI 10.1016/0304-4157(95)00011-9; SPEAR PG, 1992, ADV EXP MED BIOL, V313, P341; Trybala E, 2002, VIROLOGY, V302, P413, DOI 10.1006/viro.2002.1639; Weilke C, 1997, CLIN CHEM, V43, P45; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Wilson IBH, 2002, J BIOL CHEM, V277, P21207, DOI 10.1074/jbc.M201634200	53	28	28	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42566	42573		10.1074/jbc.M401340200	http://dx.doi.org/10.1074/jbc.M401340200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15294915	hybrid			2022-12-27	WOS:000224226400029
J	Gudlavalleti, SK; Datta, AK; Tzeng, YL; Noble, C; Carlson, RW; Stephens, DS				Gudlavalleti, SK; Datta, AK; Tzeng, YL; Noble, C; Carlson, RW; Stephens, DS			The Neisseria meningitidis serogroup A capsular polysaccharide O-3 and O-4 acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; O-ACETYLATION; ESCHERICHIA-COLI; RHIZOBIUM-LEGUMINOSARUM; SERINE ACETYLTRANSFERASE; PSEUDOMONAS-AERUGINOSA; OUTER-MEMBRANE; MENINGOCOCCAL POLYSACCHARIDES; MOLECULAR CHARACTERIZATION; STRUCTURAL DETERMINATION	Neisseria meningitidis serogroup A capsular polysaccharide (CPS) is composed of a homopolymer of O-acetylated, alpha1-->6-linked ManNAc 1-phosphate that is distinct from the capsule structures of the other meningococcal disease-causing serogroups, B, C, Y, and W-135. The serogroup A capsule biosynthetic genetic cassette consists of four open reading frames, mynA-D (sacA-D), that are specific to serogroup A, but the functions of these genes have not been well characterized. mynC was found to encode an inner membrane-associated acetyltransferase that is responsible for the O-acetylation of the CPS of serogroup A. The wild-type CPS as revealed by H-1 NMR had 60 - 70% O-acetylated ManNAc residues that contained acetyl groups at O-3, with some species acetylated at O-4 and at both O-3 and O-4. A non-polar mynC mutant generated by introducing an aphA-3 kanamycin resistance cassette produced CPS with no O-acetylation. A serogroup A capsule-specific monoclonal antibody was shown to recognize the wild-type O-acetylated CPS, but not the CPS of the mynC mutant, which lacked O-acetylation. MynC was C-terminally His-tagged and overexpressed in Escherichia coli to obtain the predicted similar to 26-kDa protein. The acetyltransferase activity of purified MynC was demonstrated in vitro using [C-14] acetyl-CoA. MynC O-acetylated the O-acetylated CPS of the mynC mutant and further acetylated the wild-type CPS of serogroup A meningococci, but not the CPS of serogroup B or C meningococci. Genetic complementation of the mynC mutant confirmed the function of MynC as the serogroup A CPS O-3 and O-4 acetyltransferase. MynC represents a new subclass of O-acetyltransferases that utilize acetyl-CoA to decorate the D-mannosamine capsule of N. meningitidis serogroup A.	Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Div Infect Dis, Atlanta, GA 30322 USA; Dept Vet Affairs, Atlanta, GA 30033 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA	Emory University; Emory University; University System of Georgia; University of Georgia	Stephens, DS (corresponding author), Dept Vet Affairs, Res Serv 151 I, 1670 Clairmont Rd, Decatur, GA 30033 USA.	dstep01@emory.edu	Stephens, David S/A-8788-2012	DATTA, ANUP/0000-0002-3796-6891	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040247, R21AI040247] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40247] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antignac A, 2003, CLIN INFECT DIS, V37, P912, DOI 10.1086/377739; Berry DS, 2002, INFECT IMMUN, V70, P3707, DOI 10.1128/IAI.70.7.3707-3713.2002; Bhasin N, 1998, MOL MICROBIOL, V27, P9, DOI 10.1046/j.1365-2958.1998.00646.x; BHATTACHARJEE AK, 1976, CAN J BIOCHEM CELL B, V54, P1, DOI 10.1139/o76-001; BHATTACHARJEE AK, 1975, J BIOL CHEM, V250, P1926; BLOEMBERG GV, 1994, MOL MICROBIOL, V11, P793, DOI 10.1111/j.1365-2958.1994.tb00357.x; BUNDLE DR, 1974, J BIOL CHEM, V249, P2275; CLARK VL, 1987, INFECT IMMUN, V55, P1359, DOI 10.1128/IAI.55.6.1359-1364.1987; Claus H, 2004, MOL MICROBIOL, V51, P227, DOI 10.1046/j.1365-2958.2003.03819.x; DEMAAGD RA, 1986, J BACTERIOL, V167, P1083, DOI 10.1128/jb.167.3.1083-1085.1986; DENK D, 1987, J GEN MICROBIOL, V133, P515; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FINBERG KE, 1995, J BACTERIOL, V177, P4881, DOI 10.1128/jb.177.17.4881-4889.1995; FIRMIN JL, 1993, MOL MICROBIOL, V10, P351, DOI 10.1111/j.1365-2958.1993.tb01961.x; Franklin MJ, 2002, J BACTERIOL, V184, P3000, DOI 10.1128/JB.184.11.3000-3007.2002; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; GOTSCHLICH EC, 1969, J EXP MED, V129, P1349, DOI 10.1084/jem.129.6.1349; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARA O, 1992, J BACTERIOL, V174, P5141, DOI 10.1128/JB.174.15.5141-5144.1992; HESTRIN S, 1949, J BIOL CHEM, V180, P249; HIGA HH, 1988, J BIOL CHEM, V263, P8872; Hindson VJ, 2000, J BIOL CHEM, V275, P461, DOI 10.1074/jbc.275.1.461; Hindson VJ, 2000, BBA-PROTEIN STRUCT M, V1479, P203, DOI 10.1016/S0167-4838(00)00039-X; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; JANIK A, 1976, J CLIN MICROBIOL, V4, P71; Jones C, 2002, J PHARMACEUT BIOMED, V30, P1233, DOI 10.1016/S0731-7085(02)00462-4; Kahler CM, 1998, INFECT IMMUN, V66, P5939, DOI 10.1128/IAI.66.12.5939-5947.1998; Karlyshev AV, 2000, MOL MICROBIOL, V35, P529, DOI 10.1046/j.1365-2958.2000.01717.x; Kroon PA, 2000, EUR J BIOCHEM, V267, P6740, DOI 10.1046/j.1432-1033.2000.01742.x; Lemercinier X, 1996, CARBOHYD RES, V296, P83, DOI 10.1016/S0008-6215(96)00253-4; LEWENDON A, 1995, J BIOL CHEM, V270, P26326, DOI 10.1074/jbc.270.44.26326; LIU TY, 1971, J BIOL CHEM, V246, P2849; Longworth E, 2002, FEMS IMMUNOL MED MIC, V32, P119, DOI 10.1111/j.1574-695X.2002.tb00543.x; LOPEZLARA IM, 1995, MOL MICROBIOL, V15, P627, DOI 10.1111/j.1365-2958.1995.tb02372.x; Luck CP, 2001, INT J MED MICROBIOL, V291, P345, DOI 10.1078/1438-4221-00140; LUTHI E, 1990, APPL ENVIRON MICROB, V56, P1017; McNeely TB, 1998, INFECT IMMUN, V66, P3705, DOI 10.1128/IAI.66.8.3705-3710.1998; MENARD R, 1993, J BACTERIOL, V175, P5899; Nivens DE, 2001, J BACTERIOL, V183, P1047, DOI 10.1128/JB.183.3.1047-1057.2001; ORSKOV F, 1979, J EXP MED, V149, P669, DOI 10.1084/jem.149.3.669; Pier GB, 2001, INFECT IMMUN, V69, P1895, DOI 10.1128/IAI.69.3.1895-1901.2001; PINNER RW, 1992, J INFECT DIS, V166, P359, DOI 10.1093/infdis/166.2.359; REUHS BL, 1993, J BACTERIOL, V175, P3570, DOI 10.1128/jb.175.11.3570-3580.1993; Richmond P, 1999, VACCINE, V18, P641, DOI 10.1016/S0264-410X(99)00276-5; Richmond P, 2001, INFECT IMMUN, V69, P2378, DOI 10.1128/IAI.69.4.2378-2382.2001; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; Sau S, 1997, J BACTERIOL, V179, P1614, DOI 10.1128/jb.179.5.1614-1621.1997; Shevchik VE, 1997, MOL MICROBIOL, V24, P1285, DOI 10.1046/j.1365-2958.1997.4331800.x; Shevchik VE, 2003, J BACTERIOL, V185, P3091, DOI 10.1128/JB.185.10.3091-3100.2003; Slauch JM, 1996, J BACTERIOL, V178, P5904, DOI 10.1128/jb.178.20.5904-5909.1996; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; STEVENSON TT, 1991, CARBOHYD RES, V11, P195; Swartley JS, 1998, J BACTERIOL, V180, P1533, DOI 10.1128/JB.180.6.1533-1539.1998; SZU SC, 1991, INFECT IMMUN, V59, P4555, DOI 10.1128/IAI.59.12.4555-4561.1991; Tzeng YL, 2002, J BACTERIOL, V184, P2379, DOI 10.1128/JB.184.9.2379-2388.2002; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; WIGLEY DB, 1990, FEBS LETT, V277, P267, DOI 10.1016/0014-5793(90)80862-D; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yi K, 2003, INFECT IMMUN, V71, P1849, DOI 10.1128/IAI.71.4.1849-1855.2003; ZOLLINGER WD, 1987, A VAN LEEUW J MICROB, V53, P403, DOI 10.1007/BF00415494	60	45	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42765	42773		10.1074/jbc.M313552200	http://dx.doi.org/10.1074/jbc.M313552200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15294916	hybrid			2022-12-27	WOS:000224226400052
J	Kim, HS; Choi, ES; Shin, JA; Jang, YK; Park, SD				Kim, HS; Choi, ES; Shin, JA; Jang, YK; Park, SD			Regulation of Swi6/HP1-dependent heterochromatin assembly by cooperation of components of the mitogen-activated protein kinase pathway and a histone deacetylase Clr6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATF1 TRANSCRIPTION FACTOR; MATING-TYPE CASSETTE; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; EPIGENETIC CONTROL; SEXUAL DEVELOPMENT; H3 METHYLATION; OSMOTIC-STRESS; SPC1 KINASE	A study of gene silencing within the mating-type region of fission yeast defines two distinct pathways responsible for the establishment of heterochromatin assembly. One is RNA interference-dependent and acts on centromere-homologous repeats (cenH). The other is a stochastic Swi6 ( the fission yeast HP1 homolog)-dependent mechanism that is not fully understood. Here we find that activating transcription factor (Atf1) and Pcr1, the fission yeast bZIP transcription factors homologous to human ATF-2, are crucial for proper histone deacetylation of both H3 and H4. This deacetylation is a prerequisite for subsequent H3 lysine 9 methylation and Swi6-dependent heterochromatin assembly across the rest of the silent mating-type ( mat) region lacking the RNA interference-dependent cenH repeat. Moreover, Atf1 and Pcr1 can form complexes with both a histone deacetylase, Clr6, and Swi6, and clr6 mutations affected the H3/H4 acetylation patterns, similar to the atf1 and pcr1 deletion mutant phenotypes at the endogenous mat loci and at the ctt1(+) promoter region surrounding ATF/CRE-binding site. These data suggest that Atf1 and Pcr1 participate in an early step essential for heterochromatin assembly at the mat locus and silencing of transcriptional targets of Atf1. Furthermore, a phosphorylation event catalyzed by the conserved mitogen-activated protein kinase pathway is important for regulation of heterochromatin silencing by Atf1 and Pcr1. These findings suggest a role for the mitogen-activated protein kinase pathway and histone deacetylase in Swi6-based heterochromatin assembly.	Natl Canc Ctr, Res Inst, Goyang 411769, Gyeonggi, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea	National Cancer Center - Korea (NCC); Seoul National University (SNU)	Jang, YK (corresponding author), Natl Canc Ctr, Res Inst, 809 Madu Dong, Goyang 411769, Gyeonggi, South Korea.	ykjang@ncc.re.kr		kim, Hyun Soo/0000-0002-1792-1928; Choi, Eun Shik/0000-0002-2306-2103				Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; Alfa C, 1993, EXPT FISSION YEAST L; ALLSHIRE RC, 1996, EPIGENETIC MECH GENE, P443; ARCANGIOLI B, 2004, MOL BIOL SCHIZOSACCH, P130; Ayoub N, 2000, GENETICS, V156, P983; Ayoub N, 1999, GENETICS, V152, P495; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bjerling P, 2002, MOL CELL BIOL, V22, P2170, DOI 10.1128/MCB.22.7.2170-2181.2002; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Choi ES, 2002, MOL CELL BIOL, V22, P8366, DOI 10.1128/MCB.22.23.8366-8374.2002; Degols G, 1997, MOL CELL BIOL, V17, P3356, DOI 10.1128/MCB.17.6.3356; EGEL R, 1989, CURR GENET, V15, P407, DOI 10.1007/BF00376796; EKWALL K, 1991, YEAST, V7, P745, DOI 10.1002/yea.320070709; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Elgin SCR, 2003, CURR BIOL, V13, pR895, DOI 10.1016/j.cub.2003.11.006; Gachet Y, 2001, NATURE, V412, P352, DOI 10.1038/35085604; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; Grewal SIS, 1998, GENETICS, V150, P563; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Grewal SIS, 1997, GENETICS, V146, P1221; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hirota K, 2004, NUCLEIC ACIDS RES, V32, P855, DOI 10.1093/nar/gkh251; Huang Y, 2002, NUCLEIC ACIDS RES, V30, P1465, DOI 10.1093/nar/30.7.1465; Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; Kon N, 1997, P NATL ACAD SCI USA, V94, P13765, DOI 10.1073/pnas.94.25.13765; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Moretti P, 2001, MOL CELL BIOL, V21, P8082, DOI 10.1128/MCB.21.23.8082-8094.2001; Nakagawa H, 2002, GENE DEV, V16, P1766, DOI 10.1101/gad.997702; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Partridge JF, 2000, GENE DEV, V14, P783; Perrod S, 2003, CELL MOL LIFE SCI, V60, P2303, DOI 10.1007/s00018-003-3246-x; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; Thon G, 1999, GENETICS, V151, P945; Watanabe Y, 1996, MOL CELL BIOL, V16, P704; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289	46	79	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42850	42859		10.1074/jbc.M407259200	http://dx.doi.org/10.1074/jbc.M407259200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292231	hybrid			2022-12-27	WOS:000224226400062
J	Lockman, K; Hinson, JS; Medlin, MD; Morris, D; Taylor, JM; Mack, CP				Lockman, K; Hinson, JS; Medlin, MD; Morris, D; Taylor, JM; Mack, CP			Sphingosine 1-phosphate stimulates smooth muscle cell differentiation and proliferation by activating separate serum response factor co-factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; ALPHA-ACTIN EXPRESSION; VASCULAR MATURATION; GENE-EXPRESSION; LYSOPHOSPHATIDIC ACID; ENDOTHELIAL-CELLS; CARG ELEMENTS; RHO-KINASE; SPHINGOSINE-1-PHOSPHATE; MIGRATION	Sphingosine 1-phosphate (S1P) is a lipid agonist that regulates smooth muscle cell (SMC) and endothelial cell functions by activating several members of the S1P subfamily of G-protein-coupled Edg receptors. We have shown previously that SMC differentiation is regulated by RhoA-dependent activation of serum response factor (SRF). Because S1P is a strong activator of RhoA, we hypothesized that S1P would stimulate SMC differentiation. Treatment of primary rat aortic SMC cells with S1P activated RhoA as measured by precipitation with a glutathione S-transferase-rhotekin fusion protein. In SMC and 10T(1/2) cells, S1P treatment up-regulated the activities of several transiently transfected SMC-specific promoters, and these effects were inhibited by the Rho-kinase inhibitor, Y-27632. S1P also increased smooth muscle alpha-actin protein levels in SMC but had no effect on SRF binding to the smooth muscle alpha-actin CArG B element. Quantitative reverse transcriptase-PCR showed that S1P treatment of SMC or 10T(1/2) cells did not increase the mRNA level of either of the recently identified SRF co-factors, myocardin or myocardin-related transcription factor-A (MRTF-A). MRTF-A protein was expressed highly in SMC and 10T(1/2) cultures, and importantly the effects of S1P were inhibited by a dominant negative form of MRTF-A indicating that S1P may regulate the transcriptional activity of MRTF-A. Indeed, S1P treatment increased the nuclear localization of FLAG-MRTF-A, and the effect of MRTF-A overexpression on smooth muscle alpha-actin promoter activity was inhibited by dominant negative RhoA. S1P also stimulated SMC growth by activating the early growth response gene, c-fos. This effect was not attenuated by Y-27632 but could be inhibited by the MEK inhibitor, UO126. S1P enhanced SMC growth through ERK-mediated phosphorylation of the SRF cofactor, Elk-1, as measured by gel shift and Elk-1 activation assays. Taken together these results demonstrate that S1P activates multiple signaling pathways in SMC and regulates proliferation by ERK-dependent activation of Elk-1 and differentiation by RhoA-dependent activation of MRTF-A.	Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Mack, CP (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, Campus Box 7525, Chapel Hill, NC 27599 USA.	cmack@med.unc.edu		Hinson, Jeremiah/0000-0002-2024-2360; Lockman, Kashelle/0000-0001-8017-8084; Taylor, Joan/0000-0002-8794-5167	NHLBI NIH HHS [R01-HL-70953, R01 HL081844, R01 HL071054] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081844, R01HL071054, R01HL070953] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood-2003-02-0460; An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; BLANK RS, 1992, J BIOL CHEM, V267, P984; Bolz SS, 2003, CIRCULATION, V108, P342, DOI 10.1161/01.CIR.0000080324.12530.0D; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Coussin F, 2002, CIRC RES, V91, P151, DOI 10.1161/01.RES.0000028150.51130.36; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Hautmann MB, 1998, J BIOL CHEM, V273, P8398, DOI 10.1074/jbc.273.14.8398; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; Herring BP, 1997, AM J PHYSIOL-CELL PH, V272, pC1394, DOI 10.1152/ajpcell.1997.272.4.C1394; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Hla T, 2003, PHARMACOL RES, V47, P401, DOI 10.1016/S1043-6618(03)00046-X; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Kluk MJ, 2001, CIRC RES, V89, P496, DOI 10.1161/hh1801.096338; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Li SJ, 2003, P NATL ACAD SCI USA, V100, P9366, DOI 10.1073/pnas.1233635100; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Mack CP, 1999, CIRC RES, V84, P852; MacLennan AJ, 2001, EUR J NEUROSCI, V14, P203, DOI 10.1046/j.0953-816x.2001.01634.x; Madsen CS, 1998, CIRC RES, V82, P908; Miano JM, 2000, J BIOL CHEM, V275, P9814, DOI 10.1074/jbc.275.13.9814; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Numaguchi K, 1999, CIRC RES, V85, P5; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Ohmori T, 2003, CARDIOVASC RES, V58, P170, DOI 10.1016/S0008-6363(03)00260-8; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Osborne N, 2003, ANNU REV PHYSIOL, V65, P23, DOI 10.1146/annurev.physiol.65.092101.142235; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rosenfeldt HM, 2003, FASEB J, V17, P1789, DOI 10.1096/fj.02-0836com; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Seasholtz TM, 1999, CIRC RES, V84, P1186, DOI 10.1161/01.RES.84.10.1186; SELYARAJ A, 2003, J BIOL CHEM, V278, P41977; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Takuwa Y, 2002, BBA-MOL CELL BIOL L, V1582, P112, DOI 10.1016/S1388-1981(02)00145-2; Tanimoto T, 2004, CIRC RES, V94, P1050, DOI 10.1161/01.RES.0000126404.41421.BE; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wang ZG, 2003, P NATL ACAD SCI USA, V100, P7129, DOI 10.1073/pnas.1232341100; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Yamakawa T, 2000, HYPERTENSION, V35, P313, DOI 10.1161/01.HYP.35.1.313; Yatomi Y, 1997, J BIOCHEM, V121, P969; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09	63	121	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42422	42430		10.1074/jbc.M405432200	http://dx.doi.org/10.1074/jbc.M405432200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292266	hybrid, Green Published			2022-12-27	WOS:000224226400012
J	Murakami, N; Yokomizo, T; Okuno, T; Shimizu, T				Murakami, N; Yokomizo, T; Okuno, T; Shimizu, T			G2A is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETRACTED ARTICLE. SEE; LEUKOTRIENE B-4; ACID; SPHINGOSYLPHOSPHORYLCHOLINE; IDENTIFICATION; EXPRESSION; FAMILY; GTPASES; TARGET; LIGAND	G2A (from G2 accumulation) is a G-protein-coupled receptor (GPCR) that regulates the cell cycle, proliferation, oncogenesis, and immunity. G2A shares significant homology with three GPCRs including ovarian cancer GPCR (OGR1/GPR68), GPR4, and T cell death-associated gene 8 (TDAG8). Lysophosphatidylcholine (LPC) and sphingosylphosphorylcholine (SPC) were reported as ligands for G2A and GPR4 and for OGR1 (SPC only), and a glycosphingolipid psychosine was reported as ligand for TDAG8. As OGR1 and GPR4 were reported as proton-sensing GPCRs (Ludwig, M. G., Vanek, M., Guerini, D., Gasser, J. A., Jones, C. E., Junker, U., Hofstetter, H., Wolf, R. M., and Seuwen, K. (2003) Nature 425, 93-98), we evaluated the proton-sensing function of G2A. Transient expression of G2A caused significant activation of the zif 268 promoter and inositol phosphate (IP) accumulation at pH 7.6, and lowering extracellular pH augmented the activation only in G2A-expressing cells. LPC inhibited the pH-dependent activation of G2A in a dose-dependent manner in these assays. Thus, G2A is another proton-sensing GPCR, and LPC functions as an antagonist, not as an agonist, and regulates the proton-dependent activation of G2A.	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Dept Metabolome, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Agcy, PRESTO, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Yokomizo, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	yokomizo-tky@umin.ac.jp	Shimizu, Takao/AAV-7052-2021; Yokomizo, Takehiko/P-5673-2016	Yokomizo, Takehiko/0000-0002-5219-1553				Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Benham CD, 2002, NEUROPHARMACOLOGY, V42, P873, DOI 10.1016/S0028-3908(02)00047-3; Bos CL, 2004, INT J BIOCHEM CELL B, V36, P1187, DOI 10.1016/j.biocel.2003.08.006; Braunwald E., 2001, HARRISONS PRINCIPLES; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chalmers DT, 2002, NAT REV DRUG DISCOV, V1, P599, DOI 10.1038/nrd872; Choi JW, 1996, CELL IMMUNOL, V168, P78, DOI 10.1006/cimm.1996.0051; de Martin R, 1999, MUTAT RES-REV MUTAT, V437, P231, DOI 10.1016/S1383-5742(99)00089-7; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukunaga K, 2001, J BIOL CHEM, V276, P43025, DOI 10.1074/jbc.M108288200; GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hasegawa H, 1997, BIOCHEM BIOPH RES CO, V234, P631, DOI 10.1006/bbrc.1997.6655; HEIBER M, 1995, DNA CELL BIOL, V14, P25, DOI 10.1089/dna.1995.14.25; Hirabayashi T, 2000, EUR J BIOCHEM, V267, P2525, DOI 10.1046/j.1432-1327.2000.01258.x; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Kabarowski JHS, 2000, P NATL ACAD SCI USA, V97, P12109, DOI 10.1073/pnas.97.22.12109; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Le LQ, 2001, IMMUNITY, V14, P561, DOI 10.1016/S1074-7613(01)00145-5; Lin P, 2003, J BIOL CHEM, V278, P14379, DOI 10.1074/jbc.M209101200; LOEFFLER DA, 1992, BRIT J CANCER, V66, P619, DOI 10.1038/bjc.1992.326; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Luther SA, 2001, NAT IMMUNOL, V2, P102, DOI 10.1038/84205; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; MIYAZAKI J, 1989, GENE, V79, P269; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Okita M, 1997, INT J CANCER, V71, P31, DOI 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4; Ozaki Harunobu, 2003, J Atheroscler Thromb, V10, P125; Palmer E, 2003, NAT REV IMMUNOL, V3, P383, DOI 10.1038/nri1085; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; Rikitake Y, 2002, ARTERIOSCL THROM VAS, V22, P2049, DOI 10.1161/01.ATV.0000040598.18570.54; Sambrook J., 2001, MOL CLONING LAB MANU; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Sin WC, 2004, ONCOGENE, V23, P6299, DOI 10.1038/sj.onc.1207838; Taha TA, 2004, BBA-MOL CELL BIOL L, V1682, P48, DOI 10.1016/S1388-1981(04)00023-X; Wang Q, 2004, J BIOL CHEM, V279, P28831, DOI 10.1074/jbc.C400105200; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Xu Y, 2002, BBA-MOL CELL BIOL L, V1582, P81, DOI 10.1016/S1388-1981(02)00140-3; Ye XQ, 2002, NEUROREPORT, V13, P2169, DOI 10.1097/00001756-200212030-00002; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	49	177	188	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42484	42491		10.1074/jbc.M406561200	http://dx.doi.org/10.1074/jbc.M406561200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15280385	hybrid			2022-12-27	WOS:000224226400020
J	Dong, JS; Lai, R; Nielsen, K; Fekete, CA; Qiu, HF; Hinnebusch, AG				Dong, JS; Lai, R; Nielsen, K; Fekete, CA; Qiu, HF; Hinnebusch, AG			The essential ATP-binding cassette protein RLI1 functions in translation by promoting preinitiation complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE GCN2; SACCHAROMYCES-CEREVISIAE; MULTIFACTOR COMPLEX; MEDIATE BINDING; SHUTTLE VECTORS; GENE DELETION; INITIATION; YEAST; EIF3; RNA	RLI1 is an essential yeast protein closely related in sequence to two soluble members of the ATP-binding cassette family of proteins that interact with ribosomes and function in translation elongation (YEF3) or translational control (GCN20). We show that affinity-tagged RLI1 co-purifies with eukaryotic translation initiation factor 3 (eIF3), eIF5, and eIF2, but not with other translation initiation factors or with translation elongation or termination factors. RLI1 is associated with 40 S ribosomal subunits in vivo, but it can interact with eIF3 and -5 independently of ribosomes. Depletion of RLI1 in vivo leads to cessation of growth, a lower polysome content, and decreased average polysome size. There was also a marked reduction in 40 S-bound eIF2 and eIF1, consistent with an important role for RLI1 in assembly of 43 S preinitiation complexes in vivo. Mutations of conserved residues in RLI1 expected to function in ATP hydrolysis were lethal. A mutation in the second ATP-binding cassette domain of RLI1 had a dominant negative phenotype, decreasing the rate of translation initiation in vivo, and the mutant protein inhibited translation of a luciferase mRNA reporter in wild-type cell extracts. These findings are consistent with a direct role for the ATP-binding cassettes of RLI1 in translation initiation. RLI1-depleted cells exhibit a deficit in free 60 S ribosomal subunits, and RLI1-green fluorescent protein was found in both the nucleus and cytoplasm of living cells. Thus, RLI1 may have dual functions in translation initiation and ribosome biogenesis.	NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Hinnebusch, AG (corresponding author), NICHD, Lab Gene Regulat & Dev, NIH, Bldg 6A,Rm B1A13, Bethesda, MD 20892 USA.	ahinnebusch@nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001004] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Algire MA, 2002, RNA, V8, P382, DOI 10.1017/S1355838202029527; ANDERSON JT, 1993, MOL CELL BIOL, V13, P6102, DOI 10.1128/MCB.13.10.6102; Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Asano K, 2002, METHOD ENZYMOL, V351, P221; Asano K, 2001, EMBO J, V20, P2326, DOI 10.1093/emboj/20.9.2326; BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; DEALDANA CRV, 1995, EMBO J, V14, P3184, DOI 10.1002/j.1460-2075.1995.tb07321.x; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; Fraser CS, 2004, J BIOL CHEM, V279, P8946, DOI 10.1074/jbc.M312745200; Garcia-Barrio M, 2000, EMBO J, V19, P1887, DOI 10.1093/emboj/19.8.1887; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Kerr ID, 2004, BIOCHEM BIOPH RES CO, V315, P166, DOI 10.1016/j.bbrc.2004.01.044; KORONAKIS E, 1995, MOL MICROBIOL, V16, P87, DOI 10.1111/j.1365-2958.1995.tb02394.x; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Majumdar R, 2003, J BIOL CHEM, V278, P6580, DOI 10.1074/jbc.M210357200; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; McKeegan KS, 2003, TRENDS MICROBIOL, V11, P21, DOI 10.1016/S0966-842X(02)00010-0; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Nielsen KH, 2004, EMBO J, V23, P1166, DOI 10.1038/sj.emboj.7600116; Olsen DS, 2003, EMBO J, V22, P193, DOI 10.1093/emboj/cdg030; PARK EC, 1992, P NATL ACAD SCI USA, V89, P1249, DOI 10.1073/pnas.89.4.1249; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Sasaki T, 2000, MOL CELL BIOL, V20, P7971, DOI 10.1128/MCB.20.21.7971-7979.2000; Schmees G, 1999, EUR J BIOCHEM, V266, P420, DOI 10.1046/j.1432-1327.1999.00871.x; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Stage-Zimmermann T, 2000, MOL BIOL CELL, V11, P3777, DOI 10.1091/mbc.11.11.3777; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P20473, DOI 10.1074/jbc.270.35.20473; Tyzack JK, 2000, J BIOL CHEM, V275, P34131, DOI 10.1074/jbc.M002868200; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; Valasek L, 2002, EMBO J, V21, P5886, DOI 10.1093/emboj/cdf563; Valasek L, 2001, J BIOL CHEM, V276, P43351, DOI 10.1074/jbc.M106887200; Valasek L, 2001, EMBO J, V20, P891, DOI 10.1093/emboj/20.4.891; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	49	144	153	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42157	42168		10.1074/jbc.M404502200	http://dx.doi.org/10.1074/jbc.M404502200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15277527	hybrid			2022-12-27	WOS:000224075500108
J	Ge, GX; Seo, NS; Liang, XW; Hopkins, DR; Hook, M; Greenspan, DS				Ge, GX; Seo, NS; Liang, XW; Hopkins, DR; Hook, M; Greenspan, DS			Bone morphogenetic protein-1/Tolloid-related metalloproteinases process osteoglycin and enhance its ability to regulate collagen fibrillogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; PROCOLLAGEN C-PROTEINASE; EHLERS-DANLOS-SYNDROME; LEUCINE-RICH PROTEOGLYCANS; MAMMALIAN TOLLOID-LIKE; OSTEOINDUCTIVE FACTOR; TARGETED DISRUPTION; DEFICIENT MICE; SKIN FRAGILITY; LYSYL OXIDASE	The mammalian bone morphogenetic protein-1 (BMP1)/ Tolloid-related metalloproteinases play key roles in regulating formation of the extracellular matrix (ECM) via biosynthetic processing of various precursor proteins into mature functional enzymes, structural proteins, and proteins involved in initiating the mineralization of hard tissue ECMs. They also have been shown to activate several members of the transforming growth factor-beta superfamily, and may serve to coordinate such activation with formation of the ECM in morphogenetic events. Osteoglycin (OGN), a small leucine-rich proteoglycan with unclear functions, is found in cornea, bone, and other tissues, and appears to undergo proteolytic processing in vivo. Here we have successfully generated recombinant OGN and have employed it to demonstrate that a pro-form of OGN is processed to varying extents by all four mammalian BMP-1/Tolloid-like proteinases, to generate a 27-kDa species that corresponds to the major form of OGN found in cornea. Moreover, whereas wild-type mouse embryo fibroblasts (MEFs) produce primarily the processed, mature form of OGN, MEFs homozygous null for genes encoding three of the four mammalian BMP-1/Tolloid-related proteinases produce only unprocessed pro-OGN. Thus, all detectable pro-OGN processing activity in MEFs is accounted for by products of these genes. We also demonstrate that both pro- and mature OGN can regulate type I collagen fibrillogenesis, and that processing of the prodomain by BMP-1 potentiates the ability of OGN to modulate the formation of collagen fibrils.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Program Mol & Cellular Pharmacol, Madison, WI 53706 USA; Univ Texas, Hlth Sci Ctr, Albert B Alkek Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Health Science Center Houston	Hook, M (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA.	mhook@ibt.tamu.edu; dsgreens@facstaff.wisc.edu		Greenspan, Daniel/0000-0001-8096-7446; Liang, Xiaowen/0000-0002-6174-2951	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044415, R56AR047746, R01AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063471] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44415, AR47746] Funding Source: Medline; NIGMS NIH HHS [GM63471] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; BENTZ H, 1989, J BIOL CHEM, V264, P20805; BIRK DE, 1984, ARCH BIOCHEM BIOPHYS, V235, P178, DOI 10.1016/0003-9861(84)90266-2; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1990, J CELL SCI, V95, P649; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Burgeson RE, 1997, CURR OPIN CELL BIOL, V9, P651, DOI 10.1016/S0955-0674(97)80118-4; Butler WT, 1998, EUR J ORAL SCI, V106, P204, DOI 10.1111/j.1600-0722.1998.tb02177.x; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; GELMAN RA, 1979, J BIOL CHEM, V254, P180; GREENSPAN DS, 2005, IN PRESS TOP CURR CH, V229; Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200; Hocking AM, 1998, MATRIX BIOL, V17, P1; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; JARVIS DL, 1992, RECOMBINANT DNA VACC, P265; Johnson HJ, 1997, J BIOL CHEM, V272, P18709, DOI 10.1074/jbc.272.30.18709; Johnson J, 1999, DEV DYNAM, V216, P499, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<499::AID-DVDY18>3.0.CO;2-S; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; Kaufmann B, 2004, GLYCOBIOLOGY, V14, P609, DOI 10.1093/glycob/cwh063; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Liu CY, 2003, J BIOL CHEM, V278, P21672, DOI 10.1074/jbc.M301169200; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Medeck RJ, 2003, BIOCHEM J, V376, P361, DOI 10.1042/BJ20030894; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pappano WN, 2003, MOL CELL BIOL, V23, P4428, DOI 10.1128/MCB.23.13.4428-4438.2003; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Roughley PJ, 1996, BIOCHEM J, V318, P779, DOI 10.1042/bj3180779; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Steiglitz BM, 2004, J BIOL CHEM, V279, P980, DOI 10.1074/jbc.M310179200; Suzuki N, 1996, DEVELOPMENT, V122, P3587; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; Tasheva ES, 2002, MOL VIS, V8, P407; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Wenstrup RJ, 1996, HUM MOL GENET, V5, P1733, DOI 10.1093/hmg/5.11.1733; Wolfman NM, 2003, P NATL ACAD SCI USA, V100, P15842, DOI 10.1073/pnas.2534946100; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; YEO TK, 1995, J VASC RES, V32, P175, DOI 10.1159/000159091	57	82	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41626	41633		10.1074/jbc.M406630200	http://dx.doi.org/10.1074/jbc.M406630200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292192	hybrid			2022-12-27	WOS:000224075500048
J	McFarland, MJ; Porter, AC; Rakhshan, FR; Rawat, DS; Gibbs, RA; Barker, EL				McFarland, MJ; Porter, AC; Rakhshan, FR; Rawat, DS; Gibbs, RA; Barker, EL			A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID AMIDE HYDROLASE; N-ARACHIDONOYLETHANOLAMINE ANANDAMIDE; MOLECULAR CHARACTERIZATION; LIPID RAFTS; RAT-BRAIN; PHOSPHOLIPASE-D; CAVEOLIN-1 EXPRESSION; ARACHIDONIC-ACID; CELLULAR UPTAKE; RNA-POLYMERASE	The mechanisms responsible for the uptake and cellular processing of the endogenous cannabinoid anandamide are not well understood. We propose that anandamide uptake may occur via a caveola/lipid raft-related endocytic process in RBL-2H3 cells. Inhibitors of caveola-related (clathrin-independent) endocytosis reduced anandamide transport by similar to 50% compared with the control. Fluorescein derived from fluorescently labeled anandamide colocalized with protein markers of caveolae at early time points following transport. In this study, we have also identified a yet unrecognized process involved in trafficking events affecting anandamide following its uptake. Following uptake of [H-3] anandamide by RBL-2H3 cells, we found an accumulation of tritium in the caveolin-rich membranes. Inhibitors of both anandamide uptake and metabolism blocked the observed enrichment of tritium in the caveolin-rich membranes. Mass spectrometry of subcellular membrane fractions revealed that the tritium accumulation observed in the caveolin-rich membrane fraction was not representative of intact anandamide, suggesting that following metabolism by the enzyme fatty acid amide hydrolase ( FAAH), anandamide metabolites are rapidly enriched in caveolae. Furthermore, HeLa cells, which do not express high levels of FAAH, showed an accumulation of tritium in the caveolin-rich membrane fraction only when transfected with FAAH cDNA. Western blot and immunocytochemistry analyses of RBL-2H3 cells revealed that FAAH was localized in intracellular compartments distinct from caveolin-1 localization. Together, these data suggest that following uptake via caveola/lipid raft-related endocytosis, anandamide is rapidly metabolized by FAAH, with the metabolites efficiently recycled to caveolin-rich membrane domains.	Purdue Univ, Sch Pharm, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; Eli Lilly & Co, Div Neurosci, Indianapolis, IN 46285 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Eli Lilly	Barker, EL (corresponding author), Purdue Univ, Sch Pharm, Dept Med Chem & Mol Pharmacol, 575 Stadium Mall Dr, W Lafayette, IN 47907 USA.	ericb@pharmacy.purdue.edu	Rawat, Diwan S/B-1150-2008	Rawat, Diwan S/0000-0002-5473-7476	NIDA NIH HHS [R21 DA13268] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA013268] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Aoki T, 1999, EXP CELL RES, V253, P629, DOI 10.1006/excr.1999.4652; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Cadas H, 1997, J NEUROSCI, V17, P1226; Cameron PL, 1997, J NEUROSCI, V17, P9520; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Czarny M, 1999, J BIOL CHEM, V274, P2717, DOI 10.1074/jbc.274.5.2717; Day TA, 2001, MOL PHARMACOL, V59, P1369, DOI 10.1124/mol.59.6.1369; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; Deutsch DG, 2001, J BIOL CHEM, V276, P6967, DOI 10.1074/jbc.M003161200; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; DIMARZO Y, 1998, BIOCHIM BIOPHYS ACTA, V1392, P153; Dobrowsky RT, 2000, CELL SIGNAL, V12, P81, DOI 10.1016/S0898-6568(99)00072-8; Egertova M, 1998, P ROY SOC B-BIOL SCI, V265, P2081, DOI 10.1098/rspb.1998.0543; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Galbiati F, 1998, GENE, V210, P229, DOI 10.1016/S0378-1119(98)00064-X; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; Glaser ST, 2003, P NATL ACAD SCI USA, V100, P4269, DOI 10.1073/pnas.0730816100; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; HILLARD CJ, 1995, BBA-LIPID LIPID MET, V1257, P249, DOI 10.1016/0005-2760(95)00087-S; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Johannes L, 2002, TRAFFIC, V3, P443, DOI 10.1034/j.1600-0854.2002.30701.x; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Muthian S, 2000, J PHARMACOL EXP THER, V293, P289; NATARAJAN V, 1983, J NEUROCHEM, V41, P1303, DOI 10.1111/j.1471-4159.1983.tb00825.x; Norkin LC, 2002, J VIROL, V76, P5156, DOI 10.1128/JVI.76.10.5156-5166.2002; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Petersen G, 1999, FEBS LETT, V455, P41, DOI 10.1016/S0014-5793(99)00861-3; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; Porter AC, 2002, J PHARMACOL EXP THER, V301, P1020, DOI 10.1124/jpet.301.3.1020; Porter AC, 2001, PHARMACOL THERAPEUT, V90, P45, DOI 10.1016/S0163-7258(01)00130-9; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Rakhshan F, 2000, J PHARMACOL EXP THER, V292, P960; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Richards AA, 2002, MOL BIOL CELL, V13, P1750, DOI 10.1091/mbc.01-12-0592; SCHNITZER JE, 1995, AM J PHYSIOL-HEART C, V268, pH48, DOI 10.1152/ajpheart.1995.268.1.H48; Sharma P, 2002, SEMIN CELL DEV BIOL, V13, P205, DOI 10.1016/S1084-9521(02)00049-6; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Stremmel W, 2001, LIPIDS, V36, P981, DOI 10.1007/s11745-001-0809-2; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x	46	111	117	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41991	41997		10.1074/jbc.M407250200	http://dx.doi.org/10.1074/jbc.M407250200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292270	hybrid			2022-12-27	WOS:000224075500092
J	Garavaglia, S; Raffaelli, N; Finaurini, L; Magni, G; Rizzi, M				Garavaglia, S; Raffaelli, N; Finaurini, L; Magni, G; Rizzi, M			A novel fold revealed by mycobacterium tuberculosis NAD kinase, a key allosteric enzyme in NADP biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; FHA DOMAIN; BINDING; PROTEIN; PHOSPHOFRUCTOKINASE; FAMILY; SITE	NAD kinase catalyzes the magnesium-dependent phosphorylation of NAD, representing the sole source of freshly synthesized NADP in all organisms. The enzyme is essential for the growth of the deadly multidrug-resistant pathogen Mycobacterium tuberculosis and is an attractive target for novel antitubercular agents. The crystal structure of NAD kinase has been solved by multi-wavelength anomalous dispersion at a resolution of 2.3 in its T state. Two crystal forms have been obtained revealing either a dimer or a tetramer. The enzyme architecture discloses a novel molecular arrangement, with each subunit consisting of an alpha/beta N-terminal domain and a C-terminal 12-stranded beta sandwich domain, connected by swapped beta strands. The C-terminal domain shows a striking internal approximate 222 symmetry and an unprecedented topology, revealing a novel fold within the family of all beta structures. The catalytic site is located in the long crevice that defines the interface between the domains. The conserved GGDG structural fingerprint of the catalytic site is reminiscent of the related region in 6-phosphofructokinase, supporting the hypothesis that NAD kinase belongs to a newly reported superfamily of kinases.	Univ Piemonte Orientale, Dipartimento Sci Chim Alimentari Farmaceut Farmac, Ist Nazl Fis Mat, I-28100 Novara, Italy; Univ Politecn Marche, Ist Biotecnol Biochim, I-60131 Ancona, Italy; Univ Pavia, Dipartimento Genet & Microbiol, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Eastern Piedmont Amedeo Avogadro; Marche Polytechnic University; University of Pavia	Rizzi, M (corresponding author), Univ Piemonte Orientale, Dipartimento Sci Chim Alimentari Farmaceut Farmac, Ist Nazl Fis Mat, Via Bovio 6, I-28100 Novara, Italy.	rizzi@ipvgen.unipv.it	garavaglia, silvia/C-5588-2013; garavaglia, silvia/AIA-1816-2022	garavaglia, silvia/0000-0001-8494-1729				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Begley TP, 2001, VITAM HORM, V61, P103; Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; Denu JM, 2003, TRENDS BIOCHEM SCI, V28, P41, DOI 10.1016/S0968-0004(02)00005-1; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; EPEL D, 1981, CELL, V23, P543, DOI 10.1016/0092-8674(81)90150-1; FRY IJ, 1991, J BACTERIOL, V173, P2506, DOI 10.1128/jb.173.8.2506-2513.1991; Garavaglia S, 2003, J BACTERIOL, V185, P4844, DOI 10.1128/JB.185.16.4844-4850.2003; Gerdes SY, 2002, J BACTERIOL, V184, P4555, DOI 10.1128/JB.184.16.4555-4572.2002; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; Hayward S, 2002, J MOL GRAPH MODEL, V21, P181, DOI 10.1016/S1093-3263(02)00140-7; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawai S, 2000, BIOCHEM BIOPH RES CO, V276, P57, DOI 10.1006/bbrc.2000.3433; KEHRER JP, 1991, FREE RADIC BIOL MED, V17, P65; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Labesse G, 2002, TRENDS BIOCHEM SCI, V27, P273, DOI 10.1016/S0968-0004(02)02093-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee SH, 1997, J BIOL CHEM, V272, P9252, DOI 10.1074/jbc.272.14.9252; Lerner F, 2001, BIOCHEM BIOPH RES CO, V288, P69, DOI 10.1006/bbrc.2001.5735; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Li HY, 2004, J MOL BIOL, V335, P371, DOI 10.1016/j.jmb.2003.10.032; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; Michael G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Michiels J, 2002, TRENDS MICROBIOL, V10, P87, DOI 10.1016/S0966-842X(01)02284-3; Mori S, 2001, ACTA CRYSTALLOGR D, V57, P1319, DOI 10.1107/S0907444901011362; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Outten CE, 2003, EMBO J, V22, P2015, DOI 10.1093/emboj/cdg211; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Raffaelli N, 2004, BIOCHEMISTRY-US, V43, P7610, DOI 10.1021/bi049650w; Rizzi M, 2002, CURR OPIN STRUC BIOL, V12, P709, DOI 10.1016/S0959-440X(02)00385-8; Rongvaux A, 2003, BIOESSAYS, V25, P683, DOI 10.1002/bies.10297; RYPNIEWSKI WR, 1989, J MOL BIOL, V207, P805, DOI 10.1016/0022-2836(89)90246-5; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SHULTZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; ZEREZ CR, 1986, ARCH MICROBIOL, V144, P313, DOI 10.1007/BF00409878; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	50	49	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40980	40986		10.1074/jbc.M406586200	http://dx.doi.org/10.1074/jbc.M406586200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15269221	hybrid			2022-12-27	WOS:000223916800095
J	Graidist, P; Phongdara, A; Fujise, K				Graidist, P; Phongdara, A; Fujise, K			Antiapoptotic protein partners fortilin and MCL1 independently protect cells from 5-fluorouracil-induced cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSLOCATION; TUMOR PROTEIN; RNA INTERFERENCE; INSULIN-RECEPTOR; DNA-DAMAGE; APOPTOSIS; BCL-2; SEQUENCE; BAX; HETERODIMERIZATION	Fortilin, a potent 172-amino acid antiapoptotic polypeptide (Li, F., Zhang, D., and Fujise, K. ( 2001) J. Biol. Chem. 276, 47542-47549), binds MCL1, a protein of the antiapoptotic Bcl-2 family. The fortilin-MCL1 interaction stabilizes and increases the half-life of fortilin but not necessarily of MCL1 (Zhang, D., Li, F., Weidner, D., Mnjoyan, Z. H., and Fujise, K. ( 2002) J. Biol. Chem. 277, 37430-37438). It is not known to what extent each protein depends on the other for its apoptotic activity. Here, we present evidence that fortilin and MCL1 are capable of functioning as antiapoptotic proteins independently of each other. Using a robust small interfering RNA (siRNA)-mediated gene silencing system developed in our laboratory, we analyzed the cytoprotective effects of fortilin and MCL1 together and apart in U2OS cell lines exposed to 5-fluorouracil (5-FU) in both monoclonal and polyclonal cell populations. When MCL1 was silenced by MCL1-targeted siRNA, fortilin was still able to protect cells from 5-FU-induced cytotoxicity in a dose-dependent manner. Conversely, when fortilin was silenced by fortilin-targeted siRNA, MCL1 was also able to protect cells from 5-FU-induced cytotoxicity in a dose-dependent manner. Together, these data clearly suggest that fortilin and MCL1 can exert their cytoprotective activities independently of each other. The silencing of fortilin and MCL1 did not qualitatively change the subcellular localization of MCL1 and fortilin, respectively. The biological significance of fortilin-MCL1 interaction may be that it increases cellular resistance to apoptosis by allowing MCL1, an independently antiapoptotic protein, to stabilize another independently antiapoptotic protein, fortilin.	Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Brown Fdn,Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Cardiol, Houston, TX 77030 USA; Prince Songkla Univ, Dept Biochem, Fac Sci, Hat Yai 90112, Songkhla, Thailand	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Prince of Songkla University	Fujise, K (corresponding author), Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Brown Fdn,Inst Mol Med Prevent Human Dis, 2121 W Holcombe,Suite 925B, Houston, TX 77030 USA.	Kenichi.Fujise@uth.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068024] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL04015, HL68024] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Cans C, 2003, P NATL ACAD SCI USA, V100, P13892, DOI 10.1073/pnas.2335950100; Chen E, 2000, EXP CELL RES, V259, P140, DOI 10.1006/excr.2000.4952; CHITPATIMA ST, 1988, NUCLEIC ACIDS RES, V16, P2350, DOI 10.1093/nar/16.5.2350; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; GROSS B, 1989, NUCLEIC ACIDS RES, V17, P8367, DOI 10.1093/nar/17.20.8367; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; Kim SJ, 1998, BIOCHEM MOL BIOL INT, V46, P187; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Li F, 2001, J BIOL CHEM, V276, P47542, DOI 10.1074/jbc.M108954200; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; PODLECKI DA, 1987, J BIOL CHEM, V262, P3362; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Stenmark H, 2001, GENOME BIOL, V2; Thaw P, 2001, NAT STRUCT BIOL, V8, P701, DOI 10.1038/90415; Thiele H, 1998, EUR J BIOCHEM, V257, P62, DOI 10.1046/j.1432-1327.1998.2570062.x; Thompson DL, 2003, MOL CELL BIOL, V23, P2277, DOI 10.1128/MCB.23.7.2277-2286.2003; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; Wu A, 2003, J CELL PHYSIOL, V195, P453, DOI 10.1002/jcp.10261; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927; Zhang D, 2002, J BIOL CHEM, V277, P37430, DOI 10.1074/jbc.M207413200; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	33	48	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40868	40875		10.1074/jbc.M401454200	http://dx.doi.org/10.1074/jbc.M401454200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262975	hybrid			2022-12-27	WOS:000223916800082
J	Kolinsky, MA; Gross, SS				Kolinsky, MA; Gross, SS			The mechanism of potent GTP cyclohydrolase I inhibition by 2,4-diamino-6-hydroxypyrimidine - Requirement of the GTP cyclohydrolase I feedback regulatory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIUM-DEPENDENT VASODILATION; NITRIC-OXIDE SYNTHASE; DIABETES-MELLITUS; TETRAHYDROBIOPTERIN DEFICIENCY; CEREBRAL SYNTHESIS; BLOOD-PRESSURE; BIOSYNTHESIS; BIOPTERIN; PURIFICATION; COFACTOR	Inhibition of GTP cyclohydrolase I (GTPCH) has been used as a selective tool to assess the role of de novo synthesis of (6R)-5,6,7,8-tetrahydro-L-biopterin (BH4) in a biological system. Toward this end, 2,4-diamino-6-hydroxypyrimidine ( DAHP) has been used as the prototypical GTPCH inhibitor. Using a novel real-time kinetic microplate assay for GTPCH activity and purified prokaryote-expressed recombinant proteins, we show that potent inhibition by DAHP is not the result of a direct interaction with GTPCH. Rather, inhibition by DAHP in phosphate buffer occurs via an indirect mechanism that requires the presence of GTPCH feedback regulatory protein ( GFRP). Notably, GFRP was previously discovered as the essential factor that reconstitutes inhibition of pure recombinant GTPCH by the pathway end product BH4. Thus, DAHP inhibits GTPCH by engaging the endogenous feedback inhibitory system. We further demonstrate that L-Phe fully reverses the inhibition of GTPCH by DAHP/GFRP, which is also a feature in common with inhibition by BH4/GFRP. These findings suggest that DAHP is not an indiscriminate inhibitor of GTPCH in biological systems; instead, it is predicted to preferentially attenuate GTPCH activity in cells that most abundantly express GFRP and/or contain the lowest levels of L-Phe.	Cornell Univ, Dept Pharmacol, Weill Med Coll, New York, NY 10021 USA; Cornell Univ, Program Pharmacol, Weill Med Coll, New York, NY 10021 USA; Cornell Univ, Program Biochem & Struct Biol, Weill Med Coll, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Gross, SS (corresponding author), Cornell Univ, Dept Pharmacol, Weill Med Coll, 1300 York Ave, New York, NY 10021 USA.	ssgross@med.cornell.edu			NHLBI NIH HHS [HL50656, HL46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050656, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Auerbach G, 2000, P NATL ACAD SCI USA, V97, P13567, DOI 10.1073/pnas.240463497; BARFORD PA, 1984, J NEUROL NEUROSUR PS, V47, P736, DOI 10.1136/jnnp.47.7.736; BOTTIGLIERI T, 1992, PSYCHOL MED, V22, P871, DOI 10.1017/S0033291700038447; Bracher A, 2001, BIOCHEMISTRY-US, V40, P7896, DOI 10.1021/bi010322v; Bune AJ, 1996, BIOCHEM BIOPH RES CO, V220, P13, DOI 10.1006/bbrc.1996.0348; COTTON RGH, 1986, J INHERIT METAB DIS, V9, P4, DOI 10.1007/BF01813895; Curtius H C, 1984, Adv Neurol, V40, P463; Delgado-Esteban M, 2002, J NEUROCHEM, V82, P1148, DOI 10.1046/j.1471-4159.2002.01055.x; GAL EM, 1978, NEUROCHEM RES, V3, P69, DOI 10.1007/BF00964361; GAL EM, 1976, NEUROCHEM RES, V1, P627, DOI 10.1007/BF00965603; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HATAKEYAMA K, 1989, J BIOL CHEM, V264, P21660; Heitzer T, 2000, DIABETOLOGIA, V43, P1435, DOI 10.1007/s001250051551; ICHINOSE H, 1994, NAT GENET, V8, P236, DOI 10.1038/ng1194-236; IIEITZER T, 2000, CIRC RES, V86, pE36; JORENS PG, 1992, BRIT J PHARMACOL, V107, P1088, DOI 10.1111/j.1476-5381.1992.tb13411.x; KAUFMAN S, 1963, P NATL ACAD SCI USA, V50, P1085, DOI 10.1073/pnas.50.6.1085; KAUFMAN S, 1990, BIOCHIM BIOPHYS ACTA, V1040, P19, DOI 10.1016/0167-4838(90)90141-2; KOLINSKY MA, 2004, PTERINS FOLATES NEUR, P22; KWON NS, 1989, J BIOL CHEM, V264, P20496; LOVENBERG W, 1967, SCIENCE, V155, P217, DOI 10.1126/science.155.3759.217; LOVENBERG W, 1979, SCIENCE, V204, P624, DOI 10.1126/science.432666; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; Mitchell BM, 2004, J CARDIOVASC PHARM, V43, P758, DOI 10.1097/00005344-200406000-00004; Mitchell BM, 2003, AM J PHYSIOL-HEART C, V285, pH2165, DOI 10.1152/ajpheart.00253.2003; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; Oddis CV, 1996, AM J PHYSIOL-HEART C, V270, pH1864, DOI 10.1152/ajpheart.1996.270.5.H1864; PABST W, 1966, H-S Z PHYSIOL CHEM, V344, P107, DOI 10.1515/bchm2.1966.344.1-3.107; Rebelo J, 2003, J MOL BIOL, V326, P503, DOI 10.1016/S0022-2836(02)01303-7; Rembold H, 1964, Hoppe Seylers Z Physiol Chem, V339, P258, DOI 10.1515/bchm2.1964.339.1.258; Saura M, 1996, J BIOL CHEM, V271, P14290, DOI 10.1074/jbc.271.24.14290; Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131; SUZUKI S, 1988, BRAIN RES, V446, P1, DOI 10.1016/0006-8993(88)91290-5; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; Thony B, 1997, HUM MUTAT, V10, P11; TIETZ A, 1964, J BIOL CHEM, V239, P4081; Timimi FK, 1998, J AM COLL CARDIOL, V31, P552, DOI 10.1016/S0735-1097(97)00536-6; Ting HH, 1996, J CLIN INVEST, V97, P22, DOI 10.1172/JCI118394; Ueda S, 2000, J AM COLL CARDIOL, V35, P71, DOI 10.1016/S0735-1097(99)00523-9; Werner-Felmayer G, 1996, METHODS NITRIC OXIDE, P271; Xie LJ, 1998, J BIOL CHEM, V273, P21091, DOI 10.1074/jbc.273.33.21091; Yoneyama T, 1997, J BIOL CHEM, V272, P9690; Yoneyama T, 2001, ARCH BIOCHEM BIOPHYS, V388, P67, DOI 10.1006/abbi.2001.2288; Yoneyama T, 1998, J BIOL CHEM, V273, P20102, DOI 10.1074/jbc.273.32.20102	47	45	47	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40677	40682		10.1074/jbc.M405370200	http://dx.doi.org/10.1074/jbc.M405370200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15292175	hybrid			2022-12-27	WOS:000223916800058
J	Martinez-Gomez, NC; Robers, M; Downs, DM				Martinez-Gomez, NC; Robers, M; Downs, DM			Mutational analysis of ThiH, a member of the radical S-adenosylmethionine (AdoMet) protein superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; ESCHERICHIA-COLI; THIAMIN BIOSYNTHESIS; LYSINE 2,3-AMINOMUTASE; CRYSTAL-STRUCTURE; BIOTIN SYNTHASE; IDENTIFICATION; 4-THIOURIDINE; CLUSTER; SULFUR	Thiamine pyrophosphate (TPP) is an essential cofactor for all forms of life. In Salmonella enterica, the thiH gene product is required for the synthesis of the 4-methyl-5-beta hydroxyethyl-thiazole monophosphate moiety of TPP. ThiH is a member of the radical S-adenosylmethionine (AdoMet) superfamily of proteins that is characterized by the presence of oxygen labile [Fe-S] clusters. Lack of an in vitro activity assay for ThiH has hampered the analysis of this interesting enzyme. We circumvented this problem by using an in vivo activity assay for ThiH. Random and directed mutagenesis of the thiH gene was performed. Analysis of auxotrophic thiH mutants defined two classes, those that required thiazole to make TPP ( null mutants) and those with thiamine auxotrophy that was corrected by either L-tyrosine or thiazole (ThiH* mutants). Increased levels of AdoMet also corrected the thiamine requirement of members of the latter class. Residues required for in vivo function were identified and are discussed in the context of structures available for AdoMet enzymes.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53726 USA	University of Wisconsin System; University of Wisconsin Madison	Downs, DM (corresponding author), Univ Wisconsin, Dept Bacteriol, 1710 Univ Ave, Madison, WI 53726 USA.	downs@bact.wisc.edu		Martinez-Gomez, Norma/0000-0002-4071-7204				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; Begley TP, 1999, ARCH MICROBIOL, V171, P293, DOI 10.1007/s002030050713; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; Chen DW, 2003, J AM CHEM SOC, V125, P11788, DOI 10.1021/ja036120z; Cosper MM, 2003, PROTEIN SCI, V12, P1573, DOI 10.1110/ps.0302203; Cosper NJ, 2000, BIOCHEMISTRY-US, V39, P15668, DOI 10.1021/bi0022184; Gralnick J, 2000, J BACTERIOL, V182, P5180, DOI 10.1128/JB.182.18.5180-5187.2000; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Leonardi R, 2004, J BIOL CHEM, V279, P17054, DOI 10.1074/jbc.M312714200; Leonardi R, 2003, FEBS LETT, V539, P95, DOI 10.1016/S0014-5793(03)00204-7; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; MirandaRios J, 1997, J BACTERIOL, V179, P6887, DOI 10.1128/jb.179.22.6887-6893.1997; Morett E, 2003, NAT BIOTECHNOL, V21, P790, DOI 10.1038/nbt834; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; Park JH, 2003, BIOCHEMISTRY-US, V42, P12430, DOI 10.1021/bi034902z; Petersen LA, 1997, J BACTERIOL, V179, P4894, DOI 10.1128/jb.179.15.4894-4900.1997; Rodionov DA, 2002, J BIOL CHEM, V277, P48949, DOI 10.1074/jbc.M208965200; Settembre EC, 2003, BIOCHEMISTRY-US, V42, P2971, DOI 10.1021/bi026916v; Skovran E, 2000, J BACTERIOL, V182, P3896, DOI 10.1128/JB.182.14.3896-3903.2000; Skovran E, 2003, J BACTERIOL, V185, P98, DOI 10.1128/JB.185.1.98-106.2003; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; VANDERHORN PB, 1993, J BACTERIOL, V175, P982, DOI 10.1128/JB.175.4.982-992.1993; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X	31	34	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40505	40510		10.1074/jbc.M403985200	http://dx.doi.org/10.1074/jbc.M403985200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15271986	hybrid			2022-12-27	WOS:000223916800037
J	Olszewska-Pazdrak, B; Townsend, CM; Hellmich, MR				Olszewska-Pazdrak, B; Townsend, CM; Hellmich, MR			Agonist-independent activation of Src tyrosine kinase by a cholecystokinin-2 (CCK2) receptor splice variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; COLON-CANCER CELLS; C-SRC; PANCREATIC-CARCINOMA; B/GASTRIN RECEPTOR; GASTRIN; BINDING; OVEREXPRESSION; EXPRESSION; PP60C-SRC	Src activity is elevated in a majority of colonic and pancreatic cancers and is associated with late stage aggressive cancers. However, the mechanisms leading to its increased activity remain largely undefined. Agonist binding to the cholecystokinin-2 (CCK2)/gastrin receptor (CCK2R), a G-protein-coupled receptor, increases Src activity in a variety of normal and neoplastic cell lines. Recently, we and others (Hellmich, M. R., Rui, X. L., Hellmich, H. L., Fleming, R. Y., Evers, B. M., and Townsend, C. M., Jr. ( 2000) J. Biol. Chem. 275, 32122 32128; Ding, W. Q., Kuntz, S. M., and Miller, L. J. ( 2002) Cancer Res. 62, 947 - 952; Smith, J. P., Verderame, M. F., McLaughlin, P., Martenis, M., Ballard, E., and Zagon, I. S. ( 2002) Int. J. Mol. Med. 10, 689 - 694) have identified a splice variant of CCK2R, called CCK2i4svR, that is expressed in human colorectal and pancreatic cancers but not by cells of the adjacent nonmalignant tissue. Compared with CCK2R, CCK2i4svR contains an additional 69 amino acids within its third intracellular loop (3il) domain. Because CCK2i4svR is the only splice variant expressed in some human colon and pancreatic cancers, we questioned whether CCK2i4svR could regulate Src activity. Stably transfected HEK293 cells were used because, unlike many cancer-derived cells, they have a low level of basal Src activity. We report that, in contrast to CCK2R, CCK2i4svR activates Src kinase in the absence of agonist stimulation. In vitro kinase assay of immunoprecipitated receptor protein showed a 6-8-fold increase in Src kinase activity associated with CCK2i4svR compared with CCK2R. Expression of the 3il domain of the CCK2i4svR alone was sufficient to partially activate Src kinase. Together, these data support the hypothesis that the increased Src activity observed in some pancreatic and colorectal cancers is due, in part, to the co-expression of CCK2i4svR.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Hellmich, MR (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mhellmic@utmb.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058119, R01DK048345] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK48345, R01 DK58119] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banker N, 1996, SURG ONCOL, V5, P201, DOI 10.1016/S0960-7404(96)80023-5; Bierkamp C, 2002, ONCOGENE, V21, P7656, DOI 10.1038/sj.onc.1205999; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; Daulhac L, 1999, FEBS LETT, V445, P251, DOI 10.1016/S0014-5793(99)00129-5; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Ding WQ, 2002, CANCER RES, V62, P947; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; Iravani S, 1998, LAB INVEST, V78, P365; Irby R, 1997, CELL GROWTH DIFFER, V8, P1287; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Masaki T, 1999, HEPATOLOGY, V29, P379, DOI 10.1002/hep.510290239; Oldenhof J, 2001, CELL SIGNAL, V13, P411, DOI 10.1016/S0898-6568(01)00157-7; Piiper A, 2003, J BIOL CHEM, V278, P7065, DOI 10.1074/jbc.M211234200; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Russello SV, 2003, FRONT BIOSCI-LANDMRK, V8, pS1068, DOI 10.2741/1138; Rustgi A K, 1994, Gastroenterology, V107, P1565; SINGH P, 1994, AM J PHYSIOL, V267, pG235, DOI 10.1152/ajpgi.1994.267.2.G235; Smith JP, 2002, INT J MOL MED, V10, P689; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yassin RR, 1998, PEPTIDES, V19, P47, DOI 10.1016/S0196-9781(97)00276-3	36	25	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40400	40404		10.1074/jbc.C400208200	http://dx.doi.org/10.1074/jbc.C400208200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15292208	hybrid			2022-12-27	WOS:000223916800024
J	Porcelli, F; Buck, B; Lee, DK; Hallock, KJ; Ramamoorthy, A; Veglia, G				Porcelli, F; Buck, B; Lee, DK; Hallock, KJ; Ramamoorthy, A; Veglia, G			Structure and orientation of pardaxin determined by NMR experiments in model membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-STATE NMR; PROTEIN-STRUCTURE DETERMINATION; HELICAL ANTIMICROBIAL PEPTIDES; ANGLE-SPINNING NMR; SEA MOSES SOLE; LIPID-BILAYERS; DODECYLPHOSPHOCHOLINE MICELLES; PARDACHIRUS-MARMORATUS; SOLUTION CONFORMATIONS; HEMOLYTIC ACTIVITIES	Pardaxins are a class of ichthyotoxic peptides isolated from fish mucous glands. Pardaxins physically interact with cell membranes by forming pores or voltage-gated ion channels that disrupt cellular functions. Here we report the high-resolution structure of synthetic pardaxin Pa4 in sodium dodecylphosphocholine micelles, as determined by H-1 solution NMR spectroscopy. The peptide adopts a bend-helix-bend-helix motif with an angle between the two structure helices of 122 +/- 9degrees, making this structure substantially different from the one previously determined in organic solvents. In addition, paramagnetic solution NMR experiments on Pa4 in micelles reveal that except for the C terminus, the peptide is not solvent-exposed. These results are complemented by solid-state NMR experiments on Pa4 in lipid bilayers. In particular, C-13-N-15 rotational echo double-resonance experiments in multilamellar vesicles support the helical conformation of the C-terminal segment, whereas H-2 NMR experiments show that the peptide induces considerable disorder in both the head-groups and the hydrophobic core of the bilayers. These solid-state NMR studies indicate that the C-terminal helix has a transmembrane orientation in DMPC bilayers, whereas in POPC bilayers, this domain is heterogeneously oriented on the lipid surface and undergoes slow motion on the NMR time scale. These new data help explain how the non-covalent interactions of Pa4 with lipid membranes induce a stable secondary structure and provide an atomic view of the membrane insertion process of Pa4.	Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; Univ Tuscia, Dept Environm Sci, Viterbo, Italy; Univ Tuscia, INFM, Sez B, Viterbo, Italy; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities; Tuscia University; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Tuscia University; University of Michigan System; University of Michigan	Veglia, G (corresponding author), Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA.	ramamoor@umich.edu; veglia@chem.umn.edu	Porcelli, Fernando/AAA-5242-2020; Buck-Koehntop, Bethany A./ABI-2583-2020; Sanguinetti, Maurizio/A-1453-2019; Porcelli, Fernando/GSN-6338-2022	Porcelli, Fernando/0000-0003-3209-0074; Sanguinetti, Maurizio/0000-0002-9780-7059; Porcelli, Fernando/0000-0003-3209-0074; Ramamoorthy, Ayyalusamy/0000-0003-1964-1900	NIAID NIH HHS [AI054515-01A1, R01 AI054515] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054515] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARRIBAS M, 1993, J NEUROCHEM, V60, P552, DOI 10.1111/j.1471-4159.1993.tb03184.x; BATENBURG AM, 1988, BIOCHEMISTRY-US, V27, P2324, DOI 10.1021/bi00407a013; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BENNETT AE, 1995, J CHEM PHYS, V103, P6951, DOI 10.1063/1.470372; Beswick V, 1998, EUR BIOPHYS J BIOPHY, V28, P48, DOI 10.1007/s002490050182; BLOOM M, 1981, CHEM PHYS LETT, V80, P198, DOI 10.1016/0009-2614(81)80089-9; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Damberg P, 2001, METHOD ENZYMOL, V339, P271, DOI 10.1016/S0076-6879(01)39318-7; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DUFOURCQ J, 1986, BIOCHIM BIOPHYS ACTA, V859, P33, DOI 10.1016/0005-2736(86)90315-9; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; Hallock KJ, 2003, BIOPHYS J, V84, P3052, DOI 10.1016/S0006-3495(03)70031-9; Hallock KJ, 2002, BIOPHYS J, V83, P1004, DOI 10.1016/S0006-3495(02)75226-0; Hallock KJ, 2002, BIOPHYS J, V82, P2499, DOI 10.1016/S0006-3495(02)75592-6; Harzer U, 2000, BIOCHEMISTRY-US, V39, P13106, DOI 10.1021/bi000770n; Henzler-Wildman KA, 2004, BIOCHEMISTRY-US, V43, P8459, DOI 10.1021/bi036284s; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Lam YH, 2001, BIOPHYS J, V81, P2752, DOI 10.1016/S0006-3495(01)75918-8; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LAZAROVICI P, 1986, J BIOL CHEM, V261, P6704; LAZAROVICI P, 2002, TOXIN REV, V21, P392; LAZAROVICI P, 1998, NEUROTOXINS NEUROCHE, P219; Lazarovici P, 1992, J NAT TOXINS, V1, P1; Lee DK, 2004, J AM CHEM SOC, V126, P2318, DOI 10.1021/ja039077o; Lee DK, 1999, J PHYS CHEM B, V103, P271, DOI 10.1021/jp983811m; LELKES PI, 1988, FEBS LETT, V230, P131, DOI 10.1016/0014-5793(88)80656-2; Martinez GV, 2004, LANGMUIR, V20, P1043, DOI 10.1021/la036063n; Mascioni A, 2003, BIOPOLYMERS, V69, P29, DOI 10.1002/bip.10305; Mascioni A, 2002, BIOCHEMISTRY-US, V41, P475, DOI 10.1021/bi011243m; METZ G, 1994, J MAGN RESON SER A, V110, P219, DOI 10.1006/jmra.1994.1208; Nagaraj R, 1997, CURR SCI INDIA, V72, P819; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Opella SJ, 1997, NAT STRUCT BIOL, V4, P845; Oren Z, 1998, BIOPOLYMERS, V47, P451; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PRIMOR N, 1985, EXPERIENTIA, V41, P693, DOI 10.1007/BF02007726; PRIMOR N, 1978, TOXICON S, V1, P539; RENNER P, 1987, NEUROSCIENCE, V23, P319, DOI 10.1016/0306-4522(87)90292-2; ROBERTS GCK, 1993, NMR MACROMOLECULES, P315; SABERWAL G, 1993, J BIOL CHEM, V268, P14081; SCHERER PG, 1989, BIOCHEMISTRY-US, V28, P7720, DOI 10.1021/bi00445a030; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SHAI Y, 1994, TOXICOLOGY, V87, P109, DOI 10.1016/0300-483X(94)90157-0; SHAI Y, 1988, FEBS LETT, V242, P161, DOI 10.1016/0014-5793(88)81007-X; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; SMITH R, 1994, J MOL BIOL, V241, P456, DOI 10.1006/jmbi.1994.1520; THAYER AM, 1981, BIOCHEMISTRY-US, V20, P6831, DOI 10.1021/bi00527a014; Thennarasu S, 1997, BIOPOLYMERS, V41, P635, DOI 10.1002/(SICI)1097-0282(199705)41:6<635::AID-BIP4>3.0.CO;2-R; THENNARASU S, 1995, INT J PEPT PROT RES, V46, P480; Thennarasu S, 1996, PROTEIN ENG, V9, P1219, DOI 10.1093/protein/9.12.1219; Tian CL, 2003, PROTEIN SCI, V12, P2597, DOI 10.1110/ps.03168503; Wildman KAH, 2003, SOLID STATE NUCL MAG, V24, P94, DOI 10.1016/S0926-2040(03)00048-1; Wildman KAH, 2002, BIOPOLYMERS, V64, P246, DOI 10.1002/bip.10180; Yang J, 2002, J MAGN RESON, V159, P101, DOI 10.1016/S1090-7807(02)00033-2; ZAGORSKI MG, 1991, BIOCHEMISTRY-US, V30, P8009, DOI 10.1021/bi00246a019; Zamoon J, 2003, BIOPHYS J, V85, P2589, DOI 10.1016/S0006-3495(03)74681-5	58	151	156	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45815	45823		10.1074/jbc.M405454200	http://dx.doi.org/10.1074/jbc.M405454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15292173	Green Accepted, hybrid			2022-12-27	WOS:000224694900066
J	Iko, Y; Kodama, TS; Kasai, N; Oyama, T; Morita, EH; Muto, T; Okumura, M; Fujii, R; Takumi, T; Tate, S; Morikawa, K				Iko, Y; Kodama, TS; Kasai, N; Oyama, T; Morita, EH; Muto, T; Okumura, M; Fujii, R; Takumi, T; Tate, S; Morikawa, K			Domain Architectures and characterization of an RNA-binding protein, TLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER DOMAIN; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; SECONDARY STRUCTURE; HNRNP A1; RECOGNITION; IDENTIFICATION; TLS/FUS; FUSION; EWS	Translocated in liposarcoma (TLS) is an important protein component of the heterogeneous nuclear ribonucleoprotein complex involved in the splicing of pre-mRNA and the export of fully processed mRNA to the cytoplasm. We examined the domain organization of human TLS by a combined approach using limited proteolysis, matrix-assisted laser desorption ionization time-of-flight mass spectrometry, circular dichroism, inductively coupled plasma atomic emission spectroscopy, and NMR spectroscopy. We found that the RNA recognition motif (RRM) and zinc finger-like domains exclusively form protease-resistant core structures within the isolated TLS protein fragments, while the remaining regions, including the Arg-Gly-Gly repeats, appear to be completely unstructured. Thus, TLS contains the unstructured N-terminal half followed by the RRM and zinc finger-like domains, which are connected to each other by a flexible linker. We also carried out NMR analyses to obtain more detailed insights into the individual RRM and zinc finger-like domains. The Cd-113 NMR analysis of the zinc finger-like domain verified that zinc is coordinated with four cysteines in the C4 type scheme. We also investigated the interaction of each domain with an oligo-RNA containing the GGUG sequence, which appears to be critical for the TLS function in splicing. The backbone amide NMR chemical shift perturbation analyses indicated that the zinc finger domain binds GGUG-containing RNA with a dissociation constant of about 1.0x10(-5) M, whereas the RRM domain showed no observable interaction with this RNA. This surprising result implies that the zinc finger domain plays a more predominant role in RNA recognition than the RRM domain.	Biomed Engn Res Inst, Osaka 5650874, Japan; Japan Biol Informat Consortium, Japan Biol Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan; Ehime Univ, Integrated Ctr Sci, Matsuyama, Ehime 7908566, Japan; Osaka Biosci Inst, Osaka 5650874, Japan	Ehime University	Morikawa, K (corresponding author), Biomed Engn Res Inst, 6-2-3 Furuedai, Osaka 5650874, Japan.	morikawa@beri.or.jp	Tate, Shin-ichi/E-3057-2015	Tate, Shin-ichi/0000-0002-5556-7712; Oyama, Takuji/0000-0002-3411-7608				Alfano C, 2004, NAT STRUCT MOL BIOL, V11, P323, DOI 10.1038/nsmb747; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; CALVIO C, 1995, RNA, V1, P724; Canadillas JMP, 2003, EMBO J, V22, P2821, DOI 10.1093/emboj/cdg259; CAVANAGH J, 1996, PROTEIN NMR; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; de Hoog CL, 2004, CELL, V117, P649, DOI 10.1016/S0092-8674(04)00456-8; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Fribourg S, 2003, NAT STRUCT BIOL, V10, P433, DOI 10.1038/nsb926; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Guex, 1996, PROTEIN DATA BANK Q, V77, P7; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; Jiang CG, 2002, TRENDS BIOCHEM SCI, V27, P506, DOI 10.1016/S0968-0004(02)02190-4; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kadlec J, 2004, NAT STRUCT MOL BIOL, V11, P330, DOI 10.1038/nsmb741; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lau CK, 2003, CURR BIOL, V13, P933, DOI 10.1016/S0960-9822(03)00328-2; Lerga A, 2001, J BIOL CHEM, V276, P6807, DOI 10.1074/jbc.M008304200; Markley JL, 1998, J BIOMOL NMR, V12, P1, DOI 10.1023/A:1008290618449; Morita EH, 1996, GENES CELLS, V1, P437, DOI 10.1046/j.1365-2443.1996.d01-252.x; Morohoshi F, 1998, GENE, V221, P191, DOI 10.1016/S0378-1119(98)00463-6; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Plambeck CA, 2003, J BIOL CHEM, V278, P22805, DOI 10.1074/jbc.M301896200; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; Rost B, 1996, METHOD ENZYMOL, V266, P525; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; Stewart M, 2003, SCIENCE, V302, P1513, DOI 10.1126/science.1092863; SUMMERS MF, 1988, COORDIN CHEM REV, V86, P43, DOI 10.1016/0010-8545(88)85012-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Varani L, 2000, NAT STRUCT BIOL, V7, P329; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Wang XQ, 2001, NAT STRUCT BIOL, V8, P141, DOI 10.1038/84131; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, J CELL SCI, V110, P1741	51	121	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44834	44840		10.1074/jbc.M408552200	http://dx.doi.org/10.1074/jbc.M408552200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15299008	hybrid			2022-12-27	WOS:000224505600073
J	Kumar, S; Huberman, JA				Kumar, S; Huberman, JA			On the slowing of S phase in response to DNA damage in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; REPLICATION CHECKPOINT; CELLULAR-RESPONSE; PROTEIN-KINASE; CDC2; MITOSIS; ACTIVATION; P34(CDC2); COMPLEX	Eukaryotic cells slow their progression through S phase upon DNA damage. The mechanism that leads to this slowing is called the intra-S-phase checkpoint. Previous studies demonstrated that in the fission yeast Schizosaccharomyces pombe this checkpoint is mediated by a pathway that includes Rad3 ( similar to human ATR and ATM) and Cds1 ( similar to human Chk1 and Chk2). Here we present evidence that a major downstream target of this pathway is the cyclin-dependent kinase, Cdc2. We also present evidence suggesting that the intra-S-phase checkpoint makes a relatively minor contribution to the survival of cells with damaged DNA.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Huberman, JA (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.	huberman@buffalo.edu			NCI NIH HHS [CA95908, P30CA16056, CA84302] Funding Source: Medline; NIGMS NIH HHS [GM49294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA084302, R01CA095908, P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bao SL, 2004, ONCOGENE, V23, P5586, DOI 10.1038/sj.onc.1207753; Berry L D, 1996, Prog Cell Cycle Res, V2, P99; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 2003, MOL CELL BIOL, V23, P5939, DOI 10.1128/MCB.23.16.5939-5946.2003; Chahwan C, 2003, MOL CELL BIOL, V23, P6564, DOI 10.1128/MCB.23.18.6564-6573.2003; Christensen PU, 2000, P NATL ACAD SCI USA, V97, P2579, DOI 10.1073/pnas.97.6.2579; Cobb JA, 2004, CURR OPIN GENET DEV, V14, P292, DOI 10.1016/j.gde.2004.04.001; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; Forbes KC, 1998, GENETICS, V150, P1361; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Kobayashi M, 2004, GENES CELLS, V9, P291, DOI 10.1111/j.1356-9597.2004.00728.x; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LEE MS, 1994, J BIOL CHEM, V269, P30530; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Marchetti MA, 2002, P NATL ACAD SCI USA, V99, P7472, DOI 10.1073/pnas.112702399; MILLAR J, 1991, COLD SH Q B, V56, P577; Mondesert O, 1996, MOL CELL BIOL, V16, P1527; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Nakada D, 2003, NUCLEIC ACIDS RES, V31, P1715, DOI 10.1093/nar/gkg252; Noguchi E, 2003, MOL CELL BIOL, V23, P7861, DOI 10.1128/MCB.23.21.7861-7874.2003; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, GENETICS, V145, P45; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Rhind N, 1998, MOL CELL BIOL, V18, P3782, DOI 10.1128/MCB.18.7.3782; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rhind N, 2001, MOL CELL BIOL, V21, P1499, DOI 10.1128/MCB.21.5.1499-1508.2001; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Usui T, 2001, MOL CELL, V7, P1255, DOI 10.1016/S1097-2765(01)00270-2; Wang Y, 2003, P NATL ACAD SCI USA, V100, P15387, DOI 10.1073/pnas.2536810100; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	57	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43574	43580		10.1074/jbc.M407819200	http://dx.doi.org/10.1074/jbc.M407819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15297457	hybrid			2022-12-27	WOS:000224383100029
J	Smith, M; Bhaskar, V; Fernandez, J; Courey, AJ				Smith, M; Bhaskar, V; Fernandez, J; Courey, AJ			Drosophila Ulp1, a nuclear pore-associated SUMO protease, prevents accumulation of cytoplasmic SUMO conjugates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASES; UBIQUITIN-LIKE PROTEIN; GTPASE-ACTIVATING PROTEIN; CELL-CYCLE PROGRESSION; AMINOACYL-TRANSFER-RNA; TRANSCRIPTIONAL ACTIVITY; P53 ACTIVITY; E3 LIGASE; PML; RANGAP1	SUMO is a small ubiquitin-like protein that becomes covalently conjugated to a variety of target proteins, the large majority of which are found in the nucleus. Ulp1 is a member of a family of proteases that control SUMO function positively, by catalyzing the proteolytic processing of SUMO to its mature form, and negatively, by catalyzing SUMO deconjugation. In Drosophila S2 cells, depletion of Ulp1 by RNA interference results in a dramatic change in the overall spectrum of SUMO conjugates, indicating that SUMO deconjugation is substrate-specific and plays a critical role in determining the steady state targets of SUMO conjugation. Ulp1 normally serves to prevent the accumulation of SUMO-conjugated forms of a number of proteins, including the aminoacyl-tRNA synthetase EPRS. In the presence of Ulp1, most SUMO conjugates reside in the nucleus. However, in its absence, SUMO-conjugated EPRS accumulates in the cytoplasm, contributing to an overall shift of SUMO from the nucleus to the cytoplasm. The ability of Ulp1 to restrict SUMO conjugates to the nucleus is independent of its role as a SUMO-processing enzyme because Ulp1-dependent nuclear localization of SUMO is even observed when SUMO is expressed in a preprocessed form. Studies of a Ulp1-GFP fusion protein suggest that Ulp1 localizes to the nucleoplasmic face of the nuclear pore complex. We hypothesize that, as a component of the nuclear pore complex, Ulp1 may prevent proteins from leaving the nucleus with SUMO still attached.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Rockefeller Univ, Proteom Resource Ctr, New York, NY 10021 USA	University of California System; University of California Los Angeles; Rockefeller University	Courey, AJ (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, POB 951569,607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	courey@chem.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063596] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM063596, GM63596] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdel-Hafiz H, 2002, J BIOL CHEM, V277, P33950, DOI 10.1074/jbc.M204573200; Alarcon-Vargas D, 2002, CANCER BIOL THER, V1, P237, DOI 10.4161/cbt.74; Azuma Y, 2002, DEV CELL, V2, P130, DOI 10.1016/S1534-5807(02)00124-7; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Bhaskar V, 2000, J BIOL CHEM, V275, P4033, DOI 10.1074/jbc.275.6.4033; Bhaskar V, 2002, MOL CELL BIOL, V22, P492, DOI 10.1128/MCB.22.2.492-504.2002; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Boddy MN, 1996, ONCOGENE, V13, P971; Chen GQ, 1998, MOL CELL BIOL, V18, P7259, DOI 10.1128/MCB.18.12.7259; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Duprez E, 1999, J CELL SCI, V112, P381; Fernandez J, 1998, ELECTROPHORESIS, V19, P1036, DOI 10.1002/elps.1150190619; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Francklyn C, 2002, RNA, V8, P1363, DOI 10.1017/S1355838202021180; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Lehembre F, 2000, MOL CELL BIOL, V20, P1072, DOI 10.1128/MCB.20.3.1072-1082.2000; LenzBohme B, 1997, J CELL BIOL, V137, P1001, DOI 10.1083/jcb.137.5.1001; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 2003, J CELL BIOL, V160, P1069, DOI 10.1083/jcb.200212052; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Liu J, 2000, MOL BIOL CELL, V11, P3937, DOI 10.1091/mbc.11.11.3937; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Moroianu J, 1998, J CELL BIOCHEM, V70, P231; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 1999, J VIROL, V73, P5137; Nathanson L, 2000, J BIOL CHEM, V275, P31559, DOI 10.1074/jbc.C000385200; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Panse VG, 2003, NAT CELL BIOL, V5, P21, DOI 10.1038/ncb893; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Shirokawa JM, 1997, MOL CELL BIOL, V17, P3345, DOI 10.1128/MCB.17.6.3345; STADE K, 2002, J BIOL CHEM; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; Takahashi Y, 2000, J BIOCHEM-TOKYO, V128, P723, DOI 10.1093/oxfordjournals.jbchem.a022807; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Vierstra RD, 1999, PLANT MOL BIOL, V41, P435, DOI 10.1023/A:1006323317890; Vierstra RD, 2003, TRENDS PLANT SCI, V8, P135, DOI 10.1016/S1360-1385(03)00014-1; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; ZHOU W, 2004, J BIOL CHEM	70	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43805	43814		10.1074/jbc.M404942200	http://dx.doi.org/10.1074/jbc.M404942200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15294908	hybrid			2022-12-27	WOS:000224383100056
J	Steindler, C; Li, Z; Algarte, M; Alcover, A; Libri, V; Ragimbeau, J; Pellegrini, S				Steindler, C; Li, Z; Algarte, M; Alcover, A; Libri, V; Ragimbeau, J; Pellegrini, S			Jamip1 (Marlin-1) defines a family of proteins interacting with Janus kinases and microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; BINDING PROTEIN; COILED COILS; JAK KINASES; FERM DOMAIN; PHOSPHORYLATION; RECEPTOR; TUBULIN; NETWORK; LOCALIZATION	Jamip1 (Jak and microtubule interacting protein), an alias of Marlin-1, was identified for its ability to bind to the FERM (band 4.1 ezrin/radixin/moesin) homology domain of Tyk2, a member of the Janus kinase (Jak) family of non-receptor tyrosine kinases that are central elements of cytokine signaling cascades. Jamip1 belongs to a family of three genes conserved in vertebrates and is predominantly expressed in neural tissues and lymphoid organs. Jamip proteins lack known domains and are extremely rich in predicted coiled coils that mediate dimerization. In our initial characterization of Jamip1 (73 kDa), we found that it comprises an N-terminal region that targets the protein to microtubule polymers and, when overexpressed in fibroblasts, profoundly perturbs the microtubule network, inducing the formation of tight and stable bundles. Jamip1 was shown to associate with two Jak family members, Tyk2 and Jak1, in Jurkat T cells via its C-terminal region. The restricted expression of Jamip1 and its ability to associate to and modify microtubule polymers suggest a specialized function of these proteins in dynamic processes, e. g. cell polarization, segregation of signaling complexes, and vesicle traffic, some of which may involve Jak tyrosine kinases.	Inst Pasteur, Unite Signalisat Cytokines, CNRS, URA 1961, F-75724 Paris 15, France; Inst Pasteur, Unite Biol Interact Cellulaires, CNRS, URA 2582, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Pellegrini, S (corresponding author), Inst Pasteur, Unite Signalisat Cytokines, CNRS, URA 1961, 25 Rue Dr Roux, F-75724 Paris 15, France.	pellegri@pasteur.fr	Pellegrini, Sandra -/G-5546-2015; LI, Zhi/Q-4790-2018; Pellegrini, Sandra/Y-6351-2019	Pellegrini, Sandra -/0000-0001-5837-7589; LI, Zhi/0000-0003-4422-4914; Pellegrini, Sandra/0000-0001-5837-7589; Alcover, Andres/0000-0002-9507-3450; Libri, Valentina/0000-0002-2080-1089				Aringer M, 1999, LIFE SCI, V64, P2173, DOI 10.1016/S0024-3205(98)00538-4; Cassimeris L, 2001, INT REV CYTOL, V210, P163; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Couve A, 2004, J BIOL CHEM, V279, P13934, DOI 10.1074/jbc.M311737200; Dondi E, 2001, J BIOL CHEM, V276, P47004, DOI 10.1074/jbc.M104316200; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fuchs E, 2001, GENE DEV, V15, P1, DOI 10.1101/gad.861501; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; Goh ELK, 1998, ENDOCRINOLOGY, V139, P4364, DOI 10.1210/en.139.10.4364; GRIFFITH LM, 1982, J BIOL CHEM, V257, P9143; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Helfand BT, 2003, ANNU REV CELL DEV BI, V19, P445, DOI 10.1146/annurev.cellbio.19.111401.092306; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Infante C, 1999, J CELL BIOL, V145, P83, DOI 10.1083/jcb.145.1.83; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kodama A, 2003, CELL, V115, P343, DOI 10.1016/S0092-8674(03)00813-4; Kohrmann M, 1999, MOL BIOL CELL, V10, P2945, DOI 10.1091/mbc.10.9.2945; KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x; Lavoie C, 2000, P NATL ACAD SCI USA, V97, P13637, DOI 10.1073/pnas.240278097; Lillemeier BF, 2001, EMBO J, V20, P2508, DOI 10.1093/emboj/20.10.2508; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Noiges R, 2002, J NEUROSCI, V22, P2106, DOI 10.1523/JNEUROSCI.22-06-02106.2002; Ozer RS, 2000, MOL BIOL CELL, V11, P3573, DOI 10.1091/mbc.11.10.3573; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Ragimbeau J, 2001, J BIOL CHEM, V276, P30812, DOI 10.1074/jbc.M103559200; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Yeh TC, 1999, CELL MOL LIFE SCI, V55, P1523, DOI 10.1007/s000180050392	38	34	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43168	43177		10.1074/jbc.M401915200	http://dx.doi.org/10.1074/jbc.M401915200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15277531	hybrid			2022-12-27	WOS:000224226400101
J	Zhang, Y; Wang, JS; Chen, LL; Zhang, Y; Cheng, XK; Heng, FY; Wu, NH; Shen, YF				Zhang, Y; Wang, JS; Chen, LL; Zhang, Y; Cheng, XK; Heng, FY; Wu, NH; Shen, YF			Repression of hsp90 beta gene by p53 in UV irradiation-induced apoptosis of Jurkat cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TRANSCRIPTIONAL REPRESSION; IN-VIVO; NEGATIVE REGULATION; BINDING-SITE; PROTEIN; SURVIVIN; KINASE; STABILIZATION; CONFORMATION	Tumor suppressor p53 has been implicated in cell stress response and determines cell fate of either growth arrest or apoptosis. Heat shock proteins ( Hsps) expressed under stress usually confer survival protection to the cell or interruption in the apoptotic pathways. Although Hsp90 can physically interact with p53, whether or not the hsp90 gene is influenced downstream of p53 in UV irradiation-induced apoptosis remains unclear. We have found that the level of p53 is elevated with the decline of Hsp90 in UV-irradiated cells and that malfunction of Hsp90, as inhibited by geldanamycin, enhances the p53-involved UV irradiation-induced apoptosis. In addition, the expression of the hsp90beta gene was reduced in both UV-irradiated and wild type p53-transfected cells. These results suggest a negative correlation between the trans factor p53 and a chaperone gene hsp90beta in apoptotic cells. Mutation analysis demonstrated that the p53 binding site in the first exon was indispensable for p53 regulation on the hsp90beta gene. In addition, with p53 bound at the promoter of the hsp90beta gene, mSin3a and p300 were differentially recruited in UV irradiation-treated or untreated Jurkat cells in vivo. The evidence of p53-repressed hsp90beta gene expression in UV-irradiated cells shed light on a novel pathway of Hsp90 in the survival control of the stressed cells.	Chinese Acad Med Sci, Inst Basic Med Sci, Lab Lab Med Mol Biol, Beijing 100005, Peoples R China; Peking Union Med Coll, Beijing 100005, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Shen, YF (corresponding author), 5 Dongdan Santiao, Beijing 100005, Peoples R China.	yfshen@ms.imicams.ac.cn	Zhang, Ye/D-5015-2011; wang, jinshan/A-5434-2010	Zhang, Ye/0000-0002-3494-7206; 				BEERE HM, 2001, SCI STKE; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Chan HM, 2001, J CELL SCI, V114, P2363; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Manfredi JJ, 2003, MOL CELL, V11, P552, DOI 10.1016/S1097-2765(03)00106-0; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Mo ZC, 2002, PROG NAT SCI, V12, P742; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Peters DM, 2002, AM J PHYSIOL-CELL PH, V283, pC878, DOI 10.1152/ajpcell.00107.2002; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; SAMBROOK J, 2000, MOL CLONING LAB MANU; Shen Y F, 1986, J Cell Physiol Suppl, V4, P35; Shen YF, 1997, FEBS LETT, V413, P92, DOI 10.1016/S0014-5793(97)00883-1; Simbulan-Rosenthal CM, 1999, MOL CELL BIOCHEM, V193, P137, DOI 10.1023/A:1006988832729; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sugars KL, 2001, NUCLEIC ACIDS RES, V29, P4530, DOI 10.1093/nar/29.22.4530; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang CG, 2003, J BIOL CHEM, V278, P2066, DOI 10.1074/jbc.M206697200; Wang YL, 1999, CHINESE SCI BULL, V44, P2058, DOI 10.1007/BF02884921; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Wu JM, 2003, J BIOL CHEM, V278, P51143, DOI 10.1074/jbc.M305537200; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Xiao L, 2000, CANCER RES, V60, P400; Yorgin PD, 2000, J IMMUNOL, V164, P2915, DOI 10.4049/jimmunol.164.6.2915; Zhang Y, 2002, J BIOL CHEM, V277, P19042, DOI 10.1074/jbc.M112442200	47	51	53	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42545	42551		10.1074/jbc.M314213200	http://dx.doi.org/10.1074/jbc.M314213200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15284248	hybrid			2022-12-27	WOS:000224226400026
J	Beckley, JR; Pauli, BU; Elble, RC				Beckley, JR; Pauli, BU; Elble, RC			Re-expression of detachment-inducible chloride channel mCLCA5 suppresses growth of metastatic breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; CYCLE-DEPENDENT EXPRESSION; EXTRACELLULAR-MATRIX; POTASSIUM CHANNELS; K+ CHANNEL; INTRACELLULAR ACIDIFICATION; FUNCTIONAL-CHARACTERIZATION; TUMOR SUPPRESSION; CYSTIC-FIBROSIS; GENE-EXPRESSION	The calcium-activated chloride channel hCLCA2 has been identified as a candidate tumor suppressor in human breast cancer. It is greatly down-regulated in breast cancer, and its re-expression suppresses tumorigenesis by an unknown mechanism. To establish a mouse model, we identified the mouse ortholog of hCLCA2, termed mCLCA5, and investigated its behavior in mammary epithelial cell lines and tissues. Expression in the immortalized cell line HC11 correlated with slow or arrested growth. Although rapidly dividing, sparsely plated cells had low levels of expression, mCLCA5 was induced by 10-fold when cells became confluent and 30-fold when cells were deprived of growth factors or anchorage. The apoptosis effector Bax was induced in parallel. Like hCLCA2, mCLCA5 was down-regulated in metastatic mammary tumor cell lines such as 4T1 and CSML-100. Ectopic re-expression in 4T1 cells caused a 20-fold reduction in colony survival relative to vector control. High mCLCA5 expression in stable clones inhibited proliferation and enhanced sensitivity to detachment. Moreover, mCLCA5 was induced in lactating and involuting mammary gland, correlating with differentiation and onset of apoptosis. Together, these results establish mCLCA5 as the mouse ortholog of hCLCA2, demonstrate that mCLCA5 is a detachment-sensitive growth inhibitor, and suggest a mechanism whereby these channels may antagonize mammary tumor progression.	Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Program, Ithaca, NY 14853 USA	Cornell University	Elble, RC (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Program, Ithaca, NY 14853 USA.	rce3@cornell.edu			NCI NIH HHS [CA47668] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047668] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Ghany M, 2003, J BIOL CHEM, V278, P49406, DOI 10.1074/jbc.M309086200; Agnel M, 1999, FEBS LETT, V455, P295, DOI 10.1016/S0014-5793(99)00891-1; AMIGORENA S, 1990, J IMMUNOL, V144, P2038; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; Barriere H, 2001, AM J PHYSIOL-CELL PH, V281, pC810, DOI 10.1152/ajpcell.2001.281.3.C810; Borsi L, 1996, INT J CANCER, V66, P632, DOI 10.1002/(SICI)1097-0215(19960529)66:5<632::AID-IJC9>3.0.CO;2-U; Bumke MA, 2003, PROTEOMICS, V3, P675, DOI 10.1002/pmic.200300395; Bustin SA, 2001, DNA CELL BIOL, V20, P331, DOI 10.1089/10445490152122442; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chen LX, 2002, AM J PHYSIOL-CELL PH, V283, pC1313, DOI 10.1152/ajpcell.00182.2002; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DEANE KHO, 1992, EUR J IMMUNOL, V22, P1165, DOI 10.1002/eji.1830220509; EBRALIDZE AK, 1989, GENETIKA+, V25, P932; Elble RC, 1997, J BIOL CHEM, V272, P27853, DOI 10.1074/jbc.272.44.27853; Elble RC, 2002, J BIOL CHEM, V277, P18586, DOI 10.1074/jbc.M200829200; Elble RC, 2001, J BIOL CHEM, V276, P40510, DOI 10.1074/jbc.M104821200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fernandez-Salas E, 2002, MOL CELL BIOL, V22, P3610, DOI 10.1128/MCB.22.11.3610-3620.2002; Freeman WM, 1999, BIOTECHNIQUES, V26, P112, DOI 10.2144/99261rv01; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Furlong IJ, 1997, J CELL SCI, V110, P653; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P3587, DOI 10.1073/pnas.93.8.3587; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Gruber A. D., 2000, Current Genomics, V1, P201, DOI 10.2174/1389202003351526; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 2002, CURR TOP MEMBR, V53, P367; Gruber AD, 1998, HISTOCHEM CELL BIOL, V110, P43, DOI 10.1007/s004180050263; Gruber AD, 1999, CANCER RES, V59, P5488; Gulbins E, 2000, AM J PHYSIOL-RENAL, V279, pF605, DOI 10.1152/ajprenal.2000.279.4.F605; Hajnoczky G, 2000, CELL CALCIUM, V28, P349, DOI 10.1054/ceca.2000.0169; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; Hovey RC, 2001, MOL ENDOCRINOL, V15, P819, DOI 10.1210/me.15.5.819; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Jensen BS, 1999, P NATL ACAD SCI USA, V96, P10917, DOI 10.1073/pnas.96.19.10917; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; KAJSTURA J, 1989, CELL BIOL INT REP, V13, P377, DOI 10.1016/0309-1651(89)90164-1; KINOSHITA T, 1992, ANAL BIOCHEM, V206, P231, DOI 10.1016/0003-2697(92)90358-E; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Merlo GR, 1996, EUR J CELL BIOL, V70, P97; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Merlo GR, 1997, CELL GROWTH DIFFER, V8, P251; NILIUS B, 1992, J PHYSIOL-LONDON, V445, P537, DOI 10.1113/jphysiol.1992.sp018938; PAPPAS CA, 1994, NEUROREPORT, V6, P193, DOI 10.1097/00001756-199412300-00049; Pei L, 2003, P NATL ACAD SCI USA, V100, P7803, DOI 10.1073/pnas.1232448100; Pillozzi S, 2002, LEUKEMIA, V16, P1791, DOI 10.1038/sj.leu.2402572; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Ullrich N, 1999, NEUROSCIENTIST, V5, P70, DOI 10.1177/107385849900500210; Ullrich N, 1996, AM J PHYSIOL-CELL PH, V270, pC1511; Ullrich N, 1997, AM J PHYSIOL-CELL PH, V273, pC1290, DOI 10.1152/ajpcell.1997.273.4.C1290; Valenzuela SM, 2000, J PHYSIOL-LONDON, V529, P541, DOI 10.1111/j.1469-7793.2000.00541.x; VILLAZ M, 1995, J PHYSIOL-LONDON, V488, P689, DOI 10.1113/jphysiol.1995.sp021000; Wang HZ, 2002, CANCER RES, V62, P4843; WILSON GF, 1993, J PHYSIOL-LONDON, V470, P501, DOI 10.1113/jphysiol.1993.sp019872; Wondergem N, 2001, J PHYSIOL-LONDON, V532, P661, DOI 10.1111/j.1469-7793.2001.0661e.x; WONDERLIN WF, 1995, J CELL PHYSIOL, V165, P177, DOI 10.1002/jcp.1041650121; WOODFORK KA, 1995, J CELL PHYSIOL, V162, P163, DOI 10.1002/jcp.1041620202; Yu SP, 2000, P NATL ACAD SCI USA, V97, P9360, DOI 10.1073/pnas.97.17.9360	68	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41634	41641		10.1074/jbc.M408334200	http://dx.doi.org/10.1074/jbc.M408334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292178	hybrid			2022-12-27	WOS:000224075500049
J	Budagian, V; Bulanova, E; Orinska, Z; Pohl, T; Borden, EC; Silverman, R; Bulfone-Paus, S				Budagian, V; Bulanova, E; Orinska, Z; Pohl, T; Borden, EC; Silverman, R; Bulfone-Paus, S			RETRACTED: Reverse signaling through membrane-bound interleukin-15 (Retracted Article. See vol 286, pg 8708, 2011)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							NECROSIS-FACTOR-ALPHA; INTRACELLULAR TRAFFICKING; PROTEIN-KINASE; CELL PROLIFERATION; CYTOPLASMIC DOMAIN; HUMAN MONOCYTES; NATURAL-KILLER; GROWTH-FACTOR; IL-15; RECEPTOR	The results from this study implicate membrane-anchored interleukin (IL)-15 constitutively expressed on the cell surface of PC-3 human prostate carcinoma cells and interferon-gamma-activated human monocytes in reverse signaling upon stimulation with soluble IL-15 receptor-alpha or anti-IL-15 antibodies, mediating the outside-to-inside signal transduction that involves the activation of members of the MAPK family (ERK and p38) and focal adhesion kinase. The presence of membrane-bound IL-15 was not dependent on the expression of the trimeric IL-15 receptor complex by these cells and resisted treatment with acidic buffer or trypsin. Reverse signaling through membrane-bound IL-15 considerably increased the production of several pro-inflammatory cytokines by monocytes, such as IL-6, IL-8, and tumor necrosis factor-alpha, thereby indicating the relevance of this process to the complex immunomodulatory function of these cells. Furthermore, stimulation of transmembrane IL-15 also enhanced the transcription of IL-6 and IL-8 in the PC-3 cell line and promoted migration of PC-3 cells as well as LNCaP human prostate carcinoma cells stably expressing IL-15 on the cell surface. Thus, IL-15 can exist as a biologically active transmembrane molecule that possesses dual ligand-receptor qualities with a potential to induce bidirectional signaling. This fact highlights a new level of complexity in the biology of IL-15 and offers novel important insights into our understanding of the cellular responses modulated by this pleiotropic cytokine.	Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany; Taussig Canc Ctr, Ctr Canc Drug Discovery & Dev, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; WITA GmbH, D-14513 Teltov, Germany	Forschungszentrum Borstel; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Bulanova, E (corresponding author), Res Ctr Borstel, Dept Immunol & Cell Biol, Parkallee 22, D-23845 Borstel, Germany.	ebulanova@fz-borstel.de						ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; Bernard J, 2004, J BIOL CHEM, V279, P24313, DOI 10.1074/jbc.M312458200; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Budagian V, 2004, J BIOL CHEM, V279, P40368, DOI 10.1074/jbc.M404125200; Bulanova E, 2003, J IMMUNOL, V170, P5045, DOI 10.4049/jimmunol.170.10.5045; BulfonePaus S, 1997, CYTOKINE, V9, P507, DOI 10.1006/cyto.1996.0194; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Domonkos A, 2001, EUR CYTOKINE NETW, V12, P411; Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6; Eissner G, 2000, J IMMUNOL, V164, P6193, DOI 10.4049/jimmunol.164.12.6193; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Gaggero A, 1999, EUR J IMMUNOL, V29, P1265, DOI 10.1002/(SICI)1521-4141(199904)29:04<1265::AID-IMMU1265>3.0.CO;2-V; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GOLD MR, 1993, CELL GROWTH DIFFER, V4, P647; Harashima S, 2001, J IMMUNOL, V166, P130, DOI 10.4049/jimmunol.166.1.130; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; KEEL BA, 1995, ENDOCRINOLOGY, V136, P1197, DOI 10.1210/en.136.3.1197; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Kurys G, 2000, J BIOL CHEM, V275, P30653, DOI 10.1074/jbc.M002373200; Langstein J, 1998, J IMMUNOL, V160, P2488; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; McInnes IB, 1997, NAT MED, V3, P189, DOI 10.1038/nm0297-189; Miyashita T, 1997, J IMMUNOL, V158, P4620; Musso T, 1999, BLOOD, V93, P3531; Nabi IR, 1999, J CELL SCI, V112, P1803; Neely GG, 2001, J IMMUNOL, V167, P5011, DOI 10.4049/jimmunol.167.9.5011; Newell MK, 1999, APOPTOSIS, V4, P311, DOI 10.1023/A:1009670802382; Onu A, 1997, J IMMUNOL, V158, P255; OWENS LV, 1995, CANCER RES, V55, P2752; Pereno R, 2000, ONCOGENE, V19, P5153, DOI 10.1038/sj.onc.1203873; Quinn LS, 2002, EXP CELL RES, V280, P55, DOI 10.1006/excr.2002.5624; Rappl G, 2001, J INVEST DERMATOL, V116, P102, DOI 10.1046/j.1523-1747.2001.00239.x; Ruchatz H, 1998, J IMMUNOL, V160, P5654; Ruckert R, 2000, J IMMUNOL, V165, P2240, DOI 10.4049/jimmunol.165.4.2240; Shinozaki M, 2002, J CLIN INVEST, V109, P951, DOI 10.1172/JCI200214574; Sieg DJ, 1999, J CELL SCI, V112, P2677; Silverman RH, 2003, BIOCHEMISTRY-US, V42, P1805, DOI 10.1021/bi027147i; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; Suzuki I, 1998, J EXP MED, V187, P123, DOI 10.1084/jem.187.1.123; Waldmann TA, 2001, IMMUNITY, V14, P105, DOI 10.1016/S1074-7613(01)00093-0; Watts AD, 1999, EMBO J, V18, P2119, DOI 10.1093/emboj/18.8.2119; Wei JY, 1998, J BIOL CHEM, V273, P5903, DOI 10.1074/jbc.273.10.5903; Wiley SR, 1996, J IMMUNOL, V157, P3635; WINSTON BW, 1995, J IMMUNOL, V155, P1525; Zheng DQ, 1999, CANCER RES, V59, P1655; ZHOU GX, 1993, BIOCHEM BIOPH RES CO, V197, P578, DOI 10.1006/bbrc.1993.2518	50	51	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42192	42201		10.1074/jbc.M403182200	http://dx.doi.org/10.1074/jbc.M403182200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15284244	Green Published, hybrid			2022-12-27	WOS:000224075500111
J	Kato, H; Tamamizu-Kato, S; Shibasaki, F				Kato, H; Tamamizu-Kato, S; Shibasaki, F			Histone deacetylase 7 associates with hypoxia-inducible factor 1 alpha and increases transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; CELLULAR-LOCALIZATION; STRUCTURAL BASIS; GENE-EXPRESSION; NUCLEAR EXPORT; FACTOR 1-ALPHA; HIF-ALPHA; ENOLASE 1; FAMILY; HYDROXYLATION	Hypoxia-inducible factor (HIF)-1alpha is a transcription factor that controls expression of genes responsive to low oxygen tension, including vascular endothelial growth factor ( VEGF), erythropoietin, and glycolytic enzymes. The activity of HIF-1alpha is regulated by binding to the transcriptional co-activator cAMP-response element-binding protein-binding protein (CBP)/p300. Using the yeast two-hybrid screening system, we found that the inhibitory domain of HIF-1alpha strongly interacted with the C-terminal domain of histone deacetylase (HDAC) 7. The o-nitrophenyl beta-D-galactopyranoside assay revealed that regions containing amino acids 735 785 of HIF-1alpha and amino acids 669 - 952 of HDAC7 were minimum contact sites of the interaction. The binding of HDAC7 with HIF-1alpha was reproduced in HEK293 cells grown under normoxic and hypoxic conditions (2% O-2). HDAC7 bound solely to HIF-1alpha among other HIF-alpha family members, including HIF-2alpha and HIF-3alpha, whereas HIF-1alpha only interacted with HDAC7 in the class II HDAC family. Although HDAC7 was localized dominantly in the cytoplasm at normal oxygen concentrations, HDAC7 co-translocated to the nucleus with HIF-1alpha under hypoxic conditions. In the nucleus, HDAC7 increased transcriptional activity of HIF-1alpha through the formation of a complex with HIF-1alpha, HDAC7, and p300. Taken together, these results indicate that HDAC7 is a novel transcriptional activator of HIF-1alpha.	Tokyo Metropolitan Inst Med Sci, Dept Mol Cell Physiol, Bunkyo Ku, Tokyo 1138613, Japan	Tokyo Metropolitan Institute of Medical Science	Kato, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Mol Cell Physiol, Bunkyo Ku, 3-18-22 Honkamagome, Tokyo 1138613, Japan.	h-kato@rinshoken.or.jp						ARNOULD T, 1992, J CELL PHYSIOL, V152, P215, DOI 10.1002/jcp.1041520127; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Caro J, 2001, HIGH ALT MED BIOL, V2, P145, DOI 10.1089/152702901750265251; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Hara S, 2001, BIOCHEM BIOPH RES CO, V287, P808, DOI 10.1006/bbrc.2001.5659; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; HORTON RM, 1991, INDIRECT MUTAGENESIS, P217; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kao HY, 2000, GENE DEV, V14, P55; Kietzmann T, 2001, BIOCHEM J, V354, P531, DOI 10.1042/0264-6021:3540531; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Zhong H, 1998, CANCER RES, V58, P5280; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	41	168	172	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41966	41974		10.1074/jbc.M406320200	http://dx.doi.org/10.1074/jbc.M406320200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15280364	hybrid			2022-12-27	WOS:000224075500089
J	Hove-Jensen, B				Hove-Jensen, B			Heterooligomeric phosphoribosyl diphosphate synthase of Saccharomyces cerevisiae - Combinatorial expression of the five PRS genes in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; SYNTHETASE; DNA; CLONING; FAMILY; PYROPHOSPHATE; NUCLEOTIDE; MUTANT; MEMBER	The yeast Saccharomyces cerevisiae contains five phosphoribosyl diphosphate (PRPP) synthase-homologous genes (PRS1 - 5), which specify PRPP synthase subunits 1 - 5. Expression of the five S. cerevisiae PRS genes individually in an Escherichia coli PRPP-less strain (Deltaprs) showed that a single PRS gene product had no PRPP synthase activity. In contrast, expression of five pairwise combinations of PRS genes resulted in the formation of active PRPP synthase. These combinations were PRS1 PRS2, PRS1 PRS3, and PRS1 PRS4, as well as PRS5 PRS2 and PRS5 PRS4. None of the remaining five possible pairwise combinations of PRS genes appeared to produce active enzyme. Extract of an E. coli strain containing a plasmid-borne PRS1 gene and a chromosome-borne PRS3 gene contained detectable PRPP synthase activity, whereas extracts of strains containing PRS1 PRS2, PRS1 PRS4, PRS5 PRS2, or PRS5 PRS4 contained no detectable PRPP synthase activity. In contrast PRPP could be detected in growing cells containing PRS1 PRS2, PRS1 PRS3, PRS5 PRS2, or PRS5 PRS4. These apparent conflicting results indicate that, apart from the PRS1 PRS3-specified enzyme, PRS-specified enzyme is functional in vivo but unstable when released from the cell. Certain combinations of three PRS genes appeared to produce an enzyme that is stable in vitro. Thus, extracts of strains harboring PRS1 PRS2 PRS5, PRS1 PRS4 PRS5, or PRS2 PRS4 PRS5 as well as extracts of strains harboring combinations with PRS1 PRS3 contained readily assayable PRPP synthase activity. The data indicate that although certain pairwise combinations of subunits produce an active enzyme, yeast PRPP synthase requires at least three different subunits to be stable in vitro. The activity of PRPP synthases containing subunits 1 and 3 or subunits 1, 2, and 5 was found to be dependent on P-i, to be temperature-sensitive, and inhibited by ADP.	Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, DK-1307 Copenhagen K, Denmark	University of Copenhagen	Hove-Jensen, B (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, 83H Solvgade, DK-1307 Copenhagen K, Denmark.	hove@mermaid.molbio.ku.dk						ARNVIG K, 1990, EUR J BIOCHEM, V192, P195, DOI 10.1111/j.1432-1033.1990.tb19214.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOWER SG, 1989, J BIOL CHEM, V264, P10287; CARTER AT, 1994, YEAST, V10, P1031, DOI 10.1002/yea.320100805; Carter AT, 1997, MOL GEN GENET, V254, P148, DOI 10.1007/s004380050402; CLARK DJ, 1967, J MOL BIOL, V23, P99, DOI 10.1016/S0022-2836(67)80070-6; Hernando Y, 1998, J BACTERIOL, V180, P6404; Hernando Y, 1999, J BIOL CHEM, V274, P12480, DOI 10.1074/jbc.274.18.12480; HOVEJENSEN B, 1989, MOL MICROBIOL, V3, P1487, DOI 10.1111/j.1365-2958.1989.tb00134.x; HOVEJENSEN B, 1983, J BACTERIOL, V154, P177, DOI 10.1128/JB.154.1.177-184.1983; HOVEJENSEN B, 1988, J BACTERIOL, V170, P1148, DOI 10.1128/jb.170.3.1148-1152.1988; HOVEJENSEN B, 1993, J BACTERIOL, V175, P5628, DOI 10.1128/JB.175.17.5628-5635.1993; HOVEJENSEN B, 1985, MOL GEN GENET, V201, P269, DOI 10.1007/BF00425670; HOVEJENSEN B, 1992, J BACTERIOL, V174, P6852, DOI 10.1128/JB.174.21.6852-6856.1992; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; JENSEN KF, 1979, ANAL BIOCHEM, V98, P254, DOI 10.1016/0003-2697(79)90138-6; Jensen KF, 1983, METABOLISM NUCLEOTID, P1; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; KHORANA HG, 1958, J BIOL CHEM, V230, P941; Krath BN, 1999, BBA-PROTEIN STRUCT M, V1430, P403, DOI 10.1016/S0167-4838(99)00022-9; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MILLER JH, 1992, SHORT COURSE BACTERI, P268; Nakamura Y, 2000, NUCLEIC ACIDS RES, V28, P292, DOI 10.1093/nar/28.1.292; Post DA, 1996, MICROBIOL-SGM, V142, P359, DOI 10.1099/13500872-142-2-359; Silhavy TJ, 1984, EXPT GENE FUSIONS, P137; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sonoda T, 1998, BBA-PROTEIN STRUCT M, V1387, P32, DOI 10.1016/S0167-4838(98)00106-X; Sorensen KI, 1996, J BACTERIOL, V178, P1003, DOI 10.1128/jb.178.4.1003-1011.1996	29	12	18	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40345	40350		10.1074/jbc.M405480200	http://dx.doi.org/10.1074/jbc.M405480200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15280369	hybrid			2022-12-27	WOS:000223916800016
J	Jin, M; Smith, C; Hsieh, HY; Gibson, DF; Tait, JF				Jin, M; Smith, C; Hsieh, HY; Gibson, DF; Tait, JF			Essential role of B-helix calcium binding sites in annexin V-membrane binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; IN-VIVO DETECTION; PHOSPHOLIPID-BINDING; CRYSTAL-STRUCTURE; MECHANISM; MUTANTS; CHANNEL; RECOGNITION; MUTAGENESIS; APOPTOSIS	Crystal structures of annexin V have shown up to 10 bound calcium ions in three different types of binding sites, but previous work concluded that only one of these sites accounted for nearly all of the membrane binding affinity of the molecule. In this study we mutated residues contributing to potential calcium binding sites in the AB and B helices in each of the four domains ( eight sites in total) and in DE helices in the first, second, and third domains ( three sites in total). We measured the affinity of each protein for phospholipid vesicles and cell membranes by quantitative calcium titration under low occupancy conditions (< 1% saturation of available membrane binding sites). Affinity was calculated from the midpoint and slope of the calcium titration curve and the concentration of membrane binding sites. The results showed that all four AB sites were essential for high affinity binding, as were three of the four B sites ( in domains 1, 2, and 3); the DE site in the first domain made a slight contribution to affinity. Multisite mutants showed that each domain contributed additively and independently to binding affinity; in contrast, AB and B sites within the same domain were interdependent. The number of functionally important sites identified was consistent with the Hill coefficient observed in calcium titrations. This study shows an essential and previously unappreciated role for B-helix calcium binding sites in the membrane binding of annexins and indicates that all four domains of the molecule are required for maximum membrane binding affinity.	Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Tait, JF (corresponding author), Univ Washington, Dept Lab Med, Box 357110, Seattle, WA 98195 USA.	tait@u.washington.edu						BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7970, DOI 10.1021/bi00246a014; BAZZI MD, 1993, CELL SIGNAL, V5, P357, DOI 10.1016/0898-6568(93)90075-W; Belhocine T, 2002, CLIN CANCER RES, V8, P2766; BERENDES R, 1993, SCIENCE, V262, P427, DOI 10.1126/science.7692599; Bitto E, 1998, BIOCHEMISTRY-US, V37, P10231, DOI 10.1021/bi980479w; Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; Boisgard R, 2003, J NUCL MED, V44, p98P; BURGER A, 1994, J MOL BIOL, V237, P479, DOI 10.1006/jmbi.1994.1249; Capila I, 2001, STRUCTURE, V9, P57, DOI 10.1016/S0969-2126(00)00549-9; Dubois T, 1998, BIOCHEM J, V330, P1277, DOI 10.1042/bj3301277; EVANS TC, 1994, BIOCHEMISTRY-US, V33, P13231, DOI 10.1021/bi00249a009; FavierPerron B, 1996, BIOCHEMISTRY-US, V35, P1740, DOI 10.1021/bi952092o; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P8087, DOI 10.1021/bi00399a011; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P5572, DOI 10.1021/bi00391a053; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Green AM, 2002, CANCER J, V8, P82, DOI 10.1097/00130404-200203000-00002; Hawkins TE, 2000, CELL BIOCHEM BIOPHYS, V33, P275, DOI 10.1385/CBB:33:3:275; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; JOST M, 1994, BIOCHEM J, V298, P553, DOI 10.1042/bj2980553; Kown MH, 2001, AM J TRANSPLANT, V1, P270, DOI 10.1034/j.1600-6143.2001.001003270.x; LEWITBENTLEY A, 1992, EUR J BIOCHEM, V210, P73, DOI 10.1111/j.1432-1033.1992.tb17392.x; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; Mira JP, 1997, J BIOL CHEM, V272, P10474; Mo Y, 2003, J BIOL CHEM, V278, P2437, DOI 10.1074/jbc.M210286200; Montaville P, 2002, J BIOL CHEM, V277, P24684, DOI 10.1074/jbc.M109595200; Moss SE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-219; Narula J, 2001, NAT MED, V7, P1347, DOI 10.1038/nm1201-1347; NELSON MR, 1995, BIOCHEMISTRY-US, V34, P3121, DOI 10.1021/bi00009a044; Oling F, 2000, J MOL BIOL, V304, P561, DOI 10.1006/jmbi.2000.4183; Patel DR, 2001, BIOCHEMISTRY-US, V40, P7054, DOI 10.1021/bi010345+; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Seaton BA, 1996, ANNEXINS MOL STRUCTU, P15; Sopkova J, 2002, PROTEIN SCI, V11, P1613, DOI 10.1110/ps.4230102; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; Tait JF, 2000, BIOCONJUGATE CHEM, V11, P918, DOI 10.1021/bc000059v; Tait JF, 2004, ANAL BIOCHEM, V329, P112, DOI 10.1016/j.ab.2004.02.043; Tait JF, 2002, BIOCONJUGATE CHEM, V13, P1119, DOI 10.1021/bc025545s; TAIT JF, 2004, J NUCL MED, V45, pP150; Thimister PWL, 2003, J NUCL MED, V44, P391; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281	41	31	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40351	40357		10.1074/jbc.M405846200	http://dx.doi.org/10.1074/jbc.M405846200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15280367	hybrid			2022-12-27	WOS:000223916800017
J	Song, BD; Leonard, M; Schmid, SL				Song, BD; Leonard, M; Schmid, SL			Dynamin GTPase domain mutants that differentially affect GTP binding, GTP hydrolysis, and clathrin-mediated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; BETA-SUBUNIT; PROTEINS; MECHANISM; BLOCK; PITS	The GTPase dynamin is essential for clathrin-mediated endocytosis. Unlike most GTPases, dynamin has a low affinity for nucleotide, a high rate of GTP hydrolysis, and can self-assemble, forming higher order structures such as rings and spirals that exhibit up to 100-fold stimulated GTPase activity. The role(s) of GTP binding and/or hydrolysis in endocytosis remain unclear because mutations in the GTPase domain so far studied impair both. We generated a new series of GTPase domain mutants to probe the mechanism of GTP hydrolysis and to further test the role of GTP binding and/or hydrolysis in endocytosis. Each of the mutations had parallel effects on assembly-stimulated and basal GTPase activities. In contrast to previous reports, we find that mutation of Thr-65 to Ala (or Asp or His) dramatically lowered both the rate of assembly-stimulated GTP hydrolysis and the affinity for GTP. The assembly-stimulated rate of hydrolysis was lowered by the mutation of Ser-61 to Asp and increased by the mutation of Thr-141 to Ala without significantly altering the K-m for GTP. For some mutants and to a lesser extent for WT dynamin, self-assembly dramatically altered the K-m for GTP, suggesting that conformational changes in the active site accompany self-assembly. Analysis of transferrin endocytosis rates in cells overexpressing mutant dynamins revealed a stronger correlation with both the basal and assembly-stimulated rates of GTP hydrolysis than with the calculated ratio of dynamin-GTP/free dynamin, suggesting that GTP binding is not sufficient, and GTP hydrolysis is required for clathrin-mediated endocytosis in vivo.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schmid, SL (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	slschmid@scripps.edu		Schmid, Sandra/0000-0002-1690-7024	NIGMS NIH HHS [GM42455] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042455] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Binns DD, 2000, BIOCHEMISTRY-US, V39, P7188, DOI 10.1021/bi000033r; Chen YJ, 2004, NAT STRUCT MOL BIOL, V11, P574, DOI 10.1038/nsmb762; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Damke H, 2001, MOL BIOL CELL, V12, P2578, DOI 10.1091/mbc.12.9.2578; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Evergren E, 2004, J NEUROSCI METH, V135, P169, DOI 10.1016/j.jneumeth.2003.12.010; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hill E, 2001, J CELL BIOL, V152, P309, DOI 10.1083/jcb.152.2.309; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Iversen TG, 2003, P NATL ACAD SCI USA, V100, P5175, DOI 10.1073/pnas.0534231100; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; Legate KR, 2000, J BIOL CHEM, V275, P27439; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Miwako I, 2003, TRAFFIC, V4, P376, DOI 10.1111/j.1365-313X.2008.03782.x; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; NEAL SE, 1988, J BIOL CHEM, V263, P19718; Niemann HH, 2001, EMBO J, V20, P5813, DOI 10.1093/emboj/20.21.5813; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; Pepperkok R, 2000, J CELL SCI, V113, P135; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Schwartz T, 2003, CELL, V112, P793, DOI 10.1016/S0092-8674(03)00161-2; Sever S, 2000, J CELL BIOL, V150, P1137, DOI 10.1083/jcb.150.5.1137; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Song BD, 2004, MOL BIOL CELL, V15, P2243, DOI 10.1091/mbc.E04-01-0015; Song BD, 2003, BIOCHEMISTRY-US, V42, P1369, DOI 10.1021/bi027062h; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Wittinghofer A, 2000, FR MOLEC B, V24, P244; Wolfenden R, 1999, J AM CHEM SOC, V121, P7419, DOI 10.1021/ja991280p	34	75	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40431	40436		10.1074/jbc.M407007200	http://dx.doi.org/10.1074/jbc.M407007200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262989	hybrid			2022-12-27	WOS:000223916800028
J	Monti, DM; D'Alessio, G				Monti, DM; D'Alessio, G			Cytosolic RNase inhibitor only affects RNases with intrinsic cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PANCREATIC RIBONUCLEASE; SEMINAL RIBONUCLEASE; ANTITUMOR ACTION; MAMMALIAN-CELLS; MEDIATED CYTOTOXICITY; EXPRESSION; PROTEIN; PURIFICATION; MECHANISM; SEQUENCE	Cytosolic RNase inhibitor binds to and neutralizes most members of the pancreatic type RNase superfamily. However, there are a few exceptions, e. g. amphibian onconase and bovine seminal RNase, and these are endowed with cytotoxic activity. Also, RNase variants created by mutagenesis to partially evade the RNase inhibitor acquire cytotoxic activity. These findings have led to the proposal that the cytosolic inhibitor acts as a sentry to protect mammalian cells from foreign RNases. We silenced the expression of the gene encoding the cytosolic inhibitor in HeLa cells and found that the cells become more sensitive to foreign cytotoxic RNases. However foreign, non-cytotoxic RNases remain non-cytotoxic. These results indicate that the cytosolic inhibitor neutralizes those foreign RNases that are intrinsically cytotoxic and have access to the cytosol. However, its normal physiological role may not be to guard against foreign RNases in general.	Univ Naples Federico II, Dept Biol Chem, I-80134 Naples, Italy	University of Naples Federico II	D'Alessio, G (corresponding author), Univ Naples Federico II, Dept Biol Chem, Via Mezzocannone 16, I-80134 Naples, Italy.	dalessio@unina.it		MONTI, Daria Maria/0000-0002-1136-0576				Antignani A, 2001, BIOCHEMISTRY-US, V40, P3492, DOI 10.1021/bi002781m; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; Bosch M, 2004, BIOCHEMISTRY-US, V43, P2167, DOI 10.1021/bi035729+; Bracale A, 2003, EUR J BIOCHEM, V270, P1980, DOI 10.1046/j.1432-1033.2003.03567.x; D'Alessio G, 2001, METHOD ENZYMOL, V341, P248, DOI 10.1016/S0076-6879(01)41156-6; DICE JF, 1990, CRIT REV THER DRUG, V7, P211; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Haigis MC, 2003, NUCLEIC ACIDS RES, V31, P1024, DOI 10.1093/nar/gkg163; Haigis MC, 2002, J BIOL CHEM, V277, P11576, DOI 10.1074/jbc.M112227200; Hofsteenge J., 1997, RIBONUCLEASES STRUCT, P621, DOI [10.1016/b978-012588945-2/50020-0, DOI 10.1016/B978-012588945-2/50020-0]; Kim JS, 1995, J BIOL CHEM, V270, P31097, DOI 10.1074/jbc.270.52.31097; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; LEE FS, 1993, PROG NUCLEIC ACID RE, V44, P1, DOI 10.1016/S0079-6603(08)60215-9; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; MASTRONICOLA MR, 1995, EUR J BIOCHEM, V230, P242, DOI 10.1111/j.1432-1033.1995.tb20557.x; Matousek J, 2003, J BIOL CHEM, V278, P23817, DOI 10.1074/jbc.M302711200; Murthy BS, 1996, BIOCHEMISTRY-US, V35, P3880, DOI 10.1021/bi952429m; Newton DL, 1997, PROTEIN ENG, V10, P463, DOI 10.1093/protein/10.4.463; Notomista E, 1999, FEBS LETT, V463, P211, DOI 10.1016/S0014-5793(99)01623-3; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; RUSSO N, 1993, FEBS LETT, V333, P233, DOI 10.1016/0014-5793(93)80660-M; Rybak SM, 1999, EXP CELL RES, V253, P325, DOI 10.1006/excr.1999.4718; Sorrentino S, 2000, FEBS LETT, V466, P35, DOI 10.1016/S0014-5793(99)01742-1; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Suzuki M, 1999, NAT BIOTECHNOL, V17, P265, DOI 10.1038/7010; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491	26	23	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39195	39198		10.1074/jbc.C400311200	http://dx.doi.org/10.1074/jbc.C400311200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15277533	hybrid			2022-12-27	WOS:000223791500002
J	Austin, MB; Izumikawa, M; Bowman, ME; Udwary, DW; Ferrer, JL; Moore, BS; Noel, JP				Austin, MB; Izumikawa, M; Bowman, ME; Udwary, DW; Ferrer, JL; Moore, BS; Noel, JP			Crystal structure of a bacterial type III polyketide synthase and enzymatic control of reactive polyketide intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-COELICOLOR A3(2); SITE-DIRECTED MUTAGENESIS; CHALCONE SYNTHASE; MALONYL-COENZYME; MYCOBACTERIUM-TUBERCULOSIS; SUBSTRATE-SPECIFICITY; MELANIN BIOSYNTHESIS; CATALYTIC CYSTEINE; AROMATIC-COMPOUNDS; HIGHER-PLANTS	In bacteria, a structurally simple type III polyketide synthase (PKS) known as 1,3,6,8-tetrahydroxynaphthalene synthase (THNS) catalyzes the iterative condensation of five CoA-linked malonyl units to form a pentaketide intermediate. THNS subsequently catalyzes dual intramolecular Claisen and aldol condensations of this linear intermediate to produce the fused ring tetrahydroxynaphthalene (THN) skeleton. The type III PKS-catalyzed polyketide extension mechanism, utilizing a conserved Cys-His-Asn catalytic triad in an internal active site cavity, is fairly well understood. However, the mechanistic basis for the unusual production of THN and dual cyclization of its malonyl-primed pentaketide is obscure. Here we present the first bacterial type III PKS crystal structure, that of Streptomyces coelicolor THNS, and identify by mutagenesis, structural modeling, and chemical analysis the unexpected catalytic participation of an additional THNS-conserved cysteine residue in facilitating malonyl-primed polyketide extension beyond the triketide stage. The resulting new mechanistic model, involving the use of additional cysteines to alter and steer polyketide reactivity, may generally apply to other PKS reaction mechanisms, including those catalyzed by iterative type I and II PKS enzymes. Our crystal structure also reveals an unanticipated novel cavity extending into the "floor" of the traditional active site cavity, providing the first plausible structural and mechanistic explanation for yet another unusual THNS catalytic activity: its previously inexplicable extra polyketide extension step when primed with a long acyl starter. This tunnel allows for selective expansion of available active site cavity volume by sequestration of aliphatic starter-derived polyketide tails, and further suggests another distinct protection mechanism involving maintenance of a linear polyketide conformation.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92037 USA; Univ Arizona, Div Med Chem, Tucson, AZ 85721 USA; Inst Biol Struct Jean Pierre Ebel, Lab Cristallog & Cristallogenese Prot, F-38027 Grenoble 1, France; Univ Arizona, Dept Chem, Tucson, AZ 85721 USA	Salk Institute; University of California System; University of California San Diego; University of Arizona; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); University of Arizona	Moore, BS (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	moore@pharmacy.arizona.edu; noel@salk.edu	Noel, Joseph P/A-9459-2009	Moore, Bradley/0000-0002-4652-1253	NIAID NIH HHS [AI52443] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052443] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abe I, 2004, FEBS LETT, V562, P171, DOI 10.1016/S0014-5793(04)00230-3; Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; AUSTIN MB, 2004, IN PRESS CHEM BIOL; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Brown H. C., 1955, DETERMINATION ORGANI; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cortes J, 2002, MOL MICROBIOL, V44, P1213, DOI 10.1046/j.1365-2958.2002.02975.x; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; Feng B, 2001, INFECT IMMUN, V69, P1781, DOI 10.1128/IAI.69.3.1781-1794.2001; Ferrer JL, 1999, NAT STRUCT BIOL, V6, P775, DOI 10.1038/11553; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Fujii I, 1999, BIOSCI BIOTECH BIOCH, V63, P1445, DOI 10.1271/bbb.63.1445; Fujii I, 2000, BIOCHEMISTRY-US, V39, P8853, DOI 10.1021/bi000644j; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; Funa N, 2002, J BIOL CHEM, V277, P4628, DOI 10.1074/jbc.M110357200; Funa N, 2002, BIOCHEM J, V367, P781, DOI 10.1042/BJ20020953; HARRIS TM, 1986, PURE APPL CHEM, V58, P283, DOI 10.1351/pac198658020283; HELLER W, 1980, ARCH BIOCHEM BIOPHYS, V200, P617, DOI 10.1016/0003-9861(80)90395-1; Izumikawa M, 2003, J IND MICROBIOL BIOT, V30, P510, DOI 10.1007/s10295-003-0075-8; Jez JM, 2000, CHEM BIOL, V7, P919, DOI 10.1016/S1074-5521(00)00041-7; Jez JM, 2000, J BIOL CHEM, V275, P39640, DOI 10.1074/jbc.M008569200; Jez JM, 2001, BIOCHEMISTRY-US, V40, P14829, DOI 10.1021/bi015621z; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; JONES TA, 1993, ACTA CRYSTALLOGR D, V49, P148; Kalaitzis JA, 2003, ORG LETT, V5, P4449, DOI 10.1021/ol035748b; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREUZALER F, 1972, FEBS LETT, V28, P69, DOI 10.1016/0014-5793(72)80679-3; KREUZALER F, 1975, ARCH BIOCHEM BIOPHYS, V169, P84, DOI 10.1016/0003-9861(75)90319-7; KYTE J, 1995, STRUCTURE PROTEIN CH, P59; LANZ T, 1991, J BIOL CHEM, V266, P9971; Moore BS, 2002, J NAT PROD, V65, P1956, DOI 10.1021/np020230m; Moore BS, 2001, CHEMBIOCHEM, V2, P35, DOI 10.1002/1439-7633(20010105)2:1<35::AID-CBIC35>3.3.CO;2-T; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qiu XY, 1999, J BIOL CHEM, V274, P36465, DOI 10.1074/jbc.274.51.36465; Qiu XY, 2001, J MOL BIOL, V307, P341, DOI 10.1006/jmbi.2000.4457; REIMOLD U, 1983, EMBO J, V2, P1801, DOI 10.1002/j.1460-2075.1983.tb01661.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Saxena P, 2003, J BIOL CHEM, V278, P44780, DOI 10.1074/jbc.M306714200; Scarsdale JN, 2001, J BIOL CHEM, V276, P20516, DOI 10.1074/jbc.M010762200; Schroder J, 2000, RECENT ADV PHYTOCHEM, V34, P55, DOI 10.1016/S0079-9920(00)80004-0; Schroder J, 1997, TRENDS PLANT SCI, V2, P373, DOI 10.1016/S1360-1385(97)01104-7; Smith M.B., 2007, ADV ORGANIC CHEM REA, V6th ed, DOI 10.1002/9780470084960.ch15; Suh DY, 2000, BIOCHEM BIOPH RES CO, V275, P725, DOI 10.1006/bbrc.2000.3368; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thomas R, 2001, CHEMBIOCHEM, V2, P612, DOI 10.1002/1439-7633(20010903)2:9<612::AID-CBIC612>3.0.CO;2-Z; UEDA K, 1995, J ANTIBIOT, V48, P638, DOI 10.7164/antibiotics.48.638	47	133	136	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45162	45174		10.1074/jbc.M406567200	http://dx.doi.org/10.1074/jbc.M406567200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15265863	hybrid			2022-12-27	WOS:000224505600110
J	Onay-Besikci, A; Altarejos, JY; Lopaschuk, GD				Onay-Besikci, A; Altarejos, JY; Lopaschuk, GD			gAd-globular head domain of adiponectin increases fatty acid oxidation in newborn rabbit hearts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ACETYL-COA CARBOXYLASE; COMPLEMENT-RELATED PROTEIN; GLUCOSE; INHIBITION; METABOLISM; INSULIN; BIRTH; AMP; ACRP30/ADIPONECTIN	Adiponectin is an adipocyte-derived hormone that has a number of metabolic effects in the body, including the control of both glucose and fatty acid metabolism. The globular head domain of adiponectin, gAd, has also been shown to increase fatty acid oxidation in skeletal muscle. Within days after birth, a rapid increase in fatty acid oxidation occurs in the heart. We examined whether adiponectin or gAd plays a role in this maturation of cardiac fatty acid oxidation. Plasma adiponectin increased in newborn rabbits following birth: 1.2 +/- 0.3 mug/ml in 1-day-old, 6.8 +/- 1.8 mug/ml in 7-day-old, and 45 +/- 5 mug/ml in 6-week-old rabbits. Because plasma insulin levels decrease and remain low throughout the suckling period, and because this decrease may contribute to the maturation of fatty acid oxidation, we examined the effects of adiponectin and gAd on fatty acid oxidation in isolated perfused 1-day-old rabbit hearts in the presence or absence of 100 microunits/ml insulin. Adiponectin (10 mug/ml) did not alter fatty acid oxidation in the presence of insulin. In the absence of insulin, the addition of recombinant gAd (1.5 mug/ml) increased fatty acid oxidation compared with control (129 +/- 18 versus 66 +/- 11 nmol.g dry weight (-1).min(-1), respectively (p < 0.05). In 7-day-old hearts, where fatty acid oxidation rates were 5-fold higher than 1-day-old hearts, gAd did not alter fatty acid oxidation rates. The increase in fatty acid oxidation in 1-day-old hearts occurred independently of changes in 5'-AMP-activated protein kinase, acetyl-CoA carboxylase, or malonyl-CoA. The effect of gAd on fatty acid oxidation was reversed in the presence of 100 microunits/ml insulin. These results suggest that a decrease in plasma insulin and increase in gAd are involved in the increase of cardiac fatty acid oxidation in the immediate newborn period.	Univ Alberta, Fac Med & Dent, Cardiovasc Res Grp, Edmonton, AB T6G 2S2, Canada	University of Alberta	Lopaschuk, GD (corresponding author), Univ Alberta, Fac Med & Dent, Cardiovasc Res Grp, 423 Heritage Med Res Bldg, Edmonton, AB T6G 2S2, Canada.	gary.lopaschuk@ualberta.ca	Onay-Besikci, Arzu/AAH-1413-2020	Onay-Besikci, Arzu/0000-0001-6883-1757				BASSETT JM, 1971, BIOL NEONATE, V17, P112, DOI 10.1159/000240306; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Besikci AO, 2003, AM J PHYSIOL-HEART C, V284, pH283, DOI 10.1152/ajpheart.00461.2002; BLAZQUEZ E, 1974, J LAB CLIN MED, V83, P957; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Combs TP, 2003, DIABETES, V52, P268, DOI 10.2337/diabetes.52.2.268; Dyck JRB, 1998, AM J PHYSIOL-HEART C, V275, pH2122, DOI 10.1152/ajpheart.1998.275.6.H2122; ELIOT RJ, 1980, J PEDIATR-US, V96, P311; Fasshauer M, 2002, BIOCHEM BIOPH RES CO, V290, P1084, DOI 10.1006/bbrc.2001.6307; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Gamble J, 1997, METABOLISM, V46, P1270, DOI 10.1016/S0026-0495(97)90229-8; GIRARD J, 1992, PHYSIOL REV, V72, P507, DOI 10.1152/physrev.1992.72.2.507; GIRARD JR, 1973, J CLIN INVEST, V52, P3190, DOI 10.1172/JCI107519; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Kobayashi H, 2004, CIRC RES, V94, pE27, DOI 10.1161/01.RES.0000119921.86460.37; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPASCHUK GD, 1992, CARDIOVASC RES, V26, P1172, DOI 10.1093/cvr/26.12.1172; LOPASCHUK GD, 1994, J BIOL CHEM, V269, P25871; LOPASCHUK GD, 1990, AM J PHYSIOL, V258, pH1274, DOI 10.1152/ajpheart.1990.258.5.H1274; LOPASCHUK GD, 1991, AM J PHYSIOL, V261, pH1698, DOI 10.1152/ajpheart.1991.261.6.H1698; Makinde AO, 1998, MOL CELL BIOCHEM, V188, P49, DOI 10.1023/A:1006860104840; Makinde AO, 1997, CIRC RES, V80, P482, DOI 10.1161/01.RES.80.4.482; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; PADBURY JF, 1981, PEDIATR RES, V15, P1483, DOI 10.1203/00006450-198112000-00005; PADBURY JF, 1988, SEMIN PERINATOL, V12, P163; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SPERLING MA, 1984, AM J PHYSIOL, V247, pE69, DOI 10.1152/ajpendo.1984.247.1.E69; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Tsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	34	44	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44320	44326		10.1074/jbc.M400347200	http://dx.doi.org/10.1074/jbc.M400347200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15269215	hybrid			2022-12-27	WOS:000224505600013
J	Wan, Y; McDevitt, A; Shen, BJ; Smythe, ML; Waters, MJ				Wan, Y; McDevitt, A; Shen, BJ; Smythe, ML; Waters, MJ			Increased site 1 affinity improves biopotency of porcine growth hormone - Evidence against diffusion dependent receptor dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; EXTRACELLULAR DOMAIN; MONOCLONAL-ANTIBODY; POTENCY; ALPHA; ERYTHROPOIETIN; ASPARTATE; MECHANISM; RESIDUES; EPITOPE	Based on phage display optimization studies with human growth hormone (GH), it is thought that the biopotency of GH cannot be increased. This is proposed to be a result of the affinity of the first receptor for hormone far exceeding that which is required to trap the hormone long enough to allow diffusion of the second receptor to form the ternary complex, which initiates signaling. We report here that despite similar site 1 kinetics to the hGH/hGH receptor interaction, the potency of porcine GH for its receptor can be increased up to 5-fold by substituting hGH residues involved in site 1 binding into pGH. Based on extensive mutations and BIAcore studies, we show that the higher potency and site 1 affinity of hGH for the pGHR is primarily a result of a decreased off-rate associated with residues in the extended loop between helices 1 and 2 that interact with the two key tryptophans Trp(104) and Trp(169) in the receptor binding hot spot. Our mutagenic analysis has also identified a second determinant (Lys(165)), which in addition to His(169), restricts the ability of non-primate hormones to activate hGH receptor. The increased biopotency of GH that we observe can be explained by a model for GH receptor activation where subunit alignment is critical for effective signaling.	Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia	University of Queensland; University of Queensland	Waters, MJ (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	m.waters@imb.uq.edu.au	waters, michael j/C-9582-2014	Smythe, Mark/0000-0001-7840-1021				Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; BARNARD R, 1985, BIOCHEM J, V231, P459, DOI 10.1042/bj2310459; Behncken SN, 1997, J BIOL CHEM, V272, P27077, DOI 10.1074/jbc.272.43.27077; Bernat B, 2003, P NATL ACAD SCI USA, V100, P952, DOI 10.1073/pnas.0235023100; Chen CM, 1997, J BIOL CHEM, V272, P5133, DOI 10.1074/jbc.272.8.5133; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DiFalco MR, 1997, BIOCHEM J, V326, P407, DOI 10.1042/bj3260407; Egrie JC, 2003, EXP HEMATOL, V31, P290, DOI 10.1016/S0301-472X(03)00006-7; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; Matthews DJ, 1996, P NATL ACAD SCI USA, V93, P9471, DOI 10.1073/pnas.93.18.9471; NISSEN C, 1994, EUR J CANCER, V30A, pS12; OKABE M, 1990, BLOOD, V75, P1788; Pearce KH, 1999, BIOCHEMISTRY-US, V38, P81, DOI 10.1021/bi9817008; Schiffer C, 2002, J MOL BIOL, V316, P277, DOI 10.1006/jmbi.2001.5348; SIMES JM, 1991, J ENDOCRINOL, V130, P93, DOI 10.1677/joe.0.1300093; SOUSA SC, 1995, P NATL ACAD SCI USA, V92, P959; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Wan WY, 1999, J MOL BIOL, V286, P1633, DOI 10.1006/jmbi.1999.2552; Wan Y, 2003, MOL ENDOCRINOL, V17, P2240, DOI 10.1210/me.2003-0162; Yamamoto Y, 2003, NAT BIOTECHNOL, V21, P546, DOI 10.1038/nbt812	25	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44775	44784		10.1074/jbc.M406092200	http://dx.doi.org/10.1074/jbc.M406092200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15297460	hybrid			2022-12-27	WOS:000224505600066
J	Natalicchio, A; Laviola, L; De Tullio, C; Renna, LA; Montrone, C; Perrini, S; Valenti, G; Procino, G; Svelto, M; Giorgino, F				Natalicchio, A; Laviola, L; De Tullio, C; Renna, LA; Montrone, C; Perrini, S; Valenti, G; Procino, G; Svelto, M; Giorgino, F			Role of the p66(Shc) isoform in insulin-like growth factor I receptor signaling through MEK/Erk and regulation of actin cytoskeleton in rat myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SKELETAL-MUSCLE DIFFERENTIATION; FOCAL ADHESION KINASE; OXIDATIVE STRESS; ADAPTER PROTEIN; LONGEVITY GENE; CELL MOTILITY; BREAST-CANCER; V-SRC; PATHWAYS	To investigate the role of Shc in IGF action and signaling in skeletal muscle cells, Shc protein levels were reduced in rat L6 myoblasts by stably overexpressing a Shc cDNA fragment in antisense orientation (L6/Shcas). L6/Shcas myoblasts showed marked reduction of the p66(Shc) protein isoform and no change in p52(Shc) or p46(Shc) proteins compared with control myoblasts transfected with the empty vector (L6/Neo). When compared with control, L6/Shcas myoblasts demonstrated 3-fold increase in Erk-1/2 phosphorylation under basal conditions and blunted Erk-1/2 stimulation by insulin-like growth factor I (IGF-I), in the absence of changes in total Erk-1/2 protein levels. Increased basal Erk-1/2 activation was paralleled by a greater proportion of phosphorylated Erk-1/2 in the nucleus of L6/Shcas myoblasts in the absence of IGF-I stimulation. The reduction of p66(Shc) in L6/Shcas myoblasts resulted in marked phenotypic abnormalities, such as rounded cell shape and clustering in islets or finger-like structures, and was associated with impaired DNA synthesis in response to IGF-I and lack of terminal differentiation into myotubes. In addition, L6/Shcas myoblasts were characterized by complete disruption of actin filaments and cell cytoskeleton. Treatment of L6/Shcas myoblasts with the MEK inhibitor PD98059 reduced the abnormal increase in Erk-1/2 activation to control levels and restored the actin cytoskeleton, re-establishing the normal cell morphology. Thus, the p66(Shc) isoform exerts an inhibitory effect on the mitogen-activated protein kinase signaling pathway in rodent myoblasts, which is necessary for maintenance of IGF responsiveness of the MEK/Erk pathway and normal cell phenotype.	Univ Bari, Dept Emergency & Organ Transplantat, Sect Internal Med Endocrinol & Metab Dis, I-70124 Bari, Italy; Univ Bari, Dept Gen & Environm Physiol, I-70124 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Giorgino, F (corresponding author), Univ Bari, Dept Emergency & Organ Transplantat, Sect Internal Med Endocrinol & Metab Dis, Piazza Giulio Cesare 11, I-70124 Bari, Italy.	f.giorgino@endo.uniba.it	Giorgino, Francesco/K-7262-2016; Svelto, Maria/P-6186-2014	Giorgino, Francesco/0000-0001-7372-2678; VALENTI, GIOVANNA/0000-0003-0233-0778; Natalicchio, Annalisa/0000-0002-6131-7517; Svelto, Maria/0000-0002-5584-9541; Procino, Giuseppe/0000-0002-0043-7523; Laviola, Luigi/0000-0001-8860-5845; Perrini, Sebastio/0000-0002-2728-7721				Adi S, 2002, ENDOCRINOLOGY, V143, P511, DOI 10.1210/en.143.2.511; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; BEGUINOT F, 1985, J BIOL CHEM, V260, P5892; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Davol PA, 2003, CANCER RES, V63, P6772; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIORGINO F, 1995, J CLIN INVEST, V96, P1473, DOI 10.1172/JCI118184; Giorgino F, 1997, J BIOL CHEM, V272, P7455, DOI 10.1074/jbc.272.11.7455; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Kao AW, 1997, ENDOCRINOLOGY, V138, P2474, DOI 10.1210/en.138.6.2474; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lai KMV, 2000, GENE DEV, V14, P1132; Lee KH, 1999, EXP CELL RES, V252, P401, DOI 10.1006/excr.1999.4648; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LeRoith D, 2000, ENDOCRINOLOGY, V141, P1287, DOI 10.1210/en.141.4.1287; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; Napoli C, 2003, P NATL ACAD SCI USA, V100, P2112, DOI 10.1073/pnas.0336359100; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nolan MK, 1997, INT J CANCER, V72, P828, DOI 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Pawlak G, 2002, J BIOL CHEM, V277, P26927, DOI 10.1074/jbc.M202261200; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; Rescan C, 2001, MOL BIOL CELL, V12, P725, DOI 10.1091/mbc.12.3.725; Roovers K, 2003, MOL CELL BIOL, V23, P4283, DOI 10.1128/MCB.23.12.4283-4294.2003; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sarbassov DD, 1997, MOL ENDOCRINOL, V11, P2038, DOI 10.1210/me.11.13.2038; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SHIMIZU M, 1986, AM J PHYSIOL, V251, pE611, DOI 10.1152/ajpendo.1986.251.5.E611; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; Ventura A, 2004, J BIOL CHEM, V279, P2299, DOI 10.1074/jbc.M307655200; Ventura A, 2002, J BIOL CHEM, V277, P22370, DOI 10.1074/jbc.M200280200; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; [No title captured]	45	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43900	43909		10.1074/jbc.M403936200	http://dx.doi.org/10.1074/jbc.M403936200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15262993	hybrid			2022-12-27	WOS:000224383100068
J	Szatmary, Z; Garabedian, MJ; Vilcek, J				Szatmary, Z; Garabedian, MJ; Vilcek, J			Inhibition of glucocorticoid receptor-mediated transcriptional activation by p38 mitogen-activated protein (MAP) kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION PATHWAY; STEROID-HORMONE RECEPTORS; JUN NH2-TERMINAL KINASE; HEAT-SHOCK-PROTEIN; FACTOR-KAPPA-B; CROSS-TALK; MOLECULAR-CLONING; FACTOR-ALPHA	Tumor necrosis factor (TNF) promotes certain immune and inflammatory responses, whereas glucocorticoids exert immunosuppressive and anti-inflammatory actions. We show that TNF treatment produced a modest inhibition of glucocorticoid receptor (GR)-mediated transcriptional activation of a mouse mammary tumor virus (MMTV) promoter-driven luciferase construct in HeLa cells. The mitogen-activated protein ( MAP) kinases, p38 and c-Jun N-terminal kinase (JNK), are important mediators of target gene activation by TNF, and JNK activation was earlier shown to inhibit GR-mediated transcriptional activation by direct phosphorylation of GR at Ser-246. Transfection of HeLa cells with MKK6b( E), a constitutively active specific upstream activator of p38, led to a potent inhibition of GR activation of the MMTV promoter-driven luciferase construct. A similar inhibition of activation of the MMTV promoter-driven luciferase construct was seen in HeLa cells transfected with MKK7(D), a constitutively functional activator of JNK. Data from "domain swap" experiments using GR chimeras indicated that the main target of the p38-mediated ( but not JNK-mediated) inhibition is the ligand-binding domain of GR ( spanning amino acids 525 795), whereas the constitutively active N-terminal AF-1 region ( spanning amino acids 106 - 237) is dispensable for the inhibitory effect of p38. We also demonstrate that activated p38 targets the GR ligand-binding domain indirectly. Suppression of GR function by activated p38 and JNK MAP kinases may be physiologically important as a mechanism of resistance to glucocorticoids seen in many patients with chronic inflammatory conditions.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University	Vilcek, J (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	jan.vilcek@med.nyu.edu			NCI NIH HHS [CA75071] Funding Source: Medline; NIDDK NIH HHS [DK54836] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bantel H, 2002, FASEB J, V16, P1832, DOI 10.1096/fj.02-0223fje; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Bertorelli G, 1998, PULM PHARMACOL THER, V11, P7, DOI 10.1006/pupt.1998.0119; Bodwell JE, 1998, J STEROID BIOCHEM, V65, P91, DOI 10.1016/S0960-0760(97)00185-4; BURNSTEIN KL, 1994, MOL ENDOCRINOL, V8, P1764, DOI 10.1210/me.8.12.1764; CAHILL MA, 1994, FEBS LETT, V344, P105, DOI 10.1016/0014-5793(94)00320-3; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dumont A, 1998, TRENDS BIOCHEM SCI, V23, P233, DOI 10.1016/S0968-0004(98)01212-2; Elenkov IJ, 2002, ANN NY ACAD SCI, V966, P290, DOI 10.1111/j.1749-6632.2002.tb04229.x; Farrell RJ, 2003, J ENDOCRINOL, V178, P339, DOI 10.1677/joe.0.1780339; HAN J, 1990, J EXP MED, V172, P391, DOI 10.1084/jem.172.1.391; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Ismaili N, 2004, ANN NY ACAD SCI, V1024, P86, DOI 10.1196/annals.1321.007; Itoh M, 2002, MOL ENDOCRINOL, V16, P2382, DOI 10.1210/me.2002-0144; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7; Ni H, 1998, BIOCHEM BIOPH RES CO, V243, P492, DOI 10.1006/bbrc.1998.8135; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pfeffer K, 2003, CYTOKINE GROWTH F R, V14, P185, DOI 10.1016/S1359-6101(03)00022-4; Poppers DM, 2000, J BIOL CHEM, V275, P29587, DOI 10.1074/jbc.M002806200; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Schaaf MJM, 2002, J STEROID BIOCHEM, V83, P37, DOI 10.1016/S0960-0760(02)00263-7; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang X, 2004, MOL PSYCHIATR, V9, P65, DOI 10.1038/sj.mp.4001339; Wang Z, 2002, J BIOL CHEM, V277, P26573, DOI 10.1074/jbc.M110530200; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Yang JH, 1998, GENE, V212, P95, DOI 10.1016/S0378-1119(98)00158-9; Yang SH, 1999, MOL CELL BIOL, V19, P4028	52	103	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43708	43715		10.1074/jbc.M406568200	http://dx.doi.org/10.1074/jbc.M406568200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15292225	hybrid			2022-12-27	WOS:000224383100045
J	Brittain, JE; Han, J; Ataga, KI; Orringer, EP; Parise, LV				Brittain, JE; Han, J; Ataga, KI; Orringer, EP; Parise, LV			Mechanism of CD47-induced alpha(4)beta(1) integrin activation and adhesion in sickle reticulocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; ALPHA(4) CYTOPLASMIC DOMAIN; COLONY-FORMING CELLS; RED-BLOOD-CELLS; SIGNAL-TRANSDUCTION; PLATELET ACTIVATION; TYROSINE KINASE; IMMOBILIZED THROMBOSPONDIN; ALPHA-4-BETA-1 INTEGRIN; ERYTHROCYTE ADHERENCE	We recently reported that CD47 (integrin-associated protein) on sickle red blood cells (SS RBCs) activates G-protein-dependent signaling, which promotes cell adhesion to immobilized thrombospondin (TSP) under relevant shear stress. These data suggested that signal transduction in SS RBCs may contribute to the vaso-occlusive pathology observed in sickle cell disease. However, the CD47-activated SS RBC adhesion receptor(s) that mediated adhesion to immobilized TSP remained unknown. Here we demonstrate that the alpha(4)beta(1) integrin (VLA-4) is the receptor that mediates CD47-stimulated SS RBC adhesion to immobilized TSP. This adhesion requires both the N-terminal heparin-binding domain and the RGD site of TSP. CD47 signaling induces an "inside-out" activation of alpha(4)beta(1) on SS RBCs as indicated by an RGD-dependent interaction of this integrin with soluble, plasma fibronectin. However, CD47 engagement also induces an alpha(4)beta(1)-mediated, RGD-independent adhesion of SS RBCs to immobilized vascular cell adhesion molecule-1 (VCAM-1). CD47 signaling in SS RBCs appears to be independent of large scale changes in cAMP formation but nonetheless promotes alpha(4)beta(1)-mediated adhesion via a protein kinase A-dependent, serine phosphorylation of the alpha(4) cytoplasmic domain. CD47-activated SS RBC adhesion absolutely requires the Src family tyrosine kinases and is also enhanced by treatment of SS RBCs with low concentrations of cytochalasin D, which may release alpha(4)beta(1) from cytoskeletal restraints. In addition, CD47 co-immunoprecipitates with alpha(4)beta(1) in a sickle reticulocyte-enriched fraction of SS RBCs. These studies therefore identify the alpha(4)beta(1) integrin on SS RBCs as a CD47-activated receptor for TSP, VCAM-1, and plasma fibronectin, revealing novel binding characteristics of this integrin.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Scripps Research Institute	Parise, LV (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.	parise@med.unc.edu			NCRR NIH HHS [RR00046] Funding Source: Medline; NHLBI NIH HHS [T32HL07149, U54 HL70769, R01 HL067440] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007149, R01HL067440, U54HL070769] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGER A, 1991, CHEM IMMUNOL, V50, P55; Avent ND, 2000, BLOOD, V95, P375, DOI 10.1182/blood.V95.2.375; BALLAS SK, 1991, AM J HEMATOL, V36, P122, DOI 10.1002/ajh.2830360211; Barazi HO, 2002, J BIOL CHEM, V277, P42859, DOI 10.1074/jbc.M206849200; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; BOLARIN DM, 1986, ACTA HAEMATOL-BASEL, V75, P209, DOI 10.1159/000206126; BRITTAIN HA, 1993, BLOOD, V81, P2137; Brittain JE, 2001, J CLIN INVEST, V107, P1555, DOI 10.1172/JCI10817; Brittain JE, 2001, BLOOD, V97, P2159, DOI 10.1182/blood.V97.7.2159; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Browne PV, 1996, AM J HEMATOL, V51, P296, DOI 10.1002/(SICI)1096-8652(199604)51:4<296::AID-AJH8>3.0.CO;2-R; Chigaev A, 2003, BIOPHYS J, V85, P3951, DOI 10.1016/S0006-3495(03)74809-7; Chigaev A, 2001, J BIOL CHEM, V276, P48670, DOI 10.1074/jbc.M103194200; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Chung J, 1999, BLOOD, V94, P642, DOI 10.1182/blood.V94.2.642.414k35_642_648; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; Coulombel L, 1997, ACTA HAEMATOL-BASEL, V97, P13, DOI 10.1159/000203655; DeFranceschi L, 1997, J CLIN INVEST, V99, P220, DOI 10.1172/JCI119150; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; Emeribe AO, 2000, BRIT J HAEMATOL, V111, P1194, DOI 10.1046/j.1365-2141.2000.02445.x; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P16800, DOI 10.1073/pnas.222659799; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Goldfinger LE, 2003, J CELL BIOL, V162, P731, DOI 10.1083/jcb.200304031; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Han JW, 2003, J BIOL CHEM, V278, P34845, DOI 10.1074/jbc.M304691200; Han JW, 2001, J BIOL CHEM, V276, P40903, DOI 10.1074/jbc.M102665200; Hebbel R P, 1980, Trans Assoc Am Physicians, V93, P94; HEBBEL RP, 1985, CLIN HAEMATOL, V14, P141; HEBBEL RP, 1980, J CLIN INVEST, V65, P154, DOI 10.1172/JCI109646; HEBBEL RP, 1980, NEW ENGL J MED, V302, P992, DOI 10.1056/NEJM198005013021803; Hines PC, 2003, BLOOD, V101, P3281, DOI 10.1182/blood-2001-12-0289; Hotchkiss KA, 1996, BIOCHEMISTRY-US, V35, P9761, DOI 10.1021/bi9603938; HUMPHRIES MJ, 1995, CIBA F SYMP, V189, P177; Igishi T, 1998, BIOCHEM BIOPH RES CO, V244, P5, DOI 10.1006/bbrc.1998.8208; Joneckis CC, 1996, BLOOD, V87, P4862, DOI 10.1182/blood.V87.11.4862.bloodjournal87114862; JONECKIS CC, 1993, BLOOD, V82, P3548; KOSFELD MD, 1991, J BIOL CHEM, V266, P24257; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEGRAND C, 1992, BLOOD, V79, P1995; Li ZQ, 2002, J CELL BIOL, V157, P509, DOI 10.1083/jcb.200109098; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma YC, 2002, TRENDS CARDIOVAS MED, V12, P46, DOI 10.1016/S1050-1738(01)00138-4; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Niu JX, 2001, CURR BIOL, V11, P1686, DOI 10.1016/S0960-9822(01)00530-9; Olearczyk JJ, 2004, AM J PHYSIOL-HEART C, V286, pH940, DOI 10.1152/ajpheart.00677.2003; OOSTENDORP RAJ, 1995, BRIT J HAEMATOL, V91, P275, DOI 10.1111/j.1365-2141.1995.tb05290.x; Oostendorp RAJ, 1997, EXP HEMATOL, V25, P345; Parise Leslie V, 2003, Curr Hematol Rep, V2, P102; Rose DM, 2002, IMMUNOL REV, V186, P118, DOI 10.1034/j.1600-065X.2002.18611.x; SANCHEZAPARICIO P, 1994, J CELL BIOL, V126, P271, DOI 10.1083/jcb.126.1.271; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SUGIHARA K, 1992, BLOOD, V80, P2634; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; SWERLICK RA, 1993, BLOOD, V82, P1891; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Ticchioni M, 1997, J IMMUNOL, V158, P677; VARSHNEY GC, 1986, FEBS LETT, V205, P97, DOI 10.1016/0014-5793(86)80873-0; Vinciguerra M, 2003, MOL BIOL CELL, V14, P2677, DOI 10.1091/mbc.E02-11-0720; Wang J, 2001, J BIOL CHEM, V276, P14474, DOI 10.1074/jbc.M007324200; Wang JH, 1998, IMMUNOL REV, V163, P197, DOI 10.1111/j.1600-065X.1998.tb01198.x; WAUTIER JL, 1983, BLOOD CELLS, V9, P221; Wick T M, 1996, Curr Opin Hematol, V3, P118; Wun T, 1997, J LAB CLIN MED, V129, P507, DOI 10.1016/S0022-2143(97)90005-6; YABKOWITZ R, 1993, J IMMUNOL, V151, P149	70	57	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42393	42402		10.1074/jbc.M407631200	http://dx.doi.org/10.1074/jbc.M407631200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292185	hybrid			2022-12-27	WOS:000224226400009
J	Li, HC; Worrell, RT; Matthews, JB; Husseinzadeh, H; Neumeier, L; Petrovic, S; Conforti, L; Soleimani, M				Li, HC; Worrell, RT; Matthews, JB; Husseinzadeh, H; Neumeier, L; Petrovic, S; Conforti, L; Soleimani, M			Identification of a carboxyl-terminal motif essential for the targeting of Na+-HCO3- cotransporter NBC1 to the basolateral membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL TUBULAR-ACIDOSIS; SODIUM-BICARBONATE COTRANSPORTER; FUNCTIONAL EXPRESSION; PROXIMAL TUBULE; HUMAN PANCREAS; KIDNEY-CELLS; CLONING; LOCALIZATION; MECHANISMS; EXCHANGER	The Na+-HCO3- cotransporter NBC1 is located exclusively on the basolateral membrane and mediates vectorial transport of bicarbonate in a number of epithelia, including kidney and pancreas. To identify the motifs that direct the targeting of kidney NBC1 to basolateral membrane, wild type and various carboxyl-terminally truncated kidney NBC1 mutants were generated, fused translationally in-frame to GFP, and transiently expressed in kidney epithelial cells. GFP was linked to the NH2 terminus of NBC1, and labeling was examined by confocal microscopy. Full-length (1035 aa) and mutants with the deletion of 3 or 20 amino acids from the COOH-terminal end of NBC1 ( lengths 1032 and 1015 aa, respectively) showed strong and exclusive targeting on the basolateral membrane. However, the deletion of 26 amino acid residues from the COOH-terminal end (length 1010 aa) resulted in retargeting of NBC1 to the apical membrane. Expression studies in oocytes demonstrated that the NBC1 mutant with the deletion of 26 amino acid residues from the COOH-terminal end is functional. Additionally, the deletion of the last 23 amino acids or mutation in the conserved residue Phe at position 1013 on the COOH-terminal end demonstrated retargeting to the apical membrane. We propose that a carboxyl-terminal motif with the sequence QQPFLS, which spans amino acid residues 1010-1015, and specifically the amino acid residue Phe (position 1013) are essential for the exclusive targeting of NBC1 to the basolateral membrane.	Univ Cincinnati, Dept Med, Div Nephrol & Hypertens, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Surg, Cincinnati, OH 45267 USA; Vet Affairs Med Ctr, Cincinnati, OH 45220 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center	Soleimani, M (corresponding author), Univ Cincinnati, Dept Med, Div Nephrol & Hypertens, 231 Albert Sabin Way,MSB G259, Cincinnati, OH 45267 USA.				NCI NIH HHS [CA095286] Funding Source: Medline; NIDDK NIH HHS [DK 51630, DK 62809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062809, R01DK051630, R01DK062809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abuladze N, 1998, J BIOL CHEM, V273, P17689, DOI 10.1074/jbc.273.28.17689; ALPERN RJ, 1990, PHYSIOL REV, V70, P79, DOI 10.1152/physrev.1990.70.1.79; Amlal H, 2001, KIDNEY INT, V60, P1824, DOI 10.1046/j.1523-1755.2001.00995.x; Amlal H, 1998, J BIOL CHEM, V273, P16810, DOI 10.1074/jbc.273.27.16810; Aronson PS, 1997, AM J PHYSIOL-RENAL, V273, pF179, DOI 10.1152/ajprenal.1997.273.2.F179; Borthwick KJ, 2002, CURR OPIN NEPHROL HY, V11, P563, DOI 10.1097/00041552-200209000-00013; Bruce LJ, 1997, J CLIN INVEST, V100, P1693, DOI 10.1172/JCI119694; Burnham CE, 1997, J BIOL CHEM, V272, P19111, DOI 10.1074/jbc.272.31.19111; Devonald MAJ, 2003, NAT GENET, V33, P125, DOI 10.1038/ng1082; Gross E, 2001, J PHYSIOL-LONDON, V531, P597, DOI 10.1111/j.1469-7793.2001.0597h.x; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P169, DOI 10.1113/jphysiol.1996.sp021582; Jarolim P, 1998, J BIOL CHEM, V273, P6380, DOI 10.1074/jbc.273.11.6380; Karet FE, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000023433.08833.88; Kurtz I, 2004, J MEMBRANE BIOL, V197, P77, DOI 10.1007/s00232-003-0643-x; Marino CR, 1999, AM J PHYSIOL-GASTR L, V277, pG487, DOI 10.1152/ajpgi.1999.277.2.G487; Maunsbach AB, 2000, J AM SOC NEPHROL, V11, P2179, DOI 10.1681/ASN.V11122179; Quilty JA, 2002, AM J PHYSIOL-RENAL, V282, pF810, DOI 10.1152/ajprenal.00216.2001; Romero MF, 2004, PFLUG ARCH EUR J PHY, V447, P495, DOI 10.1007/s00424-003-1180-2; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; Rungroj N, 2004, J BIOL CHEM, V279, P13833, DOI 10.1074/jbc.M400188200; Satoh H, 2003, AM J PHYSIOL-CELL PH, V284, pC729, DOI 10.1152/ajpcell.00166.2002; Shumaker H, 1999, AM J PHYSIOL-CELL PH, V276, pC16, DOI 10.1152/ajpcell.1999.276.1.C16; Soleimani M, 2001, J MEMBRANE BIOL, V183, P71, DOI 10.1007/s00232-001-0055-8; SOLEIMANI M, 1987, J CLIN INVEST, V79, P1276, DOI 10.1172/JCI112948; Toledo MS, 2004, J BIOL CHEM, V279, P34655, DOI 10.1074/jbc.M403857200; Toye AM, 2004, J CELL SCI, V117, P1399, DOI 10.1242/jcs.00974; Toye AM, 2002, BLOOD, V99, P342, DOI 10.1182/blood.V99.1.342; Xu J, 2003, AM J PHYSIOL-RENAL, V284, pF41, DOI 10.1152/ajprenal.00055.2002	28	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43190	43197		10.1074/jbc.M405780200	http://dx.doi.org/10.1074/jbc.M405780200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15273250	Green Submitted, hybrid			2022-12-27	WOS:000224226400103
J	Meertens, L; Chevalier, S; Weil, R; Gessain, A; Mahieux, R				Meertens, L; Chevalier, S; Weil, R; Gessain, A; Mahieux, R			A 10-amino acid domain within human T-cell leukemia virus type 1 and type 2 Tax protein sequences is responsible for their divergent subcellular distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HTLV-I TAX; PUTATIVE TRANSFORMING PROTEIN; NUCLEAR EXPORT; TRANSACTIVATOR PROTEIN; TRANSCRIPTIONAL ACTIVATION; BINDING-PROTEIN; GENE-PRODUCTS; IKK-GAMMA; P53	Human T-cell leukemia virus type 1 and type 2 (HTLV-1/2) are related retroviruses that infect T-lymphocytes. Whereas HTLV-1 infection can cause leukemia, HTLV-2 has not been demonstrated to be the agent of a hematological malignant disease. Nevertheless, the virally encoded Tax-1 and Tax-2 transactivators display a high percentage of similarity. Tax-1 is a shuttling protein that contains a noncanonical nuclear localization signal as well as a nuclear export signal. The presence of the nuclear localization signal and the nuclear export signal domains in the Tax-2 sequence has not been determined. The distribution of Tax-2 in infected cells is not known but has been assumed to be similar to that of Tax-1. By using a Tax-2-specific antibody, we report here that Tax-2 is located predominantly in the cytoplasm of the HTLV-2 immortalized or transformed infected T-cells. These results were confirmed after transient transfection of untagged Tax-1 and Tax-2 constructs, histidine tag Tax1/Tax2, GFP-Tax, and Tax-GFP fusion constructs in several cell lines. We show that this unanticipated localization is not due to a default in the Tax-2 nuclear localization signal functions nor to major differences in Tax-2 versus Tax-1 binding to the IKKgamma/NEMO protein. In addition, we demonstrate that inhibiting the proteasome results in a relocalization of Tax-1 in the cytoplasm, similar to that of Tax-2. By using a series of Tax-1/Tax-2 chimeras, we determined that the minimal domain that is necessary for Tax-2 peculiar distribution encompasses amino acids 90-100. Finally, we show a high correlation between intracellular localization of Tax and their NF-kappaB or CREB transactivating ability.	Inst Pasteur, Unite Epidemiol & Physiopathol Virus Oncogenes, F-75724 Paris 15, France; Inst Pasteur, CNRS, FRE 2364, Unite Biol Mol Express Gen, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Mahieux, R (corresponding author), Inst Pasteur, Unite Epidemiol & Physiopathol Virus Oncogenes, 28 Rue Docteur Roux, F-75724 Paris 15, France.	rmahieux@pasteur.fr	Meertens, Laurent/E-8043-2017	Meertens, Laurent/0000-0003-2811-3675; Weil, Robert/0000-0001-5235-0932; mahieux, renaud/0000-0002-5129-6804				Alefantis T, 2003, J BIOL CHEM, V278, P21814, DOI 10.1074/jbc.M211576200; Basbous J, 2003, J VIROL, V77, P13028, DOI 10.1128/JVI.77.24.13028-13035.2003; Bex F, 1997, J VIROL, V71, P3484, DOI 10.1128/JVI.71.5.3484-3497.1997; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Bovolenta C, 2002, BLOOD, V99, P224, DOI 10.1182/blood.V99.1.224; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; Casoli C, 2004, BLOOD, V103, P995, DOI 10.1182/blood-2003-07-2503; Casoli C, 1998, BLOOD, V91, P2296, DOI 10.1182/blood.V91.7.2296.2296_2296_2304; CHEN ISY, 1983, NATURE, V305, P502, DOI 10.1038/305502a0; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CHEN ISY, 1983, P NATL ACAD SCI-BIOL, V80, P7006, DOI 10.1073/pnas.80.22.7006; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; Chun ACS, 2000, AIDS RES HUM RETROV, V16, P1689, DOI 10.1089/08892220050193155; Eiraku N, 1996, J VIROL, V70, P1481, DOI 10.1128/JVI.70.3.1481-1492.1996; Endo K, 2002, J VIROL, V76, P2648, DOI 10.1128/JVI.76.6.2648-2653.2002; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; Fouchard N, 1995, LEUKEMIA, V9, P2087; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; GESSAIN A, 1985, LANCET, V2, P407; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; GOH WC, 1985, SCIENCE, V227, P1227, DOI 10.1126/science.2983419; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Hemelaar J, 2001, J VIROL, V75, P11106, DOI 10.1128/JVI.75.22.11106-11115.2001; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Huang GJ, 2002, FEBS LETT, V531, P494, DOI 10.1016/S0014-5793(02)03590-1; IJICHI S, 1992, J EXP MED, V176, P293, DOI 10.1084/jem.176.1.293; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; Kimzey AL, 1999, J BIOL CHEM, V274, P34226, DOI 10.1074/jbc.274.48.34226; KIYOKAWA T, 1985, VIROLOGY, V147, P462, DOI 10.1016/0042-6822(85)90149-7; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; Lehky TJ, 1996, ANN NEUROL, V40, P714, DOI 10.1002/ana.410400507; Lewis MJ, 2002, VIROLOGY, V295, P182, DOI 10.1006/viro.2002.1357; Lewis MJ, 2000, VIROLOGY, V271, P142, DOI 10.1006/viro.2000.0284; Li XH, 1999, GENE EXPRESSION, V7, P233; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Mahieux R, 2000, J VIROL, V74, P6866, DOI 10.1128/JVI.74.15.6866-6874.2000; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Meertens L, 2004, ONCOGENE, V23, P5447, DOI 10.1038/sj.onc.1207719; Moroianu J, 1999, J CELL BIOCHEM, P76; Mulloy JC, 1998, J VIROL, V72, P4408, DOI 10.1128/JVI.72.5.4408-4412.1998; Murayama T, 1997, J VIROL, V71, P5692, DOI 10.1128/JVI.71.7.5692-5695.1997; Neuveut C, 1997, J BIOMED SCI, V4, P229, DOI 10.1007/BF02253422; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; NIMER SD, 1989, ONCOGENE, V4, P671; ODA T, 1987, CANCER RES, V47, P2077; Orland JR, 2003, NEUROLOGY, V61, P1588, DOI 10.1212/01.WNL.0000096011.92542.DA; Poiesz B, 2000, NEW ENGL J MED, V342, P930, DOI 10.1056/NEJM200003303421304; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Renard P, 2000, J BIOL CHEM, V275, P15193, DOI 10.1074/jbc.275.20.15193; ROSENBLATT JD, 1990, BLOOD, V76, P409; Ross TM, 1996, J VIROL, V70, P5194, DOI 10.1128/JVI.70.8.5194-5202.1996; Ross TM, 1997, J VIROL, V71, P8912, DOI 10.1128/JVI.71.11.8912-8917.1997; Ross TM, 2000, J VIROL, V74, P2655, DOI 10.1128/JVI.74.6.2655-2662.2000; SAKAMOTO KM, 1992, ONCOGENE, V7, P2125; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; SEMMES OJ, 1992, VIROLOGY, V188, P754, DOI 10.1016/0042-6822(92)90530-3; Sieburg M, 2004, J VIROL, V78, P10399, DOI 10.1128/JVI.78.19.10399-10409.2004; SLAMON DJ, 1985, SCIENCE, V228, P1427, DOI 10.1126/science.2990027; SLAMON DJ, 1984, SCIENCE, V226, P61, DOI 10.1126/science.6089351; SLAMON DJ, 1988, J VIROL, V62, P680, DOI 10.1128/JVI.62.3.680-686.1988; Slattery JP, 1999, GENOME RES, V9, P525; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SMITH MR, 1992, VIROLOGY, V187, P316, DOI 10.1016/0042-6822(92)90320-O; Tanaka Y, 1996, J VIROL, V70, P8508, DOI 10.1128/JVI.70.12.8508-8517.1996; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Tripp A, 2003, J VIROL, V77, P12152, DOI 10.1128/JVI.77.22.12152-12164.2003; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; WACHSMAN W, 1987, SCIENCE, V235, P674, DOI 10.1126/science.3027894; Wang TG, 2000, AIDS RES HUM RETROV, V16, P1661, DOI 10.1089/08892220050193119; WATANABE S, 1986, JPN J CANCER RES, V77, P338; Weil R, 1997, J BIOL CHEM, V272, P9942; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	80	70	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43307	43320		10.1074/jbc.M400497200	http://dx.doi.org/10.1074/jbc.M400497200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15269214	hybrid			2022-12-27	WOS:000224226400115
J	Numakawa, T; Ishimoto, T; Suzuki, S; Numakawa, Y; Adachi, N; Matsumoto, T; Yokomaku, D; Koshimizu, H; Fujimori, KE; Hashimoto, R; Taguchi, T; Kunugi, H				Numakawa, T; Ishimoto, T; Suzuki, S; Numakawa, Y; Adachi, N; Matsumoto, T; Yokomaku, D; Koshimizu, H; Fujimori, KE; Hashimoto, R; Taguchi, T; Kunugi, H			Neuronal roles of the integrin-associated protein (IAP/CD47) in developing cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HIPPOCAMPAL-NEURONS; CEREBELLAR GRANULE NEURONS; INDUCED GLUTAMATE RELEASE; LONG-TERM POTENTIATION; NEUROTROPHIC FACTOR; DEFICIENT MICE; PHOSPHATIDYLINOSITOL 3-KINASE; SYNAPTIC PLASTICITY; PLATELET ACTIVATION; MEMORY RETENTION	Little is known about the role of the integrin-associated protein (IAP, or CD47) in neuronal development and its function in the central nervous system. We investigated neuronal responses in IAP-overexpressing cortical neurons using a virus-gene transfer system. We found that dendritic outgrowth was significantly enhanced in IAP (form 4)-transfected neurons. Furthermore, synaptic proteins including synaptotagmin, syntaxin, synapsin I, and SNAP25 (25-kDa synaptosomal associated protein) were up-regulated. In accordance with this finding, the release of the excitatory transmitter glutamate and the frequencies of Ca2+ oscillations (glutamate-mediated synaptic transmission) were increased. Interestingly, the overexpression of IAP activated mitogen-activated protein kinase (MAPK), and this activation was required for the IAP-dependent biological effects. After down-regulation of the endogenous IAP by small interfering RNA, MAPK activity, synaptic protein levels, and glutamate release decreased. These observations suggest that the IAP plays important roles in dendritic outgrowth and synaptic transmission in developing cortical neurons through the activation of MAPK.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Disorder Res, Tokyo 1878502, Japan; Natl Inst Adv Ind Sci & Technol AIST, Human Stress Signal Res Ctr, Osaka 5638577, Japan; Natl Inst Adv Ind Sci & Technol AIST, Neuron RG Special Div Human Life Technol, Osaka 5638577, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	National Center for Neurology & Psychiatry - Japan; National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); Osaka University	Numakawa, T (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Disorder Res, 4-1-1 Ogawahigashi, Tokyo 1878502, Japan.	numakawa@ncnp.go.jp	Fujimori, Kazuhiro E/J-9049-2018; Kunugi, Hiroshi/ABC-5260-2021; Koshimizu, Hisatsugu/G-5536-2010; Hashimoto, Ryota/P-8572-2014; Koshimizu, Hisatsugu/AAD-2428-2019	Fujimori, Kazuhiro E/0000-0002-2199-0889; Hashimoto, Ryota/0000-0002-5941-4238; Koshimizu, Hisatsugu/0000-0002-8619-6678; Kunugi, Hiroshi/0000-0002-7209-3790; Adachi, Naoki/0000-0002-4850-1467				Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Brown EJ, 2002, CURR OPIN CELL BIOL, V14, P603, DOI 10.1016/S0955-0674(02)00360-5; Brunger AT, 2000, CURR OPIN NEUROBIOL, V10, P293, DOI 10.1016/S0959-4388(00)00098-2; Cabelli RJ, 1997, NEURON, V19, P63, DOI 10.1016/S0896-6273(00)80348-7; Chan CS, 2003, J NEUROSCI, V23, P7107, DOI 10.1523/JNEUROSCI.23-18-07107.2003; Chang HP, 2001, NEUROSCIENCE, V102, P289, DOI 10.1016/S0306-4522(00)00478-4; Chang HP, 1999, LEARN MEMORY, V6, P448, DOI 10.1101/lm.6.5.448; CHIN LS, 1995, P NATL ACAD SCI USA, V92, P9230, DOI 10.1073/pnas.92.20.9230; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Chung J, 1999, BLOOD, V94, P642, DOI 10.1182/blood.V94.2.642.414k35_642_648; Dorahy DJ, 1997, J BIOL CHEM, V272, P1323, DOI 10.1074/jbc.272.2.1323; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Garaschuk O, 2000, NAT NEUROSCI, V3, P452, DOI 10.1038/74823; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Gu XN, 1997, DEV NEUROSCI-BASEL, V19, P33, DOI 10.1159/000111183; Higuchi H, 2003, BIOCHEM BIOPH RES CO, V301, P804, DOI 10.1016/S0006-291X(03)00029-9; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Ishimoto T, 2000, BIOCHEM BIOPH RES CO, V272, P789, DOI 10.1006/bbrc.2000.2857; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; KAWAMURA M, 2003, RRD NEUROCHEMISTRY, V6, P105; Krichevsky AM, 2002, P NATL ACAD SCI USA, V99, P11926, DOI 10.1073/pnas.182272699; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; Liu ZJ, 2003, J NEUROSCI, V23, P4156; Lu B, 1999, J NEUROSCI RES, V58, P76, DOI 10.1002/(SICI)1097-4547(19991001)58:1<76::AID-JNR8>3.0.CO;2-0; Martinez A, 1998, J NEUROSCI, V18, P7336; Minichiello L, 1996, GENE DEV, V10, P2849, DOI 10.1101/gad.10.22.2849; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Numakawa T, 2003, J BIOL CHEM, V278, P41259, DOI 10.1074/jbc.M304409200; Numakawa T, 2002, J BIOL CHEM, V277, P6520, DOI 10.1074/jbc.M109139200; Numakawa T, 2002, J BIOL CHEM, V277, P28861, DOI 10.1074/jbc.M202927200; Numakawa T, 2001, J NEUROSCI RES, V66, P96, DOI 10.1002/jnr.1201; OGURA A, 1987, NEUROSCI LETT, V78, P69, DOI 10.1016/0304-3940(87)90563-5; REINHOLD MI, 1995, J CELL SCI, V108, P3419; Ronn LCB, 2000, INT J DEV NEUROSCI, V18, P193, DOI 10.1016/S0736-5748(99)00088-X; Sanna PP, 2002, J NEUROSCI, V22, P3359; Schwartz PM, 1997, NEURON, V19, P269, DOI 10.1016/S0896-6273(00)80938-1; Seiffert M, 2001, BLOOD, V97, P2741, DOI 10.1182/blood.V97.9.2741; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Wang QH, 2003, NEURON, V38, P915, DOI 10.1016/S0896-6273(03)00356-8; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865; Wilson KE, 1999, J IMMUNOL, V163, P3621; Wu GY, 2001, NAT NEUROSCI, V4, P151, DOI 10.1038/83976; Yokomaku D, 2003, MOL ENDOCRINOL, V17, P831, DOI 10.1210/me.2002-0314	52	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43245	43253		10.1074/jbc.M406733200	http://dx.doi.org/10.1074/jbc.M406733200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15297459	hybrid			2022-12-27	WOS:000224226400109
J	Perez, E; Constant, P; Laval, F; Lemassu, A; Laneelle, MA; Daffe, M; Guilhot, C				Perez, E; Constant, P; Laval, F; Lemassu, A; Laneelle, MA; Daffe, M; Guilhot, C			Molecular dissection of the role of two methyltransferases in the biosynthesis of phenolglycolipids and phthiocerol dimycoserosate in the Mycobacterium tuberculosis complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCOSYL PHENOL-PHTHIOCEROL; TRANSPOSON MUTAGENESIS; GENE-CLUSTER; BOVIS BCG; IDENTIFICATION; SMEGMATIS; MYCOSIDES; MUTATIONS; DIESTER; LOCUS	A few mycobacterial species, most of which are pathogenic for humans, produce dimycocerosates of phthiocerol ( DIM) and of glycosylated phenolphthiocerol, also called phenolglycolipid (PGL), two groups of molecules shown to be important virulence factors. The biosynthesis of these molecules is a very complex pathway that involves more than 15 enzymatic steps and has just begun to be elucidated. Most of the genes known to be involved in these pathways are clustered on the chromosome of M. tuberculosis. Based on their amino acid sequences, we hypothesized that the proteins encoded by Rv2952 and Rv2959c, two open reading frames of this locus, are involved in the transfer of methyl groups onto various hydroxyl functions during the biosynthesis of DIM, PGL, and related p-hydroxybenzoic acid derivatives (p-HBAD). Using allelic exchange and site-specific recombination, we produced three recombinant strains of Mycobacterium tuberculosis carrying insertions in Rv2952 or Rv2959c. Analysis of these mutants revealed that (i) the protein encoded by Rv2952 is a methyltransferase catalyzing the transfer of a methyl group onto the lipid moiety of phthiotriol and glycosylated phenolphthiotriol dimycocerosates to form DIM and PGL, respectively, (ii) Rv2959c is part of an operon including the newly characterized Rv2958c gene that encodes a glycosyltransferase also involved in PGL and p-HBAD biosynthesis, and (iii) the enzyme encoded by Rv2959c catalyzes the O-methylation of the hydroxyl group located on carbon 2 of the rhamnosyl residue linked to the phenolic group of PGL and p-HBAD produced by M. tuberculosis. These data further extend our understanding of the biosynthesis of important mycobacterial virulence factors and provide additional tools to decipher the molecular mechanisms of action of these molecules during the pathogenesis of tuberculosis.	Inst Pharmacol & Biol Struct, Dept Mecanismes Mol Infect Mycobacteriennes, CNRS, F-31077 Toulouse, France; Univ Toulouse 3, Unite Mixte Rech 5089, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Daffe, M (corresponding author), Inst Pharmacol & Biol Struct, Dept Mecanismes Mol Infect Mycobacteriennes, CNRS, 205 Route Narbonne, F-31077 Toulouse, France.	Mamadou.Daffe@ipbs.fr; Christophe.Guilhot@ipbs.fr	LAUZERAL-VIZCAINO, Françoise/W-8898-2019	LAUZERAL-VIZCAINO, Françoise/0000-0002-9741-3252; Lemassu, Anne/0000-0002-9323-2497				Asselineau J, 1982, Indian J Chest Dis Allied Sci, V24, P143; Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; Azad AK, 1996, P NATL ACAD SCI USA, V93, P4787, DOI 10.1073/pnas.93.10.4787; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P203; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Constant P, 2002, J BIOL CHEM, V277, P38148, DOI 10.1074/jbc.M206538200; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; DAFFE M, 1989, BIOCHIM BIOPHYS ACTA, V1002, P257, DOI 10.1016/0005-2760(89)90295-6; DAFFE M, 1988, BIOCHIM BIOPHYS ACTA, V958, P443, DOI 10.1016/0005-2760(88)90230-5; DAFFE M, 1987, EUR J BIOCHEM, V167, P155, DOI 10.1111/j.1432-1033.1987.tb13317.x; DAFFE M, 1988, J GEN MICROBIOL, V134, P2049; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Daffe M, 2000, GLYCOMICROBIOLOGY, P225, DOI DOI 10.1007/0-306-46821-2_8; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; Fitzmaurice AM, 1998, J BIOL CHEM, V273, P8033, DOI 10.1074/jbc.273.14.8033; Jeevarajah D, 2002, MICROBIOL-SGM, V148, P3079, DOI 10.1099/00221287-148-10-3079; Malaga W, 2003, FEMS MICROBIOL LETT, V219, P261, DOI 10.1016/S0378-1097(03)00003-X; Patterson JH, 2000, J BIOL CHEM, V275, P24900, DOI 10.1074/jbc.M000147200; Pelicic V, 1996, MOL MICROBIOL, V20, P919, DOI 10.1111/j.1365-2958.1996.tb02533.x; Pelicic V, 1997, P NATL ACAD SCI USA, V94, P10955, DOI 10.1073/pnas.94.20.10955; Perez E, 2004, J BIOL CHEM, V279, P42574, DOI 10.1074/jbc.M406246200; Trivedi OA, 2004, NATURE, V428, P441, DOI 10.1038/nature02384; *WHO, 2002, 104 WHO	27	51	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42584	42592		10.1074/jbc.M406134200	http://dx.doi.org/10.1074/jbc.M406134200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292265	hybrid			2022-12-27	WOS:000224226400031
J	Zheng, YF; Saftig, P; Hartmann, D; Blobel, C				Zheng, YF; Saftig, P; Hartmann, D; Blobel, C			Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNF alpha) shedding and of the function of the TNF alpha ectodomain in ensuring selective stimulated shedding by the TNF alpha convertase (TACE/ADAM17)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOPROTEASE-DISINTEGRIN MDC9; ENZYME; PROTEIN; FAMILY; TACE; PRECURSOR; CLEAVAGE; DISTINCT; RELEASE; DOMAIN	Tumor necrosis factor-alpha (TNFalpha), a potent proinflammatory cytokine, is released from cells by proteolytic cleavage of a membrane-anchored precursor. The TNF-alpha converting enzyme ( TACE; a disintegrin and metalloprotease17; ADAM17) is known to have a key role in the ectodomain shedding of TNFalpha in several cell types. However, because purified ADAMs 9, 10, and 19 can also cleave a peptide corresponding to the TNFalpha cleavage site in vitro, these enzymes are considered to be candidate TNFalpha sheddases as well. In this study we used cells lacking ADAMs 9, 10, 17 ( TACE), or 19 to address the relative contribution of these ADAMs to TNFalpha shedding in cell-based assays. Our results corroborate that ADAM17, but not ADAM9, - 10, or - 19, is critical for phorbol ester- and pervanadate-stimulated release of TNFalpha in mouse embryonic fibroblasts. However, overexpression of ADAM19 increased the constitutive release of TNFalpha, whereas overexpression of ADAM9 or ADAM10 did not. This suggests that ADAM19 may contribute to TNFalpha shedding, especially in cells or tissues where it is highly expressed. Furthermore, we used mutagenesis of TNFalpha to explore which domains are important for its stimulated processing by ADAM17. We found that the cleavage site of TNFalpha is necessary and sufficient for cleavage by ADAM17. In addition, the ectodomain of TNFalpha makes an unexpected contribution to the selective cleavage of TNFalpha by ADAM17: it prevents one or more other enzymes from cleaving TNFalpha following PMA stimulation. Thus, selective stimulated processing of TNFalpha by ADAM17 in cells depends on the presence of an appropriate cleavage site as well as the inhibitory role of the TNF ectodomain toward other enzymes that can process this site.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, Sloan Kettering Inst, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Grad Program Physiol Biophys & Syst Biol, New York, NY 10021 USA; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany; Katholieke Univ Leuven, Dept Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol VIB4, B-3000 Louvain, Belgium	Memorial Sloan Kettering Cancer Center; Cornell University; University of Kiel; KU Leuven	Blobel, C (corresponding author), Hosp Special Surg, Caspary Res Bldg,Rm 426,535 E 70th St, New York, NY 10021 USA.	blobelc@hss.edu	Zheng, Yufang/F-1091-2011; Saftig, Paul/A-7966-2010	Zheng, Yufang/0000-0002-0488-2624; 	NIGMS NIH HHS [R01 GM058668-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058668] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Chesneau V, 2003, J BIOL CHEM, V278, P22331, DOI 10.1074/jbc.M302781200; Coeshott C, 1999, P NATL ACAD SCI USA, V96, P6261, DOI 10.1073/pnas.96.11.6261; Doedens JR, 2003, BIOCHEM BIOPH RES CO, V308, P331, DOI 10.1016/S0006-291X(03)01381-0; Garton KJ, 2001, J BIOL CHEM, V276, P37993; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MCGEEHAN GM, 1995, METHOD ENZYMOL, V248, P35; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Ruuls SR, 2001, IMMUNITY, V15, P533, DOI 10.1016/S1074-7613(01)00215-1; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; Thathiah A, 2003, J BIOL CHEM, V278, P3386, DOI 10.1074/jbc.M208326200; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; Zheng YF, 2002, J BIOL CHEM, V277, P42463, DOI 10.1074/jbc.M207459200; Zhou HM, 2004, MOL CELL BIOL, V24, P96, DOI 10.1128/MCB.24.1.96-104.2004	34	131	134	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42898	42906		10.1074/jbc.M403193200	http://dx.doi.org/10.1074/jbc.M403193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15292243	hybrid			2022-12-27	WOS:000224226400068
J	Bredeston, LM; Adamo, HP				Bredeston, LM; Adamo, HP			Loss of autoinhibition of the plasma membrane Ca2+ pump by substitution of aspartic 170 by asparagine - Activation of plasma membrane calcium ATPase 4 without disruption of the interaction between the catalytic core and the C-terminal regulatory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; RED-CELL MEMBRANES; CALCIUM-PUMP; H+-ATPASE; MONOCLONAL-ANTIBODIES; CA-2+ PUMP; SITE; REGION; ENZYME; CA2&-ATPASE	The plasma membrane calcium ATPase (PMCA) actively transports Ca2+ from the cytosol to the extra cellular space. The C-terminal segment of the PMCA functions as an inhibitory domain by interacting with the catalytic core. Ca2+-calmodulin binds to the C-terminal segment and stops inhibition. Here we showed that residue Asp(170), in the putative "A" domain of human PMCA isoform 4xb, plays a critical role in autoinhibition. In the absence of calmodulin a PMCA containing a site-specific mutation of D170N had 80% of the maximum activity of the calmodulin-activated PMCA and a similar high affinity for Ca2+. The mutation did not change the activation of the PMCA by ATP. Deletion of the C-terminal segment further downstream of the calmodulin-binding site led to an additional increase in the maximal activity of the mutant, which suggests that the mutation did not affect the inhibition because of this portion of the C-terminal segment. The calmodulin-activated PMCA was more sensitive to vanadate inhibition than the autoinhibited enzyme. In contrast, inhibition of the D170N mutant required higher concentrations of vanadate and was not affected by calmodulin. Despite its higher basal activity, the mutant had an apparent affinity for calmodulin similar to that of the wild type enzyme, and its rate of proteolysis at the C-terminal segment was still calmodulin-dependent. Altogether these results suggest that activation by mutation D170N does not involve the displacement of the calmodulin-binding autoinhibitory domain from the catalytic core and may arise directly from changes in the accessibility to the calcium-binding residues of the pump.	Univ Buenos Aires, Fac Farm & Bioquim, Inst Quim & Fisicoquim Biol IQUIFIB, RA-1113 Buenos Aires, DF, Argentina	University of Buenos Aires	Adamo, HP (corresponding author), Univ Buenos Aires, Fac Farm & Bioquim, Inst Quim & Fisicoquim Biol IQUIFIB, Junin 956, RA-1113 Buenos Aires, DF, Argentina.	hpadamo@qb.ffyb.uba.ar	Adamo, Hugo Pedro/ABB-8338-2021	Adamo, Hugo Pedro/0000-0002-1712-8049				Adamo HP, 2000, BIOCHEMISTRY-US, V39, P14893, DOI 10.1021/bi001222c; ADAMO HP, 1992, J BIOL CHEM, V267, P14244; Ba-Thein W, 2001, BIOCHEM J, V356, P241, DOI 10.1042/0264-6021:3560241; BARRABIN H, 1980, BIOCHIM BIOPHYS ACTA, V600, P796, DOI 10.1016/0005-2736(80)90482-4; Bauer A, 1996, YEAST, V12, P965, DOI 10.1002/(SICI)1097-0061(199608)12:10<965::AID-YEA999>3.0.CO;2-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bredeston LM, 2002, BIOCHEM J, V361, P355, DOI 10.1042/0264-6021:3610355; Buch-Pedersen MJ, 2000, J BIOL CHEM, V275, P39167, DOI 10.1074/jbc.M007537200; CARIDE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1027, P21, DOI 10.1016/0005-2736(90)90042-M; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; Caride AJ, 2001, J BIOL CHEM, V276, P39797, DOI 10.1074/jbc.M104380200; Curran AC, 2000, J BIOL CHEM, V275, P30301, DOI 10.1074/jbc.M002047200; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1987, J BIOL CHEM, V262, P6425; ERASO P, 1994, J BIOL CHEM, V269, P10393; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; HAO LN, 1994, J BIOL CHEM, V269, P14268; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miranda M, 2001, J BIOL CHEM, V276, P22485, DOI 10.1074/jbc.M102332200; Morsomme P, 1998, J BIOL CHEM, V273, P34837, DOI 10.1074/jbc.273.52.34837; Padanyi R, 2003, J BIOL CHEM, V278, P35798, DOI 10.1074/jbc.M305794200; Paszty K, 2002, J BIOL CHEM, V277, P36146, DOI 10.1074/jbc.M205457200; Penheiter AR, 2002, J BIOL CHEM, V277, P17728, DOI 10.1074/jbc.M111608200; RICHARDS DE, 1978, BIOCHIM BIOPHYS ACTA, V511, P194, DOI 10.1016/0005-2736(78)90313-9; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VERMA AK, 1994, J BIOL CHEM, V269, P1687	35	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41619	41625		10.1074/jbc.M403116200	http://dx.doi.org/10.1074/jbc.M403116200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15292209	hybrid			2022-12-27	WOS:000224075500047
J	Hildreth, KL; Wu, JH; Barak, LS; Exum, ST; Kim, LK; Peppel, K; Freedman, NJ				Hildreth, KL; Wu, JH; Barak, LS; Exum, ST; Kim, LK; Peppel, K; Freedman, NJ			Phosphorylation of the platelet-derived growth factor receptor-beta by G protein-coupled receptor kinase-2 reduces receptor signaling and interaction with the Na+/H+ exchanger regulatory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; BETA(1)-ADRENERGIC RECEPTOR; PDGF; DESENSITIZATION; SPECIFICITY; ASSOCIATION; CELLS; ATHEROSCLEROSIS; INTERNALIZATION; OVEREXPRESSION	G protein-coupled receptor kinase-2 (GRK2) can phosphorylate and desensitize the platelet-derived growth factor receptor-beta (PDGFRbeta) in heterologous cellular systems. To determine whether GRK2 regulates the PDGFRbeta inhysiologic systems, we examined PDGFRbeta signaling in mouse embryonic fibroblasts from GRK2-null and cognate wild type mice. To discern a mechanism by which GRK2-mediated phosphorylation can desensitize the PDGFRbeta, but not the epidermal growth factor receptor (EGFR), we investigated effects of GRK2-mediated phosphorylation on the association of the PDGFRbeta with the Na+/H+ exchanger regulatory factor (NHERF), a protein shown to potentiate dimerization of the PDGFRbeta, but not the EGFR. Physiologic expression of GRK2 diminished (a) phosphoinositide hydrolysis elicited through the PDGFRbeta but not heterotrimeric G proteins; (b) Akt activation evoked by the PDGFRbeta but not the EGFR; and (c) PDGF-induced tyrosyl phosphorylation of the PDGFRbeta itself. PDGFRbeta desensitization by physiologically expressed GRK2 correlated with a 2.5-fold increase in PDGF-promoted PDGFRbeta seryl phosphorylation. In 293 cells, GRK2 overexpression reduced PDGFRbeta/NHERF association by 60%. This effect was reproduced by S1104D mutation of the PDGFRbeta, which also diminished PDGFRbeta activation and signaling (like the S1104A mutation) to an extent equivalent to that achieved by GRK2-mediated PDGFRbeta phosphorylation. GRK2 overexpression desensitized only the wild type but not the S1104A PDGFRbeta. We conclude that GRK2-mediated PDGFRbeta seryl phosphorylation plays an important role in desensitizing the PDGFRbeta in physiologic systems. Furthermore, this desensitization appears to involve GRK2-mediated phosphorylation of PDGFRbeta Ser1104, with consequent dissociation of the PDGFRbeta from NHERF.	Duke Univ, Med Ctr, Dept Med Cardiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University; Duke University	Freedman, NJ (corresponding author), Duke Univ, Med Ctr, Dept Med Cardiol, Box 3187, Durham, NC 27710 USA.	neil.freedman@duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064744, R01HL063288] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64744, HL63288] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bioukar EB, 1999, J BIOL CHEM, V274, P21457, DOI 10.1074/jbc.274.30.21457; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Demoulin JB, 2003, BIOCHEM J, V376, P505, DOI 10.1042/BJ20030385; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Freedman NJ, 2002, J BIOL CHEM, V277, P48261, DOI 10.1074/jbc.M204431200; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; George D, 2001, SEMIN ONCOL, V28, P27, DOI 10.1053/sonc.2001.29185; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; Hu LA, 2002, J BIOL CHEM, V277, P1607, DOI 10.1074/jbc.M107297200; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; ISHII K, 1994, J BIOL CHEM, V269, P1125; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; Karthikeyan S, 2002, J BIOL CHEM, V277, P18973, DOI 10.1074/jbc.M201507200; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; MORI S, 1992, J BIOL CHEM, V267, P6429; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Peppel K, 2002, J MOL CELL CARDIOL, V34, P1399, DOI 10.1006/jmcc.2002.2092; Peppel K, 2000, CIRCULATION, V102, P793, DOI 10.1161/01.CIR.102.7.793; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Rockman HA, 1998, J BIOL CHEM, V273, P18180, DOI 10.1074/jbc.273.29.18180; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sano H, 2001, CIRCULATION, V103, P2955, DOI 10.1161/01.CIR.103.24.2955; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Wang Y, 2004, J BIOL CHEM, V279, P8038, DOI 10.1074/jbc.M311494200; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Wu JH, 2003, J BIOL CHEM, V278, P44238, DOI 10.1074/jbc.M309450200	33	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41775	41782		10.1074/jbc.M403274200	http://dx.doi.org/10.1074/jbc.M403274200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15271984	hybrid			2022-12-27	WOS:000224075500066
J	Jing, W; DeAngelis, PL				Jing, W; DeAngelis, PL			Synchronized chemoenzymatic synthesis of monodisperse hyaluronan polymers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 ACTIVE-SITES; PASTEURELLA-MULTOCIDA; MOLECULAR-CLONING; SYNTHASE; OLIGOSACCHARIDES	The length of the hyaluronan (HA) polysaccharide chain dictates its biological effects in many cellular and tissue systems. Long and short HA polymers often appear to have antagonistic or inverse effects. However, no source of very defined, uniform HA polymers with sizes greater than 10 kDa is currently available. We present a method to produce synthetic HA with very narrow size distributions in the range of similar to16 kDa to similar to2 MDa. The Pasteurella HA synthase enzyme, pmHAS, catalyzes the synthesis of HA polymer utilizing monosaccharides from UDP-sugar precursors. Recombinant pmHAS will also elongate exogenously supplied HA oligosaccharide acceptors in vitro in a nonprocessive fashion. As a result of bypassing the slow initiation step in vitro, the elongation process is synchronized in the presence of acceptor; thus all of polymer products are very similar in length. In contrast, without the use of an acceptor, the final polymer size range is difficult to predict and the products are more polydisperse. HA polymers of a desired size are constructed by controlling the reaction stoichiometry (i.e. molar ratio of precursors and acceptor molecules). The use of modified acceptors allows the synthesis of HA polymers containing tags (e.g. fluorescent, radioactive). In this scheme, each molecule has a single foreign moiety at the reducing terminus. Alternatively, the use of radioactive UDP-sugar precursors allows the synthesis of uniformly labeled native HA polymers. Overall, synthetic HA reagents with monodisperse size distributions and defined structures should assist in the elucidation of the numerous roles of HA in health and disease.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Hyalose LLC, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA.	paul-deangelis@ouhsc.edu						BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; Deangelis PL, 2003, J BIOL CHEM, V278, P35199, DOI 10.1074/jbc.M306431200; DeAngelis PL, 1999, J BIOL CHEM, V274, P26557, DOI 10.1074/jbc.274.37.26557; DeAngelis PL, 2002, GLYCOBIOLOGY, V12, p9R, DOI 10.1093/glycob/12.1.9R; Fieber C, 2004, J CELL SCI, V117, P359, DOI 10.1242/jcs.00831; Ikegami-Kawai M, 2002, ANAL BIOCHEM, V311, P157, DOI 10.1016/S0003-2697(02)00425-6; Itano N, 2002, IUBMB LIFE, V54, P195, DOI 10.1080/15216540214929; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; Jing W, 2003, GLYCOBIOLOGY, V13, P661, DOI 10.1093/glycob/cwg085; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Spicer AP, 1998, J BIOL CHEM, V273, P25117, DOI 10.1074/jbc.273.39.25117; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; Uebelhart D, 1999, Curr Opin Rheumatol, V11, P427, DOI 10.1097/00002281-199909000-00018; WEST DC, 1989, CIBA F SYMP, V143, P187	21	103	114	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42345	42349		10.1074/jbc.M402744200	http://dx.doi.org/10.1074/jbc.M402744200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15299014	hybrid			2022-12-27	WOS:000224075500127
J	Wilkens, S; Inoue, T; Forgac, M				Wilkens, S; Inoue, T; Forgac, M			Three-dimensional structure of the vacuolar ATPase - Localization of subunit H by difference imaging and chemical cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST V-ATPASE; AMINO-TERMINAL DOMAIN; PERIPHERAL STALK; MANDUCA-SEXTA; PROTON PUMP; V-1 ATPASE; RESOLUTION; COMPLEX; PROTEIN; RECONSTITUTION	The structure of the proton-pumping vacuolar ATPase (V-ATPase) from bovine brain clathrin coated vesicles was analyzed by electron microscopy and single molecule image analysis. A three-dimensional structural model of the complex was calculated by the angular reconstitution method at a resolution of 27 Angstrom. Overall, the appearance of the V-0 and V-1 domains in the three-dimensional model of the intact bovine V-ATPase resembles the models of the isolated bovine V0 and yeast V1 domains determined previously (Wilkens, S., and Forgac, M. ( 2001) J. Biol. Chem. 276, 44064 - 44068; Zhang, Z., Charsky, C., Kane, P. M., and Wilkens, S. ( 2003) J. Biol. Chem. 278, 47299 - 47306). To determine the binding position of subunit H in the V-ATPase, electron microscopy and cysteine-mediated photochemical cross-linking were used. Difference maps calculated from projection images of intact bovine V-ATPase and a V-ATPase preparation in which the two H subunit isoforms were removed by treatment with cystine revealed less protein density at the bottom of the V-1 in the subunit H-depleted enzyme, suggesting that subunit H isoforms bind at the interface of the V-1 and V-0 domains. A comparison of three-dimensional models calculated for intact and subunit H-depleted enzyme indicated that at least one of the subunit H isoforms, although poorly resolved in the three-dimensional electron density, binds near the putative N-terminal domain of the a subunit of the V-0. For photochemical cross-linking, unique cysteine residues were introduced into the yeast V-ATPase B subunit at sites that were localized based on molecular modeling using the crystal structure of the mitochondrial F-1 domain. Cross-linking was performed using the photoactivatable sulfhydryl reagent 4-(N-maleimido) benzophenone. Cross-linking to subunit H was observed from two sites on subunit B (E494 and T501) predicted to be located on the outer surface of the subunit closest to the membrane. Results from both electron microscopy and cross-linking analysis thus place subunit H near the interface of the V-1 and V-0 domains and suggest a close structural similarity between the V-ATPases of yeast and mammals.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	University of California System; University of California Riverside; Tufts University	Wilkens, S (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	stephan.wilkens@ucr.edu			NIGMS NIH HHS [GM58600, GM34478, R37 GM034478, R01 GM034478] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058600, R37GM034478, R01GM034478] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Domgall I, 2002, J BIOL CHEM, V277, P13115, DOI 10.1074/jbc.M112011200; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; Geyer M, 2002, J BIOL CHEM, V277, P28521, DOI 10.1074/jbc.M200522200; Golas MM, 2003, SCIENCE, V300, P980, DOI 10.1126/science.1084155; Gruber G, 2001, J EXP BIOL, V204, P2597; Gruber G, 2000, BIOCHEMISTRY-US, V39, P8609, DOI 10.1021/bi000103u; HIRATA T, 2003, J BIOL CHEM, V277; HO MN, 1993, J BIOL CHEM, V268, P18286; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; Iwata M, 2004, P NATL ACAD SCI USA, V101, P59, DOI 10.1073/pnas.0305165101; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Lu M, 2002, J BIOL CHEM, V277, P38409, DOI 10.1074/jbc.M203521200; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; MacLeod KJ, 1999, J BIOL CHEM, V274, P32869, DOI 10.1074/jbc.274.46.32869; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Orlova EV, 2003, J MOL BIOL, V326, P1005, DOI 10.1016/S0022-2836(02)00708-8; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Rizzo VF, 2003, J BIOL CHEM, V278, P270, DOI 10.1074/jbc.M208623200; Rubinstein JL, 2003, EMBO J, V22, P6182, DOI 10.1093/emboj/cdg608; Sagermann M, 2001, P NATL ACAD SCI USA, V98, P7134, DOI 10.1073/pnas.131192798; SCHATZ M, 1995, J STRUCT BIOL, V114, P28, DOI 10.1006/jsbi.1995.1003; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Supekova L, 1996, J EXP BIOL, V199, P1147; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Vasilyeva E, 2000, J BIOL CHEM, V275, P255, DOI 10.1074/jbc.275.1.255; Wieczorek H, 2000, J EXP BIOL, V203, P127; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 2001, CELL BIOCHEM BIOPHYS, V34, P191, DOI 10.1385/CBB:34:2:191; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; XIE XS, 1994, J BIOL CHEM, V269, P25809; Xie XS, 1996, J BIOL CHEM, V271, P30980; XIE XS, 1988, J BIOL CHEM, V263, P9859; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Yokoyama K, 2003, J BIOL CHEM, V278, P42686, DOI 10.1074/jbc.M305853200; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZHANG X, 2000, J BIOL CHEM, V275, P35592; Zhang ZY, 2003, J BIOL CHEM, V278, P47299, DOI 10.1074/jbc.M309445200; Zhou ZM, 1999, J BIOL CHEM, V274, P15913, DOI 10.1074/jbc.274.22.15913	52	84	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41942	41949		10.1074/jbc.M407821200	http://dx.doi.org/10.1074/jbc.M407821200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15269204	hybrid			2022-12-27	WOS:000224075500086
J	Goraya, TA; Masada, N; Ciruela, A; Cooper, DMF				Goraya, TA; Masada, N; Ciruela, A; Cooper, DMF			Sustained entry of Ca2+ is required to activate Ca2+-calmodulin-dependent phosphodiesterase 1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-INHIBITABLE ADENYLYL-CYCLASE; HUMAN ASTROCYTOMA-CELLS; MUSCARINIC CHOLINERGIC RECEPTORS; C6-2B GLIOMA-CELLS; PROTEIN-KINASE-C; ENDOPLASMIC-RETICULUM; ARACHIDONIC-ACID; CATION ENTRY; RAT-BRAIN; CAMP	Regulation of adenylyl cyclases (ACs) by Ca2+ requires capacitative Ca2+ entry (CCE) (Cooper, D.M.F. (2003) Biochem. J. 375, 517-529), but whether Ca2+-sensitive phosphodiesterases (PDEs) are similarly discriminating has never been addressed. In the present study, a variety of conditions were devised to manipulate [Ca2+](i) so that we could ask whether PDE1 selectively responds to different modes of elevating [Ca2+](i), viz. Ca2+ released from intracellular stores and various modes of Ca2+ entry. In 1321N1 human astrocytoma cells, the endogenous PDE1 (identified as PDE1A by reverse transcriptase-PCR) was largely insensitive to Ca2+ released from carbachol-sensitive stores but was robustly stimulated by a similar rise in [Ca2+](i) due to carbachol-induced Ca2+ influx. Gd3+, which effectively blocked thapsigargin-induced CCE and its effect on PDE1A, also inhibited the activation of PDE1A by carbachol-induced Ca2+ entry. However, non-selective ionomycin-mediated Ca2+ entry also activated PDE1A, so that, unlike Ca2+-sensitive ACs, PDE1A cannot discriminate between the different sources of Ca2+ entry. Fractionation of the cells revealed that the Ca2+-calmodulin-stimulated PDE activity was not present at the plasma membrane but was associated with the cytosol and the organellar compartments of the cell. Therefore, the apparent disparity between PDE1A and ACs is likely to be the consequence of their differential subcellular localization. Nevertheless, in a physiological context, where artificial modes of elevating [Ca2+](i) are not available, as with ACs, a dependence on CCE would be evident, and it would be the duration of this influx of Ca2+ that would determine how long PDE1A was activated.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	Cooper, DMF (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	dmfc2@cam.ac.uk						AHLIJANIAN MK, 1987, J PHARMACOL EXP THER, V241, P407; Baillie GS, 2002, J BIOL CHEM, V277, P28298, DOI 10.1074/jbc.M108353200; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; COLVIN RA, 1991, CELL CALCIUM, V12, P19, DOI 10.1016/0143-4160(91)90081-O; Conti M, 2000, MOL ENDOCRINOL, V14, P1317, DOI 10.1210/me.14.9.1317; Cooper DMF, 2003, BIOCHEM J, V375, P517, DOI 10.1042/BJ20031061; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; Dolphin AC, 1996, TRENDS NEUROSCI, V19, P35, DOI 10.1016/0166-2236(96)81865-0; EVANS T, 1984, MOL PHARMACOL, V26, P395; Fagan KA, 2000, J BIOL CHEM, V275, P26530, DOI 10.1074/jbc.M001369200; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Geoffroy V, 1999, EUR J BIOCHEM, V259, P892, DOI 10.1046/j.1432-1327.1999.00123.x; Gil J, 2001, NEUROPEPTIDES, V35, P276, DOI 10.1054/npep.2001.0870; Giorgi M, 2002, J NEUROCHEM, V80, P970, DOI 10.1046/j.0022-3042.2002.00786.x; GROSS RA, 1977, MOL PHARMACOL, V13, P242; Gu C, 2000, J BIOL CHEM, V275, P6980, DOI 10.1074/jbc.275.10.6980; Han P, 1999, J BIOL CHEM, V274, P22337, DOI 10.1074/jbc.274.32.22337; Hirota K, 1997, NEUROSCI LETT, V223, P169, DOI 10.1016/S0304-3940(97)13434-6; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Jackson EK, 2004, ANNU REV PHYSIOL, V66, P571, DOI 10.1146/annurev.physiol.66.032102.111604; JOHNSON RA, 1990, MOL PHARMACOL, V37, P296; KAKIUCHI S, 1970, BIOCHEM BIOPH RES CO, V41, P1104, DOI 10.1016/0006-291X(70)90199-3; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; LIU CM, 1978, J BIOL CHEM, V253, P5892; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; MASTERS SB, 1984, MOL PHARMACOL, V26, P149; MEEKER RB, 1982, MOL PHARMACOL, V22, P310; Mignen O, 2003, J BIOL CHEM, V278, P10174, DOI 10.1074/jbc.M212536200; Mignen O, 2001, J BIOL CHEM, V276, P35676, DOI 10.1074/jbc.M105626200; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; NAKAHATA N, 1986, MOL PHARMACOL, V29, P188; NORONHABLOB L, 1988, J NEUROCHEM, V50, P1381, DOI 10.1111/j.1471-4159.1988.tb03020.x; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; REEVES ML, 1987, BIOCHEM J, V241, P535, DOI 10.1042/bj2410535; RUNG MS, 1979, BIOCHEMISTRY-US, V18, P1689, DOI 10.1021/bi00576a009; Rybalkin SD, 2002, CIRC RES, V90, P151, DOI 10.1161/hh0202.104108; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Shahid M, 1995, Methods Mol Biol, V41, P129; Shakur Y, 2000, J BIOL CHEM, V275, P38749, DOI 10.1074/jbc.M001734200; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; Smith KE, 2002, J BIOL CHEM, V277, P6025, DOI 10.1074/jbc.M109615200; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sonnenburg WK, 1995, J BIOL CHEM, V270, P30989, DOI 10.1074/jbc.270.52.30989; TANNER LI, 1986, MOL PHARMACOL, V29, P455; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Webb JG, 2001, AM J PHYSIOL-HEART C, V281, pH1545, DOI 10.1152/ajpheart.2001.281.4.H1545; WELLS JN, 1988, METHOD ENZYMOL, V159, P489	56	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40494	40504		10.1074/jbc.M313441200	http://dx.doi.org/10.1074/jbc.M313441200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15272012	hybrid			2022-12-27	WOS:000223916800036
J	Mussmann, R; Engstler, M; Gerrits, H; Kieft, R; Toaldo, CB; Onderwater, J; Koerten, H; van Luenen, HGAM; Borst, P				Mussmann, R; Engstler, M; Gerrits, H; Kieft, R; Toaldo, CB; Onderwater, J; Koerten, H; van Luenen, HGAM; Borst, P			Factors affecting the level and localization of the transferrin receptor in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; BINDING PROTEIN COMPLEX; GENE-EXPRESSION SITES; BLOOD-STREAM FORMS; AFRICAN TRYPANOSOMES; ANTIGENIC VARIATION; ANCHORED PROTEIN; ENDOCYTOSIS; HYPOXIA; IDENTIFICATION	Transfer of bloodstream-form Trypanosoma brucei variant 221a from calf serum to dog serum-based medium induces acute iron starvation, as the transferrin receptor (Tf-R) of variant 221a binds dog Tf poorly. We show here that transfer to dog serum induces a 3-5-fold increase in Tf-R mRNA and protein within one doubling time (8 h). Because iron stores are still high 8 h after transfer, we infer that the signal for Tf-R overproduction is the decreased availability of cytosolic iron when cellular iron import drops. Up to 30% of the extra Tf-R spills out of the flagellar pocket onto the pellicular surface. Because the 5-fold increase in Tf-R is accompanied by a 5-fold increase in bovine Tf uptake, the up-regulation of Tf-R levels in response to Tf starvation helps the trypanosome to compete for limiting amounts of Tf. We noted that Tf-R levels also vary in calf serum medium. Cells in dense cultures contain up to 5-fold more Tf-R mRNA and protein than in dilute cultures. Only one-tenth of the extra Tf-R reaches the pellicular surface. The increase cannot be explained by a lack of Tf or to cell density sensing but is due to pericellular hypoxia. Our results show that bloodstream-form trypanosomes can regulate the expression of the two Tf-R subunit genes and the localization of their gene products in a flexible manner. This flexibility is made possible by the promoter-proximal position of the two genes in the variant surface glycoprotein expression site.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, Ctr Electron Microscopy, NL-2300 RA Leiden, Netherlands; Univ Munich, Dept Biol 1, D-80638 Munich, Germany	Netherlands Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Munich	Borst, P (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	p.borst@nki.nl	Engstler, Markus/E-6054-2010	van Luenen, Henri/0000-0002-5584-7968				Ansorge I, 1999, MOL BIOCHEM PARASIT, V101, P81, DOI 10.1016/S0166-6851(99)00060-2; BALDWIN GS, 1993, COMP BIOCHEM PHYS B, V106, P203, DOI 10.1016/0305-0491(93)90028-4; Barry JD, 2001, ADV PARASIT, V49, P1, DOI 10.1016/S0065-308X(01)49037-3; BERNARDS A, 1984, CELL, V36, P163, DOI 10.1016/0092-8674(84)90085-0; Berriman M, 2002, MOL BIOCHEM PARASIT, V122, P131, DOI 10.1016/S0166-6851(02)00092-0; Biebinger S, 2003, MOL BIOCHEM PARASIT, V132, P93, DOI 10.1016/j.molbiopara.2003.07.005; Bitter W, 1998, NATURE, V391, P499, DOI 10.1038/35166; Borst P, 1997, Behring Inst Mitt, P1; Borst P, 2002, CELL, V109, P5, DOI 10.1016/S0092-8674(02)00711-0; Borst P, 2001, MOL BIOCHEM PARASIT, V114, P17, DOI 10.1016/S0166-6851(01)00243-2; BORST P, 1991, TRENDS GENET, V7, P307, DOI 10.1016/0168-9525(91)90406-G; Brown JM, 2003, MOL BIOL CELL, V14, P3192, DOI 10.1091/mbc.e03-03-0166; Carrington M, 1996, MOL BIOCHEM PARASIT, V81, P119, DOI 10.1016/0166-6851(96)02706-5; CHAUDHRI M, 1994, P NATL ACAD SCI USA, V91, P6443, DOI 10.1073/pnas.91.14.6443; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; Cross GAM, 1998, MOL BIOCHEM PARASIT, V91, P77, DOI 10.1016/S0166-6851(97)00186-2; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; Cross M, 2002, MOL MICROBIOL, V46, P37, DOI 10.1046/j.1365-2958.2002.03144.x; Engstler M, 2004, J CELL SCI, V117, P1105, DOI 10.1242/jcs.00938; Fast B, 1999, BIOCHEM J, V342, P691, DOI 10.1042/0264-6021:3420691; Gerrits H, 2002, MOL BIOCHEM PARASIT, V119, P237, DOI 10.1016/S0166-6851(01)00417-0; GRAB DJ, 1992, EUR J CELL BIOL, V59, P398; Grunfelder CG, 2003, MOL BIOL CELL, V14, P2029, DOI 10.1091/mbc.E02-10-0640; Grunfelder CG, 2002, TRAFFIC, V3, P547, DOI 10.1034/j.1600-0854.2002.30805.x; HIRUMI H, 1991, PARASITOLOGY, V102, P225, DOI 10.1017/S0031182000062533; Kabiri M, 2000, EUR J BIOCHEM, V267, P3309, DOI 10.1046/j.1432-1327.2000.01361.x; LIGTENBERG MJL, 1994, EMBO J, V13, P2565, DOI 10.1002/j.1460-2075.1994.tb06546.x; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; Mussmann R, 2003, MOL MICROBIOL, V47, P23, DOI 10.1046/j.1365-2958.2003.03245.x; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; OVERATH P, 1992, DYNAMICS MEMBRANE AS, P333; Pays E, 2001, MOL BIOCHEM PARASIT, V114, P1, DOI 10.1016/S0166-6851(01)00242-0; RUDENKO G, 1995, CELL, V83, P547, DOI 10.1016/0092-8674(95)90094-2; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; Salmon D, 1997, EMBO J, V16, P7272, DOI 10.1093/emboj/16.24.7272; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SCHELL D, 1991, PARASITOL RES, V77, P558, DOI 10.1007/BF00931012; Scott DA, 1997, J BIOL CHEM, V272, P28020, DOI 10.1074/jbc.272.44.28020; Steverding D, 1998, PARASITOL RES, V84, P59, DOI 10.1007/s004360050357; STEVERDING D, 1994, EUR J CELL BIOL, V64, P78; Steverding D, 2003, TRENDS PARASITOL, V19, P125, DOI 10.1016/S1471-4922(03)00006-0; STEVERDING D, 1995, J CELL BIOL, V131, P1173, DOI 10.1083/jcb.131.5.1173; Steverding Dietmar, 2000, Parasitology International, V48, P191, DOI 10.1016/S1383-5769(99)00018-5; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; Vanhamme L, 2000, MOL MICROBIOL, V36, P328, DOI 10.1046/j.1365-2958.2000.01844.x; Vassella E, 2000, GENE DEV, V14, P615; WEBSTER P, 1989, EUR J CELL BIOL, V49, P295; WEBSTER P, 1988, J CELL BIOL, V106, P279, DOI 10.1083/jcb.106.2.279; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; WEBSTER P, 1989, EUR J CELL BIOL, V49, P303	51	39	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40690	40698		10.1074/jbc.M404697200	http://dx.doi.org/10.1074/jbc.M404697200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15263009	hybrid			2022-12-27	WOS:000223916800060
J	Schmidt, MT; Smith, BC; Jackson, MD; Denu, JM				Schmidt, MT; Smith, BC; Jackson, MD; Denu, JM			Coenzyme specificity of Sir2 protein deacetylases - Implications for physiological regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(+) SALVAGE PATHWAY; SACCHAROMYCES-CEREVISIAE; LIFE-SPAN; HISTONE/PROTEIN DEACETYLASES; DEPENDENT DEACETYLASE; STRUCTURAL BASIS; TRANSCRIPTION FACTORS; CALORIE RESTRICTION; SIR2-LIKE PROTEINS; ADP-RIBOSE	Sir2 (silent information regulator 2) enzymes catalyze a unique protein deacetylation reaction that requires the coenzyme NAD(+) and produces nicotinamide and a newly discovered metabolite, O-acetyl-ADP-ribose (OAADPr). Conserved from bacteria to humans, these proteins are implicated in the control of gene silencing, metabolism, apoptosis, and aging. Here we examine the role of NAD(+) metabolites/derivatives and salvage pathway intermediates as activators, inhibitors, or coenzyme substrates of Sir2 enzymes in vitro. Also, we probe the coenzyme binding site using inhibitor binding studies and alternative coenzyme derivatives as substrates. Sir2 enzymes showed an exquisite selectivity for the nicotinamide base coenzyme, with the most dramatic losses in binding affinity/reactivity resulting from relatively minor changes in the nicotinamide ring, either by reduction, as in NADH, or by converting the amide to its acid analogue. Both ends of the dinucleotide NAD(+) are shown to be critical for high selectivity and high affinity. Among the NAD(+) metabolites tested none were able to allosterically activate, although all led to various extents of inhibition, consistent with competition at the coenzyme binding site. Nicotinamide was the most potent inhibitor examined, suggesting that cellular nicotinamide levels would provide an effective small molecule regulator of protein deacetylation and generation of OAADPr. The presented findings also suggest that changes in the physiological NAD(+):NADH ratio, without a change in NAD(+), would yield little alteration in Sir2 activity. That is, NADH is an extremely ineffective inhibitor of Sir2 enzymes (average IC50 of 17 mM). We propose that changes in both free nicotinamide and free NAD(+) afford the greatest contribution to cellular activity of Sir2 enzymes but with nicotinamide having a more dramatic effect during smaller fluctuations in concentration.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Oregon Health & Science University	Denu, JM (corresponding author), Univ Wisconsin, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.	jmdenu@wisc.edu	Smith, Brian C/D-9949-2013	Smith, Brian C/0000-0001-6330-2768	NIDDK NIH HHS [DK07680-12] Funding Source: Medline; NIGMS NIH HHS [5 T32 GM08349, GM65386] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065386, T32GM008349] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Avalos JL, 2004, MOL CELL, V13, P639, DOI 10.1016/S1097-2765(04)00082-6; Avalos JL, 2002, MOL CELL, V10, P523, DOI 10.1016/S1097-2765(02)00628-7; Beis K, 2003, J AM CHEM SOC, V125, P11872, DOI 10.1021/ja035796r; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; BORRA MT, 2001, BIOCHEMISTRY-US, V43, P9877; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chang JH, 2002, J BIOL CHEM, V277, P34489, DOI 10.1074/jbc.M205460200; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; Denu JM, 2003, TRENDS BIOCHEM SCI, V28, P41, DOI 10.1016/S0968-0004(02)00005-1; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Jackson AD, 2002, J BIOL CHEM, V277, P18535, DOI 10.1074/jbc.M200671200; Jackson MD, 2003, J BIOL CHEM, V278, P50985, DOI 10.1074/jbc.M306552200; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Olsen RA, 2003, J AM CHEM SOC, V125, P10125, DOI 10.1021/ja028751j; Onyango P, 2002, P NATL ACAD SCI USA, V99, P13653, DOI 10.1073/pnas.222538099; Rusnak F, 2000, TRENDS BIOCHEM SCI, V25, P527, DOI 10.1016/S0968-0004(00)01659-5; Sandmeier JJ, 2002, GENETICS, V160, P877; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P9249, DOI 10.1021/bi034959l; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 2002, TRENDS CELL BIOL, V12, P404, DOI 10.1016/S0962-8924(02)02342-5; SRIVASTAVA DK, 1987, ANNU REV BIOPHYS BIO, V16, P175; Starai VJ, 2004, CURR OPIN MICROBIOL, V7, P115, DOI 10.1016/j.mib.2004.02.005; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; WU YD, 1991, J AM CHEM SOC, V113, P2353, DOI 10.1021/ja00007a002; Zhang QH, 2002, SCIENCE, V295, P1895; Zhao KH, 2003, NAT STRUCT BIOL, V10, P864, DOI 10.1038/nsb978; Zhao KH, 2004, J MOL BIOL, V337, P731, DOI 10.1016/j.jmb.2004.01.060; Zhao KH, 2003, STRUCTURE, V11, P1403, DOI 10.1016/j.str.2003.09.016; Zhao KH, 2004, P NATL ACAD SCI USA, V101, P8563, DOI 10.1073/pnas.0401057101	49	123	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40122	40129		10.1074/jbc.M407484200	http://dx.doi.org/10.1074/jbc.M407484200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15269219	hybrid			2022-12-27	WOS:000223791500110
